﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Bloch, SB
   Lund-Andersen, H
   Sander, B
   Larsen, M
AF Bloch, Sara Brandi
   Lund-Andersen, Henrik
   Sander, Birgit
   Larsen, Michael
TI Subfoveal Fibrosis in Eyes With Neovascular Age-Related Macular
   Degeneration Treated With Intravitreal Ranibizumab
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; NATURAL-HISTORY; SUBANALYSIS; BLINDNESS;
   THERAPY
AB PURPOSE: To assess baseline and follow-up characteristics of choroidal neovascularization (CNV) lesions in age-related macular degeneration in relation to the development of subfoveal subretinal fibrosis. DESIGN: Retrospective, observational case series.
   METHODS: SETTINGS AND STUDY POPULATION: One hundred ninety-seven treatment-naive eyes in 197 patients with CNV in age-related macular degeneration without subfoveal fibrosis at first presentation who were, treated with ranibizumab in a pro re nata regimen. MAIN OUTCOME MEASURE: Subfoveal fibrosis at the conclusion follow-up of 24 months or fewer.
   RESULTS: The hazard ratio of any subfoveal fibrosis developing in eyes with predominantly classic CNV was 5.95 (95% confidence interval [CI], 3.25 to 10.90) compared with minimally classic and occult CNV, whereas the hazard ratio of fibrosis developing with foveal atrophy was 3.38 (95% CI, 1.47 to 7.81; mean follow-up, 1.80 years; 95% CI, 1.75 to 1.85 years). The hazard ratio of any fibrosis developing was 3.38 (95% CI, 1.10 to 10.38) in eyes with a baseline best-corrected visual acuity of 40 or worse using Early Treatment Diabetic Retinopathy Study letter scores, as compared with eyes with a baseline best-corrected visual acuity of 70 letters or more. An interval between diagnosis and treatment of 15 days or more was associated with a hazard ratio of any fibrosis developing of 2.24 (95% CI, 1.28 to 3.94) as compared with an interval of fewer than 15 days. Compared with eyes in which fibrosis did not develop, eyes in which prominent fibrosis or fibrosis developed with foveal atrophy lost 8.5 more Early Treatment Diabetic Retinopathy Study letters (95% CI, -1.0 to -15.9; P = .0242) and 10.3 more Early Treatment Diabetic Retinopathy Study letters (95% CI, -4.0 to -16.5; P = .0012), respectively.
   CONCLUSIONS: The development of subfoveal fibrosis in neovascular age-related macular degeneration was associated with predominantly classic CNV and poorer visual acuity at first presentation, a longer interval between diagnosis and treatment, and approximately 2 lines of additional visual loss at the conclusion follow-up. (C) 2013 by Elsevier Inc. All rights reserved.
C1 [Bloch, Sara Brandi; Lund-Andersen, Henrik; Sander, Birgit; Larsen, Michael] Glostrup Cty Hosp, Dept Ophthalmol, DK-2600 Glostrup, Denmark.
   [Bloch, Sara Brandi; Lund-Andersen, Henrik; Larsen, Michael] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Larsen, Michael] Kennedy Ctr, Natl Eye Clin, Glostrup, Denmark.
C3 University of Copenhagen; University of Copenhagen
RP Bloch, SB (通讯作者)，Glostrup Cty Hosp, Dept Ophthalmol, Nordre Ringvej 57, DK-2600 Glostrup, Denmark.
EM sabrbl01@regionh.dk
RI Larsen, Michael/E-9620-2010
OI Larsen, Michael/0000-0002-5172-5891
FU Novartis; Pfizer; Alcon; Glaxo-Smith-Kline; Bayer; Eli Lilly; Allergan;
   Birgit Sander; Vaarn om Synet
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and the following were reported. The
   authors' employer, The Glostrup Hospital, has received compensation from
   Novartis, Alcon, Eli Lilly, Pfizer, GlaxoSmith-Kline, and competing
   entities for consultancies and contract research. Sara Brandi Bloch has
   participated in one European School for Advanced Studies in
   Ophthalmology (ESASO) meeting on age-related macular degeneration
   sponsored by Novartis and has received payment from Novartis for 1
   lecture. Michael Larsen has served as an advisory board member for
   Novartis, Pfizer, and Thrombogenics and has participated in multicenter
   interventional trials for Novartis, Pfizer, Alcon, Glaxo-Smith-Kline,
   Bayer, and Allergan. Michael Larsen has received payment for lectures
   from Novartis, Pfizer, Novo Nordisk, and Glaxo-Smith-Kline. Henrik
   Lund-Andersen has received grants from Novartis, Pfizer, Alcon,
   Glaxo-Smith-Kline, Bayer, Eli Lilly, and Allergan. Birgit Sander has
   participated in multicenter interventional trials for Novartis, Pfizer,
   Alcon, Glaxo-Smith-Kline, Bayer, Eli Lilly, and Allergan. Birgit Sander
   has received grants from Vaarn om Synet, the Danish Agency for Science,
   Technology and Innovation (Forskningsraadet), and Oejenfonden. Supported
   by the Bagenkop Nielsen Myopia Foundation and the Center for Biomedical
   Optics and New Laser Systems (BIOP). The funding organizations had no
   role in the design or the conduct of this study. Involved in Design and
   conduct of study (S.B.B., M.L., H.L.-A.); Data collection (S.B.B.);
   Management of data (S.B.B., M.L., B.S.); Analysis of data (S.B.B.);
   Interpretation of data (S.B.B., M.L., H.L.-A., B.S.); Preparation of
   manuscript (S.B.B.); and Review and final approval of manuscript
   (S.B.B., M.L., H.L.-A., B.S.). Sara Brandi Bloch had full access to all
   of the data in the study and takes responsibility for the integrity of
   the data and the accuracy of the data analysis.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CHAMBERLIN JA, 1989, OPHTHALMOLOGY, V96, P1526
   CHANDRA SR, 1974, AM J OPHTHALMOL, V78, P579, DOI 10.1016/S0002-9394(14)76293-2
   Friedman SL, 2013, J HEPATOL, V58, P1, DOI 10.1016/j.jhep.2012.10.014
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2006, OPHTHALMOLOGY, V113, P267, DOI 10.1016/j.ophthzi.2005.10.031
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2009, RETINA-J RET VIT DIS, V29, P592, DOI 10.1097/IAE.0b013e31819b17a5
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Mukkamala SK, 2012, ARCH OPHTHALMOL-CHIC, V130, P1547, DOI 10.1001/archophthalmol.2012.2491
   Ophthotech Corp, OPHTH NOV ANT PDGF C
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zhang H, 2012, INT J OPHTHALMOL-CHI, V5, P307, DOI 10.3980/j.issn.2222-3959.2012.03.11
   Zweifel SA, 2012, RETINA-J RET VIT DIS, V32, P1243, DOI 10.1097/IAE.0b013e3182469064
NR 34
TC 56
Z9 60
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2013
VL 156
IS 1
BP 116
EP 124
DI 10.1016/j.ajo.2013.02.012
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 179OT
UT WOS:000321531900018
PM 23664150
DA 2022-11-30
ER

PT J
AU Huang, YM
   Yan, SF
   Ma, L
   Zou, ZY
   Xu, XR
   Dou, HL
   Lin, XM
AF Huang, Yang-Mu
   Yan, Shao-Fang
   Ma, Le
   Zou, Zhi-Yong
   Xu, Xian-Rong
   Dou, Hong-Liang
   Lin, Xiao-Ming
TI Serum and macular responses to multiple xanthophyll supplements in
   patients with early age-related macular degeneration
SO NUTRITION
LA English
DT Article
DE Lutein; Zeaxanthin; Early age-related macular degeneration; Serum
   concentration; Macular pigment optical density
ID PIGMENT OPTICAL-DENSITY; FUNDUS AUTOFLUORESCENCE; HUMAN RETINA; EYE
   DISEASE; LUTEIN; ZEAXANTHIN; AREDS; CAROTENOIDS; PLASMA
AB Objective: This randomized controlled trial examined serum and macular (in vivo measured macular pigment optical density [MPOD]) responses to supplemental lutein and zeaxanthin in Chinese subjects with early age-related macular degeneration.
   Methods: One hundred and eight patients with early age-related macular degeneration older than 50 y were randomized to low lutein (LL; 10 mg/d), high lutein (HL; 20 mg/d), lutein plus zeaxanthin (LZ; each 10 mg/d), or placebo during a 48-wk intervention. Serum concentrations were quantified by C-30 high-performance liquid chromatography (at baseline and 4, 12, 24, and 48 wk), and MPOD was measured by analysis of autofluorescence images (at baseline and 24 and 48 wk).
   Results: Serum lutein levels in the LL, LZ, and HL groups increased significantly in the first 4 wk and then increased 4.24-, 4.66-, and 6.23-fold during the trial, respectively (all P < 0.001). The serum lutein level in the HL group was significantly higher than that in the LL or LZ group at 48 wk (P < 0.05). Similarly, the serum zeaxanthin concentration in the 12 group increased 3.11-fold at 48 wk. MPOD increased smoothly in all treated groups, and the increase from baseline was greatest in the HL group at 24 and 48 wk (both P < 0.05). MPOD and serum lutein levels increased linearly with the dosage and their increasing rates were statistically correlated (all P < 0.05). No notable changes were detected in the placebo group for MPOD and serum concentrations.
   Conclusion: Xanthophyll supplementation significantly increased serum concentrations and MPOD in patients with early age-related macular degeneration, and a higher lutein supplementation (20 mg/d) might be more effective in increasing these two biochemical markers in Chinese patients without significant side effects. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Huang, Yang-Mu; Yan, Shao-Fang; Ma, Le; Zou, Zhi-Yong; Xu, Xian-Rong; Lin, Xiao-Ming] Beijing Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Beijing 100871, Peoples R China.
   [Dou, Hong-Liang] Beijing Univ, Hosp 3, Ctr Eye, Beijing 100871, Peoples R China.
C3 Peking University; Peking University
RP Lin, XM (通讯作者)，Beijing Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Beijing 100871, Peoples R China.
EM linbjmu@bjmu.edu.cn
RI Zou, Zhiyong/P-8066-2019
OI Zou, Zhiyong/0000-0001-5049-5425; ma, le/0000-0001-7592-9779; Huang,
   Yangmu/0000-0002-3660-1276
FU National Natural Science Foundation of China [NSFC-30872113]
FX This work was funded by grant NSFC-30872113 from the National Natural
   Science Foundation of China.
CR Bhosale P, 2009, BIOCHEMISTRY-US, V48, P4798, DOI 10.1021/bi9004478
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P3452, DOI 10.1167/iovs.10-6713
   Elliott JG, 2012, OPTOMETRY, V83, P47, DOI 10.1016/j.optm.2011.11.006
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Kanis MJ, 2007, GRAEF ARCH CLIN EXP, V245, P767, DOI 10.1007/s00417-006-0478-0
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   KHACHIK F, 1992, J CHROMATOGR-BIOMED, V582, P153, DOI 10.1016/0378-4347(92)80314-G
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Lois N, 2000, BRIT J OPHTHALMOL, V84, P741, DOI 10.1136/bjo.84.7.741
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Woo JH, 2009, EYE, V23, P2271, DOI 10.1038/eye.2009.4
   Zou ZY, 2011, ATHEROSCLEROSIS, V219, P789, DOI 10.1016/j.atherosclerosis.2011.08.006
NR 32
TC 19
Z9 21
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0899-9007
J9 NUTRITION
JI Nutrition
PD FEB
PY 2013
VL 29
IS 2
BP 387
EP 392
DI 10.1016/j.nut.2012.06.009
PG 6
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 083DT
UT WOS:000314443600004
PM 23312760
DA 2022-11-30
ER

PT J
AU Fisher, DE
   Klein, BEK
   Wong, TY
   Rotter, JI
   Li, XH
   Shrager, S
   Burke, GL
   Klein, R
   Cotch, MF
AF Fisher, Diana E.
   Klein, Barbara E. K.
   Wong, Tien Y.
   Rotter, Jerome I.
   Li, Xiaohui
   Shrager, Sandi
   Burke, Gregory L.
   Klein, Ronald
   Cotch, Mary Frances
TI Incidence of Age-Related Macular Degeneration in a Multi-Ethnic United
   States Population The Multi-Ethnic Study of Atherosclerosis
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; BEAVER DAM EYE; NUTRITION EXAMINATION SURVEY;
   EVALUATION SEE PROJECT; BLUE MOUNTAINS EYE; RISK-FACTORS; 5-YEAR
   INCIDENCE; CARDIOVASCULAR-DISEASE; RACIAL/ETHNIC GROUPS;
   RACIAL-DIFFERENCES
AB Purpose: To describe the incidence of age-related macular degeneration (AMD) and associated risk factors in 4 racial/ethnic groups (white, black, Hispanic, and Chinese) residing in the United States.
   Design: Prospective cohort study.
   Participants: A total of 3811 participants, aged 46 to 86 years, from the Multi-Ethnic Study of Atherosclerosis (MESA) cohort, with retinal data collected twice, on average, 8 years apart.
   Methods: Fundus images, taken using a digital camera through dark-adapted pupils using a standard protocol and the same equipment at both study visits, were graded centrally for early and late AMD on the basis of drusen size, type and area, increased retinal pigment, retinal pigment epithelial depigmentation, neovascular lesions, and geographic atrophy using the modified Wisconsin Age-Related Maculopathy Grading System. Demographic, clinical, and laboratory measures were included in multivariable regression models to determine their impact on the variation in AMD incidence among racial/ethnic groups.
   Main Outcome Measures: Incident early and late AMD.
   Results: The overall 8-year age- and sex-standardized incidence of early and late AMD were 4.1% and 2.3%, respectively, with incidence of early and late AMD highest in whites (5.3% and 4.1%, respectively), intermediate in Chinese (4.5% and 2.2%, respectively) and Hispanics (3.3% and 0.8%, respectively), and lowest in blacks (1.6% and 0.4%, respectively). By adjusting for age and sex, blacks had a 70% lower risk of developing early AMD than whites, and this decreased only slightly to a 67% lower risk after multivariable adjustment. By adjusting for age, sex, and race/ethnicity, hyperopia was associated with early AMD (odds ratio [OR], 1.51; 95% confidence interval [CI], 1.04-2.20), as was astigmatism (OR, 1.47; 95% CI, 1.00-2.16), but not myopia (P = 0.29). Age, race/ethnicity, current smoking, hyperopia, and AMD-susceptibility genotypes Complement Factor H (CFH) RS1061170 and Age Related Maculopathy Susceptibility 2 (ARMS2) RS3793917 were independently associated with incident early AMD in multivariable models for the combined sample. However, the only statistically significant factor consistently associated with incident early AMD across the 4 racial/ethnic groups was increasing age. Risk factors for late AMD were not assessed because of its low incidence, particularly across racial/ethnic groups.
   Conclusions: Variation in the incidence of early AMD exists among racial/ethnic groups in the United States and is not explained by the clinical, genetic, and environmental factors included in this study. (C) 2016 Published by Elsevier on behalf of the American Academy of Ophthalmology.
C1 [Fisher, Diana E.; Cotch, Mary Frances] NEI, Div Epidemiol & Clin Applicat, Intramural Res Program, NIH, Bldg 10 CRC,Room 3-2521, Bethesda, MD 20892 USA.
   [Klein, Barbara E. K.; Klein, Ronald] Univ Wisconsin, Ophthalmol & Visual Sci, Madison, WI USA.
   [Wong, Tien Y.] Natl Univ Singapore, Ophthalmol & Visual Sci Acad Clin Program, Duke NUS Med Sch, Singapore 117548, Singapore.
   [Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Rotter, Jerome I.; Li, Xiaohui] Harbor UCLA Med Ctr, Inst Translat Genom & Populat Sci, Los Angeles BioMed Res Inst, Torrance, CA 90509 USA.
   [Rotter, Jerome I.; Li, Xiaohui] Harbor UCLA Med Ctr, Dept Pediat, Torrance, CA 90509 USA.
   [Shrager, Sandi] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Burke, Gregory L.] Wake Forest Sch Med, Div Publ Hlth Sci, Winston Salem, NC USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Wisconsin System; University of Wisconsin Madison;
   National University of Singapore; National University of Singapore;
   Singapore National Eye Center; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; Lundquist Institute; University of California
   System; University of California Los Angeles; University of California
   Los Angeles Medical Center; University of Washington; University of
   Washington Seattle; Wake Forest University
RP Fisher, DE (通讯作者)，NEI, Div Epidemiol & Clin Applicat, Intramural Res Program, NIH, Bldg 10 CRC,Room 3-2521, Bethesda, MD 20892 USA.
EM diana.fisher@nih.gov
RI Rotter, Jerome/AAY-6598-2021; Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cotch, Mary
   Frances/0000-0002-2046-4350
FU National Heart, Lung, and Blood Institute; National Institutes of Health
   Intramural Research Program [HL069979, ZIAEY000403];  [N01-HC-95159]; 
   [N01-HC-95160];  [N01-HC-95161];  [N01-HC-95162];  [N01-HC-95163]; 
   [N01-HC-95164];  [N01-HC-95165];  [N01-HC-95166];  [N01-HC-95167]; 
   [N01-HC-95168];  [N01-HC-95169];  [UL1-TR-001079];  [UL1-TR-000040]; 
   [DK063491];  [R01HL98077];  [N02-HL-64278];  [HL071205];  [UL1TR000124];
   [RD831697];  [P50 ES015915]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCES [UL1TR001079, UL1TR000124, UL1TR001420, UL1TR000040] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [ZIAEY000403] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [R43HL095167, R01HL064278, R01HL095163, R13HL095166, R21HL095165,
   R01HL098077, R43HL095161, R01HL069979, R01HL071205, R44HL095169,
   R43HL095160, R43HL095169] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK063491]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH
   SCIENCES [P50ES015915] Funding Source: NIH RePORTER
FX The Multi-Ethnic Study of Atherosclerosis (MESA) and the MESA SHARe
   project are conducted and supported by the National Heart, Lung, and
   Blood Institute in collaboration with MESA investigators. Support for
   MESA is provided by Contracts N01-HC-95159, N01-HC-95160, N01-HC-95161,
   N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166,
   N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-001079, UL1-TR-000040,
   and DK063491. Funding support for the eye datasets was provided by Grant
   HL069979 and an award from the National Institutes of Health Intramural
   Research Program ZIAEY000403. Cardiometabochip genotyping data were
   supported in part by Grants and Contracts R01HL98077, N02-HL-64278,
   HL071205, UL1TR000124, DK063491, RD831697, and P50 ES015915. The funders
   had no role in data collection, management, analysis and interpretation
   of the data, preparation, writing and approval of the manuscript, or
   decision to submit the manuscript for publication.
CR Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Chen K, 2014, ANN BIOMED ENG, V42, P678, DOI 10.1007/s10439-013-0936-x
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   Joachim N, 2014, INVEST OPHTH VIS SCI, V55, P4421, DOI 10.1167/iovs.14-14476
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2013, AM J OPHTHALMOL, V156, P1010, DOI 10.1016/j.ajo.2013.06.004
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Larson NB, 2015, ANN HUM GENET, V79, P264, DOI 10.1111/ahg.12119
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Leske MC, 2004, OPHTHALMOLOGY, V111, P706, DOI 10.1016/j.ophtha.2003.07.003
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Pan CW, 2013, OPHTHALMOLOGY, V120, P2058, DOI 10.1016/j.ophtha.2013.03.028
   Pan CW, 2013, AM J OPHTHALMOL, V155, P1129, DOI 10.1016/j.ajo.2013.01.009
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Stein JD, 2011, INVEST OPHTH VIS SCI, V52, P6842, DOI 10.1167/iovs.11-7179
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Varma R, 2010, AM J OPHTHALMOL, V149, P741, DOI 10.1016/j.ajo.2010.01.009
   Voight BF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002793
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 51
TC 34
Z9 35
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2016
VL 123
IS 6
BP 1297
EP 1308
DI 10.1016/j.ophtha.2015.12.026
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DM7BD
UT WOS:000376506400027
PM 26896123
OA Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Bailie, M
   Wolffsohn, JS
   Stevenson, M
   Jackson, AJ
AF Bailie, Maura
   Wolffsohn, James Stuart
   Stevenson, Michael
   Jackson, A. Jonathan
TI Functional and perceived benefits of wearing coloured filters by
   patients with age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE coloured filters; low vision; macular degeneration; tints; visual
   rehabilitation
ID WAVELENGTH ABSORBING FILTERS; CONTRAST SENSITIVITY; LOW-VISION; YELLOW
   FILTER; VISUAL PERFORMANCE; LENSES; GLASSES; D-15; EYE
AB Background: The aim was to investigate the visual effect of coloured filters compared to transmission-matched neutral density filters, in patients with dry age-related macular degeneration.
   Methods: Visual acuity (VA, logMAR), contrast sensitivity (Pelli-Robson) and colour vision (D15) were recorded for 39 patients (average age 79.1 +/- 7.2 years) with age-related macular degeneration, both in the presence and absence of glare from a fluorescent source. Patients then chose their preferred coloured and matched neutral density transmission filters (NoIR). Visual function tests were repeated with the chosen filters, both in the presence and absence of glare from the fluorescent source. Patients trialled the two filters for two weeks each, in random order. Following the trial of each filter, a telephone questionnaire was completed.
   Results: VA and contrast sensitivity were unaffected by the coloured filters but reduced through the neutral density filters (p < 0.01). VA and contrast sensitivity were reduced by similar amounts, following the introduction of the glare source, both in the presence and absence of filters (p < 0.001). Colour vision error scores were increased following the introduction of a neutral density filter (from 177.6 +/- 60.2 to 251.9 +/- 115.2) and still further through coloured filters (275.1 +/- 50.8; p < 0.001). In the absence of any filter, colour vision error scores increased by 29.1 +/- 55.60 units in the presence of glare (F-2,F-107 = 3.9, p = 0.02); however, there was little change in colour vision error scores, in the presence of glare, with either the neutral density or coloured filters. Questionnaires indicated that patients tended to gain more benefit from the coloured filters.
   Conclusions: Coloured filters had minimal impact on VA and contrast sensitivity in patients with age-related macular degeneration; however, they caused a small reduction in objective colour vision, although this was not registered subjectively by patients. Patients indicated that they received more benefit from the coloured filters compared with neutral density filters.
C1 [Bailie, Maura] Univ Ulster, Fac Life & Hlth Sci, Coleraine BT52 1SA, Londonderry, North Ireland.
   [Wolffsohn, James Stuart] Aston Univ, Sch Life & Hlth Sci, Ophthalm Res Grp, Birmingham B4 7ET, W Midlands, England.
   [Stevenson, Michael] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Stevenson, Michael] Australian Coll Optometry, Natl Vis Res Inst, Carlton, Vic, Australia.
   [Jackson, A. Jonathan] Queens Univ Belfast, Royal Victoria Hosp, Dept Ophthalmol, Belfast, Antrim, North Ireland.
C3 Ulster University; Aston University; Queens University Belfast; Queens
   University Belfast
RP Wolffsohn, JS (通讯作者)，Aston Univ, Sch Life & Hlth Sci, Ophthalm Res Grp, Birmingham B4 7ET, W Midlands, England.
EM j.s.w.wolffsohn@aston.ac.uk
RI Jackson, Jonathan/ABH-1264-2021
OI Jackson, Jonathan/0000-0003-4675-0272; Wolffsohn,
   James/0000-0003-4673-8927
CR AARNISALO E, 1987, ACTA OPHTHALMOL, V65, P274
   Barron C, 1987, J Am Optom Assoc, V58, P50
   BOWMAN KJ, 1982, ACTA OPHTHALMOL, V60, P907
   Coppens JE, 2006, EXP EYE RES, V82, P688, DOI 10.1016/j.exer.2005.09.007
   Department of Health, 2003, CERT VIS IMP EXPL NO
   Dickinson C., 1998, LOW VISION PRINCIPLE, P174
   Eperjesi F, 2002, OPHTHAL PHYSL OPT, V22, P68, DOI 10.1046/j.1475-1313.2002.00004.x
   Frennesson C, 1993, DOC OPHTHALMOL, V84, P135
   Hammond BR, 2010, CLIN OPHTHALMOL, V4, P1465, DOI 10.2147/OPTH.S15102
   Harper R, 1999, OPHTHAL PHYSL OPT, V19, P3, DOI 10.1046/j.1475-1313.1999.00411.x
   Kiser AK, 2005, OPTOMETRY VISION SCI, V82, P946, DOI 10.1097/01.opx.0000187863.12609.7b
   KUYK TK, 1990, OPTOMETRY VISION SCI, V67, P522, DOI 10.1097/00006324-199007000-00010
   LEAT SJ, 1990, OPHTHAL PHYSL OPT, V10, P219, DOI 10.1111/j.1475-1313.1990.tb00855.x
   Neumaier-Ammerer B, 2010, J CATARACT REFR SURG, V36, P2073, DOI 10.1016/j.jcrs.2010.06.069
   Niwa K, 1996, OPHTHAL PHYSL OPT, V16, P297, DOI 10.1046/j.1475-1313.1996.95001182.x
   Provines W F, 1997, J Am Optom Assoc, V68, P353
   RIEGER G, 1992, CAN J OPHTHALMOL, V27, P137
   Rosenblum YZ, 2000, OPHTHAL PHYSL OPT, V20, P335, DOI 10.1016/S0275-5408(00)00006-5
   STEEN R, 1993, OPHTHAL PHYSL OPT, V13, P371, DOI 10.1111/j.1475-1313.1993.tb00493.x
   THOMAS SR, 1988, AM J OPTOM PHYS OPT, V65, P697
   VANNES FL, 1967, J OPT SOC AM, V57, P401, DOI 10.1364/JOSA.57.000401
   Whitaker D, 1993, OPTOMETRY VISION SCI, V70, P93
   Wolffsohn JS, 2006, BRIT J OPHTHALMOL, V90, P432, DOI 10.1136/bjo.2005.085787
   Wolffsohn JS, 2002, OPHTHAL PHYSL OPT, V22, P300, DOI 10.1046/j.1475-1313.2002.00036.x
   YAP M, 1984, OPHTHAL PHYSL OPT, V4, P227, DOI 10.1111/j.1475-1313.1984.tb00360.x
   ZIGMAN S, 1990, OPTOMETRY VISION SCI, V67, P100, DOI 10.1097/00006324-199002000-00007
   ZIGMAN S, 1992, OPTOMETRY VISION SCI, V69, P325, DOI 10.1097/00006324-199204000-00012
NR 27
TC 7
Z9 8
U1 1
U2 30
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0816-4622
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD SEP
PY 2013
VL 96
IS 5
BP 450
EP 454
DI 10.1111/cxo.12031
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 209CE
UT WOS:000323730800003
PM 23472744
OA Bronze
DA 2022-11-30
ER

PT J
AU Chang, W
   Noh, DH
   Sagong, M
   Kim, IT
AF Chang, Woohyok
   Noh, Dong Hyoun
   Sagong, Min
   Kim, In Taek
TI Pharmacogenetic association with early response to intravitreal
   ranibizumab for age-related macular degeneration in a Korean population
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY; ENDOTHELIAL
   GROWTH-FACTOR; GENE POLYMORPHISM; PHENOTYPE; Y402H; RISK; VEGF;
   BEVACIZUMAB; MACULOPATHY
AB Purpose: To determine whether genetic factors that influence age-related macular degeneration (AMD) have an early pharmacogenetic effect on treating exudative AMD with ranibizumab in a Korean population.
   Methods: A retrospective study of 102 patients (70 with typical neovascular AMD and 32 with polypoidal choroidal vasculopathy) with exudative AMD treated with intravitreal ranibizumab monotherapy was conducted. Optical coherence tomography, fluorescein, and indocyanine green angiography were taken at the baseline. The best-corrected visual acuity (BCVA) and the central subfield macular thickness (CSMT) were recorded at the baseline and at each monthly visit. The genotypes of the polymorphisms in the known AMD susceptibility loci (CFH, AMRS2, HTRA1, VEGFA, and KDR) were determined, and association between their frequencies and the changes in the BCVA and the CSMT were evaluated.
   Results: The mean baseline visual acuity was 0.96 +/- 0.59 logMAR (approximately 20/200 in the Snellen equivalent), and the mean number of injections was 3.87 before the month 6 visit. No association was observed between the change in BCVA and each genotype. For the changes in the CSMT, a significant difference was observed only with the VEGF-A (rs833069) gene. The decrease in the CSMT at month 3 for the major allele homozygote AA genotype, the heterozygote AG genotype, and the risk allele homozygote GG genotype was 25.66 +/- 85.40, 86.93 +/- 92.31, and 85.30 +/- 105.30 mu m, respectively (p=0.012, p=0.044, and p=0.002 for AG, GG, and combined AG or GG genotype, respectively, compared to the AA genotype). This trend was maintained until month 6.
   Conclusions: The VEGF-A (rs833069) polymorphism showed a significant association with the anatomic response to intravitreal ranibizumab. No significant difference was found between the genotype of the potential risk polymorphism for development of AMD and the early visual improvement after intravitreal ranibizumab.
C1 [Chang, Woohyok; Noh, Dong Hyoun; Sagong, Min] Yeungnam Univ, Coll Med, Dept Ophthalmol, Taegu 705717, South Korea.
   [Kim, In Taek] Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Taegu, South Korea.
C3 Yeungnam University; Kyungpook National University
RP Chang, W (通讯作者)，Yeungnam Univ, Coll Med, Dept Ophthalmol, 317-1 Daemyoung Dong, Taegu 705717, South Korea.
EM changwh@ynu.ac.kr
FU Yeungnam University
FX This study was supported by a Yeungnam University research grant in
   2011. The authors have no financial conflicts of interest.
CR Bessho H, 2011, MOL VIS, V17, P977
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kim YM, 2012, AM J OPHTHALMOL, V154, P164, DOI 10.1016/j.ajo.2012.01.030
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Park DH, 2012, JPN J OPHTHALMOL, V56, P145, DOI 10.1007/s10384-012-0119-6
   Park DH, 2012, JPN J OPHTHALMOL, V56, P60, DOI 10.1007/s10384-011-0089-0
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sayed KM, 2011, GRAEF ARCH CLIN EXP, V249, P1449, DOI 10.1007/s00417-011-1672-2
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
NR 32
TC 25
Z9 29
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAR 21
PY 2013
VL 19
BP 702
EP 709
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 110BQ
UT WOS:000316417500007
PM 23559864
DA 2022-11-30
ER

PT J
AU Luttrull, JK
   Chang, DB
   Margolis, BWL
   Dorin, G
   Luttrull, DK
AF Luttrull, Jeffrey K.
   Chang, David B.
   Margolis, Benjamin W. L.
   Dorin, Giorgio
   Luttrull, David K.
TI LASER RESENSITIZATION OF MEDICALLY UNRESPONSIVE NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION Efficacy and Implications
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID MICROPULSE DIODE-LASER; PHOTOCOAGULATION; EDEMA; RANIBIZUMAB; RESPONSES;
   OUTCOMES; THERAPY; SAFETY; VEGF
AB Purpose:
   Drug tolerance is the most common cause of treatment failure in neovascular age-related macular degeneration. "Low-intensity/high-density" subthreshold diode micropulse laser (SDM) has been reported effective for a number of retinal disorders without adverse effects. It has been proposed that SDM normalizes retinal pigment epithelial function. On this basis, it has been postulated that SDM treatment might restore responsiveness to anti-vascular endothelial growth factor drugs in drug-tolerant eyes.
   Methods:
   Subthreshold diode micropulse laser treatment was performed in consecutive eyes unresponsive to all anti-vascular endothelial growth factor drugs, including at least three consecutive ineffective aflibercept injections. Monthly aflibercept was resumed 1 month after SDM treatment.
   Results:
   Thirteen eyes of 12 patients, aged 73 to 97 years (average, 84 years), receiving 16 to 67 (average, 34) anti-vascular endothelial growth factor injections before SDM treatment were included and followed for 3 months to 7 months (average, 5 months) after SDM treatment. After SDM treatment and resumption of aflibercept, 92% (12 of 13) of eyes improved, with complete resolution of macular exudation in 69% (9 of 13). Visual acuity remained unchanged. Central and maximum macular thicknesses significantly improved.
   Conclusion:
   Subthreshold diode micropulse laser treatment restored drug response in drug-tolerant eyes with neovascular age-related macular degeneration. Based on these findings, a theory of SDM action is proposed, suggesting a wider role for SDM as retinal reparative/protective therapy.
C1 [Luttrull, Jeffrey K.; Margolis, Benjamin W. L.; Dorin, Giorgio] EyEngineering Inc, Ojai, CA USA.
   [Chang, David B.] Magnetus, Tustin, CA USA.
   [Luttrull, David K.] Malcolm Grey LLC, Phoenix, AZ USA.
RP Luttrull, JK (通讯作者)，3160 Telegraph Rd,Suite 230, Ventura, CA 93003 USA.
EM jkluttrull@gmail.com
OI Margolis, Benjamin/0000-0001-5602-1888
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Baldwin RL, 2007, J MOL BIOL, V371, P283, DOI 10.1016/j.jmb.2007.05.078
   Beckham JT, 2008, THESIS VANDERBILT U
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Campochiaro PA, 2014, OPHTHALMOLOGY, V121, P209, DOI 10.1016/j.ophtha.2013.08.038
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Do DV, 2013, JAMA OPHTHALMOL, V131, P139, DOI 10.1001/2013.jamaophthalmol.91
   Dorin Giorgio, 2003, Semin Ophthalmol, V18, P147, DOI 10.1076/soph.18.3.147.29812
   Flaxel C, 2007, RETINA-J RET VIT DIS, V27, P629, DOI 10.1097/01.iae.0000249561.02567.fd
   Gao XJ, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-4
   Hattenbach LO, 2005, OPHTHALMIC RES, V37, P341, DOI 10.1159/000088263
   Iwami H, 2014, EXP EYE RES, V124, P37, DOI 10.1016/j.exer.2014.04.014
   Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355
   Kashiwagi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082899
   Kolomeyer AM, 2014, SURV OPHTHALMOL, V59, P134, DOI 10.1016/j.survophthal.2013.09.004
   Koss MJ, 2012, EYE, V26, P307, DOI 10.1038/eye.2011.282
   Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001
   Lavinsky D, 2011, INVEST OPHTH VIS SCI, V52, P4314, DOI 10.1167/iovs.10-6828
   Lund DJ, 2014, HEALTH PHYS, V106, P505, DOI 10.1097/HP.0b013e3182a2a837
   Luttrull JK, 2008, EYE, V22, P607, DOI 10.1038/sj.eye.6702725
   Luttrull JK, 2006, OPHTHAL SURG LAS IM, V37, P370, DOI 10.3928/15428877-20060901-03
   Luttrull JK, 2014, RETINA-J RET VIT DIS, V34, P2010, DOI 10.1097/IAE.0000000000000177
   Luttrull JK, 2012, CURR DIABETES REV, V8, P274, DOI 10.2174/157339912800840523
   Luttrull JK, 2012, RETINA-J RET VIT DIS, V32, P375, DOI 10.1097/IAE.0b013e3182206f6c
   Luttrull JK, 2005, BRIT J OPHTHALMOL, V89, P74, DOI 10.1136/bjo.2004.051540
   Miura Y, 2010, INVEST OPHTH VIS SCI, V51
   Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Roisman L, 2013, OSLI RETINA, V44, P465, DOI 10.3928/23258160-20130909-08
   Schatz A, 2011, INVEST OPHTH VIS SCI, V52, P4485, DOI 10.1167/iovs.10-6932
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P1045, DOI 10.1016/j.ophtha.2013.11.041
   Sivaprasad S, 2007, CLIN EXP OPHTHALMOL, V35, P640, DOI 10.1111/j.1442-9071.2007.01566.x
   Smiddy WE, 2011, OPHTHALMOLOGY, V118, P1827, DOI 10.1016/j.ophtha.2010.12.034
   Sramek C, 2011, INVEST OPHTH VIS SCI, V52, P1780, DOI 10.1167/iovs.10-5917
   Tolstoy Leo, A KARENINA
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Vujosevic S, 2010, RETINA-J RET VIT DIS, V30, P908, DOI 10.1097/IAE.0b013e3181c96986
   Wang Y, 2012, NAT MED, V18, P385, DOI 10.1038/nm.2633
NR 39
TC 27
Z9 39
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2015
VL 35
IS 6
BP 1184
EP 1194
DI 10.1097/IAE.0000000000000458
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CJ7KJ
UT WOS:000355673600018
PM 25650711
DA 2022-11-30
ER

PT J
AU Nakai, S
   Matsumiya, W
   Miki, A
   Honda, S
   Nakamura, M
AF Nakai, Shunichiro
   Matsumiya, Wataru
   Miki, Akiko
   Honda, Shigeru
   Nakamura, Makoto
TI Association of an age-related maculopathy susceptibility 2 gene variant
   with the 12-month outcomes of intravitreal aflibercept combined with
   photodynamic therapy for polypoidal choroidal vasculopathy
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Combination; Aflibercept; Photodynamic therapy; Polymorphism; 12 month
   outcome
ID COMPLEMENT-FACTOR-H; MACULAR DEGENERATION; ANGIOGRAPHIC SUBTYPES; VISUAL
   PROGNOSIS; ARMS2; CFH; RANIBIZUMAB; COMBINATION; MULTICENTER;
   PROGRESSION
AB Purpose To determine the association of age-related maculopathy susceptibility 2 (ARMS2) gene polymorphisms with the 12-month outcomes of intravitreal aflibercept combined with photodynamic therapy (IVA+PDT) in polypoidal choroidal vasculopathy (PCV). Study design Interventional cohort study. Methods This was a retrospective study of 48 consecutive treatment-naive PCV patients. The patients underwent IVA+PDT as the initial therapy and were followed up for more than 12 months under a pro re nata regimen. The single nucleotide polymorphism (SNP) at rs10490924 in the ARMS2 gene was genotyped using the TaqMan assay. The clinical characteristics and outcomes of IVA+PDT were compared among the 3 genotypes at rs10490924. Multivariate regression analysis was performed to evaluate the influence of the clinical cofactors on the association of rs10490924 with the visual outcome at 12 months after the first IVA+PDT. Results No significant difference was found in the baseline characteristics among the 3 genotypes (n = 9, 23, and 16 for the GG, GT, and TT genotypes, respectively). All the patients, regardless of genotype, showed a significant improvement in vision, central retinal thickness, and subfoveal choroidal thickness at all time points measured after the initial IVA+PDT. The number of treatments was significantly smaller in the patients with the GG genotype than in those with the GT or the TT genotype. On multivariate logistic regression analysis, the number of the T allele at rs10490924 was significantly associated with the chance of retreatment after the initial IVA+PDT. Conclusion The presence of the G allele at rs10490924 in the ARMS2 gene is likely associated with a lower chance of retreatment after IVA+PDT in patients with PCV.
C1 [Nakai, Shunichiro; Matsumiya, Wataru; Miki, Akiko; Honda, Shigeru; Nakamura, Makoto] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
   [Honda, Shigeru] Osaka City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.
C3 Kobe University; Osaka Metropolitan University
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.; Honda, S (通讯作者)，Osaka City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.
EM honda.shigeru@med.osaka-cu.ac.jp
OI Nakamura, Makoto/0000-0002-6464-4302
FU Japan Society for the Promotion of Science [16K11286]
FX this study was supported by a grant-in aid (C) (16K11286 to S. H.) from
   the Japan Society for the Promotion of Science. The funding organization
   had no role in the design or conduct of this research.
CR Alexandru Malciolu Radu, 2016, Rom J Ophthalmol, V60, P9
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Bessho H, 2011, MOL VIS, V17, P977
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brunicardi FC, 2011, WORLD J SURG, V35, P1693, DOI 10.1007/s00268-011-1056-0
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Enslow R, 2016, OPHTHALMOL EYE DIS, V8, P31, DOI 10.4137/OED.S38863
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hara C, 2016, RETINA-J RET VIT DIS, V36, P37, DOI 10.1097/IAE.0000000000000767
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Honda S, 2014, OPHTHALMOLOGICA, V232, P92, DOI 10.1159/000360308
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Hu ZZ, 2015, BRIT J OPHTHALMOL, V99, P593, DOI 10.1136/bjophthalmol-2014-305488
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/srep44020
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumiya W, 2017, GRAEF ARCH CLIN EXP, V255, P541, DOI 10.1007/s00417-016-3500-1
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   Nakai S, 2017, MOL VIS, V23, P514
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Saito M, 2017, JPN J OPHTHALMOL, V61, P74, DOI 10.1007/s10384-016-0478-5
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   She HC, 2008, INVEST OPHTH VIS SCI, V49, P5008, DOI 10.1167/iovs.07-1154
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Tsujikawa A, 2018, JPN J OPHTHALMOL, V62, P127, DOI 10.1007/s10384-017-0556-3
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   van den Bergh H, 2001, Semin Ophthalmol, V16, P181, DOI 10.1076/soph.16.4.181.10299
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
NR 38
TC 5
Z9 5
U1 0
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD SEP
PY 2019
VL 63
IS 5
BP 389
EP 395
DI 10.1007/s10384-019-00683-6
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IU6NF
UT WOS:000483702300005
PM 31376050
DA 2022-11-30
ER

PT J
AU Nagai, N
   Ibuki, M
   Shinoda, H
   Kameyama, K
   Tsubota, K
   Ozawa, Y
AF Nagai, Norihiro
   Ibuki, Mari
   Shinoda, Hajime
   Kameyama, Kaori
   Tsubota, Kazuo
   Ozawa, Yoko
TI Maculopapular rash after intravitreal injection of an antivascular
   endothelial growth factor, aflibercept, for treating age-related macular
   degeneration A case report
SO MEDICINE
LA English
DT Article
DE age-related macular degeneration; anti-VEGF drug; maculopapular rash
ID SAFETY; RANIBIZUMAB; EFFICACY
AB Rationale: Aflibercept, an anti-vascular endothelial growth factor (VEGF) drug, is used for treatment of colon cancer as well as retinal diseases, including wet age-related macular degeneration (AMD). It is injected into the vitreous cavity of eyes for treatment of AMD. Although vascular suppression-including cardiovascular events-and local infection related to the injection procedure are well-known potential adverse events, pathological immune responses after intravitreal aflibercept (IVA) injection have not been described.
   Patientconcerns: A 60-year-old Japanese man diagnosed with polypoidal choroidal vasculopathy (PCV), a subtype of wet AMD, was treated by anti-VEGF injection. Ten hours after the last IVA injection, he presented with systemic erythema with itching.
   Diagnoses: On the basis of the palpable erythema and papules observed on the trunk and extremities, along with redness of the pharynx, the patient was diagnosed with maculopapular-type drug eruption. The findings of biopsy of erythematous skin on the back revealed lymphocyte infiltration and telangiectasia in the upper dermis, thus confirming the diagnosis.
   Interventions: The patient was administered 30 mg prednisolone to resolve the immunoreaction.
   Outcomes: With this treatment, the eruption turned brown, and the pharyngeal lesion and itching were resolved, and the maculopapular rash after intravitreal IVA was resolved.
   Lessons: This case illustrates the importance of medical staff being aware of aflibercept-a widely used anti-VEGF drug in various fields, including retinal diseases-as a potential cause of drug allergy.
C1 [Nagai, Norihiro; Ozawa, Yoko] Keio Univ, Lab Retinal Cell Biol, Sch Med, Shinjuku Ku, Tokyo, Japan.
   [Nagai, Norihiro; Ibuki, Mari; Shinoda, Hajime; Tsubota, Kazuo; Ozawa, Yoko] Keio Univ, Dept Ophthalmol, Sch Med, Shinjuku Ku, Tokyo, Japan.
   [Kameyama, Kaori] Keio Univ, Dept Pathol, Sch Med, Shinjuku Ku, Tokyo, Japan.
C3 Keio University; Keio University; Keio University
RP Ozawa, Y (通讯作者)，Keio Univ, Lab Retinal Cell Biol, Dept Ophthalmol, Sch Med,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM ozawa@a5.keio.jp
RI Ozawa, Yoko/AAH-9888-2020; Tsubota, Kazuo/M-1915-2013
OI Tsubota, Kazuo/0000-0002-8874-7111
CR Bosanquet DC, 2011, INT WOUND J, V8, P317, DOI 10.1111/j.1742-481X.2011.00799.x
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cleaver N, 2013, J DRUGS DERMATOL, V12, P1052
   Giordano G, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/526178
   Hansel TT, 2010, NAT REV DRUG DISCOV, V9, P325, DOI 10.1038/nrd3003
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Macdonald JB, 2015, J AM ACAD DERMATOL, V72, P203, DOI 10.1016/j.jaad.2014.07.032
   Macdonald JB, 2015, J AM ACAD DERMATOL, V72, P221, DOI 10.1016/j.jaad.2014.07.033
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Morito H, 2014, CLIN EXP DERMATOL, V39, P284, DOI 10.1111/ced.12246
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Syed YY, 2015, DRUGS, V75, P1435, DOI 10.1007/s40265-015-0444-4
   Terme M, 2013, CANCER RES, V73, P539, DOI 10.1158/0008-5472.CAN-12-2325
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 17
TC 6
Z9 6
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAY
PY 2017
VL 96
IS 21
AR e6965
DI 10.1097/MD.0000000000006965
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EW1JE
UT WOS:000402245300033
PM 28538392
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Semba, RD
   Cotch, MF
   Gudnason, V
   Eiriksdottir, G
   Harris, TB
   Sun, K
   Klein, R
   Jonasson, F
   Ferrucci, L
   Schaumberg, DA
AF Semba, Richard D.
   Cotch, Mary Frances
   Gudnason, Vilmundur
   Eiriksdottir, Gudny
   Harris, Tamara B.
   Sun, Kai
   Klein, Ronald
   Jonasson, Fridbert
   Ferrucci, Luigi
   Schaumberg, Debra A.
TI Serum Carboxymethyllysine, an Advanced Glycation End Product, and
   Age-Related Macular Degeneration The Age, Gene/Environment
   Susceptibility-Reykjavik Study
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; RISK-FACTORS; POOLED FINDINGS; LYSINE;
   ACCUMULATION; MACULOPATHY; ENDPRODUCTS; PENTOSIDINE; PREVALENCE;
   SEVERITY
AB IMPORTANCE Advanced glycation end products have been implicated in the pathogenesis of age-related macular degeneration (AMD).
   OBJECTIVE To investigate the relationship between serum carboxymethyllysine (CML), a major circulating advanced glycation end product, and AMD in older adults.
   DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study of a population-based sample of 4907 older adults (aged-66 years) in the Age, Gene/Environment Susceptibility-Reykjavik Study in Iceland.
   EXPOSURES Serum CML and risk factors for AMD.
   MAIN OUTCOMES AND MEASURES Early or late AMD, assessed through fundus images taken through dilated pupils using a 45 digital camera and grading for drusen size, type, area, increased retinal pigment, retinal pigment epithelial depigmentation, neovascular lesions, and geographic atrophy using the modified Wisconsin Age-Related Maculopathy Grading System.
   RESULTS Of the 4907 participants, 1025 (20.9%) had early AMD and 276 (5.6%) had late AMD. Mean (SD) serum CML concentrations among adults with no AMD, early AMD, and late AMD (exudative AMD and pure geographic atrophy) were 618.8 (195.5), 634.2 (206.4), and 638.4 (192.0) ng/mL, respectively (to convert to micromoles per liter, multiply by 0.00489; P =.07). Log serum CML (per 1-SD increase) was not associated with any AMD (early and late AMD) (odds ratio = 0.97; 95% CI, 0.90-1.04; P=.44) or with late AMD (odds ratio =0.94; 95% CI, 0.82-1.08; P =.36) in respective multivariable logistic regression models adjusting for age, sex, body mass index, smoking, and renal function.
   CONCLUSIONS AND RELEVANCE Higher serum CML concentration had no significant cross-sectional association with prevalent AMD in this large population-based cohort of older adults in Iceland.
C1 [Semba, Richard D.; Sun, Kai] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
   [Cotch, Mary Frances] NEI, Div Epidemiol & Clin Res, Bethesda, MD 20892 USA.
   [Gudnason, Vilmundur; Eiriksdottir, Gudny] Iceland Heart Assoc, Reykjavik, Iceland.
   [Gudnason, Vilmundur; Jonasson, Fridbert] Univ Iceland, Dept Med, Reykjavik, Iceland.
   [Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Bethesda, MD 20892 USA.
   [Klein, Ronald] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
   [Jonasson, Fridbert] Landspitali Univ Hosp, Dept Ophthalmol, Reykjavik, Iceland.
   [Ferrucci, Luigi] NIA, Longitudinal Studies Sect, Baltimore, MD 21224 USA.
   [Schaumberg, Debra A.] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Ctr Translat Med, Salt Lake City, UT USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); Icelandic Heart
   Association; University of Iceland; National Institutes of Health (NIH)
   - USA; NIH National Institute on Aging (NIA); University of Wisconsin
   System; University of Wisconsin Madison; Landspitali National University
   Hospital; National Institutes of Health (NIH) - USA; NIH National
   Institute on Aging (NIA); Utah System of Higher Education; University of
   Utah
RP Semba, RD (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 400 N Broadway,Smith Bldg,M015, Baltimore, MD 21287 USA.
EM rdsemba@jhmi.edu
RI Jonasson, Fridbert/ABA-9889-2021; Gudnason, Vilmundur/AAE-7126-2019;
   Gudnason, Vilmundur/K-6885-2015
OI Gudnason, Vilmundur/0000-0001-5696-0084; Gudnason,
   Vilmundur/0000-0001-5696-0084; Cotch, Mary Frances/0000-0002-2046-4350
FU National Institutes of Health [R01 AG027012, R01 EY017362]; Intramural
   Research Program of the National Eye Institute [ZIAEYO0401]; Intramural
   Research Program of the National Institute on Aging [NO1-AG-1-2100];
   Icelandic Heart Association; Icelandic Parliament; University of Iceland
   Research Fund; Research to Prevent Blindness; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCES [UL1TR001079] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY017362, ZIAEY000401] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027012,
   ZIAAG007380] Funding Source: NIH RePORTER
FX This work was supported by grants R01 AG027012 and R01 EY017362 from the
   National Institutes of Health, grant ZIAEYO0401 from the Intramural
   Research Program of the National Eye Institute, grant NO1-AG-1-2100 from
   the Intramural Research Program of the National Institute on Aging, the
   Icelandic Heart Association, the Icelandic Parliament, the University of
   Iceland Research Fund, and a Lew Wasserman Merit Award to Dr Semba from
   Research to Prevent Blindness.
CR AMD Alliance International, GLOB EC COST VIS IMP
   Boehm BO, 2004, DIABETOLOGIA, V47, P1376, DOI 10.1007/s00125-004-1455-y
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Handa J. T., 1998, IOVS, V39, pS370
   Harris TB, 2007, AM J EPIDEMIOL, V165, P1076, DOI 10.1093/aje/kwk115
   Hirata K, 2004, ENDOCR J, V51, P537, DOI 10.1507/endocrj.51.537
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kilhovd BK, 2007, DIABETOLOGIA, V50, P1409, DOI 10.1007/s00125-007-0687-z
   Kilhovd BK, 2003, METABOLISM, V52, P163, DOI 10.1053/meta.2003.50035
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Leveziel N, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000328981
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   Miura J, 2003, J DIABETES COMPLICAT, V17, P16, DOI 10.1016/S1056-8727(02)00183-6
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Piroddi M, 2011, J RENAL NUTR, V21, P329, DOI 10.1053/j.jrn.2010.06.024
   Qiu CX, 2008, DIABETES, V57, P1645, DOI 10.2337/db07-1455
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schleicher ED, 1997, J CLIN INVEST, V99, P457, DOI 10.1172/JCI119180
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Semba RD, 2012, EUR J CLIN NUTR, V66, P3, DOI 10.1038/ejcn.2011.139
   Semba RD, 2010, J NUTR HEALTH AGING, V14, P507, DOI 10.1007/s12603-010-0105-y
   Semba RD, 2010, J GERONTOL A-BIOL, V65, P963, DOI 10.1093/gerona/glq074
   Sharp PS, 2003, DIABETIC MED, V20, P575, DOI 10.1046/j.1464-5491.2003.00973.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang XH, 2005, CLIN CHEM LAB MED, V43, P503, DOI 10.1515/CCLM.2005.089
NR 42
TC 14
Z9 14
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD APR
PY 2014
VL 132
IS 4
BP 464
EP 470
DI 10.1001/jamaophthalmol.2013.7664
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ7QF
UT WOS:000337890500013
PM 24481410
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Teh, BL
   Megaw, R
   Borooah, S
   Dhillon, B
AF Teh, Boon Lin
   Megaw, Roly
   Borooah, Shyamanga
   Dhillon, Baljean
TI Optimizing cataract surgery, in patients with age-related macular
   degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE cataract; cataract surgery; age-related macular degeneration;
   intraocular lens; intravitreal antivascular endothelial; growth factor
   injection
ID IMPLANTABLE MINIATURE TELESCOPE; FILTERING INTRAOCULAR LENSES;
   INTRAVITREAL TRIAMCINOLONE ACETONIDE; BLUE MOUNTAINS EYE; VISUAL-ACUITY;
   CONTRAST SENSITIVITY; RISK-FACTORS; PHOTODYNAMIC THERAPY; SAFETY
   OUTCOMES; SEVERITY SCALE
AB Age-related macular degeneration (AMD) is one of the leading causes of visual impairment. The development of cataract in AMD patients poses challenges in assessing timing of surgery, predicting potential benefit to the patient of surgery, and predicting short- and long-term effects of surgery on progression of their AMD. Although traditional cataract surgery remains the mainstay of treatment, recently several devices have been developed to address the specific needs of AMD patients with cataract. We look at the associations between cataract and AMD and outline the treatment approaches to cataract surgery in AMD, looking at the potential benefits and risks of both traditional approaches and newer devices. We provide clinicians treating patients with AMD and cataract with a framework for choosing the appropriate management. Crown Copyright (C) 2016 Published by Elsevier Inc. All rights reserved.
C1 [Teh, Boon Lin] Royal Infirm Edinburgh NHS Trust, 51 Little France Crescent, Edinburgh EH16 4SA, Midlothian, Scotland.
   [Megaw, Roly; Borooah, Shyamanga; Dhillon, Baljean] Princess Alexandra Eye Pavil, Edinburgh, Midlothian, Scotland.
   [Dhillon, Baljean] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland.
C3 Royal Infirmary of Edinburgh; University of Edinburgh; University of
   Edinburgh
RP Teh, BL (通讯作者)，Royal Infirm Edinburgh NHS Trust, 51 Little France Crescent, Edinburgh EH16 4SA, Midlothian, Scotland.
EM boonlinteh@gmail.com
RI Borooah, Shyamanga/AAM-6581-2021
OI Megaw, Roly/0000-0001-5605-4540
CR AARNISALO EA, 1988, AM J OPHTHALMOL, V105, P408, DOI 10.1016/0002-9394(88)90307-8
   Agarwal A, 2007, OCUL SURG NEWS EUROP
   Agarwal A, 2009, KERALA J OPHTHALMOL, VXXI, P375
   Agarwal A, 2008, J CATARACT REFR SURG, V34, P87, DOI 10.1016/j.jcrs.2007.08.031
   Ahmad BU, 2014, RETINA-J RET VIT DIS, V34, P1046, DOI 10.1097/IAE.0000000000000237
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Amselem L, 2008, J CATARACT REFR SURG, V34, P1571, DOI 10.1016/j.jcrs.2008.05.032
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Avery Robert L, 2014, Retina, V34 Suppl 12, pS1, DOI 10.1097/IAE.0000000000000399
   Baatz H, 2009, INVEST OPHTH VIS SCI, V49, P1079
   Banta James T, 2012, Int Ophthalmol Clin, V52, P73, DOI 10.1097/IIO.0b013e31824b3ed3
   Bellucci R, 2005, J CATARACT REFR SURG, V31, P712, DOI 10.1016/j.jcrs.2004.08.049
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   Bethke W., 2008, REV OPHTHALMOL, VXV
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Boyer D, 2015, CLIN OPHTHALMOL, V9, P1099, DOI 10.2147/OPTH.S86208
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Cajochen C, 2005, J CLIN ENDOCR METAB, V90, P1311, DOI 10.1210/jc.2004-0957
   Casparis H, 2012, COCHRANE DB SYST REV, V6
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Colby KA, 2007, ARCH OPHTHALMOL-CHIC, V125, P1118, DOI 10.1001/archopht.125.8.1118
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Vries NE, 2013, J CATARACT REFR SURG, V39, P268, DOI 10.1016/j.jcrs.2012.12.002
   Demirel S., 2015, RET VIT, V23, P26
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Furino C, 2009, J CATARACT REFR SURG, V35, P1518, DOI 10.1016/j.jcrs.2009.04.032
   Gayton JL, 2012, J CATARACT REFR SURG, V38, P415, DOI 10.1016/j.jcrs.2011.12.022
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Hahn P, 2016, OPHTHALMOLOGY, V123, P309, DOI 10.1016/j.ophtha.2015.06.040
   Hayashi K, 2006, BRIT J OPHTHALMOL, V90, P1019, DOI 10.1136/bjo.2006.090712
   Hengerer FH, 2015, J REFRACT SURG, V31, P158, DOI 10.3928/1081597X-20150220-03
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   Huang K, 2015, J CLIN RES OPHTHALMO, V2, P036
   Hudson HL, 2008, AM J OPHTHALMOL, V146, P664, DOI 10.1016/j.ajo.2008.07.003
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   Jacob S, 2008, EUROTIMES, V13, P41
   Jacob S, EUROTIMES, V17
   Jonas JB, 2005, EUR J OPHTHALMOL, V15, P462, DOI 10.1177/112067210501500407
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2007, J OCUL PHARMACOL TH, V23, P599, DOI 10.1089/jop.2007.0050
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Kara N, 2011, J CATARACT REFR SURG, V37, P2115, DOI 10.1016/j.jcrs.2011.06.024
   Kernt M, 2012, CLIN EXP OPHTHALMOL, V40, pE87, DOI 10.1111/j.1442-9071.2011.02620.x
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Lane SS, 2004, AM J OPHTHALMOL, V137, P993, DOI 10.1016/j.ajo.2004.01.030
   Lavric A, 2014, OPTOMETRY VISION SCI, V91, P1348, DOI 10.1097/OPX.0000000000000390
   Lim JI, 2015, BRIT J OPHTHALMOL, V99, P618, DOI 10.1136/bjophthalmol-2014-306002
   Lin MY, 2004, J AM GERIATR SOC, V52, P1996, DOI 10.1111/j.1532-5415.2004.52554.x
   Lipshitz I, 1997, OPHTHALMIC SURG LAS, V28, P513
   Lipshitz I., 2015, EUR OPHTHALMIC REV, V9, P159, DOI DOI 10.17925/EOR.2015.09.02.159
   Lipshitz I., 2013, OCUL SURG NEWS US ED
   Lu Lawrence P. L., 2007, Hong Kong Medical Journal, V13, P460
   Mainster MA, 2006, BRIT J OPHTHALMOL, V90, P784, DOI 10.1136/bjo.2005.086553
   Medical Advisory Secretariat, 2009, Ont Health Technol Assess Ser, V9, P1
   Mester U, 2008, J REFRACT SURG, V24, P817, DOI 10.3928/1081597X-20081001-09
   Muzyka-Wozniak M, 2011, EUR J OPHTHALMOL, V21, P766, DOI 10.5301/EJO.2011.6389
   Huynh N, 2014, OPHTHALMOLOGY, V121, P1229, DOI 10.1016/j.ophtha.2013.12.035
   Orzalesi N, 2007, OPHTHALMOLOGY, V114, P860, DOI 10.1016/j.ophtha.2007.01.005
   OTHER CITED MATERIAL A, 2010, J CLIN ENG, V35, P166
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pham TQ, 2004, CLIN EXP OPHTHALMOL, V32, P383, DOI 10.1111/j.1442-9071.2004.00842.x
   Pierre A, 2007, J CATARACT REFR SURG, V33, P1248, DOI 10.1016/j.jcrs.2007.03.024
   Pipis A, 2015, EUR J OPHTHALMOL, V25, P128, DOI 10.5301/ejo.5000520
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Qian CX, 2014, SEMIN OPHTHALMOL, V29, P301, DOI 10.3109/08820538.2014.962166
   Qureshi MA, 2015, J CATARACT REFR SURG, V41, P2125, DOI 10.1016/j.jcrs.2015.03.021
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Santarelli M, 2015, EXPERT OPIN PHARMACO, V16, P1769, DOI 10.1517/14656566.2015.1067679
   Saraf SS, 2015, AM J OPHTHALMOL, V160, P487, DOI 10.1016/j.ajo.2015.06.006
   Shentu XC, 2008, CLIN EXP OPHTHALMOL, V36, P620, DOI 10.1111/j.1442-9071.2008.01856.x
   Elias FTS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139556
   Singer MA, 2012, CLIN OPHTHALMOL, V6, P33, DOI 10.2147/OPTH.S15028
   Smith AF, 2010, BRIT J OPHTHALMOL, V94, P1116, DOI 10.1136/bjo.2010.179945
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   Stock MV, 2015, INVEST OPHTH VIS SCI, V56, P2536, DOI 10.1167/iovs.14-16069
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
   Tabernero J, 2015, BIOMED OPT EXPRESS, V6, P1010, DOI 10.1364/BOE.6.001010
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   Wang JJ, 2012, OPHTHALMOLOGY, V119, P2298, DOI 10.1016/j.ophtha.2012.07.003
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wirtitsch MG, 2009, OPHTHALMOLOGY, V116, P39, DOI 10.1016/j.ophtha.2008.08.035
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yoshizawa C, 2013, JPN J OPHTHALMOL, V57, P68, DOI 10.1007/s10384-012-0206-8
   Zeng MB, 2007, CLIN EXP OPHTHALMOL, V35, P355, DOI 10.1111/j.1442-9071.2007.01452.x
NR 100
TC 14
Z9 14
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2017
VL 62
IS 3
BP 346
EP 356
DI 10.1016/j.survophthal.2016.12.003
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ET5JA
UT WOS:000400318800007
PM 28012877
DA 2022-11-30
ER

PT J
AU Montgomery, MP
   Kamel, F
   Pericak-Vance, MA
   Haines, JL
   Postel, EA
   Agarwal, A
   Richards, M
   Scott, WK
   Schmidt, S
AF Montgomery, Martha P.
   Kamel, Freya
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
   Postel, Eric A.
   Agarwal, Anita
   Richards, Marie
   Scott, William K.
   Schmidt, Silke
TI Overall Diet Quality and Age-Related Macular Degeneration
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE AHEI alternate healthy eating index; AMD age-related macular
   degeneration; HEI healthy eating index
ID MAJOR CHRONIC DISEASE; GUIDELINES-FOR-AMERICANS; HEALTHY EATING INDEX;
   MEDITERRANEAN DIET; PRIMARY PREVENTION; FISH INTAKE; RISK; ADHERENCE;
   LUTEIN; FAT
AB Purpose: To examine overall diet quality in relation to advanced age-related macular degeneration (AMD).
   Methods: This case-control study identified 437 advanced AMD patients and 259 unrelated controls using stereoscopic color fundus photographs. Participants were predominantly non-Hispanic White men and women from North Carolina and Tennessee. A 97-item Block food frequency questionnaire was used to gather diet information, and overall diet quality was measured using the Healthy Eating Index (HEI) and Alternate Healthy Eating Index (AHEI).
   Results: Participants in the highest quartile of diet quality had significantly reduced odds of AMD according to the AHEI score (0.54, 95% confidence interval 0.30-0.99) and non-significantly reduced odds of AMD according to the HEI (0.75, 0.41-1.38). Odds of AMD were also 51% lower in the highest quartile of fish intake compared to the lowest quartile (odds ratio = 0.49, 0.26-0.90).
   Conclusions: We found that advanced AMD was significantly related to overall diet quality. The AHEI score may be a useful instrument for assessing AMD risk due to diet, and it could potentially be improved by incorporating more specific information regarding micronutrient intake.
C1 [Schmidt, Silke] Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC 27710 USA.
   [Montgomery, Martha P.; Kamel, Freya; Scott, William K.] Natl Inst Environm Hlth Sci, Epidemiol Branch, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC USA.
   [Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, Dept Human Genet, Dr John T Macdonald Fdn, Miami, FL 33136 USA.
   [Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, Inst Human Genom, Miami, FL 33136 USA.
   [Haines, Jonathan L.] Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
   [Postel, Eric A.] Duke Univ, Ctr Eye, Durham, NC 27710 USA.
   [Postel, Eric A.] Duke Univ, Dept Ophthalmol, Med Ctr, Durham, NC 27710 USA.
   [Agarwal, Anita] Vanderbilt Univ, Med Ctr, Vanderbilt Eye Ctr, Nashville, TN USA.
   [Richards, Marie] WESTAT Corp, Durham, NC USA.
C3 Duke University; National Institutes of Health (NIH) - USA; NIH National
   Institute of Environmental Health Sciences (NIEHS); University of Miami;
   University of Miami; Vanderbilt University; Duke University; Duke
   University; Vanderbilt University; Westat
RP Schmidt, S (通讯作者)，Duke Univ, Med Ctr, Ctr Human Genet, Box 3445, Durham, NC 27710 USA.
EM silke.schmidt@duke.edu
RI Haines, Jonathan/C-3374-2012
OI Haines, Jonathan/0000-0002-4351-4728; Scott,
   William/0000-0001-9336-6404; Kamel, Freya/0000-0001-5052-6615
FU National Eye Institute, National Institutes of Health (NIH) [EY12118];
   National Institute of Environmental Health Sciences; General Clinical
   Research Center [RR 00095]; NATIONAL CENTER FOR RESEARCH RESOURCES
   [M01RR000095] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [U10EY012118, R01EY012118] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES049030] Funding Source:
   NIH RePORTER
FX William K. Scott and Silke Schmidt are co-senior authors. This study was
   supported by grant EY12118 from the National Eye Institute, National
   Institutes of Health (NIH) and in part by the Intramural Research
   Program of the NIH, National Institute of Environmental Health Sciences.
   It was also supported in part by a General Clinical Research Center
   award (RR 00095) to Vanderbilt University. We express our appreciation
   to all the participants and their relatives who generously participated
   in the study We thank Kristen Hutchins, Dr. Monica de la Paz, Jennifer
   Caldwell, Ruth Domurath, Maureen Shaw, and Jason Galloway for
   participant ascertainment and data management. Drs. Scott and Schmidt
   had full access to all the data in the study and take responsibility for
   the integrity of the data and the accuracy of the data analysis.
CR Bartlett HE, 2007, EUR J CLIN NUTR, V61, P1121, DOI 10.1038/sj.ejcn.1602626
   Basiotis P., 2002, HLTH EATING INDEX 19
   BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   Dubois L, 2000, PUBLIC HEALTH NUTR, V3, P357, DOI 10.1017/S1368980000000409
   Fung TT, 2005, AM J CLIN NUTR, V82, P163
   Gerber MJ, 2000, J AM DIET ASSOC, V100, P1164, DOI 10.1016/S0002-8223(00)00340-0
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Haines PS, 1999, J AM DIET ASSOC, V99, P697, DOI 10.1016/S0002-8223(99)00168-6
   Hann CS, 2001, AM J CLIN NUTR, V74, P479
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KENNEDY ET, 1995, J AM DIET ASSOC, V95, P1103, DOI 10.1016/S0002-8223(95)00300-2
   Kim S, 2003, J NUTR, V133, P3476, DOI 10.1093/jn/133.11.3476
   McCullough ML, 2000, AM J CLIN NUTR, V72, P1223
   McCullough ML, 2000, AM J CLIN NUTR, V72, P1214
   McCullough ML, 2006, PUBLIC HEALTH NUTR, V9, P152, DOI 10.1079/PHN2005938
   McCullough ML, 2002, AM J CLIN NUTR, V76, P1261, DOI 10.1093/ajcn/76.6.1261
   Morris MS, 2007, OPHTHAL EPIDEMIOL, V14, P288, DOI 10.1080/09286580601186759
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   PATTERSON RE, 1994, J AM DIET ASSOC, V94, P57, DOI 10.1016/0002-8223(94)92042-7
   Postel EA, 2005, AM J OPHTHALMOL, V139, P820, DOI 10.1016/j.ajo.2004.12.029
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schmidt S, 2000, MOL VIS, V6, P287
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2007, AM J CLIN NUTR, V85, p304S, DOI 10.1093/ajcn/85.1.304S
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457
   Trichopoulou A, 2005, BMJ-BRIT MED J, V330, P991, DOI 10.1136/bmj.38415.644155.8F
   Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039
   Waijers PMCM, 2007, BRIT J NUTR, V97, P219, DOI 10.1017/S0007114507250421
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
NR 43
TC 27
Z9 27
U1 0
U2 13
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD FEB
PY 2010
VL 17
IS 1
BP 58
EP 65
DI 10.3109/09286580903450353
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 569IX
UT WOS:000275590900008
PM 20100101
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Keenan, TDL
   Goldacre, R
   Goldacre, MJ
AF Keenan, Tiarnan D. L.
   Goldacre, Raph
   Goldacre, Michael J.
TI ASSOCIATIONS BETWEEN AGE-RELATED MACULAR DEGENERATION, OSTEOARTHRITIS
   AND RHEUMATOID ARTHRITIS Record Linkage Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; aging; complement factor H;
   epidemiology; extracellular matrix; macula; osteoarthritis; record
   linkage; rheumatoid arthritis; inflammation
ID COMPLEMENT FACTOR-H; MEMBRANE ATTACK COMPLEX; RISK-FACTORS; DISEASE;
   GENETICS; SUSCEPTIBILITY; DISORDERS; ASPIRIN
AB Purpose: The epidemiologic relationship between age-related macular degeneration (AMD) and arthritis is unknown and has implications for understanding disease pathogenesis and treatment strategies.
   Methods: An AMD cohort of 245,912 people was constructed from English linked hospital episode statistics (1999-2011), principally comprising neovascular AMD patients undergoing anti-vascular endothelial growth factor therapy. We compared the AMD cohort with a reference cohort (2,134,771 people) for rates of subsequent osteoarthritis (OA) and rheumatoid arthritis. Osteoarthritis (2,032,472 people) and rheumatoid arthritis (261,232 people) cohorts were also constructed and compared with the reference cohort for rates of subsequent AMD.
   Results: Risk of arthritis after AMD was not elevated. The rate ratio for OA was 0.96 (95% confidence interval 0.95-0.97) and for rheumatoid arthritis was 0.98 (0.94-1.02). However, risk of AMD after arthritis was modestly raised. For OA, the rate ratio was 1.06 (1.04-1.08), but risk increased with longer OA duration, for example, 1.15 (1.08-1.23) for >10 years. For rheumatoid arthritis, the rate ratio was also modestly elevated at 1.15 (1.12-1.19).
   Conclusion: Age-related macular degeneration and arthritis are degenerative aging conditions that share some disease mechanisms and extracellular matrix involvement. However, considering arthritis after AMD, they are not positively associated. By contrast, people with OA experience modestly increased AMD risk, perhaps owing to medical treatments for OA.
C1 [Keenan, Tiarnan D. L.] Univ Manchester, Fac Med & Human Sci, Inst Human Dev, Ctr Hearing & Vis Res, Manchester, Lancs, England.
   [Keenan, Tiarnan D. L.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Royal Eye Hosp, Manchester, Lancs, England.
   [Goldacre, Raph; Goldacre, Michael J.] Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford, England.
C3 University of Manchester; Manchester Royal Eye Hospital; University of
   Manchester; University of Oxford
RP Keenan, TDL (通讯作者)，Manchester Royal Eye Hosp, Oxford Rd, Manchester M13 9WH, Lancs, England.
EM tiarnan.keenan@doctors.org.uk
OI Goldacre, Raphael/0000-0002-7393-1880
FU English National Institute for Health Research
FX The Unit of Health-Care Epidemiology was funded by the English National
   Institute for Health Research to build the linked data set and to make
   it available for analysis.
CR Al-Ubaidi MR, 2013, INVEST OPHTH VIS SCI, V54, P8119, DOI 10.1167/iovs.13-13536
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Christen WG, 2014, EXPERT OPIN DRUG SAF, V13, P421, DOI 10.1517/14740338.2014.889680
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Crofford LJ, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4174
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gill TK, 2013, INT J RHEUM DIS, V16, P766, DOI 10.1111/1756-185X.12175
   Goldacre MJ, 2012, BRIT J OPHTHALMOL, V96, P872, DOI 10.1136/bjophthalmol-2012-301519
   Hunter DJ, 2014, NAT REV RHEUMATOL, V10, P437, DOI 10.1038/nrrheum.2014.44
   Ikegawa S, 2013, ANNU REV GENOM HUM G, V14, P245, DOI 10.1146/annurev-genom-091212-153427
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Keenan TDL, 2012, BRIT J OPHTHALMOL, V96, P413, DOI 10.1136/bjophthalmol-2011-300338
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Li L, 2015, J CLIN PHARM THER
   Loeser RF, 2013, CURR OPIN RHEUMATOL, V25, P108, DOI 10.1097/BOR.0b013e32835a9428
   Maldonado M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/284873
   McGeer PL, 2005, NEUROBIOL AGING, V26, P1199, DOI 10.1016/j.neurobiolaging.2005.02.003
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mullins RF, 2012, AGE RELATED MACULAR
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Nowak JZ, 2014, EXPERT OPIN DRUG SAF, V13, P687, DOI 10.1517/14740338.2014.915939
   Reynard LN, 2013, EXPERT REV MOL MED, V15, DOI 10.1017/erm.2013.4
   Sohn DH, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3555
   Sokolove J, 2013, THER ADV MUSCULOSKEL, V5, P77, DOI 10.1177/1759720X12467868
   Tonge DP, 2014, OSTEOARTHR CARTILAGE, V22, P609, DOI 10.1016/j.joca.2014.03.004
   Trouw LA, 2011, CLIN EXP IMMUNOL, V166, P333, DOI 10.1111/j.1365-2249.2011.04482.x
   Urano T, 2010, J BONE MINER METAB, V28, P220, DOI 10.1007/s00774-009-0124-0
   Wang Q, 2011, NAT MED, V17, P1674, DOI 10.1038/nm.2543
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Zlateva GP, 2007, RETINA-J RET VIT DIS, V27, P1292, DOI 10.1097/01.iae.0000300915.81866.b8
NR 36
TC 15
Z9 15
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2015
VL 35
IS 12
BP 2613
EP 2618
DI 10.1097/IAE.0000000000000651
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DF4OV
UT WOS:000371329800027
PM 25996429
DA 2022-11-30
ER

PT J
AU Wong, D
   Durnian, JM
AF Wong, David
   Durnian, Jon M.
TI Surgical treatment of age-related macular degeneration: will there be a
   role in the future?
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE AMD; macula translocation; surgery
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RETINAL-PIGMENT EPITHELIUM;
   360-DEGREE PERIPHERAL RETINECTOMY; OPTICAL COHERENCE TOMOGRAPHY;
   TISSUE-PLASMINOGEN ACTIVATOR; C-REACTIVE PROTEIN; PHOTODYNAMIC THERAPY;
   SUBMACULAR HEMORRHAGE; VISUAL FUNCTION; FOLLOW-UP
AB Surgical treatment has been shown to be able to improve vision that is lost as a result of age-related macular degeneration. Surgery is complex, such that improvement has always to be weighed against risk of complications. The availability of Ranibizumab and Bevacizumab is set to dramatically alter our management options. Surgical treatment will have a limited role to play in the next few years.
C1 Univ Hong Kong, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China.
   Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
C3 University of Hong Kong
RP Wong, D (通讯作者)，Univ Hong Kong, Li Ka Shing Fac Med, 2-F William Mong Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.
EM saihungdavid@mac.com
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   BARTZSCHMIDT KU, 2005, 3 INT C INN VITR RET
   Bass EB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1856
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   BINDER S, 2005, 3 INT C INN VITR RET
   Black N, 1996, BRIT MED J, V312, P1215
   BLINDER KJ, 1991, INT OPHTHALMOL, V15, P215
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boulton ME, 2004, OPHTHALMOLOGE, V101, P877
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   BRUCE I, 1991, BLIND PARTIALLY SIGH, V1
   Chang AA, 2003, CLIN EXP OPHTHALMOL, V31, P103, DOI 10.1046/j.1442-9071.2003.00614.x
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Devereaux PJ, 2005, BMJ-BRIT MED J, V331, P313, DOI 10.1136/bmj.38503.623646.8F
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Ellwein LB, 1996, OPHTHALMOLOGY, V103, P1732, DOI 10.1016/S0161-6420(96)30433-8
   EVANS J, 1995, CAUSES BLINDNESS PAR
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Fujii GY, 2002, AM J OPHTHALMOL, V134, P69, DOI 10.1016/S0002-9394(02)01511-8
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Goverdhan S, 2005, EYENEWS, V12, P9
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   GUERNE D, 1991, OPHTHALMOLOGY, V98, P602
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Knoernschild T, 2003, CURR EYE RES, V27, P25, DOI 10.1076/ceyr.27.2.25.15453
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LIM JI, 1995, OPHTHALMOLOGY, V102, P1393, DOI 10.1016/S0161-6420(95)30858-5
   LINDSEY P, 1983, INVEST OPHTHALMOL  S, V24, P242
   *MAC PHOT STUD GRO, 1994, ARCH OPHTHALMOL-CHIC, V112, P800
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P629, DOI 10.1007/BF00921956
   Mauget-Faysse M, 1999, BRIT J OPHTHALMOL, V83, P923
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   MORIARTY AP, 1995, EYE, V9, P582, DOI 10.1038/eye.1995.144
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   *NAT STAT ONL, 2006, POP AG UK
   Ohji M, 2001, AM J OPHTHALMOL, V132, P888, DOI 10.1016/S0002-9394(01)01255-7
   Pawlak D, 2004, AM J OPHTHALMOL, V137, P880, DOI 10.1016/j.ajo.2003.12.041
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Saigo Y, 2004, INVEST OPHTH VIS SCI, V45, P1996, DOI 10.1167/iovs.03-0777
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Senn S, 2003, DICING DEATH
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Sheridan CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI 10.1167/iovs.05-0779
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
   THOMAS MA, 1992, CURR OPIN OPHTHALMOL, V3, P349, DOI 10.1097/00055735-199206000-00009
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P975
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
   Wong D, 2004, BRIT J OPHTHALMOL, V88, P186, DOI 10.1136/bjo.2003.019273
   Wright SE, 2000, CLIN EXP OPHTHALMOL, V28, P140, DOI 10.1046/j.1442-9071.2000.00296.x
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 74
TC 3
Z9 4
U1 0
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD MAR
PY 2007
VL 35
IS 2
BP 167
EP 173
DI 10.1111/j.1442-9071.2006.01410.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 143RK
UT WOS:000244741500014
PM 17362461
DA 2022-11-30
ER

PT J
AU Connolly, E
   Rhatigan, M
   O'Halloran, AM
   Muldrew, KA
   Chakravarthy, U
   Cahill, M
   Kenny, RA
   Doyle, SL
AF Connolly, Emma
   Rhatigan, Maedbh
   O'Halloran, Aisling M.
   Muldrew, Katherine Alyson
   Chakravarthy, Usha
   Cahill, Mark
   Kenny, Rose Anne
   Doyle, Sarah L.
TI Prevalence of age-related macular degeneration associated genetic risk
   factors and 4-year progression data in the Irish population
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; COMPONENT 2 C2; FACTOR-B BF; 5-YEAR INCIDENCE;
   FOLLOW-UP; MACULOPATHY; VARIANTS; SMOKING; INCREASES; DRUSEN
AB Background/aims Age-related macular degeneration (AMD) is estimated to affect 196 million people > 50 years old globally. Prevalence of AMD-associated genetic risk factors and rate of disease progression are unknown in Ireland.
   Methods Prevalence of AMD-associated genetic risk variants, complement factor H (CFH) rs1061170, age-related maculopathy susceptibility 2 (ARMS2) rs10490924, component 3 (C3) rs2230199, complement factor B (CFB) rs641153 and superkiller viralicidic activity 2-like (SKIV2L) rs429608 and 4-year progression data in a population-representative cohort (The Irish Longitudinal study on Ageing (TILDA)) were assessed. 4473 participants >= 50 years were assessed. 4173 had no disease n=1843; 44% male and n=2330; 56% female, mean age 60 +/- 9.0, 300 had AMD n=136; 45% male and n=164; 55% female, mean age 64 +/- 9.0. A 4-year follow-up was undertaken with 66% of AMD cases attending. Progression and regression from early to late AMD were measured. Genetic association as indicators of disease and as predictors of progression were assessed by multinomial logistic regression.
   Results Older age and the presence of CFH and ARMS2 risk alleles are two main risk factors associated with the prevalence of AMD in the TILDA cohort. 23% progressed to a higher grade of AMD. Carriers of CFH risk allele showed a strong association for disease progression. Heterozygosity for ARMS2 risk allele predicted progression to late AMD. 75% of those who progressed from early to late disease had soft drusen and hyperpigmentation at baseline.
   Conclusions The prevalence of risk-associated genes and 4-year progression rates of AMD in this Ireland cohort are comparable with other Caucasian populations. CFH Y402H is associated with disease progression, with soft drusen and hyperpigmentation as high-risk features.
C1 [Connolly, Emma; Rhatigan, Maedbh; Doyle, Sarah L.] Trinity Coll Dublin, Sch Med, Dept Clin Med, Dublin, Ireland.
   [O'Halloran, Aisling M.; Kenny, Rose Anne] Trinity Coll Dublin, Sch Med, Dept Med Gerontol, Irish Longitudinal Study Ageing TILDA, Dublin, Ireland.
   [Muldrew, Katherine Alyson; Chakravarthy, Usha] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Cahill, Mark] Royal Victoria Eye & Ear Hosp, Dublin, Ireland.
C3 Trinity College Dublin; Trinity College Dublin; Queens University
   Belfast
RP Doyle, SL (通讯作者)，Trinity Coll Dublin, Sch Med, Dept Clin Med, Dublin, Ireland.
EM doyles8@tcd.ie
OI O'Halloran, Aisling/0000-0001-5498-4453; Connolly,
   Emma/0000-0002-6964-6139; Doyle, Sarah/0000-0002-6294-9380; Kenny, Rose
   Anne/0000-0002-9336-8124
FU Health Research Board Ireland [HRB HRA/2013.290]; Science Foundation
   Ireland [SFI 15/TIDA/2920, SFI 15/CDA/3497]; RVEEH
FX This work was supported by Health Research Board Ireland grant number
   HRB HRA/2013.290, Science Foundation Ireland SFI 15/TIDA/2920; SFI
   15/CDA/3497 and the RVEEH.
CR Akuffo KO, 2015, BRIT J OPHTHALMOL, V99, P1037, DOI 10.1136/bjophthalmol-2014-305768
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Green D, 2016, J OPHTHALMOL, V2016, P1
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Joachim NDL, 2015, JAMA OPHTHALMOL, V133, P698, DOI 10.1001/jamaophthalmol.2015.0498
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lechanteur YTE, 2015, JAMA OPHTHALMOL, V133, P533, DOI 10.1001/jamaophthalmol.2015.18
   Mckay GJ, 2010, MOL VIS, V16, P194
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Sallo FB, 2009, BRIT J OPHTHALMOL, V93, P1345, DOI 10.1136/bjo.2008.150334
   Schwartz SG, 2012, RETINA-J RET VIT DIS, V32, P1486, DOI 10.1097/IAE.0b013e318240a540
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Whelan BJ, 2013, J AM GERIATR SOC, V61, pS265, DOI 10.1111/jgs.12199
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 25
TC 6
Z9 6
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2018
VL 102
IS 12
BP 1691
EP 1695
DI 10.1136/bjophthalmol-2017-311673
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HI6GO
UT WOS:000456552200016
PM 29453225
DA 2022-11-30
ER

PT J
AU Sundaresan, P
   Vashist, P
   Ravindran, RD
   Shanker, A
   Nitsch, D
   Nonyane, BAS
   Smeeth, L
   Chakravarthy, U
   Fletcher, AE
AF Sundaresan, Periasamy
   Vashist, Praveen
   Ravindran, Ravilla D.
   Shanker, Ashwini
   Nitsch, Dorothea
   Nonyane, Bareng A. S.
   Smeeth, Liam
   Chakravarthy, Usha
   Fletcher, Astrid E.
TI Polymorphisms in ARMS2/HTRA1 and Complement Genes and Age-Related
   Macular Degeneration in India: Findings from the INDEYE Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; FACTOR-B; CIGARETTE-SMOKING; FRENCH POPULATION;
   COMPONENT 2; CFH; RISK; VARIANT; SUSCEPTIBILITY; LOC387715
AB PURPOSE. Association between genetic variants in complement factor H (CFH), factor B (CFB), component 2 (C2), and in the ARMS2/HTRA1 region with age-related macular degeneration (AMD) comes mainly from studies of European ancestry and case-control studies of late-stage disease. We investigated associations of both early and late AMD with these variants in a population-based study of people aged 60 years and older in India.
   METHODS. Fundus images were graded using the Wisconsin Age-Related Maculopathy Grading System and participants assigned to one of four mutually exclusive stages based on the worse affected eye (0 = no AMD, 1-3 = early AMD, 4 = late AMD). Multinomial logistic regression was used to derive risk ratios (RR) accounting for sampling method and adjusting for age, sex, and study center.
   RESULTS. Of 3569 participants, 53.2% had no signs of AMD, 45.6% had features of early AMD, and 1.2% had late AMD. CFH (rs1061170), C2 (rs547154), or CFB (rs438999) was not associated with early or late AMD. In the ARMS2 locus, rs10490924 was associated with both early (adjusted RR 1.22, 95% confidence interval [CI]: 1.13-1.33, P < 0.0001) and late AMD (adjusted RR 1.81, 95% CI: 1.15-2.86; P = 0.01); rs2672598 was associated only with early AMD (adjusted RR 1.12, 95% CI: 1.02-1.23; P = 0.02); rs10490923 was not associated with early or late AMD.
   CONCLUSIONS. Two variants in ARMS2/HTRA1 were associated with increased risk of early AMD, and for one of these, the increased risk was also evident for late AMD. The study provides new insights into the role of these variants in early stages of AMD in India. (Invest Ophthalmol Vis Sci. 2012; 53: 7492-7497) DOI:10.1167/iovs.12-10073
C1 [Nitsch, Dorothea; Nonyane, Bareng A. S.; Smeeth, Liam; Fletcher, Astrid E.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1, England.
   [Sundaresan, Periasamy; Shanker, Ashwini] Aravind Eye Hosp, Aravind Med Res Fdn, Dr G Venkataswamy Eye Res Inst, Dept Genet, Madurai, Tamil Nadu, India.
   [Vashist, Praveen] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, India.
   [Ravindran, Ravilla D.] Aravind Eye Hosp, Pondicherry, India.
   [Chakravarthy, Usha] Queens Univ Belfast, Sch Med & Hlth Sci, Ctr Vis & Vasc Sci, Belfast BT7 1NN, Antrim, North Ireland.
C3 University of London; London School of Hygiene & Tropical Medicine; All
   India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra
   Prasad Centre for Ophthalmic Sciences; Queens University Belfast
RP Nitsch, D (通讯作者)，London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1, England.
EM Dorothea.Nitsch@lshtm.ac.uk
RI .P, Sundaresan/AAR-8426-2021; Nonyane, Bareng A.S./AAC-8118-2020;
   Smeeth, Liam/X-5862-2018
OI Nonyane, Bareng A.S./0000-0001-5633-7487; Nitsch,
   Dorothea/0000-0001-5767-248X; Smeeth, Liam/0000-0002-9168-6022;
   Chakravarthy, Usha/0000-0002-2606-3734
FU Wellcome Trust UK [073300, G082571]; National Institute for Health
   Research [NF-SI-0510-10090] Funding Source: researchfish
FX Supported by Wellcome Trust UK Grants 073300 and G082571. The sponsor or
   funding organization had no role in the design or conduct of this
   research.
CR Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   [Anonymous], RS2672598 NAT CTR BI
   [Anonymous], RS10490923 NAT CTR B
   [Anonymous], RS10490924 NAT CTR B
   [Anonymous], 2011, RS547154 NAT CTR BIO
   [Anonymous], REF SNP REFSNP CLUST
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Francis PJ, 2008, MOL VIS, V14, P1395
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Leveziel N, 2007, MOL VIS, V13, P2153
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Nonyane BAS, 2010, INVEST OPHTH VIS SCI, V51, P2393, DOI 10.1167/iovs.09-4228
   Pulido JS, 2007, OPHTHALMIC GENET, V28, P203, DOI 10.1080/13816810701649617
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Souied EH, 2005, MOL VIS, V11, P1135
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 43
TC 20
Z9 20
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2012
VL 53
IS 12
BP 7492
EP 7497
DI 10.1167/iovs.12-10073
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 064EE
UT WOS:000313053500009
PM 23060141
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Cipriani, V
   Hogg, RE
   Sofat, R
   Moore, AT
   Webster, AR
   Yates, JRW
   Fletcher, AE
AF Cipriani, Valentina
   Hogg, Ruth E.
   Sofat, Reecha
   Moore, Anthony T.
   Webster, Andrew R.
   Yates, John R. W.
   Fletcher, Astrid E.
CA European Eye EUREYE Study Grp
TI Association of C-Reactive Protein Genetic Polymorphisms With Late
   Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; CORONARY-HEART-DISEASE; RISK-FACTORS;
   CARDIOVASCULAR-DISEASE; INFLAMMATORY MARKERS; MACULOPATHY; VARIANT; CRP;
   METAANALYSIS; GENOTYPES
AB IMPORTANCE C-reactive protein (CRP) is a circulating inflammatory marker associated with late age-related macular degeneration (AMD). It remains uncertain whether the association between CRP concentrations and AMD is causal.
   OBJECTIVE To assess whether CRP (OMIM 123260) single-nucleotide polymorphisms that influence circulating CRP concentrations are associated with late AMD.
   DESIGN, SETTING, AND PARTICIPANTS Participants in 2 UK, hospital-based, case-control studies (Cambridge AMD study and Moorfields Eye Hospital AMD study) and 1 pan-European, cross-sectional, population-based study (the European Eye [EUREYE] Study) were recruited between November 6, 2000, and April 30, 2007. Participants underwent dilated stereo-digital fundus photography graded according to the International Classification of Age-related Maculopathy and Macular Degeneration. There were 1727 cases of late AMD (1151 neovascular, 384 geographic atrophy, and 192 mixed [neovascular AMD and geographic atrophy]) and 1153 controls. Early AMD cases (n = 574) were included only from the EUREYE Study. Data analysis was performed from August 1 to November 30, 2016. Four common single-nucleotide polymorphisms (rs1205, rs1130864, rs1800947, and rs3093077) were selected based on demonstrated influence on circulating CRP concentrations in the literature. In one study, genotyping of rs3093077 failed, and rs1800947 was typed in only 1 study.
   MAIN OUTCOMES AND MEASURES A genetic multiplicative modelwas used for the association of single-nucleotide polymorphisms with late AMD adjusted for age and sex.
   RESULTS Among the 1727 patients with late AMD, the mean (SD) age was 78.7 (7.4) years, and 668 (38.7%) were men. The mean (SD) age of the controls was 74.9 (7.0) years, and 510 (44.2%) were men. In the pooled results of all 3 studies, neither rs1205 (odds ratio [OR], 0.99; 95% CI, 0.86-1.14) nor rs1130864 (OR, 0.96; 95% CI, 0.83-1.11) was associated with late AMD. For geographic atrophy, rs1205 had an OR of 0.91 (95% CI, 0.74-1.13) and rs1130864 had an OR of 0.94 (95% CI, 0.76-1.16). For neovascular AMD, rs1205 had an OR of 1.01 (95% CI, 0.87-1.19) and rs1130864 had an OR of 0.99 (95% CI, 0.84-1.16). There was no association of rs3093077 and rs1800947 with late AMD or any late AMD phenotype. There were no significant findings for early AMD.
   CONCLUSIONS AND RELEVANCE Our results do not support a causal association between CRP concentrations and AMD.
C1 [Cipriani, Valentina; Moore, Anthony T.; Webster, Andrew R.; Yates, John R. W.] UCL, UCL Inst Ophthalmol, Dept Ocular Biol & Therapeut, 11-43 Bath St,Wolfson Bldg,3rd Floor,Room 3-5, London EC1V 9EL, England.
   [Cipriani, Valentina; Moore, Anthony T.; Webster, Andrew R.] Moorfields Eye Hosp, London, England.
   [Cipriani, Valentina] UCL, Genet Inst, London, England.
   [Hogg, Ruth E.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Sofat, Reecha] UCL, Div Med, Ctr Clin Pharmacol, London, England.
   [Moore, Anthony T.] Univ Calif San Francisco, Sch Med, Dept Ophthalmol, San Francisco, CA USA.
   [Yates, John R. W.] Univ Cambridge, Dept Med Genet, Cambridge, England.
   [Fletcher, Astrid E.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London, England.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; Queens University
   Belfast; University of London; University College London; University of
   California System; University of California San Francisco; University of
   Cambridge; University of London; London School of Hygiene & Tropical
   Medicine
RP Cipriani, V (通讯作者)，UCL, UCL Inst Ophthalmol, Dept Ocular Biol & Therapeut, 11-43 Bath St,Wolfson Bldg,3rd Floor,Room 3-5, London EC1V 9EL, England.
EM v.cipriani@ucl.ac.uk
RI Hogg, Ruth E./ABC-9602-2020
OI Hogg, Ruth E./0000-0001-9413-2669; Sofat, Reecha/0000-0002-0242-6115
FU European Commission [QLK6-CT-1999-02094]; Macular Disease Society UK for
   DNA extraction and genotyping (MRC Biomarkers Award) [G0601354]; Medical
   Research Council [G0000067]; Fight for Sight; Mercer Fund; National
   Institute for Health Research Biomedical Research Centre at Moorfields
   Eye Hospital National Health Service Foundation Trust; University
   College London Institute of Ophthalmology; British Heart Foundation
   (Schillingford) Clinical Research Training Fellowship [FS/07/011]; MRC
   [G0000067] Funding Source: UKRI
FX The European Eye (EUREYE) Study was supported by grant
   QLK6-CT-1999-02094 from the European Commission Vth Framework, with
   additional funding for cameras provided by the Macular Disease Society
   UK for DNA extraction and genotyping (MRC Biomarkers Award G0601354).
   The Cambridge Age-related Macular Degeneration (AMD) study was funded by
   grant G0000067 from the Medical Research Council. The Moorfields Eye
   Hospital AMD study was partly supported by Fight for Sight, including
   the Mercer Fund. Dr Cipriani is funded by the National Institute for
   Health Research Biomedical Research Centre at Moorfields Eye Hospital
   National Health Service Foundation Trust and the University College
   London Institute of Ophthalmology. Dr Sofat was funded by the British
   Heart Foundation (Schillingford) Clinical Research Training Fellowship
   FS/07/011.
CR Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Carlson CS, 2005, AM J HUM GENET, V77, P64, DOI 10.1086/431366
   Danesh J, 2008, EUR J EPIDEMIOL, V23, P531, DOI 10.1007/s10654-008-9249-z
   Dehghan A, 2011, CIRCULATION, V123, P731, DOI 10.1161/CIRCULATIONAHA.110.948570
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elliott P, 2009, JAMA-J AM MED ASSOC, V302, P37, DOI 10.1001/jama.2009.954
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Kaptoge S, 2010, LANCET, V375, P132, DOI 10.1016/S0140-6736(09)61717-7
   Kim IK, 2008, MOL VIS, V14, P1487
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Nimptsch K, 2015, INT J CANCER, V136, P1181, DOI 10.1002/ijc.29086
   Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Salazar J, 2014, CARDIOL RES PRACT, V2014, DOI 10.1155/2014/605810
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Smith GD, 2005, BMJ-BRIT MED J, V330, P1076, DOI 10.1136/bmj.330.7499.1076
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Sudmant PH, 2015, NATURE, V526, P75, DOI 10.1038/nature15394
   Ulas F, 2013, INT OPHTHALMOL, V33, P485, DOI 10.1007/s10792-013-9728-4
   Verzilli C, 2008, AM J HUM GENET, V82, P859, DOI 10.1016/j.ajhg.2008.01.016
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wensley F, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d548
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
NR 43
TC 12
Z9 12
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD SEP
PY 2017
VL 135
IS 9
BP 909
EP 916
DI 10.1001/jamaophthalmol.2017.2191
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FG8HA
UT WOS:000410669300008
PM 28750115
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Chen, LJ
   Cheng, CK
   Yeung, L
   Yang, CH
   Chen, SJ
AF Chen, Lee-Jen
   Cheng, Cheng-Kuo
   Yeung, Ling
   Yang, Chang-Hao
   Chen, Shih-Jen
CA Taiwan PCV Consensus Grp
TI Management of polypoidal choroidal vasculopathy: Experts consensus in
   Taiwan
SO JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
LA English
DT Article
DE Choroidal neovascularization; PCV; Photodynamic therapy; Vascular
   endothelial growth factors; Wet age-related macular degeneration
ID VERTEPORFIN PHOTODYNAMIC THERAPY; OPTICAL COHERENCE TOMOGRAPHY; MACULAR
   DEGENERATION; TRIAMCINOLONE ACETONIDE; INTRAVITREAL BEVACIZUMAB; EXTEND
   REGIMEN; RANIBIZUMAB; COMBINATION; GUIDELINES; INJECTIONS
AB Polypoidal choroidal vasculopathy (PCV) is a prevalent retinal disease predominantly occurs in Asians that shares some similarities seen in neovascular age-related macular degeneration. Recent large multicenter clinical trials on intravitreal anti-vascular endothelial growth factor (VEGF) agents and photodynamic therapy (PDT) have shed lights on the management of PCV. The Taiwan National Health Insurance had granted limited anti-VEGF agents and PDT for patients with PCV after the approval of required data submission, especially fundus angiography, optical coherence tomography, and visual acuity. In order to best utilize these limited resources for the patients, an expert meeting was held to provide updated Taiwan consensus recommendations for the management of PCV, including initial therapy selection, assessment of treatment response, re-treatment/rescue treatment, and determination of treatment extension/follow-up schedule. An algorithm for treatment allocation under both initial and re-treatment setting was proposed. Further mechanistic and clinical studies are required to investigate the prognostic factors and optimal treatment protocols that will improve healthcare quality and reduce burden of disease and treatment for patients with PCV. Copyright (C) 2019, Formosan Medical Association. Published by Elsevier Taiwan LLC.
C1 [Chen, Lee-Jen] Mackay Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Cheng, Cheng-Kuo] Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Cheng, Cheng-Kuo] Natl Taiwan Univ, Sch Med, Dept Ophthalmol, Taipei, Taiwan.
   [Cheng, Cheng-Kuo] Fu Jen Catholic Univ, Sch Med, Dept Ophthalmol, New Taipei, Taiwan.
   [Yeung, Ling] Chang Gung Mem Hosp, Dept Ophthalmol, Keelung, Taiwan.
   [Yeung, Ling] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
   [Yang, Chang-Hao] Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Shih-Jen] Natl Yang Ming Univ, Sch Med, Dept Ophthalmol, Taipei, Taiwan.
C3 Mackay Memorial Hospital; Shin Kong Wu Ho Su Memorial Hospital; National
   Taiwan University; Fu Jen Catholic University; Chang Gung Memorial
   Hospital; Chang Gung University; National Taiwan University; National
   Taiwan University Hospital; Taipei Veterans General Hospital; National
   Yang Ming Chiao Tung University
RP Chen, SJ (通讯作者)，201,Sec 2,Shih Pai Rd, Taipei 11217, Taiwan.
EM sjchen@vghtpe.gov.tw
RI Yang, Chang-Hao/AAR-3759-2021
OI YANG, CHANG-HAO/0000-0002-4328-8716; YANG,
   CHUNG-MAY/0000-0003-4082-420X; Lai, Chi-Chun/0000-0001-9547-7212
FU Taiwan Retina Society
FX Editorial assistance in the preparation of this manuscript was provided
   by Chian-Yi Liu at EMD Asia Scientific Communication (Taiwan branch)
   Co., Ltd. The panel meeting and support of this assistance was organized
   and funded by the Taiwan Retina Society. The content of this article was
   expressed according to the opinions of authors and the manuscript
   submission for publication was completed with the final approval of all
   authors.
CR [Anonymous], AS PAC VIT RET SOC C
   [Anonymous], RETINA
   [Anonymous], C AS PAC VITR RET SO
   [Anonymous], RETINA
   Asano S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197042
   Chaikitmongkol V, 2018, AM J OPHTHALMOL, V192, P77, DOI 10.1016/j.ajo.2018.05.005
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Chang Young Suk, 2016, Korean J Ophthalmol, V30, P272, DOI 10.3341/kjo.2016.30.4.272
   Chang Young Suk, 2016, Korean J Ophthalmol, V30, P198, DOI 10.3341/kjo.2016.30.3.198
   Chen XL, 2018, GRAEF ARCH CLIN EXP, V256, P1449, DOI 10.1007/s00417-018-4020-y
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chi YT, 2017, JAMA OPHTHALMOL, V135, P1310, DOI 10.1001/jamaophthalmol.2017.4360
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   de Carlo TE, 2018, OPHTHALMOLOGICA, V239, P103, DOI 10.1159/000481540
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Fujiwara K, 2018, SEMIN OPHTHALMOL, V33, P813, DOI 10.1080/08820538.2018.1506483
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hikichi T, 2018, BRIT J OPHTHALMOL, V102, P97, DOI 10.1136/bjophthalmol-2017-310448
   Hikichi T, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0026-y
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Huang YM, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/3479695
   Huang Z, 2019, RETINA-J RET VIT DIS, V39, P889, DOI 10.1097/IAE.0000000000002035
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jeon S, 2013, RETINA-J RET VIT DIS, V33, P1193, DOI 10.1097/IAE.0b013e318276e096
   Kim J, 2017, EYE, V31, P1678, DOI 10.1038/eye.2017.126
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2017, ASIA-PAC J OPHTHALMO, V6, P296, DOI 10.22608/APO.2016125
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kong M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184058
   Lai TYY, 2010, J OCUL PHARMACOL TH, V26, P91, DOI 10.1089/jop.2009.0073
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Liang IC, 2017, J OCUL PHARMACOL TH, V33, P42, DOI 10.1089/jop.2015.0150
   Lin JC, 2012, J FORMOS MED ASSOC, V111, P572, DOI 10.1016/j.jfma.2011.09.021
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Mehta H, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011599.pub2
   Miyata M, 2019, BRIT J OPHTHALMOL, V103, P617, DOI 10.1136/bjophthalmol-2018-311963
   Mori R, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011188
   Morizane-Hosokawa M, 2018, ACTA MED OKAYAMA, V72, P379, DOI 10.18926/AMO/56175
   Musashi K, 2007, AM J OPHTHALMOL, V143, P883, DOI 10.1016/j.ajo.2006.12.024
   Nakata I, 2013, GRAEF ARCH CLIN EXP, V251, P1073, DOI 10.1007/s00417-012-2137-y
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Peng YT, 2018, DRUG DES DEV THER, V12, P339, DOI 10.2147/DDDT.S158368
   Qian TW, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12840
   Sakai T, 2014, BRIT J OPHTHALMOL, V98, P1642, DOI 10.1136/bjophthalmol-2014-305189
   Sen Parveen, 2016, Oman J Ophthalmol, V9, P139
   Takahashi Kanji, 2012, Nippon Ganka Gakkai Zasshi, V116, P1150
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Yeung L, 2018, RETINA-J RET VIT DIS, V38, P263, DOI 10.1097/IAE.0000000000001556
   Yong M, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0064-5
NR 55
TC 8
Z9 8
U1 3
U2 8
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 0929-6646
EI 1876-0821
J9 J FORMOS MED ASSOC
JI J. Formos. Med. Assoc.
PD FEB
PY 2020
VL 119
IS 2
BP 569
EP 576
DI 10.1016/j.jfma.2019.04.012
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA KM1BG
UT WOS:000513851500002
PM 31076317
OA gold
DA 2022-11-30
ER

PT J
AU Fung, AT
   Yannuzzi, LA
   Freund, KB
AF Fung, Adrian T.
   Yannuzzi, Lawrence A.
   Freund, K. Bailey
TI TYPE 1 (SUB-RETINAL PIGMENT EPITHELIAL) NEOVASCULARIZATION IN CENTRAL
   SEROUS CHORIORETINOPATHY MASQUERADING AS NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE central serous chorioretinopathy; Type 1 neovascularization; age-related
   macular degeneration; pigment epithelial detachment; polypoidal
   choroidal vasculopathy
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; INDOCYANINE GREEN ANGIOGRAPHY;
   OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; SECONDARY;
   CLASSIFICATION; CHOROIDOPATHY; RANIBIZUMAB; FEATURES
AB Purpose: The purpose of this study was to describe clinical and multimodal imaging features of patients with Type 1 neovascularization who lack findings of age-related macular degeneration but instead have features consistent with long-standing central serous chorioretinopathy (CSC).
   Methods: Nonconsecutive, retrospective, observational case series. Two groups of patients were identified and analyzed. Group 1 included patients presenting with Type 1 neovascularization who at the time of diagnosis were found to have findings more consistent with long-standing CSC than age-related macular degeneration. Group 2 included patients with a known history of CSC who developed Type 1 neovascularization over their course of follow-up. Clinical histories and multimodal imaging findings (color and red-free photography, fundus autofluorescence imaging, fluorescein angiography, indocyanine green angiography, spectral domain optical coherence tomography, and enhanced depth imaging optical coherence tomography) were analyzed.
   Results: Twenty-seven eyes of 22 patients were identified. Thirteen patients presented with Type 1 neovascularization thought to be secondary to CSC (Group 1), and 9 patients with CSC were observed to develop Type 1 neovascularization over their course of follow-up (Group 2). Eight patients (36%) had polypoidal neovascular structures within their Type 1 neovascular lesions, of which 4 (18% of all patients) had bilateral Type 1 neovascularization. The mean age of patients was 61 years (range, 48-76 years), and the median age was 58.5 years. Thirteen patients (59%) were men. For those patients in Group 2, the mean duration between diagnosis of CSC and detection of Type 1 neovascularization was 139 months (range, 7-365 months). The mean subfoveal choroidal thickness was 354 mu m (range, 186-666 mu m).
   Conclusion: Some patients presenting with Type 1 neovascularization may have clinical and multimodal imaging findings more consistent with long-standing CSC than with age-related macular degeneration. These patients are more likely to be younger, men, have thicker choroids, and have a higher prevalence of polypoidal neovasculopathy than those patients with Type 1 neovascularization secondary to age-related macular degeneration. Proper identification of these patients may have implications for their natural course and management. RETINA 32:1829-1837, 2012
C1 [Fung, Adrian T.; Yannuzzi, Lawrence A.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Fung, Adrian T.; Yannuzzi, Lawrence A.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Yannuzzi, Lawrence A.; Freund, K. Bailey] NYU, Dept Ophthalmol, New York, NY 10016 USA.
   [Yannuzzi, Lawrence A.; Freund, K. Bailey] Columbia Univ Coll Phys & Surg, Edward S Harkness Eye Inst, New York, NY 10032 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; New York University; Columbia University
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Macula Foundation, Inc.
FX Supported by The Macula Foundation, Inc.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   BERGER AR, 1991, OPHTHALMIC SURG LAS, V22, P583
   Canakis C, 2004, OPHTHAL SURG LAS IM, V35, P168, DOI 10.3928/1542-8877-20040301-17
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan WM, 2007, AM J OPHTHALMOL, V143, P977, DOI 10.1016/j.ajo.2007.02.039
   Chan WM, 2003, AM J OPHTHALMOL, V136, P836, DOI 10.1016/S0002-9394(03)00462-8
   Cho M, 2010, BRIT J OPHTHALMOL, V94, P597, DOI 10.1136/bjo.2008.149724
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Cooper BA, 2000, AM J OPHTHALMOL, V130, P187, DOI 10.1016/S0002-9394(00)00395-0
   Ergun E, 2004, ARCH OPHTHALMOL-CHIC, V122, P37, DOI 10.1001/archopht.122.1.37
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Iida T, 2003, RETINA-J RET VIT DIS, V23, P1, DOI 10.1097/00006982-200302000-00001
   Iida T, 2003, RETINA, V23, P137, DOI DOI 10.1097/00006982-200302000-00001
   Imamura Y, 2011, OPHTHALMOLOGY, V118, P700, DOI 10.1016/j.ophtha.2010.08.017
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Koh A.H.C., 1999, INVESTIG OPHTHALMOL, V40, P5958
   Konstantinidis L, 2010, EUR J OPHTHALMOL, V20, P955, DOI 10.1177/112067211002000524
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 1998, GRAEF ARCH CLIN EXP, V236, P513, DOI 10.1007/s004170050114
   Loo RH, 2002, RETINA-J RET VIT DIS, V22, P19, DOI 10.1097/00006982-200202000-00004
   Lumbroso B, 2011, RETINA-J RET VIT DIS, V31, P553, DOI 10.1097/IAE.0b013e3181eef3eb
   Maia Hugo Soares, 2005, Arq. Bras. Oftalmol., V68, P561, DOI 10.1590/S0004-27492005000400027
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   MARSHALL GE, 1994, GRAEF ARCH CLIN EXP, V232, P133, DOI 10.1007/BF00176781
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mudvari SS, 2007, RETINA-J RET VIT DIS, V27, P1168, DOI 10.1097/IAE.0b013e318156db8a
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   SCHATZ H, 1992, OPHTHALMOLOGY, V99, P63
   SCHATZ H, 1993, BRIT J OPHTHALMOL, V77, P744, DOI 10.1136/bjo.77.11.744
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Yang CS, 2009, J CHIN MED ASSOC, V72, P501, DOI 10.1016/S1726-4901(09)70417-4
   Yannuzzi LA, 2003, RETINA-J RET VIT DIS, V23, P288, DOI 10.1097/00006982-200306000-00002
   Yannuzzi LA, 2010, AM J OPHTHALMOL, V149, P361, DOI 10.1016/j.ajo.2009.11.017
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 47
TC 159
Z9 169
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2012
VL 32
IS 9
BP 1829
EP 1837
DI 10.1097/IAE.0b013e3182680a66
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 012EH
UT WOS:000309217800018
PM 22850219
DA 2022-11-30
ER

PT J
AU Yu, Y
   Ren, XR
   Wen, F
   Chen, H
   Su, SB
AF Yu, Ying
   Ren, Xiang Rong
   Wen, Feng
   Chen, Hui
   Su, Shao Bo
TI T-helper-associated cytokines expression by peripheral blood mononuclear
   cells in patients with polypoidal choroidal vasculopathy and age-related
   macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE T-helper cell; Cytokine; Peripheral blood mononuclear cell; Age-related
   macular degeneration; Polypoidal choroidal vasculopath
ID IFN-GAMMA; INCREASED RISK; ACTIVATION; GENE; STIMULATION; DISEASES;
   PATHWAY
AB Background: Immune responses play a key role in the pathogenesis and progression of polypoidal choroidal vasculopath (PCV) and age-related macular degeneration (AMD). In this study, we determined the Th cell-associated immune responses by measuring the cytokine expression of peripheral blood mononuclear cells (PBMC) in both PCV and neovascular AMD (nAMD) patients.
   Methods: Twenty-seven nAMD patients, 33 PCV patients and a gender-and age-matched group of 18 healthy individuals were involved in this study. The Th-cell cytokine profiles including levels of interferon-gamma (INF-gamma), interleukin (IL)-17A and IL-4 in cultures of PBMCs were determined by enzyme-linked immunosorbent assay (ELISA).
   Results: IFN-gamma, IL-17A and IL-4 production was significantly increased after stimulation with PHA. The levels of IFN-gamma and IL-4 in PHA-stimulated cultures were higher in PCV and nAMD patients than that in healthy controls (P = 0.038, P = 0.014), while no difference was found between PCV and nAMD (all P > 0.05). No significant difference in IL-17A level in PHA-stimulated cultures was found among PCV, nAMD and control groups (P > 0.05).
   Conclusions: These findings suggest that circulating IFN-gamma and IL-4 producing Th1 and Th2 cells may involve in the pathogenesis of PCV and nAMD. PCV may have the similar immune responses with nAMD.
C1 [Yu, Ying; Ren, Xiang Rong; Wen, Feng; Chen, Hui; Su, Shao Bo] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 S Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Su, SB (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 S Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM sushaobo7836@gmail.com
FU National Natural Science Foundation of China [31471122]
FX This project was supported in part by the grants from the National
   Natural Science Foundation of China (grant number: 31471122).
CR Ardeljan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095900
   Battle TE, 2006, CANCER RES, V66, P3649, DOI 10.1158/0008-5472.CAN-05-3612
   Benedetti G, 2014, EUR J IMMUNOL, V44, P339, DOI 10.1002/eji.201344184
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Brown JN, 2010, J LEUKOCYTE BIOL, V87, P655, DOI 10.1189/jlb.0809570
   Chakrabarty P, 2010, J IMMUNOL, V184, P5333, DOI 10.4049/jimmunol.0903382
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Huang Y, 2001, EUR J IMMUNOL, V31, P3676, DOI 10.1002/1521-4141(200112)31:12<3676::AID-IMMU3676>3.0.CO;2-K
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jiang K, 2013, J CLIN EXP OPHTHA S2
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Kutty RK, 2015, CYTOKINE, V74, P335, DOI 10.1016/j.cyto.2015.03.016
   Lau LI, 2011, INVEST OPHTH VIS SCI, V52, P6832, DOI 10.1167/iovs.11-7815
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee H, 2014, INVEST OPHTH VIS SCI, V55, P2885, DOI 10.1167/iovs.14-14093
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu BY, 2010, MOL VIS, V16, P184
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Pappu R, 2010, J CLIN IMMUNOL, V30, P185, DOI 10.1007/s10875-010-9369-6
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   ROMAGNANI S, 1995, J CLIN IMMUNOL, V15, P121, DOI 10.1007/BF01543103
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Tay SS, 2009, CURR OPIN ORGAN TRAN, V14, P16, DOI 10.1097/MOT.0b013e32831ebdf5
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557
   Zhang SR, 2015, INFLAMMATION, V38, P658, DOI 10.1007/s10753-014-9973-3
   Zhang XZ, 2011, INVEST OPHTH VIS SCI, V52, P8063, DOI 10.1167/iovs.11-7820
   Zuo CG, 2012, MOL VIS, V18, P1787
NR 35
TC 8
Z9 9
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUN 7
PY 2016
VL 16
AR 80
DI 10.1186/s12886-016-0251-z
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DO1JU
UT WOS:000377535100004
PM 27266510
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pan, HT
   Wang, JJ
   Huang, JL
   Shuai, YL
   Li, J
   Hu, ZZ
   Ding, YZ
   Liu, QH
AF Pan, Hai-Tao
   Wang, Jun-Jun
   Huang, Jun-Long
   Shuai, Yuan-Lu
   Li, Jia
   Hu, Zi-Zhong
   Ding, Yu-Zhi
   Liu, Qing-Huai
TI Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone
   for exudative age-related macular degeneration
SO JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
LA English
DT Article
DE Fufang xueshuantong; ranibizumab; combination therapy; age-related
   macular degeneration; choroidal neovascularization; traditional Chinese
   medicine
ID ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL RANIBIZUMAB; LASER PHOTOCOAGULATION; THERAPY; ASSOCIATION;
   VERTEPORFIN; BEVACIZUMAB; TRIALS; VEGF
AB Objective To compare the efficacy of ranibizumab plus fufang xueshuantong capsule (cFXST) with the efficacy of ranibizumab alone in treatment of exudative age-related macular degeneration. Methods This prospective, randomized, controlled, pilot study included 38 eyes from 38 patients with exudative age-related macular degeneration (AMD) that were randomly allocated into two cohorts of 19 eyes each: ranibizumab (C-r) and ranibizumab plus cFXST (C-fr). All patients received three monthly injections of ranibizumab. Patients in C(fr)also received daily oral supplementation of cFXST. Best corrected visual acuity (BCVA) and thickness of the choroidal neovascularization-pigment epithelial detachment (CNV-PED) complex (measured by optical coherence tomography) were recorded at baseline and at 1 and 3 months after the first intravitreal injection of ranibizumab. Results In the C-fr, the CNV-PED complex thickness was reduced by 31.7% and 36.1% at 1 and 3 months, respectively; these reductions were significantly greater than the 19.7% and 24.2% reductions in the C-r. BCVA improvement was significantly greater in the C(fr)than in the C(r)after 3 months; the proportion of patients with functional response was also greater in the C(fr)than in the C-r(16/16 vs. 8/17). Conclusion Oral cFXST increases the efficacy of short-term ranibizumab treatment for exudative AMD.
C1 [Pan, Hai-Tao; Wang, Jun-Jun; Huang, Jun-Long; Shuai, Yuan-Lu; Li, Jia; Hu, Zi-Zhong; Liu, Qing-Huai] Nanjing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Nanjing 210029, Peoples R China.
   [Pan, Hai-Tao] Nanjing Med Univ, Dept Cadre Hlth Care, Jinling Hosp, Nanjing, Peoples R China.
   [Wang, Jun-Jun] Rudong Country Hosp Tradit Chinese Med, Dept Ophthalmol, Nantong, Peoples R China.
   [Ding, Yu-Zhi] Southeast Univ, Dept Ophthalmol, Zhongda Hosp, Nanjing, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Southeast
   University - China
RP Liu, QH (通讯作者)，Nanjing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Nanjing 210029, Peoples R China.
EM liuqh@njmu.edu.cn
OI hu, zizhong/0000-0001-6289-1804
FU National Natural Science Foundation of China [81900875]; Natural Science
   Foundation of Jiangsu Province [BK20191059]; National Key Project of
   Research and Development Plan [2017YFA0104101]; General Project of the
   National Natural Science Fund [81770973]
FX This study was supported by the National Natural Science Foundation of
   China (grant no. 81900875), Natural Science Foundation of Jiangsu
   Province (grant no. BK20191059), and National Key Project of Research
   and Development Plan (grant no. 2017YFA0104101), and General Project of
   the National Natural Science Fund (grant no. 81770973).
CR Arnold J, 1997, GRAEF ARCH CLIN EXP, V235, P208, DOI 10.1007/BF00941761
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Calvo P, 2015, BRIT J OPHTHALMOL, V99, P723, DOI 10.1136/bjophthalmol-2014-305684
   Chen KJ, 2012, CHIN J INTEGR MED, V18, P891, DOI 10.1007/s11655-012-1291-5
   Duan HH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/408268
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Ersoy L, 2014, GRAEF ARCH CLIN EXP, V252, P889, DOI 10.1007/s00417-013-2519-9
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Hatcher LQ, 2007, ABSTR PAP AM CHEM S, V234
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jian WJ, 2016, J ETHNOPHARMACOL, V182, P50, DOI 10.1016/j.jep.2015.11.021
   Kim BJ, 2014, AM J OPHTHALMOL, V158, P128, DOI 10.1016/j.ajo.2014.04.004
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Liu HX, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0111175, 10.1371/journal.pone.0110887]
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Michalska-Malecka K, 2008, CLIN HEMORHEOL MICRO, V38, P209
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Rezende FA, 2014, AM J OPHTHALMOL, V158, P1071, DOI 10.1016/j.ajo.2014.07.036
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schramm K, 2014, ACTA OPHTHALMOL, V92, P465, DOI 10.1111/aos.12326
   Sheng SJ, 2014, BIOTECHNOL BIOTEC EQ, V28, P322, DOI 10.1080/13102818.2014.911611
   Sheng SJ, 2014, J ETHNOPHARMACOL, V154, P735, DOI 10.1016/j.jep.2014.04.048
   Shin HJ, 2013, RETINA-J RET VIT DIS, V33, P964, DOI 10.1097/IAE.0b013e3182835f70
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Soderberg AC, 2012, BRIT J OPHTHALMOL, V96, P714, DOI 10.1136/bjophthalmol-2011-300721
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Sridhar J, 2016, JAMA OPHTHALMOL, V134, P437, DOI 10.1001/jamaophthalmol.2016.0045
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Wen-gui MA., 2004, CHINESE J TRADITIONA, V3, P1
   Xu JZ, 2012, TEACH COLL REC, V114
   Yi ZHZ, 2015, CURR EYE RES, V40, P1166, DOI 10.3109/02713683.2014.990638
   Yuan YZ, 2011, CHIN J INTEGR MED, V17, P296, DOI 10.1007/s11655-011-0690-6
NR 40
TC 3
Z9 3
U1 1
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0300-0605
EI 1473-2300
J9 J INT MED RES
JI J. Int. Med. Res.
PD SEP
PY 2020
VL 48
IS 9
AR 0300060520931618
DI 10.1177/0300060520931618
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NW7NA
UT WOS:000575204700001
PM 32962487
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Coscas, G
   Yamashiro, K
   Coscas, F
   De Benedetto, U
   Tsujikawa, A
   Miyake, M
   Cheung, CMG
   Wong, TY
   Yoshimura, N
AF Coscas, Gabriel
   Yamashiro, Kenji
   Coscas, Florence
   De Benedetto, Umberto
   Tsujikawa, Akitaka
   Miyake, Masahiro
   Cheung, Chui Ming Gemmy
   Wong, Tien Yin
   Yoshimura, Nagahisa
TI Comparison of Exudative Age-related Macular Degeneration Subtypes in
   Japanese and French Patients: Multicenter Diagnosis With Multimodal
   Imaging
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL ANGIOMATOUS PROLIFERATION;
   INDOCYANINE GREEN ANGIOGRAPHY; PHOTODYNAMIC THERAPY; VASCULAR
   HYPERPERMEABILITY; INTRAVITREAL INJECTION; NEOVASCULARIZATION;
   BEVACIZUMAB; RANIBIZUMAB; POPULATION
AB PURPOSE: To compare and analyze differences and similarities between Japanese and French patients in subtype diagnosis of exudative age-related macular degeneration (AMD) as determined by fundus photography (FP) and fluorescein angiography (FA), and a multimodal imaging involving FP, FA, indocyanine green angiography (ICGA), and optical coherence tomography (OCT).
   DESIGN: Retrospective chart review.
   METHODS: We determined the subtype diagnosis for 99 consecutive Japanese eyes and 94 consecutive French eyes with exudative AMD. The first-step diagnosis was made using FP and FA, while the second-step diagnosis was made using FP, FA/ICGA, and OCT. The diagnoses made by Japanese and French physicians were compared, and when the diagnoses differed, a third institute was consulted to arrive at a final consensus and diagnosis.
   RESULTS: The first-step diagnosis showed 20%-30% disagreement against the final diagnosis, but the second-step diagnosis showed only 10% disagreement. Polypoidal choroidal vasculopathy (PCV) was observed more in Japanese patients (48%) than in French (9%), and the rate of PCV with type 1 or 2 choroidal neovascularization (CNV) was extremely low: 3% in Japanese and 0% in French. Type 1 CNV was found significantly more in French cases (53.3% vs 35.1%, P = .018), while the rate of eyes with type 2 CNV only or chorioretinal anastomosis was similar between populations.
   CONCLUSIONS: Multimodality imaging significantly improved the sub-classification of AMD. There were significant differences between the 2 series in the proportions of type 1 CNV and PCV, while the proportions of type 2 CNV only and chorioretinal anastomosis were similar between groups. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Coscas, Gabriel; Coscas, Florence; De Benedetto, Umberto] Ctr Ophtalmol Paris, Paris, France.
   [Coscas, Gabriel; Coscas, Florence; De Benedetto, Umberto] Univ Paris Est Creteil, Dept Ophthalmol, F-94000 Creteil, France.
   [Yamashiro, Kenji; Tsujikawa, Akitaka; Miyake, Masahiro; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Natl Univ Singapore, Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 117548, Singapore.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Kyoto University;
   National University of Singapore; Singapore National Eye Center
RP Coscas, G (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM gabriel.coscas@gmail.com
RI Wong, Tien Yin/AAC-9724-2020; Miyake, Masahiro/V-1261-2019
OI Wong, Tien Yin/0000-0002-8448-1264; Miyake,
   Masahiro/0000-0001-7410-3764; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Tsujikawa, Akitaka/0000-0003-0779-7799;
   Yamashiro, Kenji/0000-0001-9354-8558
FU Allergan; Bayer; Novartis; Pfizer; Roche; GlaxoSmithKline; Topcon
   Corporation; Nidek; Canon; Japan Society for the Promotion of Science
   (JSPS) [24592624]
FX Financial disclosures: G. Coscas: Allergan (financial support,
   consultant), Bayer (financial support, consultant), Novartis (financial
   support, consultant); F. Coscas: Bayer (financial support); A.
   Tsujikawa: Pfizer (grant support); C.M.G. Cheung: Bayer (financial
   support, consultant), Novartis (financial support, consultant), Roche
   (grant support), GlaxoSmithKline (grant support); N. Yoshimura: Topcon
   Corporation (financial support), Nidek (financial support, consultant),
   Canon (financial support). This research was supported in part by the
   Grant-in-Aid for Scientific Research (24592624) from the Japan Society
   for the Promotion of Science (JSPS). Author contributions: conception
   and deign (G.C., K.Y., N.Y.); analysis and interpretation (K.Y., F.C.,
   U.D.B., A.T., M.M., C.M.G.C., T.Y.W., N.Y.); writing the article (G.C.,
   K.Y., A.T., T.Y.W., N.Y.); critical revision of the article (G.C.,
   T.Y.W., N.Y.); final approval of the article (G.C., K.Y., F.C., U.D.B.,
   A.T., M.M., C.M.G.C., T.Y.W., and N.Y.); data collection (F.C., U.D.B.,
   M.M.); provision of materials (F.C., U.D.B., M.M.); statistical
   expertise (K.Y.); obtaining funding (G.C., T.Y.W., N.Y.); literature
   search (K.Y., AT.).
CR Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   George S, 2010, EYE, V24, P1247, DOI 10.1038/eye.2009.301
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Iwama D, 2010, JPN J OPHTHALMOL, V54, P364, DOI 10.1007/s10384-010-0819-8
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tsujikawa A, 2011, EYE, V25, P481, DOI 10.1038/eye.2010.232
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Yamashiro K, 2007, JPN J OPHTHALMOL, V51, P368, DOI 10.1007/s10384-007-0465-y
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 25
TC 67
Z9 69
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2014
VL 158
IS 2
BP 309
EP 318
DI 10.1016/j.ajo.2014.05.004
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN6EB
UT WOS:000340686600015
PM 24844973
DA 2022-11-30
ER

PT J
AU Adams, MKM
   Simpson, JA
   Aung, KZ
   Makeyeva, GA
   Giles, GG
   English, DR
   Hopper, J
   Guymer, RH
   Baird, PN
   Robman, LD
AF Adams, Madeleine K. M.
   Simpson, Julie A.
   Aung, Khin Zaw
   Makeyeva, Galina A.
   Giles, Graham G.
   English, Dallas R.
   Hopper, John
   Guymer, Robyn H.
   Baird, Paul N.
   Robman, Liubov D.
TI Abdominal Obesity and Age-related Macular Degeneration
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE aging; macular degeneration; obesity
ID BODY-MASS INDEX; CARDIOVASCULAR RISK-FACTORS; ALL-CAUSE MORTALITY;
   BLUE-MOUNTAINS-EYE; COLON-CANCER RISK; WAIST CIRCUMFERENCE; PROSPECTIVE
   COHORT; POOLED FINDINGS; 3 CONTINENTS; MACULOPATHY
AB Evidence for an association between age-related macular degeneration (AMD) and obesity is inconsistent. The authors examined associations between adiposity and AMD prevalence using 21,287 participants from the Melbourne Collaborative Cohort Study aged 40-69 years at baseline (1990-1994). For men, each increase of 0.1 in waist/hip ratio (similar to 1 standard deviation) was associated with a 13% increase in the odds of early AMD (odds ratio - 1.13, 95% confidence interval: 1.01, 1.26; P = 0.03) and a 75% increase in the odds of late AMD (odds ratio = 1.75, 95% confidence interval: 1.11, 2.76; P = 0.02). No other adiposity measure was associated with early AMD for men. Smoking status modified the relation between waist/hip ratio and early AMD (P = 0.05), with no association for former smokers. For women, there were inverse associations with early AMD for all adiposity measures (odds ratios = 0.89-0.93; P = 0.002-0.02), but no associations were observed for late AMD. This study confirms abdominal obesity as an AMD risk factor for men despite a survivorship effect from competing risks in morbidity and mortality. The inverse associations for women may reflect weaker true positive associations with AMD that are insufficient to overcome the survivorship effect. New data are provided on complex interactions between environmental exposures and AMD risk.
C1 [Adams, Madeleine K. M.; Aung, Khin Zaw; Makeyeva, Galina A.; Guymer, Robyn H.; Baird, Paul N.; Robman, Liubov D.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Simpson, Julie A.; Giles, Graham G.; English, Dallas R.; Hopper, John] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne Sch Populat Hlth, Melbourne, Vic, Australia.
   [Simpson, Julie A.; Giles, Graham G.; English, Dallas R.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne; Cancer Council
   Victoria
RP Adams, MKM (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM m.adams@pgrad.unimelb.edu.au
RI Simpson, Julie A/P-7299-2014; English, Dallas/AAH-5005-2019; Adams,
   Madeleine K M/B-7915-2016
OI English, Dallas/0000-0001-7828-8188; Adams, Madeleine K
   M/0000-0002-5277-5487; Giles, Graham/0000-0003-4946-9099; Baird,
   Paul/0000-0002-1305-3502; Simpson, Julie/0000-0002-2660-2013; Guymer,
   Robyn/0000-0002-9441-4356
FU VicHealth; Cancer Council Victoria; National Health and Medical Research
   Council of Australia (NHMRC) [209057, 251533, 396414]; Ophthalmic
   Research Institute of Australia; American Health Assistance Foundation;
   John Reid Charitable Trust; Perpetual Trustees; Royal Victorian Eye and
   Ear Hospital; Wagstaff Fellowship
FX This work was supported by VicHealth; the Cancer Council Victoria
   (initial cohort recruitment); and the National Health and Medical
   Research Council of Australia (NHMRC) (program grant 209057, capacity
   building grant 251533, and enabling grant 396414). The ophthalmic
   component was funded by the Ophthalmic Research Institute of Australia,
   American Health Assistance Foundation, John Reid Charitable Trust,
   Perpetual Trustees, and the Royal Victorian Eye and Ear Hospital. People
   support was provided through the NHMRC Practitioner Fellowship to R. H.
   G., Wagstaff Fellowship to L. D. R., and an NHMRC PhD. scholarship and
   Hugh Noel Puckle Scholarship to M. K. M. A. The Centre for Eye Research
   Australia (CERA) receives operational infrastructure support from the
   Victorian Government.
CR Adams KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMoa055643
   Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Atmon G, 2005, MECH AGEING DEV, V126, P341, DOI 10.1016/j.mad.2004.08.026
   Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRENNER DE, 1993, NEUROLOGY, V43, P293, DOI 10.1212/WNL.43.2.293
   Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501
   Connell PP, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/360764
   Das UN, 2010, NUTRITION, V26, P459, DOI 10.1016/j.nut.2009.09.020
   de Craen A J M, 2009, Tijdschr Gerontol Geriatr, V40, P237
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dixon JB, 2010, MOL CELL ENDOCRINOL, V316, P104, DOI 10.1016/j.mce.2009.07.008
   Elliot S, 2008, EXP EYE RES, V86, P653, DOI 10.1016/j.exer.2008.01.010
   FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   GARN SM, 1986, AM J CLIN NUTR, V44, P996, DOI 10.1093/ajcn/44.6.996
   Ghandehari H, 2009, INT J OBESITY, V33, P239, DOI 10.1038/ijo.2008.252
   Giles GG, 1990, P NUTR SOC AUST, V15, P61
   Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Li HK, 2010, INVEST OPHTH VIS SCI, V51, P3184, DOI 10.1167/iovs.09-4886
   Lohman TG, 1988, ANTROPOMETRIC STANDA
   MacInnis RJ, 2006, INT J CANCER, V118, P2628, DOI 10.1002/ijc.21638
   MacInnis RJ, 2006, INT J CANCER, V118, P1496, DOI 10.1002/ijc.21508
   MacInnis RJ, 2004, CANCER EPIDEM BIOMAR, V13, P2117
   MacInnis RJ, 2004, CANCER EPIDEM BIOMAR, V13, P553
   MacInnis RJ, 2003, CANCER EPIDEM BIOMAR, V12, P1417
   MacInnis RJ, 2006, CANCER CAUSE CONTROL, V17, P1291, DOI 10.1007/s10552-006-0074-y
   Marinou K, 2010, INT J CARDIOL, V138, P3, DOI 10.1016/j.ijcard.2009.03.135
   Marshall Stephen W, 2007, Epidemiol Perspect Innov, V4, P4, DOI 10.1186/1742-5573-4-4
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Moeini HA, 2005, BRIT J OPHTHALMOL, V89, P964, DOI 10.1136/bjo.2005.066241
   Nejat EJ, 2010, MATURITAS, V65, P106, DOI 10.1016/j.maturitas.2009.09.006
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Paunksnis A, 2005, EUR J OPHTHALMOL, V15, P255, DOI 10.1177/112067210501500213
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Reeves GK, 2007, BRIT MED J, V335, P1134, DOI 10.1136/bmj.39367.495995.AE
   Romero-Corral A, 2008, INT J OBESITY, V32, P959, DOI 10.1038/ijo.2008.11
   Rozing MP, 2009, AGING-US, V1, P714, DOI 10.18632/aging.100071
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seidell JC, 2010, EUR J CLIN NUTR, V64, P35, DOI 10.1038/ejcn.2009.71
   SIITERI PK, 1987, AM J CLIN NUTR, V45, P277, DOI 10.1093/ajcn/45.1.277
   Simpson JA, 2007, OBESITY, V15, P994, DOI 10.1038/oby.2007.622
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Teucher B, 2010, MATURITAS, V65, P112, DOI 10.1016/j.maturitas.2009.11.018
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   WeverlingRijnsburger AWE, 1997, LANCET, V350, P1119, DOI 10.1016/S0140-6736(97)04430-9
   Willett W., 1990, NUTR EPIDEMIOLOGY
NR 67
TC 70
Z9 71
U1 0
U2 16
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 1
PY 2011
VL 173
IS 11
BP 1246
EP 1255
DI 10.1093/aje/kwr005
PG 10
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 770AC
UT WOS:000291058400005
PM 21422060
OA Bronze
DA 2022-11-30
ER

PT J
AU El Chehab, H
   Kodjikian, L
   Lagenaite-Desmaizere, C
   Agard, E
   De Bats, F
   Mathis, T
   Dot, C
AF El Chehab, Hussam
   Kodjikian, Laurent
   Lagenaite-Desmaizere, Constance
   Agard, Emilie
   De Bats, Flore
   Mathis, Thibaud
   Dot, Corinne
TI Idiopathic polypoidal choroidal vasculopathy in Caucasians: The POLYON
   real-life study in 50 naive patients
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; retina-medical therapies; retinal
   pathology; research
ID RANIBIZUMAB; VERTEPORFIN; AFLIBERCEPT
AB Objectives: Polypoidal choroidal vasculopathy is a common disease in Asia, but it has been less described in the Caucasian population. The aim of this real-life observational study was to describe the diagnostic and therapeutic practices as well as the prognosis in this population.
   Method: Fifty Caucasian patients with polypoidal choroidal vasculopathy were included in this study. All patients underwent angiography to confirm the diagnosis. Patients were divided into two treatment groups: patients of group 1 only received anti-vascular endothelial growth factor injections and those of group 2 required photodynamic therapy rescue in addition to intravitreal injections in case of suboptimal (anatomically or functionally) response. Clinical (visual acuity, fundus examination), paraclinical (retinal pigment epithelium detachment height and central retinal thickness on optical coherence tomography), and therapeutic (number of intravitreal injections) criteria were analyzed after 24months.
   Results: Patient mean age was 73.99.1years, and half of the patients had age-related macular degeneration. In the whole cohort, the initial visual acuity was equivalent to the final visual acuity (59.9 +/- 24.0 letters vs 62.5 +/- 21.1 letters, p=0.259). In group 1, the final visual acuity was significantly increased (from 56.9 +/- 24.7 letters to 63.4 +/- 21.6 letters, p=0.016), while in group 2, it remained stable (from 61.7 +/- 23.4 letters to 61.0 +/- 21.4 letters, p=0.249). The number of intravitreal injections was similar between both groups.
   Conclusion: In a Caucasian population, polypoidal choroidal vasculopathy seems to have a later onset. A non-standardized management allows stabilizing the functional prognosis. Patients requiring photodynamic therapy rescue have a poorer prognosis.
C1 [El Chehab, Hussam; Lagenaite-Desmaizere, Constance; Agard, Emilie; Dot, Corinne] Hop Instruct Armees DESGENETTES, Serv Ophtalmol, 108 Blvd Pinel, F-69003 Lyon, France.
   [Kodjikian, Laurent; Mathis, Thibaud] Ctr Hosp Univ Croix Rousse, Serv Ophtalmol, Lyon, France.
   [De Bats, Flore] Clin Val Ouest, Pole Vis, Ecully, France.
   [Dot, Corinne] Ecole Val de Grace, Paris, France.
C3 CHU Lyon
RP El Chehab, H (通讯作者)，Hop Instruct Armees DESGENETTES, Serv Ophtalmol, 108 Blvd Pinel, F-69003 Lyon, France.
EM hussam.el-chehab@intradef.gouv.fr
RI Mathis, Thibaud/AAK-5745-2021; kodjikian, laurent/A-3025-2015
OI kodjikian, laurent/0000-0002-3908-6716
CR Agorogiannis EI, 2018, EYE, V32, P1731, DOI 10.1038/s41433-018-0168-2
   Baek J, 2019, INVEST OPHTH VIS SCI, V60, P590, DOI 10.1167/iovs.18-24244
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Di Pierdomenico J, 2016, INVEST OPHTH VIS SCI, V57, P3533, DOI 10.1167/iovs.16-19618
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   Khatri A, 2017, BMJ OPEN OPHTHALMOL, V2, DOI 10.1136/bmjophth-2017-000102
   Kinoshita T, 2017, BRIT J OPHTHALMOL, V101, P360, DOI 10.1136/bjophthalmol-2016-308594
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Moon Da Ru Chi, 2015, Korean J Ophthalmol, V29, P226, DOI 10.3341/kjo.2015.29.4.226
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Pak KY, 2017, RETINA-J RET VIT DIS, V37, P561, DOI 10.1097/IAE.0000000000001195
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wolff B, 2018, OPHTHALMOLOGICA, V240, P208, DOI 10.1159/000488808
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 1982, ARCH OPHTHALMOL-CHIC, V116, P382
NR 24
TC 4
Z9 4
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP
PY 2020
VL 30
IS 5
BP 948
EP 955
AR 1120672119874674
DI 10.1177/1120672119874674
EA SEP 2019
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OB6JS
UT WOS:000491080000001
PM 31505993
DA 2022-11-30
ER

PT J
AU Hogg, RE
AF Hogg, Ruth Esther
TI Reticular Pseudodrusen in Age-Related Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Review
DE age-related macular degeneration; reticular drusen; reticular
   pseudodrusen; subretinal drusenoid deposits
ID SUBRETINAL DRUSENOID DEPOSITS; GEOGRAPHIC ATROPHY; FUNDUS
   AUTOFLUORESCENCE; FELLOW EYES; HIGH-RISK; PREVALENCE; CLASSIFICATION;
   SENSITIVITY
AB Historically, drusen, which are recognized as the hallmark of age-related macular degeneration (AMD), have been described in terms of size, margins, and texture, and several studies have emphasized the importance of large soft drusen particularly when combined with focal pigmentary irregularities in determining the risk of progression to neovascular AMD. However, recent developments in imaging over the past decade have revealed a further distinct phenotype strongly associated with the development of late AMD, namely, reticular pseudodrusen (RPD) or reticular drusen. Reticular pseudodrusen appear as yellowish interlacing networks in the fundus and, although visible on color photography, are better visualized using infrared imaging or spectral domain optical coherence tomography. Studies correlating spectral domain optical coherence tomography and confocal scanning laser ophthalmoscopy have shown that RPD are subretinal deposits located internal to the retinal pigment epithelium in contrast to traditional drusen, which are located external to the retinal pigment epithelium. As multiple longitudinal studies have revealed RPD are strong predictors for progression to both neovascular AMD and geographic atrophy, the interest in understanding the role that RPD play in the pathogenesis of AMD has grown. This review focuses on the current literature concerning RPD and considers what is currently known regarding their epidemiology, risk factors, appearance in both retinal imaging and histology, impact on visual function, relationship to other AMD lesions, and association with the development of late AMD.
C1 [Hogg, Ruth Esther] Royal Victoria Hosp, Ctr Med Expt, Inst Clin Sci A, Belfast BT12 6BA, Antrim, North Ireland.
RP Hogg, RE (通讯作者)，Queens Unviers Belfast, Inst Clin Sci A, Ctr Med Expt, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM r.e.hogg@qub.ac.uk
RI Hogg, Ruth E./ABC-9602-2020
OI Hogg, Ruth E./0000-0001-9413-2669
CR Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Alten F, 2012, INVEST OPHTH VIS SCI, V53, P6263, DOI 10.1167/iovs.12-10094
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2013, OPHTHALMOLOGY, V120, P872, DOI 10.1016/j.ophtha.2012.12.007
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1163, DOI 10.1097/IAE.0b013e3181ed8d05
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 43
TC 18
Z9 18
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 854
EP 859
DI 10.1097/OPX.0000000000000287
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500007
PM 24950032
DA 2022-11-30
ER

PT J
AU Wang, SS
   Koster, KM
   He, YG
   Zhou, QB
AF Wang, Shusheng
   Koster, Kyle M.
   He, Yuguang
   Zhou, Qinbo
TI miRNAs as potential therapeutic targets for age-related macular
   degeneration
SO FUTURE MEDICINAL CHEMISTRY
LA English
DT Article
DE Age-related macular degeneration; Geographic atrophy; Choroidal
   neovascularization; miRNA
ID RETINAL-PIGMENT EPITHELIUM; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   FACTOR-H POLYMORPHISM; INFLAMMATORY RESPONSE; TUMOR ANGIOGENESIS;
   IN-VIVO; VASCULAR INTEGRITY; MICRORNA MIR-126; OXIDATIVE STRESS;
   GROWTH-FACTOR
AB Since their recent discovery, miRNAs have been shown to play critical roles in a variety of pathophysiological processes. Such processes include pathological angiogenesis, the oxidative stress response, immune response and inflammation, all of which have been shown to have important and interdependent roles in the pathogenesis and progression of age-related macular degeneration (AMD). Here we present a brief review of the pathological processes involved in AMD and review miRNAs and other noncoding RNAs involved in regulating these processes. Specifically, we discuss several candidate miRNAs that show promise as AMD therapeutic targets due to their direct involvement in choroidal neovascularization or retinal pigment epithelium atrophy. We discuss potential miRNA-based therapeutics and delivery methods for AMD and provide future directions for the field of miRNA research with respect to AMD. We believe the future of miRNAs in AMD therapy is promising.
C1 [Wang, Shusheng; Koster, Kyle M.; He, Yuguang; Zhou, Qinbo] Univ Texas SW Med Ctr Dallas, Dept Ophthalmol, Dallas, TX 75390 USA.
   [Wang, Shusheng] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; University of Texas
   Southwestern Medical Center Dallas
RP Wang, SS (通讯作者)，Univ Texas SW Med Ctr Dallas, Dept Ophthalmol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM shusheng.wang@utsouthwestern.edu
OI Zhou, Qinbo/0000-0002-7967-2138
FU Department of Ophthalmology at UT Southwestern Medical Center;
   President's Research Council; NIH [EY021862, EY020799]; Research to
   Prevent Blindness; NATIONAL EYE INSTITUTE [P30EY020799, R01EY021862]
   Funding Source: NIH RePORTER
FX S Wang was supported by a Startup fund from the Department of
   Ophthalmology at UT Southwestern Medical Center, President's Research
   Council New Investigator Award, NIH Grants EY021862 and EY020799,
   Research to Prevent Blindness Career Development Award and by an
   unrestricted grant from Research to Prevent Blindness. The authors have
   no other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand S, 2010, NAT MED, V16, P909, DOI 10.1038/nm.2186
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Bader AG, 2010, CANCER RES, V70, P7027, DOI 10.1158/0008-5472.CAN-10-2010
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bazzoni F, 2009, P NATL ACAD SCI USA, V106, P5282, DOI 10.1073/pnas.0810909106
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beckman JD, 2011, J BIOL CHEM, V286, P3194, DOI 10.1074/jbc.M110.148726
   Bhaumik D, 2009, AGING-US, V1, P402, DOI 10.18632/aging.100042
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Cha ST, 2010, CANCER RES, V70, P2675, DOI 10.1158/0008-5472.CAN-09-2448
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chang CL, 2011, ENDOCRINOLOGY, V152, P384, DOI 10.1210/en.2010-0493
   Cheloufi S, 2010, NATURE, V465, P584, DOI 10.1038/nature09092
   Chen Z, 2010, ONCOGENE, V29, P4362, DOI 10.1038/onc.2010.193
   Cheng YH, 2009, J MOL CELL CARDIOL, V47, P5, DOI 10.1016/j.yjmcc.2009.01.008
   Cifuentes D, 2010, SCIENCE, V328, P1694, DOI 10.1126/science.1190809
   Csaky K, 2004, ARCH OPHTHALMOL-CHIC, V122, P650, DOI 10.1001/archopht.122.4.650
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dentelli P, 2010, ARTERIOSCL THROM VAS, V30, P1562, DOI 10.1161/ATVBAHA.110.206201
   Devlin C, 2011, IUBMB LIFE, V63, P94, DOI [10.1002/iub.427, 10.1002/iub.00427]
   Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ebert MS, 2010, RNA, V16, P2043, DOI 10.1261/rna.2414110
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200
   Favaro E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010345
   Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008
   Fleissner F, 2010, CIRC RES, V107, P138, DOI 10.1161/CIRCRESAHA.110.216770
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gong AY, 2009, J IMMUNOL, V182, P1325, DOI 10.4049/jimmunol.182.3.1325
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Grundmann S, 2011, CIRCULATION, V123, P999, DOI 10.1161/CIRCULATIONAHA.110.000323
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Hua Z, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000116
   Huang RS, 2010, J INVEST MED, V58, P961, DOI 10.231/JIM.0b013e3181ff46d7
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jennewein C, 2010, J BIOL CHEM, V285, P11846, DOI 10.1074/jbc.M109.066399
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kim YM, 2011, ANTIOXID REDOX SIGN, V14, P137, DOI 10.1089/ars.2010.3153
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Krutzfeldt J, 2007, NUCLEIC ACIDS RES, V35, P2885, DOI 10.1093/nar/gkm024
   Kuhnert F, 2008, DEVELOPMENT, V135, P3989, DOI 10.1242/dev.029736
   Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06
   Kumar M, 2011, J ALLERGY CLIN IMMUN, V128, P1077, DOI 10.1016/j.jaci.2011.04.034
   Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178
   Lee DY, 2007, P NATL ACAD SCI USA, V104, P20350, DOI 10.1073/pnas.0706901104
   Li GR, 2011, INVEST OPHTH VIS SCI, V52, P2999, DOI 10.1167/iovs.10-6708
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Liu LZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019139
   Magenta A, 2011, CELL DEATH DIFFER, V18, P1628, DOI 10.1038/cdd.2011.42
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   Mingozzi F, 2011, NAT REV GENET, V12, P341, DOI 10.1038/nrg2988
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Moschos SA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-240
   Mutharasan RK, 2011, AM J PHYSIOL-HEART C, V301, pH1519, DOI 10.1152/ajpheart.01080.2010
   Niu YN, 2011, IMMUNOLOGY, V133, P8, DOI 10.1111/j.1365-2567.2010.03374.x
   O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104
   Perry MM, 2008, J IMMUNOL, V180, P5689, DOI 10.4049/jimmunol.180.8.5689
   Pieramici DJ, 2008, EYE, V22, P1330, DOI 10.1038/eye.2008.88
   Pogue AI, 2009, J INORG BIOCHEM, V103, P1591, DOI 10.1016/j.jinorgbio.2009.05.012
   Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266
   Qian L, 2011, J EXP MED, V208, P549, DOI 10.1084/jem.20101547
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Sabatel C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016979
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Seto AG, 2010, INT J BIOCHEM CELL B, V42, P1298, DOI 10.1016/j.biocel.2010.03.003
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Sonkoly E, 2008, SEMIN CANCER BIOL, V18, P131, DOI 10.1016/j.semcancer.2008.01.005
   Synowiec E, 2012, MOL BIOL REP, V39, P2081, DOI 10.1007/s11033-011-0955-3
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Thulasingam S, 2011, MOL CELL BIOCHEM, V352, P181, DOI 10.1007/s11010-011-0752-2
   Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   van Solingen C, 2009, J CELL MOL MED, V13, P1577, DOI 10.1111/j.1582-4934.2008.00613.x
   Walker JC, 2009, GENE DEV, V23, P1046, DOI 10.1101/gad.1777709
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002
   Wang SS, 2009, CURR OPIN GENET DEV, V19, P205, DOI 10.1016/j.gde.2009.04.002
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228
   Wurdinger T, 2008, CANCER CELL, V14, P382, DOI 10.1016/j.ccr.2008.10.005
   Xiao JA, 2011, INT J CARDIOL, V148, P110, DOI 10.1016/j.ijcard.2011.01.029
   Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107
   Yang K, 2011, FEBS LETT, V585, P854, DOI 10.1016/j.febslet.2011.02.009
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 105
TC 48
Z9 54
U1 0
U2 17
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 1756-8919
EI 1756-8927
J9 FUTURE MED CHEM
JI Future Med. Chem.
PD MAR
PY 2012
VL 4
IS 3
BP 277
EP 287
DI 10.4155/fmc.11.176
PG 11
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 912XE
UT WOS:000301833900007
PM 22393936
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Smith, AG
   Kaiser, PK
AF Smith, Adiel G.
   Kaiser, Peter K.
TI Emerging treatments for wet age-related macular degeneration
SO EXPERT OPINION ON EMERGING DRUGS
LA English
DT Review
DE aflibercept; age-related macular degeneration; bevacizumab; choroidal
   neovascularization; ranibizumab; vascular endothelial growth factor
ID THERAPIES; SAFETY; BRACHYTHERAPY; RANIBIZUMAB; PEGAPTANIB
AB Introduction: Wet or exudative age-related macular degeneration (AMD) is the leading cause of blindness in the United States for individuals over the age of 65 years. Wet AMD is characterized by the formation of choroidal neovascularization, which can lead to edema, hemorrhage and scarring of the macula. This leads to metamorphopsia and vision loss. Without treatment, the loss of vision is permanent. The current gold standard treatment of wet AMD consists of intravitreal injections of anti-vascular endothelial growth factor (VEGF) medications.
   Areas covered: Numerous new therapies in the drug pipeline aim at addressing limitations of current treatments. Future therapies involve novel compounds that attack different parts of the VEGF cascade, novel delivery systems aimed at reducing the frequency of intraocular injections, combination therapies and the use of radiation in conjunction with intravitreal therapies.
   Expert opinion: Limitations of current treatments include the need for repeated injections, the high financial costs and treatment burdens of repeated injections, the risk of adverse ocular and systemic adverse events, and the inability to completely reverse the disease process of wet AMD. There are many new therapies and approaches in the pipeline which hold promise for improving the treatment of wet AMD.
C1 [Smith, Adiel G.; Kaiser, Peter K.] Cole Eye Inst, Cleveland, OH 44195 USA.
RP Kaiser, PK (通讯作者)，Cole Eye Inst, 9500 Euclid Ave,Desk i3, Cleveland, OH 44195 USA.
EM pkkaiser@gmail.com
OI Kaiser, Peter/0000-0001-5126-045X
CR Bagley RG, 2011, MOL CANCER THER, V10, P404, DOI 10.1158/1535-7163.MCT-10-0813
   Beutel J, 2009, EXPERT OPIN EMERG DR, V14, P341, DOI [10.1517/14728210902824141, 10.1517/14728210902824141 ]
   Biomedical Clearside, CLEARS BIOM LAUNCH P
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Di Pietro C., 2013, OSN RETINA, V31, P30
   Dugel P, 2009, RETINA TODAY, V4, P38
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Dugel PU, 2012, RET SUBSP DAY 9 10 N
   Englander M, 2013, CURR OPIN OPHTHALMOL, V24, P233, DOI 10.1097/ICU.0b013e32835f8eaa
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Helzner J., 2013, OPHTH MANAG
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Joussen AM, 2009, DTSCH ARZTEBL INT, V106, P312, DOI 10.3238/arztebl.2009.0312
   Kaiser PK, 2012, GRAEF ARCH CLIN EXP, V250, P1563, DOI 10.1007/s00417-012-2123-4
   Kuno N, 2012, RETINA TODAY, P54
   Martin D, 2012, TLS-TIMES LIT SUPPL, P6
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Petrarca R, 2013, OPHTHALMOLOGY, V120, P328, DOI 10.1016/j.ophtha.2012.07.091
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saati S, 2010, CURR EYE RES, V35, P192, DOI 10.3109/02713680903521936
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Tetz M, 2012, OPHTHALMOLOGICA, V227, P183, DOI 10.1159/000336045
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 32
TC 36
Z9 37
U1 2
U2 42
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1472-8214
EI 1744-7623
J9 EXPERT OPIN EMERG DR
JI Expert Opin Emerg. Drugs
PD MAR
PY 2014
VL 19
IS 1
BP 157
EP 164
DI 10.1517/14728214.2014.884559
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AC7YY
UT WOS:000332751400011
PM 24555421
DA 2022-11-30
ER

PT J
AU Haapanen, MJ
   von Bonsdorff, MB
   Fisher, D
   Jonasson, F
   Eiriksdottir, G
   Gudnason, V
   Cotch, MF
AF Haapanen, Markus J.
   von Bonsdorff, Mikaela B.
   Fisher, Diana
   Jonasson, Fridbert
   Eiriksdottir, Gudny
   Gudnason, Vilmundur
   Cotch, Mary Frances
TI Body size at birth and age-related macular degeneration in old age
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; body size at birth
ID CORONARY-HEART-DISEASE; SUBSEQUENT RISK; WEIGHT; PREVALENCE;
   MACULOPATHY; HYPERTENSION; POPULATION; LIFE
AB Purpose To study associations between body size at birth and age-related macular degeneration (AMD) in old age. Methods The study sample consists of 1497 community-dwelling individuals (56.1% women) aged 67-89 years with birth data and retinal data collected twice in old age 5 years apart. Birth data (weight, length, birth order) were extracted from original birth records. Digital retinal photographs were graded to determine AMD status. Data on covariates were collected at the baseline physical examination in old age. Multivariable regression analyses were used to study the association between birth data and AMD adjusting for known confounding factors, including birth year cohort effects. Results The prevalence and 5-year incidence of any AMD were 33.1% and 17.0%, respectively. Men and women born in 1930-1936 were significantly leaner and slightly longer at birth compared to those in earlier birth cohorts. There were no consistent associations between weight, length or ponderal index (PI) at birth and AMD in old age even when stratified by birth cohort. Age-related macular degeneration (AMD) prevalence (39.8%) and 5-year incidence (28.6%) were highest in individuals who were in the highest quartile of PI at birth and who were obese in old age. Conclusion Body size at birth was not consistently associated with AMD in old age, suggesting that intrauterine growth might have little direct importance in the development of AMD in old age. It is possible that some yet unknown factors related to larger size at birth and obesity in old age may explain differences in the prevalence and incidence of AMD in the ageing population.
C1 [Haapanen, Markus J.] Univ Helsinki, Dept Gen Practice & Primary Hlth Care, POB 20, FI-00014 Helsinki, Finland.
   [Haapanen, Markus J.] Helsinki Univ Hosp, Helsinki, Finland.
   [Haapanen, Markus J.; von Bonsdorff, Mikaela B.] Folkhalsan Res Ctr, Helsinki, Finland.
   [von Bonsdorff, Mikaela B.] Univ Jyvaskyla, Fac Sport & Hlth Sci, Gerontol Res Ctr, Jyvaskyla, Finland.
   [Fisher, Diana; Cotch, Mary Frances] NEI, Div Epidemiol & Clin Applicat, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
   [Jonasson, Fridbert; Eiriksdottir, Gudny; Gudnason, Vilmundur] Univ Iceland, Fac Med, Reykjavik, Iceland.
   [Jonasson, Fridbert] Natl Univ Hosp Iceland, Landspitali, Dept Ophthalmol, Reykjavik, Iceland.
   [Eiriksdottir, Gudny; Gudnason, Vilmundur] Iceland Heart Assoc, Kopavogur, Iceland.
C3 University of Helsinki; University of Helsinki; Helsinki University
   Central Hospital; Folkhalsan Research Center; University of Jyvaskyla;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Iceland; Landspitali National University Hospital;
   Icelandic Heart Association
RP Haapanen, MJ (通讯作者)，Univ Helsinki, Dept Gen Practice & Primary Hlth Care, POB 20, FI-00014 Helsinki, Finland.
EM markus.haapanen@helsinki.fi
RI Jonasson, Fridbert/ABA-9889-2021; Gudnason, Vilmundur/K-6885-2015; von
   Bonsdorff, Mikaela/A-5218-2015
OI Haapanen, Markus/0000-0002-8632-7906; Gudnason,
   Vilmundur/0000-0001-5696-0084; von Bonsdorff,
   Mikaela/0000-0001-8530-5230; Cotch, Mary Frances/0000-0002-2046-4350
FU National Institutes of Health (Intramural Research Program of the
   National Institute of Aging); National Institutes of Health (National
   Eye Institute) [ZIAEY00401]; National Institute of Health
   [N01-AG-1-2100]; Icelandic Heart Association; University of Iceland
   Research Fund; Helga Jonsdottir and Sigurlidi Kristjansson Research
   Fund; Icelandic Parliament; NATIONAL EYE INSTITUTE [ZIAEY000401] Funding
   Source: NIH RePORTER
FX This work was supported by the National Institutes of Health (Intramural
   Research Program of the National Institute of Aging and the National Eye
   Institute, ZIAEY00401), National Institute of Health contract number
   N01-AG-1-2100, the Icelandic Heart Association, the Icelandic
   Parliament, the University of Iceland Research Fund and the Helga
   Jonsdottir and Sigurlidi Kristjansson Research Fund. The sponsor or
   funding organization had no role in the design or conduct of this
   research.
CR [Anonymous], 2015, ESAPWP241
   Atladottir H, 2000, EUR J CLIN NUTR, V54, P695, DOI 10.1038/sj.ejcn.1601078
   Barker D.J.P., 1998, MOTHERS BABIES HLTH
   BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171
   Birgisdottir BE, 2002, AM J CLIN NUTR, V76, P399, DOI 10.1093/ajcn/76.2.399
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Fiess A, 2019, JAMA OPHTHALMOL, V137, P507, DOI 10.1001/jamaophthalmol.2018.7121
   Gunnarsdottir I, 2002, J HYPERTENS, V20, P623, DOI 10.1097/00004872-200204000-00018
   Haapanen MJ, 2018, AGE AGEING, V47, P569, DOI 10.1093/ageing/afy052
   Hall NF, 2002, INVEST OPHTH VIS SCI, V43, P3641
   Hanson MA, 2016, J PHYSIOL-LONDON, V594, P2147, DOI 10.1113/JP270579
   Harder T, 2007, AM J EPIDEMIOL, V165, P849, DOI 10.1093/aje/kwk071
   Harris TB, 2007, AM J EPIDEMIOL, V165, P1076, DOI 10.1093/aje/kwk115
   Hendrickson A, 2016, AM J OPHTHALMOL, V161, P29, DOI 10.1016/j.ajo.2015.09.023
   Huang GH, 2003, AM J EPIDEMIOL, V157, P721, DOI 10.1093/aje/kwg011
   Imai CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044551
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Li XQ, 2015, INVEST OPHTH VIS SCI, V56, P617, DOI 10.1167/iovs.14-15016
   Liew G, 2008, OPHTHAL EPIDEMIOL, V15, P56, DOI 10.1080/09286580701613769
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Sayer AA, 1998, AGE AGEING, V27, P579, DOI 10.1093/ageing/27.5.579
   SIGURDSSON E, 1993, EUR HEART J, V14, P584, DOI 10.1093/eurheartj/14.5.584
   Wang SF, 2014, J DEV ORIG HLTH DIS, V5, P408, DOI 10.1017/S2040174414000440
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu ZB, 2011, OBES REV, V12, P525, DOI 10.1111/j.1467-789X.2011.00867.x
   Zhang Y, 2013, HYPERTENS RES, V36, P725, DOI 10.1038/hr.2013.33
NR 31
TC 0
Z9 0
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2020
VL 98
IS 5
BP 455
EP 463
DI 10.1111/aos.14340
EA DEC 2019
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ML4LC
UT WOS:000504680000001
PM 31885211
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Falavarjani, KG
   Sadda, SR
AF Falavarjani, Khalil Ghasemi
   Sadda, Srinivas R.
TI Hot Topics in Pharmacotherapy for Neovascular Age-Related Macular
   Degeneration
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Aflibercept; age-related macular degeneration; choroidal
   neovascularization; conbercept; designed ankyrin repeat proteins;
   encapsulated cell technology; pharmacotherapy; platelet derived growth
   factor; ranibizumab; squalamine; vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB; VERTEPORFIN; EFFICACY; DELIVERY;
   SAFETY; RISK; WET
AB Background: The preferred approach for the treatment of neovascular age-related macular degeneration (AMD) is frequent intravitreal injections of the anti-vascular endothelial growth factor (VEGF) agents. However, considering the limitations of current anti-VEGF approaches, including the need for frequent injections, inadequate response in some patients, and a relatively short duration of effect, several new therapeutic modalities are under evaluation.
   Methods: A comprehensive review of the literature was performed on the new treatment modalities for neovascular AMD, and the relevant studies were discussed.
   Results: The treatment modalities for neovascular AMD include new anti-VEGF drugs, new drug delivery systems and new targets in the pathogenic cascade of choroidal neovascularization. These new modalities are in different phases of clinical development.
   Conclusion: The results of the completed studies reporting the new therapeutic modalities for neovascular AMD thus far are promising.
C1 [Falavarjani, Khalil Ghasemi; Sadda, Srinivas R.] Doheny Eye Inst, 1355 San Pablo St,DVRC 211, Los Angeles, CA 90033 USA.
   [Falavarjani, Khalil Ghasemi; Sadda, Srinivas R.] Univ Calif Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA USA.
   [Falavarjani, Khalil Ghasemi] Iran Univ Med Sci, Rassoul Akram Hosp, Eye Res Ctr, Tehran, Iran.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Iran University of
   Medical Sciences
RP Falavarjani, KG (通讯作者)，Doheny Eye Inst, 1355 San Pablo St,DVRC 211, Los Angeles, CA 90033 USA.
EM drghasemi@yahoo.com
RI Falavarjani, Khalil Ghasemi/I-4029-2019
OI Ghasemi Falavarjani, Khalil/0000-0001-5221-1844
FU Optos; Genentech; Allergan; Carl Zeiss Meditec
FX Dr. Falavarjani has no financial interest to declare. Dr. Sadda is a
   consultant for Optos, Genentech, and Allergan and receives research
   support from Optos, Genentech, Allergan, and Carl Zeiss Meditec.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Barakat MR DP, 2015, RETIN PHYS, V12, P26
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Dalal M, 2013, GRAEF ARCH CLIN EXP, V251, P2705, DOI 10.1007/s00417-013-2375-7
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hanout M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/830837
   Hashemi S, 2014, EXPERT OPIN BIOL TH, V14, P1837, DOI 10.1517/14712598.2014.967210
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Humayun M, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.6.5
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Kaiser PK, 2009, CURR MED RES OPIN, V25, P1853, DOI 10.1185/03007990903038616
   Kauper K, 2012, INVEST OPHTH VIS SCI, V53, P7484, DOI 10.1167/iovs.12-9970
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lu F, 2009, INVEST OPHTH VIS SCI, V50, P3890, DOI 10.1167/iovs.08-2833
   Lu Lawrence P. L., 2007, Hong Kong Medical Journal, V13, P460
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Pecen PE, 2015, CURR OPIN OPHTHALMOL, V26, P188, DOI 10.1097/ICU.0000000000000147
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Prea SM, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/201726
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Santulli RJ, 2008, J PHARMACOL EXP THER, V324, P894, DOI 10.1124/jpet.107.131656
   Schmid MK, 2014, BR J OPHTHALMOL, P14
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Vinores SA, 2006, INT J NANOMED, V1, P263
   Wang GF, 2012, INT J OPHTHALMOL-CHI, V5, P609, DOI 10.3980/j.issn.2222-3959.2012.05.13
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yazdi MH, 2015, EXPERT OPIN BIOL TH, V15, P1349, DOI 10.1517/14712598.2015.1057565
   Zampros I, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/319728
NR 34
TC 7
Z9 7
U1 2
U2 13
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2017
VL 23
IS 4
BP 535
EP 541
DI 10.2174/1381612822666161216121105
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EN0FI
UT WOS:000395685300002
PM 27981904
DA 2022-11-30
ER

PT J
AU Shughoury, A
   Sevgi, DD
   Ciulla, TA
AF Shughoury, Aumer
   Sevgi, Duriye Damla
   Ciulla, Thomas A.
TI Molecular Genetic Mechanisms in Age-Related Macular Degeneration
SO GENES
LA English
DT Review
DE age-related macular degeneration; AMD; genetics; CFH; ARMS2; HTRA1;
   TIMP-3; gene therapy
ID COMPLEMENT-FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; SINGLE-NUCLEOTIDE
   POLYMORPHISMS; POLYPOIDAL CHOROIDAL VASCULOPATHY; GENOME-WIDE
   ASSOCIATION; MATRIX METALLOPROTEINASES POLYMORPHISMS; SEQUENCING
   IDENTIFIES RARE; MESSENGER-RNA EXPRESSION; APOLIPOPROTEIN-E GENE; BRUCHS
   MEMBRANE
AB Age-related macular degeneration (AMD) is among the leading causes of irreversible blindness worldwide. In addition to environmental risk factors, such as tobacco use and diet, genetic background has long been established as a major risk factor for the development of AMD. However, our ability to predict disease risk and personalize treatment remains limited by our nascent understanding of the molecular mechanisms underlying AMD pathogenesis. Research into the molecular genetics of AMD over the past two decades has uncovered 52 independent gene variants and 34 independent loci that are implicated in the development of AMD, accounting for over half of the genetic risk. This research has helped delineate at least five major pathways that may be disrupted in the pathogenesis of AMD: the complement system, extracellular matrix remodeling, lipid metabolism, angiogenesis, and oxidative stress response. This review surveys our current understanding of each of these disease mechanisms, in turn, along with their associated pathogenic gene variants. Continued research into the molecular genetics of AMD holds great promise for the development of precision-targeted, personalized therapies that bring us closer to a cure for this debilitating disease.
C1 [Shughoury, Aumer; Sevgi, Duriye Damla; Ciulla, Thomas A.] Indiana Univ Sch Med, Eugene & Marilyn Glick Eye Inst, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Ciulla, Thomas A.] Clearside Biomed Inc, Alpharetta, GA 30005 USA.
   [Ciulla, Thomas A.] Midwest Eye Inst, Indianapolis, IN 46290 USA.
C3 Indiana University System; Indiana University Bloomington
RP Ciulla, TA (通讯作者)，Indiana Univ Sch Med, Eugene & Marilyn Glick Eye Inst, Dept Ophthalmol, Indianapolis, IN 46202 USA.; Ciulla, TA (通讯作者)，Clearside Biomed Inc, Alpharetta, GA 30005 USA.; Ciulla, TA (通讯作者)，Midwest Eye Inst, Indianapolis, IN 46290 USA.
EM ashughou@iu.edu; dsevgi@iu.edu; thomasciulla@gmail.com
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   Ajana S, 2021, OPHTHALMOLOGY, V128, P587, DOI 10.1016/j.ophtha.2020.08.031
   Akagi-Kurashige Y, 2015, OPHTHALMOLOGY, V122, P2295, DOI 10.1016/j.ophtha.2015.07.032
   Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Albig AR, 2004, DNA CELL BIOL, V23, P367, DOI 10.1089/104454904323145254
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Ardeljan D, 2013, EUR J HUM GENET, V21, P1152, DOI 10.1038/ejhg.2013.14
   Armento A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67292-z
   Arpino V, 2015, MATRIX BIOL, V44-46, P247, DOI 10.1016/j.matbio.2015.03.005
   Auer-Grumbach M, 2011, BRAIN, V134, P1839, DOI 10.1093/brain/awr076
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Baas DC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013786
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Bailey TA, 2001, EXP EYE RES, V73, P851, DOI 10.1006/exer.2001.1089
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Barter P, 2003, ATHEROSCLEROSIS, V168, P195, DOI 10.1016/S0021-9150(03)00006-6
   Battu P, 2021, CURR NEUROVASC RES, V18, P181, DOI 10.2174/1567202618666210531130711
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beguier F, 2020, IMMUNITY, V53, P429, DOI 10.1016/j.immuni.2020.07.021
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Blasiak J, 2012, INT J MOL SCI, V13, P13378, DOI 10.3390/ijms131013378
   Bojanowski Christine M, 2005, Trans Am Ophthalmol Soc, V103, P37
   Bonilla B, 2020, ANNU REV GENET, V54, P25, DOI 10.1146/annurev-genet-021920-092410
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   Budiene B, 2018, OPHTHALMIC GENET, V39, P463, DOI 10.1080/13816810.2018.1484928
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Canfield AE, 2007, BIOCHEM SOC T, V35, P669, DOI 10.1042/BST0350669
   Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chavali VRM, 2019, INVEST OPHTH VIS SCI, V60
   Chen H, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-2447
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheng J, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008190
   Cheng Y, 2019, MOL IMMUNOL, V106, P119, DOI 10.1016/j.molimm.2018.12.026
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Chu XK, 2014, AGE, V36, P1453, DOI 10.1007/s11357-014-9627-2
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Colijn JM, 2021, OPHTHALMOLOGY, V128, P1039, DOI 10.1016/j.ophtha.2020.11.024
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Connolly E, 2018, BRIT J OPHTHALMOL, V102, P1691, DOI 10.1136/bjophthalmol-2017-311673
   Corominas J, 2018, OPHTHALMOLOGY, V125, P1433, DOI 10.1016/j.ophtha.2018.03.040
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Csaky K.G., 2017, J VITR DIS, V1, P75, DOI [10.1177/2474126416680671, DOI 10.1177/2474126416680671]
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD182, DOI 10.1167/iovs.18-24883
   Curcio CA, 2011, P NATL ACAD SCI USA, V108, P18569, DOI 10.1073/pnas.1115497108
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Danobeitia JS, 2014, FIBROGENESIS TISSUE, V7, DOI 10.1186/1755-1536-7-16
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   de Breuk Anita, 2021, Ophthalmol Sci, V1, P100087, DOI 10.1016/j.xops.2021.100087
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Guimaraes TAC, 2021, BRIT J OPHTHALMOL, V105, P151, DOI 10.1136/bjophthalmol-2020-316195
   de Guimaraes TAC, 2022, BRIT J OPHTHALMOL, V106, P297, DOI 10.1136/bjophthalmol-2020-318452
   de Jong S, 2020, HUM MOL GENET, V29, P2313, DOI 10.1093/hmg/ddaa114
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   den Hollander AI, 2019, OPHTHALMOLOGY, V126, P1422, DOI 10.1016/j.ophtha.2019.04.033
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   DISCIPIO RG, 1992, J BIOL CHEM, V267, P17087
   Duvvari MR, 2015, MOL VIS, V21, P285
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ellis S, 2020, INVEST OPHTH VIS SCI, V61
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fang AM, 2009, MOL VIS, V15, P2710
   Fang K, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/821918
   Fariss RN, 1997, AM J PATHOL, V150, P323
   Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Fernandez-Vega B, 2020, ACTA OPHTHALMOL, V98, pE282, DOI 10.1111/aos.14280
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Ferrara N, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.10
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Fiotti N, 2005, GENET MED, V7, P272, DOI 10.1097/01.GIM.0000159903.69597.73
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Forneris F, 2010, SCIENCE, V330, P1816, DOI 10.1126/science.1195821
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Garcia-Onrubia L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165934
   Geerlings MJ, 2018, MOL VIS, V24, P75
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gerhardt MJ, 2017, J MOL CELL BIOL, V9, P516, DOI 10.1093/jmcb/mjx024
   Gili P, 2022, EUR J OPHTHALMOL, V32, P651, DOI 10.1177/11206721211002698
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gourgouli K, 2020, INT OPHTHALMOL, V40, P985, DOI 10.1007/s10792-019-01274-7
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Guerra R, 1997, P NATL ACAD SCI USA, V94, P4532, DOI 10.1073/pnas.94.9.4532
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hallam TM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.18
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   Hautamaki A, 2015, ACTA OPHTHALMOL, V93, P726, DOI 10.1111/aos.12799
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   HOGAN M J, 1961, Trans Pac Coast Otoophthalmol Soc Annu Meet, V42, P61
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Horiuchi T, 1998, J IMMUNOL, V160, P1509
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jacobo SMP, 2013, MOL CELL BIOL, V33, P1976, DOI 10.1128/MCB.01283-12
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Janeway CA, 2001, MICROBES INFECT, V3, P1167, DOI 10.1016/S1286-4579(01)01477-0
   Java A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.37
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda H, 2017, J NEURAL ENG, V14, DOI 10.1088/1741-2552/aa7d5c
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Kauer WKH, 2010, J GASTROINTEST SURG, V14, P9, DOI 10.1007/s11605-009-1014-4
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kilgore KS, 1997, LAB INVEST, V76, P191
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kitchens JW, 2013, CLIN OPHTHALMOL, V7, P1987, DOI 10.2147/OPTH.S39635
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kremlitzka M, 2018, HUM MOL GENET, V27, P2678, DOI 10.1093/hmg/ddy178
   Kucukevcilioglu M, 2016, INT OPHTHALMOL, V36, P569, DOI 10.1007/s10792-015-0164-5
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Lee J, 2013, EYE, V27, P266, DOI 10.1038/eye.2012.276
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lin LY, 2018, JAMA OPHTHALMOL, V136, P682, DOI 10.1001/jamaophthalmol.2018.1231
   Liu K, 2019, EYE VISION, V6, DOI 10.1186/s40662-019-0161-2
   Liu MM, 2011, INVEST OPHTH VIS SCI, V52, P3129, DOI 10.1167/iovs.10-6735
   Liutkeviciene R, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/9602949
   Liutkeviciene R, 2019, GENE, V686, P8, DOI 10.1016/j.gene.2018.11.004
   Liutkeviciene R, 2018, OPHTHALMIC GENET, V39, P457, DOI 10.1080/13816810.2018.1479429
   Liutkeviciene R, 2018, INDIAN J OPHTHALMOL, V66, P551, DOI 10.4103/ijo.IJO_1050_17
   Liutkeviciene R, 2017, INT J OPHTHALMOL-CHI, V10, P1349, DOI 10.18240/ijo.2017.09.03
   Liutkeviciene R, 2015, OPHTHALMIC GENET, V36, P149, DOI 10.3109/13816810.2013.838274
   Liutkeviciene R, 2012, MEDICINA-LITHUANIA, V48, P404, DOI 10.3390/medicina48080060
   LOKKI ML, 1991, IMMUNOGENETICS, V34, P242, DOI 10.1007/BF00215259
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   Lu FT, 2018, GENET TEST MOL BIOMA, V22, P526, DOI 10.1089/gtmb.2018.0110
   Lu Z.G., 2021, VESSEL PLUS, V5, P4, DOI [10.20517/2574-1209.2020.48, DOI 10.20517/2574-1209.2020.48]
   Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203
   Maguire MG, 2016, JAMA OPHTHALMOL, V134, P674, DOI 10.1001/jamaophthalmol.2016.0669
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   MAHLEY RW, 1984, J LIPID RES, V25, P1277
   Makou E, 2013, BIOCHEMISTRY-US, V52, P3949, DOI 10.1021/bi4003452
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mantel I, 2014, OPHTHALMIC GENET, V35, P12, DOI 10.3109/13816810.2013.766217
   Mao XY, 2017, ARCH MED RES, V48, P370, DOI 10.1016/j.arcmed.2017.08.002
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Marmorstein AD, 2007, TRENDS GENET, V23, P225, DOI 10.1016/j.tig.2007.03.001
   Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075
   Matuskova V, 2020, ACTA OPHTHALMOL, V98, pE691, DOI 10.1111/aos.14357
   Maugeri A, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7532507
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   McMahon O, 2021, HUM MOL GENET, V30, P1188, DOI 10.1093/hmg/ddab086
   Mead JR, 2002, J MOL MED, V80, P753, DOI 10.1007/s00109-002-0384-9
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Meyer KJ, 2011, HUM GENET, V129, P91, DOI 10.1007/s00439-010-0904-6
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Miyake M, 2015, JPN J OPHTHALMOL, V59, P273, DOI 10.1007/s10384-015-0394-0
   Mohamad NA, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0197-3
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Mori K, 2022, HUM MOL GENET, V31, P2194, DOI 10.1093/hmg/ddac020
   Mulfaul K, 2022, J PATHOL, V257, P29, DOI 10.1002/path.5867
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2007, EXP EYE RES, V84, P378, DOI 10.1016/j.exer.2006.09.021
   Murphy AJ, 2008, ARTERIOSCL THROM VAS, V28, P2071, DOI 10.1161/ATVBAHA.108.168690
   Nakai S, 2019, JPN J OPHTHALMOL, V63, P389, DOI 10.1007/s10384-019-00683-6
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Neto JM, 2021, EXP BIOL MED, V246, P2290, DOI 10.1177/15353702211024543
   Nielsen MK, 2019, ACTA OPHTHALMOL, V97, P84, DOI 10.1111/aos.13894
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ortak H, 2013, OPHTHALMIC GENET, V34, P217, DOI 10.3109/13816810.2013.781192
   Oszajca K, 2018, OPHTHALMIC GENET, V39, P684, DOI 10.1080/13816810.2018.1525752
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Peters F, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23063194
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Popp NA, 2017, CURR EYE RES, V42, P470, DOI 10.1080/02713683.2016.1196708
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Rajendran A, 2018, BRIT J OPHTHALMOL, V102, P1213, DOI 10.1136/bjophthalmol-2017-311384
   Ratnapriya R, 2020, HUM MOL GENET, V29, P2022, DOI 10.1093/hmg/ddaa057
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Sartorius U, 2001, CHEMBIOCHEM, V2, P20, DOI 10.1002/1439-7633(20010105)2:1<20::AID-CBIC20>3.0.CO;2-X
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Seitzman RL, 2008, AM J EPIDEMIOL, V167, P1217, DOI 10.1093/aje/kwn024
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   Sharma K, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-021-04269-6
   Shen L, 2015, INVEST OPHTH VIS SCI, V56, P4290, DOI 10.1167/iovs.15-16533
   Shijo T, 2020, INT OPHTHALMOL, V40, P2735, DOI 10.1007/s10792-020-01460-y
   Shin HT, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-021-01830-9
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sohn E.H., 2021, OPHTHALMOL SCI, V1, P100002, DOI [DOI 10.1016/J.XOPS.2020.100002, 10.1016/j.xops.2020.100002]
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Storti F, 2019, ELIFE, V8, DOI 10.7554/eLife.45100
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun C, 2012, CURR EYE RES, V37, P259, DOI 10.3109/02713683.2011.635401
   Sun YY, 2013, INVEST OPHTH VIS SCI, V54, P8199, DOI 10.1167/iovs.13-12867
   Sun YW, 2020, SAUDI J BIOL SCI, V27, P2770, DOI 10.1016/j.sjbs.2020.06.037
   Supanji Supanji, 2021, BIO Web of Conferences, V41, DOI 10.1051/bioconf/20214106001
   Supanji S, 2021, CLIN OPHTHALMOL, V15, P1101, DOI 10.2147/OPTH.S298310
   Tall AR, 2015, NAT REV IMMUNOL, V15, P104, DOI 10.1038/nri3793
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   TAMURA Y, 1991, INVEST OPHTH VIS SCI, V32, P2636
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   Trillo AH, 2012, INVEST OPHTH VIS SCI, V53, P4234, DOI 10.1167/iovs.12-9580
   TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Usategui-Martin R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213624
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van der Vaart H, 2004, THORAX, V59, P713, DOI 10.1136/thx.2003.012468
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Vilkeviciute A, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11060996
   Viturino MG, 2021, EXP BIOL MED, V246, P1148, DOI 10.1177/1535370220985466
   Vlaicu SI, 2013, IMMUNOL RES, V56, P109, DOI 10.1007/s12026-012-8381-8
   Wang GF, 2013, EXP EYE RES, V112, P102, DOI 10.1016/j.exer.2013.04.019
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   Wang W, 2010, DISCOV MED, V9, P13
   Wang YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep15711
   Wang YF, 2016, GRAEF ARCH CLIN EXP, V254, P323, DOI 10.1007/s00417-015-3211-z
   Wang ZL, 2022, ACTA OPHTHALMOL, V100, pE669, DOI 10.1111/aos.14970
   WEBER BHF, 1994, NAT GENET, V7, P158, DOI 10.1038/ng0694-158
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Williams BL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103617118
   Winkler BS, 1999, VISUAL NEUROSCI, V16, P345, DOI 10.1017/S095252389916214X
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Wyatt MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068088
   Yamashiro K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072034
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yasuma T., 2009, INVESTIG OPHTHALMOL, V50, P3436
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yokoyama S, 2006, J ATHEROSCLER THROMB, V13, P1, DOI 10.5551/jat.13.1
   Yoneyama S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64301-z
   Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200
   Yu Y, 2016, HUM MOL GENET, V25, P5276, DOI 10.1093/hmg/ddw336
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   ZANNIS VI, 1993, ADV HUM GENET, V21, P145
   ZANNIS VI, 1981, AM J HUM GENET, V33, P11
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zeng JX, 2010, MOL VIS, V16, P2273
   Zeng RP, 2012, OPHTHALMIC GENET, V33, P139, DOI 10.3109/13816810.2011.643440
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhang J, 2021, OPHTHALMIC RES, V64, P192, DOI 10.1159/000508738
   Zhang J, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0945-5
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
   Zhou J, 2013, CLIN BIOCHEM, V46, P1689, DOI 10.1016/j.clinbiochem.2013.07.002
   Zhou TQ, 2015, GENET MOL RES, V14, P17432, DOI 10.4238/2015.December.21.13
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 338
TC 0
Z9 0
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4425
J9 GENES-BASEL
JI Genes
PD JUL
PY 2022
VL 13
IS 7
AR 1233
DI 10.3390/genes13071233
PG 28
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 3K1LI
UT WOS:000833845000001
PM 35886016
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dalal, M
   Jacobs-El, N
   Nicholson, B
   Tuo, J
   Chew, E
   Chan, CC
   Nussenblatt, R
   Ferris, F
   Meyerle, C
AF Dalal, Monica
   Jacobs-El, Naima
   Nicholson, Benjamin
   Tuo, Jingsheng
   Chew, Emily
   Chan, Chi-Chao
   Nussenblatt, Robert
   Ferris, Frederick
   Meyerle, Catherine
TI Subconjunctival Palomid 529 in the treatment of neovascular age-related
   macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Akt/mTOR; Choroidal neovascularization; Neovascular age-related macular
   degeneration; Palomid 529
ID ANGIOGENESIS; NLRP3
AB Recent evidence suggests that neovascular age-related macular degeneration (AMD) may have an immune mediated component. Palomid 529, an investigational medication involving the immune Akt/mTOR pathway, is unique in dissociating both targets of rapamycin complexes TORC1 and TORC2. This small short-term pilot study assesses the safety of subconjunctival Palomid 529 in the treatment of neovascular AMD, with some limited efficacy information.
   In this 12-week phase I open-label prospective pilot study, five participants with neovascular age-related macular degeneration that were refractory to intravitreal anti-vascular endothelial growth factor (VEGF) received three serial monthly subconjunctival doses of 1.9 mg Palomid 529. All participants were also offered concomitant monthly intravitreal anti-VEGF injections. Safety was monitored via adverse events recording. Additional outcome measures included visual acuity, optical coherence tomography, fluorescein angiography, indocyanine green angiography and fundus photography.
   The study drug was well-tolerated by all participants. There were no drug-related adverse events and no serious adverse events. A depot formed at the injection site, which persisted at the end of the study. In these anti-VEGF refractory patients, no clinically important changes in best-corrected visual acuity, fluorescein leakage pattern, choroidal neovascularization size on indocyanine green angiography, or autofluorescence pattern on fundus autofluorescence were observed compared to baseline. The fluid status, assessed with optical coherence tomography showed that central retinal thickness and macular volume remained stable in three participants, while the other two participants clinically progressed.
   Serial subconjunctival injections of Palomid 529 were well-tolerated and resulted in depot formation. There were no concerns for any ocular or systemic toxicity during this small short-term study. Larger randomized studies are required to determine efficacy.
C1 [Dalal, Monica; Tuo, Jingsheng; Chan, Chi-Chao; Nussenblatt, Robert] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Jacobs-El, Naima; Nicholson, Benjamin; Chew, Emily; Ferris, Frederick; Meyerle, Catherine] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI)
RP Meyerle, C (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, Bldg 10 Magnuson Room 10D40,10 Ctr Dr, Bethesda, MD 20892 USA.
EM meyerlec@nei.nih.gov
OI Ferris, Frederick/0000-0002-4933-0639; Tuo,
   Jingsheng/0000-0002-1372-7810
FU Intramural NIH HHS [ZIA EY000418-10] Funding Source: Medline; NATIONAL
   EYE INSTITUTE [ZIAEY000523, ZIAEY000356, ZIAEY000464, ZICEY000461,
   ZIEEY000487, ZIAEY000222, ZIAEY000527, ZIAEY000497, ZIAEY000526,
   ZIAEY000418, ZIAEY000524] Funding Source: NIH RePORTER
CR Ackah E, 2005, J CLIN INVEST, V115, P2119, DOI 10.1172/JCI24726
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Dejneka NS, 2004, MOL VIS, V10, P964
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218
   Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com
   Janes MR, 2010, NAT MED, V16, P205, DOI 10.1038/nm.2091
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Liu BY, 2010, MOL VIS, V16, P184
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   Paloma Pharmaceuticals Inc, 2009, PAL 529 INV BROCH
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Rosenbaum JT, 2012, NEW ENGL J MED, V367, P768, DOI 10.1056/NEJMcibr1204973
   Shor B, 2009, CELL CYCLE, V8, P3831, DOI 10.4161/cc.8.23.10070
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Xue Q, 2008, CANCER RES, V68, P9551, DOI 10.1158/0008-5472.CAN-08-2058
NR 18
TC 22
Z9 23
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2013
VL 251
IS 12
BP 2705
EP 2709
DI 10.1007/s00417-013-2375-7
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 270US
UT WOS:000328345000006
PM 23689994
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chen, L
   Yang, PZ
   Curcio, CA
AF Chen, Ling
   Yang, Peizeng
   Curcio, Christine A.
TI Visualizing lipid behind the retina in aging and age-related macular
   degeneration, via indocyanine green angiography (ASHS-LIA)
SO EYE
LA English
DT Review
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; SCATTERED HYPOFLUORESCENT SPOTS;
   BRUCHS MEMBRANE; CLINICOPATHOLOGICAL CORRELATION; DRUSEN FORMATION; SOFT
   DRUSEN; MACULOPATHY; FLUORESCEIN; NEOVASCULARIZATION; ACCUMULATION
AB Age-related macular degeneration (AMD) causes legal blindness in older adults worldwide. Soft drusen are the most extensively documented intraocular risk factor for progression to advanced AMD. A long-standing paradox in AMD pathophysiology has been the vulnerability of Asian populations to polypoidal choroidal vasculopathy (PCV) in the presence of relatively few drusen. Age-related scattered hypofluorescent spots on late phase indocyanine green angiography (ASHS-LIA) was recently proposed as precursors of PCV. Herein, we offer a resolution to the paradox by reviewing evidence that ASHS-LIA indicates the diffuse form of lipoprotein-related lipids accumulating in Bruch's membrane (BrM) throughout adulthood. Deposition of these lipids leads to soft drusen and basal linear deposit (BLinD), a thin layer of soft drusen material in AMD; Pre-BLinD is the precursor. This evidence includes: 1. Both ASHS-LIA and pre-BLinD/BLinD accumulate in older adults and start under the macula; 2. ASHS-LIA shares hypofluorescence with soft drusen, known to be physically continuous with pre-BLinD/BLinD. 3. Model system studies illuminated a mechanism for indocyanine green uptake by retinal pigment epithelium. 4. Neither ASHS-LIA nor pre-BLinD/ BLinD are visible by multimodal imaging anchored on current optical coherence tomography, as confirmed with direct clinicopathologic correlation. To contextualize ASHS-LIA, we also summarize angiographic characteristics of different drusen subtypes in AMD. As possible precursors for PCV, lipid accumulation in forms beyond soft drusen may contribute to the pathogenesis of this prevalent disease in Asia. ASHS-LIA also might help identify patients at risk for progression, of value to clinical trials for therapies targeting early or intermediate AMD.
C1 [Chen, Ling; Yang, Peizeng] Chongqing Med Univ, Chongqing Key Lab Ophthalmol, Affiliated Hosp 1, Chongqing, Peoples R China.
   [Chen, Ling; Yang, Peizeng] Chongqing Eye Inst, Chongqing, Peoples R China.
   [Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL 35294 USA.
C3 Chongqing Medical University; University of Alabama System; University
   of Alabama Birmingham
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL 35294 USA.
EM christinecurcio@uabmc.edu
OI Curcio, Christine/0000-0001-9769-1538
FU National Natural Science Foundation of China [82171083]; Macula
   Foundation, New York; Heidelberg Engineering; NIH [R01EY06109]
FX This work was supported by The National Natural Science Foundation of
   China (grant numbers: 82171083) and the Macula Foundation, New York, an
   anonymous donor to UAB for AMD research, and Heidelberg Engineering.
   Basic research in drusen biology and AMD histopathology was supported by
   NIH grant R01EY06109 (CAC).
CR Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   Chang AA, 1998, OPHTHALMOLOGY, V105, P1060, DOI 10.1016/S0161-6420(98)96008-0
   Chang AA, 2005, INVEST OPHTH VIS SCI, V46, P1463, DOI 10.1167/iovs.04-0825
   Chen L, 2021, OPHTHALMOL RETINA, V5, P1085, DOI 10.1016/j.oret.2021.01.012
   Chen L, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.1.33
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P1644, DOI 10.1097/IAE.0000000000002893
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Chen L, 2019, INVEST OPHTH VIS SCI, V60, P2102, DOI 10.1167/iovs.19-26968
   Chen L, 2018, INVEST OPHTH VIS SCI, V59, P5237, DOI 10.1167/iovs.18-25124
   Chen L, 2018, CLIN EXP OPHTHALMOL, V46, P908, DOI 10.1111/ceo.13306
   Cheng CY., 2015, NAT COMMUN, V6
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD182, DOI 10.1167/iovs.18-24883
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Dzurinko Victoria L, 2004, Optometry, V75, P743, DOI 10.1016/S1529-1839(04)70234-1
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   FLOWER RW, 1972, AM J OPHTHALMOL, V73, P458, DOI 10.1016/0002-9394(72)90079-7
   Francisco SG, 2020, NUTRIENTS, V12, DOI 10.3390/nu12092862
   Holz FG, 1998, AM J OPHTHALMOL, V125, P227, DOI 10.1016/S0002-9394(99)80095-6
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson M, 2007, CURR EYE RES, V32, P791, DOI 10.1080/02713680701550660
   Jung Jesse J, 2014, Retin Cases Brief Rep, V8, P141, DOI 10.1097/ICB.0000000000000026
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Li ML, 2019, RETINA-J RET VIT DIS, V39, P802, DOI 10.1097/IAE.0000000000002461
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Ludwig CA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252878
   Matsubara Takashi, 1999, Nippon Ganka Gakkai Zasshi, V103, P497
   Neale Benjamin M, 2010, Proc Natl Acad Sci U S A, V107, P7395, DOI 10.1073/pnas.0912019107
   Nishiyama Y, 2001, RETINA-J RET VIT DIS, V21, P237, DOI 10.1097/00006982-200106000-00007
   NOVOTNY H R, 1960, Tech Doc Rep SAMTDR USAF Sch Aerosp Med, V60-82, P1
   Opremcak E Mitchel, 2013, Insight, V38, P21
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Pollreisz A, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.2.26
   RABB MF, 1978, SURV OPHTHALMOL, V22, P387, DOI 10.1016/0039-6257(78)90134-0
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Rudolf M, 2019, INVEST OPHTH VIS SCI, V60, P461, DOI 10.1167/iovs.18-25786
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sasaki M, 2014, OPTOMETRY VISION SCI, V91, P849, DOI 10.1097/OPX.0000000000000317
   Sharma A, 2021, GRAEF ARCH CLIN EXP, V259, P1381, DOI 10.1007/s00417-021-05164-6
   Shiraki Kunihiko, 1999, International Ophthalmology, V23, P105, DOI 10.1023/A:1026571327117
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Tam J, 2016, INVEST OPHTH VIS SCI, V57, P4376, DOI 10.1167/iovs.16-19503
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Yiu G, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.32
   Yiu G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14715-z
   Yoneya S, 1998, INVEST OPHTH VIS SCI, V39, P1286
   Zhang XY, 2021, EYE, V35, P121, DOI 10.1038/s41433-020-01265-4
NR 68
TC 2
Z9 2
U1 4
U2 5
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2022
VL 36
IS 9
BP 1735
EP 1746
DI 10.1038/s41433-022-02016-3
EA MAR 2022
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3W0KK
UT WOS:000771350100002
PM 35314773
DA 2022-11-30
ER

PT J
AU Parameswaran, S
   Krishnakumar, S
AF Parameswaran, Sowmya
   Krishnakumar, Subramanian
TI Pluripotent stem cells: A therapeutic source for age-related macular
   degeneration
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular degeneration; embryonic stem cells; retinal pigment
   epithelial; stem cells
ID RETINAL-PIGMENT EPITHELIUM; MESENCHYMAL STROMAL CELLS; BONE-MARROW;
   DIRECTED DIFFERENTIATION; EFFICIENT GENERATION; GLATIRAMER ACETATE; RAT
   MODEL; IN-VITRO; TRAP-EYE; TRANSPLANTATION
AB Age-related macular degeneration (AMD) leads to progressive loss of central vision in the elderly. At a cellular level, there is aging of the retinal pigment epithelial (RPE) cells, and accumulation of lipofuscin that interferes with the proper functioning of RPE which eventually leads to apoptosis. Treatment depends on the stage of the disease. Wet AMD which has neovascularization is managed by local therapies such as laser photocoagulation and photodynamic therapy and is managed with injections of antivascular endothelial growth factor-based therapy. Unlike the wet AMD, an effective therapy does not exist for dry AMD and geographic atrophy. Cell replacement therapy has shown promise. This review discusses the opportunities in the various types of cell-based therapy, their limitations, and what is possible for India.
C1 [Parameswaran, Sowmya; Krishnakumar, Subramanian] Sankara Nethralaya, Vis Res Lab, Radheshyam Kanoi Stem Cell Lab, L&T Ophthalm Pathol, Old 18,New 41,Coll Rd, Madras 600006, Tamil Nadu, India.
RP Krishnakumar, S (通讯作者)，Sankara Nethralaya, Vis Res Lab, Radheshyam Kanoi Stem Cell Lab, L&T Ophthalm Pathol, Old 18,New 41,Coll Rd, Madras 600006, Tamil Nadu, India.
EM drkrishnakumar_2000@yahoo.com
RI Sowmya, Parameswaran/GZK-8635-2022
CR Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   [Anonymous], 1994, Arch Ophthalmol, V112, P489
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1232
   Arnhold S, 2007, GRAEF ARCH CLIN EXP, V245, P414, DOI 10.1007/s00417-006-0382-7
   Arnhold S, 2006, INVEST OPHTH VIS SCI, V47, P4121, DOI 10.1167/iovs.04-1501
   Atmaca-Sonmez P, 2006, EXP EYE RES, V83, P1295, DOI 10.1016/j.exer.2006.07.013
   Bazley FA, 2015, STEM CELLS DEV, V24, P2634, DOI 10.1089/scd.2015.0100
   Bieback K, 2016, METHODS MOL BIOL, V1416, P245, DOI 10.1007/978-1-4939-3584-0_14
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown MTC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015870
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Butovsky O, 2006, P NATL ACAD SCI USA, V103, P11784, DOI 10.1073/pnas.0604681103
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   Cai H, 2006, ARCH OPHTHALMOL-CHIC, V124, P1276, DOI 10.1001/archopht.124.9.1276
   Carr AJ, 2009, MOL VIS, V15, P283
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Croze RH, 2014, STEM CELL TRANSL MED, V3, P1066, DOI 10.5966/sctm.2014-0079
   Cuenca N, 2013, INVEST OPHTH VIS SCI, V54, P6745, DOI 10.1167/iovs.13-12860
   Das T, 1999, EXP NEUROL, V157, P58, DOI 10.1006/exnr.1998.6992
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365-2184.1970.tb00347.x
   Fusaki N, 2009, P JPN ACAD B-PHYS, V85, P348, DOI 10.2183/pjab.85.348
   Garber K, 2015, NAT BIOTECHNOL, V33, P890, DOI 10.1038/nbt0915-890
   Gehlbach P, 2012, COCHRANE DB SYST REV, V3
   Gong J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143272
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-12
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hoogduijn MJ, 2014, CURR OPIN ORGAN TRAN, V19, P41, DOI 10.1097/MOT.0000000000000036
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Inoue Y, 2007, EXP EYE RES, V85, P234, DOI 10.1016/j.exer.2007.04.007
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   Kaiser PK, 2009, CURR MED RES OPIN, V25, P1853, DOI 10.1185/03007990903038616
   Khan M., 2014, ISRN OPHTHALMOL, V2014, DOI DOI 10.1155/2014/608390
   Kim DW, 2013, INT J MOL SCI, V14, P11692, DOI 10.3390/ijms140611692
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Landa G, 2011, J OCUL PHARMACOL TH, V27, P77, DOI 10.1089/jop.2010.0109
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   Leach LL, 2016, J OCUL PHARMACOL TH, V32, P317, DOI 10.1089/jop.2016.0022
   Li Y, 2006, INVEST OPHTH VIS SCI, V47, P1646, DOI 10.1167/iovs.05-1092
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   Macias MI, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.06.045
   Mack AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027956
   Maeda T, 2013, J BIOL CHEM, V288, P34484, DOI 10.1074/jbc.M113.518571
   Majore I, 2011, STEM CELL REV REP, V7, P17, DOI 10.1007/s12015-010-9165-y
   Malik Nasir, 2013, Methods Mol Biol, V997, P23, DOI 10.1007/978-1-62703-348-0_3
   Mariappan I, 2015, INVEST OPHTH VIS SCI, V56, P6714, DOI 10.1167/iovs.15-17364
   Marquez-Curtis LA, 2015, CRYOBIOLOGY, V71, P181, DOI 10.1016/j.cryobiol.2015.07.003
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   Mekala SR, 2013, J BIOSCIENCES, V38, P123, DOI 10.1007/s12038-012-9296-1
   Mosna F, 2010, STEM CELLS DEV, V19, P1449, DOI 10.1089/scd.2010.0140
   Mu YL, 2014, INT J CLIN EXP MED, V7, P3843
   Okamoto S, 2011, INVEST OPHTH VIS SCI, V52, P8785, DOI 10.1167/iovs.11-8129
   Portmann-Lanz CB, 2006, AM J OBSTET GYNECOL, V194, P664, DOI 10.1016/j.ajog.2006.01.101
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rowland TJ, 2013, J TISSUE ENG REGEN M, V7, P642, DOI 10.1002/term.1458
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Schwartz SD, 2015, LANCET, V386, P30, DOI 10.1016/S0140-6736(15)61203-X
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seki T, 2012, NAT PROTOC, V7, P718, DOI 10.1038/nprot.2012.015
   Shroff G, 2015, CLIN CASE REP, V3, P632, DOI 10.1002/ccr3.310
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Steigman SA, 2007, CURR PROTOC STEM CEL, V35
   Stewart MC, 2011, VET CLIN N AM-EQUINE, V27, P243, DOI 10.1016/j.cveq.2011.06.004
   Sunness JS, 2015, LANCET, V386, P29, DOI 10.1016/S0140-6736(15)61201-6
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tamagawa T, 2007, HUM CELL, V20, P77, DOI 10.1111/j.1749-0774.2007.00032.x
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
   Virgili G, 2007, COCHRANE DB SYST REV, V3
   Wang SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009200
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Yue FM, 2010, BIOCHEM BIOPH RES CO, V394, P877, DOI 10.1016/j.bbrc.2010.03.008
   Zhang GY, 2015, LANCET, V386, P29, DOI 10.1016/S0140-6736(15)61202-8
NR 91
TC 4
Z9 5
U1 0
U2 6
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD MAR
PY 2017
VL 65
IS 3
BP 177
EP 183
DI 10.4103/ijo.IJO_1026_15
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ET9GV
UT WOS:000400616400002
PM 28440245
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Levy, AR
   Szabo, S
   Briggs, A
   Pleil, A
   Davie, A
   Zlateva, G
   Javitt, J
AF Levy, Adrian R.
   Szabo, Shelagh
   Briggs, Andrew
   Pleil, Andreas
   Davie, Alison
   Zlateva, Gergana
   Javitt, Jonathan
TI Joint Assessment of Intended and Unintended Effects of Medications: An
   Example Using Vascular Endothelial Growth Factor Inhibitors for
   Neovascular Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ADJUSTED LIFE YEARS; COST-EFFECTIVENESS; RANIBIZUMAB; VERTEPORFIN;
   PEGAPTANIB; UTILITIES; DISEASE; TIME; RISK
AB Objective. To estimate the net health benefits of pegaptanib and ranibizumab by considering the impact of visual acuity and unintended effects (cardiovascular and hemorrhagic events) on quality-of-life among persons with neovascular age-related macular degeneration. Methods. We designed a probabilistic decision-analytic model using published data. It employed 17 visual health states and three for unintended effects. We calculated incremental net health benefits by subtracting the harms of each medication from the benefit using the quality-adjusted life year (QALY). Results. In a hypothetical cohort of 1,000 75-year olds with new-onset bilateral age-related macular degeneration followed for ten years, the mean QALYs per patient is 3.7 for usual care, 4.2 for pegaptanib, and 4.3 for ranibizumab. Net benefits decline with increasing baseline rates of unintended effects. Interpretation. Net health benefits present a quantitative, potentially useful tool to assist patients and ophthalmologists in balancing the benefits and harms of interventions for age-related macular degeneration. Copyright (C) 2009 Adrian R. Levy et al.
C1 [Levy, Adrian R.] Dalhousie Univ, Dept Community Hlth & Epidemiol, Halifax, NS B3H 1V7, Canada.
   [Levy, Adrian R.; Szabo, Shelagh; Briggs, Andrew; Davie, Alison] Oxford Outcomes Ltd, Vancouver, BC V6B 1P1, Canada.
   [Briggs, Andrew] Univ Glasgow, Sect Publ Hlth & Hlth Policy, Glasgow G12 8RZ, Lanark, Scotland.
   [Pleil, Andreas; Zlateva, Gergana] Pfizer, Outcomes Res, La Jolla, CA 92121 USA.
   [Javitt, Jonathan] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21287 USA.
C3 Dalhousie University; University of Glasgow; Pfizer; Johns Hopkins
   University; Johns Hopkins Medicine
RP Levy, AR (通讯作者)，Dalhousie Univ, Dept Community Hlth & Epidemiol, Halifax, NS B3H 1V7, Canada.
EM adrian.levy@dal.ca
RI Javitt, Jonathan/AAJ-5574-2021; Briggs, Andrew/ABA-9009-2020
OI Javitt, Jonathan/0000-0003-2371-1609; Briggs, Andrew/0000-0002-0777-1997
FU Pfizer US Inc
FX This study was carried out by Oxford Outcomes Ltd., a consultancy
   specializing in contract research for a wide range of clients in the
   life sciences industry, including public sector organizations as well as
   pharmaceutical and other private companies. The model described in this
   manuscript was developed by Oxford Outcomes under contract to, and
   funding provided by, Pfizer US Inc, manufacturer of pegaptanib. A. Pleil
   and G. Zlateva are employees of Pfizer Inc.
CR ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Briggs A., 2006, DECISION MODELLING H
   Briggs AH, 2003, MED DECIS MAKING, V23, P341, DOI 10.1177/0272989X03255922
   Briggs AH, 2006, PHARMACOECONOMICS, V24, P1079, DOI 10.2165/00019053-200624110-00005
   Brown, 2000, Am J Ophthalmol, V129, P833, DOI 10.1016/S0002-9394(00)00513-4
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Flanagan William, 2006, Popul Health Metr, V4, P13, DOI 10.1186/1478-7954-4-13
   Fu AZ, 2008, MED CARE, V46, P984, DOI 10.1097/MLR.0b013e3181791a9c
   Furlong W., 1990, 909 MCMAST U
   Genentech, 2007, SAILOR SAF INF INT A
   GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Groeneveld PW, 2001, AM J GASTROENTEROL, V96, P338
   Health Canada, 2008, WHAT IS PROGR LIC PR
   Hughes DA, 2007, CLIN PHARMACOL THER, V82, P123, DOI 10.1038/sj.clpt.6100240
   ISPOR, 2007, PHARM GUID WORLD
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lipscomb J, 1996, COST EFFECTIVENESS H, P214
   Maetzel A, 2001, 23 CAN COORD OFF HLT
   MEHREZ A, 1993, MED DECIS MAKING, V13, P287, DOI 10.1177/0272989X9301300404
   MEHREZ A, 1989, MED DECIS MAKING, V9, P142, DOI 10.1177/0272989X8900900209
   *NAT COLL CTR CHRO, 2006, HYP MAN AD PRIM CAR
   Pleil A. M., 2009, INVESTIGATIVE OPHTHA, V50
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Statistics Canada, 2006, COMPL LIF TABL CAN 2
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tengs TO, 2003, PHARMACOECONOMICS, V21, P191, DOI 10.2165/00019053-200321030-00004
   TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210
   WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 37
TC 0
Z9 0
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2009
VL 2009
AR 540431
DI 10.1155/2009/540431
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V24IH
UT WOS:000208403600012
PM 20339464
OA Green Published, Green Submitted, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Nehemy, MB
   Brocchi, DN
   Veloso, CE
AF Nehemy, Marcio B.
   Brocchi, Daniel N.
   Veloso, Carlos E.
TI Optical Coherence Tomography Angiography Imaging of Quiescent Choroidal
   Neovascularization in Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
AB A 67-year-old asymptomatic man presented with bilateral drusen. Spectral-domain optical coherence tomography (OCT) showed no signs of choroidal neovascularization (CNV) and no intraretinal or subretinal fluid. OCT angiography (OCTA) revealed the presence of a type 1 CNV in the right eye. Management options were discussed with the patient, who opted for a clinical follow-up. This is the first description demonstrating the OCTA characteristics of a quiescent CNV secondary to age-related macular degeneration.
C1 [Nehemy, Marcio B.; Brocchi, Daniel N.; Veloso, Carlos E.] Univ Fed Minas Gerais, Dept Ophthalmol, Belo Horizonte, MG, Brazil.
C3 Universidade Federal de Minas Gerais
RP Nehemy, MB (通讯作者)，Rua Otoni 881-13 Andar, BR-30150270 Belo Horizonte, MG, Brazil.
RI Veloso, Carlos Eduardo dos Reis/E-1815-2016; Nehemy,
   Marcio/ABD-5089-2021
OI Veloso, Carlos Eduardo dos Reis/0000-0002-8817-7200; Nehemy,
   Marcio/0000-0002-4104-0346
CR BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Lumbroso B, 2015, CLIN GUIDE ANGIO OCT
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
NR 7
TC 19
Z9 22
U1 0
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD NOV-DEC
PY 2015
VL 46
IS 10
BP 1056
EP 1057
DI 10.3928/23258160-20151027-13
PG 2
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA DP9UH
UT WOS:000378842400014
PM 26599251
DA 2022-11-30
ER

PT J
AU Chen, LJ
   Ma, L
   Chu, WK
   Lai, TYY
   Chen, HY
   Brelen, ME
   Rong, SS
   Young, AL
   Tam, POS
   Zhang, MZ
   Pang, CP
AF Chen, Li Jia
   Ma, Li
   Chu, Wai Kit
   Lai, Timothy Y. Y.
   Chen, Haoyu
   Brelen, Marten E.
   Rong, Shi Song
   Young, Alvin L.
   Tam, Pancy O. S.
   Zhang, Mingzhi
   Pang, Chi Pui
TI Identification of PGF as a New Gene for Neovascular Age-Related Macular
   Degeneration in a Chinese Population
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE PGF; AMD; genetic association
ID ENDOTHELIAL GROWTH-FACTOR; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   INTRAVITREAL AFLIBERCEPT; VEGF POLYMORPHISMS; FACTOR FAMILY;
   ASSOCIATION; VARIANTS; RISK; CONTRIBUTES; THERAPY
AB PURPOSE. To determine the associations of the VEGFA, VEGFB, and placental growth factor (PGF) genes with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV).
   METHODS. Seven single-nucleotide polymorphisms (SNPs) in VEGFA, three SNPs in VEGFB, and five SNPs in PGF were genotyped in 1722 unrelated Chinese participants, including a Hong Kong cohort of 214 nAMD patients, 236 PCV patients, and 365 controls, and an independent Shantou cohort of 189 nAMD patients, 187 PCV patients, and 531 controls, using TaqMan genotyping assays.
   RESULTS. Placental growth factor SNPs rs2268615 (G allele, P = 0.0047; odds ratio [OR] = 1.54, 95% confidence interval [CI], 1.14-2.08) and rs2268614 (G allele, P = 0.015; OR = 1.46, 95% CI, 1.07-1.97) were associated with nAMD. A significant omnibus haplotype association with nAMD was detected for a two-SNP window containing rs2268615 and rs2268614, with a haplotype G-G conferring a 1.54-fold increased risk (P = 0.0042) in the Hong Kong cohort and a 1.42-fold risk (P = 0.012) in the Shantou cohort. Pooling of the Hong Kong and Shantou data enhanced the association of nAMD with rs2268615 (P = 0.0022; OR = 1.38, 95% CI, 1.12-1.69; I2 = 0%), rs2268614 (P = 0.0067; OR = 1.33, 95% CI, 1.08-1.63; I2 = 0%), and the G-G haplotype (P = 0.0013; OR = 1.46, 95% CI, 1.16-1.84; I2 = 0%). In contrast, the PGF SNPs and haplotype were not associated with PCV. Our results also revealed no association of SNPs in VEGFA and VEGFB with nAMD or PCV.
   CONCLUSION. Placental growth factor is a susceptibility gene for nAMD in a Chinese population, providing new evidence to support a biological role of PGF in choroidal neovascularization.
C1 [Chen, Li Jia; Ma, Li; Chu, Wai Kit; Lai, Timothy Y. Y.; Brelen, Marten E.; Rong, Shi Song; Young, Alvin L.; Tam, Pancy O. S.; Pang, Chi Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Chen, Li Jia; Brelen, Marten E.; Young, Alvin L.; Pang, Chi Pui] Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Chen, Li Jia; Chen, Haoyu; Zhang, Mingzhi; Pang, Chi Pui] Joint Shantou Int Eye Ctr, Shantou, Peoples R China.
   [Lai, Timothy Y. Y.] Hong Kong Eye Hosp, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital
RP Pang, CP (通讯作者)，Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM cppang@cuhk.edu.hk
RI Brelen, Marten E./D-1133-2016; Chen, Li Jia/I-5078-2014; Chu, Wai
   Kit/F-9405-2016; Chen, Haoyu/A-7432-2013; Lai, Timothy Y
   Y/AAC-2120-2020; Rong, Shi Song/L-9735-2019
OI Chen, Li Jia/0000-0003-3500-5840; Chu, Wai Kit/0000-0003-2903-3247;
   Chen, Haoyu/0000-0003-0676-4610; Lai, Timothy Y Y/0000-0002-7832-6428;
   Rong, Shi Song/0000-0001-8352-6363
FU National Natural Science Foundation of China (China) [81500764]; Chinese
   University of Hong Kong (Hong Kong) [4054119]; Endowment Fund for Lim
   Por-Yen Eye Genetics Research Centre, Hong Kong
FX Supported by the National Natural Science Foundation of China (81500764,
   LJC; China), a Direct Grant of the Chinese University of Hong Kong
   (4054119, CPP; Hong Kong), and the Endowment Fund for Lim Por-Yen Eye
   Genetics Research Centre, Hong Kong.
CR Al-Habboubi HH, 2011, EUR CYTOKINE NETW, V22, P154, DOI 10.1684/ecn.2011.0289
   Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   Andraweera PH, 2013, J MATERN-FETAL NEO M, V26, P532, DOI 10.3109/14767058.2012.743520
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Castellon R, 2002, EXP EYE RES, V74, P523, DOI 10.1006/exer.2001.1161
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chen ZTY, 2009, OPHTHALMOLOGY, V116, P1920, DOI 10.1016/j.ophtha.2009.03.023
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   de Jong EK, 2015, OPHTHALMOLOGY, V122, P562, DOI 10.1016/j.ophtha.2014.09.026
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Guo YF, 2009, EUR J HUM GENET, V17, P785, DOI 10.1038/ejhg.2008.244
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hayreh SS, 2008, OPHTHALMOLOGY, V115, P2275, DOI 10.1016/j.ophtha.2008.08.007
   Huang C, 2013, MOL VIS, V19, P1211
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Li Y, 2014, OPHTHALMOLOGY, V121, P2290, DOI 10.1016/j.ophtha.2014.06.016
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07018
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Mckay GJ, 2009, OPHTHALMOLOGY, V116, P1227, DOI 10.1016/j.ophtha.2009.01.008
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Nongpiur ME, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004089
   Nourinia Ramin, 2013, J Ophthalmic Vis Res, V8, P4
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sorice R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042537
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Thorleifsson G, 2010, NAT GENET, V42, P906, DOI 10.1038/ng.661
   Traynor K, 2012, AM J HEALTH-SYST PH, V69, P6, DOI 10.2146/news120001
   Yuan Y, 2014, BIORESOURCE TECHNOL, V174, P1, DOI 10.1016/j.biortech.2014.07.104
   Zehetner C, 2015, INVEST OPHTH VIS SCI, V56, P3279, DOI 10.1167/iovs.15-16686
NR 51
TC 14
Z9 16
U1 1
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2016
VL 57
IS 4
BP 1714
EP 1720
DI 10.1167/iovs.IOVS-15-18677
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL8XY
UT WOS:000375926700025
PM 27064391
OA gold
DA 2022-11-30
ER

PT J
AU Holliday, EG
   Smith, AV
   Cornes, BK
   Buitendijk, GHS
   Jensen, RA
   Sim, XL
   Aspelund, T
   Aung, T
   Baird, PN
   Boerwinkle, E
   Cheng, CY
   van Duijn, CM
   Eiriksdottir, G
   Gudnason, V
   Harris, T
   Hewitt, AW
   Inouye, M
   Jonasson, F
   Klein, BEK
   Launer, L
   Li, XH
   Liew, G
   Lumley, T
   McElduff, P
   McKnight, B
   Mitchell, P
   Psaty, BM
   Rochtchina, E
   Rotter, JI
   Scott, RJ
   Tay, WT
   Taylor, K
   Teo, YY
   Uitterlinden, AG
   Viswanathan, A
   Xie, S
   Vingerling, JR
   Klaver, CCW
   Tai, ES
   Siscovick, D
   Klein, R
   Cotch, MF
   Wong, TY
   Attia, J
   Wang, JJ
AF Holliday, Elizabeth G.
   Smith, Albert V.
   Cornes, Belinda K.
   Buitendijk, Gabrielle H. S.
   Jensen, Richard A.
   Sim, Xueling
   Aspelund, Thor
   Aung, Tin
   Baird, Paul N.
   Boerwinkle, Eric
   Cheng, Ching Yu
   van Duijn, Cornelia M.
   Eiriksdottir, Gudny
   Gudnason, Vilmundur
   Harris, Tamara
   Hewitt, Alex W.
   Inouye, Michael
   Jonasson, Fridbert
   Klein, Barbara E. K.
   Launer, Lenore
   Li, Xiaohui
   Liew, Gerald
   Lumley, Thomas
   McElduff, Patrick
   McKnight, Barbara
   Mitchell, Paul
   Psaty, Bruce M.
   Rochtchina, Elena
   Rotter, Jerome I.
   Scott, Rodney J.
   Tay, Wanting
   Taylor, Kent
   Teo, Yik Ying
   Uitterlinden, Andre G.
   Viswanathan, Ananth
   Xie, Sophia
   Vingerling, Johannes R.
   Klaver, Caroline C. W.
   Tai, E. Shyong
   Siscovick, David
   Klein, Ronald
   Cotch, Mary Frances
   Wong, Tien Y.
   Attia, John
   Wang, Jie Jin
CA Wellcome Trust Case Control Consor
TI Insights into the Genetic Architecture of Early Stage Age-Related
   Macular Degeneration: A Genome-Wide Association Study Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID SUSCEPTIBILITY LOCI; APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; SKIN
   PIGMENTATION; IDENTIFIES 3; RISK; PROGRESSION; POPULATION; EYE; VARIANTS
AB Genetic factors explain a majority of risk variance for age-related macular degeneration (AMD). While genome-wide association studies (GWAS) for late AMD implicate genes in complement, inflammatory and lipid pathways, the genetic architecture of early AMD has been relatively under studied. We conducted a GWAS meta-analysis of early AMD, including 4,089 individuals with prevalent signs of early AMD (soft drusen and/or retinal pigment epithelial changes) and 20,453 individuals without these signs. For various published late AMD risk loci, we also compared effect sizes between early and late AMD using an additional 484 individuals with prevalent late AMD. GWAS meta-analysis confirmed previously reported association of variants at the complement factor H (CFH) (peak P = 1.5x10(-31)) and age-related maculopathy susceptibility 2 (ARMS2) (P = 4.3x10(-24)) loci, and suggested Apolipoprotein E (ApoE) polymorphisms (rs2075650; P = 1.1x10(-6)) associated with early AMD. Other possible loci that did not reach GWAS significance included variants in the zinc finger protein gene GLI3 (rs2049622; P = 8.9x10(-6)) and upstream of GLI2 (rs6721654; P = 6.5x10(-6)), encoding retinal Sonic hedgehog signalling regulators, and in the tyrosinase (TYR) gene (rs621313; P = 3.5x10(-6)), involved in melanin biosynthesis. For a range of published, late AMD risk loci, estimated effect sizes were significantly lower for early than late AMD. This study confirms the involvement of multiple established AMD risk variants in early AMD, but suggests weaker genetic effects on the risk of early AMD relative to late AMD. Several biological processes were suggested to be potentially specific for early AMD, including pathways regulating RPE cell melanin content and signalling pathways potentially involved in retinal regeneration, generating hypotheses for further investigation.
C1 [Holliday, Elizabeth G.; McElduff, Patrick; Attia, John] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2300, Australia.
   [Holliday, Elizabeth G.; McElduff, Patrick; Attia, John] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2300, Australia.
   [Smith, Albert V.; Aspelund, Thor; Eiriksdottir, Gudny; Gudnason, Vilmundur; Wellcome Trust Case Control Consor] Iceland Heart Assoc, Kopavogur, Iceland.
   [Smith, Albert V.; Aspelund, Thor; Gudnason, Vilmundur; Jonasson, Fridbert] Univ Iceland, Fac Med, Reykjavik, Iceland.
   [Cornes, Belinda K.; Aung, Tin; Cheng, Ching Yu; Tay, Wanting; Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Buitendijk, Gabrielle H. S.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Buitendijk, Gabrielle H. S.; van Duijn, Cornelia M.; Uitterlinden, Andre G.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Jensen, Richard A.; Lumley, Thomas; McKnight, Barbara; Psaty, Bruce M.; Siscovick, David] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
   [Jensen, Richard A.; Psaty, Bruce M.; Siscovick, David] Univ Washington, Dept Med, Seattle, WA USA.
   [Sim, Xueling] Natl Univ Singapore, Ctr Mol Epidemiol, Singapore 117548, Singapore.
   [Sim, Xueling] Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [Baird, Paul N.; Hewitt, Alex W.; Xie, Sophia; Wong, Tien Y.; Wang, Jie Jin] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Boerwinkle, Eric] Univ Texas Houston, Ctr Human Genet, Houston, TX USA.
   [Boerwinkle, Eric] Univ Texas Houston, Human Genome Sequencing Ctr, Houston, TX USA.
   [Cheng, Ching Yu] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Cheng, Ching Yu] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.
   [Cheng, Ching Yu] Duke NUS Grad Med Sch, Off Clin Sci, Ctr Quantitat Med, Singapore, Singapore.
   [Harris, Tamara; Launer, Lenore] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
   [Inouye, Michael] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia.
   [Jonasson, Fridbert] Landspitali Univ Hosp, Dept Ophthalmol, Reykjavik, Iceland.
   [Klein, Barbara E. K.; Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Li, Xiaohui; Rotter, Jerome I.; Taylor, Kent] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
   [Liew, Gerald; Mitchell, Paul; Rochtchina, Elena; Wang, Jie Jin] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Liew, Gerald; Mitchell, Paul; Rochtchina, Elena; Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Lumley, Thomas] Univ Auckland, Dept Stat, Auckland 1, New Zealand.
   [McKnight, Barbara] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Psaty, Bruce M.; Siscovick, David] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
   [Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
   [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
   [Scott, Rodney J.] Univ Newcastle, Sch Biomed Sci, Newcastle, NSW 2300, Australia.
   [Scott, Rodney J.] Hunter Med Res Inst, Newcastle, NSW, Australia.
   [Scott, Rodney J.] Hunter Area Pathol Serv, Newcastle, NSW, Australia.
   [Teo, Yik Ying; Tai, E. Shyong] Natl Univ Singapore, Dept Epidemiol & Publ Hlth, Singapore 117548, Singapore.
   [Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [Uitterlinden, Andre G.] Erasmus MC, Dept Clin Chem, Rotterdam, Netherlands.
   [Viswanathan, Ananth] Moorfields Eye Hosp, London, England.
   [Tai, E. Shyong] Natl Univ Singapore, Dept Med, Singapore 117548, Singapore.
   [Tai, E. Shyong] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore.
   [Cotch, Mary Frances] NEI, Div Epidemiol & Clin Applicat, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
   [Wong, Tien Y.] Natl Univ Singapore, Dept Ophthalmol, Singapore 117548, Singapore.
   [Attia, John] John Hunter Hosp, Dept Med, Newcastle, NSW, Australia.
   [Attia, John] Hunter Med Res Inst, Newcastle, NSW, Australia.
C3 University of Newcastle; University of Newcastle; Icelandic Heart
   Association; University of Iceland; National University of Singapore;
   Singapore National Eye Center; Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; University of Washington;
   University of Washington Seattle; University of Washington; University
   of Washington Seattle; National University of Singapore; University of
   Michigan System; University of Michigan; Centre for Eye Research
   Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne;
   University of Texas System; University of Texas Health Science Center
   Houston; University of Texas System; University of Texas Health Science
   Center Houston; National University of Singapore; National University of
   Singapore; National University of Singapore; National Institutes of
   Health (NIH) - USA; NIH National Institute on Aging (NIA); University of
   Melbourne; Landspitali National University Hospital; University of
   Wisconsin System; University of Wisconsin Madison; Cedars Sinai Medical
   Center; University of Sydney; University of Sydney; Westmead Institute
   for Medical Research; University of Auckland; University of Washington;
   University of Washington Seattle; University of Washington; University
   of Washington Seattle; University of Washington; University of
   Washington Seattle; Group Health Cooperative; University of Newcastle;
   Hunter Medical Research Institute; University of Newcastle; National
   University of Singapore; Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   National University of Singapore; National University of Singapore;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National University of Singapore; John Hunter Hospital; Hunter
   Medical Research Institute; University of Newcastle
RP Holliday, EG (通讯作者)，Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2300, Australia.
EM Liz.Holliday@newcastle.edu.au
RI wang, jie/GRS-0942-2022; Wong, Tien Yin/AAC-9724-2020; Gudnason,
   Vilmundur/K-6885-2015; Cheng, Ching-Yu/Y-2229-2019; Aspelund,
   Thor/C-5983-2008; Blackwell, Jenefer M/H-3015-2015; Smith, Albert
   Vernon/K-5150-2015; Scott, Rodney J/B-2827-2013; Klaver, Caroline
   C.W./A-2013-2016; Sim, Xueling/AAZ-6652-2020; Liew,
   Gerald/AAB-6870-2022; Cheng, Ching-Yu/K-7017-2013; Tai, E
   Shyong/J-9831-2013; Belllenguez, Céline/Y-3183-2018; Jonasson,
   Fridbert/ABA-9889-2021; Gudnason, Vilmundur/AAE-7126-2019; Wang, Jie
   Jin/P-1499-2014; Aspelund, Thor/K-7022-2019; Mitchell, Paul/P-1498-2014;
   Bellenguez, Céline/X-4004-2019; Rotter, Jerome/AAY-6598-2021; Brown,
   Matthew A/E-5749-2010; Jankowski, Janusz/H-2706-2012; Hewitt, Alex
   W/D-1936-2013; Attia, John R/F-5376-2013; Kritharides,
   Leonard/AAQ-2720-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Gudnason,
   Vilmundur/0000-0001-5696-0084; Cheng, Ching-Yu/0000-0003-0655-885X;
   Aspelund, Thor/0000-0002-7998-5433; Smith, Albert
   Vernon/0000-0003-1942-5845; Scott, Rodney J/0000-0001-7724-3404; Sim,
   Xueling/0000-0002-1233-7642; Cheng, Ching-Yu/0000-0003-0655-885X;
   Belllenguez, Céline/0000-0002-1240-7874; Gudnason,
   Vilmundur/0000-0001-5696-0084; Wang, Jie Jin/0000-0001-9491-4898;
   Aspelund, Thor/0000-0002-7998-5433; Bellenguez,
   Céline/0000-0002-1240-7874; Brown, Matthew A/0000-0003-0538-8211;
   Jankowski, Janusz/0000-0003-2130-9181; Hewitt, Alex
   W/0000-0002-5123-5999; Attia, John R/0000-0001-9800-1308; Tai, E
   Shyong/0000-0003-2929-8966; Banks, Emily/0000-0002-4617-1302; Cotch,
   Mary Frances/0000-0002-2046-4350; Gillman, Matthew
   S./0000-0002-2340-6930; Klaver, Caroline/0000-0002-2355-5258; Van Duijn,
   Cornelia/0000-0002-2374-9204; Plomin, Robert/0000-0002-0756-3629; Baird,
   Paul/0000-0002-1305-3502; /0000-0001-6694-3587; Inouye,
   Michael/0000-0001-9413-6520; Klein, Ronald/0000-0002-4428-6237; Magee,
   Christopher/0000-0002-0465-6328
FU National Institutes of Health (NIH) [N01-AG-12100, HHSN268200625226C,
   UL1RR025005]; NIA; NEI Intramural Research Programs at the National
   Institutes of Health [ZIAAG007380, ZIAEY000401]; Hjartavernd (the
   Icelandic Heart Association); Althingi (the Icelandic Parliament);
   National Heart, Lung, and Blood Institute [HHSN268201100005C,
   HHSN268201100006C, HHSN268201100007C, HHSN268201100008C,
   HHSN268201100009C, HHSN268201100010C, HHSN268201100011C,
   HHSN268201100012C, R01HL087641, R01HL59367, R01HL086694, N01-HC-85239,
   N01-HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103]; National Human
   Genome Research Institute [U01HG004402]; NIH Roadmap for Medical
   Research; Australian National Health & Medical Research Council (NHMRC)
   [974159, 991407, 211069, 457349, 512423, 475604,529912, 590204]; Centre
   for Clinical Research Excellence (CCRE) in Translational Clinical
   Research in Eye Diseases, CCRE in TCR-Eye [529923]; Wellcome Trust,
   United Kingdom, as part of Wellcome Trust Case Control Consortium 2
   [085475/B/08/Z, 085475/08/Z]; NHMRC [631096, APP1028444, 358702,
   632909]; National Center of Advancing Translational Technologies CTSI
   [UL1TR000124]; National Institute of Diabetes and Digestive and Kidney
   Diseases [DK063491]; Cedars-Sinai Board of Governors' Chair in Medical
   Genetics; Netherlands Organization of Scientific Research NWO
   [175.010.2005.011]; Erasmus Medical Center; Erasmus University,
   Rotterdam; Netherlands Organization for Scientific Research (NWO);
   Netherlands Organization for Health Research and Development (ZonMw);
   Research Institute for Diseases in the Elderly (RIDE); Ministry of
   Education, Culture and Science; Ministry for Health, Welfare and Sports;
   European Commission (DG XII); Municipality of Rotterdam; Lijf en Leven,
   Netherlands; Krimpen a/d Lek, Netherlands; MD Fonds, Utrecht,
   Netherlands; Oogfonds Nederland, Utrecht, Netherlands; Stichting
   Nederlands Oogheelkundig Onderzoek, Nijmegen/Rotterdam, Netherlands;
   Swart van Essen, Rotterdam, Netherlands; Netherlands Organisation for
   Scientific Research (NWO), Netherlands; Bevordering van Volkskracht,
   Rotterdam, Netherlands; Blindenhulp, The Hague, Netherlands; Rotterdamse
   Vereniging Blindenbelangen, Rotterdam, Netherlands; OOG, The Hague,
   Netherlands; Algemene Nederlandse Vereniging ter Voorkoming van
   Blindheid, Doorn, Netherlands; Blinden-Penning, Amsterdam, Netherlands;
   Blindenhulp, 's Gravenzande, Netherlands; Henkes Stichting, Rotterdam,
   Netherlands; Topcon Europe BV, Netherlands; Capelle aan de IJssel,
   Netherlands; Medical Workshop BV, Groningen, Netherlands; Heidelberg
   Engineering, Dossenheim, Germany; Biomedical Research Council of
   Singapore [BMRC 08/1/35/19/550]; National Medical Research Council of
   Singapore [NMRC/STaR/0003/2008, CG/SERI/2010]; American Health
   Assistance Foundation, USA; National Medical Research Council
   [CG/SERI/2010, 0796/2003,, IRG07nov013, IRG09nov014, STaR/0003/2008];
   Biomedical Research Council of Singapore, Singapore [09/1/35/19/616];
   DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085080,
   N01HC085082, N01HC045133, N01HC075150, N01HC055222, N01HC085086,
   N01HC085085, N01HC085083, N01HC015103, N01HC085081, N01HC085084,
   N01HC035129, N01HC085079] Funding Source: NIH RePORTER; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000124] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025005] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [ZIAEY000426, ZIAEY000401]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [R01HL080295, R01HL086694, R01HL105756, U01HL080295, R01HL087652,
   R01HL087641, R01HL059367] Funding Source: NIH RePORTER; NATIONAL HUMAN
   GENOME RESEARCH INSTITUTE [U01HG004402] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
   [P30DK063491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [N01AG012100, R01AG027058, R56AG023629, R01AG015928, ZIAAG007270,
   R56AG020098, ZIAAG007380, R01AG023629, R01AG020098] Funding Source: NIH
   RePORTER
FX Age, Gene/Environment Susceptibility-Reykjavik Study has been funded by
   National Institutes of Health (NIH) contract N01-AG-12100, the NIA and
   NEI Intramural Research Programs at the National Institutes of Health
   (ZIAAG007380 and ZIAEY000401), Hjartavernd (the Icelandic Heart
   Association), and the Althingi (the Icelandic Parliament). The
   Atherosclerosis Risk in Communities Study is carried out as a
   collaborative study supported by National Heart, Lung, and Blood
   Institute contracts HHSN268201100005C, HHSN268201100006C,
   HHSN268201100007C, HHSN268201100008C, HHSN268201100009C,
   HHSN268201100010C, HHSN268201100011C, HHSN268201100012C, R01HL087641,
   R01HL59367 and R01HL086694; National Human Genome Research Institute
   contract U01HG004402; and National Institutes of Health contract
   HHSN268200625226C. Infrastructure was partly supported by Grant Number
   UL1RR025005, a component of the National Institutes of Health and NIH
   Roadmap for Medical Research. The Blue Mountains Eye Study was supported
   by the Australian National Health & Medical Research Council (NHMRC)
   project grants (IDs 974159, 991407, 211069 and 457349) and Centre for
   Clinical Research Excellence (CCRE) in Translational Clinical Research
   in Eye Diseases, CCRE in TCR-Eye (ID 529923). The Blue Mountains Eye
   Study GWAS and genotyping costs were supported by Australian NHMRC
   project grants (IDs 512423, 475604,529912 and 590204), and the Wellcome
   Trust, United Kingdom, as part of Wellcome Trust Case Control Consortium
   2 (grant IDs 085475/B/08/Z and 085475/08/Z). EGH (631096), PNB
   (APP1028444) and JJW (358702 and 632909) are supported by the NHMRC
   fellowship scheme. This CHS research was supported by NHLBI contracts
   N01-HC-85239, N01-HC-85079 through N01-HC-85086; N01-HC-35129, N01
   HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, HHSN268201200036C
   and NHLBI grants HL080295, HL087652, HL105756 with additional
   contribution from NINDS. Additional support was provided through
   AG-023629, AG-15928, AG-20098, and AG-027058 from the NIA. See also
   http://www.chs-nhlbi.org/pi.htm. DNA handling and genotyping was
   supported in part by National Center of Advancing Translational
   Technologies CTSI grant UL1TR000124 and National Institute of Diabetes
   and Digestive and Kidney Diseases grant DK063491 to the Southern
   California Diabetes Endocrinology Research Center and Cedars-Sinai Board
   of Governors' Chair in Medical Genetics (JIR). The GWA database of the
   Rotterdam Study was funded through the Netherlands Organization of
   Scientific Research NWO (nr. 175.010.2005.011). The Rotterdam Study is
   supported by the Erasmus Medical Center and Erasmus University,
   Rotterdam; the Netherlands Organization for Scientific Research (NWO),
   the Netherlands Organization for Health Research and Development
   (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the
   Ministry of Education, Culture and Science, the Ministry for Health,
   Welfare and Sports, the European Commission (DG XII), and the
   Municipality of Rotterdam. The ophthalmologic part of the Rotterdam
   Study was supported by Lijf en Leven, Krimpen a/d Lek; MD Fonds,
   Utrecht.; Oogfonds Nederland, Utrecht; Stichting Nederlands
   Oogheelkundig Onderzoek, Nijmegen/Rotterdam; Swart van Essen, Rotterdam;
   Netherlands Organisation for Scientific Research (NWO); Bevordering van
   Volkskracht, Rotterdam; Blindenhulp, The Hague; Rotterdamse Vereniging
   Blindenbelangen, Rotterdam; OOG, The Hague; Algemene Nederlandse
   Vereniging ter Voorkoming van Blindheid, Doorn; Blinden-Penning,
   Amsterdam; Blindenhulp, 's Gravenzande; Henkes Stichting, Rotterdam;
   Topcon Europe BV, Capelle aan de IJssel; Medical Workshop BV, Groningen;
   all in the Netherlands; Heidelberg Engineering, Dossenheim, Germany. The
   Singapore Indian Eye Study (SINDI) was funded by grants from Biomedical
   Research Council of Singapore (BMRC 08/1/35/19/550), National Medical
   Research Council of Singapore (NMRC/STaR/0003/2008 and CG/SERI/2010),
   and American Health Assistance Foundation, USA. The Singapore BioBank
   and the Genome Institute of Singapore, Agency for Science, Technology
   and Research, Singapore provided services for tissue archival and
   genotyping, respectively. The Singapore Malay Eye Study (SiMES) is
   funded by National Medical Research Council (grants 0796/2003,
   IRG07nov013, IRG09nov014, STaR/0003/2008 and CG/SERI/2010) and
   Biomedical Research Council of Singapore (grants 09/1/35/19/616),
   Singapore and the American Health Assistance Foundation, USA. The
   Singapore Tissue Network and the Genome Institute of Singapore, Agency
   for Science, Technology and Research, Singapore provided services for
   tissue archival and genotyping, respectively. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Altaba ARI, 1999, DEVELOPMENT, V126, P3205
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Aulchenko YS, 2007, BIOINFORMATICS, V23, P1294, DOI 10.1093/bioinformatics/btm108
   Aulchenko YS, 2009, NAT GENET, V41, P47, DOI 10.1038/ng.269
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Barrett JH, 2011, NAT GENET, V43, P1108, DOI 10.1038/ng.959
   Bhatia B, 2009, EXP EYE RES, V89, P373, DOI 10.1016/j.exer.2009.04.005
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bishop DT, 2009, NAT GENET, V41, P920, DOI 10.1038/ng.411
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   CLOGG CC, 1995, AM J SOCIOL, V100, P1261, DOI 10.1086/230638
   de Bakker PIW, 2008, HUM MOL GENET, V17, pR122, DOI 10.1093/hmg/ddn288
   Estrada K, 2009, BIOINFORMATICS, V25, P2750, DOI 10.1093/bioinformatics/btp497
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   Fried Linda P., 1991, Annals of Epidemiology, V1, P263
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440
   Harris TB, 2007, AM J EPIDEMIOL, V165, P1076, DOI 10.1093/aje/kwk115
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Heinzen EL, 2010, J ALZHEIMERS DIS, V19, P69, DOI 10.3233/JAD-2010-1212
   Hofman A, 2011, EUR J EPIDEMIOL, V26, P657, DOI 10.1007/s10654-011-9610-5
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   Jin Y, 2010, NEW ENGL J MED, V362, P1686, DOI 10.1056/NEJMoa0908547
   Kim S, 2011, NEUROLOGY, V76, P69, DOI 10.1212/WNL.0b013e318204a397
   Kinnunen K, 2011, ACTA OPHTHALMOL
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Li Y, 2009, ANNU REV GENOM HUM G, V10, P387, DOI 10.1146/annurev.genom.9.081307.164242
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Memoli S, 1997, BBA-LIPID LIPID MET, V1346, P61, DOI 10.1016/S0005-2760(97)00018-0
   Middelberg RPS, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-123
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Muto A, 2009, EXP EYE RES, V89, P549, DOI 10.1016/j.exer.2009.05.006
   Naj AC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001130
   Nan H, 2009, J INVEST DERMATOL, V129, P2250, DOI 10.1038/jid.2009.62
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Raymond P A, 1997, Adv Neurol, V72, P171
   Riobo NA, 2007, BIOCHEM J, V403, P369, DOI 10.1042/BJ20061723
   Sallo FB, 2009, CURR EYE RES, V34, P238, DOI 10.1080/02713680802714058
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seshadri S, 2010, JAMA-J AM MED ASSOC, V303, P1832, DOI 10.1001/jama.2010.574
   Stokowski RP, 2007, AM J HUM GENET, V81, P1119, DOI 10.1086/522235
   Sulem P, 2007, NAT GENET, V39, P1443, DOI 10.1038/ng.2007.13
   Sundelin SP, 2001, FREE RADICAL BIO MED, V30, P74, DOI 10.1016/S0891-5849(00)00444-5
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zheng YF, 2011, OPHTHALMOLOGY, V118, P1798, DOI 10.1016/j.ophtha.2011.02.014
NR 67
TC 190
Z9 195
U1 0
U2 27
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 11
PY 2013
VL 8
IS 1
AR e53830
DI 10.1371/journal.pone.0053830
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 086RY
UT WOS:000314705800079
PM 23326517
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Farzaneh, A
   Riazi, A
   Khabazkhoob, M
   Doostdar, A
   Farzaneh, M
   Falavarjani, KG
AF Farzaneh, Abdollah
   Riazi, Abbas
   Khabazkhoob, Mehdi
   Doostdar, Asgar
   Farzaneh, Mehrnaz
   Falavarjani, Khalil Ghasemi
TI Location and stability of the preferred retinal locus in native
   Persian-speaking patients with age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE age-related macular degeneration; fixation stability; microperimetry;
   optical coherence tomography; preferred retinal locus
ID FIXATION STABILITY; MICROPERIMETRY; DISEASE; FOVEA; EYES; SCOTOMAS
AB Clinical relevance The findings of this study can be used in the selection of the preferred retinal locus to establish better rehabilitation services such as eccentric viewing training for patients with age-related macular degeneration. Background The aim of this study was to determine the characteristics of the preferred retinal locus in native Persian-speaking patients with age-related macular degeneration. Methods In this non-interventional case series, all patients with a diagnosis of age-related macular degeneration referred to the Retina Clinic of the Rassoul Akram Hospital, Tehran, Iran, were evaluated. The fixation characteristics were evaluated monocularly using the MP1 microperimeter (Nidek Technologies, Padua, Italy). Optical coherence tomography was used to determine the location of the central fovea. The images were overlaid and the preferred retinal locus-fovea distance was measured using Image J software. Results Fifty-one eyes of 35 patients with a mean age of 73.8 +/- 7.7 years were evaluated in this study. Inferior-field, left-field, central-field, right-field, and superior-field preferred retinal locus were detected in 49 per cent, 33.3 per cent, 7.8 per cent, 5.9 per cent, and 3.9 per cent of the subjects, respectively. Fixation was stable in 70.6 per cent, relatively unstable in 15.7 per cent, and unstable in 13.7 per cent of the participants. Significant differences were not found in the mean values of logMAR visual acuity between different fields of the preferred retinal locus after Bonferroni correction (p = 0.031). Analysis of co-variance showed no significant difference in mean sensitivity values between different locations of the preferred retinal locus (p = 0.07). The mean preferred retinal locus-fovea distance was not significantly different between different fields of the preferred retinal locus (p = 0.063). Conclusions Native Persian-speaking patients with central scotoma secondary to age-related macular degeneration place their self-selected preferred retinal locus most frequently in the inferior and left visual field, which would result in scotoma displacement to the superior and right visual field. Fixation stability was statistically similar in different locations of preferred retinal locus, but it improved with decreasing the preferred retinal locus-fovea distance.
C1 [Farzaneh, Abdollah; Riazi, Abbas; Doostdar, Asgar; Farzaneh, Mehrnaz] Iran Univ Med Sci, Rehabil Res Ctr, Dept Optometry, Sch Rehabil Sci, Tehran, Iran.
   [Khabazkhoob, Mehdi] Shahid Beheshti Univ Med Sci, Sch Nursing & Midwifery, Dept Basic Sci, Tehran, Iran.
   [Falavarjani, Khalil Ghasemi] Iran Univ Med Sci, Eye Res Ctr, Five Senses Inst, Rassoul Akram Hosp, Tehran, Iran.
C3 Iran University of Medical Sciences; Shahid Beheshti University Medical
   Sciences; Iran University of Medical Sciences
RP Falavarjani, KG (通讯作者)，Iran Univ Med Sci, Eye Res Ctr, Five Senses Inst, Rassoul Akram Hosp, Tehran, Iran.
EM drghasemi@yahoo.com
RI Falavarjani, Khalil Ghasemi/I-4029-2019; Doostdar, Asgar/AAT-2487-2021;
   Khabazkhoob, Mehdi/Q-4537-2017; farzaneh, abdollah/AAR-5463-2021
OI Doostdar, Asgar/0000-0002-7370-5437; farzaneh,
   abdollah/0000-0002-4116-0612; Khabazkhoob, Mehdi/0000-0003-0801-8793;
   Ghasemi Falavarjani, Khalil/0000-0001-5221-1844
CR Barraza-Bernal MJ, 2017, J VISION, V17, DOI 10.1167/17.2.11
   Bernard JB, 2018, OPTOMETRY VISION SCI, V95, P829, DOI 10.1097/OPX.0000000000001229
   Calabrese A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170743
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   Crossland MD, 2011, RETINA-J RET VIT DIS, V31, P2109, DOI 10.1097/IAE.0b013e31820d3fba
   Crossland MD, 2009, RETINA-J RET VIT DIS, V29, P651, DOI 10.1097/IAE.0b013e318196bd65
   Csaky KG, 2019, SURV OPHTHALMOL, V64, P353, DOI 10.1016/j.survophthal.2019.01.014
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   DITCHBURN RW, 1953, J PHYSIOL-LONDON, V119, P1
   Duret F, 1999, VISION RES, V39, P873, DOI 10.1016/S0042-6989(98)00179-5
   Erbezci M, 2018, RETINA-J RET VIT DIS, V38, P2372, DOI 10.1097/IAE.0000000000001897
   Farid M, 1996, BRAIN LANG, V53, P351, DOI 10.1006/brln.1996.0053
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   Greenstein VC, 2008, RETINA-J RET VIT DIS, V28, P1234, DOI 10.1097/IAE.0b013e31817c1b47
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   Hildebrand GD, 2011, PEDIATRIC RETINA, P39, DOI 10.1007/978-3-642-12041-1_2
   Jonas RA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138701
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   KISILEVSKY E, 2015, INVEST OPHTH VIS SCI, V56
   KOSNIK W, 1986, INVEST OPHTH VIS SCI, V27, P1720
   Krauzlis RJ, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0205
   Lindner M, 2019, OPHTHALMOL RETINA, V3, P201, DOI 10.1016/j.oret.2018.11.005
   Marita EA, 2007, GRAEF ARCH CLIN EXP, V245, P1659, DOI 10.1007/s00417-007-0585-6
   Markowitz M, 2018, CAN J OPHTHALMOL, V53, P3, DOI 10.1016/j.jcjo.2017.10.042
   Markowitz SN, 2019, CAN J OPHTHALMOL, V54, pE161, DOI 10.1016/j.jcjo.2018.10.011
   Midena E, 2014, MICROPERIMETRY MULTI
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Molina-Martin A, 2018, SEMIN OPHTHALMOL, V33, P620, DOI 10.1080/08820538.2017.1375125
   Nagpal M, 2018, INDIAN J OPHTHALMOL, V66, P1790, DOI 10.4103/ijo.IJO_866_18
   Nilsson UL, 1998, OPTOMETRY VISION SCI, V75, P873, DOI 10.1097/00006324-199812000-00009
   POLLATSEK A, 1981, BRAIN LANG, V14, P174, DOI 10.1016/0093-934X(81)90073-0
   Raphanel M, 2018, AGING SCI, V6, P192
   Rohrschneider K, 2004, INVEST OPHTH VIS SCI, V45, P3257, DOI 10.1167/iovs.03-1157
   Schonbach EM, 2017, OPHTHALMOL RETINA, V1, P68, DOI 10.1016/j.oret.2016.08.009
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   Sullivan B, 2015, VISION RES, V116, P68, DOI 10.1016/j.visres.2015.07.007
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Talib M, 2018, METHODS MOL BIOL, V1715, P339, DOI 10.1007/978-1-4939-7522-8_25
   Tarita-Nistor L, 2009, VISUAL NEUROSCI, V26, P487, DOI 10.1017/S0952523809990265
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   Vingolo Enzo Maria, 2018, Front Biosci (Schol Ed), V10, P48
   Yow AP, 2018, 2018 40 ANN INT C IE
NR 47
TC 3
Z9 3
U1 0
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD FEB 17
PY 2021
VL 104
IS 2
BP 194
EP 200
DI 10.1111/cxo.13132
EA AUG 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QP2BD
UT WOS:000564237800001
PM 32869411
DA 2022-11-30
ER

PT J
AU Marsiglia, M
   Boddu, S
   Chen, CY
   Jung, JJ
   Mrejen, S
   Gallego-Pinazo, R
   Freund, KB
AF Marsiglia, Marcela
   Boddu, Sucharita
   Chen, Christine Y.
   Jung, Jesse J.
   Mrejen, Sarah
   Gallego-Pinazo, Roberto
   Freund, K. Bailey
TI CORRELATION BETWEEN NEOVASCULAR LESION TYPE AND CLINICAL CHARACTERISTICS
   OF NONNEOVASCULAR FELLOW EYES IN PATIENTS WITH UNILATERAL, NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascularization; choroidal neovascularization; geographic atrophy;
   reticular pseudodrusen; drusen; choroidal thickness; retinal angiomatous
   proliferation; fluorescein angiography; optical coherence tomography
ID GEOGRAPHIC ATROPHY; RETICULAR PSEUDODRUSEN; CHOROIDAL
   NEOVASCULARIZATION; FUNDUS AUTOFLUORESCENCE; VISUAL IMPAIRMENT; 2ND
   EYES; PROGRESSION; THICKNESS; DRUSEN; RISK
AB Purpose: To investigate the association between the type of neovascularization (NV) and the clinical characteristics of nonneovascular fellow eyes in patients with unilateral, neovascular age-related macular degeneration.
   Methods: Eighty-three patients with treatment-naive, unilateral, neovascular age-related macular degeneration were retrospectively analyzed. Neovascular lesions were classified using both fluorescein angiography and optical coherence tomography as Type 1 (subretinal pigment epithelium), 2 (subretinal), 3 (intraretinal), or mixed NV. The associations between NV lesion type and baseline clinical and imaging characteristics of the fellow eye, including central geographic atrophy, noncentral geographic atrophy, pigmentary changes, soft drusen, cuticular drusen, reticular pseudodrusen, and subfoveal choroidal thickness, were examined. Subfoveal choroidal thickness was defined as thin if thickness was,120 mm.
   Results: In the fellow eyes of patients with treatment-naive, unilateral, neovascular age-related macular degeneration, Type 3 NV had an increased adjusted odds ratio of reticular pseudodrusen (15.361, P < 0.001) and thin subfoveal choroidal thickness (21.537, P < 0.001) as well as a tendency toward an increased adjusted odds ratio of central geographic atrophy (4.775, P = 0.028). Fellow eyes of patients with Type 1 NV showed a decreased adjusted odds ratio of reticular pseudodrusen (0.233, P = 0.007) and thin subfoveal choroidal thickness (0.080, P = 0.005).
   Conclusion: In patients with unilateral, neovascular age-related macular degeneration, certain nonneovascular features of the fellow eye correlate with the NV lesion composition based on type, as anatomically classified utilizing both fluorescein angiography and optical coherence tomography. Patients with Type 3 NV were more likely to have reticular pseudodrusen and/or thin subfoveal choroidal thickness in the fellow eye compared with those with Type 1 NV. Patients with Type 3 NV also showed a trend toward increased central geographic atrophy in the fellow eye.
C1 [Marsiglia, Marcela; Boddu, Sucharita; Chen, Christine Y.; Jung, Jesse J.; Mrejen, Sarah; Gallego-Pinazo, Roberto; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Marsiglia, Marcela; Boddu, Sucharita; Chen, Christine Y.; Jung, Jesse J.; Mrejen, Sarah; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Marsiglia, Marcela; Jung, Jesse J.; Freund, K. Bailey] Columbia Univ, Coll Phys & Surg, Dept Ophthalmol, Edward S Harkness Eye Inst, New York, NY USA.
   [Boddu, Sucharita; Jung, Jesse J.; Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
   [Chen, Christine Y.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia.
   [Chen, Christine Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
   [Gallego-Pinazo, Roberto] Univ Valencia, Dept Ophthalmol, Valencia, Spain.
   [Gallego-Pinazo, Roberto] Polytech Hosp La Fe, Valencia, Spain.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; Columbia University; New York University; Monash
   University; Centre for Eye Research Australia; University of Melbourne;
   University of Valencia
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Mrejen, Sarah/G-2089-2016; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Macula Foundation, Inc.; Bayer; Novartis; Heidelberg Engineering; Thea;
   Sensimed
FX Supported by The Macula Foundation, Inc.; R. Gallego-Pinazo: Carl Zeiss
   Meditec (consultant); Bayer (honorarium and research support); Novartis
   (honorarium and research support); Heidelberg Engineering (research
   support); Thea (research support); Sensimed (research support). K. B.
   Freund: Genentech, Inc (consultant); Regeneron Pharmaceuticals, Inc
   (consultant); Heidelberg Engineering (consultant); Bayer HealthCare
   (consultant). The other authors have no conflicting interests to
   disclose.
CR Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bellmann C, 2002, ARCH OPHTHALMOL-CHIC, V120, P579, DOI 10.1001/archopht.120.5.579
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   CHUANG EL, 1988, BRIT J OPHTHALMOL, V72, P918, DOI 10.1136/bjo.72.12.918
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   George S, 2010, EYE, V24, P1247, DOI 10.1038/eye.2009.301
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Holz FG, 2004, FUNDUS ANGIOGRAPHY A, P107
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kim JH, 2014, BRIT J OPHTHALMOL, V98, P1066, DOI 10.1136/bjophthalmol-2013-304405
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LAVIN MJ, 1991, BRIT J OPHTHALMOL, V75, P133, DOI 10.1136/bjo.75.3.133
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Maguire MG, 2008, OPHTHALMOLOGY, V115, P1468, DOI 10.1016/j.ophtha.2008.02.028
   Mann SS, 2011, GRAEF ARCH CLIN EXP, V249, P209, DOI 10.1007/s00417-010-1483-x
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Park SY, 2013, AM J OPHTHALMOL, V156, P557, DOI 10.1016/j.ajo.2013.04.027
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   Pauleikhoff D, 1992, Ger J Ophthalmol, V1, P12
   Pauleikhoff D, 1990, Fortschr Ophthalmol, V87, P429
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1241, DOI 10.1097/IAE.0b013e31827b639e
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sainz Gomez C, 2002, Arch Soc Esp Oftalmol, V77, P123
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Seland JH, 2011, ACTA OPHTHALMOL, V89, P608, DOI 10.1111/j.1755-3768.2009.01794.x
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 61
TC 32
Z9 32
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2015
VL 35
IS 5
BP 966
EP 974
DI 10.1097/IAE.0000000000000460
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CG6KI
UT WOS:000353408900018
PM 25627089
DA 2022-11-30
ER

PT J
AU Jin, GM
   Ding, XH
   Xiao, W
   Xu, X
   Wang, LH
   Han, XT
   Xiao, O
   Liu, R
   Wang, W
   Yan, W
   An, L
   Zhao, JL
   He, MG
AF Jin, Guangming
   Ding, Xiaohu
   Xiao, Wei
   Xu, Xiao
   Wang, Lanhua
   Han, Xiaotong
   Xiao, Ou
   Liu, Ran
   Wang, Wei
   Yan, William
   An, Lei
   Zhao, Jialiang
   He, Mingguang
TI Prevalence of age-related macular degeneration in rural southern China:
   the Yangxi Eye Study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ANGELES LATINO EYE; BEAVER DAM EYE; RISK-FACTORS; JAPANESE POPULATION;
   SINGAPOREAN CHINESE; MACULOPATHY; TAIWAN
AB Purpose To describe the prevalence of age-related macular degeneration (AMD) among older adults in rural southern mainland China.
   Methods Eligible persons aged 50 years or over were identified by geographically defined cluster sampling from Yangxi County, Guangdong Province, China. Participants underwent a standardised interview and comprehensive eye examinations from August to November in 2014. Digital retinal photographs were graded for AMD lesions using the Clinical Classification of Age-Related Macular Degeneration developed by the Beckman Initiative for Macular Research Classification Committee. Age-standardised prevalence of AMD and AMD lesions was calculated using the 2010 world population data and compared with those of other populations.
   Results Of 5825 subjects who participated (90.7% response rate), 4881 (83.8%) had fundus photographs gradable for AMD. Early, intermediate and late AMD were present in 2003 (41.0%), 879 (18.0%) and 42 (0.86%) participants. The age-standardised prevalence of early, intermediate and late AMD was 40.4% (95% CI 39.6% to 41.2%), 17.6% (95% CI 17.0% to 18.2%) and 0.79% (95% CI 0.65% to 0.95%), respectively. Total AMD was more prevalent in men than in women (62.8% vs 57.1%).
   Conclusions AMD is an important public health concern for rural southern China, and the prevalence of AMD was higher in men than in women.
C1 [Jin, Guangming; Ding, Xiaohu; Xiao, Wei; Wang, Lanhua; Han, Xiaotong; Xiao, Ou; Liu, Ran; Wang, Wei; He, Mingguang] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
   [Xu, Xiao; An, Lei] Chinese Natl Hlth & Family Planning Commiss, Natl Inst Hosp Adm, Rehabil Adm Dept, Beijing, Peoples R China.
   [Yan, William; He, Mingguang] Univ Melbourne, Ctr Eye Res Australia, East Melbourne, Australia.
   [Yan, William; He, Mingguang] Univ Melbourne, Ophthalmol, Dept Surg, East Melbourne, Australia.
   [Zhao, Jialiang] Chinese Acad Med Sci, Peking Union Med Coll Hosp, 1 Dongjiaomin St, Beijing 100730, Peoples R China.
C3 Sun Yat Sen University; Centre for Eye Research Australia; University of
   Melbourne; University of Melbourne; Chinese Academy of Medical Sciences
   - Peking Union Medical College; Peking Union Medical College Hospital
RP Zhao, JL (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, 1 Dongjiaomin St, Beijing 100730, Peoples R China.; He, MG (通讯作者)，Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie South Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM 13501132676@163.com; mingguanghe@gmail.com
RI He, Mingguang/AAY-5239-2020; An, Lei/GQB-0039-2022; Wang,
   Wei/J-4000-2016
OI He, Mingguang/0000-0002-6912-2810; Han, Xiaotong/0000-0001-6836-3447;
   Jin, Guangming/0000-0001-9994-6338; Wang, Wei/0000-0002-5273-3332
FU National Institute of Hospital Administration, Chinese National Health
   and Family Planning Commission under ORBIS International North Asia
   (Beijing, China) [1541]; Fundamental Research Funds of the State Key
   Laboratory in Ophthalmology, Science and Technology Planning Project of
   Guangdong Province [2013B20400003]; University of Melbourne at Research
   Accelerator Program; CERA Foundation
FX This work was supported by National Institute of Hospital
   Administration, Chinese National Health and Family Planning Commission
   under ORBIS International North Asia (Beijing, China) contract no 1541.
   MH receives support from Fundamental Research Funds of the State Key
   Laboratory in Ophthalmology, Science and Technology Planning Project of
   Guangdong Province 2013B20400003. MH receives support from the
   University of Melbourne at Research Accelerator Program and the CERA
   Foundation. The Centre for Eye Research Australia receives Operational
   Infrastructure Support from the Victorian State Government.
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein BEK, 2009, JAMA-J AM MED ASSOC, V301, P2152, DOI 10.1001/jama.2009.729
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Varma R, 2016, JAMA OPHTHALMOL
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   Zetterberg M., 2016, MATURITAS, P83
NR 26
TC 15
Z9 17
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2018
VL 102
IS 5
BP 625
EP 630
DI 10.1136/bjophthalmol-2017-310368
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GD3YN
UT WOS:000430439800008
PM 28848023
DA 2022-11-30
ER

PT J
AU Maloney, SC
   Fernandes, BF
   Castiglione, E
   Antecka, E
   Martins, C
   Marshall, JC
   Di Cesare, S
   Logan, P
   Burnier, MN
AF Maloney, Shawn C.
   Fernandes, Bruno F.
   Castiglione, Enzo
   Antecka, Emilia
   Martins, Claudia
   Marshall, Jean-Claude
   Di Cesare, Sebastian
   Logan, Patrick
   Burnier, Miguel N., Jr.
TI EXPRESSION OF CYCLOOXYGENASE-2 IN CHOROIDAL NEOVASCULAR MEMBRANES FROM
   AGE-RELATED MACULAR DEGENERATION PATIENTS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE COX-2; choroidal neovascularization; macular degeneration; AMD
ID GROWTH-FACTOR EXPRESSION; ENDOTHELIAL-CELLS; GENE-EXPRESSION; COX-2;
   MODEL; RAT; ANGIOGENESIS; INHIBITOR; LOCALIZATION; MACULOPATHY
AB Purpose: The objective of this study was to investigate the expression of cyclooxygenase (COX)-2 in human choroidal neovascular membranes.
   Methods: Paraffin-embedded sections of choroidal neovascular membranes excised from 16 patients with wet age-related macular degeneration were used for this study. Sections were subjected to immunohistochemistry using a monoclonal mouse antihuman COX-2 antibody. Staining was classified as either negative or positive in retinal pigment epithelial cells, vascular endothelial cells, and fibroblasts. Serial sections were stained for vimentin expression to confirm tissue antigenicity.
   Results: Eleven of 16 (69%) choroidal neovascular membranes stained positive for COX-2 in retinal pigment epithelial cells, with 6 (38%) of these also expressing COX-2 in vascular endothelial cells and 6 (38%) in fibroblasts. None of the sections that were negative for COX-2 in the retinal pigment epithelial cells showed COX-2 expression in the other cell types assessed. There was a statistically significant difference (P = 0.0097) in the mean ages between the COX-2 positive group (65.6 years) and COX-2 negative group (76.8 years) as determined by a two-tailed, unpaired Student's t-test.
   Conclusion: The expression of COX-2 in human choroidal neovascular membranes suggests a possible role for this modulator in age-related macular degeneration pathogenesis. The age-dependent expression observed is novel and warrants further investigation.
C1 [Maloney, Shawn C.; Fernandes, Bruno F.; Castiglione, Enzo; Antecka, Emilia; Martins, Claudia; Marshall, Jean-Claude; Di Cesare, Sebastian; Logan, Patrick; Burnier, Miguel N., Jr.] McGill Univ, Henry C Witelson Ocular Pathol Lab & Registry, Montreal, PQ H3A 2B4, Canada.
C3 McGill University
RP Maloney, SC (通讯作者)，McGill Univ, Henry C Witelson Ocular Pathol Lab, 3775 Univ St,Lyman Duff Bldg,Room 216, Montreal, PQ H3A 2B4, Canada.
EM shawn.maloney@mail.mcgill.ca
RI Fernandes, Bruno F./ABA-3567-2020; Castiglione, Enzo/AAP-6843-2020
OI Fernandes, Bruno F./0000-0002-5385-3571; Di Cesare,
   Sebastian/0000-0002-6279-7639; Burnier, Miguel/0000-0002-2335-7470
CR Amrite AC, 2008, J PHARMACOL EXP THER, V324, P749, DOI 10.1124/jpet.107.128918
   Ayalasomayajula SP, 2003, EUR J PHARMACOL, V458, P283, DOI 10.1016/S0014-2999(02)02793-0
   Chin MS, 2001, INVEST OPHTH VIS SCI, V42, P2338
   Chung HY, 1999, MECH AGEING DEV, V111, P97, DOI 10.1016/S0047-6374(99)00061-5
   Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063
   Ershov AV, 1999, J NEUROSCI RES, V58, P254, DOI 10.1002/(SICI)1097-4547(19991015)58:2<254::AID-JNR5>3.0.CO;2-U
   Gilroy DW, 2001, AM J PHYSIOL-CELL PH, V281, pC188, DOI 10.1152/ajpcell.2001.281.1.C188
   Heymes C, 2000, BRIT J PHARMACOL, V131, P804, DOI 10.1038/sj.bjp.0703632
   Hu WZ, 2005, RETINA-J RET VIT DIS, V25, P1054, DOI 10.1097/00006982-200512000-00015
   Ju WK, 2002, J COMP NEUROL, V452, P392, DOI 10.1002/cne.10400
   Kang KB, 2006, TRANSL RES, V148, P289, DOI 10.1016/j.trsl.2006.06.004
   Kim JW, 2001, J GERONTOL A-BIOL, V56, pB350, DOI 10.1093/gerona/56.8.B350
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Leung WK, 2003, INT J ONCOL, V23, P1317
   Matz RL, 2000, BRIT J PHARMACOL, V131, P303, DOI 10.1038/sj.bjp.0703568
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Parfenova H, 2001, AM J PHYSIOL-CELL PH, V281, pC166, DOI 10.1152/ajpcell.2001.281.1.C166
   Skold M, 2000, EUR J NEUROSCI, V12, P3675, DOI 10.1046/j.1460-9568.2000.00263.x
   Takahashi H, 2004, BIOCHEM BIOPH RES CO, V325, P461, DOI 10.1016/j.bbrc.2004.10.054
   Takahashi K, 2003, INVEST OPHTH VIS SCI, V44, P409, DOI 10.1167/iovs.02-0346
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   Wilkinson-Berka JL, 2003, INVEST OPHTH VIS SCI, V44, P974, DOI 10.1167/iovs.02-0392
   Wu GF, 2003, AM J PHYSIOL-HEART C, V285, pH2420, DOI 10.1152/ajpheart.00187.2003
   Yamada M, 1999, CURR EYE RES, V19, P300, DOI 10.1076/ceyr.19.4.300.5301
NR 24
TC 33
Z9 36
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2009
VL 29
IS 2
BP 176
EP 180
DI 10.1097/IAE.0b013e3181884fa6
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 407BR
UT WOS:000263339100006
PM 18827739
DA 2022-11-30
ER

PT J
AU Liutkeviciene, R
   Vilkeviciute, A
   Botov, R
   Botova, O
   Buteikiene, D
   Kriauciuniene, L
AF Liutkeviciene, Rasa
   Vilkeviciute, Alvita
   Botov, Roman
   Botova, Olga
   Buteikiene, Dovile
   Kriauciuniene, Loresa
TI Associations between CYP2J2 (-76G > T) rs890293 polymorphism and
   age-related macular degeneration
SO BIOMEDICAL PAPERS-OLOMOUC
LA English
DT Article
DE age-related macular degeneration; rs890293; gene polymorphisms
ID CARDIOVASCULAR RISK-FACTORS; CORONARY-ARTERY-DISEASE;
   ALZHEIMERS-DISEASE; GENE; SMOKING; ONSET
AB Backgroung. Age-related macular degeneration (AMD) is a disease of the macula, which significantly affects the eyesight and leads to irreversible central vision loss. The etiopathogenesis of AMD is still not absolutely clear. It is thought that age-related macular degeneration has a multifactorial etiology, the development of which may be caused by interrelation of environmental with innate factors, while genetic factors also have an impact. Macular degenerative changes occur due to the formation of drusen, about 40% of which is lipids. As the CYP2J2 gene is involved in the metabolism of lipids, it was selected for investigation in this study.
   Purpose. To determine the relation between early stage and exudative AMD and CYP2J2 (-76G>T) gene rs890293 polymorphism in a Lithuanian population.
   Methods. The study enrolled 204 patients with early AMD, 197 patients with exudative AMD and 198 healthy controls. Samples of DNA from peripheral white blood cells were purified using commercial kits. The genotyping was carried out using a real-time PCR method.
   Results. The CYP2J2 (-76G>T) rs890293 TT genotype in patients with early AMD was statistically significantly less frequent than in the control group: 0% vs. 2.5% (P=0.028). There were no significant differences in rs890293 gene polymorphisms between the exudative AMD and control groups. Also, the CYP212 (-76G>T) rs890293 TT genotype was statistically significantly less frequent in older early AMD patients (a65 years) compared to control group persons (>= 65 years): 0% vs. 5.4% (P=0.03).
   Conclusion. The CYP2J2 (-76G>T) TT genotype may be associated with reduced manifestation of early stage AMD; therefore, a larger sample size is required for further analysis.
C1 [Liutkeviciene, Rasa; Vilkeviciute, Alvita; Kriauciuniene, Loresa] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Eiveniu 2, LT-50009 Kaunas, Lithuania.
   [Liutkeviciene, Rasa; Botova, Olga; Buteikiene, Dovile; Kriauciuniene, Loresa] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, LT-50009 Kaunas, Lithuania.
   [Botov, Roman] Lithuanian Univ Hlth Sci, Med Acad, Eiveniu 2, LT-50009 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences
RP Liutkeviciene, R (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Eiveniu 2, LT-50009 Kaunas, Lithuania.; Liutkeviciene, R (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, LT-50009 Kaunas, Lithuania.
EM rliutkeviciene@gmail.com
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ali A. A. A., 2013, Journal of Basic and Applied Zoology, V66, P234, DOI 10.1016/j.jobaz.2012.12.001
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheng J, 2014, FASEB J, V28, P2915, DOI 10.1096/fj.13-241927
   Colak E, 2017, J CLIN BIOCHEM NUTR, V60, P100, DOI 10.3164/jcbn.16-30
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Geng S, 2017, BEHAV BRAIN RES, V322, P362, DOI 10.1016/j.bbr.2016.07.010
   Gilroy DW, 2016, P NATL ACAD SCI USA, V113, pE3240, DOI 10.1073/pnas.1521453113
   Hardwick James P., 2015, PREFACE ADV PHARM SA, V74, pxv, DOI [10.1016/S1054-3589(15)00047-2., DOI 10.1016/S1054-3589(15)00047-2]
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   King LM, 2002, MOL PHARMACOL, V61, P840, DOI 10.1124/mol.61.4.840
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Lee CR, 2007, PHARMACOGENET GENOM, V17, P349, DOI 10.1097/FPC.0b013e32809913ea
   Liu PY, 2007, ATHEROSCLEROSIS, V195, P199, DOI 10.1016/j.atherosclerosis.2006.11.001
   Liutkeviciene R, 2015, OPHTHALMIC GENET, V36, P149, DOI 10.3109/13816810.2013.838274
   Liutkeviciene R, 2010, MEDICINA-LITHUANIA, V46, P89, DOI 10.3390/medicina46020013
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Sakiene Ruta, 2016, Adv Med, V2016, P3917916, DOI 10.1155/2016/3917916
   Sharma K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00151
   Spiecker M, 2004, CIRCULATION, V110, P2132, DOI 10.1161/01.CIR.0000143832.91812.60
   Stasiukonyte N, 2017, OPHTHALMIC GENET, V38, P357, DOI 10.1080/13816810.2016.1242018
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Ulas F, 2013, INT OPHTHALMOL, V33, P485, DOI 10.1007/s10792-013-9728-4
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Xu MJ, 2013, DRUG METAB REV, V45, P311, DOI 10.3109/03602532.2013.806537
   Yan HC, 2015, NEUROSCI LETT, V593, P56, DOI 10.1016/j.neulet.2015.03.024
   Zhu Q, 2013, CLIN BIOCHEM, V46, P1047, DOI 10.1016/j.clinbiochem.2013.05.003
NR 36
TC 0
Z9 0
U1 0
U2 1
PU PALACKY UNIV, MEDICAL FAC
PI OLOMOUC
PA CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC
SN 1213-8118
EI 1804-7521
J9 BIOMED PAP
JI Biomed. Pap-Olomouc
PD SEP
PY 2020
VL 164
IS 3
BP 267
EP 272
DI 10.5507/bp.2019.019
PG 6
WC Engineering, Biomedical; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Research & Experimental Medicine
GA PA4ZK
UT WOS:000595645600007
PM 31132075
OA gold
DA 2022-11-30
ER

PT J
AU Ardeljan, D
   Tuo, J
   Chan, CC
AF Ardeljan, D.
   Tuo, J.
   Chan, C. -C.
TI CARBOXYETHYLPYRROLE PLASMA BIOMARKERS IN AGE-RELATED MACULAR
   DEGENERATION
SO DRUGS OF THE FUTURE
LA English
DT Article
ID CARDIOVASCULAR RISK-FACTORS; STRESS-INDUCED APOPTOSIS; OXIDATIVE STRESS;
   CHOROIDAL NEOVASCULARIZATION; COMPLEMENT ACTIVATION; RETINA
   PHOTORECEPTORS; DOCOSAHEXAENOIC ACID; VISUAL IMPAIRMENT; RPE LIPOFUSCIN;
   UNITED-STATES
AB Age-related macular degeneration causes irreversible central blindness in people over the age of 50 and is increasing in prevalence among elderly populations. There are currently limited treatment options available for the exudative form of the disease and no formal treatments for the geographic atrophy form, aside from lifestyle change and incorporation of antioxidant supplements in the diet. As such, it is important to be able to assess high-risk AMD patients as early as possible in order to prescribe preventive measures. Carboxyethylpyrrole (CEP) is a promising plasma biomarker suited to this purpose. Both CEP immunoreactivity levels, as well as anti-CEP autoantibody titers, are significantly elevated in AMD patients and thus provide the potential to assess AMD susceptibility with approximately 80% accuracy when evaluated alongside genomic AMD markers. Moreover, strong evidence implicates CEP as functionally related to AMD pathogenesis, a role which must be explored further. This avenue of research will foster improved understanding of the disease itself and perhaps reveal better therapeutic targets and options. Further research into the role of CEP in AMD pathogenesis and the application of CEP as an AMD biomarker is merited.
C1 [Ardeljan, D.; Tuo, J.; Chan, C. -C.] NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Chan, CC (通讯作者)，NEI, Immunopathol Sect, Immunol Lab, NIH, 10 Ctr Dr,10-10N103, Bethesda, MD 20892 USA.
EM chanc@nel.nih.gov
OI Tuo, Jingsheng/0000-0002-1372-7810; Ardeljan, Daniel/0000-0002-5593-421X
FU NEI
FX This review was funded by the NEI Intramural Research Program. Only
   those individuals listed as authors contributed to writing this article.
CR Bazan NG, 2005, BRAIN PATHOL, V15, P159
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   German OL, 2006, J NEUROCHEM, V98, P1507, DOI 10.1111/j.1471-4159.2006.04061.x
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t
   Haas P, 2011, ACTA OPHTHALMOL, V89, P335, DOI 10.1111/j.1755-3768.2009.01697.x
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaarniranta K, 2009, EXP GERONTOL, V44, P685, DOI 10.1016/j.exger.2009.09.002
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Kahr WHA, 2010, BLOOD, V116, P4393, DOI 10.1182/blood-2010-08-297648
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Langer HF, 2010, BLOOD, V116, P4395, DOI 10.1182/blood-2010-01-261503
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13158, DOI 10.1073/pnas.0705963104
   Murdaugh LS, 2010, EXP EYE RES, V90, P564, DOI 10.1016/j.exer.2010.01.014
   NEURINGER M, 1984, J CLIN INVEST, V73, P272, DOI 10.1172/JCI111202
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Pawlosky RJ, 1997, AM J CLIN NUTR, V65, P465, DOI 10.1093/ajcn/65.2.465
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   Rutkowski MJ, 2010, INFLAMM RES, V59, P897, DOI 10.1007/s00011-010-0220-6
   Ryu E, 2010, MOL VIS, V16, P2811
   Schweigert FJ, 2011, KLIN MONATSBL AUGENH, V228, P537, DOI 10.1055/s-0029-1245527
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   World Health Organization, 2011, VIS IMP BLINDN
   Yu Y., 2011, HUM MOL GENET
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 56
TC 6
Z9 6
U1 0
U2 4
PU PROUS SCIENCE, SA-THOMSON REUTERS
PI BARCELONA
PA PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN
SN 0377-8282
J9 DRUG FUTURE
JI Drug Future
PD SEP
PY 2011
VL 36
IS 9
BP 713
EP 718
DI 10.1358/dof.2011.36.9.1678338
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 847CE
UT WOS:000296948700007
PM 23847393
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Alten, F
   Eter, N
AF Alten, F.
   Eter, N.
TI Current knowledge on reticular pseudodrusen in age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID SUBRETINAL DRUSENOID DEPOSITS; OPTICAL COHERENCE TOMOGRAPHY; SCANNING
   LASER OPHTHALMOSCOPY; GEOGRAPHIC-ATROPHY; CHOROIDAL THICKNESS; ADAPTIVE
   OPTICS; CLINICAL CHARACTERISTICS; PIGMENT-EPITHELIUM; JAPANESE PATIENTS;
   FELLOW-EYES
AB Drusen are focal deposits of extracellular material located between the retinal pigment epithelium (RPE) and Bruch's membrane and represent the major phenotypic characteristic of age-related macular degeneration (AMD). Due to evolving imaging techniques and recent histological studies, reticular pseudodrusen (RPD) have received increasing attention and have been recently identified as an additional phenotypic entity in AMD. In contrast to conventional drusen, RPD proved to be located internal to the RPE. In the past few years, numerous studies collected new findings on RPD related to their pathogenesis, imaging properties and impact on retinal function. While most former natural history studies as well as interventional studies in early AMD did not include imaging RPD beyond colour fundus photography, this phenotype must be included in every future large-scale study on AMD. This review summarises the current knowledge on RPD.
C1 [Alten, F.; Eter, N.] Univ Munster, Dept Ophthalmol, Med Ctr, D-48149 Munster, Germany.
C3 University of Munster
RP Alten, F (通讯作者)，Univ Munster, Dept Ophthalmol, Med Ctr, Domagkstr 15, D-48149 Munster, Germany.
EM florian.alten@ukmuenster.de
CR Alten F, 2014, GRAEF ARCH CLIN EXP, V252, P715, DOI 10.1007/s00417-013-2525-y
   Alten F, 2014, INVEST OPHTH VIS SCI, V55, P6073, DOI 10.1167/iovs.13-13804
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Alten F, 2012, RETINA-J RET VIT DIS, V32, P1727, DOI 10.1097/IAE.0b013e3182475b03
   Alten F, 2012, INVEST OPHTH VIS SCI, V53, P6263, DOI 10.1167/iovs.12-10094
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Auge J, 2014, OPHTHALMOLOGE, V111, P765, DOI 10.1007/s00347-013-2965-0
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Forte R, 2014, OPHTHALMIC RES, V51, P32, DOI 10.1159/000354117
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Grewal DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092841
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Meadway A, 2014, BIOMED OPT EXPRESS, V5, P713, DOI 10.1364/BOE.5.000713
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mrejen S, 2014, RETINA-J RET VIT DIS, V34, P1560, DOI 10.1097/IAE.0000000000000139
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2014, BRIT J OPHTHALMOL, V98, P1522, DOI 10.1136/bjophthalmol-2014-305455
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Radu RA, 2014, J BIOL CHEM, V289, P9113, DOI 10.1074/jbc.M114.548669
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Vongkulsiri S, 2014, AM J OPHTHALMOL, V158, P710, DOI 10.1016/j.ajo.2014.07.009
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 70
TC 42
Z9 41
U1 0
U2 9
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2015
VL 99
IS 6
BP 717
EP 722
DI 10.1136/bjophthalmol-2014-305339
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CI7NO
UT WOS:000354950600001
PM 25232026
DA 2022-11-30
ER

PT J
AU Zhang, M
   Jiang, NS
   Chu, Y
   Postnikova, O
   Varghese, R
   Horvath, A
   Cheema, AK
   Golestaneh, N
AF Zhang, Meng
   Jiang, Nisi
   Chu, Yi
   Postnikova, Olga
   Varghese, Rency
   Horvath, Anelia
   Cheema, Amrita K.
   Golestaneh, Nady
TI Dysregulated metabolic pathways in age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; OXIDATIVE STRESS; MITOCHONDRIAL
   DEPOLARIZATION; DIRECT PHOSPHORYLATION; HIPPOCAMPAL SLICES; MAMMALIAN
   TARGET; LIPID-METABOLISM; SKELETAL-MUSCLE; DNA DAMAGE; SIRT1
AB Age-related macular degeneration is a major cause of vision impairment in the Western world among people of 55 years and older. Recently we have shown that autophagy is dysfunctional in the retinal pigment epithelium (RPE) of the AMD donor eyes (AMD RPE). We also showed increased reactive oxygen (ROS) production, increased cytoplasmic glycogen accumulation, mitochondrial dysfunction and disintegration, and enlarged and annular LAMP-1-positive organelles in AMD RPE. However, the underlying mechanisms inducing these abnormalities remain to be elucidated. Here, by performing a comprehensive study, we show increased PAPR2 expression, deceased NAD+, and SIRT1, increased PGC-1 alpha acetylation (inactive form), lower AMPK activity, and overactive mTOR pathway in AMD RPE as compared to normal RPE. Metabolomics and lipidomics revealed dysregulated metabolites in AMD RPE as compared to normal RPE, including glycerophospholipid metabolism, involved in autophagy, lipid, and protein metabolisms, glutathione, guanosine, and L-glutamic acid, which are implicated in protection against oxidative stress and neurotoxicity, further supporting our observations. Our data show dysregulated metabolic pathways as important contributors to AMD pathophysiology, and facilitate the development of new treatment strategies for this debilitating disease of the visual system.
C1 [Zhang, Meng; Jiang, Nisi; Chu, Yi; Golestaneh, Nady] Georgetown Univ, Med Ctr, Dept Ophthalmol, Washington, DC 20057 USA.
   [Golestaneh, Nady] Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20057 USA.
   [Cheema, Amrita K.; Golestaneh, Nady] Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC 20057 USA.
   [Postnikova, Olga] NEI, Lab Retinal Cell & Mol Biol HNW28, NIH, Bethesda, MD 20814 USA.
   [Horvath, Anelia] George Washington Univ, Dept Pharmacol & Physiol, Dept Biochem & Mol Med, Washington, DC 20037 USA.
   [Varghese, Rency; Cheema, Amrita K.] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20057 USA.
C3 Georgetown University; Georgetown University; Georgetown University;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); George Washington University; Georgetown University
RP Golestaneh, N (通讯作者)，Georgetown Univ, Med Ctr, Dept Ophthalmol, Washington, DC 20057 USA.; Golestaneh, N (通讯作者)，Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20057 USA.; Golestaneh, N (通讯作者)，Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC 20057 USA.
EM ncg8@georgetown.edu
OI Jiang, Nisi/0000-0003-1837-7618
FU Prevention of Blindness Society of Metropolitan Washington (POB) from
   the National Eye Institute (NEI) [R01 EY028917]; BrightFocus Foundation
FX This research was supported by the donors of Macular Degeneration
   Research, a program of BrightFocus Foundation, and Prevention of
   Blindness Society of Metropolitan Washington (POB), grant number R01
   EY028917 from the National Eye Institute (NEI). We thank Dr. Yetrib
   Hathout, Children's National Health System, for sharing the RPE cells.
CR Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Austin S, 2012, J CELL SCI, V125, P4963, DOI 10.1242/jcs.113662
   Austin S, 2011, FREE RADICAL BIO MED, V51, P2243, DOI 10.1016/j.freeradbiomed.2011.08.036
   Bai P, 2011, CELL METAB, V13, P450, DOI 10.1016/j.cmet.2011.03.013
   Balmanno K, 2009, CELL DEATH DIFFER, V16, P368, DOI 10.1038/cdd.2008.148
   Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4
   Chang JS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26244-4
   Chen Y, 2010, INVEST OPHTH VIS SCI, V51, P5314, DOI 10.1167/iovs.10-5280
   Cheng CF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113447
   Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310
   Crunkhorn S, 2007, J BIOL CHEM, V282, P15439, DOI 10.1074/jbc.M611214200
   Cunningham JT, 2007, NATURE, V450, P736, DOI 10.1038/nature06322
   Corte CLD, 2012, BRAIN RES, V1430, P101, DOI 10.1016/j.brainres.2011.10.049
   DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251
   Dengler MA, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.552
   Egger A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031272
   Fediuc S, 2006, J LIPID RES, V47, P412, DOI 10.1194/jlr.M500438-JLR200
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Finn PF, 2006, NUTRITION, V22, P830, DOI 10.1016/j.nut.2006.04.008
   Fliesler SJ, 2010, J LIPID RES, V51, P1, DOI 10.1194/jlr.E003533-JLR200
   Fronk AH, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731416650838
   Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010
   Garipler G, 2014, P NATL ACAD SCI USA, V111, P1473, DOI 10.1073/pnas.1312399111
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633
   Ghosh HS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009199
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gottlieb RA, 2010, AM J PHYSIOL-CELL PH, V299, pC203, DOI 10.1152/ajpcell.00097.2010
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506
   Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Holz MK, 2005, J BIOL CHEM, V280, P26089, DOI 10.1074/jbc.M504045200
   Huang CF, 2015, INT J MOL SCI, V16, P924, DOI 10.3390/ijms16010924
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104
   Jarrett Stuart G, 2013, Methods Mol Biol, V935, P227, DOI 10.1007/978-1-62703-080-9_16
   Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861
   Jornayvaz FR, 2010, ESSAYS BIOCHEM, V47, P69, DOI [10.1042/BSE0470069, 10.1042/bse0470069]
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim YH, 2016, PLATELETS, V27, P735, DOI 10.1080/09537104.2016.1190005
   KNORR HLJ, 1993, OPHTHALMIC RES, V25, P226, DOI 10.1159/000267318
   Lanznaster D, 2016, AGING DIS, V7, P657, DOI 10.14336/AD.2016.0208
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Lee SM, 2009, CELL DEATH DIFFER, V16, P738, DOI 10.1038/cdd.2009.5
   Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268
   Lelliott CJ, 2006, PLOS BIOL, V4, P2042, DOI 10.1371/journal.pbio.0040369
   Li DW, 2014, INT J MOL MED, V34, P1358, DOI 10.3892/ijmm.2014.1904
   Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004
   Lo ASY, 2005, J CELL BIOCHEM, V94, P763, DOI 10.1002/jcb.20343
   Lopez-Lluch G, 2006, P NATL ACAD SCI USA, V103, P1768, DOI 10.1073/pnas.0510452103
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Morita M, 2013, CELL METAB, V18, P698, DOI 10.1016/j.cmet.2013.10.001
   Moroni F, 2009, BRIT J PHARMACOL, V157, P854, DOI 10.1111/j.1476-5381.2009.00232.x
   Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Plotnikov A, 2011, BBA-MOL CELL RES, V1813, P1619, DOI 10.1016/j.bbamcr.2010.12.012
   Ramanathan A, 2009, P NATL ACAD SCI USA, V106, P22229, DOI 10.1073/pnas.0912074106
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Ribback S, 2015, ONCOTARGET, V6, P13036, DOI 10.18632/oncotarget.3675
   Ricoult SJH, 2013, EMBO REP, V14, P242, DOI 10.1038/embor.2013.5
   Riehle C, 2012, TRENDS CARDIOVAS MED, V22, P98, DOI 10.1016/j.tcm.2012.07.003
   Ruderman NB, 2010, AM J PHYSIOL-ENDOC M, V298, pE751, DOI 10.1152/ajpendo.00745.2009
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Saint-Geniez M, 2013, AM J PATHOL, V182, P255, DOI 10.1016/j.ajpath.2012.09.003
   Salminen A, 2013, INT J MOL SCI, V14, P3834, DOI 10.3390/ijms14023834
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]
   Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x
   Sheikh Kathryn D, 2011, J Biomol Tech, V22, P1
   Singh SP, 2016, J NUTR METAB, V2016, DOI 10.1155/2016/9039754
   Slodzinski MK, 2008, J MOL CELL CARDIOL, V45, P650, DOI 10.1016/j.yjmcc.2008.07.017
   St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200
   Tan BE, 2012, FRONT BIOSCI-LANDMRK, V17, P2237, DOI 10.2741/4047
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Thomaz DT, 2016, PURINERG SIGNAL, V12, P707, DOI 10.1007/s11302-016-9534-3
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Vainshtein A, 2015, AM J PHYSIOL-CELL PH, V308, pC710, DOI 10.1152/ajpcell.00380.2014
   Vainshtein A, 2015, SKELET MUSCLE, V5, DOI 10.1186/s13395-015-0033-y
   Vergun O, 1999, J PHYSIOL-LONDON, V519, P451, DOI 10.1111/j.1469-7793.1999.0451m.x
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Weydt P, 2006, CELL METAB, V4, P349, DOI 10.1016/j.cmet.2006.10.004
   White RJ, 1996, J NEUROSCI, V16, P5688
   Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076
   Zhang BX, 2017, J CANCER, V8, P2088, DOI 10.7150/jca.19373
   Zhang J, 2017, EMBO J, V36, P1302, DOI 10.15252/embj.201696151
   Zhao C, 2011, AGING-US, V3, P346, DOI 10.18632/aging.100303
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 96
TC 30
Z9 30
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 12
PY 2020
VL 10
IS 1
AR 2464
DI 10.1038/s41598-020-59244-4
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NE8RC
UT WOS:000562871900002
PM 32051464
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lynch, AM
   Patnaik, JL
   Cathcart, JN
   Mathias, MT
   Siringo, FS
   Echalier, EL
   Wagner, BD
   Oliver, SCN
   Pecen, PE
   Olson, JL
   Fine, SL
   Palestine, AG
   Mandava, N
AF Lynch, Anne M.
   Patnaik, Jennifer L.
   Cathcart, Jennifer N.
   Mathias, Marc T.
   Siringo, Frank S.
   Echalier, E. Lacey
   Wagner, Brandie D.
   Oliver, Scott C. N.
   Pecen, Paula E.
   Olson, Jeffrey L.
   Fine, Stuart L.
   Palestine, Alan G.
   Mandava, Naresh
TI COLORADO AGE-RELATED MACULAR DEGENERATION REGISTRY Design and Clinical
   Risk Factors of the Cohort
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AMD; AMD phenotypes; asthma; colorado; epidemiology; family history;
   race
ID RACIAL-DIFFERENCES; PREVALENCE; COMPLEMENT; MACULOPATHY; FEATURES;
   SMOKING; HISTORY; DISEASE
AB Purpose: To study new and existing risk factors related to age-related macular degeneration (AMD) phenotypes in a Colorado cohort.
   Methods: Age-related macular degeneration was categorized into early, intermediate, or advanced forms. Controls (n = 180) were patients with cataract and no AMD. Demographic and clinical data were gathered by patient interview and verified by chart review. Image data were reviewed by vitreoretinal specialists. Statistical analysis included univariable and multivariate logistic regression analysis (P < 0.05).
   Results: Among the 456 patients with AMD, 157 (34.4%), 80 (17.6%), and 219 (48.0%) had the early/intermediate, geographic atrophy, and neovascular forms of the disease, respectively. Adjusted for age, African-American race was associated with a reduced risk of early/intermediate (adjusted odds ratio [AOR] = 0.08, confidence interval [CI] = 0.01-0.67) and neovascular AMD (AOR = 0.15, CI = 0.03-0.72). A family history of AMD was a risk factor for early/intermediate (AOR = 4.08, CI = 2.30-7.25), geographic atrophy (AOR = 8.62, CI = 3.77-19.7), and neovascular AMD (AOR = 3.76, CI = 2.16-6.56). A history of asthma was related to the early/intermediate form of AMD (AOR = 2.34, CI = 1.22-4.46).
   Conclusion: Studying AMD in specific populations may reveal novel risk factors such as our finding of a relationship between asthma history and AMD.
C1 [Lynch, Anne M.; Patnaik, Jennifer L.; Cathcart, Jennifer N.; Mathias, Marc T.; Siringo, Frank S.; Echalier, E. Lacey; Oliver, Scott C. N.; Pecen, Paula E.; Olson, Jeffrey L.; Fine, Stuart L.; Palestine, Alan G.; Mandava, Naresh] Univ Colorado, Dept Ophthalmol, Sch Med, Mail Stop F731,1675 Aurora Court, Aurora, CO 80045 USA.
   [Wagner, Brandie D.] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; Colorado School of Public Health
RP Lynch, AM (通讯作者)，Univ Colorado, Dept Ophthalmol, Sch Med, Mail Stop F731,1675 Aurora Court, Aurora, CO 80045 USA.
EM Anne.Lynch@ucdenver.edu
OI Patnaik, Jennifer/0000-0002-0375-0187
FU Research to Prevent Blindness, Inc; Frederic C. Hamilton Macular
   Degeneration Center
FX Support from a Challenge Grant to the Department of Ophthalmology from
   Research to Prevent Blindness, Inc and the Frederic C. Hamilton Macular
   Degeneration Center.
CR Akuffo KO, 2015, BRIT J OPHTHALMOL, V99, P1037, DOI 10.1136/bjophthalmol-2014-305768
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 2017, HIGH ALTITUDE MED GU
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   BrightFocus Foundation, 2017, SOURC MAC DEG FACTS
   Cogo A, 2004, HIGH ALT MED BIOL, V5, P435, DOI 10.1089/ham.2004.5.435
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P840, DOI 10.1001/archopht.126.6.840
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Moorthy S, 2011, AM J OPHTHALMOL, V151, P375, DOI 10.1016/j.ajo.2010.09.001
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   National Eye Institute, 2017, FACTS AG REL MAC DEG
   NHLBI, 2017, CALC YOUR BOD MASS I
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 36
TC 14
Z9 14
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2019
VL 39
IS 4
BP 656
EP 663
DI 10.1097/IAE.0000000000002023
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4TY
UT WOS:000480744900004
PM 29283981
DA 2022-11-30
ER

PT J
AU Dias, JRD
   De Andrade, GC
   Kniggendorf, VF
   Novais, EA
   Takahashi, VKL
   Maia, A
   Meyer, C
   Watanabe, SES
   Farah, ME
   Rodrigues, EB
AF de Oliveira Dias, Joao R.
   De Andrade, Gabriel Costa
   Kniggendorf, Vinicius F.
   Novais, Eduardo A.
   Takahashi, Vitor K. L.
   Maia, Andre
   Meyer, Carsten
   Watanabe, Sung E. S.
   Farah, Michel E.
   Rodrigues, Eduardo B.
TI INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION 52-Week Results
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE anti-vascular endothelial growth factor; intravitreal injections;
   neovascular age-related macular degeneration; ziv-aflibercept
ID SHORT-TERM SAFETY; ANGIOGENESIS; EFFICACY; ELECTRORETINOGRAPHY
AB Purpose: To evaluate the 52-week safety and efficacy of intravitreal ziv-aflibercept in patients with neovascular age-related macular degeneration.
   Methods: All patients received three monthly intravitreal injections of 0.05 mL of ziv-aflibercept (1.25 mg) followed by a pro re nata regimen. The best-corrected visual acuity and spectral domain optical coherence tomography were obtained at baseline and monthly. Full-field and multifocal electroretinograms were obtained at baseline and 4, 13, 26, and 52 weeks. For some full-field electroretinography parameters, we calculated the differences between baseline and 52 weeks and then compared those differences between treated and untreated fellow eyes.
   Results: Fifteen patients were included and 14 completed the 52-week follow-up. The mean best-corrected visual acuity improved from 0.95 +/- 0.41 (20/200) at baseline to 0.75 +/- 0.51 (20/125) logarithm of the minimum angle of resolution at 52 weeks (P = 0.0066). The baseline central retinal thickness decreased from 478.21 +/- 153.48 mu m to 304.43 +/- 98.59 mu m (P = 0.0004) at 52 weeks. Full-field electroretinography parameters used to assess retinal toxicity after intravitreal injections (rod response and oscillatory potentials) remained unchanged during follow-up. The average multifocal electroretinography macular response in 5 degrees showed increased N-1-P-1 amplitude and decreased P-1 implicit time (P < 0.05). One patient presented with intraocular inflammation after the seventh intravitreal procedure.
   Conclusion: The results suggested that intravitreal ziv-aflibercept might be safe and effective for treating neovascular age-related macular degeneration. More patients and a longer follow-up are needed to confirm the long-term outcomes of intravitreal ziv-aflibercept.
C1 [de Oliveira Dias, Joao R.; De Andrade, Gabriel Costa; Kniggendorf, Vinicius F.; Novais, Eduardo A.; Takahashi, Vitor K. L.; Maia, Andre; Meyer, Carsten; Watanabe, Sung E. S.; Farah, Michel E.; Rodrigues, Eduardo B.] Univ Fed Sao Paulo, Dept Ophthalmol, Paulista Med Sch, Rua Botucatu 821, BR-04023062 Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP)
RP Dias, JRD (通讯作者)，Univ Fed Sao Paulo, Dept Ophthalmol, Paulista Med Sch, Rua Botucatu 821, BR-04023062 Sao Paulo, Brazil.
EM dias_joaor@yahoo.com.br
RI Meyer, Carsten/A-3981-2017; Andrade, Gabriel/AAV-3155-2020; Farah,
   Michel Eid/F-3285-2012
OI Meyer, Carsten/0000-0002-0530-5298; Andrade,
   Gabriel/0000-0002-5881-8126; Farah, Michel Eid/0000-0001-5951-0193
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP; Sao Paulo,
   Brazil); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq; Brasilia, Brazil); Pan-American Association of
   Ophthalmology/Pan-American Ophthalmological Foundation, Paul Kayser/RRF
   Global Award (PAAO/PAOF; Arlington, TX)
FX Supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP; Sao Paulo, Brazil), Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq; Brasilia, Brazil), and Pan-American
   Association of Ophthalmology/Pan-American Ophthalmological Foundation,
   Paul Kayser/RRF Global Award (PAAO/PAOF; Arlington, TX).
CR Berezovsky A, 2003, DOC OPHTHALMOL, V107, P243, DOI 10.1023/B:DOOP.0000005333.76622.c2
   Braimah IZ, 2017, BRIT J OPHTHALMOL, V101, P1201, DOI 10.1136/bjophthalmol-2016-309994
   Cheng YD, 2013, DRUG DES DEV THER, V7, P1315, DOI 10.2147/DDDT.S52485
   Chhablani J, 2017, RETINA-J RET VIT DIS, V37, P1859, DOI 10.1097/IAE.0000000000001440
   Chhablani J, 2016, RETINA-J RET VIT DIS, V36, P1126, DOI 10.1097/IAE.0000000000000913
   Chu QSC, 2009, EXPERT OPIN BIOL TH, V9, P263, DOI [10.1517/14712590802666397, 10.1517/14712590802666397 ]
   Chung C, 2013, AM J HEALTH-SYST PH, V70, P1887, DOI 10.2146/ajhp130143
   de Andrade GC, 2016, OPHTHALMOLOGICA, V236, P223, DOI 10.1159/000452677
   Dias JRDO, 2017, RETINA-J RET VIT DIS, V37, P1499, DOI 10.1097/IAE.0000000000001385
   Dias JRD, 2014, OSLI RETINA, V45, P577, DOI 10.3928/23258160-20141118-15
   Frenkel REP, 2010, CLIN OPHTHALMOL, V4, P1279, DOI 10.2147/OPTH.S12846
   Hahn P, 2013, OPHTHALMOLOGY, V120, P1100, DOI 10.1016/j.ophtha.2012.11.018
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   Mansour AM, 2017, BRIT J OPHTHALMOL, V101, P1374, DOI 10.1136/bjophthalmol-2016-309724
   MARMOR MF, 1980, INVEST OPHTH VIS SCI, V19, P1016
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Paulose R, 2016, CLIN OPHTHALMOL, V10, P1853, DOI 10.2147/OPTH.S116343
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Salomao SR, 2007, CURR EYE RES, V32, P345, DOI 10.1080/02713680701229638
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Sutter EE, 2001, VISION RES, V41, P1241, DOI 10.1016/S0042-6989(01)00078-5
NR 24
TC 7
Z9 7
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2019
VL 39
IS 4
BP 648
EP 655
DI 10.1097/IAE.0000000000002001
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4TY
UT WOS:000480744900003
PM 29232334
DA 2022-11-30
ER

PT J
AU Johnson, TM
   Glaser, BM
AF Johnson, TM
   Glaser, BM
TI Micropulse laser treatment of retinal-choroidal anastomoses in
   age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID CHORIORETINAL ANASTOMOSES; PHOTODYNAMIC THERAPY; NEOVASCULARIZATION
AB Background: Retinal choroidal anastomoses (RCA) are a common finding in advanced cases of age-related macular degeneration. These high-flow lesions are associated with extensive subretinal exudation. This study examines the role of high-energy, short-duration (micropulse) laser pulses in effectively closing these shunts and reducing subretinal fluid. Methods: Nineteen consecutive eyes with advanced age-related macular degeneration undergoing treatment of RCAs to reduce subretinal exudation in a referral-only retina practice were reviewed retrospectively. RCA were identified using high-speed indocyanine green angiography. RCA were closed using a high-energy, short-duration laser pulse technique. Outcome measures included visual acuity, resolution of subretinal fluid and persistence of RCA. Results: Nineteen eyes with RCA associated with macular degeneration were successfully treated. Mean baseline visual acuity was 20/140 (HM to 20/50). One hundred percent of eyes had subretinal exudation and 73% had subretinal fibrosis at the time initial treatment. At mean follow-up of 11.7 ( 2 - 23) months, patients had undergone an average of 3.52 ( 1 - 12) sessions of laser treatment. Average final visual acuity was 20/146 (CF to 20/40). Fifty-three percent of eyes had complete resolution of subretinal fluid. One hundred percent had subretinal fibrosis. Forty-three percent had complete closure of RCA. No significant complications were encountered. Conclusion: High-energy, short-duration laser appears to be a reproducible technique to obtain closure of RCA associated with advanced macular degeneration. It appears to be effective in reducing subretinal exudation associated with these lesions. The technique is associated with stabilization of visual acuity without significant risk of complication.
C1 Natl Retina Inst, Chevy Chase, MD 20815 USA.
RP Johnson, TM (通讯作者)，Natl Retina Inst, Suite 101,5530 Wisconsin Ave, Chevy Chase, MD 20815 USA.
EM mjohnson@bmgnri.com
CR Anderson R R, 1981, Lasers Surg Med, V1, P263
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   CIALDINI AP, 1989, OPHTHALMIC SURG LAS, V20, P316
   DIERICKX CC, 1995, J INVEST DERMATOL, V105, P709, DOI 10.1111/1523-1747.ep12324514
   GARDEN JM, 1986, J INVEST DERMATOL, V87, P653, DOI 10.1111/1523-1747.ep12456368
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Silva RM, 2004, GRAEF ARCH CLIN EXP, V242, P368, DOI 10.1007/s00417-003-0844-0
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   1904, OELLERS ATLAS RARE C
NR 10
TC 4
Z9 5
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2005
VL 243
IS 6
BP 570
EP 575
DI 10.1007/s00417-004-1082-9
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 937DA
UT WOS:000229903600010
PM 15650856
DA 2022-11-30
ER

PT J
AU Yasuda, M
   Kiyohara, Y
   Hata, Y
   Arakawa, S
   Yonemoto, K
   Doi, Y
   Iida, M
   Ishibashi, T
AF Yasuda, Miho
   Kiyohara, Yutaka
   Hata, Yasuaki
   Arakawa, Satoshi
   Yonemoto, Koji
   Doi, Yasufumi
   Iida, Mitsuo
   Ishibashi, Tatsuro
TI Nine-Year Incidence and Risk Factors for Age-Related Macular
   Degeneration in a Defined Japanese Population The Hisayama Study
SO OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; LONG-TERM INCIDENCE; 10-YEAR INCIDENCE; GRADING
   SYSTEM; MACULOPATHY; PROGRESSION; PREVALENCE; SMOKING
AB Purpose: To estimate the 9-year incidence and risk factors for age-related macular degeneration (AMD) in a general Japanese population.
   Design: Population-based, cohort study.
   Participants: In 1998, a total of 1775 Hisayama residents aged >= 40 years underwent a baseline eye examination. Of those, 1401 subjects (78.9%) took part in the follow-up eye examination in 2007 and were enrolled in the present study.
   Methods: At both time points, the characteristics of AMD were determined by grading color fundus photographs using the Wisconsin Age-Related Maculopathy Grading System.
   Main Outcome Measures: Incident early and late AMD.
   Results: The age-standardized, 9-year cumulative incidence of early AMD was 10.0%, and that of late AMD was 1.4%. Men were found to have a significantly higher incidence of late AMD than women (age-adjusted odds ratio [OR], 2.97; 95% confidence interval [CI], 1.25-7.09). The incidence of both early and late AMD increased significantly with age. Multiple logistic regression analysis showed that older age (per 1 year; OR, 1.10; 95% CI, 1.05-1.16), smoking habits (OR, 3.98; 95% CI, 1.07-14.7), and higher circulating white blood cell (WBC) count (per 1000 cells/mm(3)) (OR, 1.38; 95% CI, 1.07-1.79) were significantly associated with the development of late AMD.
   Conclusions: Our findings suggest that the 9-year incidences of late AMD are lower among the Japanese than among white people in Western countries, and it is higher than among black people. Smoking habits and higher circulating WBC count are significant risk factors for the development of late AMD in the Japanese.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009; 116:2135-2140 (C) 2009 by the American Academy of Ophthalmology.
C1 [Yasuda, Miho] Kyushu Univ, Grad Sch Med, Dept Ophthalmol, Higashi Ku, Fukuoka 8128582, Japan.
   [Kiyohara, Yutaka; Yonemoto, Koji] Kyushu Univ, Grad Sch Med, Dept Environm Med, Fukuoka 8128582, Japan.
   [Doi, Yasufumi; Iida, Mitsuo] Kyushu Univ, Grad Sch Med, Dept Med & Clin Sci, Fukuoka 8128582, Japan.
C3 Kyushu University; Kyushu University; Kyushu University
RP Yasuda, M (通讯作者)，Kyushu Univ, Grad Sch Med, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM miho-m@med.kyushu-u.ac.jp
FU Ministry of Health, Labor and Welfare, Japan
FX Partially supported by the Strategic Study of Sensory Organ founded by
   the Ministry of Health, Labor and Welfare, Japan.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   Katsuki S, 1966, Prog Brain Res, V21, P64
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
NR 26
TC 104
Z9 108
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2009
VL 116
IS 11
BP 2135
EP 2140
DI 10.1016/j.ophtha.2009.04.017
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 512ZQ
UT WOS:000271291600014
PM 19744734
DA 2022-11-30
ER

PT J
AU Kahawita, SK
   Casson, RJ
AF Kahawita, Shyalle K.
   Casson, Robert J.
TI Aspirin use and early age-related macular degeneration: a meta-analysis
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID RISK-FACTORS; CUMULATIVE INCIDENCE; MACULOPATHY; PREVALENCE;
   CLASSIFICATION
AB Objective: The aim of this review was to evaluate the evidence for an association between Aspirin use and early age-related macular degeneration (ARMD).
   Methods: A literature search was performed in 5 databases with no restrictions on language or date of publication. Four studies involving 10292 individuals examining the association between aspirin and ARMD met the inclusion criteria. Meta-analysis was carried out by Cochrane Collaboration Review Manager 5.2 software (Cochrane Collaboration, Copenhagen, Denmark).
   Results: The pooled odd ratios showed that Aspirin use was associated with early ARMD (pooled odds ratio 1.43, 95% CI 1.09-1.88).
   Conclusions: There is a small but statistically significant association between Aspirin use and early ARMD, which may warrant further investigation.
C1 [Kahawita, Shyalle K.; Casson, Robert J.] Royal Adelaide Hosp, South Australian Inst Ophthalmol, Adelaide, SA 5000, Australia.
C3 Royal Adelaide Hospital
RP Kahawita, SK (通讯作者)，Queen Elizabeth Hosp, 28 Woodville Rd, Woodville South, SA 5011, Australia.
EM s.kahawita@gmail.com
OI Kahawita, Shyalle/0000-0002-4736-5336
CR American Academy of Ophthalmology Retina Panel, 2008, AG REL MAC DEG
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung N, 2013, BRIT J OPHTHALMOL, V97, P785, DOI 10.1136/bjophthalmol-2012-302253
   Christen W G, 1998, Ophthalmic Epidemiol, V5, P133, DOI 10.1076/opep.5.3.133.8368
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   de Jong PTVM, 2010, OPHTHALMOLOGY, V117, P1279, DOI 10.1016/j.ophtha.2010.03.011
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   He SK, 2013, MOL VIS, V19, P665
   HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301
   Hennekens CH, 2013, AM J MED, V126, P373, DOI 10.1016/j.amjmed.2012.12.013
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Liew G, 2013, JAMA INTERN MED, V173, P258, DOI 10.1001/jamainternmed.2013.1583
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moon BG, 2012, J KOREAN MED SCI, V27, P537, DOI 10.3346/jkms.2012.27.5.537
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Viringipurampeer IA, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/581751
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Zhu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058821
NR 34
TC 11
Z9 11
U1 0
U2 5
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD FEB
PY 2014
VL 49
IS 1
BP 35
EP 39
DI 10.1016/j.jcjo.2013.07.016
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA5OV
UT WOS:000331150300021
PM 24513354
DA 2022-11-30
ER

PT J
AU Koh, AHC
   Ang, CL
AF Koh, AHC
   Ang, CL
TI Age-related macular degeneration: What's new
SO ANNALS ACADEMY OF MEDICINE SINGAPORE
LA English
DT Article
DE choroidal neovascularisation; laser photocoagulation; macular
   translocation; photodynamic therapy
ID NEOVASCULARIZATION; IRRADIATION
AB Introduction: Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed western world, accounting for approximately 50% of all cases of registered blindness. The rising prevalence of this disease in Asia seems to parallel the same trend in the developed world. Because of the socio-economic impact of this disorder, much attention has been paid to elucidating the underlying pathogenic mechanisms, as well as seeking alternative forms of treatment. This review discusses the latest advances in AMD diagnosis, treatment and prophylaxis. Methods: Medline search with emphasis on randomised controlled clinical trials and large case-control series. Only articles cited on the Index Medicus were included in this review. Results: Recent advances in the diagnosis and treatment of AMD include conventional argon laser photocoagulation, photodynamic therapy (PDT), radiation therapy, surgical options and gene therapy. Conclusions: There have been numerous advances in the management of AMD and exciting new research applications have emerged. The introduction of exciting new modalities, such as PDT, has revolutionised the approach to treating CNVM and their effects on central vision. However, there has been no breakthrough in achieving satisfactory outcomes with the available techniques for treating occult neovascular lesions. As results of large prospective randomised clinical trials evaluating new treatment alternatives become available, a treatment algorithm for neovascular AMD will emerge that best minimises visual loss and may even result in visual improvement.
C1 Singapore Natl Eye Ctr, Vitreoretinal Serv, Singapore 168751, Singapore.
C3 Singapore National Eye Center
RP Koh, AHC (通讯作者)，Singapore Natl Eye Ctr, Vitreoretinal Serv, 11 3rd Hosp Ave, Singapore 168751, Singapore.
CR ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   ENGENHART R, 1994, INT J RADIAT ONCOL, V30, P521, DOI 10.1016/0360-3016(92)90937-D
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Ho T., 1997, SMJ, V38, P149
   *MAC PHOT STUD GRO, 1996, ARCH OPHTHALMOL-CHIC, V114, P1023
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Niffenegger J, 1998, OPHTHALMOLOGY, V105, P1364
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schilling H, 1997, BRIT J OPHTHALMOL, V81, P267, DOI 10.1136/bjo.81.4.267
   SLAKTER JS, 1994, ARCH OPHTHALMOL-CHIC, V112, P465, DOI 10.1001/archopht.1994.01090160041020
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
NR 21
TC 13
Z9 14
U1 0
U2 3
PU ACAD MEDICINE SINGAPORE
PI REPUBLIC SINGAPORE
PA 142 NEIL RD, REPUBLIC SINGAPORE 088871, SINGAPORE
SN 0304-4602
J9 ANN ACAD MED SINGAP
JI Ann. Acad. Med. Singap.
PD MAY
PY 2002
VL 31
IS 3
BP 399
EP 404
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 558QB
UT WOS:000175977100022
PM 12061304
DA 2022-11-30
ER

PT J
AU Pappas, D
   Hollenbach, J
   Coleman, AL
   Gorin, MB
   Yu, F
   Williams, K
   Noble, J
   Tranah, GJ
AF Pappas, Derek
   Hollenbach, Jill
   Coleman, Anne L.
   Gorin, Michael B.
   Yu, Fe
   Williams, Kevin
   Noble, Janelle
   Tranah, Gregory J.
CA Study Osteoporotic Fractures SOF R
TI HLA class II genotypes are not associated with age related macular
   degeneration in a case-control, population-based study
SO HUMAN IMMUNOLOGY
LA English
DT Article
DE AMD; Age related macular degeneration; HLA; Class II; Next generation
   sequencing
ID OLDER WOMEN; MACULOPATHY; POLYMORPHISMS; EXPRESSION; HAPLOTYPE;
   ANTIGENS; DRUSEN; COMMON
AB Multiple lines of evidence support an immunologic basis and genetic disposition for the development of age-related macular degeneration (AMD). Comprehensive human leukocyte antigens (HLA) class II typing at four loci (DRB1, DQA1, DQB1, and DPB1) was assessed using next generation sequencing methods and tested for association with age-related macular degeneration (AMD) in a case-control study of 456 AMD cases and 499 controls from the population-based Study of Osteoporotic Fractures (SOF) cohort. No statistically significant associations were identified for any of the class II loci and a previously identified association between DRB1*13:01 was not replicated in this dataset. These results reported here suggest that common HLA class II genetic variation does not contribute to AMD disease risk. (C) 2015 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
C1 [Pappas, Derek; Hollenbach, Jill; Noble, Janelle] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA.
   [Coleman, Anne L.; Gorin, Michael B.; Yu, Fe] Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Coleman, Anne L.; Gorin, Michael B.; Yu, Fe] Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA USA.
   [Williams, Kevin] Atreca Inc, San Carlos, CA 94070 USA.
   [Tranah, Gregory J.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94107 USA.
C3 Children's Hospital Oakland Research Institute; University of California
   System; University of California San Francisco; UCSF Medical Center;
   UCSF Benioff Children's Hospital Oakland; University of California
   System; University of California Los Angeles; California Pacific Medical
   Center; California Pacific Medical Center Research Institute
RP Tranah, GJ (通讯作者)，UCSF, Calif Pacific Med Ctr, Res Inst, Dept Epidemiol & Biostat, Mission Hall,550 16th St,2nd Floor,Box 0560, San Francisco, CA 94158 USA.
EM gtranah@sfcc-cpmc.net
OI Pappas, Derek/0000-0001-5484-8806
FU National Institutes of Health; National Institute on Aging (NIA) [R01
   AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01
   AG027574, R01 AG027576]; National Eye Institute [R01 IEY019900];
   NATIONAL EYE INSTITUTE [R01EY019900] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
   [R01AR035583, R01AR035582, R01AR035584] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM109030] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027574] Funding
   Source: NIH RePORTER
FX The Study of Osteoporotic Fractures (SOF) is supported by National
   Institutes of Health funding. The National Institute on Aging (NIA)
   provides support under the following Grant Numbers: R01 AG005407, R01
   AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, and R01
   AG027576. The National Eye Institute supported the HLA genetics study
   under Grant Number R01 IEY019900.
CR ABIHANNA D, 1988, TRANSPLANTATION, V45, P610, DOI 10.1097/00007890-198803000-00021
   BAKKER M, 1986, DOC OPHTHALMOL, V61, P271, DOI 10.1007/BF00142353
   Chongsuvivatwong V, 2012, EPICALC EPIDEMIOLOGI
   Core-Team R., 2013, R LANG ENV STAT COMP
   Erlich HA, 2013, DIABETES, V62, P2618, DOI 10.2337/db12-1387
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Goverdhan SV, 2008, INVEST OPHTH VIS SCI, V49, P5077, DOI 10.1167/iovs.08-1837
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Lancaster Alex, 2003, Pac Symp Biocomput, P514
   Martin AM, 2004, GENE, V335, P121, DOI 10.1016/j.gene.2004.03.018
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ozaki E, 2014, ADV EXP MED BIOL, V801, P229, DOI 10.1007/978-1-4614-3209-8_30
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   PENFOLD PL, 1993, J NEUROIMMUNOL, V45, P183, DOI 10.1016/0165-5728(93)90179-3
   Seitzman RL, 2008, AM J EPIDEMIOL, V167, P1217, DOI 10.1093/aje/kwn024
   Seitzman RL, 2007, J AM GERIATR SOC, V55, P740, DOI 10.1111/j.1532-5415.2007.01138.x
   Stanton CM, 2014, ADV EXP MED BIOL, V801, P251, DOI 10.1007/978-1-4614-3209-8_32
   STREILEIN JW, 1992, J NEUROIMMUNOL, V39, P185, DOI 10.1016/0165-5728(92)90253-H
   Becerri EV, 2009, CELL MOL IMMUNOL, V6, P303, DOI 10.1038/cmi.2009.40
NR 24
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0198-8859
EI 1879-1166
J9 HUM IMMUNOL
JI Hum. Immunol.
PD MAR
PY 2015
VL 76
IS 2-3
BP 142
EP 145
DI 10.1016/j.humimm.2015.01.010
PG 4
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA CC7EP
UT WOS:000350530800013
PM 25665771
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Park, SS
   Daftari, I
   Phillips, T
   Morse, LS
AF Park, Susanna S.
   Daftari, Inder
   Phillips, Theodore
   Morse, Lawrence S.
TI THREE-YEAR FOLLOW-UP OF A PILOT STUDY OF RANIBIZUMAB COMBINED WITH
   PROTON BEAM IRRADIATION AS TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF therapy; choroidal
   neovascularization; combination therapy; exudative age-related macular
   degeneration; neovascular age-related macular degeneration; proton beam
   irradiation; ranibizumab; radiation; radiotherapy
ID ENDOTHELIAL GROWTH-FACTOR; BEVACIZUMAB; RADIATION; NEOVASCULARIZATION;
   MACULOPATHY; CELLS; VEGF
AB Background: To investigate the safety and tolerability of ranibizumab combined with proton beam irradiation in treating exudative age-related macular degeneration.
   Methods: Six eyes (6 subjects) with exudative age-related macular degeneration (4 newly diagnosed; 2 previous treated with ranibizumab) were treated with 4 monthly ranibizumab and 24 GyE proton beam irradiation (2 fractions, 24 hours apart) and seen monthly thereafter and retreated with ranibizumab for decrease in best-corrected visual acuity of >= 2 lines, new macular hemorrhage or fluid noted on optical coherence tomography.
   Results: Follow-up ranged from 12 months to 36 months (mean, 28 months). Baseline best-corrected visual acuity ranged from 20/40 to 20/250. Final best-corrected visual acuity ranged from 20/25 to 20/400. No radiation retinopathy was noted in any eye. Calculated radiation distribution dose curves indicate that <= 10% of retina received >= 90% of radiation dose in all eyes. Two subjects lost >= 3 lines of best-corrected visual acuity during follow-up, 1 subject in both eyes from enlarging geographic atrophy and the other from worsening fibrovascular pigment epithelial detachment, which was refractory to multiple ranibizumab treatments before enrollment. Among 4 eyes with newly diagnosed exudative age-related macular degeneration, 3 had no fluid on optical coherence tomography at month 12 without further treatment.
   Conclusion: No safety concerns were noted after 3 years in eyes with exudative age-related macular degeneration treated with ranibizumab combined with proton beam irradiation in this small pilot study. A larger randomized prospective study is under way to further evaluate this combination therapy. RETINA 32:956-966, 2012
C1 [Park, Susanna S.; Morse, Lawrence S.] Univ Calif Davis, Ctr Eye, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
   [Daftari, Inder; Phillips, Theodore] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA.
C3 University of California System; University of California Davis;
   University of California System; University of California San Francisco
RP Park, SS (通讯作者)，Univ Calif Davis, Ctr Eye, Dept Ophthalmol & Vis Sci, 4860 Y St,Suite 2400, Sacramento, CA 95817 USA.
EM susanna.park@ucdmc.ucdavis.edu
OI Morse, Lawrence/0000-0002-1758-2348
FU Genentech, Inc; U.S. Food and Drug Administration [100,481]
FX Supported by an investigator-sponsored trial grant funded by Genentech,
   Inc, and based on an investigational new drug approved by the U.S. Food
   and Drug Administration (IND #100,481).; Drs. S. S. Park and L. S. Morse
   have received research grant and honoraria from Genentech, Inc.
CR Avci B, 2009, INVEST OPHTH VIS SCI, V50, P3438, DOI 10.1167/iovs.08-2871
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   COHEN M, 1972, BRIT J RADIOL, V11, P8
   Daftari IK, 1996, NUCL INSTRUM METH A, V380, P597, DOI 10.1016/0168-9002(96)00707-3
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finger PT, 2008, INT J RADIAT ONCOL, V70, P974, DOI 10.1016/j.ijrobp.2007.11.045
   Flaxel Christina J, 2002, Ophthalmol Clin North Am, V15, P437, DOI 10.1016/S0896-1549(02)00038-X
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GUYER DR, 1992, OPHTHALMOLOGY, V99, P1278
   Hanlon J, 2009, MED PHYS, V36, P3671, DOI 10.1118/1.3168554
   Hess C, 2001, BRIT J CANCER, V85, P2010, DOI 10.1054/bjoc.2001.2166
   Hori K, 2004, INT J RADIAT ONCOL, V60, P1564, DOI 10.1016/j.ijrobp.2004.06.208
   Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265
   Lopez PF, 1991, AM J OPHTHALMOL, V112, P642
   Moshfeghi DM, 2010, BR J OPHTHALMOL
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Rosenfeld P.J., 2010, OPHTHALMOLOGY
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sheen M., 1994, P 20 PTCOG M ENGL, P29
   Silvagnanavel V, 2004, COCHRANE DB SYST REV, V4
   Storkebaum E, 2004, J CLIN INVEST, V113, P14, DOI 10.1172/JCI200420682
   Trikha R, RETINA IN PRESS
   YONEMOTO LT, 2000, J RADIOSURG, V3, P47
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
NR 28
TC 12
Z9 12
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2012
VL 32
IS 5
BP 956
EP 966
DI 10.1097/IAE.0b013e31822a8d6a
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 935EQ
UT WOS:000303502200012
PM 22183743
DA 2022-11-30
ER

PT J
AU You, QS
   Xu, L
   Yang, H
   Li, YB
   Wang, S
   Wang, JD
   Zhang, JS
   Wang, YX
   Jonas, JB
AF You, Qi Sheng
   Xu, Liang
   Yang, Hua
   Li, Yi Bin
   Wang, Shuang
   Wang, Jin Da
   Zhang, Jing Shang
   Wang, Ya Xing
   Jonas, Jost B.
TI Five-Year Incidence of Age-related Macular Degeneration The Beijing Eye
   Study
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT; RISK-FACTORS; ADULT-POPULATION; REFRACTIVE ERROR;
   4-YEAR INCIDENCE; MACULOPATHY; PREVALENCE; PROGRESSION; SMOKING;
   ASSOCIATIONS
AB Purpose: To examine the incidence of age-related macular degeneration (AMD) and its associated factors in an adult Chinese population.
   Design: Population-based study.
   Participants: The Beijing Eye Study, which included 4439 subjects (age >= 40 years) in 2001, was repeated in 2006 with 3251 (73.2%) subjects participating.
   Methods: Fundus photographs were graded using the International Age-related Maculopathy Epidemiological Study Group grading system.
   Main Outcome Measures: Incidence of AMD.
   Results: Gradable slides were available on 3049 (93.9%) subjects who participated in the survey of 2001 and again in 2006. The incidence of early, late, and neovascular AMD per eye was 2.6% (95% confidence interval [CI], 2.2-3.0), 0.1% (95% CI, 0.00-0.2), and 0.1% (95% CI, 0.00-0.2), respectively. The incidence of early, late, and neovascular AMD per person was 4.2 +/- 0.4% (95% CI, 3.5-5.0), 0.1 +/- 0.1% (95% CI, 0.0-0.2), and 0.1 +/- 0.1% (95% CI, 0.0-0.2), respectively. By multivariate analysis, incident early AMD was associated significantly with greater age at baseline (P = 0.01; odds ratio [OR], 1.03; 95% CI, 1.01-1.06), smaller optic disc size (P = 0.007; OR, 0.50; 95% CI, 0.30-0.83), smaller scleral spur distance (P = 0.04; OR, 0.59; 95% CI, 0.36-0.98), and hyperopic refractive error (P = 0.057; OR, 1.15; 95% CI, 1.00-1.33), with the latter being significant only marginally. It was not associated with the systemic parameters of gender, body height, body mass index, region of habitation, level of education, profession, smoking, arterial blood pressure, diabetes mellitus, fasting blood concentrations of glucose, triglycerides, high-density or low-density lipoproteins; or the ocular parameters of intraocular pressure, retinal arterial and vein diameters, retinal microvascular abnormalities, amount of nuclear cataract, cortical cataract or subcapsular cataract, pseudophakia, glaucoma, nonglaucomatous optic neuropathy, retinal vein occlusions, size of the beta zone of parapapillary atrophy, or progression of the zone of atrophy during the follow-up from 2001 to 2006.
   Conclusions: Hyperopia, short interscleral spur distance, and small optic disc size were, beside older age, the main factors associated with incident early AMD. This may point to a small globe size, potentially in relation to a firmly attached vitreous, playing a role in early incident AMD.
   Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials discussed in this article. Ophthalmology 2012;119:2519-2525 (C) 2012 by the American Academy of Ophthalmology.
C1 [You, Qi Sheng; Xu, Liang; Yang, Hua; Li, Yi Bin; Wang, Shuang; Wang, Jin Da; Zhang, Jing Shang; Wang, Ya Xing; Jonas, Jost B.] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing 100005, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, Heidelberg, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg
RP Xu, L (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, 17 Hougou Lane, Beijing 100005, Peoples R China.
EM xlbio1@163.com
RI You, Qisheng/AAG-7153-2020; wang, YA XING/K-9671-2016; You,
   Qisheng/A-3619-2014
OI You, Qisheng/0000-0003-0743-7320; wang, YA XING/0000-0003-2749-7793;
   You, Qisheng/0000-0003-0743-7320
FU Beijing Nova Program [2010B032]; National Natural Science Foundation of
   China [81170890]
FX Supported by Beijing Nova Program (No. 2010B032) and National Natural
   Science Foundation of China (No. 81170890).
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Hall ER, 2006, AM J OPHTHALMOL, V141, P494, DOI 10.1016/j.ajo.2005.10.049
   Hayreh SS, 2004, OPHTHALMOLOGICA, V218, P333, DOI 10.1159/000079476
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe185, DOI 10.1111/j.1755-3768.2011.02316.x
   Jonas JB, 2010, OPHTHALMOLOGY, V117, P2234, DOI 10.1016/j.ophtha.2009.12.006
   Jonas JB, 2009, ARCH OPHTHALMOL-CHIC, V127, P826, DOI 10.1001/archophthalmol.2009.118
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Lavanya R, 2010, INVEST OPHTH VIS SCI, V51, P6247, DOI 10.1167/iovs.10-5229
   Leske MC, 2004, OPHTHALMOLOGY, V111, P706, DOI 10.1016/j.ophtha.2003.07.003
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   PAPASTATHOPOULOS KI, 1995, EXP EYE RES, V60, P459, DOI 10.1016/S0014-4835(05)80102-2
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Tao Y, 2010, EYE, V24, P648, DOI 10.1038/eye.2009.160
   Varma R, 2010, AM J OPHTHALMOL, V149, P741, DOI 10.1016/j.ajo.2010.01.009
   Wang JJ, 2004, CLIN EXP OPHTHALMOL, V32, P255, DOI 10.1111/j.1442-9071.2004.00813.x
   Wang YX, 2011, ACTA OPHTHALMOL, V89, pE210, DOI 10.1111/j.1755-3768.2009.01787.x
   Wang YX, 2010, AM J OPHTHALMOL, V150, P917, DOI 10.1016/j.ajo.2010.06.037
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
   Xie XW, 2008, GRAEF ARCH CLIN EXP, V246, P1519, DOI 10.1007/s00417-008-0884-6
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2008, AM J OPHTHALMOL, V145, P929, DOI 10.1016/j.ajo.2008.01.004
   Xu LA, 2006, AM J OPHTHALMOL, V142, P688, DOI 10.1016/j.ajo.2006.05.028
   Xu L, 2010, GRAEF ARCH CLIN EXP, V248, P49, DOI 10.1007/s00417-009-1204-5
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 40
TC 54
Z9 58
U1 0
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2012
VL 119
IS 12
BP 2519
EP 2525
DI 10.1016/j.ophtha.2012.06.043
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 049AL
UT WOS:000311954300015
PM 22921389
DA 2022-11-30
ER

PT J
AU Kang, EC
   Choi, S
   Koh, HJ
AF Kang, Eui Chun
   Choi, Seonghee
   Koh, Hyoung Jun
TI Inner nuclear layer cystoid spaces are a poor prognostic factor in
   typical age-related macular degeneration and polypoidal choroidal
   vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal thickness; Inner nuclear
   layer cystoid spaces; Spectral-domain optical coherence tomography
ID TREAT-AND-EXTEND; QUALITY-OF-LIFE; VISUAL-ACUITY; RANIBIZUMAB TREATMENT;
   OUTCOMES; THERAPY; NEOVASCULARIZATION; BEVACIZUMAB; MORPHOLOGY
AB To investigate predictive factors for changes in best-corrected visual acuity (BCVA) at 24 months after intravitreal ranibizumab (IVR) for neovascular age-related macular degeneration (nAMD).
   This retrospective study included 55 eyes of 55 consecutive patients (32 men and 23 women) with nAMD who received three consecutive monthly IVR injections and were re-treated as needed over a 24-month period. We used the mean changes in logarithm of the minimal angle of resolution (logMAR) BCVA at 24 months as the dependent variable in regression analysis.
   The presence of intraretinal cystoid spaces in the inner nuclear layer (INLc, P = 0.004) and baseline subfoveal choroidal thickness (SFCT, P = 0.013) predicted BCVA changes from baseline to 24 months. The presence of INLc and thinning of SFCT were associated with decreased BCVA at 24 months. Thirty-five eyes without INLc showed improved logMAR BCVA, from 0.550 +/- 0.273 to 0.368 +/- 0.274 (P = 0.045); however, 20 eyes with INLc showed decreased logMAR BCVA, from 0.708 +/- 0.347 to 0.971 +/- 0.523 (P < 0.001) through the 24-month follow-up. The mean number of IVR injections during the follow-up period was 8.74 +/- 4.76 in eyes without INLc and 10.63 +/- 4.72 in eyes with INLc, without a statistically significant difference (P = 0.144).
   Eyes with INLc or thinned SFCT showed worse visual outcomes compared with eyes without the INLc or with thick SFCT. Furthermore, eyes without INLc showed improved BCVA; however, eyes with INLc showed decreased BCVA with an as-needed regimen.
C1 [Kang, Eui Chun; Choi, Seonghee; Koh, Hyoung Jun] Yonsei Univ, Inst Vis Res, Dept Ophthalmol, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Koh, HJ (通讯作者)，Yonsei Univ, Inst Vis Res, Dept Ophthalmol, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea.
EM hjkoh@yuhs.ac
OI Koh, Hyoung Jun/0000-0002-5932-8516
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Antcliff R J, 1999, Semin Ophthalmol, V14, P223, DOI 10.3109/08820539909069541
   Antcliff RJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P539
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kodjikian L, 2014, GRAEF ARCH CLIN EXP, V252, P1529, DOI 10.1007/s00417-014-2764-6
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Marmor MF, 1999, DOC OPHTHALMOL, V97, P239, DOI 10.1023/A:1002192829817
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 41
TC 5
Z9 5
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2017
VL 255
IS 11
BP 2157
EP 2163
DI 10.1007/s00417-017-3776-9
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FJ8HR
UT WOS:000413006000010
PM 28819823
DA 2022-11-30
ER

PT J
AU Ding, JD
   Lin, J
   Mace, BE
   Herrmann, R
   Sullivan, P
   Rickman, CB
AF Ding, Jin-Dong
   Lin, John
   Mace, Brian E.
   Herrmann, Rolf
   Sullivan, Patrick
   Rickman, Catherine Bowes
TI Targeting age-related macular degeneration with Alzheimer's disease
   based immunotherapies: Anti-amyloid-beta antibody attenuates pathologies
   in an age-related macular degeneration mouse model
SO VISION RESEARCH
LA English
DT Article
DE age-related macular degeneration (AMD); amyloid; choroidal
   neovascularization (CNV); retinal pigment epithelium (RPE);
   immunotherapy; Alzheimer's disease
ID FACTOR-H POLYMORPHISM; APOLIPOPROTEIN-E; TRANSGENIC MICE; THIOFLAVIN-T;
   PROTEIN; DRUSEN; IMMUNIZATION; PATHOGENESIS; COMMON; RISK
AB Age-related macular degeneration (AMD) is a late-onset, neurodegenerative retinal disease that shares several clinical and pathological features with Alzheimer's disease (AD) including extracellular deposits containing amyloid-beta (A beta) peptides. Immunotherapy targeting the A beta protein has been investigated as a potential treatment for AD. Here, we present the rationale for extending this approach to treat AMD. We tested an anti-A beta antibody administered systemically in a mouse model of AMD. Histological and functional measurements in treated animals compared to controls showed that following immunotherapy, the amounts of A beta in the retina and brain were decreased and the ERG deficits in the retina were attenuated. These data support the hypothesis that A beta is a therapeutic target for AMD. (c) 2007 Elsevier Ltd. All rights reserved.
C1 [Ding, Jin-Dong; Herrmann, Rolf; Rickman, Catherine Bowes] Duke Univ, Med Ctr, Dept Ophthalmol, Albert Eye Res Inst, Durham, NC 27710 USA.
   [Lin, John] Pfizer Inc, Rinat Labs, San Francisco, CA 94080 USA.
   [Mace, Brian E.; Sullivan, Patrick] Duke Univ, Dept Med, Durham, NC 27710 USA.
   [Rickman, Catherine Bowes] Duke Univ, Dept Cell Biol, Durham, NC 27710 USA.
C3 Duke University; Pfizer; Duke University; Duke University
RP Rickman, CB (通讯作者)，Duke Univ, Med Ctr, Dept Ophthalmol, Albert Eye Res Inst, Room 5010,Box 3802,Erwin Rd, Durham, NC 27710 USA.
EM bowes007@duke.edu
RI Ding, Jindong/B-3324-2008
OI Ding, Jindong/0000-0003-0427-0369; Bowes Rickman,
   Catherine/0000-0002-8555-9596; Mace, Brian/0000-0002-5478-6227
FU NEI NIH HHS [R21 EY017128, R21 EY01712, R21 EY017128-01A1, R21
   EY017128-02, P30 EY005722] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [P30EY005722, R21EY017128] Funding Source: NIH RePORTER
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Arai T, 1999, BRAIN RES, V823, P202, DOI 10.1016/S0006-8993(98)01366-3
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7
   Canevari L, 2007, NEUROCHEM RES, V32, P739, DOI 10.1007/s11064-006-9200-1
   Carty NC, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-11
   Dentchev T, 2003, MOL VIS, V9, P184
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans K, 1996, BRIT J OPHTHALMOL, V80, P763, DOI 10.1136/bjo.80.8.763
   Ferrer I, 2004, BRAIN PATHOL, V14, P11, DOI 10.1111/j.1750-3639.2004.tb00493.x
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krebs MRH, 2005, J STRUCT BIOL, V149, P30, DOI 10.1016/j.jsb.2004.08.002
   LeVine H, 1999, METHOD ENZYMOL, V309, P274
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   MALEK G, 2007, IN PRESS ADV EXPT ME
   Masliah E, 2005, NEUROLOGY, V64, P129, DOI 10.1212/01.WNL.0000148590.39911.DF
   Melnikova I, 2007, NAT REV DRUG DISCOV, V6, P341, DOI 10.1038/nrd2314
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840
   Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   PUCHTLER H, 1965, J HISTOCHEM CYTOCHEM, V13, P693, DOI 10.1177/13.8.693
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007
   Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wilcock DM, 2004, J NEUROSCI, V24, P6144, DOI 10.1523/JNEUROSCI.1090-04.2004
   Wilcock DM, 2006, J NEUROSCI, V26, P5340, DOI 10.1523/JNEUROSCI.0695-06.2006
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
NR 39
TC 83
Z9 109
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
EI 1878-5646
J9 VISION RES
JI Vision Res.
PD FEB
PY 2008
VL 48
IS 3
BP 339
EP 345
DI 10.1016/j.visres.2007.07.025
PG 7
WC Neurosciences; Ophthalmology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA 272BG
UT WOS:000253832000004
PM 17888483
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Arrigo, A
   Romano, F
   Aragona, E
   Di Nunzio, C
   Battista, M
   Bandello, F
   Parodi, MB
AF Arrigo, Alessandro
   Romano, Francesco
   Aragona, Emanuela
   Di Nunzio, Carlo
   Battista, Marco
   Bandello, Francesco
   Parodi, Maurizio Battaglia
TI OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CAN CATEGORIZE DIFFERENT
   SUBGROUPS OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; OCT; OCTA; CNV; vessel density; vessel
   tortuosity; vessel dispersion
AB Purpose: Choroidal neovascularization (CNV) is a common complication of patients affected by age-related macular degeneration, showing a highly variable visual outcome. The main aim of the study was, at baseline, to perform a quantitative optical coherence tomography angiography assessment of CNV secondary to age-related macular degeneration and to assess posttreatment outcomes.
   Methods: Seventy-eight naive age-related macular degeneration-related CNV patients (39 men, mean age 78 +/- 8 years) were recruited and underwent complete ophthalmologic evaluation and multimodal imaging. Several OCT and optical coherence tomography angiography parameters were collected, including vessel tortuosity and vessel dispersion (VDisp), measured for each segmented CNV. All patients underwent anti-vascular endothelial growth factor PRN treatment. Vessel tortuosity and VDisp values of CNVs were tested at baseline to establish a cutoff able to distinguish clinically different patient subgroups.
   Results: Mean best-corrected visual acuity was 0.49 +/- 0.57 (20/62) at baseline, improving to 0.31 +/- 0.29 (20/41) at the 1-year follow-up (P < 0.01), with a mean number of 6.4 +/- 1.9 injections. Our cohort included the following CNV types: occult (45 eyes; 58%), classic (14 eyes; 18%), and mixed (19 eyes; 24%). Observing optical coherence tomography angiography parameters, classic, mixed, and occult CNV revealed significantly different values of VDisp, with classic forms showing the highest values and the occult CNVs showing the lowest (P < 0.01); mixed forms displayed intermediate VDisp values. The ROC analysis revealed that a CNV vessel tortuosity cut-off of 8.40, calculated at baseline, enabled two patient subgroups differing significantly in visual outcomes after anti-vascular endothelial growth factor treatment to be distinguished.
   Conclusion: A baseline quantitative optical coherence tomography angiography-based parameter could provide information regarding both clinical and functional outcomes after anti-vascular endothelial growth factor treatment in age-related macular degenerationrelated CNV.
C1 [Arrigo, Alessandro; Romano, Francesco; Aragona, Emanuela; Di Nunzio, Carlo; Battista, Marco; Bandello, Francesco; Parodi, Maurizio Battaglia] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
   [Romano, Francesco] Luigi Sacco Univ Hosp, Eye Clin, Dept Biomed & Clin Sci, Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   University of Milan; Luigi Sacco Hospital
RP Arrigo, A (通讯作者)，Univ Vita Salute, IRCCS Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM alessandro.arrigo@hotmail.com
RI Battista, Marco/AAO-3106-2021
OI Battista, Marco/0000-0001-5940-6177; bandello,
   francesco/0000-0003-3238-9682; Di Nunzio, Carlo/0000-0003-1280-6856;
   Battaglia Parodi, Maurizio/0000-0002-0385-7961
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Arganda-Carreras I, 2010, MICROSC RES TECHNIQ, V73, P1019, DOI 10.1002/jemt.20829
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Coscas F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205513
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Grisan E, 2008, IEEE T MED IMAGING, V27, P310, DOI 10.1109/TMI.2007.904657
   LIU ZQ, 1991, APPL OPTICS, V30, P1369, DOI 10.1364/AO.30.001369
   Manikandan S, 2011, J PHARMACOL PHARMACO, V2, P315, DOI 10.4103/0976-500X.85931
   Padnick-Silver L, 2012, RETINA-J RET VIT DIS, V32, P1045, DOI 10.1097/IAE.0b03e31823fb82b
   Patel R, 2018, INVEST OPHTH VIS SCI, V59, P4285, DOI 10.1167/iovs.18-24624
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 17
TC 17
Z9 17
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2020
VL 40
IS 12
BP 2263
EP 2269
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QI4NW
UT WOS:000618957100002
PM 32032255
DA 2022-11-30
ER

PT J
AU Klein, R
   Klein, R
   Myers, CE
   Meuer, SM
   Gangnon, RE
   Sivakumaran, TA
   Iyengar, SK
   Lee, KE
   Klein, BEK
AF Klein, Ronald
   Klein, Ronald
   Myers, Chelsea E.
   Meuer, Stacy M.
   Gangnon, Ronald E.
   Sivakumaran, Theru A.
   Iyengar, Sudha K.
   Lee, Kristine E.
   Klein, Barbara E. K.
CA Beaver Dam Eye Study
TI Risk Alleles in CFH and ARMS2 and the Long-term Natural History of
   Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT-FACTOR-H; BEAVER-DAM-EYE; 5-YEAR INCIDENCE; GENOMEWIDE-SCAN;
   VISUAL-ACUITY; MULTISTATE-MODELS; MACULOPATHY; DRUSEN; SUSCEPTIBILITY;
   PROGRESSION
AB Objective: To describe the relationships of risk alleles in complement factor H (CFH, rs1061170) and age-related maculopathy susceptibility 2 (ARMS2, rs10490924) to the incidence and progression of age-related macular degeneration (AMD) during a 20-year period.
   Methods: There were 4282 persons aged 43 to 86 years at the baseline examination in 1988-1990 enrolled in a population-based cohort study who participated in at least 1 examination spaced 5 years apart during a 20-year period and had gradable fundus photographs for AMD and genotype information on CFH and ARMS2. Low, intermediate, and high genetic risk for AMD was defined by the presence of 0 to 1, 2, or 3 to 4 risk alleles for CFH and ARMS2, respectively. Multistate models were used to estimate the progression of AMD throughout the entire age range.
   Results: There were 2820 (66%), 1129 (26%), and 333 persons (8%) with low, intermediate, and high genetic risk for AMD, respectively. The 5-year incidences of early and late AMD were 9.1% and 1.6%, respectively, and increased with age but did not differ significantly by sex. Using the multistate model, of persons aged 45 years with no AMD in the low, intermediate, and high AMD genetic risk groups, 33.0%, 39.9%, and 46.5%, respectively, were estimated to develop early AMD, and 1.4%, 5.2%, and 15.3% were estimated to develop late AMD by age 80 years.
   Conclusions: These population-based data provide estimates of the long-term risk of the incidence and progression of AMD and its lesions by age and genetic risk alleles for CFH and ARMS2. They also show that when early AMD is present, knowing the phenotype contributes more to risk assessment than knowing the genetic risk based on these 2 AMD genes. JAMA Ophthalmol. 2013;131(3):383-392. Published online November 9, 2012. doi: 10.1001/jamaophthalmol.2013.713
C1 [Klein, Ronald; Myers, Chelsea E.; Meuer, Stacy M.; Lee, Kristine E.; Klein, Barbara E. K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53726 USA.
   [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA.
   [Sivakumaran, Theru A.; Iyengar, Sudha K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Sivakumaran, Theru A.; Iyengar, Sudha K.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
   [Sivakumaran, Theru A.; Iyengar, Sudha K.] Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA.
   [Sivakumaran, Theru A.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison; Case
   Western Reserve University; Case Western Reserve University; Case
   Western Reserve University; Cincinnati Children's Hospital Medical
   Center
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,417 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI /S-1190-2019
OI /0000-0001-7488-250X; Gangnon, Ronald/0000-0003-2587-6714; Klein,
   Ronald/0000-0002-4428-6237
FU National Institutes of Health grant [EY06594]; Research to Prevent
   Blindness; NATIONAL EYE INSTITUTE [U10EY006594] Funding Source: NIH
   RePORTER
FX The National Institutes of Health grant EY06594 (Drs R. Klein and B. E.
   K. Klein) provided funding for the entire study, including collection
   and analyses of data; further support for data analyses was provided by
   Research to Prevent Blindness (Drs R. Klein and B. E. K. Klein, Senior
   Scientific Investigator Awards).
CR BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Efron B., 1994, INTRO BOOTSTRAP
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Huang L, 2009, AM J HUM GENET, V84, P235, DOI 10.1016/j.ajhg.2009.01.013
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jackson CH, 2011, J STAT SOFTW, V38, P1
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein BE, 2010, NTIS PUBLICATION, VPB2010-114194
   Klein BE, 1999, NTIS PUBLICATION, VPB99-137861
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1995, NTIS PUBLICATION, VPB95-273827
   KLEIN R, 1991, NTIS PUBLICATION
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1605, DOI 10.1001/archophthalmol.2011.372
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   R Development Core Team, 2020, R VERS 4 0 3 LANG EN
   Rennie CA, 2012, EYE, V26, P109, DOI 10.1038/eye.2011.256
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ryu E, 2010, MOL VIS, V16, P2811
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2010, MOL VIS, V16, P2412
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   Thompson CL, 2007, INVEST OPHTH VIS SCI, V48, P3005, DOI 10.1167/iovs.06-1325
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Ying GS, 2011, OPHTHALMOLOGY, V118, P332, DOI 10.1016/j.ophtha.2010.06.030
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zanke B, 2010, CAN J OPHTHALMOL, V45, P22, DOI 10.3129/i09-209
NR 70
TC 34
Z9 34
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2013
VL 131
IS 3
BP 383
EP 392
DI 10.1001/jamaophthalmol.2013.713
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 113SD
UT WOS:000316687600018
PM 23494043
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Barnett, BR
   Handa, JT
AF Barnett, Brad R.
   Handa, James T.
TI Retinal Microenvironment in Dry Age-Related Macular Degeneration: A
   Mini-Review
SO GERONTOLOGY
LA English
DT Review
DE Aging; Age-related macular degeneration; Complement; Innate immunity;
   Oxidative stress; Oxidation-specific epitopes
ID COMPLEMENT FACTOR-H; PIGMENT EPITHELIUM; OXIDATIVE DAMAGE; RISK-FACTORS;
   GENE; POLYMORPHISM; VARIANT; NRF2; SUSCEPTIBILITY; ASSOCIATION
AB Background: Age-related macular degeneration (AMD) is the leading cause of blindness in the western world. To prevent what will certainly be a tremendous health and economic burden, effective therapeutics for AMD are urgently needed. To develop these agents in a timely fashion, the molecular pathways that cause disease progression must be elucidated. Objective:To briefly describe the clinical features of AMD, and review the current understanding of the molecular basis of AMD. Methods: A literature review. Results: The discussion will primarily focus on the interplay of oxidative stress and complement dysregulation and the resulting chronic proinflammatory state thought to be central in AMD pathogenesis. Conclusions: Oxidative stress and complement dysregulation play a substantive role in the development of AMD. Copyright (C) 2013 S. Karger AG, Basel
C1 [Barnett, Brad R.; Handa, James T.] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Handa, JT (通讯作者)，Johns Hopkins Sch Med, Wilmer Eye Inst, 400 N Broadway,Smith Bldg,Room 3015, Baltimore, MD 21287 USA.
EM jthanda@jhmi.edu
RI Barnett, Bradley/AAN-1628-2020; Barnett, Brad/AAY-2578-2020
OI Barnett, Bradley/0000-0002-8301-404X; 
FU Research to Prevent Blindness [NEI EY14005, EY019904]; NIH
   [P30EY001765]; NATIONAL EYE INSTITUTE [P30EY001765, R01EY019904,
   R01EY014005] Funding Source: NIH RePORTER
FX NEI EY14005 (J.T.H.), EY019904 (J.T.H.), Thome Foundation (J.T.H.),
   Beckman Foundation Initiative for Macular Research, Research to Prevent
   Blindness Senior Scientist Award (J.T.H.), Unrestricted grant from
   Research to Prevent Blindness to the Wilmer Eye Institute, NIH
   P30EY001765 core grant, Robert Bond Welch Professorship (J.T.H.), and a
   gift from the Merlau family and Aleda Wright.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Amarilyo G, 2010, EUR J IMMUNOL, V40, P699, DOI 10.1002/eji.200838951
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Booij JC, 2011, PLOS ONE, V5, pe9341
   Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chou MY, 2008, J INTERN MED, V263, P479, DOI 10.1111/j.1365-2796.2008.01968.x
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dinkova-Kostova AT, 2005, CHEM RES TOXICOL, V18, P1779, DOI 10.1021/tx050217c
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Glenn JV, 2012, GRAEF ARCH CLIN EXP, V250, P349, DOI 10.1007/s00417-011-1856-9
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Kondo N, 2009, MOL VIS, V15, P1819
   Li J, 2004, PHYSIOL GENOMICS, V18, P261, DOI 10.1152/physiolgenomics.00209.2003
   Lykkesfeldt J, 2000, AM J CLIN NUTR, V71, P530
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Nagai N, 2009, FREE RADICAL BIO MED, V47, P300, DOI 10.1016/j.freeradbiomed.2009.04.033
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Osburn WO, 2008, TOXICOL SCI, V104, P218, DOI 10.1093/toxsci/kfn079
   Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Suzuki M, 2008, AM J RESP CELL MOL, V39, P673, DOI 10.1165/rcmb.2007-0424OC
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Wang A.L., 2009, PLOS ONE, V4
   Warburg O, 1928, SCIENCE, V68, P437, DOI 10.1126/science.68.1767.437
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu X, 2005, MUTAT RES-FUND MOL M, V591, P93, DOI 10.1016/j.mrfmmm.2005.04.017
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zampros I, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/319728
NR 50
TC 14
Z9 14
U1 1
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0304-324X
EI 1423-0003
J9 GERONTOLOGY
JI Gerontology
PY 2013
VL 59
IS 4
BP 297
EP 306
DI 10.1159/000346169
PG 10
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 172VB
UT WOS:000321031900002
PM 23406680
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Gopinath, B
   Liew, G
   Kifley, A
   Lewis, JR
   Bondonno, C
   Joachim, N
   Hodgson, JM
   Mitchell, P
AF Gopinath, Bamini
   Liew, Gerald
   Kifley, Annette
   Lewis, Joshua R.
   Bondonno, Catherine
   Joachim, Nichole
   Hodgson, Jonathan M.
   Mitchell, Paul
TI Association of Dietary Nitrate Intake with the 15-Year Incidence of
   Age-Related Macular Degeneration
SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS
LA English
DT Article
DE Age-related macular degeneration; Blue Mountains Eye Study; Nitrates;
   Vegetables
ID NITRIC-OXIDE
AB Background Dietary nitrate, found predominantly in green leafy vegetables and beetroot, is a precursor of nitric oxide. Under- or overproduction of nitric oxide is implicated in the etiology of several eye diseases. However, the potential influence of dietary nitrate intake on age-related macular degeneration (AMD) risk has not been assessed.
   Objective To investigate the temporal association between dietary nitrate intake (from both vegetable and nonvegetable sources) and the 15-year incidence of AMD, independent of potential confounders.
   Design A longitudinal cohort study conducted from 1992-1994 to 2007-2009.
   Participants/setting The Blue Mountains Eye Study is a population-based study of adults aged 49+ at baseline, from a region west of Sydney, Australia. At baseline, 2,856 participants with complete dietary data and AMD information were examined, and of these, 2,037 participants were re-examined 15 years later and thus included in incidence analysis.
   Main outcomes measured Incidence of AMD (main outcome) was assessed from retinal photographs. Dietary intake was assessed using a semiquantitative food-frequency questionnaire. Nitrate intake from vegetables and nonvegetable sources was calculated by use of a validated comprehensive database.
   Results After adjusting for age, sex, smoking, energy intake, fish consumption, and AMD risk alleles (complement factor H and age-related maculopathy susceptibility-2 single nucleotide polymorphisms), participants in the third quartile compared with those in the first quartile (reference group) of total nitrate and total vegetable nitrate intake had reduced risk of incident early AMD: odds ratio (OR) 0.61 (95% CI 0.41 to 0.90) and OR 0.65 (95% CI 0.44 to 0.96), respectively. Significant associations were not observed between the fourth vs first quartile of total nitrate and vegetable nitrate intake with incident early AMD: OR 0.74 (95% CI 0.51 to 1.08) and OR 0.69 (95% CI 0.47 to 1.00), respectively. Nonsignificant associations were also observed with 15-year incidence of late AMD and total nonvegetable nitrate intake.
   Conclusions These novel findings could have important implications, if the association between total nitrate intake and vegetable nitrate intake and 15-year incidence of early AMD is confirmed in other observational or intervention studies.
C1 [Gopinath, Bamini; Liew, Gerald; Kifley, Annette; Joachim, Nichole; Mitchell, Paul] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW, Australia.
   [Gopinath, Bamini; Liew, Gerald; Kifley, Annette; Joachim, Nichole; Mitchell, Paul] Univ Sydney, Ctr Vis Res, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Lewis, Joshua R.] Univ Sydney, Ctr Kidney Res, Sch Publ Hlth, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Lewis, Joshua R.; Bondonno, Catherine; Hodgson, Jonathan M.] Edith Cowan Univ, Sch Med & Hlth Sci, Perth, WA, Australia.
   [Lewis, Joshua R.; Bondonno, Catherine; Hodgson, Jonathan M.] Univ Western Australia, Sch Med, Perth, WA, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Sydney; Westmead Institute for Medical
   Research; Edith Cowan University; University of Western Australia
RP Gopinath, B (通讯作者)，Westmead Hosp, Ctr Vis Res, Westmead, NSW 2145, Australia.
EM bamini.gopinath@sydney.edu.au
RI Liew, Gerald/AAB-6870-2022; lewis, josh/GZG-7164-2022
FU Australian National Health and Medical Research Council [974159, 991407,
   211069, 262120]; Westmead Institute for Medical Research; National
   Health and Medical Research Council (NHMRC) Senior Research Fellowship;
   Royal Perth Hospital Medical Research Foundation Fellowship; NHMRC
   Career Development Fellowship [1107474]
FX The Blue Mountains Eye Study was funded by the Australian National
   Health and Medical Research Council (grant nos. 974159, 991407, 211069,
   262120), and the Westmead Institute for Medical Research. The salary of
   J. M. Hodgson was supported by a National Health and Medical Research
   Council (NHMRC) Senior Research Fellowship, and a Royal Perth Hospital
   Medical Research Foundation Fellowship. The salary of J. R. Lewis is
   supported by a NHMRC Career Development Fellowship (ID: 1107474).
CR Blekkenhorst LC, 2018, AM J CLIN NUTR, V107, P504, DOI 10.1093/ajcn/nqx046
   Blekkenhorst LC, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600982
   Blekkenhorst LC, 2017, AM J CLIN NUTR, V106, P207, DOI 10.3945/ajcn.116.146761
   Bondonno CP, 2016, CRIT REV FOOD SCI, V56, P2036, DOI 10.1080/10408398.2013.811212
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chiou GCY, 2001, J OCUL PHARMACOL TH, V17, P189, DOI 10.1089/10807680151125555
   Food Standards Australia New Zealand, 2011, SURV NITR NITR FOOD
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Griesenbeck John S, 2009, Nutr J, V8, P16, DOI 10.1186/1475-2891-8-16
   Hobbs DA, 2013, NUTR RES REV, V26, P210, DOI 10.1017/S0954422413000188
   Inoue-Choi M, 2016, PUBLIC HEALTH NUTR, V19, P1934, DOI 10.1017/S1368980015003407
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   McLennan W, 1995, 48070 AUSTR BUR STAT
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
NR 15
TC 10
Z9 10
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2212-2672
EI 2212-2680
J9 J ACAD NUTR DIET
JI J. Acad. Nutr. Diet.
PD DEC
PY 2018
VL 118
IS 12
BP 2311
EP 2314
DI 10.1016/j.jand.2018.07.012
PG 4
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA HB7FS
UT WOS:000451243500012
PM 30342988
OA Green Published
DA 2022-11-30
ER

PT J
AU Immonen, I
   Seitsonen, S
   Saijonmaa, O
   Fyhrquist, F
AF Immonen, Ilkka
   Seitsonen, Sanna
   Saijonmaa, Outi
   Fyhrquist, Frej
TI Leucocyte telomere length in age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; genetics; retina; telomere
ID C-REACTIVE PROTEIN; PROGRESSION; DISEASE
AB . Purpose: To evaluate the association between telomere length and age-related macular degeneration (AMD). Methods: Circulating leucocyte telomere length and the proportion of telomeres <5kb were analysed in blood DNA samples taken from 121 patients with exudative AMD (83%), large drusen (14%) or central geographic atrophy (3%). Controls consisted of 77 age-matched subjects without AMD. The AMD status was assessed by a masked analysis of fundus photographs or angiographs. Telomere length was measured by Southern blotting. Results: Mean (SD) telomere length was 7.76kb (0.68) in AMD patients and 7.83 (0.69) in controls (p=0.485). The corresponding proportions of telomeres <5kb were 10.60 (2.76) and 10.05 (2.64) (p=0.197). In this material, there was no correlation between telomere length and age, gender or smoking status. There were no differences between the major AMD risk single-nucleotide polymorphisms (SNPs) of the CFH, HTRA1 or C3 genes, expect for somewhat longer telomeres in controls with the C3 risk SNP. There were no differences in telomere length between patients with drusen or exudative AMD. Conclusions: Telomere length is not associated with exudative AMD or high-risk drusen.
C1 [Immonen, Ilkka; Seitsonen, Sanna] Helsinki Univ Hosp, Dept Ophthalmol, Helsinki, Finland.
   [Saijonmaa, Outi; Fyhrquist, Frej] Minerva Fdn, Helsinki, Finland.
   [Saijonmaa, Outi; Fyhrquist, Frej] Helsinki Univ Hosp, Dept Internal Med, Helsinki, Finland.
C3 University of Helsinki; Helsinki University Central Hospital; University
   of Helsinki; Helsinki University Central Hospital
RP Immonen, I (通讯作者)，Helsinki Univ Hosp, Dept Ophthalmol, Haartmaninkatu 4 C 00029 JP 220, Helsinki, Finland.
EM ilkka.immonen@hus.fi
CR Benetos A, 2001, HYPERTENSION, V37, P381, DOI 10.1161/01.HYP.37.2.381
   Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5
   Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Fitzpatrick AL, 2007, AM J EPIDEMIOL, V165, P14, DOI [10.1093/aje/kw346, 10.1093/aje/kwj346]
   Fyhrquist F, 2010, J INTERN MED, V267, P278, DOI 10.1111/j.1365-2796.2009.02139.x
   Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9
   Martin-Ruiz CM, 2005, AGING CELL, V4, P287, DOI 10.1111/j.1474-9726.2005.00171.x
   Matsunaga H, 1999, INVEST OPHTH VIS SCI, V40, P197
   Pallini R, 2006, INT J CANCER, V118, P2158, DOI 10.1002/ijc.21613
   Samani NJ, 2001, LANCET, V358, P472, DOI 10.1016/S0140-6736(01)05633-1
   Schonland SO, 2003, P NATL ACAD SCI USA, V100, P13471, DOI 10.1073/pnas.2233561100
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Valdes AM, 2005, LANCET, V366, P662, DOI 10.1016/S0140-6736(05)66630-5
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zou Y, 2004, MOL BIOL CELL, V15, P3709, DOI 10.1091/mbc.E04-03-0207
NR 18
TC 7
Z9 8
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2013
VL 91
IS 5
BP 453
EP 456
DI 10.1111/j.1755-3768.2012.02427.x
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 180VD
UT WOS:000321626000033
PM 22551349
DA 2022-11-30
ER

PT J
AU Kymes, SN
AF Kymes, Steven N.
TI The cost-effectiveness of treatment of age-related macular degeneration:
   a review
SO MINERVA MEDICA
LA English
DT Review
DE Macular degeneration; Retina; Eye diseases
ID BEVACIZUMAB AVASTIN THERAPY; PHOTODYNAMIC THERAPY; RANIBIZUMAB LUCENTIS;
   VISUAL IMPAIRMENT; ECONOMIC BURDEN; VERTEPORFIN; PEGAPTANIB; UTILITY;
   DEPRESSION; ACUITY
AB Age-related macular degeneration (AMD) is a disease of the retina, most often seen among people over the age of 50. The disease is typically manifested by the loss of central vision and as such represents a major threat to the quality of life to those suffering with it. This report reviewed the evidence concerning the economic impact of macular degeneration in the developed world, examining reports on direct and indirect medical costs, as well as those that have attempted to estimate non-health care costs. It also aimed to review reports of the cost-effectiveness of treatment of the disease, examining nutritional supplements, photodynamic therapy, and anti-VEGF treatments.
C1 [Kymes, Steven N.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Kymes, Steven N.] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA.
   [Kymes, Steven N.] Washington Univ, Sch Med, Ctr Hlth Policy, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL)
RP Kymes, SN (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid,Campus Box 8096, St Louis, MO 63110 USA.
EM kymes@vrcc.wustl.edu
CR AHRQ, MED EXP PAN SURV MEP
   ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S
   Bandello F, 2008, DRUG AGING, V25, P255, DOI 10.2165/00002512-200825030-00007
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   BRANCATO R, STUDIO EPIDEMIOLOGIC
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   BROWN A, 2008, 10 CAN AG DRUGS TECH
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Coleman AL, 2004, OPHTHALMOLOGY, V111, P857, DOI 10.1016/j.ophtha.2003.09.033
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Earnshaw SR, 2007, CLIN THER, V29, P2096, DOI 10.1016/j.clinthera.2007.09.001
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Frick KD, 2007, ARCH OPHTHALMOL-CHIC, V125, P544, DOI 10.1001/archopht.125.4.544
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Garattini Livio, 2004, Eur J Health Econ, V5, P22
   Garrett S K, 1999, Ophthalmic Epidemiol, V6, P195, DOI 10.1076/opep.6.3.195.1500
   Gillick MR, 2004, NEW ENGL J MED, V350, P2199, DOI 10.1056/NEJMsb032612
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greiner R A, 2001, Semin Ophthalmol, V16, P218, DOI 10.1076/soph.16.4.218.10302
   GYGER M, 1989, NEW ENGL J MED, V321, P120
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Jampel HD, 2007, AM J OPHTHALMOL, V144, P238, DOI 10.1016/j.ajo.2007.04.048
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kymes SM, 2005, BRIT J OPHTHALMOL, V89, P643, DOI 10.1136/bjo.2004.063784
   Kymes SM, 2008, OPHTHAL EPIDEMIOL, V15, P76, DOI 10.1080/09286580801939346
   Kymes SM, 2007, OPTOMETRY VISION SCI, V84, P809, DOI 10.1097/OPX.0b013e3181337638
   Meads C, 2003, BRIT J OPHTHALMOL, V87, P1201, DOI 10.1136/bjo.87.10.1201
   Meads C, 2003, Health Technol Assess, V7, pv
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   *NAT I HLTH CLIN E, MAC DEG AG REL PEG R
   Neubauer AS, 2007, KLIN MONATSBL AUGENH, V224, P727, DOI 10.1055/s-2007-963470
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   *ROYAL NAT I BLIND, NEW ANT VEGF TREATM
   Ruiz-Moreno JM, 2008, CURR MED RES OPIN, V24, P2103, DOI [10.1185/03007990802214300 , 10.1185/03007990802214300]
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Wailoo A, 2004, BMJ-BRIT MED J, V328, P536, DOI 10.1136/bmj.328.7439.536
   Wolowacz SE, 2007, PHARMACOECONOMICS, V25, P863, DOI 10.2165/00019053-200725100-00005
   World Health Organization, PREV BLINDN VIS IMP
NR 53
TC 4
Z9 4
U1 0
U2 6
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0026-4806
EI 1827-1669
J9 MINERVA MED
JI Minerva Med.
PD FEB
PY 2009
VL 100
IS 1
BP 69
EP 77
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 431AD
UT WOS:000265032800006
PM 19277005
DA 2022-11-30
ER

PT J
AU Takasago, Y
   Shiragami, C
   Kobayashi, M
   Osaka, R
   Ono, A
   Yamashita, A
   Tsujikawa, A
   Hirooka, K
AF Takasago, Yukari
   Shiragami, Chieko
   Kobayashi, Mamoru
   Osaka, Rie
   Ono, Aoi
   Yamashita, Ayana
   Tsujikawa, Akitaka
   Hirooka, Kazuyuki
TI MACULAR ATROPHY FINDINGS BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY
   COMPARED WITH FUNDUS AUTOFLUORESCENCE IN TREATED EXUDATIVE AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE macular atrophy; choriocapillaris non-perfusion; fundus
   autofluorescence; optical coherence tomography angiography; exudative
   age-related macular degeneration; choroidal ischemia
ID PIGMENT EPITHELIAL ATROPHY; GEOGRAPHIC ATROPHY; CHOROIDAL
   NEOVASCULARIZATION; VEGF; EYES; RPE
AB Purpose: To compare the areas of choriocapillaris (CC) nonperfusion and macular atrophy (MA) in treated exudative age-related macular degeneration.
   Methods: This was a prospective, observational, cross-sectional study. Forty-four eyes exhibiting MA (42 patients with age-related macular degeneration), with a dry macula, underwent fundus autofluorescence and optical coherence tomography angiography. The area of MA detected by fundus autofluorescence and CC nonperfusion detected by optical coherence tomography angiography was measured using image analysis software. The rates of concordance between the MA and CC nonperfusion areas were calculated. We qualitatively and quantitatively compared the areas of MA and CC nonperfusion in agerelated macular degeneration eyes.
   Results: The mean areas of MA and CC nonperfusion were 5.95 +/- 4.50 mm(2) and 10.66 +/- 7.05 mm(2), respectively (paired t-test, P < 0.001). In 39 eyes (88.6%), the CC nonperfusion area was larger than the MA area, and the mean CC nonperfusion area was significantly larger than the mean MA area. Fundus autofluorescence matching optical coherence tomography angiography showed that the CC nonperfusion area was almost included in the MA area. The mean concordance rate for the MA area inside the CC nonperfusion area was 87.7 +/- 13.9%.
   Conclusion: The MA and CC nonperfusion areas markedly overlapped. The area of CC nonperfusion correlated with the MA area. Choroidal ischemia might be involved in the pathogenesis of MA in treated age-related macular degeneration.
C1 [Takasago, Yukari; Shiragami, Chieko; Kobayashi, Mamoru; Osaka, Rie; Ono, Aoi; Yamashita, Ayana; Hirooka, Kazuyuki] Kagawa Univ, Dept Ophthalmol, Fac Med, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.
   [Tsujikawa, Akitaka] Kyoto Univ, Fac Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
C3 Kagawa University; Kyoto University
RP Shiragami, C (通讯作者)，Kagawa Univ, Dept Ophthalmol, Fac Med, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.
EM chappi@kms.ac.jp
OI Tsujikawa, Akitaka/0000-0003-0779-7799
FU Pfizer (Tokyo, Japan); Bayer (Whippany, NJ); Novartis (Tokyo, Japan);
   Santen (Osaka, Japan); Senju, (Osaka, Japan); Alcon (Tokyo, Japan); AMO
   Japan (Tokyo, Japan); Hoya (Tokyo, Japan); Kowa (Nagoya, Japan);
   Ministry of Health Labour and Welfare of Japan; Japan Society for the
   Promotion of Science (Tokyo, Japan); Ministry of Education, Culture,
   Sports, Science, and Technology of Japan [26462689]; Bayer (Osaka,
   Japan); Senju (Osaka, Japan); Nidek (Gamagori, Japan); Sanwa Kagaku
   (Nagoya, Japan)
FX A. Tsujikawa received a funding from Pfizer (Tokyo, Japan), Bayer
   (Whippany, NJ), Novartis (Tokyo, Japan), Santen (Osaka, Japan), Senju,
   (Osaka, Japan), Alcon (Tokyo, Japan), AMO Japan (Tokyo, Japan), Hoya
   (Tokyo, Japan), Kowa (Nagoya, Japan), the Ministry of Health Labour and
   Welfare of Japan, and Japan Society for the Promotion of Science (Tokyo,
   Japan). K. Hirooka received a funding from Novartis (Tokyo, Japan),
   Alcon (Tokyo, Japan), and Grant-in-Aid for Scientific Research from the
   Ministry of Education, Culture, Sports, Science, and Technology of Japan
   (26462689).; C. Shiragami received financial support from Bayer (Osaka,
   Japan) and Novartis (Tokyo, Japan). A. Tsujikawa received financial
   support from Pfizer (Tokyo, Japan), Bayer (Osaka, Japan), Novartis
   (Tokyo, Japan), Santen (Osaka, Japan), Senju (Osaka, Japan), Alcon
   (Tokyo, Japan), Nidek (Gamagori, Japan), AMO Japan (Tokyo, Japan), Kowa
   (Nagoya, Japan), and Sanwa Kagaku (Nagoya, Japan). The remaining authors
   have no conflicting interests to disclose.
CR Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Domalpally A, 2016, OPHTHALMOLOGY, V123, P2401, DOI 10.1016/j.ophtha.2016.06.025
   GRUNWALD JE, 1993, INVEST OPHTH VIS SCI, V34, P3609
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Grunwald JE, 2001, AM J OPHTHALMOL, V131, P751, DOI 10.1016/S0002-9394(00)00944-2
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Kojima Shota, 1997, Nippon Ganka Gakkai Zasshi, V101, P605
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Shiragami C, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006422
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 27
TC 4
Z9 4
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2019
VL 39
IS 2
BP 296
EP 302
DI 10.1097/IAE.0000000000001980
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4RW
UT WOS:000480739100010
PM 29190232
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Wang, ZL
   Zou, MJ
   Chen, AM
   Liu, ZZ
   Young, CA
   Wang, SB
   Zheng, DY
   Jin, GM
AF Wang, Zilin
   Zou, Minjie
   Chen, Aiming
   Liu, Zhenzhen
   Young, Charlotte Aimee
   Wang, Shi-bin
   Zheng, Danying
   Jin, Guangming
TI Genetic associations of anti-vascular endothelial growth factor therapy
   response in age-related macular degeneration: a systematic review and
   meta-analysis
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; anti-VEGF therapy response;
   pharmacogenetics
ID PROMOTER POLYMORPHISM; APOLIPOPROTEIN-E; SUSCEPTIBILITY; ANGIOGENESIS;
   RANIBIZUMAB; BEVACIZUMAB; PREVALENCE; VARIANTS
AB Purpose To investigate the association of all reported common polymorphisms in anti-vascular endothelial growth factor (VEGF) therapy response and to identify potential clinically useful biomarkers for anti-VEGF therapy response in patients with age-related macular degeneration (AMD). Methods We searched the Embase, PubMed, Web of Science databases in English and the China National Knowledge Infrastructure, WanFang and VIP databases in Chinese for pharmacogenetics studies on anti-VEGF therapy response in AMD. Odds ratios with 95% confidence intervals were calculated using the random effects model. Results Among the 10 468 records yielded by the literature search, 33 articles that met the eligibility criteria were included in the meta-analysis. Nine single-nucleotide polymorphisms (SNP) in four genes were observed to be associated with the anti-VEGF therapy response in AMD patients. That is, rs1120063 in the HTRA1 gene; rs10490924 in the age-related maculopathy susceptibility (ARMS2) gene; rs1061170 in the complement factor H (CFH) gene; and rs323085 in the OR52B4 gene were associated with good anti-VEGF therapy responses, while rs800292, rs1410996 and rs1329428 in the CFH gene and rs4910623 and rs10158937 in the OR52B4 gene were associated with poor anti-VEGF therapy response in the AMD patients in our sample. Conclusion In this study, nine SNPs of four genes were indicated to be significantly associated with the anti-VEGF therapy response in the samples: rs11200638 in the HTRA1 gene; rs10490924 in the ARMS2 gene; rs1061170, rs800292, rs1410996 and rs1329428 in the CFH gene; and rs323085, rs4910623 and rs10158937 in the OR52B4 gene. Further studies based on various ethnicities and large sample sizes are warranted to strengthen the evidence found in the present study.
C1 [Wang, Zilin; Zou, Minjie; Liu, Zhenzhen; Zheng, Danying; Jin, Guangming] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie South Rd, Guangzhou 510060, Peoples R China.
   [Wang, Zilin; Zou, Minjie] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou, Peoples R China.
   [Chen, Aiming] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Pharm, Zhuhai, Peoples R China.
   [Young, Charlotte Aimee] Nanchang Univ, Affiliated Hosp 3, Nanchang Eye Hosp, Nanchang, Jiangxi, Peoples R China.
   [Wang, Shi-bin] Guangdong Acad Med Sci, Guangdong Mental Hlth Ctr, Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University;
   Nanchang University; Guangdong Academy of Medical Sciences & Guangdong
   General Hospital
RP Zheng, DY; Jin, GM (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie South Rd, Guangzhou 510060, Peoples R China.
EM spiriorwang@126.com; zhengdyy@163.com; jingm@mail2.sysu.edu.com
OI Jin, Guangming/0000-0001-9994-6338
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241
   Chaudhary V, 2016, OPHTHALMOLOGICA, V236, P88, DOI 10.1159/000446819
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fang K, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/676049
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Hautamaki A, 2013, RETINA-J RET VIT DIS, V33, P1815, DOI 10.1097/IAE.0b013e318285cf92
   Hu ZZ, 2015, BRIT J OPHTHALMOL, V99, P593, DOI 10.1136/bjophthalmol-2014-305488
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Merle BMJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130816
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mohamad NA, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0197-3
   Mouallem-Beziere A, 2020, RETINA-J RET VIT DIS, V40, P663, DOI 10.1097/IAE.0000000000002454
   Park DH, 2012, RETINA-J RET VIT DIS, V32, P299, DOI 10.1097/IAE.0b013e318225290f
   Park UC, 2014, RETINA-J RET VIT DIS, V34, P288, DOI 10.1097/IAE.0b013e3182979e1e
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Riaz M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37924
   van Asten F, 2014, OPHTHAL EPIDEMIOL, V21, P347, DOI 10.3109/09286586.2014.949010
   Wickremasinghe SS, 2014, RETINA-J RET VIT DIS, V34, P2367, DOI 10.1097/IAE.0000000000000258
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamashiro K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09632-0
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoneyama S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64301-z
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
NR 34
TC 6
Z9 6
U1 3
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2022
VL 100
IS 3
BP E669
EP E680
DI 10.1111/aos.14970
EA AUG 2021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0L1ID
UT WOS:000685428000001
PM 34403208
DA 2022-11-30
ER

PT J
AU Mimura, K
   Matsumoto, H
   Morimoto, M
   Akiyama, H
AF Mimura, Kensuke
   Matsumoto, Hidetaka
   Morimoto, Masahiro
   Akiyama, Hideo
TI Development of Age-Related Macular Degeneration (AMD) in the Fellow Eye
   of Patients with AMD Treated by Treat-and-Extend Intravitreal Therapy
   with Aflibercept
SO OPHTHALMOLOGICA
LA English
DT Article
DE Neovascular age-related macular degeneration; Retinal angiomatous
   proliferation; Anti-vascular endothelial growth factor; Intravitreal
   aflibercept injection; Treat-and-extend regimen; Clinical study
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL ANGIOMATOUS PROLIFERATION; JAPANESE
   PATIENTS; NEOVASCULARIZATION; RANIBIZUMAB; BINDING; RISK; VEGF
AB Purpose: To evaluate the development of neovascular age-related macular degeneration (nAMD) in the fellow eye in patients with unilateral nAMD treated by a treat-and-extend (TAE) regimen with intravitreal aflibercept injections. Methods: We retrospectively studied 104 patients with treatment-naive unilateral nAMD. We assessed best-corrected visual acuity (BCVA) and exudative changes in the treated eyes and development of nAMD in the fellow eye for 2 years. Results: The subjects included 46 patients with typical AMD (tAMD), 44 with polypoidal choroidal vasculopathy (PCV), and 14 with retinal angiomatous proliferation (RAP). BCVA was significantly improved after the loading phase in all subtypes. Forty-six patients (44.2%) had no recurrence within 2 years after the loading phase, including 12 (26.1%) with tAMD, 23 (52.2%) with PCV, and 11 (78.6%) with RAP (p < 0.01). Eleven patients (10.6%) developed nAMD in the fellow eye within 2 years, including 4 (8.7%) with tAMD, 0 (0%) with PCV, and 7 (50.0%) with RAP (p < 0.001). Conclusions: Patients with RAP had significantly more frequent development of nAMD in the fellow eye compared to other subtypes, while they showed significantly less recurrence during the TAE regimen with intravitreal aflibercept injections. Development of nAMD in the fellow eye should be monitored in RAP when the injection interval is extended. (c) 2017 S. Karger AG, Basel.
C1 [Mimura, Kensuke; Matsumoto, Hidetaka; Morimoto, Masahiro; Akiyama, Hideo] Gunma Univ, Dept Ophthalmol, Sch Med, 3-39-15 Showa Machi, Maebashi, Gunma 3718511, Japan.
C3 Gunma University
RP Matsumoto, H (通讯作者)，Gunma Univ, Dept Ophthalmol, Sch Med, 3-39-15 Showa Machi, Maebashi, Gunma 3718511, Japan.
EM hide-m@gunma-u.ac.jp
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Campa C, 2010, EYE, V24, P1585, DOI 10.1038/eye.2010.88
   Chang YS, 2016, ACTA OPHTHALMOL, V94, pE49, DOI 10.1111/aos.12748
   Chou HD, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0497-0
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Kaszubski PA, 2017, INT OPHTHALMOL
   Kim JH, 2017, RETINA-J RET VIT DIS, V37, P1508, DOI 10.1097/IAE.0000000000001383
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Matsumoto H, 2016, RETINA-J RET VIT DIS, V36, P2282, DOI 10.1097/IAE.0000000000001104
   Matsuyama K, 2011, J OCUL PHARMACOL TH, V27, P379, DOI 10.1089/jop.2010.0194
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas A, 2009, OPHTHALMOLOGICA, V223, P383, DOI 10.1159/000228590
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Yanai H., 2015, STATCEL USEFUL ADD I
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
   YUZAWA M, 1991, JPN J OPHTHALMOL, V35, P87
NR 28
TC 2
Z9 2
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2018
VL 239
IS 2-3
BP 121
EP 127
DI 10.1159/000484099
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ0QL
UT WOS:000427276000007
PM 29169154
DA 2022-11-30
ER

PT J
AU Ramtohul, P
   Gascon, P
   Comet, A
   Denis, D
AF Ramtohul, Prithvi
   Gascon, Pierre
   Comet, Alban
   Denis, Daniele
TI ULTRAWIDEFIELD PSEUDOCOLOR RETINAL IMAGING VERSUS REAL-COLOR FUNDUS
   PHOTOGRAPHY FOR DETECTION OF INTRARETINAL PIGMENT MIGRATION IN
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; color fundus photography;
   hyperpigmentation; hyperreflective foci; multimodal imaging; optical
   coherence tomography; pigment migration; retinal imaging; ultrawidefield
   fundus photography
ID HYPERREFLECTIVE FOCI; SEVERITY SCALE; EYE DISEASE; AGREEMENT; LESIONS;
   PEOPLE
AB Purpose: To compare pseudocolor Optos ultrawidefield (UWF) retinal images with conventional real-color fundus photography (CFP) for detecting macular hyperpigmentary changes in intermediate age-related macular degeneration. Methods: This retrospective study included 50 patients diagnosed with intermediate age-related macular degeneration. All patients underwent Optos imaging and CFP. The overall accuracy to visualize hyperpigmentation and its morphologic features was graded by two independent readers using a standardized grid. Structural and en face optical coherence tomography images were correlated with UWF and CFP images to determine spatial correspondence of pigment clumping on fundus images and hyperreflective foci on optical coherence tomography. Results: One hundred eyes of 50 patients had hyperpigmentary changes on funduscopic examination and were included. The intragraders and intergraders agreements were high for all measurements (P < 0.001). At least one hyperpigmentary changes within the standardized grid was detected in 93% using CFP and 100% using UWF camera (P = 0.02). The total area of hyperpigmentation measured on UWF images was significantly higher than on CFP images (P < 0.001). There was a significant correlation between the presence of hyperpigmentary changes on both CFP and UWF images and hyperreflective foci on structural optical coherence tomography (P < 0.001). Conclusion: Ultrawidefield fundus images allow high detection and accurate quantification of macular hyperpigmentary changes in intermediate age-related macular degeneration compared with conventional CFP.
C1 [Ramtohul, Prithvi; Gascon, Pierre; Comet, Alban; Denis, Daniele] Marseille North Univ Hosp, Chemin Bourrely, Marseille, France.
C3 UDICE-French Research Universities; Aix-Marseille Universite
RP Ramtohul, P (通讯作者)，Ctr Hosp Univ Hop Nord, Chemin Bourrely, F-13015 Marseille, France.
EM pramtohul@me.com
CR Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Csutak A, 2010, EYE, V24, P1568, DOI 10.1038/eye.2010.85
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Domalpally A, 2017, OPHTHALMOLOGY, V124, P479, DOI 10.1016/j.ophtha.2016.12.004
   Evans JR, 2002, BRIT J OPHTHALMOL, V86, P795, DOI 10.1136/bjo.86.7.795
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Gramatikov BI, 2014, BIOMED ENG ONLINE, V13, DOI 10.1186/1475-925X-13-52
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   KIRKPATRICK JNP, 1995, BRIT J OPHTHALMOL, V79, P892, DOI 10.1136/bjo.79.10.892
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lengyel I, 2015, OPHTHALMOLOGY, V122, P1340, DOI 10.1016/j.ophtha.2015.03.005
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Meshi A, 2019, RETINA-J RET VIT DIS, V39, P1333, DOI 10.1097/IAE.0000000000002156
   Nagiel A, 2016, RETINA-J RET VIT DIS, V36, P660, DOI 10.1097/IAE.0000000000000937
   Neubauer AS, 2008, GRAEF ARCH CLIN EXP, V246, P229, DOI 10.1007/s00417-007-0631-4
   Ramtohul P., 2020, OPHTHALMOL RETINA
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Tan ACS, 2016, OPHTHALMOLOGICA, V236, P8, DOI 10.1159/000446857
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
NR 28
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2021
VL 41
IS 3
BP 563
EP 571
DI 10.1097/IAE.0000000000002886
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SL1OK
UT WOS:000656688600023
PM 33600133
DA 2022-11-30
ER

PT J
AU Moussa, K
   Lee, JY
   Stinnett, SS
   Jaffe, GJ
AF Moussa, Kareem
   Lee, Joo Yong
   Stinnett, Sandra S.
   Jaffe, Glenn J.
TI SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY-DETERMINED MORPHOLOGIC
   PREDICTORS OF AGE-RELATED MACULAR DEGENERATION-ASSOCIATED GEOGRAPHIC
   ATROPHY PROGRESSION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; geographic atrophy; retinal imaging;
   spectral domain optical coherence tomography
ID RETINAL-PIGMENT EPITHELIUM; FUNDUS AUTOFLUORESCENCE PATTERNS; BRUCHS
   MEMBRANE; CHOROIDAL NEOVASCULARIZATION; MACULOPATHY; DRUSEN;
   RANIBIZUMAB; TRANSPORT; DEPOSIT
AB Purpose: To correlate spectral domain optical coherence tomography (SD OCT)-determined morphologic alterations in eyes with geographic atrophy because of age-related macular degeneration with lesion size, enlargement rate, and the presence of multifocal patches of atrophy.
   Methods: Forty-three eyes of 43 patients with age-related macular degeneration-associated geographic atrophy were visualized by SD OCT and fundus autofluorescence imaging. The baseline area of geographic atrophy and enlargement rates over at least 24 weeks were calculated from the fundus autofluorescence images. The mean and median follow-up times were 47.4 and 48 weeks, respectively. Morphologic alterations were evaluated in the baseline SD OCT images. Ninety-seven SD OCT scans per eye were graded and included in the analysis. Correlations between morphologic alterations and the rate of lesion enlargement, size, and focality, and the diffuse trickling fundus autofluorescence pattern were determined.
   Results: The mean and median enlargement rates were 2.07 mm(2)/year (n = 43; SD, 1.30) and 2.02 mm(2)/year, respectively. Outer retinal tubulations (P = 0.003) and irregular elevations of the retinal pigment epithelium/Bruch membrane complex (P < 0.001) in the atrophic region, and splitting of the retinal pigment epithelium/Bruch membrane complex at 2 junctional zone borders (P = 0.02) correlated with faster enlargement. Outer retinal tubulations (P = 0.096), irregular elevations of the retinal pigment epithelium/Bruch membrane complex (P = 0.010), and crown-like elevations with debris beneath in the atrophic region (P = 0.063) correlated with larger lesion size. Hyperreflective plaques in the outer retina appeared more frequently in eyes with multifocal patches of atrophy (P = 0.005).
   Conclusion: Distinct morphologic alterations visible on SD OCT imaging in eyes with geographic atrophy because of age-related macular degeneration are associated with faster enlargement rates, larger lesion size, and multifocal patches of atrophy.
C1 [Moussa, Kareem; Lee, Joo Yong; Stinnett, Sandra S.; Jaffe, Glenn J.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Lee, Joo Yong] Univ Ulsan, Asan Med Ctr, Dept Ophthalmol, Seoul, South Korea.
C3 Duke University; University of Ulsan; Asan Medical Center
RP Jaffe, GJ (通讯作者)，Duke Eye Ctr, Duke Reading Ctr, Box 3802, Durham, NC 27710 USA.
EM glenn.jaffe@dm.duke.edu
OI LEE, JOO YONG/0000-0002-2187-196X
CR Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Bressler SBBN, 2006, AGE RELATED MACULAR
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hillenkamp J, 2004, INVEST OPHTH VIS SCI, V45, P1493, DOI 10.1167/iovs.03-0765
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Messmer EP., 1997, PATHOLOGIE DES AUGES, P1010
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sarks SH, 1994, AGE RELATED MACULAR
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 34
TC 48
Z9 50
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2013
VL 33
IS 8
BP 1590
EP 1599
DI 10.1097/IAE.0b013e31828d6052
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297CP
UT WOS:000330233200014
PM 23538573
DA 2022-11-30
ER

PT J
AU Farah, SE
AF Farah, Samer E.
TI Treatment of neovascular age-related macular degeneration with
   pegaptanib and boosting with bevacizumab or ranibizumab as needed
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID CONTROLLED CLINICAL-TRIALS; ENDOTHELIAL GROWTH-FACTOR; EFFICACY;
   THERAPY; REGIMEN; SAFETY; SODIUM
AB BACKGROUND AND OBJECTIVE: Neovascular age-related macular degeneration presents a therapeutic challenge. The efficacy of pegaptanib sodium, a selective inhibitor of vascular endothelial growth factor 165, was examined as a therapeutic mainstay combined with "as needed" boosts of nonselective vascular endothelial growth factor blockade with bevacizumab or ranibizumab.
   PATIENTS AND METHODS: A retrospective chart review of outcomes of patients treated with pegaptanib and later boosted with bevacizumab or ranibizumab was conducted. Visual acuity, optical coherence tomography, and fluorescein angiography findings were recorded and assessed.
   RESULTS: During a mean follow-up of 12.1 months, an average of 7.8 injections of pegaptanib 0.3 mg, 1.4 injections of bevacizumab 1.25 mg, and 0.9 injections of ranibizumab 0.5 mg were administered to 17 eyes. In all, 47% of eyes gained 3 or more lines of visual acuity and 76% gained 0 or more lines.
   CONCLUSION: Pegaptanib as a mainstay of neovascular age-related macular degeneration therapy with an occasional boost of bevacizumab or ranibizumab appears to be an effective treatment option.
C1 [Farah, Samer E.] Albert Einstein Coll Med, Dept Ophthalmol & Visual Sci, New York, NY USA.
C3 Yeshiva University
RP Farah, SE (通讯作者)，3250 Westchester Ave,203A, Pelham Bay, NY 10461 USA.
CR [Anonymous], 2006, LUC PACK INS
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CANNISTRA SA, 2006, J CLIN ONCOL, V24, P5006
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FRIBERG TR, 2007, INVEST OPHTHALMOL VI, V48
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   *GEN INC, LUC SAILOR DEAR HEAL
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gordon MS, 2005, ONCOLOGY-BASEL, V69, P25, DOI 10.1159/000088481
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hughes MS, 2006, OPHTHAL SURG LAS IM, V37, P446, DOI 10.3928/15428877-20061101-01
   LUPOVITCH J, 2006, INVEST OPHTHALMOL VI, V47
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scappaticci FA, 2008, JNCI-J NATL CANCER I, V100, P156
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   SINGERMAN LJ, 2008, BR J OPHTHA IN PRESS
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
NR 25
TC 7
Z9 8
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD JUL-AUG
PY 2008
VL 39
IS 4
BP 294
EP 298
DI 10.3928/15428877-20080701-05
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 334AA
UT WOS:000258193500004
PM 18717434
DA 2022-11-30
ER

PT J
AU Hodge, WG
   Schachter, HM
   Barnes, D
   Pan, Y
   Lowcock, EC
   Zhang, L
   Sampson, M
   Morrison, A
   Tran, K
   Miguelez, M
   Lewin, G
AF Hodge, William G.
   Schachter, Howard M.
   Barnes, David
   Pan, Yi
   Lowcock, Elizabeth C.
   Zhang, Li
   Sampson, Margaret
   Morrison, Andra
   Tran, Khai
   Miguelez, Maia
   Lewin, Gabriela
TI Efficacy of omega-3 fatty acids in preventing age-related macular
   degeneration - A systematic review
SO OPHTHALMOLOGY
LA English
DT Review
ID DIETARY-FAT; METHODOLOGICAL QUALITY; DOCOSAHEXAENOIC ACID; DEFICIENCY;
   METABOLISM; RHODOPSIN; HEALTH; RISK; ROD
AB Topic: What is the evidence for efficacy of dietary and/or supplemental omega-3 fatty acids in preventing age-related macular degeneration (AMD)?
   Clinical Relevance: Age-related macular degeneration is the leading cause of blindness and vision impairment in persons older than 50 years living in North America. There is no cure for AMD, and treatment does not usually restore vision but only prevents disease progression to a modest degree. w-3 fatty acids are considered potentially important antioxidants and are being considered as an arm of the Age-Related Eye Disease Study 11 clinical trial.
   Methods/Literature Reviewed. Keywords were searched in Medline, Pre-Medline, Embase, and the Cochrane Library on Ovid. There was no restriction on the year or language of publication.
   Results: There were 6 observational studies found, but the specific outcomes, exposures, and covariates studied all varied greatly.
   Conclusion: There is some clinical evidence for protection of AMD from omega-3 fatty acids. However, the results are not consistent. Hence, our conclusion is that this issue is neither clearly supported nor refuted by the present world literature. This is an intriguing and extremely important question but needs further study first with prospective cohort designs and, if positive, randomized clinical trials.
C1 Univ Ottawa, Inst Eye, Dept Ophthalmol, Ottawa, ON K1H 8L6, Canada.
   CHEO Res Inst, Chalmers Systemat Review Res Grp, Ottawa, ON, Canada.
C3 University of Ottawa; Ottawa Hospital Research Institute; University of
   Ottawa; Children's Hospital of Eastern Ontario
RP Hodge, WG (通讯作者)，Univ Ottawa, Inst Eye, Dept Ophthalmol, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.
EM whodge@ottawahospital.on.ca
RI Sampson, Margaret/A-9128-2011
OI Sampson, Margaret/0000-0003-2550-9893; Zhang, Li/0000-0001-9056-7868
CR BROWN MF, 1994, CHEM PHYS LIPIDS, V73, P159, DOI 10.1016/0009-3084(94)90180-5
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   CLANDININ MT, 1991, FASEB J, V5, P2761, DOI 10.1096/fasebj.5.13.1916101
   Deeks J J, 2003, Health Technol Assess, V7, piii
   DETURCO EBR, 1991, J NEUROSCI, V11, P3667
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   GIBSON NJ, 1993, BIOCHEMISTRY-US, V32, P2438, DOI 10.1021/bi00060a040
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   JADAD A, 1998, RANDOMISED CONTROLLE, P1
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   James MJ, 2000, AM J CLIN NUTR, V71, p343S, DOI 10.1093/ajcn/71.1.343s
   Litman BJ, 2001, J MOL NEUROSCI, V16, P237, DOI 10.1385/JMN:16:2-3:237
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   McAuley L, 2000, LANCET, V356, P1228, DOI 10.1016/S0140-6736(00)02786-0
   Moher D, 2003, Health Technol Assess, V7, P1
   NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021
   NEURINGER M, 1984, J CLIN INVEST, V73, P272, DOI 10.1172/JCI111202
   Ouchi M, 2002, OPHTHALMOLOGICA, V216, P363, DOI 10.1159/000066178
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Stephens R J, 1988, Basic Life Sci, V49, P283
   STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wells GA., NEWCASTLE OTTAWA SCA
NR 27
TC 54
Z9 57
U1 2
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2006
VL 113
IS 7
BP 1165
EP 1172
DI 10.1016/j.ophtha.2006.02.043
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 059IV
UT WOS:000238727400017
PM 16815401
DA 2022-11-30
ER

PT J
AU Gokce, G
   Durukan, AH
   Koylu, MT
   Kucukevcilioglu, M
AF Gokce, Gokcen
   Durukan, Ali Hakan
   Koylu, Mehmet Talay
   Kucukevcilioglu, Murat
TI Efficacy of aflibercept on exudative age-related macular degeneration in
   patients exhibiting complete ranibizumab resistance and tachyphylaxis
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Angiogenesis inhibitors; Macular degeneration; Ranibizumab;
   Tachyphylaxis; Vascular endothelial growth factor A
ID 2.0 MG RANIBIZUMAB; INTRAVITREAL AFLIBERCEPT; VEGF TRAP; BEVACIZUMAB;
   OUTCOMES; THERAPY; EYES; INJECTION; RECURRENT; SAFETY
AB Purpose: The present study compared the efficacy of aflibercept for neovascular age-related macular degeneration (NV-AMD) in patients with complete ranibizumab resistance and tachyphylaxis.
   Methods: Forty-four eyes of 38 neovascular age-related macular degeneration patients were evaluated. Eyes were divided into a complete resistance group (n=23 eyes) and tachyphylaxis group (n=21 eyes).
   Results: After three injections, eight (38.1%) patients in the tachyphylaxis group and nine (39.1%) in the complete resistance group presented with macular dryness. After the first injection of aflibercept, the mean visual acuity improved significantly in the tachyphylaxis group (p=0.018) but remained unchanged in the complete resistance group (p=0.37). There was a non-significant trend towards improved mean visual acuity in both groups after the second and third injections relative to the acuity at the final visit for ranibizumab treatment. In the tachyphylaxis group, the presence of subfoveal pigmented epithelium detachment (PED) decreased significantly after intravitreal aflibercept treatment.
   Conclusions: Although treatment with aflibercept yielded generally positive anatomical results in both groups, no significant increase in visual acuity was achieved.
C1 [Gokce, Gokcen] Kayseri Mil Hosp, Dept Ophthalmol, TR-38100 Kayseri, Turkey.
   [Durukan, Ali Hakan; Kucukevcilioglu, Murat] Gulhane Mil Med Acad, Dept Ophthalmol, Ankara, Turkey.
   [Koylu, Mehmet Talay] Tatvan Mil Hosp, Dept Ophthalmol, Bitlis, Turkey.
C3 Kayseri Military Hospital; Gulhane Military Medical Academy; Tatvan
   Military Hospital
RP Gokce, G (通讯作者)，Kayseri Mil Hosp, Dept Ophthalmol, TR-38100 Kayseri, Turkey.
EM drgokcengokce@gmail.com
RI Kucukevcilioglu, Murat/AAH-3033-2021; Durukan, Ali Hakan/GSN-1422-2022;
   Durukan, Ali Hakan/AFS-8050-2022
OI Durukan, Ali Hakan/0000-0001-6571-6155; koylu, mehmet
   talay/0000-0002-7283-3760
CR Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Egho MS, 2012, BR J OPHTHALMOL, V96, P1
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Hariri A, 2015, OSLI RETINA, V46, P195, DOI 10.3928/23258160-20150213-18
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V365, P2237
   Martin DF, 2011, CLIN EXP OPHTHALMOL, V39, P718, DOI 10.1111/j.1442-9071.2011.02703.x
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martin DF, 2014, JAMA-J AM MED ASSOC, V311, P1491
   Martin DF, 2015, JAMA OPHTHALMOL, V133, P363
   Martin DF, 2012, J COMP EFFECT RES, V1, P485
   Martin DF, 2015, JAMA OPHTHALMOL, V133, P726
   Martin DF, 2011, NEW ENGL J MED, V364, P1966
   Miura M, 2013, CLIN OPHTHALMOL, V7, P1591, DOI 10.2147/OPTH.S50634
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Wykoff CC, 2013, OPHTHALMOLOGY, V120, P1945, DOI 10.1016/j.ophtha.2013.06.030
   Wykoff CC, 2013, OPHTHAL SURG LAS IM, V44, P121, DOI 10.3928/23258160-20130313-04
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 35
TC 7
Z9 7
U1 0
U2 4
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD NOV-DEC
PY 2016
VL 79
IS 6
BP 384
EP 389
DI 10.5935/0004-2749.20160109
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EJ2EH
UT WOS:000393022300009
PM 28076566
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Vojnikovic, B
   Radeljak, S
   Dessardo, S
   Zarkovic-Palijan, T
   Bajek, G
   Linsak, Z
AF Vojnikovic, Bozo
   Radeljak, Sanja
   Dessardo, Sandro
   Zarkovic-Palijan, Tija
   Bajek, Goran
   Linsak, Zeljko
TI What Associates Charles Bonnet Syndrome with Age-Related Macular
   Degeneration?
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE Charles Bonnet syndrome; age-related macular degeneration; visual
   hallucinations; micropsia; release phenomenon; deafferentiation
ID VISUAL HALLUCINATIONS; BRAIN; CORTEX; PERCEPTION; VISION; RETINA
AB Charles Bonnet syndrome (CBS) is a condition related to patients with visual loss due to age related macular degeneration or glaucoma that are having complex visual hallucinations. The CBS was first described by Swiss physician Charles Bonnet in 1760. Affected patients, who are otherwise mentally healthy people with significant visual loss, have vivid, complex recurrent visual hallucinations (VHs). One characteristic of these hallucinations is that they usually are "Lilliputian hallucinations" as patients experience micropsia (hallucinations in which the characters or objects are distorted and much smaller than normal). The prevalence of Charles Bonnet Syndrome has been reported to be between 10% and 40%; a recent Australian study has found the prevalence to be 17.5%. The high incidence of non-reported CBS is thought to be as a result of patient's fear to report the symptoms as they could be labeled as mentally insane since those type of visual hallucinations could be found in variety of psychiatric and neurological disorders such as drug or alcohol abuse (delirium tremens), Alice in Wonderland syndrome (AIWS), psychosis, schizophrenia, dementia, narcolepsy, epilepsy, Parkinson disease, brain tumors, migraine, as well as, in long term sleep deprivation. VHs can also be presented as the initial sign of the Epstein-Barr virus infection in infectious mononucleosis. Patients who suffer from CBS usually possess insight into the unreality of their visual experiences, which are commonly pleasant but may sometimes cause distress. The hallucinations consist of well-defined, organized, and clear images over which the subject has little control. It is believed that they represent release phenomena due to deafferentiation of the visual association areas of the cerebral cortex, leading to a form of phantom vision. Cognitive defects, social isolation, and sensory deprivation have also been implicated in the etiology of this condition. This study was conducted on 350 patients diagnosed with Age-Related Macular Degeneration (AMD) and shows incidence of CBS in 13% of patients with AMD. Furthermore, we have found higher incidence of CBS in patients with massive loss of vision in peripheral visual field which is not age related.
C1 [Vojnikovic, Bozo] Daily Eye Clin Dr Bozo Vojnikovic, Rijeka 51000, Croatia.
   [Radeljak, Sanja; Zarkovic-Palijan, Tija] Neuropsychiat Hosp Dr Ivan Barbot, Dept Forens Psychiat, Popovaca, Croatia.
   [Dessardo, Sandro] Rijeka Univ Hosp, Dept Pediat, Rijeka, Croatia.
   [Bajek, Goran] Rijeka Univ Hosp, Dept Neurosurg, Rijeka, Croatia.
   [Linsak, Zeljko] Teaching Inst Publ Hlth, Rijeka, Croatia.
C3 University of Rijeka; University of Rijeka; University of Rijeka
RP Vojnikovic, B (通讯作者)，Daily Eye Clin Dr Bozo Vojnikovic, A Barca 3B, Rijeka 51000, Croatia.
EM decv@decv.com
RI Linšak, Željko ŽL/R-4873-2018; Dessardo, Sandro/F-3097-2018; Palijan,
   Tija Zarkovic/D-4801-2017; Linšak, Željko/AAX-1764-2020
OI Linšak, Željko ŽL/0000-0003-2389-1128; Palijan, Tija
   Zarkovic/0000-0002-4113-2726; 
CR Abbou EJ, 2007, INVEST OPHTH VIS SCI, V48, P1416, DOI 10.1167/iovs.06-0942
   Allen P, 2008, NEUROSCI BIOBEHAV R, V32, P175, DOI 10.1016/j.neubiorev.2007.07.012
   Boksa P, 2009, J PSYCHIATR NEUROSCI, V34
   Braun CMJ, 2003, J PSYCHIATR NEUROSCI, V28, P432
   BURKE W, 2002, PSYCHIATRY, V73, P535
   DEMORSIER G, 1967, ANN MED-PSYCHOL, V125, P677
   Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402
   Gilmour G, 2009, CAN J OPHTHALMOL, V44, P49, DOI 10.3129/i08-169
   Halgren E, 1999, HUM BRAIN MAPP, V7, P29
   HIROAKI K, 2009, PSYCHOGERIATRICS, V9, P77
   JACKSON ML, 2009, CMAJ, V18, P3
   Kanwisher N, 1997, J NEUROSCI, V17, P4302
   Kester EM, 2009, OPTOMETRY, V80, P360, DOI 10.1016/j.optm.2008.10.017
   Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9
   Mewasingh LD, 2002, PEDIATR NEUROL, V26, P143, DOI 10.1016/S0887-8994(01)00358-7
   Plummer C, 2007, J CLIN NEUROSCI, V14, P709, DOI 10.1016/j.jocn.2006.08.006
   Puce A, 1998, J NEUROSCI, V18, P2188
   Rovner BW, 2006, CURR OPIN OPHTHALMOL, V17, P275, DOI 10.1097/01.icu.0000193100.13551.ac
   Santhouse AM, 2000, BRAIN, V123, P2055, DOI 10.1093/brain/123.10.2055
   SCWARTZ TL, 1998, JAAPOS, V2, P310
   TODD J, 1968, ADDICTION, V63, P3
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P29
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P3
   Vojnikovic B, 2009, COLLEGIUM ANTROPOL, V33, P747
   WHITE CP, 1992, MED CHIL NEUROL, V34, P359
   Wicker B, 1998, NEUROIMAGE, V8, P221, DOI 10.1006/nimg.1998.0357
NR 26
TC 11
Z9 12
U1 0
U2 37
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RES, P O BOX 290, ULICA GRADA VUKOVARA 72/IV, 10000
   ZAGREB, CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD APR
PY 2010
VL 34
SU 2
BP 45
EP 48
PG 4
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 677AI
UT WOS:000283961100009
PM 21305724
DA 2022-11-30
ER

PT J
AU Farwick, A
   Dasch, B
   Weber, BHF
   Pauleikhoff, D
   Stoll, M
   Hense, HW
AF Farwick, A.
   Dasch, B.
   Weber, B. H. F.
   Pauleikhoff, D.
   Stoll, M.
   Hense, H-W
TI Variations in five genes and the severity of age-related macular
   degeneration: results from the Muenster aging and retina study
SO EYE
LA English
DT Article
DE age-related macular degeneration; severity; CFH; ARMS2; HtrA1; C2; CFB
ID COMPLEMENT FACTOR-H; HTRA1 PROMOTER POLYMORPHISM; VARIANT INCREASES;
   FACTOR-B; MACULOPATHY; ASSOCIATION; RISK; LOC387715; SUSCEPTIBILITY; CFH
AB Aims Little is known about the role of genetic variants in the early stages of age-related macular degeneration (AMD). We aimed to investigate how genetic variations within five well-defined genes relate to AMD severity.
   Methods We analysed SNPs in the genes for complement factor H (CFH), age-related maculopathy susceptibility (ARMS2), HtrA serine peptidase 1 (HtrA1), complement factor B (CFB), and complement component 2 (C2) in 183 controls and 730 patients with increasing severity of AMD from the Muenster aging and retina study (MARS). Severity scoring was based on the Rotterdam classification of fundus photographs.
   Results Compared with controls, patients with very early AMD showed a significantly increased minor allele frequency (MAF) only for CFH-rs1061170. With increasing severity of AMD, SNPs in CFH-rs1061170, as well as ARMS2-rs10490924, became consistently more common (P<0.001). Likewise, HtrA1-rs11200638 was less clearly associated with AMD severity, whereas C2-rs9332739 and CFB-rs641153 showed no relation. Multifactorial models confirmed CFH and ARMS2 as major determinants of AMD severity, whereas addition of HtrA1, C2 and CFB did not improve model prediction. In the models, age did not contribute to very early but to all more severe AMD stages, whereas smoking history had a significant impact only for late AMD.
   Conclusion Our findings indicate that the CFH gene is involved in the onset of AMD, whereas both, the CFH and ARMS2 genes, and more weakly, the HtrA1 gene, appear to account for the advancement of AMD. The results for SNPs in the C2 and CFB genes were inconclusive. Genetic factors dominated in their impact over age and smoking history. Eye (2009) 23, 2238-2244; doi:10.1038/eye.2008.426; published online 23 January 2009
C1 [Farwick, A.; Dasch, B.; Hense, H-W] Univ Munster, Clin Epidemiol Sect, Inst Epidemiol & Social Med, D-48129 Munster, Germany.
   [Farwick, A.; Stoll, M.] Univ Munster, Leibniz Inst Arteriosclerosis Res, Dept Genet Epidemiol Vasc Disorders, D-48129 Munster, Germany.
   [Weber, B. H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Pauleikhoff, D.] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
C3 University of Munster; University of Munster; University of Regensburg;
   St. Franziskus-Hospital
RP Hense, HW (通讯作者)，Univ Munster, Clin Epidemiol Sect, Inst Epidemiol & Social Med, 3 Domagk St, D-48129 Munster, Germany.
EM hense@uni-muenster.de
OI Weber, Bernhard H.F./0000-0002-8808-7723
FU Deutsche Forschungsgemeinschaft [He 2293/5-1, 5-2, 5-3, We 1259/14-3];
   University of Muenster; Pro Retina Foundation
FX This study was supported in part by grants from the Deutsche
   Forschungsgemeinschaft He 2293/5-1, 5-2, 5-3; We 1259/14-3, the
   intramural IMF fund of the University of Muenster, and the Pro Retina
   Foundation
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Dasch B, 2005, OPHTHALMOLOGE, V102, P1057, DOI 10.1007/s00347-005-1225-3
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Jong PTVM, 2001, EYE, V15, P396, DOI 10.1038/eye.2001.143
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Janssens ACJW, 2006, GENET MED, V8, P395, DOI 10.1097/01.gim.0000229689.18263.f4
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Leveziel N, 2007, MOL VIS, V13, P2153
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P1416, DOI 10.1097/IAE.0b013e318184661d
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rothman K, 2002, EPIDEMIOLOGY INTRO
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scholl HPN, 2007, MOL VIS, V13, P196
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Weger M, 2007, MOL VIS, V13, P1274
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
NR 43
TC 32
Z9 32
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2009
VL 23
IS 12
BP 2238
EP 2244
DI 10.1038/eye.2008.426
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 530JK
UT WOS:000272585500015
PM 19169232
OA Bronze
DA 2022-11-30
ER

PT J
AU Mukhopadhyay, C
   Boyce, TM
   Gehrs, KM
   Folk, JC
   Mullins, RF
   Luo, Y
   Kreder, K
   Sohn, EH
AF Mukhopadhyay, Chirantan
   Boyce, Timothy M.
   Gehrs, Karen M.
   Folk, James C.
   Mullins, Robert F.
   Luo, Yi
   Kreder, Karl
   Sohn, Elliott H.
TI Age-Related Macular Degeneration Masquerade: A Review of Pentosan
   Polysulfate Maculopathy and Implications for Clinical Practice
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; Elmiron; masquerade syndrome; medical
   retina; pentosan polysulfate maculopathy
ID PAIN SYNDROME/INTERSTITIAL CYSTITIS; QUALITY-OF-LIFE; INTERSTITIAL
   CYSTITIS; BLADDER PAIN; SODIUM; PREVALENCE; STRATEGIES; INSIGHTS;
   DISEASE; HEALTH
AB Pentosan polysulfate (PPS) sodium (Elmiron) is the only Food and Drug Administration (FDA)-approved oral medication to treat interstitial cystitis, also known as bladder pain syndrome. A symptomatic pigmentary maculopathy associated with PPS was reported in 2018. Since then, recognition of this unique drug toxicity has increased rapidly. This potentially sight-threatening side effect prompted the FDA in June 2020 to update the label for PPS to warn about "retinal pigmentary changes." A challenging feature of pentosan maculopathy is its ability to mimic many other retinal conditions, including inherited retinal dystrophies such as pattern dystrophy, mitochondrially inherited diabetes and deafness, and Stargardt disease, and age-related macular degeneration. In this review, we discuss the history of PPS maculopathy and its implications for thousands of at-risk interstitial cystitis patients. We use published literature and an illustrative case from our institution to highlight the importance of diagnosing PPS maculopathy. We also compare PPS maculopathy to age-related macular degeneration, explain why differentiating between the 2 is clinically important, and highlight avenues for further research. Finally, we highlight the paucity of data on patients of color and why this lack of understanding may impact patient care.
C1 [Mukhopadhyay, Chirantan; Boyce, Timothy M.; Folk, James C.; Mullins, Robert F.; Sohn, Elliott H.] Univ Iowa, Carver Coll Med, Inst Vis Res, Iowa City, IA 52242 USA.
   [Mukhopadhyay, Chirantan; Boyce, Timothy M.; Gehrs, Karen M.; Folk, James C.; Mullins, Robert F.; Sohn, Elliott H.] Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
   [Luo, Yi; Kreder, Karl] Univ Iowa, Dept Urol, Carver Coll Med, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa; University of Iowa
RP Sohn, EH (通讯作者)，Univ Iowa, Carver Coll Med, Inst Vis Res, Iowa City, IA 52242 USA.
EM Elliott.sohn@gmail.com
OI Kreder, Karl/0000-0002-8981-5286; Luo, Yi/0000-0002-4013-6805
FU NEI [R01 EY026547, P30 EY025580]
FX Supported by the NEI R01 EY026547, P30 EY025580.
CR Abou-Jaoude MM, 2021, OSLI RETINA, V52, P13, DOI 10.3928/23258160-20201223-04
   Anderson VR, 2006, DRUGS, V66, P821, DOI 10.2165/00003495-200666060-00006
   Barnes AC, 2020, OPHTHALMOL RETINA, V4, P1196, DOI 10.1016/j.oret.2020.05.008
   Barnett Joshua M, 2022, Retin Cases Brief Rep, V16, P724, DOI 10.1097/ICB.0000000000001090
   Burmester GR, 2017, LANCET, V389, P2338, DOI 10.1016/S0140-6736(17)31491-5
   Christiansen JS, 2022, CAN J OPHTHALMOL, V57, P16, DOI 10.1016/j.jcjo.2021.02.007
   Cleland SC, 2021, OPHTHALMOL RETINA, V5, P721, DOI 10.1016/j.oret.2020.12.019
   Cui XR, 2019, AM J PHYSIOL-RENAL, V317, pF90, DOI 10.1152/ajprenal.00017.2019
   Dallas KB, 2022, UROLOGY, V163, P22, DOI 10.1016/j.urology.2021.07.019
   De Larochelliere Elianne, 2022, Retin Cases Brief Rep, V16, P482, DOI 10.1097/ICB.0000000000001013
   Foster HE, 2010, J UROLOGY, V183, P1853, DOI 10.1016/j.juro.2009.12.106
   Gaffney P J, 1986, Folia Haematol Int Mag Klin Morphol Blutforsch, V113, P262
   Giusto LL, 2018, EXPERT OPIN PHARMACO, V19, P1097, DOI 10.1080/14656566.2018.1491968
   Greenlee T, 2019, OPHTHALMOLOGY, V126, pE51, DOI 10.1016/j.ophtha.2018.12.037
   Hadad A, 2020, OPHTHALMOLOGY, V127, P429, DOI 10.1016/j.ophtha.2019.10.013
   Hanif AM, 2019, JAMA OPHTHALMOL, V137, P1275, DOI 10.1001/jamaophthalmol.2019.3392
   Hanif AM, 2019, OPHTHALMOLOGY, V126, P1464, DOI 10.1016/j.ophtha.2019.04.024
   Hanif Adam M, 2019, Int Ophthalmol Clin, V59, P173, DOI 10.1097/IIO.0000000000000262
   Hanno PM, 2015, J UROLOGY, V193, P1545, DOI 10.1016/j.juro.2015.01.086
   Higgins K, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/8866961
   Hochmann S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030365
   Huckfeldt RM, 2019, OSLI RETINA, V50, P656, DOI 10.3928/23258160-20191009-10
   Ito T, 2000, BJU INT, V86, P634, DOI 10.1046/j.1464-410X.2000.00855.x
   Jain N, 2020, BRIT J OPHTHALMOL, V104, P1093, DOI 10.1136/bjophthalmol-2019-314765
   Kusek JW, 2001, UROLOGY, V57, P95, DOI 10.1016/S0090-4295(01)01141-4
   Lindeke-Myers A, 2022, SURV OPHTHALMOL, V67, P83, DOI 10.1016/j.survophthal.2021.05.005
   Lyons R, 2020, INVEST OPHTH VIS SCI, V61
   Lyons RJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.33
   Malde S, 2018, BJU INT, V122, P729, DOI 10.1111/bju.14399
   Marcu I, 2018, SEMIN REPROD MED, V36, P123, DOI 10.1055/s-0038-1676089
   Marmor MF, 2011, OPHTHALMOLOGY, V118, P415, DOI 10.1016/j.ophtha.2010.11.017
   Mishra K, 2020, OPHTHALMOL RETINA, V4, P111, DOI 10.1016/j.oret.2019.08.006
   Mishra NN, 2015, TRANSL ANDROL UROL, V4, P512, DOI 10.3978/j.issn.2223-4683.2015.10.05
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mullins RF, 2019, OPHTHALMOLOGY, V126, P591, DOI 10.1016/j.ophtha.2018.10.037
   Nickel J Curtis, 2018, J Urol, V200, P39, DOI 10.1016/j.juro.2018.02.011
   Nickel JC, 2015, J UROLOGY, V193, P857, DOI 10.1016/j.juro.2014.09.036
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   PARSONS CL, 1983, J UROLOGY, V130, P51, DOI 10.1016/S0022-5347(17)50948-9
   Patnaik SS, 2017, ARCH GYNECOL OBSTET, V295, P1341, DOI 10.1007/s00404-017-4364-2
   Pearce WA, 2018, OPHTHALMOLOGY, V125, P1793, DOI 10.1016/j.ophtha.2018.04.026
   Pouw AE, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030687
   Ricca AM, 2021, CURR OPIN OPHTHALMOL, V32, P214, DOI 10.1097/ICU.0000000000000750
   Rothrock NE, 2003, J UROLOGY, V169, P233, DOI 10.1016/S0022-5347(05)64075-X
   Rothrock NE, 2002, J UROLOGY, V167, P1763, DOI 10.1016/S0022-5347(05)65195-6
   Sant G R, 1993, J Assoc Acad Minor Phys, V4, P89
   Sant GR, 2003, J UROLOGY, V170, P810, DOI 10.1097/01.ju.0000083020.06212.3d
   Schuchman EH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054459
   Sohn EH., 2018, RYANS RETINA, V44, P953
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Starr MR, 2021, OSLI RETINA, V52, P123, DOI 10.3928/23258160-20210302-02
   Teichman JMH, 2007, UROLOGY, V69, P41, DOI 10.1016/j.urology.2006.08.1111
   Tripp DA, 2012, EUR UROL, V62, P1188, DOI 10.1016/j.eururo.2012.05.023
   Uner OE, 2021, RETINA-J RET VIT DIS, V41, P1562, DOI 10.1097/IAE.0000000000003078
   United States Food and Drug Administration, ELM 100 MG PENT POLY
   Vora RA, 2020, OPHTHALMOLOGY, V127, P835, DOI 10.1016/j.ophtha.2020.01.017
   Wang D, 2020, CAN J OPHTHALMOL, V55, P116, DOI 10.1016/j.jcjo.2019.12.001
   Warren JW, 2009, UROLOGY, V73, P52, DOI 10.1016/j.urology.2008.06.031
   Wheeler SM, 2017, OBSTET GYN CLIN N AM, V44, P1, DOI 10.1016/j.ogc.2016.10.001
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yusuf IH, 2020, JAMA OPHTHALMOL, V138, P900, DOI 10.1001/jamaophthalmol.2020.2364
   Zhang CO, 2003, UROLOGY, V61, P897, DOI 10.1016/S0090-4295(02)02597-9
NR 63
TC 0
Z9 0
U1 0
U2 1
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD MAR-APR
PY 2022
VL 11
IS 2
BP 100
EP 110
DI 10.1097/APO.0000000000000504
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1A1JH
UT WOS:000791521300005
PM 35533330
OA Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Serra, R
   Coscas, F
   Cabral, D
   Pinna, A
   Coscas, G
AF Serra, Rita
   Coscas, Florence
   Cabral, Diogo
   Pinna, Antonio
   Coscas, Gabriel
TI POLYPOIDAL CHOROIDAL NEOVASCULARIZATION VERSUS TYPE 1 CHOROIDAL
   NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION A Fractal
   Analysis Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; fractal dimension; lacunarity; optical
   coherence tomography angiography; polypoidal choroidal
   neovascularization; Type 1 choroidal neovascularization
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; PHOTODYNAMIC THERAPY; VASCULOPATHY;
   FEATURES
AB Purpose: To compare quantitative optical coherence tomography angiography parameters between polypoidal choroidal neovascularizations (PCNVs) and Type 1 choroidal neovascularizations (CNVs) in patients with age-related macular degeneration. Methods: PCNV and Type 1 CNV lesions were retrospectively recruited in a cohort of patients with age-related macular degeneration. All the patients underwent a comprehensive ophthalmic evaluation, including best-corrected visual acuity, fluorescein and indocyanine green angiography, structural optical coherence tomography (OCT), and optical coherence tomography angiography. Vascular perfusion density, fractal dimension, and lacunarity were computed by means of fractal analysis of neovascular en face optical coherence tomography angiography slabs. Results: Sixty-eight eyes were included in the analysis. Of them, 35 of 68 eyes (51.5%) had PCNV and 33 of 68 (48.5%) had Type 1 CNV. Patients with PCNV were significantly younger (P = 0.0003) and had a higher best-corrected visual acuity (P < 0.0001). The mean vascular perfusion density was 0.83 +/- 0.11% in PCNVs and 0.46 +/- 0.10% in Type 1 CNVs (P < 0.0001). The mean fractal dimension was 1.44 +/- 0.1 in PCNVs and 1.45 +/- 0.09 in Type 1 CNVs (P = 0.86) while the mean lacunarity was 2.46 +/- 1.03 in PCNVs and 1.86 +/- 0.52 in Type 1 CNVs (P = 0.006). Conclusion: PCNVs resulted to be more heterogeneous and characterized by higher vascular perfusion density and lacunarity values than Type 1 CNVs. These interesting findings seem to support the idea that PCNVs and Type 1 CNVs are two separate clinical entities. However, future studies based on optical coherence tomography angiography fractal analysis, but also involving other relevant parameters such as demographics, presentation, morphology on multimodal imaging, and response to treatment, are necessary before drawing any definitive conclusions on whether PCNV is a specific clinical entity or a neovascular age-related macular degeneration variant.
C1 [Serra, Rita] Univ Sassari, Dept Surg & Biomed Sci, Sassari, Italy.
   [Serra, Rita] Cittadella Univ Cagliari, Ist Ric Genet & Biomed IRGB, CNR, Cagliari, Italy.
   [Serra, Rita; Coscas, Florence] Ctr Ophtalmol Odeon, 113 Bd St Germain, F-75006 Paris, France.
   [Cabral, Diogo; Coscas, Gabriel] Inst Oftalmol Dr Gama Pinto, Lisbon, Portugal.
   [Pinna, Antonio] Univ Sassari, Dept Med Surg & Expt Sci, Ophthalmol Unit, Sassari, Italy.
C3 University of Sassari; Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Ricerca Genetica e Biomedica (IRGB-CNR); University of
   Sassari
RP Coscas, F (通讯作者)，Ctr Ophtalmol Odeon, 113 Bd St Germain, F-75006 Paris, France.
EM coscas.f@gmail.com
RI Pinna, Antonio/H-5067-2018
OI Pinna, Antonio/0000-0003-3052-2662; SERRA, RITA/0000-0002-6341-1435
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Coscas F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205513
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Gass J D, 1994, Trans Am Ophthalmol Soc, V92, P91
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Huang CH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37384-y
   Ichiyama Y, 2017, RETINA-J RET VIT DIS, V37, P724, DOI 10.1097/IAE.0000000000001576
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Pece A, 2000, ARCH OPHTHALMOL-CHIC, V118, P630
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Serra R, 2021, RETINA-J RET VIT DIS, V41, P93, DOI 10.1097/IAE.0000000000002807
   Serra R, 2021, BRIT J OPHTHALMOL, V105, P1421, DOI 10.1136/bjophthalmol-2020-317011
   Serra R, 2020, RETINA-J RET VIT DIS, V40, P1224, DOI 10.1097/IAE.0000000000002604
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 29
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2022
VL 42
IS 6
BP 1005
EP 1011
DI 10.1097/IAE.0000000000003439
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1K9HA
UT WOS:000798904200004
PM 35594074
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Rispoli, M
   Eandi, CM
   Di Antonio, L
   Kilian, R
   Montesel, A
   Savastano, MC
AF Rispoli, Marco
   Eandi, Chiara M.
   Di Antonio, Luca
   Kilian, Raphael
   Montesel, Andrea
   Savastano, Maria C.
TI Biomarkers in Early Response to Brolucizumab on Pigment Epithelium
   Detachment Associated with Exudative Age-Related Macular Degeneration
SO BIOMEDICINES
LA English
DT Article
DE age-related macular degeneration; innovative biotechnologies;
   Brolucizumab; exudative AMD; OCT angiography; personalized medicine
ID ENDOTHELIAL GROWTH-FACTOR; GEOGRAPHIC ATROPHY; AFLIBERCEPT; RANIBIZUMAB;
   PREVALENCE; THERAPY
AB Background: The purpose of this study was to describe early changes in the morphology of pigment epithelium detachments (PED) after an intravitreal injection of Brolucizumab into eyes with macular neovascularization secondary to exudative age-related macular degeneration (e-AMD). Method: We included twelve eyes of 12 patients with PED secondary to e-AMD which were not responding to prior anti-VEGF treatments. An ophthalmic examination and an assessment of PED-horizontal maximal diameter (PED-HMD), PED-maximum high (PED-MH) and macular neovascularization (MNV) flow area (MNV-FA) by the means of structural optical coherence tomography (OCT) and OCT Angiography (OCT-A) were performed at baseline, as well as 1, 7, 14 and 30 days after the injection. Results: The mean age of the population of study was 78.4 (SD +/- 4.8). The mean number of previous Ranibizumab or Aflibercept injections was 13 (SD +/- 8). At the last follow-up visit, the PED-HMD did not significantly change (p = 0.16; F(DF:1.94, 20,85) = 1.9), the PED-MH showed a significant reduction [p = 0.01; F(DF:1.31, 14.13) = 6.84.] and the MNV-FA did not significantly differ (p = 0.1; F(1.97, 21.67) = 2.54) from baseline. No signs of ocular inflammation were observed during follow-up. Conclusions: A single Brolucizumab injection was able to determine the short-term effects on PEDs' anatomical features of eyes with an unresponsive e-AMD.
C1 [Rispoli, Marco] Eye Hosp, Surg & Emergency Ophthalmol Dept, Chorioretinal Vasculopathies Unit, I-00136 Rome, Italy.
   [Eandi, Chiara M.; Montesel, Andrea] Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, Fdn Asile Aveugles, CH-1002 Lausanne, Switzerland.
   [Eandi, Chiara M.] Univ Torino, Dept Surg Sci, I-10126 Turin, Italy.
   [Di Antonio, Luca] ASL 1 Avezzano Sulmona, UOC Ophthalmol & Surg Dept, I-67051 Laquila, Italy.
   [Kilian, Raphael] Univ Verona, Dept Neurosci Biomed & Movement Sci, I-37134 Verona, Italy.
   [Savastano, Maria C.] IRCCS, Fdn Policlin A Gemelli, Unit Ophthalmol, I-00168 Rome, Italy.
   [Savastano, Maria C.] Univ Cattolica Sacro Cuore, Dept Ophthalmol, I-00168 Rome, Italy.
C3 University of Lausanne; University of Turin; University of Verona;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli
RP Eandi, CM (通讯作者)，Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, Fdn Asile Aveugles, CH-1002 Lausanne, Switzerland.; Eandi, CM (通讯作者)，Univ Torino, Dept Surg Sci, I-10126 Turin, Italy.
EM rispolimarco@gmail.com; chiara.eandi@unito.it; monsieurluca@yahoo.com;
   raphaelkilian8@yahoo.it; andrea.montesel@gmail.com;
   mariacristina.savastano@gmail.com
RI Savastano, Maria Cristina/I-5355-2015; rispoli, marco/N-1054-2016
OI Savastano, Maria Cristina/0000-0003-1397-4333; rispoli,
   marco/0000-0003-2689-9002; Montesel, Andrea/0000-0002-1910-9976
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Avaylon J, 2020, INT MED CASE REP J, V13, P145, DOI 10.2147/IMCRJ.S252260
   Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   Banerjee I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72359-y
   Barca F, 2020, J CLIN MED, V9, DOI 10.3390/jcm9123982
   Bulirsch LM, 2022, BRIT J OPHTHALMOL, V106, P1288, DOI 10.1136/bjophthalmol-2020-318672
   Cabral D, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.3.18
   Cennamo G, 2019, EUR J OPHTHALMOL, V29, P239, DOI 10.1177/1120672118785495
   Corvi F, 2021, GRAEF ARCH CLIN EXP, V259, P2887, DOI 10.1007/s00417-021-05167-3
   Di Antonio L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33926-6
   Donato L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073484
   Donato L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010070
   Donato L, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111158
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Faatz H, 2019, EYE, V33, P1466, DOI 10.1038/s41433-019-0429-8
   Falsini B, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11020213
   Desideri LF, 2021, EXPERT OPIN BIOL TH, V21, P553, DOI 10.1080/14712598.2021.1915278
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grechenig C, 2021, RETINA-J RET VIT DIS, V41, P2221, DOI 10.1097/IAE.0000000000003180
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jain Atul, 2020, Am J Ophthalmol Case Rep, V18, P100687, DOI 10.1016/j.ajoc.2020.100687
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Lam D, 2018, RETINA-J RET VIT DIS, V38, P1100, DOI 10.1097/IAE.0000000000001698
   Lumbroso B, 2011, RETINA-J RET VIT DIS, V31, P553, DOI 10.1097/IAE.0b013e3181eef3eb
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nassisi M, 2021, ADV EXP MED BIOL, V1256, P33, DOI 10.1007/978-3-030-66014-7_2
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Romo-Bucheli D, 2020, IEEE J BIOMED HEALTH, V24, P3456, DOI 10.1109/JBHI.2020.3000136
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacconi R, 2018, EYE, V32, P734, DOI 10.1038/eye.2017.295
   Sato T, 2015, RETINA-J RET VIT DIS, V35, P1292, DOI 10.1097/IAE.0000000000000505
   Savastano MC, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092973
   Savastano MC, 2021, EUR J OPHTHALMOL, V31, P514, DOI 10.1177/1120672120909769
   Scimone C, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111154
   Sedeh FB, 2017, DAN MED J, V64
   Serra R, 2020, RETINA-J RET VIT DIS, V40, P1224, DOI 10.1097/IAE.0000000000002604
   Shi YY, 2021, AM J OPHTHALMOL, V224, P321, DOI 10.1016/j.ajo.2020.12.015
   Siggel R, 2020, OPHTHALMOL RETINA, V4, P471, DOI 10.1016/j.oret.2019.11.018
   Solanki A, 2019, CURR DRUG DELIV, V16, P226, DOI 10.2174/1567201815666181031163111
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Tan ACS, 2018, RETINA-J RET VIT DIS, V38, P1759, DOI 10.1097/IAE.0000000000002016
   Thomas CJ, 2021, MED CLIN N AM, V105, P473, DOI 10.1016/j.mcna.2021.01.003
   Vogl WD, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85110-y
   Wang J, 2020, BIOMED OPT EXPRESS, V11, P927, DOI 10.1364/BOE.379977
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 50
TC 5
Z9 5
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD JUN
PY 2021
VL 9
IS 6
AR 668
DI 10.3390/biomedicines9060668
PG 11
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA SX6ZC
UT WOS:000665349400001
PM 34200829
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bakall, B
   Folk, JC
   Boldt, HC
   Sohn, EH
   Stone, EM
   Russell, SR
   Mahajan, VB
AF Bakall, Benjamin
   Folk, James C.
   Boldt, H. Culver
   Sohn, Elliott H.
   Stone, Edwin M.
   Russell, Stephen R.
   Mahajan, Vinit B.
TI Aflibercept Therapy for Exudative Age-related Macular Degeneration
   Resistant to Bevacizumab and Ranibizumab
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VEGF-TRAP; INTRAVITREAL BEVACIZUMAB; TACHYPHYLAXIS
AB PURPOSE: To evaluate the outcome of intravitreal injection of aflibercept in cases with exudative age-related macular degeneration, (AMD) resistant to injections of bevacizumab or ranibizumab.
   DESIGN: Retrospective observational case series.
   METHODS: A retrospective chart review at a single institution was conducted to identify patients with exudative AMD and choroidal neovascularization (CNV) in 1 or both eyes resistant to treatment with ranibizumab or bevacizumab who were switched to treatment with at least 3 monthly injections of aflibercept. In total, 36 eyes from 31 patients were included. The demographic data, visual acuities, central macular thickness on optical coherence tomography (OCT), complications, and number of injections were reviewed.
   RESULTS: The mean patient age was 79 years (range 60-88). There were 13 male and 18 female patients. The number of prior injections with either bevacizumab or ranibizumab ranged from 6-74. After 3 monthly injections of aflibercept, there was a reduction of either subretinal or intraretinal fluid in 18 of 36 (50.0%) of the treated eyes; the amount of fluid remained stable in 15 eyes (41.7%) and worsened in 3 eyes (8.3%). A significant average decrease was observed for the central macular thickness after 3 injections of 65 mu m (P = 2.9 x 10(-6)), with no significant change in visual acuity.
   CONCLUSIONS: Aflibercept therapy appears to be beneficial in a subset of patients with neovascular age-related macular degeneration who exhibit recurrent or resistant intraretinal or subretinal fluid following multiple injections with either bevacizumab or ranibizumab. (C) 2013 by Elsevier Inc. All rights reserved.
C1 [Bakall, Benjamin; Folk, James C.; Boldt, H. Culver; Sohn, Elliott H.; Stone, Edwin M.; Russell, Stephen R.; Mahajan, Vinit B.] Univ Iowa Hosp & Clin, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Mahajan, Vinit B.] Univ Iowa, Omics Lab, Iowa City, IA USA.
C3 University of Iowa; University of Iowa
RP Mahajan, VB (通讯作者)，Univ Iowa Hosp & Clin, Dept Ophthalmol & Visual Sci, 200 Hawkins Dr, Iowa City, IA 52242 USA.
EM mahajanlab@gmail.com
OI Boldt, H. Culver/0000-0002-7292-2093; Stone, Edwin
   M./0000-0003-3343-4414; Folk, James/0000-0002-6271-2906; Russell,
   Stephen/0000-0003-3776-1367; Mahajan, Vinit/0000-0003-1886-1741; Sohn,
   Elliott/0000-0002-3778-9362
FU NIH, Bethesda, Maryland [K08EY020530]; BrightFocus Foundation,
   Clarksburg, Maryland; Research to Prevent Blindness, Inc, New York, NY;
   Foundation Fighting Blindness, Columbia, Maryland; NATIONAL EYE
   INSTITUTE [K08EY020530] Funding Source: NIH RePORTER
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and none were reported. The authors
   are supported by NIH, Bethesda, Maryland, Grant K08EY020530 and the
   BrightFocus Foundation, Clarksburg, Maryland (V.B.M.), Research to
   Prevent Blindness, Inc, New York, NY (V.B.M., J.C.F.), and a career
   development award grant by Foundation Fighting Blindness, Columbia,
   Maryland (B.B.). Contributions of authors: design and conduct of the
   study, data collection, and management (B.B., J.C.F., V.B.M.); analysis
   and interpretation of the data and preparation, review, and approval of
   the manuscript (B.B., E.H.S., H.C.B., E.M.S., S.R.R., J.C.F., V.B.M.).
CR Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown SM, 2004, AM J OPHTHALMOL, V138, P149, DOI 10.1016/j.ajo.2004.02.017
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Roller AB, 2011, RETINA-J RET VIT DIS, V31, P1848, DOI 10.1097/IAE.0b013e31820d3feb
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Smretschnig E, 2010, GRAEF ARCH CLIN EXP, V248, P1693, DOI 10.1007/s00417-010-1415-9
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Svenson M, 2007, RHEUMATOLOGY, V46, P1828, DOI 10.1093/rheumatology/kem261
NR 18
TC 187
Z9 193
U1 0
U2 29
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2013
VL 156
IS 1
BP 15
EP 22
DI 10.1016/j.ajo.2013.02.017
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 179OT
UT WOS:000321531900004
PM 23706500
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Gensler, G
   Klein, ML
   Milton, RC
AF Seddon, JM
   Gensler, G
   Klein, ML
   Milton, RC
TI C-reactive protein and homocysteine are associated with dietary and
   behavioral risk factors for age-related macular degeneration
SO NUTRITION
LA English
DT Article
DE age-related macular degeneration; biomarkers; C-reactive protein;
   homocysteine; diet; lutein/zeaxanthin; fish intake; body mass index;
   smoking
ID ADULTS
AB Objective: We investigated whether age-related macular degeneration risk factors are associated with high-sensitivity C-reactive protein (CRP) and homocysteine (HCY), systemic biomarkers for cardiovascular disease.
   Methods: Subjects with a range of age-related macular maculopathies or no maculopathy at two centers in the United States were evaluated. Risk factors and biomarkers were assessed by questionnaire, direct measurement, or analyses of blood specimens.
   Results: Higher levels of serum antioxidants vitamin C and lutein/zeaxanthin and higher fish intake were associated with lower serum CRP levels, whereas serum vitamin E, smoking, and increased body mass index were associated with increased CRP. Serum vitamin E, serum a-carotene, and dietary intake of antioxidants and vitamin 86 were associated with lower levels of plasma HCY, whereas hypertension was associated with increased HCY.
   Conclusions: C-reactive protein and HCY levels are related to traditional dietary and behavioral factors associated with age-related macular degeneration. (c) 2006 Elsevier Inc. All rights reserved.
C1 Harvard Univ, Sch Med, Dept Ophthalmol, Epidemiol Unit,Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   EMMES Corp, Rockville, MD USA.
   Devers Eye Inst, Portland, OR USA.
   Casey Eye Inst, Portland, OR USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard T.H. Chan School of Public
   Health; Emmes Corporation; Devers Eye Institute
RP Seddon, JM (通讯作者)，Harvard Univ, Sch Med, Dept Ophthalmol, Epidemiol Unit,Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.
EM jseddon@earthlink.net
FU NEI NIH HHS [N01EY02126, N01EY02117, R01 EY013982, R01 EY011309] Funding
   Source: Medline; NATIONAL EYE INSTITUTE [R01EY013982, N01EY002117,
   N01EY002126] Funding Source: NIH RePORTER
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SEDDON JM, 2005, INVEST OPHTH VIS SCI, V46, P2300
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131
   Zampelas A, 2005, J AM COLL CARDIOL, V46, P120, DOI 10.1016/j.jacc.2005.03.048
NR 10
TC 51
Z9 52
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0899-9007
J9 NUTRITION
JI Nutrition
PD APR
PY 2006
VL 22
IS 4
BP 441
EP 443
DI 10.1016/j.nut.2005.12.004
PG 3
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 027FC
UT WOS:000236398500015
PM 16530626
DA 2022-11-30
ER

PT J
AU Maeda, T
   Sugita, S
   Kurimoto, Y
   Takahashi, M
AF Maeda, Tadao
   Sugita, Sunao
   Kurimoto, Yasuo
   Takahashi, Masayo
TI Trends of Stem Cell Therapies in Age-Related Macular Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE regenerative medicine; retinal pigment epithelium; iPS cell; ES cell;
   stem cell; age-related macular degeneration; clinical trial; retina;
   immune reaction; transplantation
AB Age-related macular degeneration (AMD) is a highly prevalent irreversible impairment in the elderly population worldwide. Stem cell therapies have been considered potentially viable for treating AMD through the direct replacement of degenerated cells or secretion of trophic factors that facilitate the survival of existing cells. Among them, the safety of pluripotent stem cell-derived retinal pigment epithelial (RPE) cell transplantation against AMD, and some hereditary retinal degenerative diseases, has been discussed to a certain extent in clinical studies of RPE cell transplantation. Preparations are in progress for its clinical application. On the other hand, clinical trials using somatic stem cells are also being conducted, though these had controversial outcomes. Retinal regenerative medicine using stem cells is expected to make steady progress toward practical use while new technologies are incorporated from various fields, thereby making the role of ophthalmologists in this field increasingly important.
C1 [Maeda, Tadao; Sugita, Sunao; Kurimoto, Yasuo; Takahashi, Masayo] Kobe City Eye Hosp, Dept Ophthalmol, Kobe, Hyogo 6500047, Japan.
   [Maeda, Tadao; Sugita, Sunao; Kurimoto, Yasuo; Takahashi, Masayo] RIKEN Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Kobe, Hyogo 6500047, Japan.
C3 RIKEN
RP Takahashi, M (通讯作者)，Kobe City Eye Hosp, Dept Ophthalmol, Kobe, Hyogo 6500047, Japan.; Takahashi, M (通讯作者)，RIKEN Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Kobe, Hyogo 6500047, Japan.
EM tadao_maeda@kcho.jp; sunao.sugita@riken.jp; ykurimoto@mac.com;
   retinalab@ml.riken.jp
FU AMED [JP18bm0204002, JP17bk0104002]; KAKENHI [25293357, 18H02959]
FX This research was supported by AMED under Grant Number JP18bm0204002 and
   JP17bk0104002 to M.T. In addition, this study was also supported by
   grants from KAKENHI (25293357, 18H02959) to S.S.
CR Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Butler D., 2014, NAT CELL BIOL, V516, P311, DOI [10.1038/480437a, DOI 10.1038/480437A]
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Daniel E, 2020, JAMA OPHTHALMOL, V138, P510, DOI 10.1001/jamaophthalmol.2020.0437
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Fujii S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093077
   Gandhi JK, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227641
   Gandhi JK, 2018, ACTA BIOMATER, V67, P134, DOI 10.1016/j.actbio.2017.11.058
   Gardiner KL, 2020, MOL THER, V28, P266, DOI 10.1016/j.ymthe.2019.08.013
   GOURAS P, 1985, CURR EYE RES, V4, P253, DOI 10.3109/02713688509000857
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Hayashi T, 2006, ACTA OPHTHALMOL SCAN, V84, P254, DOI 10.1111/j.1600-0420.2005.00575.x
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Iraha S, 2018, STEM CELL REP, V10, P1059, DOI 10.1016/j.stemcr.2018.01.032
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Koenekoop RK, 2008, OPHTHALMIC GENET, V29, P89, DOI 10.1080/13816810802216480
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Li ML, 2019, RETINA-J RET VIT DIS, V39, P802, DOI 10.1097/IAE.0000000000002461
   Lukovic D, 2015, SCI REP-UK, V5, DOI 10.1038/srep12910
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Maeda A, 2019, ANNU REV GENOM HUM G, V20, P201, DOI 10.1146/annurev-genom-083118-015043
   Maguire AM, 2019, OPHTHALMOLOGY, V126, P1273, DOI 10.1016/j.ophtha.2019.06.017
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mandai M, 2017, STEM CELL REP, V8, P69, DOI 10.1016/j.stemcr.2016.12.008
   Matsuzaki M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64601-4
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Nakamura M, 2003, DOC OPHTHALMOL, V107, P3, DOI 10.1023/A:1024498826904
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Palczewski K, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15502
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Scholl HPN, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2838
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Singh MS, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100779
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Sugita S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072217
   Sugita S, 2016, STEM CELL REP, V7, P619, DOI 10.1016/j.stemcr.2016.08.011
   Sugita S, 2016, STEM CELL REP, V7, P635, DOI 10.1016/j.stemcr.2016.08.010
   Sung Y, 2021, BRIT J OPHTHALMOL, V105, P829, DOI 10.1136/bjophthalmol-2020-316225
   Takagi S, 2019, OPHTHALMOL RETINA, V3, P850, DOI 10.1016/j.oret.2019.04.021
   Tanna P, 2017, BRIT J OPHTHALMOL, V101, P25, DOI 10.1136/bjophthalmol-2016-308823
   Wang YQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02955-3
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
NR 58
TC 6
Z9 6
U1 3
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD APR
PY 2021
VL 10
IS 8
AR 1785
DI 10.3390/jcm10081785
PG 20
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA RT5EG
UT WOS:000644481900001
PM 33923985
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Javitt, NB
   Javitt, JC
AF Javitt, Norman B.
   Javitt, Jonathan C.
TI The retinal oxysterol pathway: a unifying hypothesis for the cause of
   age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; ketocholesterol; light toxicity;
   oxysterol; photooxiclation
ID 7-KETOCHOLESTEROL-INDUCED APOPTOSIS; CHOLESTEROL; IDENTIFICATION;
   ACCUMULATION; EXPRESSION
AB Purpose of review To summarize recent findings implicating toxic agents resulting in photooxidation of cholesterol in the etiology of age-related macular degeneration. Understanding the role of these agents and the existing pathways for their neutralization may lead to novel therapeutic approaches.
   Recent findings The human eye is now known to produce significant quantities of 7-ketocholesterol and related substances as a direct result of photoreceptor function. These substances are highly toxic to retinal cells and the eye has been shown to be unique among human organs in expressing three separate enzymatic pathways that neutralize these agents. Drusen are recently shown to contain significant accumulations of 7-ketocholesterol, likely as a result of failure of these neutralization pathways. In addition to its direct tissue toxicity, which may trigger death of retinal pigment epithelium and photoreceptor cells, ketocholesterol is a potent attractor of macrophages and induces macrophages to express both vascular endothelial growth factor F and metalloproteinases. The role of the former in neovascularization is well understood, whereas the latter is capable of directly inducing breaks in Bruch's membrane.
   Summary The toxic role of 7-ketocholesterol and existing pathways for its neutralization may point the way to a unified theory that explains the cause of age-related macular degeneration and points towards novel therapeutic interventions.
C1 [Javitt, Norman B.] NYU, Langone Med Ctr, New York, NY USA.
   [Javitt, Jonathan C.] Johns Hopkins Sch Med, Wilmer Ophthalmol Inst, Baltimore, MD USA.
C3 New York University; NYU Langone Medical Center; Johns Hopkins
   University; Johns Hopkins Medicine
RP Javitt, JC (通讯作者)，8300 Twin Forks Lane, Chevy Chase, MD 20815 USA.
EM jjavitt@healthdirections.net
RI Javitt, Jonathan/AAJ-5574-2021
OI Javitt, Jonathan/0000-0003-2371-1609; Javitt, Norman
   B/0000-0001-9265-3508
CR ASAI T, 1998, ARTERIOSCLER THROMB, V18, P1188
   Berthier A, 2005, FEBS J, V272, P3093, DOI 10.1111/j.1742-4658.2005.04723.x
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Diczfalusy U, 2004, J AOAC INT, V87, P467
   DOMINIEK DG, 2006, JAMA-J AM MED ASSOC, V296, P301
   Dulakk J, 2001, ATHEROSCLEROSIS, V159, P325, DOI 10.1016/S0021-9150(01)00520-2
   Fuda H, 2007, J LIPID RES, V48, P1343, DOI 10.1194/jlr.M700018-JLR200
   Glickman RD, 2002, INT J TOXICOL, V21, P473, DOI 10.1080/10915810290169909
   Hawkins BS, 1999, MOL VIS, V5
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JAVITT NB, 1981, J BIOL CHEM, V256, P2644
   Javitt NB, 2001, ENDOCRINOLOGY, V142, P2978, DOI 10.1210/en.142.7.2978
   Jessup W, 2002, VASC PHARMACOL, V38, P239, DOI 10.1016/S1537-1891(02)00174-X
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lee JW, 2006, EXP EYE RES, V83, P465, DOI 10.1016/j.exer.2005.11.018
   Lemaire-Ewing S, 2005, CELL BIOL TOXICOL, V21, P97, DOI 10.1007/s10565-005-0141-2
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Martin KO, 1997, J LIPID RES, V38, P1053
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   OKUDA KI, 1994, J LIPID RES, V35, P361
   Ong JM, 2003, NEUROCHEM RES, V28, P883, DOI 10.1023/A:1023223409798
   Pikuleva IA, 2006, DRUG METAB DISPOS, V34, P513, DOI 10.1124/dmd.105.008789
   Prunet C, 2005, J BIOCHEM MOL TOXIC, V19, P311, DOI 10.1002/jbt.20096
   Reiss AB, 1997, J LIPID RES, V38, P1254
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SMITH JA, 1992, BIOCHEM INT, V28, P1009
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Vejux A, 2005, CYTOM PART A, V64A, P87, DOI 10.1002/cyto.a.20124
   WALLS GL, 1942, VERTEBRATE EYE ADAPT
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Winkler BS, 1999, MOL VIS, V5
   Zuzarte-Luis V, 2006, APOPTOSIS, V11, P701, DOI 10.1007/s10495-006-5481-8
NR 32
TC 35
Z9 38
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2009
VL 20
IS 3
BP 151
EP 157
DI 10.1097/ICU.0b013e32832af468
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 446TN
UT WOS:000266144200002
PM 19390436
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Koh, KM
   Kim, JH
   Kim, HS
   Il Han, J
   Lew, YJ
   Lee, TG
   Kim, JW
AF Cho, Han Joo
   Koh, Kyoung Min
   Kim, Jae Hui
   Kim, Hyoung Seok
   Il Han, Jung
   Lew, Young Ju
   Lee, Tae Gon
   Kim, Jong Woo
TI INTRAVITREAL RANIBIZUMAB INJECTIONS WITH AND WITHOUT PNEUMATIC
   DISPLACEMENT FOR TREATING SUBMACULAR HEMORRHAGE SECONDARY TO NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE anti-vascular endothelial growth factor; age-related macular
   degeneration; pnuematic displacement; submacular hemorrhage
ID TISSUE-PLASMINOGEN ACTIVATOR; SUBRETINAL HEMORRHAGE; NATURAL-HISTORY;
   BEVACIZUMAB; MANAGEMENT; GAS
AB Purpose: To evaluate the efficacy of intravitreal ranibizumab with and without pneumatic displacement for the treatment of submacular hemorrhage secondary to neovascular age-related macular degeneration.
   Methods: We retrospectively reviewed the medical records of 93 treatment-naive patients (93 eyes) with submacular hemorrhage secondary to neovascular age-related macular degeneration. All patients were treated with an initial series of 3 monthly intravitreal ranibizumab injections, followed by as-needed injections. For the patients treated with pneumatic displacement, expansive gas was injected at the time of the first ranibizumab injection.
   Results: Mean submacular hemorrhage area was 8.2 +/- 5.8 disk areas, and mean symptom duration was 8.2 +/- 5.2 days at baseline. Twelve months into treatment, the mean logarithm of the minimum angle of resolution of best-corrected visual acuity of all subjects significantly improved from 1.19 +/- 0.55 (20/309) at baseline to 0.96 +/- 0.39 (20/182, P = 0.007) at 12 months. The mean central foveal thickness also significantly improved from 473 +/- 223 mu m at baseline to 279 +/- 134 mu m (P < 0.001) at 12 months. However, no significant difference in best-corrected visual acuity and mean central foveal thickness between ranibizumab monotherapy (58 eyes) and combination therapy groups (35 eyes) was observed at 12 months.
   Conclusion: Intravitreal ranibizumab injections with and without pneumatic displacement are viable treatment options for submacular hemorrhage secondary to neovascular age-related macular degeneration.
C1 [Cho, Han Joo; Koh, Kyoung Min; Kim, Jae Hui; Kim, Hyoung Seok; Il Han, Jung; Lew, Young Ju; Lee, Tae Gon; Kim, Jong Woo] Konyang Univ, Myung Gok Eye Res Inst, Kims Eye Hosp, Coll Med,Dept Ophthalmol, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Cho, HJ (通讯作者)，Kims Eye Hosp, 156,4 Ga,KS013 Seoul, Seoul, South Korea.
EM chojoo@kimeye.com
OI Cho, Han Joo/0000-0001-7336-5762
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1232
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Chen SN, 2003, OPHTHALMOLOGY, V110, P704, DOI 10.1016/S0161-6420(02)01979-6
   Cho HJ, 2013, AM J OPHTHALMOL
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Fang IM, 2009, EYE, V23, P397, DOI 10.1038/sj.eye.6703017
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Hasegawa T, 2010, AM J OPHTHALMOL, V149, P322, DOI 10.1016/j.ajo.2009.09.012
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Hohn F, 2010, OPHTHALMOLOGE, V107, P328, DOI 10.1007/s00347-009-2004-3
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Luke M, 2007, BRIT J OPHTHALMOL, V91, P1077, DOI 10.1136/bjo.2006.111260
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Mizutani T, 2011, GRAEF ARCH CLIN EXP, V249, P1153, DOI 10.1007/s00417-011-1649-1
   Ron Y, 2007, OPHTHALMOLOGICA, V221, P57, DOI 10.1159/000096524
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Thompson John T, 2005, Trans Am Ophthalmol Soc, V103, P98
   THOMPSON JT, 2005, T AM OPHTHAL SOC, V103, P107
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 30
TC 14
Z9 14
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2015
VL 35
IS 2
BP 205
EP 212
DI 10.1097/IAE.0000000000000295
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CA2UU
UT WOS:000348764200007
PM 25105310
DA 2022-11-30
ER

PT J
AU Ricci, F
   Missiroli, F
   Cedrone, C
   Grossi, M
   Regine, F
AF Ricci, Federico
   Missiroli, Filippo
   Cedrone, Claudio
   Grossi, Massimo
   Regine, Federico
TI Compassionate Use of Intravitreal Pegaptanib in Patients with
   Age-Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE pegaptanib; choroidal neovascularization; VEGF inhibitors
ID CHOROIDAL NEOVASCULARIZATION; SODIUM; RANIBIZUMAB; BEVACIZUMAB;
   EXPRESSION
AB The study aim was to evaluate the short-term safety and efficacy of pegaptanib sodium injections (Macugen, Eyetech Pharmaceuticals, Inc., New York, NY) in the compassionate-use therapy of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Intravitreal pegaptanib was used to treat 41 eyes in 40 patients with CNV. Injections were given every 6 weeks, and a minimum of three injections were planned. The mean change in BCVA for all lesions was a loss of 0.03 Snellen lines. Seven eyes (17.1%) gained more than 3 lines, three (7.31%) lost 6 lines or more, and in 75.6% the BCVA stabilized or improved.
C1 [Ricci, Federico; Missiroli, Filippo; Cedrone, Claudio; Grossi, Massimo; Regine, Federico] Univ Roma Tor Vergata, Unita Operat, Dipartimentale Patol Retiniche Policlin Tor Verga, Rome, Italy.
C3 University of Rome Tor Vergata
RP Ricci, F (通讯作者)，Via Giorgio Baglivi 5D, I-00161 Rome, Italy.
EM federico.ricci@uniroma2.it
RI ricci, federico/AAC-3836-2020
OI ricci, federico/0000-0002-4224-9280
CR Atmani K, 2009, EYE, V23, P1150, DOI 10.1038/eye.2008.194
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Ehlers JP, 2007, OPHTHAL SURG LAS IM, V38, P371, DOI 10.3928/15428877-20070901-03
   Eyetech Study Group, 2002, RETINA, V22, P43
   Farah SE, 2008, OPHTHAL SURG LAS IM, V39, P294, DOI 10.3928/15428877-20080701-05
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   PATEL PJ, 2008, TRIALS, V14, P9
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P851, DOI 10.1097/IAE.0b013e31806458f0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Tano Yasuo, 2008, Nippon Ganka Gakkai Zasshi, V112, P590
   World Health Organization (WHO), 1992, INT STAT CLASS DIS R, P456
NR 20
TC 1
Z9 1
U1 1
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD JAN-MAR
PY 2010
VL 25
IS 1-2
BP 16
EP 20
DI 10.3109/08820538.2010.481508
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 801YP
UT WOS:000293476800004
PM 20507192
DA 2022-11-30
ER

PT J
AU Ichiyama, Y
   Sawada, T
   Ito, Y
   Kakinoki, M
   Ohji, M
AF Ichiyama, Yusuke
   Sawada, Tomoko
   Ito, Yuka
   Kakinoki, Masashi
   Ohji, Masahito
TI OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY REVEALS BLOOD FLOW IN CHOROIDAL
   NEOVASCULAR MEMBRANE IN REMISSION PHASE OF NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography
   angiography; remission; inactive; blood flow; choroidal neovascular
   membrane
ID VERTEPORFIN PHOTODYNAMIC THERAPY; GEOGRAPHIC ATROPHY; BENZOPORPHYRIN;
   RANIBIZUMAB
AB Purpose: The aim of the study was to investigate blood flow in choroidal neovascular membrane in remission phase of neovascular age-related macular degeneration using optical coherence tomography (OCT) angiography.
   Methods: OCT angiography was obtained in eyes with remission phase of neovascular age-related macular degeneration after treatments, defined as no exudative change (such as macular edema, subretinal fluid, and subretinal hemorrhage) observed in eyes without any treatment for neovascular age-related macular degeneration within the previous 6 months. Irregular blood flows shown in the segmentation of outer retina detected by OCT angiography were considered as blood flows in choroidal neovascular membrane. The vascular area and vessel density were obtained from OCT angiography images.
   Results: Twenty eyes of 20 patients were included in this analysis. The blood flows in choroidal neovascular membrane were observed in all eyes (100%) using OCT angiography. The mean vascular area was 3.81 +/- 3.41 mm2 and the mean vessel density of lesion was 28.9 +/- 8.2%. The vessel density was significantly correlated with best-corrected visual acuity and duration of remission (best-corrected visual acuity: P = 0.008, r = -0.576; duration of remission: P = 0.017, r = -0.525, respectively).
   Conclusion: Optical coherence tomography angiography revealed that blood flows in choroidal neovascular membrane remained in eyes with clinically inactive neovascular agerelated macular degeneration.
C1 [Ichiyama, Yusuke; Sawada, Tomoko; Ito, Yuka; Kakinoki, Masashi; Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga 5202192, Japan.
C3 Shiga University of Medical Science
RP Ichiyama, Y (通讯作者)，Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga 5202192, Japan.
EM ichiyama@belle.shiga-med.ac.jp
RI Ichiyama, Yusuke/AAN-5983-2021
FU Shiga University of Medical Science
FX Supported in part by a grant from the Shiga University of Medical
   Science.
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Liang MC, 2016, RETINA, P1
   Lopez-Saez MP, 1998, ANN ALLERG ASTHMA IM, V81, P428, DOI 10.1016/S1081-1206(10)63140-7
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Mariampillai A, 2008, OPT LETT, V33, P1530, DOI 10.1364/OL.33.001530
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Miura M, 2011, INVEST OPHTH VIS SCI, V52, P2689, DOI 10.1167/iovs.10-6282
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Querques G, 2012, BRIT J OPHTHALMOL, V96, P1479, DOI 10.1136/bjophthalmol-2012-302191
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
NR 31
TC 18
Z9 18
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2017
VL 37
IS 4
BP 724
EP 730
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ES2SK
UT WOS:000399378000019
PM 28248824
DA 2022-11-30
ER

PT J
AU Park, YG
   Park, YS
   Kim, IB
AF Park, Young Gun
   Park, Yong Soo
   Kim, In-Beom
TI Complement System and Potential Therapeutics in Age-Related Macular
   Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; complement cascade; clinical trial;
   therapeutics
ID RETINAL-PIGMENT EPITHELIUM; INDUCED CHOROIDAL NEOVASCULARIZATION;
   SIMPLIFIED SEVERITY SCALE; FACTOR-H; BRUCHS MEMBRANE; FACTOR-B;
   ALTERNATIVE PATHWAY; GEOGRAPHIC ATROPHY; CYNOMOLGUS MONKEYS; DRUSEN
   FORMATION
AB Age-related macular degeneration (AMD) is a complex multifactorial disease characterized in its late form by neovascularization (wet type) or geographic atrophy of the retinal pigment epithelium cell layer (dry type). The complement system is an intrinsic component of innate immunity. There has been growing evidence that the complement system plays an integral role in maintaining immune surveillance and homeostasis in AMD. Based on the association between the genotypes of complement variants and AMD occurrence and the presence of complement in drusen from AMD patients, the complement system has become a therapeutic target for AMD. However, the mechanism of complement disease propagation in AMD has not been fully understood. This concise review focuses on an overall understanding of the role of the complement system in AMD and its ongoing clinical trials. It provides further insights into a strategy for the treatment of AMD targeting the complement system.
C1 [Park, Young Gun] Catholic Univ Korea, Coll Med, Dept Ophthalmol & Visual Sci, Seoul St Marys Hosp, Seoul 06591, South Korea.
   [Park, Yong Soo; Kim, In-Beom] Catholic Univ Korea, Coll Med, Dept Anat, Seoul 06591, South Korea.
   [Kim, In-Beom] Catholic Univ Korea, Coll Med, Catholic Neurosci Inst, Seoul 06591, South Korea.
   [Kim, In-Beom] Catholic Univ Korea, Coll Med, Catholic Inst Appl Anat, Seoul 06591, South Korea.
C3 Catholic University of Korea; Seoul St. Mary's Hospital; Catholic
   University of Korea; Catholic University of Korea; Catholic University
   of Korea
RP Kim, IB (通讯作者)，Catholic Univ Korea, Coll Med, Dept Anat, Seoul 06591, South Korea.; Kim, IB (通讯作者)，Catholic Univ Korea, Coll Med, Catholic Neurosci Inst, Seoul 06591, South Korea.; Kim, IB (通讯作者)，Catholic Univ Korea, Coll Med, Catholic Inst Appl Anat, Seoul 06591, South Korea.
EM cuteyg2000@catholic.ac.kr; yongsoopark88@gmail.com;
   ibkimmd@catholic.ac.kr
OI Kim, In-Beom/0000-0002-1932-8407
FU Basic Science Research Program through the National Research Foundation
   (NRF) of Korea - Ministry of Education, Science, and Technology
   [2017R1A2B2005309, 2019R1G1A1100084]
FX This research was funded by the Basic Science Research Program through
   the National Research Foundation (NRF) of Korea funded by the Ministry
   of Education, Science, and Technology (grant number 2017R1A2B2005309
   (I.-B.K.); 2019R1G1A1100084 (Y.G.P.)).
CR Alexion, 2017, COMPL INH EC TREATM
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Apellis Pharmaceuticals Inc, 2018, FILLY PHAS 2 STUD AP
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Chuo JY, 2007, OPHTHAL EPIDEMIOL, V14, P367, DOI 10.1080/09286580701421684
   Clark SJ, 2015, J CLIN MED, V4, P18, DOI 10.3390/jcm4010018
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2015, EUR J PHARM BIOPHARM, V95, P194, DOI 10.1016/j.ejpb.2015.04.039
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hong N, 2016, ACTA OPHTHALMOL, V94, P334, DOI 10.1111/aos.13049
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   ISHIBASHI T, 1987, INVEST OPHTH VIS SCI, V28, P1116
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kaushal S., 2009, INVESTIG OPHTHALMOL, V50, P1
   Kim SJ, 2013, BRIT J OPHTHALMOL, V97, P367, DOI 10.1136/bjophthalmol-2012-302307
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2020, OPHTHALMOLOGY, V127, pS122, DOI 10.1016/j.ophtha.2020.01.033
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Le KN, 2015, J PHARMACOL EXP THER, V355, P288, DOI 10.1124/jpet.115.227223
   Lenis TL, 2017, P NATL ACAD SCI USA, V114, P3987, DOI 10.1073/pnas.1620299114
   Leung E, 2013, EXPERT REV CLIN PHAR, V6, P565, DOI 10.1586/17512433.2013.829645
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   LOKKI ML, 1991, IMMUNOGENETICS, V34, P242, DOI 10.1007/BF00215259
   Lorthiois E, 2017, J MED CHEM, V60, P5717, DOI 10.1021/acs.jmedchem.7b00425
   Loyet KM, 2014, J PHARMACOL EXP THER, V351, P527, DOI 10.1124/jpet.114.215921
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Maga TK, 2010, HUM MUTAT, V31, pE1445, DOI 10.1002/humu.21256
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mastellos DC, 2018, SEMIN HEMATOL, V55, P167, DOI 10.1053/j.seminhematol.2018.02.002
   Mastellos DC, 2015, EUR J CLIN INVEST, V45, P423, DOI 10.1111/eci.12419
   Maugeri A, 2019, ACTA OPHTHALMOL, V97, pE8, DOI 10.1111/aos.13849
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Miao H, 2012, MOL VIS, V18, P574
   Mitchell P, 2005, ARCH OPHTHALMOL-CHIC, V123, P1598, DOI 10.1001/archopht.123.11.1598
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nakanishi M, 2016, INVEST OPHTH VIS SCI, V57, P2213, DOI 10.1167/iovs.15-17934
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Novartis, 2016, SAF TOL INTR LFG316
   Novartis, 2016, INTR LFG316 PAT AG R
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Ophthotech, 2018, ZIM SUBJ GEOGR ATR S
   Ophthotech, 2018, ZIMURA COMB LUCENTIS
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Ratnapriya R, 2020, HUM MOL GENET, V29, P2022, DOI 10.1093/hmg/ddaa057
   Roche, 2018, STUD INV SAF EFF LAM
   Roche, 2018, STUD INV EFF SAF LAM
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Sacca SC, 2009, MUTAT RES-FUND MOL M, V667, P98, DOI 10.1016/j.mrfmmm.2008.11.002
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schnabolk G, 2015, INVEST OPHTH VIS SCI, V56, P1850, DOI 10.1167/iovs.14-15910
   Scholl HPN, 2005, OPHTHALMOLOGE, V102, P1029, DOI 10.1007/s00347-005-1270-y
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang Q, 2016, INT J OPHTHALMOL-CHI, V9, P298, DOI 10.18240/ijo.2016.02.23
   Wang X, 2013, INT J OPHTHALMOL-CHI, V6, P861, DOI 10.3980/j.issn.2222-3959.2013.06.21
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Wu MX, 2016, OPHTHALMIC RES, V55, P135, DOI 10.1159/000442257
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu QQ, 2015, GENE, V561, P249, DOI 10.1016/j.gene.2015.02.039
   Zhang MX, 2015, GENET MOL RES, V14, P12567, DOI 10.4238/2015.October.16.24
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 111
TC 8
Z9 8
U1 3
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2021
VL 22
IS 13
AR 6851
DI 10.3390/ijms22136851
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA TG1EU
UT WOS:000671155300001
PM 34202223
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Shienbaum, G
   Gupta, OP
   Fecarotta, C
   Patel, AH
   Kaiser, RS
   Regillo, CD
AF Shienbaum, Gary
   Gupta, Omesh P.
   Fecarotta, Christopher
   Patel, Avni H.
   Kaiser, Richard S.
   Regillo, Carl D.
TI Bevacizumab for Neovascular Age-Related Macular Degeneration Using a
   Treat-and-Extend Regimen: Clinical and Economic Impact
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB;
   AVASTIN; CATT
AB PURPOSE: To evaluate the visual outcomes, number of injections, and direct medical cost of a treat-and-extend regimen in managing neovascular age-related macular degeneration with intravitreal bevacizumab.
   DESIGN: Retrospective, interventional, consecutive case series.
   METHODS: Seventy-four eyes of 73 patients with treatment-naive neovascular age-related macular degeneration from a single clinical practice were treated monthly with intravitreal bevacizumab until no intraretinal or subretinal fluid was observed on optical coherence tomography. The treatment intervals then were lengthened sequentially by 2 weeks until signs of exudation recurred and then were reduced accordingly to maintain an exudation-free macula. Main outcomes measured included mean change from baseline visual acuity, proportion of eyes losing fewer than 3 and gaining 3 or more Snellen visual acuity lines at 1 year of follow-up, annual mean number of injections, optical coherence tomography mean central retinal thickness change from baseline, mean maximum period of extension, adverse events, and mean direct annual medical cost.
   RESULTS: The mean follow-up period was 1.41 years. Mean Snellen visual acuity improved from 20/230 at baseline to 20/109 at 12 months (P < .001) and 20/106 at 24 months (P < .001). The mean number of injections over the first year was 7.94. The mean optical coherence tomography central retinal thickness decreased from 316 to 239 pm at 12 months (P < .001). The mean direct medical cost over the first year was $3493.85.
   CONCLUSIONS: Eyes with neovascular age-related macular degeneration experienced significant visual improvements on average when managed with intravitreal bevacizumab using a treat-and-extend regimen with fewer patient visits and injections along with lower costs compared with a fixed, monthly dosing regimen. (Am J Ophthalmol 2012;153:468-473. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Shienbaum, Gary; Gupta, Omesh P.; Fecarotta, Christopher; Patel, Avni H.; Kaiser, Richard S.; Regillo, Carl D.] Thomas Jefferson Univ, Wills Eye Hosp, Retina Serv, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Gupta, OP (通讯作者)，Thomas Jefferson Univ, Wills Eye Hosp, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM ogupta@midatlanticretina.com
FU Genentech; Novartis; QLT; Regeneron; NeoVista; Alcon; GlaxoSmithKline
FX THE AUTHORS INDICATE NO FINANCIAL SUPPORT. DR REGILLO IS A CONSULTANT TO
   GENENTECH, INC., NOVARTIS Pharmaceuticals Corp, GlaxoSmithKline, and
   Alcon Laboratories, Inc, and has received research grants from
   Genentech, Novartis, QLT, Regeneron, NeoVista, Alcon, and
   GlaxoSmithKline. Dr Kaiser is a consultant to Ophthotec Corp., NeoVista,
   Inc, and Alimera Sciences, Inc, and has received research grants from
   Genentech, Novartis, QLT, Regeneron, NeoVista, Alcon, and
   GlaxoSmithKline. Involved in Design and conduct of study (OS., O.P.G.,
   C.F., A.H.P., R.S.K., C.D.R.); Collection (G.S., O.P.G., C.F., AMP.),
   management (OS., O.P.G.), analysis (O.P.G.), and interpretation (OS.,
   O.P.G., C.D.R.) of data; and Preparation (OS., O.P.G., C.D.R.), review
   (G.S., O.P.G., R.S.K., C.D.R.), and approval (OS., O.P.G., R.S.K.,
   C.D.R.) of manuscript. Institutional review board approval from the
   Wills Eye Institute was obtained for this retrospective study. Informed
   consent was not required for this deidentified review.
CR Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Arevalo JF, 2010, OPHTHALMOLOGY, V117, P1974, DOI 10.1016/j.ophtha.2010.01.056
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mantel I, 2008, OPHTHALMOLOGICA, V222, P321, DOI 10.1159/000144075
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Sears J, 2011, BRIT J OPHTHALMOL, V95, P761, DOI 10.1136/bjophthalmol-2011-300406
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
NR 24
TC 67
Z9 67
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2012
VL 153
IS 3
BP 468
EP 473
DI 10.1016/j.ajo.2011.08.011
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 907CB
UT WOS:000301394300011
PM 21996309
DA 2022-11-30
ER

PT J
AU Yenice, E
   Sengun, A
   Demirok, GS
   Turacli, E
AF Yenice, E.
   Sengun, A.
   Demirok, G. Soyugelen
   Turacli, E.
TI Ganglion cell complex thickness in nonexudative age-related macular
   degeneration
SO EYE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; LAYER THICKNESS; MORPHOMETRIC-ANALYSIS;
   RETINITIS-PIGMENTOSA; PRESERVATION; POPULATION; GLAUCOMA; NEURONS
AB Purpose To evaluate ganglion cell complex GCC) thickness with spectral domain optical coherence tomography (SD-OCT) in eyes with nonexudative age-related macular degeneration (NEAMD).
   Methods Forty-seven eyes of 28 patients with nonexudative age-related macular degeneration (NEAMD) and 54 eyes of 28 age-matched healthy subjects were enrolled. Each subject underwent a complete ophthalmic examination before SD-OCT were obtained. Macular scans were taken with software version 6.0 of the ganglion cell analysis (GCA) algorithm. GCC thickness was evaluated automatically as the average, minimum, temporal superior, superior, nasal superior, nasal inferior, inferior, and temporal-inferior segments by SD-OCT and parameters were compared between groups.
   Results The mean age was 68.7+/-8.73 years in patient group, and 61.51+/-5.66 years in control group. There were no significant differences in mean age, gender distribution, intraocular pressure, and sferic equivalent at imaging between the groups (P>0.05). The mean (+/-SD) GCC thicknesses were as follows; average 71.53+/-16.53 mu m, minumum 62.36+/-21.51 mu m, temporal superior 72.23+/-14.60 mu m, superior 72.76+/-20.40 mu m, nasal superior 72.31+/-20.13 mu m, nasal inferior 69.74+/-20.51 mu m, inferior 69.38+/-19.03 mu m, and temporal-inferior 73.12+/-15.44 mu m in patient group. Corresponding values in control group were 81.46+/-4.90 mu m, 78.66+/-6.00 mu m, 81.51+/-4.66 mu m, 82.94+/-5.14 mu m, 81.79+/-5.86 mu m, 80.94+/-6.18 mu m, 80.14+/-6.30 mu m, and 81.75+/-5.26 mu m, respectively. There were significant differences between two groups in each segments (Mann-Whitney U-test, P<0.05).
   Conclusion The average GCC thickness values (in all segments) of NEAMD patients were lower than control group. NEAMD, which is considered as a disease of outer layers of retina, may be accompanied with a decrease of ganglion cell thickness, so inner layers of retina may be affected.
C1 [Yenice, E.; Sengun, A.; Demirok, G. Soyugelen; Turacli, E.] Ufuk Univ, Dr Ridvan Ege Hosp, Fac Med, Ankara, Turkey.
C3 Ufuk University
RP Yenice, E (通讯作者)，Konutkent 2 Site B6 Block 20-1, Ankara, Turkey.
EM esay_kiran@hotmail.com
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brucker Alexander J, 2009, Retina, V29, pS2, DOI 10.1097/IAE.0b013e3181ad255f
   Chauhan DS, 1999, INVEST OPHTH VIS SCI, V40, P2332
   DeBuc DC, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3268773
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Garas A, 2013, J GLAUCOMA, V22, P195, DOI 10.1097/IJG.0b013e31824083e6
   Garas A, 2010, OPHTHALMOLOGY, V117, P738, DOI 10.1016/j.ophtha.2009.08.039
   Harman A, 2000, ANAT REC, V260, P124
   Heckenlively J. R., 1988, RETINITIS PIGMENTOSA
   Ishikawa H, 2005, INVEST OPHTH VIS SCI, V46, P2012, DOI 10.1167/iovs.04-0335
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Koh VT, 2012, INVEST OPHTH VIS SCI, V53, P5853, DOI 10.1167/iovs.12-10414
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Meyer-Rusenberg B, 2007, GRAEF ARCH CLIN EXP, V245, P1009, DOI 10.1007/s00417-006-0489-x
   Mwanza JC, 2011, INVEST OPHTH VIS SCI, V52, P8323, DOI 10.1167/iovs.11-7962
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   Sato S, 2013, INVEST OPHTH VIS SCI, V54, P3046, DOI 10.1167/iovs.12-11173
   Seong M, 2009, INVEST OPHTH VIS SCI, V51, P1446
   STONE JL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1634, DOI 10.1001/archopht.1992.01080230134038
   Tan O, 2009, OPHTHALMOLOGY, V116, P2305, DOI 10.1016/j.ophtha.2009.05.025
   Wang M, 2009, ARCH OPHTHALMOL-CHIC, V127, P875, DOI 10.1001/archophthalmol.2009.145
   Yang K, 2014, RETINA-J RET VIT DIS, V34, P1539, DOI 10.1097/IAE.0000000000000118
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
NR 24
TC 22
Z9 23
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2015
VL 29
IS 8
BP 1076
EP 1080
DI 10.1038/eye.2015.86
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CO9GF
UT WOS:000359481500012
PM 26021868
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Anantharaman, G
   Sheth, J
   Bhende, M
   Narayanan, R
   Natarajan, S
   Rajendran, A
   Manayath, G
   Sen, P
   Biswas, R
   Banker, A
   Gupta, C
AF Anantharaman, Giridhar
   Sheth, Jay
   Bhende, Muna
   Narayanan, Raja
   Natarajan, Sundaram
   Rajendran, Anand
   Manayath, George
   Sen, Parveen
   Biswas, Rupak
   Banker, Alay
   Gupta, Charu
TI Polypoidal choroidal vasculopathy: Pearls in diagnosis and management
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Abnormal vascular network; indocyanine green angiography; optical
   coherence tomography; photodynamic therapy; polypoidal choroidal
   vasculopathy; thermal laser
ID OPTICAL COHERENCE TOMOGRAPHY; VERTEPORFIN PHOTODYNAMIC THERAPY;
   INDOCYANINE GREEN ANGIOGRAPHY; MACULAR DEGENERATION; INTRAVITREAL
   AFLIBERCEPT; LASER PHOTOCOAGULATION; CLINICAL-FEATURES; JAPANESE
   PATIENTS; RANIBIZUMAB MONOTHERAPY; VASCULAR NETWORK
AB Polypoidal choroidal vasculopathy (PCV) is increasingly recognized as an important cause of exudative maculopathy in Asians as against Wet age-related macular degeneration in Caucasians. A panel of retinal experts methodically evaluated pertinent updated literature on PCV with thorough PubMed/MEDLINE search. Based on this, the panel agreed upon and proposed the current consensus recommendations in the diagnosis (clinical and imaging), management and follow-up schedule of PCV. Diagnosis of PCV should be based on the gold standard indocyanine green angiography which demonstrates early nodular hyperfluorescence signifying the polyp with additional features such as abnormal vascular network (AVN). Optical coherence tomography is an excellent adjuvant for diagnosing PCV, monitoring disease activity, and decision-making regarding the treatment. Current treatment modalities for PCV include photodynamic therapy, anti-vascular endothelial growth factor agents, and thermal laser. Choice of specific treatment modality and prognosis depends on multiple factors such as the location and size of PCV lesion, presence or absence of polyp with residual AVN, amount of submacular hemorrhage, presence or absence of leakage on fundus fluorescein angiography, visual acuity, and so on. Current recommendations would be invaluable for the treating physician in diagnosing PCV and in formulating the best possible individualized treatment strategy for optimal outcomes in PCV management.
C1 [Anantharaman, Giridhar; Sheth, Jay] Giridhar Eye Inst, Dept Vitreoretina, Kochi, Kerala, India.
   [Sheth, Jay; Sen, Parveen] Med Res Fdn, Sri Bhagwan Mahavir Vitreoretinal Serv, Dept Vitreoretinal Serv, Madras, Tamil Nadu, India.
   [Narayanan, Raja] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreo Retinal Dis, Hyderabad, Telangana, India.
   [Natarajan, Sundaram] Aditya Jyot Eye Hosp Pvt Ltd, Dept Vitreoretina, Bombay, Maharashtra, India.
   [Rajendran, Anand] Aravind Eye Hosp, Postgrad Inst Ophthalmol, Retina Vitreous Serv, Madurai, Tamil Nadu, India.
   [Manayath, George] Aravind Eye Hosp, Dept Retina & Ocular Oncol, Coimbatore, Tamil Nadu, India.
   [Biswas, Rupak] BB Eye Fdn, Dept Vitreoretina, Kolkata, W Bengal, India.
   [Banker, Alay] Bankers Retina Clin & Laser Ctr, Ahmadabad, Gujarat, India.
   [Gupta, Charu] Shroff Eye Ctr, New Delhi, India.
C3 L. V. Prasad Eye Institute; Aditya Jyot Eye Hospital
RP Anantharaman, G (通讯作者)，Giridhar Eye Inst, Ponneth Temple Rd, Kochi 682020, Kerala, India.
EM giri_eye@hotmail.com
RI Sheth, Jay/AAZ-6612-2020; Sen, Parveen/W-4707-2019; Narayanan,
   Raja/AAT-3098-2021
OI Narayanan, Raja/0000-0001-9688-5859; Bhende, Muna/0000-0002-9251-170X;
   Gupta, Charu/0000-0002-8908-4911
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   Ampornpruet Atchara, 2005, Journal of the Medical Association of Thailand, V88, pS51
   Anantharaman G, 2010, INDIAN J OPHTHALMOL, V58, P399, DOI 10.4103/0301-4738.67052
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   Cheung G., 2016, 10 APVRS ANN M BANGK
   Cho Han Joo, 2012, Korean J Ophthalmol, V26, P157, DOI 10.3341/kjo.2012.26.3.157
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Desmettre T, 2000, SURV OPHTHALMOL, V45, P15, DOI 10.1016/S0039-6257(00)00123-5
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Fan NW, 2014, J CHIN MED ASSOC, V77, P101, DOI 10.1016/j.jcma.2013.10.012
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Hara C, 2016, RETINA-J RET VIT DIS, V36, P37, DOI 10.1097/IAE.0000000000000767
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Imai H, 2006, BRIT J OPHTHALMOL, V90, P1524, DOI 10.1136/bjo.2006.092783
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kang SW, 2009, BRIT J OPHTHALMOL, V93, P759, DOI 10.1136/bjo.2008.145862
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Mantel I, 2012, AM J OPHTHALMOL, V153, P910, DOI 10.1016/j.ajo.2011.10.017
   Marcus DM, 2015, EYE, V29, P1427, DOI 10.1038/eye.2015.150
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Moon Da Ru Chi, 2015, Korean J Ophthalmol, V29, P226, DOI 10.3341/kjo.2015.29.4.226
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Ogino T, 2007, JPN J OPHTHALMOL, V51, P210, DOI 10.1007/s10384-007-0436-3
   Oishi A, 2011, EYE, V25, P1020, DOI 10.1038/eye.2011.110
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Rogers AH, 2003, OPHTHALMIC SUR LA IM, V34, P60, DOI 10.3928/1542-8877-20030101-14
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Videkar Chetan, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-212988
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yamaoka S, 2010, OPHTHALMOLOGICA, V224, P147, DOI 10.1159/000236040
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   Yannuzzi LA, 1982, MACULA SOCIETY MEETI
   Yodoi Y, 2007, AM J OPHTHALMOL, V143, P984, DOI 10.1016/j.ajo.2007.01.026
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
NR 82
TC 21
Z9 22
U1 0
U2 2
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUL
PY 2018
VL 66
IS 7
BP 896
EP 908
DI 10.4103/ijo.IJO_1136_17
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GL5IG
UT WOS:000437197400004
PM 29941728
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mathenge, W
   Bastawrous, A
   Peto, T
   Leung, I
   Foster, A
   Kuper, H
AF Mathenge, Wanjiku
   Bastawrous, Andrew
   Peto, Tunde
   Leung, Irene
   Foster, Allen
   Kuper, Hannah
TI Prevalence of Age-Related Macular Degeneration in Nakuru, Kenya: A
   Cross-Sectional Population-Based Study
SO PLOS MEDICINE
LA English
DT Article
ID VISUAL-IMPAIRMENT; RISK-FACTORS; AVOIDABLE BLINDNESS;
   RACIAL-DIFFERENCES; RURAL-POPULATION; 4-YEAR INCIDENCE; RAPID
   ASSESSMENT; MACULOPATHY; CATARACT; INDIA
AB Background: Diseases of the posterior segment of the eye, including age-related macular degeneration (AMD), have recently been recognised as the leading or second leading cause of blindness in several African countries. However, prevalence of AMD alone has not been assessed. We hypothesized that AMD is an important cause of visual impairment among elderly people in Nakuru, Kenya, and therefore sought to assess the prevalence and predictors of AMD in a diverse adult Kenyan population.
   Methods and Findings: In a population-based cross-sectional survey in the Nakuru District of Kenya, 100 clusters of 50 people 50 y of age or older were selected by probability-proportional-to-size sampling between 26 January 2007 and 11 November 2008. Households within clusters were selected through compact segment sampling. All participants underwent a standardised interview and comprehensive eye examination, including dilated slit lamp examination by an ophthalmologist and digital retinal photography. Images were graded for the presence and severity of AMD lesions following a modified version of the International Classification and Grading System for Age-Related Maculopathy. Comparison was made between slit lamp biomicroscopy (SLB) and photographic grading. Of 4,381 participants, fundus photographs were gradable for 3,304 persons (75.4%), and SLB was completed for 4,312 (98%). Early and late AMD prevalence were 11.2% and 1.2%, respectively, among participants graded on images. Prevalence of AMD by SLB was 6.7% and 0.7% for early and late AMD, respectively. SLB underdiagnosed AMD relative to photographic grading by a factor of 1.7. After controlling for age, women had a higher prevalence of early AMD thanmen (odds ratio 1.5; 95% CI, 1.2-1.9). Overall prevalence rose significantly with each decade of age. We estimate that, in Kenya, 283,900 to 362,800 people 50 y and older have early AMD and 25,200 to 50,500 have late AMD, based on population estimates in 2007.
   Conclusions: AMD is an important cause of visual impairment and blindness in Kenya. Greater availability of low vision services and ophthalmologist training in diagnosis and treatment of AMD would be appropriate next steps.
C1 [Mathenge, Wanjiku; Bastawrous, Andrew; Foster, Allen; Kuper, Hannah] Univ London London Sch Hyg & Trop Med, Dept Clin Res, Int Ctr Eye Hlth, London WC1E 7HT, England.
   [Mathenge, Wanjiku] Kigali Hlth Inst, Dept Ophthalmol, Kigali, Rwanda.
   [Mathenge, Wanjiku] Fred Hollows Fdn Eastern Africa, Nairobi, Kenya.
   [Peto, Tunde; Leung, Irene] Moorfields Eye Hosp NHS Fdn Trust, Natl Inst Hlth Res, Biomed Res Ctr, London, England.
   [Peto, Tunde; Leung, Irene] UCL Inst Ophthalmol, London, England.
C3 University of London; London School of Hygiene & Tropical Medicine;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Mathenge, W (通讯作者)，Univ London London Sch Hyg & Trop Med, Dept Clin Res, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.
EM Andrew.bastawrous@lshtm.ac.uk
RI MATHENGE, WANJIKU/W-3993-2019; Peto, Tunde/G-8812-2018
OI Peto, Tunde/0000-0001-6265-0381; Foster, Allen/0000-0003-2368-4436
FU British Council for the Prevention of Blindness (BCPB); Fred Hollows
   Foundation; Medical Research Council and Fight for Sight Fellowship;
   International Glaucoma Association; BCPB; MRC [G1001934] Funding Source:
   UKRI; Medical Research Council [G1001934] Funding Source: researchfish;
   Fight for Sight [1310/11] Funding Source: researchfish
FX This study was supported by funding from: British Council for the
   Prevention of Blindness (BCPB) and the Fred Hollows Foundation (to WM).
   AB is funded by a Medical Research Council and Fight for Sight
   Fellowship and is in receipt of an International Glaucoma Association
   Award Fellowship and funding from BCPB. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bjornsson OM, 2006, ACTA OPHTHALMOL SCAN, V84, P636, DOI 10.1111/j.1600-0420.2006.00696.x
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Dineen B, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-17
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Goatman K, 2003, COLOUR NORMALISATION
   GREGOR Z, 1978, BRIT J OPHTHALMOL, V62, P547, DOI 10.1136/bjo.62.8.547
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Habiyakire C, 2010, OPHTHAL EPIDEMIOL, V17, P90, DOI 10.3109/09286580903453514
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P167
   Kenya National Bureau of Statistics, 2010, KEN 2009 POP HOUS CE
   Kikira Susan, 2007, Community Eye Health, V20, P71
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Kuper H, 2008, PLOS MED, V5, P1716, DOI 10.1371/journal.pmed.0050244
   Leske MC, 2007, OPHTHALMOLOGY, V114, P1058, DOI 10.1016/j.ophtha.2006.08.051
   Leske MC, 2004, OPHTHALMOLOGY, V111, P706, DOI 10.1016/j.ophtha.2003.07.003
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathenge W, 2007, PLOS MED, V4, P1187, DOI 10.1371/journal.pmed.0040217
   Mathenge W, 2007, OPHTHALMOLOGY, V114, P599, DOI 10.1016/j.ophtha.2006.06.057
   Mathenge W, 2012, OPHTHALMOLOGY, V119, P2033, DOI 10.1016/j.ophtha.2012.04.019
   Moser CL, 2002, BRIT J OPHTHALMOL, V86, P257, DOI 10.1136/bjo.86.3.257
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Olson JH, 2011, SEMIN OPHTHALMOL, V26, P131, DOI 10.3109/08820538.2011.577131
   Oye JE, 2007, BRIT J OPHTHALMOL, V91, P1435, DOI 10.1136/bjo.2007.115840
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   PIERAMICI DJ, 1994, ARCH OPHTHALMOL-CHIC, V112, P1043, DOI 10.1001/archopht.1994.01090200049020
   Polack S, 2007, BRIT J OPHTHALMOL, V91, P927, DOI 10.1136/bjo.2006.110973
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosser DA, 2001, BRIT J OPHTHALMOL, V85, P432, DOI 10.1136/bjo.85.4.432
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Turner AG, 1996, INT J EPIDEMIOL, V25, P198, DOI 10.1093/ije/25.1.198
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wolf-Schnurrbusch UEK, 2007, INVEST OPHTH VIS SCI, V48, P3783, DOI 10.1167/iovs.06-1218
   World Health Organization Regional Office for Africa, 2009, VID REP BLINDN DEAFN
   WU LZ, 1987, JPN J OPHTHALMOL, V31, P349
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 48
TC 18
Z9 18
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1277
EI 1549-1676
J9 PLOS MED
JI PLos Med.
PD FEB
PY 2013
VL 10
IS 2
AR e1001393
DI 10.1371/journal.pmed.1001393
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 099BC
UT WOS:000315592800010
PM 23431274
OA gold, Green Published, Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Neely, DC
   Bray, KJ
   Huisingh, CE
   Clark, ME
   McGwin, G
   Owsley, C
AF Neely, David C.
   Bray, Kevin J.
   Huisingh, Carrie E.
   Clark, Mark E.
   McGwin, Gerald, Jr.
   Owsley, Cynthia
TI Prevalence of Undiagnosed Age-Related Macular Degeneration in Primary
   Eye Care
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID CORONARY-HEART-DISEASE; QUALITY-OF-LIFE; HEALTH; MACULOPATHY; WOMEN
AB IMPORTANCE Age-related macular degeneration (AMD) is the leading cause of irreversible vision impairment in older adults in the United States, yet little is known about whether AMD is appropriately diagnosed in primary eye care.
   OBJECTIVES To examine the prevalence of eyes with AMD in patients seen in primary eye care clinics who purportedly have normal macular health per their medical record and the association of AMD with patient and physician characteristics.
   DESIGN, SETTING, AND PARTICIPANTS In this cross-sectional study of primary eye care practices in Birmingham, Alabama, 644 persons 60 years or older with normal macular health per medical record based on their most recent dilated comprehensive eye examination by a primary eye care ophthalmologist or optometrist were enrolled from May 1, 2009, through December 31, 2011. Data analysis was performed from May 1, 2016, through December 20, 2016.
   MAIN OUTCOMES AND MEASURES Presence of AMD as defined by the Clinical Age-Related Maculopathy Staging system based on color fundus photography and a masked grader. Types of AMD-associated lesions were noted. Patient health and physician characteristics were collected.
   RESULTS The sample consisted of 1288 eyes from 644 participants (231 [35.9%] male and 413 [64.1%] female; mean [SD] age, 69.4 [6.1] years; 611 white [94.9%]) seen by 31 primary eye care ophthalmologists or optometrists. A total of 968 eyes (75.2%) had no AMD, in agreement with their medical record; 320 (24.8%) had AMD despite no diagnosis of AMD in the medical record. Among eyes with undiagnosed AMD, 32 (10.0%) had hyperpigmentation, 43 (13.4%) had hypopigmentation, 249 (77.8%) had small drusen, 250 (78.1%) had intermediate drusen, and 96 (30.0%) had large drusen. Undiagnosed AMD was associated with older patient age (odds ratio [OR], 1.06; 95% CI, 1.04-1.09; P < .001), male sex (age-adjusted OR, 1.39; 95% CI, 1.02-1.91; P = .04), and less than a high school education (age-adjusted OR, 2.40; 95% CI, 1.03-5.62; P = .04). Prevalence of undiagnosed AMD was not different for ophthalmologists and optometrists (age adjusted OR, 0.99; 95% CI, 0.71-1.36; P = .94).
   CONCLUSIONS AND RELEVANCE Approximately 25.0% of eyes deemed to be normal based on dilated eye examination by primary eye care physicians had macular characteristics that indicated AMD revealed by fundus photography and trained raters. A total of 30.0% of eyes with undiagnosed AMD had AMD with large drusen that would have been treatable with nutritional supplements had it been diagnosed. Improved AMD detection strategies may be needed in primary eye care as more effective treatment strategies for early AMD become available in the coming years.
C1 [Neely, David C.; Bray, Kevin J.; Huisingh, Carrie E.; Clark, Mark E.; McGwin, Gerald, Jr.; Owsley, Cynthia] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Neely, DC (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, 700 S 18th St,Ste 601, Birmingham, AL 35294 USA.
EM dcneely@uabmc.edu
OI Huisingh, Carrie/0000-0002-7010-2024
FU National Institute on Aging, National Institutes of Health [R01AG04212];
   Dorsett Davis Discovery Fund; Alfreda J. Schueler Trust; EyeSight
   Foundation of Alabama; Research to Prevent Blindness; National Eye
   Institute, National Institutes of Health [P30EY003039]
FX This research was funded by grant R01AG04212 from the National Institute
   on Aging, National Institutes of Health (Dr Owsley); the Dorsett Davis
   Discovery Fund (Dr Owsley); the Alfreda J. Schueler Trust (Dr Owsley),
   the EyeSight Foundation of Alabama (Dr Owsley); Research to Prevent
   Blindness (Dr Owsley); and grant P30EY003039 from the National Eye
   Institute, National Institutes of Health (Dr Owsley).
CR Adler NE, 2002, HEALTH AFFAIR, V21, P60, DOI 10.1377/hlthaff.21.2.60
   Ancochea J, 2013, ARCH BRONCONEUMOL, V49, P223, DOI 10.1016/j.arbres.2012.11.010
   CAMPBELL MK, 1993, J GERONTOL, V48, pS230, DOI 10.1093/geronj/48.4.S230
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chapman KR, 2001, CHEST, V119, P1691, DOI 10.1378/chest.119.6.1691
   Cimarolli VR, 2016, CLIN OPHTHALMOL, V10, P55, DOI 10.2147/OPTH.S80489
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mikhail GW, 2005, BMJ-BRIT MED J, V331, P467, DOI 10.1136/bmj.331.7515.467
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Owsley C, 2008, J VISUAL IMPAIR BLIN, V102, P621, DOI 10.1177/0145482X0810201007
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Owsley C, 2011, VISION RES, V51, P1610, DOI 10.1016/j.visres.2010.10.020
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Wenger NK, 2012, CIRCULATION, V126, P604, DOI 10.1161/CIRCULATIONAHA.111.086892
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
NR 21
TC 32
Z9 32
U1 0
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUN
PY 2017
VL 135
IS 6
BP 570
EP 575
DI 10.1001/jamaophthalmol.2017.0830
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX8AT
UT WOS:000403471700015
PM 28448669
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Hollyfield, JG
   Bonilha, VL
   Rayborn, ME
   Yang, XP
   Shadrach, KG
   Lu, L
   Ufret, RL
   Salomon, RG
   Perez, VL
AF Hollyfield, Joe G.
   Bonilha, Vera L.
   Rayborn, Mary E.
   Yang, Xiaoping
   Shadrach, Karen G.
   Lu, Liang
   Ufret, Rafael L.
   Salomon, Robert G.
   Perez, Victor L.
TI Oxidative damage-induced inflammation initiates age-related macular
   degeneration
SO NATURE MEDICINE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; CIGARETTE-SMOKING; BRUCHS MEMBRANE; DRUSEN;
   LIPIDS; MODEL; RISK; MICE; PHOSPHOLIPIDS; PATHOGENESIS
AB Oxidative damage and inflammation are postulated to be involved in age-related macular degeneration (AMD). However, the molecular signal(s) linking oxidation to inflammation in this late-onset disease is unknown. Here we describe AMD-like lesions in mice after immunization with mouse serum albumin adducted with carboxyethylpyrrole, a unique oxidation fragment of docosahexaenoic acid that has previously been found adducting proteins in drusen from AMD donor eye tissues(1) and in plasma samples(2) from individuals with AMD. Immunized mice develop antibodies to this hapten, fix complement component-3 in Bruch's membrane, accumulate drusen below the retinal pigment epithelium during aging, and develop lesions in the retinal pigment epithelium mimicking geographic atrophy, the blinding end-stage condition characteristic of the dry form of AMD. We hypothesize that these mice are sensitized to the generation of carboxyethylpyrrole adducts in the outer retina, where docosahexaenoic acid is abundant and conditions for oxidative damage are permissive. This new model provides a platform for dissecting the molecular pathology of oxidative damage in the outer retina and the immune response contributing to AMD.
C1 [Hollyfield, Joe G.; Bonilha, Vera L.; Rayborn, Mary E.; Yang, Xiaoping; Shadrach, Karen G.; Ufret, Rafael L.; Perez, Victor L.] Cleveland Clin, Lerner Coll Med, Dept Ophthalmol, Cleveland, OH 44195 USA.
   [Lu, Liang; Salomon, Robert G.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; Cleveland Clinic Foundation; Case
   Western Reserve University
RP Hollyfield, JG (通讯作者)，Cleveland Clin, Lerner Coll Med, Dept Ophthalmol, Cleveland, OH 44195 USA.
EM hollyfj@ccf.org; vperez4@med.miami.edu
RI Perez, Victor L./AAY-8633-2020; Mohammed, Imran/J-8271-2012; Salomon,
   Robert G/C-3463-2008; Bonilha, Vera/AAS-8566-2020
OI Mohammed, Imran/0000-0002-8412-0768; Bonilha, Vera/0000-0002-6166-5124;
   Salomon, Robert/0000-0001-9456-3557
FU NEI NIH HHS [K08EY014912, R01 EY014240, K08 EY014912, R01EY014240,
   R56EY10240, R56 EY014240-06, R56 EY014240, R21 EY017153, R24EY015638,
   R24 EY015638, R24 EY015638-05, R01 EY014240-06, R21EY017153] Funding
   Source: Medline; NIGMS NIH HHS [R01 GM021249, R01GM21249] Funding
   Source: Medline; NATIONAL EYE INSTITUTE [R21EY017153, R01EY014240,
   K08EY014912, R56EY014240, R24EY015638] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021249] Funding
   Source: NIH RePORTER
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ANDERSON RE, 1970, EXP EYE RES, V10, P339, DOI 10.1016/S0014-4835(70)80046-X
   ANDERSON RE, 1976, EXP EYE RES, V23, P149, DOI 10.1016/0014-4835(76)90198-6
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOTTSCH JD, 1993, ARCH OPHTHALMOL-CHIC, V111, P126, DOI 10.1001/archopht.1993.01090010130039
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G
   PEAKMAN M, 1989, J CLIN PATHOL, V42, P1018, DOI 10.1136/jcp.42.10.1018
   PERCOPO CM, 1990, J IMMUNOL, V145, P4101
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 29
TC 536
Z9 586
U1 2
U2 73
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD FEB
PY 2008
VL 14
IS 2
BP 194
EP 198
DI 10.1038/nm1709
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 259NT
UT WOS:000252946700029
PM 18223656
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Feng, LW
   Nie, KL
   Jiang, H
   Fan, W
AF Feng, Liwen
   Nie, Kailai
   Jiang, Hui
   Fan, Wei
TI Effects of lutein supplementation in age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID PIGMENT OPTICAL-DENSITY; VISUAL FUNCTION; COGNITIVE FUNCTION; ZEAXANTHIN
   LEVELS; RETINAL FUNCTION; PROTECTIVE ROLE; DOUBLE-BLIND; CAROTENOIDS;
   SERUM; EYES
AB The purpose of this meta-analysis was to evaluate the effects of lutein supplementation on macular pigment optical density (MPOD) in randomized controlled trials involving patients with age-related macular degeneration (AMD). A comprehensive search of the literature was performed in PubMed, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, and Wan Fang database through December 2018. Nine randomized controlled trials involving 920 eyes (855 with AMD) were included. Meta-analysis suggested that lutein supplementation (10 or 20 mg per day) was associated with an increase in MPOD (mean difference (MD) 0.07; 95% confidence interval (CI) 0.03 to 0.10), visual acuity (MD 0.28; 95%CI 0.06 to 0.50) and contrast sensitivity (MD 0.26; 95%CI 0.22 to 0.30). Stratified analyses showed the increase in MPOD to be faster and greater with higher dose and longer treatment. The available evidence suggests that dietary lutein may be beneficial to AMD patients and the higher dose could make MPOD increase in a shorter time.
C1 [Feng, Liwen; Nie, Kailai; Jiang, Hui; Fan, Wei] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu, Sichuan, Peoples R China.
   [Feng, Liwen; Nie, Kailai] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Res Lab Ophthalmol & Vis Sci, Chengdu, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University
RP Fan, W (通讯作者)，Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu, Sichuan, Peoples R China.
EM fanwei55@yahoo.com
OI Feng, liwen/0000-0002-2309-8018
FU National Natural Science Foundation of China [81670869]
FX This study was supported by National Natural Science Foundation of China
   (No. 81670869). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Akuffo KO, 2017, BRIT J OPHTHALMOL, V101, P190, DOI 10.1136/bjophthalmol-2016-308418
   Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   Arslan S, 2019, J AM COLL NUTR, V38, P424, DOI 10.1080/07315724.2018.1538830
   Azar G, 2017, J FR OPHTALMOL, V40, P303, DOI 10.1016/j.jfo.2016.11.009
   Bartlett H, 2010, CLIN EXP OPTOM, V93, P300, DOI 10.1111/j.1444-0938.2010.00499.x
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chae SY, 2018, MOL MED REP, V18, P5182, DOI 10.3892/mmr.2018.9538
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Chung RWS, 2019, FOOD CHEM, V277, P573, DOI 10.1016/j.foodchem.2018.11.023
   Dieguez HH, 2019, FREE RADICAL BIO MED, V131, P72, DOI 10.1016/j.freeradbiomed.2018.11.035
   Eggersdorfer M, 2018, ARCH BIOCHEM BIOPHYS, V652, P18, DOI 10.1016/j.abb.2018.06.001
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Fujimura S, 2016, CLIN OPHTHALMOL, V10, P2149, DOI 10.2147/OPTH.S119251
   Gao RY, 2018, J BINZHOU MED U, V41, P185
   Garcia-Layana A, 2013, NUTRIENTS, V5, P543, DOI 10.3390/nu5020543
   Gopinath B, 2020, CLIN NUTR, V39, P580, DOI 10.1016/j.clnu.2019.03.009
   Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928
   Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Johnson EJ, 2014, NUTR REV, V72, P605, DOI 10.1111/nure.12133
   Kanis MJ, 2008, INVEST OPHTH VIS SCI, V49, P2077, DOI 10.1167/iovs.07-1181
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kirby ML, 2011, BRIT J NUTR, V105, P1036, DOI 10.1017/S0007114510004721
   Koo E, 2014, AM J CLIN NUTR, V100, p336S, DOI 10.3945/ajcn.113.071563
   Korobelnik JF, 2017, JAMA OPHTHALMOL, V135, P1259, DOI 10.1001/jamaophthalmol.2017.3398
   Li BX, 2010, ARCH BIOCHEM BIOPHYS, V504, P56, DOI 10.1016/j.abb.2010.07.024
   Li S, 2018, INT J OPHTHALMOL-CHI, V11, P970, DOI 10.18240/ijo.2018.06.12
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   Madhavan J, 2018, PHARMACOGN MAG, V14, P268, DOI 10.4103/pm.pm_340_17
   Meagher KA, 2013, BRIT J NUTR, V110, P289, DOI 10.1017/S0007114512004837
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   MOHER D, 2015, SYST REV, V4, DOI DOI 10.1186/2046-4053-4-1
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Ozawa Y, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0557-5
   Papudesu C, 2018, OPHTHALMOLOGY, V125, P512, DOI 10.1016/j.ophtha.2017.10.028
   Puell MC, 2013, ACTA OPHTHALMOL, V91, pE298, DOI 10.1111/aos.12067
   Putnam CM, 2017, CLIN EXP OPTOM, V100, P333, DOI 10.1111/cxo.12500
   Ravikrishnan R, 2011, FOOD CHEM TOXICOL, V49, P2841, DOI 10.1016/j.fct.2011.08.011
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Sabour-Pickett S, 2012, MOL NUTR FOOD RES, V56, P270, DOI 10.1002/mnfr.201100219
   Sasamoto Y, 2011, GRAEF ARCH CLIN EXP, V249, P1847, DOI 10.1007/s00417-011-1780-z
   Shao A, 2006, REGUL TOXICOL PHARM, V45, P289, DOI 10.1016/j.yrtph.2006.05.007
   Sharifzadeh M, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.9.096010
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sui CLWRYJ, 2017, INT EYE SCI
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tudosescu Ruxandra, 2018, Rom J Ophthalmol, V62, P42
   Tuzcu M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0524-1
   WALD G, 1945, SCIENCE, V101, P653, DOI 10.1126/science.101.2635.653
   Wang X, 2014, OPHTHALMIC RES, V52, P198, DOI 10.1159/000363327
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xudong GRZJSXH, 2018, BMU J, V41, P240
   Yanai R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196037
   Yonova-Doing E, 2013, EXP EYE RES, V115, P172, DOI 10.1016/j.exer.2013.07.020
   Zareba M, 2016, FREE RADICAL BIO MED, V101, P446, DOI 10.1016/j.freeradbiomed.2016.11.012
   Zwetsloot PP, 2017, ELIFE, V6, DOI 10.7554/eLife.24260
NR 65
TC 21
Z9 21
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 30
PY 2019
VL 14
IS 12
AR e0227048
DI 10.1371/journal.pone.0227048
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA KN8JV
UT WOS:000515092200066
PM 31887124
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lee, SE
   Lim, HB
   Shin, YI
   Ryu, CK
   Lee, WH
   Kim, JY
AF Lee, Seong Eun
   Lim, Hyung Bin
   Shin, Yong Il
   Ryu, Cheon Kuk
   Lee, Woo Hyuk
   Kim, Jung-Yeul
TI Characteristics of the inner retinal layer in the fellow eyes of
   patients with unilateral exudative age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID NERVE-FIBER LAYER; POLYPOIDAL CHOROIDAL VASCULOPATHY; PLEXIFORM LAYER;
   RETICULAR PSEUDODRUSEN; THICKNESS; SEGMENTATION; OCT; PREVALENCE;
   PROTOCOL; DISEASE
AB Objective To investigate the thicknesses of the ganglion cell-inner plexiform layer (GC-IPL) and retinal nerve fiber layer (RNFL) of the fellow eyes of patients with unilateral exudative age-related macular degeneration (AMD). Methods A total of 107 patients with unilateral exudative AMD [34 of typical choroidal neovascularization (tCNV), Group A; 73 of polypoidal choroidal vasculopathy (PCV), Group B] and 73 normal control eyes (Group C) were included. Drusen and subretinal drusenoid deposits were assessed in all participants using fundus photography, autofluorescence, and optical coherence tomography (OCT). The GC-IPL and RNFL thicknesses were measured using Cirrus HD-OCT and compared among groups. Linear regression analyses were used to evaluate the factors associated with GC-IPL thicknesses. Results The average GC-IPL thicknesses of Groups A, B, and C were 77.09 +/- 3.87, 80.10 +/- 6.61, and 80.88 +/- 6.50 mu m, respectively (p = 0.022). Sectoral GC-IPLs and central macular thicknesses (CMTs) were significantly different among groups (all, p <0.05), whereas none of the RNFL parameters differed significantly (all, p >0.05). Multivariate linear regression analyses revealed that age (p <0.001), CMT (p <0.001), and tCNV (p = 0.013) were significantly associated with average GC-IPL thickness, and the rate of reduction of GC-IPL thickness with increasing age in the fellow eyes of tCNV patients was higher than those in the PCV and control groups. Conclusions Unilateral tCNV patients exhibited statistically significant reduction of the GC-IPL thickness in the fellow eyes, compared to values of the fellow eyes of unilateral PCV patients or control patients. RNFL values trended to be lower but did not reach statistical significance.
C1 [Lee, Seong Eun; Lim, Hyung Bin; Shin, Yong Il; Ryu, Cheon Kuk; Lee, Woo Hyuk; Kim, Jung-Yeul] Chungnam Natl Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
   [Shin, Yong Il] Rhees Eye Hosp, Daejeon, South Korea.
C3 Chungnam National University
RP Kim, JY (通讯作者)，Chungnam Natl Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
EM kimjy@cnu.ac.kr
OI Kim, Jung yeul/0000-0003-3679-1310
CR Abdolrahimzadeh S, 2019, EYE, V33, P1290, DOI 10.1038/s41433-019-0405-3
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Baek J, 2019, INVEST OPHTH VIS SCI, V60, P590, DOI 10.1167/iovs.18-24244
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   BLANKS JC, 1974, J COMP NEUROL, V156, P95, DOI 10.1002/cne.901560108
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   CLARKE S, 1994, EUR J NEUROSCI, V6, P725, DOI 10.1111/j.1460-9568.1994.tb00984.x
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Han J, 2015, GRAEF ARCH CLIN EXP, V253, P2293, DOI 10.1007/s00417-015-3150-8
   Hendrickson A, 2015, BRAIN STRUCT FUNCT, V220, P351, DOI 10.1007/s00429-013-0659-7
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006
   Ishikawa H, 2005, INVEST OPHTH VIS SCI, V46, P2012, DOI 10.1167/iovs.04-0335
   Kang SW, 2017, GRAEF ARCH CLIN EXP, V255, P281, DOI 10.1007/s00417-016-3452-5
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee B, 2018, INVEST OPHTH VIS SCI, V59, P5246, DOI 10.1167/iovs.17-23600
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee HJ, 2015, AM J OPHTHALMOL, V160, P283, DOI 10.1016/j.ajo.2015.05.015
   Lee WH, 2020, ACTA OPHTHALMOL, V98, pE479, DOI 10.1111/aos.14291
   Leung CKS, 2013, OPHTHALMOLOGY, V120, P2485, DOI 10.1016/j.ophtha.2013.07.021
   Lim HB, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58465-x
   Lim HB, 2019, JAMA OPHTHALMOL, V137, P1125, DOI 10.1001/jamaophthalmol.2019.2537
   Lim HB, 2019, AM J OPHTHALMOL, V199, P167, DOI 10.1016/j.ajo.2018.11.016
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Meshi A., 2015, WORLD J OPHTHALMOL, V5, P86
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P1478, DOI 10.1097/IAE.0000000000001759
   Pazos M, 2017, OPHTHALMOLOGY, V124, P1218, DOI 10.1016/j.ophtha.2017.03.044
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Ramkumar HL, 2018, RETINA-J RET VIT DIS, V38, P2159, DOI 10.1097/IAE.0000000000001867
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rimayanti U, 2014, GRAEF ARCH CLIN EXP, V252, P563, DOI 10.1007/s00417-013-2496-z
   Sari ES, 2015, J NEURO-OPHTHALMOL, V35, P117, DOI 10.1097/WNO.0000000000000203
   Sato S, 2013, INVEST OPHTH VIS SCI, V54, P3046, DOI 10.1167/iovs.12-11173
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Strettoi E, 2002, J NEUROSCI, V22, P5492
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Xu Q, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0842-y
   Yuda K, 2010, GRAEF ARCH CLIN EXP, V248, P353, DOI 10.1007/s00417-009-1222-3
   Zhang X, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.1
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 52
TC 1
Z9 1
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 23
PY 2020
VL 15
IS 9
AR e0239555
DI 10.1371/journal.pone.0239555
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NX4NF
UT WOS:000575688700064
PM 32966311
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Querques, G
   Cicinelli, MV
   Rabiolo, A
   de Vitis, L
   Sacconi, R
   Querques, L
   Bandello, F
AF Querques, Giuseppe
   Cicinelli, Maria Vittoria
   Rabiolo, Alessandro
   de Vitis, Luigi
   Sacconi, Riccardo
   Querques, Lea
   Bandello, Francesco
TI Laser photocoagulation as treatment of non-exudative age-related macular
   degeneration: state-of-the-art and future perspectives
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular degeneration; Reticular pseudodrusen; Laser
   photocoagulation; Subthreshold laser
ID NASCENT GEOGRAPHIC ATROPHY; DIODE MICROPULSE LASER; RETICULAR
   PSEUDODRUSEN; CHOROIDAL NEOVASCULARIZATION; PROPHYLACTIC TREATMENT; GRID
   PHOTOCOAGULATION; FUNDUS AUTOFLUORESCENCE; 810-NANOMETER LASER; DRUSEN
   REDUCTION; SOFT DRUSEN
AB To give an updated review of laser approaches to non-exudative age-related macular degeneration (AMD).
   PubMed and Medline database searches were carried out using the terms "laser" and "photocoagulation" associated with "age-related macular degeneration", and latest publications up to May 2017 have been reviewed. Moreover, the design of an ongoing single-center, non-randomized, phase I-II, pilot study, the PASCAL-GA trial, coordinated by F. Bandello, MD and G. Querques, MD from the IRCCS Ospedale San Raffaele, is described.
   Either standard or subthreshold laser strategies have been tried to induce regression of distinct phenotypes of AMD, as reticular pseudodrusen (RPD), nascent geographic atrophy (nGA), and drusen-associated geographic atrophy (DAGA), with heterogeneous results. The aim of the PASCAL-GA protocol is to assess if subthreshold laser can restore the retinal pigment epithelium function in eyes with RPD and nGA offering a protective effect against extensive GA.
   New-generation medical and surgical approaches, including subthreshold laser photocoagulation, may have some success in downstaging AMD.
C1 [Querques, Giuseppe; Cicinelli, Maria Vittoria; Rabiolo, Alessandro; de Vitis, Luigi; Sacconi, Riccardo; Querques, Lea; Bandello, Francesco] Univ Vita Salute San Raffaele, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
   [Sacconi, Riccardo] Univ Verona, Univ Hosp Verona, Dept Ophthalmol, Verona, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   University of Verona; Azienda Ospedaliera Universitaria Integrata Verona
RP Querques, G (通讯作者)，Univ Vita Salute San Raffaele, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
EM giuseppe.querques@hotmail.it
RI Rabiolo, Alessandro/J-2831-2019; cicinelli, maria vittoria/M-1611-2019;
   De Vitis, Luigi/ADV-6918-2022; bandello, francesco/AAH-2405-2019; De
   Vitis, Luigi Antonio/I-1667-2016
OI cicinelli, maria vittoria/0000-0003-2938-0409; bandello,
   francesco/0000-0003-3238-9682; Rabiolo, Alessandro/0000-0002-7772-5929;
   De Vitis, Luigi Antonio/0000-0003-3778-8666; Querques,
   Giuseppe/0000-0002-3292-9581; Sacconi, Riccardo/0000-0003-2891-2012
CR American Academy of Ophthalmology-Retina/ Vitreous Panel, 2015, AG REL MAC DEG, V2015, P12
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Bowling B, 2016, KANSKIS CLIN OPHTHAL
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Cleasby G W, 1979, Mod Probl Ophthalmol, V20, P141
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P348, DOI 10.1136/bjophthalmol-2016-308548
   Dorin Giorgio, 2003, Semin Ophthalmol, V18, P147, DOI 10.1076/soph.18.3.147.29812
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Figueroa M, 2006, AM J OPHTHALMOL, V141, P863, DOI 10.1016/j.ajo.2005.11.049
   Figueroa MS, 1997, RETINA-J RET VIT DIS, V17, P378
   Framme C, 2002, BRIT J OPHTHALMOL, V86, P1099, DOI 10.1136/bjo.86.10.1099
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Frennesson CI, 2009, ACTA OPHTHALMOL, V87, P720, DOI 10.1111/j.1755-3768.2008.01396.x
   Friberg TR, 2009, OPHTHAL SURG LAS IM, V40, P530, DOI 10.3928/15428877-20091030-01
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   Guymer RH, 2001, BRIT J OPHTHALMOL, V85, P40, DOI 10.1136/bjo.85.1.40
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim HD, 2015, INVEST OPHTH VIS SCI, V56, P122, DOI 10.1167/iovs.14-15132
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Ladas ID, 2012, OPHTHALMOLOGICA, V228, P93, DOI 10.1159/000337347
   Lek J, 2017, OPHTHALMOLOGY RETINA, V3, P227
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   Luttrull JK, 2008, EYE, V22, P607, DOI 10.1038/sj.eye.6702725
   Luttrull JK, 2016, RETINA-J RET VIT DIS, V36, P1658, DOI 10.1097/IAE.0000000000001005
   Luttrull JK, 2016, INVEST OPHTH VIS SCI, V57, P265, DOI 10.1167/iovs.15-18163
   Luttrull JK, 2015, RETINA-J RET VIT DIS, V35, P1184, DOI 10.1097/IAE.0000000000000458
   Luttrull JK, 2012, CURR DIABETES REV, V8, P274, DOI 10.2174/157339912800840523
   Luttrull JK, 2005, BRIT J OPHTHALMOL, V89, P74, DOI 10.1136/bjo.2004.051540
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Owens SL, 2006, AM J OPHTHALMOL, V141, P276, DOI 10.1016/j.ajo.2005.08.019
   Owens SL, 2003, EYE, V17, P623, DOI 10.1038/sj.eye.6700442
   PANKRATOV MM, 1990, P SOC PHOTO-OPT INS, V1202, P205, DOI 10.1117/12.17626
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Parodi MB, 2006, OPHTHALMOLOGY, V113, P2237, DOI 10.1016/j.ophtha.2006.05.056
   Prahs P, 2010, GRAEF ARCH CLIN EXP, V248, P651, DOI 10.1007/s00417-009-1208-1
   PRIEBE LA, 1975, AM J OPHTHALMOL, V79, P405, DOI 10.1016/0002-9394(75)90613-3
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4
   Roider J, 2000, BRIT J OPHTHALMOL, V84, P40, DOI 10.1136/bjo.84.1.40
   Sarks SH, 1996, AUST NZ J OPHTHALMOL, V24, P15, DOI 10.1111/j.1442-9071.1996.tb01546.x
   Schuele G, 2005, INVEST OPHTH VIS SCI, V46, P714, DOI 10.1167/iovs.04-0136
   Scorolli L, 2003, CAN J OPHTHALMOL, V38, P489, DOI 10.1016/S0008-4182(03)80028-5
   SIGELMAN J, 1991, OPHTHALMOLOGY, V98, P1379
   Stefansson E, 2001, ACTA OPHTHALMOL SCAN, V79, P435, DOI 10.1034/j.1600-0420.2001.790502.x
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   Sternberg P, 1998, OPHTHALMOLOGY, V105, P11
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Vujosevic S, 2010, RETINA-J RET VIT DIS, V30, P908, DOI 10.1097/IAE.0b013e3181c96986
   Wetzig P C, 1988, Trans Am Ophthalmol Soc, V86, P276
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yadav NK, 2014, INDIAN J OPHTHALMOL, V62, P50, DOI 10.4103/0301-4738.126179
   Zhang JJ, 2012, INVEST OPHTH VIS SCI, V53, P2928, DOI 10.1167/iovs.11-8585
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 68
TC 9
Z9 9
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2018
VL 256
IS 1
BP 1
EP 9
DI 10.1007/s00417-017-3848-x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FR5WO
UT WOS:000419137400001
PM 29177712
DA 2022-11-30
ER

PT J
AU Thakkinstian, A
   Bowe, S
   McEvoy, M
   Smith, W
   Attia, J
AF Thakkinstian, Ammarin
   Bowe, Steve
   McEvoy, Mark
   Smith, Wayne
   Attia, John
TI Association between apolipoprotein E polymorphisms and age-related
   macular degeneration: A HuGE review and meta-analysis
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Review
DE ApoE; apolipoproteins E; epidemiology; genetics; macular degeneration;
   meta-analysis; polymorphism, genetic
ID BEAVER DAM EYE; HARDY-WEINBERG; MOLECULAR ASSOCIATION; SUSCEPTIBILITY
   LOCI; E GENE; DISEQUILIBRIUM COEFFICIENT; MULTIVARIATE APPROACH;
   FAMILIAL AGGREGATION; EPSILON-4 ALLELE; DRUSEN FORMATION
AB A possible association between apolipoprotein E polymorphisms and age-related macular degeneration has been investigated numerous times, with conflicting results. A previous analysis pooling results from four studies (Schmidt et al., Ophthalmic Genet 2002;23:209-23) suggested an association, but those investigators did not document allele frequencies, the magnitude of the association, or the possible genetic mode of action. Thus, the authors searched MEDLINE from 1966 to December 2005 for any English-language studies reporting genetic associations. Data and study quality were assessed in duplicate. Pooling was performed while checking for heterogeneity and publication bias. Frequencies of the E-2 and E-4 alleles in Caucasians were approximately 8% and 15%, respectively. Allele- and genotype-based tests of association indicated a risk effect of up to 20% for E-2 and a protective effect of up to 40% for E-4. E-2 appeared to act in a recessive mode and E-4 in a dominant mode. There appears to be a differential effect of the E-2 and E-4 alleles on the risk of age-related macular degeneration, although the possibility of survivor bias needs to be ruled out more definitively.
C1 Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2300, Australia.
   Mahidol Univ, Ramathibodi Hosp, Clin Epidemiol Unit, Fac Med, Bangkok 10700, Thailand.
C3 University of Newcastle; Mahidol University
RP Attia, J (通讯作者)，Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2300, Australia.
EM John.Attia@newcastle.edu.au
RI Thakkinstian, Ammarin/J-4788-2019; Attia, John R/F-5376-2013
OI Attia, John R/0000-0001-9800-1308; Bowe, Steven/0000-0003-3813-842X;
   McEvoy, Mark/0000-0002-5505-5557
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Attia J, 2003, J CLIN EPIDEMIOL, V56, P297, DOI 10.1016/S0895-4356(03)00011-8
   Ayres KL, 1998, HEREDITY, V80, P769, DOI 10.1046/j.1365-2540.1998.00360.x
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Chen JJ, 1999, BIOMETRICS, V55, P1269, DOI 10.1111/j.0006-341X.1999.01269.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   EGGER M, 2001, SYSTEMATIC REV HLTH
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Gorin MB, 1999, MOL VIS, V5, pU31
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HERNANDEZ JL, 1989, BIOMETRICS, V45, P53, DOI 10.2307/2532034
   Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Jun G, 2005, INVEST OPHTH VIS SCI, V46, P3081, DOI 10.1167/iovs.04-1360
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Kuhrt H, 1997, J BRAIN RES, V38, P223
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Minelli C, 2005, INT J EPIDEMIOL, V34, P1319, DOI 10.1093/ije/dyi169
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NAM JM, 1995, BIOMETRICS, V51, P354, DOI 10.2307/2533343
   *NAT CTR BIOT INF, 2006, OMIM ONL MEND INH MA
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Pang CP, 2002, HUM MUTAT, V19, P189, DOI 10.1002/humu.10053
   RALL SC, 1982, P NATL ACAD SCI-BIOL, V79, P4696, DOI 10.1073/pnas.79.15.4696
   Robman L, 2004, OPHTHAL EPIDEMIOL, V11, P161, DOI 10.1080/09286580490514469
   Santos Arturo, 2002, Ophthalmic Genet, V23, P13, DOI 10.1076/opge.23.1.13.2203
   SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467
   Schaid DJ, 1999, AM J EPIDEMIOL, V149, P706
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spiegelhalter D., 2003, WINBUGS USER MANUAL
   *STAT CORP, 2005, STAT STAT SOFTW REL
   Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184
   Thakkinstian A, 2004, J BONE MINER RES, V19, P419, DOI 10.1359/JBMR.0301265
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Thompson JR, 2005, STAT MED, V24, P2241, DOI 10.1002/sim.2100
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Trikalinos TA, 2006, AM J EPIDEMIOL, V163, P300, DOI 10.1093/aje/kwj046
   van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   VANHOUWELINGEN HC, 1993, STAT MED, V12, P2273, DOI 10.1002/sim.4780122405
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 70
TC 64
Z9 67
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD NOV 1
PY 2006
VL 164
IS 9
BP 813
EP 822
DI 10.1093/aje/kwj279
PG 10
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 097FI
UT WOS:000241432000001
PM 16916985
OA Bronze
DA 2022-11-30
ER

PT J
AU Uyama, M
   Wada, M
   Nagai, Y
   Matsubara, T
   Matsunaga, H
   Fukushima, I
   Takahashi, K
   Matsumura, M
AF Uyama, M
   Wada, M
   Nagai, Y
   Matsubara, T
   Matsunaga, H
   Fukushima, I
   Takahashi, K
   Matsumura, M
TI Polypoidal choroidal vasculopathy: Natural history
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENTS; INDOCYANINE GREEN ANGIOGRAPHY; OPTICAL
   COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; CLINICOPATHOLOGICAL
   CORRELATION; JAPANESE PATIENTS; BLACK-WOMEN
AB PURPOSE: The present study was performed to clarify the long-term natural history of polypoidal choroidal vasculopathy (PCV).
   DESIGN: Prospective, consecutive observational case cries.
   METHODS: Fourteen eyes of 12 consecutive patients with PCV were prospectively followed in our clinic for at least 2 years without any treatment after a first visit to the clinic between February 1996 and November 1998. All patients underwent complete ophthalmologic examination, color fundus photography, and fluorescein and indocyanine green (ICG) angiography at regular intervals. Inclusion criteria were as follows: eyes had serous and/or hemorrhagic pigment epithelium detachment (PED) and retinal detachment in the posterior pole, and ICG angiography revealed a branching vascular network with polypoidal dilations at the terminals of the network. Exclusion criteria were as follows: other diseases such as exudative age-related macular degeneration, high myopia, angioid streaks, and presumed ocular histoplasmosis syndrome, and patients who previously underwent any ocular surgery.
   RESULTS: Patients were followed for mean of 39.9 months (range, 24-54 months). PCV was present in 10 (83%) men and two women and in the elderly (mean age 68.1 years), usually unilateral (83%) with vascular lesions located at the macula (93%). The PCV manifested in two patterns, exudative and hemorrhagic. In the exudative pattern, serous PED and retinal detachment were predominant at the macula. The hemorrhagic pattern was characterized by hemorrhagic PED and subretinal hemorrhage at the macula. ICG angiography revealed polypoidal choroidal neovascularization that was changeable in appearance and repeatedly grew and spontaneously regressed, but the vascular network persisted. In some eyes, a collection of small aneurysmal dilations of vessels resembling a cluster of grapes appeared and all of them had marked bleeding and leakage and worse out, come.
   CONCLUSION: Polypoidal choroidal vasculopathy is a long persistent chronic disease and the patients had a T variable course. Fifty percent of the patients had a favorable course. In the remaining half of the patients, the disorder persisted for a long time with occasional repeated bleeding and leakage, resulting in macular de, generation and visual loss. Eyes with a cluster of grapes-like polypoidal dilatations of the vessels had a high risk for severe visual loss.
C1 Kansai Med Univ, Dept Ophthalmol, Osaka 5708507, Japan.
C3 Kansai Medical University
RP Uyama, M (通讯作者)，Kansai Med Univ, Dept Ophthalmol, 10-15 Fumizono Cho, Osaka 5708507, Japan.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   GASS JDM, 1997, STEREOSCOPIC ATLAS M, V1, P250
   Gomez-Ulla F, 1998, RETINA-J RET VIT DIS, V18, P481, DOI 10.1097/00006982-199805000-00021
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   IMAIZUMI H, 1999, J JPN OPHTHALMOL SOC, V103, P527
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Phillips WB, 1996, OPHTHALMIC SURG LAS, V27, P467
   PULIAFITO CA, 1996, OPTICAL COHERENCE TO
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Schneider U, 1998, BRIT J OPHTHALMOL, V82, P98, DOI 10.1136/bjo.82.1.98
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   SPRAUL CW, 1997, KLIN MONATSBL AUGENH, V16, P105
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   UYAMA M, 1991, Nippon Ganka Gakkai Zasshi, V95, P1145
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 31
TC 303
Z9 331
U1 2
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2002
VL 133
IS 5
BP 639
EP 648
AR PII S0002-9394(02)01404-6
DI 10.1016/S0002-9394(02)01404-6
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 550QL
UT WOS:000175513700007
PM 11992861
DA 2022-11-30
ER

PT J
AU Etter, J
   Fekrat, S
AF Etter, Jonathan
   Fekrat, Sharon
TI Photodynamic therapy and intravitreal triamcinolone for extrafoveal
   choroidal neovascularization in neovascular age-related macular
   degeneration
SO ANNALS OF OPHTHALMOLOGY
LA English
DT Article
AB We report a case of extrafoveal choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration treated with photodynamic therapy (PDT) and intravitreal triamcinolone. Nine months following PDT and intravitreal triamcinolone, no ophthalmoscopic or angiographic evidence of recurrent CNV in the left eye was found. The intraocular pressure (IOP) increased from 10 mmHg on presentation to 20 mmHg at 9 months. No IOP-lowering agents were required. The mild nuclear sclerosis remained unchanged.
C1 [Fekrat, Sharon] Duke Univ, Ctr Eye, DUMC, Albert Eye Res Inst, Durham, NC 27710 USA.
C3 Duke University
RP Fekrat, S (通讯作者)，Duke Univ, Ctr Eye, DUMC, Albert Eye Res Inst, Box 3802, Durham, NC 27710 USA.
EM fekra001@mc.duke.edu
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Frennesson CI, 2004, ACTA OPHTHALMOL SCAN, V82, P651, DOI 10.1111/j.1600-0420.2004.00382.x
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
NR 5
TC 2
Z9 2
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1530-4086
J9 ANN OPHTHALMOL
JI Ann. Ophthalmol.
PD FAL
PY 2006
VL 38
IS 3
BP 239
EP 241
DI 10.1007/s12009-006-0012-3
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V49IX
UT WOS:000203335500012
PM 17416961
DA 2022-11-30
ER

PT J
AU Patel, RD
   Momi, RS
   Hariprasad, SM
AF Patel, Ravi D.
   Momi, Rominder S.
   Hariprasad, Seenu M.
TI Review of Ranibizumab Trials for Neovascular Age-Related Macular
   Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE ANCHOR; MARINA; PIER; PrONTO; SAILOR; SUSTAIN; CATT
ID GROWTH-FACTOR; VERTEPORFIN; FAMILY
AB Ranibizumab, a recombinant, humanized, monoclonal antibody antigen-binding fragment that neutralizes all VEGF-A isoforms, is the first US FDA-approved therapy for neovascular age-related macular degeneration (AMD) to result in improvement in visual acuity. The benefit of intravitreal ranibizumab applies to all angiographic subtypes of neovascular AMD and across all lesion sizes. The two original phase III studies (ANCHOR and MARINA) demonstrated sustained visual acuity (VA) gains over a two-year monthly dosing schedule. Following these trials, several studies looked at ways to decrease the treatment burden while maintaining similar visual gains. These trials included PIER, PrONTO, EXCITE, SUSTAIN, HORIZON, and CATT. Visual acuity data shows that monthly dosing of ranibizumab produces superior vision outcomes compared to a less-frequent, fixed-dosing schedule. Intravitreal ranibizumab is well tolerated and shown to have a very low rate of adverse ocular or systemic side-effects.
C1 [Patel, Ravi D.; Momi, Rominder S.; Hariprasad, Seenu M.] Univ Chicago, Dept Surg, Sect Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
C3 University of Chicago
RP Hariprasad, SM (通讯作者)，Univ Chicago, Dept Surg, Sect Ophthalmol & Visual Sci, 5841 S Maryland Ave,MC2114, Chicago, IL 60637 USA.
EM retina@uchicago.edu
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   ANTOSZYK AN, AM J OPHTHALMOL
   AWH CC, 2008, 26 ANN M AM SOC RET
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   BOLZ M, 2008, 8 EURETINA C 22 25 M
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   *CATT RES GROUP, 2011, N ENGL J MED    0428
   ELDEM B, 2009, COMB M AM SOC RET SP
   FEINER L, 2009, 2009 ASS RES VIS OPH
   FERRONE PJ, 2008, 26 ANN M AM SOC RET
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   HOLZ FG, 2008, AAO SOE JOINT ANN M
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   KIRCHHOF B, 2009, 2009 ASS RES VIS OPH
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   MEYER CH, 2008, INVEST OPHTHALMOL VI, V49
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   REGILLO CD, 2008, 2008 ANN M AM AC OPH
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   SIMADER C, 2009, 2009 ASS RES VIS OPH
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 31
TC 28
Z9 31
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD NOV
PY 2011
VL 26
IS 6
BP 372
EP 379
DI 10.3109/08820538.2011.570845
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 839UC
UT WOS:000296393900003
PM 22044335
DA 2022-11-30
ER

PT J
AU Chen, YH
   Bedell, M
   Zhang, K
AF Chen, Yuhong
   Bedell, Matthew
   Zhang, Kang
TI Age-related Macular Degeneration: Genetic and Environmental Factors of
   Disease
SO MOLECULAR INTERVENTIONS
LA English
DT Review
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; PHOTODYNAMIC THERAPY;
   APOLIPOPROTEIN-E; CHOROIDAL NEOVASCULARIZATION; CIGARETTE-SMOKING;
   RECEPTOR POLYMORPHISMS; FAMILIAL AGGREGATION; LOC387715 GENOTYPES;
   STRONG ASSOCIATION
AB Age-related macular degeneration (AMD) is the most common cause of visual impairment among the elderly in developed countries, and its prevalence is thus increasing as the population ages; however, treatment options remain limited because the etiology and pathogenesis of AMD are incompletely defined. Recently, much progress has been made in gene discovery and mechanistic which clearly indicate that AMD involves the interaction of multiple genetic and environmental factors. The identification of genes that have a substantial impact on the risk for AMD is not only facilitating the diagnosis and screening of populations at risk but is also elucidating key molecular pathways of pathogenesis. Pharmacogenetic studies of treatment responsiveness among patients with the "wet" form of AMD are increasingly proving to be clinically relevant; pharmacogenetic approaches hold great promise for both identifying patients with the best chance for vision recovery as well as tailoring individualized therapies.
C1 [Chen, Yuhong; Bedell, Matthew; Zhang, Kang] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
   [Chen, Yuhong; Bedell, Matthew; Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   [Chen, Yuhong] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol & Visi Sci, Shanghai 200031, Peoples R China.
   [Zhang, Kang] Sichuan Univ, W China Hosp, Dept Ophthalmol, Chengdu 610041, Peoples R China.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   Fudan University; Sichuan University
RP Zhang, K (通讯作者)，Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
EM kang.zhang@gmail.com
RI Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697
FU National Institutes of Health [R01EY14428, RO1EY18660]; Research to
   Prevent Blindness; Ruth and Milton Steinbach Fund; Ronald McDonald House
   Charities; Macular Vision Research Foundation; Burroughs Wellcome Fund
   Clinical Scientist Award in Translational Research; West China Hospital
   of Sichuan University; NATIONAL EYE INSTITUTE [R01EY018660, R01EY014428]
   Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health [Grants
   R01EY14428, RO1EY18660]. We further wish to acknowledge support from
   Research to Prevent Blindness, the Ruth and Milton Steinbach Fund,
   Ronald McDonald House Charities, the Macular Vision Research Foundation,
   Burroughs Wellcome Fund Clinical Scientist Award in Translational
   Research, and West China Hospital of Sichuan University.
CR Aithal GP, 1999, LANCET, V353, P717, DOI 10.1016/S0140-6736(98)04474-2
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Anderson RE, 2002, MOL VIS, V8, P351
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Chowers I, 2008, MOL VIS, V14, P2263
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dhubhghaill SSN, 2010, ADV EXP MED BIOL, V664, P437, DOI 10.1007/978-1-4419-1399-9_50
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   DOSSO AA, 1992, OPHTHALMOLOGICA, V205, P24, DOI 10.1159/000310307
   Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fang AM, 2009, MOL VIS, V15, P2710
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Grizzard WS, 2003, OPHTHAL EPIDEMIOL, V10, P315, DOI 10.1076/opep.10.5.315.17317
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Pangburn MK, 2000, J IMMUNOL, V164, P4742, DOI 10.4049/jimmunol.164.9.4742
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Parmeggiani F, 2009, PHARMACOGENOMICS, V10, P81, DOI 10.2217/14622416.10.1.81
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Ranganathan S, 2000, Pac Symp Biocomput, P155
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tang NP, 2009, ANN EPIDEMIOL, V19, P740, DOI 10.1016/j.annepidem.2009.03.002
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Tocharus J, 2004, DEV GROWTH DIFFER, V46, P257
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 118
TC 86
Z9 91
U1 0
U2 6
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 1534-0384
J9 MOL INTERV
JI Mol. Interv.
PD OCT
PY 2010
VL 10
IS 5
BP 271
EP 281
DI 10.1124/mi.10.5.4
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 674FU
UT WOS:000283722000004
PM 21045241
OA Green Published
DA 2022-11-30
ER

PT J
AU Mittra, RA
   Singerman, LJ
AF Mittra, RA
   Singerman, LJ
TI Recent advances in the management of age-related macular degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization;
   verteporfin therapy; Visudyne; photodynamic therapy
ID NEOVASCULAR MEMBRANES; CHOROIDAL NEOVASCULARIZATION; RADIATION-THERAPY;
   EYE
AB Choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) can cause rapid and severe central vision loss in many older people. Until recently, the only treatment proven beneficial was thermal laser photocoagulation, which was applicable to only a small subset of patients. Furthermore, the thermal laser damaged the retina overlying the CNV, which is especially problematic for lesions involving the foveal center. Photodynamic therapy is a new treatment consisting of intravenous infusion of a drug that is then activated by a low-energy laser, causing damage to CNV. Photodynamic therapy with verteporfin (Visudyne, Novartis AG) has been shown to reduce the risk of moderate and severe vision loss in patients with predominantly classic subfoveal CNV secondary to AMD. With the advent of verteporfin therapy, eye care providers will play an increasingly important role in managing patients with AMD, especially in the early detection and rapid referral of appropriate cases.
C1 Vitreo Retinal Surg, Minneapolis, MN USA.
   Retina Associates Cleveland, Cleveland, OH USA.
C3 Retina Associates of Cleveland, Inc.
RP Singerman, LJ (通讯作者)，Vitreo Retinal Surg, Minneapolis, MN USA.
RI Mittra, Robert/AAC-8249-2021
CR Alexander L J, 1993, J Am Optom Assoc, V64, P822
   *AM AC OPHTH, 1990, 808 AM AC OPHTH
   *AMD ALL INT, 2001, AW RES
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Butler RN, 1997, GERIATRICS, V52, P30
   CAVALLERANO AA, 1997, OPTOMETRIC CLIN PRAC
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Hyman L, 1992, AGE RELATED MACULAR, P1
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   MANTON KG, 1991, J GERONTOL, V46, pS170, DOI 10.1093/geronj/46.3.S170
   Rosenfeld PJ, 2001, INVEST OPHTH VIS SCI, V42, pS512
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Seddon Johanna M., 1997, P447
   SHERR DL, 1997, SEM OPHTHALMOL, V12, P26
   Shiraga F, 1998, Semin Ophthalmol, V13, P31, DOI 10.3109/08820539809066080
   Singerman L, 2000, INVEST OPHTH VIS SCI, V41, pS531
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Stalmans P, 1997, RETINA-J RET VIT DIS, V17, P481
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   TAP and VIP Study Group, 2002, RETINA, V22, P6
   Wang F, 1998, Ophthalmic Epidemiol, V5, P69, DOI 10.1076/opep.5.2.69.1575
NR 38
TC 13
Z9 14
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD APR
PY 2002
VL 79
IS 4
BP 218
EP 224
DI 10.1097/00006324-200204000-00008
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 541CW
UT WOS:000174968500002
PM 11999147
DA 2022-11-30
ER

PT J
AU Blasiak, J
   Szaflik, JP
AF Blasiak, Janusz
   Szaflik, Jacek Pawel
TI DNA damage and repair in age-related macular degeneration
SO FRONTIERS IN BIOSCIENCE-LANDMARK
LA English
DT Article
DE age-related macular degeneration; AMD; mitochondrial DNA; DNA damage;
   oxidative DNA damage; DNA repair; review
ID PIGMENT EPITHELIAL-CELLS; VISUAL-EVOKED POTENTIALS; MITOCHONDRIAL-DNA;
   OXIDATIVE STRESS; SKELETAL-MUSCLE; PROGRESSIVE STAGES; GENE-EXPRESSION;
   HUMAN RETINA; NUCLEAR-DNA; RPE CELLS
AB Oxidative stress may play an important role in the pathogenesis of age-related macular degeneration (AMD). Mitochondria produce reactive oxygen species (ROS), which induce degenerative changes typical for AMD. Mitochondrial DNA (mtDNA) is targeted by ROS and it is considered to be more vulnerable to damage than nuclear DNA (nDNA) due to the impaired DNA repair system, lack of nucleosomal organization and close vicinity of mitochondrial oxidative chain. Some reports suggest the association between mtDNA damage and AMD. However, the metabolism of mtDNA is mainly determined by the expression of nDNA. Therefore, the extent of damage to mtDNA in retinal cells depends on the overall efficacy of nDNA repair, which decreases with age. We showed an association between nDNA damage and repair and AMD. Also well-recognized factors of AMD pathogenesis, age and smoking, may exert their effects through the DNA damage and repair. In conclusion, DNA damage and repair, both in mitochondrial and nuclear genome, may play an important role in the pathogenesis of AMD, and their mutual relationship in this disease needs further study.
C1 [Szaflik, Jacek Pawel] Med Univ Warsaw, Dept Ophthalmol, PL-03709 Warsaw, Poland.
   [Szaflik, Jacek Pawel] Samodzielny Szpital Okulistyczny, PL-03709 Warsaw, Poland.
   [Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90237 Lodz, Poland.
C3 Medical University of Warsaw; University of Lodz
RP Szaflik, JP (通讯作者)，Med Univ Warsaw, Dept Ophthalmol, Sierakowskiego 13, PL-03709 Warsaw, Poland.
EM jps01@eranet.pl
OI Blasiak, Janusz/0000-0001-9539-9584
FU Ministry of Science and Higher Education [N N402 248336]
FX There is no conflict of interest. This work was supported by Ministry of
   Science and Higher Education, grant number N N402 248336. We thank Ms.
   Monika Kicinska for helping us preparing the manuscript.
CR Alexander P, 1967, Symp Soc Exp Biol, V21, P29
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreassen PR, 2006, CARCINOGENESIS, V27, P883, DOI 10.1093/carcin/bgi319
   Andrews RM, 1999, BRIT J OPHTHALMOL, V83, P231, DOI 10.1136/bjo.83.2.231
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Barazzoni R, 2000, J BIOL CHEM, V275, P3343, DOI 10.1074/jbc.275.5.3343
   Barreau E, 1996, INVEST OPHTH VIS SCI, V37, P384
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   BATTELLI D, 1992, BIOCHIM BIOPHYS ACTA, V1117, P33, DOI 10.1016/0304-4165(92)90158-Q
   Baynes JW, 2002, ANN NY ACAD SCI, V959, P360, DOI 10.1111/j.1749-6632.2002.tb02107.x
   Berneburg M, 1999, J BIOL CHEM, V274, P15345, DOI 10.1074/jbc.274.22.15345
   Birch-Machin MA, 1998, J INVEST DERMATOL, V110, P149, DOI 10.1046/j.1523-1747.1998.00099.x
   Blasiak Janusz, 2009, Klin Oczna, V111, P174
   Bogenhagen DF, 2001, PROG NUCLEIC ACID RE, V68, P257
   Bohr VA, 1999, J BIOENERG BIOMEMBR, V31, P391, DOI 10.1023/A:1005484004167
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Brainard GC, 1999, CLIN NEUROPHYSIOL, V110, P379, DOI 10.1016/S1388-2457(98)00022-4
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Brierley EJ, 1997, REV CLIN GERONTOL, V7, P95
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Crompton M, 2004, AGING CELL, V3, P3, DOI 10.1046/j.1474-9728.2003.00073.x
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DOMENA JD, 1988, BIOCHEMISTRY-US, V27, P6742, DOI 10.1021/bi00418a015
   DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042
   Essers J, 2006, CURR OPIN CELL BIOL, V18, P240, DOI 10.1016/j.ceb.2006.03.004
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Garinis GA, 2008, NAT CELL BIOL, V10, P1241, DOI 10.1038/ncb1108-1241
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Godley BF, 2002, EXP EYE RES, V74, P663, DOI 10.1006/exer.2001.1146
   Gross HJ, 1969, J BIOL CHEM, V244, P1552
   Hagelberg E, 2003, TRENDS GENET, V19, P84, DOI 10.1016/S0168-9525(02)00048-3
   Hasegawa Y, 2004, DNA REPAIR, V3, P515, DOI 10.1016/j.dnarep.2004.01.014
   Heuser VD, 2008, CELL BIOL INT, V32, P1223, DOI 10.1016/j.cellbi.2008.07.005
   Howell N, 1999, INT REV CYTOL, V186, P49
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   James AM, 2002, J BIOMED SCI, V9, P475, DOI 10.1159/000064721
   Jarrett SG, 2005, FREE RADICAL BIO MED, V38, P1382, DOI 10.1016/j.freeradbiomed.2005.02.003
   Jarrett SG, 2007, OPHTHALMIC RES, V39, P213, DOI 10.1159/000104683
   Jarrett SG, 2006, FREE RADICAL RES, V40, P1155, DOI 10.1080/10715760600876613
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Kaarniranta K, 2010, ACTA OPHTHALMOL, V88, P387, DOI 10.1111/j.1755-3768.2009.01840.x
   Kanki T, 2010, MOL MICROBIOL, V75, P795, DOI 10.1111/j.1365-2958.2009.07035.x
   KASAMATSU H, 1974, ANNU REV BIOCHEM, V43, P695, DOI 10.1146/annurev.bi.43.070174.003403
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Kowald A, 2001, BIOL SIGNAL RECEPT, V10, P162
   Kraytsberg Y, 2004, SCIENCE, V304, P981, DOI 10.1126/science.1096342
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Ksiazek K, 2008, BIOCHEM BIOPH RES CO, V373, P335, DOI 10.1016/j.bbrc.2008.06.026
   Lanza IR, 2008, DIABETES, V57, P2933, DOI 10.2337/db08-0349
   Lanza IR, 2010, PFLUG ARCH EUR J PHY, V459, P277, DOI 10.1007/s00424-009-0724-5
   LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6
   Lesnefsky EJ, 2006, FASEB J, V20, P1543, DOI 10.1096/fj.05-4535fje
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lieber MR, 2004, NAT REV MOL CELL BIO, V5, P69, DOI 10.1038/nrm1281
   LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0
   Ling F, 2000, NUCLEIC ACIDS RES, V28, P4956, DOI 10.1093/nar/28.24.4956
   Mainster MA, 2006, RETINA, V2, P1857
   Mainster MA, 2010, SURV OPHTHALMOL, V55, P272, DOI 10.1016/j.survophthal.2009.07.006
   MARCHESE AL, 1992, DOC OPHTHALMOL, V79, P117, DOI 10.1007/BF00156571
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   Miceli MV, 2005, INVEST OPHTH VIS SCI, V46, P1765, DOI 10.1167/iovs.04-1327
   Mostoslavsky R, 2008, FRONT BIOSCI-LANDMRK, V13, P6966, DOI 10.2741/3203
   MYERS KA, 1988, CARCINOGENESIS, V9, P285, DOI 10.1093/carcin/9.2.285
   Navarro A, 2007, AM J PHYSIOL-CELL PH, V292, pC670, DOI 10.1152/ajpcell.00213.2006
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0
   Paradies G, 1997, FEBS LETT, V406, P136, DOI 10.1016/S0014-5793(97)00264-0
   Plafker SM, 2010, ADV EXP MED BIOL, V664, P447, DOI 10.1007/978-1-4419-1399-9_51
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   Sanford BE, 1996, ACTA OPHTHALMOL SCAN, V74, P553
   SATOH MS, 1988, J BIOL CHEM, V263, P6854
   Schon EA, 2003, J CLIN INVEST, V111, P303, DOI 10.1172/JCI200317741
   Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102
   SINGER TP, 1990, FEBS LETT, V274, P1, DOI 10.1016/0014-5793(90)81315-F
   Soong NW, 1996, NEUROBIOL AGING, V17, P827, DOI 10.1016/S0197-4580(96)00163-7
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Synowiec E, 2010, 42 C POL SOC OPHTH W
   Szaflik JP, 2009, MUTAT RES-FUND MOL M, V669, P169, DOI 10.1016/j.mrfmmm.2009.06.008
   Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3
   Taioli E, 2008, CARCINOGENESIS, V29, P1467, DOI 10.1093/carcin/bgn062
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   WALLACE DC, 1995, BBA-MOL BASIS DIS, V1271, P141, DOI 10.1016/0925-4439(95)00021-U
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wang AL, 2008, MOL VIS, V14, P644
   Wei YH, 1998, P SOC EXP BIOL MED, V217, P53
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wozniak K, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/827562
   Xu H, 2008, INVEST OPHTH VIS SCI, V49, P230
   Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9
   Zammit VA, 1998, LIPIDS, V33, P371, DOI 10.1007/s11745-998-0217-7
NR 103
TC 13
Z9 14
U1 0
U2 12
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093-9946
J9 FRONT BIOSCI-LANDMRK
JI Front. Biosci.
PD JAN 1
PY 2011
VL 16
BP 1291
EP 1301
DI 10.2741/3789
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 757NI
UT WOS:000290093700006
PM 21196232
DA 2022-11-30
ER

PT J
AU Liu, TYA
   Shah, AR
   Del Priore, LV
AF Liu, Tin Yan A.
   Shah, Ankoor R.
   Del Priore, Lucian V.
TI Progression of Lesion Size in Untreated Eyes With Exudative Age-Related
   Macular Degeneration A Meta-analysis Using Lineweaver-Burk Plots
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN THERAPY; VISUAL
   FUNCTION; FEATURES; RANIBIZUMAB; PEGAPTANIB; MEMBRANES; SECONDARY;
   SURGERY; TRIAL
AB Objective: To test the hypothesis that the natural history of choroidal neovascularization lesion size is uniform across prior randomized controlled clinical trials of exudative age-related macular degeneration (AMD), with apparent differences arising from different entry times of eyes into clinical trials.
   Methods: We conducted a retrospective meta-analysis of control eye data from 5 age-related macular degeneration trials (Treatment of Age-Related Macular Degeneration with Photodynamic Therapy; Verteporfin in Photodynamic Therapy; VEGF Inhibition Study in Ocular Neovascularization; Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration; and Phase 3b, Multicenter, Randomized, Double-masked, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization with or without Classic Choroidal Neovascularization Secondary to AMD Study), which were plotted on a double reciprocal plot of 1/lesion size (disc area) vs 1/time (months after enrollment). To account for the different entry times, we introduced a horizontal translation factor to shift each data subset until r(2) was maximized for the cumulative trend line.
   Results: Cumulative data for untreated control eyes fit a straight line on a double reciprocal plot (r(2) = 0.98) after the introduction of horizontal translation factors. Our model predicts that a choroidal neovascular lesion will eventually enlarge to a size of 10.6 disc areas without treatment and that the lesion will reach half of its maximum size within 14.0 months after onset of exudation. The linear expansion rate of untreated lesions is approximately 26.0 mu m per day for the smallest lesions and decreases gradually as the lesions enlarge.
   Conclusions: The pattern of choroidal neovascularization lesion size enlargement in AMD eyes is uniform across a wide range of clinical trials, with apparent differences arising from different entry times of patients into various trials. The main determinant of choroidal neovascularization lesion size enlargement is the duration of exudative disease. JAMA Ophthalmol. 2013;131(3):335-340. Published online November 9, 2012. doi:10.1001/jamaophthalmol.2013.818
C1 [Liu, Tin Yan A.] Columbia Univ Coll Phys & Surg, Dept Ophthalmol, Edward Harkness Eye Inst, New York, NY 10032 USA.
   [Shah, Ankoor R.] Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA.
   [Del Priore, Lucian V.] Med Univ S Carolina, Albert Florens Storm Eye Inst, Charleston, SC USA.
C3 Columbia University; University of Pennsylvania; Pennsylvania Medicine;
   Medical University of South Carolina
RP Del Priore, LV (通讯作者)，Albert Florens Storm Eye Inst, 167 Ashley Ave, Charleston, SC 29425 USA.
EM ldelpriore@yahoo.com
CR ADELBERG DA, 1995, RETINA-J RET VIT DIS, V15, P198, DOI 10.1097/00006982-199515030-00003
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown, 2005, T AM OPHTHAL SOC, P184
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   BYNOE LA, 1994, OPHTHALMOLOGY, V101, P1112
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   HSU JK, 1995, RETINA-J RET VIT DIS, V15, P43, DOI 10.1097/00006982-199515010-00009
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Schmidt-Erfurth U, 2005, EUR J OPHTHALMOL, V15, P482, DOI 10.1177/112067210501500411
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Shah AR, 2009, OPHTHALMOLOGY, V116, P1901, DOI 10.1016/j.ophtha.2009.03.055
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   VANDER JF, 1989, OPHTHALMOLOGY, V96, P1422
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 35
TC 29
Z9 30
U1 0
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2013
VL 131
IS 3
BP 335
EP 340
DI 10.1001/jamaophthalmol.2013.818
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 113SD
UT WOS:000316687600009
PM 23494038
OA Bronze
DA 2022-11-30
ER

PT J
AU Ehlers, JP
   Spirn, MJ
   Shah, CP
   Fenton, GL
   Baker, PS
   Regillo, CD
   Ho, AC
AF Ehlers, Justis P.
   Spirn, Marc J.
   Shah, Chirag P.
   Fenton, Gregoy L.
   Baker, Paul S.
   Regillo, Carl D.
   Ho, Allen C.
TI Ranibizumab for Exudative Age-Related Macular Degeneration in Eyes
   Previously Treated With Alternative Vascular Endothelial Growth Factor
   Inhibitors
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID PIGMENT EPITHELIAL TEAR; CHOROIDAL NEOVASCULARIZATION SECONDARY;
   INTRAVITREAL BEVACIZUMAB AVASTIN; INJECTION; PHARMACOKINETICS; THERAPY;
   SAFETY
AB BACKGROUND AND OBJECTIVE: To evaluate ranibizumab for exudative age-related macular degeneration previously treated with pegaptanib, bevacizumab or both.
   PATIENTS AND METHODS: This was a retrospective, interventional case series of patients with exudative,e age-related macular degeneration who were treated with ranibizumab after being initially treated with pegaptanib, bevacizumab, or both. The primary outcome was change in visual acuity, following the switch to ranibizumab.
   RESULTS: One hundred two eyes of 92 patients were identified. Following the switch to ranibizumab, there was an average gain of 0.7 lines In visual acuity. Ninety-four eyes (92%) lost 3 or fewer lines, 29 eyes (28%) gained more than 3 lines, and 3 eyes (3%) lost more than 6 lines after switching to ranibizumab. Lesion type and time between previous vascular endothelial growth factor inhibitor and ranibizumab did not affect the response.
   CONCLUSION: Ranibizumab maintained visual acuity In the majority of patients and appears to be an effective treatment regardless of previous anti-vascular endothelial growth factor therapy.
C1 [Ho, Allen C.] Wills Eye Inst, Retina Serv, Philadelphia, PA 19107 USA.
   [Regillo, Carl D.; Ho, Allen C.] Mid Atlantic Retina, Philadelphia, PA USA.
C3 Jefferson University
RP Ho, AC (通讯作者)，Wills Eye Inst, Retina Serv, Suite 1020,840 Walnut St, Philadelphia, PA 19107 USA.
OI Ho, Allen/0000-0003-3921-608X
CR Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P846, DOI 10.1097/IAE.0b013e31813c68b7
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jonas JB, 2006, EUR J OPHTHALMOL, V16, P774, DOI 10.1177/112067210601600522
   Kiss C, 2007, ACTA OPHTHALMOL SCAN, V85, P902, DOI 10.1111/j.1600-0420.2007.00928.x
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lee GKY, 2007, GRAEF ARCH CLIN EXP, V245, P1225, DOI 10.1007/s00417-007-0536-2
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
NR 31
TC 17
Z9 18
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAR-APR
PY 2010
VL 41
IS 2
BP 182
EP 189
DI 10.3928/15428877-20100303-05
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 569OG
UT WOS:000275606400005
PM 20307035
DA 2022-11-30
ER

PT J
AU Sarao, V
   Parravano, M
   Veritti, D
   Arias, L
   Varano, M
   Lanzetta, P
AF Sarao, Valentina
   Parravano, Mariacristina
   Veritti, Daniele
   Arias, Luis
   Varano, Monica
   Lanzetta, Paolo
TI INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO
   AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE anti-VEGF; aflibercept; choroidal neovascularization; ranibizumab;
   unresponsive
ID PHOTODYNAMIC THERAPY; ANATOMICAL OUTCOMES; VEGF-TRAP; BEVACIZUMAB; EYES;
   TACHYPHYLAXIS; INJECTIONS; CONVERSION; RECURRENT; FLUID
AB Purpose:To assess the efficacy of intravitreal injection of aflibercept for treating choroidal neovascularization due to age-related macular degeneration unresponsive to ranibizumab.Methods:Prospective noncomparative study. Indication for conversion to aflibercept (2.0 mg) was a failed response to ranibizumab, defined as persistent or recurrent subretinal and/or intraretinal fluid on spectral domain optical coherence tomography. Best-corrected visual acuity (Early Treatment Diabetic Retinopathy Study letter score), fluorescein angiography, indocyanine green angiography, and spectral domain optical coherence tomography were performed at baseline. Patients were followed up monthly, and retreatment was considered at physician discretion based on functional and morphological patterns.Results:Ninety-two eyes were included in the study. At 12 months, mean best-corrected visual acuity (SD) change was +1.8 (+/- 10.3), Early Treatment Diabetic Retinopathy Study letters and central retinal thickness (+/- SD) decreased on average by 112 (+/- 173) m. Patients received a mean of 3.5 +/- 1.8 injections. No significant adverse event was observed during the follow-up.Conclusion:A low number of intravitreal aflibercept injections reversed the preswitching trend toward losing vision and produced stable visual acuity and morphological improvements for up to 12 months in patients with neovascular age-related macular degeneration, not responding to ranibizumab.
C1 [Sarao, Valentina; Veritti, Daniele; Lanzetta, Paolo] Univ Udine, Dept Med & Biol Sci Ophthalmol, Piazzale Santa Maria della Misericordia, I-33100 Udine, Italy.
   [Parravano, Mariacristina; Varano, Monica] Fdn GB Bietti, IRCCS, Dept Ophthalmol, Rome, Italy.
   [Veritti, Daniele; Lanzetta, Paolo] Ist Europeo Microchirugia Oculare, Udine, Italy.
   [Arias, Luis] Univ Barcelona, Bellvitge Univ Hosp, Dept Ophthalmol, Barcelona, Spain.
C3 University of Udine; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia; Institut d'Investigacio Biomedica de Bellvitge
   (IDIBELL); Bellvitge University Hospital; University of Barcelona
RP Lanzetta, P (通讯作者)，Univ Udine, Dept Med & Biol Sci Ophthalmol, Piazzale Santa Maria della Misericordia, I-33100 Udine, Italy.
EM paolo.lanzetta@uniud.it
RI Varano, Monica/K-8573-2016
OI Varano, Monica/0000-0002-6530-1563; VERITTI, Daniele/0000-0003-0148-5348
CR Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Helfrich I, 2010, J EXP MED, V207, P491, DOI 10.1084/jem.20091846
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lu C, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.12.028
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Pachydaki SI, 2012, J OPHTHALMIC INFLAMM, V2, P29, DOI 10.1007/s12348-011-0050-x
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
   Veritti D, 2013, OPHTHALMOLOGICA, V230, P131, DOI 10.1159/000351651
   Veritti D, 2013, J OCUL PHARMACOL TH, V29, P437, DOI 10.1089/jop.2012.0173
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 41
TC 21
Z9 21
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2016
VL 36
IS 4
BP 770
EP 777
DI 10.1097/IAE.0000000000000751
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DJ0IC
UT WOS:000373884700016
PM 26398691
DA 2022-11-30
ER

PT J
AU Zago, LA
   Moreira, ATR
   Malafaia, O
   Matias, JEF
AF Zago Filho, Luiz Alberto
   Ramos Moreira, Ana Tereza
   Malafaia, Osvaldo
   Fouto Matias, Jorge Eduardo
TI Grid laser photocoagulation in the treatment of serous avascular pigment
   epithelial detachment in age-related macular degeneration
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Retinal pigment epithelium; Retinal drusen; Laser; Macular degeneration;
   Retina
ID CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; BRUCHS MEMBRANE;
   FELLOW EYES; RANIBIZUMAB; BEVACIZUMAB; MACULOPATHY; PREVALENCE;
   FEATURES; TRIAL
AB Purpose: Describe the outcomes of thermal laser photocoagulation in three cases of retinal pigment epithelium detachment associated to age-related macular degeneration.
   Methods: Three patients with avascular retinal pigment epithelium detachment were treated with green diode laser photocoagulation. Mild macular grid laser application, similar to the treatment of diabetic macular edema was performed after an unsuccessful intravitreal anti-angiogenic treatment.
   Results: After one year of the laser treatment, two cases reached anatomic resolution, with complete absorption of sub-epithelium serum fluid and improvement of the visual acuity. There was stability of the visual acuity and sub-epithelium fluid reduction, which, however, was partial in the third case. No complications related to the treatment occurred until the conclusion of this study.
   Conclusions: Macular photocoagulation in grid pattern produced regression of avascular serous pigment epithelium detachment associated with age-related macular degeneration in a short follow-up period. Although long term prospective studies with an increased sample are necessary, it is a method that can be applied in selected patients, with absence of sub-retinal neovascularization or sub-epithelium fibrovascular component.
C1 [Zago Filho, Luiz Alberto; Malafaia, Osvaldo; Fouto Matias, Jorge Eduardo] Univ Fed Parana, Dept Surg, BR-80060000 Curitiba, Parana, Brazil.
   [Ramos Moreira, Ana Tereza] Univ Fed Parana, Dept Otolaryngol Ophthalmol, BR-80060000 Curitiba, Parana, Brazil.
C3 Universidade Federal do Parana; Universidade Federal do Parana
RP Zago, LA (通讯作者)，Rua Nilo Pecanha 605, BR-88523330 Lages, SC, Brazil.
EM luzago@gmail.com
RI Malafaia, Osvaldo/C-9080-2013
OI Malafaia, Osvaldo/0000-0002-1829-7071
CR BARONDES MJ, 1992, BRIT J OPHTHALMOL, V76, P5, DOI 10.1136/bjo.76.1.5
   Battaglia-Parodi M, 2009, EUR J OPHTHALMOL, V19, P887, DOI 10.1177/112067210901900501
   BIRD AC, 1991, EYE, V5, P1
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Fong DS, 2007, ARCH OPHTHALMOL-CHIC, V125, P469
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   Goto S, 2012, AM J OPHTHALMOL, V154, P865, DOI 10.1016/j.ajo.2012.05.001
   Gross-Jendroska M, 1998, AM J OPHTHALMOL, V126, P77, DOI 10.1016/S0002-9394(98)00061-0
   Guymer R. H., 1997, Investigative Ophthalmology and Visual Science, V38, pS353
   Haddad WM, 2002, BRIT J OPHTHALMOL, V86, P663, DOI 10.1136/bjo.86.6.663
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Kaiser RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P826
   Kim KS, 2010, RETINA-J RET VIT DIS, V30, P93, DOI 10.1097/IAE.0b013e3181b094a1
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   YANNUZZI LA, 1989, J FR OPHTALMOL, V12, P761
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   Zago LA, 2008, ARQ BRAS OFTALMOL, V71, P357, DOI 10.1590/S0004-27492008000300010
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 29
TC 1
Z9 1
U1 0
U2 0
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD SEP-OCT
PY 2014
VL 77
IS 5
BP 315
EP 320
DI 10.5935/0004-2749.20140079
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AW3DY
UT WOS:000346167000011
PM 25494379
OA gold
DA 2022-11-30
ER

PT J
AU Gehlbach, P
   Li, TJ
   Hatef, E
AF Gehlbach, Peter
   Li, Tianjing
   Hatef, Elham
TI Statins for age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Hydroxymethylglutaryl-CoA Reductase Inhibitors [therapeutic use];
   Macular Degeneration [prevention & control]; Randomized Controlled
   Trials as Topic; Simvastatin [therapeutic use]; Humans
ID REDUCTASE INHIBITORS STATINS; 5-YEAR INCIDENCE; RISK-FACTORS;
   MACULOPATHY; PROGRESSION; PREVALENCE; COHORT; SERUM
AB Background
   Age-related macular degeneration (AMD) is a progressive late onset disorder of the macula affecting central vision. Age-related macular degeneration is the leading cause of blindness in people over 65 years in industrialized countries. Recent epidemiologic, genetic, and pathological evidence has shown AMD shares a number of risk factors with atherosclerosis, leading to the hypothesis that statins may exert protective effects in AMD.
   Objectives
   The objective of this review was to examine the effectiveness of statins compared with other treatments, no treatment, or placebo in delaying the onset and progression of AMD.
   Search methods
   We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2014, Issue 6), Ovid MEDLINE, OvidMEDLINE In-Process andOtherNon-Indexed Citations, OvidMEDLINE Daily, OvidOLDMEDLINE (January 1946 to June 2014), EMBASE (January 1980 to June 2014), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to June 2014), PubMed (January 1946 to June 2014), themetaRegister of Controlled Trials (mRCT) (www. controlled-trials. com), ClinicalTrials.gov (www.clinicaltrials.gov), and theWHOInternational Clinical Trials Registry Platform(ICTRP) (www. who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 5 June 2014.
   Selection criteria
   We included randomized controlled trials (RCTs) that compared statins with other treatments, no treatment, or placebo in participants who were either susceptible to or diagnosed as having early stages of AMD.
   Data collection and analysis
   We used standardmethodological procedures expected byTheCochraneCollaboration. Two authors independently evaluated the search results against the selection criteria, abstracted data, and assessed risk of bias. We did not perform meta-analysis due to heterogeneity in the interventions and outcomes among the included studies.
   Main results
   Two RCTs with 144 total participants met the selection criteria. Both trials compared simvastatin versus placebo in older people (> 50 or 60 years) with high risk of developing AMD (drusen present on examination). The larger trial with 114 participants was conducted in Australia and used a higher dose (40 mg daily) of simvastatin for three years. Participants and study personnel in this trial were adequately masked; however, data were missing for 30% of participants at three years follow-up. The smaller trial of 30 participants was conducted in Italy and used a lower dose (20 mg) of simvastatin for three months. This trial reported insufficient details to assess the risk of bias.
   Neither trial reported data for change in visual acuity. Analysis of 30 participants in the smaller trial did not show a statistically significant difference between the simvastatin and placebo groups in visual acuity values at three months of treatment (decimal visual acuity 0.21 +/- 0.56 in simvastatin group and 0.19 +/- 0.40 in placebo group) or 45 days after the completion of treatment (decimal visual acuity 0.20 +/- 0.50 in simvastatin group and 0.19 +/- 0.48 in placebo group). The lack of a difference in visual acuity was not explained by lens or retina status, which remained unchanged during and after the treatment period for both groups.
   Preliminary analyses of 42 participants who had completed 12months follow-up in the larger trial did not show a statistically significant difference between simvastatin and the placebo groups for visual acuity, drusen score, or visual function (effect estimates and confidence intervals were not available). Complete data for these outcomes at three years follow-up were not reported. At three years, the effect of simvastatin in slowing progression of AMD compared with placebo was uncertain (odds ratio 0.51, 95% confidence interval 0.23 to 1.09).
   One trial did not report adverse outcomes. The second trial reported no difference between groups in terms of adverse events such as death, muscle aches, and acute hepatitis.
   Authors' conclusions
   Evidence from currently available RCTs is insufficient to conclude that statins have a role in preventing or delaying the onset or progression of AMD.
C1 [Gehlbach, Peter] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21231 USA.
   [Li, Tianjing] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Hatef, Elham] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21231 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Bloomberg School of Public Health; Johns
   Hopkins University; Johns Hopkins Medicine
RP Gehlbach, P (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 1550 Orleans St,Canc Res Bldg 2, Baltimore, MD 21231 USA.
EM pgelbach@jhmi.edu
FU Johns Hopkins Bloomberg School of Public Health, USA.; National Eye
   Institute, National Institutes of Health, USA. [1 U01 EY020522];
   National Institute for Health Research, UK.; Department of Health
   through the National Institute for Health Research; UCL Institute of
   Ophthalmology for a Specialist Biomedical Research Centre for
   Ophthalmology; NATIONAL EYE INSTITUTE [U01EY020522] Funding Source: NIH
   RePORTER
FX Internal sources; Johns Hopkins Bloomberg School of Public Health, USA.;
   External sources; Grant 1 U01 EY020522, National Eye Institute, National
   Institutes of Health, USA.; National Institute for Health Research, UK.;
   Richard Wormald, Co-ordinating Editor for the Cochrane Eyes and Vision
   Group (CEVG) acknowledges financial support for his CEVG research
   sessions from the Department of Health through the award made by the
   National Institute for Health Research to Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology for a Specialist
   Biomedical Research Centre for Ophthalmology.
CR Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2
   American Academy of Ophthalmology, PREF PRACT PATT GUID
   [Anonymous], 1994, Arch Ophthalmol, V112, P500
   [Anonymous], 2014, REV MAN REVMAN VERS
   Berendschot TTJM, 2009, BRIT J NUTR, V101, P1607, DOI 10.1017/S0007114508111448
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Della Valle V, 2000, ANN OTTALMOLOGIA CLI, V126, P89
   Della Valle V, 2000, ANN OTTALMOLOGIA CLI, V126, P249
   Dichtl W, 2003, ARTERIOSCL THROM VAS, V23, P58, DOI 10.1161/01.ATV.0000043456.48735.20
   Drobek-Slowik Monika, 2008, Klin Oczna, V110, P50
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub3
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Gehlbach P, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub2
   Gehlbach P, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006927, DOI 10.1002/14651858.CD006927]
   Gehlbach P, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub3
   Geltzer A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005022.pub3
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Guymer RH, 2005, INVEST OPHTH VIS SCI, V46
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Guymer RH, 2003, INVESTIGATIVE OPHTHA, V44
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Guymer RH, 2008, CLIN INTERV AGING, V3, P581
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Li TJ, 2014, J CLIN EPIDEMIOL, V67, P15, DOI 10.1016/j.jclinepi.2013.08.013
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   Mao YQ, 2009, INT J OPHTHALMOLOGY, V9, P1521
   MARTINI E, 1991, Annali di Ottalmologia e Clinica Oculistica, V117, P1121
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Sagara N, 2007, EXP EYE RES, V84, P1074, DOI 10.1016/j.exer.2007.02.005
   Sen K, 2002, DIABETES RES CLIN PR, V56, P1, DOI 10.1016/S0168-8227(01)00341-2
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smeeth L, 2009, BRIT J CLIN PHARMACO, V67, P99, DOI 10.1111/j.1365-2125.2008.03308.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
NR 52
TC 12
Z9 12
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2015
IS 2
AR CD006927
DI 10.1002/14651858.CD006927.pub4
PG 31
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CC6PB
UT WOS:000350486800022
PM 25675254
OA Green Accepted
DA 2022-11-30
ER

PT J
AU DeAngelis, MM
   Silveira, AC
   Carr, EA
   Kim, IK
AF DeAngelis, Margaret M.
   Silveira, Alexandra C.
   Carr, Elizabeth A.
   Kim, Ivana K.
TI Genetics of Age-Related Macular Degeneration: Current Concepts, Future
   Directions
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE ARMS2/HTRA1; CFH; choroidal neovascularization; complement; geographic
   atrophy; susceptibility
ID COMPLEMENT FACTOR-H; HEMOLYTIC-UREMIC SYNDROME; STARGARDT-DISEASE GENE;
   APOLIPOPROTEIN-E GENE; BEAVER DAM EYE; POLYPOIDAL CHOROIDAL
   VASCULOPATHY; MANGANESE SUPEROXIDE-DISMUTASE; FAMILIAL
   ALZHEIMERS-DISEASE; GENOME-WIDE ASSOCIATION; CASE-CONTROL SAMPLES
AB Age-related macular degeneration (AMD) is a progressive degenerative disease which leads to blindness, affecting the quality of life of millions of Americans. More than 1.75 million individuals in the United States are affected by the advanced form of AMD. The etiological pathway of AMD is not yet fully understood, but there is a clear genetic influence on disease risk. To date, the 1q32 (CFH) and 10q26 (PLEKHA1/ARMS2/HTRA1) loci are the most strongly associated with disease; however, the variation in these genomic regions alone is unable to predict disease development with high accuracy. Therefore, current genetic studies are aimed at identifying new genes associated with AMD and their modifiers, with the goal of discovering diagnostic or prognostic biomarkers. Moreover, these studies provide the foundation for further investigation into the pathophysiology of AMD by utilizing a systems-biology-based approach to elucidate underlying mechanistic pathways.
C1 [Kim, Ivana K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Retina Serv, Dept Ophthalmol,Med Sch, Boston, MA 02114 USA.
   [DeAngelis, Margaret M.; Silveira, Alexandra C.] Harvard Univ, Massachusetts Eye & Ear Infirm, Ocular Mol Genet Inst, Dept Ophthalmol,Med Sch, Boston, MA 02114 USA.
   [DeAngelis, Margaret M.; Carr, Elizabeth A.] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye
   & Ear Infirmary; Utah System of Higher Education; University of Utah
RP Kim, IK (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Retina Serv, Dept Ophthalmol,Med Sch, 243 Charles St, Boston, MA 02114 USA.
EM Margaret.DeAngelis@utah.edu; ivana_kim@meei.harvard.edu
RI DeAngelis, e/J-7863-2015
OI Kim, Ivana/0000-0003-0310-6129
FU NEI NIH HHS [P30 EY014800] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [P30EY014800] Funding Source: NIH RePORTER
CR Abarrategui-Garrido C, 2009, BLOOD, V114, P4261, DOI 10.1182/blood-2009-05-223834
   Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Akimoto A, 2001, GRAEF ARCH CLIN EXP, V239, P66, DOI 10.1007/PL00007900
   Allikmets R, 1999, HUM GENET, V104, P449, DOI 10.1007/s004390050986
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Allikmets R, 2009, NEW ENGL J MED, V360, P2252
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   ARVILOMMI H, 1974, NATURE, V251, P740, DOI 10.1038/251740a0
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Baird PN, 2004, AM J OPHTHALMOL, V138, P665, DOI 10.1016/j.ajo.2004.04.053
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bernstein PS, 2002, INVEST OPHTH VIS SCI, V43, P466
   Bertram L, 2009, HUM MOL GENET, V18, pR137, DOI 10.1093/hmg/ddp406
   Besnard S, 2001, CIRC RES, V89, P1209, DOI 10.1161/hh2401.101755
   Boekholdt SM, 2003, CIRCULATION, V107, P2416, DOI 10.1161/01.CIR.0000068311.40161.28
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Boukhtouche F, 2004, ARTERIOSCL THROM VAS, V24, P637, DOI 10.1161/01.ATV.0000119355.56036.de
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Cichon S, 2009, AM J PSYCHIAT, V166, P540, DOI 10.1176/appi.ajp.2008.08091354
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Cui L, 2010, INVEST OPHTH VIS SCI, V51, P1116, DOI 10.1167/iovs.09-4265
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DEANGELIS M, 2008, ALBERT JAKOBIECS PRI, P1881
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Edwards AO, 2009, NEW ENGL J MED, V360, P2254
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fang AM, 2009, MOL VIS, V15, P2710
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Felbor U, 1997, INVEST OPHTH VIS SCI, V38, P1054
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2008, MOL VIS, V14, P1395
   Frazer KA, 2009, NAT REV GENET, V10, P241, DOI 10.1038/nrg2554
   Fremeaux-Bacchi V, 2005, J MED GENET, V42, P852, DOI 10.1136/jmg.2005.030783
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Girirajan S, 2010, HUM MOL GENET, V19, pR176, DOI 10.1093/hmg/ddq366
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GORIN MB, 1995, OPHTHALMOLOGY, V102, P246
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Gotoh N, 2008, AM J OPHTHALMOL, V146, P146, DOI 10.1016/j.ajo.2008.03.017
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gubitz AK, 2009, CURR MOL MED, V9, P801, DOI 10.2174/156652409789105534
   Guymer RH, 2002, CLIN EXP OPHTHALMOL, V30, P419, DOI 10.1046/j.1442-9071.2002.00572.x
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hadley D, 2010, INVEST OPHTH VIS SCI, V51, P2191, DOI 10.1167/iovs.09-3798
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakonarson H, 2009, SEMIN IMMUNOL, V21, P355, DOI 10.1016/j.smim.2009.06.001
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hamsten A, 2008, J INTERN MED, V263, P538, DOI 10.1111/j.1365-2796.2008.01958.x
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   Hastings PJ, 2009, NAT REV GENET, V10, P551, DOI 10.1038/nrg2593
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Hollams EM, 2002, NEUROCHEM RES, V27, P957, DOI 10.1023/A:1020992418511
   Hosaka M, 1998, J BIOL CHEM, V273, P13371, DOI 10.1074/jbc.273.22.13371
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Ioannidis JPA, 2009, CIRC-CARDIOVASC GENE, V2, P7, DOI 10.1161/CIRCGENETICS.108.833392
   Ishii K, 2001, NEUROBIOL AGING, V22, P367, DOI 10.1016/S0197-4580(01)00216-0
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Johnson EJ, 2005, NUTR REV, V63, P9, DOI 10.1301/nr.2004.janr.9-15
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Jun G, 2005, INVEST OPHTH VIS SCI, V46, P3081, DOI 10.1167/iovs.04-1360
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Kelly M, 2009, CIRC-CARDIOVASC GENE, V2, P182, DOI 10.1161/CIRCGENETICS.108.836478
   KEMP CM, 1994, INVEST OPHTH VIS SCI, V35, P3154
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Kennedy JL, 2003, SCIENCE, V302, P822, DOI 10.1126/science.1092132
   Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Kondo N, 2009, MOL VIS, V15, P1819
   Kramer F, 2000, EUR J HUM GENET, V8, P286, DOI 10.1038/sj.ejhg.5200447
   Ku CS, 2010, J HUM GENET, V55, P403, DOI 10.1038/jhg.2010.55
   Lau P, 2008, J BIOL CHEM, V283, P18411, DOI 10.1074/jbc.M710526200
   Lewin AS, 2009, NEW ENGL J MED, V360, P2251, DOI 10.1056/NEJMc082233
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   LOSONCZY G, 2009, ACTA OPHTHALMOL
   Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   Lu L, 2009, BIOORGAN MED CHEM, V17, P7548, DOI 10.1016/j.bmc.2009.09.009
   Lupski JR, 2007, NAT GENET, V39, pS43, DOI 10.1038/ng2084
   Lusis AJ, 2010, CIRCULATION, V121, P157, DOI 10.1161/CIRCULATIONAHA.108.847699
   Macgregor AM, 2009, J HISTOCHEM CYTOCHEM, V57, P207, DOI 10.1369/jhc.2008.952531
   Maddox DM, 2008, J PHYSIOL-LONDON, V586, P4409, DOI 10.1113/jphysiol.2008.157289
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Margulies EH, 2008, NAT REV GENET, V9, P303, DOI 10.1038/nrg2185
   Matsumoto M, 2008, ADV DRUG DELIVER REV, V60, P805, DOI 10.1016/j.addr.2007.11.005
   Mckay GJ, 2010, MOL VIS, V16, P194
   Moonesinghe R, 2010, EUR J HUM GENET, V18, P485, DOI 10.1038/ejhg.2009.209
   Moore I, 2010, BLOOD, V115, P379, DOI 10.1182/blood-2009-05-221549
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Narendran N, 2005, EYE, V19, P11, DOI 10.1038/sj.eye.6701435
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   O'Rahilly S, 2009, NATURE, V462, P307, DOI 10.1038/nature08532
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Reitz C, 2009, ANN NY ACAD SCI, V1180, P75, DOI 10.1111/j.1749-6632.2009.04945.x
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Richer Stuart, 2002, Am J Ther, V9, P25, DOI 10.1097/00045391-200201000-00006
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Saunders AM, 2000, J NEUROPATH EXP NEUR, V59, P751, DOI 10.1093/jnen/59.9.751
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schaumberg DA, 2010, ARCH OPHTHALMOL-CHIC, V128, P1462, DOI 10.1001/archophthalmol.2010.261
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Schmidt S, 2003, INVEST OPHTH VIS SCI, V44, P2868, DOI 10.1167/iovs.02-0957
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2001, OPHTHALMOLOGY, V108, P2060, DOI 10.1016/S0161-6420(01)00777-1
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   Souied EH, 1999, AM J OPHTHALMOL, V128, P173, DOI 10.1016/S0002-9394(99)00145-2
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Taylor HR, 1990, T AM OPHTHAL SOC, V88, P173
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   West SK, 1998, JAMA-J AM MED ASSOC, V280, P714, DOI 10.1001/jama.280.8.714
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu P, 2000, PHARMACOL RES, V42, P107, DOI 10.1006/phrs.2000.0670
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
   Zhu Y, 2006, ONCOGENE, V25, P2901, DOI 10.1038/sj.onc.1209314
   Zipfel PF, 2010, PEDIATR NEPHROL, V25, P2009, DOI 10.1007/s00467-010-1446-9
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 231
TC 63
Z9 66
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 77
EP 93
DI 10.3109/08820538.2011.577129
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200003
PM 21609220
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Samanta, A
   Aziz, AA
   Jhingan, M
   Singh, SR
   Khanani, AM
   Chhablani, J
AF Samanta, Anindya
   Aziz, Aamir A.
   Jhingan, Mahima
   Singh, Sumit Randhir
   Khanani, Arshad M.
   Chhablani, Jay
TI Emerging Therapies in Nonexudative Age-Related Macular Degeneration in
   2020
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE dry AMD; emerging therapies; nonexudative AMD; non-neovascular AMD
ID GEOGRAPHIC ATROPHY; EYE DISEASE; PREVALENCE; VISION
AB Age-related macular degeneration (AMD) is one of the most common causes of severe vision loss in the developed world. Advanced forms of AMD are seen in primarily 2 types, exudative AMD involving the presence of choroidal neovascularization and nonexudative or dry AMD with geographic atrophy. For the latter, the combination of vitamins and minerals known as the Age-Related Eye Disease Study-2 formulation has been shown to decrease the rate of progression of nonexudative to exudative AMD, as no other treatments are currently approved for nonexudative AMD. This review will highlight upcoming treatments for nonexudative AMD. Six upcoming agents have shown results at least in the 2A phase. This includes intravitreal agents that are inhibitors of integrin (Risuteganib), intravitreal agents that disrupt the complement pathway (Zimura, APL-2), neuroprotective implants (Brimonidine DDS), a subcutaneous injectable (Elamipretide), and photobiomodulation (Valeda Light Delivery System).
C1 [Samanta, Anindya] Texas Tech Univ, Hlth Sci Ctr, Dept Ophthalmol & Visual Sci, Lubbock, TX 79430 USA.
   [Aziz, Aamir A.; Khanani, Arshad M.] Sierra Eye Associates, Reno, NV USA.
   [Jhingan, Mahima; Singh, Sumit Randhir] Univ Calif San Diego, Shiley Eye Ctr, Jacobs Retina Ctr, La Jolla, CA 92093 USA.
   [Khanani, Arshad M.] Univ Nevada, Sch Med, Reno, NV 89557 USA.
   [Chhablani, Jay] Univ Pittsburgh, Dept Ophthalmol, Inst Eye & Ear, Pittsburgh, PA 15260 USA.
C3 Texas Tech University System; Texas Tech University; Texas Tech
   University Health Science Center; University of California System;
   University of California San Diego; Nevada System of Higher Education
   (NSHE); University of Nevada Reno; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh
RP Chhablani, J (通讯作者)，Univ Pittsburgh, UPMC Eye Ctr, 203 Lothrop St, Pittsburgh, PA 15213 USA.
EM jay.chhablani@gmail.com
CR An Open-Label, 2020, PHAS 1 CLIN STUD EV
   [Anonymous], 2020, EV PHARM SAF TOL SIN
   [Anonymous], 2020, RECL 2 STUD EV SAF E
   [Anonymous], 2019, STUD PHOT TREAT DRY
   [Anonymous], 2019, STUD PHOT TREAT DRY
   [Anonymous], 2019, IVERIC BIOS ZIMURA N
   [Anonymous], 2020, STUD APL 2 THER PAT
   [Anonymous], 2020, SAF TOL STUD 7171009
   [Anonymous], 2020, EV OR MIN TREAT GEOG
   [Anonymous], 2014, PHAS 2 3 STUD EFF SA
   [Anonymous], 2016, ANT C5 MON IN RED GE
   [Anonymous], 2019, 1 HUM STUD EV SAF EF
   [Anonymous], 2020, STUD COMP EFF SAF IN
   [Anonymous], 2020, CLIN TRIAL DES EV SA
   [Anonymous], 2020, ZIM SUBJ GEOGR ATR S
   [Anonymous], 2020, SAFET EFF STUD BRIM
   Boyer DS., 2012, INVEST OPHTHALMOL VI, V53, P1337
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Drolet DW, 2016, NUCLEIC ACID THER, V26, P127, DOI 10.1089/nat.2015.0573
   Elshatory Y., 2019, AAOORG
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Freeman W, 2019, RETIN PHYS
   Freeman W, 2016, AM ACAD OPHTH ANN M
   Freeman WR, 2019, INVEST OPHTH VIS SCI, V60
   Hsu ST, 2019, OPHTHALMOL RETINA, V3, P637, DOI 10.1016/j.oret.2019.03.010
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   Jaffe GJ, 2019, AM ACAD OPHTH AAO 20
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Karageozian V., 2019, OPHTHAMOLOGY INNOVAT
   Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Levy B, 2019, OPHTH INN SUMM
   Markowitz SN, 2020, RETINA-J RET VIT DIS, V40, P1471, DOI 10.1097/IAE.0000000000002632
   McCarthy R., STEALTH BIOTHEREUPET
   Merry GF, 2017, ACTA OPHTHALMOL, V95, pE270, DOI 10.1111/aos.13354
   Mettu P., 2019, RETIN PHYS
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Puliafito CA, 2020, INT J RETINA VITR, V6, DOI 10.1186/s40942-020-00221-4
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rogers A., 2018, OPHTH INN SUMM OCT 1
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Shaw LT, 2020, EXPERT OPIN INV DRUG, V29, P547, DOI 10.1080/13543784.2020.1763953
   Slakter J, 2018, EURETINA
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Wheeler L, 2003, SURV OPHTHALMOL, V48, pS47, DOI 10.1016/S0039-6257(03)00004-3
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarbin M, 2020, RETINA 2020 NEW TREN
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
NR 54
TC 7
Z9 7
U1 2
U2 13
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD JUL-AUG
PY 2021
VL 10
IS 4
BP 408
EP 416
DI 10.1097/APO.0000000000000355
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UE2PT
UT WOS:000687736600014
PM 33512911
OA gold
DA 2022-11-30
ER

PT J
AU Forest, DL
   Johnson, LV
   Clegg, DO
AF Forest, David L.
   Johnson, Lincoln V.
   Clegg, Dennis O.
TI Cellular models and therapies for age-related macular degeneration
SO DISEASE MODELS & MECHANISMS
LA English
DT Review
DE AMD; RPE; Cell-culture models; hESC; iPSC; Stem-cell therapy
ID RETINAL-PIGMENT EPITHELIUM; PLURIPOTENT STEM-CELLS; ADULT HUMAN RPE;
   COMPLEMENT ACTIVATION; SUBRETINAL IMPLANTATION; DRUSEN FORMATION; VISUAL
   FUNCTION; CULTURE MODELS; IN-VITRO; DIFFERENTIATION
AB Age-related macular degeneration (AMD) is a complex neurodegenerative visual disorder that causes profound physical and psychosocial effects. Visual impairment in AMD is caused by the loss of retinal pigmented epithelium (RPE) cells and the light-sensitive photoreceptor cells that they support. There is currently no effective treatment for the most common form of this disease (dry AMD). A new approach to treating AMD involves the transplantation of RPE cells derived from either human embryonic or induced pluripotent stem cells. Multiple clinical trials are being initiated using a variety of cell therapies. Although many animal models are available for AMD research, most do not recapitulate all aspects of the disease, hampering progress. However, the use of cultured RPE cells in AMD research is well established and, indeed, some of the more recently described RPE-based models show promise for investigating the molecular mechanisms of AMD and for screening drug candidates. Here, we discuss innovative cell-culture models of AMD and emerging stem-cell-based therapies for the treatment of this vision-robbing disease.
C1 [Forest, David L.; Johnson, Lincoln V.; Clegg, Dennis O.] Univ Calif Santa Barbara, Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.
C3 University of California System; University of California Santa Barbara
RP Clegg, DO (通讯作者)，Univ Calif Santa Barbara, Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.
EM dennis.clegg@lifesci.ucsb.edu
FU Beckman Initiative for Macular Research; Garland Initiative for Vision;
   Wynn-Gund Translational Research Acceleration Program of the Foundation
   Fighting Blindness; UCSB Institute for Collaborative Biotechnologies
   through grant from U.S. Army Research Office [W911NF-09-0001];
   California Institute for Regenerative Medicine [DR1-01444, CL1-00521,
   FA1-00616]
FX This work was supported by the Beckman Initiative for Macular Research,
   the Garland Initiative for Vision, the Wynn-Gund Translational Research
   Acceleration Program of the Foundation Fighting Blindness, the UCSB
   Institute for Collaborative Biotechnologies through grant W911NF-09-0001
   from the U.S. Army Research Office, and the California Institute for
   Regenerative Medicine grants DR1-01444, CL1-00521 and FA1-00616
   (D.O.C.).
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Abyzov A, 2012, NATURE, V492, P438, DOI 10.1038/nature11629
   Adijanto J, 2014, EXP EYE RES, V126, P77, DOI 10.1016/j.exer.2014.01.015
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Amin S, 2004, INVEST OPHTH VIS SCI, V45, P1281, DOI 10.1167/iovs.03-0671
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481
   Bock C, 2011, CELL, V144, P439, DOI 10.1016/j.cell.2010.12.032
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Carlson C, 2013, J BIOMOL SCREEN, V18, P1203, DOI 10.1177/1087057113500812
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Coffey P, 2012, CELL STEM CELL, V10, P1, DOI 10.1016/j.stem.2011.12.014
   Cristofalo Vincent J., 1995, P53
   Croze RH, 2014, DEV OPHTHALMOL, V53, P81, DOI 10.1159/000357361
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Cyranoski D, 2014, NATURE
   Demontis F, 2013, DIS MODEL MECH, V6, P1339, DOI 10.1242/dmm.012559
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Eiraku M, 2012, NAT PROTOC, V7, P69, DOI 10.1038/nprot.2011.429
   Enzmann V, 2009, ARCH OPHTHALMOL-CHIC, V127, P563, DOI 10.1001/archophthalmol.2009.65
   Feigl B, 2013, ADV HEALTHC MATER, V2, P1056, DOI 10.1002/adhm.201200445
   Ford KM, 2012, INVEST OPHTH VIS SCI, V53, P7520, DOI 10.1167/iovs.12-10098
   Gamm DM, 2013, EXPERT REV OPHTHALMO, V8, P213, DOI 10.1586/EOP.13.14
   Gorham RD, 2013, EXP EYE RES, V116, P96, DOI 10.1016/j.exer.2013.07.023
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hamilton RD, 2011, METHODS MOL BIOL, V686, P401, DOI 10.1007/978-1-60761-938-3_20
   HEWITT AT, 1989, RETINA, V1, P57
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hornof M, 2005, EUR J PHARM BIOPHARM, V60, P207, DOI 10.1016/j.ejpb.2005.01.009
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kawasaki M, 2014, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2014/02/001
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Krohne TU, 2012, STEM CELL TRANSL MED, V1, P96, DOI 10.5966/sctm.2011-0057
   Kvanta A, 2014, ACTA OPHTHALMOL, V92, P21, DOI 10.1111/aos.12185
   Lehr CM, 2005, EUR J PHARM BIOPHARM, V60, pV, DOI 10.1016/j.ejpb.2005.05.001
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Mack DL, 2014, AM J PHYS MED REHAB, V93, pS155, DOI 10.1097/PHM.0000000000000141
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Maruotti J, 2013, STEM CELL TRANSL MED, V2, P341, DOI 10.5966/sctm.2012-0106
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McHugh KJ, 2014, INVEST OPHTH VIS SCI, V55, P1754, DOI 10.1167/iovs.13-12833
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Nakatsuji N, 2008, NAT BIOTECHNOL, V26, P739, DOI 10.1038/nbt0708-739
   Nasonkin IO, 2013, DEVELOPMENT, V140, P1330, DOI 10.1242/dev.086603
   Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pera MF, 2011, NATURE, V471, P46, DOI 10.1038/471046a
   Pfeffer B.A., 1991, PROG RETIN RES, V10, P251
   Phillips MJ, 2014, STEM CELLS, V32, P1480, DOI 10.1002/stem.1667
   Rabin DM, 2013, AGING-US, V5, P51
   Radu RA, 2014, J BIOL CHEM, V289, P9113, DOI 10.1074/jbc.M114.548669
   Ratner M, 2014, NAT BIOTECHNOL, V32, P701, DOI 10.1038/nbt0814-701
   Raya A, 2009, NATURE, V460, P53, DOI 10.1038/nature08129
   Rohrer B, 2010, ADV EXP MED BIOL, V703, P137, DOI 10.1007/978-1-4419-5635-4_10
   Rowland TJ, 2013, J TISSUE ENG REGEN M, V7, P642, DOI 10.1002/term.1458
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Selvaraj V, 2010, TRENDS BIOTECHNOL, V28, P214, DOI 10.1016/j.tibtech.2010.01.002
   Shadforth AMA, 2012, BIOMATERIALS, V33, P4110, DOI 10.1016/j.biomaterials.2012.02.040
   Sheridan C, 2014, NAT BIOTECHNOL, V32, P1173, DOI 10.1038/nbt1214-1173
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sorkio A, 2014, TISSUE ENG PT A, V20, P622, DOI 10.1089/ten.TEA.2013.0049
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   SUNNESS JS, 1999, AGE RELATED MACULAR, P155
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Wahlin KJ, 2014, ADV EXP MED BIOL, V801, P157, DOI 10.1007/978-1-4614-3209-8_20
   Westenskow PD, 2014, ADV EXP MED BIOL, V801, P323, DOI 10.1007/978-1-4614-3209-8_41
   WILLIAMS DF, 1990, INVEST OPHTH VIS SCI, V31, P1717
   Yabut O, 2011, AGING-US, V3, P494, DOI 10.18632/aging.100328
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
NR 92
TC 42
Z9 46
U1 0
U2 32
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 1754-8403
EI 1754-8411
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD MAY
PY 2015
VL 8
IS 5
BP 421
EP 427
DI 10.1242/dmm.017236
PG 7
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA CJ5UW
UT WOS:000355558000002
PM 26035859
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Matuskova, V
   Zeman, T
   Ewerlingova, L
   Hlinomazova, Z
   Soucek, J
   Vlkova, E
   Goswami, N
   Balcar, VJ
   Sery, O
AF Matuskova, Veronika
   Zeman, Tomas
   Ewerlingova, Laura
   Hlinomazova, Zuzana
   Soucek, Jan
   Vlkova, Eva
   Goswami, Nandu
   Balcar, Vladimir J.
   Sery, Omar
TI An association of neovascular age-related macular degeneration with
   polymorphisms of CFH, ARMS2, HTRA1 and C3 genes in Czech population
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE gene; inflammation; obesity; polymorphism; retina; risk
ID COMPLEMENT FACTOR-H; RISK; VARIANT; SUSCEPTIBILITY; HYPERTENSION;
   PATHOGENESIS; MACULOPATHY; ARMS2/HTRA1; SYSTEM; RARE
AB Purpose We investigated associations between neovascular age-related macular degeneration (AMD) and rs10490924 polymorphism of ARMS2 gene (age-related maculopathy susceptibility 2), rs1061170 polymorphism of gene for complement factor H (CFH), rs2230199 polymorphism of gene for complement component C3 and rs11200638 polymorphism of gene for serine protease high-temperature requirement A1 (HTRA1) in the Czech population. Methods We analysed samples of DNA from 307 patients diagnosed with neovascular form of late AMD (average age: 73.7 +/- 7.7 years) and 191 control subjects, recruited from patients awaiting cataract surgery (average age, 73.6 +/- 8.7 years). Results HTRA1, CFH and ARMS2 genes polymorphisms were found to be related to neovascular AMD in the Czech population. All analysed polymorphisms were statistically significantly associated with neovascular AMD, with stronger associations in females than in males. In whole group, CC genotype of CFH gene polymorphism, TT genotype of ARMS2 gene polymorphism and AA genotype of HTRA1 gene polymorphism showed the greatest risk for neovascular AMD with odds ratios equal to 8.43, 10.07, 9.83, respectively (p < 0.0001). Only CG polymorphism of C3 gene showed statistically significant risk for neovascular AMD. In addition, we observed an association between waist circumference and neovascular AMD in both sexes, which further suggests the significance of excessive abdominal fat as a risk factor of AMD. We found a statistically significant association between polymorphisms in HTRA1, CFH and ARMS2 genes and neovascular AMS in the Czech population. The association was stronger in females than in males. Conclusion We demonstrated a relationship between neovascular AMD and genes for HTRA1, CFH, ARMS2 and C3 in Czech population. To our knowledge, the relationship between these polymorphisms and neovascular AMD in Czech population has never been investigated before.
C1 [Matuskova, Veronika; Soucek, Jan; Vlkova, Eva] Univ Hosp Brno, Dept Ophthalmol, Brno, Czech Republic.
   [Matuskova, Veronika; Soucek, Jan; Vlkova, Eva] Masaryk Univ, Med Fac, Brno, Czech Republic.
   [Zeman, Tomas; Ewerlingova, Laura; Sery, Omar] Masaryk Univ, Fac Sci, Dept Biochem, Lab Neurobiol & Mol Psychiat, Kamenice 5, Brno 62500, Czech Republic.
   [Zeman, Tomas; Hlinomazova, Zuzana; Balcar, Vladimir J.; Sery, Omar] Acad Sci Czech Republ, Inst Anim Physiol & Genet, Lab Neurobiol & Pathol Physiol, Brno, Czech Republic.
   [Goswami, Nandu] Med Univ Graz, Otto Loewi Res Ctr Vasc Biol Immunol & Inflammat, Physiol Div, Graz, Austria.
   [Balcar, Vladimir J.] Univ Sydney, Fac Med & Hlth, Sch Med Sci, Bosch Inst, Sydney, NSW, Australia.
   [Balcar, Vladimir J.] Univ Sydney, Fac Med & Hlth, Sch Med Sci, Discipline Anat & Histol, Sydney, NSW, Australia.
C3 University Hospital Brno; Masaryk University Brno; Masaryk University
   Brno; Czech Academy of Sciences; Institute of Animal Physiology &
   Genetics of the Czech Academy of Sciences; Medical University of Graz;
   University of Sydney; University of Sydney
RP Sery, O (通讯作者)，Masaryk Univ, Fac Sci, Dept Biochem, Lab Neurobiol & Mol Psychiat, Kamenice 5, Brno 62500, Czech Republic.
EM omarsery@sci.muni.cz
RI Matuskova, Veronika/ABE-1154-2020; Matuskova, Veronika/AAD-7189-2021;
   Goswami, Nandu/B-4021-2011; Zeman, Tomáš/AAX-6235-2021
OI Matuskova, Veronika/0000-0002-3308-463X; Sery, Omar/0000-0002-6062-8997
FU Ministry of Health of the Czech Republic - conceptual development of
   research organization (FNBr) [65269705]; Czech Health Research Council,
   Ministry of Health of the Czech Republic [NV16-27243A]
FX This work has been supported by Ministry of Health of the Czech Republic
   - conceptual development of research organization (FNBr, 65269705) and
   by the Czech Health Research Council, Ministry of Health of the Czech
   Republic, grant project No. NV16-27243A.
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   BURGESS CA, 1992, OPTOMETRY VISION SCI, V69, P320, DOI 10.1097/00006324-199204000-00011
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Casparis H, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub4
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Drobek-Slowik Monika, 2008, Klin Oczna, V110, P40
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Fourgeux C, 2012, INVEST OPHTH VIS SCI, V53, P7026, DOI 10.1167/iovs.12-9652
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fu ZJ, 2017, INVEST OPHTH VIS SCI, V58, P3862, DOI 10.1167/iovs.17-21796
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Getts DR, 2008, J NEUROCHEM, V104, P1167, DOI 10.1111/j.1471-4159.2007.05171.x
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Howard KP, 2014, INVEST OPHTH VIS SCI, V55, P2592, DOI 10.1167/iovs.13-13763
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Janosikova B, 2005, EUR J HUM GENET, V13, P86, DOI 10.1038/sj.ejhg.5201282
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Katsi VK, 2015, J HYPERTENS, V33, P2382, DOI 10.1097/HJH.0000000000000766
   Lana TP, 2018, OPHTHALMIC GENET, V39, P46, DOI 10.1080/13816810.2017.1354382
   Lee A, 2016, NEUROCHEM INT, V101, P76, DOI 10.1016/j.neuint.2016.10.013
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Lu FT, 2018, GENET TEST MOL BIOMA, V22, P526, DOI 10.1089/gtmb.2018.0110
   Mao XY, 2017, ARCH MED RES, V48, P370, DOI 10.1016/j.arcmed.2017.08.002
   Matuskova V, 2018, OPHTHALMIC GENET, V39, P4, DOI 10.1080/13816810.2017.1326508
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Ng TK, 2017, LAB INVEST, V97, P43, DOI 10.1038/labinvest.2016.117
   Ng TK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28639
   Park S, 2015, INT J OPHTHALMOL-CHI, V8, P804, DOI 10.3980/j.issn.2222-3959.2015.04.29
   Pascual-Camps I, 2014, J OPHTHALMIC INFLAMM, V4, DOI 10.1186/s12348-014-0026-8
   Pinazo-Duran MD, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6215745
   Pow D. V., 2005, TRANSPORTERS OXIDATI, P123
   R Core Team, 2017, R: A language and environment for statistical computing
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Sun C, 2012, CURR EYE RES, V37, P259, DOI 10.3109/02713683.2011.635401
   Sundaresan P, 2012, INVEST OPHTH VIS SCI, V53, P7492, DOI 10.1167/iovs.12-10073
   Swinkels M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18395-7
   Tosi GM, 2017, INVEST OPHTH VIS SCI, V58, P162, DOI 10.1167/iovs.16-20922
   Wray NR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000864
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang MX, 2015, GENET MOL RES, V14, P12567, DOI 10.4238/2015.October.16.24
   Zlateva GP, 2007, RETINA-J RET VIT DIS, V27, P1292, DOI 10.1097/01.iae.0000300915.81866.b8
NR 63
TC 10
Z9 10
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2020
VL 98
IS 6
BP E691
EP E699
DI 10.1111/aos.14357
EA JAN 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NC0UA
UT WOS:000508630500001
PM 31970928
DA 2022-11-30
ER

PT J
AU Herzlich, AA
   Tuo, JS
   Chan, CC
AF Herzlich, Alexandra A.
   Tuo, Jingsheng
   Chan, Chi-Chao
TI Peroxisome Proliferator-Activated Receptor and Age-Related Macular
   Degeneration
SO PPAR RESEARCH
LA English
DT Review
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; PPAR-GAMMA ACTIVATION;
   CIGARETTE-SMOKING; CHOROIDAL NEOVASCULARIZATION; MATRIX
   METALLOPROTEINASES; RESPONSE ELEMENT; DRUSEN FORMATION;
   APOLIPOPROTEIN-E; BRUCHS MEMBRANE
AB Age-related macular degeneration (AMD) is the leading cause of new blindness in the western world and is becoming more of a socio-medical problem as the proportion of the aged population increases. There are multiple efforts underway to better understand this disease process. AMD involves the abnormal retinal pigment epithelium (RPE), drusen formation, photoreceptor atrophy, and choroidal neovascularization. Peroxisome proliferator-activated receptors (PPARs) play an important role in lipid degeneration, immune regulation, regulation of reactive oxygen species (ROSs), as well as regulation of vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and docosahexaenoic acid (DHA). These molecules have all been implicated in the pathogenesis of AMD. In addition, PPAR gamma is expressed in RPE, an essential cell in photoreceptor regeneration and vision maintenance. This review summarizes the interactions between PPAR, AMD-related molecules, and AMD-related disease processes. Copyright (C) 2008 Alexandra A. Herzlich et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
C1 [Herzlich, Alexandra A.; Tuo, Jingsheng; Chan, Chi-Chao] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Chan, CC (通讯作者)，NEI, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
OI Tuo, Jingsheng/0000-0002-1372-7810
FU NATIONAL EYE INSTITUTE [ZICEY000461, ZIAEY000222, Z01EY000222,
   ZIAEY000418, Z01EY000461, Z01EY000418] Funding Source: NIH RePORTER
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Al-Shammri S, 2005, CLIN CHIM ACTA, V351, P203, DOI 10.1016/j.cccn.2004.09.015
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268
   Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bordet R, 2006, J NEUROL NEUROSUR PS, V77, P285, DOI 10.1136/jnnp.2005.077495
   Chau K. Y., EYE IN PRESS
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Collins AR, 2001, ARTERIOSCL THROM VAS, V21, P365, DOI 10.1161/01.ATV.21.3.365
   Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Daub K, 2007, SEMIN THROMB HEMOST, V33, P173, DOI 10.1055/s-2007-969031
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding QX, 2007, CURR ALZHEIMER RES, V4, P73, DOI 10.2174/156720507779939788
   Dirkx R, 2005, HEPATOLOGY, V41, P868, DOI 10.1002/hep.20628
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Fiotti N, 2005, GENET MED, V7, P272, DOI 10.1097/01.GIM.0000159903.69597.73
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af
   Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251
   Girnun GD, 2002, MOL ENDOCRINOL, V16, P2793, DOI 10.1210/me.2002-0020
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gralinski MR, 1998, J CARDIOVASC PHARM, V31, P909, DOI 10.1097/00005344-199806000-00015
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Green S, 1995, MUTAT RES-FUND MOL M, V333, P101, DOI 10.1016/0027-5107(95)00136-0
   Green W R, 1999, Mol Vis, V5, P27
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hirsch EC, 2003, ANN NY ACAD SCI, V991, P214
   Huang SJ, 2003, RETINA-J RET VIT DIS, V23, P429, DOI 10.1097/00006982-200306000-00036
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kanki J., 2002, DISS MACULA, V23, P57
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318
   KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lee KJ, 2004, EXP MOL MED, V36, P534, DOI 10.1038/emm.2004.68
   Lu Ming, 2006, Ophthalmol Clin North Am, V19, P323
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Marx N, 2003, ARTERIOSCL THROM VAS, V23, P283, DOI 10.1161/01.ATV.0000054195.35121.5E
   Marx N, 1999, ARTERIOSCL THROM VAS, V19, P546, DOI 10.1161/01.ATV.19.3.546
   Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, pS641
   MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895
   Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220
   Perl DP, 2000, NEUROL CLIN, V18, P847, DOI 10.1016/S0733-8619(05)70229-2
   Pialat JB, 2007, NMR BIOMED, V20, P335, DOI 10.1002/nbm.1157
   Qin SF, 2006, INVEST OPHTH VIS SCI, V47, P5098, DOI 10.1167/iovs.06-0318
   Quillen DA, 1999, AM FAM PHYSICIAN, V60, P99
   Reiss AB, 2006, CURR MED CHEM, V13, P3227, DOI 10.2174/092986706778742909
   Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rojas CV, 2002, LIPIDS, V37, P367, DOI 10.1007/s1145-002-0904-4
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Schrader M, 2006, BBA-MOL CELL RES, V1763, P1755, DOI 10.1016/j.bbamcr.2006.09.006
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Smith JD, 2000, ANN MED, V32, P118, DOI 10.3109/07853890009011761
   Souied EH, 2005, MOL VIS, V11, P1135
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994
   Tan ZS, 2007, NEUROLOGY, V68, P1902, DOI 10.1212/01.wnl.0000263217.36439.da
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P1183, DOI 10.1136/bjo.2007.114769
   Touyz RM, 2006, VASC PHARMACOL, V45, P19, DOI 10.1016/j.vph.2005.11.014
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Victor VM, 2007, CURR PHARM DESIGN, V13, P845, DOI 10.2174/138161207780363077
   Vinores SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525
   Wang J. J., OPHTHALMOLO IN PRESS
   Weber SM, 2004, AM J PHYSIOL-ENDOC M, V287, pE1171, DOI 10.1152/ajpendo.00331.2004
   Winkler BS, 1999, MOL VIS, V5
   Wong T., OPHTHALMOLO IN PRESS
   Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhao XR, 2006, J CEREBR BLOOD F MET, V26, P811, DOI 10.1038/sj.jcbfm.9600233
NR 116
TC 32
Z9 33
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-4757
EI 1687-4765
J9 PPAR RES
JI PPAR Res.
PY 2008
VL 2008
AR 389507
DI 10.1155/2008/389507
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA V13ZA
UT WOS:000207703500001
PM 18288287
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Laude, A
   Wong, WL
   Mathur, R
   Chan, CM
   Wong, E
   Wong, D
   Wong, TY
   Lim, TH
AF Cheung, Chui Ming Gemmy
   Laude, Augustinus
   Wong, Wanling
   Mathur, Ranjana
   Chan, Choi Mun
   Wong, Edmund
   Wong, Doric
   Wong, Tien Yin
   Lim, Tock Han
TI IMPROVED SPECIFICITY OF POLYPOIDAL CHOROIDAL VASCULOPATHY DIAGNOSIS
   USING A MODIFIED EVEREST CRITERIA
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; indocyanine green angiography;
   diagnosis; specificity
ID PHOTODYNAMIC THERAPY; VERTEPORFIN
AB Purpose:To evaluate the performance of polypoidal choroidal vasculopathy (PCV) diagnosis using fundus camera-based indocyanine green angiography, comparing a single sign of subretinal focal hyperfluorescence on indocyanine green angiography with a modification of the EVEREST criteria.Methods:Color fundus photograph, flash fundus camera-based fluorescein angiography, and indocyanine green angiography of 241 eyes of 230 consecutive patients with exudative maculopathy due to PCV or typical age-related macular degeneration were graded independently by 2 retinal specialists using a modified EVEREST criteria, which requires the presence of subretinal focal hyperfluorescence plus any 1 of 5 additional criteria. Discordant cases were adjudicated by a senior retinal specialist to arrive at the final diagnosis. Sensitivity, specificity, and area under the receiver operating curve of subretinal focal hyperfluorescence versus the EVEREST criteria and combinations of individual EVEREST criteria were compared.Results:Among the 241 eyes with exudative maculopathy, 131 eyes had PCV and 110 eyes had typical age-related macular degeneration. Using a single sign of subretinal focal hyperfluorescence alone for the diagnosis of PCV, sensitivity was 85.3% and specificity was 80.9%, with an area under the receiver operating curve of 83.1%. When applying the EVEREST definition, sensitivity was reduced to 78.4% but specificity improved to 87.1% with a similar area under the receiver operating curve of 82.8%. The frequency of individual criteria was highly variable, with stereo nodular appearance (73.7%) and orange nodule (55.0%) being the most common and branching vascular network, massive hemorrhage, and hypofluorescent halo in the presence of subretinal focal hyperfluorescence being less common (21.5%-28.1%).Conclusion:The EVEREST criteria have a higher specificity for the diagnosis of PCV than subretinal focal hyperfluorescence alone and may be applied to flash fundus camera-based indocyanine green angiography in a clinical setting. Stereo nodular appearance is the most important additional criterion.
C1 [Cheung, Chui Ming Gemmy; Wong, Wanling; Mathur, Ranjana; Chan, Choi Mun; Wong, Edmund; Wong, Doric; Wong, Tien Yin] Singapore Natl Eye Ctr, Med Retina Serv, Singapore 168751, Singapore.
   [Cheung, Chui Ming Gemmy; Laude, Augustinus; Wong, Wanling; Wong, Tien Yin; Lim, Tock Han] Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Wong, Wanling; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Cheung, Chui Ming Gemmy; Wong, Wanling; Mathur, Ranjana; Chan, Choi Mun; Wong, Edmund; Wong, Doric; Wong, Tien Yin] Duke NUS Grad Med Sch, Acad Clin Program Ophthalmol & Visual Sci, Singapore, Singapore.
   [Laude, Augustinus; Lim, Tock Han] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore, Singapore.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore; Tan Tock Seng Hospital
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Wong, Damon/0000-0003-4601-9121
FU National Medical Research Council [NMRC/NIG/1003/2009]; BMRC
FX Supported by National Medical Research Council grant:
   NMRC/NIG/1003/2009; BMRC.
CR Cheung CMG, 2014, RETINA
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cohen SY, 2011, RETINA-J RET VIT DIS, V31, P209, DOI 10.1097/IAE.0b013e31820a69db
   De Salvo G, 2014, AM J OPHTHALMOL
   Fleiss J.L., 2013, STAT METHODS RATES P
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2012, RETINA-J RET VIT DIS, V32, P1446, DOI 10.1097/IAE.0b013e3182695bf8
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Maruko I, 2010, GRAEF ARCH CLIN EXP, V248, P361, DOI 10.1007/s00417-009-1276-2
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 20
TC 24
Z9 25
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2015
VL 35
IS 7
BP 1375
EP 1380
DI 10.1097/IAE.0000000000000482
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM2AA
UT WOS:000357480600011
PM 26102436
DA 2022-11-30
ER

PT J
AU Tan, JH
   Bhandary, SV
   Sivaprasad, S
   Hagiwara, Y
   Bagchi, A
   Raghavendra, U
   Rao, AK
   Raju, B
   Shetty, NS
   Gertych, A
   Chua, KC
   Acharya, UR
AF Tan, Jen Hong
   Bhandary, Sulatha V.
   Sivaprasad, Sobha
   Hagiwara, Yuki
   Bagchi, Akanksha
   Raghavendra, U.
   Rao, A. Krishna
   Raju, Biju
   Shetty, Nitin Shridhara
   Gertych, Arkadiusz
   Chua, Kuang Chua
   Acharya, U. Rajendra
TI Age-related Macular Degeneration detection using deep convolutional
   neural network
SO FUTURE GENERATION COMPUTER SYSTEMS-THE INTERNATIONAL JOURNAL OF ESCIENCE
LA English
DT Article
DE Age-related Macular Degeneration; Aging; Computer-aided diagnosis
   system; Convolutional neural network; Deep learning; Fundus images
ID SEGMENTATION; FEATURES
AB Age-related Macular Degeneration (AMD) is an eye condition that affects the elderly. Further, the prevalence of AMD is rising because of the aging population in the society. Therefore, early detection is necessary to prevent vision impairment in the elderly. However, organizing a comprehensive eye screening to detect AMD in the elderly is laborious and challenging. To address this need, we have developed a fourteen-layer deep Convolutional Neural Network (CNN) model to automatically and accurately diagnose AMD at an early stage. The performance of the model was evaluated using the blindfold and ten-fold cross-validation strategies, for which the accuracy of 91.17% and 95.45% were respectively achieved. This new model can be utilized in a rapid eye screening for early detection of AMD in the elderly. It is cost-effective and highly portable, hence, it can be utilized anywhere. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Tan, Jen Hong; Hagiwara, Yuki; Chua, Kuang Chua; Acharya, U. Rajendra] Ngee Ann Polytech, Dept Elect & Comp Engn, Singapore, Singapore.
   [Bhandary, Sulatha V.; Rao, A. Krishna] Kasturba Med Coll & Hosp, Dept Ophthalmol, Manipal, Karnataka, India.
   [Sivaprasad, Sobha; Bagchi, Akanksha] NIHR Moorfields Biomed Res Ctr, London, England.
   [Raghavendra, U.] Manipal Acad Higher Educ, Manipal Inst Technol, Dept Instrumentat & Control Engn, Manipal, Karnataka, India.
   [Raju, Biju] Dr NSD Rajus Eye Hosp & Res Ctr, Kochi, Kerala, India.
   [Shetty, Nitin Shridhara] Manipal Hosp, Dept Ophthalmol, Bangalore, Karnataka, India.
   [Gertych, Arkadiusz] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Dept Surg, Los Angeles, CA 90048 USA.
   [Acharya, U. Rajendra] Singapore Sch Social Sci, Sch Sci & Technol, Dept Biomed Engn, Singapore, Singapore.
   [Acharya, U. Rajendra] Univ Malaya, Fac Engn, Dept Biomed Engn, Kuala Lumpur, Malaysia.
C3 Manipal Academy of Higher Education (MAHE); Kasturba Medical College,
   Manipal; Manipal Academy of Higher Education (MAHE); Cedars Sinai
   Medical Center; Universiti Malaya
RP Hagiwara, Y (通讯作者)，Ngee Ann Polytech, Dept Elect & Comp Engn, Singapore, Singapore.
EM yukihagiwara92@gmail.com
RI Tan, Jen Hong/ABE-6525-2020; Tan, Jenhong/AAD-3664-2020; Sivaprasad,
   S./D-6876-2015; Gertych, Arkadiusz/AAW-2572-2021; Acharya, Rajendra
   U/E-3791-2010
OI Sivaprasad, S./0000-0001-8952-0659; Gertych,
   Arkadiusz/0000-0002-3107-602X; Acharya, Rajendra U/0000-0003-2689-8552;
   Bhandary, Sulatha/0000-0002-3150-707X; Hagiwara,
   Yuki/0000-0002-5418-738X
CR Acharya U. R., 2017, INF SCI, V405
   Acharya U. R., 2017, J COMPUT SCI, V20
   Acharya U. R., 2017, KNOWL-BASED SYST, V946, P1
   Acharya UR, 2017, INFORM SCIENCES, V415, P190, DOI 10.1016/j.ins.2017.06.027
   Acharya UR, 2016, COMPUT BIOL MED, V73, P131, DOI 10.1016/j.compbiomed.2016.04.009
   Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Bouvrie J., 2006, PRACTICES, P47, DOI DOI 10.1016/J.PROTCY.2014.09.007
   Department of Economic and Social Affairs, 2017, WORLD POP PROSP 2017
   DEVROYE LP, 1979, IEEE T INFORM THEORY, V25, P601, DOI 10.1109/TIT.1979.1056087
   Duda RO., 2001, PATTERN CLASSIFICATI
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Greenspan H, 2016, IEEE T MED IMAGING, V35, P1153, DOI 10.1109/TMI.2016.2553401
   He KM, 2015, IEEE I CONF COMP VIS, P1026, DOI 10.1109/ICCV.2015.123
   Hijazi MHA, 2014, INT J SIMUL SYST SCI, V15, P57
   Hijazi MHA, 2012, KNOWL-BASED SYST, V29, P83, DOI 10.1016/j.knosys.2011.07.002
   Kingma J., 2014, ARXIV
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   Koh J. E. W., 2017, APPL INTELL, P1
   Koh J. E. W., 2017, COMPUT BIOL MED, V84
   Koh JEW, 2018, COMPUT BIOL MED, V92, P204, DOI 10.1016/j.compbiomed.2017.11.019
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Lee JG, 2017, KOREAN J RADIOL, V18, P570, DOI 10.3348/kjr.2017.18.4.570
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mookiah M. R. K., 2015, KNOWLEDGE BASED SYST, V89
   Mookiah MRK, 2015, COMPUT BIOL MED, V63, P208, DOI 10.1016/j.compbiomed.2015.05.019
   Mookiah MRK, 2014, COMPUT BIOL MED, V53, P55, DOI 10.1016/j.compbiomed.2014.07.015
   Mookiah MRK, 2014, MED BIOL ENG COMPUT, V52, P781, DOI 10.1007/s11517-014-1180-8
   National Eye Institute, 2015, FACTS AG REL MAC DEG
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Prince MJ, 2015, LANCET, V385, P549, DOI 10.1016/S0140-6736(14)61347-7
   Ruder S., 2017, OVERVIEW GRADIENT DE
   Ryan S. J., 2012, EXPERT CONSULT PREMI
   Tan JH, 2017, J COMPUT SCI-NETH, V20, P70, DOI 10.1016/j.jocs.2017.02.006
   Theano Development Team, 2016, ARXIV E PRINTS, P19
   van Grinsven MJJP, 2016, IEEE T MED IMAGING, V35, P1273, DOI 10.1109/TMI.2016.2526689
   van Stralen KJ, 2009, KIDNEY INT, V75, P1257, DOI 10.1038/ki.2009.92
   WHO, 2017, WORLD REP AG HLTH
   Yann LeCun, 2015, Nature, V521, P436, DOI 10.1038/nature14539
   Zhao BD, 2017, J SYST ENG ELECTRON, V28, P162, DOI 10.21629/JSEE.2017.01.18
   Zheng Y., 2012, INVEST OPHTHALMOL VI, V53
NR 42
TC 62
Z9 62
U1 1
U2 28
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167-739X
EI 1872-7115
J9 FUTURE GENER COMP SY
JI Futur. Gener. Comp. Syst.
PD OCT
PY 2018
VL 87
BP 127
EP 135
DI 10.1016/j.future.2018.05.001
PG 9
WC Computer Science, Theory & Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA GM3IH
UT WOS:000437997500010
DA 2022-11-30
ER

PT J
AU Sakurada, Y
   Kubota, T
   Imasawa, M
   Mabuchi, F
   Tateno, Y
   Tanabe, N
   Iijima, H
AF Sakurada, Yoichi
   Kubota, Takeo
   Imasawa, Mitsuhiro
   Mabuchi, Fumihiko
   Tateno, Yasushi
   Tanabe, Naohiko
   Iijima, Hiroyuki
TI Role of Complement Factor H I62V and Age-Related Maculopathy
   Susceptibility 2 A69S Variants in the Clinical Expression of Polypoidal
   Choroidal Vasculopathy
SO OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; JAPANESE POPULATION; GENE POLYMORPHISM;
   CIGARETTE-SMOKING; NO ASSOCIATION; LOC387715 A69S; HTRA1; RISK;
   PHENOTYPE; GENOTYPE
AB Purpose: To investigate the role of complement factor H (CFH) I62V (rs800292) and age-related maculopathy susceptibility 2 (ARMS2) A69S (rs10490924) variants in the clinical characteristics of polypoidal choroidal vasculopathy (PCV).
   Design: Cross-sectional study.
   Participants: A total of 226 Japanese patients with PCV in both eyes (44 cases) or in 1 eye (182 cases).
   Methods: Genotyping was performed in all cases for CFH I62V using TaqMan technology and for ARMS2 A69S by denaturing high-performance chromatography. The incidence of 5 characteristic funduscopic findings was studied, including serous retinal detachment, subretinal hemorrhage, serous pigment epithelial detachment (PED), hemorrhagic PED, and classic choroidal neovascularization (CNV).
   Main Outcome Measures: The association of clinical phenotypes, including the incidence of each of 5 specific fundus findings, bilaterality of the disease, and age at onset, with variants of CFH I62V or ARMS2 A69S.
   Results: Although there was no association of CFH I62V variants with any of the phenotypes in PCV, at-risk variants of ARMS2 A69S were associated with higher incidences of subretinal hemorrhage, serous PED, and hemorrhagic PED. In particular, the at-risk allele homozygosity of ARMS2 A69S increased the likelihood for hemorrhagic PED by 12.4-fold compared with non-carriers of the allele (confidence interval, 1.60-95.1, P = 0.0001). However, the at-risk allele of ARMS2 A69S was associated with a lower incidence of serous retinal detachment (P = 0.0092). Classic CNV was not associated with either variant. The mean age at the onset of PCV was significantly younger (68.8 years) in those with homozygosity of the at-risk allele of ARMS2 A69S than in those with heterozygosity (71.6 years) or in non-carriers (72.6 years) (P = 0.026). Moreover, the at-risk allele frequencies of the ARMS2 A69S were significantly higher in bilateral cases than in unilateral cases (75.0% vs. 59.3%, P = 0.007).
   Conclusions: ARMS2 A69S variants were significantly associated with hemorrhagic or subpigment epithelium lesions of PCV, and with earlier onset and bilateral involvement. The genotyping of ARMS2 A69S is more informative than that of CFH I62V in understanding the clinical features in patients with PCV.
C1 [Sakurada, Yoichi; Imasawa, Mitsuhiro; Mabuchi, Fumihiko; Tateno, Yasushi; Tanabe, Naohiko; Iijima, Hiroyuki] Univ Yamanashi, Dept Ophthalmol, Fac Med, Chuo, Yamanashi 4093898, Japan.
   [Sakurada, Yoichi; Kubota, Takeo] Univ Yamanashi, Dept Epigenet, Fac Med, Chuo, Yamanashi 4093898, Japan.
C3 University of Yamanashi; University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Dept Ophthalmol, Fac Med, 1110 Shimokato, Chuo, Yamanashi 4093898, Japan.
EM sakurada@yamanashi.ac.jp
CR Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   KINOSHITA T, 1995, CANCER, V76, P2504, DOI 10.1002/1097-0142(19951215)76:12<2504::AID-CNCR2820761215>3.0.CO;2-I
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Pai ASI, 2009, ARCH OPHTHALMOL-CHIC, V127, P1339, DOI 10.1001/archophthalmol.2009.239
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Skotheim RI, 2001, NEOPLASIA, V3, P196, DOI 10.1038/sj.neo.7900153
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 43
TC 36
Z9 41
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2011
VL 118
IS 7
BP 1402
EP 1407
DI 10.1016/j.ophtha.2010.12.010
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 786JL
UT WOS:000292303000025
PM 21397333
DA 2022-11-30
ER

PT J
AU Wei, L
   Liu, BY
   Tuo, JS
   Shen, DF
   Chen, P
   Li, ZY
   Liu, XX
   Ni, J
   Dagur, P
   Sen, HN
   Jawad, S
   Ling, D
   Park, S
   Chakrabarty, S
   Meyerle, C
   Agron, E
   Ferris, FL
   Chew, EY
   McCoy, JP
   Blum, E
   Francis, PJ
   Klein, ML
   Guymer, RH
   Baird, PN
   Chan, CC
   Nussenblatt, RB
AF Wei, Lai
   Liu, Baoying
   Tuo, Jingsheng
   Shen, Defen
   Chen, Ping
   Li, Zhiyu
   Liu, Xunxian
   Ni, Jia
   Dagur, Pradeep
   Sen, H. Nida
   Jawad, Shayma
   Ling, Diamond
   Park, Stanley
   Chakrabarty, Sagarika
   Meyerle, Catherine
   Agron, Elvira
   Ferris, Frederick L.
   Chew, Emily Y.
   McCoy, J. Philip
   Blum, Emily
   Francis, Peter J.
   Klein, Michael L.
   Guymer, Robyn H.
   Baird, Paul N.
   Chan, Chi-Chao
   Nussenblatt, Robert B.
TI Hypomethylation of the IL17RC Promoter Associates with Age-Related
   Macular Degeneration
SO CELL REPORTS
LA English
DT Article
ID DNA METHYLATION; CELL-DIFFERENTIATION; MONOZYGOTIC TWINS; IL-17;
   MACULOPATHY; MECHANISMS; EPIGENOME; DISEASE; GENOME
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly population worldwide. Although recent studies have demonstrated strong genetic associations between AMD and SNPs in a number of genes, other modes of regulation are also likely to play a role in the etiology of this disease. We identified a significantly decreased level of methylation on the IL17RC promoter in AMD patients. Furthermore, we showed that hypomethylation of the IL17RC promoter in AMD patients led to an elevated expression of its protein and messenger RNA in peripheral blood as well as in the affected retina and choroid, suggesting that the DNA methylation pattern and expression of IL17RC may potentially serve as a biomarker for the diagnosis of AMD and likely plays a role in disease pathogenesis.
C1 [Wei, Lai; Liu, Baoying; Tuo, Jingsheng; Shen, Defen; Chen, Ping; Li, Zhiyu; Ni, Jia; Sen, H. Nida; Jawad, Shayma; Ling, Diamond; Park, Stanley; Chakrabarty, Sagarika; Chan, Chi-Chao; Nussenblatt, Robert B.] NEI, Lab Immunol, NIH, Bethesda, MD 20892 USA.
   [Wei, Lai; Nussenblatt, Robert B.] NIH, Ctr Human Immunol Autoimmun & Inflammat, Bethesda, MD 20892 USA.
   [Wei, Lai; Liu, Xunxian; Nussenblatt, Robert B.] NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA.
   [Dagur, Pradeep] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.
   [Meyerle, Catherine; Agron, Elvira; Ferris, Frederick L.; Chew, Emily Y.] NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.
   [Blum, Emily; Francis, Peter J.; Klein, Michael L.] Oregon Hlth & Sci Univ, Macular Degenerat Ctr, Portland, OR 97239 USA.
   [Blum, Emily; Francis, Peter J.] Oregon Hlth & Sci Univ, Leonard Christensen Eye Pathol Lab, Casey Eye Inst, Portland, OR 97239 USA.
   [Guymer, Robyn H.; Baird, Paul N.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3002, Australia.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; National Institutes of
   Health (NIH) - USA; NIH National Center for Complementary & Alternative
   Medicine; National Institutes of Health (NIH) - USA; NIH National Heart
   Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) -
   USA; NIH National Eye Institute (NEI); Oregon Health & Science
   University; Oregon Health & Science University; Centre for Eye Research
   Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne
RP Wei, L (通讯作者)，NEI, Lab Immunol, NIH, Bethesda, MD 20892 USA.
EM lai.wei@nih.gov; drbob@nei.nih.gov
RI mccoy, john philip/ABD-9348-2021; Wei, Lai/D-1088-2014
OI Blum, Emily/0000-0002-3110-9944; Guymer, Robyn/0000-0002-9441-4356;
   Baird, Paul/0000-0002-1305-3502; Ferris, Frederick/0000-0002-4933-0639;
   Tuo, Jingsheng/0000-0002-1372-7810
FU intramural research program of the NEI; National Center for
   Complementary and Alternative Medicine; National Heart Lung and Blood
   Institute; Foundation Fighting Blindness; Macular Degeneration Center
   Research Fund of the CEI; Research to Prevent Blindness; National Health
   and Medical Research Council Centre for Clinical Research Excellence
   [529923]; NATIONAL EYE INSTITUTE [ZIAEY000527, ZIAEY000497, ZIAEY000376,
   ZIEEY000482, ZIAEY000222, ZIAEY000418, ZIAEY000524, ZIAEY000526,
   ZICEY000461, ZIAEY000523] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [ZICHL005905] Funding Source: NIH RePORTER
FX The authors thank the ATR for access to this national resource, the
   twins who volunteered for the study, and Andrea Richardson for DNA
   extraction and genotyping of twin samples. We also thank Dr. Neal Young
   for critically reading the manuscript. This study was supported by
   grants from the intramural research program of the NEI (to R.B.N.,
   C.-C.C., F.L.F., and E.Y.C.), the National Center for Complementary and
   Alternative Medicine (to L.W. and R.B.N.), the National Heart Lung and
   Blood Institute (to J.P.M.), the Foundation Fighting Blindness (to
   P.J.F.), the Macular Degeneration Center Research Fund of the CEI (to
   M.L.K. and P.J.F.), Research to Prevent Blindness (unrestricted grant to
   the CEI, Career Development Award to P.J.F.), and the National Health
   and Medical Research Council Centre for Clinical Research Excellence
   (grant 529923, Translational Clinical Research in Major Eye Diseases and
   through a Practitioner Fellowship to R.H.G.). The CERA receives
   operational infrastructure support from the Victorian Government
CR Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baranzini SE, 2010, NATURE, V464, P1351, DOI 10.1038/nature08990
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fazzari MJ, 2010, METHODS MOL BIOL, V620, P243, DOI 10.1007/978-1-60761-580-4_7
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586
   Ge Dongxia, 2008, Int Arch Med, V1, P19, DOI 10.1186/1755-7682-1-19
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hashimoto M, 2010, J EXP MED, V207, P1135, DOI 10.1084/jem.20092301
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Ho AW, 2010, SEMIN IMMUNOPATHOL, V32, P33, DOI 10.1007/s00281-009-0185-0
   Javierre BM, 2010, GENOME RES, V20, P170, DOI 10.1101/gr.100289.109
   Kaminsky ZA, 2009, NAT GENET, V41, P240, DOI 10.1038/ng.286
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710
   Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   Peter I, 2010, AM J OPHTHALMOL, V150, P450, DOI 10.1016/j.ajo.2010.06.012
   Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
NR 34
TC 130
Z9 144
U1 1
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD NOV
PY 2012
VL 2
IS 5
BP 1151
EP 1158
DI 10.1016/j.celrep.2012.10.013
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 083IU
UT WOS:000314457700012
PM 23177625
OA Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Matteoli, S
   Finocchio, L
   Biagini, I
   Giacomelli, G
   Sodi, A
   Corvi, A
   Virgili, G
   Rizzo, S
AF Matteoli, Sara
   Finocchio, Lucia
   Biagini, Ilaria
   Giacomelli, Giovanni
   Sodi, Andrea
   Corvi, Andrea
   Virgili, Gianni
   Rizzo, Stanislao
TI A thermographic study on eyes affected by Age-related Macular
   Degeneration: Comparison among various forms of the pathology and
   analysis of risk factors
SO INFRARED PHYSICS & TECHNOLOGY
LA English
DT Article
DE AMD development; Ocular hemodynamics; Ocular temperature; Infrared
   thermography
ID OCULAR SURFACE-TEMPERATURE; CHOROIDAL BLOOD-FLOW; RETROBULBAR
   HEMODYNAMICS; INFRARED THERMOGRAPHY; CORNEAL TEMPERATURE; BRUCHS
   MEMBRANE; PATHOGENESIS; MACULOPATHY; POLYMORPHISM; PERFUSION
AB The aims of this study are to investigate (1) the ocular thermographic profiles in eyes affected by Age related Macular Degeneration (AMD) and age-matched controls to detect possible hemodynamic abnormalities that could be involved in the pathogenesis of the disease, (2) whether any risk factors associated with the disease could affect the development of a form of AMD rather than another. Thirty-four eyes with Age-Related Maculopathy (ARM), 41 eyes with dry AMD, 60 eyes affected by wet AMD, and 74 eyes with fibrotic AMD were included in the study. The control group consisted of 48 healthy eyes. Exclusion criteria were represented by any other ocular diseases other than AMD, tear film abnormalities, systemic cardiovascular abnormalities, systemic diseases and a body temperature higher than 37.5 degrees C. A total of 210 eyes without pupil dilation were investigated by infrared thermography (FLIR A320). The Ocular Surface Temperature (OST) of five ocular areas was calculated by means of an image processing technique from the infrared images. Two-sample t-test, one-way ANOVA test and multivariate analysis were used for statistical analyses. ANOVA analyses showed no significant differences among AMD groups (P-value > 0.05), however, OST in AMD patients was significantly lower than in controls (P-value < 0.0001). Smokers showed higher possibility (P-value = 0.012) of developing wet AMD instead of dry AMD. Infrared thermography may be a helpful, non-invasive and not time-consuming method to be used in the management of patients with this common degenerative maculopathy. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Matteoli, Sara; Corvi, Andrea] Univ Florence, Dept Ind Engn, Lab Ocular Thermog, I-50139 Florence, Italy.
   [Finocchio, Lucia; Biagini, Ilaria; Giacomelli, Giovanni; Sodi, Andrea; Virgili, Gianni; Rizzo, Stanislao] Univ Florence, Eye Clin, Dept Surg & Translat Med, I-50139 Florence, Italy.
C3 University of Florence; University of Florence
RP Matteoli, S (通讯作者)，Univ Florence, Dept Ind Engn, Via S Marta 3, I-50139 Florence, Italy.
EM sara.matteoli@unifi.it
RI giacomelli, giovanni/ABC-6173-2020; Finocchio, Lucia/X-4835-2019;
   Virgili, Gianni/P-6607-2014
OI Corvi, Andrea/0000-0002-6714-1110; Virgili, Gianni/0000-0002-9960-2989;
   RIZZO, Stanislao/0000-0001-6302-063X; Finocchio,
   Lucia/0000-0003-1986-045X
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boiko E V, 2013, Vestn Oftalmol, V129, P86
   BUCKHOUT BC, 1980, AM J SPORT MED, V8, P206, DOI 10.1177/036354658000800313
   CHAN AW, 1991, DIABETES CARE, V14, P918, DOI 10.2337/diacare.14.10.918
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Colak E, 2012, BIOCHEM MEDICA, V22, P39
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   EAGLE RC, 1984, OPHTHALMOLOGY, V91, P613
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   FRIEDMAN E, 1965, BIBL ANAT, P129
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Galassi F, 2007, BRIT J OPHTHALMOL, V91, P878, DOI 10.1136/bjo.2007.114397
   Galassi Fernando, 2008, International Ophthalmology, V28, P399, DOI 10.1007/s10792-007-9160-8
   Girardin F, 1999, ARCH OPHTHALMOL-CHIC, V117, P166
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Grunwald JE, 2001, AM J OPHTHALMOL, V131, P751, DOI 10.1016/S0002-9394(00)00944-2
   Gugleta K, 1999, CURR EYE RES, V19, P496, DOI 10.1076/ceyr.19.6.496.5286
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jones BF, 1998, IEEE T MED IMAGING, V17, P1019, DOI 10.1109/42.746635
   Klamann MKJ, 2013, OPHTHALMIC RES, V49, P52, DOI 10.1159/000343774
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   Leveziel N, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000328981
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Morgan P B, 1999, Cont Lens Anterior Eye, V22, P11, DOI 10.1016/S1367-0484(99)80025-3
   Morgan P.B., 1994, THESIS
   MORGAN PB, 1995, EYE, V9, P615, DOI 10.1038/eye.1995.149
   Morgan PB, 1999, OPTOMETRY VISION SCI, V76, P850, DOI 10.1097/00006324-199912000-00021
   Pahl L, 2012, EXP EYE RES, V98, P75, DOI 10.1016/j.exer.2012.03.007
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sawitzke J, 2011, OPHTHALMOLOGY, V118, P2442, DOI 10.1016/j.ophtha.2011.05.027
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Sodi A, 2007, EUR J OPHTHALMOL, V17, P755, DOI 10.1177/112067210701700511
   Sodi A, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/281010
   Sodi A, 2009, EUR J OPHTHALMOL, V19, P1004, DOI 10.1177/112067210901900617
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Turlea C, 2012, Oftalmologia, V56, P36
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 58
TC 5
Z9 5
U1 1
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1350-4495
EI 1879-0275
J9 INFRARED PHYS TECHN
JI Infrared Phys. Technol.
PD MAY
PY 2016
VL 76
BP 402
EP 407
DI 10.1016/j.infrared.2016.03.016
PG 6
WC Instruments & Instrumentation; Optics; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Instruments & Instrumentation; Optics; Physics
GA DO4AV
UT WOS:000377725100049
DA 2022-11-30
ER

PT J
AU Kim, JM
   Kang, SW
   Son, DY
   Bae, K
AF Kim, Jong Min
   Kang, Se Woong
   Son, Dae Yong
   Bae, Kunho
TI RISK FACTORS AND CLINICAL SIGNIFICANCE OF PRECHOROIDAL CLEFT IN
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; prechoroidal cleft; subfoveal fibrosis
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PIGMENT EPITHELIAL DETACHMENT;
   OPTICAL COHERENCE TOMOGRAPHY; GROWTH-FACTOR THERAPY; SUBRETINAL
   HEMORRHAGE; RANIBIZUMAB; VERTEPORFIN; MEMBRANE; CELLS; SCAR
AB Purpose: To investigate the risk factors associated with prechoroidal cleft occurrence after treatment for neovascular age-related macular degeneration (nAMD) and to elucidate its clinical significance.
   Methods: Two hundred thirty-four subjects who were treated for neovascular agerelated macular degeneration were assessed to identify prechoroidal cleft on optical coherence tomography. Clinical variables were compared between patients manifesting a cleft (cleft group) and patients who did not (control group).
   Results: Prechoroidal cleft was detected in 29 of 234 patients (8.1%). Although the baseline visual acuity was not different between the 2 groups, logMAR visual acuity at final visit was 0.89 +/- 0.74 (with approximate Snellen equivalent of 20/160) in the cleft group and 0.65 +/- 0.69 (with approximate Snellen equivalent of 20/100) in controls (P < 0.05). Within cleft group, the early-onset (< 6 months) subgroup had even worse visual outcomes than the late- onset subgroup (P < 0.05). Multiple logistic regression analyses revealed that the incidence of prechoroidal cleft was positively correlated with having received intravitreal gas injection to displace a submacular hemorrhage and a diagnosis of retinal angiomatous proliferation and typical neovascular age-related macular degeneration (P < 0.05).
   Conclusion: Diagnosis of retinal angiomatous proliferation and typical neovascular agerelatedmacular degeneration, and a submacular hemorrhage treated by pneumatic displacement were the independent risk factors for development of prechoroidal cleft. Eyes with a cleft, especially clefts that develop early, generally had worse prognoses than eyes without clefts.
C1 [Kim, Jong Min; Kang, Se Woong; Son, Dae Yong; Bae, Kunho] Sungkyunkwan Univ, Sch Med, Dept Ophthalmol, Samsung Med Ctr, 81 Irwon Ro, Seoul 06351, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Sch Med, Dept Ophthalmol, Samsung Med Ctr, 81 Irwon Ro, Seoul 06351, South Korea.
EM swkang@skku.edu
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Bloch SB, 2011, ACTA OPHTHALMOL, V89, pe665, DOI 10.1111/j.1755-3768.2010.02023.x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chuah CT, 2003, CLIN EXP OPHTHALMOL, V31, P163, DOI 10.1046/j.1442-9071.2003.00627.x
   Clemens CR, 2014, ACTA OPHTHALMOL, V92, pE50, DOI 10.1111/aos.12234
   Clemens CR, 2012, BRIT J OPHTHALMOL, V96, P1088, DOI 10.1136/bjophthalmol-2011-301415
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dong A, 2014, ANGIOGENESIS, V17, P553, DOI 10.1007/s10456-013-9402-5
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   GEHRS KM, 1992, ARCH OPHTHALMOL-CHIC, V110, P833, DOI 10.1001/archopht.1992.01080180105036
   Gibran SK, 2007, BRIT J OPHTHALMOL, V91, P602, DOI 10.1136/bjo.2006.108795
   Green WR, AG REL MAC DEG HIST
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Mukai R, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-159
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shin JY, 2015, GRAEF ARCH CLIN EXP, V253, P2151, DOI 10.1007/s00417-015-2977-3
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 33
TC 10
Z9 11
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2017
VL 37
IS 11
BP 2047
EP 2055
DI 10.1097/IAE.0000000000001435
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FW3LV
UT WOS:000425208800023
PM 28114175
DA 2022-11-30
ER

PT J
AU Wickens, J
   Blinder, KJ
AF Wickens, J
   Blinder, KJ
TI A preliminary benefit-risk assessment of verteporfin in age-related
   macular degeneration
SO DRUG SAFETY
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL TRIAMCINOLONE
   ACETONIDE; RANDOMIZED CLINICAL-TRIALS; PHOTODYNAMIC THERAPY;
   COST-EFFECTIVENESS; VISUAL-ACUITY; TAP; SECONDARY; INJECTION; EYES
AB The prevalence of neovascular age-related macular degeneration (AMD) is expected to increase significantly during the next 20 years. New treatment alternatives to laser photocoagulation are on the horizon - the first of these, photodynamic therapy (PDT) with verteporfin, was approved by the US FDA in 2000. In this article we present a preliminary risk-benefit assessment of verteporfin in AMD, focusing on the landmark randomised, double-blind, placebo-controlled studies. The TAP (Treatment of Age-related macular degeneration with Photodynamic therapy) trial established the efficacy of PDT for classic subfoveal neovascularisation in AMD at 2 years follow-up. The VIP (Verteporfin in Photodynamic therapy) study concentrated on subfoveal occult-only lesions not included in the TAP study. After 2 years, treated eyes were less likely to experience visual loss. Exploratory analyses of TAP and VIP suggest that lesion size is a more significant predictor of the treatment benefit than either lesion composition or visual activity. The VIM (Visudyne (R) in Minimally classic) trial altered the standard PDT light fluence rate in the treatment of subfoveal minimally classic lesions. This trial again demonstrated a beneficial effect for those receiving treatment with PDT. The VIO (Visudyne (R) in Occult) trial, evaluating PDT in occult-only lesions as a confirmatory study of the VIP trial, did not achieve its primary end-point at 2 years. Further analyses are pending.
   PDT with verteporfin has an excellent safety profile that has been established with > 1 million treatment applications. Cost-effectiveness data are limited but suggest that PDT may be a cost-effective treatment modality. Other FDA-approved treatments (pegaptanib, ranibizurnab and bevacizumab) for neovascular AMD are discussed, as well as investigational substances such as anecortave acetate.
C1 Washington Univ, Sch Med, Barnes Retina Inst, Dept Ophthalmol, St Louis, MO 63144 USA.
C3 Washington University (WUSTL)
RP Blinder, KJ (通讯作者)，Washington Univ, Sch Med, Barnes Retina Inst, Dept Ophthalmol, 1600 S Brentwood Blvd,8th Floor, St Louis, MO 63144 USA.
EM kjblinder@pol.net
CR ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Bhavsar A, 2004, RETINA-J RET VIT DIS, V24, P512
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   CLARK AF, 1997, EXPERT OPIN INV DRUG, V6, P2867
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Houle JM, 2002, J CLIN PHARMACOL, V42, P547, DOI 10.1177/00912700222011607
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   *QLT INC, QLT ANN 2 YEAR RES V
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   REICHEL E, 2004, RETINA 2004 EVERYTHI
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Scott LJ, 2000, DRUG AGING, V16, P139, DOI 10.2165/00002512-200016020-00005
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
NR 41
TC 13
Z9 14
U1 0
U2 3
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114-5916
EI 1179-1942
J9 DRUG SAFETY
JI Drug Saf.
PY 2006
VL 29
IS 3
BP 189
EP 199
DI 10.2165/00002018-200629030-00003
PG 11
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
GA 026WD
UT WOS:000236372800003
PM 16524319
DA 2022-11-30
ER

PT J
AU Borrelli, E
   Bandello, F
   Souied, EH
   Barresi, C
   Miere, A
   Querques, L
   Sacconi, R
   Querques, G
AF Borrelli, Enrico
   Bandello, Francesco
   Souied, Eric H.
   Barresi, Costanza
   Miere, Alexandra
   Querques, Lea
   Sacconi, Riccardo
   Querques, Giuseppe
TI Neovascular age-related macular degeneration: advancement in retinal
   imaging builds a bridge between histopathology and clinical findings
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular degeneration; Optical coherence tomography
   angiography; Optical coherence tomography; Imaging; Histology;
   Geographic atrophy; Drusen; Macular neovascularization
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; CLINICOPATHOLOGICAL CORRELATION;
   TYPE-3 NEOVASCULARIZATION; CHORIOCAPILLARIS
AB Purpose To provide a review of the salient histological and imaging features in neovascular age-related macular degeneration (AMD) that will be integrated in order to have a better comprehension of the pathogenesis and clinical aspects of this disease.
   Methods A literature review of histology and imaging features in neovascular AMD was conducted.
   Results Histology has granted a detailed characterization of neovascular AMD ex vivo. In details, histological features in these eyes have offered important insights into the pathogenesis of neovascular AMD. In addition, histology donated a detailed characterization of the different types of macular neovascularization (MNV) that may complicate AMD. The introduction of optical coherence tomography angiography (OCTA) has enormously amplified our knowledge of neovascular AMD through in vivo assessment of the anatomical and pathological characteristics of this disease. New insights elucidating the morphological features of the choriocapillaris confirmed that this vascular structure plays a crucial role in the pathogenesis of neovascular AMD. OCTA also offered a detailed visualization of MNV complicating neovascular AMD.
   Conclusions New imaging technologies offer a remarkable chance to build a bridge between histology and clinical findings in neovascular AMD.
C1 [Borrelli, Enrico; Bandello, Francesco; Barresi, Costanza; Querques, Lea; Sacconi, Riccardo; Querques, Giuseppe] San Raffaele Univ Hosp, Ophthalmol Dept, Via Olgettina 60, I-20132 Milan, Italy.
   [Souied, Eric H.; Miere, Alexandra] Univ Paris XII, Ctr Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，San Raffaele Univ Hosp, Ophthalmol Dept, Via Olgettina 60, I-20132 Milan, Italy.
EM giuseppe.querques@hotmail.it
RI Miere, Alexandra/AIC-4074-2022
OI Miere, Alexandra/0000-0003-4123-8210; Sacconi,
   Riccardo/0000-0003-2891-2012; Querques, Giuseppe/0000-0002-3292-9581
CR Borrelli E, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78201-9
   Borrelli E, 2020, OPHTHALMOL THER, V9, P697, DOI 10.1007/s40123-020-00286-2
   Borrelli E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53307-x
   Borrelli E, 2019, OPHTHALMOL THER, V8, P215, DOI 10.1007/s40123-019-0178-6
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Borrelli E, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.18-23943
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Breazzano MP, 2020, RETINA-J RET VIT DIS, V40, pE55, DOI 10.1097/IAE.0000000000002892
   Capuano V, 2016, BRIT J OPHTHALMOL, V100, P677, DOI 10.1136/bjophthalmol-2015-307169
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Le HM, 2021, RETINA-J RET VIT DIS, V41, P1819, DOI 10.1097/IAE.0000000000003119
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Mastropasqua L, 2017, RETINA-J RET VIT DIS, V37, P247, DOI 10.1097/IAE.0000000000001145
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Querques G, 2021, EUR J OPHTHALMOL, V31, P3164, DOI 10.1177/1120672120986370
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1241, DOI 10.1097/IAE.0b013e31827b639e
   Querques L, 2020, BRIT J OPHTHALMOL, V104, P47, DOI 10.1136/bjophthalmol-2018-313685
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P222, DOI 10.1136/bjophthalmol-2020-316054
   Seddon Johanna M, 2016, JAMA Ophthalmol, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Skalet AH, 2017, RETINA-J RET VIT DIS, V37, P1620, DOI 10.1097/IAE.0000000000001672
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2019, RETINA-J RET VIT DIS, V39, P1451, DOI 10.1097/IAE.0000000000002412
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Yang J, 2019, AM J OPHTHALMOL, V208, P1, DOI 10.1016/j.ajo.2019.06.017
NR 42
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2022
VL 260
IS 7
BP 2087
EP 2093
DI 10.1007/s00417-022-05577-x
EA FEB 2022
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2H0GI
UT WOS:000751195800003
PM 35122134
DA 2022-11-30
ER

PT J
AU Hoyle, D
   Aslam, TM
AF Hoyle, David
   Aslam, Tariq Mehmood
TI Generative mathematical modelling to demonstrate virtual simulations of
   neovascular age related macular degeneration
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB; VEGF; CHORIOCAPILLARIS;
   BEVACIZUMAB; AFLIBERCEPT; BINDING; CELLS
AB Purpose
   To develop a generative mathematical model of wet age-related macular degeneration (AMD) and model the impact of injections of anti-vascular endothelial growth factor to virtual patients with the condition.
   Methods
   We isolated key pathophysiological components of macular degeneration in terms of macular edema development and response to anti-vascular endothelial growth factor (VEGF) agents. We developed mathematical models for each of these components using constants determined from published biological experimentation. Consequently, we combined the mathematical models of the separate components to arrive at an end-to-end model of the evolution of macular edema size and its response to treatment.
   Results
   We present a series of simulations based upon our idealised model. Initially, we demonstrate the theoretical change in macular edema height in wet macular degeneration over time without and with anti-VEGF interventions. In our final simulation, we demonstrate the powerful possibilities of virtual clinical trials by simulating a virtual model of a landmark study using our existing mathematical AMD model.
   Conclusions
   Using our mathematical modelling based upon known pathological and pharmacological processes we have been able to model the effect of intravitreal injection of an anti-VEGF agent on macular edema from age related macular degeneration. We were subsequently able to mathematically simulate a major clinical trial with results that mirror many key features of the clinical established study. We anticipate that the generative model presented here can evolve to be a useful supportive tool in the challenge to deliver optimal therapy for patients with wet macular degeneration.
C1 [Aslam, Tariq Mehmood] Univ Manchester, Sch Pharm & Optometry, Fac Biol Med & Hlth, Manchester, Lancs, England.
   [Aslam, Tariq Mehmood] NHS Cent Manchester Univ Hosp, Royal Eye Hosp, Manchester, Lancs, England.
   [Aslam, Tariq Mehmood] Heriot Watt Univ, Edinburgh, Midlothian, Scotland.
C3 University of Manchester; Manchester Royal Eye Hospital; Heriot Watt
   University
RP Aslam, TM (通讯作者)，Univ Manchester, Sch Pharm & Optometry, Fac Biol Med & Hlth, Manchester, Lancs, England.; Aslam, TM (通讯作者)，NHS Cent Manchester Univ Hosp, Royal Eye Hosp, Manchester, Lancs, England.; Aslam, TM (通讯作者)，Heriot Watt Univ, Edinburgh, Midlothian, Scotland.
EM Tariq.aslam@manchester.ac.uk
RI Aslam, Tariq/A-8532-2016
OI Aslam, Tariq/0000-0002-9739-7280; Hoyle, David/0000-0003-3483-5885
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chong V, 2016, EYE, V30, P1526, DOI 10.1038/eye.2016.202
   Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Imoukhuede PI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044791
   Klettner A, 2014, BRIT J OPHTHALMOL, V98, P1448, DOI 10.1136/bjophthalmol-2014-305105
   Martin KRG, 2003, INVEST OPHTH VIS SCI, V44, P4357, DOI 10.1167/iovs.02-1332
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Ohno-Matsui Kyoko, 2004, Curr Opin Ophthalmol, V15, P197, DOI 10.1097/01.icu.0000120709.35941.e9
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   RCoreTeam, 2015, LANGUAGE ENV STAT CO
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Soetaert K, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i09
   Stefanini MO, 2010, CANCER RES, V70, P9886, DOI 10.1158/0008-5472.CAN-10-1419
   Strunnikova NV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008402
   Yang JH, 2014, MOL PHARMACEUT, V11, P3421, DOI 10.1021/mp500160v
NR 21
TC 2
Z9 2
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 6
PY 2017
VL 12
IS 12
AR e0189053
DI 10.1371/journal.pone.0189053
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FO9MS
UT WOS:000417212200061
PM 29211782
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Teper, SJ
   Nowinska, A
   Pilat, J
   Palucha, A
   Wylegala, E
AF Teper, Slawomir J.
   Nowinska, Anna
   Pilat, Jaroslaw
   Palucha, Andrzej
   Wylegala, Edward
TI Involvement of genetic factors in the response to a variable-dosing
   ranibizumab treatment regimen for age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; PHOTODYNAMIC THERAPY; LOC387715 GENOTYPES;
   ASSOCIATION; VARIANTS; HTRA1; AMD
AB Purpose: To determine whether gene polymorphisms of the major genetic risk factor for age-related macular susceptibility 2 (ARMS2 A69S) and the complement factor H Y402H influence the response to a variable-dosing treatment regimen with ranibizumab for age-related macular degeneration.
   Methods: This prospective cohort study included 90 patients (90 eyes) with exudative age related macular degeneration (AMD) treated with ranibizumab. Patients underwent a 1-year treatment as in the Study of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (Mitchell et al.). Injections were administered monthly when a patient lost five letters on the Early Treatment Diabetic Retinopathy Study chart or gained 100 mu m in central subfield retinal thickness (CSRT). Genotypes (rs10490924 and rs1061170) were analyzed using gene sequence analysis. Best-corrected visual acuity (BCVA) and CSRT values were compared between ARMS2 and complement factor H genotypes. Multiple regression analysis was used to assess the statistical significance.
   Results: Mean increase in visual acuity was 4.44 +/- 8.12 letters with a 103.63 +/- 94.7 mu m decrease in CSRT. BCVA improvement was statistically significant in all genotype groups except in homozygous 69S in the AMRS2 gene. CSRT and BCVA changes were correlated (r=0.2521; 95% CI: 0.04746-0.4364, p=0.0165). Multiple regression analysis revealed a significant impact of 69S (p=0.015) on the change in BCVA.
   Conclusions: Visual acuity did not improve during the study in patients homozygous for ARMS2 69S, despite a decrease in CSRT. Further investigation is needed to confirm our findings and understand the mechanisms involved.
C1 [Teper, Slawomir J.; Nowinska, Anna; Pilat, Jaroslaw; Wylegala, Edward] Okregowy Szpital Kolejowy Katowicach, Dept Ophthalmol, PL-40760 Katowice, Poland.
   [Palucha, Andrzej] Genomed, Warsaw, Poland.
RP Teper, SJ (通讯作者)，Okregowy Szpital Kolejowy Katowicach, Dept Ophthalmol, Ul Panewnicka 65, PL-40760 Katowice, Poland.
EM slawomir.teper@gmail.com
RI Wylegala, Edward/AAD-3961-2019; Teper, Slawomir/AAQ-1938-2021; Nowinska,
   Anna K/G-6165-2013
OI Teper, Slawomir/0000-0002-0935-8880; Nowinska, Anna
   K/0000-0002-8418-3486
FU Polish Ministry of Science, Warsaw, Poland [N N402 194335]; Medical
   University of Silesia
FX Research funded by the Polish Ministry of Science, Warsaw, Poland
   (project grant no: N N402 194335), and the Medical University of
   Silesia.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chowers I, 2008, MOL VIS, V14, P2263
   Francis PJ, 2008, MOL VIS, V14, P1395
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Ioannidis JPA, 2006, AM J EPIDEMIOL, V164, P609, DOI 10.1093/aje/kwj259
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Mataix J, 2009, OPHTHAL SURG LAS IM, V40, P277, DOI 10.3928/15428877-20090430-09
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637
NR 17
TC 64
Z9 69
U1 0
U2 5
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD DEC 7
PY 2010
VL 16
IS 277-79
BP 2598
EP 2604
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 697IC
UT WOS:000285505700002
PM 21151600
DA 2022-11-30
ER

PT J
AU Calvo-Gonzalez, C
   Reche-Frutos, J
   Fernandez-Vigo, JI
   Donate-Lopez, J
   Serrano-Garcia, I
   Fernandez-Perez, C
AF Calvo-Gonzalez, Cristina
   Reche-Frutos, Juan
   Ignacio Fernandez-Vigo, Jose
   Donate-Lopez, Juan
   Serrano-Garcia, Irene
   Fernandez-Perez, Cristina
TI Indocyanine green angiography findings in patients with neovascular
   age-related macular degeneration refractory to ranibizumab switched to
   aflibercept
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Indocyanine green angiography; Polypoidal choroidal vasculopathy;
   Age-related macular degeneration; Ranibizumab; Poor responders;
   Aflibercept
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; TREAT-AND-EXTEND; VERTEPORFIN
   PHOTODYNAMIC THERAPY; ONE-YEAR OUTCOMES; INTRAVITREAL AFLIBERCEPT;
   DIAGNOSIS; RESISTANT; COMBINATION; EFFICACY
AB Purpose To describe indocyanine green angiography (ICGA) and visual acuity (VA) results in patients with neovascular age-related macular degeneration (nAMD) refractory to ranibizumab switched to aflibercept. Methods This study is a prospective interventional case series. Thirty-two eyes of 32 patients with nAMD showing a poor response after at least 24 months of ranibizumab were switched to aflibercept. Twenty eyes had type I choroidal neovascularization (CNV group), and 12 eyes had polypoidal choroidal vasculopathy (PCV group). After an initial loading dose of three monthly aflibercept injections, treatment was continued on a treat-and-extend basis. ICGA was performed just before the first aflibercept injection (baseline) and 12 and 24 months later. The variables recorded were: closure of polyps and lesion area, VA, number of aflibercept injections, dry macula, and pigment epithelium detachment. Results The following means were recorded in the CNV and PCV groups, respectively: number of ranibizumab injections 20.4 +/- 11.2 and 22.4 +/- 12.9 (p = 0.740); baseline VA (before aflibercept) 73.2 +/- 9.1 and 70.3 +/- 13.7 letters (p = 0.654); and final VA 73.0 +/- 7.6 and 69.3 +/- 15.6 letters (p = 0.509). VA remained stable (p = 0.761 and 0.964) after 15.5 +/- 3 and 15.1 +/- 3.5 aflibercept injections (p = 0.244). At 24 months, dry macula was noted in 40 to 50% of the eyes (p = 0.620). Complete resolution of polyps was observed in 58% at 12 months and 92% at 24 months. Conclusions In patients with nAMD refractory to ranibizumab, aflibercept was effective at maintaining VA and closing numerous polyps. In half of the patients, dry macula was observed at 24 months.
C1 [Calvo-Gonzalez, Cristina; Reche-Frutos, Juan; Ignacio Fernandez-Vigo, Jose; Donate-Lopez, Juan] Hosp Univ Clin San Carlos, Inst Invest Sanitaria San Carlos IdISSC, Dept Ophthalmol, C Prof Martin Lagos, Madrid 28040, Spain.
   [Serrano-Garcia, Irene; Fernandez-Perez, Cristina] Hosp Univ Clin San Carlos, Inst Invest Sanitaria San Carlos IdISSC, Dept Prevent Med, Madrid, Spain.
RP Calvo-Gonzalez, C (通讯作者)，Hosp Univ Clin San Carlos, Inst Invest Sanitaria San Carlos IdISSC, Dept Ophthalmol, C Prof Martin Lagos, Madrid 28040, Spain.
EM calvo_glez@yahoo.es
RI Fernandez-Vigo, Jose Ignacio/G-9779-2017; Fernandez Perez,
   Cristina/I-2220-2015
OI Fernandez-Vigo, Jose Ignacio/0000-0001-8745-3464; Serrano Garcia,
   Irene/0000-0001-7184-5447; Fernandez Perez,
   Cristina/0000-0001-9853-6257; DONATE, JUAN/0000-0002-9944-6736
CR Agorogiannis EI, 2018, EYE, V32, P1731, DOI 10.1038/s41433-018-0168-2
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Cahuzac V, 2018, OPHTHALMOLOGICA, V25, P1
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Hara C, 2019, BRIT J OPHTHALMOL, V103, P623, DOI 10.1136/bjophthalmol-2018-312275
   Hara C, 2016, RETINA-J RET VIT DIS, V36, P37, DOI 10.1097/IAE.0000000000000767
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0305-2
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Matsumiya W, 2017, GRAEF ARCH CLIN EXP, V255, P541, DOI 10.1007/s00417-016-3500-1
   Medina-Baena M, 2018, CASE REP OPHTHALM, V9, P172, DOI 10.1159/000487227
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Oshima Y, 2017, OPHTHALMOLOGICA, V238, P163, DOI 10.1159/000477448
   Ozkaya A, 2016, EYE, V30, P958, DOI 10.1038/eye.2016.71
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Takayama K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176100
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 32
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD NOV
PY 2019
VL 39
IS 11
BP 2441
EP 2448
DI 10.1007/s10792-019-01082-z
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JJ3GP
UT WOS:000494050000002
PM 30767090
DA 2022-11-30
ER

PT J
AU Ozkan, B
   Karabas, LV
   Altintas, O
   Tamer, GS
   Yuksel, N
   Caglar, Y
AF Ozkan, Berna
   Karabas, Levent V.
   Altintas, Ozgul
   Tamer, Gulden Sonmez
   Yuksel, Nursen
   Caglar, Yusuf
TI Plasma antiphospholipid antibody levels in age-related macular
   degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID LONG-TERM INCIDENCE; CARDIOVASCULAR-DISEASE; ANTICARDIOLIPIN ANTIBODIES;
   COMPLEMENT ACTIVATION; ASSOCIATION; PATHOGENESIS; DEMENTIA; DRUSEN;
   RISK; EPIDEMIOLOGY
AB Purpose: To investigate the association of age-related macular degeneration (AMD) with plasma antiphospholipid antibody levels.
   Methods: This prospective study included 19 patients diagnosed as having dry-type AMD, 23 patients with exudative-type AMD, and 25 control subjects. Venous blood samples of the participants were obtained. Anticardiolipin antibodies (aCL) isotypes IgG and IgM were measured by means of an enzyme-linked immunosorbent assay. Lupus anticoagulant (LA) antibodies were measured by the dilute Russell viper venom time screen test.
   Results: The mean aCL IgG concentration in patients with exudative-type AMD was significantly higher than in patients with dry-type AMD and control subjects. The mean +/- SE of aCL IgG levels in patients with exudative-type AMD and dry-type AMD and control subjects was 5.46 +/- 1.26; 2:55 +/- 0.78; and 0.32 +/- 0.1, respectively. The mean aCL IgM levels and LA levels in the 3 groups were not statistically different.
   Conclusions: Our findings suggest that elevated levels of serum aCL, a risk factor for cardiovascular and cerebrovascular diseases, may be associated with exudative-type AMD.
C1 [Ozkan, Berna; Karabas, Levent V.; Altintas, Ozgul; Yuksel, Nursen; Caglar, Yusuf] Kocaeli Univ, Dept Ophthalmol, Fac Med, Kocaeli, Turkey.
   [Tamer, Gulden Sonmez] Kocaeli Univ, Dept Microbiol, Fac Med, Kocaeli, Turkey.
C3 Kocaeli University; Kocaeli University
RP Ozkan, B (通讯作者)，A12-1 Samandira, TR-34885 Istanbul, Turkey.
EM berna.ozkan@kocaeli.edu.tr
RI Karabas, Levent/AAR-8531-2020; Özkan, Berna/C-3705-2019; Yüksel,
   Nurşen/AAR-8438-2020; Altintas, Ozgul/E-6705-2016; Altintas,
   Ozgul/AAS-2085-2020
OI Özkan, Berna/0000-0002-2212-4448; Altintas, Ozgul/0000-0001-8533-5026
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Behbehani Raed, 2004, Curr Opin Ophthalmol, V15, P483, DOI 10.1097/01.icu.0000144389.97491.52
   Bili A, 2000, CIRCULATION, V102, P1258, DOI 10.1161/01.CIR.102.11.1258
   Brey RL, 2000, J AUTOIMMUN, V15, P133, DOI 10.1006/jaut.2000.0426
   Caronti B, 1998, J AUTOIMMUN, V11, P425, DOI 10.1006/jaut.1998.0214
   Chapman J, 1999, LUPUS, V8, P127, DOI 10.1191/096120399678847524
   Chapman J, 2002, J NEUROL SCI, V203, P81, DOI 10.1016/S0022-510X(02)00271-X
   CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701
   DelPapa N, 1997, AM J REPROD IMMUNOL, V38, P212
   Demirci FYK, 1998, INT OPHTHALMOL, V22, P323, DOI 10.1023/A:1006305705080
   Eikelboom JW, 2000, STROKE, V31, P1069, DOI 10.1161/01.STR.31.5.1069
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gomez-Puerta JA, 2005, RHEUMATOLOGY, V44, P95, DOI 10.1093/rheumatology/keh408
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Holers VM, 2002, J EXP MED, V195, P211, DOI 10.1084/jem.200116116
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Iyer HV, 2007, ANN PHARMACOTHER, V41, P528, DOI 10.1345/aph.1H186
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Kovacs Katalin A, 2007, Ideggyogy Sz, V60, P169
   Levine SR, 1996, LUPUS, V5, P347, DOI 10.1177/096120339600500503
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Miserocchi E, 2001, AM J OPHTHALMOL, V131, P451, DOI 10.1016/S0002-9394(00)00884-9
   MISEROCCHI E, 2001, DIAGNOSIS TREATMENT, P683
   Mosek A, 2000, DEMENT GERIATR COGN, V11, P36, DOI 10.1159/000017211
   Nosbaum A, 2007, EUR J DERMATOL, V17, P546
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Petri M, 2000, J AUTOIMMUN, V15, P145, DOI 10.1006/jaut.2000.0409
   Pierangeli SS, 2006, CURR OPIN HEMATOL, V13, P366
   Piette JC, 1998, CIRCULATION, V97, P2195, DOI 10.1161/01.CIR.97.22.2195
   Ramos-Casals M, 2007, MEDICINE, V86, P242, DOI 10.1097/MD.0b013e3181441a68
   Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202
   Salmon JE, 2002, ANN RHEUM DIS, V61, P46
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Sherer Y, 2003, IMMUNOBIOLOGY, V207, P13, DOI 10.1078/0171-2985-00212
   Shoenfeld Y, 1998, LUPUS, V7, pS140, DOI 10.1177/096120339800700231
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Verro P, 1998, STROKE, V29, P2245, DOI 10.1161/01.STR.29.11.2245
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wiechens B, 1997, AM J OPHTHALMOL, V123, P848, DOI 10.1016/S0002-9394(14)71142-0
NR 49
TC 7
Z9 7
U1 0
U2 7
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2012
VL 47
IS 3
BP 264
EP 268
DI 10.1016/j.jcjo.2012.03.016
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 978RL
UT WOS:000306763100015
PM 22687304
DA 2022-11-30
ER

PT J
AU Aggermann, T
   Haas, P
   Binder, S
AF Aggermann, Tina
   Haas, Paulina
   Binder, Susanne
TI Anecortave acetate for fibrotic lesions with presence of residual
   peripheral activity in age-related macular degeneration
SO ANNALS OF OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; PEGAPTANIB; NEOVASCULARIZATION; BEVACIZUMAB
AB We retrospectively examined the efficacy of a single juxtascleral anecortave acetate depot injection for the treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration in 20 consecutive patients who rejected intravitreal treatment. As a second line-therapy of classic and occult fibrotic lesions with active peripheral zones, anecortave seems to be a vision conserving therapeutic option.
C1 [Aggermann, Tina; Haas, Paulina; Binder, Susanne] Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, A-1030 Vienna, Austria.
   [Aggermann, Tina; Binder, Susanne] Rudolf Fdn Clin, Dept Ophthalmol, Vienna, Austria.
C3 Ludwig Boltzmann Institute
RP Aggermann, T (通讯作者)，Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Juchgasse 25, A-1030 Vienna, Austria.
EM tina@aggermann.at
CR Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chapman JA, 2006, ANN PHARMACOTHER, V40, P1322, DOI 10.1345/aph.1G604
   Hayek S, 2007, KLIN MONATSBL AUGENH, V224, P279, DOI 10.1055/s-2007-962848
   Jonas JB, 2006, EUR J OPHTHALMOL, V16, P774, DOI 10.1177/112067210601600522
   Jonas JB, 2006, OPHTHALMIC RES, V38, P324, DOI 10.1159/000096226
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Pieramici DJ, 2006, EXPERT OPIN BIOL TH, V6, P1237, DOI 10.1517/14712598.6.11.1237
   Regillo CD, 2007, SURV OPHTHALMOL, V52, pS70, DOI 10.1016/j.survophthal.2006.11.001
   Russell SR, 2007, SURV OPHTHALMOL, V52, pS79, DOI 10.1016/j.survophthal.2006.11.005
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
NR 13
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CONTEMPORARY MEDICINE SURGERY & OPHTHALMOLOGY
PI LINCOLNWOOD
PA 7250 N CICERO AVE, STE LL 6, LINCOLNWOOD, IL 60172 USA
SN 1530-4086
J9 ANN OPHTHALMOL
JI Ann. Ophthalmol.
PD SPR
PY 2008
VL 40
IS 1
BP 28
EP 30
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 332AK
UT WOS:000258053800007
PM 18556978
DA 2022-11-30
ER

PT J
AU Holz, FG
   Figueroa, MS
   Bandello, F
   Yang, Y
   Ohji, M
   Dai, H
   Wykrota, H
   Sharma, S
   Dunger-Baldauf, C
   Lacey, S
   Macfadden, W
   Mitchell, P
AF Holz, Frank G.
   Figueroa, Marta S.
   Bandello, Francesco
   Yang, Yit
   Ohji, Masahito
   Dai, Hong
   Wykrota, Halina
   Sharma, Sanjay
   Dunger-Baldauf, Cornelia
   Lacey, Sue
   Macfadden, Wayne
   Mitchell, Paul
TI RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION Results From LUMINOUS, a Global Real-World Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE anti-VEGF therapy; LUMINOUS; effectiveness; neovascular age-related
   macular degeneration; ranibizumab; observational study; real-world;
   treatment-naive; visual acuity
ID VISUAL-ACUITY; INTRAVITREAL RANIBIZUMAB; STABILIZATION CRITERIA;
   TREATMENT PATTERNS; 12-MONTH OUTCOMES; CLINICAL-PRACTICE; EXTEND
   REGIMEN; 0.5 MG; PREVALENCE; THERAPY
AB Purpose: To evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5 mg in treatment-naive patients with neovascular age-related macular degeneration enrolled in LUMINOUS study. Methods: This 5-year, prospective, multicenter, observational study recruited 30,138 adult patients (treatment-naive or previously treated with ranibizumab or other ocular treatments) who were treated according to the local ranibizumab label. Results: Six thousand two hundred and forty-one treatment-naive neovascular age-related macular degeneration patients were recruited. Baseline (BL) demographics were, mean (SD) age 75.0 (10.2) years, 54.9% females, and 66.5% Caucasian. The mean (SD) visual acuity (VA; letters) gain at 1 year was 3.1 (16.51) (n = 3,379; BLVA, 51.9 letters [Snellen: 20/92]) with a mean (SD) of 5.0 (2.7) injections and 8.8 (3.3) monitoring visits. Presented by injection frequencies <3 (n = 537), 3 to 6 (n = 1,924), and >6 (n = 918), visual acuity gains were 1.6 (14.93), 3.3 (16.57), and 3.7 (17.21) letters, respectively. Stratified by BLVA <23 (n = 382), 23 to <39 (n = 559), 39 to <60 (n = 929), 60 to <74 (n = 994), and >= 74 (n = 515), visual acuity change was 12.6 (20.63), 6.7 (17.88), 3.6 (16.41), 0.3 (13.83), and -3.0 (11.82) letters, respectively. The incidence of ocular/nonocular adverse events was 8.2%/12.8% and serious adverse events were 0.9%/7.4%, respectively. Conclusion: These results demonstrate the effectiveness and safety of ranibizumab in treatment-naive neovascular age-related macular degeneration patients.
C1 [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Figueroa, Marta S.] Ramon Y Cajal Univ Hosp, Dept Ophthalmol, Madrid, Spain.
   [Bandello, Francesco] Univ Vita Salute, Sci Inst San Raffaele, Dept Ophthalmol, Milan, Italy.
   [Yang, Yit] Wolverhampton Eye Infirm, Dept Ophthalmol, Wolverhampton, England.
   [Yang, Yit] Aston Univ, Sch Hlth & Life Sci, Dept Ophthalmol, Birmingham, W Midlands, England.
   [Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga, Japan.
   [Dai, Hong] Beijing Hosp, Natl Ctr Gerontol, Dept Ophthalmol, Beijing, Peoples R China.
   [Wykrota, Halina] I Klin Okulistyki Slaskiej Akad Med, Dept Ophthalmol, Katowicach, Poland.
   [Sharma, Sanjay] Queens Univ, Dept Ophthalmol & Epidemiol, Kingston, ON, Canada.
   [Dunger-Baldauf, Cornelia; Macfadden, Wayne] Novartis Pharma AG, Dept Ophthalmol, Basel, Switzerland.
   [Lacey, Sue] Novartis Pharmaceut UK Ltd, Dept Ophthalmol, Frimley, Camberley, England.
   [Mitchell, Paul] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW, Australia.
   [Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia.
C3 University of Bonn; Hospital Universitario Ramon y Cajal; Vita-Salute
   San Raffaele University; IRCCS Ospedale San Raffaele; Aston University;
   Shiga University of Medical Science; Beijing Hospital; Queens University
   - Canada; Novartis; Novartis; University of Sydney; University of
   Sydney; Westmead Institute for Medical Research
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Frank.Holz@ukbonn.de
OI bandello, francesco/0000-0003-3238-9682
FU Novartis Pharma AG [NCT01318941]
FX Supported and sponsored by Novartis Pharma AG and is registered with
   www.clinicaltrials.gov (NCT01318941). The sponsor participated in the
   study design, conducting the study, and data collection, management,
   analysis, and interpretation. Proprietary or commercial disclosures may
   be found after the references.
CR [Anonymous], 2017, BUSINESS WIRE
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bertelmann T, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0536-1
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1594, DOI 10.1016/j.ophtha.2011.02.022
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campochiaro PA, 2014, OPHTHALMOLOGY, V121, P209, DOI 10.1016/j.ophtha.2013.08.038
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   ClinicalTrials.gov, OBS EFF SAF RAN REAL
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   European Medicines Agency, 2016, LUC ASS REP
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Food and Drug Administration, 2017, LOC PRESCR INF
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holekamp Nancy M, 2016, Am J Manag Care, V22, ps284
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Ishibashi T, 2015, OPHTHALMOLOGY, V122, P1402, DOI 10.1016/j.ophtha.2015.02.006
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414
   Lai TYY, 2018, RETINA-J RET VIT DIS, V38, P1464, DOI 10.1097/IAE.0000000000001744
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larsen M, 2016, OPHTHALMOLOGY, V123, P1101, DOI 10.1016/j.ophtha.2016.01.011
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Prunte C, 2016, BRIT J OPHTHALMOL, V100, P787, DOI 10.1136/bjophthalmol-2015-307249
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Rousseau C, 2015, VALUE HEALTH, V18, pA428, DOI 10.1016/j.jval.2015.09.594
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Tadayoni R, 2016, OPHTHALMOLOGY, V123, P1332, DOI 10.1016/j.ophtha.2016.02.030
   Teper Slawomir, 2014, Pol Merkur Lekarski, V37, P56
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Vaz-Pereira S, 2017, EUR J OPHTHALMOL, V27, P756, DOI 10.5301/ejo.5000943
   Vorum H, 2016, CURR MED RES OPIN, V32, P1943, DOI 10.1080/03007995.2016.1221803
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
   Wolf S, 2014, OPHTHALMOLOGY, V121, P682, DOI 10.1016/j.ophtha.2013.10.023
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu B, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7689862
   Yang Y, 2017, OPHTHALMOL THER, V6, P175, DOI 10.1007/s40123-017-0091-9
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
   Ziemssen F, 2017, ANN M ASS RES VIS OP
NR 52
TC 48
Z9 48
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2020
VL 40
IS 9
BP 1673
EP 1685
DI 10.1097/IAE.0000000000002670
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NQ9JY
UT WOS:000571183800006
PM 31764612
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Hsu, CC
   Lee, CY
   Lin, CJ
   Yeh, H
AF Hsu, Chih-Chung
   Lee, Chia-Yen
   Lin, Cheng-Jhong
   Yeh, Hung
TI A comprehensive study of age-related macular degeneration detection
SO MULTIMEDIA TOOLS AND APPLICATIONS
LA English
DT Article
DE Age-related macular degeneration (AMD); Segmentation; Deep learning;
   Annotation quality; Small-symptom dilation (SSD)
ID AUTOMATIC DETECTION; EXUDATE DETECTION; RETINAL IMAGES; SEGMENTATION
AB Age-related macular degeneration (AMD) is an illness involving the degeneration of the macula of the retina. Fundus photography is the most affordable and convenient way to monitor individuals, in which AMD symptoms segmentation is necessary to assist clinical diagnosis. This study conducted a large number of experimental discussions on the annotation quality and symptoms categories to find a reliable learning strategy, and then applied it to early detection of AMD. Specifically, we discuss the inference of the representational power of the deep neural network, loss function selection, the preprocessing scheme of annotation augmentation, and the annotation quality of the dataset on prediction performance. This paper verified that different learning strategies need to be selected for the AMD symptoms segmentation tasks with varying characteristics of database, which can be used as a reference for developing the related research in the future. On the other hand, we demonstrated that current medical datasets suffer from annotation quality uncertainty, leading to limited learning capabilities. In the future, it is necessary to develop methods to overcome the impact of datasets with poor annotation quality.
C1 [Hsu, Chih-Chung] Natl Cheng Kung Univ, Inst Data Sci, Tainan, Taiwan.
   [Lee, Chia-Yen; Lin, Cheng-Jhong; Yeh, Hung] Natl United Univ, Dept Elect Engn, Miaoli, Taiwan.
C3 National Cheng Kung University; National United University
RP Lee, CY (通讯作者)，Natl United Univ, Dept Elect Engn, Miaoli, Taiwan.
EM leecyya@gmail.com
CR Francia GA, 2020, IEEE ACCESS, V8, P38493, DOI 10.1109/ACCESS.2020.2975745
   Badar M, 2018, COMM COM INF SC, V894, P313, DOI 10.1007/978-3-319-95921-4_29
   Bertasius G, 2017, PROC CVPR IEEE, P6137, DOI 10.1109/CVPR.2017.650
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Chen L, 2018, PROCEEDINGS OF THE 2ND INTERNATIONAL CONFERENCE ON COMPUTER SCIENCE AND APPLICATION ENGINEERING (CSAE2018), DOI 10.1145/3207677.3278067
   Chen LC, 2018, IEEE T PATTERN ANAL, V40, P834, DOI 10.1109/TPAMI.2017.2699184
   Chen LB, 2017, IEEE INT SYMP NANO, P1, DOI 10.1109/NANOARCH.2017.8053709
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fleming AD, 2007, PHYS MED BIOL, V52, P7385, DOI 10.1088/0031-9155/52/24/012
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Guo S, 2019, NEUROCOMPUTING, V349, P52, DOI 10.1016/j.neucom.2019.04.019
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Heller N, 2018, LECT NOTES COMPUT SC, V11043, P112, DOI 10.1007/978-3-030-01364-6_13
   Hu K, 2018, NEUROCOMPUTING, V309, P179, DOI 10.1016/j.neucom.2018.05.011
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Joshi S, 2020, EUR J OPHTHALMOL, V30, P1135, DOI 10.1177/1120672119843021
   Karimi D, 2020, MED IMAGE ANAL, V65, DOI 10.1016/j.media.2020.101759
   Kats E, 2019, I S BIOMED IMAGING, P1563, DOI 10.1109/ISBI.2019.8759518
   Kerfoot E, 2019, P INT WORKSH STAT AT, P371, DOI [DOI 10.1007/978-3-030-12029-0_40, 10.1007/978-3-030-12029-0_40]
   Khanna A, 2020, BIOCYBERN BIOMED ENG, V40, P1314, DOI 10.1016/j.bbe.2020.07.007
   Kou CX, 2019, J MED IMAGING, V6, DOI 10.1117/1.JMI.6.2.025008
   Li D, 2019, IEEE IMAGE PROC, P1425, DOI 10.1109/ICIP.2019.8803101
   Lin TY, 2017, IEEE I CONF COMP VIS, P2999, DOI 10.1109/ICCV.2017.324
   Long J, 2015, PROC CVPR IEEE, P3431, DOI 10.1109/CVPR.2015.7298965
   Marino C, 2008, WSEAS Transactions on Computers, V7, P207
   Cardenas JM, 2013, ADV INTELL SYST, V184, P73
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Pham QTM, 2020, ELECTRONICS-SWITZ, V9, DOI 10.3390/electronics9101617
   Quellec G, 2017, MED IMAGE ANAL, V39, P178, DOI 10.1016/j.media.2017.04.012
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Shen WH, 2021, INVERSE PROBL IMAG, V15, P1333, DOI 10.3934/ipi.2020057
   Sopharak A, 2009, SENSORS-BASEL, V9, P2148, DOI 10.3390/s90302148
   Spanhol FA, 2016, IEEE IJCNN, P2560, DOI 10.1109/IJCNN.2016.7727519
   Tajbakhsh N, 2020, MED IMAGE ANAL, V63, DOI 10.1016/j.media.2020.101693
   Walter T, 2007, MED IMAGE ANAL, V11, P555, DOI 10.1016/j.media.2007.05.001
   Yan F, 2018, LECT NOTES COMPUT SC, V11071, P48, DOI 10.1007/978-3-030-00934-2_6
   Yazid H, 2012, J MED SYST, V36, P1997, DOI 10.1007/s10916-011-9659-4
   Yu W, 2019, IEEE IMAGE PROC, P250, DOI 10.1109/ICIP.2019.8802951
   Zabihollahy F, 2019, PROC SPIE, V10953, DOI 10.1117/12.2513034
   Zhang JX, 2020, SYMMETRY-BASEL, V12, DOI 10.3390/sym12050721
   Zhang XW, 2014, MED IMAGE ANAL, V18, P1026, DOI 10.1016/j.media.2014.05.004
   Zong YS, 2020, IEEE ACCESS, V8, P167225, DOI 10.1109/ACCESS.2020.3023273
NR 43
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1380-7501
EI 1573-7721
J9 MULTIMED TOOLS APPL
JI Multimed. Tools Appl.
PD APR
PY 2022
VL 81
IS 9
BP 11897
EP 11916
DI 10.1007/s11042-021-11896-8
EA FEB 2022
PG 20
WC Computer Science, Information Systems; Computer Science, Software
   Engineering; Computer Science, Theory & Methods; Engineering, Electrical
   & Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering
GA 0P3ES
UT WOS:000756332700005
DA 2022-11-30
ER

PT J
AU Lee, JH
   Lee, SC
   Byeon, SH
   Koh, HJ
   Kim, SS
   Lee, CS
AF Lee, Ji Hwan
   Lee, Sung Chul
   Byeon, Suk Ho
   Koh, Hyoung Jun
   Kim, Sung Soo
   Lee, Christopher Seungkyu
TI EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR
   ENDOTHELIAL GROWTH FACTOR THERAPY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE dorzolamide; macular degeneration; therapeutics; timolol; vascular
   endothelial growth factor A
ID PHARMACOKINETICS; RANIBIZUMAB; VEGF; BEVACIZUMAB; EDEMA
AB Purpose: To evaluate the efficacy of adjuvant topical dorzolamide-timolol in patients with neovascular age-related macular degeneration unresponsive to anti-vascular endothelial growth factor therapy.
   Methods: This retrospective, interventional study included 15 patients with neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor. Patients used topical dorzolamide-timolol twice daily in the neovascular age-related macular degeneration eye and received anti-vascular endothelial growth factor therapy at each visit, with the same fixed interval and agent as before the addition of dorzolamide-timolol. Central macular thickness, maximal subretinal fluid height, and maximal pigment epithelial detachment height were measured at baseline and every visit.
   Results: The mean follow-up period was 17.2 +/- 5.5 weeks. The mean central macular thickness decreased from 383.5 mu m at baseline to 298.3 mu m at the final visit (P = 0.041). The mean maximal subretinal fluid height decreased from 105.0 mu m at baseline to 58.3 mu m at the final visit (P = 0.021). Complete resolution of subretinal fluid was observed in 3 of 11 subretinal fluid-type eyes. There was no significant change in the maximal pigment epithelial detachment height. The mean logarithm of the minimum angle of resolution visual acuity decreased from 0.61 (20/81 Snellen) at baseline to 0.66 (20/91 Snellen) at final visit, which was not significant (P = 0.314). The mean intraocular pressure decreased significantly from 14.9 mmHg at baseline to 12.3 mmHg at the final visit (P = 0.005).
   Conclusion: The use of adjuvant topical dorzolamide-timolol was effective in decreasing central macular thickness and subretinal fluid in patients with neovascular age-related macular degeneration refractory to continual fixed-interval intravitreal anti-vascular endothelial growth factor therapy, but did not result in functional improvement in this short-term study.
C1 [Lee, Ji Hwan] Ewha Womans Univ, Sch Med, Dept Ophthalmol, Seoul, South Korea.
   [Lee, Ji Hwan; Lee, Sung Chul; Byeon, Suk Ho; Koh, Hyoung Jun; Kim, Sung Soo; Lee, Christopher Seungkyu] Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol, Seoul, South Korea.
C3 Ewha Womans University; Yonsei University; Yonsei University Health
   System
RP Lee, CS (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Yonsei Ro 50-1, Seoul 03722, South Korea.
EM sklee219@yuhs.ac
OI Koh, Hyoung Jun/0000-0002-5932-8516; Byeon, suk ho/0000-0001-8101-0830;
   , Sung Chul/0000-0001-9438-2385; Lee, Ji Hwan/0000-0003-1759-8195; Kim,
   Sung Soo/0000-0002-0574-7993
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [NRF-2016R1D1A1A02937349]
FX Supported by Basic Science Research Program through the National
   Research Foundation of Korea (NRF) funded by the Ministry of Education
   (NRF-2016R1D1A1A02937349).
CR Ahn J, 2013, J OCUL PHARMACOL TH, V29, P612, DOI 10.1089/jop.2013.0009
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Brubaker RF, 2000, OPHTHALMOLOGY, V107, P283, DOI 10.1016/S0161-6420(99)00044-5
   Byeon SH, 2009, GRAEF ARCH CLIN EXP, V247, P35, DOI 10.1007/s00417-008-0917-1
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P841, DOI 10.1097/IAE.0000000000000520
   Eadie BD, 2017, JAMA OPHTHALMOL, V135, P363, DOI 10.1001/jamaophthalmol.2017.0059
   Ehlers JP, 2013, EYE, V27, P102, DOI 10.1038/eye.2012.228
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Genead MA, 2012, RETINA-J RET VIT DIS, V32, P826, DOI 10.1097/IAE.0b013e3182215ae9
   Genead MA, 2010, ARCH OPHTHALMOL-CHIC, V128, P190, DOI 10.1001/archophthalmol.2009.398
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Grover S, 2006, AM J OPHTHALMOL, V141, P850, DOI 10.1016/j.ajo.2005.12.030
   Kang EC, 2017, GRAEF ARCH CLIN EXP, V255, P2157, DOI 10.1007/s00417-017-3776-9
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Lavine JA, 2017, INVEST OPHTH VIS SCI, V58, P299, DOI 10.1167/iovs.16-20204
   Lavine JA, 2013, JAMA OPHTHALMOL, V131, P376, DOI 10.1001/jamaophthalmol.2013.1476
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Park SJ, 2015, EYE, V29, P561, DOI 10.1038/eye.2014.329
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sridhar J, 2016, JAMA OPHTHALMOL, V134, P437, DOI 10.1001/jamaophthalmol.2016.0045
   Steinle JJ, 2008, GROWTH FACTORS, V26, P325, DOI 10.1080/08977190802442070
   Stewart MW, 2007, RETINA-J RET VIT DIS, V27, P1196, DOI 10.1097/IAE.0b013e318158ea28
   Zhou YD, 2016, SCI REP-UK, V6, DOI 10.1038/srep39301
NR 26
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2019
VL 39
IS 10
BP 1953
EP 1958
DI 10.1097/IAE.0000000000002293
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KC9EX
UT WOS:000507475300015
PM 30161096
DA 2022-11-30
ER

PT J
AU Veloso, CED
   de Almeida, LNF
   De Marco, LA
   Vianna, RNG
   Nehemy, MB
AF dos Reis Veloso, Carlos Eduardo
   Frota de Almeida, Luciana Negrao
   De Marco, Luiz Armando
   Galvarro Vianna, Raul Nunes
   Nehemy, Marcio Bittar
TI Importance of genetic polymorphisms in the response to age-related
   macular degeneration treatment
SO REVISTA BRASILEIRA DE OFTALMOLOGIA
LA English
DT Article
DE Macular degeneration/genetics; Antioxidants; Polymorphism, genetic;
   Treatment outcome
ID COMPLEMENT-FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; POLYPOIDAL CHOROIDAL
   VASCULOPATHY; SINGLE NUCLEOTIDE POLYMORPHISMS; FACTOR HY402H
   POLYMORPHISM; C-REACTIVE PROTEIN; PHOTODYNAMIC THERAPY; Y402H
   POLYMORPHISM; LOC387715 GENOTYPES; CIGARETTE-SMOKING
AB Age-related macular degeneration (AMD) is a degenerative disorder that affects the central retina and involves the Bruch's membrane, the retinal pigment epithelium and the photoreceptors. Recent studies have shown that polymorphisms of the CFH, LOC387715 and VEGF genes are associated with AMD. Herein, we review the literature to analyze the association between the main genetic polymorphisms and the response to the existing therapeutic modalities. Patients with CFH high-risk alleles show a poorer response to preventive treatment of AMD with antioxidants and zinc. The association between genetic polymorphisms and response to photodynamic therapy and antiangiogenic drugs, however, is controversial until now.
C1 [dos Reis Veloso, Carlos Eduardo; Frota de Almeida, Luciana Negrao] Univ Fed Minas Gerais, Dept Oftalmol, Fac Med, Belo Horizonte, MG, Brazil.
   [Galvarro Vianna, Raul Nunes] UFF, Rio De Janeiro, RJ, Brazil.
C3 Universidade Federal de Minas Gerais; Universidade Federal Fluminense
RP Veloso, CED (通讯作者)，Rua Otoni 881,13 Andar, BR-30150270 Belo Horizonte, MG, Brazil.
RI Nehemy, Marcio/ABD-5089-2021
CR Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Brown G, 2010, CURR OPIN OPHTHALMOL, V21, P169, DOI 10.1097/ICU.0b013e3283388605
   Chowers I, 2008, MOL VIS, V14, P2263
   Chowers I, 2008, MOL VIS, V14, P1829
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P532, DOI 10.1016/j.survophthal.2006.06.004
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fang AM, 2009, MOL VIS, V15, P2710
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Francis PJ, 2008, MOL VIS, V14, P1395
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kim IK, 2008, MOL VIS, V14, P1487
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lee SE, 2010, DERMATOL SIN, V28, P1
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Neuner B, 2008, OPHTHAL EPIDEMIOL, V15, P148, DOI 10.1080/09286580802105830
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   SCHAUMBERG DA, 2007, JAMA-J AM MED ASSOC, V297, P401
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scholl HPN, 2007, MOL VIS, V13, P196
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Seddon JM, 2006, RETINA
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V298, P1637, DOI 10.1001/jama.298.14.1637-b
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   SIMONELLI F, 2006, BR J OPHTHALMOL, V90, P1080
   Souied EH, 2005, MOL VIS, V11, P1135
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Teixeira AG, 2010, ACTA OPHTHALMOL, V88, pE165, DOI 10.1111/j.1755-3768.2010.01932.x
   Tong Y, 2010, MOL VIS, V16, P1958
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 72
TC 2
Z9 5
U1 0
U2 4
PU SOC BRASILEIRA OFTALMOLOGIA
PI RIO DE JANEIRO
PA RUA SAO SALVADOR 107, RIO DE JANEIRO, 22231-170, BRAZIL
SN 0034-7280
J9 REV BRAS OFTALMOL
JI Rev. Bras. Oftalmol.
PD MAY-JUN
PY 2012
VL 71
IS 3
BP 194
EP 198
DI 10.1590/S0034-72802012000300011
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 034EV
UT WOS:000310854100011
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Hamdi, HK
   Kenney, C
AF Hamdi, HK
   Kenney, C
TI Age-related macular degeneration: A new viewpoint
SO FRONTIERS IN BIOSCIENCE-LANDMARK
LA English
DT Review
DE age; macula; degeneration; ACE; Alu; review
ID INSERTION DELETION POLYMORPHISM; GEOGRAPHIC ATROPHY FORM;
   APOLIPOPROTEIN-E GENE; ALL-TRANS-RETINOIDS; NA+-K+ PUMP; RISK-FACTORS;
   ACE GENE; 5-YEAR INCIDENCE; CANDIDATE GENE; CARDIOVASCULAR-DISEASE
AB Age-related macular degeneration (AMD) is a major cause of blindness in the United States. AMD can be categorized into an atrophic ( dry) form and a neovascular ( wet, exudative) form. The atrophic form involves alterations of pigment distribution, loss of RPE cells and photoreceptors and diminished retinal function due to an overall atrophy of the cells. The neovascular AMD involves proliferation of abnormal choroidal vessels, which penetrate the Bruch's membrane and RPE layer into the subretinal space, thereby forming extensive clots and/or scars. Both environmental and genetic factors are suspected to play a role in AMD. Despite extensive genetic screening of candidate genes only two associations have been identified with AMD ( Adenosine triphosphate (ATP)binding cassette rim ( ABCR) protein and apolipoprotein E gene-ApoE). The ABCR protein is retinal specific and accounts for only 3% of AMD cases. ApoE is not specific to the retina, and has been more intriguingly associated with Alzheimer's, another disease of age. The most consistent major risk factor in AMD is age. Our studies on the ACE gene show an association of protection with an Alu element insert, which might be affecting the level of the ACE gene. The ApoE 4 allele and the ACE Alu(+/+) genotype have both been shown to be a risk for Alzheimer's and protective for AMD. Given these recent genetic associations, we should examine possible common pathways in diseases of age and their interaction with human genetic polymorphisms.
C1 Univ Calif Irvine, Ophthalmol Res Labs, Med Ctr, Orange, CA 92868 USA.
C3 University of California System; University of California Irvine
RP Hamdi, HK (通讯作者)，Univ Calif Irvine, Ophthalmol Res Labs, Med Ctr, 101 City Dr,Bldg 55,Room 206, Orange, CA 92868 USA.
EM hhamdi@uci.edu
OI Hamdi, Hamdi/0000-0001-6976-0874
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Algvere PV, 1997, ACTA OPHTHALMOL SCAN, V75, P1
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Allikmets R, 1997, NAT GENET, V17, P122, DOI 10.1038/ng0997-122b
   Allikmets R, 1998, GENE, V215, P111, DOI 10.1016/S0378-1119(98)00269-8
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Bensaoula T, 2001, J OCUL PHARMACOL TH, V17, P573, DOI 10.1089/10807680152729266
   BERNSTEIN PS, 1986, BIOCHEMISTRY-US, V25, P6473, DOI 10.1021/bi00369a020
   BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849
   Briggs CE, 2001, INVEST OPHTH VIS SCI, V42, P2229
   Buhagiar KA, 1999, AM J PHYSIOL-CELL PH, V277, pC461, DOI 10.1152/ajpcell.1999.277.3.C461
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   DAS HK, 1985, J BIOL CHEM, V260, P6240
   de Jong PTVM, 2001, EYE, V15, P396, DOI 10.1038/eye.2001.143
   DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   DOSSO AA, 1992, OPHTHALMOLOGICA, V205, P24, DOI 10.1159/000310307
   Dryja TP, 1999, INVEST OPHTH VIS SCI, V40, P1859
   Eksandh L, 2001, Ophthalmic Genet, V22, P107, DOI 10.1076/opge.22.2.107.2226
   Evans K, 1997, ARCH OPHTHALMOL-CHIC, V115, P904, DOI 10.1001/archopht.1997.01100160074012
   Fava S, 2001, DIABETES CARE, V24, P2115, DOI 10.2337/diacare.24.12.2115
   Felbor U, 1997, HUM MUTAT, V10, P301, DOI 10.1002/(SICI)1098-1004(1997)10:4<301::AID-HUMU6>3.0.CO;2-J
   Francois J, 1969, Arch Ophtalmol Rev Gen Ophtalmol, V29, P899
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029
   Gorin MB, 1999, MOL VIS, V5, pU31
   GORIN MB, 1995, OPHTHALMOLOGY, V102, P246
   Gutman F A, 1979, Trans Am Ophthalmol Soc, V77, P515
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hamdi HK, 2000, J MOL BIOL, V299, P931, DOI 10.1006/jmbi.2000.3795
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Hardcastle AJ, 1999, AM J HUM GENET, V64, P1210, DOI 10.1086/302325
   Hashimoto M, 2001, NEUROLOGY, V57, P1461, DOI 10.1212/WNL.57.8.1461
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   HOOL LC, 1995, AM J PHYSIOL-CELL PH, V268, pC366, DOI 10.1152/ajpcell.1995.268.2.C366
   Hool LC, 1996, AM J PHYSIOL-CELL PH, V271, pC172, DOI 10.1152/ajpcell.1996.271.1.C172
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Janka Z, 2002, MOL PSYCHIATR, V7, P110, DOI 10.1038/sj/mp/4000916
   JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72
   KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715
   Kim JE, 2001, BIOCHEMISTRY-US, V40, P13774, DOI 10.1021/bi0116137
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Kochendoerfer GG, 1997, BIOCHEMISTRY-US, V36, P13153, DOI 10.1021/bi971541c
   Kuehn MH, 2001, INVEST OPHTH VIS SCI, V42, P3123
   LAMB TD, 1992, TRENDS NEUROSCI, V15, P291, DOI 10.1016/0166-2236(92)90079-N
   Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291
   Mathies R A, 1999, Novartis Found Symp, V224, P70
   Miano MG, 1999, EUR J HUM GENET, V7, P687, DOI 10.1038/sj.ejhg.5200352
   MILTON RC, 1979, AM J OPHTHALMOL, V88, P269, DOI 10.1016/0002-9394(79)90480-X
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   Molday, 2000, Am J Ophthalmol, V130, P689, DOI 10.1016/S0002-9394(00)00756-X
   Moss SE, 1998, OPHTHALMOLOGY, V105, P789, DOI 10.1016/S0161-6420(98)95016-3
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Narain Y, 2000, J MED GENET, V37, P695, DOI 10.1136/jmg.37.9.695
   Ottlecz A, 1996, INVEST OPHTH VIS SCI, V37, P1633
   PANAHLOO A, 1995, CIRCULATION, V92, P3390, DOI 10.1161/01.CIR.92.12.3390
   Pauleikhoff D, 1995, Curr Opin Ophthalmol, V6, P51
   Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X
   PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H
   RABB M F, 1981, International Ophthalmology Clinics, V21, P51, DOI 10.1097/00004397-198102130-00006
   RALL SC, 1982, P NATL ACAD SCI-BIOL, V79, P4696, DOI 10.1073/pnas.79.15.4696
   RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a
   RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1975, MED J AUSTRALIA, V2, P602, DOI 10.5694/j.1326-5377.1975.tb106118.x
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   Schmidt S, 2000, MOL VIS, V6, P287
   Shastry BS, 1999, OPHTHALMOLOGICA, V213, P165, DOI 10.1159/000027413
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   Siegel G.J., 1994, BASIC NEUROCHEMISTRY
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sorbi S, 2001, MECH AGEING DEV, V122, P1951, DOI 10.1016/S0047-6374(01)00308-6
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spaide R F, 1999, Curr Opin Ophthalmol, V10, P177, DOI 10.1097/00055735-199906000-00005
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Sullivan LS, 1999, NAT GENET, V22, P255, DOI 10.1038/10314
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Takezako T, 1999, AM J HYPERTENS, V12, P291, DOI 10.1016/S0895-7061(98)00263-5
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang Q, 1996, INVEST OPHTH VIS SCI, V37, P2234
   WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077
   YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700
NR 102
TC 27
Z9 32
U1 0
U2 10
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093-9946
EI 1093-4715
J9 FRONT BIOSCI-LANDMRK
JI Front. Biosci.
PD MAY
PY 2003
VL 8
BP E305
EP E314
DI 10.2741/1019
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 669LG
UT WOS:000182352300054
PM 12700041
DA 2022-11-30
ER

PT J
AU Krishnadev, N
   Meleth, AD
   Chew, EY
AF Krishnadev, Nupura
   Meleth, Annal D.
   Chew, Emily Y.
TI Nutritional supplements for age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; antioxidant vitamins; lutein; omega-3
   fatty acids; zeaxanthin
ID EYE DISEASE; PLASMA HOMOCYSTEINE; FATTY-ACIDS; CAROTENOIDS; HEALTH;
   ANTIOXIDANTS; ANCILLARY; RISK; RANIBIZUMAB; VITAMIN-B12
AB Purpose of review
   Age-related macular degeneration (AMD), a leading cause of visual loss in older adults, has limited therapeutic options. This review describes the current literature on the role of nutritional supplementation in primary and secondary prevention of AMD.
   Recent findings
   Many observational studies have explored the association between diet, nutrient intake, and AMD. In particular, high dietary intakes of omega-3 fatty acids, and macular xanthophylls lutein and zeaxanthin have been associated with a lower risk of prevalent and incident AMD. However, the Age-Related Eye Disease study (AREDS) is the only large-scale randomized controlled clinical trial to show a 25% beneficial effect of nutritional supplementation in reducing the risk progression to advanced AMD in patients with intermediate AMD or with advanced AMD in one eye at 5 years of follow-up. On the basis of the results of AREDS, these patients are recommended to take AREDS formulation of vitamins C, E, beta-carotene, and zinc with copper.
   Summary
   At the present time, there is insufficient evidence in the literature to recommend routine nutritional supplementation in healthy adults for primary prevention of AMD. However, patients with intermediate risk of AMD or advanced AMD in one eye should consider taking AREDS-type supplements. Observational studies have also suggested benefit from increased dietary intake of macular xanthophylls and omega-3 fatty acids. These are currently being evaluated prospectively in a randomized controlled clinical trial, the AREDS2.
C1 [Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, CRC, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Chew, EY (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, CRC, Bldg 10,Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
FU Intramural NIH HHS [ZIE EY000487-01, Z99 EY999999] Funding Source:
   Medline; NATIONAL EYE INSTITUTE [ZIEEY000487] Funding Source: NIH
   RePORTER
CR Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Bazan N G, 1989, Prog Clin Biol Res, V312, P95
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2000, ANN EPIDEMIOL, V10, P125, DOI 10.1016/S1047-2797(99)00042-3
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Clarke R, 2005, AM J CLIN NUTR, V82, P806, DOI 10.1093/ajcn/82.4.806
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
NR 34
TC 80
Z9 81
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2010
VL 21
IS 3
BP 184
EP 189
DI 10.1097/ICU.0b013e32833866ee
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 591NR
UT WOS:000277308300004
PM 20216418
OA Green Accepted
DA 2022-11-30
ER

PT J
AU McHarg, S
   Clark, SJ
   Day, AJ
   Bishop, PN
AF McHarg, Selina
   Clark, Simon J.
   Day, Anthony J.
   Bishop, Paul N.
TI Age-related macular degeneration and the role of the complement system
SO MOLECULAR IMMUNOLOGY
LA English
DT Review
DE Age-related macular degeneration; Complement system; Alternative pathway
ID BRUCHS MEMBRANE IMPLICATIONS; HEPARIN-BINDING DOMAIN; FACTOR-H
   POLYMORPHISM; HIGH-RISK; ALLOTYPIC VARIANT; ATTACK COMPLEX; FOLLOW-UP;
   DRUSEN; RARE; IDENTIFICATION
AB Age-related macular degeneration (AMD) is a leading cause of visual impairment. It is characterised by damage to a tissue complex composed of the retinal pigment epithelium, Bruch's membrane and choriocapillaris. In early AMD extracellular debris including drusen accumulates in Bruch's membrane and then in late AMD geographic atrophy and/or neovascularisation develop. Variants in genes encoding components of the alternative pathway of the complement cascade have a major influence on AMD risk, especially at the RCA locus on chromosome 1, which contains CFH and the CFHR genes. Immunohistochemical studies have demonstrated complement components in unaffected and AMD macular tissue. Whilst other factors, including oxidative stress, play important roles in AMD pathogenesis, evidence for the central role played by complement dysregulation is discussed in this review. (C) 2015 Published by Elsevier Ltd.
C1 [McHarg, Selina; Clark, Simon J.; Bishop, Paul N.] Univ Manchester, Inst Human Dev, Ctr Ophthalmol & Vis Sci, Manchester, Lancs, England.
   [McHarg, Selina; Clark, Simon J.; Bishop, Paul N.] Manchester Acad Hlth Sci Ctr, Cent Manchester Univ Hosp NHS Fdn Trust, Ctr Adv Discovery & Expt Therapeut, Manchester, Lancs, England.
   [Day, Anthony J.] Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester, Lancs, England.
   [Bishop, Paul N.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.
C3 University of Manchester; University of Manchester; University of
   Manchester; Manchester Royal Eye Hospital; University of Manchester
RP Bishop, PN (通讯作者)，Univ Manchester, Inst Human Dev, Ctr Ophthalmol & Vis Sci, Manchester, Lancs, England.
EM Paul.Bishop@Manchester.ac.uk
RI Day, Anthony/O-1658-2015
OI Day, Anthony/0000-0002-1415-3134; Clark, Simon/0000-0001-8394-8355;
   Bishop, Paul/0000-0001-7937-7932
FU Fight for Sight [1517/18] Funding Source: researchfish; MRC
   [MR/K004441/1, MR/K024418/1, G0900538] Funding Source: UKRI; Medical
   Research Council [MR/K024418/1, MR/K004441/1, K004441, G0900538] Funding
   Source: Medline; Wellcome Trust [088785] Funding Source: Medline
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Blaum BS, 2015, NAT CHEM BIOL, V11, P77, DOI [10.1038/NCHEMBIO.1696, 10.1038/nchembio.1696]
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2013, BRIT J OPHTHALMOL, V97, P1089, DOI 10.1136/bjophthalmol-2013-303134
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klos A, 2013, PHARMACOL REV, V65, P500, DOI 10.1124/pr.111.005223
   Langford-Smith A, 2014, J INNATE IMMUN, V6, P407, DOI 10.1159/000356513
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rees A, 2014, EYE, V28, P832, DOI 10.1038/eye.2014.103
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Seddon JM, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-13234
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031
   Ugarte M, 2013, SURV OPHTHALMOL, V58, P585, DOI 10.1016/j.survophthal.2012.12.002
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Whitmore S.S., 2014, PROG RETIN EYE RES, DOI [http://dx.doi.org/10.1016/j.preteyeres.2014.11.00, DOI 10.1016/J.PRETEYERES.2014.11.00]
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 71
TC 87
Z9 92
U1 1
U2 42
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD SEP
PY 2015
VL 67
IS 1
SI SI
BP 43
EP 50
DI 10.1016/j.molimm.2015.02.032
PG 8
WC Biochemistry & Molecular Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Immunology
GA CL7HW
UT WOS:000357144100006
PM 25804937
DA 2022-11-30
ER

PT J
AU Kokotas, H
   Grigoriadou, M
   Petersen, MB
AF Kokotas, Haris
   Grigoriadou, Maria
   Petersen, Michael B.
TI Age-related macular degeneration: genetic and clinical findings
SO CLINICAL CHEMISTRY AND LABORATORY MEDICINE
LA English
DT Review
DE age-related macular degeneration; blindness; clinical signs; genes
ID COMPLEMENT FACTOR-H; GLOMERULONEPHRITIS TYPE-II; HEMOLYTIC-UREMIC
   SYNDROME; DENSE DEPOSIT DISEASE; TRANSLATIONAL MINIREVIEW SERIES;
   RETINAL-PIGMENT EPITHELIUM; MITOCHONDRIAL-DNA DAMAGE;
   AMINO-ACID-SEQUENCE; LONG-TERM INCIDENCE; APOLIPOPROTEIN-E
AB Age-related macular degeneration (AMD) is a sight threatening eye disease that affects millions of humans over the age of 65 years. It is considered to be the major cause of irreversible blindness in the elderly population in the developed world. The disease is prevalent in Europe and the United States, which has a large number of individuals of European descent. AMD is characterized by a progressive loss of central vision attributable to degenerative and neovascular changes that occur in the interface between the neural retina and the underlying choroid. This location contains the retinal photoreceptors, the retinal pigmented epithelium, a basement membrane complex known as Bruch's membrane and a network of choroidal capillaries. AMD is increasingly recognized as a complex genetic disorder where one or more genes contribute to an individual's susceptibility to development of the condition, while the prevailing view is that the disease stems from the interaction of multiple genetic and environmental factors. Although it has been proposed that a threshold event occurs during normal aging, the sequelae of biochemical, cellular, and molecular events leading to AMD are not fully understood. Here, we review the clinical aspects of AMD and summarize the genes which have been reported to have a positive association with the disease.
C1 [Kokotas, Haris; Grigoriadou, Maria; Petersen, Michael B.] Aghia Sophia Childrens Hosp, Inst Child Hlth, Dept Genet, Athens 11527, Greece.
C3 The Aghia Sophia Children's Hospital
RP Kokotas, H (通讯作者)，Aghia Sophia Childrens Hosp, Inst Child Hlth, Dept Genet, Athens 11527, Greece.
EM hkokotas@yahoo.gr
RI Petersen, Michael Bjørn B/D-1483-2017
OI Petersen, Michael Bjørn B/0000-0003-0316-8207
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2009, NEW ENGL J MED, V360, P2252
   Amara U, 2008, ADV EXP MED BIOL, V632, P71, DOI 10.1007/978-0-387-78952-1_6
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 1999, INVEST OPHTH VIS SCI, V40, P3305
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boekhoorn SS, 2007, INVEST OPHTH VIS SCI, V48, P1012, DOI 10.1167/iovs.06-0577
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   CHRISTIE DL, 1983, BIOCHEM J, V209, P61, DOI 10.1042/bj2090061
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Cideciyan AV, 2009, HUM MOL GENET, V18, P931, DOI 10.1093/hmg/ddn421
   COATS G, 1905, ROY LONDON OPHTHAL H, V16, P164
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   D'souza Y, 2000, INVEST OPHTH VIS SCI, V41, pS164
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   de Cordoba SR, 1999, MOL IMMUNOL, V36, P803, DOI 10.1016/S0161-5890(99)00100-5
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DECORDOBA SR, 1985, J EXP MED, V161, P1189, DOI 10.1084/jem.161.5.1189
   DECORDOBA SR, 1987, IMMUNOGENETICS, V25, P267, DOI 10.1007/BF00404698
   DEJONG PT, 2007, INVEST OPHTH VIS SCI, V48, pE2119
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   DEUTSCH TA, 1985, OPHTHALMOLOGY, V92, P73
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Diaz-Guillen MA, 1999, IMMUNOGENETICS, V49, P549, DOI 10.1007/s002510050534
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P900, DOI 10.1136/bjo.73.11.900
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Edwards AO, 2009, NEW ENGL J MED, V360, P2254
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ESTALLER C, 1991, EUR J IMMUNOL, V21, P799, DOI 10.1002/eji.1830210337
   Evans K, 1997, ARCH OPHTHALMOL-CHIC, V115, P904, DOI 10.1001/archopht.1997.01100160074012
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fang CJ, 2008, BRIT J HAEMATOL, V143, P336, DOI 10.1111/j.1365-2141.2008.07324.x
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Felbor U, 1997, INVEST OPHTH VIS SCI, V38, P1054
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FISHMAN G A, 1975, Annals of Ophthalmology, V7, P487
   FISHMAN GA, 1975, ANN OPHTHALMOL, V7, P491
   FRENNESSON C, 1995, DOC OPHTHALMOL, V90, P377, DOI 10.1007/BF01268123
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 2005, EUR J HUM GENET, V13, P793, DOI 10.1038/sj.ejhg.5201431
   Gorin MB, 1999, MOL VIS, V5, pU31
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GUYMER R, 1988, RETINAL PIGMENT EPIT, P693
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hasham SN, 2006, CLIN CHIM ACTA, V372, P179, DOI 10.1016/j.cca.2006.04.020
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   Hocking HG, 2008, J BIOL CHEM, V283, P9475, DOI 10.1074/jbc.M709587200
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jozsi M, 2005, EUR J HUM GENET, V13, P321, DOI 10.1038/sj.ejhg.5201324
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kavanagh D, 2007, CLIN J AM SOC NEPHRO, V2, P591, DOI 10.2215/CJN.03270906
   Kavanagh D, 2006, BRIT MED BULL, V77-78, P5, DOI 10.1093/bmb/ldl004
   KILLINGSWORTH MC, 1987, GRAEF ARCH CLIN EXP, V225, P406, DOI 10.1007/BF02334166
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LEWIS H, 1986, OPHTHALMOLOGY, V93, P1098
   LEYS A, 1991, GRAEF ARCH CLIN EXP, V229, P406, DOI 10.1007/BF00166300
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   LOKKI ML, 1991, IMMUNOGENETICS, V34, P242, DOI 10.1007/BF00215259
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Malthieu D, 1988, Bull Soc Ophtalmol Fr, V88, P645
   MARSHALL GE, 1994, GRAEF ARCH CLIN EXP, V232, P133, DOI 10.1007/BF00176781
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   McRae JL, 2002, GENETICA, V114, P157, DOI 10.1023/A:1015114512924
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2007, EXP EYE RES, V84, P378, DOI 10.1016/j.exer.2006.09.021
   NAUMANN G, 1966, ARCH OPHTHALMOL-CHIC, V76, P784, DOI 10.1001/archopht.1966.03850010786004
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Okamoto H, 2006, MOL VIS, V12, P156
   Pangburn MK, 2000, J IMMUNOL, V164, P4742, DOI 10.4049/jimmunol.164.9.4742
   PARUMS DV, 1990, ARCH PATHOL LAB MED, V114, P383
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   PIGUET B, 1995, EYE, V9, P34, DOI 10.1038/eye.1995.5
   POLKINGHORNE PJ, 1989, OPHTHALMOLOGY, V96, P1763
   Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588
   Ross R, 1999, AM HEART J, V138, pS419, DOI 10.1016/S0002-8703(99)70266-8
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   Schmidt CQ, 2008, CLIN EXP IMMUNOL, V151, P14, DOI 10.1111/j.1365-2249.2007.03553.x
   Schultz Dennis W, 2005, Ophthalmic Genet, V26, P101, DOI 10.1080/13816810590968023
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   SCHWAEBLE W, 1991, EUR J BIOCHEM, V198, P399, DOI 10.1111/j.1432-1033.1991.tb16028.x
   Shen WY, 2004, ARCH OPHTHALMOL-CHIC, V122, P353, DOI 10.1001/archopht.122.3.353
   Shen Y, 2003, PROG NEUROBIOL, V70, P463, DOI 10.1016/j.pneurobio.2003.08.001
   SMITH SR, 2007, INVEST OPHTH VIS SCI, V48, pE2097
   Soares DC, 2005, PROTEIN ENG DES SEL, V18, P379, DOI 10.1093/protein/gzi039
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Walker PD, 2007, CURR OPIN NEPHROL HY, V16, P204, DOI 10.1097/MNH.0b013e3280bdc0f4
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wang QL, 2004, HUM MOL GENET, V13, P1025, DOI 10.1093/hmg/ddh117
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zumbrunn J, 1997, GENOMICS, V45, P461, DOI 10.1006/geno.1997.4953
   Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 174
TC 35
Z9 35
U1 0
U2 4
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1434-6621
EI 1437-4331
J9 CLIN CHEM LAB MED
JI Clin. Chem. Lab. Med.
PD APR
PY 2011
VL 49
IS 4
BP 601
EP 616
DI 10.1515/CCLM.2011.091
PG 16
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 749KH
UT WOS:000289464200005
PM 21175380
DA 2022-11-30
ER

PT J
AU Honda, M
   Mizota, A
   Sakuma, T
   Tanaka, M
AF Honda, Miki
   Mizota, Atsushi
   Sakuma, Toshiro
   Tanaka, Minoru
TI Is transpupillary thermotherapy applicable to the treatment of
   age-related macular degeneration with pigment epithelial detachment?
SO ANNALS OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION
AB The cause of pigment epithelial tears at the edge of a pigment epithelial detachment (PED) following transpupillary thermotherapy in eyes with associated age-related macular degeneration is unclear. We have treated 2 eyes which had a PIED with TTT. Our findings suggest pigment epithelial tears are probably related to the shape of the PED and TTT should not applied to a balloon-shaped PED.
C1 Juntendo Univ, Urayasu Hosp, Dept Ophthalmol, Urayusu 2790021, Japan.
C3 Juntendo University
RP Mizota, A (通讯作者)，Juntendo Univ, Urayasu Hosp, Dept Ophthalmol, 2-1-1 Tomioka, Urayusu 2790021, Japan.
EM mizota@juntendo-urayasu.jp
CR KEISHAN NR, 1985, AM J OPHTHALMOL, V100, P698
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   NISHIMURA T, JPN J CLIN OPHTHALMO, V44, P806
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
NR 5
TC 0
Z9 0
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1530-4086
J9 ANN OPHTHALMOL
JI Ann. Ophthalmol.
PD WIN
PY 2006
VL 38
IS 4
BP 339
EP 342
DI 10.1007/BF02697217
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 188SG
UT WOS:000247939000011
PM 17726222
DA 2022-11-30
ER

PT J
AU Lois, N
   Mcbain, V
   Abdelkader, E
   Scott, NW
   Kumari, R
AF Lois, Noemi
   Mcbain, Vikki
   Abdelkader, Ehab
   Scott, Neil W.
   Kumari, Reena
TI RETINAL PIGMENT EPITHELIAL ATROPHY IN PATIENTS WITH EXUDATIVE
   AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTI-VASCULAR ENDOTHELIAL
   GROWTH FACTOR THERAPY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; autofluorescence; choroidal
   neovascular membrane; exudative AMD; near-infrared autofluorescence;
   vascular endothelial growth factor; ranibizumab; bevacizumab
ID FUNDUS AUTOFLUORESCENCE; INTRAVITREAL INJECTION; RANIBIZUMAB;
   VERTEPORFIN; HOLE; VEGF
AB Purpose: To evaluate the occurrence of retinal pigment epithelial atrophy in patients with age-related macular degeneration undergoing anti-vascular endothelial growth factor therapy.
   Methods: The study is a retrospective review. Eligible were patients with age-related macular degeneration and choroidal neovascular membranes treated with anti-vascular endothelial growth factor between October 2007 and February 2011; they were followed for >3 months, with fundus photographs and fluorescein angiography at baseline and with autofluorescence and near-infrared autofluorescence images at baseline and follow-up. Demographics, visual acuity, the type of choroidal neovascular membranes, the number of treatments performed, and the length of follow-up were recorded. Autofluorescence and near-infrared autofluorescence images were evaluated for the presence or absence of areas of reduced signal. A multilevel logistic regression model was used to investigate the factors that may be associated with "progression of atrophy" at follow-up, which was the primary outcome of this study.
   Results: Sixty-three patients (72 eyes) were followed for a median of 16 months (range, 3-36 months). Atrophy at baseline was observed in 47% (34/72) of eyes; progression of atrophy occurred in 62%(45/72) of eyes at the last visit. The number of anti-vascular endothelial growth factor injections received was statistically significantly associated with the progression of atrophy at follow-up (odds ratio, 1.35; 95% confidence interval, 1.05-1.73; P = 0.02).
   Conclusion: Atrophy was frequently observed in patients with age-related macular degeneration and choroidal neovascular membranes undergoing anti-vascular endothelial growth factor therapy. RETINA 33:13-22, 2013
C1 [Lois, Noemi; Mcbain, Vikki; Abdelkader, Ehab; Kumari, Reena] Grampian Univ Hosp NHS Trust, Dept Ophthalmol, Aberdeen, Scotland.
   [Scott, Neil W.] Univ Aberdeen, Div Appl Hlth Sci, Med Stat Team, Aberdeen, Scotland.
C3 University of Aberdeen; University of Aberdeen
RP Lois, N (通讯作者)，Grampian Univ Hosp NHS Trust, Dept Ophthalmol, Aberdeen, Scotland.
EM noemilois@aol.com
OI Scott, Neil/0000-0002-8067-9660
CR [Anonymous], 1991, ARCH OPHTHALMOL, V109, P1242
   [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Grigoropoulos V, 2010, EUR J OPHTHALMOL, V20, P469, DOI 10.1177/112067211002000235
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kellner U, 2009, FUNDUS AUTOFLUORESCE, P60
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Konstantinidis L, 2010, ACTA OPHTHALMOL, V88, P736, DOI 10.1111/j.1755-3768.2009.01547.x
   Lois N, 2009, FUNDUS AUTOFLUORESCE
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Pelle G, 2011, AM J KIDNEY DIS, V57, P756, DOI 10.1053/j.ajkd.2010.11.030
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Querques G, 2009, ACTA OPHTHALMOL, V87, P235, DOI 10.1111/j.1755-3768.2008.01226.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saeed MU, 2009, J CATARACT REFR SURG, V35, P1857, DOI 10.1016/j.jcrs.2009.05.050
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   Schmitz-valckenburgh S, 2009, FUNDUS AUTOFLUORESCE, P131
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
NR 24
TC 72
Z9 79
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2013
VL 33
IS 1
BP 13
EP 22
DI 10.1097/IAE.0b013e3182657fff
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 069GE
UT WOS:000313422500003
PM 22846802
DA 2022-11-30
ER

PT J
AU Nguyen, T
   Urrutia-Cabrera, D
   Liou, RHC
   Luu, CD
   Guymer, R
   Wong, RCB
AF Nguyen, Tu
   Urrutia-Cabrera, Daniel
   Liou, Roxanne Hsiang-Chi
   Luu, Chi D.
   Guymer, Robyn
   Wong, Raymond Ching-Bong
TI New Technologies to Study Functional Genomics of Age-Related Macular
   Degeneration
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Review
DE age-related macular degeneration; retina; CRISPR; Cas; induced
   pluripotent stem cell models; single cell transcriptomics; organoids
ID COMPLEMENT FACTOR-H; PLURIPOTENT STEM-CELLS; GENE-EXPRESSION;
   TRANSCRIPTIONAL ACTIVATION; SERINE-PROTEASE; BRUCHS MEMBRANE; NEURAL
   RETINA; TGF-BETA; HTRA1; POLYMORPHISM
AB Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in people over 50 years old in developed countries. Currently, we still lack a comprehensive understanding of the genetic factors contributing to AMD, which is critical to identify effective therapeutic targets to improve treatment outcomes for AMD patients. Here we discuss the latest technologies that can facilitate the identification and functional study of putative genes in AMD pathology. We review improved genomic methods to identify novel AMD genes, advances in single cell transcriptomics to profile gene expression in specific retinal cell types, and summarize recent development of in vitro models for studying AMD using induced pluripotent stem cells, organoids and biomaterials, as well as new molecular technologies using CRISPR/Cas that could facilitate functional studies of AMD-associated genes.
C1 [Nguyen, Tu; Urrutia-Cabrera, Daniel; Liou, Roxanne Hsiang-Chi; Luu, Chi D.; Guymer, Robyn; Wong, Raymond Ching-Bong] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   [Nguyen, Tu; Urrutia-Cabrera, Daniel; Liou, Roxanne Hsiang-Chi; Luu, Chi D.; Guymer, Robyn; Wong, Raymond Ching-Bong] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Wong, RCB (通讯作者)，Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.; Wong, RCB (通讯作者)，Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
EM wongcb@unimelb.edu.au
FU National Health and Medical Research Council [GNT1184076]; Centre for
   Eye Research Australia; Melbourne Research Scholarship from University
   of Melbourne
FX This work was supported by funding from the National Health and Medical
   Research Council (RCBW: GNT1184076; RG) and the Centre for Eye Research
   Australia (RCBW). TN, DU, and RHCL are supported by the Melbourne
   Research Scholarship from University of Melbourne. The Centre for Eye
   Research Australia receives operational infrastructure support from the
   Victorian Government.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Baldi A, 2002, ONCOGENE, V21, P6684, DOI 10.1038/sj.onc.1205911
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Blythe EE, 2019, STRUCTURE, V27, P1820, DOI 10.1016/j.str.2019.09.011
   Boettcher M, 2015, MOL CELL, V58, P575, DOI 10.1016/j.molcel.2015.04.028
   Brodie A, 2016, NUCLEIC ACIDS RES, V44, P6046, DOI 10.1093/nar/gkw500
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Cannon ME, 2018, AM J HUM GENET, V103, P637, DOI 10.1016/j.ajhg.2018.10.001
   Chang M, 2018, METHODS MOL BIOL, V1754, P97, DOI 10.1007/978-1-4939-7717-8_6
   Chavez A, 2016, NAT METHODS, V13, P563, DOI [10.1038/NMETH.3871, 10.1038/nmeth.3871]
   Chavez A, 2015, NAT METHODS, V12, P326, DOI [10.1038/NMETH.3312, 10.1038/nmeth.3312]
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Cho SW, 2013, NAT BIOTECHNOL, V31, P230, DOI 10.1038/nbt.2507
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Djigo AD, 2019, ACTA BIOMATER, V84, P305, DOI 10.1016/j.actbio.2018.11.033
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Falcon-Perez JM, 2002, J BIOL CHEM, V277, P28191, DOI 10.1074/jbc.M204011200
   Fang LJ, 2019, MOL THER-NUCL ACIDS, V14, P184, DOI 10.1016/j.omtn.2018.11.008
   Farazdaghi MK, 2019, J OPHTHAL VIS RES, V14, P78, DOI 10.4103/jovr.jovr_125_18
   Farkas MH, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-486
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Gilbert LA, 2014, CELL, V159, P647, DOI 10.1016/j.cell.2014.09.029
   Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044
   Glatz DC, 2006, J NEUROCHEM, V96, P635, DOI 10.1111/j.1471-4159.2005.03552.x
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gonzalez-Cordero A, 2017, STEM CELL REP, V9, P820, DOI 10.1016/j.stemcr.2017.07.022
   Graham JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074094
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Grindberg RV, 2013, P NATL ACAD SCI USA, V110, P19802, DOI 10.1073/pnas.1319700110
   Gusev A, 2016, NAT GENET, V48, P245, DOI 10.1038/ng.3506
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Hadfield KD, 2008, J BIOL CHEM, V283, P5928, DOI 10.1074/jbc.M709299200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   Hartwig C, 2018, DEV NEUROBIOL, V78, P311, DOI 10.1002/dneu.22542
   Hasegawa Y, 2016, DEVELOPMENT, V143, P3895, DOI 10.1242/dev.134601
   Hazim RA, 2019, EXP EYE RES, V179, P18, DOI 10.1016/j.exer.2018.10.009
   Hormozdiari F, 2016, AM J HUM GENET, V99, P1245, DOI 10.1016/j.ajhg.2016.10.003
   Hoshino A, 2017, DEV CELL, V43, P763, DOI 10.1016/j.devcel.2017.10.029
   Housden BE, 2016, NAT BIOTECHNOL, V34, P621, DOI 10.1038/nbt.3599
   Hung SSC, 2017, PHARMACOL THERAPEUT, V177, P32, DOI 10.1016/j.pharmthera.2017.02.026
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jansen JC, 2016, AM J HUM GENET, V98, P322, DOI 10.1016/j.ajhg.2015.12.011
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Khan S, 2016, CURR OPIN ORGAN TRAN, V21, P484, DOI 10.1097/MOT.0000000000000348
   Khanna S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000398
   Kiel C, 2017, SCI REP-UK, V7, DOI 10.1038/srep41835
   Kim Y, 2015, BIOCHEM BIOPH RES CO, V462, P112, DOI 10.1016/j.bbrc.2015.04.084
   Klann TS, 2018, CURR OPIN BIOTECH, V52, P32, DOI 10.1016/j.copbio.2018.02.004
   KLEIN BEK, 1992, INVEST OPHTH VIS SCI, V33, P2224
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Konermann S, 2018, CELL, V173, P665, DOI 10.1016/j.cell.2018.02.033
   Konermann S, 2015, NATURE, V517, P583, DOI 10.1038/nature14136
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kulkarni A, 2019, CURR OPIN BIOTECH, V58, P129, DOI 10.1016/j.copbio.2019.03.001
   Kuznetsova AV, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/801787
   Lake BB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04426-w
   Langemeyer L, 2015, DEV CELL, V33, P121, DOI 10.1016/j.devcel.2015.04.008
   Launay S, 2008, CELL DEATH DIFFER, V15, P1408, DOI 10.1038/cdd.2008.82
   Li HY, 2017, ADV EXP MED BIOL, V976, P1, DOI 10.1007/978-94-024-1088-4_1
   Liang QN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12917-9
   Lidgerwood GE, 2016, STEM CELL REV REP, V12, P179, DOI 10.1007/s12015-015-9636-2
   Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6
   Lin MK, 2018, AGING CELL, V17, DOI 10.1111/acel.12710
   Liu JQ, 2019, FRONT LIFE SCI, V12, P1, DOI 10.1080/21553769.2019.1670739
   Lukowski SW, 2019, EMBO J, V38, DOI 10.15252/embj.2018100811
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2011, TRENDS GENET, V27, P72, DOI 10.1016/j.tig.2010.10.006
   Malek G., 2020, TOPICS MED CHEM, P1
   Mali P, 2013, NAT BIOTECHNOL, V31, P833, DOI 10.1038/nbt.2675
   Masaeli E, 2020, BIOFABRICATION, V12, DOI 10.1088/1758-5090/ab4a20
   Mauney J, 2010, MATRIX BIOL, V29, P657, DOI 10.1016/j.matbio.2010.08.008
   McCaughey T, 2016, CELL STEM CELL, V18, P307, DOI 10.1016/j.stem.2016.02.006
   McHugh KJ, 2014, INVEST OPHTH VIS SCI, V55, P1754, DOI 10.1167/iovs.13-12833
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Mijaljica D, 2011, AUTOPHAGY, V7, P666, DOI 10.4161/auto.7.6.15812
   Miles AL, 2017, ELIFE, V6, DOI 10.7554/eLife.22693
   Tran MTN, 2019, MOL VIS, V25, P174
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mokhtarinia K, 2018, J POLYM SCI POL PHYS, V56, P1567, DOI 10.1002/polb.24744
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Mullany SA, 2011, CLIN CANCER RES, V17, P427, DOI 10.1158/1078-0432.CCR-09-3069
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Perez-Pinera P, 2013, NAT METHODS, V10, P973, DOI [10.1038/NMETH.2600, 10.1038/nmeth.2600]
   Pinelli M, 2016, NUCLEIC ACIDS RES, V44, P5773, DOI 10.1093/nar/gkw486
   Ran FA, 2015, NATURE, V520, P186, DOI 10.1038/nature14299
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sanson KR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07901-8
   Seddon AWR, 2016, NATURE, V531, P229, DOI 10.1038/nature16986
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shokoohmand A, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201700221
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Smith EN, 2019, STEM CELL REP, V12, P1342, DOI 10.1016/j.stemcr.2019.04.012
   Souied EH, 2005, MOL VIS, V11, P1135
   Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737
   Strunz T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58510-9
   Supanji, 2013, EXP EYE RES, V112, P79, DOI 10.1016/j.exer.2013.04.013
   Tam V, 2019, NAT REV GENET, V20, P467, DOI 10.1038/s41576-019-0127-1
   Tanenbaum ME, 2014, CELL, V159, P635, DOI 10.1016/j.cell.2014.09.039
   Tasoglu S, 2013, TRENDS BIOTECHNOL, V31, P10, DOI 10.1016/j.tibtech.2012.10.005
   Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232
   Tosi GM, 2017, INVEST OPHTH VIS SCI, V58, P162, DOI 10.1167/iovs.16-20922
   Trese M, 2012, MATERIALS, V5, P108, DOI 10.3390/ma5010108
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Volkner M, 2016, STEM CELL REP, V6, P525, DOI 10.1016/j.stemcr.2016.03.001
   Voigt AP, 2019, EXP EYE RES, V184, P234, DOI 10.1016/j.exer.2019.05.001
   Wainberg M, 2019, NAT GENET, V51, P592, DOI 10.1038/s41588-019-0385-z
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Whitmore SS, 2014, EXP EYE RES, V129, P93, DOI 10.1016/j.exer.2014.11.001
   Wong RCB, 2017, AGING-US, V9, P1341, DOI 10.18632/aging.101231
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   Xu YT, 2012, INT J OPHTHALMOL-CHI, V5, P125, DOI 10.3980/j.issn.2222-3959.2012.02.02
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yeo NC, 2018, NAT METHODS, V15, P611, DOI 10.1038/s41592-018-0048-5
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
   Zhou SF, 2015, DEVELOPMENT, V142, P3294, DOI 10.1242/dev.125385
   Zhu ZH, 2016, NAT GENET, V48, P481, DOI 10.1038/ng.3538
NR 153
TC 5
Z9 5
U1 0
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD JAN 11
PY 2021
VL 8
AR 604220
DI 10.3389/fcell.2020.604220
PG 12
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA PX1CN
UT WOS:000611101300001
PM 33505962
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Hazin, R
   Freeman, PD
   Kahook, MY
AF Hazin, Ribhi
   Freeman, P. David
   Kahook, Malik Y.
TI Age-Related Macular Degeneration: A Guide for the Primary Care Physician
SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
LA English
DT Article
DE ophthalmic; nutrition
ID RISK
AB Age-related macular degeneration (AMD) is the leading cause of visual loss in Americans over the age of 50 years. AMD often results in profound disability due to the disease destroying the macula, the part of the retina responsible for central visual acuity and color vision. Risk factors for AMD include age greater than 50, female gender, Caucasian race, cigarette smoking, and family history of AMD. African Americans and other racial or ethnic groups can be affected by AMD. Although there is no cure for AMD, early diagnosis and treatment may slow disease progression and minimize irreversible visual dysfunction. Individuals suffering from central vision loss from AMD often retain peripheral vision. These affected individuals can benefit from low vision therapy, visual rehabilitation, or both to maintain or enhance activities of daily living.
C1 [Hazin, Ribhi] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Ophthalmol & Visual Sci, Omaha, NE 68198 USA.
   [Freeman, P. David; Kahook, Malik Y.] Univ Colorado, Sch Med, Dept Ophthalmol, Rocky Mt Lions Eye Inst, Aurora, CO USA.
C3 University of Nebraska System; University of Nebraska Medical Center;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Hazin, R (通讯作者)，Univ Nebraska Med Ctr, Dept Genet Cell Biol & Ophthalmol & Visual Sci, Omaha, NE 68198 USA.
EM hazin@fas.harvard.edu
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   ARIAS L, 2008, EYE
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   CHANG MA, 2008, INVEST OPHTHALMOL VI
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Elner SG, 1999, CLIN GERIATR MED, V15, P25
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Hornan DM, 2007, INVEST OPHTH VIS SCI, V48, P5388, DOI 10.1167/iovs.07-0355
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   LIEW G, 2008, J AM SOC NEPHROL
   Montero MIM, 2007, IEEE T POWER ELECTR, V22, P229, DOI 10.1109/TPEL.2006.886616
   Miskala PH, 2007, OPHTHAL EPIDEMIOL, V14, P205, DOI 10.1080/09286580701502970
   PARISI V, 2007, OPHTHALMOLOGY
   Quillen DA, 1999, AM FAM PHYSICIAN, V60, P99
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Seddon JM, 2007, AM J CLIN NUTR, V85, p304S, DOI 10.1093/ajcn/85.1.304S
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 25
TC 8
Z9 8
U1 1
U2 5
PU NATL MED ASSOC
PI WASHINGON
PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA
SN 0027-9684
EI 1943-4693
J9 J NATL MED ASSOC
JI J. Natl. Med. Assoc.
PD FEB
PY 2009
VL 101
IS 2
BP 134
EP 138
DI 10.1016/S0027-9684(15)30825-7
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 425XW
UT WOS:000264672300006
PM 19378629
DA 2022-11-30
ER

PT J
AU Cipriani, V
   Leung, HT
   Plagnol, V
   Bunce, C
   Khan, JC
   Shahid, H
   Moore, AT
   Harding, SP
   Bishop, PN
   Hayward, C
   Campbell, S
   Armbrecht, AM
   Dhillon, B
   Deary, IJ
   Campbell, H
   Dunlop, M
   Dominiczak, AF
   Mann, SS
   Jenkins, SA
   Webster, AR
   Bird, AC
   Lathrop, M
   Zelenika, D
   Souied, EH
   Sahel, JA
   Leveillard, T
   Cree, AJ
   Gibson, J
   Ennis, S
   Lotery, AJ
   Wright, AF
   Clayton, DG
   Yates, JRW
AF Cipriani, Valentina
   Leung, Hin-Tak
   Plagnol, Vincent
   Bunce, Catey
   Khan, Jane C.
   Shahid, Humma
   Moore, Anthony T.
   Harding, Simon P.
   Bishop, Paul N.
   Hayward, Caroline
   Campbell, Susan
   Armbrecht, Ana Maria
   Dhillon, Baljean
   Deary, Ian J.
   Campbell, Harry
   Dunlop, Malcolm
   Dominiczak, Anna F.
   Mann, Samantha S.
   Jenkins, Sharon A.
   Webster, Andrew R.
   Bird, Alan C.
   Lathrop, Mark
   Zelenika, Diana
   Souied, Eric H.
   Sahel, Jose-Alain
   Leveillard, Thierry
   Cree, Angela J.
   Gibson, Jane
   Ennis, Sarah
   Lotery, Andrew J.
   Wright, Alan F.
   Clayton, David G.
   Yates, John R. W.
CA French AMD Investigators
TI Genome-wide association study of age-related macular degeneration
   identifies associated variants in the TNXBFKBPLNOTCH4 region of
   chromosome 6p21.3
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; TENASCIN-X; COMPONENT 2;
   RISK; SUSCEPTIBILITY; POLYMORPHISM; GENES; MACULOPATHY; EXPRESSION
AB Age-related macular degeneration (AMD) is a leading cause of visual loss in Western populations. Susceptibility is influenced by age, environmental and genetic factors. Known genetic risk loci do not account for all the heritability. We therefore carried out a genome-wide association study of AMD in the UK population with 893 cases of advanced AMD and 2199 controls. This showed an association with the well-established AMD risk loci ARMS2 (age-related maculopathy susceptibility 2)HTRA1 (HtrA serine peptidase 1) (P 2.7 10(72)), CFH (complement factor H) (P 2.3 10(47)), C2 (complement component 2)CFB (complement factor B) (P 5.2 10(9)), C3 (complement component 3) (P 2.2 10(3)) and CFI (P 3.6 10(3)) and with more recently reported risk loci at VEGFA (P 1.2 10(3)) and LIPC (hepatic lipase) (P 0.04). Using a replication sample of 1411 advanced AMD cases and 1431 examined controls, we confirmed a novel association between AMD and single-nucleotide polymorphisms on chromosome 6p21.3 at TNXB (tenascin XB)FKBPL (FK506 binding protein like) [rs12153855/rs9391734; discovery P 4.3 10(7), replication P 3.0 10(4), combined P 1.3 10(9), odds ratio (OR) 1.4, 95 confidence interval (CI) 1.31.6] and the neighbouring gene NOTCH4 (Notch 4) (rs2071277; discovery P 3.2 10(8), replication P 3.8 10(5), combined P 2.0 10(11), OR 1.3, 95 CI 1.21.4). These associations remained significant in conditional analyses which included the adjacent C2CFB locus. TNXB, FKBPL and NOTCH4 are all plausible AMD susceptibility genes, but further research will be needed to identify the causal variants and determine whether any of these genes are involved in the pathogenesis of AMD.
C1 [Cipriani, Valentina] UCL, Dept Ocular Biol & Therapeut, Inst Ophthalmol, London EC1V 9EL, England.
   [Cipriani, Valentina; Bunce, Catey; Moore, Anthony T.; Mann, Samantha S.; Jenkins, Sharon A.; Webster, Andrew R.; Bird, Alan C.; Yates, John R. W.] Moorfields Eye Hosp, London EC1V 2PD, England.
   [Leung, Hin-Tak; Khan, Jane C.; Shahid, Humma; Clayton, David G.; Yates, John R. W.] Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Cambridge CB2 0XY, England.
   [Leung, Hin-Tak] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Plagnol, Vincent] UCL, Genet Inst, London WC1E 6BT, England.
   [Bunce, Catey] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   [Khan, Jane C.] Royal Perth Hosp, Dept Ophthalmol, Perth, WA 6001, Australia.
   [Shahid, Humma] Addenbrookes Hosp, Dept Ophthalmol, Cambridge CB2 0QQ, England.
   [Harding, Simon P.] Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, Liverpool L69 3GA, Merseyside, England.
   [Bishop, Paul N.] Univ Manchester, Sch Biomed, Fac Med & Human Sci, Manchester M13 9PT, Lancs, England.
   [Bishop, Paul N.] Cent Manchester Fdn Trust, Manchester Acad Hlth Sci Ctr, Ctr Adv Discovery & Expt Therapeut, Manchester M13 9PL, Lancs, England.
   [Hayward, Caroline; Campbell, Susan; Wright, Alan F.] Univ Edinburgh, Inst Genet & Mol Med, Med Res Council Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Armbrecht, Ana Maria; Dhillon, Baljean] Univ Edinburgh, Dept Ophthalmol, Edinburgh EH3 9HA, Midlothian, Scotland.
   [Armbrecht, Ana Maria; Dhillon, Baljean] Princess Alexandra Eye Pavil, Edinburgh EH3 9HA, Midlothian, Scotland.
   [Deary, Ian J.] Univ Edinburgh, Ctr Cognit Ageing & Cognit Epidemiol, Dept Psychol, Edinburgh EH8 9JZ, Midlothian, Scotland.
   [Campbell, Harry; Dunlop, Malcolm] Univ Edinburgh, Inst Genet & Mol Med, Colon Canc Genet Grp, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Campbell, Harry; Dunlop, Malcolm] Univ Edinburgh, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Campbell, Harry] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland.
   [Dominiczak, Anna F.] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow G12 8QQ, Lanark, Scotland.
   [Mann, Samantha S.] St Thomas Hosp, London SE1 7EH, England.
   [Jenkins, Sharon A.] Heart Hosp, Dept Inherited Cardiovasc Dis, London W1G 8PH, England.
   [Lathrop, Mark; Zelenika, Diana] CEA, Inst Genom, Ctr Natl Genotypage, Evry, France.
   [Lathrop, Mark] Fdn Jean Dausset CEPH, Paris, France.
   [Souied, Eric H.] Ctr Hosp Intercommunal Creteil, Creteil, France.
   [Sahel, Jose-Alain; Leveillard, Thierry] Univ Paris 06, UPMC, Inst Vis, CNRS,INSERM,U968,UMR S 968,UMR 7210,Dept Genet, F-75012 Paris, France.
   [Sahel, Jose-Alain] Ctr Hosp Natl Ophtalmol Quinze Vingts, Clin Invest Ctr 503, F-75012 Paris, France.
   [Gibson, Jane; Ennis, Sarah] Univ Southampton, Fac Med, Genet Epidemiol & Genom Informat Grp, Southampton SO16 6YD, Hants, England.
   [Cree, Angela J.; Lotery, Andrew J.] Univ Southampton, Clin Neurosci Res Grp, Fac Med, Southampton SO16 6YD, Hants, England.
   [Lotery, Andrew J.] Southampton Gen Hosp, Southampton Eye Unit, Southampton SO16 6YD, Hants, England.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of Cambridge; Chinese University of Hong Kong; University of
   London; University College London; University of London; London School
   of Hygiene & Tropical Medicine; Royal Perth Hospital; University of
   Western Australia; Cambridge University Hospitals NHS Foundation Trust;
   Addenbrooke's Hospital; University of Cambridge; University of
   Liverpool; University of Manchester; University of Manchester;
   University of Edinburgh; University of Edinburgh; University of
   Edinburgh; University of Edinburgh; University of Edinburgh; University
   of Edinburgh; University of Glasgow; Guy's & St Thomas' NHS Foundation
   Trust; University College London Hospitals NHS Foundation Trust; CEA;
   UDICE-French Research Universities; Universite Paris Saclay; Foundation
   Jean Dausset-CEPH; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI
   Creteil; Centre National de la Recherche Scientifique (CNRS); CNRS -
   National Institute for Biology (INSB); Institut National de la Sante et
   de la Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; Universite Paris Cite; CHNO des Quinze-Vingts;
   UDICE-French Research Universities; Sorbonne Universite; University of
   Southampton; University of Southampton; University of Southampton
RP Cipriani, V (通讯作者)，UCL, Dept Ocular Biol & Therapeut, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM v.cipriani@ucl.ac.uk
RI Hayward, Caroline/M-8818-2016; Sahel, Jose-Alain/F-3172-2017; Dunlop,
   Malcolm G/F-1973-2011; Cipriani, Valentina/A-8549-2012; Deary, Ian
   J/C-6297-2009; Campbell, Harry/E-2959-2010; Léveillard,
   Thierry/AAR-1804-2020; Gibson, Jane/I-1630-2012; Plagnol,
   Vincent/A-5667-2011; Dominiczak, Anna F/P-9390-2017
OI Hayward, Caroline/0000-0002-9405-9550; Sahel,
   Jose-Alain/0000-0002-4831-1153; Dunlop, Malcolm G/0000-0002-3033-5851;
   Cipriani, Valentina/0000-0002-0839-9955; Deary, Ian
   J/0000-0002-1733-263X; Campbell, Harry/0000-0002-6169-6262; Léveillard,
   Thierry/0000-0001-5692-8770; Gibson, Jane/0000-0002-0973-8285;
   Dominiczak, Anna F/0000-0003-4913-3608; Bishop,
   Paul/0000-0001-7937-7932; Plagnol, Vincent/0000-0002-5597-9215; Harding,
   Simon/0000-0003-4676-1158; Lotery, Andrew/0000-0001-5541-4305; Bunce,
   Catey/0000-0002-0935-3713; Cree, Angela/0000-0002-1987-8900
FU Medical Research Council, UK [G0000067]; Macular Disease Society; Guide
   Dogs for the Blind Association [OR2006-02d]; Fight for Sight; Wellcome
   Trust [061860, 091388, 061858, 091157]; Juvenile Diabetes Research
   Foundation [4-2000-948, 9-2005-25, 9-2011-253]; Giles' Family Memorial
   Funds; Macula Vision Research Foundation; Chief Scientist Office,
   Scotland [CZB/4/79]; Brian Mercer Charitable Trust; British Council for
   the Prevention of Blindness; TFC Frost Charitable Trust; Gift of Sight;
   Centre National de Genotypage; Inserm (Centre d'Investigation Clinique
   des Quinze-Vingts); Department of Health's NIHR Biomedical Research
   Centre for Ophthalmology at Moorfields Eye Hospital; UCL Institute of
   Ophthalmology; Manchester NIHR Biomedical Research Centre; Cancer
   Research UK [12076] Funding Source: researchfish; Medical Research
   Council [G0000067, MC_U127527198, MC_U127584475, G0000934,
   MC_PC_U127584475, G0700704B, MC_PC_U127527198] Funding Source:
   researchfish; National Institute for Health Research [NF-SI-0507-10094]
   Funding Source: researchfish; Chief Scientist Office [ETM/55, CZB/4/449,
   CZB/4/505] Funding Source: researchfish; MRC [MC_U127527198,
   MC_U127584475, MC_PC_U127527198, G0000934, G0000067] Funding Source:
   UKRI
FX This work was supported by the Medical Research Council, UK (grant
   G0000067 to J.R.W.Y., A. T. M., D. G. C., A. C. B.; separate grants to
   A. R. W., A. C. B., A. F. W.); the Macular Disease Society (grants to
   J.R.W.Y., A. T. M., A.J.L. and S. E.); the Guide Dogs for the Blind
   Association (OR2006-02d to A. T. M., J.R.W.Y., A. R. W., D. G. C., C.
   B.); Fight for Sight (Mercer Fund to A. R. W.); the Wellcome Trust
   (grants 061860, 091388, 061858 and 091157 to D. G. C.); the Juvenile
   Diabetes Research Foundation (grants 4-2000-948, 9-2005-25 and
   9-2011-253 to D. G. C.); the Giles' Family Memorial Funds (H.-T.L.); the
   Macula Vision Research Foundation (A. F. W.); the Chief Scientist
   Office, Scotland (CZB/4/79 to B. D., C. H., A. M. A., A. F. W.); The
   Brian Mercer Charitable Trust (A.J.L.); The British Council for the
   Prevention of Blindness (A.J.L.); The TFC Frost Charitable Trust
   (A.J.L.); The Gift of Sight (A.J.L.); Centre National de Genotypage (T.
   L.) and Inserm (Centre d'Investigation Clinique des Quinze-Vingts,
   J.-A.S.); the Department of Health's NIHR Biomedical Research Centre for
   Ophthalmology at Moorfields Eye Hospital and UCL Institute of
   Ophthalmology (A. T. M., A. R. W., J.R.W.Y., C. B.); and the Manchester
   NIHR Biomedical Research Centre (P.N.B.). The views expressed in the
   publication are those of the authors and not necessarily those of the
   Department of Health. We acknowledge the use of genotype data from the
   British 1958 Birth Cohort DNA collection, funded by the Medical Research
   Council (G0000934) and the Wellcome Trust (068545/Z/02). H. C. and M. D.
   have been supported by Cancer Research UK (C3 48/A3758 and A8896,
   C48/A6361); the Medical Research Council UK (G0000657-53203); the
   Scottish Executive Chief Scientist's Office (K/OPR/2/2/D333, CZB/4/449);
   and a Centre Grant from CORE as part of the Digestive Cancer Campaign.
   The Lothian Birth Cohort collection was supported by the Biotechnology
   and Biological Sciences Research Council, a Royal Society-Wolfson
   Research Merit Award to I.J.D. and two awards from the Chief Scientist
   Office of the Scottish Government's Health Directorates (ETM/55 and
   CZB/4/505).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ahmad I, 2011, INVEST OPHTH VIS SCI, V52, P2868, DOI 10.1167/iovs.10-6608
   Andersson ER, 2011, DEVELOPMENT, V138, P3593, DOI 10.1242/dev.063610
   Barrett JC, 2009, NAT GENET, V41, P703, DOI 10.1038/ng.381
   Bennet AM, 2011, J ALZHEIMERS DIS, V24, P475, DOI 10.3233/JAD-2011-101848
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Cipriani V, 2012, EUR J HUM GENET, V20, P1, DOI 10.1038/ejhg.2011.118
   Claxton S, 2004, GENE EXPR PATTERNS, V5, P123, DOI 10.1016/j.modgep.2004.05.004
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Deary IJ, 2004, J PERS SOC PSYCHOL, V86, P130, DOI 10.1037/0022-3514.86.1.130
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Egging DF, 2006, CELL TISSUE RES, V323, P465, DOI 10.1007/s00441-005-0100-5
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Ikuta T, 2001, BIOL PHARM BULL, V24, P1320, DOI 10.1248/bpb.24.1320
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   MANTEL N, 1963, J AM STAT ASSOC, V58, P690
   Mao JR, 2002, NAT GENET, V30, P421, DOI 10.1038/ng850
   Margaron Y, 2010, BIOPHYS CHEM, V147, P87, DOI 10.1016/j.bpc.2009.12.011
   McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   McKeen HD, 2011, BIOCHEM SOC T, V39, P663, DOI 10.1042/BST0390663
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Power C, 2006, INT J EPIDEMIOL, V35, P34, DOI 10.1093/ije/dyi183
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Valentine A, 2011, CLIN CANCER RES, V17, P1044, DOI 10.1158/1078-0432.CCR-10-2241
   Wallace C, 2010, NAT GENET, V42, P68, DOI 10.1038/ng.493
   Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
NR 56
TC 69
Z9 73
U1 0
U2 29
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD SEP 15
PY 2012
VL 21
IS 18
BP 4138
EP 4150
DI 10.1093/hmg/dds225
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 998IJ
UT WOS:000308230800018
PM 22694956
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Courtney, RJ
   McClintic, JI
   Ehlers, JP
AF Courtney, Robert J.
   McClintic, Jedediah I.
   Ehlers, Justis P.
TI COMPARISON OF SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY SCAN PATTERNS
   AND CLINICAL REVIEW STRATEGIES IN NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE optical coherence tomography; age-related macular degeneration;
   exudation; choroidal neovascularization; intraretinal fluid; subretinal
   fluid; neovascular AMD; anti-VEGF
ID LINE SCANS; RANIBIZUMAB; BEVACIZUMAB; REGIMEN
AB Purpose:To compare various spectral domain optical coherence tomography scan patterns and review strategies to identify an optimal imaging workflow for neovascular age-related macular degeneration.Methods:A retrospective consecutive case series was performed in eyes after anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration with concurrent spectral domain optical coherence tomography imaging (Zeiss Cirrus), including horizontal/vertical five-line rasters, and macular cube analysis. For each scan pattern, a single report was independently reviewed in a masked fashion within the clinical image review software, whereas the cube was reviewed line-by-line in the reader software for the presence of fluid.Results:One hundred and fifty-six reports and 39 cube scans of 39 patients were included. Among all spectral domain optical coherence tomography scans, 64% (25/39) had definitive fluid and 95% (37/39) had possible fluid. Sensitivities for definite fluid detection for horizontal, combined horizontal/vertical, and horizontal/vertical/map reviews were 68%, 76%, and 88%, respectively. When assessing for possible fluid, sensitivities for the detection for horizontal, combined horizontal/vertical, and horizontal/vertical/map reviews were 76%, 92%, and 97%, respectively. Line-by-line review of the cube scan had a sensitivity for definite and possible fluid detection of 96% and 86%, respectively.Conclusion:Optimizing both clinical accuracy and workflow are important factors in managing neovascular age-related macular degeneration. A zero-tolerance strategy with vertical/horizontal raster scans and thickness maps was comparable with line-by-line review of the cube to detect possible fluid.
C1 [Courtney, Robert J.; McClintic, Jedediah I.; Ehlers, Justis P.] Cleveland Clin, Cole Eye Inst, Dept Ophthalmol, Vitreoretinal Serv, Cleveland, OH 44195 USA.
   [Ehlers, Justis P.] Cleveland Clin, Cole Eye Inst, Ophthalm Imaging Ctr, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation
RP Ehlers, JP (通讯作者)，Cleveland Clin, Cole Eye Inst, 9500 Euclid Avenue I32, Cleveland, OH 44195 USA.
EM ehlersj@ccf.org
FU NIH/NEI [K23-EY022947-01A1]; Ohio Department of Development
   [TECH-13-059]; NATIONAL EYE INSTITUTE [K23EY022947] Funding Source: NIH
   RePORTER
FX Supported by NIH/NEI K23-EY022947-01A1 and Ohio Department of
   Development TECH-13-059 (J.P.E.).
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   De Niro JE, 2014, RETINA-J RET VIT DIS, V34, P1163, DOI 10.1097/IAE.0000000000000077
   Eriksson U, 2012, ACTA OPHTHALMOL, V90, P620, DOI 10.1111/j.1755-3768.2011.02112.x
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Major JC, 2014, RETINA-J RET VIT DIS, V34, P48, DOI 10.1097/IAE.0b013e3182965743
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Pierro L, 2012, CLIN OPHTHALMOL, V6, P219, DOI 10.2147/OPTH.S27656
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Sayanagi K, 2009, AM J OPHTHALMOL, V148, P431, DOI 10.1016/j.ajo.2009.04.008
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Taban M, 2009, OPHTHALMOLOGY, V116, P964, DOI 10.1016/j.ophtha.2008.12.033
NR 15
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2015
VL 35
IS 7
BP 1315
EP 1322
DI 10.1097/IAE.0000000000000478
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM2AA
UT WOS:000357480600004
PM 25658176
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Matsumoto, H
   Hoshino, J
   Mukai, R
   Nakamura, K
   Akiyama, H
AF Matsumoto, Hidetaka
   Hoshino, Junki
   Mukai, Ryo
   Nakamura, Kosuke
   Akiyama, Hideo
TI One-year results of treat-and-extend regimen with intravitreal
   brolucizumab for treatment-naive neovascular age-related macular
   degeneration with type 1 macular neovascularization
SO SCIENTIFIC REPORTS
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; AFLIBERCEPT; EFFICACY; SAFETY;
   RANIBIZUMAB
AB We evaluated 1-year outcomes of loading phase treatment followed by maintenance treatment using a treat-and-extend (TAE) regimen with intravitreal brolucizumab for neovascular age-related macular degeneration (nAMD) associated with type 1 macular neovascularization (MNV). We analyzed 68 eyes of 65 consecutive patients with treatment-naive nAMD associated with type 1 MNV. Forty-five eyes (66.2%) completed the 1-year treatment with intravitreal brolucizumab. In those cases, best-corrected visual acuity (BCVA) showed significant improvement, while there were significant reductions in foveal thickness and central choroidal thickness, after the initial brolucizumab injection, which were maintained until the last visit. The average total number of injections over 1 year was 6.4 +/- 0.6. The average intended injection interval at the last visit was 14.0 +/- 2.9 weeks. Moreover, 17of 23 eyes (73.9%) with polypoidal lesions showed complete regression of these lesions after the loading phase treatment. Although intraocular inflammation (IOI) was observed in 15 of 68 eyes (22.1%) within 1 year, amelioration in response to combination therapy with topical and subtenon injection of steroids, without visual decline, was obtained. These results indicate that loading phase treatment followed by the TAE regimen with intravitreal brolucizumab might improve BCVA and ameliorate exudative changes in eyes with treatment-naive nAMD associated with type 1 MNV. Moreover, intravitreal brolucizumab can potentially reduce the treatment burden of nAMD. Prompt steroid therapy might be efficacious for ameliorating brolucizumab-related IOI without visual decline.
C1 [Matsumoto, Hidetaka; Hoshino, Junki; Mukai, Ryo; Nakamura, Kosuke; Akiyama, Hideo] Gunma Univ, Grad Sch Med, Dept Ophthalmol, 3-39-15 Showa Machi, Maebashi, Gunma 3718511, Japan.
C3 Gunma University
RP Matsumoto, H (通讯作者)，Gunma Univ, Grad Sch Med, Dept Ophthalmol, 3-39-15 Showa Machi, Maebashi, Gunma 3718511, Japan.
EM hide-m@gunma-u.ac.jp
CR Baumal CR, 2021, OPHTHALMOL RETINA, V5, P519, DOI 10.1016/j.oret.2020.09.020
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Fallico M, 2021, EUR J OPHTHALMOL, V31, P2496, DOI 10.1177/1120672120964699
   Fukuda Y, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9091164
   Gale RP, 2019, EYE, V33, DOI 10.1038/s41433-018-0300-3
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2021, GRAEF ARCH CLIN EXP, V259, P2857, DOI 10.1007/s00417-021-05136-w
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Mukai RG, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0259879
   Ohji M, 2021, GRAEF ARCH CLIN EXP, V259, P3637, DOI 10.1007/s00417-021-05293-y
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Sharma A, 2022, OCUL IMMUNOL INFLAMM, V30, P1508, DOI 10.1080/09273948.2021.1897628
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yamashiro K, 2021, JPN J OPHTHALMOL, V65, P741, DOI 10.1007/s10384-021-00869-x
   Yanai H., 2015, STATCEL USEFUL ADD I
NR 24
TC 2
Z9 2
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 17
PY 2022
VL 12
IS 1
AR 8195
DI 10.1038/s41598-022-10578-1
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 2J2GR
UT WOS:000815482800131
PM 35581196
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ciulla, TA
   Hammond, BR
AF Ciulla, TA
   Hammond, BR
TI Macular pigment density and aging, assessed in the normal elderly and
   those with cataracts and age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL-DENSITY; LENS; AUTOFLUORESCENCE; CAROTENOIDS; FOVEAL; RISK
AB PURPOSE: Increasing evidence has linked retinal lutein and zeaxanthin (termed macular pigment, MP) to the risk of age-related macular degeneration (AMD). Currently, however, studies differ regarding the question of whether MP declines with age or age has an effect in patient populations being assessed. This study assessed MP across the lifespan with an emphasis on assessing MP in a cross-section of elderly including those with lenticular or age-related macular degeneration, or both.
   DESIGN: Prospective, observational, cross-sectional study.
   METHODS: SETTING: Institution. STUDY POPULATION: Cross,sectional study of normal, cataractous, and AMD subjects tested in Indianapolis, Indiana, including 390 subjects, 22 with cataracts and 59 with age,related macular degeneration. OBSERVATIONAL PROCEDURE: MP density was measured with a one-degree diameter test field at 460 nm using a psychophysical method based on heterochromatic flicker photometry. MAIN OUTCOME MEASURES: MP optical density.
   RESULTS: MP does not appear to change as a function of age (r = +.04) when examining subjects across the lifespan (from 18-88 years). There was a slight tendency (slope = -.0027, r = -.11) for MP to decline when only the elderly subjects were considered, but this trend was not significant (P < .12) for any of the groups considered (normal, cataractous, or AMD).
   CONCLUSIONS: MP does not change significantly with age, even when elderly subjects with cataracts and AMD are considered. Using heterochromic flicker photometry, elderly subjects display a full range of MP density that is similar to young subjects. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Midwest Eye Inst, Retina Serv, Indianapolis, IN 46280 USA.
   Univ Georgia, Vis Sci Lab, Athens, GA 30602 USA.
C3 University System of Georgia; University of Georgia
RP Ciulla, TA (通讯作者)，Midwest Eye Inst, Retina Serv, Methodist Med Plaza N,201 Penn Pkwy, Indianapolis, IN 46280 USA.
EM thomasciulla@yahoo.com
RI Ciulla, Thomas/AAA-1299-2020
OI Ciulla, Thomas/0000-0001-5557-6777; Hammond, Billy/0000-0002-5762-0206
CR Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   ALEXANDER KR, 1987, VISION RES, V27, P1077, DOI 10.1016/0042-6989(87)90022-8
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1732, DOI 10.1001/archopht.120.12.1732
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Celentano JC, 2002, J NUTR, V132, p535S, DOI 10.1093/jn/132.3.535S
   Chen SF, 2001, CURR EYE RES, V23, P422, DOI 10.1076/ceyr.23.6.422.6963
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P1338
   Cooper DA, 2000, J NUTR, V130, P642, DOI 10.1093/jn/130.3.642
   Davies NP, 2002, INVEST OPHTH VIS SCI, V43, P281
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Duncan JL, 2002, EXP EYE RES, V74, P371, DOI 10.1006/exer.2001.1126
   Gellermann W, 2002, J OPT SOC AM A, V19, P1172, DOI 10.1364/JOSAA.19.001172
   Hammond BR, 2001, ARCH BIOCHEM BIOPHYS, V385, P41, DOI 10.1006/abbi.2000.2184
   HAMMOND BR, 1992, INVEST OPHTH VIS SCI, V33, P350
   Hammond BR, 1996, EXP EYE RES, V62, P713
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   HAMMOND BR, 2003, RETINA OPTIC NERVE I, P231
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1999, CRC MOD NUT, P251
   WERNER JS, 1987, VISION RES, V27, P257, DOI 10.1016/0042-6989(87)90188-X
   Werner JS, 2000, J OPT SOC AM A, V17, P1918, DOI 10.1364/JOSAA.17.001918
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   WOOTEN BR, 1999, INVEST OPHTHAMOL VIS
   Zhao DY, 2003, ARCH OPHTHALMOL-CHIC, V121, P967, DOI 10.1001/archopht.121.7.967
NR 31
TC 70
Z9 73
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2004
VL 138
IS 4
BP 582
EP 587
DI 10.1016/j.ajo.2004.05.057
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 864UO
UT WOS:000224658600010
PM 15488784
DA 2022-11-30
ER

PT J
AU Miller, JW
AF Miller, Joan W.
TI Treatment of Age-Related Macular Degeneration: Beyond VEGF
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; anti-VEGF therapies; apoptosis; Bruch
   membrane; genetic associations
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL TRIAMCINOLONE
   ACETONIDE; COMBINED PHOTODYNAMIC THERAPY; FACTOR-H POLYMORPHISM;
   RETINAL-DETACHMENT; EXPERIMENTAL-MODEL; BRUCHS MEMBRANE; CLINICAL-TRIAL;
   VERTEPORFIN; GENE
AB Current therapy for age-related macular degeneration (AMD) shows a dramatic change from clinical practice a decade ago. While the first pharmacologic treatment, verteporfin photodynamic therapy (PDT) slowed disease progression, newer anti-vascular epithelial growth factor (VEGF) therapies have also shown vision improvement in many patients. Combination therapies (PDT + steroid + anti-VEGF) have shown some promise, particularly in certain classes of disease. Genetic studies have identified common gene variants in the complement factor H gene that confers susceptibility to AMD, and treatments targeting the complement pathway are being explored. Another area of research is directed at the components of Bruch membrane; studies of changes in the elastic fibers and collagen within Bruch may yield drug targets for prevention and halting of disease progression. Finally, studies in photoreceptor apoptosis have identified the role of cytokines, such as monocyte chemotactic protein 1, tumor necrosis factor a, and interleukin 1 beta, associated with photoreceptor cell death and should be pursued as potential therapies to improve vision outcomes in neovascular AMD. Today's research into the biology of AMD will lead us to better treatment and perhaps even preventive measures in the decades ahead. Jpn J Ophthalmol 2010;54:523-528 (C) Japanese Ophthalmological Society 2010
C1 [Miller, Joan W.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
   [Miller, Joan W.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard Medical School
RP Miller, JW (通讯作者)，Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM ophthalmology@meei.harvard.edu
OI Miller, Joan/0000-0003-2046-3996
CR [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2006, JPN J OPHTHALMOL, V50, P161, DOI 10.1007/s10384-005-0259-z
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fan BJ, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-5
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Gillies MC, 2007, AM J OPHTHALMOL, V144, P134, DOI 10.1016/j.ajo.2007.03.019
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hisatomi T, 2008, J CLIN INVEST, V118, P2025, DOI 10.1172/JCI34267
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Kaiser PK, 2010, BRIT J OPHTHALMOL, V94, P143, DOI 10.1136/bjo.2009.159863
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   KISS S, 2008, OPHTHALMOLOGY REPORT, V1, P1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Liu XQ, 2004, NAT GENET, V36, P178, DOI 10.1038/ng1297
   Marneros AG, 2005, FASEB J, V19, P716, DOI 10.1096/fj.04-2134rev
   Marneros AG, 2007, FASEB J, V21, P3809, DOI 10.1096/fj.07-8422com
   MILLER J, 2005, AM SOC RET SPEC 23 A
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Mitka M, 2007, JAMA-J AM MED ASSOC, V297, P1538, DOI 10.1001/jama.297.14.1538
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Nakazawa T, 2006, MOL VIS, V12, P867
   Ng EWM, 2006, ANN NY ACAD SCI, V1082, P151, DOI 10.1196/annals.1348.062
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   *NIH, 2009, COMP AG REL MAC DEG
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   She HC, 2008, INVEST OPHTH VIS SCI, V49, P5008, DOI 10.1167/iovs.07-1154
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Thorleifsson G, 2007, SCIENCE, V317, P1397, DOI 10.1126/science.1146554
   Yu HG, 2008, INVEST OPHTH VIS SCI, V49, P2599, DOI 10.1167/iovs.07-1508
   Zacks DN, 2004, INVEST OPHTH VIS SCI, V45, pU479
   Zacks DN, 2003, INVEST OPHTH VIS SCI, V44, P1262, DOI 10.1167/iovs.02-0492
   2001, ARCH OPHTHALMOL, V119, P1417
NR 51
TC 23
Z9 25
U1 0
U2 7
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2010
VL 54
IS 6
BP 523
EP 528
DI 10.1007/s10384-010-0863-4
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 709VK
UT WOS:000286469300001
PM 21191711
DA 2022-11-30
ER

PT J
AU Knupp, C
   Amin, SZ
   Munro, PMG
   Luthert, PJ
   Squire, JM
AF Knupp, C
   Amin, SZ
   Munro, PMG
   Luthert, PJ
   Squire, JM
TI Collagen VI assemblies in age-related macular degeneration
SO JOURNAL OF STRUCTURAL BIOLOGY
LA English
DT Article
DE collagen; blindness; macula; Bruch's membrane; age-related macular
   degeneration; network forming collagens
ID RETINAL-PIGMENT EPITHELIUM; BRUCHS MEMBRANE; RISK-FACTORS; DRUSEN; EYES;
   FILAMENTS; DEPOSITS; TIMP-3
AB Age-related macular degeneration (AMD) is the most common cause of incurable blindness in the developed world. Little is known about the pathogenesis of this condition, but deposits in Bruch's membrane and immediately beneath the retinal pigment epithelium are frequent findings associated with this disease. Within these deposits, molecular assemblies with an similar to100-nm axial periodicity are seen. Two types of assembly are present: one exhibiting transverse double bands of protein density that are 30nm apart and repeat axially every similar to100nm; the other with transverse double bands of protein density, 30 nm apart and repeating axially every similar to50nm. In this second type of assembly, more prominent pairs of bands alternate with less prominent ones. By comparison with analogous aggregates found in the vitreous of a patient with a full-thickness macular hole, collagen VI was singled out as the most probable protein constituent of the AMD aggregates. Possible models for the aggregation patterns of these assemblies are discussed in terms of collagen VI dimers and tetramers. Understanding the structure and chemical composition of the assemblies within the AMD basal deposits may prove of great help in understanding the pathophysiology of AMD itself. (C) 2002 Elsevier Science (USA). All rights reserved.
C1 Univ London Imperial Coll Sci Technol & Med, Div Biol Sci, Biol Struct & Funct Sect, London SW7 2AZ, England.
   Univ London, Dept Pathol, Inst Ophthalmol, London EC1V 9EL, England.
C3 Imperial College London; University of London; University College London
RP Knupp, C (通讯作者)，Univ London Imperial Coll Sci Technol & Med, Div Biol Sci, Biol Struct & Funct Sect, London SW7 2AZ, England.
OI Squire, John/0000-0001-5731-253X; Luthert, Philip/0000-0001-7276-6898;
   Squire, John/0000-0001-6656-7390
CR Ayad S, 1994, EXTRACELLULAR MATRIX
   BRUNS RR, 1984, J ULTRA MOL STRUCT R, V89, P136, DOI 10.1016/S0022-5320(84)80010-6
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Fariss RN, 1997, AM J PATHOL, V150, P323
   FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303
   GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Knupp C, 2002, J STRUCT BIOL, V137, P31, DOI 10.1006/jsbi.2002.4449
   Knupp C, 2001, EMBO J, V20, P372, DOI 10.1093/emboj/20.3.372
   Knupp C, 2000, J STRUCT BIOL, V129, P38, DOI 10.1006/jsbi.1999.4202
   KUO HJ, 1995, EUR J BIOCHEM, V232, P364, DOI 10.1111/j.1432-1033.1995.364zz.x
   MISELL SL, 1978, PRACTICAL METHODS EL, P125
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Reale E, 2001, MATRIX BIOL, V20, P37, DOI 10.1016/S0945-053X(00)00132-3
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Spraul CW, 1998, OPHTHALMOLOGE, V95, P73, DOI 10.1007/s003470050240
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   VANDERSCHAFT TL, 1991, ARCH OPHTHALMOL-CHIC, V109, P420, DOI 10.1001/archopht.1991.01080030122052
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P410
   VONDERMARK H, 1984, EUR J BIOCHEM, V142, P493
   Vranka JA, 1997, CURR EYE RES, V16, P102, DOI 10.1076/ceyr.16.2.102.5086
   WU JJ, 1987, BIOCHEM J, V248, P373, DOI 10.1042/bj2480373
NR 34
TC 22
Z9 22
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1047-8477
J9 J STRUCT BIOL
JI J. Struct. Biol.
PD SEP
PY 2002
VL 139
IS 3
BP 181
EP 189
AR PII S0147-8477(02)00534-8
DI 10.1016/S1047-8477(02)00534-8
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 623BF
UT WOS:000179682700006
PM 12457848
DA 2022-11-30
ER

PT J
AU Galindo-Camacho, RM
   Blanco-Llamero, C
   da Ana, R
   Fuertes, MA
   Senorans, FJ
   Silva, AM
   Garcia, ML
   Souto, EB
AF Galindo-Camacho, Ruth M.
   Blanco-Llamero, Cristina
   da Ana, Raquel
   Fuertes, Mayra A.
   Senorans, Francisco J.
   Silva, Amelia M.
   Garcia, Maria L.
   Souto, Eliana B.
TI Therapeutic Approaches for Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; vascular endothelial growth factor;
   nanocarriers; drusen; retinal pigment epithelium; 3D bioprinting
ID GENE-THERAPY; EYE DISEASE; IN-VITRO; PLGA NANOPARTICLES; DRUG-DELIVERY;
   LUTEIN; NLC; NANOCARRIERS; PROGRESSION; BEVACIZUMAB
AB Damage to the retinal pigment epithelium, Bruch's membrane and/or tissues underlying macula is known to increase the risk of age-related macular degeneration (AMD). AMD is commonly categorized in two distinct types, namely, the nonexudative (dry form) and the exudative (wet form). Currently, there is no ideal treatment available for AMD. Recommended standard treatments are based on the use of vascular endothelial growth factor (VEGF), with the disadvantage of requiring repeated intravitreal injections which hinder patient's compliance to the therapy. In recent years, several synthetic and natural active compounds have been proposed as innovative therapeutic strategies against this disease. There is a growing interest in the development of formulations based on nanotechnology because of its important role in the management of posterior eye segment disorders, without the use of intravitreal injections, and furthermore, with the potential to prolong drug release and thus reduce adverse effects. In the same way, 3D bioprinting constitutes an alternative to regeneration therapies for the human retina to restore its functions. The application of 3D bioprinting may change the current and future perspectives of the treatment of patients with AMD, especially those who do not respond to conventional treatment. To monitor the progress of AMD treatment and disease, retinal images are used. In this work, we revised the recent challenges encountered in the treatment of different forms of AMD, innovative nanoformulations, 3D bioprinting, and techniques to monitor the progress.
C1 [Galindo-Camacho, Ruth M.; Blanco-Llamero, Cristina; da Ana, Raquel; Souto, Eliana B.] Univ Porto, Fac Pharm, Dept Pharmaceut Technol, Rua Jorge Viterbo Ferreira 228, P-4050313 Porto, Portugal.
   [Galindo-Camacho, Ruth M.; Fuertes, Mayra A.; Garcia, Maria L.] Univ Barcelona, Fac Pharm & Food Sci, Dept Pharm & Pharmaceut Technol & Phys Chem, Barcelona 08028, Spain.
   [Galindo-Camacho, Ruth M.] CSIC, Unit Synth & Biomed Applicat Peptides, IQAC, Barcelona 08034, Spain.
   [Galindo-Camacho, Ruth M.; Garcia, Maria L.] Univ Barcelona, Inst Nanosci & Nanotechnol IN2UB, Barcelona 08028, Spain.
   [Blanco-Llamero, Cristina; Senorans, Francisco J.] Autonomous Univ Madrid, Fac Sci, Dept Sect Food Sci, Hlth Lipids Grp, Madrid 28049, Spain.
   [Silva, Amelia M.] Univ Tras Os Montes & Alto Douro, Dept Biol & Environm, UTAD, P-5001801 Vila Real, Portugal.
   [Silva, Amelia M.] UTAD, Ctr Res & Technol Agroenvironm & Biol Sci, CITAB, P-5001801 Vila Real, Portugal.
   [Souto, Eliana B.] Univ Porto, Fac Pharm, REQUIMTE UCIBIO, Rua Jorge Viterbo Ferreira 228, P-4050313 Porto, Portugal.
C3 Universidade do Porto; University of Barcelona; Consejo Superior de
   Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y
   Desarrollo Pascual Vila (CID-CSIC); CSIC - Instituto de Quimica Avanzada
   de Cataluna (IQAC); University of Barcelona; Autonomous University of
   Madrid; University of Tras-os-Montes & Alto Douro; University of
   Tras-os-Montes & Alto Douro; Universidade do Porto
RP Souto, EB (通讯作者)，Univ Porto, Fac Pharm, Dept Pharmaceut Technol, Rua Jorge Viterbo Ferreira 228, P-4050313 Porto, Portugal.; Souto, EB (通讯作者)，Univ Porto, Fac Pharm, REQUIMTE UCIBIO, Rua Jorge Viterbo Ferreira 228, P-4050313 Porto, Portugal.
EM ebsouto@ff.up.pt
RI Silva, Amélia M/J-7128-2013; Souto, Eliana/T-1645-2019; Souto,
   Eliana/GQZ-3071-2022; Senorans, Francisco Javier/L-2583-2013
OI Silva, Amélia M/0000-0002-7524-9914; Souto, Eliana/0000-0002-9737-6017;
   Blanco Llamero, Cristina/0000-0002-1064-0306; Senorans, Francisco
   Javier/0000-0002-0775-6957; Galindo, Ruth M./0000-0002-7070-9061
FU UAM/Santander program; Portuguese Science and Technology Foundation
   (FCT/MTC) [SFRH/BD/04729/2020, UIDB/04033/2020]; Scholarships Santander
   Research/Convocatoria d'estades 2022 per a doctorands de la UB
FX This work was funded by Scholarships Santander Research/Convocatoria
   d'estades 2022 per a doctorands de la UB granted to R. Galindo, by
   UAM/Santander program for the mobility of young researchers granted to
   C. Blanco and by the Portuguese Science and Technology Foundation
   (FCT/MTC) for the scholarship SFRH/BD/04729/2020 granted to R. da Ana
   and the project UIDB/04033/2020 (CITAB) granted to A. M. Silva.
CR Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Al-Halafi AM, 2014, SAUDI J OPHTHALMOL, V28, P304, DOI 10.1016/j.sjopt.2014.02.009
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Alis A, 2021, PHOTODIAGN PHOTODYN, V36, DOI 10.1016/j.pdpdt.2021.102582
   Alshamrani M, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1404-1
   Araujo J, 2010, INT J PHARMACEUT, V393, P167, DOI 10.1016/j.ijpharm.2010.03.034
   Araujo J, 2012, NANOMED-NANOTECHNOL, V8, P1034, DOI 10.1016/j.nano.2011.10.015
   Bhatt P, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01836-4
   Blasiak J, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6819736
   Bohley M, 2022, DRUG DISCOV TODAY, V27, P2497, DOI 10.1016/j.drudis.2022.05.024
   Bolla PK, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12090798
   Bordet T, 2019, DRUG DISCOV TODAY, V24, P1685, DOI 10.1016/j.drudis.2019.05.038
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Brilliant MH, 2016, AM J MED, V129, P292, DOI 10.1016/j.amjmed.2015.10.015
   Carrasco-Leon A, 2021, CANCERS, V13, DOI 10.3390/cancers13081976
   Chen SN, 2022, J FORMOS MED ASSOC, V121, P2020, DOI 10.1016/j.jfma.2022.02.005
   Chew EY, 2020, AM J OPHTHALMOL, V217, P335, DOI 10.1016/j.ajo.2020.05.042
   Cho HJ, 2022, AM J OPHTHALMOL, V234, P6, DOI 10.1016/j.ajo.2021.07.026
   Cicinelli MV, 2018, SURV OPHTHALMOL, V63, P236, DOI 10.1016/j.survophthal.2017.06.005
   Colijn JM, 2021, OPHTHALMOLOGY, V128, P1039, DOI 10.1016/j.ophtha.2020.11.024
   Potilinski MC, 2021, NEUROPHARMACOLOGY, V188, DOI 10.1016/j.neuropharm.2021.108513
   Das RA, 2011, CURR DRUG TARGETS, V12, P182
   Deng YH, 2022, GENES DIS, V9, P62, DOI 10.1016/j.gendis.2021.02.009
   Dewell TE, 2021, STEM CELL RES, V53, DOI 10.1016/j.scr.2021.102368
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dubey SK, 2021, INT J PHARMACEUT, V600, DOI 10.1016/j.ijpharm.2021.120499
   Fan H, 2022, CURR OPIN PHARMACOL, V63, DOI 10.1016/j.coph.2022.102186
   Fernandes AR, 2022, INT J PHARMACEUT, V623, DOI 10.1016/j.ijpharm.2022.121938
   Fernandes AR, 2022, INT J PHARMACEUT, V617, DOI 10.1016/j.ijpharm.2022.121615
   Fernandes AR, 2021, MATERIALS, V14, DOI 10.3390/ma14247541
   Fernandes AR, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13101652
   Figueroa AG, 2021, AM J MED, V134, P122, DOI 10.1016/j.amjmed.2020.05.038
   Galindo R, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14020285
   Gammone MA, 2015, FOOD NUTR RES, V59, DOI 10.3402/fnr.v59.26762
   Ge Y, 2020, EXPERT OPIN DRUG DEL, V17, P603, DOI 10.1080/17425247.2020.1735348
   Georgiou Tassos, 2014, PharmaNutrition, V2, P8, DOI 10.1016/j.phanu.2013.10.001
   Ghezzi M, 2022, J CONTROL RELEASE, V349, P744, DOI 10.1016/j.jconrel.2022.07.019
   Gorin MB, 2020, EXP EYE RES, V191, DOI 10.1016/j.exer.2019.107894
   Gote V, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12111072
   Hadziahmetovic M, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.612812
   Han XJ, 2022, BIOACT MATER, V17, P29, DOI 10.1016/j.bioactmat.2022.01.011
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hyttinen JMT, 2021, AGEING RES REV, V67, DOI 10.1016/j.arr.2021.101260
   Jabbehdari S, 2021, SURV OPHTHALMOL, V66, P423, DOI 10.1016/j.survophthal.2020.09.002
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang H, 2021, CLIN NUTR, V40, P5662, DOI 10.1016/j.clnu.2021.10.005
   Kaarniranta K, 2009, EXP GERONTOL, V44, P685, DOI 10.1016/j.exger.2009.09.002
   Karumanchi DK, 2018, J DRUG DELIV SCI TEC, V47, P275, DOI 10.1016/j.jddst.2018.07.003
   Kesharwani P, 2019, PROG MATER SCI, V103, P484, DOI 10.1016/j.pmatsci.2019.03.003
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Lai SS, 2019, J NANOBIOTECHNOL, V17, DOI 10.1186/s12951-019-0498-7
   Laradji AM, 2021, ACS OMEGA, V6, P6172, DOI 10.1021/acsomega.0c05535
   Leung Ivan Y-F, 2008, Optometry, V79, P266, DOI 10.1016/j.optm.2007.03.017
   Li YL, 2022, J ETHNOPHARMACOL, V282, DOI 10.1016/j.jep.2021.114531
   Lin FL, 2020, MOL THER, V28, P2120, DOI 10.1016/j.ymthe.2020.06.029
   Liu JX, 2019, INT J NANOMED, V14, P8819, DOI 10.2147/IJN.S217038
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Lorber B, 2016, CURR OPIN OPHTHALMOL, V27, P262, DOI 10.1097/ICU.0000000000000252
   Lores-Motta L, 2021, AM J HUM GENET, V108, P1367, DOI 10.1016/j.ajhg.2021.06.002
   Ly A, 2018, CLIN EXP OPTOM, V101, P243, DOI 10.1111/cxo.12607
   Ly A, 2017, OPTOMETRY VISION SCI, V94, P246, DOI 10.1097/OPX.0000000000000997
   Maeda T, 2022, TRENDS MOL MED, V28, P388, DOI 10.1016/j.molmed.2022.03.001
   Masaeli E, 2020, BIOFABRICATION, V12, DOI 10.1088/1758-5090/ab4a20
   McCusker MM, 2016, CLIN DERMATOL, V34, P276, DOI 10.1016/j.clindermatol.2015.11.009
   Mettu PS, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100906
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitra S, 2021, FOOD CHEM TOXICOL, V154, DOI 10.1016/j.fct.2021.112328
   Moghassemi S, 2021, J CONTROL RELEASE, V339, P75, DOI 10.1016/j.jconrel.2021.09.024
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Narvekar P, 2019, ASSAY DRUG DEV TECHN, V17, P167, DOI 10.1089/adt.2019.920
   Ohno Y, 2022, J PHARMACOL SCI, V149, P20, DOI 10.1016/j.jphs.2022.02.007
   Ozawa Y, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101779
   Pan XH, 2021, ASIAN J PHARM SCI, V16, P687, DOI 10.1016/j.ajps.2021.05.003
   Pan Y, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100456
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Patel V, 2022, J INDIAN CHEM SOC, V99, DOI 10.1016/j.jics.2022.100516
   Peng ML, 2016, J FUNCT FOODS, V24, P122, DOI 10.1016/j.jff.2016.04.006
   Poor SH, 2022, AM J OPHTHALMOL, V239, P180, DOI 10.1016/j.ajo.2022.02.019
   Qiao H, 2022, J DRUG DELIV SCI TEC, V75, DOI 10.1016/j.jddst.2022.103654
   Qiu FF, 2019, MOL PHARMACEUT, V16, P1958, DOI 10.1021/acs.molpharmaceut.8b01319
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Querques G, 2014, SURV OPHTHALMOL, V59, P532, DOI 10.1016/j.survophthal.2014.01.001
   Rezende FA, 2014, AM J OPHTHALMOL, V158, P1071, DOI 10.1016/j.ajo.2014.07.036
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Fernandes AR, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052592
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   Sanchez-Lopez E, 2017, EUR J PHARM BIOPHARM, V110, P70, DOI 10.1016/j.ejpb.2016.10.009
   Sanchez-Lopez E, 2016, COLLOID SURFACE B, V145, P241, DOI 10.1016/j.colsurfb.2016.04.054
   Sanchez-Lopez E, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10040720
   Sanchez-Lopez E, 2018, SMALL, V14, DOI 10.1002/smll.201701808
   Sanie-Jahromi F, 2022, EXP EYE RES, V217, DOI 10.1016/j.exer.2022.108961
   Sharma K, 2021, GENOMICS, V113, P514, DOI 10.1016/j.ygeno.2020.09.044
   Sharma P, 2021, EXPERT OPIN DRUG DEL, V18, P1131, DOI 10.1080/17425247.2021.1888925
   She KQ, 2022, MOL THER-METH CLIN D, V24, P210, DOI 10.1016/j.omtm.2022.01.002
   Shi PJ, 2017, INT J BIOPRINTING, V3, P138, DOI 10.18063/IJB.2017.02.008
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Suri R, 2021, INT J BIOL MACROMOL, V191, P548, DOI 10.1016/j.ijbiomac.2021.09.069
   Suri R, 2020, EUR J PHARM SCI, V153, DOI 10.1016/j.ejps.2020.105489
   Suri R, 2020, MED HYPOTHESES, V136, DOI 10.1016/j.mehy.2019.109518
   Tan G, 2022, INT J PHARMACEUT, V625, DOI 10.1016/j.ijpharm.2022.122094
   Thomas CJ, 2021, MED CLIN N AM, V105, P473, DOI 10.1016/j.mcna.2021.01.003
   Tian Y, 2015, ARCH BIOCHEM BIOPHYS, V572, P49, DOI 10.1016/j.abb.2015.01.019
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Truong V, 2021, SLAS TECHNOL, V26, P287, DOI 10.1177/2472630320972110
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Wang GW, 2022, CURR OPIN BIOMED ENG, V22, DOI 10.1016/j.cobme.2022.100390
   Wang JJ, 2018, INVEST OPHTH VIS SCI, V59
   Wang YF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08690-4
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wuputra K, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01584-0
   Xu D, 2021, ASIA-PAC J OPHTHALMO, V10, P5, DOI 10.1097/APO.0000000000000362
   Yadav M, 2020, DRUG DELIV TRANSL RE, V10, P919, DOI 10.1007/s13346-020-00733-4
   Yang B, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13122035
   Yeh CC, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050790
   Young CM, 2022, DRUG DISCOV TODAY, V27, P17, DOI 10.1016/j.drudis.2021.09.001
   Zadeh MA, 2019, DRUG DISCOV TODAY, V24, P1669, DOI 10.1016/j.drudis.2019.04.009
   Zhang GC, 2012, STEM CELLS DEV, V21, P955, DOI 10.1089/scd.2011.0649
   Zhou M, 2021, BRIT J OPHTHALMOL, V105, P1427, DOI 10.1136/bjophthalmol-2020-316820
NR 120
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2022
VL 23
IS 19
AR 11769
DI 10.3390/ijms231911769
PG 24
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 5H5ST
UT WOS:000867739700001
PM 36233066
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kloosterboer, A
   Yannuzzi, N
   Topilow, N
   Patel, N
   Kuriyan, A
   Sridhar, J
AF Kloosterboer, Amy
   Yannuzzi, Nicolas
   Topilow, Nicole
   Patel, Nimesh
   Kuriyan, Ajay
   Sridhar, Jayanth
TI Assessing the Quality, Content, and Readability of Freely Available
   Online Information for Patients Regarding Age-Related Macular
   Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration retina online health information
AB Importance: One of the top ten causes of disability in the United States is vision loss, primarily due to age-related eye diseases such as age-related macular degeneration. With an aging population, the number of people affected by this condition is expected to rise. Patients increasingly turn to the internet for health-related information, but no standard exists across published websites.
   Objective: To assess the quality, content, accountability and readability of information found online for age-related macular degeneration.
   Design: This cross-sectional study analyzed 12 freely available medical sites with information on age-related macular degeneration and used PubMed as a gold standard for comparison. Thirty-four questions were composed to include information most relevant to patients and each website was independently evaluated by one vitreoretinal surgeon, two vitreoretinal fellows and one ophthalmology resident. Readability was analyzed using an online readability tool. The JAMA benchmarks were used to evaluate the accountability of each site.
   Setting: Freely available online information was used in this study.
   Results: The average questionnaire score for all websites was 90.23 (SD 17.56, CI 95% +/- 9.55) out of 136 possible points. There was a significant difference between the content quality of the websites (P = .01). The mean reading grade for all websites was 11.44 (SD 1.75, CI 95% +/- 0.99). No significant correlation was found between content accuracy and the mean reading grade or Google rank (r = 0.392, P = .207 and r = 0.133, P = .732, respectively). Without including PubMed, only one website achieved the full 4 JAMA benchmarks. There was no correlation between the accuracy of the content of the website and JAMA benchmarks (r = 0.344, P = .273). The interobserver reproducibility was similar among 3 out of 4 observers (r = 0.747 between JS and NT, r = 0.643 between JS and NP, r = 0.686 between NP and NT, r = 0.581 between JS and NY; P <= 0.05).
   Conclusion and Relevance: The freely available information online on age-related macular degeneration varies by source but is generally of low quality. The material presented is difficult to interpret and exceeds the recommended reading level for health information. Most websites reviewed did not provide sufficient information using the grading scheme we used to support the patient in making medical decisions.
C1 [Kloosterboer, Amy; Yannuzzi, Nicolas; Topilow, Nicole; Patel, Nimesh; Sridhar, Jayanth] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, 900 NW 17th St, Miami, FL 33136 USA.
   [Kuriyan, Ajay] Thomas Jefferson Univ, Wills Eye Hosp, Mid Atlantic Retina, Philadelphia, PA 19107 USA.
C3 Bascom Palmer Eye Institute; University of Miami; Jefferson University
RP Sridhar, J (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, 900 NW 17th St, Miami, FL 33136 USA.
EM jsridhar119@gmail.com
FU NEI NIH HHS [P30 EY014801] Funding Source: Medline
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   [Anonymous], 2013, HLTH ONLINE
   Ashraf AA, 2013, J SURG RES, V184, P665, DOI 10.1016/j.jss.2013.04.057
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Daraz L, 2018, AM J MED QUAL, V33, P487, DOI 10.1177/1062860617751639
   Ditzler N, 2016, ANN ALLERG ASTHMA IM, V117, P258, DOI 10.1016/j.anai.2016.07.011
   Dutton W. H., CULTURES INTERNET IN
   EYSENBACH G, 2002, BMJ-BRIT MED J, V324
   Fahy E, 2014, AUSTRALAS MED J, V7, P24, DOI 10.4066/AMJ.2014.1900
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Ivastinovic D, 2019, JAMA OPHTHALMOL, V137, P113, DOI 10.1001/jamaophthalmol.2018.4682
   Jin, 2003, HLTH LITERACY AMERIC
   Kloosterboer A, 2019, JAMA OPHTHALMOL, V137, P1240, DOI 10.1001/jamaophthalmol.2019.3116
   Lagan BM, 2011, BIRTH-ISS PERINAT C, V38, P336, DOI 10.1111/j.1523-536X.2011.00488.x
   Laurent MR, 2009, J AM MED INFORM ASSN, V16, P471, DOI 10.1197/jamia.M3059
   Linn AJ, 2019, HEALTH COMMUN, V34, P1461, DOI 10.1080/10410236.2018.1500430
   Litsa T, 2018, IS IT IMPORTANT SEO
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Nutbeam D, 2008, SOC SCI MED, V67, P2072, DOI 10.1016/j.socscimed.2008.09.050
   Paolino L, 2015, OBES SURG, V25, P738, DOI 10.1007/s11695-015-1578-x
   Polar O, 2017, TURK OFTALMOL DERG, V47, P205, DOI 10.4274/tjo.28003
   Powell J, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1600
   Rikard RV, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3621-9
   SHEPPERD S, 1999, BMJ-BRIT MED J, V319
   Shuyler KS, 2003, J MED INTERNET RES, V5, DOI 10.2196/jmir.5.4.e24
   Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.1997.03540390074039
   Sillence E, 2007, SOC SCI MED, V64, P1853, DOI 10.1016/j.socscimed.2007.01.012
   Sommerhalder K, 2009, PATIENT EDUC COUNS, V77, P266, DOI 10.1016/j.pec.2009.03.028
   Tan SSL, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.5729
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ybarra M, 2008, HEALTH EDUC RES, V23, P512, DOI 10.1093/her/cyl062
NR 32
TC 2
Z9 2
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD AUG 18
PY 2021
VL 36
IS 5-6
BP 400
EP 405
DI 10.1080/08820538.2021.1893761
EA MAR 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA TS9JL
UT WOS:000623995900001
PM 33646928
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Guymer, RH
   McNeil, R
   Cain, M
   Tomlin, B
   Allen, PJ
   Dip, CL
   Baird, PN
AF Guymer, RH
   McNeil, R
   Cain, M
   Tomlin, B
   Allen, PJ
   Dip, CL
   Baird, PN
TI Analysis of the Arg345Trp disease-associated allele of the EFEMP1 gene
   in individuals with early onset drusen or familial age-related macular
   degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; Doyne honeycomb retinal dystrophy;
   drusen; genetics; malattia leventinese
ID MUTATIONS; PROTEIN; ABCR; DNA
AB Background: A single base change within the EFEMP1 gene has been associated with malattia leventinese and Doyne honeycomb retinal dystrophy, two dominantly inherited macular diseases with early onset drusen. The aim of this study was to determine whether the same disease allele was also associated with other forms of early onset drusen or familial cases of age-related macular degeneration.
   Methods: Thirteen index cases of early onset drusen together with 15 other family members were examined. In addition, 54 familial cases of age-related macular degeneration were examined. Blood was taken for DNA analysis and screened for the Arg345Trp disease-associated allele of the EFEMP1 gene. Twenty-four cases of malattia leventinese or Doyne honeycomb retinal dystrophy were also screened as positive controls. Another 150 ethnicity- and age-matched individuals acted as controls.
   Results: The Arg345Trp disease-associated allele in the EFEMP1 gene was confirmed in individuals with malattia leventinese and Doyne honeycomb retinal dystrophy. However, involvement of this allele was not evident in either early onset drusen or familial age-related macular degeneration.
   Conclusions: The Arg345Trp disease-associated allele of the EFEMP1 gene does not appear to be associated with cases of early onset drusen that fall outside the diagnosis of malattia leventinese or Doyne honeycomb retinal dystrophy, nor does it appear to play a role in familial age-related macular degeneration. These findings do not exclude the involvement of other alleles of the EFEMP1 gene in either phenotype. The genetic mechanisms involved in the heterogeneous group of early onset drusen remain to be elucidated but should lead to insights into the genetic causes of macular diseases.
C1 Univ Melbourne, Dept Ophthalmol, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; University of Melbourne
RP Guymer, RH (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Dept Ophthalmol, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM rhg@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356; Baird, Paul/0000-0002-1305-3502
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I
   BURNS RP, 1980, T AM OPHTHAL SOC, V18, P206
   Doyne R., 1899, T OPHTHAL SOC UK, V19, P71
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Livingston P M, 1994, Ophthalmic Epidemiol, V1, P139, DOI 10.3109/09286589409047222
   Marquardt A, 1998, HUM MOL GENET, V7, P1517, DOI 10.1093/hmg/7.9.1517
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Sambrook J, 1989, MOL CLONING LAB MANU, V1
   Sauer C G, 2001, Ophthalmic Genet, V22, P27, DOI 10.1076/opge.22.1.27.2239
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4
   VOGT A, 1925, HDB GESAMTEN AUGENHE, V3, P1
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   WELLS J, 1993, NAT GENET, V3, P213, DOI 10.1038/ng0393-213
NR 22
TC 17
Z9 18
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD DEC
PY 2002
VL 30
IS 6
BP 419
EP 423
DI 10.1046/j.1442-9071.2002.00572.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 616CR
UT WOS:000179284600008
PM 12427233
DA 2022-11-30
ER

PT J
AU Vaze, A
   Nguyen, V
   Daien, V
   Arnold, JJ
   Young, SH
   Cheung, CM
   Lamoureux, E
   Bhargava, M
   Barthelmes, D
   Gillies, MC
AF Vaze, Anagha
   Vuong Nguyen
   Daien, Vincent
   Arnold, Jennifer J.
   Young, Stephanie H.
   Cheung, Chui M.
   Lamoureux, Ecosse
   Bhargava, Mayuri
   Barthelmes, Daniel
   Gillies, Mark C.
CA Fight Retinal Blindness Study Grp
TI RANIBIZUMAB AND AFLIBERCEPT FOR THE TREATMENT OF PIGMENT EPITHELIAL
   DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Data from an
   Observational Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; vascular endothelial growth factor
   inhibitors; retinal pigment epithelial detachment
ID OCCULT CHOROIDAL NEOVASCULARIZATION; OPTICAL COHERENCE TOMOGRAPHY;
   INTRAVITREAL RANIBIZUMAB; GROWTH-FACTOR; 12-MONTH OUTCOMES;
   VISUAL-ACUITY; VEGF TRAP; BEVACIZUMAB; SECONDARY; EYES
AB Purpose: To assess the effect of intravitreal ranibizumab and aflibercept on retinal pigment epithelial detachment (RPED) in patients with neovascular age-related macular degeneration.
   Methods: This was a retrospective analysis of data from a prospectively designed and implemented clinical audit. Analysis included change in RPED dimensions and visual acuity in 92/233 treatment-naive eyes with neovascular age-related macular degeneration and RPED 6 months after treatment with either aflibercept or ranibizumab.
   Results: There was no significant between-group difference in the adjusted mean change for maximum RPED height (P = 0.195), diameter (P = 0.522) or visual acuity (P = 0.836) at 6 months. Injection frequency was the only clinical variable that affected RPED height (P = 0.050) and visual acuity change for both treatment groups (P = 0.004). Around 30% of eyes in each group had complete resolution of RPED at 6 months.
   Conclusion: Eyes with neovascular age-related macular degeneration and RPED showed significant functional and anatomical responses after 6 months of intravitreal anti-vascular endothelial growth factor injections. However, we found no significant difference in anatomical response or change in visual acuity between eyes treated with ranibizumab compared with aflibercept. Larger, prospectively designed, randomized studies with longer term follow-up may identify a difference between the two drugs that we did not detect.
C1 [Vaze, Anagha; Vuong Nguyen; Daien, Vincent; Barthelmes, Daniel; Gillies, Mark C.] Univ Sydney, Save Sight Inst, Sydney Med Sch, Sydney, NSW, Australia.
   [Arnold, Jennifer J.] Marsden Eye Specialists, Parramatta, NSW, Australia.
   [Young, Stephanie H.] Gosford Eye Surg, Gosford, NSW, Australia.
   [Cheung, Chui M.; Lamoureux, Ecosse; Bhargava, Mayuri] Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, Chui M.; Lamoureux, Ecosse] Duke NUS Med Sch, Singapore, Singapore.
   [Barthelmes, Daniel] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Sydney; National University of Singapore; Singapore
   National Eye Center; National University of Singapore; University of
   Zurich; University Zurich Hospital
RP Vaze, A (通讯作者)，Sydney Eye Hosp, Save Sight Inst, Level 1,South Block,8 Macquarie St, Sydney, NSW 2000, Australia.
EM anagha.vaze@gmail.com
RI Lamoureux, Ecosse/Z-5482-2019; DAIEN, Vincent/Z-5516-2019
OI DAIEN, Vincent/0000-0001-5675-0861; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516
FU Novartis
FX Supported by unrestricted educational grant from Novartis.
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Baba T, 2012, OPHTHALMOLOGICA, V228, P102, DOI 10.1159/000337251
   Beaumont PE, 2014, OPHTHALMOLOGY, V121, pE4, DOI 10.1016/j.ophtha.2013.09.020
   Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   Bressler SB, 2014, JAMA OPHTHALMOL, V132, P1113, DOI 10.1001/jamaophthalmol.2014.1698
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Chan Clement K, 2014, Trans Am Ophthalmol Soc, V112, P160
   Clemens CR, 2012, BRIT J OPHTHALMOL, V96, P1088, DOI 10.1136/bjophthalmol-2011-301415
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Frampton JE, 2013, DRUGS, V73, P2031, DOI 10.1007/s40265-013-0142-z
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho J, 2015, RETINA-J RET VIT DIS, V35, P467, DOI 10.1097/IAE.0000000000000355
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Parodi MB, 2013, AM J OPHTHALMOL, V155, P103, DOI 10.1016/j.ajo.2012.07.001
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Penha FM, 2013, RETINA-J RET VIT DIS, V33, P459, DOI 10.1097/IAE.0b013e31827d2657
   Punjabi OS, 2013, BRIT J OPHTHALMOL, V97, P1024, DOI 10.1136/bjophthalmol-2013-303155
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 30
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2018
VL 38
IS 10
BP 1954
EP 1961
DI 10.1097/IAE.0000000000001815
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VS
UT WOS:000454005600017
PM 28820848
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kulkarni, SR
   Aghashe, SR
   Khandekar, RB
   Deshpande, MD
AF Kulkarni, Sucheta R.
   Aghashe, Supriya R.
   Khandekar, Rajiv B.
   Deshpande, Madan D.
TI Prevalence and determinants of age-related macular degeneration in the
   50 years and older population: A hospital based study in Maharashtra,
   India
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; blindness; low vision; prevalence;
   retina
ID RISK-FACTORS; EYE DISEASE; CATARACT-SURGERY; ASSOCIATION; CONSUMPTION;
   MACULOPATHY; PATTERN
AB Background: We present the magnitude and determinants of age-related macular degeneration (ARMD) among the 50 year and older population that visited our hospital. Materials and Methods: This was a cohort of eye patients with ARMD, seen from 2006 to 2009. Optometrist noted the best-corrected vision. Ophthalmologists examined eyes using a slit-lamp bio-microscope. The ARMD was confirmed by fluoresceine angiography and optical coherent tomography. The age, sex, history of smoking, sun exposure, family history of ARMD, diet, body mass index (BMI), hypertension, and diabetes were associated with ARMD. Result: Of the 19,140 persons of >= 50 years of age-attending eye clinic in our hospital, 302 persons had ARMD in at least one eye. The proportion of overall ARMD was 1.38% (95% CI 1.21-1.55). The proportion of age-related maculopathy (ARM) and late ARMD was 1.14% (95% CI 0.99-1.29) and 0.24% (95% CI 0.21-0.24) respectively. ARM was unilateral and bilateral in 64 (29.2%) and 155 (70.8%) persons respectively. Dry ARMD was found in 47.8%. On regression analysis, old age (OR = 1.05), male (OR = 0.54), and history of smoking (OR = 2.32) were significant risk factors of ARMD. A total of 4.2% of persons with ARMD were blind (vision <3/60). Only 43% of persons with ARMD had J6 grade of the best-corrected near vision. Conclusion: ARMD does not seem to be of public health magnitude in the study area. Early stages of ARMD were common among patients. ge, being male, and history of smoking were significant risk factors for ARMD.
C1 [Kulkarni, Sucheta R.; Aghashe, Supriya R.] HV Desai Eye Hosp, Dept Community Ophthalmol, Pune, Maharashtra, India.
   [Khandekar, Rajiv B.; Deshpande, Madan D.] Minist Hlth, Dept Non Communicable Dis Surveillance & Control, Muscat, Oman.
RP Khandekar, RB (通讯作者)，MOH HQ, DGHA, NCD, EHCP, POB 393, Muscat 113, Oman.
EM rajshpp@omantel.net.om
RI Khandekar, Rajiv/ABE-6707-2020
OI Khandekar, Rajiv/0000-0002-3925-1005; Kulkarni,
   Sucheta/0000-0002-3217-8108
CR American Academy of Ophthalmology, AG REL MAC DEG PREF
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Bialek-Szymanska Anna, 2007, Klin Oczna, V109, P127
   Cackett P, 2008, BRIT J OPHTHALMOL, V92, P1312, DOI 10.1136/bjo.2007.136077
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Goold LA, 2010, BRIT J OPHTHALMOL, V94, P150, DOI 10.1136/bjo.2009.163808
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Hatef E, 2008, RETINA-J RET VIT DIS, V28, P755, DOI 10.1097/IAE.0b013e3181613463
   Hazin R, 2009, J NATL MED ASSOC, V101, P134, DOI 10.1016/S0027-9684(15)30825-7
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Krishnaiah S, 2009, BRIT J OPHTHALMOL, V93, P1146, DOI 10.1136/bjo.2009.159723
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Plestina-Borjan I, 2007, COLLEGIUM ANTROPOL, V31, P33
   Pokharel S, 2009, J NEPAL MED ASSOC, V48, P217
   Roh MI, 2008, YONSEI MED J, V49, P931, DOI 10.3349/ymj.2008.49.6.931
   Shrivastava RK, 2006, NPCB INDIA, V1, P5
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Woo JH, 2009, ACTA OPHTHALMOL, V87, P262, DOI 10.1111/j.1755-3768.2008.01376.x
   World Health Organization, AG REL MAC DEG PRIOR
   World Health Organization United Nations Children's Fund and International Council for the Control of Iodine Deficiency Disorders., 2007, ASS IOD DEF DIS MON, P32
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 28
TC 16
Z9 16
U1 0
U2 13
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD MAY
PY 2013
VL 61
IS 5
BP 196
EP 201
DI 10.4103/0301-4738.99870
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 173HZ
UT WOS:000321071200003
PM 23571245
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yoneyama, S
   Sakurada, Y
   Mabuchi, F
   Imasawa, M
   Sugiyama, A
   Kubota, T
   Iijima, H
AF Yoneyama, Seigo
   Sakurada, Yoichi
   Mabuchi, Fumihiko
   Imasawa, Mitsuhiro
   Sugiyama, Atsushi
   Kubota, Takeo
   Iijima, Hiroyuki
TI Genetic and clinical factors associated with reticular pseudodrusen in
   exudative age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Reticular pseudodrusen; Age-related macular degeneration; Retinal
   angiomatous proliferation; Polypoidal choroidal vasculopathy; Subfoveal
   choroidal thickness
ID RETINAL ANGIOMATOUS PROLIFERATION; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   ARMS2; DRUSEN; MACULOPATHY; PREVALENCE; THICKNESS; RISK; CFH
AB Reticular pseudodrusen (RPD) is considered to be a distinct entity from soft drusen and a risk factor for age-related macular degeneration (AMD). In the present study, we investigate the genetic and clinical factors associated with reticular pseudodrusen (RPD) in patients with exudative AMD, including polypoidal choroidal vasculopathy (PCV), typical neovascular AMD, and retinal angiomatous proliferation (RAP).
   The presence or absence of RPD was studied among 408 patients with exudative AMD in at least one eye, and the clinical characteristics of those with RPD were investigated as well as genetic polymorphisms of ARMS2 A69S (rs10490924) and CFH I62V (rs800292). Subfoveal choroidal thickness was also evaluated in a limited number of subjects using the EDI mode of spectral-domain optical coherence tomography.
   The prevalence of RPD was significantly higher in RAP eyes than in typical neovascular AMD or in PCV eyes (38.2 % of 26 eyes, 13.6 % of 132 eyes and 0 % of 250 eyes respectively, P < 0.0001). RPD was significantly more prevalent in the elderly (P < 0.0001) and female (P < 0.0001) subjects. The subfoveal choroidal thickness was thinner in eyes with RPD than in those without (129.7 +/- 61.7 mu m vs 42.6 +/- 84.9 mu m, P < 0.0001). The frequency of risk variants of ARMS2 A69S was significantly higher in eyes with RPD than in those without RPD (85.7 % vs 63.8 %, P = 0.0009), although the frequency of CFH I62V was not significantly different between those with and without RPD. Logistic regression analysis revealed that age (odds ratio [OR]:1.10; 95 % confidence interval [CI]: 1.04-1.18; p = 0.002), female gender (OR:4.26; 95%CI: 1.72-10.4; p = 0.002), T-allele at ARMS2 A69S (OR: 3.23; 95%CI: 1.36-7.68; p = 0.008) and RAP (OR: 4.25; 95%CI:1.49-12.1; p = 0.007) were risk factors for RPD.
   Among eyes with exudative AMD, RPD is more common in eyes with RAP having a thin choroid at the fovea, especially in old, female patients with the risk variant of ARMS2 A69S.
C1 [Yoneyama, Seigo; Sakurada, Yoichi; Mabuchi, Fumihiko; Imasawa, Mitsuhiro; Sugiyama, Atsushi; Iijima, Hiroyuki] Univ Yamanashi, Dept Ophthalmol, Fac Med, Chuo Yamanashi 4093898, Japan.
   [Kubota, Takeo] Univ Yamanashi, Fac Med, Kofu, Yamanashi, Japan.
C3 University of Yamanashi; University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Dept Ophthalmol, Fac Med, Shimokato 1110, Chuo Yamanashi 4093898, Japan.
EM sakurada@yamanashi.ac.jp
CR Abbas RO, 2013, OPHTHALMIC GENET, V34, P209, DOI 10.3109/13816810.2012.762934
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Marioli DI, 2009, GRAEF ARCH CLIN EXP, V247, P1547, DOI 10.1007/s00417-009-1129-z
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 23
TC 33
Z9 33
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2014
VL 252
IS 9
BP 1435
EP 1441
DI 10.1007/s00417-014-2601-y
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO9WA
UT WOS:000341709000010
PM 24595987
DA 2022-11-30
ER

PT J
AU Panigrahi, PK
AF Panigrahi, Pradeep Kumar
TI A case of recalcitrant neovascular wet age-related macular degeneration
   treated with Intravitreal Brolucizumab
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Brolucizumab; Age related macular degeneration; Intravitreal injection;
   Optical coherence tomography
ID MANAGEMENT
AB A 72-year-old male presented with loss of vision in left eye of 1 year duration. Patient had been diagnosed with wet neovascular age related macular degeneration in left eye and had received multiple injections of anti vascular endothelial growth factor agents in past. Clinical and imaging studies showed persistent subretinal fluid. The patient was shifted to intravitreal Brolucizumab. There was complete resolution of subretinal fluid with improvement of vision 1 month following injection. Improvement of vison was maintained 3 months following injection with macula remaining dry.
C1 [Panigrahi, Pradeep Kumar] SOA Deemed Univ, Dept Ophthalmol, Inst Med Sci, 8 Kalinga Nagar, Bhubaneswar 751003, India.
   [Panigrahi, Pradeep Kumar] SOA Deemed Univ, SUM Hosp, 8 Kalinga Nagar, Bhubaneswar 751003, India.
C3 Siksha 'O' Anusandhan University; Siksha 'O' Anusandhan University
RP Panigrahi, PK (通讯作者)，SOA Deemed Univ, Dept Ophthalmol, Inst Med Sci, 8 Kalinga Nagar, Bhubaneswar 751003, India.; Panigrahi, PK (通讯作者)，SOA Deemed Univ, SUM Hosp, 8 Kalinga Nagar, Bhubaneswar 751003, India.
EM doc.pkp25@gmail.com
RI Panigrahi, Pradeep Kumar/ABC-2879-2021
OI Panigrahi, Pradeep Kumar/0000-0003-1236-2845
CR Avaylon J, 2020, INT MED CASE REP J, V13, P145, DOI 10.2147/IMCRJ.S252260
   Bulirsch LM, 2022, BRIT J OPHTHALMOL, V106, P1288, DOI 10.1136/bjophthalmol-2020-318672
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Fernandes CFC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00653
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
NR 6
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD SEP
PY 2021
VL 35
AR 102450
DI 10.1016/j.pdpdt.2021.102450
EA AUG 2021
PG 3
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA UO5NN
UT WOS:000694742500011
PM 34303030
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Gan, A
   Fan, Q
   Chee, ML
   Apte, RS
   Khor, CC
   Yeo, I
   Mathur, R
   Cheng, CY
   Wong, TY
   Tai, ES
AF Cheung, Chui Ming Gemmy
   Gan, Alfred
   Fan, Qiao
   Chee, Miao Ling
   Apte, Rajendra S.
   Khor, Chiea Chuen
   Yeo, Ian
   Mathur, Ranjana
   Cheng, Ching-Yu
   Wong, Tien Yin
   Tai, E. Shyong
TI Plasma lipoprotein subfraction concentrations are associated with lipid
   metabolism and age-related macular degeneration
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE high density lipoprotein; genetics; cholesterylester transfer protein
ID HIGH-DENSITY-LIPOPROTEIN; POLYPOIDAL CHOROIDAL VASCULOPATHY; TRANSFER
   PROTEIN GENE; CARDIOVASCULAR-DISEASE; CHOLESTEROL EFFLUX; BRUCH
   MEMBRANE; RISK-FACTORS; ANGIOGENESIS; RETINA; LOCI
AB concentration. AMD is associated with variation in many lipoprotein subclasses, including increased HDL and IDL particles and decreased Apo A-1, VLDL, and chylomicron particles. These data suggest widespread systemic disturbance in lipid metabolism in the pathogenesis of AMD, including possible alterations in lipoprotein carrier capacity.-Cheung, C. M. G., A. Gan, Q. Fan, M. L. Chee, R. S. Apte, C. C. Khor, I. Yeo, R. Mathur, C-Y. Cheng, T. Y. Wong, and E. S. Tai. Plasma lipoprotein subfraction concentrations are associated with lipid metabolism and age-related macular degeneration. Disturbance in lipid metabolism has been suggested as a major pathogenic factor for age-related macular degeneration (AMD). Conventional lipid measures have been inconsistently associated with AMD. Other factors that can alter lipid metabolism include lipoprotein phenotype and genetic mutations. We performed a case-control study to examine the association between lipoprotein profile and neovascular AMD (nAMD) and whether the cholesterylester transfer protein (CETP) D442G mutation modulates these associations. Patients with nAMD had significantly higher concentrations of HDL and IDL compared with controls. The increase in HDL particles in nAMD patients was driven by an excess of medium-sized particles. Concurrently, patients with nAMD also had lower Apo A-1, lower VLDL and chylomicron lipoprotein. Many of these associations showed a dose-dependent association between controls, early AMD cases, and nAMD cases. Adjustment for the presence of the D442G mutation at the CETP locus did not significantly alter the increased AMD risk associated with HDL particle
C1 [Cheung, Chui Ming Gemmy; Gan, Alfred; Chee, Miao Ling; Yeo, Ian; Mathur, Ranjana; Cheng, Ching-Yu; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Tai, E. Shyong] Natl Univ Singapore, Dept Med, Cardiovasc & Metab Disorders Programme, Singapore, Singapore.
   [Fan, Qiao] Natl Univ Singapore, Duke NUS Med Sch, Ctr Quantitat Med, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Yeo, Ian; Mathur, Ranjana; Cheng, Ching-Yu; Wong, Tien Yin] Natl Univ Singapore, Duke NUS Med Sch, Ophthalmol & Visual Sci Program, Singapore, Singapore.
   [Apte, Rajendra S.] Washington Univ, Sch Med, Dev Biol & Med, Ophthalmol & Visual Sci, St Louis, MO USA.
   [Khor, Chiea Chuen] Genome Inst Singapore, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore;
   National University of Singapore; National University of Singapore;
   Washington University (WUSTL); Agency for Science Technology & Research
   (A*STAR); A*STAR - Genome Institute of Singapore (GIS)
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.; Cheung, CMG (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.; Cheung, CMG (通讯作者)，Natl Univ Singapore, Duke NUS Med Sch, Ophthalmol & Visual Sci Program, Singapore, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Cheng, Ching-Yu/Y-2229-2019; Wong, Tien Yin/AAC-9724-2020
OI Cheng, Ching-Yu/0000-0003-0655-885X; Wong, Tien Yin/0000-0002-8448-1264;
   Apte, Rajendra/0000-0003-2281-2336; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Tai, E Shyong/0000-0003-2929-8966
FU National Medical Research Council [1003/2009, 0796/2003]; Biomedical
   Research Council [10/1/35/19/671, 501/25-5, SPF2014/002]; National
   Institutes of Health [R01EY019287]; Research to Prevent Blindness
   Physician Scientist Award, an unrestricted grant from Research to
   Prevent Blindness to Washington University; Starr Foundation; Jeffrey
   Fort Innovation Fund; Carl Marshall and Mildred Allen Reeves Foundation;
   American Foundation for Aging Research Vision Core [P30EY02687];
   NATIONAL EYE INSTITUTE [P30EY002687, R01EY019287] Funding Source: NIH
   RePORTER
FX This work was supported by National Medical Research Council Grants
   1003/2009 and 0796/2003 and Biomedical Research Council Grants
   10/1/35/19/671, 501/25-5, and SPF2014/002. R. S. A. was supported by
   National Institutes of Health Grant R01EY019287, a Research to Prevent
   Blindness Physician Scientist Award, an unrestricted grant from Research
   to Prevent Blindness to Washington University, the Starr Foundation, the
   Jeffrey Fort Innovation Fund, the Carl Marshall and Mildred Allen Reeves
   Foundation, and American Foundation for Aging Research Vision Core Grant
   P30EY02687. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the National
   Institutes of Health. The lead author affirms that the manuscript is an
   honest, accurate, and transparent account of the study being reported;
   that no important aspects of the study have been omitted; and that any
   discrepancies from the study as planned (and, if relevant, registered)
   have been explained.
CR Apte RS, 2016, EBIOMEDICINE, V5, P26, DOI 10.1016/j.ebiom.2016.02.003
   Arashiro R, 2001, PEDIATR RES, V50, P455, DOI 10.1203/00006450-200110000-00006
   Barzilai N, 2003, JAMA-J AM MED ASSOC, V290, P2030, DOI 10.1001/jama.290.15.2030
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cheung CMG, 2013, GRAEF ARCH CLIN EXP, V251, P19, DOI 10.1007/s00417-012-2029-1
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Driver SL, 2016, J AM COLL CARDIOL, V67, P1227, DOI 10.1016/j.jacc.2015.12.047
   Fenwick EK, 2017, BRIT J OPHTHALMOL, V101, P591, DOI 10.1136/bjophthalmol-2016-308541
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   Freedman DS, 2004, CLIN CHEM, V50, P1189, DOI 10.1373/clinchem.2004.032763
   GULCAN HG, 1993, INVEST OPHTH VIS SCI, V34, P3187
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hill SA, 1997, CLIN BIOCHEM, V30, P517, DOI 10.1016/S0009-9120(97)00098-2
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   INAZU A, 1994, J CLIN INVEST, V94, P1872, DOI 10.1172/JCI117537
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Kathiresan S, 2008, NAT GENET, V40, P189, DOI 10.1038/ng.75
   Khera AV, 2011, NEW ENGL J MED, V364, P127, DOI 10.1056/NEJMoa1001689
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kontush A, 2006, PHARMACOL REV, V58, P342, DOI 10.1124/pr.58.3.1
   Langsted A, 2008, CIRCULATION, V118, P2047, DOI 10.1161/CIRCULATIONAHA.108.804146
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P5897, DOI 10.1167/iovs.09-4878
   Mabuchi H, 2014, MOL CELLS, V37, P777, DOI 10.14348/molcells.2014.0265
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenson RS, 2012, CIRCULATION, V125, P1905, DOI 10.1161/CIRCULATIONAHA.111.066589
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Sene A, 2014, TRENDS ENDOCRIN MET, V25, P107, DOI 10.1016/j.tem.2013.10.007
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Stalenhoef AFH, 2008, CURR OPIN LIPIDOL, V19, P355, DOI 10.1097/MOL.0b013e328304b63c
   TAKAHASHI K, 1993, J CLIN INVEST, V92, P2060, DOI 10.1172/JCI116802
   Thompson A, 2008, JAMA-J AM MED ASSOC, V299, P2777, DOI 10.1001/jama.299.23.2777
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   van der Steeg WA, 2008, J AM COLL CARDIOL, V51, P634, DOI 10.1016/j.jacc.2007.09.060
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang Y., 2015, J NANOMATER, V2015, P1, DOI DOI 10.1038/SREP18296
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76
   Wojczynski MK, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-181
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xia CH, 2011, INVEST OPHTH VIS SCI, V52, P6572, DOI 10.1167/iovs.10-7082
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
   Zheng WC, 2015, J LIPID RES, V56, P81, DOI 10.1194/jlr.M053439
NR 69
TC 17
Z9 17
U1 0
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD SEP
PY 2017
VL 58
IS 9
BP 1785
EP 1796
DI 10.1194/jlr.M073684
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA FF4KI
UT WOS:000408912600006
PM 28698208
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Carr, AJF
   Smart, MJK
   Ramsden, CM
   Powner, MB
   da Cruz, L
   Coffey, PJ
AF Carr, Amanda-Jayne F.
   Smart, Matthew J. K.
   Ramsden, Conor M.
   Powner, Michael B.
   da Cruz, Lyndon
   Coffey, Peter J.
TI Development of human embryonic stem cell therapies for age-related
   macular degeneration
SO TRENDS IN NEUROSCIENCES
LA English
DT Review
DE age-related macular degeneration; retinal pigment epithelium; human
   embryonic stem cells; induced pluripotent stem cells; transplantation;
   cellular therapy
ID RETINAL-PIGMENT EPITHELIUM; EARLY EYE DEVELOPMENT; RCS RAT; DIRECTED
   DIFFERENTIATION; VISUAL FUNCTION; MOLECULAR CHARACTERIZATION; OPTIC
   VESICLE; TRANSPLANTATION; RPE; GENERATION
AB Age-related macular degeneration (AMD) is the leading cause of vision loss in older adults and ultimately leads to the death of photoreceptor cells in the macular area of the neural retina. Currently, treatments are only available for patients with the wet form of AMD. In this review, we describe recent approaches to develop cell-based therapies for the treatment of AMD. Recent research has focused on replacing the retinal pigment epithelium (RPE), a monolayer of cells vital to photoreceptor cell health. We discuss the various methods used to differentiate and purify RPE from human embryonic stem cells (HESC), and describe the surgical approaches being used to transplant these cells in existing and forthcoming clinical trials.
C1 [Carr, Amanda-Jayne F.; Smart, Matthew J. K.; Ramsden, Conor M.; Powner, Michael B.; Coffey, Peter J.] UCL, Inst Ophthalmol, Div ORBIT, London Project Cure Blindness, London EC1V 9EL, England.
   [da Cruz, Lyndon] Moorfields Eye Hosp, London EC1V 2PD, England.
   [Ramsden, Conor M.; da Cruz, Lyndon; Coffey, Peter J.] NHS Fdn Trust, Moorfields Eye Hosp, NIHR Biomed Res Ctr, London, England.
   [Ramsden, Conor M.; da Cruz, Lyndon; Coffey, Peter J.] UCL Inst Ophthalmol, London, England.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   Oxford University Hospitals NHS Foundation Trust; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London
RP Carr, AJF (通讯作者)，UCL, Inst Ophthalmol, Div ORBIT, London Project Cure Blindness, 11-43 Bath St, London EC1V 9EL, England.
EM a.carr@ucl.ac.uk
RI Carr, Amanda/ABG-6282-2020; Powner, Michael/CAG-7455-2022
OI Carr, Amanda/0000-0002-5469-0030; Coffey, Peter/0000-0002-5427-2939;
   Powner, Michael/0000-0003-4913-1004
FU The London Project to Cure Blindness; The Medical Research Council (MRC)
   UK; The Californian Institute of Regenerative Medicine (CIRM); Fight for
   Sight UK; The Lincy Foundation; The Macular Society; The National
   Institute for Health Research; MRC [G1000730] Funding Source: UKRI;
   Medical Research Council [G1000730] Funding Source: researchfish
FX The authors would like to thank Shazeen Hasan and Sakina Gooljar for
   providing images of the HESC-RPE patch. This work was supported by
   funding from The London Project to Cure Blindness, The Medical Research
   Council (MRC) UK, The Californian Institute of Regenerative Medicine
   (CIRM), Fight for Sight UK, The Lincy Foundation, The Macular Society,
   and The National Institute for Health Research.
CR Aftab U, 2009, EXP EYE RES, V89, P301, DOI 10.1016/j.exer.2009.03.025
   Alge CS, 2003, INVEST OPHTH VIS SCI, V44, P3629, DOI 10.1167/iovs.02-1225
   Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912
   Banin E, 2006, STEM CELLS, V24, P246, DOI 10.1634/stemcells.2005-0009
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJ, 2009, MOL VIS, V15, P283
   Chen FK, 2010, BRIT J OPHTHALMOL, V94, P1337, DOI 10.1136/bjo.2009.172593
   Chow RL, 2001, ANNU REV CELL DEV BI, V17, P255, DOI 10.1146/annurev.cellbio.17.1.255
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Fuhrmann S, 2000, DEVELOPMENT, V127, P4599
   Fusaki N, 2009, P JPN ACAD B-PHYS, V85, P348, DOI 10.2183/pjab.85.348
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Gelisken F, 2007, GRAEF ARCH CLIN EXP, V245, P1085, DOI 10.1007/s00417-006-0524-y
   Gias C, 2007, EUR J NEUROSCI, V25, P1940, DOI 10.1111/j.1460-9568.2007.05459.x
   Girman SV, 2003, VISION RES, V43, P1817, DOI 10.1016/S0042-6989(03)00276-1
   Graw J, 2010, CURR TOP DEV BIOL, V90, P343, DOI 10.1016/S0070-2153(10)90010-0
   Gust J, 2011, INVEST OPHTH VIS SCI, V52, P5266, DOI 10.1167/iovs.10-6329
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hirano M, 2003, DEV DYNAM, V228, P664, DOI 10.1002/dvdy.10425
   Hongisto H., 2012, STEM CELL DISCOV, V2, P180
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Humayun MS, 2000, INVEST OPHTH VIS SCI, V41, P3100
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   JAFFE GJ, 1994, INVEST OPHTH VIS SCI, V35, P2924
   Joussen AM, 2003, GRAEF ARCH CLIN EXP, V241, P966, DOI 10.1007/s00417-003-0792-8
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199
   Kearns V, 2012, J MATER SCI-MATER M, V23, P2013, DOI 10.1007/s10856-012-4675-6
   Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Krohne TU, 2012, STEM CELL TRANSL MED, V1, P96, DOI 10.5966/sctm.2011-0057
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2011, INVEST OPHTH VIS SCI, V52, P4897, DOI 10.1167/iovs.10-6504
   Lawrence JM, 2000, INVEST OPHTH VIS SCI, V41, P518
   LI LX, 1988, EXP EYE RES, V47, P911, DOI 10.1016/0014-4835(88)90073-5
   Li Yunping, 2012, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V37, P433, DOI 10.3969/j.issn.1672-7347.2012.05.001
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Little CW, 1998, EXP NEUROL, V149, P151, DOI 10.1006/exnr.1997.6642
   Liu YJ, 2012, GENET MOL BIOL, V35, P693, DOI 10.1590/S1415-47572012005000050
   Liu YQ, 2009, INVEST OPHTH VIS SCI, V50, P5080, DOI 10.1167/iovs.08-2911
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martinez-Morales JR, 2004, BIOESSAYS, V26, P766, DOI 10.1002/bies.20064
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Mellough CB, 2012, STEM CELLS, V30, P673, DOI 10.1002/stem.1037
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Okita K, 2011, PHILOS T R SOC B, V366, P2198, DOI 10.1098/rstb.2011.0016
   Onnela N, 2012, MED BIOL ENG COMPUT, V50, P107, DOI 10.1007/s11517-011-0850-z
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]
   Park Un Chul, 2011, Clin Exp Reprod Med, V38, P216, DOI 10.5653/cerm.2011.38.4.216
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Radke ND, 2004, ARCH OPHTHALMOL-CHIC, V122, P1159, DOI 10.1001/archopht.122.8.1159
   Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447
   Rizzolo LJ, 2011, PROG RETIN EYE RES, V30, P296, DOI 10.1016/j.preteyeres.2011.06.002
   Rowland TJ, 2013, J TISSUE ENG REGEN M, V7, P642, DOI 10.1002/term.1458
   Sakami S, 2008, MECH DEVELOP, V125, P106, DOI 10.1016/j.mod.2007.10.001
   Schmitt S, 2009, INVEST OPHTH VIS SCI, V50, P5901, DOI 10.1167/iovs.08-3067
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   SEATON AD, 1994, INVEST OPHTH VIS SCI, V35, P162
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stanzel BV, 2012, INVEST OPHTH VIS SCI, V53, P490, DOI 10.1167/iovs.11-8260
   Stover AE, 2011, METHODS MOL BIOL, V767, P391, DOI 10.1007/978-1-61779-201-4_28
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Subrizi A, 2012, BIOMATERIALS, V33, P8047, DOI 10.1016/j.biomaterials.2012.07.033
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P4979, DOI 10.1167/iovs.10-5386
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takeuchi K, 2012, EYE, V26, P52, DOI 10.1038/eye.2011.302
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Vaajasaari H, 2011, MOL VIS, V17, P558
   VINORES SA, 1995, EXP EYE RES, V60, P385, DOI 10.1016/S0014-4835(05)80095-8
   Vugler A, 2007, MECH DEVELOP, V124, P807, DOI 10.1016/j.mod.2007.08.002
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang SM, 2005, INVEST OPHTH VIS SCI, V46, P2552, DOI 10.1167/iovs.05-0279
   Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012
   Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402
   Westenskow PD, 2012, INVEST OPHTH VIS SCI, V53, P6282, DOI 10.1167/iovs.12-9721
   Wohl SG, 2012, PROG RETIN EYE RES, V31, P213, DOI 10.1016/j.preteyeres.2012.02.001
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
NR 109
TC 126
Z9 136
U1 1
U2 100
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0166-2236
EI 1878-108X
J9 TRENDS NEUROSCI
JI Trends Neurosci.
PD JUL
PY 2013
VL 36
IS 7
BP 385
EP 395
DI 10.1016/j.tins.2013.03.006
PG 11
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 185TD
UT WOS:000321992300002
PM 23601133
DA 2022-11-30
ER

PT J
AU Bradley, DT
   Zipfel, PF
   Hughes, AE
AF Bradley, D. T.
   Zipfel, P. F.
   Hughes, A. E.
TI Complement in age-related macular degeneration: a focus on function
SO EYE
LA English
DT Article
DE age-related macular degeneration; genetics; complement; alternative
   pathway; evolution
ID FACTOR-H AUTOANTIBODIES; CLASSICAL PATHWAY; PHYSICAL-ACTIVITY;
   GENETIC-VARIANTS; BRUCHS MEMBRANE; SERPING1 GENE; COMPONENT 2; FACTOR-I;
   ACTIVATION; RISK
AB Age-related macular degeneration (AMD) is an inflammatory disease, which causes visual impairment and blindness in older people. The proteins of the complement system are central to the development of this disease. Local and systemic inflammation in AMD are mediated by the deregulated action of the alternative pathway of the complement system. Variants in complement system genes alter an individual's risk of developing AMD. Recent studies have shown how some risk-associated genetic variants alter the function of the complement system. In this review, we describe the evolution of the complement system and bring together recent research to form a picture of how changes in complement system genes and proteins affect the function of the complement cascade, and how this affects the development of AMD. We discuss the application of this knowledge to prevention and possible future treatments of AMD. Eye (2011) 25, 683-693; doi:10.1038/eye.2011.37; published online 11 March 2011
C1 [Bradley, D. T.; Hughes, A. E.] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Publ Hlth, Belfast BT12 6BA, Antrim, North Ireland.
   [Zipfel, P. F.] Univ Jena, Jena, Germany.
   [Zipfel, P. F.] Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Jena, Germany.
C3 Queens University Belfast; Friedrich Schiller University of Jena; Hans
   Knoll Institute (HKI)
RP Bradley, DT (通讯作者)，Queens Univ Belfast, Royal Victoria Hosp, Ctr Publ Hlth, Inst Clin Sci, Block B,Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM dbradley09@qub.ac.uk
RI Bradley, Declan T/AFO-1353-2022; Hughes, Anne/A-1307-2012; Bradley,
   Declan/AFN-7904-2022
OI Bradley, Declan/0000-0003-1468-1823
FU Public Health Agency (Northern Ireland); Public Health Agency
   [EAT/3976/08] Funding Source: researchfish
FX DTB is funded by a research and development doctoral fellowship from the
   Public Health Agency (Northern Ireland).
CR Abarrategui-Garrido C, 2009, BLOOD, V114, P4261, DOI 10.1182/blood-2009-05-223834
   Agbeko RS, 2010, PEDIATR CRIT CARE ME, V11, P561, DOI 10.1097/PCC.0b013e3181d900ba
   Allikmets R, 2009, LANCET, V374, P875, DOI 10.1016/S0140-6736(09)61618-4
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985
   Bexborn F, 2008, MOL IMMUNOL, V45, P2370, DOI 10.1016/j.molimm.2007.11.003
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brouwer MC, 2009, LANCET INFECT DIS, V9, P31, DOI 10.1016/S1473-3099(08)70261-5
   Brown KM, 2006, NEW ENGL J MED, V354, P2014, DOI 10.1056/NEJMoa052825
   Buttner-Mainik A, 2011, PLANT BIOTECHNOL J, V9, P373, DOI 10.1111/j.1467-7652.2010.00552.x
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   COLTEN HR, 1972, J IMMUNOL, V108, P1184
   COOPER DN, 1999, HUMAN GENE EVOLUTION
   Cvirn G, 2002, THROMB RES, V105, P433, DOI 10.1016/S0049-3848(02)00042-7
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dhillon B, 2010, INVEST OPHTH VIS SCI, V51, P5858, DOI 10.1167/iovs.09-5124
   Dinu V, 2007, GENET EPIDEMIOL, V31, P224, DOI 10.1002/gepi.20204
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Flierman R, 2007, IMMUNOBIOLOGY, V212, P363, DOI 10.1016/j.imbio.2006.11.005
   Friese MA, 2000, CLIN EXP IMMUNOL, V121, P406, DOI 10.1046/j.1365-2249.2000.01285.x
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haas PJ, 2007, IMMUNOL RES, V37, P161, DOI 10.1007/BF02697367
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Halkes CJM, 2001, ARTERIOSCL THROM VAS, V21, P1526, DOI 10.1161/hq0901.095276
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   HUGHES AE, MOL VIS IN PRESS
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   JACKSON M, 2004, HUMAN GENOME EVOLUTI
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Jozsi M, 2007, MOL IMMUNOL, V44, P2697, DOI 10.1016/j.molimm.2006.12.001
   Jozsi M, 2007, BLOOD, V110, P1516, DOI 10.1182/blood-2007-02-071472
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   KOETHE SM, 1995, J IMMUNOL, V155, P826
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Larhammar D, 2009, ANN NY ACAD SCI, V1163, P201, DOI 10.1111/j.1749-6632.2008.03659.x
   Lee AY, 2010, BRIT J OPHTHALMOL, V94, P915, DOI 10.1136/bjo.2009.172007
   LUNDIN LG, 1993, GENOMICS, V16, P1, DOI 10.1006/geno.1993.1133
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Manthey HD, 2009, INT J BIOCHEM CELL B, V41, P2114, DOI 10.1016/j.biocel.2009.04.005
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173
   Mullins RF, 2009, EXP EYE RES, V89, P767, DOI 10.1016/j.exer.2009.07.001
   Nonaka M, 2006, IMMUNOGENETICS, V58, P701, DOI 10.1007/s00251-006-0142-1
   Nordahl EA, 2004, P NATL ACAD SCI USA, V101, P16879, DOI 10.1073/pnas.0406678101
   Pangburn MK, 2002, BIOCHEM SOC T, V30, P1006, DOI 10.1042/bst0301006
   PANGBURN MK, 1981, J EXP MED, V154, P856, DOI 10.1084/jem.154.3.856
   Persson BD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001122
   Pinto MR, 2007, ADV EXP MED BIOL, V598, P372
   Ricklin D, 2008, ADV EXP MED BIOL, V632, P273, DOI 10.1007/978-0-387-78952-1_20
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   ROSENFELD SI, 1983, J CLIN INVEST, V71, P795, DOI 10.1172/JCI110833
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schneider MC, 2009, NATURE, V458, P890, DOI 10.1038/nature07769
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sjoberg A, 2005, J BIOL CHEM, V280, P32301, DOI 10.1074/jbc.M504828200
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Thiel S, 2007, MOL IMMUNOL, V44, P3875, DOI 10.1016/j.molimm.2007.06.005
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Vaisar T, 2007, J CLIN INVEST, V117, P746, DOI 10.1172/JCI26206
   Walport MJ, 2002, ARTHRITIS RES THER, V4, pS279, DOI 10.1186/ar586
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
   Yang KD, 2010, CLIN CHEM, V56, P127, DOI 10.1373/clinchem.2009.126615
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zipfel PF, 2007, MOL IMMUNOL, V44, P3850, DOI 10.1016/j.molimm.2007.06.149
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 2009, IMMUNOL LETT, V126, P1, DOI 10.1016/j.imlet.2009.07.005
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
   Zipfel PF, 2001, SEMIN THROMB HEMOST, V27, P191, DOI 10.1055/s-2001-15248
NR 92
TC 55
Z9 59
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2011
VL 25
IS 6
BP 683
EP 693
DI 10.1038/eye.2011.37
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 775BA
UT WOS:000291430100003
PM 21394116
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Blasiak, J
   Pawlowska, E
   Chojnacki, J
   Szczepanska, J
   Chojnacki, C
   Kaarniranta, K
AF Blasiak, Janusz
   Pawlowska, Elzbieta
   Chojnacki, Jan
   Szczepanska, Joanna
   Chojnacki, Cezary
   Kaarniranta, Kai
TI Zinc and Autophagy in Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; AMD; zinc; autophagy; melanosomes;
   lipofuscin
ID RETINAL-PIGMENT EPITHELIUM; DIETARY ANTIOXIDANTS; SIGNALING PATHWAY;
   OXIDATIVE STRESS; GENETIC RISK; EYE; PREVALENCE; DISEASE; MELANIN;
   CANCER
AB Zinc supplementation is reported to slow down the progression of age-related macular degeneration (AMD), but there is no general consensus on the beneficiary effect on zinc in AMD. As zinc can stimulate autophagy that is declined in AMD, it is rational to assume that it can slow down its progression. As melanosomes are the main reservoir of zinc in the retina, zinc may decrease the number of lipofuscin granules that are substrates for autophagy. The triad zinc-autophagy-AMD could explain some controversies associated with population studies on zinc supplementation in AMD as the effect of zinc on AMD may be modulated by genetic background. This aspect was not determined in many studies regarding zinc in AMD. Zinc deficiency induces several events associated with AMD pathogenesis, including increased oxidative stress, lipid peroxidation and the resulting lipofuscinogenesis. The latter requires autophagy, which is impaired. This is a vicious cycle-like reaction that may contribute to AMD progression. Promising results with zinc deficiency and supplementation in AMD patients and animal models, as well as emerging evidence of the importance of autophagy in AMD, are the rationale for future research on the role of autophagy in the role of zinc supplementation in AMD.
C1 [Blasiak, Janusz] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, PL-90236 Lodz, Poland.
   [Pawlowska, Elzbieta] Med Univ Lodz, Dept Orthodont, PL-92216 Lodz, Poland.
   [Chojnacki, Jan; Chojnacki, Cezary] Med Univ Lodz, Dept Clin Nutr & Gastroenterol Diagnost, PL-90647 Lodz, Poland.
   [Szczepanska, Joanna] Med Univ Lodz, Dept Pediat Dent, PL-92216 Lodz, Poland.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Kuopio 70211, Finland.
C3 University of Lodz; Medical University Lodz; Medical University Lodz;
   Medical University Lodz; University of Eastern Finland; Kuopio
   University Hospital; University of Eastern Finland
RP Blasiak, J (通讯作者)，Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, PL-90236 Lodz, Poland.
EM janusz.blasiak@biol.uni.lodz.pl; elzbieta.pawlowska@umed.lodz.pl;
   jan.chojnacki@umed.lodz.pl; joanna.szczepanska@umed.lodz.pl;
   cezary.chojnacki@umed.lodz.pl; kai.kaarniranta@kuh.fi
OI Szczepanska, JOANNA/0000-0001-9912-5345; Chojnacki,
   Jan/0000-0001-8766-7868; Kaarniranta, Kai/0000-0003-2600-8679; Blasiak,
   Janusz/0000-0001-9539-9584; Chojnacki, Cezary/0000-0002-1620-4775;
   Pawlowska, Elzbieta/0000-0002-5373-4783
CR Abdallah NH, 2018, J CELL PHYSIOL, V233, P8677, DOI 10.1002/jcp.26747
   Anastassov I, 2014, J NEUROCHEM, V129, P249, DOI 10.1111/jnc.12627
   Andreini C, 2006, J PROTEOME RES, V5, P196, DOI 10.1021/pr050361j
   Assel MJ, 2018, OPHTHALMOLOGY, V125, P391, DOI 10.1016/j.ophtha.2017.09.008
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Domenech EB, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040347
   Bafaro E, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.29
   Bian XY, 2018, FREE RADICAL RES, V52, P80, DOI 10.1080/10715762.2017.1414949
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1551, DOI 10.2741/3804
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   Bosomworth HJ, 2012, METALLOMICS, V4, P771, DOI 10.1039/c2mt20088k
   Botti J, 2006, AUTOPHAGY, V2, P67, DOI 10.4161/auto.2.2.2458
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2435963
   Chatterjee S, 2018, J BIOL CHEM, V293, P20157, DOI 10.1074/jbc.RA118.005791
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Cheng Y, 2019, ADV MATER, V31, DOI 10.1002/adma.201806808
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   da Costa B, 2020, MYCOSES, V63, P993, DOI 10.1111/myc.13127
   Denton D, 2015, IMMUNOL CELL BIOL, V93, P35, DOI 10.1038/icb.2014.85
   Ding BB, 2017, J BIOL CHEM, V292, P8531, DOI 10.1074/jbc.H116.762948
   Djajadikerta A, 2020, J MOL BIOL, V432, P2799, DOI 10.1016/j.jmb.2019.12.035
   EVANS BD, 1987, MOL IMMUNOL, V24, P1345, DOI 10.1016/0161-5890(87)90130-1
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Flinn JM, 2014, METALLOMICS, V6, P1223, DOI 10.1039/c4mt00058g
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Garufi A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.217
   Garufi A, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-72
   Gilbert R, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201801049
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gopinath B, 2017, BRIT J OPHTHALMOL, V101, P1027, DOI 10.1136/bjophthalmol-2016-309490
   Grzywacz A, 2015, ACTA BIOCHIM POL, V62, P491, DOI 10.18388/abp.2015_1038
   Hansen M, 2018, NAT REV MOL CELL BIO, V19, P579, DOI 10.1038/s41580-018-0033-y
   Hellinen L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50324-8
   Herrling T, 2008, SPECTROCHIM ACTA A, V69, P1429, DOI 10.1016/j.saa.2007.09.030
   Hewitt G, 2017, TRENDS CELL BIOL, V27, P340, DOI 10.1016/j.tcb.2016.11.011
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   HORCICKO J, 1973, H-S Z PHYSIOL CHEM, V354, P203
   Hung HH, 2013, CELL BIOL TOXICOL, V29, P415, DOI 10.1007/s10565-013-9261-2
   Hwang JJ, 2010, BIOMETALS, V23, P997, DOI 10.1007/s10534-010-9346-9
   Hyodo F, 2019, FREE RADICAL BIO MED, V134, P99, DOI 10.1016/j.freeradbiomed.2019.01.002
   Ikram MA, 2017, EUR J EPIDEMIOL, V32, P807, DOI 10.1007/s10654-017-0321-4
   International Zinc Nutrition Consultative Group (IZiNCG), 2004, Food Nutr Bull, V25, pS99
   Jarosz M, 2017, INFLAMMOPHARMACOLOGY, V25, P11, DOI 10.1007/s10787-017-0309-4
   Joerger AC, 2016, ANNU REV BIOCHEM, V85, P375, DOI 10.1146/annurev-biochem-060815-014710
   Julien S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029245
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawamata T, 2017, J BIOL CHEM, V292, P8520, DOI 10.1074/jbc.M116.762948
   King JC, 2000, J NUTR, V130, p1360S, DOI 10.1093/jn/130.5.1360S
   Klionsky DJ, 2020, CELL DEATH DIFFER, V27, P831, DOI 10.1038/s41418-020-0511-6
   Koh JY, 2019, MOL BRAIN, V12, DOI 10.1186/s13041-019-0439-2
   Kosmidou C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17634-1
   Krezel A, 2016, ARCH BIOCHEM BIOPHYS, V611, P3, DOI 10.1016/j.abb.2016.04.010
   Kusanaga M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092192
   Lee MG, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51438-9
   Lee SJ, 2010, MOL BRAIN, V3, DOI 10.1186/1756-6606-3-30
   Liuzzi JP, 2013, BIOL TRACE ELEM RES, V156, P350, DOI 10.1007/s12011-013-9816-3
   Liuzzi JP, 2014, BIOMETALS, V27, P1087, DOI 10.1007/s10534-014-9773-0
   Lu XD, 2020, AM J PHYSIOL-CELL PH, V318, pC640, DOI 10.1152/ajpcell.00152.2019
   Maret W, 2013, ADV NUTR, V4, P82, DOI 10.3945/an.112.003038
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S
   Mecklenburg L, 2007, TOXICOL PATHOL, V35, P252, DOI 10.1080/01926230601178199
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Michaelides M, 2011, ARCH OPHTHALMOL-CHIC, V129, P30, DOI 10.1001/archophthalmol.2010.321
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Nakamura T, 2007, CELL MOL LIFE SCI, V64, P1609, DOI 10.1007/s00018-007-6525-0
   Nakatogawa H, 2020, NAT REV MOL CELL BIO, V21, P439, DOI 10.1038/s41580-020-0241-0
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Newsome DA, 1995, J TRACE ELEM EXP MED, V8, P193
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   Ni H, 2011, BIOL TRACE ELEM RES, V143, P1607, DOI 10.1007/s12011-011-8982-4
   Njaria PM, 2015, EXPERT OPIN THER PAT, V25, P1003, DOI 10.1517/13543776.2015.1050791
   Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008
   Organisciak D, 2012, PHOTOCHEM PHOTOBIOL, V88, P1396, DOI 10.1111/j.1751-1097.2012.01134.x
   Park MH, 2011, NEUROBIOL DIS, V42, P242, DOI 10.1016/j.nbd.2011.01.009
   Peters S, 2006, OPHTHAL RES, V38, P83, DOI 10.1159/000090268
   Petr MA, 2020, TRENDS CELL BIOL, V30, P117, DOI 10.1016/j.tcb.2019.12.001
   Prasad AS, 2014, J TRACE ELEM MED BIO, V28, P357, DOI 10.1016/j.jtemb.2014.09.002
   Prasad AS, 2014, J TRACE ELEM MED BIO, V28, P364, DOI 10.1016/j.jtemb.2014.07.019
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Ripps H, 2014, MOL VIS, V20, P1067
   Rousseau A, 2018, NAT REV MOL CELL BIO, V19, P697, DOI 10.1038/s41580-018-0040-z
   Rozanowska M, 1997, PHOTOCHEM PHOTOBIOL, V65, P472, DOI 10.1111/j.1751-1097.1997.tb08593.x
   Saito Y, 2018, REDOX BIOL, V19, P354, DOI 10.1016/j.redox.2018.09.004
   Sekler I, 2007, MOL MED, V13, P337, DOI 10.2119/2007-00037.Sekler
   Seo BR, 2015, NEUROBIOL AGING, V36, P3228, DOI 10.1016/j.neurobiolaging.2015.09.006
   Sharif R, 2015, MOL NUTR FOOD RES, V59, P1200, DOI 10.1002/mnfr.201400784
   Shinozaki D, 2020, PLANT PHYSIOL, V182, P1284, DOI 10.1104/pp.19.01522
   Shu WT, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11040112
   Sulzer D, 2018, NPJ PARKINSON DIS, V4, DOI 10.1038/s41531-018-0047-3
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Toler SM, 2004, EXP BIOL MED, V229, P607, DOI 10.1177/153537020422900704
   Ugarte M, 2014, METALLOMICS, V6, P189, DOI 10.1039/c3mt00291h
   van Kuijk Frederik J G M, 2017, Trans Am Ophthalmol Soc, V115, pT3
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013
   Wang L, 2019, BIOL REV, V94, P503, DOI 10.1111/brv.12464
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   Wills NK, 2008, EXP EYE RES, V87, P80, DOI 10.1016/j.exer.2008.04.013
   Wong P, 2017, MOL VIS, V23, P718
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xia HK, 2020, MOL THER-NUCL ACIDS, V20, P217, DOI 10.1016/j.omtn.2020.02.010
   Yildiz A, 2019, J CANCER PREV, V24, P146, DOI 10.15430/JCP.2019.24.3.146
   Yoneyama S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64301-z
   Yu Z, 2019, J CELL PHYSIOL, V234, P20648, DOI 10.1002/jcp.28670
   Yuan N, 2012, BIOSCI BIOTECH BIOCH, V76, P2014, DOI 10.1271/bbb.120216
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang JL, 2015, INT J MOL SCI, V16, P1644, DOI 10.3390/ijms16011644
   Zhang XY, 2016, SCI REP-UK, V6, DOI 10.1038/srep37279
   Zhou X, 2017, TOXICOL IN VITRO, V44, P392, DOI 10.1016/j.tiv.2017.08.006
   Zientara-Rytter K, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010040
NR 124
TC 10
Z9 12
U1 2
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2020
VL 21
IS 14
AR 4994
DI 10.3390/ijms21144994
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA MS5FZ
UT WOS:000554303000001
PM 32679798
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Hou, HY
   Liang, HL
   Wang, YS
AF Hou, Hui-Yuan
   Liang, Hong-Liang
   Wang, Yu-Sheng
TI Bone Marrow-Derived Cells in Neovascular Age-Related Macular
   Degeneration: Contribution and Potential Application
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE Bone marrow-derived cells; Stem cells; Choroidal neovascularization;
   Age-related macular degeneration
ID MESENCHYMAL STEM-CELLS; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   ENDOTHELIAL PROGENITOR CELLS; THERAPY; DELIVERY; MODEL
AB Neovascular age-related macular degeneration, characterized by the formation of choroidal neovascularization (CNV), is a predominant cause of serious loss of vision. The pathogenesis of CNV is complex and still imperfectly understood. Prior studies have shown that bone marrow-derived cells (BMC) play a role in CNV. In this review article, we describe the contribution of BMC to CNV development, and discuss the potential use of BMC in the anticipation and treatment of CNV-associated diseases as well as research needs in the future. Copyright (C) 2010 S. Karger AG, Basel
C1 [Hou, Hui-Yuan; Wang, Yu-Sheng] Fourth Mil Med Univ, Xijing Hosp, Dept Ophthalmol, Eye Inst Chinese PLA, Xian 710032, Peoples R China.
   [Liang, Hong-Liang] Fourth Mil Med Univ, Xijing Hosp, Inst Cardiovasc Dis Chinese PLA, Dept Cardiovasc Surg, Xian 710032, Peoples R China.
C3 Air Force Military Medical University; Air Force Military Medical
   University
RP Wang, YS (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Dept Ophthalmol, Eye Inst Chinese PLA, Xian 710032, Peoples R China.
EM wangys@fmmu.edu.cn
RI Hou, Huiyuan/AAI-3718-2020
OI Hou, Huiyuan/0000-0003-0082-8353
CR Afzal A, 2007, MICROVASC RES, V74, P131, DOI 10.1016/j.mvr.2007.04.011
   Aghi M, 2005, MOL THER, V12, P994, DOI 10.1016/j.ymthe.2005.07.693
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Ball SG, 2007, J CELL MOL MED, V11, P1012, DOI 10.1111/j.1582-4934.2007.00120.x
   Chan-Ling T, 2006, AM J PATHOL, V168, P1031, DOI 10.2353/ajpath.2006.050697
   Csaky KG, 2004, EXP EYE RES, V78, P1107, DOI 10.1016/j.exer.2004.01.010
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Gao F, 2007, CAN J CARDIOL, V23, P891
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Guerin E, 2008, MICROVASC RES, V75, P302, DOI 10.1016/j.mvr.2007.12.001
   Hall B, 2007, INT J HEMATOL, V86, P8, DOI 10.1532/IJH97.06230
   Harris JR, 2006, INVEST OPHTH VIS SCI, V47, P2108, DOI 10.1167/iovs.05-0928
   Hou HY, 2008, EXP EYE RES, V86, P983, DOI 10.1016/j.exer.2008.03.018
   Hou HY, 2006, CURR EYE RES, V31, P1051, DOI 10.1080/02713680601100459
   Huang SD, 2006, J THORAC CARDIOV SUR, V132, P1329, DOI 10.1016/j.jtcvs.2006.08.021
   Noel A, 2007, TRENDS MOL MED, V13, P345, DOI 10.1016/j.molmed.2007.06.005
   Nolan DJ, 2007, GENE DEV, V21, P1546, DOI 10.1101/gad.436307
   Ozawa K, 2008, J AUTOIMMUN, V30, P121, DOI 10.1016/j.jaut.2007.12.008
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Sengupta N, 2005, INVEST OPHTH VIS SCI, V46, P343, DOI 10.1167/iovs.04-0153
   Sheridan CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI 10.1167/iovs.05-0779
   Studeny M, 2002, CANCER RES, V62, P3603
   Tamaki Yasuhiro, 2007, Nippon Ganka Gakkai Zasshi, V111, P232
   Yodoi Y, 2007, INVEST OPHTH VIS SCI, V48, P5464, DOI 10.1167/iovs.07-0093
   Yoshida Takeshi, 2007, Nippon Ganka Gakkai Zasshi, V111, P881
NR 27
TC 8
Z9 11
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2011
VL 45
IS 1
BP 1
EP 4
DI 10.1159/000313983
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 638XP
UT WOS:000280932900001
PM 20714185
DA 2022-11-30
ER

PT J
AU Cheng, CL
   Saw, SM
   Pang, CE
   Chee, C
AF Cheng, C. L.
   Saw, S. M.
   Pang, C. E.
   Chee, C.
TI Age-related macular degeneration in Singapore
SO SINGAPORE MEDICAL JOURNAL
LA English
DT Article
DE age-related macular degeneration; drusen; dry age-related macular
   degeneration; exudative age-related macular degeneration; macular
   degeneration
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; 5-YEAR INCIDENCE; MACULOPATHY;
   PREVALENCE; PROGRESSION; EYE
AB Introduction: This study aimed to describe the morphology of age-related macular degeneration (AMD) as well as to obtain an estimate of the population-based incidence rate in Singapore.
   Methods: This is a retrospective hospital-based study of AMD cases seen in 1991 and 1992 at the Singapore National Eye Centre (SNEC), a tertiary eye centre. All case notes recorded with the International Classification of Diseases, ninth revision, clinical modification code '362.5', which is 'degenerations of the macula', were retrieved and analysed. Only case notes of patients who were aged 50 years and above and with documented AMD were included in the study.
   Results: There were 41 (21.8 percent) patients with drusen alone, 39 (20.7 percent) with dry AMD and 108 (57.5 percent) with exudative AMD. The morphology of the disease was similar among the Chinese and non-Chinese and there were no gender differences. A significant majority of patients with dry and exudative AMD had legal blindness at presentation (p-value is less than 0.0001). Notably, 27 (33.3 percent) patients with exudative AMD had improved vision with time. In comparison, the majority of patients with dry AMD or drusen alone tended to have the same or worsening visual acuity over time. The two-year SNEC hospital incidence rate of AMD in 1991-1992 was 0.38 percent or equivalent to 3.8 per 1,000 new cases seen at SNEC. The estimated population-based incidence rate of exudative AMD was 0.02 percent.
   Conclusion: The population incidence of exudative AMD is lower but comparable to the Western population. Patients with exudative AMD tend to have poorer vision as compared to patients with geographical atrophy or drusen. The proportion of exudative AMD to geographical atrophy appears to be higher than in the West.
C1 [Cheng, C. L.; Pang, C. E.; Chee, C.] Singapore Natl Eye Ctr, Res Inst, Singapore 168751, Singapore.
   [Saw, S. M.] Natl Univ Singapore, Dept Community Occupat & Family Med, Singapore 117598, Singapore.
C3 Singapore National Eye Center; National University of Singapore
RP Cheng, CL (通讯作者)，Singapore Natl Eye Ctr, Res Inst, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM bobby_cheng@snec.com.sg
CR BAASANHU J, 1994, B WORLD HEALTH ORGAN, V72, P771
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lee S. Y., 1999, SMJ, V40, P256
   MARUO T, 1991, JPN J OPHTHALMOL, V35, P268
   *MIN HLTH SING, 1992, POP STAT
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 2002, OPHTHALMOLOGY, V109, P1588
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
NR 14
TC 4
Z9 4
U1 0
U2 1
PU SINGAPORE MEDICAL ASSOC
PI SINGAPORE
PA 2985 JALAN BUKIT MERAH, #02-2C, SMF BUILDING, SINGAPORE, SINGAPORE
SN 0037-5675
J9 SINGAP MED J
JI Singap. Med. J.
PD FEB
PY 2009
VL 50
IS 2
BP 126
EP 131
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 429BB
UT WOS:000264894700003
PM 19296026
DA 2022-11-30
ER

PT J
AU Li, ML
   Zhang, XZ
   Liao, NY
   Ye, BK
   Peng, YT
   Ji, YY
   Wen, F
AF Li, Miaoling
   Zhang, Xiongze
   Liao, Nanying
   Ye, Baikang
   Peng, Yuting
   Ji, Yuying
   Wen, Feng
TI Analysis of the Serum Lipid Profile in Polypoidal Choroidal Vasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PLATELET-ACTIVATING-FACTOR; FACTOR-INDUCED ANGIOGENESIS; MACULAR
   DEGENERATION; VARIANTS; ASIANS
AB Polypoidal choroidal vasculopathy (PCV), the predominant subtype of neovascular age-related macular degeneration in the Asian population, is associated with genetic polymorphism of lipid metabolism. In this study, we performed the untargeted lipidomics approach of ultra-performance liquid chromatography coupled with mass spectrometry (UPLC-MS) to reveal the potential discriminating lipid profile of PCV patients in serum (21 PCV patients and 19 age-matched controls). Unsupervised principal component, supervised orthogonal partial least squares analysis, correlation analysis, and heatmap analysis were performed with the data obtained by UPLC-MS. Forty-one discriminating metabolites were identified. Receiver operating characteristic curve analysis, pathway analysis and functional analysis were performed subsequently, and platelet-activating factor (PAF) was further selected as the key indicator of the distinct lipid metabolism in PCV patients. Finally, the serum level of PAF was validated by enzyme-linked immunosorbent assay, which is significantly higher in PCV patients compared to controls (65 PCV patients and 63 age-matched controls, p < 0.0001), consistent with the UPLC-MS analysis. Our results suggested that PAF is considered as the major indicator of the distinct lipid metabolism in PCV patients.
C1 [Li, Miaoling; Zhang, Xiongze; Liao, Nanying; Ye, Baikang; Peng, Yuting; Ji, Yuying; Wen, Feng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.
EM wenfeng208@foxmail.com
FU National Natural Science Foundation of China [81470647, 81200705];
   Fundamental Research Funds of the State Key Laboratory of Ophthalmology
FX This study was supported by the National Natural Science Foundation of
   China (grant number: 81470647 and 81200705) and the Fundamental Research
   Funds of the State Key Laboratory of Ophthalmology.
CR Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Dashti M, 2011, SCI REP-UK, V1, DOI 10.1038/srep00139
   Davis SJ, 2014, RETINA-J RET VIT DIS, V34, P2185, DOI 10.1097/IAE.0000000000000206
   He YG, 2009, CURR EYE RES, V34, P957, DOI 10.3109/02713680903231135
   Holmes E, 2008, NATURE, V453, P396, DOI 10.1038/nature06882
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Ko HM, 2005, FEBS LETT, V579, P2369, DOI 10.1016/j.febslet.2005.03.035
   Ko HM, 2002, CANCER RES, V62, P1809
   Legido-Quigley C, 2011, ELECTROPHORESIS, V32, P2063, DOI 10.1002/elps.201000512
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Wang D, 2015, OPHTHALMIC GENET, V36, P303, DOI 10.3109/13816810.2014.881506
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Xia JG, 2011, NAT PROTOC, V6, P743, DOI 10.1038/nprot.2011.319
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P1
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068173
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
NR 19
TC 18
Z9 18
U1 2
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 2
PY 2016
VL 6
AR 38342
DI 10.1038/srep38342
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ED8LZ
UT WOS:000389124300001
PM 27910906
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tzoumas, N
   Hallam, D
   Harris, CL
   Lako, M
   Kavanagh, D
   Steel, DHW
AF Tzoumas, Nikolaos
   Hallam, Dean
   Harris, Claire L.
   Lako, Majlinda
   Kavanagh, David
   Steel, David H. W.
TI Revisiting the role of factor H in age-related macular degeneration:
   Insights from complement-mediated renal disease and rare genetic
   variants
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; atypical hemolytic uremic syn-drome;
   C3 glomerulopathy; complement system; alternative pathway; complement
   factor H; subretinal inflammation; genetic variants; pharmacogenomics;
   complement therapeutics
ID HEMOLYTIC-UREMIC SYNDROME; POLYPOIDAL CHOROIDAL VASCULOPATHY; C-REACTIVE
   PROTEIN; II MESANGIOCAPILLARY GLOMERULONEPHRITIS; BRUCHS MEMBRANE
   IMPLICATIONS; FACTOR HY402H POLYMORPHISM; PIGMENT EPITHELIAL-CELLS; CFH
   GENE; RETICULAR PSEUDODRUSEN; ALTERNATIVE PATHWAY
AB Ophthalmologists are long familiar with the eye showing signs of systemic disease, but the association between age-related macular degeneration and abnormal complement activation, common to several renal disorders, has only recently been elucidated. Although complement activation products were identified in drusen almost three decades ago, it was not until the early 21st century that a single-nucleotide polymorphism in the complement factor H gene was identified as a major heritable determinant of age-related macular degeneration, galvanizing global efforts to unravel the pathogenesis of this common disease. Advances in proteomic analyses and familial aggregation studies have revealed distinctive clinical phenotypes segregated by the functional effects of common and rare genetic variants on the mature protein and its splice variant, factor H-like protein 1. The predominance of loss-of-function, N-terminal mutations implicate age-related macular degeneration as a disease of general complement dysregulation, offering several therapeutic avenues for its modulation. Here, we explore the molecular impact of these mutations/polymorphisms on the ability of variant factor H/factor H-like protein 1 to localize to polyanions, pentraxins, proinflammatory triggers, and cell surfaces across ocular and renal tissues and exert its multimodal regulatory functions and their clinical implications. Finally, we critically evaluate key therapeutic and diagnostic efforts in this rapidly evolving field.
   2020 Elsevier Inc. All rights reserved.
C1 [Tzoumas, Nikolaos; Hallam, Dean; Lako, Majlinda; Steel, David H. W.] Newcastle Univ, Biosci Inst, Newcastle Upon Tyne, Tyne & Wear, England.
   [Harris, Claire L.; Kavanagh, David] Newcastle Univ, Translat & Clin Res Inst, Complement Therapeut Res Grp, Newcastle Upon Tyne, Tyne & Wear, England.
   [Harris, Claire L.; Kavanagh, David] Royal Victoria Infirm, Natl Renal Complement Therapeut Ctr, Newcastle Upon Tyne, Tyne & Wear, England.
   [Steel, David H. W.] Sunderland Eye Infirm, Sunderland, England.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle
   University - UK
RP Tzoumas, N (通讯作者)，Newcastle Univ, Int Ctr Life, Biosci Inst, Cent Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
EM nik.tzoumas@ncl.ac.uk
OI Tzoumas, Nikolaos/0000-0003-2081-6042; lako,
   majlinda/0000-0003-1327-8573
FU Macular Society UK
FX This research was in part supported by grants from the Macular Society
   UK. Nikolaos Tzoumas, no disclosures; Dean Hallam, no disclosures;
   Claire L. Harris, is a consultant or SAB member for Gyroscope
   Therapeutics, Q32 Bio, Biocryst Pharmaceuticals, and Freeline
   Therapeutics, has received research income from Ra Pharmaceuticals, has
   active patents in the area of factor H variants and diagnosis of AMD,
   and will be seconded by Newcastle University to Gyroscope Therapeutics
   from September 2020 for 18 months but was not seconded at the time of
   writing this manuscript; Majlinda Lako, no disclosures; David Kavanagh,
   Alexion Pharmaceuticals (F, C, R), Apellis (C), Gyroscope Therapeutics
   (I, C), Novartis Pharmaceuticals (C); David H. W. Steel, Alcon (C, F),
   Bayer Pharmaceuticals (F), Gyroscope Therapeutics (C), Roche (C). The
   financial relationships of the authors did not influence the collection,
   analysis, and interpretation of data, the writing of the report, or the
   decision to submit the article for publication.
CR Amadi-Obi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045801
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Barlow P. N., 2018, COMPLEMENT FACTSBOOK, P317
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Benlian P, 2015, PLoS One, V10
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bexborn F, 2008, MOL IMMUNOL, V45, P2370, DOI 10.1016/j.molimm.2007.11.003
   Blanc C, 2015, J IMMUNOL, V194, P5129, DOI 10.4049/jimmunol.1402770
   Blaum BS, 2015, NAT CHEM BIOL, V11, P77, DOI [10.1038/NCHEMBIO.1696, 10.1038/nchembio.1696]
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Caire J, 2014, JAMA OPHTHALMOL, V34, P132
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Calippe B, 2014, CR BIOL, V337, P178, DOI 10.1016/j.crvi.2013.12.003
   Cantsilieris S, 2018, P NATL ACAD SCI USA, V115, pE4433, DOI 10.1073/pnas.1717600115
   Cerniauskas E, 2020, STEM CELL TRANSL MED, V9, P1585, DOI 10.1002/sctm.20-0211
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep09510
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Chen HY, 2012, MOL VIS, V18, P816
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Clark SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01778
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Cocuzzi E, 2000, CURR EYE RES, V21, P856, DOI 10.1076/ceyr.21.5.856.5539
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Deban L, 2008, J IMMUNOL, V181, P8433, DOI 10.4049/jimmunol.181.12.8433
   DECORDOBA SR, 1985, J EXP MED, V161, P1189, DOI 10.1084/jem.161.5.1189
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P381, DOI 10.1097/IAE.0000000000000466
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   DEVINE DV, 1987, P NATL ACAD SCI USA, V84, P5873, DOI 10.1073/pnas.84.16.5873
   Dhillon B, 2010, INVEST OPHTH VIS SCI, V51, P5858, DOI 10.1167/iovs.09-5124
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   Dinu V, 2007, GENET EPIDEMIOL, V31, P224, DOI 10.1002/gepi.20204
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Dragon-Durey MA, 2005, J AM SOC NEPHROL, V16, P555, DOI 10.1681/ASN.2004050380
   Dutheil C, 2020, JAMA OPHTHALMOL, V138, P467, DOI 10.1001/jamaophthalmol.2020.0266
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P900, DOI 10.1136/bjo.73.11.900
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   Duvvari MR, 2015, MOL VIS, V21, P285
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elvington M, 2017, J CLIN INVEST, V127, P970, DOI 10.1172/JCI89412
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Fan Q, 2017, J HUM GENET, V62, P1049, DOI 10.1038/jhg.2017.83
   Farrah TE, 2020, KIDNEY INT, V98, P323, DOI 10.1016/j.kint.2020.01.039
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Ferreira VP, 2010, MOL IMMUNOL, V47, P2187, DOI 10.1016/j.molimm.2010.05.007
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Formeck C, 2019, PEDIATR NEPHROL, V34, P1337, DOI 10.1007/s00467-018-4039-7
   Fraczek LA, 2010, MOL IMMUNOL, V48, P9, DOI 10.1016/j.molimm.2010.08.016
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gao Y, 2010, RETINA-J RET VIT DIS, V30, P443, DOI 10.1097/IAE.0b013e3181c2e086
   Geerlings MJ, 2018, CLIN GENET, V94, P330, DOI 10.1111/cge.13392
   Geerlings MJ, 2018, MOL VIS, V24, P75
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goodship THJ, 2017, KIDNEY INT, V91, P539, DOI 10.1016/j.kint.2016.10.005
   Goodship THJ, 2012, MOL IMMUNOL, V52, P200, DOI 10.1016/j.molimm.2012.05.009
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Haines JL, 2007, JAMA-J AM MED ASSOC, V297, P401, DOI 10.1001/jama.297.4.401
   Hajishengallis G, 2017, NAT IMMUNOL, V18, P1288, DOI 10.1038/ni.3858
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Harboe M, 2004, CLIN EXP IMMUNOL, V138, P439, DOI 10.1111/j.1365-2249.2004.02627.x
   Harris CL, 2018, MOL IMMUNOL, V102, P89, DOI 10.1016/j.molimm.2018.06.008
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hong N, 2016, ACTA OPHTHALMOL, V94, P334, DOI 10.1111/aos.13049
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Howard JF, 2013, MUSCLE NERVE, V48, P76, DOI 10.1002/mus.23839
   Huang L, 2015, EYE, V29, P691, DOI 10.1038/eye.2015.32
   Huang LZ, 2014, INVEST OPHTH VIS SCI, V55, P2534, DOI 10.1167/iovs.13-13437
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hughes AE, 2016, ACTA OPHTHALMOL, V94, pE247, DOI 10.1111/aos.12822
   Joachim N, 2017, BRIT J OPHTHALMOL, V101, P1185, DOI 10.1136/bjophthalmol-2016-309729
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Kahr WHA, 2010, BLOOD, V116, P4393, DOI 10.1182/blood-2010-08-297648
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Kaur G, 2018, P NATL ACAD SCI USA, V115, P9014, DOI 10.1073/pnas.1805039115
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Keenan TDL, 2012, INVEST OPHTH VIS SCI, V53, P7528, DOI 10.1167/iovs.12-10797
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Khandhadia S, 2013, OPHTHALMOLOGY, V120, P1612, DOI 10.1016/j.ophtha.2013.01.004
   Kim YH, 2009, GRAEF ARCH CLIN EXP, V247, P651, DOI 10.1007/s00417-009-1049-y
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Kolev M, 2017, Mol Immunol, V89, P2
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Kopp A, 2012, J IMMUNOL, V189, P1858, DOI 10.4049/jimmunol.1200357
   Kopp A, 2012, BIOMOLECULES, V2, P46, DOI 10.3390/biom2010046
   Koss MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096895
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lee HM, 2010, LEUKEMIA, V24, P573, DOI 10.1038/leu.2009.271
   Leffler J, 2010, J BIOL CHEM, V285, P3766, DOI 10.1074/jbc.M109.045427
   Lenis TL, 2017, P NATL ACAD SCI USA, V114, P3987, DOI 10.1073/pnas.1620299114
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li X, 2014, Lancet Glob Health, V2, P106
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269
   Licht C, 2009, BLOOD, V114, P4538, DOI 10.1182/blood-2009-03-205096
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Long Q, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6958752
   Lores-Motta L, 2018, JAMA OPHTHALMOL, V136, P875, DOI 10.1001/jamaophthalmol.2018.2019
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Martin M, 2016, CELL DEATH DIFFER, V23, P903, DOI 10.1038/cdd.2015.164
   Martinez-Barricarte R, 2008, J AM SOC NEPHROL, V19, P639, DOI 10.1681/ASN.2007080923
   Mastellos DC, 2019, NAT REV DRUG DISCOV, V18, P707, DOI 10.1038/s41573-019-0031-6
   Mastellos DC, 2013, SEMIN IMMUNOL, V25, P29, DOI 10.1016/j.smim.2013.04.002
   Miyake M, 2015, INVEST OPHTH VIS SCI, V56, P5353, DOI 10.1167/iovs.14-16020
   Mohlin C, 2017, MOL IMMUNOL, V89, P84, DOI 10.1016/j.molimm.2017.05.028
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Mondino BJ, 1996, INVEST OPHTH VIS SCI, V37, P1576
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Morgan BP, 2016, IMMUNOBIOLOGY, V221, P747, DOI 10.1016/j.imbio.2015.04.006
   Morgan BP, 2016, IMMUNOL REV, V274, P141, DOI 10.1111/imr.12461
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2019, OPHTHALMOLOGY, V126, P591, DOI 10.1016/j.ophtha.2018.10.037
   Murinello S, 2014, INVEST OPHTH VIS SCI, V55, P247, DOI 10.1167/iovs.13-11821
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Naldini L, 2015, NATURE, V526, P351, DOI 10.1038/nature15818
   Nan R, 2011, J MOL BIOL, V408, P714, DOI 10.1016/j.jmb.2011.03.006
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Niederkorn JY, 2010, OCUL IMMUNOL INFLAMM, V18, P19, DOI 10.3109/09273940903564766
   OBRIEN C, 1993, BRIT J OPHTHALMOL, V77, P778, DOI 10.1136/bjo.77.12.778
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Olivar R, 2016, J IMMUNOL, V196, P4274, DOI 10.4049/jimmunol.1500455
   Parmeggiani F, 2011, MOL DIAGN THER, V15, P195, DOI 10.2165/11592270-000000000-00000
   Pechtl IC, 2011, J BIOL CHEM, V286, P11082, DOI 10.1074/jbc.M110.211839
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Porter LF, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0608-2
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Recalde S, 2016, J AM SOC NEPHROL, V27, P1305, DOI 10.1681/ASN.2015050580
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2017, Nat Struct Biol, V24, P643
   Ricklin D, 2016, NAT REV NEPHROL, V12, P383, DOI 10.1038/nrneph.2016.70
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rodriguez E, 2014, BIOSCIENCE REP, V34, P635, DOI 10.1042/BSR20140117
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Saksens NTM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144367
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Sardell RJ, 2016, INVEST OPHTH VIS SCI, V57, P6107, DOI 10.1167/iovs.16-19519
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schellevis RL, 2018, JAMA OPHTHALMOL, V136, P1128, DOI 10.1001/jamaophthalmol.2018.3190
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Schick T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156778
   SCHIFFERLI JA, 1983, LANCET, V2, P957
   Schmidt CQ, 2008, J IMMUNOL, V181, P2610, DOI 10.4049/jimmunol.181.4.2610
   Schnabolk G, 2018, MOL THER-METH CLIN D, V9, P1, DOI 10.1016/j.omtm.2017.11.003
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   SCHWAEBLE W, 1987, EUR J IMMUNOL, V17, P1485, DOI 10.1002/eji.1830171015
   Schwartz SG, 2012, RETINA-J RET VIT DIS, V32, P1486, DOI 10.1097/IAE.0b013e318240a540
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2019, INVEST OPHTH VIS SCI, V60, P4469, DOI 10.1167/iovs.19-27475
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Seitsonen S, 2008, ACTA OPHTHALMOL, V86, P390, DOI 10.1111/j.1600-0420.2007.01050.x
   Servais A, 2007, J MED GENET, V44, P193, DOI 10.1136/jmg.2006.045328
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Sirugo G, 2019, CELL, V177, P26, DOI 10.1016/j.cell.2019.02.048
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Skerka C, 2020, J Am Soc Nephrol, V31, P241
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Smailhodzic D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112682
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Sodi A, 2018, OPHTHALMIC GENET, V39, P699, DOI 10.1080/13816810.2018.1525753
   Sofat R, 2013, J IMMUNOL METHODS, V390, P63, DOI 10.1016/j.jim.2013.01.009
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Stone EM, 2012, OPHTHALMOLOGY, V119, P2408, DOI 10.1016/j.ophtha.2012.05.047
   Swinkels M., 2018, SCI REP-UK, V8, P1
   Tan LX, 2016, P NATL ACAD SCI USA, V113, P8789, DOI 10.1073/pnas.1523061113
   Taylor RL, 2019, OPHTHALMOLOGY, V126, P1410, DOI 10.1016/j.ophtha.2019.03.013
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Thompson CL, 2007, INVEST OPHTH VIS SCI, V48, P3005, DOI 10.1167/iovs.06-1325
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Toops KA, 2015, MOL BIOL CELL, V26, P1, DOI 10.1091/mbc.E14-05-1028
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   Trouw LA, 2008, MOL IMMUNOL, V45, P1199, DOI 10.1016/j.molimm.2007.09.008
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   van Asten F, 2018, OPHTHALMOLOGY, V125, P559, DOI 10.1016/j.ophtha.2017.09.023
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Warwick A, 2018, EYE, V32, P849, DOI 10.1038/eye.2017.245
   Warwick A, 2014, J CLIN MED, V3, P1234, DOI 10.3390/jcm3041234
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Weinberger AWA, 2014, OPHTHALMIC RES, V51, P59, DOI 10.1159/000351624
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wong CW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119570
   Wong EKS, 2018, SEMIN IMMUNOPATHOL, V40, P49, DOI 10.1007/s00281-017-0663-8
   Wong EKS, 2014, J AM SOC NEPHROL, V25, P2425, DOI 10.1681/ASN.2013070732
   Woo JM, 2013, MOL VIS, V19, P303
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Wu L, 2013, INVEST OPHTH VIS SCI, V54, P170, DOI 10.1167/iovs.12-10453
   Wu MX, 2016, OPHTHALMIC RES, V55, P135, DOI 10.1159/000442257
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Yanamadala V, 2010, TRENDS MOL MED, V16, P69, DOI 10.1016/j.molmed.2009.12.001
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yeh ETH, 2004, CIRCULATION, V109, P11, DOI 10.1161/01.CIR.0000129507.12719.80
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zipfel PF, 1999, IMMUNOL TODAY, V20, P135, DOI 10.1016/S0167-5699(98)01432-7
NR 257
TC 9
Z9 9
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAR-APR
PY 2021
VL 66
IS 2
BP 378
EP 401
DI 10.1016/j.survophthal.2020.10.008
EA FEB 2021
PG 24
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QQ1VV
UT WOS:000624315700014
PM 33157112
DA 2022-11-30
ER

PT J
AU Eshtiaghi, A
   Issa, M
   Popovic, MM
   Muni, RH
   Kertes, PJ
AF Eshtiaghi, Arshia
   Issa, Mariam
   Popovic, Marko M.
   Muni, Rajeev H.
   Kertes, Peter J.
TI GEOGRAPHIC ATROPHY INCIDENCE AND PROGRESSION AFTER INTRAVITREAL
   INJECTIONS OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS FOR
   AGE-RELATED MACULAR DEGENERATION A Meta-Analysis
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; geographic atrophy;
   intravitreal; macular atrophy
ID RANIBIZUMAB INJECTIONS; VISUAL-ACUITY; VEGF; RISK; NEOVASCULARIZATION
AB Purpose: Geographic atrophy (GA) is a complication of advanced neovascular age-related macular degeneration that can lead to permanent vision loss. We sought to estimate the incidence and progression of GA after intravitreal injections of antivascular endothelial growth factor agents in eyes with neovascular age-related macular degeneration. Methods: Ovid MEDLINE, EMBASE, and Cochrane CENTRAL were searched from inception to May 2020. Included studies reported on the progression or development of GA in eyes with neovascular age-related macular degeneration after antivascular endothelial growth factor therapy. Results: Thirty-one articles and 4,609 study eyes (4,501 patients) were included. Eyes received a mean of 17.7 injections over 35.2 months. The prevalence of GA at baseline was 9.7%. The pooled incidence of GA was 30.5% at the end of follow-up. There was a positive, moderate linear correlation between the mean total number of injections and GA incidence at the final follow-up (R-2 = 0.30; P = 0.01). Monthly treatment was associated with a significantly higher risk for GA development relative to pro re nata (relative risk = 1.40, 95% confidence interval = [1.21-1.61], P < 0.001). Risk factors for GA development included GA in the fellow eye, retinal angiomatous proliferation, drusen, and reticular pseudodrusen. Conclusion: We found an association between the frequency and number of treatments with antivascular endothelial growth factor agents and the development of GA in neovascular age-related macular degeneration. Future studies should clarify risk factors, population characteristics, and relative contributions of treatment and disease progression on GA development in this context.
C1 [Eshtiaghi, Arshia; Issa, Mariam] Univ Toronto, Fac Med, Toronto, ON, Canada.
   [Popovic, Marko M.; Muni, Rajeev H.; Kertes, Peter J.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Muni, Rajeev H.] St Michaels Hosp, Dept Ophthalmol, Unity Hlth Toronto, Toronto, ON, Canada.
   [Kertes, Peter J.] Sunnybrook Hlth Sci Ctr, John & Liz Tory Eye Ctr, 2075 Bayview Ave,Room M1-202a, Toronto, ON M4N 3M5, Canada.
C3 University of Toronto; University of Toronto; University of Toronto;
   University Toronto Affiliates; Saint Michaels Hospital Toronto;
   University of Toronto; Sunnybrook Research Institute; University Toronto
   Affiliates; Sunnybrook Health Science Center
RP Kertes, PJ (通讯作者)，Sunnybrook Hlth Sci Ctr, John & Liz Tory Eye Ctr, 2075 Bayview Ave,Room M1-202a, Toronto, ON M4N 3M5, Canada.
EM peter.kertes@sunnybrook.ca
OI Eshtiaghi, Arshia/0000-0002-0047-8157; Popovic,
   Marko/0000-0002-0370-5968
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Baek J, 2016, INVEST OPHTH VIS SCI, V57, P1500, DOI 10.1167/iovs.15-18837
   Bailey C, 2019, OPHTHALMOLOGY, V126, P75, DOI 10.1016/j.ophtha.2018.07.013
   Bhavsar KV, 2014, SAUDI J OPHTHALMOL, V28, P129, DOI 10.1016/j.sjopt.2014.03.001
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Cho HJ, 2018, RETINA-J RET VIT DIS, V38, P2150, DOI 10.1097/IAE.0000000000001862
   Christakis PG, 2020, OPHTHALMOLOGY, V127, P784, DOI 10.1016/j.ophtha.2019.11.016
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Gonzalez-Buendia L, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0544-x
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guyatt G, 2011, J CLIN EPIDEMIOL, V64, P383, DOI 10.1016/j.jclinepi.2010.04.026
   Hayden JA, 2013, ANN INTERN MED, V158, P280, DOI 10.7326/0003-4819-158-4-201302190-00009
   Hernandez-Pastor LJ, 2008, AM J HEALTH-SYST PH, V65, P1805, DOI 10.2146/ajhp070342
   Kaynak S, 2018, TURK OFTALMOL DERG, V48, P81, DOI 10.4274/tjo.27448
   Kim JH, 2016, BRIT J OPHTHALMOL, V100, P1634, DOI 10.1136/bjophthalmol-2015-308074
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Mantel I, 2019, RETINA-J RET VIT DIS, V39, P906, DOI 10.1097/IAE.0000000000002054
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Saito M, 2017, JPN J OPHTHALMOL, V61, P74, DOI 10.1007/s10384-016-0478-5
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Sitnilska V, 2019, OPHTHALMOLOGICA, V241, P154, DOI 10.1159/000492924
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Thavikulwat AT, 2017, OPHTHALMOL RETINA, V1, P34, DOI 10.1016/j.oret.2016.09.005
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
NR 31
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2021
VL 41
IS 12
BP 2424
EP 2435
DI 10.1097/IAE.0000000000003207
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XF9PZ
UT WOS:000724397400003
PM 34101693
DA 2022-11-30
ER

PT J
AU Lechner, J
   Chen, M
   Hogg, RE
   Toth, L
   Silvestri, G
   Chakravarthy, U
   Xu, HP
AF Lechner, Judith
   Chen, Mei
   Hogg, Ruth E.
   Toth, Levente
   Silvestri, Giuliana
   Chakravarthy, Usha
   Xu, Heping
TI Higher plasma levels of complement C3a, C4a and C5a increase the risk of
   subretinal fibrosis in neovascular age-related macular degeneration
SO IMMUNITY & AGEING
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularisation;
   Complement; Subretinal fibrosis
ID MEMBRANE ATTACK COMPLEX; ALTERNATIVE PATHWAY; FACTOR-B; ACTIVATION;
   DRUSEN; ANAPHYLATOXINS; PATHOGENESIS; INFLAMMATION; EXPRESSION; GENES
AB Background: The aim of this study was to investigate the plasma levels of complement C3a, C4a, and C5a in different types of neovascular age-related macular degeneration (nAMD) and whether the levels were related to patients' responsiveness to anti-VEGF therapy.
   Results: Ninety-six nAMD patients (including 61 with choroidal neovascularisation (CNV), 17 with retinal angiomatous proliferation (RAP), 14 with polypoidal choroidal vasculopathy (PCV) and 4 unclassified patients) and 43 controls were recruited to this case-control study. Subretinal fibrosis was observed in 45 nAMD patients and was absent in 51 nAMD patients. In addition, the responsiveness to anti-VEGF (Lucentis) therapy was also evaluated in nAMD patients. Forty-four patients were complete responders, 48 were partially responders, and only 4 patients did not respond to the therapy. The plasma levels of C3a, C4a and C5a were significantly higher in nAMD patients compared to controls. Further analysis of nAMD subgroups showed that the levels of C3a, C4a and C5a were significantly increased in patients with CNV but not RAP and PCV. Significantly increased levels of C3a, C4a and C5a were also observed in nAMD patients with subretinal fibrosis but not in those without subretinal fibrosis. Higher levels of C3a were observed in nAMD patients who responded partially to anti-VEGF therapy.
   Conclusions: Our results suggest increased systemic complement activation in nAMD patients with CNV but not RAP and PCV. Our results also suggest that higher levels of systemic complement activation may increase the risk of subretinal fibrosis in nAMD patients.
C1 [Lechner, Judith; Chen, Mei; Hogg, Ruth E.; Toth, Levente; Silvestri, Giuliana; Chakravarthy, Usha; Xu, Heping] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
C3 Queens University Belfast
RP Xu, HP (通讯作者)，Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM heping.xu@qub.ac.uk
RI Hogg, Ruth E./ABC-9602-2020; Lechner, Judith/GQH-8616-2022; Xu,
   Heping/A-4430-2008
OI Hogg, Ruth E./0000-0001-9413-2669; Xu, Heping/0000-0003-4000-931X;
   Chakravarthy, Usha/0000-0002-2606-3734
FU Dunhill Medical Trust [R188/0211]; Guide Gods for the Blind Association
   UK [2008-5a]; The Dunhill Medical Trust [R188/0211] Funding Source:
   researchfish
FX We thank the patients who participated in this study. Special thanks to
   the research nurses Rebecca Denham and Georgina Sterrett for their help
   in patient recruitment. The study was funded by the Dunhill Medical
   Trust (R188/0211) and Guide Gods for the Blind Association UK (2008-5a).
CR Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Barnum SR, 2015, J INNATE IMMUN, V7, P333, DOI 10.1159/000371423
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hunter Megan A, 2004, Optometry, V75, P577, DOI 10.1016/S1529-1839(04)70190-6
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klos A, 2009, MOL IMMUNOL, V46, P2753, DOI 10.1016/j.molimm.2009.04.027
   Liszewski MK, 2013, IMMUNITY, V39, P1143, DOI 10.1016/j.immuni.2013.10.018
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu J, 2011, J BIOL CHEM, V286, P20991, DOI 10.1074/jbc.M111.226266
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Monsinjon T, 2003, FASEB J, V17, P1003, DOI 10.1096/fj.02-0737com
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Otsuji T, 2013, CLIN OPHTHALMOL, V7, P1487, DOI 10.2147/OPTH.S46317
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sendler M, 2015, GASTROENTEROLOGY, V149, P765, DOI 10.1053/j.gastro.2015.05.012
   Seow V, 2013, J IMMUNOL, V191, P4308, DOI 10.4049/jimmunol.1301355
   Silva AS, 2012, MOL VIS, V18, P2288
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Williams MA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009300.pub2
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 43
TC 67
Z9 73
U1 0
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-4933
J9 IMMUN AGEING
JI Immun. Ageing
PD FEB 16
PY 2016
VL 13
AR 4
DI 10.1186/s12979-016-0060-5
PG 9
WC Geriatrics & Gerontology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Immunology
GA DE0LT
UT WOS:000370317100001
PM 26884800
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sodi, A
   Matteoli, S
   Giacomelli, G
   Finocchio, L
   Corvi, A
   Menchini, U
AF Sodi, Andrea
   Matteoli, Sara
   Giacomelli, Giovanni
   Finocchio, Lucia
   Corvi, Andrea
   Menchini, Ugo
TI Ocular Surface Temperature in Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL BLOOD-FLOW; CORNEAL TEMPERATURE; RETROBULBAR HEMODYNAMICS;
   INFRARED THERMOGRAPHY; BRUCHS MEMBRANE; MACULOPATHY; EYES; PATHOGENESIS;
   THICKNESS; VASCULOPATHY
AB Background. The aim of this study is to investigate the ocular thermographic profiles in age-related macular degeneration (AMD) eyes and age-matched controls to detect possible hemodynamic abnormalities, which could be involved in the pathogenesis of the disease. Methods. 32 eyes with early AMD, 37 eyes with atrophic AMD, 30 eyes affected by untreated neovascular AMD, and 43 eyes with fibrotic AMD were included. The control group consisted of 44 healthy eyes. Exclusion criteria were represented by any other ocular diseases other than AMD, tear film abnormalities, systemic cardiovascular abnormalities, diabetes mellitus, and a body temperature higher than 37.5 degrees C. A total of 186 eyes without pupil dilation were investigated by infrared thermography (FLIR A320). Theocular surface temperature (OST) of three ocular points was calculated by means of an image processing technique from the infrared images. Two-sample t-test and one-way analysis of variance (ANOVA) test were used for statistical analyses. Results. ANOVA analyses showed no significant differences among AMD groups (P value > 0.272). OST in AMD patients was significantly lower than in controls (P > 0.05). Conclusions. Considering the possible relationship between ocular blood flow and OST, these findings might support the central role of ischemia in the pathogenesis of AMD.
C1 [Sodi, Andrea; Giacomelli, Giovanni; Finocchio, Lucia; Menchini, Ugo] Univ Florence, Eye Clin, Dept Translat Surg & Med, I-50134 Florence, Italy.
   [Matteoli, Sara; Corvi, Andrea] Univ Florence, Dept Ind Engn, Lab Ocular Thermog, I-50134 Florence, Italy.
C3 University of Florence; University of Florence
RP Giacomelli, G (通讯作者)，Univ Florence, Eye Clin, Dept Translat Surg & Med, Largo Brambilla 3, I-50134 Florence, Italy.
EM giovanni.giacomelli@unifi.it
RI giacomelli, giovanni/ABC-6173-2020; Finocchio, Lucia/X-4835-2019
OI Finocchio, Lucia/0000-0003-1986-045X; Corvi, Andrea/0000-0002-6714-1110
CR AUKER CR, 1982, ARCH OPHTHALMOL-CHIC, V100, P1323, DOI 10.1001/archopht.1982.01030040301020
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boiko E V, 2013, Vestn Oftalmol, V129, P86
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Colak E, 2012, BIOCHEM MEDICA, V22, P39
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   EAGLE RC, 1984, OPHTHALMOLOGY, V91, P613
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   FRIEDMAN E, 1965, BIBL ANAT, P129
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Galassi F, 2007, BRIT J OPHTHALMOL, V91, P878, DOI 10.1136/bjo.2007.114397
   Galassi Fernando, 2008, International Ophthalmology, V28, P399, DOI 10.1007/s10792-007-9160-8
   Girardin F, 1999, ARCH OPHTHALMOL-CHIC, V117, P166
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Grunwald JE, 2001, AM J OPHTHALMOL, V131, P751, DOI 10.1016/S0002-9394(00)00944-2
   Gugleta K, 1999, CURR EYE RES, V19, P496, DOI 10.1076/ceyr.19.6.496.5286
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   HORVEN I, 1975, ACTA OPHTHALMOL, V53, P863
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Klamann MKJ, 2013, OPHTHALMIC RES, V49, P52, DOI 10.1159/000343774
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   Leveziel N, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000328981
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   MORGAN PB, 1995, EYE, V9, P615, DOI 10.1038/eye.1995.149
   Morgan PB, 1999, OPTOMETRY VISION SCI, V76, P850, DOI 10.1097/00006324-199912000-00021
   Pahl L, 2012, EXP EYE RES, V98, P75, DOI 10.1016/j.exer.2012.03.007
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rishi P, 2013, EYE, V27, P1038, DOI 10.1038/eye.2013.106
   Sawitzke J, 2011, OPHTHALMOLOGY, V118, P2442, DOI 10.1016/j.ophtha.2011.05.027
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Sodi A, 2007, EUR J OPHTHALMOL, V17, P755, DOI 10.1177/112067210701700511
   Sodi A, 2009, EUR J OPHTHALMOL, V19, P1004, DOI 10.1177/112067210901900617
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Turlea C, 2012, Oftalmologia, V56, P36
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 59
TC 12
Z9 13
U1 2
U2 11
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2014
VL 2014
AR 281010
DI 10.1155/2014/281010
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU7EI
UT WOS:000345763200001
PM 25436140
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Parmeggiani, F
   Romano, MR
   Costagliola, C
   Semeraro, F
   Incorvaia, C
   D'Angelo, S
   Perri, P
   De Palma, P
   De Nadai, K
   Sebastiani, A
AF Parmeggiani, Francesco
   Romano, Mario R.
   Costagliola, Ciro
   Semeraro, Francesco
   Incorvaia, Carlo
   D'Angelo, Sergio
   Perri, Paolo
   De Palma, Paolo
   De Nadai, Katia
   Sebastiani, Adolfo
TI Mechanism of Inflammation in Age-Related Macular Degeneration
SO MEDIATORS OF INFLAMMATION
LA English
DT Review
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; GENOME-WIDE ASSOCIATION;
   ENDOTHELIAL GROWTH-FACTOR; PHOTODYNAMIC THERAPY; CHOROIDAL
   NEOVASCULARIZATION; INTRAVITREAL DEXAMETHASONE; GENE POLYMORPHISMS;
   CIGARETTE-SMOKING; BRUCHS MEMBRANE
AB Age-related macular degeneration (AMD) is a multifactorial disease that represents the most common cause of irreversible visual impairment among people over the age of 50 in Europe, the United States, and Australia, accounting for up to 50% of all cases of central blindness. Risk factors of AMD are heterogeneous, mainly including increasing age and different genetic predispositions, together with several environmental/epigenetic factors, that is, cigarette smoking, dietary habits, and phototoxic exposure. In the aging retina, free radicals and oxidized lipoproteins are considered to be major causes of tissue stress resulting in local triggers for parainflammation, a chronic status which contributes to initiation and/or progression of many human neurodegenerative diseases such as AMD. Experimental and clinical evidences strongly indicate the pathogenetic role of immunologic processes in AMD occurrence, consisting of production of inflammatory related molecules, recruitment of macrophages, complement activation, microglial activation and accumulation within those structures that compose an essential area of the retina known as macula lutea. This paper reviews some attractive aspects of the literature about the mechanisms of inflammation in AMD, especially focusing on those findings or arguments more directly translatable to improve the clinical management of patients with AMD and to prevent the severe vision loss caused by this disease.
C1 [Parmeggiani, Francesco; Incorvaia, Carlo; D'Angelo, Sergio; Perri, Paolo; De Palma, Paolo; De Nadai, Katia; Sebastiani, Adolfo] Univ Ferrara, Dept Ophthalmol, Ferrara, Italy.
   [Romano, Mario R.; Costagliola, Ciro] Univ Molise, Dept Hlth Sci, Campobasso, Italy.
   [Romano, Mario R.] Ist Clin Humanitas, Dept Ophthalmol, Milan, Italy.
   [Semeraro, Francesco] Univ Brescia, Dept Ophthalmol, Brescia, Italy.
   [De Nadai, Katia] Ctr Retinitis Pigmentosa Veneto Reg, Camposampiero, Italy.
C3 University of Ferrara; University of Molise; IRCCS Humanitas Research
   Hospital; University of Brescia
RP Parmeggiani, F (通讯作者)，Univ Ferrara, Dept Ophthalmol, Ferrara, Italy.
EM francesco.parmeggiani@unife.it
RI Perri, Paolo/L-3047-2015; Semeraro, Francesco fs/K-8667-2016;
   Costagliola, Ciro/G-5707-2012
OI Perri, Paolo/0000-0003-4652-9842; Semeraro, Francesco
   fs/0000-0002-2275-4917; Costagliola, Ciro/0000-0001-8477-6188; D'Angelo,
   Sergio/0000-0003-1118-3845
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 2010, SIR TREAT GEOGR ATR
   Arias L, 2010, RETINA-J RET VIT DIS, V30, P1601, DOI 10.1097/IAE.0b013e3181e9f942
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, AM J OPHTHALMOL, V138, P665, DOI 10.1016/j.ajo.2004.04.053
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Burton GJ, 2009, J ANAT, V215, P27, DOI 10.1111/j.1469-7580.2008.00978.x
   Calder PC, 2011, BRIT J NUTR, V106, pS1, DOI 10.1017/S0007114511005460
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chowers I, 2008, MOL VIS, V14, P2263
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Colquitt J. L., 2008, HLTH TECHNOLOGY ASSE, V12
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Csaky KG, 2012, RETINA-J RET VIT DIS, V32, P413, DOI 10.1097/IAE.0B013E3182493C05
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Davis J, 2011, AM J OPHTHALMOL, V152, P509, DOI 10.1016/j.ajo.2011.07.004
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Du Clos TW, 2000, ANN MED, V32, P274, DOI 10.3109/07853890009011772
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ehmann D, 2010, CAN J OPHTHALMOL, V45, P36, DOI 10.3129/i09-243
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Forte R, 2011, OPHTHALMIC RES, V45, P129, DOI 10.1159/000318877
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Gandhi J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021621
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Garbin U, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008225
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Heck DE, 2003, J BIOL CHEM, V278, P22432, DOI 10.1074/jbc.C300048200
   Hekimi S, 2011, TRENDS CELL BIOL, V21, P569, DOI 10.1016/j.tcb.2011.06.008
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Hjelmeland LM, 2011, INVEST OPHTH VIS SCI, V52, P1622, DOI 10.1167/iovs.10-6765
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kajimoto H, 2007, CIRCULATION, V115, P1777, DOI 10.1161/CIRCULATIONAHA.106.649566
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kim IK, 2008, MOL VIS, V14, P1487
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Kuno N, 2010, DRUG AGING, V27, P117, DOI 10.2165/11530970-000000000-00000
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Leveziel N, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000328981
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Lommatzsch A, 2007, GRAEF ARCH CLIN EXP, V245, P1713, DOI 10.1007/s00417-007-0649-7
   London NJS, 2011, ADV THER, V28, P351, DOI 10.1007/s12325-011-0019-z
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Melo A, 2011, OXID MED CELL LONGEV, V2011, DOI 10.1155/2011/467180
   Meyer KJ, 2011, HUM GENET, V129, P91, DOI 10.1007/s00439-010-0904-6
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mullins RF, 1997, DEGENERATIVE RETINAL DISEASES, P1
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Naik E, 2011, J EXP MED, V208, P417, DOI 10.1084/jem.20110367
   Nakata I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019108
   Neale Benjamin M, 2010, Proc Natl Acad Sci U S A, V107, P7395, DOI 10.1073/pnas.0912019107
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   Ng TK, 2011, INVEST OPHTH VIS SCI, V52, P3706, DOI 10.1167/iovs.10-6773
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Olson JH, 2011, SEMIN OPHTHALMOL, V26, P131, DOI 10.3109/08820538.2011.577131
   PACKARD BD, 1983, INFECT IMMUN, V40, P1011, DOI 10.1128/IAI.40.3.1011-1014.1983
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Parmeggiani F, 2011, MOL DIAGN THER, V15, P195, DOI 10.2165/11592270-000000000-00000
   Parmeggiani F, 2011, CURR DRUG TARGETS, V12, P138, DOI 10.2174/138945011794182773
   Parmeggiani Francesco, 2009, Recent Pat DNA Gene Seq, V3, P114
   Parmeggiani F, 2009, PHARMACOGENOMICS, V10, P81, DOI 10.2217/14622416.10.1.81
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Perkins SJ, 2010, ADV EXP MED BIOL, V703, P25, DOI 10.1007/978-1-4419-5635-4_3
   Peter I, 2010, AM J OPHTHALMOL, V150, P450, DOI 10.1016/j.ajo.2010.06.012
   Ramo K, 2008, INVEST OPHTH VIS SCI, V49, P4126, DOI 10.1167/iovs.08-2025
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Ranchod TM, 2008, RETINA-J RET VIT DIS, V28, P711, DOI 10.1097/IAE.0b013e31816079c3
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Rienhoff HY, 2010, NEW ENGL J MED, V363, P2077, DOI 10.1056/NEJMc1010310
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334
   Ryu E, 2010, MOL VIS, V16, P2811
   Saitta A., 2009, THESIS U FERRARA
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Seddon JM, 2010, MOL VIS, V16, P2412
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Shastry B, 2010, GRAEF ARCH CLIN EXP, V248, P1057, DOI 10.1007/s00417-010-1333-x
   Sin H. P., ACTA OPHTHA IN PRESS
   Singer M., 2011, P ASS RES VIS OPHTH
   Sivaprasad S, 2011, OPHTHALMOLOGICA, V225, P200, DOI 10.1159/000322363
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Sweigard JH, 2011, GENE THER, V18, P613, DOI 10.1038/gt.2011.6
   Takahashi A, 2004, BRAIN RES BULL, V62, P497, DOI 10.1016/j.brainresbull.2003.07.009
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Teper SJ, 2010, MOL VIS, V16, P2598
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Tuo JS, 2004, FASEB J, V18, pA934
   Ushio-Fukai M, 2007, ANTIOXID REDOX SIGN, V9, P731, DOI 10.1089/ars.2007.1556
   Ushio-Fukai M, 2006, CARDIOVASC RES, V71, P226, DOI 10.1016/j.cardiores.2006.04.015
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang H, 2011, EYE BRAIN, V3, P19, DOI 10.2147/EB.S24951
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Wei YH, 1998, ANN NY ACAD SCI, V854, P155, DOI 10.1111/j.1749-6632.1998.tb09899.x
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wilkinson JT, 2011, DRUGS, V71, P2421, DOI 10.2165/11596840-000000000-00000
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Xu HP, 2007, INVEST OPHTH VIS SCI, V48, P1701, DOI 10.1167/iovs.06-0697
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zeng SM, 2012, INVEST OPHTH VIS SCI, V53, P1041, DOI 10.1167/iovs.11-8531
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Ziemssen F, 2011, DRUG AGING, V28, P853, DOI 10.2165/11594720-000000000-00000
NR 225
TC 89
Z9 90
U1 0
U2 39
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2012
VL 2012
AR 546786
DI 10.1155/2012/546786
PG 16
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA 038TZ
UT WOS:000311198300001
PM 23209345
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hussain, RM
   Weng, CY
   Wykoff, CC
   Gandhi, RA
   Hariprasad, SM
AF Hussain, Rehan M.
   Weng, Christina Y.
   Wykoff, Charles C.
   Gandhi, Raya A.
   Hariprasad, Seenu M.
TI Abicipar pegol for neovascular age-related macular degeneration
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE Neovascular age-related macular degeneration; vascular endothelial
   growth factor; abicipar pegol; choroidal neovascular membrane; DARPin;
   Designed Ankyrin Repeat Protein
ID ENDOTHELIAL GROWTH-FACTOR; TREAT-AND-EXTEND; DAILY CLINICAL-PRACTICE;
   VISUAL-ACUITY OUTCOMES; INTRAVITREAL RANIBIZUMAB; VEGF; AFLIBERCEPT;
   BEVACIZUMAB; INJECTION; DARPINS
AB Introduction The development of intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized management of neovascular age-related macular degeneration (nAMD) and serves as the standard of care for treating this chronic, progressive disease. One shortcoming is the need for frequent intravitreal injections to maintain visual gains, which has led to pursuit of long-acting agents to reduce treatment burden. Areas covered A literature search was conducted using the keywords 'abicipar pegol' and 'DARPin' on PubMed. Expert opinion DARPin (Designed Ankyrin Repeat Proteins) molecules such as abicipar pegol offer potential therapeutic advantages over antibodies or antibody fragments, including high affinity, stability, and high molar concentration. The phase III SEQUOIA and CEDAR clinical trials suggest that abicipar allows >90% of patients to maintain stable vision with 12-week dosing intervals, comparable to results achieved with monthly ranibizumab injections. Relative to other anti-VEGF agents, intraocular inflammation has been noted in a concerning percentage of patients, which is hypothesized to be related to the manufacturing process rather than the drug itself. Modifications to reduce pro-inflammatory components resulted in reduced inflammation (8.9%) in the MAPLE study. If this high inflammation rate can be further reduced, abicipar has the potential to decrease treatment burden for nAMD patients.
C1 [Hussain, Rehan M.] Retina Associates Ltd, Elmhurst, IL 60126 USA.
   [Weng, Christina Y.] Baylor Coll Med, Cullen Eye Inst, Dept Ophthalmol, Houston, TX 77030 USA.
   [Wykoff, Charles C.] Houston Methodist Hosp, Dept Ophthalmol, Blanton Eye Inst, Retina Consultants Houston, Houston, TX 77030 USA.
   [Gandhi, Raya A.] Northwestern Univ, Evanston, IL 60208 USA.
   [Hariprasad, Seenu M.] Univ Chicago, Dept Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
C3 Baylor College of Medicine; The Methodist Hospital System; The Methodist
   Hospital - Houston; Northwestern University; University of Chicago
RP Hussain, RM (通讯作者)，Retina Associates Ltd, Elmhurst, IL 60126 USA.
EM rhussain27@gmail.com
CR Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V12, P1
   Allergan and Molecular Partners Announce Two Positive Phase, 2018, 3 CLIN TRIALS AB PEG
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Baek SU, 2016, CUTAN OCUL TOXICOL, V35, P310, DOI 10.3109/15569527.2015.1124886
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bracha P, 2018, SURV OPHTHALMOL, V63, P281, DOI 10.1016/j.survophthal.2017.08.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cunningham Jr. ET, 2018, CLIN TRIAL CLOSEUP D
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Dalvin LA, 2019, JAMA OPHTHALMOL, V137, P483, DOI 10.1001/jamaophthalmol.2018.6891
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Donald J, 1967, AM J OPHTHALMOL 2, V63, p573/1
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dunn EN, 2017, OSLI RETINA, V48, P100, DOI 10.3928/23258160-20170130-02
   Eggel A, 2011, ALLERGY, V66, P961, DOI 10.1111/j.1398-9995.2011.02546.x
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Greenberg JP, 2019, OPHTHALMOL RETINA, V3, P753, DOI 10.1016/j.oret.2019.04.006
   Hariprasad SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P178, DOI 10.1001/archopht.124.2.178
   Hariprasad SM, 2005, ARCH OPHTHALMOL-CHIC, V123, P39, DOI 10.1001/archopht.123.1.39
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holmes DIR, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-2-209
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hussain RM, 2019, EXPERT OPIN INV DRUG, V28, P861, DOI 10.1080/13543784.2019.1667333
   Hussain RM, 2017, OSLI RETINA, V48, P780, DOI 10.3928/23258160-20170928-01
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Khurana RN, 2019, AM AC OPHTH ANN M 20
   Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Kunimoto D, 2019, OSLI RETINA, V50, pE10, DOI 10.3928/23258160-20190129-13
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumiya W, 2015, OPHTHALMOLOGICA, V234, P33, DOI 10.1159/000431000
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Moisseiev E, 2019, EYE LOND
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pluckthun A, 2015, ANNU REV PHARMACOL, V55, P489, DOI 10.1146/annurev-pharmtox-010611-134654
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rayess N, 2016, AM J OPHTHALMOL, V165, P88, DOI 10.1016/j.ajo.2016.02.028
   Reed K, 2018, RETINAL PHYS, V15, P26
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Stahl A, 2013, ANGIOGENESIS, V16, P101, DOI 10.1007/s10456-012-9302-0
   Stumpp MT, 2008, DRUG DISCOV TODAY, V13, P695, DOI 10.1016/j.drudis.2008.04.013
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   van Asten F, 2015, ACTA OPHTHALMOL, V93, P126, DOI 10.1111/aos.12610
   Wetzel SK, 2008, J MOL BIOL, V376, P241, DOI 10.1016/j.jmb.2007.11.046
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 71
TC 11
Z9 11
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD SEP 1
PY 2020
VL 20
IS 9
BP 999
EP 1007
DI 10.1080/14712598.2020.1782379
EA JUL 2020
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA MZ0PV
UT WOS:000547432400001
PM 32552072
DA 2022-11-30
ER

PT J
AU Lee, J
   Kang, HG
   Kim, HR
   Lee, CS
   Kim, M
   Kim, SS
   Byeon, SH
AF Lee, Junwon
   Kang, Hyun Goo
   Kim, Hae Rang
   Lee, Christopher Seungkyu
   Kim, Min
   Kim, Sung Soo
   Byeon, Suk Ho
TI Pigmentary abnormality without significant drusen as a risk factor for
   late age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; SUBCLINICAL NEOVASCULARIZATION;
   SEVERITY SCALE; RANIBIZUMAB; EPITHELIUM
AB We investigated the incidence and risk factors of late age-related macular degeneration (AMD) in the fellow eye (FE) without significant drusen of patients with unilateral exudative macular neovascularization (MNV). In this retrospective study, 241 eligible patients who were followed-up for more than 3 years were enrolled. We analyzed the incidence and hazard ratios (HRs) of late AMD in the FE according to demographic and ophthalmologic variables. Hypopigmentation on color fundus photography (CFP) corresponds to shallow irregular RPE elevation (SIRE), so-called "double-layer sign" and/or "attenuation or disruption of RPE and/or ellipsoid zone" on OCT. The 5-year incidence of FE exudative MNV conversion was 8.6%. The 5-year incidence of FE exudative MNV of large hypopigmentation (>= 0.5 disc area; DA) and small hypopigmentation (< 0.5 DA) on CFP, and SIRE (>= 1000 mu m) and small RPE elevation (< 1000 mu m) on OCT were 36.2%, 14.2%, 55.0%, and 15.6%, respectively. The multivariate Cox proportional hazard model revealed that large hypopigmentation, small hypopigmentation, SIRE, and small RPE elevation showed HRs of 23.230, 8.037, 132.589, and 41.823 for FE exudative MNV occurrence, respectively. Hypopigmentation on CFP and SIRE on OCT could represent the same lesion. Even small hypopigmentation and small RPE elevation were significant risk factors for progression to exudative MNV.
C1 [Lee, Junwon; Kang, Hyun Goo; Kim, Min] Yonsei Univ, Inst Human Barrier Res, Gangnam Severance Hosp, Dept Ophthalmol,Coll Med, Seoul, South Korea.
   [Kim, Hae Rang; Lee, Christopher Seungkyu; Kim, Sung Soo; Byeon, Suk Ho] Yonsei Univ, Inst Vision Res, Hosp Eye, Severance Hosp,Coll Med, Yonsei Ro 50-1, Seoul 03722, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System
RP Byeon, SH (通讯作者)，Yonsei Univ, Inst Vision Res, Hosp Eye, Severance Hosp,Coll Med, Yonsei Ro 50-1, Seoul 03722, South Korea.
EM shbyeon@yuhs.ac
RI ; Kang, Hyun Goo/C-5569-2018
OI Lee, Christopher/0000-0001-5054-9470; Kang, Hyun
   Goo/0000-0001-8359-9618; Lee, Junwon/0000-0003-0543-7132; Kim, Sung
   Soo/0000-0002-0574-7993; Byeon, suk ho/0000-0001-8101-0830; Kim,
   Min/0000-0003-1873-6959
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, ICT & Future Planning
   [2019R1A2C2086729]
FX This research was supported by grants for the Basic Science Research
   Program through the National Research Foundation of Korea (NRF), funded
   by the Ministry of Science, ICT & Future Planning (Grant Number:
   2019R1A2C2086729). The funding organization had no role in the design or
   conduct of this research.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee J, 2019, AM J OPHTHALMOL, V208, P103, DOI 10.1016/j.ajo.2019.07.013
   Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Narita C, 2020, OPHTHALMOLOGY, V127, P637, DOI 10.1016/j.ophtha.2019.11.007
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P2433, DOI 10.1097/IAE.0000000000000761
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Shi YY, 2019, OPHTHALMOL RETINA, V3, P211, DOI 10.1016/j.oret.2018.10.012
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yanagi Y, 2019, EYE, V33, P34, DOI 10.1038/s41433-018-0225-x
NR 30
TC 1
Z9 1
U1 2
U2 6
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 14
PY 2022
VL 12
IS 1
AR 769
DI 10.1038/s41598-022-04798-8
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA YG8TL
UT WOS:000742753500013
PM 35031679
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Khandhadia, S
   Lotery, A
AF Khandhadia, Sam
   Lotery, Andrew
TI Oxidation and age-related macular degeneration: insights from molecular
   biology
SO EXPERT REVIEWS IN MOLECULAR MEDICINE
LA English
DT Review
ID PIGMENT EPITHELIAL-CELLS; COMPLEMENT FACTOR-H; NF-KAPPA-B; MANGANESE
   SUPEROXIDE-DISMUTASE; LOW-DENSITY-LIPOPROTEIN; ANTIOXIDANT ENZYMES;
   INDUCED APOPTOSIS; RISK-FACTORS; INCREASED EXPRESSION; PLASMA
   HOMOCYSTEINE
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. It is a multifactorial disease, and current therapy predominantly limits damage only when it has already occurred. The macula is a source of high metabolic activity, and is therefore exposed to correspondingly high levels of reactive oxygen species (ROS). With age, the balance between production of ROS and local antioxidant levels is shifted, and damage ensues. Systemic ROS and antioxidant levels in AMD reflect these local processes. Genetic studies investigating mutations in antioxidant genes in AMD are inconclusive and further studies are indicated, especially to determine the role of mitochondria. Oral antioxidant supplements could be beneficial, and diet modification may help. Future treatments might either increase antioxidant capacity or reduce the production of ROS, using methods such as genetic manipulation. This article reviews the role of oxidative stress in AMD and the potential therapies that might have a role in preventing the blindness resulting from this disease.
C1 [Lotery, Andrew] Southampton Gen Hosp, Adm Off, Southampton SO16 6YD, Hants, England.
   [Khandhadia, Sam; Lotery, Andrew] Univ Southampton, Sch Med, Clin Neurosci Div, Southampton SO9 5NH, Hants, England.
C3 University of Southampton; University of Southampton
RP Lotery, A (通讯作者)，Southampton Gen Hosp, Adm Off, LD74,S Lab & Path Block, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@soton.ac.uk
OI Lotery, Andrew/0000-0001-5541-4305
FU Frimley Park Hospital NHS Trust; TFC Frost Charitable Trust; Gift of
   Sight Appeal; National Institute for Health Research [NF-SI-0507-10094]
   Funding Source: researchfish
FX This work was supported by grants from the Frimley Park Hospital NHS
   Trust, the TFC Frost Charitable Trust and the Gift of Sight Appeal. We
   thank the peer reviewers for their comments.
CR Abe Y, 1999, PHARMACOL RES, V39, P41, DOI 10.1006/phrs.1998.0404
   Adelfalk C, 2001, FEBS LETT, V506, P22, DOI 10.1016/S0014-5793(01)02869-1
   Age-Related Eye Disease Study Research Group, 2008, ARCH OPHTHALMOL-CHIC, V126, P1251
   [Anonymous], ONL MEND INH MAN OMI
   Arner ESJ, 2006, SEMIN CANCER BIOL, V16, P420, DOI 10.1016/j.semcancer.2006.10.009
   Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Baskol G, 2006, OPHTHALMOLOGICA, V220, P12, DOI 10.1159/000089269
   Behndig A, 1998, INVEST OPHTH VIS SCI, V39, P471
   Berndt C, 2007, AM J PHYSIOL-HEART C, V292, pH1227, DOI 10.1152/ajpheart.01162.2006
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Butler H, 2009, EUR J ENDOCRINOL, V161, P655, DOI 10.1530/EJE-09-0511
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cano MD, 2008, INVEST OPHTH VIS SCI, V49, P2606, DOI 10.1167/iovs.07-0960
   Capitani N, 2010, BLOOD, V115, P3726, DOI 10.1182/blood-2009-08-239244
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   CASTORINA C, 1992, NEUROCHEM RES, V17, P599, DOI 10.1007/BF00968789
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Chen BH, 2009, INVEST OPHTH VIS SCI, V50, P5587, DOI 10.1167/iovs.09-3633
   Chen JP, 2006, NAT NANOTECHNOL, V1, P142, DOI 10.1038/nnano.2006.91
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Choudhary S, 2005, TOXICOL APPL PHARM, V204, P122, DOI 10.1016/j.taap.2004.08.023
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   Chung H, 2009, J NEUROSCI RES, V87, P2365, DOI 10.1002/jnr.22046
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   *CTR RECH NUTR HUM, 2000, SUP DISM SOD ANT TRE
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   DelaPaz MA, 1996, BRIT J OPHTHALMOL, V80, P445, DOI 10.1136/bjo.80.5.445
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   Dong A, 2007, J NEUROCHEM, V103, P1041, DOI 10.1111/j.1471-4159.2007.04839.x
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Dubey A-K, 2004, Kathmandu Univ Med J (KUMJ), V2, P225
   Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ENNIS S, 2009, EUROPEAN J HUMAN GEN, V18, P15
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fawcett RJ, 2007, BRAIN RES BULL, V73, P278, DOI 10.1016/j.brainresbull.2007.04.002
   Feigl B, 2007, CLIN NEUROPHYSIOL, V118, P887, DOI 10.1016/j.clinph.2006.12.012
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuchshofer R, 2009, EXP EYE RES, V88, P889, DOI 10.1016/j.exer.2008.11.036
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Godley BF, 2002, EXP EYE RES, V74, P663, DOI 10.1006/exer.2001.1146
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Golden TR, 2001, MECH AGEING DEV, V122, P1577, DOI 10.1016/S0047-6374(01)00288-3
   Gotoh N, 2008, AM J OPHTHALMOL, V146, P146, DOI 10.1016/j.ajo.2008.03.017
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   Gouras P, 2008, GRAEF ARCH CLIN EXP, V246, P1395, DOI 10.1007/s00417-008-0910-8
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3
   HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   IWASAKI M, 1988, INVEST OPHTH VIS SCI, V29, P671
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Javadzadeh A, 2007, SAUDI MED J, V28, P221
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Jiang SN, 2005, INVEST OPHTH VIS SCI, V46, P1054, DOI 10.1167/iovs.04-0949
   Johnson Felicity, 2005, Molecular Aspects of Medicine, V26, P340, DOI 10.1016/j.mam.2005.07.006
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Kalariya NM, 2009, EXP EYE RES, V89, P494, DOI 10.1016/j.exer.2009.05.011
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kannan R, 2006, MOL VIS, V12, P1649
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katavetin P, 2007, KIDNEY INT, V72, pS10, DOI 10.1038/sj.ki.5002482
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   Kondo N, 2009, MOL VIS, V15, P1819
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Kumar A, 2010, BIOCHEM BIOPH RES CO, V394, P360, DOI 10.1016/j.bbrc.2010.03.014
   KUTTY RK, 1995, P NATL ACAD SCI USA, V92, P1177, DOI 10.1073/pnas.92.4.1177
   Lacombe C, 1998, HAEMATOLOGICA, V83, P724
   Lakshminarayana R, 2008, FREE RADICAL BIO MED, V45, P982, DOI 10.1016/j.freeradbiomed.2008.06.011
   Li DY, 2003, BIOCHEM BIOPH RES CO, V309, P457, DOI 10.1016/j.bbrc.2003.08.020
   Li L, 2010, J NUTR BIOCHEM, V21, P544, DOI 10.1016/j.jnutbio.2009.03.002
   Li QH, 2008, MOL THER, V16, P1688, DOI 10.1038/mt.2008.164
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   LIM BP, 1992, BIOCHIM BIOPHYS ACTA, V1126, P178
   Liu XP, 2007, LIFE SCI, V80, P1586, DOI 10.1016/j.lfs.2007.01.034
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Lu LL, 2009, ANTIOXID REDOX SIGN, V11, P715, DOI 10.1089/ARS.2008.2171
   LUNDBERG WO, 1958, AM J CLIN NUTR, V6, P601, DOI 10.1093/ajcn/6.6.601
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Mankan AK, 2009, J CELL MOL MED, V13, P631, DOI 10.1111/j.1582-4934.2009.00632.x
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Matias I, 2006, PROSTAG LEUKOTR ESS, V75, P413, DOI 10.1016/j.plefa.2006.08.002
   Mattison Julie A., 2007, V35, P137
   Melo P, 2010, NEUROCHEM INT, V56, P431, DOI 10.1016/j.neuint.2009.11.017
   MEYERS SM, 1993, T AM OPHTHALMOLOGICA, V102, P83
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Michikawa T, 2009, ASIA PAC J CLIN NUTR, V18, P1
   Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311
   Muller FL, 2007, FREE RADICAL BIO MED, V43, P477, DOI 10.1016/j.freeradbiomed.2007.03.034
   Nakajima Y, 2009, CURR EYE RES, V34, P311, DOI 10.1080/02713680902745408
   *NEI, 2000, AG REL EY DIS STUD, V2
   *NEI, 2000, EFF ANT HUM MAC PIGM
   NEWSOME DA, 1986, INVEST OPHTH VIS SCI, V27, P1675
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9
   Nork TM, 2006, ARCH OPHTHALMOL-CHIC, V124, P860, DOI 10.1001/archopht.124.6.860
   Nowak M, 2005, EUR J OPHTHALMOL, V15, P764, DOI 10.1177/112067210501500617
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Onaivi ES, 2009, INT REV NEUROBIOL, V88, P335, DOI 10.1016/S0074-7742(09)88012-4
   Organisciak DT, 1998, INVEST OPHTH VIS SCI, V39, P1107
   PACKER L, 1993, ANN NY ACAD SCI, V691, P48, DOI 10.1111/j.1749-6632.1993.tb26156.x
   Pemp B, 2010, INVEST OPHTH VIS SCI, V51, P2, DOI 10.1167/iovs.09-3888
   Peters S, 2006, Z NATURFORSCH C, V61, P427
   Petronelli A, 2009, ANTI-CANCER DRUG, V20, P880, DOI 10.1097/CAD.0b013e328330fd90
   Pitha-Rowe I, 2009, INVEST OPHTH VIS SCI, V50, P5339, DOI 10.1167/iovs.09-3648
   PRASHAR S, 1993, ACTA OPHTHALMOL, V71, P214
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rex TS, 2009, EXP EYE RES, V89, P735, DOI 10.1016/j.exer.2009.06.017
   Rex TS, 2004, HUM GENE THER, V15, P960, DOI 10.1089/hum.2004.15.960
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Roehlecke C, 2009, MOL VIS, V15, P1929
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rozanowski B, 2008, PHOTOCHEM PHOTOBIOL, V84, P650, DOI 10.1111/j.1751-1097.2007.00259.x
   Rubio MA, 2004, EXP CELL RES, V298, P17, DOI 10.1016/j.yexcr.2004.04.004
   Ryan S. J., 2006, RETINA
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Sanvicens N, 2004, J BIOL CHEM, V279, P39268, DOI 10.1074/jbc.M402202200
   Sari A, 2009, RETINA-J RET VIT DIS, V29, P1346, DOI 10.1097/IAE.0b013e3181b26343
   Scapagnini G, 2006, ANTIOXID REDOX SIGN, V8, P395, DOI 10.1089/ars.2006.8.395
   Schmid-Kubista KE, 2009, ACTA OPHTHALMOL, V87, P89, DOI 10.1111/j.1755-3768.2008.01173.x
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Shah Shaival S, 2009, BMC Res Notes, V2, P234, DOI 10.1186/1756-0500-2-234
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Simonelli F, 2002, CLIN CHIM ACTA, V320, P111, DOI 10.1016/S0009-8981(02)00056-6
   SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, pS145
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, pS943
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Sreekumar PG, 2005, BIOCHEM BIOPH RES CO, V334, P245, DOI 10.1016/j.bbrc.2005.06.081
   Sundelin SP, 2001, FREE RADICAL BIO MED, V31, P217, DOI 10.1016/S0891-5849(01)00573-1
   Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381
   Suzuki M, 2007, MOL VIS, V13, P772
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Talalay P, 2003, ADV ENZYME REGUL, V43, P121, DOI 10.1016/S0065-2571(02)00038-9
   Talalay P, 2000, BIOFACTORS, V12, P5, DOI 10.1002/biof.5520120102
   Tanito M, 2002, INVEST OPHTH VIS SCI, V43, P1162
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   *VAND U US, 2010, ANT SYST AG REL MAC
   VANKUIJK FJGM, 1992, INVEST OPHTH VIS SCI, V33, P3493
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1996, ROTTERDAM STUDY ARCH, V114, P1193
   Wan FY, 2010, CELL RES, V20, P24, DOI 10.1038/cr.2009.137
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang XW, 2008, FREE RADICAL BIO MED, V45, P336, DOI 10.1016/j.freeradbiomed.2008.04.028
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P474, DOI 10.1562/2005-10-21-RA-725
   Wang ZY, 2009, FREE RADICAL BIO MED, V46, P1032, DOI 10.1016/j.freeradbiomed.2008.11.027
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   Wei Y, 2009, MOL VIS, V15, P1243
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wielgus AR, 2007, PHOTOCHEM PHOTOBIOL, V83, P706, DOI 10.1562/2006-08-09-RA-1001
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   WONG WT, 2010, INVESTIGATIVE O 0623
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Wu ZH, 2006, J CELL PHYSIOL, V209, P996, DOI 10.1002/jcp.20819
   YAMASHITA H, 1992, RETINA-J RET VIT DIS, V12, P59, DOI 10.1097/00006982-199212010-00012
   Yang DL, 2009, INVEST OPHTH VIS SCI, V50, P4998, DOI 10.1167/iovs.09-3620
   Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yildirim O, 2004, OPHTHALMOLOGICA, V218, P202, DOI 10.1159/000076845
   Yodoi Y, 2007, INVEST OPHTH VIS SCI, V48, P5464, DOI 10.1167/iovs.07-0093
   Young AJ, 2001, ARCH BIOCHEM BIOPHYS, V385, P20, DOI 10.1006/abbi.2000.2149
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
   YUAN HT, 1995, MECH AGEING DEV, V81, P159, DOI 10.1016/0047-6374(95)01584-M
   Zareba M, 2006, PHOTOCHEM PHOTOBIOL, V82, P1024, DOI 10.1562/2006-03-08-RA-836
   Zhang B, 2006, BRAIN RES, V1124, P176, DOI 10.1016/j.brainres.2006.09.067
   Zhang B, 2009, INVEST OPHTH VIS SCI, V50, P3943, DOI 10.1167/iovs.08-2954
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 223
TC 140
Z9 142
U1 0
U2 34
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1462-3994
J9 EXPERT REV MOL MED
JI Expert Rev. Mol. Med.
PD OCT 20
PY 2010
VL 12
AR e34
DI 10.1017/S146239941000164X
PG 28
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 674UA
UT WOS:000283774300001
PM 20959033
DA 2022-11-30
ER

PT J
AU Langagergaard, U
   Ganer, HJ
   Baggesen, K
AF Langagergaard, U
   Ganer, HJ
   Baggesen, K
TI Age-related macular degeneration: filter lenses help in certain
   situations
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE age-related macular degeneration; filter lenses; Corning photo chromic
   filters; LVI; visual acuity; contrast sensitivity; low vision
ID CONTRAST SENSITIVITY FUNCTION; VISUAL IMPAIRMENT; GRADING SYSTEM;
   MACULOPATHY; VISION; EYE
AB Purpose: To investigate the ability of different filter lenses to enhance the contrast sensitivity of patients with age-related macular degeneration (AMD).
   Methods: A total of 32 patients with non-exudative AMD and no other significant eye diseases underwent the study tests using their optimal correction. We used Hyvarinen's contrast sensitivity tests with 100%, 10%, 5%, 2.5% and 1.25% charts. All the tests were made without filter lenses and with the Corning 527 and LVI 527 lenses.
   Results: With the 100% charts, there was a slight tendency towards contrast sensitivity improvement with LVI filter lenses, but the degree of improvement was not statistically significant. With the 10% charts, contrast sensitivity improved significantly with LVI 527 filter lenses, but not with Corning 527 lenses. It was not possible to perform statistical analyses of the results with the 5%, 2.5% and 1.25% charts.
   Conclusion: Use of LVI filter lenses may improve contrast sensitivity in certain situations in patients with AMD.
C1 Aalborg Hosp, Dept Ophthalmol, Aalborg, Denmark.
   Synsinst, Aalborg, Denmark.
C3 Aalborg University; Aalborg University Hospital
RP Langagergaard, U (通讯作者)，Ellebaek Parkueo 4, DK-8520 Lystrup, Denmark.
CR Barron C, 1987, J Am Optom Assoc, V58, P50
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bither P P, 1988, J Am Optom Assoc, V59, P623
   CARTER TL, 1994, GERIATRICS, V49, P37
   CHOU BR, 1985, CAN J OPTOM, V47, P77
   *CORN GLASS WORKS, CPF PROD MAN CORN CP
   ELKINGTON AR, 1991, CLIN OPTICS
   Faubert J, 2000, J AM GERIATR SOC, V48, P375, DOI 10.1111/j.1532-5415.2000.tb04693.x
   FRENNESSON IC, 1993, DOC OPHTHALMOL, V84, P134
   HOVIS JK, 1989, OPTOMETRY VISION SCI, V66, P682, DOI 10.1097/00006324-198910000-00004
   HOWE JW, 1984, BRIT J OPHTHALMOL, V68, P626, DOI 10.1136/bjo.68.9.626
   HYVARINEN L, 1998, PRODUCTS MANUAL CONT
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   LEGUIRE LE, 1993, OPHTHAL PHYSL OPT, V13, P124, DOI 10.1111/j.1475-1313.1993.tb00440.x
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   RIEGER G, 1992, CAN J OPHTHALMOL, V27, P137
   Valberg A, 2002, J OPT SOC AM A, V19, P223, DOI 10.1364/JOSAA.19.000223
NR 19
TC 8
Z9 9
U1 0
U2 2
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD OCT
PY 2003
VL 81
IS 5
BP 455
EP 458
DI 10.1034/j.1600-0420.2003.00142.x
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 726JQ
UT WOS:000185596300006
PM 14510791
OA Bronze
DA 2022-11-30
ER

PT J
AU Lee, MW
   Kim, JM
   Lim, HB
   Shin, YI
   Lee, YH
   Kim, JY
AF Lee, Min-Woo
   Kim, Ju-Mi
   Lim, Hyung-Bin
   Shin, Yong-Il
   Lee, Young-Hoon
   Kim, Jung-Yeul
TI Longitudinal Changes in Ganglion Cell-Inner Plexiform Layer of Fellow
   Eyes in Unilateral Neovascular Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID NERVE-FIBER LAYER; POLYPOIDAL CHOROIDAL VASCULOPATHY; CLINICAL
   CHARACTERISTICS; RETICULAR PSEUDODRUSEN; THICKNESSES; HEALTHY; DISEASE
AB PURPOSE: To determine longitudinal changes in the ganglion cell-inner plexiform layer (GC-IPL) thickness of the fellow eyes of patients with neovascular age-related macular degeneration (AMD).
   DESIGN: Prospective cohort study.
   METHODS: Patients with unilateral neovascular AMD, unilateral polypoidal choroidal vasculopathy (PCV), and control subjects were included. After the initial visit, GC-IPL thickness was measured twice more with at least a 1-year interval between examinations using spectral domain optical coherence tomography.
   RESULTS: Twenty-seven fellow eyes of patients with unilateral choroidal neovascularization (CNV), 33 fellow eyes of patients with unilateral PCV, and 35 eyes of control subjects were enrolled. The GC-IPL thickness of the fellow eyes was 78.41 +/- 9.23, 81.20 +/- 5.52, and 81.60 +/- 3.83 mu m in the CNV, PCV, and control groups, respectively, and they showed a significant change over time (P < .001, P = .001, and P = .003, respectively). The reduction rate of GC-IPL thickness was - 0.88, - 0.41, and -0.31 mu m per year in the fellow eyes of the CNV, PCV, and control groups, respectively (CNV > PCV, control, P < .001). In a linear mixed model determination of factors associated with GC-IPL reduction in the fellow eyes of the CNV group, the interaction between baseline GC-IPL thickness and duration showed a significant result (P < .001).
   CONCLUSIONS: The fellow eyes of patients with neovascular AMD showed a greater reduction rate of GC-IPL thickness compared with fellow eyes of patients with unilateral PCV and control subjects. In patients with unilateral neovascular AMD, fellow eyes with a thicker GC-IPL at baseline showed a greater reduction in GC-IPL thickness over time. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Lee, Min-Woo; Lee, Young-Hoon] Konyang Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
   [Kim, Ju-Mi; Lim, Hyung-Bin; Shin, Yong-Il; Kim, Jung-Yeul] Chungnam Natl Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
C3 Konyang University; Konyang University Hospital; Chungnam National
   University
RP Kim, JY (通讯作者)，Chungnam Natl Univ Hosp, Dept Ophthalmol, 640 Daesa Dong, Daejeon 301721, South Korea.
EM kimjy@cnu.ac.kr
OI Kim, Jung yeul/0000-0003-3679-1310
CR Abdolrahimzadeh S, 2019, CURR EYE RES, V44, P1000, DOI 10.1080/02713683.2019.1610179
   Abdolrahimzadeh S, 2019, EYE, V33, P1290, DOI 10.1038/s41433-019-0405-3
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Baek J, 2019, INVEST OPHTH VIS SCI, V60, P590, DOI 10.1167/iovs.18-24244
   Bochicchio S, 2019, OPHTHALMOL RETINA, V3, P27, DOI 10.1016/j.oret.2018.08.003
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Hendrickson A, 2015, BRAIN STRUCT FUNCT, V220, P351, DOI 10.1007/s00429-013-0659-7
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Hollo G, 2016, J GLAUCOMA, V25, pE905, DOI 10.1097/IJG.0000000000000410
   Hwang YH, 2014, OPHTHALMOLOGY, V121, P1508, DOI 10.1016/j.ophtha.2014.02.019
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kenmochi J, 2017, RETINA-J RET VIT DIS, V37, P47, DOI 10.1097/IAE.0000000000001131
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Leung CKS, 2013, OPHTHALMOLOGY, V120, P2485, DOI 10.1016/j.ophtha.2013.07.021
   Leung CKS, 2012, OPHTHALMOLOGY, V119, P731, DOI 10.1016/j.ophtha.2011.10.010
   Lim HB, 2019, AM J OPHTHALMOL, V199, P167, DOI 10.1016/j.ajo.2018.11.016
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nittala MG, 2019, OPHTHALMOL RETINA, V3, P112, DOI 10.1016/j.oret.2018.09.017
   Patel NB, 2014, INVEST OPHTH VIS SCI, V55, P5134, DOI 10.1167/iovs.14-14303
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Sullivan R, 2003, INVEST OPHTH VIS SCI, V44, P856, DOI 10.1167/iovs.02-0416
   Sung KR, 2009, OPHTHALMOLOGY, V116, P1119, DOI 10.1016/j.ophtha.2009.01.004
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 38
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2020
VL 212
BP 17
EP 25
DI 10.1016/j.ajo.2019.12.003
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LG1DC
UT WOS:000527849400003
PM 31830437
DA 2022-11-30
ER

PT J
AU Waldstein, SM
   Sponer, U
   Simader, C
   Sacu, S
   Schmidt-Erfurth, U
AF Waldstein, Sebastian M.
   Sponer, Ulrike
   Simader, Christian
   Sacu, Stefan
   Schmidt-Erfurth, Ursula
TI INFLUENCE OF VITREOMACULAR ADHESION ON THE DEVELOPMENT OF EXUDATIVE
   AGE-RELATED MACULAR DEGENERATION 4-Year Results of a Longitudinal Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; optical
   coherence tomography; vitreomacular adhesion; vitreomacular interface;
   vitreous
ID OPTICAL COHERENCE TOMOGRAPHY; POSTERIOR VITREOUS DETACHMENT
AB Purpose: To investigate the influence of vitreomacular adhesion (VMA) on development of choroidal neovascularization (CNV) in eyes with age-related macular degeneration.
   Methods: In a prospective study, patients with Age-Related Eye Disease Study Category IV age-related macular degeneration underwent standardized examinations, including optical coherence tomography and fluorescein angiography every 3 months for 4 years. Vitreomacular adhesion was evaluated using time-and spectral-domain optical coherence tomography. Development of CNV was detected using fluorescein angiography and optical coherence tomography. Incidences of CNV were compared concerning the presence or absence of VMA.
   Results: Forty-nine patients were available for follow-up according to protocol. Vitreomacular adhesion was present at baseline in 18% (9 of 49) and absent in 82% (40 of 49) of patients. Thirty-seven percent of patients (18 of 49) developed exudative changes during the observation period. In patients with preexisting VMA, de novo development of CNV occurred in 33% (3 of 9). In patients without VMA, 38% developed CNV (15 of 40). Mean interval from baseline to disease progression was 20 +/- 19 months in patients with VMA and 22 +/- 13 months in patients without VMA. There was no significant difference between the groups regarding rate of CNV development or time to disease progression (P = 0.64).
   Conclusion: No significant influence of VMA on the development of exudative age-related macular degeneration could be found during a 4-year prospective observation of a high-risk cohort. RETINA 32: 424-433, 2012
C1 [Waldstein, Sebastian M.; Sponer, Ulrike; Simader, Christian; Sacu, Stefan; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
C3 Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311; Waldstein,
   Sebastian/0000-0003-2899-6279; Simader, Christian/0000-0002-1784-2883
FU Bayer Healthcare; Novartis Pharmaceuticals
FX U. Schmidt-Erfurth has served as consultant/advisor for Alcon
   Laboratories, INC, Bayer Healthcare, Novartis Pharmaceuticals
   Corporation, and Regeneron and has obtained lecture fees from Bayer
   Healthcare and Novartis Pharmaceuticals. The other authors declare no
   conflict of interest.
CR FOOS RY, 1982, OPHTHALMOLOGY, V89, P1502
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Holekamp NM, 2010, AM J OPHTHALMOL, V149, P32, DOI 10.1016/j.ajo.2009.07.036
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Mirza RG, 2007, SURV OPHTHALMOL, V52, P397, DOI 10.1016/j.survophthal.2007.04.007
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nigam N, 2010, RETINA-J RET VIT DIS, V30, P246, DOI 10.1097/IAE.0b013e3181baf6dc
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   Sebag J, 2008, Dev Ophthalmol, V42, P5, DOI 10.1159/000138754
   SEBAG J, 1991, ARCH OPHTHALMOL-CHIC, V109, P966, DOI 10.1001/archopht.1991.01080070078039
   Solomon SD, 2009, RETINA-J RET VIT DIS, V29, P1080, DOI 10.1097/IAE.0b013e3181b1baeb
   Uchino E, 2001, ARCH OPHTHALMOL-CHIC, V119, P1475
   YONEMOTO J, 1994, GRAEF ARCH CLIN EXP, V232, P67, DOI 10.1007/BF00171665
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 22
TC 15
Z9 15
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2012
VL 32
IS 3
BP 424
EP 433
DI 10.1097/IAE.0b013e3182278b80
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 900RU
UT WOS:000300907200003
PM 22105497
DA 2022-11-30
ER

PT J
AU Shijo, T
   Sakurada, Y
   Tanaka, K
   Miki, A
   Sugiyama, A
   Onoe, H
   Chubachi, A
   Kikushima, W
   Wakatsuki, Y
   Yoneyama, S
   Mori, R
   Kashiwagi, K
AF Shijo, Taiyo
   Sakurada, Yoichi
   Tanaka, Koji
   Miki, Akiko
   Sugiyama, Atsushi
   Onoe, Hajime
   Chubachi, Aya
   Kikushima, Wataru
   Wakatsuki, Yu
   Yoneyama, Seigo
   Mori, Ryusaburo
   Kashiwagi, Kenji
TI Incidence and risk of advanced age-related macular degeneration in eyes
   with drusenoid pigment epithelial detachment
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RETICULAR PSEUDODRUSEN; SEVERITY SCALE; FELLOW-EYES
AB To investigate the incidence and risk of advanced age-related macular degeneration (AMD), including geographic atrophy (GA) and macular neovascularization (MNV), in eyes with drusenoid pigment epithelial detachment (PED). Eighty-five eyes with drusenoid PED from 85 patients (77.2 +/- 7.0 years, male/female: 44/41) were included in this study. Patients were followed up every 1-3 months via spectral-domain optical coherence tomography (SD-OCT) and color fundus photography. If exudation was observed on SD-OCT, fluorescein and indocyanine green angiography were performed to confirm the MNV subtype accordingly. The maximum follow-up period was 60 months. During the study period, GA developed in 8 eyes while MNV also developed in 8 eyes. The Kaplan-Meier estimator revealed that the cumulative incidence for 60 months was 17.9% and 12.2% for GA and MNV, respectively. In eyes developing MNV, retinal angiomatous proliferation was the most common. Cox regression analysis revealed that baseline PED width was the only factor associated with advanced AMD. (p = 0.0026, Cox regression analysis). The 5-year cumulative incidence of advanced AMD, including GA and MNV, was approximately 30% in eyes with drusenoid PED among the Japanese elderly. A larger baseline PED width was the only risk factor for advanced AMD.
C1 [Shijo, Taiyo; Sakurada, Yoichi; Sugiyama, Atsushi; Kikushima, Wataru; Yoneyama, Seigo; Kashiwagi, Kenji] Univ Yamanashi, Fac Med, Dept Ophthalmol, Shimokato 1110, Chuo, Yamanashi 4093821, Japan.
   [Tanaka, Koji; Onoe, Hajime; Wakatsuki, Yu; Mori, Ryusaburo] Nihon Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
   [Miki, Akiko; Chubachi, Aya] Kobe Univ, Dept Surg, Div Ophthalmol, Grad Sch Med, Kobe, Hyogo, Japan.
C3 University of Yamanashi; Nihon University; Kobe University
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Shimokato 1110, Chuo, Yamanashi 4093821, Japan.
EM sakurada@yamanashi.ac.jp
CR Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V191, P23, DOI 10.1016/j.ajo.2018.03.038
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fragiotta S, 2018, RETINA-J RET VIT DIS, V38, P245, DOI 10.1097/IAE.0000000000001540
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Kim KL, 2022, ACTA OPHTHALMOL, V100, pE710, DOI 10.1111/aos.14960
   Notomi S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255213
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Sakurada Y, 2019, JPN J OPHTHALMOL, V63, P374, DOI 10.1007/s10384-019-00680-9
   Shijo T, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084074
   Shijo T, 2017, GRAEF ARCH CLIN EXP, V255, P1125, DOI 10.1007/s00417-017-3622-0
   Sunness JS, 2006, BRIT J OPHTHALMOL, V90, P398, DOI 10.1136/bjo.2005.084830
   Tan ACS, 2016, AM J OPHTHALMOL, V172, P13, DOI 10.1016/j.ajo.2016.09.004
   Tateno Y, 2016, OPHTHALMIC GENET, V37, P177, DOI 10.3109/13816810.2015.1020557
   Terao R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134758
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Yu JJ, 2019, OPHTHALMOLOGY, V126, P261, DOI 10.1016/j.ophtha.2018.08.017
NR 24
TC 0
Z9 0
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 18
PY 2022
VL 12
IS 1
AR 4715
DI 10.1038/s41598-022-08626-x
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ZV7IC
UT WOS:000770698200067
PM 35304557
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Cohn, AC
   Wu, ZC
   Jobling, AI
   Fletcher, EL
   Guymer, RH
AF Cohn, Amy C.
   Wu, Zhichao
   Jobling, Andrew I.
   Fletcher, Erica L.
   Guymer, Robyn H.
TI Subthreshold Nano-Second Laser Treatment and Age-Related Macular
   Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE drusen; age-related macular degeneration; laser
ID BRUCHS MEMBRANE IMPLICATIONS; ARGON-LASER; CONVENTIONAL PHOTOCOAGULATOR;
   CHOROIDAL NEOVASCULARIZATION; GEOGRAPHIC-ATROPHY; BASAL DEPOSITS;
   RETINAL LASER; FELLOW-EYES; DRUSEN; NANOSECOND
AB The presence of drusen is an important hallmark of age-related macular degeneration (AMD). Laser-induced regression of drusen, first observed over four decades ago, has led to much interest in the potential role of lasers in slowing the progression of the disease. In this article, we summarise the key insights from pre-clinical studies into the possible mechanisms of action of various laser interventions that result in beneficial changes in the retinal pigment epithelium/Bruch's membrane/choriocapillaris interface. Key learnings from clinical trials of laser treatment in AMD are also summarised, concentrating on the evolution of laser technology towards short pulse, non-thermal delivery such as the nanosecond laser. The evolution in our understanding of AMD, through advances in multimodal imaging and functional testing, as well as ongoing investigation of key pathological mechanisms, have all helped to set the scene for further well-conducted randomised trials to further explore potential utility of the nanosecond and other subthreshold short pulse lasers in AMD.
C1 [Cohn, Amy C.; Wu, Zhichao; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Wu, Zhichao; Guymer, Robyn H.] Univ Melbourne, Dept Ophthalmol, Dept Surg, Parkville, Vic 3052, Australia.
   [Jobling, Andrew I.; Fletcher, Erica L.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3052, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne
RP Cohn, AC (通讯作者)，Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
EM amycohn1@gmail.com; wu.z@unimelb.edu.au; aij@unimelb.edu.au;
   e.fletcher@unimelb.edu.au; rh.guymer@unimelb.edu.au
RI Jobling, Andrew/C-8221-2015
OI Jobling, Andrew/0000-0002-7827-3135
FU National Health & Medical Research Council of Australia [APP1027624,
   GNT1103013, APP1104985, APP1054712, APP1142962, GNT1128343]; BUPA Health
   Foundation (Australia); Ellex R&D Pty Ltd. (Adelaide, Australia); CERA,
   an independent medical research institute
FX This study was supported by the National Health & Medical Research
   Council of Australia (project grant no.: APP1027624 [RHG and CDL], and
   fellowship grant no.: GNT1103013 (RHG), APP1104985 [ZW], APP1054712
   [FKC], APP1142962 [FKC] and GNT1128343 [SSW]), and the BUPA Health
   Foundation (Australia) (RHG and CDL). The Centre for Eye Research
   Australia (CERA) receives operational infrastructure support from the
   Victorian Government. Ellex R&D Pty Ltd. (Adelaide, Australia) provided
   partial funding of the central coordinating centre and the in-kind
   provision of Ellex 2RTTM laser systems, ongoing support of those
   systems, and the Macular Integrity Assessment micro-perimeters for the
   duration of the study. The web-based Research Electronic Data Capture
   (REDCap) application and open-source platform OpenClinica allowed secure
   electronic data capture. The study is sponsored by CERA, an independent
   medical research institute and a not-for-profit company.
CR Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Brinkmann R, 2000, LASER SURG MED, V27, P451, DOI 10.1002/1096-9101(2000)27:5<451::AID-LSM1006>3.0.CO;2-1
   Brinkmann R, 2006, Bull Soc Belge Ophtalmol, P51
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chidlow G, 2016, LASER SURG MED, V48, P602, DOI 10.1002/lsm.22506
   Chidlow G, 2013, INVEST OPHTH VIS SCI, V54, P2319, DOI 10.1167/iovs.12-11204
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Dorin Giorgio, 2003, Semin Ophthalmol, V18, P147, DOI 10.1076/soph.18.3.147.29812
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Framme C, 2004, LASER SURG MED, V34, P206, DOI 10.1002/lsm.20022
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   Guymer RH, 2001, BRIT J OPHTHALMOL, V85, P40, DOI 10.1136/bjo.85.1.40
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Humphrey MF, 1997, EXP EYE RES, V64, P361, DOI 10.1006/exer.1996.0219
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kaiser RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P826
   Karampelas M, 2013, BRIT J OPHTHALMOL, V97, P1256, DOI 10.1136/bjophthalmol-2013-303219
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Lek JJ, 2017, OPHTHALMOL RETINA, V1, P227, DOI 10.1016/j.oret.2016.12.001
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   MARSHALL J, 1975, BRIT J OPHTHALMOL, V59, P610, DOI 10.1136/bjo.59.11.610
   Matsunaga Hiroshi, 1995, Nippon Ganka Gakkai Zasshi, V99, P460
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Musashi K, 2005, INVEST OPHTH VIS SCI, V46, P2561, DOI 10.1167/iovs.04-1102
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Owens SL, 2003, EYE, V17, P623, DOI 10.1038/sj.eye.6700442
   PANKRATOV MM, 1990, P SOC PHOTO-OPT INS, V1202, P205, DOI 10.1117/12.17626
   Park YG, 2017, GRAEF ARCH CLIN EXP, V255, P1375, DOI 10.1007/s00417-017-3672-3
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Paulus YM, 2008, INVEST OPHTH VIS SCI, V49, P5540, DOI 10.1167/iovs.08-1928
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   RABB MF, 1988, SURV OPHTHALMOL, V33, P73, DOI 10.1016/0039-6257(88)90160-9
   Richardson PRS, 1996, BRIT J OPHTHALMOL, V80, P1092, DOI 10.1136/bjo.80.12.1092
   ROSENBERG N, 1986, ARCH OPHTHALMOL-CHIC, V104, P34
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schule G., 2000, P SPIE
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Tackenberg MA, 2009, MOL VIS, V15, P1886
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Tode J, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.11
   Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031
   VARLEY MP, 1988, OPHTHALMOLOGY, V95, P567
   Vessey KA, 2018, INVEST OPHTH VIS SCI, V59, P731, DOI 10.1167/iovs.17-23098
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Wang J, 2017, INVEST OPHTH VIS SCI, V58, P4722, DOI 10.1167/iovs.17-21610
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang LHV, 2016, NAT METHODS, V13, P627, DOI [10.1038/nmeth.3925, 10.1038/NMETH.3925]
   Wetzig P C, 1988, Trans Am Ophthalmol Soc, V86, P276
   Wood JPM, 2013, INVEST OPHTH VIS SCI, V54, P2305, DOI 10.1167/iovs.12-11203
   Wood JPM, 2011, LASER SURG MED, V43, P499, DOI 10.1002/lsm.21087
   Wu ZC, 2019, OPHTHALMOL RETINA, V3, P1026, DOI 10.1016/j.oret.2019.07.008
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yamamoto C, 1996, GRAEF ARCH CLIN EXP, V234, P695, DOI 10.1007/BF00292356
   Zhang JJ, 2012, INVEST OPHTH VIS SCI, V53, P2928, DOI 10.1167/iovs.11-8585
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
NR 78
TC 2
Z9 2
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD FEB
PY 2021
VL 10
IS 3
AR 484
DI 10.3390/jcm10030484
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA QD2JX
UT WOS:000615352500001
PM 33525639
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Verner-Cole, EA
   Davis, SJ
   Lauer, AK
AF Verner-Cole, E. A.
   Davis, S. J.
   Lauer, A. K.
TI AFLIBERCEPT FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION
SO DRUGS OF TODAY
LA English
DT Article
DE Aflibercept; Vascular endothelial growth factor; Age-related macular
   degeneration
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR TRAP-EYE; EXPERIMENTAL CHOROIDAL
   NEOVASCULARIZATION; VEGF-TRAP; INTRAVITREAL INJECTION; PHASE-I;
   RANIBIZUMAB; BEVACIZUMAB; PHARMACOKINETICS; EDEMA
AB Age-related macular degeneration (AMD) can have devastating effects on vision, especially in its neovascular form. In the last decade, the use of intravitreal pharmacotherapy targeted to vascular endothelial growth factor (VEGF) has significantly improved the visual outcomes in patients with neovascular AMD. Although we have become accustomed to these unprecedented improvement outcomes, maintaining good visual results with anti-VEGF therapy requires tremendous effort, time and cost, typically involving monthly clinic visits and intravitreal injections. The introduction of aflibercept, an anti-VEGF drug that targets all isoforms of VEGF as well as placenta growth factor, has shown promise throughout recent clinical trials as an equally effective treatment for neovascular AMD that requires less frequent dosing than either ranibizumab or bevacizumab. Based on clinical trial results, the U.S. Food and Drug Administration approved aflibercept in November 2011 for use in neovascular AMD, giving patients the hope of alleviating some of the burden associated with treatment.
C1 [Verner-Cole, E. A.; Davis, S. J.; Lauer, A. K.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, Portland, OR 97201 USA.
C3 Oregon Health & Science University
RP Lauer, AK (通讯作者)，3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM lauera@ohsu.edu
FU Research to Prevent Blindness, New York, New York, USA
FX This paper was supported in part by an unrestricted grant from the
   Research to Prevent Blindness, New York, New York, USA. The authors
   state no conflicts of interest.
CR [Anonymous], 2008, DRUGS R D, V9, P261
   [Anonymous], STUD BIOM VEGF TRAP
   Boyer D.M., 2011, ANG EX DEG 2012 FEB
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Chung AS, 2010, NAT REV CANCER, V10, P505, DOI 10.1038/nrc2868
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Do DV, 2009, BRIT J OPHTHALMOL, V93, P144, DOI 10.1136/bjo.2008.138271
   Do DV, 2011, OPHTHALMOLOGY, V118, P1819, DOI 10.1016/j.ophtha.2011.02.018
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fong DS, 2007, ARCH OPHTHALMOL-CHIC, V125, P469
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lockhart AC, 2010, J CLIN ONCOL, V28, P207, DOI 10.1200/JCO.2009.22.9237
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lutty GA, 2011, INVEST OPHTH VIS SCI, V52, P4039, DOI 10.1167/iovs.10-6798
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Nork TM, 2011, ARCH OPHTHALMOL-CHIC, V129, P1042, DOI 10.1001/archophthalmol.2011.210
   Regeneron Pharmaceuticals Inc, 2011, VEGF TRAP EYE AFL OP
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rudge JS, 2007, P NATL ACAD SCI USA, V104, P18363, DOI 10.1073/pnas.0708865104
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Singer M.A., 2012, OPHTHALMOLOGY
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2007, RETINA-J RET VIT DIS, V27, P1196, DOI 10.1097/IAE.0b013e318158ea28
   TERMAN BI, 1991, ONCOGENE, V6, P1677
   Thai HT, 2011, BRIT J CLIN PHARMACO, V72, P402, DOI 10.1111/j.1365-2125.2011.04015.x
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Ziemssen F, 2009, DRUG AGING, V26, P295, DOI 10.2165/00002512-200926040-00002
NR 46
TC 12
Z9 13
U1 0
U2 7
PU PROUS SCIENCE, SA-THOMSON REUTERS
PI BARCELONA
PA PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN
SN 1699-3993
J9 DRUG TODAY
JI Drugs Today
PD MAY
PY 2012
VL 48
IS 5
BP 317
EP 329
DI 10.1358/dot.2012.48.5.1805931
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 966WE
UT WOS:000305867300001
PM 22645720
DA 2022-11-30
ER

PT J
AU Heier, JS
AF Heier, Jeffrey S.
TI Neovascular Age-Related Macular Degeneration Individualizing Therapy in
   the Era of Anti-Angiogenic Treatments
SO OPHTHALMOLOGY
LA English
DT Article
AB The treatment of neovascular age-related macular degeneration (AMD) had been revolutionized by the use of anti-vascular endothelial growth factor (VEGF) drugs: bevacizumab and ranibizumab. With the introduction of a third anti-VEGF drug, aflibercept, ophthalmologists have several options to choose from, as well as various treatment regimens they can follow. In this Interview, Jeffrey S. Heier, MD, of Ophthalmic Consultants of Boston, Massachusetts, discusses his approaches to managing the treatment of patients with AMD and providing them with individualized care. (c) 2013 by the American Academy of Ophthalmology.
C1 [Heier, Jeffrey S.] Ophthalm Consultants Boston, Vitreoretinal Serv, Boston, MA 02114 USA.
C3 Ophthalmic Consultants of Boston
RP Heier, JS (通讯作者)，Ophthalm Consultants Boston, 50 Stanford St,Suite 600, Boston, MA 02114 USA.
EM jsheier@eyeboston.com
FU Alimera Sciences; Alcon Laboratories; Allergan, Inc.; Genentech, Inc.;
   Genzyme Corporation; GlaxoSmithKline; NeoVista, Inc.; Notal Vision;
   Novartis Pharmaceuticals Corporation; Ophthotech Corporation; Paloma
   Pharmaceuticals; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.;
   Regeneron Pharmaceuticals, Inc, Tarrytown, NY
FX Jeffrey S. Heier - Consultant - Acucela, Alcon Laboratories, Allergan,
   Inc., ForSight Labs, Fovea Pharmaceuticals, Genentech, Inc., Genzyme
   Corporation, GlaxoSmithKline, NeoVista, Inc., Notal Vision, Oraya
   Therapeutics, Paloma Pharmaceuticals, Pfizer, Inc., Regeneron
   Pharmaceuticals, Inc., and Sequenom, Inc.; Financial support - Alimera
   Sciences, Alcon Laboratories, Allergan, Inc., Genentech, Inc., Genzyme
   Corporation, GlaxoSmithKline, NeoVista, Inc., Notal Vision, Novartis
   Pharmaceuticals Corporation, Ophthotech Corporation, Paloma
   Pharmaceuticals, Pfizer, Inc., and Regeneron Pharmaceuticals, Inc.;
   Supported by an educational grant from Regeneron Pharmaceuticals, Inc,
   Tarrytown, NY.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
NR 6
TC 3
Z9 4
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2013
VL 120
IS 5
SU S
BP S23
EP S25
DI 10.1016/j.ophtha.2013.01.059
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 140UW
UT WOS:000318682500006
PM 23642783
DA 2022-11-30
ER

PT J
AU Markun, S
   Brandle, E
   Dishy, A
   Rosemann, T
   Frei, A
AF Markun, Stefan
   Braendle, Elisabeth
   Dishy, Avraham
   Rosemann, Thomas
   Frei, Anja
TI The Concordance of Care for Age Related Macular Degeneration with the
   Chronic Care Model: A Multi-Centered Cross-Sectional Study
SO PLOS ONE
LA English
DT Article
ID CHRONIC ILLNESS CARE; RANDOMIZED CONTROLLED-TRIAL; PATIENT ASSESSMENT;
   CASE-MANAGEMENT; HEALTH-CARE; DEPRESSION; QUESTIONNAIRE; PHQ-9;
   INSTRUMENT; VALIDITY
AB Aims: The aim of the study was to assess the concordance of care for age related macular degeneration with the evidence-based framework for care for chronic medical conditions known as the chronic care model. Furthermore we aimed to identify factors associated with the concordance of care with the chronic care model.
   Methods: Multi-centered cross-sectional study. 169 patients beginning medical treatment for age related macular degeneration were recruited and analyzed. Patients completed the Patient Assessment of Chronic Illness Care (PACIC) questionnaire, reflecting accordance to the chronic care model from a patient's perspective, the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) and Patient Health Questionnaire (PHQ-9). Visual acuity and chronic medical conditions were assessed. Nonparametric tests and correlation analyses were performed, also multivariable regression analysis.
   Results: The median PACIC summary score was 2.4 (interquartile range 1.75 to 3.25), the lowest PACIC subscale score was "follow-up/coordination" with a median of 1.8 (interquartile range 1.00 to 2.60). In multivariable regression analysis the presence of diabetes type 2 was strongly associated with low PACIC scores (coefficient = -0.85, p = 0.007).
   Conclusion: Generally, care for patients with age related macular degeneration by ophthalmologists is in moderate concordance with the chronic care model. Concerning follow-up and coordination of health service, large improvements are possible. Future research should answer the question how healthcare delivery can be improved effecting relevant benefits to patients with AMD.
C1 [Markun, Stefan; Braendle, Elisabeth; Rosemann, Thomas; Frei, Anja] Univ Zurich, Univ Zurich Hosp, Inst Gen Practice & Hlth Serv Res, Zurich, Switzerland.
   [Dishy, Avraham] Cantonal Hosp Aarau, Dept Ophthalmol, Aarau, Switzerland.
   [Frei, Anja] Univ Zurich, Inst Social & Prevent Med, CH-8006 Zurich, Switzerland.
C3 University of Zurich; University Zurich Hospital; Kantonsspital Aarau AG
   (KSA); University of Zurich
RP Markun, S (通讯作者)，Univ Zurich, Univ Zurich Hosp, Inst Gen Practice & Hlth Serv Res, Zurich, Switzerland.
EM stefan.markun@usz.ch
OI Markun, Stefan/0000-0003-3317-0957
FU non-commercial foundation "Zukunft Hausarzt, Zurcher Stiftung zur
   Forderung der Hausarztmedizin", Zurich
FX This trial was supported by the non-commercial foundation "Zukunft
   Hausarzt, Zurcher Stiftung zur Forderung der Hausarztmedizin", Zurich
   (www.zukunfthausarzt.ch). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Brand CS, 2012, EYE, V26, pS1, DOI 10.1038/eye.2012.32
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Chakravarthy U, 2013, EYE, V27, P1429, DOI 10.1038/eye.2013.233
   Epping-Jordan JE, 2004, QUAL SAF HEALTH CARE, V13, P299, DOI 10.1136/qshc.2004.010744
   Frei A, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-70
   Frei A, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-221
   Gensichen J, 2009, ANN INTERN MED, V151, P369, DOI 10.7326/0003-4819-151-6-200909150-00001
   Glasgow RE, 2005, MED CARE, V43, P436, DOI 10.1097/01.mlr.0000160375.47920.8c
   Gugiu C, 2010, J EVAL CLIN PRACT, V16, P509, DOI 10.1111/j.1365-2753.2009.01151.x
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Lamoureux EL, 2009, OPTOMETRY VISION SCI, V86, P139, DOI 10.1097/OPX.0b013e318194eb47
   Lochner KA, 2013, PREV CHRONIC DIS, V10, DOI 10.5888/pcd10.120137
   Lowe B, 2004, J AFFECT DISORDERS, V81, P61, DOI 10.1016/S0165-0327(03)00198-8
   Mangione C., 2000, NATL EYE I 25 ITEM V
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Randell RL, 2013, INFLAMM BOWEL DIS, V19, P1428, DOI 10.1097/MIB.0b013e3182813434
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Rosemann T, 2007, ARTHRIT RHEUM-ARTHR, V57, P1390, DOI 10.1002/art.23080
   Rosemann T, 2007, J EVAL CLIN PRACT, V13, P806, DOI 10.1111/j.1365-2753.2007.00786.x
   Schmittdiel J, 2008, J GEN INTERN MED, V23, P77, DOI 10.1007/s11606-007-0452-5
   Stellefson M, 2013, PREV CHRONIC DIS, V10, DOI 10.5888/pcd10.120180
   Thorpe KE, 2010, HEALTH AFFAIR, V29, P718, DOI 10.1377/hlthaff.2009.0474
   Tsai AC, 2005, AM J MANAG CARE, V11, P478
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Wagner E H, 1998, Eff Clin Pract, V1, P2
   Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64
NR 27
TC 3
Z9 3
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 7
PY 2014
VL 9
IS 10
AR e108536
DI 10.1371/journal.pone.0108536
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AQ4VK
UT WOS:000342798000019
PM 25290915
OA Green Published, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Bianchi, E
   Scarinci, F
   Ripandelli, G
   Feher, J
   Pacella, E
   Magliulo, G
   Gabrieli, CB
   Plateroti, R
   Plateroti, P
   Mignini, F
   Artico, M
AF Bianchi, Enrica
   Scarinci, Fabio
   Ripandelli, Guido
   Feher, Janos
   Pacella, Elena
   Magliulo, Giuseppe
   Gabrieli, Corrado Balacco
   Plateroti, Rocco
   Plateroti, Pasquale
   Mignini, Fiorenzo
   Artico, Marco
TI Retinal pigment epithelium, age-related macular degeneration and
   neurotrophic keratouveitis
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE retinal pigment epithelium; mitochondria; lipofuscin; peroxisomes;
   age-related macular degeneration; pigment epithelium-derived factor;
   light microscopy; electron microscopy; morphometry
ID ENDOTHELIAL GROWTH-FACTOR; ACTIVATED RECEPTORS ALPHA; FATTY-ACIDS;
   MITOCHONDRIAL DYSFUNCTION; PERMEABILITY TRANSITION; SUBSTANCE-P;
   NEUROGENIC INFLAMMATION; NEURONAL DEGENERATION; GENE-EXPRESSION;
   CELL-FUNCTION
AB Age-related macular degeneration (AMD) is the leading cause of impaired vision and blindness in the aging population. The aims of our studies were to identify qualitative and quantitative alterations in mitochondria in human retinal pigment epithelium (RPE) from AMD patients and controls and to test the protective effects of pigment epithelium-derived factor (PEDF), a known neurotrophic and antiangiogenic substance, against neurotrophic keratouveitis. Histopathological alterations were studied by means of morphometry, light and electron microscopy. Unexpectedly, morphometric data showed that the RPE alterations noted in A MD may also develop in normal aging, 10-15 years later than appearing in AMD patients. Reduced tear secretion, corneal ulceration and leukocytic infiltration were found in capsaicin (CAP)-treated rats, but this effect was significantly attenuated by PEDF. These findings suggest that PEDF accelerated the recovery of tear secretion and also prevented neurotrophic keratouveitis and vitreoretinal inflammation. PEDF may have a clinical application in inflammatory and neovascular diseases of the eye.
C1 [Bianchi, Enrica; Feher, Janos; Pacella, Elena; Magliulo, Giuseppe; Gabrieli, Corrado Balacco; Plateroti, Rocco; Plateroti, Pasquale; Artico, Marco] Univ Roma La Sapienza, Dept Sensory Organs, I-00161 Rome, Italy.
   [Scarinci, Fabio; Ripandelli, Guido] Bietti Eye Fdn IRCCS, Rome, Italy.
   [Mignini, Fiorenzo] Univ Camerino, Sch Drug & Hlth Prod Sci, I-62032 Camerino, Italy.
C3 Sapienza University Rome; IRCCS - Fondazione "G.B. Bietti" per lo Studio
   e la Ricerca in Oftalmologia; University of Camerino
RP Bianchi, E (通讯作者)，Univ Roma La Sapienza, Dept Sensory Organs, Viale Policlin 155, I-00161 Rome, Italy.
EM enrica.bianchi@uniroma1.it
RI Scarinci, Fabio/AAB-5126-2020
OI Bianchi, Enrica/0000-0002-8135-9730; Scarinci,
   Fabio/0000-0001-5444-4377; PACELLA, ELENA/0000-0002-5431-6399
CR Aloe L, 2008, PHARMACOL RES, V57, P253, DOI 10.1016/j.phrs.2008.01.010
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Andrews RM, 1999, BIOCHIM BIOPHYS ACTA, V83, P231
   [Anonymous], 2006, POL J ENV STUD
   Bagnoli P, 2003, HISTOL HISTOPATHOL, V18, P1219, DOI 10.14670/HH-18.1219
   BATTELLI D, 1992, BIOCHIM BIOPHYS ACTA, V1117, P33, DOI 10.1016/0304-4165(92)90158-Q
   Baudouin C, 2007, J FR OPHTALMOL, V30, P239, DOI 10.1016/S0181-5512(07)89584-2
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BEAUMONT K, 1988, BIOCHEM PHARMACOL, V37, P1009, DOI 10.1016/0006-2952(88)90502-3
   BECERRA SP, 1993, J BIOL CHEM, V268, P23148
   Ben-Shachar D, 2002, J NEUROCHEM, V83, P1241, DOI 10.1046/j.1471-4159.2002.01263.x
   Beuerman RW, 2005, OCUL SURF, V3, pS203
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6
   BRECHA NC, 1989, VISUAL NEUROSCI, V3, P527, DOI 10.1017/S095252380000986X
   Bronzetti E, 2007, EUR J HISTOCHEM, V51, P251
   Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x
   Campbell AM, 2002, BBA-BIOMEMBRANES, V1567, P123, DOI 10.1016/S0005-2736(02)00607-7
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   CARUSO DM, 1990, VISUAL NEUROSCI, V5, P389, DOI 10.1017/S095252380000047X
   Chung C, 2008, ADV EXP MED BIOL, V617, P591, DOI 10.1007/978-0-387-69080-3_61
   Crompton M, 2004, AGING CELL, V3, P3, DOI 10.1046/j.1474-9728.2003.00073.x
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   DENTON RM, 1975, MOL CELL BIOCHEM, V9, P27, DOI 10.1007/BF01731731
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Feher J, 2003, OPHTHALMOLOGICA, V217, P351, DOI 10.1159/000071351
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feher J, 2009, INVEST OPHTH VIS SCI, V50, P5173, DOI 10.1167/iovs.08-1852
   Feller J, 2002, ADV EXP MED BIOL, V506, P1047
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312
   Fox DA, 2003, EUR J OPHTHALMOL, V13, pS44
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   FUJITA S, 1984, EXP EYE RES, V38, P165, DOI 10.1016/0014-4835(84)90100-3
   Furuno T, 2001, BIOCHEM PHARMACOL, V62, P1037, DOI 10.1016/S0006-2952(01)00745-6
   Gabbita SP, 1998, BBA-BIOMEMBRANES, V1372, P163, DOI 10.1016/S0005-2736(98)00040-6
   GALLAR J, 1990, INVEST OPHTH VIS SCI, V31, P1968
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Gaspar MN, 2004, PHARMACOLOGY, V70, P152, DOI 10.1159/000074978
   Gosker HR, 2000, AM J CLIN NUTR, V71, P1033
   Gunthorpe MJ, 2008, CURR PHARM DESIGN, V14, P32
   Hansson M, 2003, BBA-MOL CELL RES, V1593, P283, DOI 10.1016/S0167-4889(02)00398-1
   Hettema EH, 2000, BBA-MOL CELL BIOL L, V1486, P18, DOI 10.1016/S1388-1981(00)00045-7
   Hirai K, 2001, DIABETES, V21, P3017
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   James AM, 2002, J BIOMED SCI, V9, P475, DOI 10.1159/000064721
   Jin GF, 2001, CURR EYE RES, V23, P11, DOI 10.1076/ceyr.23.1.11.5423
   Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242
   Katz ML, 1999, INVEST OPHTH VIS SCI, V40, P175
   KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000
   Khaibullina AA, 2004, DEV BRAIN RES, V148, P59, DOI 10.1016/j.devbrainres.2003.09.022
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318
   Kovacs I, 2005, NEUROPEPTIDES, V39, P395, DOI 10.1016/j.npep.2005.04.003
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Kuksa V, 2003, VISION RES, V43, P2959, DOI 10.1016/S0042-6989(03)00482-6
   Lazar J, 2004, LIFE SCI, V75, P153, DOI 10.1016/j.lfs.2003.11.023
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   May A, 1998, BRAIN, V121, P1231, DOI 10.1093/brain/121.7.1231
   McConnell V, 2005, Ulster Med J, V74, P82
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3
   Nowak J.Z., 2005, MAG OKUL, V2
   NOWAK JZ, 2005, MAG OKUL, V2, P103
   Nucci C, 2007, INVEST OPHTH VIS SCI, V48, P2997, DOI 10.1167/iovs.06-1355
   OGILVY CS, 1991, INVEST OPHTH VIS SCI, V32, P112
   Papadopoulos V., 2003, Annales Pharmaceutiques Francaises, V61, P30
   Paradies G, 1997, FEBS LETT, V406, P136, DOI 10.1016/S0014-5793(97)00264-0
   Pepe S, 2000, CLIN EXP PHARMACOL P, V27, P745, DOI 10.1046/j.1440-1681.2000.03326.x
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   RITTER S, 1990, J COMP NEUROL, V296, P447, DOI 10.1002/cne.902960310
   ROBISON WG, 1975, INVEST OPHTH VISUAL, V14, P866
   Rottenberg H, 1997, BIOCHEM BIOPH RES CO, V240, P68, DOI 10.1006/bbrc.1997.7605
   Schon EA, 2003, J CLIN INVEST, V111, P303, DOI 10.1172/JCI200317741
   Shaban H, 2002, EXP EYE RES, V75, P99, DOI 10.1006/exer.2001.1192
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Spranger J, 2001, DIABETES, V50, P2641, DOI 10.2337/diabetes.50.12.2641
   Sprecher H, 2000, BBA-MOL CELL BIOL L, V1486, P219, DOI 10.1016/S1388-1981(00)00077-9
   Stern ME, 2004, EXP EYE RES, V78, P409, DOI 10.1016/j.exer.2003.09.003
   Sugrue MM, 2001, BIOL SIGNAL RECEPT, V10, P176
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Szabo I, 2004, PFLUG ARCH EUR J PHY, V448, P304, DOI 10.1007/s00424-004-1259-4
   Szolcsanyi J, 2004, NEUROPEPTIDES, V38, P377, DOI 10.1016/j.npep.2004.07.005
   Toescu EC, 2000, CELL CALCIUM, V28, P329, DOI 10.1054/ceca.2000.0167
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   Troger J, 2007, BRAIN RES REV, V53, P39, DOI 10.1016/j.brainresrev.2006.06.002
   Tyni T, 2002, PEDIATR RES, V52, P595, DOI 10.1203/01.PDR.0000030874.20888.2D
   von Ruckmann A, 1998, KLIN MONATSBL AUGENH, V213, P32, DOI 10.1055/s-2008-1034940
   WALDREP JC, 1988, CURR EYE RES, V7, P1173, DOI 10.3109/02713688809033221
   Winkler BS, 1999, MOL VIS, V5
   Wolf G, 2003, NUTR REV, V61, P342, DOI 10.1301/nr.2003.oct.342-346
   Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637
   Zammit VA, 1998, LIPIDS, V33, P371, DOI 10.1007/s11745-998-0217-7
   Zingsheim H. P., 1976, METHODS MEMBRANE BIO, P1
NR 101
TC 26
Z9 26
U1 1
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JAN
PY 2013
VL 31
IS 1
BP 232
EP 242
DI 10.3892/ijmm.2012.1164
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 057MF
UT WOS:000312567000030
PM 23128960
OA Bronze
DA 2022-11-30
ER

PT J
AU Foss, A
   Rotsos, T
   Empeslidis, T
   Chong, VC
AF Foss, Alexander
   Rotsos, Tryfon
   Empeslidis, Theo
   Chong, Victor
TI Development of Macular Atrophy in Patients with Wet Age-Related Macular
   Degeneration Receiving Anti-VEGF Treatment
SO OPHTHALMOLOGICA
LA English
DT Review
DE Macular atrophy; Geographic atrophy; Age-related macular degeneration;
   Anti-vascular endothelial growth factors
ID RETINAL-PIGMENT EPITHELIUM; SUBFOVEAL CHOROIDAL THICKNESS; GROWTH-FACTOR
   THERAPY; INTRAVITREAL RANIBIZUMAB INJECTIONS; SUBRETINAL DRUSENOID
   DEPOSITS; GEOGRAPHIC ATROPHY; RISK-FACTORS; RETICULAR PSEUDODRUSEN;
   PROGRESSION; TUBULATION
AB Age-related macular degeneration (AMD) is a leading cause of blindness. Late AMD can be classified into exudative (commonly known as wet AMD [wAMD]) or dry AMD, both of which may progress to macular atrophy (MA). MA causes irreversible vision loss and currently has no approved pharmacological treatment. The standard of care for wAMD is treatment with anti-vascular endothelial growth factors (VEGFs). However, recent evidence suggests that anti-VEGF treatment may play a role in the development of MA. Therefore, it is important to identify risk factors for the development of MA in patients with wAMD. For example, excessive blockade of VEGF through intense use of anti-VEGF agents may accelerate the development of MA. Patients with type III macular neovascularization (retinal angiomatous proliferation) have a particularly high risk of MA. These patients are characterized as having a pre-existing thin choroid (age-related choroidopathy), suggesting that the choroidal circulation is unable to respond to increased VEGF expression. Evidence suggests that subretinal fluid (possibly indicative of residual VEGF activity) may play a protective role. Patients receiving anti-VEGF agents must be assessed for overall risk of MA, and there is an unmet medical need to prevent the development of MA without undertreating wAMD.
C1 [Foss, Alexander] Univ Nottingham, Queens Med Ctr, Med Sch, Nottingham, England.
   [Rotsos, Tryfon] Natl & Kapodistrian Univ Athens, Dept Ophthalmol, Athens, Greece.
   [Empeslidis, Theo; Chong, Victor] Boehringer Ingelheim Int GmbH, Ingelheim, Germany.
C3 University of Nottingham; National & Kapodistrian University of Athens;
   Boehringer Ingelheim
RP Foss, A (通讯作者)，Univ Nottingham, Queens Med Ctr, Med Sch, Nottingham, England.
EM alexander.foss@nottingham.ac.uk
OI Foss, Alexander/0000-0001-9649-0072
FU Boeh-ringer Ingelheim
FX Funding for medical writing support was provided by Boeh-ringer
   Ingelheim.
CR Abdelfattah NS, 2018, AM J OPHTHALMOL, V192, P84, DOI 10.1016/j.ajo.2018.05.008
   Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Baek J, 2016, INVEST OPHTH VIS SCI, V57, P1500, DOI 10.1167/iovs.15-18837
   Bailey C, 2019, OPHTHALMOLOGY, V126, P75, DOI 10.1016/j.ophtha.2018.07.013
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Biarnes M, 2020, OPHTHALMOL RETINA, V4, P1129, DOI 10.1016/j.oret.2020.04.014
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Campa C, 2010, EYE, V24, P1585, DOI 10.1038/eye.2010.88
   Chakravarthy U, 2020, OPHTHALMOL RETINA, V4, P662, DOI 10.1016/j.oret.2020.01.012
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Cheng SY, 2020, P NATL ACAD SCI USA, V117, P13094, DOI 10.1073/pnas.2000339117
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Christenbury JG, 2018, RETINA-J RET VIT DIS, V38, P1276, DOI 10.1097/IAE.0000000000001766
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Cui J, 2018, EYE, V32, P391, DOI 10.1038/eye.2017.187
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Damasceno NA, 2018, OSLI RETINA, V49, P870, DOI 10.3928/23258160-20181101-08
   Daniel E, 2020, JAMA OPHTHALMOL, V138, P510, DOI 10.1001/jamaophthalmol.2020.0437
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   De Bats Flore, 2013, ISRN Ophthalmol, V2013, P273085, DOI 10.1155/2013/273085
   Eng KT, 2006, CLIN INTERV AGING, V1, P451, DOI 10.2147/ciia.2006.1.4.451
   Enslow R, 2016, OPHTHALMOL EYE DIS, V8, P31, DOI 10.4137/OED.S38863
   Ersoz MG, 2017, SURV OPHTHALMOL, V62, P493, DOI 10.1016/j.survophthal.2017.03.004
   Eshtiaghi A., 2021, RETINA-J RET VIT DIS
   Faria-Correia F, 2013, OPHTHALMOLOGICA, V229, P147, DOI 10.1159/000346854
   Ferrara N, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.10
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fleckenstein M, 2016, INVEST OPHTH VIS SCI, V57, P2463, DOI 10.1167/iovs.15-18593
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Food and Drug Administration, 2005, DRUG APPR PACK KAL I
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Gale RP, 2019, EYE, V33, DOI 10.1038/s41433-018-0300-3
   Gattoussi S, 2019, RETINA-J RET VIT DIS, V39, P34, DOI 10.1097/IAE.0000000000002237
   Gelfand BD, 2015, CELL REP, V11, P1686, DOI 10.1016/j.celrep.2015.05.023
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Giachetti Filho Richard Geraldo, 2016, Int J Retina Vitreous, V2, P6, DOI 10.1186/s40942-016-0029-8
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Grob S, 2012, EYE, V26, P333, DOI 10.1038/eye.2011.278
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Horani M, 2020, OPHTHALMOL THER, V9, P35, DOI 10.1007/s40123-019-00227-8
   Horani M, 2019, OPHTHALMOL THER, V8, P235, DOI 10.1007/s40123-019-0177-7
   Hsu J, 2020, OPHTHALMOLOGY, V127, P1189, DOI 10.1016/j.ophtha.2020.03.034
   Ibbett P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43906-z
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kapoor KG, 2013, EYE, V27, P770, DOI 10.1038/eye.2013.52
   Karampelas M, 2020, OPHTHALMOL THER, V9, P739, DOI 10.1007/s40123-020-00291-5
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25557-8
   Kaynak S, 2018, TURK OFTALMOL DERG, V48, P81, DOI 10.4274/tjo.27448
   Keenan TDL., 2021, OPHTHALMOL RETINA
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Khanani AM, 2018, RETINA-J RET VIT DIS, V38, P2103, DOI 10.1097/IAE.0000000000002195
   Kim JH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72030-6
   Kim YH, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84650-7
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Lee J, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1108-z
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Llorente-Gonzalez S, 2022, ACTA OPHTHALMOL, V100, pE521, DOI 10.1111/aos.14905
   Loh A, 2009, BBA-GEN SUBJECTS, V1790, P637, DOI 10.1016/j.bbagen.2008.11.001
   Lujan BJ, 2015, RETINA-J RET VIT DIS, V35, P1511, DOI 10.1097/IAE.0000000000000527
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mantel I, 2019, RETINA-J RET VIT DIS, V39, P906, DOI 10.1097/IAE.0000000000002054
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitamura Y, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/518170
   Miura M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39688-z
   Mones J, 2017, OPHTHALMOL RETINA, V1, P461, DOI 10.1016/j.oret.2017.02.006
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Nebbioso M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071693
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nivison-Smith L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67829-2
   Patel HR, 2015, OSLI RETINA, V46, P8, DOI 10.3928/23258160-20150101-01
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Roizenblatt M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113688
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Ryoo NK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209276
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Schmitz-Valckenberg S., 2021, OPHTHALMOLOGICA, V244, P523
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Semba RD, 2019, LIPIDS HEALTH DIS, V18, DOI 10.1186/s12944-018-0954-7
   Shen LL, 2021, OPHTHALMOL RETINA, V5, P761, DOI 10.1016/j.oret.2020.11.003
   Siedlecki J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64901-9
   Singh RP, 2018, AM J OPHTHAL CLIN TR, V1, DOI 10.25259/AJOCT-2-2018
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Takagi S, 2017, CLIN OPHTHALMOL, V11, P1219, DOI 10.2147/OPTH.S134338
   Takahashi A, 2018, OPHTHALMOL RETINA, V2, P295, DOI 10.1016/j.oret.2017.08.016
   Thiele S, 2021, BRIT J OPHTHALMOL, V105, P239, DOI 10.1136/bjophthalmol-2020-316004
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tvenning AO, 2019, CLIN OPHTHALMOL, V13, P233, DOI 10.2147/OPTH.S188315
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Wang WQ, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2016.23
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Ying GS, 2011, OPHTHALMOLOGY, V118, P332, DOI 10.1016/j.ophtha.2010.06.030
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
   Zarubina AV, 2017, INVEST OPHTH VIS SCI, V58, P6038, DOI 10.1167/iovs.17-22378
   Zhang XY, 2021, EYE, V35, P121, DOI 10.1038/s41433-020-01265-4
   Zhao L, 2013, CURR MOL MED, V13, P929, DOI 10.2174/15665240113139990048
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 141
TC 3
Z9 3
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD JUN
PY 2022
VL 245
IS 3
BP 204
EP 217
DI 10.1159/000520171
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3E9GV
UT WOS:000830285800002
PM 34695835
OA hybrid
DA 2022-11-30
ER

PT J
AU Wang, HB
   Ramshekar, A
   Kunz, E
   Hartnett, ME
AF Wang, Haibo
   Ramshekar, Aniket
   Kunz, Eric
   Hartnett, M. Elizabeth
TI 7-ketocholesterol induces endothelial-mesenchymal transition and
   promotes fibrosis: implications in neovascular age-related macular
   degeneration and treatment
SO ANGIOGENESIS
LA English
DT Article
DE Age-related macular degeneration; 7-ketocholesterol; Choroidal
   endothelial cells; Endothelial-mesenchymal transition; Non-responsive
   (or unresponsive) neovascular AMD; Macular fibrosis
AB Oxidized cholesterols and lipids accumulate in Bruch's membrane in age-related macular degeneration (AMD). It remains unknown what causal relationship exists between these substances and AMD pathophysiology. We addressed the hypothesis that a prevalent form, 7-ketocholesterol (7KC), promotes choroidal endothelial cell (CEC) migration and macular neovascularization in AMD. Compared to control, 7KC injection caused 40% larger lectin-stained lesions, but 70% larger lesions measured by optical coherence tomography one week after laser-injury. At two weeks, 7KC-injected eyes had 86% larger alpha smooth muscle actin (alpha SMA)-labeled lesions and more collagen-labeling than control. There was no difference in cell death. 7KC-treated RPE/choroids had increased alpha SMA but decreased VE-cadherin. Compared to control-treated CECs, 7KC unexpectedly reduced endothelial VE-cadherin, CD31 and VEGFR2 and increased alpha SMA, fibroblast activation protein (FAP) and transforming growth factor beta (TGF beta). Inhibition of TGF beta receptor-mediated signaling by SB431542 abrogated 7KC-induced loss of endothelial and increase in mesenchymal proteins in association with decreased transcription factor, SMAD3. Knockdown of SMAD3 partially inhibited 7KC-mediated loss of endothelial proteins and increase in alpha SMA and FAP. Compared to control, 7KC-treatment of CECs increased Rac1GTP and migration, and both were inhibited by the Rac1 inhibitor; however, CECs treated with 7KC had reduced tube formation. These findings suggest that 7KC, which increases in AMD and with age, induces mesenchymal transition in CECs making them invasive and migratory, and causing fibrosis in macular neovascularization. Further studies to interfere with this process may reduce fibrosis and improve responsiveness to anti-VEGF treatment in non-responsive macular neovascularization in AMD.
C1 [Wang, Haibo; Ramshekar, Aniket; Kunz, Eric; Hartnett, M. Elizabeth] Univ Utah, John A Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah
RP Hartnett, ME (通讯作者)，Univ Utah, John A Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84112 USA.
EM ME.Hartnett@hsc.utah.edu
OI Hartnett, Mary Elizabeth/0000-0002-7270-5670
FU National Institutes of Health [EY014800, R01EY015130, R01EY017011];
   Research to Prevent Blindness, Inc., New York, NY
FX This work was supported by the National Institutes of Health EY014800
   and an Unrestricted Grant from Research to Prevent Blindness, Inc., New
   York, NY, to the Department of Ophthalmology & Visual Sciences,
   University of Utah; and the National Institutes of Health R01EY015130
   and R01EY017011 to M.E.H.
CR Alyaseer AAA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00883
   Anderson A, 2020, REDOX BIOL, V29, DOI 10.1016/j.redox.2019.101380
   Becker S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20278-4
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bischoff J, 2019, CIRC RES, V124, P1163, DOI 10.1161/CIRCRESAHA.119.314813
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Chakravarthy U, 2020, OPHTHALMOL RETINA, V4, P662, DOI 10.1016/j.oret.2020.01.012
   Cheung CMG, 2019, OPHTHALMOL RETINA, V3, P1045, DOI 10.1016/j.oret.2019.06.002
   Crabb JW, 2020, P NATL ACAD SCI
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Dugas B, 2010, EUR J NUTR, V49, P435, DOI 10.1007/s00394-010-0102-2
   Evans RN, 2020, JAMA OPHTHALMOL
   Fernandez-Godino R, 2018, ADV EXP MED BIOL, V1074, P29, DOI 10.1007/978-3-319-75402-4_4
   Fliesler SJ, 2015, J LIPID RES, V56, P1, DOI 10.1194/jlr.C056358
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gurzu S, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/2962580
   Inagaki S, 2020, CURR NEUROVASC RES
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   Li W, 2011, BIOCHEM BIOPH RES CO, V409, P711, DOI 10.1016/j.bbrc.2011.05.071
   Merle BMJ, 2016, AM J CLIN NUTR, V103, P1135, DOI 10.3945/ajcn.115.117606
   Monaghan-Benson E, 2009, J BIOL CHEM M109
   Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878
   Nowak-Sliwinska P, 2018, ANGIOGENESIS, V21, P425, DOI 10.1007/s10456-018-9613-x
   Peterson LJ, 2007, EXP EYE RES, V84, P737, DOI 10.1016/j.exer.2006.12.012
   Piera-Velazquez S, 2019, PHYSIOL REV, V99, P1281, DOI 10.1152/physrev.00021.2018
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Rodriguez IR, 2014, EXP EYE RES, V128, P151, DOI 10.1016/j.exer.2014.09.009
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rossato FA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092057
   Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Souilhol C, 2018, CARDIOVASC RES, V114, P565, DOI 10.1093/cvr/cvx253
   Syed V, 2016, J CELL BIOCHEM, V117, P1279, DOI 10.1002/jcb.25496
   Thulliez M, 2019, OPHTHALMOL RETINA, V3, P478, DOI 10.1016/j.oret.2019.01.024
   Vejux A, 2020, BIOCHEM PHARMACOL, V173, DOI 10.1016/j.bcp.2019.113648
   Wang HB, 2020, ANGIOGENESIS, V23, P685, DOI 10.1007/s10456-020-09740-y
   Wang HB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157748
   Wang HB, 2016, MOL VIS, V22, P189
   Wang HB, 2015, AM J PATHOL, V185, P3316, DOI 10.1016/j.ajpath.2015.08.017
   Wang HB, 2011, INVEST OPHTH VIS SCI, V52, P8271, DOI 10.1167/iovs.11-8230
   Wang H, 2011, INVEST OPHTH VIS SCI, V52, P570, DOI 10.1167/iovs.10-5595
NR 45
TC 2
Z9 2
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-6970
EI 1573-7209
J9 ANGIOGENESIS
JI Angiogenesis
PD AUG
PY 2021
VL 24
IS 3
BP 583
EP 595
DI 10.1007/s10456-021-09770-0
EA FEB 2021
PG 13
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA TL6NZ
UT WOS:000623733200001
PM 33646466
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lin, JB
   Sene, A
   Santeford, A
   Fujiwara, H
   Sidhu, R
   Ligon, MM
   Shankar, VA
   Ban, N
   Mysorekar, IU
   Ory, DS
   Apte, RS
AF Lin, Jonathan B.
   Sene, Abdoulaye
   Santeford, Andrea
   Fujiwara, Hideji
   Sidhu, Rohini
   Ligon, Marianne M.
   Shankar, Vikram A.
   Ban, Norimitsu
   Mysorekar, Indira U.
   Ory, Daniel S.
   Apte, Rajendra S.
TI Oxysterol Signatures Distinguish Age-Related Macular Degeneration from
   Physiologic Aging
SO EBIOMEDICINE
LA English
DT Article
DE Age-related macular degeneration; Aging; Lipids; Cholesterol
ID MACROPHAGE ACTIVATION; CHOLESTEROL EFFLUX; EXPRESSION; DISEASE; RISK;
   RANIBIZUMAB; AFLIBERCEPT; SENESCENCE; SEVERITY; ADULT
AB Macrophage aging is pathogenic in numerous diseases, including age-related macular degeneration (AMD), a leading cause of blindness in older adults. Although prior studies have explored the functional consequences of macrophage aging, less is known about its cellular basis or what defines the transition from physiologic aging to disease. Here, we showthat despite their frequent self-renewal, macrophages from old mice exhibited numerous signs of aging, such as impaired oxidative respiration. Transcriptomic profiling of aged murine macrophages revealed dysregulation of diverse cellular pathways, especially in cholesterol homeostasis, that manifested in altered oxysterol signatures. Although the levels of numerous oxysterols in human peripheral blood mononuclear cells and plasma exhibited age-associated changes, plasma 24-hydroxycholesterol levels were specifically associated with AMD. These novel findings demonstrate that oxysterol levels can discriminate disease from physiologic aging. Furthermore, modulation of cholesterol homeostasis may be a novel strategy for treating age-associated diseases in which macrophage aging is pathogenic. (C) 2018 The Authors. Published by Elsevier B.V.
C1 [Lin, Jonathan B.; Sene, Abdoulaye; Shankar, Vikram A.; Ban, Norimitsu; Apte, Rajendra S.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63130 USA.
   [Lin, Jonathan B.] Washington Univ, Sch Med, Div Biol & Biomed Sci, Neurosci Grad Program, St Louis, MO 63130 USA.
   [Fujiwara, Hideji; Sidhu, Rohini; Ory, Daniel S.; Apte, Rajendra S.] Washington Univ, Sch Med, Diabet Cardiovasc Dis Ctr, St Louis, MO 63130 USA.
   [Fujiwara, Hideji; Sidhu, Rohini; Ory, Daniel S.; Apte, Rajendra S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63130 USA.
   [Ligon, Marianne M.; Mysorekar, Indira U.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63130 USA.
   [Mysorekar, Indira U.] Washington Univ, Sch Med, Ctr Reprod Hlth Sci, Dept Obstet & Gynecol, St Louis, MO 63130 USA.
   [Apte, Rajendra S.] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63130 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL); Washington University (WUSTL); Washington University
   (WUSTL); Washington University (WUSTL); Washington University (WUSTL)
RP Apte, RS (通讯作者)，660 South Euclid Ave,Box 8096, St Louis, MO 63110 USA.
EM apte@vision.wustl.edu
RI Mysorekar, Indira U./GRS-4574-2022
OI Mysorekar, Indira U./0000-0003-3917-8677; Ligon,
   Marianne/0000-0001-6632-1163
FU NIH [P30 CA91842, UL1 TR000448]; NATIONAL CANCER INSTITUTE [P30CA091842]
   Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCES [UL1TR002345, UL1TR000448] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [P30EY002687] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
   [T32AI007172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, P30DK020579]
   Funding Source: NIH RePORTER
FX The authors thank the Genome Technology Access Center in the Department
   of Genetics at Washington University School of Medicine for help with
   genomic analysis (NIH Grants P30 CA91842 and UL1 TR000448). We also
   thank David Scherrer for technical assistance and Stephanie Schultz for
   helpful discussions.
CR Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Apte RS, 2016, EBIOMEDICINE, V5, P26, DOI 10.1016/j.ebiom.2016.02.003
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   Grunin M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29046
   Hagbi-Levi S, 2017, NEUROBIOL AGING, V51, P71, DOI 10.1016/j.neurobiolaging.2016.11.018
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Hashimoto D, 2013, IMMUNITY, V38, P792, DOI 10.1016/j.immuni.2013.04.004
   Huang SCC, 2014, NAT IMMUNOL, V15, P846, DOI 10.1038/ni.2956
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Inoue M, 2016, AM J OPHTHALMOL, V169, P95, DOI 10.1016/j.ajo.2016.06.021
   Jiang XT, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2326
   Jiang XT, 2011, J LIPID RES, V52, P1435, DOI 10.1194/jlr.D015735
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Kim JH, 2016, GRAEF ARCH CLIN EXP, V254, P2101, DOI 10.1007/s00417-016-3353-7
   Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475
   Lin JB, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120157
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nielsen GP, 1999, LAB INVEST, V79, P1137
   Poli G, 2013, REDOX BIOL, V1, P125, DOI 10.1016/j.redox.2012.12.001
   Porter FD, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001417
   Randle DH, 2001, P NATL ACAD SCI USA, V98, P9654, DOI 10.1073/pnas.171217498
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sarwar S, 2016, COCHRANE DB SYST REV, V2
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Sene A, 2014, TRENDS ENDOCRIN MET, V25, P107, DOI 10.1016/j.tem.2013.10.007
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Spann NJ, 2013, NAT IMMUNOL, V14, P893, DOI 10.1038/ni.2681
   Tavakoli S, 2013, J NUCL MED, V54, P1661, DOI 10.2967/jnumed.112.119099
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Umetani M, 2014, CELL METAB, V20, P172, DOI 10.1016/j.cmet.2014.05.013
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Vats D, 2006, CELL METAB, V4, P13, DOI 10.1016/j.cmet.2006.05.011
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
   Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178
   Zinkernagel MS, 2015, INVEST OPHTH VIS SCI, V56, P1894, DOI 10.1167/iovs.14-16204
NR 48
TC 12
Z9 12
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD JUN
PY 2018
VL 32
BP 9
EP 20
DI 10.1016/j.ebiom.2018.05.035
PG 12
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA GK6PU
UT WOS:000436312000006
PM 29903570
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Brown, GC
   Basha, MM
   Brown, MM
AF Brown, Gary C.
   Basha, Mahdi M.
   Brown, Melissa M.
TI Neovascular Age-Related Macular Degeneration Associated With No Light
   Perception
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
AB BACKGROUND AND OBJECTIVE: To study eyes with no light perception (NLP) occurring secondary to neovascular age-related macular degeneration (AMD).
   PATIENTS AND METHODS: Records of consecutive patients with neovascular AMD seen during a 10-year period were reviewed to ascertain which patients had NLP due to neovascular AMD.
   RESULTS: Ten of 1,150 patients (0.9%) with neovascular AMD had NLP in one eye (study eye) from neovascular AMD. All 10 patients had bilateral neovascular AMD. Each study eye had a large macular disciform scar and 360 degrees peripapillary subretinal fibrovascular tissue. Seven of nine (78%) study eyes had optic disc pallor, versus none of eight fellow eyes (P = .04). Mean fellow eye vision was 20/231, ranging from 20/50 to NLP (P = .006 vs study eyes). No seeing fellow eye had choroidal neovascularization encircling the optic disc (P = .0004).
   CONCLUSION: NLP from neovascular AMD is associated with 360 degrees peripapillary subretinal fibrosis. This fibrosis may cause chronic ischemic optic neuropathy contributing to extinguished vision.
C1 [Brown, Gary C.; Basha, Mahdi M.; Brown, Melissa M.] Ctr Value Based Med, Flourtown, PA USA.
   [Brown, Gary C.] Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Hosp, Retina Serv, Philadelphia, PA 19107 USA.
   [Brown, Gary C.; Brown, Melissa M.] Eye Res Inst, Philadelphia, PA USA.
   [Basha, Mahdi M.] Fraser Eye Care Ctr, New Orleans, LA USA.
   [Brown, Melissa M.] Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Hosp, Res Dept, Philadelphia, PA 19107 USA.
C3 Jefferson University; Jefferson University
RP Brown, GC (通讯作者)，Wills Eye Hosp & Res Inst, Ctr Value Based Med, Attending Surg, Box 335, Flourtown, PA 19031 USA.
EM brown@valuebasedmedicine.com
CR Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   BROWN GC, 1982, BRIT J OPHTHALMOL, V66, P77, DOI 10.1136/bjo.66.2.77
   BROWN GC, 1986, OPHTHALMOLOGY, V93, P1373
   Brown MM, 2008, CURR OPIN OPHTHALMOL, V19, P202, DOI 10.1097/ICU.0b013e3282fc9c35
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Medical Advisory Secretariat, 2009, Ont Health Technol Assess Ser, V9, P1
   Rath EZ, 2003, EYE, V17, P1019, DOI 10.1038/sj.eye.6700691
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
NR 13
TC 1
Z9 1
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD FEB
PY 2015
VL 46
IS 2
BP 229
EP 234
DI 10.3928/23258160-20150213-03
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA CG5TZ
UT WOS:000353360100011
PM 25707049
DA 2022-11-30
ER

PT J
AU Cachulo, L
   Silva, R
   Fonseca, P
   Pires, I
   Carvajal-Gonzalez, S
   Bernardes, R
   Cunha-Vaz, JG
AF Cachulo, Luz
   Silva, Rufino
   Fonseca, Pedro
   Pires, Isabel
   Carvajal-Gonzalez, Santos
   Bernardes, Rui
   Cunha-Vaz, Jose G.
TI Early Markers of Choroidal Neovascularization in the Fellow Eye of
   Patients with Unilateral Exudative Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Choroidal neovascularization; Exudative age-related macular
   degeneration; Age-related maculopathy
ID FUNDUS AUTOFLUORESCENCE; MACULOPATHY; RISK
AB Objective: To identify morphological and/or functional early markers of choroidal neovascularization (CNV) development in fellow eyes of patients with exudative age-related macular degeneration (AMD). Design: This is a single-center, prospective, observational, longitudinal 2-year study. Patients: Patients were enrolled with the diagnosis of neovascular AMD in 1 eye and early age-related maculopathy (ARM) in the fellow eye. Intervention or Methods: All patients completed the baseline assessment and were followed up for up to 24 months with repeated ophthalmic and imaging assessments performed at 6-month intervals. Main Outcome Measures: Each patient underwent a detailed ocular and medical history, a complete ophthalmologic examination with color fundus photography, fluorescein angiography, indocyanine green angiography (ICG), optical coherence tomography (OCT), fundus autofluorescence (FAF) imaging and retinal leakage analysis (RLA). Results: Sixty-two patients were enrolled in the study. Large or intermediate drusen were present in 100% of the study eyes and hyperpigmentation in 46% (24 eyes). Fifty-two patients completed the 2-year study follow-up. Large soft drusen (>125 mu m) were observed in 15 out of 17 eyes (88%) that converted and developed CNV during the study and in 25 out of 35 eyes (71.4%) that did not develop CNV. Among the 17 eyes that developed CNV, 9 (53%) showed abnormal findings before conversion, on ICG. No particular FAF pattern was found to be correlated with conversion to wet AMD. OCT was able to document the presence of intra- or subretinal fluid at the time of conversion in all 17 eyes that developed CNV during the study. Alterations of the blood-retinal barrier were identified by RLA before conversion in 76% of the eyes that converted and 23% of the eyes that did not convert during the study. Conclusions: Characterization of early ARM phenotypes is challenging. By combining different imaging modalities of the macula and correlating this information, we were able to determine the presence of functional macular alterations in the fellow eye of patients with this disease before development of CNV. Copyright (C) 20105. Karger AG, Basel
C1 [Cachulo, Luz; Silva, Rufino; Fonseca, Pedro; Pires, Isabel; Bernardes, Rui; Cunha-Vaz, Jose G.] AIBILI Assoc Innovat & Biomed Res Light & Image, PT-3000548 Coimbra, Portugal.
   [Cachulo, Luz; Silva, Rufino; Fonseca, Pedro; Pires, Isabel] Coimbra Univ Hosp, Dept Ophthalmol, Coimbra, Portugal.
   [Carvajal-Gonzalez, Santos] Pfizer Inc, New York, NY USA.
C3 Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e
   Universitario de Coimbra (CHUC); Pfizer
RP Cachulo, L (通讯作者)，AIBILI Assoc Innovat & Biomed Res Light & Image, PT-3000548 Coimbra, Portugal.
EM mluzcachulo@interacesso.pt
RI Silva, Rufino M/J-2817-2012; Bernardes, Rui/M-4231-2013
OI Silva, Rufino M/0000-0001-8676-0833; Bernardes, Rui/0000-0002-6677-2754;
   Pires, Isabel/0000-0002-5764-0178; Cunha-Vaz, Jose/0000-0002-0947-9850
CR [Anonymous], 1998, Ophthalmology, V105, P1364
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   GUYER DR, 1986, OPHTHALMOLOGY, V101, P727
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MERIN S, 1987, INVEST OPHTH VIS SCI, V28, P756
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Silva RM, 2007, GRAEF ARCH CLIN EXP, V245, P1131, DOI 10.1007/s00417-006-0532-y
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   2007, ARCH OPHTHALMOL, V125, P1323
NR 24
TC 27
Z9 27
U1 0
U2 10
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2011
VL 225
IS 3
BP 144
EP 149
DI 10.1159/000321064
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 739CU
UT WOS:000288691000003
PM 21071996
DA 2022-11-30
ER

PT J
AU Kanda, A
   Stambolian, D
   Chen, W
   Curcio, CA
   Abecasis, GR
   Swaroop, A
AF Kanda, Atsuhiro
   Stambolian, Dwight
   Chen, Wei
   Curcio, Christine A.
   Abecasis, Goncalo R.
   Swaroop, Anand
TI Age-related macular degeneration-associated variants at chromosome 10q26
   do not significantly alter ARMS2 and HTRA1 transcript levels in the
   human retina
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENE-EXPRESSION; SUSCEPTIBILITY; RISK;
   POLYMORPHISM; DISEASE; CFH; MACULOPATHY; MECHANISMS; LOC387715
AB Purpose: Multiple studies demonstrate a strong association between three variants at chromosome 10q26 - rs10490924, del443ins54, and rs11200638 - near the age-related maculopathy susceptibility 2 (ARMS2) and high-temperature requirement factor A1 (HTRA1) genes with susceptibility to age-related macular degeneration (AMD). In different reports, the del443ins54 and rs11200638 variants are suggested to affect ARMS2 mRNA stability and/or HTRA1 mRNA expression, respectively. The goal of this study is to examine whether these AMD-associated variants alter expression levels of ARMS2 and HTRA1 in human retina samples.
   Methods: Genomic DNA and total RNA were obtained from 35 human retinas (three young controls, average age=32 years; twenty aged controls, average age=72 years; and twelve AMD retinas, average age=77 years) using standard procedures. As ARMS2 exhibits higher expression in the human placenta, we also included eighteen placenta samples in our analysis. Four polymorphisms - rs2736911, rs10490924, del443ins54, and rs11200638 - were genotyped by PCR followed by sequencing. Expression of ARMS2, HTRA1 and three endogenous control genes (rRNA [rRNA], hypoxanthine phosphoribosyltransferase 1 [HPRT1], and glyceraldehyde-3-phosphate dehydrogenase [GAPDH]) was measured by real-time quantitative RT-PCR using Taqman gene expression or SYBR Green assays.
   Results: ARMS2 and HTRA1 mRNA levels did not show a significant difference in expression among the control (young and elderly) and AMD retinas. No association of del443ins54 and rs11200638 variants was detected with mRNA expression levels of ARMS2 or HTRA1 in the retina. Human placenta samples showed high variability in expression levels.
   Conclusions: We did not find association between AMD susceptibility variants at 10q26 and steady-state expression levels of either ARMS2 or HTRA1 in the human retina.
C1 [Kanda, Atsuhiro; Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Stambolian, Dwight] Univ Penn, Dept Ophthalmol & Human Genet, Philadelphia, PA 19104 USA.
   [Chen, Wei; Abecasis, Goncalo R.] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Pennsylvania; University of Michigan System;
   University of Michigan; University of Alabama System; University of
   Alabama Birmingham
RP Swaroop, A (通讯作者)，NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bldg 6-338,MSC0610,6 Ctr Dr, Bethesda, MD 20892 USA.
EM swaroopa@nei.nih.gov
RI Abecasis, Goncalo R/B-7840-2010; Chen, Wei/AAX-5994-2020
OI Chen, Wei/0000-0001-7196-8703; Swaroop, Anand/0000-0002-1975-1141;
   Abecasis, Goncalo/0000-0003-1509-1825
FU National Eye Institute; Foundation Fighting Blindness; Research to
   Prevent Blindness; International Retinal Research Foundation; NATIONAL
   EYE INSTITUTE [ZIAEY000475] Funding Source: NIH RePORTER
FX We thank Matthew Brooks, Tiziana Cogliati and members of the Swaroop
   laboratory for advice and comments. This work was supported by
   intramural funds and grants from the National Eye Institute, The
   Foundation Fighting Blindness, and Research to Prevent Blindness. Also,
   this work was supported from International Retinal Research Foundation
   (C.C.).
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheung VG, 2005, NATURE, V437, P1365, DOI 10.1038/nature04244
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Pastinen T, 2006, HUM MOL GENET, V15, pR9, DOI 10.1093/hmg/ddl044
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sambrook JF., 2001, MOL CLONING LAB MANU
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434
   Stranger BE, 2005, PLOS GENET, V1, P695, DOI 10.1371/journal.pgen.0010078
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wray GA, 2003, INT J DEV BIOL, V47, P675
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 35
TC 44
Z9 45
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 15
PY 2010
VL 16
IS 145-50
BP 1317
EP 1323
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 643GN
UT WOS:000281283700001
PM 20664794
DA 2022-11-30
ER

PT J
AU Nagai, N
   Kawashima, H
   Toda, E
   Homma, K
   Osada, H
   Guzman, NA
   Shibata, S
   Uchiyama, Y
   Okano, H
   Tsubota, K
   Ozawa, Y
AF Nagai, Norihiro
   Kawashima, Hirohiko
   Toda, Eriko
   Homma, Kohei
   Osada, Hideto
   Guzman, Naymel A.
   Shibata, Shinsuke
   Uchiyama, Yasuo
   Okano, Hideyuki
   Tsubota, Kazuo
   Ozawa, Yoko
TI Renin-angiotensin system impairs macrophage lipid metabolism to promote
   age-related macular degeneration in mouse models
SO COMMUNICATIONS BIOLOGY
LA English
DT Article
ID II TYPE-1 RECEPTOR; RETINAL-PIGMENT EPITHELIUM; ACTIVATED
   PROTEIN-KINASE; BETA MESSENGER-RNA; NLRP3 INFLAMMASOME; CHOROIDAL
   NEOVASCULARIZATION; CHOLESTEROL EFFLUX; MURINE MODEL;
   CARDIOVASCULAR-DISEASE; BASAL DEPOSITS
AB Metabolic syndrome, a condition involving obesity and hypertension, increases the risk of aging-associated diseases such as age-related macular degeneration (AMD). Here, we demonstrated that high-fat diet (HFD)-fed mice accumulated oxidized low-density lipoprotein (ox-LDL) in macrophages through the renin-angiotensin system (RAS). The ox-LDL-loaded macrophages were responsible for visual impairment in HFD mice along with a disorder of the retinal pigment epithelium (RPE), which is required for photoreceptor outer segment renewal. RAS repressed ELAVL1, which reduced PPAR gamma, impeding ABCA1 induction to levels that are sufficient to excrete overloaded cholesterol within the macrophages. The ox-LDL-loaded macrophages expressed inflammatory cytokines and attacked the RPE. An antihypertensive drug, angiotensin II type 1 receptor (AT1R) blocker, resolved the decompensation of lipid metabolism in the macrophages and reversed the RPE condition and visual function in HFD mice. AT1R signaling could be a future therapeutic target for macrophage-associated aging diseases, such as AMD. Nagai et al. show that mice fed high-fat diet (HFD) accumulate oxidized low-density lipoprotein in macrophages through the renin-angiotensin system, which impairs visual function. They find that angiotensin II type 1 receptor (AT1R) improves the visual function of HFD mice, suggesting AT1R signaling as a potential therapeutic target for age-related macular degeneration.
C1 [Nagai, Norihiro; Kawashima, Hirohiko; Toda, Eriko; Homma, Kohei; Osada, Hideto; Guzman, Naymel A.; Ozawa, Yoko] Keio Univ, Dept Ophthalmol, Lab Retinal Cell Biol, Sch Med,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
   [Nagai, Norihiro; Kawashima, Hirohiko; Guzman, Naymel A.; Tsubota, Kazuo; Ozawa, Yoko] Keio Univ, Dept Ophthalmol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
   [Shibata, Shinsuke; Okano, Hideyuki] Keio Univ, Dept Physiol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
   [Uchiyama, Yasuo] Juntendo Univ, Dept Cellular & Mol Neuropathol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan.
   [Ozawa, Yoko] St Lukes Int Hosp, Dept Ophthalmol, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan.
   [Ozawa, Yoko] St Lukes Int Hosp, 9-1 Akashi Cho, Tokyo 1048560, Japan.
C3 Keio University; Keio University; Keio University; Juntendo University;
   St. Luke's International Hospital; St. Luke's International Hospital
RP Ozawa, Y (通讯作者)，Keio Univ, Dept Ophthalmol, Lab Retinal Cell Biol, Sch Med,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.; Ozawa, Y (通讯作者)，Keio Univ, Dept Ophthalmol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.; Ozawa, Y (通讯作者)，St Lukes Int Hosp, Dept Ophthalmol, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan.; Ozawa, Y (通讯作者)，St Lukes Int Hosp, 9-1 Akashi Cho, Tokyo 1048560, Japan.
EM ozawa@a5.keio.jp
RI Homma, Kohei/AAF-6716-2021; Tsubota, Kazuo/M-1915-2013
OI Homma, Kohei/0000-0002-6253-8047; Osada, Hideto/0000-0001-9971-8992;
   Tsubota, Kazuo/0000-0002-8874-7111
FU Novartis Pharma K.K.; Japan Society of the Promotion of Science
FX We thank the members of the Laboratory of Retinal Cell Biology for their
   kind assistance. The study was partially supported by a grant from
   Novartis Pharma K.K. to Y.O. and a Grants-in-Aid for Scientific Research
   from Japan Society of the Promotion of Science to Y.O. and N.N.
CR Adamus G, 2017, AUTOIMMUN REV, V16, P231, DOI 10.1016/j.autrev.2017.01.005
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Apte RS, 2010, ADV EXP MED BIOL, V664, P15, DOI 10.1007/978-1-4419-1399-9_2
   Babu SS, 2015, TRENDS CARDIOVAS MED, V25, P676, DOI 10.1016/j.tcm.2015.02.006
   Ban N, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120824
   Bhuiyan MA, 2009, J PHARMACOL SCI, V111, P227, DOI 10.1254/jphs.09202FP
   Bieghs V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034378
   Burnier M, 2000, LANCET, V355, P637, DOI 10.1016/S0140-6736(99)10365-9
   Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cherry J, 2008, J BIOL CHEM, V283, P30812, DOI 10.1074/jbc.M805659200
   Coughlin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23794
   CRISCIONE L, 1993, BRIT J PHARMACOL, V110, P761, DOI 10.1111/j.1476-5381.1993.tb13877.x
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD182, DOI 10.1167/iovs.18-24883
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   de Kloet AD, 2010, PHYSIOL BEHAV, V100, P525, DOI 10.1016/j.physbeh.2010.03.018
   De Mello WC, 2012, J AM SOC HYPERTENS, V6, P369, DOI 10.1016/j.jash.2012.08.006
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Dithmar S, 2000, ARCH OPHTHALMOL-CHIC, V118, P1085, DOI 10.1001/archopht.118.8.1085
   ELNER SG, 1991, LAB INVEST, V64, P819
   Engin AB, 2017, ADV EXP MED BIOL, V960, pV, DOI [10.1007/978-3-319-48382-5, 10.1007/978-3-319-48382-5_1]
   Erbe DV, 2006, VASC PHARMACOL, V45, P154, DOI 10.1016/j.vph.2006.05.002
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   GANTEN D, 1971, SCIENCE, V173, P64, DOI 10.1126/science.173.3991.64
   Gantt K, 2005, J BIOL CHEM, V280, P24768, DOI 10.1074/jbc.M502011200
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Habiba U, 2018, EXP CELL RES, V369, P218, DOI 10.1016/j.yexcr.2018.05.021
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Hasegawa E, 2013, J IMMUNOL, V190, P1778, DOI 10.4049/jimmunol.1202495
   Helmer O M, 1965, Prog Cardiovasc Dis, V8, P117, DOI 10.1016/S0033-0620(65)80003-2
   Hirasawa M, 2016, J BIOL CHEM, V291, P7373, DOI 10.1074/jbc.M115.710186
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Horio E, 2014, ARTERIOSCL THROM VAS, V34, P790, DOI 10.1161/ATVBAHA.113.303116
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Izumi-Nagai K, 2008, INVEST OPHTH VIS SCI, V49, P1679, DOI 10.1167/iovs.07-1426
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Kamoshita M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30226
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Koike M, 2005, AM J PATHOL, V167, P1713, DOI 10.1016/S0002-9440(10)61253-9
   Koike M, 2000, J NEUROSCI, V20, P6898, DOI 10.1523/JNEUROSCI.20-18-06898.2000
   Kubota S, 2011, INVEST OPHTH VIS SCI, V52, P9142, DOI 10.1167/iovs.11-8041
   Kurihara T, 2008, DIABETES, V57, P2191, DOI 10.2337/db07-1281
   Kurihara T, 2006, INVEST OPHTH VIS SCI, V47, P5545, DOI 10.1167/iovs.06-0478
   Lenis TL, 2018, P NATL ACAD SCI USA, V115, pE11120, DOI 10.1073/pnas.1802519115
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Mao XY, 2017, ARCH MED RES, V48, P370, DOI 10.1016/j.arcmed.2017.08.002
   Garcia PJM, 2014, WORLD J CARDIOL, V6, P968, DOI 10.4330/wjc.v6.i9.968
   Matsuo Y, 2019, BIOCHEM BIOPH RES CO, V514, P791, DOI 10.1016/j.bbrc.2019.05.015
   Matsushima Y, 2001, J Atheroscler Thromb, V8, P71
   McGeough MD, 2017, J CLIN INVEST, V127, P4488, DOI 10.1172/JCI90699
   Michel MC, 2013, PHARMACOL REV, V65, P809, DOI 10.1124/pr.112.007278
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Miura SI, 2008, MOL ENDOCRINOL, V22, P139, DOI 10.1210/me.2007-0312
   Montgomery MK, 2013, DIABETOLOGIA, V56, P1129, DOI 10.1007/s00125-013-2846-8
   Moore KJ, 2011, CELL, V145, P341, DOI 10.1016/j.cell.2011.04.005
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P2321, DOI 10.1167/iovs.06-1296
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Nagai N, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051347
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Nagai N, 2014, J NUTR BIOCHEM, V25, P1218, DOI 10.1016/j.jnutbio.2014.05.015
   Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298
   Narimatsu T, 2014, FREE RADICAL BIO MED, V71, P176, DOI 10.1016/j.freeradbiomed.2014.03.020
   Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Nehme A, 2019, J CARDIOVASC DEV DIS, V6, DOI 10.3390/jcdd6020014
   Notomi S, 2019, P NATL ACAD SCI USA, V116, P23724, DOI 10.1073/pnas.1906643116
   Ojima M, 2011, J PHARMACOL EXP THER, V336, P801, DOI 10.1124/jpet.110.176636
   Ozawa Y, 2019, MOL NEUROBIOL, V56, P8124, DOI 10.1007/s12035-019-01661-2
   Perona JS, 2017, BBA-BIOMEMBRANES, V1859, P1690, DOI 10.1016/j.bbamem.2017.04.015
   Pfeffer SR, 2019, J BIOL CHEM, V294, P1706, DOI 10.1074/jbc.TM118.004165
   Sasaki M, 2010, DIABETOLOGIA, V53, P971, DOI 10.1007/s00125-009-1655-6
   Schuler R, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004465
   Seko Y, 2006, AUTOIMMUN REV, V5, P299, DOI 10.1016/j.autrev.2005.10.013
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Sodhi RK, 2014, PHARMACOL BIOCHEM BE, V120, P117, DOI 10.1016/j.pbb.2014.02.016
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Srikantan S, 2012, FRONT BIOSCI-LANDMRK, V17, P189, DOI 10.2741/3921
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Suzuki M, 2016, AM J OPHTHALMOL, V166, P52, DOI 10.1016/j.ajo.2016.03.024
   Takezako T, 2017, PHARMACOL RES, V123, P40, DOI 10.1016/j.phrs.2017.06.013
   Tall AR, 2008, CELL METAB, V7, P365, DOI 10.1016/j.cmet.2008.03.001
   Tan LX, 2016, P NATL ACAD SCI USA, V113, P8789, DOI 10.1073/pnas.1523061113
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Trpkovic A, 2015, CRIT REV CL LAB SCI, V52, P70, DOI 10.3109/10408363.2014.992063
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001
   Wu MX, 2019, CURR CANCER DRUG TAR, V19, P382, DOI 10.2174/1568009618666181031145953
   Xi HK, 2016, J EXP MED, V213, P189, DOI 10.1084/jem.20150894
   Xu XY, 2017, AM J OPHTHALMOL, V175, P87, DOI 10.1016/j.ajo.2016.11.021
   Yamagishi S, 2007, INT J CARDIOL, V118, P270, DOI 10.1016/j.ijcard.2006.06.058
   Yamazaki Y, 2019, NAT REV NEUROL, V15, P501, DOI 10.1038/s41582-019-0228-7
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zou YZ, 2004, NAT CELL BIOL, V6, P499, DOI 10.1038/ncb1137
NR 113
TC 8
Z9 8
U1 0
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2399-3642
J9 COMMUN BIOL
JI Commun. Biol.
PD DEC 9
PY 2020
VL 3
IS 1
AR 767
DI 10.1038/s42003-020-01483-2
PG 15
WC Biology; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Science & Technology - Other
   Topics
GA PH0TN
UT WOS:000600136500001
PM 33299105
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mato-Gondelle, T
   Bande, MF
   Paniagua, L
   Rodriguez-Cid, MJ
   Abraldes, M
   Fernandez, M
   Blanco-Teijeiro, MJ
   Pineiro, A
AF Mato-Gondelle, Tamara
   Bande, Manuel F.
   Paniagua, Laura
   Rodriguez-Cid, Maria J.
   Abraldes, Maximino
   Fernandez, Maribel
   Blanco-Teijeiro, Maria J.
   Pineiro, Antonio
TI ULTRASONOGRAPHIC FINDINGS IN THE VITREOUS OF PATIENTS WITH AGE-RELATED
   MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL
   GROWTH FACTOR INJECTIONS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF injection; ultrasonography
ID VITREOMACULAR ADHESION; DETACHMENT; RANIBIZUMAB; RISK
AB Purpose: We aimed to assess the relationship of repeated intravitreal injection of anti-vascular endothelial growth factor, the main treatment for exudative age-related macular degeneration, with changes in vitreous ultrasonographic findings in patients with age-related macular degeneration.
   Methods: We retrospectively collected data from 41 patients (41 age-related macular degeneration eyes, 41 control eyes) on age, sex, number of injections, and type of anti-vascular endothelial growth factor (ranibizumab, aflibercept). Ocular ultrasonography was performed with open eyelids, under topical anesthesia, and using carbomers as ultrasonographic gel. Topographic, quantitative, and kinetic ultrasonography was performed in all eye quadrants using a 10-MHz posterior pole probe, and vitreous reflectivity was assessed.
   Results: The mean age of patients was 79 (range: 59294) years, with a mean of five intravitreal anti-vascular endothelial growth factor injections (range: 1213). No significant ultrasonographic differences were found relative to the incidence of partial or complete posterior vitreous detachment. Vitreous hyperechogenicity increased in the treated eye (P < 0.001), and the vitreous reflectivity range increased with the number of injections (P = 0.041, R-2 = 0.214). However, the type of anti-vascular endothelial growth factor used and the time elapsed since the last intravitreal injection was not significant (P > 0.05).
   Conclusion: These preliminary results indicate a proportional increase in ultrasonographic reflectivity of vitreous gel with the number of injections.
C1 [Mato-Gondelle, Tamara; Bande, Manuel F.; Paniagua, Laura; Rodriguez-Cid, Maria J.; Abraldes, Maximino; Fernandez, Maribel; Blanco-Teijeiro, Maria J.; Pineiro, Antonio] Univ Hosp Santiago de Compostela, Dept Ophthalmol, Santiago De Compostela, Spain.
C3 Complexo Hospitalario Universitario de Santiago de Compostela
RP Bande, MF (通讯作者)，Complexo Hosp Univ Santiago de Compostela, Dept Ophthalmol, Santiago De Compostela 15706, Spain.
EM verman017@hotmail.com
CR Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Chong V, 2012, OPHTHALMOLOGICA, V227, P2, DOI 10.1159/000337152
   Fong AHC, 2013, CLIN INTERV AGING, V8, P467, DOI 10.2147/CIA.S36811
   FOOS RY, 1982, OPHTHALMOLOGY, V89, P1502
   Gawecki Maciej, 2010, Klin Oczna, V112, P210
   Geck U, 2013, GRAEF ARCH CLIN EXP, V251, P1691, DOI 10.1007/s00417-013-2266-y
   Johnson MW, 2010, AM J OPHTHALMOL, V149, P371, DOI 10.1016/j.ajo.2009.11.022
   Le Goff MM, 2008, EYE, V22, P1214, DOI 10.1038/eye.2008.21
   Carrero JL, 2012, AM J OPHTHALMOL, V153, P497, DOI 10.1016/j.ajo.2011.08.036
   Maggio E, 2017, OPHTHALMOLOGY, V124, P657, DOI 10.1016/j.ophtha.2017.01.018
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Schmidt JC, 2008, AM J OPHTHALMOL, V145, P1107, DOI 10.1016/j.ajo.2008.03.011
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Tomlinson A, 2015, MOL PHARMACEUT, V12, P3805, DOI 10.1021/acs.molpharmaceut.5b00311
   Toprak I, 2014, EYE, V28, P1126, DOI 10.1038/eye.2014.147
   Uney GO, 2014, RETINA-J RET VIT DIS, V34, P32, DOI 10.1097/IAE.0b013e318295f72e
   Veloso CE, 2015, OPHTHALMOLOGY, V122, P1569, DOI 10.1016/j.ophtha.2015.04.028
   Yamaguchi T, 2007, GRAEF ARCH CLIN EXP, V245, P305, DOI 10.1007/s00417-005-0236-8
   Yonemoto J, 1996, Curr Opin Ophthalmol, V7, P73, DOI 10.1097/00055735-199606000-00012
NR 20
TC 1
Z9 1
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2018
VL 38
IS 10
BP 1962
EP 1967
DI 10.1097/IAE.0000000000001819
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VS
UT WOS:000454005600018
PM 28820850
DA 2022-11-30
ER

PT J
AU Lazzeri, S
   Orlandi, P
   Piaggi, P
   Sartini, MS
   Casini, G
   Guidi, G
   Figus, M
   Fioravanti, A
   Di Desidero, T
   Ripandelli, G
   Parravano, M
   Varano, M
   Nardi, M
   Bocci, G
AF Lazzeri, Stefano
   Orlandi, Paola
   Piaggi, Paolo
   Sartini, Maria Sole
   Casini, Giamberto
   Guidi, Gianluca
   Figus, Michele
   Fioravanti, Anna
   Di Desidero, Teresa
   Ripandelli, Guido
   Parravano, Mariacristina
   Varano, Monica
   Nardi, Marco
   Bocci, Guido
TI IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to
   intravitreal ranibizumab in exudative age-related macular degeneration
SO PHARMACOGENOMICS
LA English
DT Article
DE age-related macular degeneration; IL-8; pharmacogenetics; ranibizumab;
   SNPs; VEGF-2
ID ENDOTHELIAL GROWTH-FACTOR; INTERLEUKIN-8 GENE-EXPRESSION; BEVACIZUMAB;
   THERAPY; ASSOCIATION; INDUCTION; RISK; PHARMACOGENETICS; SUSCEPTIBILITY;
   CANCER
AB Aim: To investigate possible associations between VEGFR-2 and IL-8 gene SNPs and 1-year response to intravitreal ranibizumab for exudative age-related macular degeneration. Materials & methods: Sixty-four eyes underwent a loading phase of three monthly intravitreal injections of ranibizumab 0.5 mg/0.05 ml followed by Pro Re Nata retreatment. VEGFR-2 rs2071559 (-604 A/G) and IL-8 rs4073 (-251 A/T) were analyzed. Results: Ranibizumab was significantly more effective as measured by visual acuity in patients harboring the IL-8 rs4073 TT genotype (p = 0.045), whereas patients carrying the VEGFR-2 rs2071559 CC genotype revealed better functional response as measured by mean retinal sensitivity (p = 0.034). Conclusion: IL-8 rs4073 and VEGFR-2 rs2071559 genotypes may represent important molecular determinants to modulate final outcomes in neovascular age-related macular degeneration patients.
C1 [Lazzeri, Stefano; Sartini, Maria Sole; Casini, Giamberto; Guidi, Gianluca; Figus, Michele; Nardi, Marco] Univ Pisa, Ophthalmol Unit, Pisa, Italy.
   [Lazzeri, Stefano; Ripandelli, Guido; Parravano, Mariacristina; Varano, Monica] IRCCS Rome, Fdn GB Bietti, Rome, Italy.
   [Orlandi, Paola; Fioravanti, Anna; Di Desidero, Teresa; Bocci, Guido] Univ Pisa, Div Pharmacol, Dept Clin & Expt Med, Pisa, Italy.
   [Piaggi, Paolo] Univ Pisa, Dept Endocrinol & Metab, Pisa, Italy.
   [Piaggi, Paolo] Univ Pisa, Dept Energy & Syst Engn, Pisa, Italy.
C3 University of Pisa; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia; University of Pisa; University of Pisa;
   University of Pisa
RP Bocci, G (通讯作者)，Univ Pisa, Div Pharmacol, Dept Clin & Expt Med, Pisa, Italy.
EM guido.bocci@med.unipi.it
RI Bocci, Guido/AAC-7515-2022; Figus, Michele/AAA-9808-2019; Figus,
   Michele/AAD-6850-2020; Piaggi, Paolo/E-2539-2011
OI Figus, Michele/0000-0003-2243-9033; Piaggi, Paolo/0000-0003-2774-9161;
   Varano, Monica/0000-0002-6530-1563; Di Desidero,
   Teresa/0000-0002-5487-071X
FU Ministry of Health; Fondazione Roma
FX The research for this paper was financially supported by the Ministry of
   Health and Fondazione Roma. The authors have no other relevant
   affiliations or financial involvement with any organization or entity
   with a financial interest in or financial conflict with the subject
   matter or materials discussed in the manuscript apart from those
   disclosed.
CR Agosta E, 2012, PHARMACOGENOMICS, V13, P1037, DOI [10.2217/PGS.12.77, 10.2217/pgs.12.77]
   Baird PN, 2009, CLIN EXP OPHTHALMOL, V37, P814, DOI 10.1111/j.1442-9071.2009.02136.x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang W, 2013, MOL VIS, V19, P702
   Cruz-Gonzalez F, 2014, GRAEF ARCH CLIN EXP, V252, P469, DOI 10.1007/s00417-014-2585-7
   Cruz-Gonzalez F, 2013, CURR EYE RES, V38, P1274, DOI 10.3109/02713683.2013.819926
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   DEFORGE LE, 1993, J BIOL CHEM, V268, P25568
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Excoffier L, 2005, EVOL BIOINFORM, V1, P47, DOI 10.1177/117693430500100003
   Fonollosa A, 2010, EYE, V24, P1284, DOI 10.1038/eye.2009.340
   Funk M, 2010, RETINA-J RET VIT DIS, V30, P1412, DOI 10.1097/IAE.0b013e3181e095c0
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hautamaki A, 2014, OPHTHALMOLOGY, V121, P973, DOI 10.1016/j.ophtha.2013.11.035
   Hautamaki A, 2013, RETINA-J RET VIT DIS, V33, P1815, DOI 10.1097/IAE.0b013e318285cf92
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Hildebrand F, 2007, CYTOKINE, V37, P192, DOI 10.1016/j.cyto.2007.03.008
   Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52
   Lazzeri S, 2013, CLIN EXPT OPHTHALMOL, V4, P4
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P1239, DOI 10.2217/pgs.13.100
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   Lazzeri S, 2012, SCI WORLD J, DOI 10.1100/2012/420190
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Martin D, 2009, J BIOL CHEM, V284, P6038, DOI 10.1074/jbc.C800207200
   Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294
   Ohyauchi M, 2005, GUT, V54, P330, DOI 10.1136/gut.2003.033050
   Pasqualetti G, 2007, PHARMACOGENOMICS, V8, P49, DOI 10.2217/14622416.8.1.49
   Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236
   Petreaca ML, 2007, MOL BIOL CELL, V18, P5014, DOI 10.1091/mbc.E07-01-0004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scholl HPN, 2007, MOL VIS, V13, P196
   Schwartz SG, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/252549
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Sohn HJ, 2011, AM J OPHTHALMOL, V152, P686, DOI 10.1016/j.ajo.2011.03.033
   Taguchi A, 2005, CANCER EPIDEM BIOMAR, V14, P2487, DOI 10.1158/1055-9965.EPI-05-0326
   Talavera D, 2004, J GEN VIROL, V85, P1801, DOI 10.1099/vir.0.19652-0
   Vairaktaris E, 2007, EJSO-EUR J SURG ONC, V33, P504, DOI 10.1016/j.ejso.2006.11.002
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Wang VM, 2012, MOL VIS, V18, P2578
   Wang Y, 2007, J AM COLL CARDIOL, V50, P760, DOI 10.1016/j.jacc.2007.04.074
   Wang Y, 2010, EXP EYE RES, V91, P135, DOI 10.1016/j.exer.2010.02.008
   Wang ZX, 2010, CYTOKINE, V50, P268, DOI 10.1016/j.cyto.2010.02.007
NR 47
TC 15
Z9 18
U1 0
U2 4
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1462-2416
EI 1744-8042
J9 PHARMACOGENOMICS
JI Pharmacogenomics
PY 2016
VL 17
IS 1
BP 27
EP 35
DI 10.2217/pgs.15.153
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CZ6DS
UT WOS:000367192000004
PM 26653034
DA 2022-11-30
ER

PT J
AU Garcia-Onrubia, L
   Valentin-Bravo, FJ
   Coco-Martin, RM
   Gonzalez-Sarmiento, R
   Pastor, JC
   Usategui-Martin, R
   Pastor-Idoate, S
AF Garcia-Onrubia, Luis
   Javier Valentin-Bravo, Fco
   Coco-Martin, Rosa M.
   Gonzalez-Sarmiento, Rogelio
   Carlos Pastor, J.
   Usategui-Martin, Ricardo
   Pastor-Idoate, Salvador
TI Matrix Metalloproteinases in Age-Related Macular Degeneration (AMD)
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; extracellular matrix; Bruch's
   membrane; matrix metalloproteinases; tissue inhibitors of
   metalloproteinases; MMPs polymorphisms
ID RETINAL-PIGMENT EPITHELIUM; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   DOXYCYCLINE-MEDIATED INHIBITION; ANGIOTENSIN-CONVERTING ENZYME;
   ENDOTHELIAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; SORSBYS FUNDUS
   DYSTROPHY; NONLETHAL OXIDANT INJURY; EXTRACELLULAR-MATRIX; BRUCHS
   MEMBRANE
AB Age-related macular degeneration (AMD) is a complex, multifactorial and progressive retinal disease affecting millions of people worldwide. In developed countries, it is the leading cause of vision loss and legal blindness among the elderly. Although the pathogenesis of AMD is still barely understood, recent studies have reported that disorders in the regulation of the extracellular matrix (ECM) play an important role in its etiopathogenesis. The dynamic metabolism of the ECM is closely regulated by matrix metalloproteinases (MMPs) and the tissue inhibitors of metalloproteinases (TIMPs). The present review focuses on the crucial processes that occur at the level of the Bruch's membrane, with special emphasis on MMPs, TIMPs, and the polymorphisms associated with increased susceptibility to AMD development. A systematic literature search was performed, covering the years 1990-2020, using the following keywords: AMD, extracellular matrix, Bruch's membrane, MMPs, TIMPs, and MMPs polymorphisms in AMD. In both early and advanced AMD, the pathological dynamic changes of ECM structural components are caused by the dysfunction of specific regulators and by the influence of other regulatory systems connected with both genetic and environmental factors. Better insight into the pathological role of MMP/TIMP complexes may lead to the development of new strategies for AMD treatment and prevention.
C1 [Garcia-Onrubia, Luis; Javier Valentin-Bravo, Fco; Carlos Pastor, J.; Pastor-Idoate, Salvador] Clin Univ Hosp Valladolid, Av Ramon y Cajal 3, Valladolid 47003, Spain.
   [Coco-Martin, Rosa M.; Carlos Pastor, J.; Usategui-Martin, Ricardo; Pastor-Idoate, Salvador] Univ Valladolid, Inst Appl Ophthalmobiol IOBA, Valladolid 47011, Spain.
   [Coco-Martin, Rosa M.; Carlos Pastor, J.; Pastor-Idoate, Salvador] ISCIII, Natl Inst Hlth Carlos III, Cooperat Hlth Network Res Ophthalmol Oftared, Madrid 28040, Spain.
   [Gonzalez-Sarmiento, Rogelio] Inst Biomed Res Salamanca IBSAL, Salamanca 37007, Spain.
   [Gonzalez-Sarmiento, Rogelio] Univ Salamanca, Inst Mol & Cellular Biol Canc IBMCC, CSIC, Salamanca 37007, Spain.
C3 Universidad de Valladolid; Instituto de Salud Carlos III; University of
   Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC);
   CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de
   Salamanca (IBMCC); University of Salamanca
RP Pastor-Idoate, S (通讯作者)，Clin Univ Hosp Valladolid, Av Ramon y Cajal 3, Valladolid 47003, Spain.; Usategui-Martin, R; Pastor-Idoate, S (通讯作者)，Univ Valladolid, Inst Appl Ophthalmobiol IOBA, Valladolid 47011, Spain.; Pastor-Idoate, S (通讯作者)，ISCIII, Natl Inst Hlth Carlos III, Cooperat Hlth Network Res Ophthalmol Oftared, Madrid 28040, Spain.
EM luisonrubia91@gmail.com; franciscojavier.valentin@gmail.com;
   rosa@ioba.med.uva.es; gonzalez@usal.es; pastor@ioba.med.uva.es;
   rusateguim@ioba.med.uva.es; spastori@ioba.med.uva.es
RI Jimeno, J Carlos Pastor/AAP-1156-2020; Martin, Rosa Maria
   Coco/H-4511-2015; PASTOR-IDOATE, SALVADOR/G-2548-2016
OI Jimeno, J Carlos Pastor/0000-0001-5934-7306; Martin, Rosa Maria
   Coco/0000-0002-1811-1417; Valentin-Bravo, Francisco
   Javier/0000-0002-2062-3243; PASTOR-IDOATE, SALVADOR/0000-0002-6463-4227;
   Usategui-Martin, Ricardo/0000-0001-7699-4388; Gonzalez-Sarmiento,
   Rogelio/0000-0002-2726-6795; Garcia-Onrubia, Luis/0000-0003-3563-2369
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Abu El-Asrar AM, 2018, MOL VIS, V24, P394
   Abu El-Asrar AM, 2018, ACTA OPHTHALMOL, V96, pE27, DOI 10.1111/aos.13451
   Abu El-Asrar AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085857
   Adnane L, 2006, METHOD ENZYMOL, V407, P597, DOI 10.1016/S0076-6879(05)07047-3
   Ahir A, 2002, INVEST OPHTH VIS SCI, V43, P458
   Akagi-Kurashige Y, 2015, OPHTHALMOLOGY, V122, P2295, DOI 10.1016/j.ophtha.2015.07.032
   Akahane T, 2004, EXP CELL RES, V301, P158, DOI 10.1016/j.yexcr.2004.08.002
   Alcazar O, 2007, INVEST OPHTH VIS SCI, V48, P5662, DOI 10.1167/iovs.07-0392
   Alcazar O, 2009, EXP EYE RES, V89, P638, DOI 10.1016/j.exer.2009.06.014
   Alge-Priglinger CS, 2009, INVEST OPHTH VIS SCI, V50, P5495, DOI 10.1167/iovs.08-3193
   Alp E, 2017, KAOHSIUNG J MED SCI, V33, P78, DOI 10.1016/j.kjms.2016.12.002
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Ardeljan D, 2013, EUR J HUM GENET, V21, P1152, DOI 10.1038/ejhg.2013.14
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Austin BA, 2009, INVEST OPHTH VIS SCI, V50, P2896, DOI 10.1167/iovs.08-2495
   Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Beeghly-Fadiel A, 2009, CANCER EPIDEM BIOMAR, V18, P1770, DOI 10.1158/1055-9965.EPI-09-0125
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Bevitt DJ, 2003, BBA-GENE STRUCT EXPR, V1626, P83, DOI 10.1016/S0167-4781(03)00047-2
   Bian F, 2016, J CELL PHYSIOL, V231, P2506, DOI 10.1002/jcp.25364
   Bola C, 2014, GRAEF ARCH CLIN EXP, V252, P699, DOI 10.1007/s00417-014-2604-8
   Briggs ELA, 2015, MOL VIS, V21, P1162
   Budiene B, 2018, OPHTHALMIC GENET, V39, P463, DOI 10.1080/13816810.2018.1484928
   BURNS FR, 1989, INVEST OPHTH VIS SCI, V30, P1569
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   CAWSTON TE, 1986, FEBS LETT, V209, P9, DOI 10.1016/0014-5793(86)81074-2
   CHAKRAVARTHY U, 2010, BMJ-BRIT MED J, V340, DOI DOI 10.1136/BMJ.C981
   Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)02122-5
   Chang JH, 2016, SURV OPHTHALMOL, V61, P478, DOI 10.1016/j.survophthal.2015.11.006
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen QS, 2013, MEDIAT INFLAMM, V2013, DOI [10.1155/2013/928315, 10.1155/2013/434010]
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   Cheng J, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008190
   Cheng Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177337
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   Cox CA, 2010, OPHTHALMOLOGY, V117, P1782, DOI 10.1016/j.ophtha.2010.01.037
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cui N, 2017, PROG MOL BIOL TRANSL, V147, P1, DOI 10.1016/bs.pmbts.2017.02.005
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Damasceno RW, 2011, ORBIT, V30, P132, DOI 10.3109/01676830.2011.569049
   Das A, 1999, ARCH OPHTHALMOL-CHIC, V117, P498
   De Groef L, 2013, INVEST OPHTH VIS SCI, V54, P7756, DOI 10.1167/iovs.13-13088
   de Jong EK, 2020, GENETICS AND GENOMICS OF EYE DISEASE: ADVANCING TO PRECISION MEDICINE, P155, DOI 10.1016/B978-0-12-816222-4.00010-1
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   DeLeon-Pennell KY, 2017, PROG MOL BIOL TRANSL, V147, P75, DOI 10.1016/bs.pmbts.2017.02.001
   Descamps FJ, 2006, EXP EYE RES, V83, P401, DOI 10.1016/j.exer.2006.01.017
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dewing JM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010039
   Ecker SM, 2012, MOL VIS, V18, P1658
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Eichler W, 2002, INVEST OPHTH VIS SCI, V43, P2767
   El Bradey M, 2004, J OCUL PHARMACOL TH, V20, P217, DOI 10.1089/1080768041223657
   Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.0.CO;2-J
   Elliot S, 2006, INVEST OPHTH VIS SCI, V47, P1696, DOI 10.1167/iovs.05-1258
   Elner SG, 2003, EXP EYE RES, V76, P585, DOI 10.1016/S0014-4835(03)00028-9
   English JL, 2006, J BIOL CHEM, V281, P10337, DOI 10.1074/jbc.M512009200
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Fernandez-Godino R, 2018, HUM MOL GENET, V27, P147, DOI 10.1093/hmg/ddx392
   Fiotti N, 2005, GENET MED, V7, P272, DOI 10.1097/01.GIM.0000159903.69597.73
   Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af
   Fraunfelder FT, 2018, J OCUL PHARMACOL TH, V34, P432, DOI 10.1089/jop.2018.0019
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Garcia CR, 2002, CURR EYE RES, V24, P33, DOI 10.1076/ceyr.24.1.33.5429
   Garcia RA, 2005, MOL PHARMACOL, V67, P1128, DOI 10.1124/mol.104.006346
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOLUB LM, 1995, J CLIN PERIODONTOL, V22, P100
   Gourier HCY, 2015, J CLIN MED, V4, P874, DOI 10.3390/jcm4050874
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hammer T, 2001, ARCH OPHTHALMOL-CHIC, V119, P1023, DOI 10.1001/archopht.119.7.1023
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   He M, 2017, OPHTHALMIC GENET, V38, P211, DOI 10.1080/13816810.2016.1193877
   Herman MP, 2001, J CLIN INVEST, V107, P1117, DOI 10.1172/JCI10403
   Herzlich Alexandra A, 2009, Open Biol J, V2, P141
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   Hoffmann S, 2006, RETINA-J RET VIT DIS, V26, P454, DOI 10.1097/00006982-200604000-00012
   Hollborn M, 2007, INVEST OPHTH VIS SCI, V48, P4360, DOI 10.1167/iovs.06-1234
   HOSODA Y, 1993, OPHTHALMIC RES, V25, P289, DOI 10.1159/000267327
   Hu DN, 2018, EXP EYE RES, V175, P181, DOI 10.1016/j.exer.2018.06.023
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Hussain Ali Aijaz, 2017, J Neurodegener Dis, V2017, P4810232, DOI 10.1155/2017/4810232
   Inoue K, 2012, CLIN CANCER RES, V18, P3924, DOI 10.1158/1078-0432.CCR-11-2041
   Itoh Y, 2017, PROG MOL BIOL TRANSL, V148, P327, DOI 10.1016/bs.pmbts.2017.03.002
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   JONES SE, 1994, FEBS LETT, V352, P171, DOI 10.1016/0014-5793(94)00951-1
   Joussen AM, 2019, BRIT J CLIN PHARMACO, V85, P347, DOI 10.1111/bcp.13794
   Kadonosono K, 1999, AM J OPHTHALMOL, V128, P382, DOI 10.1016/S0002-9394(99)00135-X
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kaur I, 2010, P NATL ACAD SCI USA, V107, pE112, DOI 10.1073/pnas.1007476107
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim B, 2014, INVEST OPHTH VIS SCI, V55, P2031, DOI 10.1167/iovs.13-13374
   Kim D, 2017, EXP THER MED, V13, P1415, DOI 10.3892/etm.2017.4110
   Kim YH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169675
   Kohri T, 2003, GRAEF ARCH CLIN EXP, V241, P943, DOI 10.1007/s00417-003-0761-2
   Kon CH, 1998, INVEST OPHTH VIS SCI, V39, P1524
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kwon JW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159720
   Kyosseva SV, 2016, OPHTHALMOL EYE DIS, V8, P23, DOI 10.4137/OED.S32200
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Lecomte J, 2011, CELL MOL LIFE SCI, V68, P677, DOI 10.1007/s00018-010-0476-6
   Lee H, 2019, YONSEI MED J, V60, P679, DOI 10.3349/ymj.2019.60.7.679
   Leu ST, 2002, EXP EYE RES, V74, P141, DOI 10.1006/exer.2001.1112
   Li DQ, 2001, ARCH OPHTHALMOL-CHIC, V119, P71
   Liu JH, 2010, J OCUL PHARMACOL TH, V26, P421, DOI 10.1089/jop.2010.0063
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Liutkeviciene R., 2017, ROLE MATRIX METALLOP
   Liutkeviciene R, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/9602949
   Liutkeviciene R, 2018, INDIAN J OPHTHALMOL, V66, P551, DOI 10.4103/ijo.IJO_1050_17
   Liutkeviciene R, 2017, INT J OPHTHALMOL-CHI, V10, P1349, DOI 10.18240/ijo.2017.09.03
   Liutkeviciene R, 2016, OPHTHALMIC GENET, V37, P170, DOI 10.3109/13816810.2015.1020556
   Liutkeviciene R, 2015, OPHTHALMIC GENET, V36, P149, DOI 10.3109/13816810.2013.838274
   Liutkeviciene R, 2012, MEDICINA-LITHUANIA, V48, P404, DOI 10.3390/medicina48080060
   Liva F, 2019, CURR DRUG TARGETS, V20, P903, DOI 10.2174/1389450120666190122114857
   Long H, 2011, INT J OPHTHALMOL-CHI, V4, P489, DOI 10.3980/j.issn.2222-3959.2011.05.06
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Luo Y, 2021, BRIT J OPHTHALMOL, V105, P1029, DOI 10.1136/bjophthalmol-2019-315358
   Mansoor Naima, 2019, Curr Mol Med, V19, P705, DOI 10.2174/1566524019666190828150625
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   Marin-Castano ME, 2003, INVEST OPHTH VIS SCI, V44, P50, DOI 10.1167/iovs.01-1276
   Matsumura T, 2015, INVEST OPHTH VIS SCI, V56, P3559, DOI 10.1167/iovs.15-16489
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mikoajczyk-Stecyna J, 2015, J VASC SURG, V61, P1114, DOI 10.1016/j.jvs.2013.12.045
   Mirshahi Ahmad, 2017, Med Hypothesis Discov Innov Ophthalmol, V6, P23
   Mohammad Ghulam, 2012, J Ocul Biol Dis Infor, V5, P1, DOI 10.1007/s12177-012-9091-0
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Mulholland B, 2005, EYE, V19, P584, DOI 10.1038/sj.eye.6701557
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murphy G, 2008, NAT REV CANCER, V8, P929, DOI 10.1038/nrc2459
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P2321, DOI 10.1167/iovs.06-1296
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Nagai N, 2014, J NUTR BIOCHEM, V25, P1218, DOI 10.1016/j.jnutbio.2014.05.015
   Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Nielsen MK, 2019, ACTA OPHTHALMOL, V97, P84, DOI 10.1111/aos.13894
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Noda K, 2003, INVEST OPHTH VIS SCI, V44, P2163, DOI 10.1167/iovs.02-0662
   Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Ong BB, 2016, BRIT J HOSP MED, V77, pC18, DOI 10.12968/hmed.2016.77.2.C18
   Ortak H, 2013, OPHTHALMIC GENET, V34, P217, DOI 10.3109/13816810.2013.781192
   Oszajca K, 2018, OPHTHALMIC GENET, V39, P684, DOI 10.1080/13816810.2018.1525752
   Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   Pan H, 2017, INT J CLIN EXP PATHO, V10, P7325
   Parry DA, 2009, AM J HUM GENET, V84, P683, DOI 10.1016/j.ajhg.2009.04.005
   Pasquale TR, 2005, EXPERT OPIN PHARMACO, V6, P1681, DOI 10.1517/14656566.6.10.1681
   Patel HR, 2015, OSLI RETINA, V46, P8, DOI 10.3928/23258160-20150101-01
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   Polina ER, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27857-5
   Pons M, 2011, AM J PATHOL, V178, P2665, DOI 10.1016/j.ajpath.2011.02.006
   Price SJ, 2001, J BIOL CHEM, V276, P7549, DOI 10.1074/jbc.M010242200
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Ra HJ, 2007, MATRIX BIOL, V26, P587, DOI 10.1016/j.matbio.2007.07.001
   Richer S, 2014, NUTRIENTS, V6, P4404, DOI 10.3390/nu6104404
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Ritch R, 2001, SURV OPHTHALMOL, V45, P265, DOI 10.1016/S0039-6257(00)00196-X
   Rivera S, 2019, CELL MOL LIFE SCI, V76, P3167, DOI 10.1007/s00018-019-03178-2
   Sahay P, 2017, INVEST OPHTH VIS SCI, V58, pBIO106, DOI 10.1167/iovs.17-21723
   Samtani S, 2009, INVEST OPHTH VIS SCI, V50, P5098, DOI 10.1167/iovs.08-3174
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SchlotzerSchrehardt U, 1997, INVEST OPHTH VIS SCI, V38, P970
   Sebag J, 2000, EUR J OPHTHALMOL, V10, P1
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seitzman RL, 2008, AM J EPIDEMIOL, V167, P1217, DOI 10.1093/aje/kwn024
   Sethi CS, 2000, BRIT J OPHTHALMOL, V84, P654, DOI 10.1136/bjo.84.6.654
   Shen GL, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2415867
   Shin JA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167102
   Sivak JM, 2002, PROG RETIN EYE RES, V21, P1, DOI 10.1016/S1350-9462(01)00015-5
   Sivaprasad S, 2005, INVEST OPHTH VIS SCI, V46, P3046, DOI 10.1167/iovs.04-1277
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Smith VA, 2006, BBA-MOL BASIS DIS, V1762, P431, DOI 10.1016/j.bbadis.2006.01.010
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Striker GE, 2008, AM J PHYSIOL-CELL PH, V295, pC1633, DOI 10.1152/ajpcell.00092.2008
   Su WR, 2013, INVEST OPHTH VIS SCI, V54, P783, DOI 10.1167/iovs.12-10323
   Swendeman S, 2008, CIRC RES, V103, P916, DOI 10.1161/CIRCRESAHA.108.184416
   Symeonidis C., 2006, ARCH CLIN EXP OPHTHA, V245, P560, DOI [10.1007/S00417-006-0386-3, DOI 10.1007/S00417-006-0386-3]
   Symeonidis C, 2011, CYTOKINE, V54, P212, DOI 10.1016/j.cyto.2011.02.001
   Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221
   Tang NP, 2009, ANN EPIDEMIOL, V19, P740, DOI 10.1016/j.annepidem.2009.03.002
   Thomas AS, 2015, RETINA-J RET VIT DIS, V35, P1964, DOI 10.1097/IAE.0000000000000603
   Toni M, 2013, DIABETOLOGIA, V56, P2743, DOI 10.1007/s00125-013-3052-4
   Tranah GJ, 2008, CALCIFIED TISSUE INT, V83, P155, DOI 10.1007/s00223-008-9165-y
   Usategui-Martin R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213624
   Vaisanen A, 1999, J PATHOL, V188, P56
   Van Hove I, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111825
   Vandenbroucke RE, 2014, NAT REV DRUG DISCOV, V13, P904, DOI 10.1038/nrd4390
   Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   Vranka JA, 2015, EXP EYE RES, V133, P112, DOI 10.1016/j.exer.2014.07.014
   Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   Webb AH, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3418-y
   Webster L, 1999, EXP EYE RES, V68, P91, DOI 10.1006/exer.1998.0585
   Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu MY, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0442-2
   Xu J, 2012, ANGIOGENESIS, V15, P213, DOI 10.1007/s10456-012-9254-4
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Yeow KM, 2002, MATRIX BIOL, V21, P75, DOI 10.1016/S0945-053X(01)00180-9
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zeng RP, 2013, MOL VIS, V19, P729
   Zeng RP, 2012, OPHTHALMIC GENET, V33, P139, DOI 10.3109/13816810.2011.643440
   Zhang JJ, 2012, INVEST OPHTH VIS SCI, V53, P2928, DOI 10.1167/iovs.11-8585
   Zhang YQ, 2016, OPHTHALMIC RES, V55, P172, DOI 10.1159/000443627
   Zhou Lin, 2010, Yan Ke Xue Bao, V25, P62
   Zhu JY, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1975-3
NR 236
TC 16
Z9 16
U1 3
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2020
VL 21
IS 16
AR 5934
DI 10.3390/ijms21165934
PG 32
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA NI1BP
UT WOS:000565093600001
PM 32824762
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Tabernero, J
   Qureshi, MA
   Robbie, SJ
   Artal, P
AF Tabernero, Juan
   Qureshi, Muhammad A.
   Robbie, Scott J.
   Artal, Pablo
TI An aspheric intraocular telescope for age-related macular degeneration
   patients
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID RETINAL IMAGE; LENS SYSTEM; REHABILITATION; MAGNIFICATION; IMPLANTATION
AB We have designed an intraocular telescope for the posterior chamber of the human eye of patients with age related macular degeneration. The basic design is composed of two decentered high optical power lenses (+66D and -66D) inducing a 3 degrees prismatic effect to project a magnified central field of view into a healthier location off the central fovea. Aspheric surfaces were used to ensure a compromise between good optical quality and high tolerance to the final axial position of both lenses after surgery. With this particular design, the telescope affords an extended range of depth of focus, high tolerance to different axial lengths of the eye and robustness against typical values of astigmatism and higher order aberrations. The final design has been manufactured in a foldable material and is compact enough to facilitate surgical implantation. This telescope is a simple but promising intraocular visual aid for AMD patients. (C)2015 Optical Society of America
C1 [Tabernero, Juan; Artal, Pablo] Univ Murcia, Lab Opt, E-30100 Murcia, Spain.
   [Qureshi, Muhammad A.; Robbie, Scott J.] London Eye Hosp Pharma, London, England.
C3 University of Murcia
RP Tabernero, J (通讯作者)，Univ Murcia, Lab Opt, Campus Espinardo Edificio 34, E-30100 Murcia, Spain.
EM pablo@um.es
RI Artal, Pablo/AGV-7547-2022; Tabernero, Juan/D-1120-2014; Artal,
   Pablo/AAG-4485-2020; Tabernero, Juan/AAO-9855-2020
OI Artal, Pablo/0000-0003-1284-6591; Tabernero, Juan/0000-0002-5149-8350;
   Artal, Pablo/0000-0003-1284-6591; 
FU London Eye Hospital Pharma (UK); SEIDI, Spain [FIS2013-41237-R]
FX This research has been supported by London Eye Hospital Pharma (UK) and
   SEIDI, Spain, grant FIS2013-41237-R.
CR Agarwal A, 2008, J CATARACT REFR SURG, V34, P87, DOI 10.1016/j.jcrs.2007.08.031
   Amselem L, 2008, J CATARACT REFR SURG, V34, P1571, DOI 10.1016/j.jcrs.2008.05.032
   Bailey I L, 1987, CLAO J, V13, P217
   Dallos J, 1936, ARCH OPHTHALMOL-CHIC, V15, P617
   Felipe A, 2010, J MOD OPTIC, V57, P152, DOI 10.1080/09500340902912910
   Guirao A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1143
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   KOZIOL JE, 1994, OPHTHALMIC SURG LAS, V25, P675
   Liou HL, 1997, J OPT SOC AM A, V14, P1684, DOI 10.1364/JOSAA.14.001684
   Lipshitz I, 1997, OPHTHALMIC SURG LAS, V28, P513
   Nguyen A., 1993, J VIS REHAB, V7, P5
   Orzalesi N, 2007, OPHTHALMOLOGY, V114, P860, DOI 10.1016/j.ophtha.2007.01.005
   Peli E, 2002, OPTOMETRY VISION SCI, V79, P225, DOI 10.1097/00006324-200204000-00009
   Peli E, 2001, OPTOMETRY VISION SCI, V78, P304, DOI 10.1097/00006324-200105000-00014
   Qureshi M. A., 2015, J CATARACT REFRACT S
   SPITZBERG LA, 1989, OPTOMETRY VISION SCI, V66, P616, DOI 10.1097/00006324-198909000-00008
   Tabernero J, 2006, INVEST OPHTH VIS SCI, V47, P4651, DOI 10.1167/iovs.06-0444
NR 17
TC 17
Z9 21
U1 0
U2 6
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PY 2015
VL 6
IS 3
BP 1010
EP 1020
DI 10.1364/BOE.6.001010
PG 11
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA CD0ZB
UT WOS:000350802000030
PM 25798322
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Kaiser, PK
   Wang, YZ
   He, YG
   Weisberger, A
   Wolf, S
   Smith, CH
AF Kaiser, Peter K.
   Wang, Yi-Zhong
   He, Yu-Guang
   Weisberger, Annemarie
   Wolf, Stephane
   Smith, Craig H.
TI FEASIBILITY OF A NOVEL REMOTE DAILY MONITORING SYSTEM FOR AGE-RELATED
   MACULAR DEGENERATION USING MOBILE HANDHELD DEVICES Results of a Pilot
   Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; best-corrected visual acuity; central
   retinal subfield thickness; choroidal neovascularization; Health
   Management Tool; myVisionTrack; ranibizumab; retinal disease; remote
   monitoring; shape discrimination hyperacuity
ID BLOOD-PRESSURE CONTROL; SUBGROUP ANALYSIS; RANIBIZUMAB
AB Purpose: This pilot study evaluated the feasibility of the Health Management Tool (HMT), a novel computing system using mobile handheld devices, to remotely monitor retinal visual function daily in patients with neovascular age-related macular degeneration treated with ranibizumab.
   Methods: Patients with neovascular age-related macular degeneration in at least 1 eye (newly diagnosed or successfully treated < 1 year) and eligible for ranibizumab therapy were enrolled in this 16-week, prospective, open-label, single-arm study. Patients performed a shape discrimination hyperacuity test (myVisionTrack [mVT]) daily on the HMT device (iPhone 3GS) remotely and at all clinic visits. Data entered into HMT devices were collected in the HMT database, which also sent reminders for patients to take mVT.
   Results: Among 160 patients from 24 U. S. centers enrolled in the study (103 [64%] >= 75 years of age), 84.7% on average complied with daily mVT testing and similar to 98.9% complied with at least weekly mVT testing. The HMT database successfully uploaded more than 17,000 mVT assessment values and sent more than 9,000 reminders.
   Conclusion: Elderly patients with neovascular age-related macular degeneration were willing and able to comply with daily self-testing of retinal visual function using mobile handheld devices in this novel system of remote vision monitoring.
C1 [Kaiser, Peter K.] Cole Eye Inst, Cleveland, OH 44195 USA.
   [Wang, Yi-Zhong] Retina Fdn SW, Dallas, TX USA.
   [Wang, Yi-Zhong; He, Yu-Guang] UT Southwestern Med Ctr, Dept Ophthalmol, Dallas, TX USA.
   [Weisberger, Annemarie] Novartis Pharmaceut, E Hanover, NJ USA.
   [Wolf, Stephane] Novartis Pharma AG, Basel, Switzerland.
   [Smith, Craig H.] Aegis Creat Commun Inc, Lakewood, CO USA.
C3 Retina Foundation of the Southwest; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; Novartis;
   Novartis
RP Kaiser, PK (通讯作者)，Cole Eye Inst, Cleveland Clin Main Campus,Mail Code I32, Cleveland, OH 44195 USA.
EM pkkaiser@gmail.com
OI Kaiser, Peter/0000-0001-5126-045X
FU Novartis Pharma AG
FX Supported by Novartis Pharma AG.
CR Bosworth HB, 2007, AM HEART J, V153, P918, DOI 10.1016/j.ahj.2007.03.004
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Chhetri AP, 2010, IHI 10 P 1 ACM INT H
   Crossland M, 2007, BRIT J OPHTHALMOL, V91, P391, DOI 10.1136/bjo.2006.095315
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kuchenbecker J, 2004, Strabismus, V12, P97
   Loewenstein A, 2010, RETINA-J RET VIT DIS, V30, P1058, DOI 10.1097/IAE.0b013e3181d1a75e
   McCant F, 2009, J TELEMED TELECARE, V15, P281, DOI 10.1258/jtt.2009.090202
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   National Eye Institute, 2013, FACTS AG REL MAC DEG
   Trevino R, 2008, OPHTHAL PHYSL OPT, V28, P183, DOI 10.1111/j.1475-1313.2008.00561.x
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
NR 12
TC 34
Z9 35
U1 0
U2 23
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2013
VL 33
IS 9
BP 1863
EP 1870
DI 10.1097/IAE.0b013e3182899258
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297DL
UT WOS:000330235500014
PM 23609122
DA 2022-11-30
ER

PT J
AU Samanta, A
   Aziz, AA
   Jhingan, M
   Singh, SR
   Khanani, A
   Chhablani, J
AF Samanta, Anindya
   Aziz, Aamir A.
   Jhingan, Mahima
   Singh, Sumit Randhir
   Khanani, Arshad
   Chhablani, Jay
TI Emerging Therapies in Neovascular Age-Related Macular Degeneration in
   2020
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE emerging treatments; neovascular AMD; wet AMD
ID RANIBIZUMAB; VERTEPORFIN; AFLIBERCEPT; PREVALENCE; ENDOGLIN; DISEASE
AB Age-related macular degeneration (AMD) is one of the most common causes of vision loss. Advanced forms of AMD are seen in primarily 2 types-neovascular AMD (nAMD) with the presence of choroid neovascularization and nonneovascular AMD (nnAMD) with geographic atrophy. Although there are 4 anti-vascular endothelial growth factor drugs either widely used or approved for the former, there are no current treatments for the latter. This review will highlight upcoming treatments for AMD currently in clinical trials. For nAMD: Abicipar pegol, an intravitreal anti-vascular endothelial growth factor based on designed ankyrin repeat proteins (DARP) in protein, is currently pending approval. Conbercept and Faricimab, 2 intravitreal anti-growth factors, are currently in phase 3. Nine other upcoming agents have at least produced results in the 2A phase including intravitreal injections (KSI-301, OPT-302, RGX-314, ICON-1, and DE-122), depot (GB-102), drug reservoir (PDS), topical drops (PAN-90806), and oral formulations (AKST4290). We summarize all the newer molecules.
C1 [Samanta, Anindya] Allegheny Hlth Network, Dept Med, Pittsburgh, PA USA.
   [Aziz, Aamir A.] Univ Nevada, Reno Sch Med, Reno, NV 89557 USA.
   [Jhingan, Mahima; Singh, Sumit Randhir] Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   [Khanani, Arshad] Sierra Eye Associates, Reno, NV USA.
   [Chhablani, Jay] Univ Pittsburgh, Dept Ophthalmol, Eye & Ear Inst, Pittsburgh, PA 15213 USA.
C3 Nevada System of Higher Education (NSHE); University of Nevada Reno;
   University of California System; University of California San Diego;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Chhablani, J (通讯作者)，Univ Pittsburgh, UPMC Eye Ctr, 203 Lothrop St, Pittsburgh, PA 15213 USA.
EM jay.chhablani@gmail.com
OI Chhablani, Jay/0000-0003-1772-3558
FU Adverum; Allergan; Chengdu Kanghong Biotechnology Co.; Gemini;
   Genentech, Inc.; Roche; Novartis; Gyroscope; Kodiak Sciences Inc.;
   Opthea; Ophthotech; Oxurion; Regenxbio
FX Research support-Adverum, Allergan, Chengdu Kanghong Biotechnology Co.,
   Gemini, Genentech, Inc., Roche, Novartis, Gyroscope, Kodiak Sciences
   Inc., Novartis, Opthea, Ophthotech, Oxurion, Regenxbio. Lecture fees
   -Allergan, Genentech, Inc., Novartis.
CR Boyer DS., 2019, HAW EYE RET ANN M JA
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Calugaru D, 2019, AM J OPHTHALMOL, V198, P262, DOI 10.1016/j.ajo.2018.09.027
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Gonzales CR, 2017, INVEST OPHTH VIS SCI, V58
   Grisanti S, 2004, EXP EYE RES, V78, P207, DOI 10.1016/j.exer.2003.11.008
   Grzybowski A, 2020, AM J OPHTHALMOL, V209, P216, DOI 10.1016/j.ajo.2019.07.026
   Heier J., 2019, KEY TAKEAWAYS RGX 31
   Jeong SY, 2017, BRIT J OPHTHALMOL, V101, P758, DOI 10.1136/bjophthalmol-2016-309144
   Joussen AM, 2019, BRIT J CLIN PHARMACO, V85, P347, DOI 10.1111/bcp.13794
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kunimoto D, 2019, OSLI RETINA, V50, pE10, DOI 10.3928/23258160-20190129-13
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lien S., 2008, V181, P131
   Liu K, 2019, AM J OPHTHALMOL, V198, P263, DOI 10.1016/j.ajo.2018.09.029
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Poor SH, 2018, INVEST OPHTH VIS SCI, V59
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Sharma A, 2020, EYE, V34, P797, DOI 10.1038/s41433-019-0607-8
   Shen WY, 2018, INVEST OPHTH VIS SCI, V59, P6075, DOI 10.1167/iovs.18-25628
   Trichonas G, 2013, OPHTHALMOL THER, V2, P89, DOI 10.1007/s40123-013-0015-2
   Wells JA, 2018, OSLI RETINA, V49, P336, DOI 10.3928/23258160-20180501-07
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 45
TC 27
Z9 28
U1 1
U2 15
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD MAY-JUN
PY 2020
VL 9
IS 3
BP 250
EP 259
DI 10.1097/APO.0000000000000291
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LY2AH
UT WOS:000540322300011
PM 32511123
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Downie, LE
   Keller, PR
AF Downie, Laura Elizabeth
   Keller, Peter Richard
TI Nutrition and Age-Related Macular Degeneration: Research Evidence in
   Practice
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE age-related macular degeneration; nutrition; diet; nutritional
   supplements; vitamin; mineral; antioxidant; zinc; AREDS; drusen
ID EYE DISEASE; VITAMIN-E; DOCOSAHEXAENOIC ACID; FLICKER PERIMETRY; RETINAL
   FUNCTION; BETA-CAROTENE; FATTY-ACIDS; SUPPLEMENTATION; RISK; MACULOPATHY
AB Age-related macular degeneration (AMD) is the leading cause of irreversible visual impairment in developed countries. In the absence of effective treatments to slow AMD progression, it is predicted that the prevalence of AMD will double over the next 20 years. One area of significant interest is the potential role that nutrition may play in preventing and/or delaying the progression of AMD. Specifically, is there any benefit in oral antioxidant and/or mineral supplementation? This review critically evaluates the currently available evidence relating to nutrition and AMD, with particular reference to the key findings of two large National Eye Institute-sponsored clinical studies, namely, the Age-Related Eye Disease Study (AREDS) and AREDS2. Topical controversies relating to nutrition and AMD are considered and analyzed in the context of the published literature to guide practitioners through assessing the merit, or otherwise, of common claims. This article provides a foundation for clinicians to provide informed advice to AMD patients based on available research evidence.
C1 [Downie, Laura Elizabeth; Keller, Peter Richard] Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3010, Australia.
   [Keller, Peter Richard] Royal Victorian Eye & Ear Hosp, Macular Res Unit, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
C3 University of Melbourne; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital
RP Downie, LE (通讯作者)，Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3010, Australia.
EM ldownie@unimelb.edu.au
OI Keller, Peter/0000-0003-4431-184X; Downie, Laura/0000-0002-1596-2259
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Australian Macular Degeneration Foundation, AREDS2 RES
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bartlett HE, 2007, EUR J CLIN NUTR, V61, P1121, DOI 10.1038/sj.ejcn.1602626
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blackmores, FISH OIL 1000
   Buring Julie E., 1995, P223
   Chew E, 2009, AGE RELATED EYE DIS
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chew EY, 2005, ARCH OPHTHALMOL-CHIC, V123, P395, DOI 10.1001/archopht.123.3.395
   Chew EY, 2005, ENCY DIETARY SUPPLEM, P409
   College of Optometrists, HLTH LIF HLTH EYES
   Collins K., INNISFIL EYE CARE CA
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DietaryGuidelines.gov, DIET GUID AM
   Downie LE, 2014, OPTOMETRY VISION SCI, V91, P932, DOI 10.1097/OPX.0000000000000246
   Downie LE, 2013, J HYPERTENS, V31, P960, DOI 10.1097/HJH.0b013e32835efea3
   Downie LE, 2014, JAMA OPHTHA IN PRESS
   DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5
   Druesne-Pecollo N, 2010, INT J CANCER, V127, P172, DOI 10.1002/ijc.25008
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Evans JR, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000253.PUB3
   FEENEY L, 1976, INVEST OPHTH VISUAL, V15, P789
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Garrett S K, 1999, Ophthalmic Epidemiol, V6, P195, DOI 10.1076/opep.6.3.195.1500
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Harvey B, OPTICIAN
   HAYES KC, 1974, INVEST OPHTH VISUAL, V13, P499
   HOFFMAN DR, 1995, INVEST OPHTH VIS SCI, V36, P1009
   Huang LL, 2008, INVEST OPHTH VIS SCI, V49, P3864, DOI 10.1167/iovs.07-1420
   Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42
   KAISER HJ, 1995, OPHTHALMOLOGICA, V209, P302, DOI 10.1159/000310646
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Leffondre K, 2002, AM J EPIDEMIOL, V156, P813, DOI 10.1093/aje/kwf122
   Litman BJ, 1996, LIPIDS, V31, pS193, DOI 10.1007/BF02637075
   Luu CD, 2013, INVEST OPHTH VIS SCI, V54, P3560, DOI 10.1167/iovs.12-10465
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Musch DC, 2014, JAMA OPHTHALMOL, V132, P139, DOI 10.1001/jamaophthalmol.2013.7443
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706
   Richer S, 1996, J Am Optom Assoc, V67, P30
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   Rotstein NP, 1997, J NEUROCHEM, V69, P504
   Royal College of Ophthalmologists, 2009, AG REL MAC DEG GUID
   Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI [10.1186/1741-7015-8-18, 10.1136/bmj.c332]
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003
   Stead LF, 2008, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000165.PUB3
   Thomson CD, 2008, AM J CLIN NUTR, V87, P379, DOI 10.1093/ajcn/87.2.379
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   U.S. Food and Drug Administration (FDA), Q A DIET SUPPL
   U.S. Preventive Services Task Force (USPSTF), 1989, GUID CLIN PREV SERV
   Valavanidis A, 2009, INT J ENV RES PUB HE, V6, P445, DOI 10.3390/ijerph6020445
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 74
TC 28
Z9 30
U1 0
U2 33
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 821
EP 831
DI 10.1097/OPX.0000000000000285
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500004
PM 24950031
DA 2022-11-30
ER

PT J
AU Kinnunen, K
   Petrovski, G
   Moe, MC
   Berta, A
   Kaarniranta, K
AF Kinnunen, Kati
   Petrovski, Goran
   Moe, Morten C.
   Berta, Andras
   Kaarniranta, Kai
TI Molecular mechanisms of retinal pigment epithelium damage and
   development of age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE drusen; lipofuscin; macular degeneration; retinal pigment epithelium
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; FUNDUS AUTOFLUORESCENCE
   PATTERNS; ENDOPLASMIC-RETICULUM STRESS; HTRA1 PROMOTER POLYMORPHISM;
   GLYCATION END-PRODUCTS; BRUCHS MEMBRANE; APOLIPOPROTEIN-E; SEQUESTOSOME
   1/P62; VARIANT INCREASES
AB Age-related macular degeneration (AMD) is attributed to a complex interaction of genetic and environmental factors. It is characterized by degeneration involving the retinal photoreceptors, retinal pigment epithelium (RPE) and Bruch's membrane, as well as alterations in choroidal capillaries. AMD pathogenesis is strongly associated with chronic oxidative stress and inflammation that ultimately lead to protein damage, aggregation and degeneration of RPE. Specific degenerative findings for AMD are accumulation of intracellular lysosomal lipofuscin and extracellular drusens. In this review, we discuss thoroughly RPE-derived mechanisms in AMD pathology.
C1 [Kinnunen, Kati; Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, FIN-70211 Kuopio, Finland.
   [Kinnunen, Kati; Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
   [Petrovski, Goran] Univ Debrecen, Dept Biochem & Mol Biol, Apoptosis & Genom Res Grp, Hungarian Acad Sci, H-4012 Debrecen, Hungary.
   [Petrovski, Goran; Berta, Andras] Univ Debrecen, Dept Ophthalmol, Med & Hlth Sci Ctr, H-4012 Debrecen, Hungary.
   [Moe, Morten C.] Univ Oslo, Ctr Eye Res, Dept Ophthalmol, Oslo Univ Hosp, Oslo, Norway.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; Hungarian Academy of Sciences; University of Debrecen;
   University of Debrecen; University of Oslo
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, POB 1627, FIN-70211 Kuopio, Finland.
EM kai.kaarniranta@uef.fi
OI Petrovski, Goran/0000-0003-2905-9252; Kaarniranta,
   Kai/0000-0003-2600-8679
CR Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548
   Akiyama H, 2005, MOL PHARMACOL, V68, P1543, DOI 10.1124/mol.105.015628
   Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164
   Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109-005-0688-7
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bjorkoy G, 2006, AUTOPHAGY, V2, P138, DOI 10.4161/auto.2.2.2405
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   BOYLE D, 1991, INVEST OPHTH VIS SCI, V32, P1464
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529
   Caberoy NB, 2010, EXP CELL RES, V316, P245, DOI 10.1016/j.yexcr.2009.10.008
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Ciechanover A, 2005, CELL DEATH DIFFER, V12, P1178, DOI 10.1038/sj.cdd.4401692
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2
   Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dice JF, 2007, AUTOPHAGY, V3, P295, DOI 10.4161/auto.4144
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ebihara N, 2007, OPHTHAL RES, V39, P155, DOI 10.1159/000103235
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elner SG, 2005, INVEST OPHTH VIS SCI, V46, P4627, DOI 10.1167/iovs.05-0658
   Elner VM, 2003, EXP EYE RES, V76, P321, DOI 10.1016/S0014-4835(02)00310-X
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305
   Fesus L, 2011, ANTIOXID REDOX SIGNA
   Filleur S, 2009, J CELL BIOCHEM, V106, P769, DOI 10.1002/jcb.22072
   Forrester JV, 2010, IMMUNOL REV, V234, P282, DOI 10.1111/j.0105-2896.2009.00873.x
   FORRESTER JV, 1994, INVEST OPHTH VIS SCI, V35, P64
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239
   Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200
   Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723
   Green W Richard, 2005, Retina, V25, P1519, DOI 10.1097/00006982-200507001-00015
   Green W Richard, 2005, Retina, V25, P180, DOI 10.1097/00006982-200507001-00005
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Hafezi F, 1997, EXP EYE RES, V64, P963, DOI 10.1006/exer.1997.0288
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0
   Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408
   Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Ikeda Y, 2006, EXP EYE RES, V83, P1031, DOI 10.1016/j.exer.2006.05.007
   Irschick EU, 2004, OPHTHALMIC RES, V36, P200, DOI 10.1159/000078778
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnston JA, 2002, CELL MOTIL CYTOSKEL, V53, P26, DOI 10.1002/cm.10057
   Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883
   Joukov V, 1997, J CELL PHYSIOL, V173, P211, DOI 10.1002/(SICI)1097-4652(199711)173:2<211::AID-JCP23>3.0.CO;2-H
   Kaarniranta K, 2005, MOL BRAIN RES, V137, P126, DOI 10.1016/j.molbrainres.2005.02.027
   Kaarniranta K, 1998, P NATL ACAD SCI USA, V95, P2319, DOI 10.1073/pnas.95.5.2319
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta K, 2011, J ALZHEIMERS DIS
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaarniranta K, 2010, ACTA OPHTHALMOL, V88, P387, DOI 10.1111/j.1755-3768.2009.01840.x
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kim PK, 2008, P NATL ACAD SCI USA, V105, P20567, DOI 10.1073/pnas.0810611105
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Kuusisto E, 2002, NEUROPATH APPL NEURO, V28, P228, DOI 10.1046/j.1365-2990.2002.00394.x
   Kuusisto E, 2001, BIOCHEM BIOPH RES CO, V280, P223, DOI 10.1006/bbrc.2000.4107
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Majai G, 2006, IMMUNOL LETT, V104, P94, DOI 10.1016/j.imlet.2005.11.016
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Minnnaugh EG, 2004, MOL CANCER THER, V3, P551
   Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507
   Miyake K, 2007, SEMIN IMMUNOL, V19, P3, DOI 10.1016/j.smim.2006.12.002
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Nagaoka U, 2004, J NEUROCHEM, V91, P57, DOI 10.1111/j.1471-4159.2004.02692.x
   Nandrot EF, 2007, P NATL ACAD SCI USA, V104, P12005, DOI 10.1073/pnas.0704756104
   Niederkorn J Y, 1990, Adv Immunol, V48, P191, DOI 10.1016/S0065-2776(08)60755-5
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Ohno-Matsui K, 2003, BIOCHEM BIOPH RES CO, V303, P962, DOI 10.1016/S0006-291X(03)00446-7
   Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576
   Oskolkova OV, 2008, BLOOD, V112, P330, DOI 10.1182/blood-2007-09-112870
   Paimela T, 2007, IMMUNOL LETT, V110, P139, DOI 10.1016/j.imlet.2007.04.008
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002
   Petrovski G, 2011, ACTA OPHTHALMOL, V89, pE30, DOI 10.1111/j.1755-3768.2010.02047.x
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Ryeom SW, 1996, J CELL SCI, V109, P387
   Ryhanen T, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/798052
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   Schmid D, 2007, IMMUNITY, V27, P11, DOI 10.1016/j.immuni.2007.07.004
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Seibenhener ML, 2007, FEBS LETT, V581, P175, DOI 10.1016/j.febslet.2006.12.027
   Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004
   Seitsonen S, 2006, MOL VIS, V12, P796
   Seitz HM, 2007, J IMMUNOL, V178, P5635, DOI 10.4049/jimmunol.178.9.5635
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SENGER DR, 1990, CANCER RES, V50, P1774
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Shima DT, 2004, INVEST OPHTH VIS SCI, V45, P3270
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 2005, MOL VIS, V11, P1135
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, ADV EXP MED BIOL, V533, P205
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   Valamanesh F, 2007, MOL VIS, V13, P1746
   Viiri J, 2010, MOL VIS, V16, P1399
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Warburton S, 2005, MOL VIS, V11, P1122
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   Weger M, 2007, MOL VIS, V13, P1274
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Winkler BS, 1999, MOL VIS, V5
   Wojcik C, 2002, J CELL MOL MED, V6, P25, DOI 10.1111/j.1582-4934.2002.tb00309.x
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xu HP, 2007, INVEST OPHTH VIS SCI, V48, P1701, DOI 10.1167/iovs.06-0697
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yi XJ, 1998, EXP BRAIN RES, V118, P155, DOI 10.1007/s002210050267
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zatloukal K, 2002, AM J PATHOL, V160, P255, DOI 10.1016/S0002-9440(10)64369-6
NR 176
TC 144
Z9 151
U1 1
U2 45
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2012
VL 90
IS 4
BP 299
EP 309
DI 10.1111/j.1755-3768.2011.02179.x
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 980OQ
UT WOS:000306903100023
PM 22112056
DA 2022-11-30
ER

PT J
AU Riedl, S
   Cooney, L
   Grechenig, C
   Sadeghipour, A
   Pablik, E
   Seaman, JW
   Waldstein, SM
   Schmidt-Erfurth, U
AF Riedl, Sophie
   Cooney, Lewis
   Grechenig, Christoph
   Sadeghipour, Amir
   Pablik, Eleonore
   Seaman, John W., III
   Waldstein, Sebastian M.
   Schmidt-Erfurth, Ursula
TI TOPOGRAPHIC ANALYSIS OF PHOTORECEPTOR LOSS CORRELATED WITH DISEASE
   MORPHOLOGY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE optical coherence tomography; age-related macular degeneration;
   anti-VEGF therapy; imaging biomarkers; photoreceptor; subretinal fluid;
   intraretinal fluid; pigment epithelial detachment; structure&#8211;
   function correlation; retinal morphology
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIAL DETACHMENT;
   VISUAL-ACUITY; SUBRETINAL FLUID; THERAPY; RANIBIZUMAB; SENSITIVITY;
   AFLIBERCEPT; VIEW
AB Purpose: To quantify morphologic photoreceptor integrity during anti-vascular endothelial growth factor (anti-VEGF) therapy of neovascular age-related macular degeneration and correlate these findings with disease morphology and function. Methods: This presents a post hoc analysis on spectral-domain optical coherence tomography data of 185 patients, acquired at baseline, Month 3, and Month 12 in a multicenter, prospective trial. Loss of the ellipsoid zone (EZ) was manually quantified in all optical coherence tomography volumes. Intraretinal cystoid fluid, subretinal fluid (SRF), and pigment epithelial detachments were automatically segmented in the full volumes using validated deep learning methods. Spatiotemporal correlation of fluid markers with EZ integrity as well as bivariate analysis between EZ integrity and best-corrected visual acuity was performed. Results: At baseline, EZ integrity was predominantly impaired in the fovea, showing progressive recovery during anti-vascular endothelial growth factor therapy. Topographic analysis at baseline revealed EZ integrity to be more likely intact in areas with SRF and vice versa. Moreover, we observed a correlation between EZ integrity and resolution of SRF. Foveal EZ integrity correlated with best-corrected visual acuity at all timepoints. Conclusion: Improvement of EZ integrity during anti-VEGF therapy of neovascular age-related macular degeneration occurred predominantly in the fovea. Photoreceptor integrity correlated with best-corrected visual acuity. Ellipsoid zone integrity was preserved in areas of SRF and showed deterioration upon SRF resolution.
C1 [Riedl, Sophie; Cooney, Lewis; Grechenig, Christoph; Sadeghipour, Amir; Waldstein, Sebastian M.; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Christian Doppler Lab Ophthalm Image Anal, Vienna, Austria.
   [Pablik, Eleonore] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria.
   [Seaman, John W., III] Novartis Pharma AG, Basel, Switzerland.
C3 Medical University of Vienna; Medical University of Vienna; Novartis
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Spitalgasse 23, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
FU Austrian Federal Ministry of Education, Science and Research; Austrian
   National Foundation for Research, Technology and Development; Christian
   Doppler Research Association; Novartis
FX Supported by the Austrian Federal Ministry of Education, Science and
   Research, the Austrian National Foundation for Research, Technology and
   Development, and the Christian Doppler Research Association. The OCTAVE
   study was funded and conducted by Novartis. The funding organizations
   had no role in the design and conduct of the study; collection,
   management, analysis, and interpretation of the data and preparation of
   the manuscript. Novartis participated in review and approval of the
   manuscript and decision to submit for publication.
CR Bird AC, 2018, EYE, V32, P858, DOI 10.1038/eye.2017.247
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen YM, 2011, INVEST OPHTH VIS SCI, V52, P3281, DOI 10.1167/iovs.10-6538
   Nguyen CL, 2019, OPHTHALMOLOGY, V126, P735, DOI 10.1016/j.ophtha.2018.11.036
   Coscas F, 2015, INVEST OPHTH VIS SCI, V56, P4129, DOI 10.1167/iovs.15-16735
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Gao WH, 2008, OPT EXPRESS, V16, P6486, DOI 10.1364/OE.16.006486
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Kim YM, 2012, AM J OPHTHALMOL, V154, P164, DOI 10.1016/j.ajo.2012.01.030
   Klimscha S, 2017, INVEST OPHTH VIS SCI, V58, P4039, DOI 10.1167/iovs.16-20201
   Kumar JB, 2019, RETINA
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Pelosini L, 2011, INVEST OPHTH VIS SCI, V52, P2741, DOI 10.1167/iovs.09-4493
   Philip AM, 2016, ARVO
   Sander B, 2005, BRIT J OPHTHALMOL, V89, P207, DOI 10.1136/bjo.2004.045989
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wu J, 2016, INT J BIOMED IMAGING, V2016, DOI 10.1155/2016/7468953
NR 33
TC 12
Z9 12
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2020
VL 40
IS 11
BP 2148
EP 2157
DI 10.1097/IAE.0000000000002717
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OP0WT
UT WOS:000587803100016
PM 31842189
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Guymer, RH
AF Wu, Zhichao
   Guymer, Robyn H.
TI Can the Onset of Atrophic Age-Related Macular Degeneration Be an
   Acceptable Endpoint for Preventative Trials?
SO OPHTHALMOLOGICA
LA English
DT Review
DE Age-related macular degeneration; Geographic atrophy; Endpoints; Trials
ID CLINICAL-TRIALS; PROPORTION; PREVALENCE; VALIDATION
AB The slowly progressive nature of age-related macular degeneration (AMD) means that establishing the efficacy of novel preventative treatments aiming to slow progression of disease, remains challenging, and where earlier endpoints are needed to improve their feasibility. This review examines whether the onset of atrophic AMD, as seen as anatomical signs on optical coherence tomography termed nascent geographic atrophy, could act as a useful surrogate endpoint for early intervention trials.
C1 [Wu, Zhichao; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   [Wu, Zhichao; Guymer, Robyn H.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Wu, ZC (通讯作者)，Ctr Eye Res Australia, Level 7,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM wu.z@unimelb.edu.au
FU Margaret Miller Foundation
FX This study was supported by the Margaret Miller Foundation (Z.W.).
CR Amur S, 2015, CLIN PHARMACOL THER, V98, P34, DOI 10.1002/cpt.136
   Buyse M, 1998, BIOMETRICS, V54, P1014, DOI 10.2307/2533853
   Buyse M, 2010, NAT REV CLIN ONCOL, V7, P309, DOI 10.1038/nrclinonc.2010.43
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Daniels MJ, 1997, STAT MED, V16, P1965, DOI 10.1002/(SICI)1097-0258(19970915)16:17<1965::AID-SIM630>3.0.CO;2-M
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Flandre P, 1999, STAT MED, V18, P107, DOI 10.1002/(SICI)1097-0258(19990115)18:1<107::AID-SIM965>3.3.CO;2-G
   Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011
   FREEDMAN LS, 1992, STAT MED, V11, P167, DOI 10.1002/sim.4780110204
   Friberg TR, 2009, OPHTHAL SURG LAS IM, V40, P530, DOI 10.3928/15428877-20091030-01
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Lin DY, 1997, STAT MED, V16, P1515, DOI 10.1002/(SICI)1097-0258(19970715)16:13<1515::AID-SIM572>3.0.CO;2-1
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2020, OPHTHALMOL RETINA, V4, P568, DOI 10.1016/j.oret.2019.12.011
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
NR 28
TC 4
Z9 3
U1 1
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD DEC
PY 2020
VL 243
IS 6
BP 399
EP 403
DI 10.1159/000510887
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PG4NP
UT WOS:000599714000001
PM 32805732
OA Bronze
DA 2022-11-30
ER

PT J
AU Munoz, B
   Klein, R
   Rodriguez, J
   Snyder, R
   West, SK
AF Munoz, B
   Klein, R
   Rodriguez, J
   Snyder, R
   West, SK
TI Prevalence of age-related macular degeneration in a population-based
   sample of hispanic people in Arizona; Proyecto VER
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
AB Objective: To report the prevalence of age-related macular degeneration (AMD) in a population-based sample of Hispanic individuals aged 50 years and older.
   Methods: Proyecto VER (Vision and Eye Research) is a population-based study of blindness and visual impairment of Hispanic people in Arizona. Participants underwent complete ophthalmic evaluation, including stereoscopic fundus photography of fields 1, 2, and 4. All photographs for participants aged 50 years and older were graded using the Wisconsin Age-Related Maculopathy Grading system. The following signs were graded: drusen size, drusen type, and the area covered by drusen; pigmentary abnormalities; geographic atrophy; and exudative AMD.
   Results: Sixty-seven percent (3178) of the original 4774 participants were 50 years of age or older. Of those, 92% (2928) had fundus photographs in at least 1 eye, and 95% (2780) of the photographs were of sufficient quality to grade early and late AMD.
   Outcome Measures: The overall prevalence of late AMD was 0.5%. The prevalence increased from 0.1% in the 50- to 59-year age group to 4.3% in the group aged 80 years and older. Likewise, early AMD was strongly associated with age with a prevalence of 20% in the 50- to 59-year age group, increasing to 54% in the group aged 80 years and older. The prevalence of early AMD in Hispanic people was significantly higher than the reported prevalence in the white population. However, the prevalence of late AMD was lower than the estimates for the white population of the United States.
   Conclusions: Although early macular changes were very common among Hispanic people, the prevalence of late AMD was infrequent. Further work is necessary to understand the underlying reasons for the different patterns of presentation of early and late signs of AMD among racial/ethnic groups and to characterize early AMD based on predictive value for severe disease in different populations.
C1 Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21287 USA.
   Univ Wisconsin, Dept Ophthalmol, Madison, WI USA.
   Univ Arizona, Dept Ophthalmol, Tucson, AZ USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of
   Wisconsin System; University of Wisconsin Madison; University of Arizona
RP Munoz, B (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Room 118,600 N Wolfe St, Baltimore, MD 21287 USA.
EM bmunoz@jhmi.edu
FU NEI NIH HHS [EY13783] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R01EY013783] Funding Source: NIH RePORTER
CR Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   KLEIN R, 1995, BEAVER DAM EYE STUDY, V2
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Ostenfeld-Akerblom A, 1999, ACTA OPHTHALMOL SCAN, V77, P76, DOI 10.1034/j.1600-0420.1999.770117.x
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   West SK, 2001, DIABETES CARE, V24, P1204, DOI 10.2337/diacare.24.7.1204
NR 32
TC 46
Z9 46
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2005
VL 123
IS 11
BP 1575
EP 1580
DI 10.1001/archopht.123.11.1575
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 981BM
UT WOS:000233062100012
PM 16286621
OA Bronze
DA 2022-11-30
ER

PT J
AU Roisman, L
   Zhang, QQ
   Wang, RK
   Gregori, G
   Zhang, AQ
   Chen, CL
   Durbin, MK
   An, L
   Stetson, PF
   Robbins, G
   Miller, A
   Zheng, F
   Rosenfeld, PJ
AF Roisman, Luiz
   Zhang, Qinqin
   Wang, Ruikang K.
   Gregori, Giovanni
   Zhang, Anqi
   Chen, Chieh-Li
   Durbin, Mary K.
   An, Lin
   Stetson, Paul F.
   Robbins, Gillian
   Miller, Andrew
   Zheng, Fang
   Rosenfeld, Philip J.
TI Optical Coherence Tomography Angiography of Asymptomatic
   Neovascularization in Intermediate Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SOURCE OCT ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB;
   MICROANGIOGRAPHY; VERTEPORFIN; DRUSEN
AB Purpose: To determine whether angiography with swept-source (SS) optical coherence tomography (OCT) identifies subclinical type 1 neovascularization in asymptomatic eyes with intermediate age-related macular degeneration (iAMD).
   Design: Prospective, observational, consecutive case series.
   Participants: Patients with asymptomatic iAMD in one eye and neovascular age-related macular degeneration (AMD) in their fellow eye.
   Methods: The patients underwent SS OCT angiography (OCTA), fluorescein angiography (FA), and indocyanine green angiography (ICGA), and the images from these 3 angiographic techniques were compared.
   Main Outcome Measures: Identification of subclinical type 1 neovascularization with SS OCTA in asymptomatic eyes with iAMD.
   Results: Eleven consecutive patients with iAMD in one eye and neovascular AMD in their fellow eye were imaged with FA, ICGA, and SS OCTA between August 2014 and September 2015. Clinical examination of the 11 eyes revealed drusen and pigmentary abnormalities in the central macula and no evidence of macular fluid on routine OCT imaging. Ten of the 11 eyes had no evidence of leakage on FA and 1 eye had questionable fluorescein leakage. Indocyanine green angiography revealed the presence of central macular plaques in 3 of the 11 asymptomatic eyes with iAMD, and SS OCTA revealed unambiguous type 1 neovascularization corresponding to the plaques in all 3 eyes. Optical coherence tomography angiography did not identify neovascularization in the remaining 8 eyes.
   Conclusions: Swept-source OCTA identified type 1 neovascularization corresponding to ICGA plaques in asymptomatic eyes with iAMD. The ability of OCTA to provide noninvasive, fast, detailed, depth-resolved identification of nonexudative neovascular lesions in eyes with iAMD suggests the need for a new classification system that distinguishes between neovascular and nonneovascular iAMD. (C) 2016 by the American Academy of Ophthalmology.
C1 [Roisman, Luiz; Gregori, Giovanni; Robbins, Gillian; Miller, Andrew; Zheng, Fang; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
   [Roisman, Luiz] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Zhang, Qinqin; Wang, Ruikang K.; Zhang, Anqi; Chen, Chieh-Li] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   [Durbin, Mary K.; An, Lin; Stetson, Paul F.] Carl Zeiss Meditec Inc, Adv Dev, Dublin, CA USA.
C3 Bascom Palmer Eye Institute; University of Miami; Universidade Federal
   de Sao Paulo (UNIFESP); University of Washington; University of
   Washington Seattle; Carl Zeiss AG
RP Rosenfeld, PJ (通讯作者)，Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@miami.edu
RI roisman, luiz/AAD-3822-2019; Wang, Ruikang/L-3889-2019
OI Wang, Ruikang/0000-0001-5169-8822
FU Carl Zeiss Meditec, Inc (Dublin, CA); Carl Zeiss Meditec, Inc, (Dublin,
   CA); Acucela; Apellis; Genentech/Roche; GlaxoSmithKline; Neurotech;
   Ocata Therapeutics; Tyrogenex; NATIONAL EYE INSTITUTE [R01EY024158,
   P30EY014801] Funding Source: NIH RePORTER
FX The author(s) have made the following disclosure(s): R.K.W.: Financial
   support - Carl Zeiss Meditec, Inc (Dublin, CA); Patent (with Oregon
   Health & Science University, Portland, OR) - Carl Zeiss Meditec, Inc.;
   G.G.: Financial support - Carl Zeiss Meditec, Inc, (Dublin, CA); Patent
   (with University of Miami, Miami, FL) - Carl Zeiss Meditec, Inc.;
   P.J.R.: Consultant - Achillion; Acucela; Alcon; Bayer; Chengdu Kanghong
   Biotech; CoDa Therapeutics; Genentech/Roche; Healios K.K.; Merck;
   Regeneron; Stealth; Tyrogenex; Supported by Acucela; Apellis;
   Genentech/Roche; GlaxoSmithKline; Neurotech; Ocata Therapeutics;
   Tyrogenex.
CR An L, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3369811
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dansingani KK, 2016, AM J OPHTHALMOL, DOI [10.1016/j.ajo.2015.12.019, DOI 10.1016/J.AJ0.2015.12.019]
   FLOWER RW, 1993, INVEST OPHTH VIS SCI, V34, P2720
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Friberg TR, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.02.048
   Gess AJ, 2011, SEMIN OPHTHALMOL, V26, P225, DOI 10.3109/08820538.2011.582533
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Huang YP, 2014, OSLI RETINA, V45, P382, DOI 10.3928/23258160-20140909-08
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Nagiel A, 2015, JAMA OPHTHALMOL, V133, P629, DOI 10.1001/jamaophthalmol.2015.0668
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Querques G, 2012, GRAEF ARCH CLIN EXP, V250, P479, DOI 10.1007/s00417-011-1831-5
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Wang RK, 2007, OPT EXPRESS, V15, P4083, DOI 10.1364/OE.15.004083
   Wang RK, 2010, OPT LETT, V35, P1467, DOI 10.1364/OL.35.001467
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Yin X, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.8.086020
   Zhang AQ, 2015, BIOMED OPT EXPRESS, V6, P4130, DOI 10.1364/BOE.6.004130
   Zhang QQ, 2015, RETINA-J RET VIT DIS, V35, P2285, DOI 10.1097/IAE.0000000000000840
NR 27
TC 172
Z9 177
U1 0
U2 45
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2016
VL 123
IS 6
BP 1309
EP 1319
DI 10.1016/j.ophtha.2016.01.044
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DM7BD
UT WOS:000376506400029
PM 26876696
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kirkova, R
   Murgova, S
   Kirkov, V
   Tanev, I
AF Kirkova, Radina
   Murgova, Snezhana
   Kirkov, Vidin
   Tanev, Ivan
TI Personalized Approach in Treatment of Neovascular Age-Related Macular
   Degeneration
SO JOURNAL OF PERSONALIZED MEDICINE
LA English
DT Article
DE OCT-A; neovascularization; AMD; anti-VEGF; vascular remodeling;
   personalized; approach
ID OPTICAL COHERENCE TOMOGRAPHY; VISUAL IMPAIRMENT; ANGIOGRAPHY; TYPE-1
AB Background: Age-related macular degeneration (AMD) is a progressive, degenerative disease of the central retina. AMD is subdivided into "dry" (atrophic), "wet" (exudative), and neovascular (nAMD) forms. In recent years, the concepts about nAMD changed with the development of optical coherence tomography-angiography (OCT-A) and intravitreal anti-VEGF treatment. The aim of this study was to define the morphologic type of the neovascular membrane (NVM) before treatment with OCT-A and to register vascular remodeling after treatment with anti-VEGF. We also analyzed the relationship between NVM and visual acuity. Methods: The study was retrospective and included 119 patients with newly diagnosed, treatment-naive nAMD. All the patients underwent full ophthalmic examination and also fluoresceine angiography and optical coherence tomography-angiography (OCT-A). Results: Based on the collected data, we found repetitive regularities. Conclusion: The analysis of our results could be used as prognostic markers for the evolution of the disease and as a basis for new treatment strategies, depending on the naive NVM morphologic type.
C1 [Kirkova, Radina; Murgova, Snezhana] Med Univ Pleven, Dept Ophthalmol ENT & Maxillofacial Surg, Pleven 5800, Bulgaria.
   [Kirkova, Radina] IRCCS Humanitas Res Hosp, Dept Ophthalmol, I-20089 Rozzano, Italy.
   [Murgova, Snezhana] Univ Hosp Dr Georgi Stranski, Dept Ophthalmol, Pleven 5800, Bulgaria.
   [Kirkov, Vidin] Med Univ Sofia, Fac Publ Hlth Prof Dr Tzekomir Vodenicharov, Dept Hlth Policy & Management, Sofia 1000, Bulgaria.
   [Tanev, Ivan] Eye Clin Zrenie, Sofia 1000, Bulgaria.
C3 Medical University Pleven; Medical University Pleven; Medical University
   Sofia
RP Kirkova, R (通讯作者)，Med Univ Pleven, Dept Ophthalmol ENT & Maxillofacial Surg, Pleven 5800, Bulgaria.; Kirkova, R (通讯作者)，IRCCS Humanitas Res Hosp, Dept Ophthalmol, I-20089 Rozzano, Italy.
EM dr_rkirkova@abv.bg
RI Murgova, Snejana/AAC-4876-2022
OI Murgova, Snejana/0000-0002-7413-8614; Kirkova,
   Radina/0000-0002-1712-9877
CR Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Anger EM, 2004, EXP EYE RES, V78, P1117, DOI 10.1016/j.exer.2004.01.011
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   de Almodovar C.R., 2007, RETINAL VASCULAR DIS, P38
   Enfield J, 2011, BIOMED OPT EXPRESS, V2, P1184, DOI 10.1364/BOE.2.001184
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Gess AJ, 2011, SEMIN OPHTHALMOL, V26, P225, DOI 10.3109/08820538.2011.582533
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Potsaid B, 2010, OPT EXPRESS, V18, P20029, DOI 10.1364/OE.18.020029
   Souied EH, 2016, DEV OPHTHALMOL, V56, P52, DOI 10.1159/000442777
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Vakoc BJ, 2009, NAT MED, V15, P1219, DOI 10.1038/nm.1971
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
NR 18
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4426
J9 J PERS MED
JI J. Pers. Med.
PD SEP
PY 2022
VL 12
IS 9
AR 1456
DI 10.3390/jpm12091456
PG 10
WC Health Care Sciences & Services; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine
GA 4S9RD
UT WOS:000857767600001
PM 36143241
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Xu, L
   Yi, YB
   Wang, YX
   Jonas, JB
AF Xu, Liang
   Li, Yi Bin
   Wang, Ya Xing
   Jonas, Jost B.
TI Age-Related Macular Degeneration and Mortality: The Beijing Eye Study
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related maculopathy; Mortality; Beijing Eye Study
ID BLUE MOUNTAINS EYE; ATHEROSCLEROSIS RISK; VISUAL IMPAIRMENT; PREVALENCE;
   MACULOPATHY; COMMUNITIES; ROTTERDAM; CATARACT
AB Purpose: To assess the association between age-related macular degeneration (AMD) and mortality in a population-based setting. Procedures: At baseline in 2001, the Beijing Eye Study examined 4,378 subjects for AMD with a detected frequency of 110/4,378 (2.5%) subjects for early AMD and of 12/4,378 (0.3%) subjects for late AMD. In 2006, all study participants were re-invited for a follow-up examination. Results: Out of the 4,378 subjects, 3,218 (73.5%) returned for a follow-up examination while 138 (3.2%) were dead and 1,022 (23.3%) did not agree to be re-examined or had moved away. Early AMD and late AMD were not significantly associated with mortality (p = 0.40 and 0.33, respectively), neither in univariate analysis nor in multivariate analysis. Conclusions: AMD may not be associated with an increased mortality in adult Chinese. Copyright (C) 2008 S. Karger AG, Basel
C1 [Xu, Liang; Li, Yi Bin; Wang, Ya Xing; Jonas, Jost B.] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing 100005, Peoples R China.
   [Jonas, Jost B.] Univ Heidelberg, Fac Med, Dept Ophthalmol, D-6800 Mannheim, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg
RP Xu, L (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, 17 Hougou Lane Chong Wen Men, Beijing 100005, Peoples R China.
EM xuliang5918@yahoo.com.cn
RI wang, YA XING/K-9671-2016
OI wang, YA XING/0000-0003-2749-7793
CR Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Cheung N, 2007, ARCH OPHTHALMOL-CHIC, V125, P1241, DOI 10.1001/archopht.125.9.1241
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
NR 10
TC 12
Z9 12
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2008
VL 222
IS 6
BP 378
EP 379
DI 10.1159/000151468
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 375SH
UT WOS:000261133100004
PM 18714172
DA 2022-11-30
ER

PT J
AU Lindekleiv, H
   Erke, MG
AF Lindekleiv, Haakon
   Erke, Maja Gran
TI Projected prevalence of age-related macular degeneration in Scandinavia
   2012-2040
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE epidemiology; prevalence; age-related macular degeneration
ID QUALITY-OF-LIFE; BEAVER DAM EYE; VISUAL IMPAIRMENT; UNITED-STATES;
   RESOURCE UTILIZATION; BETA-CAROTENE; VITAMIN-E; POPULATION; MACULOPATHY;
   BLINDNESS
AB Abstract.
   Purpose: To project the number of persons with late age-related macular degeneration (AMD) in Scandinavia through 2040.
   Methods: Age- and sex-specific prevalence rates of late AMD (choroidal neovascularization and geographic atrophy) from the European Eye Study and the Eye Diseases Prevalence Research Group were applied to the projected Danish, Norwegian and Swedish population from 2012 to 2040.
   Results: A total of 187 000 persons aged >= 65 years in Scandinavia are currently affected by late AMD: 47 000 in Denmark, 43 000 in Norway and 97 000 in Sweden. Owing to an ageing population, the number of persons affected by late AMD will increase 75% to 328 000 in 2040.
   Conclusion: The number of patients with late AMD in Scandinavia is expected to increase substantially over the next three decades, resulting in increased demand for ophthalmic health services.
C1 [Lindekleiv, Haakon; Erke, Maja Gran] Univ Tromso, Fac Hlth Sci, Dept Community Med, N-9038 Tromso, Norway.
   [Erke, Maja Gran] Univ Hosp North Norway, Div Ophthalmol, Tromso, Norway.
C3 UiT The Arctic University of Tromso; UiT The Arctic University of
   Tromso; University Hospital of North Norway
RP Lindekleiv, H (通讯作者)，Univ Tromso, Fac Hlth Sci, Dept Community Med, N-9038 Tromso, Norway.
EM haakon.lindekleiv@gmail.com
CR Anastasopoulos E, 2006, AM J OPHTHALMOL, V142, P1081, DOI 10.1016/j.ajo.2006.06.058
   Arroyo J, 2011, AGE RELATED MACULAR
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bjornsson OM, 2006, ACTA OPHTHALMOL SCAN, V84, P636, DOI 10.1111/j.1600-0420.2006.00696.x
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Christen WG, 2007, ARCH OPHTHALMOL-CHIC, V125, P333, DOI 10.1001/archopht.125.3.333
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P4381, DOI 10.1167/iovs.10-6987
   Frennesson C, 2010, ACTA OPHTHALMOL, V88, P420, DOI 10.1111/j.1755-3768.2009.01576.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Geirsdottir A, 2011, BR J OPHTHALMOL
   Gunnlaugsdottir E, 2010, ACTA OPHTHALMOL, V88, P358, DOI 10.1111/j.1755-3768.2008.01445.x
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Laitinen A, 2010, ACTA OPHTHALMOL, V88, P463, DOI 10.1111/j.1755-3768.2009.01566.x
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Seland JH, 2011, ACTA OPHTHALMOL, V89, P608, DOI 10.1111/j.1755-3768.2009.01794.x
   Sjostrand J, 2011, ACTA OPHTHALMOL, V89, P116, DOI 10.1111/j.1755-3768.2009.01653.x
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Tuulonen A, 2009, ACTA OPHTHALMOL, V87, P820, DOI 10.1111/j.1755-3768.2009.01532.x
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
NR 32
TC 26
Z9 26
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2013
VL 91
IS 4
BP 307
EP 311
DI 10.1111/j.1755-3768.2012.02399.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AF0FE
UT WOS:000334387500012
PM 22578252
OA Bronze
DA 2022-11-30
ER

PT J
AU Patel, P
   Sheth, V
AF Patel, Prem
   Sheth, Veeral
TI New and Innovative Treatments for Neovascular Age-Related Macular
   Degeneration (nAMD)
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE emerging treatment; neovascular age-related macular degeneration (nAMD);
   Vascular Endothelial Growth Factor (VEGF)
ID INTRAVITREAL INJECTIONS; EPITHELIAL-CELLS; ABICIPAR-PEGOL;
   PHARMACOKINETICS; ANGIOPOIETIN; PATHOGENESIS; INFLAMMATION; THERAPIES;
   PROGNOSIS; PROTEIN
AB Age-related macular degeneration (AMD) is one of the most common causes of vision loss. Advanced forms of AMD are seen in primarily two types-neovascular AMD (nAMD) with the presence of choroid neovascularization and non-neovascular AMD (nnAMD) with geographic atrophy. Neovascular AMD is characterized by choroidal neovascularization (CNV), which leads to a cascade of complications, including exudation, leakage, and ultimately fibrosis with photoreceptor loss. Inhibition of VEGF represents the current standard of care. However, there is a tremendous gap between the outcomes in randomized clinical trials and real-world settings. New agents for nAMD might offer the potential to improve treatment outcomes and reduce treatment of frequent intravitreal injections. We summarize all the newer molecules, their pivotal clinical trial results, and their unique mechanisms of action; these include longer-acting agents, combination strategies, sustained release, and genetic therapies.
C1 [Patel, Prem] Univ Texas Southwestern Med Ctr Dallas, Dept Ophthalmol, Dallas, TX 75390 USA.
   [Sheth, Veeral] Univ Retina & Macula Associates, Oak Forest, IL 60452 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas
RP Sheth, V (通讯作者)，Univ Retina & Macula Associates, Oak Forest, IL 60452 USA.
EM prem.patel@utsouthwestern.edu; vsheth@uretina.com
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], EYEWIRE NEWS
   [Anonymous], BUSINESSWIRE, DOI DOI 14005914/EN
   [Anonymous], BIOTECH DISPATCH
   [Anonymous], PRNEWSWIRE
   [Anonymous], REGENXBIOS GENE THER
   Binz HK, 2003, J MOL BIOL, V332, P489, DOI 10.1016/S0022-2836(03)00896-9
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Cabral T, 2018, OPHTHALMOL RETINA, V2, P31, DOI 10.1016/j.oret.2017.04.004
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chen ER, 2020, CLIN OPHTHALMOL, V14, P1349, DOI 10.2147/OPTH.S194234
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   Cox JT, 2021, J CLIN MED, V10, DOI 10.3390/jcm10050981
   Daien V, 2018, OPHTHALMOLOGY, V125, P66, DOI 10.1016/j.ophtha.2017.07.005
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   de Vries VA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70269-7
   Dugel PU, 2020, OPHTHALMOL RETINA, V4, P250, DOI 10.1016/j.oret.2019.10.008
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grau S, 2011, J NEURO-ONCOL, V104, P103, DOI 10.1007/s11060-010-0480-6
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Kaiser P.K., 2019, RETINA-J RET VIT DIS
   Khan M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9081869
   Klein BEK, 2009, JAMA-J AM MED ASSOC, V301, P2152, DOI 10.1001/jama.2009.729
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Knickelbein JE, 2016, OPHTHAL EPIDEMIOL, V23, P69, DOI 10.3109/09286586.2015.1122067
   Kolar P., 2013, AGE RELATED MACULAR, P105
   Korhonen EA, 2016, J CLIN INVEST, V126, P3495, DOI 10.1172/JCI84923
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Li D, 2014, CANCER LETT, V346, P45, DOI 10.1016/j.canlet.2013.12.004
   Li H, 2012, EXP EYE RES, V97, P154, DOI 10.1016/j.exer.2011.09.002
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lieu CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077117
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Munoz-Ramon P V, 2020, Arch Soc Esp Oftalmol (Engl Ed), V95, P75, DOI 10.1016/j.oftal.2019.09.011
   Nam HJ, 2007, J VIROL, V81, P12260, DOI 10.1128/JVI.01304-07
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Patel SS, 2019, INVEST OPHTH VIS SCI, V60
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Samanta A, 2020, ASIA-PAC J OPHTHALMO, V9, P250, DOI 10.1097/APO.0000000000000291
   Stumpp MT, 2008, DRUG DISCOV TODAY, V13, P695, DOI 10.1016/j.drudis.2008.04.013
   Tadayoni Ramin, 2014, J Ophthalmic Vis Res, V9, P405, DOI 10.4103/2008-322X.150799
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Usui V, 2015, J CLIN INVEST, V125, P2335, DOI 10.1172/JCI80297
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 63
TC 8
Z9 8
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUN
PY 2021
VL 10
IS 11
AR 2436
DI 10.3390/jcm10112436
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA SQ2UJ
UT WOS:000660212300001
PM 34070899
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Iranmanesh, R
   Reddy, S
   Peiretti, E
   Slakter, JS
AF Iranmanesh, Reza
   Reddy, Shantan
   Peiretti, Enrico
   Slakter, Jason S.
TI Macular hole formation following thermal laser photocoagulation in a
   patient with choroidal neovascular membrane and age-related macular
   degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
AB A woman with age-related macular degeneration and an extrafoveal choroidal neovascularization was treated with thermal laser photocoagulation. Three years later, an optical coherence tomography image showed a full-thickness macular hole with some contracture toward the adjacent atrophic laser scar, suggestive of some presumptive tangential forces.
C1 Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
   Manhattan Eye Ear & Throat Hosp, New York, NY 10021 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital
RP Iranmanesh, R (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
OI Peiretti, Enrico/0000-0003-1088-0163
CR CURTIN TL, 1968, AM J OPHTHALMOL, V65, P188, DOI 10.1016/0002-9394(68)93585-X
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   LIM JI, 1991, ARCH OPHTHALMOL-CHIC, V109, P1500, DOI 10.1001/archopht.1991.01080110034023
NR 3
TC 1
Z9 1
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD SEP-OCT
PY 2006
VL 37
IS 5
BP 423
EP 424
DI 10.3928/15428877-20060901-11
PG 2
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 087BE
UT WOS:000240716400011
PM 17017203
DA 2022-11-30
ER

PT J
AU Miura, M
   Makita, S
   Yasuno, Y
   Iwasaki, T
   Azuma, S
   Mino, T
   Yamaguchi, T
AF Miura, Masahiro
   Makita, Shuichi
   Yasuno, Yoshiaki
   Iwasaki, Takuya
   Azuma, Shinnosuke
   Mino, Toshihiro
   Yamaguchi, Tatsuo
TI Evaluation of retinal pigment epithelium changes in serous pigment
   epithelial detachment in age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
AB The purpose of this study was to quantitatively evaluate retinal pigment epithelium (RPE) changes in serous pigment epithelial detachment (PED) among patients with age-related macular degeneration by means of prototype multi-contrast optical coherence tomography (OCT), which is capable of simultaneous collection of OCT angiography, polarization-sensitive OCT, and standard OCT images. We evaluated 26 eyes of 21 patients with serous PED. RPE-melanin OCT images were calculated from the multi-contrast OCT dataset and compared with near-infrared autofluorescence images. An active RPE lesion was defined as an area of thickened RPE-melanin (>= 70 mu m; RPE70) on RPE-melanin OCT. Each PED area was divided into peak and slope regions. RPE70 area ratios were compared with the maximum PED height, PED area, PED volume, and slope area ratio (area of slope region/area of whole PED). RPE-melanin OCT images were consistent with near-infrared autofluorescence images. The RPE70 area ratio in the slope region was significantly negatively correlated with the slope area ratio. Development of active RPE lesions in the slope region was correlated with the PED configuration. Multi-contrast OCT is useful for objective evaluation of changes in the RPE in patients with age-related macular degeneration.
C1 [Miura, Masahiro; Iwasaki, Takuya] Tokyo Med Univ, Ibaraki Med Ctr, Dept Ophthalmol, 3-20-1 Chuo, Inashiki, Ibaraki 300395, Japan.
   [Makita, Shuichi; Yasuno, Yoshiaki] Univ Tsukuba, Computat Opt Grp, Tsukuba, Ibaraki, Japan.
   [Azuma, Shinnosuke; Mino, Toshihiro; Yamaguchi, Tatsuo] Topcon Corp, Tokyo, Japan.
C3 Tokyo Medical University; University of Tsukuba; Topcon Corporation
RP Miura, M (通讯作者)，Tokyo Med Univ, Ibaraki Med Ctr, Dept Ophthalmol, 3-20-1 Chuo, Inashiki, Ibaraki 300395, Japan.
EM m-miura@tokyo-med.ac.jp
RI Makita, Shuichi/G-3806-2011
OI Makita, Shuichi/0000-0002-6614-3640
FU Japan Society for the Promotion of Science [18K09460, 15K13371,
   18H01893, 18J13841]; Japan Science and Technology Agency [JPMJMI18G8]
FX This study was supported by a Grant-in-Aid for Scientific Research
   (18K09460, 15K13371, 18H01893, 18J13841) from the Japan Society for the
   Promotion of Science and JST Mirai Program (JPMJMI18G8) from Japan
   Science and Technology Agency. We thank Claire Barnes, Ph.D., and Ryan
   Chastain-Gross, Ph.D., from Edanz Group
   (https://en-author-services.edanz.com/ac) for editing a draft of this
   manuscript.
CR Azuma S, 2019, BIOMED OPT EXPRESS, V10, P5724, DOI 10.1364/BOE.10.005724
   Azuma S, 2018, BIOMED OPT EXPRESS, V9, P2955, DOI 10.1364/BOE.9.002955
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   BENNETT AG, 1994, GRAEF ARCH CLIN EXP, V232, P361, DOI 10.1007/BF00175988
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   de Boer JF, 2017, BIOMED OPT EXPRESS, V8, P1838, DOI 10.1364/BOE.8.001838
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Eamegdool SS, 2020, FREE RADICAL BIO MED, V146, P357, DOI 10.1016/j.freeradbiomed.2019.11.018
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Ho J, 2015, RETINA-J RET VIT DIS, V35, P467, DOI 10.1097/IAE.0000000000000355
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hong YJ, 2014, INVEST OPHTH VIS SCI, V55, P5016, DOI 10.1167/iovs.14-14005
   Hou X, 2009, GRAEF ARCH CLIN EXP, V247, P1477, DOI 10.1007/s00417-009-1135-1
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Lammer J, 2014, INVEST OPHTH VIS SCI, V55, P1564, DOI 10.1167/iovs.13-13539
   Lapierre-Landry M, 2018, J BIOL ENG, V12, DOI 10.1186/s13036-018-0124-5
   Makita S, 2018, BIOMED OPT EXPRESS, V9, P4372, DOI 10.1364/BOE.9.004372
   Makita S, 2016, BIOMED OPT EXPRESS, V7, P1525, DOI 10.1364/BOE.7.001525
   Makita S, 2014, OPT LETT, V39, P6783, DOI 10.1364/OL.39.006783
   Matsuzaki M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64601-4
   Miura M, 2019, INVEST OPHTH VIS SCI, V60, P3352, DOI 10.1167/iovs.19-27378
   Miura M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39688-z
   Miura M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03529-8
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Notani S, 2015, JPN J OPHTHALMOL, V59, P305, DOI 10.1007/s10384-015-0391-3
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   PRAKASH YS, 1994, NEUROIMAGE, V1, P325, DOI 10.1006/nimg.1994.1017
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schmitz-Valckenberg S, 2011, BRIT J OPHTHALMOL, V95, P1134, DOI 10.1136/bjo.2010.189498
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Sugiyama S, 2015, BIOMED OPT EXPRESS, V6, P4951, DOI 10.1364/BOE.6.004951
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Vermeer KA, 2014, BIOMED OPT EXPRESS, V5, P322, DOI 10.1364/BOE.5.000322
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
NR 43
TC 3
Z9 2
U1 0
U2 4
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 2
PY 2021
VL 11
IS 1
AR 2764
DI 10.1038/s41598-021-82563-z
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA QG6PP
UT WOS:000617706100001
PM 33531591
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ersoy, L
   Ristau, T
   Hahn, M
   Karlstetter, M
   Langmann, T
   Droge, K
   Caramoy, A
   den Hollander, AI
   Fauser, S
AF Ersoy, Lebriz
   Ristau, Tina
   Hahn, Moritz
   Karlstetter, Marcus
   Langmann, Thomas
   Droege, Katharina
   Caramoy, Albert
   den Hollander, Anneke I.
   Fauser, Sascha
TI Genetic and Environmental Risk Factors for Age-Related Macular
   Degeneration in Persons 90 Years and Older
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; age; genetics
ID COMPLEMENT FACTOR-H; BEAVER-DAM-EYE; CARDIOVASCULAR-DISEASE; HUMAN
   LONGEVITY; ASSOCIATION; MORTALITY; POLYMORPHISM; MACULOPATHY;
   HYPERTENSION; PROGRESSION
AB PURPOSE. We studied associations of genetic polymorphisms in age-related maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH) in nonagenarians with age-related macular degeneration (AMD).
   METHODS. This case-control study comprised 2737 persons (1204 controls, 1433 AMD cases), including 166 nonagenarians (52 controls, 114 AMD cases). Single nucleotide polymorphisms (SNPs) in the genes ARMS2 and CFH were determined. Risk scores were computed by multiple logistic regression analysis, including genetic and environmental risk factors (smoking, hypertension, body mass index, diabetes) for different age groups (<70, 70-79, 80-89, >= 90 years [nonagenarians]).
   RESULTS. In nonagenarians, ARMS2 showed the weakest associations with AMD (odds ratio [OR] = 1.52, P = 0.127) compared to the other groups (OR, 70 years = 2.23, P = 1.03 x 10(-13); OR, 70-79 years = 2.70, P = 1.00 x 10(-13); OR, 80-89 years = 3.11, P = 6.56 x 10(-8)). For CFH, ORs for AMD increased with age (<70 years OR = 1.96, P = 1.80 x 10(-11); 70-79 years OR = 1.89, P = 4.48 x 10(-13); 80-89 years OR = 2.71, P = 1.28 x 10(-7)), but decreased again in the nonagenarians (OR = 2.21, P = 0.005). Compared to the group <70 years, reduced minor allele frequencies (MAFs) for AMD patients were observed in the nonagenarians (CFH 0.54 vs. 0.43, P = 0.009; ARMS2 0.44 vs. 0.29, P = 2.97 x 10(-5)), while the MAFs in controls were not significantly different. The genetic risk score revealed the lowest discriminative power in the nonagenarians with an area-under-curve (AUC) of 0.658 for receiver-operating characteristics (AUC 80-89 years = 0.768, 70-79 years = 0.704, <70 years = 0.682), while no significant difference was seen for the environmental risk score (AUC <70 years = 0.579, 70-79 years = 0.567, 80-89 years = 0.600, >90 years = 0.608).
   CONCLUSIONS. Risk alleles in CFH and ARMS2 have a significantly smaller effect on AMD development in nonagenarians, while environmental factors retain a similar effect.
C1 [Ersoy, Lebriz; Ristau, Tina; Karlstetter, Marcus; Langmann, Thomas; Droege, Katharina; Caramoy, Albert; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, D-50924 Cologne, Germany.
   [Hahn, Moritz] Univ Cologne, Inst Med Stat Informat & Epidemiol, D-50931 Cologne, Germany.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.
C3 University of Cologne; University of Cologne; Radboud University
   Nijmegen; Radboud University Nijmegen
RP Fauser, S (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM Sascha.fauser@uk-koeln.de
RI Hollander, Anneke den/N-4911-2014
CR Adams MKM, 2012, HUM MOL GENET, V21, P5229, DOI 10.1093/hmg/dds364
   Beekman M, 2013, AGING CELL, V12, P184, DOI 10.1111/acel.12039
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hermann M, 2012, ACTA OPHTHALMOL, V90, pe500, DOI 10.1111/j.1755-3768.2011.02347.x
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jylhava J, 2009, EXP GERONTOL, V44, P297, DOI 10.1016/j.exger.2008.10.006
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Slagboom PE, 2011, PHILOS T R SOC B, V366, P35, DOI 10.1098/rstb.2010.0284
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Weger M, 2007, MOL VIS, V13, P1274
   Xu L, 2008, OPHTHALMOLOGICA, V222, P378, DOI 10.1159/000151468
NR 29
TC 17
Z9 18
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2014
VL 55
IS 3
BP 1842
EP 1847
DI 10.1167/iovs.13-13420
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AE0HZ
UT WOS:000333645900017
PM 24576882
OA Green Published
DA 2022-11-30
ER

PT J
AU El-Mollayess, GM
   Noureddine, BN
   Bashshur, ZF
AF El-Mollayess, Georges M.
   Noureddine, Baha' N.
   Bashshur, Ziad F.
TI Bevacizumab and Neovascular Age Related Macular Degeneration:
   Pathogenesis and Treatment
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE choroidal neovascularization; age-related macular degeneration;
   bevacizumab; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; SUBFOVEAL
   CHOROIDAL NEOVASCULARIZATION; RETINA STUDY-GROUP; VERTEPORFIN
   PHOTODYNAMIC THERAPY; PRIMARY INTRAVITREAL BEVACIZUMAB; STUDY-GROUP
   PACORES; 12-MONTH FOLLOW-UP; FACTOR PHARMACOTHERAPY; TYROSINE KINASE
AB The pathogenesis of neovascular age related macular degeneration (AMD) is multifactorial including inflammation and angiogenesis leading to choroidal neovascularization (CNV). Therapy against vascular endothelial growth factor (VEGF) has revolutionized the treatment of neovascular AMD. Intravitreal off-label use of bevacizumab proved to be safe. This literature review was conducted to study improvement in visual acuity, change in central retinal thickness (CRT), safety, pharmacodynamics, and possible resistance to intravitreal bevacizumab over a one-year period in eyes with neovascular AMD. We reviewed articles between 1997 and January 2010 that included at least 30 patients with AMD who received intravitreal bevacizumab monotherapy for at least 1 year. The mean number of letters gained, decrease in CRT, and number of injections were 8 letters, 125.3 mu m, and 4.3 injections, respectively. Further, randomized prospective clinical trials are needed to determine the efficacy and safety of intravitreal bevacizumab in the treatment of neovascular AMD.
C1 [Bashshur, Ziad F.] Amer Univ Beirut, Med Ctr, Dept Ophthalmol, Beirut, Lebanon.
C3 American University of Beirut
RP Bashshur, ZF (通讯作者)，Amer Univ Beirut, Med Ctr, Dept Ophthalmol, POB 11-0236-B11, Beirut, Lebanon.
EM zb00@aub.edu.lb
CR Abdollahi A, 2005, DRUG RESIST UPDATE, V8, P59, DOI 10.1016/j.drup.2005.03.001
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   [Anonymous], COMPARISON AGE RELAT
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhutto IA, 2006, BRIT J OPHTHALMOL, V90, P906, DOI 10.1136/bjo.2006.090357
   BREMENMITTE K, PREVENTION VISION LO
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carneiro AM, 2010, RETINA-J RET VIT DIS, V30, P85, DOI 10.1097/IAE.0b013e3181c700a9
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Costagliola C, 2009, RETINA-J RET VIT DIS, V29, P1227, DOI 10.1097/IAE.0b013e3181b773e1
   Dempke WCM, 2009, EUR J CANCER, V45, P1117, DOI 10.1016/j.ejca.2008.11.038
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   DVORAK HF, 1987, LAB INVEST, V57, P673
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fajnkuchen F, 2008, J FR OPHTALMOL, V31, P630, DOI 10.1016/S0181-5512(08)75469-X
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fong KCS, 2008, CLIN EXP OPHTHALMOL, V36, P748, DOI 10.1111/j.1442-9071.2008.01873.x
   FOROOGHIAN F, 2009, ACTA OPHTHALMOL 1107
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gordon-Angelozzi M, 2009, OPHTHALMOLOGY, V116, P2264, DOI 10.1016/j.ophtha.2009.07.027
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Guerin E, 2008, MICROVASC RES, V75, P302, DOI 10.1016/j.mvr.2007.12.001
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Hermans P, 2003, OPHTHALMOLOGE, V100, P378, DOI 10.1007/s00347-002-0742-6
   Hoffmann S, 2006, RETINA-J RET VIT DIS, V26, P454, DOI 10.1097/00006982-200604000-00012
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jeganathan VSE, 2009, CURR OPIN OPHTHALMOL, V20, P223, DOI 10.1097/ICU.0b013e328329b656
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   KHORRAM D, HEAD TO HEAD LUCENTI
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   LAPOSTOLLE S, AVASTIN LUCENTIS UPD
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Lee K, 2009, RETINA-J RET VIT DIS, V29, P1409, DOI 10.1097/IAE.0b013e3181b21056
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Leydolt C, 2010, ACTA OPHTHALMOL, V88, P594, DOI 10.1111/j.1755-3768.2008.01485.x
   Lima LH, 2009, RETINA-J RET VIT DIS, V29, P1213, DOI 10.1097/IAE.0b013e3181b32d27
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Matsuyama K, 2009, JPN J OPHTHALMOL, V53, P243, DOI 10.1007/s10384-008-0645-4
   Mekjavic PJ, 2011, ACTA OPHTHALMOL, V89, P647, DOI 10.1111/j.1755-3768.2009.01740.x
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miyake T, 2010, INVEST OPHTH VIS SCI, V51, P1606, DOI 10.1167/iovs.09-4140
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Presta LG, 1997, CANCER RES, V57, P4593
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shah AR, 2009, BRIT J OPHTHALMOL, V93, P1027, DOI 10.1136/bjo.2008.149674
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Sheybani A, 2009, RETINA-J RET VIT DIS, V29, P1404, DOI 10.1097/IAE.0b013e3181b32d13
   Shima C, 2009, GRAEF ARCH CLIN EXP, V247, P899, DOI 10.1007/s00417-009-1067-9
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stahl A, 2009, GRAEF ARCH CLIN EXP, V247, P767, DOI 10.1007/s00417-009-1058-x
   Takahashi H, 2004, BIOCHEM BIOPH RES CO, V320, P372, DOI 10.1016/j.bbrc.2004.05.177
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P782, DOI 10.1001/archopht.126.6.782
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P1183, DOI 10.1136/bjo.2007.114769
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Wu L, 2009, JPN J OPHTHALMOL, V53, P125, DOI 10.1007/s10384-008-0622-y
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   MANTA STUDY AVASTIN
NR 84
TC 15
Z9 16
U1 1
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 69
EP 76
DI 10.3109/08820538.2010.545100
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200002
PM 21609219
DA 2022-11-30
ER

PT J
AU Sawa, M
   Kamei, M
   Ohji, M
   Motokura, M
   Saito, Y
   Tano, Y
AF Sawa, M
   Kamei, M
   Ohji, M
   Motokura, M
   Saito, Y
   Tano, Y
TI Changes in fluorescein angiogram early after surgical removal of
   choroidal neovascularization in age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; SUBMACULAR MEMBRANECTOMY; IN-VIVO; SURGERY;
   REPOPULATION; EXCISION; FEATURES; CULTURE; CELLS
AB Background: Retinal pigment epithelial (RPE) defects inevitably occur in surgical removal of choroidal neovascularization (CNV) in age-related macular degeneration (AMD). RPE can proliferate and cover the denuded area, but the healing process has not been investigated in humans. To understand the RPE wound-healing process, we estimated the changes in fluorescein angiograms early after CNV removal. Methods: Ten consecutive patients with exudative AMD underwent CNV removal without gas tamponade. Fluorescein angiography was performed within 4 days of surgery and again 1 or 2 weeks postoperatively. Areas of leak-age were measured using a computer-assisted image analyser. The decreasing rate of leakage was calculated as the change in disc areas of leakage per day (DA/day). Results: The rates of decreasing leakage ranged from 0 to 0.42 DA/day (mean, 0.24 +/- 0.15 DA/day; median, 0.26 DA/day). The rate of decreasing leakage correlated with changes in visual acuity (r=0.642, P=0.0456). Conclusion: The retinal pigment epithelial wound after surgical removal of choroidal neovascularization may heal at the rate of 0.24 disc areas/day based on the blood retinal barrier function in patients with age-related macular degeneration. A faster rate of decreasing leakage may be associated with better visual prognosis.
C1 Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan.
C3 Osaka University
RP Kamei, M (通讯作者)，Osaka Univ, Sch Med, Dept Ophthalmol, Room E7,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
CR BERGER AS, 1992, OPHTHALMOLOGY, V99, P969
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   DELPRIORE LV, 1995, ARCH OPHTHALMOL-CHIC, V113, P939, DOI 10.1001/archopht.1995.01100070113034
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus H. E., 1997, Investigative Ophthalmology and Visual Science, V38, pS458
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   HERGOTT GJ, 1993, INVEST OPHTH VIS SCI, V34, P2761
   HERIOT WJ, 1992, GRAEF ARCH CLIN EXP, V230, P91, DOI 10.1007/BF00166769
   HSU JK, 1995, RETINA-J RET VIT DIS, V15, P43, DOI 10.1097/00006982-199515010-00009
   HUDSON HL, 1995, BRIT J OPHTHALMOL, V79, P417, DOI 10.1136/bjo.79.5.417
   Kamei M, 1996, CURR EYE RES, V15, P714
   Kamei M, 1998, MICROSC RES TECHNIQ, V42, P311, DOI 10.1002/(SICI)1097-0029(19980901)42:5<311::AID-JEMT2>3.0.CO;2-S
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   LOPEZ PF, 1995, ARCH OPHTHALMOL-CHIC, V113, P1437, DOI 10.1001/archopht.1995.01100110097032
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   MELLER K, 1979, J NEUROCYTOL, V8, P229, DOI 10.1007/BF01175563
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Ohji M., 1997, Investigative Ophthalmology and Visual Science, V38, pS658
   ORMEROD LD, 1994, OPHTHALMOLOGY, V101, P1201
   QUIGLEY HA, 1990, ARCH OPHTHALMOL-CHIC, V108, P51, DOI 10.1001/archopht.1990.01070030057028
   Rosa RH, 1996, ARCH OPHTHALMOL-CHIC, V114, P480, DOI 10.1001/archopht.1996.01100130476025
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P767
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   VALENTINO TL, 1995, ARCH OPHTHALMOL-CHIC, V113, P932, DOI 10.1001/archopht.1995.01100070106033
NR 28
TC 6
Z9 6
U1 0
U2 0
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2002
VL 240
IS 1
BP 12
EP 16
DI 10.1007/s004170100358
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 528CJ
UT WOS:000174226300004
PM 11954774
DA 2022-11-30
ER

PT J
AU Biarnes, M
   Mones, J
   Villalbi, JR
   Arias, L
AF Biarnes, Marc
   Mones, Jordi
   Villalbi, Joan R.
   Arias, Lluis
TI As-needed treatment with ranibizumab 0.5 mg in patients with neovascular
   age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE As-needed treatment; Neovascular age-related macular degeneration;
   Ranibizumab; Treatment
ID INTRAVITREAL BEVACIZUMAB; SUBGROUP ANALYSIS; VERTEPORFIN; LUCENTIS;
   ANCHOR
AB Purpose. To describe the results obtained in patients with neovascular age-related macular degeneration treated with ranibizumab 0.5 mg on an as-needed basis from the start after 1 year of follow-up.
   Methods. Retrospective, consecutive interventional case series of patients with all angiographic types of neovascular age-related macular degeneration (mean baseline size, 3.4 disk areas) in a tertiary retinal center (Institut de la Macula i la Retina; Barcelona, Spain). Main outcome was mean vision change; secondary outcomes were center retinal thickness change, number of injections, adverse events, and independent covariates associated with a good response.
   Results. Mean visual acuity change was an increase of 1.3 letters (95% confidence interval -2.7 to +5.3), and difference between angiographic patterns did not reach statistical significance (p = 0.30). A decrease in retinal thickness of 44.6 mu m was identified (p < 0.001), with a median of 3 injections. Absence of baseline arterial hypertension, lower visual acuity, and lesions located outside the fovea were associated with a better response to therapy.
   Conclusions. As-needed treatment from the start achieved stabilization of visual acuity and a moderate decrease of retinal thickness with a low number of injections, but did not achieve the same efficacy as regular monthly injections.
C1 [Biarnes, Marc; Mones, Jordi; Arias, Lluis] Ctr Med Teknon, Macula & Retina Inst, Barcelona 08022, Spain.
   [Villalbi, Joan R.] Barcelona Publ Hlth Agcy, Barcelona, Spain.
   [Arias, Lluis] Bellvitge Hosp, Barcelona, Spain.
C3 Public Health Agency of Barcelona; Institut d'Investigacio Biomedica de
   Bellvitge (IDIBELL); Bellvitge University Hospital; University of
   Barcelona
RP Biarnes, M (通讯作者)，Ctr Med Teknon, Macula & Retina Inst, C Vilana 12,Off 116-117, Barcelona 08022, Spain.
EM biarnes@oo.upc.edu
RI mones, jordi/CAJ-2963-2022
OI mones, jordi/0000-0003-3685-2160; ARIAS, LUIS/0000-0001-7041-5576;
   Villalbi, Joan/0000-0001-6915-2545; Biarnes, Marc/0000-0003-2584-4894
FU Novartis; Allergan; Ophthotech; Notalvision
FX Marc Biarnes and Joan R. Villalbi report no conflicts of interest. Luis
   Arias has received lecture fees from Novartis. Jordi Mones has received
   consulting fees from Novartis, Allergan, Ophthotech, and Notalvision.
CR Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Fung AE, 2009, OPHTHALMOLOGY, V116, P286, DOI 10.1016/j.ophtha.2008.09.014
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P399, DOI 10.1167/iovs.08-1697
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 19
TC 12
Z9 12
U1 0
U2 2
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY-JUN
PY 2011
VL 21
IS 3
BP 282
EP 289
DI 10.5301/EJO.2010.5766
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 760UL
UT WOS:000290349300010
PM 20890885
DA 2022-11-30
ER

PT J
AU Smith, HJ
   Dickinson, CM
   Cacho, I
   Reeves, BC
   Harper, RA
AF Smith, HJ
   Dickinson, CM
   Cacho, I
   Reeves, BC
   Harper, RA
TI A randomized controlled trial to determine the effectiveness of prism
   spectacles for patients with age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL LOCUS; VISION; OUTCOMES; REHABILITATION; QUESTIONNAIRE; LIFE
AB Objective: To determine the effectiveness of prism spectacles in people with age-related macular degeneration by relocating the retinal image.
   Methods: We implemented a randomized, placebo-controlled, double-masked trial. Participants with age-related macular degeneration received a standard low-vision assessment and the prescription of conventional low-vision aids 6 weeks before the study intervention. Participants were randomized to receive I of the following, including the optimal refractive correction: (1) custom, incorporating bilateral prisms to match participants' preferred power and base direction; (2) standard, incorporating standard bilateral prisms (6 prism diopters [Delta] base up for logMAR [logarithm of the minimum angle of resolution] visual acuity (VA) of 0.48-1.00 and 10 Delta base up for logMAR VA of 1.02-1.68); or (3) placebo, consisting of spectacles matched in weight and thickness to prism spectacles but without prism.
   Main Outcome Measures: Outcomes measured binocularly at baseline and 3-month follow-up included distance logMAR VA, reading speed, critical print size, visual functioning questionnaires, and observed visual task performance. Scores on the 25-item National Eye Institute Visual Functioning Questionnaire and the Melbourne Low-Vision ADL (Activities of Daily Living) Index were converted to linear estimates using Rasch analysis. The Manchester Low Vision Questionnaire was used to collect descriptive data.
   Results: A total of 225 participants completed the trial (median age, 81 years). We found no significant effect of treatment group on any of the outcome measures, including VA, the primary outcome (adjusted for baseline) (P=.63). Participants' responses to the Manchester Low Vision Questionnaire suggested that the prism spectacles added to their problems.
   Conclusions: Prism spectacles are no more effective than conventional spectacles for people with age-related macular degeneration.
C1 Univ Manchester, Dept Optometry & Neurosci, Inst Sci & Technol, Manchester, Lancs, England.
   Manchester Royal Eye Hosp, Acad Dept Ophthalmol, Manchester M13 9WH, Lancs, England.
   London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1, England.
C3 University of Manchester; Manchester Royal Eye Hospital; University of
   London; London School of Hygiene & Tropical Medicine
RP Smith, HJ (通讯作者)，Robert Jones & Agnes Hunt Orthopaed Hosp, Oswestry SY10 7AG, Shrops, England.
EM heatherj.smith@rjah.nhs.uk
OI Harper, Robert/0000-0001-5437-2553
CR Andrich D., 1988, APPL MEAS EDUC, V1, P363, DOI [10.1207/s15324818ame0104_7, DOI 10.1207/S15324818AME0104_7]
   BAILEY IL, 1983, OPTOM MONTHLY, V74, P360
   Bertrand T, 1997, J FR OPHTALMOL, V20, P271
   Bond T.G., 2001, APPLYING RASCH MODEL, V1st
   Bowers AR, 2004, OPTOMETRY VISION SCI, V81, P205, DOI 10.1097/00006324-200403000-00013
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Duret F, 1999, NEURO-OPHTHALMOLOGY, V22, P209, DOI 10.1076/noph.22.4.209.3718
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Harper R, 1999, OPHTHAL PHYSL OPT, V19, P3, DOI 10.1046/j.1475-1313.1999.00411.x
   Haymes SA, 2001, INVEST OPHTH VIS SCI, V42, P1215
   Leat Susan J, 2001, Clin Exp Optom, V84, P132
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Massof RW, 2001, VISION RES, V41, P397, DOI 10.1016/S0042-6989(00)00249-2
   Massof RW, 2001, SURV OPHTHALMOL, V45, P531, DOI 10.1016/S0039-6257(01)00194-1
   NILSSON UL, 1990, CLIN VISION SCI, V6, P3
   Nilsson UL, 1998, OPTOMETRY VISION SCI, V75, P873, DOI 10.1097/00006324-199812000-00009
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Noble BA, 2004, BRIT J OPHTHALMOL, V88, P647, DOI 10.1136/bjo.2003.026211
   PELI E, 1986, AM J OPTOM PHYS OPT, V63, P113
   Pesudovs K, 2004, OPTOMETRY VISION SCI, V81, P769, DOI 10.1097/00006324-200410000-00009
   Pesudovs K, 2003, INVEST OPHTH VIS SCI, V44, P2892, DOI 10.1167/iovs.02-1075
   Reischies FM, 1997, BRIT J PSYCHIAT, V171, P449, DOI 10.1192/bjp.171.5.449
   ROMAYANANDA N, 1982, OPHTHALMOLOGY, V89, P937
   ROSENBERG R, 1989, OPTOMETRY VISION SCI, V66, P747, DOI 10.1097/00006324-198911000-00004
   Stelmack JA, 2002, INVEST OPHTH VIS SCI, V43, P2859
   Trautner C, 2003, INVEST OPHTH VIS SCI, V44, P1031, DOI 10.1167/iovs.02-0304
   Verezen CA, 1996, OPTOMETRY VISION SCI, V73, P413, DOI 10.1097/00006324-199606000-00009
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
NR 32
TC 37
Z9 38
U1 0
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD AUG
PY 2005
VL 123
IS 8
BP 1042
EP 1050
DI 10.1001/archopht.123.8.1042
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 955OY
UT WOS:000231236900001
PM 16087836
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Fujiwara, K
   Yasuda, M
   Hata, J
   Oshima, Y
   Hashimoto, S
   Yoshitomi, T
   Kiyohara, Y
   Ishibashi, T
   Ninomiya, T
   Sonoda, KH
AF Fujiwara, Kohta
   Yasuda, Miho
   Hata, Jun
   Oshima, Yuji
   Hashimoto, Sawako
   Yoshitomi, Takeshi
   Kiyohara, Yutaka
   Ishibashi, Tatsuro
   Ninomiya, Toshiharu
   Sonoda, Koh-Hei
TI Prevalence and Risk Factors for Polypoidal Choroidal Vasculopathy in a
   General Japanese Population: The Hisayama Study
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; age-related macular degeneration;
   population-based study; risk factors; prevalence
ID AGE-RELATED MACULOPATHY; BLUE MOUNTAINS EYE; MACULAR DEGENERATION;
   CIGARETTE-SMOKING; CLINICAL CHARACTERISTICS; GRADING SYSTEM; CHINESE
AB Purpose: To estimate the prevalence and risk factors for polypoidal choroidal vasculopathy (PCV) in a general Japanese population. Methods: This population-based, cross-sectional study was conducted in 2007 with subjects from the Hisayama Study. Of the 3,648 residents in Hisayama, Japan, 2,663 who were 50 years old were enrolled in this study. The characteristics of PCV were determined by fundus examination or based on indocyanine green and fluorescein angiographic findings. We evaluated the contributions of the risk factors for PCV. Results: Among the 207 participants with age-related macular degeneration (AMD), 174 (6.5%) had early AMD, and 33 (1.2%) had late AMD, including 10 participants with PCV (0.4%). Male and smoking habit were significant risk factors for the development of PCV. Conclusions: The prevalence of PCV is higher among Japanese subjects than Caucasians in Western countries. Male gender and smoking habit were significant risk factors for PCV in a general Japanese population.
C1 [Fujiwara, Kohta; Hata, Jun; Hashimoto, Sawako; Ninomiya, Toshiharu] Kyushu Univ, Grad Sch Med Sci, Dept Epidemiol & Publ Hlth, Fukuoka, Fukuoka, Japan.
   [Fujiwara, Kohta; Yasuda, Miho; Oshima, Yuji; Hashimoto, Sawako; Ishibashi, Tatsuro; Sonoda, Koh-Hei] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka, Fukuoka, Japan.
   [Fujiwara, Kohta; Yoshitomi, Takeshi] Akita Univ, Grad Sch Med Sci, Dept Ophthalmol, Akita, Japan.
   [Hata, Jun; Ninomiya, Toshiharu] Kyushu Univ, Ctr Cohort Studies, Grad Sch Med Sci, Fukuoka, Fukuoka, Japan.
   [Kiyohara, Yutaka] Hisayama Res Inst Lifestyle Dis, Fukuoka, Japan.
C3 Kyushu University; Kyushu University; Akita University; Kyushu
   University
RP Yasuda, M (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka, Fukuoka 8128582, Japan.
EM miho-m@info.med.kyushu-u.ac.jp
FU Japanese Ministry of Education, Culture, Sports, Science, and Technology
   [18K09412, 18K16960]
FX This work was supported by the Japanese Ministry of Education, Culture,
   Sports, Science, and Technology [grant number 18K09412 to MY], [grant
   number 18K16960 to KF].
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   HECHT SS, 1988, CARCINOGENESIS, V9, P875, DOI 10.1093/carcin/9.6.875
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Katsuki S, 1966, Prog Brain Res, V21, P64
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LEVINE PH, 1973, CIRCULATION, V48, P619, DOI 10.1161/01.CIR.48.3.619
   Li Y, 2014, OPHTHALMOLOGY, V121, P2290, DOI 10.1016/j.ophtha.2014.06.016
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   OGSTON D, 1970, ATHEROSCLEROSIS, V11, P349, DOI 10.1016/0021-9150(70)90073-0
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 25
TC 11
Z9 11
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PY 2018
VL 33
IS 6
BP 813
EP 819
DI 10.1080/08820538.2018.1506483
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GT8VD
UT WOS:000444817100011
PM 30084710
DA 2022-11-30
ER

PT J
AU Corbelli, E
   Iuliano, L
   Fogliato, G
   Bandello, F
   Codenotti, M
AF Corbelli, Eleonora
   Iuliano, Lorenzo
   Fogliato, Giovanni
   Bandello, Francesco
   Codenotti, Marco
TI Silicone oil-induced displacement of subretinal hemorrhage in
   age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Subretinal hemorrhage; tissue plasminogen activator; ultra-wide field
   imaging; vitrectomy; silicone oil
ID TISSUE-PLASMINOGEN ACTIVATOR; PARS-PLANA VITRECTOMY; SUBMACULAR
   HEMORRHAGE; INJECTION
AB Purpose: To describe the use of silicone oil (SO) in combination with subretinal recombinant tissue plasminogen activator (rtPA) to achieve dislocation of large subretinal hemorrhage secondary to exudative age-related macular degeneration (AMD). Methods: A single-eye 81-year-old woman, known for exudative AMD, presented for a profound vision loss in her left eye since 7 days due to a massive subretinal hemorrhage. She promptly underwent standard three-port pars plana vitrectomy with subretinal injection of rtPA and SO tamponade. Results: The surgical technique showed favorable anatomical and functional outcomes, achieving a substantial peripheral displacement of blood and visual improvement. Conclusion: This report favorably supports the use of SO in adjunction to subretinal rtPA in selected cases of subretinal hemorrhage secondary to wet AMD.
C1 [Corbelli, Eleonora; Iuliano, Lorenzo; Fogliato, Giovanni; Bandello, Francesco; Codenotti, Marco] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Iuliano, L (通讯作者)，Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM iuliano.lorenzo@hsr.it
RI Iuliano, Lorenzo/X-1333-2019
OI Iuliano, Lorenzo/0000-0001-6664-1327; bandello,
   francesco/0000-0003-3238-9682
CR DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   HAYASAKA S, 1990, GRAEF ARCH CLIN EXP, V228, P277, DOI 10.1007/BF00920048
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Martel JN, 2013, JAMA OPHTHALMOL, V131, P1632, DOI 10.1001/jamaophthalmol.2013.5464
   Novelli FJD, 2017, RETINA-J RET VIT DIS, V37, P1607, DOI 10.1097/IAE.0000000000001491
   Parolini B, 2020, RETINA-J RET VIT DIS, V40, P507, DOI 10.1097/IAE.0000000000002429
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P575
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Wei YT, 2015, RETINA-J RET VIT DIS, V35, P1631, DOI 10.1097/IAE.0000000000000501
   Yamanaka A, 1986, 5 VAIL VITR SEM VAIL
NR 15
TC 0
Z9 0
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY
PY 2021
VL 31
IS 3
BP 1483
EP 1486
AR 1120672120952349
DI 10.1177/1120672120952349
EA AUG 2020
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TZ2CF
UT WOS:000561848500001
PM 32811180
DA 2022-11-30
ER

PT J
AU Klein, R
   Myers, CE
   Buitendijk, GHS
   Rochtchina, E
   Gao, XY
   de Jong, PTVM
   Sivakumaran, TA
   Burlutsky, G
   McKean-Cowdin, R
   Hofman, A
   Iyengar, SK
   Lee, KE
   Stricker, BH
   Vingerling, JR
   Mitchell, P
   Klein, BEK
   Klaver, CCW
   Wang, JJ
AF Klein, Ronald
   Myers, Chelsea E.
   Buitendijk, Gabrielle H. S.
   Rochtchina, Elena
   Gao, Xiaoyi
   de Jong, Paulus T. V. M.
   Sivakumaran, Theru A.
   Burlutsky, George
   McKean-Cowdin, Roberta
   Hofman, Albert
   Iyengar, Sudha K.
   Lee, Kristine E.
   Stricker, Bruno H.
   Vingerling, Johannes R.
   Mitchell, Paul
   Klein, Barbara E. K.
   Klaver, Caroline C. W.
   Wang, Jie Jin
TI Lipids, Lipid Genes, and Incident Age-Related Macular Degeneration: The
   Three Continent Age-Related Macular Degeneration Consortium
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID LONG-TERM INCIDENCE; BEAVER-DAM-EYE; 5-YEAR INCIDENCE; POOLED FINDINGS;
   VISUAL-ACUITY; RISK-FACTORS; MEDICATION USE; MACULOPATHY; CHOLESTEROL;
   PROGRESSION
AB PURPOSE: To describe associations of serum lipid levels and lipid pathway genes to the incidence of age-related macular degeneration (AMD).
   DESIGN: Meta-analysis.
   METHODS: SETTING: Three population-based cohorts. POPULATION: A total of 6950 participants from the Beaver Dam Eye Study (BDES), Blue Mountains Eye Study (BMES), and Rotterdam Study (RS). OBSERVATION PROCEDURES: Participants were followed over 20 years and examined at 5-year intervals. Hazard ratios associated with lipid levels per standard deviation above the mean or associated with each additional risk allele for each lipid pathway gene were calculated using random-effects inverse-weighted meta-analysis models, adjusting for known AMD risk factors. MAIN OUTCOME MEASURES: Incidence of AMD.
   RESULTS: The average 5-year incidences of early AMD were 8.1%, 15.1%, and 13.0% in the BDES, BMES, and RS, respectively. Substantial heterogeneity in the effect of cholesterol and lipid pathway genes on the incidence and progression of AMD was evident when the data from the 3 studies were combined in meta-analysis. After correction for multiple comparisons, we did not find a statistically significant association between any of the cholesterol measures, statin use, or serum lipid genes and any of the AMD outcomes in the meta-analysis.
   CONCLUSION: In a meta-analysis, there were no associations of cholesterol measures, history of statin use, or lipid pathway genes to the incidence and progression of AMD. These findings add to inconsistencies in earlier reports from our studies and others showing weak associations, no associations, or inverse associations of high-density lipoprotein cholesterol and total cholesterol with AMD. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Klein, Ronald; Myers, Chelsea E.; Lee, Kristine E.; Klein, Barbara E. K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [Buitendijk, Gabrielle H. S.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Buitendijk, Gabrielle H. S.; Hofman, Albert; Stricker, Bruno H.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Rochtchina, Elena; Burlutsky, George; Wang, Jie Jin] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Westmead, NSW 2145, Australia.
   [Rochtchina, Elena; Burlutsky, George; Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   [Rochtchina, Elena; Burlutsky, George; Mitchell, Paul] Univ Sydney, Westmead, NSW 2145, Australia.
   [Gao, Xiaoyi; McKean-Cowdin, Roberta] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
   [McKean-Cowdin, Roberta] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA.
   [de Jong, Paulus T. V. M.] Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Leiden Univ, Med Ctr, Dept Ophthalmol, Leiden, Netherlands.
   [Sivakumaran, Theru A.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA.
   [Sivakumaran, Theru A.; Iyengar, Sudha K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Hofman, Albert] Netherlands Genom Initiat, Netherlands Consortium Hlth Aging, The Hague, Netherlands.
   [Stricker, Bruno H.] Erasmus Univ, Dept Internal Med, Med Ctr, Rotterdam, Netherlands.
C3 University of Wisconsin System; University of Wisconsin Madison; Erasmus
   University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus
   MC; University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Sydney; University of Southern
   California; University of Southern California; Royal Netherlands Academy
   of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW);
   University of Amsterdam; Academic Medical Center Amsterdam; Leiden
   University; Leiden University Medical Center (LUMC); Leiden University -
   Excl LUMC; Cincinnati Children's Hospital Medical Center; Case Western
   Reserve University; Erasmus University Rotterdam; Erasmus MC
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,4th Floor WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI Wang, Jie Jin/P-1499-2014; Mitchell, Paul/P-1498-2014; /S-1190-2019;
   wang, jie/GRS-0942-2022; Klaver, Caroline C.W./A-2013-2016
OI Wang, Jie Jin/0000-0001-9491-4898; /0000-0001-7488-250X; Klaver,
   Caroline/0000-0002-2355-5258; Klein, Ronald/0000-0002-4428-6237
FU National Institutes of Health [EY06594]; Research to Prevent Blindness
   (RPB), New York, New York; National Health & Medical Research Council,
   Canberra, Australia [974159, 211069, 457349, 512423]; Wellcome Trust, UK
   as part of Wellcome Trust Case Control Consortium 2 [085475/B/08/Z,
   085475/08/Z]; Stichting Lijf en Leven, Krimpen aan de Lek; MD Fonds,
   Utrecht; Rotterdamse Vereniging Blindenbelangen, Rotterdam; Stichting
   Oogfonds Nederland, Utrecht; Blindenpenning, Amsterdam; Blindenhulp, The
   Hague; Algemene Nederlandse Vereniging ter Voorkoming van Blindheid
   (ANVVB), Doom; Landelijke Stichting voor Blinden en Slechtzienden,
   Utrecht; Swart van Essen, Rotterdam; Stichting Winckel-Sweep, Utrecht;
   Henkes Stichting, Rotterdam; Lameris Ootech BV, Nieuwegein; Medical
   Workshop, de Meern, the Netherlands; Topcon Europe BV, the Netherlands;
   Capelle aan de IJssel, the Netherlands; Heidelberg Engineering,
   Dossenheim, Germany; NATIONAL EYE INSTITUTE [U10EY006594] Funding
   Source: NIH RePORTER
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and had no financial disclosures to
   make. The Beaver Dam Eye Study was supported by National Institutes of
   Health grant EY06594 (B.E.K. Klein and R. Klein) and, in part, by an
   unrestricted grant from Research to Prevent Blindness (RPB), New York,
   New York. The Blue Mountains Eye Study was supported by grants 974159,
   211069, 457349, and 512423 from the National Health & Medical Research
   Council, Canberra, Australia, and genotyping cost was supported by the
   Wellcome Trust, UK as part of Wellcome Trust Case Control Consortium 2
   (grant IDs 085475/B/08/Z and 085475/08/Z). The Rotterdam Study is
   supported by Stichting Lijf en Leven, Krimpen aan de Lek; MD Fonds,
   Utrecht; Rotterdamse Vereniging Blindenbelangen, Rotterdam; Stichting
   Oogfonds Nederland, Utrecht; Blindenpenning, Amsterdam; Blindenhulp, The
   Hague; Algemene Nederlandse Vereniging ter Voorkoming van Blindheid
   (ANVVB), Doom; Landelijke Stichting voor Blinden en Slechtzienden,
   Utrecht; Swart van Essen, Rotterdam; Stichting Winckel-Sweep, Utrecht;
   Henkes Stichting, Rotterdam; Lameris Ootech BV, Nieuwegein; Medical
   Workshop, de Meern; Topcon Europe BV, Capelle aan de IJssel, all in the
   Netherlands; and Heidelberg Engineering, Dossenheim, Germany.
   Contributions of authors: design and conduct of the study (R.K.,
   P.T.V.M.D.J., A.H., J.R.V., C.C.W.K., J.J.W.); collection (R.K.,
   P.T.V.M.D.J., A.H., J.R.V., P.M., B.E.K.K., C.C.W.K., J.J.W.),
   management (R.K., P.T.V.M.D.J., A.H., J.R.V., P.M., B.E.K.K., C.C.W.K.,
   J.J.W.), analysis (C.E.M., G.H.S.B., E.R., X.G., T.A.S., G.B., S.K.I.,
   K.E.L., B.H.S.), and interpretation of data (R.K., C.E.M., G.H.S.B.,
   E.R., G.B., A.H., S.K.I., K.E.L., B.H.S., B.E.K.K., C.C.W.K., J.J.W.);
   preparation (R.K., C.E.M.), review (G.H.S.B., E.R., X.G., P.T.V.M.D.J.,
   T.A.S., G.B., R.M.-C., A.H., S.K.I., K.E.L., B.H.S., J.R.V., P.M.,
   B.E.K.K., C.C.W.K., J.J.W.), and approval of manuscript (R.K., C.E.M.,
   G.H.S.B., E.R., X.G., P.T.V.M.D.J., T.A.S., G.B., R.M.-C., A.H., S.K.I.,
   K.E.L., B.H.S., J.R.V., P.M., B.E.K.K., C.C.W.K., J.J.W.).
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   ALLAIN CC, 1974, CLIN CHEM, V20, P470
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hofman A, 2013, EUR J EPIDEMIOL, V28, P889, DOI 10.1007/s10654-013-9866-z
   Hofman A, 2011, EUR J EPIDEMIOL, V26, P657, DOI 10.1007/s10654-011-9610-5
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Huang L, 2009, AM J HUM GENET, V84, P235, DOI 10.1016/j.ajhg.2009.01.013
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 54
TC 60
Z9 62
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2014
VL 158
IS 3
BP 513
EP 524
DI 10.1016/j.ajo.2014.05.027
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO2CZ
UT WOS:000341124400014
PM 24879949
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Fein, JG
   Branchini, LA
   Manjunath, V
   Regatieri, CV
   Fujimoto, JG
   Duker, JS
AF Fein, Jordana G.
   Branchini, Lauren A.
   Manjunath, Varsha
   Regatieri, Caio V.
   Fujimoto, James G.
   Duker, Jay S.
TI Analysis of Short-Term Change in Subfoveal Choroidal Thickness in Eyes
   With Age-Related Macular Degeneration Using Optical Coherence Tomography
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID BLOOD-FLOW; PRESSURE; RABBIT; AUTOREGULATION; RANIBIZUMAB; PREVALENCE;
   THERAPY
AB BACKGROUND AND OBJECTIVE: To measure the sub-foveal choroidal thickness in patients with age-related macular degeneration (AMD) over 6 months.
   PATIENTS AND METHODS: A retrospective, observational study of patients with AMD followed up for 6 months at the New England Eye Center. Baseline and 6-month follow-up subfoveal choroidal thickness was measured using spectral-domain OCT and compared.
   RESULTS: For the entire cohort, there was statistically significant thinning of the subfoveal choroidal thickness at 6 months compared to baseline that was driven by the cohort of patients with neovascular AMD (181.2 +/- 75 mu m to 173.4 +/- 63 mu m; P=.049).
   CONCLUSION: There was a statistically significant decrease in subfoveal choroidal thickness observed in this cohort of patients with AMD over 6 months, but it was driven by the subgroup of patients with neovascular age-related macular degeneration.
C1 [Fein, Jordana G.; Branchini, Lauren A.; Manjunath, Varsha; Regatieri, Caio V.; Duker, Jay S.] Tufts Med Ctr, New England Eye Ctr, Boston, MA USA.
   [Regatieri, Caio V.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Elect Res Lab, Cambridge, MA 02139 USA.
C3 Tufts Medical Center; Universidade Federal de Sao Paulo (UNIFESP);
   Massachusetts Institute of Technology (MIT)
RP Fein, JG (通讯作者)，New England Eye Ctr, 800 Washington St,POB 450, Boston, MA 02111 USA.
EM jfein@tuftsmedicalcenter.org
RI Regatieri, Caio/G-8152-2014
OI Regatieri, Caio/0000-0003-1511-8696
FU Research to Prevent Blindness; NIH [RO1-EY11289-25, R01-EY13178-10,
   R01-EY013516-07, R01-EY019029-02]; Air Force Office of Scientific
   Research [FA9550-10-1-0551, FA9550-10-1-0063]; NATIONAL EYE INSTITUTE
   [R01EY011289, R01EY013516, R01EY019029, R01EY013178] Funding Source: NIH
   RePORTER
FX Supported in part by a Research to Prevent Blindness challenge grant to
   the New England Eye Center, Department of Ophthalmology-Tufts University
   School of Medicine; NIH contracts RO1-EY11289-25, R01-EY13178-10,
   R01-EY013516-07, and R01-EY019029-02; and Air Force Office of Scientific
   Research FA9550-10-1-0551 and FA9550-10-1-0063.
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakraborty R, 2011, INVEST OPHTH VIS SCI, V52, P5121, DOI 10.1167/iovs.11-7364
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Ferguson RD, 2004, OPT LETT, V29, P2139, DOI 10.1364/OL.29.002139
   Forte R, 2012, J OCUL PHARMACOL TH, V28, P69, DOI 10.1089/jop.2010.0181
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   KIEL JW, 1992, INVEST OPHTH VIS SCI, V33, P2399
   KIEL JW, 1995, INVEST OPHTH VIS SCI, V36, P579
   Kiel JW, 1999, EXP EYE RES, V69, P413, DOI 10.1006/exer.1999.0717
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Potsaid B, 2008, OPT EXPRESS, V16, P15149, DOI 10.1364/OE.16.015149
   Rahman W, 2013, GRAEF ARCH CLIN EXP, V251, P1483, DOI 10.1007/s00417-012-2199-x
   Reiner A, 2003, EXP EYE RES, V76, P273, DOI 10.1016/S0014-4835(02)00316-0
   Sander B, 2005, BRIT J OPHTHALMOL, V89, P207, DOI 10.1136/bjo.2004.045989
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
NR 30
TC 16
Z9 17
U1 1
U2 5
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD JAN-FEB
PY 2014
VL 45
IS 1
BP 32
EP 37
DI 10.3928/23258160-20131220-04
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA AE2OI
UT WOS:000333812200004
PM 24392909
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Dag, MY
   Afrashi, F
   Nalcaci, S
   Mentes, J
   Akkin, C
AF Dag, Medine Yilmaz
   Afrashi, Filiz
   Nalcaci, Serhad
   Mentes, Jale
   Akkin, Cezmi
TI The efficacy of "IOL-Vip Revolution" telescopic intraocular lens in
   age-related macular degeneration cases with senile cataract
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; cataract; IOL-Vip Revolution system;
   telescopic intraocular lens
ID SYSTEM
AB Purpose: To evaluate the efficacy of the IOL-Vip Revolution telescopic intraocular lens in age-related macular degeneration patients. Methods: A total of 13 eyes of 12 age-related macular degeneration patients with senile cataract were enrolled. Selection of the patients was done by means of a low vision diagnostic and rehabilitative program (IOL-Vip software) that evaluates residual visual function. After standard phacoemulsification surgery, the incision site was enlarged and the IOL-Vip Revolution system was implanted in the capsular bag. The outcome measures were best corrected visual acuity, contrast sensitivity, anterior chamber depth, endothelial cell density, central corneal thickness, and quality-of-life questionnaire. Results: The mean age of the subjects was 72.3 +/- 8.5 years. The mean positive power of the intraocular lens was 59 +/- 2 D and the negative intraocular lens power was standard (-46 D). Pre- and postoperative best corrected visual acuity were 1.08 +/- 0.14 and 0.81 +/- 0.16 logMAR in the operated eye and 1.13 +/- 0.36 and 1.01 +/- 0.40 logMAR in the unoperated eye, respectively. The best corrected visual acuity was increased significantly in both operated and unoperated eyes (p = 0.005 and 0.021, respectively). Quality of life and anterior chamber depth increased significantly (p = 0.018 and 0.008, respectively), while endothelial cell density decreased (p = 0.002). No significant differences were detected in central corneal thickness or contrast sensitivity (p = 0.133 and 0.684, respectively). Conclusion: The results showed that IOL-Vip Revolution telescopic intraocular lens is a promising treatment option in age-related macular degeneration patients. The rehabilitation program may have an important role in the restored clinical results, which also provided visual improvement in the unoperated eyes.
C1 [Dag, Medine Yilmaz] Izmir Katip Celebi Univ Ataturk Training & Res Ho, Dept Ophthalmol, Izmir, Turkey.
   [Afrashi, Filiz; Nalcaci, Serhad; Mentes, Jale; Akkin, Cezmi] Ege Univ, Fac Med, Dept Ophthalmol, Izmir, Turkey.
C3 Izmir Katip Celebi University; Ege University
RP Dag, MY (通讯作者)，Izmir Katip Celebi Univ Ataturk Training & Res Ho, Dept Ophthalmol, Goz Hast AD, TR-35150 Izmir, Turkey.
EM drmedocan@yahoo.com
RI MENTES, JALE/AFO-2110-2022; afrashi, filiz/ABB-6647-2020; akkın,
   cezmi/ABG-4054-2021
OI afrashi, filiz/0000-0001-6359-1600; 
FU scientific research committee of Ege University
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This study
   was funded by the scientific research committee of Ege University.
CR Agarwal A, 2008, J CATARACT REFR SURG, V34, P87, DOI 10.1016/j.jcrs.2007.08.031
   Ahuja AK, 2011, BRIT J OPHTHALMOL, V95, P539, DOI 10.1136/bjo.2010.179622
   Amselem L, 2008, J CATARACT REFR SURG, V34, P1571, DOI 10.1016/j.jcrs.2008.05.032
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gohdes Dorothy M, 2005, Prev Chronic Dis, V2, pA17
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Lane SS, 2004, AM J OPHTHALMOL, V137, P993, DOI 10.1016/j.ajo.2004.01.030
   Lipshitz I, 2000, OPERATIVE TECHNIQUES, V3, P53
   Orzalesi N, 2007, OPHTHALMOLOGY, V114, P860, DOI 10.1016/j.ophtha.2007.01.005
   Peli E, 2002, OPTOMETRY VISION SCI, V79, P225, DOI 10.1097/00006324-200204000-00009
   Savaresi C, 2013, GIORNALE ITALIANO VI, V5
   Singer MA, 2012, CLIN OPHTHALMOL, V6, P33, DOI 10.2147/OPTH.S15028
   Toprak AB, 2005, OPHTHAL EPIDEMIOL, V12, P259, DOI 10.1080/09286580590967763
NR 13
TC 4
Z9 4
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV
PY 2019
VL 29
IS 6
BP 615
EP 620
DI 10.1177/1120672118803831
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JD0BL
UT WOS:000489640400006
PM 30280594
DA 2022-11-30
ER

PT J
AU Hernandez-Pastor, LJ
   Ortega, A
   Garcia-Layana, A
   Giraldez, J
AF Hernandez-Pastor, Luis Javier
   Ortega, Ana
   Garcia-Layana, Alfredo
   Giraldez, Joaquin
TI Ranibizumab for neovascular age-related macular degeneration
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Review
DE antibodies; macular degeneration; mechanism of action;
   pharmacoeconomics; pharmacokinetics; ranibizumab; toxicity
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL TRIAMCINOLONE
   ACETONIDE; COMBINED PHOTODYNAMIC THERAPY; BEVACIZUMAB AVASTIN;
   VERTEPORFIN; INJECTION; SAFETY; PEGAPTANIB; PHARMACOKINETICS;
   PENETRATION
AB Purpose. The pharmacology, pharmacokinetics, clinical efficacy, safety, pharmacoeconomics, and place in therapy of ranibizumab are reviewed.
   Summary. Ranibizumab is the humanized fragment of the murine monoclonal antibody that binds all the active forms of the vascular endothelial growth factor, leading to the inhibition of the neovascular process underlying age-related macular degeneration (AMD). In animal studies, intravitreal administration of ranibizumab resulted in penetration of the drug into all layers of the retina and subsequent slow absorption into the systemic circulation. Improvement in visual acuity by 15 or more letters has been observed in 33.8-40.3% of patients treated with ranibizumab in pivotal clinical trials, compared with 5% of patients treated with sham injections and photodynamic therapy (PDT). The addition of PDT to ranibizumab has not been shown to offer any benefit in terms of efficacy and has been found to worsen ocular adverse reactions. The most common adverse ocular reactions reported in patients receiving ranibizumab during clinical trials include conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, and intraocular inflammation. Ranibizumab's efficacy in the treatment of neovascular AMD is well established; however, questions remain regarding the drug's optimal dosing strategy, duration of therapy, and combined therapy with other agents. While ranibizumab has been defined as the best available weapon against AMD, it is also the most expensive.
   Conclusion. The efficacy of ranibizumab in the treatment of AMD is well established, but more studies are needed to determine ranibizumab's optimal dosage interval, duration of therapy, and combined use with other agents.
C1 [Hernandez-Pastor, Luis Javier; Giraldez, Joaquin] Univ Navarra, Dept Pharm, Clin Univ, Pamplona 31008, Spain.
   [Ortega, Ana; Garcia-Layana, Alfredo; Giraldez, Joaquin] Univ Navarra, Fac Pharm, Pamplona 31008, Spain.
C3 University of Navarra; University of Navarra
RP Hernandez-Pastor, LJ (通讯作者)，Univ Navarra, Dept Pharm, Clin Univ, Av Pio XII 36,PC, Pamplona 31008, Spain.
EM luisjaher@unav.es
RI ORTEGA, ANA/D-2408-2017
OI ORTEGA, ANA/0000-0003-1456-2437
CR Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Epstein P, 2007, ANN INTERN MED, V146, P532, DOI 10.7326/0003-4819-146-7-200704030-00011
   *EUR MED AG, LUC EUR PUBL ASS REP
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   *GEN, 2008, LUC RAN INJ PACK INS
   *GEN INC, 2007, DEAR HLTH CAR PROV L
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P12, DOI 10.1186/1478-7547-6-12
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jampol LM, 2007, ARCH OPHTHALMOL-CHIC, V125, P557, DOI 10.1001/archopht.125.4.557
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   Lobo ED, 2004, J PHARM SCI-US, V93, P2645, DOI 10.1002/jps.20178
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Mitka M, 2007, JAMA-J AM MED ASSOC, V297, P1538, DOI 10.1001/jama.297.14.1538
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   *NAT EYE I, COMP AMD TREATM TRIA
   *NOV, 2007, VIS VERT INJ PACK IN
   *NOV OPHTH, 2007, DAT FIL
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   *OSI EYET, 2006, MAC PEG SOD INJ PACK
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Raftery JP, 2007, BRIT MED J, V334, P381, DOI 10.1136/bmj.39128.708565.3A
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Ruiz-Moreno JM, 2007, RETINA-J RET VIT DIS, V27, P458, DOI 10.1097/IAE.0b013e318030c77c
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   Schellekens H, 2002, CLIN THER, V24, P1720, DOI 10.1016/S0149-2918(02)80075-3
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   WOCHNER RD, 1967, J EXP MED, V126, P207, DOI 10.1084/jem.126.2.207
NR 51
TC 23
Z9 23
U1 0
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-2082
EI 1535-2900
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD OCT 1
PY 2008
VL 65
IS 19
BP 1805
EP 1814
DI 10.2146/ajhp070342
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 350NM
UT WOS:000259359400011
PM 18796421
DA 2022-11-30
ER

PT J
AU Huisingh, C
   McGwin, G
   Neely, D
   Zarubina, A
   Clark, M
   Zhang, YH
   Curcio, CA
   Owsley, C
AF Huisingh, Carrie
   McGwin, Gerald, Jr.
   Neely, David
   Zarubina, Anna
   Clark, Mark
   Zhang, Yuhua
   Curcio, Christine A.
   Owsley, Cynthia
TI The Association Between Subretinal Drusenoid Deposits in Older Adults in
   Normal Macular Health and Incident Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; normal macular health; subretinal
   drusenoid deposits
ID C-REACTIVE PROTEIN; RETICULAR PSEUDODRUSEN; GEOGRAPHIC-ATROPHY;
   CUMULATIVE INCIDENCE; DARK-ADAPTATION; RISK-FACTOR; PROGRESSION; EYES;
   PREVALENCE; MACULOPATHY
AB PURPOSE. Subretinal drusenoid deposits (SDD) have been associated with the progression to late age-related macular degeneration (AMD). To determine whether SDD in eyes in normal macular health increases risk for early AMD, this study examined the association between presence of SDD at baseline in a cohort of older adults in normal macular health and incident AMD 3 years later.
   METHODS. Subjects enrolled in the Alabama Study on Early Age-Related Macular Degeneration (ALSTAR) were assessed for the presence of SDD using color fundus photos, infrared reflectance and fundus autofluorescence images, and spectral-domain optical coherence tomography volumes. The study sample included 799 eyes from 455 participants in normal macular health per grading of color fundus photographs using the 9-step Age-Related Eye Disease Study (AREDS) classification system. Age-related macular degeneration was defined as eyes having an AREDS grade >= 2 at the 3-year follow-up.
   RESULTS. Twenty-five percent of participants had SDD in one or both eyes at baseline. At follow-up visit, 11.9% of eyes in the sample developed AMD. Compared to eyes without SDD, those with SDD were 2.24 (95% confidence interval [CI] 1.36-3.70) times more likely to have AMD at follow-up. After adjusting for age, C-reactive protein quartile, and family history of AMD, the association persisted.
   CONCLUSIONS. Results suggest that SDD in older eyes with normal macular health as defined by the AREDS scale is a risk factor for the development of early AMD. Older adults in seemingly normal macular health yet having SDD may warrant closer clinical monitoring for the possible onset of early AMD.
C1 [Huisingh, Carrie; McGwin, Gerald, Jr.; Neely, David; Zarubina, Anna; Clark, Mark; Zhang, Yuhua; Curcio, Christine A.; Owsley, Cynthia] Univ Alabama Birmingham, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Owsley, C (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM owsley@uab.edu
OI Huisingh, Carrie/0000-0002-7010-2024
FU National Institutes of Health (NIH) [R01AG04212, R01EY06109,
   R01EY024378]; EyeSight Foundation of Alabama; Alfreda J. Schueler Trust;
   Research to Prevent Blindness, Inc.; NATIONAL EYE INSTITUTE
   [R01EY024378, R01EY006109] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON AGING [R01AG004212] Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health (NIH R01AG04212,
   R01EY06109, R01EY024378); the EyeSight Foundation of Alabama; Alfreda J.
   Schueler Trust; and Research to Prevent Blindness, Inc.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Alten F, 2014, INVEST OPHTH VIS SCI, V55, P6073, DOI 10.1167/iovs.13-13804
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   National Health Interview Survey, QUEST DAT REL DOC 19
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Ooto S, 2015, RETINA-J RET VIT DIS, V35, P1726, DOI 10.1097/IAE.0000000000000608
   Owsley C, 2002, JAMA-J AM MED ASSOC, V288, P841, DOI 10.1001/jama.288.7.841
   Owsley C, OPHTHALMOLO IN PRESS
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Saade C, 2014, CLIN EXP OPHTHALMOL, V42, P865, DOI 10.1111/ceo.12353
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Schaal KB, 2015, OSLI RETINA, V46, P550, DOI 10.3928/23258160-20150521-06
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Szalai AJ, 2000, J IMMUNOL, V165, P1030, DOI 10.4049/jimmunol.165.2.1030
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarubina AV, 2016, OPHTHALMOLO IN PRESS
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 54
TC 19
Z9 19
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2016
VL 57
IS 2
BP 739
EP 745
DI 10.1167/iovs.15-18316
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DI6EF
UT WOS:000373591300053
PM 26906160
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Toalster, N
   Russell, M
   Ng, P
AF Toalster, Nicholas
   Russell, Matthew
   Ng, Paul
TI A 12-MONTH PROSPECTIVE TRIAL OF INJECT AND EXTEND REGIMEN FOR
   RANIBIZUMAB TREATMENT OF AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE ranibizumab; inject and extend; intravitreal; age-related macular
   degeneration; variable dosing; PrONTO; neovascular; optical coherence
   tomography; visual acuity; central retinal thickness
ID GROWTH-FACTOR THERAPY; DOSING REGIMEN
AB Purpose: To evaluate the safety and efficacy of a strictly applied inject and extend protocol for ranibizumab treatment of age-related macular degeneration.
   Methods: This is a prospective, multicenter, nonrandomized trial. Patients underwent standard induction with 3 intravitreal doses of 0.5 mg ranibizumab, each 1 month apart. Following this induction, patients were evaluated and received an injection at each visit. If they did not meet set criteria for signs of exudative disease the interval to the next visit was extended by 2 weeks and if exudative disease was present the interval was shortened by 2 weeks.
   Results: Vision improved by 1.3 lines (P = 0.008); 26% gained >= 3 lines of vision, 74% lost no lines of vision, and 95% avoided loss of >= 3 lines of vision.
   Conclusion: This study shows that the Inject and Extend protocol is safe and efficacious for the treatment of age-related macular degeneration. Head-to-head studies are needed to compare directly with other regimens currently in use, as well as economic analysis to investigate the financial implications.
C1 [Toalster, Nicholas] Univ Queensland, Sch Med, Brisbane, Qld 4072, Australia.
   [Russell, Matthew; Ng, Paul] Ctr Eye, Southport, Qld, Australia.
   [Russell, Matthew; Ng, Paul] Vis Eye Inst, Brisbane, Qld, Australia.
C3 University of Queensland
RP Toalster, N (通讯作者)，288 Herston Rd, Brisbane, Qld 4006, Australia.
EM nicktoalster@me.com
CR Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P12, DOI 10.1186/1478-7547-6-12
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
NR 15
TC 58
Z9 61
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2013
VL 33
IS 7
BP 1351
EP 1358
DI 10.1097/IAE.0b013e3182831265
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 300NN
UT WOS:000330470700008
PM 23538578
DA 2022-11-30
ER

PT J
AU Roizenblatt, M
   Naranjit, N
   Maia, M
   Gehlbach, PL
AF Roizenblatt, Marina
   Naranjit, Nara
   Maia, Mauricio
   Gehlbach, Peter L.
TI The Question of a Role for Statins in Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; atherosclerotic disease; cholesterol;
   retina; statins
ID REDUCTASE INHIBITORS STATINS; UNESTERIFIED CHOLESTEROL;
   APOLIPOPROTEIN-B; NATIONAL-HEALTH; BASAL DEPOSITS; GROWTH-FACTOR;
   PROGRESSION; METABOLISM; RETINA; RISK
AB Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in patients over the age of 65 years in industrialized countries. Epidemiologic studies suggest that high dietary fat intake is a risk factor for the development and progression of both vascular and retinal disease. These, and other associations, suggest a hypothesis linking elevated cholesterol and AMD progression. It follows, therefore, that cholesterol-lowering medications, such as statins, may influence the onset and progression of AMD. However, the findings have been inconclusive as to whether statins play a role in AMD. Due to the significant public health implications of a potential inhibitory effect of statins on the onset and progression of AMD, it is important to continually evaluate emerging findings germane to this question.
C1 [Roizenblatt, Marina; Naranjit, Nara; Gehlbach, Peter L.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Roizenblatt, Marina; Maia, Mauricio] Univ Fed Sao Paulo, Dept Ophthalmol, BR-04023062 Sao Paulo, Brazil.
   [Roizenblatt, Marina; Maia, Mauricio] Univ Fed Sao Paulo, Paulista Med Sch, Dept Ophthalmol, Vis Inst,IPEPO, BR-04038032 Sao Paulo, Brazil.
C3 Johns Hopkins University; Universidade Federal de Sao Paulo (UNIFESP);
   Universidade Federal de Sao Paulo (UNIFESP)
RP Gehlbach, PL (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
EM maroizenb@gmail.com; nnaranj2@jhmi.edu; maiamauricio@terra.com.br;
   pgelbach@jhmi.edu
RI Roizenblatt, Marina/ABF-6408-2021; Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
FU Lemann Foundation; Instituto de Visao-IPEPO, Sao Paulo, Brazil; Research
   to Prevent Blindness, New York, New York, USA; J. Willard and Alice S.
   Marriott Foundation; Gale Trust; CNPq-National Council for Scientific
   and Technological Development, Brasilia, DF, Brazil
FX (M.R.) Lemann Foundation, Instituto de Visao-IPEPO, Sao Paulo, Brazil.
   (P.G.) Research to Prevent Blindness, New York, New York, USA, and gifts
   by the J. Willard and Alice S. Marriott Foundation, the Gale Trust, Herb
   Ehlers, Bill Wilbur, Rajandre Shaw, Don Feiner and Maggie Feiner, Helen
   Nassif and Ronald Stiff. (M.M.) CNPq-National Council for Scientific and
   Technological Development, Brasilia, DF, Brazil.
CR Al-Holou SN, 2015, OPHTHALMOLOGY, V122, P2490, DOI 10.1016/j.ophtha.2015.08.028
   Albert A, 2016, CHEM PHYS LIPIDS, V199, P94, DOI 10.1016/j.chemphyslip.2016.04.008
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Barathi VA, 2014, INVEST OPHTH VIS SCI, V55, P460, DOI 10.1167/iovs.13-11636
   Barbosa DTQ, 2014, EYE, V28, P472, DOI 10.1038/eye.2014.8
   Blum A, 2009, ATHEROSCLEROSIS, V203, P325, DOI 10.1016/j.atherosclerosis.2008.08.022
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brautbar A, 2011, NAT REV CARDIOL, V8, P253, DOI 10.1038/nrcardio.2011.2
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Cavelier C, 2006, BBA-MOL CELL BIOL L, V1761, P655, DOI 10.1016/j.bbalip.2006.04.012
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Do DV, 2009, OPHTHALMOLOGY, V116, pS24, DOI 10.1016/j.ophtha.2009.06.049
   Dryja TP, 2016, JAMA OPHTHALMOL, V134, P1281, DOI 10.1001/jamaophthalmol.2016.3031
   Eandi CM, 2016, EUR J PHARMACOL, V787, P78, DOI 10.1016/j.ejphar.2016.03.002
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Fong DS, 2010, AM J OPHTHALMOL, V149, P955, DOI 10.1016/j.ajo.2009.12.037
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Funatsu T, 2001, ATHEROSCLEROSIS, V157, P107, DOI 10.1016/S0021-9150(00)00714-0
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   Green W Richard, 2005, Retina, V25, P1519, DOI 10.1097/00006982-200507001-00015
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Guymer RH, 2008, CLIN INTERV AGING, V3, P581
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin JB, 2016, J LIPID RES, V57, P258, DOI 10.1194/jlr.M064469
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep18280
   Machalinska Anna, 2013, Klin Oczna, V115, P74
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Martini E., 1991, VALUTAZIONE EFFETTI, V117
   Mast N, 2011, INVEST OPHTH VIS SCI, V52, P594, DOI 10.1167/iovs.10-6021
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Ostadal P, 2012, EXP CLIN CARDIOL, V17, P227
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Rader DJ, 2000, MOL MED TODAY, V6, P170, DOI 10.1016/S1357-4310(00)01673-7
   Rodriguez IR, 2014, EXP EYE RES, V128, P151, DOI 10.1016/j.exer.2014.09.009
   Roizenblatt M., 2018, INSIGHT, V43, P5
   Saadane A, 2016, J BIOL CHEM, V291, P20427, DOI 10.1074/jbc.M116.744656
   Sackett Catherine Stewart, 2002, Insight, V27, P5
   Saeed MU, 2013, CLIN OPHTHALMOL, V7, P533, DOI 10.2147/OPTH.S31016
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Terai N, 2011, ACTA OPHTHALMOL, V89, pE500, DOI 10.1111/j.1755-3768.2011.02154.x
   Tian B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02407-7
   Tian J, 2005, P NATL ACAD SCI USA, V102, P11846, DOI 10.1073/pnas.0504759102
   Tolentino MJ, 2015, EXPERT OPIN INV DRUG, V24, P183, DOI 10.1517/13543784.2015.961601
   Tsao SW, 2013, DRUG AGING, V30, P205, DOI 10.1007/s40266-013-0061-4
   Tserentsoodol N, 2006, MOL VIS, V12, P18
   Tserentsoodol N, 2006, MOL VIS, V12, pe33
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   Wilkinson-Berka JL, 2004, CURR PHARM DESIGN, V10, P3331, DOI 10.2174/1381612043383142
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zheng WC, 2015, J LIPID RES, V56, P81, DOI 10.1194/jlr.M053439
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
NR 86
TC 12
Z9 13
U1 3
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2018
VL 19
IS 11
AR 3688
DI 10.3390/ijms19113688
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HC0ZM
UT WOS:000451528500404
PM 30469381
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Jayaraman, MS
   Bharali, DJ
   Sudha, T
   Mousa, SA
AF Jayaraman, Melamangalam S.
   Bharali, Dhruba J.
   Sudha, Thangirala
   Mousa, Shaker A.
TI Nano chitosan peptide as a potential therapeutic carrier for retinal
   delivery to treat age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID IMPLANTABLE MINIATURE TELESCOPE; DRUG-DELIVERY; OXIDATIVE STRESS;
   NANOPARTICLES; MERTK; ALPHA-V-BETA-5; RANIBIZUMAB; INHIBITION;
   MECHANISM; TYROSINE
AB Purpose: We describe the synthesis and use of an efficient nano carrier molecule for retinal delivery of a nano chitosan peptide that has potential application for treating age-related macular degeneration (AMD). We chose serine-threonine-tyrosine as the peptide sequence because it is well known to act as a transduction signaling agent within and between retinal pigmented epithelium cells.
   Methods: A nanoformulation of a water-soluble chitosan conjugated with a peptide (serine-threonine-tyrosine) was synthesized by a method developed in our laboratory and characterized with dynamic light scattering, zeta potential, transmission electron microscopy, nuclear magnetic resonance, and Fourier transform infrared spectroscopy. The in vitro efficacy of the formulation was evaluated in retinal cells with confocal microscopy by studying the formulation's action on tyrosine kinase activity.
   Results: The conjugated nano chitosan peptide showed evidence of tyrosine kinase activity as seen by fluorescent signals under confocal microscopy, while nano chitosan or peptide alone did not show such activity.
   Conclusions: Conjugated nano chitosan peptide may promote binding and engulfment. This molecule is an excellent carrier for retinal drug delivery and has the potential to treat age-related macular degeneration.
C1 [Jayaraman, Melamangalam S.; Bharali, Dhruba J.; Sudha, Thangirala; Mousa, Shaker A.] Albany Coll Pharm & Hlth Sci, Pharmaceut Res Inst, Rensselaer, NY 12144 USA.
C3 Albany College of Pharmacy & Health Sciences
RP Mousa, SA (通讯作者)，Albany Coll Pharm & Hlth Sci, Pharmaceut Res Inst, 1 Discovery Dr, Rensselaer, NY 12144 USA.
EM shaker.mousa@acphs.edu
RI Mousa, Shaker A/A-7151-2017
OI Mousa, Shaker A/0000-0002-9294-015X
FU Pharmaceutical Research Institute (General Fund)
FX We thank Laura Stellato for taking special interest in organizing
   references and procuring materials for research, and Dr. Kelly A.
   Keating for manuscript editing. Disclosures: The authors report no
   conflicts of interest. Financial research support was provided by the
   Pharmaceutical Research Institute (General Fund).
CR Alonso MJ, 2003, J PHARM PHARMACOL, V55, P1451, DOI 10.1211/0022357022476
   Artcanuthurry Valerie, 1996, Seminars in Thrombosis and Hemostasis, V22, P317, DOI 10.1055/s-2007-999026
   Brown S B, 2001, Expert Opin Pharmacother, V2, P351
   Cashman SM, 2006, INVEST OPHTH VIS SCI, V47, P3496, DOI 10.1167/iovs.05-1610
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   de Campos AM, 2004, PHARM RES-DORDR, V21, P803, DOI 10.1023/B:PHAM.0000026432.75781.cb
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Salamanca AE, 2006, INVEST OPHTH VIS SCI, V47, P1416, DOI 10.1167/iovs.05-0495
   Dung TH, 2007, J NANOSCI NANOTECHNO, V7, P3695, DOI 10.1166/jnn.2007.041
   Feng W, 2002, J BIOL CHEM, V277, P17016, DOI 10.1074/jbc.M107876200
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gaspar VM, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/1/015101
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Han HD, 2010, CLIN CANCER RES, V16, P3910, DOI 10.1158/1078-0432.CCR-10-0005
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Hunt DWC, 2003, IDRUGS, V6, P464
   Kumar A, 2010, NANOMED-NANOTECHNOL, V6, P64, DOI 10.1016/j.nano.2009.04.002
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Mallavarapu M, 2010, ADV EXP MED BIOL, V664, P123, DOI 10.1007/978-1-4419-1399-9_15
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Mochizuki M, 2007, BIOPOLYMERS, V88, P122, DOI 10.1002/bip.20684
   ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009
   Paolicelli P, 2009, EXPERT OPIN DRUG DEL, V6, P239, DOI 10.1517/17425240902762818
   Primo SA, 2010, OPTOMETRY, V81, P86, DOI 10.1016/j.optm.2009.08.014
   Qin SF, 2012, EXP EYE RES, V94, P63, DOI 10.1016/j.exer.2011.11.007
   Quan HZ, 2009, MED HYPOTHESES, V73, P205, DOI 10.1016/j.mehy.2009.02.018
   Rajendran NN, 2010, ASIAN J PHARM, V4, DOI 10.4103/0973-8398.76749
   Richter C, 2001, CELL DEATH DIFFER, V8, P207, DOI 10.1038/sj.cdd.4400849
   Schraermeyer U, 2006, EXP EYE RES, V83, P315, DOI 10.1016/j.exer.2005.12.015
   Seagle BLL, 2005, P NATL ACAD SCI USA, V102, P8978, DOI 10.1073/pnas.0501971102
   Szeto HH, 2006, AAPS J, V8, pE521, DOI 10.1208/aapsj080362
   TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Vi L, 2011, J INVEST DERMATOL, V131, P586, DOI 10.1038/jid.2010.362
   Waisbourd M, 2011, ISR MED ASSOC J, V13, P141
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P474, DOI 10.1562/2005-10-21-RA-725
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Yamagata N, 2007, 4 INT PEPT S CONJ 7
   Zhang P, 2000, SHOCK, V13, P34, DOI 10.1097/00024382-200013010-00007
NR 41
TC 25
Z9 25
U1 1
U2 30
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD SEP 3
PY 2012
VL 18
IS 244
BP 2300
EP 2308
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 001KQ
UT WOS:000308459900001
PM 22977298
DA 2022-11-30
ER

PT J
AU Lazzeri, S
   Figus, M
   Orlandi, P
   Fioravanti, A
   Di Desidero, T
   Agosta, E
   Sartini, MS
   Posarelli, C
   Nardi, M
   Danesi, R
   Bocci, G
AF Lazzeri, Stefano
   Figus, Michele
   Orlandi, Paola
   Fioravanti, Anna
   Di Desidero, Teresa
   Agosta, Elisa
   Sartini, Maria Sole
   Posarelli, Chiara
   Nardi, Marco
   Danesi, Romano
   Bocci, Guido
TI VEGF-A polymorphisms predict short-term functional response to
   intravitreal ranibizumab in exudative age-related macular degeneration
SO PHARMACOGENOMICS
LA English
DT Article
DE exudative age-related macular degeneration; pharmacogenetics;
   polymorphisms; ranibizumab; VEGF-A
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION SECONDARY;
   FACTOR GENE; PHARMACOGENETICS; VERTEPORFIN; BEVACIZUMAB; PEGAPTANIB;
   THERAPY; LESIONS
AB Aim: To investigate the association between VEGF gene SNPs and early response to intravitreal ranibizumab for exudative age-related macular degeneration. Materials & methods: Sixty-four patients (64 eyes) were prospectively enrolled and treated for neovascular age-related macular degeneration with ranibizumab monotherapy. Visual acuity was measured using the ETDRS chart. A loading phase of 3 monthly intravitreal injections of ranibizumab 0.5 mg/0.05 ml was performed. The analyzed VEGF-A gene SNPs were rs699947 (-2578A/C) and rs1570360 (-1154G/A); the allelic discrimination was performed in real-time PCR platform. The difference of best corrected visual acuity (ETDRS letters) read before and after treatment was considered as functional outcome. Results: Ranibizumab was significantly more effective as measured by best corrected visual acuity in patients harboring the VEGF-A -2578C allele (from +6.26 to +7.44 ETDRS letters), whereas patients carrying the VEGF-A -2578AA genotype revealed an absence of early functional response to ranibizumab (-1.78 ETDRS letters; p = 0.0192). Conclusion: This study suggests that the VEGF-A -2578A/C SNP may represent an important molecular determinant of the early functional outcome of ranibizumab.
C1 [Lazzeri, Stefano; Figus, Michele; Sartini, Maria Sole; Posarelli, Chiara; Nardi, Marco] Univ Pisa, Ophthalmol Unit, I-56126 Pisa, Italy.
   [Orlandi, Paola; Fioravanti, Anna; Di Desidero, Teresa; Agosta, Elisa; Danesi, Romano; Bocci, Guido] Univ Pisa, Dept Clin & Expt Med, Div Pharmacol, I-56126 Pisa, Italy.
C3 University of Pisa; University of Pisa
RP Bocci, G (通讯作者)，Univ Pisa, Dept Clin & Expt Med, Div Pharmacol, Via Roma 55, I-56126 Pisa, Italy.
EM guido.bocci@med.unipi.it
RI Bocci, Guido/AAC-7515-2022; Danesi, Romano/AAC-9410-2019; Posarelli,
   Chiara/AAA-8278-2019; Danesi, Romano/J-7239-2018; Figus,
   Michele/AAD-6850-2020; Posarelli, Chiara/AAW-9528-2020; Figus,
   Michele/AAA-9808-2019
OI Danesi, Romano/0000-0002-4414-8934; Posarelli,
   Chiara/0000-0003-0222-5177; Danesi, Romano/0000-0002-4414-8934; Figus,
   Michele/0000-0003-2243-9033; nardi, marco/0000-0003-3422-9498; Di
   Desidero, Teresa/0000-0002-5487-071X
FU University of Pisa
FX The present work was supported by academic funding from the University
   of Pisa to G Bocci. The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.
CR Agosta E, 2012, PHARMACOGENOMICS, V13, P1037, DOI [10.2217/PGS.12.77, 10.2217/pgs.12.77]
   Ahn JK, 2009, AM J OPHTHALMOL, V148, P718, DOI 10.1016/j.ajo.2009.06.012
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Chowers I, 2008, MOL VIS, V14, P2263
   Churchill AJ, 2008, INVEST OPHTH VIS SCI, V49, P3611, DOI 10.1167/iovs.07-1383
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Excoffier L, 2005, EVOL BIOINFORM, V1, P47, DOI 10.1177/117693430500100003
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Garcia-Closas M, 2007, PLOS GENET, V3, P287, DOI 10.1371/journal.pgen.0030029
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P1218, DOI 10.1097/IAE.0b013e3181b32c45
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Parmeggiani Francesco, 2009, Recent Pat DNA Gene Seq, V3, P114
   Pasqualetti G, 2007, PHARMACOGENOMICS, V8, P49, DOI 10.2217/14622416.8.1.49
   Patel RD, 2011, SEMIN OPHTHALMOL, V26, P372, DOI 10.3109/08820538.2011.570845
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawada O, 2010, RETINA-J RET VIT DIS, V30, P1034, DOI 10.1097/IAE.0b013e3181ce74c8
   Scholl HPN, 2007, MOL VIS, V13, P196
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Wickremasinghe SS, 2012, CLIN EXP OPHTHALMOL, V40, P59, DOI 10.1111/j.1442-9071.2011.02613.x
NR 42
TC 23
Z9 27
U1 0
U2 10
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1462-2416
EI 1744-8042
J9 PHARMACOGENOMICS
JI Pharmacogenomics
PD APR
PY 2013
VL 14
IS 6
BP 623
EP 630
DI 10.2217/PGS.13.43
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 123QL
UT WOS:000317405300013
PM 23570466
DA 2022-11-30
ER

PT J
AU Mori, K
   Horie-Inoue, K
   Gehlbach, PL
   Takita, H
   Kabasawa, S
   Kawasaki, I
   Ohkubo, T
   Kurihara, S
   Iizuka, H
   Miyashita, Y
   Katayama, S
   Awata, T
   Yoneya, S
   Inoue, S
AF Mori, Keisuke
   Horie-Inoue, Kuniko
   Gehlbach, Peter L.
   Takita, Hiroyasu
   Kabasawa, Sho
   Kawasaki, Izumi
   Ohkubo, Tomoko
   Kurihara, Susumu
   Iizuka, Hiroyuki
   Miyashita, Yumi
   Katayama, Shigehiro
   Awata, Takuya
   Yoneya, Shin
   Inoue, Satoshi
TI Phenotype and Genotype Characteristics of Age-related Macular
   Degeneration in a Japanese Population
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT-FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY; FACTOR GENE;
   HEMICENTIN-1 GENES; POLYMORPHISM; VARIANT; RISK; ASSOCIATION; HTRA1;
   Y402H
AB Purpose: To describe phenotype and genotype characteristics of age-related macular degeneration (AMD) in Japanese patients.
   Design: A case-control study.
   Participants: A total of 550 case-control samples composed of 408 consecutive AMD cases and 142 controls.
   Methods: Clinical information assessing age, gender, affected eyes, fundus features, and fluorescein/indocyanine green angiograms were systematically evaluated. Four single nucleotide polymorphisms ( SNPs; rs800292, rs1061170, rs1410996, rs2274700) in the complement factor H (CFH) gene, 1 SNP (rs11200638) in the high-temperature requirement factor A1 (HTRA1) gene, 3 SNPs (rs699947, rs1570360, rs2010963) in the vascular endothelial growth factor ( VEGF) gene, and 4 SNPs (rs12150053, rs12948385, rs9913583, rs1136287) in the pigment epithelium-derived factor ( PEDF) gene were assessed using TaqMan technology.
   Main Outcome Measures: The clinical phenotype information and genotypes of CFH, HTRA1, VEGF, and PEDF polymorphisms.
   Results: Of Japanese patients with neovascular AMD (nAMD), 219 (58.7%) had typical nAMD and 154 (41.3%) had polypoidal choroidal vasculopathy (PCV). The frequency of bilateral exudative involvement was similar between typical nAMD (15.5%) and PCV (13.6%) (P = 0.613). Significant soft drusen were observed in the fellow eyes of 88 (47.6%) of 185 patients with unilateral typical nAMD and in 25 (18.8%) of 133 patients with unilateral PCV (P = 1.24 x 10(-7)). A serous pigment epithelium detachment was seen in 55 (25.1%) of 219 patients with typical nAMD and in 64 (41.6%) of 154 patients with PCV. A significant association was noted in CFH-rs800292, CFH-rs1410996, CFH-rs2274700, and HTRA1-rs11200638 with AMD development (P = 2.36 x 10(-5), 7.18 x 10(-5), 7.18 x 10(-5), 2.70 x 10(-7), respectively; population attributable risk = 57.3%, 57.8%, 57.8%, and 58.9%, respectively). We estimated the highest-risk group to have an approximately 70-fold greater risk of nAMD compared with the lowest-risk group when analyzing a combination of 4 SNPs in the CFH and HTRA1 genes.
   Conclusions: The Japanese AMD phenotype is characterized by a higher frequency of PCV, male predominance, and lower frequency of bilateral presentation compared with Caucasian AMD. Genotype analyses demonstrate a significant population attributable risk for SNPs in the CFH and HTRA1 genes and demonstrate joint effects for both genes. Gene variants in both CFH and HTRA1 contribute significantly to the AMD phenotype in a Japanese population.
C1 [Mori, Keisuke; Takita, Hiroyasu; Kabasawa, Sho; Kawasaki, Izumi; Yoneya, Shin] Saitama Med Univ, Dept Ophthalmol, Iruma, Saitama 3500495, Japan.
   [Horie-Inoue, Kuniko; Inoue, Satoshi] Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Iruma, Saitama 3500495, Japan.
   [Ohkubo, Tomoko; Kurihara, Susumu; Katayama, Shigehiro; Awata, Takuya] Saitama Med Univ, Dept Med, Div Endocrinol & Diabet, Iruma, Saitama 3500495, Japan.
   [Iizuka, Hiroyuki; Miyashita, Yumi] Saitama Med Univ, Ctr Biomed Res, Div RI Lab, Iruma, Saitama 3500495, Japan.
   [Gehlbach, Peter L.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
C3 Saitama Medical University; Saitama Medical University; Saitama Medical
   University; Saitama Medical University; Johns Hopkins University
RP Mori, K (通讯作者)，Saitama Med Univ, Dept Ophthalmol, 38 Morohongo, Iruma, Saitama 3500495, Japan.
EM keisuke@saitama-med.ac.jp
OI Awata, Takuya/0000-0003-2622-8129
FU Eye Research Foundation for the Aged (KM); Medical Research Center,
   Saitama Medical University [20-1-2-02, KM]; Ministry of Education,
   Science and Culture, Tokyo, Japan [C-21592242]
FX Financial Support: This research was supported in part by a Grant from
   the Eye Research Foundation for the Aged (KM), Institutional Grant from
   the Medical Research Center, Saitama Medical University (#20-1-2-02, KM)
   and a grant-in-aid (C-21592242) from the Ministry of Education, Science
   and Culture, Tokyo, Japan.
CR Awata T, 2005, BIOCHEM BIOPH RES CO, V333, P679, DOI 10.1016/j.bbrc.2005.05.167
   Awata T, 2002, DIABETES, V51, P1635, DOI 10.2337/diabetes.51.5.1635
   Bessho H, 2009, MOL VIS, V15, P1107
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Chang TS, 1999, CAN J OPHTHALMOL, V34, P266
   Chen LJ, 2006, MOL VIS, V12, P1536
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Iizuka H, 2007, BIOCHEM BIOPH RES CO, V361, P421, DOI 10.1016/j.bbrc.2007.07.025
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lin JM, 2008, AM J OPHTHALMOL, V145, P716, DOI 10.1016/j.ajo.2007.11.006
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mattes D, 2009, MOL VIS, V15, P343
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Ohida T, 2001, JAMA-J AM MED ASSOC, V285, P2643, DOI 10.1001/jama.285.20.2643
   Okamoto H, 2006, MOL VIS, V12, P156
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Souied EH, 2005, MOL VIS, V11, P1135
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshida T, 2007, MOL VIS, V13, P545
   YOSHIMURA N, 2004, NIPPON GANKA KIYOFOL, V55, P155
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 58
TC 96
Z9 97
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2010
VL 117
IS 5
BP 928
EP 938
DI 10.1016/j.ophtha.2009.10.001
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 590XM
UT WOS:000277261800013
PM 20132989
DA 2022-11-30
ER

PT J
AU Roth, DB
   Kulkarni, KM
   Feuer, WJ
AF Roth, Daniel B.
   Kulkarni, Kaushal M.
   Feuer, William J.
TI The temporal sequence of combined intravitreal triamcinolone acetonide
   and photodynamic therapy for exudative age-related macular degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN; INJECTION; OCCULT
AB BACKGROUND AND OBJECTIVE: To compare visual acuity results in patients with exudative age-related macular degeneration treated with two different temporal sequences of combination intravitreal triamcinolone acetonide and photodynamic therapy with verteporfin.
   PATIENTS AND METHODS: A retrospective, comparative, interventional case series was used. Thirty-one eyes received intravitreal triamcinolone acetonide 1 week prior to photodynamic therapy, and 30 eyes received intravitreal triamcinolone acetonide followed by photodynamic therapy the same day.
   RESULTS: There was no significant difference in visual acuity between the groups at baseline (P = .084), 6 to 12 weeks of follow-up (P =.085), or I year of follow-up (P = .093). When visual acuity outcomes were adjusted for baseline visual acuity, spot size, lesion type, age, and gender, there was no significant difference in visual acuity at 6 to 12 weeks (P = .44) or 1 year (P = .28).
   CONCLUSIONS: There appears to be no significant difference in visual outcomes in eyes with exudative age-related macular degeneration treated with intravitreal triamcinolone acetonide I week prior to photodynamic therapy or those treated with intravitreal triamcinolone acetonide on the same day as photodynamic therapy.
C1 [Roth, Daniel B.; Kulkarni, Kaushal M.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Ophthalmol, Retina Vitreous Ctr, New Brunswick, NJ 08901 USA.
   [Feuer, William J.] Univ Miami, Sch Med, Bascom Palmer Eye Inst, Miami, FL USA.
C3 Rutgers State University New Brunswick; Rutgers State University Medical
   Center; Bascom Palmer Eye Institute; University of Miami
RP Roth, DB (通讯作者)，Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Ophthalmol, Retina Vitreous Ctr, Clin Acad Bldg,4th Floor,125 Paterson St, New Brunswick, NJ 08901 USA.
CR Arias L, 2006, OPHTHALMOLOGY, V113, P2243, DOI 10.1016/j.ophtha.2006.04.039
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BUNSE A, 2005, ASS RES VIS OPHTH AN
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Ergun E, 2006, AM J OPHTHALMOL, V142, P10, DOI 10.1016/j.ajo.2006.02.048
   Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864
   KAISER PK, 2005, ASS RES VIS OPHTH AN
   Krebs I, 2006, GRAEF ARCH CLIN EXP, V244, P863, DOI 10.1007/s00417-005-0155-8
   Nicolo M, 2006, RETINA-J RET VIT DIS, V26, P58, DOI 10.1097/00006982-200601000-00010
   Nicolo M, 2006, GRAEF ARCH CLIN EXP, V244, P1336, DOI 10.1007/s00417-006-0306-6
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   SCHMIDTERFURTH U, 2006, BRIT J CANCER, V124, P561
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
NR 22
TC 1
Z9 1
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD JAN-FEB
PY 2008
VL 39
IS 1
BP 12
EP 16
DI 10.3928/15428877-20080101-11
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 253GA
UT WOS:000252505500002
PM 18254345
DA 2022-11-30
ER

PT J
AU Chen, JJ
   Han, BS
   Xu, SG
   Vu, HH
   Farrow, JW
   Rodman, CL
   Zhu, Y
   Wang, WZ
AF Chen, Jia-Jia
   Han, Bing-Sha
   Xu, Shao-Gang
   Vu, Honghua
   Farrow, James W.
   Rodman, Connie L.
   Zhu, Yu
   Wang, Wen-Zhan
TI Hypersensitivity toward bacterial stimuli in patients with age-related
   macular degeneration
SO APMIS
LA English
DT Article
DE B cell; age-related macular degeneration; antibody
ID FACTOR-H POLYMORPHISM; ALTERNATIVE PATHWAY; IMMUNE-RESPONSE; COMPLEMENT;
   ACTIVATION; AMD; IGA; PATHOGENESIS; HYPOTHESIS; BIOMARKERS
AB Although the pathogenesis of age-related macular degeneration (AMD) is unclear, genetic screening has revealed that polymorphisms in the complement system may be associated with AMD development. Production of autoantibodies was also found in AMD patients. In this study, we analyzed the antibody response in AMD patients. We found that purified B cells from AMD patients tended to respond to lower concentrations of bacterial antigen stimulation, and produced higher amounts of antibodies, especially in IgM and IgA secretions. When examining clinical symptoms, patients with more severe wet-form AMD tended to exhibit higher sensitivity to bacterial antigens and secreted more IgM and IgA antibodies than those with less severe dry-form cases. In conclusion, our study discovered an altered B-cell antibody production in response to bacterial antigens in AMD patients, which potentially contributes to AMD pathogenesis.
C1 [Chen, Jia-Jia; Zhu, Yu; Wang, Wen-Zhan] Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China.
   [Han, Bing-Sha] Henan Prov Peoples Hosp, Dept Intervent Radiol, Zhengzhou, Peoples R China.
   [Xu, Shao-Gang] Zhengzhou Orthoped Hosp, Dept Orthoped, Zhengzhou, Henan, Peoples R China.
   [Vu, Honghua; Farrow, James W.; Rodman, Connie L.] McGene Ctr, Res Lab, Detroit, MI USA.
C3 Zhengzhou University; Zhengzhou University
RP Wang, WZ (通讯作者)，Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China.
EM wenzhanwang@sina.com
CR ALLANSMITH MR, 1985, J ALLERGY CLIN IMMUN, V76, P569, DOI 10.1016/0091-6749(85)90777-8
   Beutler BA, 2009, BLOOD, V113, P1399, DOI 10.1182/blood-2008-07-019307
   Browne EP, 2012, IMMUNOLOGY, V136, P370, DOI 10.1111/j.1365-2567.2012.03587.x
   Cerutti A, 2011, ANNU REV IMMUNOL, V29, P273, DOI 10.1146/annurev-immunol-031210-101317
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   DELPRIORE LV, 1995, OPHTHALMOLOGY, V102, P1125, DOI 10.1016/S0161-6420(95)30903-7
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HIEMSTRA PS, 1987, EUR J IMMUNOL, V17, P321, DOI 10.1002/eji.1830170304
   Ivashkiv LB, 2008, NAT REV IMMUNOL, V8, P816, DOI 10.1038/nri2396
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   O'Neill LAJ, 2003, BIOCHEM SOC T, V31, P643, DOI 10.1042/bst0310643
   RUSSELL MW, 1989, SCAND J IMMUNOL, V30, P175, DOI 10.1111/j.1365-3083.1989.tb01199.x
   Tamm SA, 2001, OCUL IMMUNOL INFLAMM, V9, P75, DOI 10.1076/ocii.9.2.75.3972
   Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305
   Vos Q, 2000, IMMUNOL REV, V176, P154
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262
   Zhou Ru, 2010, F1000 Biol Rep, V2, DOI 10.3410/B2-3
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 25
TC 3
Z9 3
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0903-4641
EI 1600-0463
J9 APMIS
JI APMIS
PD MAY
PY 2016
VL 124
IS 5
BP 406
EP 413
DI 10.1111/apm.12511
PG 8
WC Immunology; Microbiology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Microbiology; Pathology
GA DJ6QL
UT WOS:000374337900008
PM 26853231
DA 2022-11-30
ER

PT J
AU Chang, YC
   Wu, WC
AF Chang, Yo-Chen
   Wu, Wen-Chuan
TI Polypoidal Choroidal Vasculopathy in Taiwanese Patients
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENTS; PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; INTRAVITREAL BEVACIZUMAB; JAPANESE PATIENTS; BLACK-WOMEN;
   NEOVASCULARIZATION; VERTEPORFIN
AB BACKGROUND AND OBJECTIVE: To investigate the incidence of polypoidal choroidal vasculopathy (PCV) in patients with presumed neovascular age-related macular degeneration (AMD) using indocyanine green angiography (ICGA). The efficacy of photodynamic therapy (PDT) with verteporfin in eyes with PCV and neovascular AMD was also evaluated.
   PATIENTS AND METHODS: The medical records of 100 patients with neovascular AMD diagnosed according to ICGA findings were reviewed. Patients who underwent PDT were scheduled for follow-up appointments every 2 months.
   RESULTS: Forty-nine (49.0%) and 51 (51.0%) patients were diagnosed as having PCV and neovascular AMD, respectively. The mean age of presentation was younger in the PCV group than in the neovascular AMD group (63.6 vs 69.7 years, respectively; P = .002). There were 35 men (71.4%) in the PCV group and 37 men (72.5%) in the neovascular AMD group. Seventeen patients (33.3%) with neovascular AMD had bilateral involvement compared with only 4 patients (8.2%) with PCV (P = .004). Twenty eyes with PCV and 22 eyes with neovascular AMID received one PDT treatment. After PDT, 10 eyes (50%) with PCV and 11 eyes (50%) with neovascular AMD experienced visual improvement.
   CONCLUSION: PCV is not uncommon in Taiwanese patients diagnosed as having neovascular AMD by ICGA and these patients have a younger age of onset, male predominance, unilateral involvement, and macular polyps. Both PCV and neovascular AMD can achieve favorable visual improvement following PDT with verteporfin.
C1 [Chang, Yo-Chen; Wu, Wen-Chuan] Kaohsiung Med Univ, Dept Ophthalmol, Coll Med, Kaohsiung, Taiwan.
   [Chang, Yo-Chen] Kaohsiung Municipal Hsia Kang Hosp, Dept Ophthalmol, Kaohsiung, Taiwan.
C3 Kaohsiung Medical University
RP Wu, WC (通讯作者)，Kaohsiung Med Univ, Dept Ophthalmol, Coll Med, Kaohsiung, Taiwan.
RI Wu, Wen-Chuan/D-5296-2009
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Phillips WB, 1996, OPHTHALMIC SURG LAS, V27, P467
   PIERAMICI DJ, 1994, ARCH OPHTHALMOL-CHIC, V112, P1043, DOI 10.1001/archopht.1994.01090200049020
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yannuzzi LA, 1982, MAC SOC M FEBR 5 MIA
   Yeung Ling, 2004, Chang Gung Med J, V27, P366
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 22
TC 43
Z9 45
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD NOV-DEC
PY 2009
VL 40
IS 6
BP 576
EP 581
DI 10.3928/15428877-20091030-07
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 529IY
UT WOS:000272510500008
PM 19928723
DA 2022-11-30
ER

PT J
AU Choi, YJ
   Hyun, J
   Choi, KS
   Rhee, MR
   Lee, SJ
AF Choi, Youn Joo
   Hyun, Joo
   Choi, Kyung Seek
   Rhee, Mi Ri
   Lee, Sung Jin
TI BULLOUS HEMORRHAGIC RETINAL DETACHMENT BECAUSE OF MASSIVE SUBRETINAL
   HEMORRHAGE IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration (AMD); hemorrhagic retinal detachment;
   subretinal hemorrhage (SRH); retinotomy
ID PARS-PLANA VITRECTOMY; VITREOUS HEMORRHAGE; INTRAOCULAR HEMORRHAGE;
   NATURAL-HISTORY; SILICONE OIL; SECONDARY; ANTICOAGULATION
AB Purpose: The authors investigated the surgical outcomes of massive subretinal hemorrhage draining via a retinotomy procedure in bullous hemorrhagic retinal detachment (HRD).
   Methods: Clinical records of consecutive patients with age-related macular degeneration who underwent surgery for bullous HRD were reviewed. Outcomes included anatomical success, visual acuity, and postoperative complications.
   Results: Seventeen consecutive eyes of 17 patients were included in this series. Of the 17 eyes, 8 eyes had total HRD and 9 eyes had half total inferior HRD including the macula. The mean interval between initial symptom presentation and operation was 22.6 +/- 11.7 days. All patients underwent pars plana vitrectomy and internal drainage of the subretinal hemorrhage through a posterior drainage retinotomy. The mean follow-up period was 37.1 months (range, 12-66 months). Finally, successful retinal reattachment was achieved in 15 of the 17 eyes (88.2%), but 2 remained nonprogressive localized inferior retinal detachment because of proliferative vitreoretinopathy. All preoperative visual acuities were hand movements or worse, and 10 eyes (58.8%) achieved a postoperative minimum functional vision of 20/1000 or better.
   Conclusion: Successful retinal reattachment and achievement of minimum functional vision is possible after PPV and retinotomy with evacuation of a massive subretinal hemorrhage for bullous HRD secondary to age-related macular degeneration.
C1 [Choi, Youn Joo; Hyun, Joo; Choi, Kyung Seek; Lee, Sung Jin] Soonchunhyang Univ, Dept Ophthalmol, Coll Med, Seoul 140743, South Korea.
   [Rhee, Mi Ri] Myeong Ophthalm Clin, Ilsan, Gyeonggi, South Korea.
C3 Soonchunhyang University
RP Lee, SJ (通讯作者)，Soonchunhyang Univ, Dept Ophthalmol, Coll Med, 22 Daesaguan Gil, Seoul 140743, South Korea.
EM wismile@schmc.ac.kr
OI Choi, Youn Joo/0000-0001-5713-5043
CR BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   CHANDRA SR, 1974, AM J OPHTHALMOL, V78, P579, DOI 10.1016/S0002-9394(14)76293-2
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   FEMAN SS, 1972, J AMER MED ASSOC, V220, P1354, DOI 10.1001/jama.220.10.1354
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   GOOGE JM, 1987, SURV OPHTHALMOL, V32, P123, DOI 10.1016/0039-6257(87)90104-4
   Hasegawa T, 2010, AM J OPHTHALMOL, V149, P322, DOI 10.1016/j.ajo.2009.09.012
   Jang JH, 2009, J KOREAN OPHTHALMOL, V50, P870
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   KAMPIK A, 1992, RETINA-J RET VIT DIS, V12, pS11, DOI 10.1097/00006982-199212031-00004
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   KREIGER AE, 1983, RETINA-J RET VIT DIS, V3, P318, DOI 10.1097/00006982-198300340-00017
   LEWIS H, 1988, GRAEF ARCH CLIN EXP, V226, P59, DOI 10.1007/BF02172720
   Lincoff H, 2003, ARCH OPHTHALMOL-CHIC, V121, P91
   Oshima Y, 2007, BRIT J OPHTHALMOL, V91, P193, DOI 10.1136/bjo.2006.101444
   Sakamoto T, 2010, RETINA-J RET VIT DIS, V30, P856, DOI 10.1097/IAE.0b013e3181c969cb
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shen YD, 2007, EUR J OPHTHALMOL, V17, P954, DOI 10.1177/112067210701700614
   TANI PM, 1980, AM J OPHTHALMOL, V90, P525, DOI 10.1016/S0002-9394(14)75023-8
   TEETERS VW, 1973, AM J OPHTHALMOL, V76, P1
   Tennant Matthew T S, 2002, Ophthalmol Clin North Am, V15, P445, DOI 10.1016/S0896-1549(02)00049-4
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
   WOLTER JR, 1965, AM J OPHTHALMOL, V59, P1044, DOI 10.1016/0002-9394(65)93421-5
NR 24
TC 7
Z9 9
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2013
VL 33
IS 7
BP 1365
EP 1374
DI 10.1097/IAE.0b013e31827b640c
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 300NN
UT WOS:000330470700010
PM 23518899
DA 2022-11-30
ER

PT J
AU Aisenbrey, S
   Lafaut, BA
   Reynders, S
   Szurman, P
   Grisanti, S
   Vanden Broecke, C
   Walter, P
   Bartz-Schmidt, KU
AF Aisenbrey, S
   Lafaut, BA
   Reynders, S
   Szurman, P
   Grisanti, S
   Vanden Broecke, C
   Walter, P
   Bartz-Schmidt, KU
TI Clinicopathological correlation of choroidal neovascularization after
   external beam radiotherapy in age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID RADIATION-THERAPY; MEMBRANES; TELETHERAPY; TRIAL; IRRADIATION
AB Purpose: To analyze the histopathology of choroidal neovascularization after external beam radiotherapy in age-related macular degeneration. Methods: A retrospective non-case-matched comparative histopathologic study. The histoarchitecture of nine surgically removed subretinal specimens from nine patients that had undergone external beam radiotherapy for exudative age-related macular degeneration was studied. Seven patients had received 20 Gy in 10 fractions and two 15 Gy in 5 fractions with an average time interval between radiotherapy and surgical extraction of 14 months (range 3-28). A consecutive series of classic, mixed and occult choroidal neovascular membranes served as controls. Results: Clinical findings. Radiation-associated choroidal neovasculopathy was angiographically suspected in four patients: a coarse net of vessels on fluorescein angiography developing at the border of previously irradiated choroidal neovascularization was observed in three patients; blebs at the margin of a plaque on indocyanine green angiography were observed in two patients. Pathological findings. Diffuse drusen as well as intra-Bruch's fibrovascular tissue was found in all irradiated specimens. In four specimens an edematous vascularized layer was seen between diffuse drusen and normal-appearing intra-Bruch's fibrovascular tissue. This lesion was not found in the control specimens. A particular correlation for the bleb lesion was not recognized. Conclusion: The appearance of an edematous subretinal pigment epithelial vascularized layer between diffuse drusen and normal-appearing fibrovascular tissue in four of nine irradiated membranes may be secondary to previous irradiation. It may correlate with the unusual exudative manifestations observed after external beam radiotherapy.
C1 AZ St Jan Ruddershove, Dept Ophthalmol, B-8000 Brugge, Belgium.
   Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, Cologne, Germany.
   Ghent Univ Hosp, Dept Ophthalmol, B-9000 Ghent, Belgium.
   Univ Tubingen Hosp, Dept Ophthalmol, Tubingen, Germany.
   Ghent Univ Hosp, Dept Pathol, B-9000 Ghent, Belgium.
C3 University of Cologne; Ghent University; Ghent University Hospital;
   Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Ghent University; Ghent University Hospital
RP Lafaut, BA (通讯作者)，AZ St Jan Ruddershove, Dept Ophthalmol, Ruddershove 10, B-8000 Brugge, Belgium.
EM bart.lafaut@azbrugge.be
RI Walter, Peter/L-5982-2018
OI Walter, Peter/0000-0001-8745-6593
CR Augsburger JJ, 1998, ARCH OPHTHALMOL-CHIC, V116, P1509, DOI 10.1001/archopht.116.11.1509
   BERGINK GJ, 1994, GRAEF ARCH CLIN EXP, V232, P591, DOI 10.1007/BF00193119
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   BERGINK GJ, 1995, DOC OPHTHALMOL, V90, P67, DOI 10.1007/BF01203296
   Brady LW, 1997, INT J RADIAT ONCOL, V39, P945, DOI 10.1016/S0360-3016(97)00708-6
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Chakravarthy U, 2000, BRIT J RADIOL, V73, P305, DOI 10.1259/bjr.73.867.10817048
   Chakravarthy U, 2000, EYE, V14, P151, DOI 10.1038/eye.2000.45
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Churchill AJ, 1998, BRIT J OPHTHALMOL, V82, P373, DOI 10.1136/bjo.82.4.373
   Donati G, 1999, BRIT J OPHTHALMOL, V83, P646, DOI 10.1136/bjo.83.6.646
   Fine SL, 2001, ARCH OPHTHALMOL-CHIC, V119, P275
   Finger PT, 1996, OPHTHALMOLOGY, V103, P878, DOI 10.1016/S0161-6420(96)30592-7
   Finger PT, 1998, ARCH OPHTHALMOL-CHIC, V116, P1507, DOI 10.1001/archopht.116.11.1507
   Flaxel CJ, 2000, EYE, V14, P155, DOI 10.1038/eye.2000.46
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Haas A, 2000, OPHTHALMOLOGY, V107, P1358, DOI 10.1016/S0161-6420(00)00154-8
   HART PM, 1995, BRIT J OPHTHALMOL, V79, P562, DOI 10.1136/bjo.79.6.562
   Hart PM, 1996, BRIT J OPHTHALMOL, V80, P1046, DOI 10.1136/bjo.80.12.1046
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Hollick EJ, 1996, EYE, V10, P609, DOI 10.1038/eye.1996.139
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Hoyng CB, 2002, GRAEF ARCH CLIN EXP, V240, P337, DOI 10.1007/s00417-002-0428-4
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   Krott R, 1998, GRAEF ARCH CLIN EXP, V236, P916, DOI 10.1007/s004170050180
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Lambooij AC, 2001, GRAEF ARCH CLIN EXP, V239, P539, DOI 10.1007/s004170100314
   Mandai M, 2000, JPN J OPHTHALMOL, V44, P530, DOI 10.1016/S0021-5155(00)00217-3
   Marcus DM, 1999, RETINA-J RET VIT DIS, V19, P525, DOI 10.1097/00006982-199911000-00008
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Mauget-Faysse M, 2000, J FR OPHTALMOL, V23, P127
   Mauget-Faysse M, 1999, BRIT J OPHTHALMOL, V83, P923
   REYNDERS S, 2002, GRAEFES ARCH CLIN EX, V120, P451
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Spaide RF, 1999, OPHTHALMOLOGY, V106, P2254, DOI 10.1016/S0161-6420(99)90524-9
   Stalmans P, 1998, RETINA-J RET VIT DIS, V18, P388, DOI 10.1097/00006982-199808000-00022
   Stalmans P, 1997, RETINA-J RET VIT DIS, V17, P481
   TOTH CA, 1990, OPHTHALMOLOGY, V108, P1687
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
NR 43
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2003
VL 241
IS 4
BP 269
EP 276
DI 10.1007/s00417-003-0634-8
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 682ZH
UT WOS:000183121900004
PM 12719987
DA 2022-11-30
ER

PT J
AU Desideri, LF
   Barra, F
   Ferrero, S
AF Desideri, L. Ferro
   Barra, F.
   Ferrero, S.
TI Brolucizumab Anti-VEGF-A monoclonal antibody Treatment of age-related
   macular degeneration
SO DRUGS OF THE FUTURE
LA English
DT Article
DE Brolucizumab; ESBA-1008; RTH-258; Wet age-related macular degeneration;
   Vascular endothelial growth factor; Anti-VEGF agents
ID ENDOTHELIAL GROWTH-FACTOR; PROGENITOR CELLS; AFLIBERCEPT
AB Wet age-related macular degeneration (wAMD) is the leading cause of irreversible vision loss in people older than 50 years of age in Western countries. Given the crucial role of vascular endothelial growth factor (VEGF) in the pathogenesis of wAMD, anti-VEGF drugs currently represent the first-line treatment option in the management of the disease. Among the novel anti-VEGF agents investigated, brolucizumab is a single-chain antibody fragment inhibiting all isoforms of VEGF-A. In this regard, the phase III HAWK and HARRIER trials have shown promising results of brolucizumab in terms of clinical efficacy and safety for treating wAMD. In this review, we will discuss brolucizumab's pharmacokinetics, pharmacodynamics and clinical efficacy, focusing also on its safety and tolerability profile.
C1 [Desideri, L. Ferro; Barra, F.; Ferrero, S.] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy.
   [Barra, F.; Ferrero, S.] IRCCS Osped Policlin San Martino, Acad Unit Obstet & Gynecol, Genoa, Italy.
C3 University of Genoa
RP Desideri, LF (通讯作者)，Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy.
EM lorenzoferrodes@gmail.com
RI Desideri, Lorenzo Ferro/AAM-5368-2020; Barra, Fabio/E-2539-2017
OI Barra, Fabio/0000-0003-4117-6603
CR Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Barra F, 2019, GYNECOL OBSTET INVES, V84, P107, DOI 10.1159/000493361
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Desideri LF, 2019, EPILEPSY BEHAV, V94, P312, DOI 10.1016/j.yebeh.2019.02.027
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Gaudreault J., 2012, INVEST OPHTHALMOL VI, V53, P3025
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Kaplon H, 2019, MABS-AUSTIN, V11, P219, DOI 10.1080/19420862.2018.1556465
   Lagana AS, 2017, ARCH GYNECOL OBSTET, V295, P867, DOI 10.1007/s00404-017-4296-x
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Melincovici CS, 2018, ROM J MORPHOL EMBRYO, V59, P455
   Mucciolo DP, 2020, EUR J OPHTHALMOL, V30, P956, DOI 10.1177/1120672119863306
   Nimz EL, 2016, INVEST OPHTH VIS SCI, V57
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ogura Y., 2019, OPHTHALMOLOGY
   Rezzola S, 2014, ANGIOGENESIS, V17, P429, DOI 10.1007/s10456-013-9398-x
   Shams Naveed, 2006, Ophthalmol Clin North Am, V19, P335
   Tietz J, 2015, INVEST OPHTH VIS SCI, V56
   Weissgerber G., 2012, INVEST OPHTHALMOL VI, V53
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 23
TC 4
Z9 4
U1 0
U2 9
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD OCT
PY 2019
VL 44
IS 10
BP 761
EP 765
DI 10.1358/dof.2019.44.10.3058864
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA JN2GB
UT WOS:000496718000001
DA 2022-11-30
ER

PT J
AU Sato, T
   Ooto, S
   Suzuki, M
   Spaide, RF
AF Sato, Taku
   Ooto, Sotaro
   Suzuki, Mihoko
   Spaide, Richard F.
TI Retinal Pigment Epithelial Tear After Intravitreal Aflibercept for
   Neovascular Age-Related Macular Degeneration
SO Ophthalmic Surgery Lasers & Imaging Retina
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RANIBIZUMAB; VEGF
AB Two eyes with neovascular age-related macular degeneration and a suboptimal response to intravitreal ranibizumab and bevacizumab developed tears after being switched to intravitreal aflibercept, a drug with enhanced binding characteristics to vascular endothelial growth factor. Both eyes had sub-retinal pigment epithelium (RPE) choroidal neovascularization adherent to the back surface of the RPE in the fibrovascular RPE detachment that showed increased contracture of the fibrovascular tissue following the use of aflibercept. The driving force to develop the tears may be related to the recently described angiofibrotic switch, which is governed by the ration of connective tissue growth factor to vascular endothelial growth factor.
C1 [Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital
RP Spaide, RF (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM rick.spaide@gmail.com
RI Spaide, Richard/ABD-7368-2020
CR Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
NR 6
TC 11
Z9 13
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JAN
PY 2015
VL 46
IS 1
BP 87
EP 90
DI 10.3928/23258160-20150101-16
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA CG5TO
UT WOS:000353358500015
PM 25559517
DA 2022-11-30
ER

PT J
AU Yucel, D
   Yilmaz, M
   Durukan, AH
   Ozgul, RK
AF Yucel, Didem
   Yilmaz, Murat
   Durukan, Ali Hakan
   Ozgul, Riza Koksal
TI Association of CFH Y402H Polymorphism with Both Forms of Advanced
   Age-Related Macular Degeneration in Turkish Patients
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; complement factor H; Y402H
   polymorphism; association; Turkish patients
ID COMPLEMENT FACTOR-H; FACTOR HY402H POLYMORPHISM; GENE POLYMORPHISMS;
   VARIANT INCREASES; RISK; SUSCEPTIBILITY; MACULOPATHY; LOC387715;
   PHENOTYPE; GENOTYPE
AB Purpose: The purpose of this study was to investigate the association between complement factor H Y402H polymorphism and age-related macular degeneration (AMD) development in a cohort of Turkish patients.
   Methods: A total of 182 individuals, including 95 individuals with unrelated late age-related macular degeneration and 87 age-matched healthy individuals as a control group were genotyped with polymerase chain reaction followed by restriction enzyme digestion and direct sequence analysis. The statistical analysis was performed with statistical software R 2.9.2 and epicalc package.
   Results: The Y402H variant in the CFH gene was found to be associated with late AMD in our study population. Genotypic frequencies were highly different between all patients and control individuals compared for the heterozygotes carrying the risk allele C (AMD patients (CT) 70.5%, control individuals (CT) 54.02%; chi(2) = 5.285, d.f. = 1, p = 0.02). When all AMD patients were compared with the healthy control group, TC heterozygotes showed a significantly increased risk of AMD (O.R = 2.32, CI% 1.23-4.35).
   Conclusion: This study suggests that the CFH Y402H polymorphism is associated with increased risk for both types of end-stage AMD in Turkish patients.
C1 [Yucel, Didem; Ozgul, Riza Koksal] Hacettepe Univ, Dept Pediat, Metab Unit, Ankara, Turkey.
   [Yucel, Didem] Hacettepe Univ, Dept Mol Biol, Ankara, Turkey.
   [Yilmaz, Murat] Hacettepe Univ, Dept Genet, Ankara, Turkey.
   [Durukan, Ali Hakan] Gulhane Mil Med Acad, Dept Ophthalmol, Ankara, Turkey.
   [Ozgul, Riza Koksal] Hacettepe Univ, Inst Child Hlth, Ankara, Turkey.
C3 Hacettepe University; Hacettepe University; Hacettepe University;
   Gulhane Military Medical Academy; Hacettepe University
RP Ozgul, RK (通讯作者)，Hacettepe Univ, Dept Pediat, Metab & Nutr Unit, Ankara, Turkey.
EM rkozgul@hacettepe.edu.tr
RI OZGUL, RIZA KOKSAL/J-1569-2013; Durukan, Ali Hakan/GSN-1422-2022;
   Durukan, Ali Hakan/AFS-8050-2022
OI Durukan, Ali Hakan/0000-0001-6571-6155; Ozgul, Riza
   Koksal/0000-0002-0283-635X
FU Scientific Research Fund of Hacettepe University (BAP) [0401601001]
FX This study was supported by Scientific Research Fund of Hacettepe
   University (BAP Project No: 0401601001). The authors report no conflicts
   of interest. The authors alone are responsible for the content and
   writing of the paper.
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chongsuvivatwong Virasakdi, 2010, EP EP CALC R PACK VE
   Chowers I, 2008, MOL VIS, V14, P1829
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Haas P, 2009, EYE, V23, P2228, DOI 10.1038/eye.2008.422
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P1416, DOI 10.1097/IAE.0b013e318184661d
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Okamoto H, 2006, MOL VIS, V12, P156
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   R Development Core Team, 2020, R VERS 4 0 3 LANG EN
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Souied EH, 2005, MOL VIS, V11, P1135
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 53
TC 10
Z9 10
U1 0
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD SEP
PY 2012
VL 33
IS 3
BP 144
EP 149
DI 10.3109/13816810.2012.660225
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 977TN
UT WOS:000306687800005
PM 22486323
DA 2022-11-30
ER

PT J
AU Desmettre, TJ
AF Desmettre, T. J.
TI Epigenetics in Age-related Macular Degeneration (AMD)
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Review
DE Epigenetics; Age-Related Macular Degeneration; Gene-environment
   interaction; Gene expression; Retina
ID FACTOR-H POLYMORPHISM; PRENATAL EXPOSURE; GENE-EXPRESSION; IL17RC
   PROMOTER; DNA METHYLATION; NADPH OXIDASE; DUTCH FAMINE; RISK-FACTORS;
   CANCER; HYPOMETHYLATION
AB Age-related Macular Degeneration (AMD) is a complex multifactorial condition involving multiple genetic, environmental and constitutional factors. Inflammation, oxidative stress and lipid metabolism seem to be the most important factors in the pathogenesis of the disease. The importance of genetic factors has mainly been revealed with the influence of histo-compatibility complement factor H (CFH) variations and the ARSM2 susceptibility gene. Another component, epigenetics, could help to explain some of the relationships between environmental and genetic factors. Epigenetics is defined as the study of modulations of gene activity that can be transmitted over cell divisions without involving mutation of the DNA sequence. The molecules that are involved in these mechanisms are referred to as the epigenome. The mechanisms involve DNA methylation, histone modification, chromatin remodeling, and gene inhibition by non-coding RNA. Epigenetics could explain how the environment may induce relatively stable changes in traits or even diseases, possibly inheritable over several generations. Epigenetic traits established during development, and/or acquired under the influence of nutritional factors or other environmental factors, could influence the interactions between genes and the environment. Several authors have recently shown the influence of epigenetic factors in the pathogenesis of ocular diseases such as cataract, dry eye, glaucoma, diabetic retinopathy and more recently AMD. A better understanding of the involvement of genetic variants at risk, their relationship with epigenetics and environmental factors would certainly help to better assess the risk of developing AMD or better understand recent changes in the incidence of the disease. (C) 2018 Elsevier Masson SAS. All rights reserved.
C1 [Desmettre, T. J.] Ctr Retine Med, 187 Rue Menin, F-59520 Marquette Lez Lille, France.
   [Desmettre, T. J.] London Int Med Ctr, 18-22 Queen Anne St, London W1G 8HU, England.
RP Desmettre, TJ (通讯作者)，Ctr Retine Med, 187 Rue Menin, F-59520 Marquette Lez Lille, France.
EM thomas@desmettre.org
CR Al-Shabrawey M, 2008, INVEST OPHTH VIS SCI, V49, P3239, DOI 10.1167/iovs.08-1755
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Bell JT, 2011, TRENDS GENET, V27, P116, DOI 10.1016/j.tig.2010.12.005
   Bonyadi M, 2018, OPHTHALMIC GENET, V39, P189, DOI 10.1080/13816810.2017.1393829
   Boumber Y, 2011, ONCOLOGY-NY, V25, P220
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Busanello A, 2017, OCUL SURF, V15, P680, DOI 10.1016/j.jtos.2017.05.012
   Chesterton M., 2017, CAN YOUR LIFESTYLE B
   Cheung CMG, 2018, OPHTHALMOLOGY
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Clausell J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007243
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crosson CE, 2010, INVEST OPHTH VIS SCI, V51, P3639, DOI 10.1167/iovs.09-4538
   Cruickshanks KJ, 2017, JAMA OPHTHALMOL, V135, P1417, DOI 10.1001/jamaophthalmol.2017.5001
   Darwin C., 1859, ORIGIN SPECIES MEANS
   de Rooij SR, 2006, DIABETES CARE, V29, P1897, DOI 10.2337/dc06-0460
   DUTTA SK, 1967, GENETICS, V57, P719
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eyres I, 2016, MOL ECOL, V25, P4197, DOI 10.1111/mec.13771
   Francis PJ, 2005, BRIT J OPHTHALMOL, V89, P1115, DOI 10.1136/bjo.2004.062695
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gao KP, 2017, APPL PHYSIOL NUTR ME, V42, P1316, DOI 10.1139/apnm-2017-0232
   Gemenetzi M, 2014, EYE, V28, P1407, DOI 10.1038/eye.2014.225
   Glaser TS, 2015, OPHTHALMOLOGY, V122, P1471, DOI 10.1016/j.ophtha.2015.04.007
   Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   He SK, 2013, MOL VIS, V19, P665
   Hewitt AW, 2017, SCI REP-UK, V7, DOI 10.1038/srep46330
   Hjelmeland LM, 2011, INVEST OPHTH VIS SCI, V52, P1622, DOI 10.1167/iovs.10-6765
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Johnson AB, 2008, MUTAT RES-FUND MOL M, V640, P174, DOI 10.1016/j.mrfmmm.2008.01.001
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kiel C, 2017, SCI REP-UK, V7, DOI 10.1038/srep41835
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Lamarck JB, 1809, INFLUENCE CIRCONSTAN
   Leenen FAD, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0256-8
   Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311
   Lyons DB, 2014, BBA-GENE REGUL MECH, V1839, P1373, DOI 10.1016/j.bbagrm.2014.05.010
   Mazzio EA, 2012, EPIGENETICS-US, V7, P119, DOI 10.4161/epi.7.2.18764
   MIRSKY AE, 1951, J GEN PHYSIOL, V34, P451, DOI 10.1085/jgp.34.4.451
   Nicoli S, 2010, NATURE, V464, P1196, DOI 10.1038/nature08889
   Oeverhaus M, 2001, AM J OPHTHALMOL, V5, P682
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Painter RC, 2008, BJOG-INT J OBSTET GY, V115, P1243, DOI 10.1111/j.1471-0528.2008.01822.x
   Painter RC, 2006, AM J HUM BIOL, V18, P853, DOI 10.1002/ajhb.20564
   Painter RC, 2005, EUR J EPIDEMIOL, V20, P673, DOI 10.1007/s10654-005-7921-0
   Painter RC, 2006, J HYPERTENS, V24, P1771, DOI 10.1097/01.hjh.0000242401.45591.e7
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007
   Pogue AI, 2018, CELL MOL NEUROBIOL
   Rapino C, 2005, AGING CELL, V4, P177, DOI 10.1111/j.1474-9726.2005.00161.x
   Roseboom T, 2006, EARLY HUM DEV, V82, P485, DOI 10.1016/j.earlhumdev.2006.07.001
   Rutherford A., 2010, EPIGENETICS
   Sabatel C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016979
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Suuronen T, 2007, BIOCHEM BIOPH RES CO, V357, P397, DOI 10.1016/j.bbrc.2007.03.135
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Ushijima T, 2003, GENOME RES, V13, P868, DOI 10.1101/gr.969603
   Ushio-Fukai M, 2008, CANCER LETT, V266, P37, DOI 10.1016/j.canlet.2008.02.044
   Veenendaal MVE, 2013, BJOG-INT J OBSTET GY, V120, P548, DOI 10.1111/1471-0528.12136
   Vicent GP, 2016, BBA-GENE REGUL MECH, V1859, P520, DOI 10.1016/j.bbagrm.2015.10.016
   Waddington CH, 2012, INT J EPIDEMIOL, V41, P10, DOI 10.1093/ije/dyr184
   WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304
   Wang YB, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2862-4
   WATTS D C, 1967, Guy's Hospital Reports, V116, P277
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Zeng J, 2014, OPHTHALMOLOGICA, V232, P1, DOI 10.1159/000357824
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
NR 82
TC 18
Z9 19
U1 0
U2 12
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD NOV
PY 2018
VL 41
IS 9
BP E407
EP E415
DI 10.1016/j.jfo.2018.09.001
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HA5AY
UT WOS:000450280600002
PM 30458925
DA 2022-11-30
ER

PT J
AU Liu, L
   Wang, YZ
   Bedell, HE
AF Liu, Lei
   Wang, Yi-Zhong
   Bedell, Harold E.
TI Visual-Function Tests for Self-monitoring of Age-Related Macular
   Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Review
DE AMD; aging; visual psychophysics; self-monitoring
ID PREFERENTIAL HYPERACUITY PERIMETER; DARK-ADAPTATION; CONTRAST
   SENSITIVITY; FLICKER PERIMETRY; NATURAL-HISTORY; SHAPE-DISCRIMINATION;
   ACUITY LOSS; PREVALENCE; EYES; MICROPERIMETRY
AB Age-related macular degeneration (AMD) is one of the leading causes of severe visual impairment in the United States. Changes in lifestyle can slow the progression of AMD, and new therapies that arrest choroidal neovascularization can preserve vision in patients who progress to the neovascular form of advanced AMD. Appropriate timing is required for these interventions to be optimally effective, which, in turn, depends critically on early diagnosis. Because annual or semiannual eye examinations may not be sufficient to ensure an early diagnosis, the preferred practice for AMD management must include self-monitoring by patients for disease onset or progression. In this review, we discuss a number of visual functions that have been shown to be impaired in eyes with AMD and specify desirable characteristics of visual-function tests that can be used for self-monitoring by populations at risk for AMD.
C1 [Liu, Lei] Univ Alabama Birmingham, Sch Optometry, Dept Optometry, Birmingham, AL 35294 USA.
   [Wang, Yi-Zhong] Retina Fdn SW, Dallas, TX USA.
   [Bedell, Harold E.] Univ Houston, Coll Optometry, Houston, TX 77204 USA.
C3 University of Alabama System; University of Alabama Birmingham; Retina
   Foundation of the Southwest; University of Houston System; University of
   Houston
RP Bedell, HE (通讯作者)，Univ Houston, Coll Optometry, 505 J Davis Armistead Bldg, Houston, TX 77204 USA.
EM HBedell@Optometry.uh.edu
OI Liu, Lei/0000-0002-1332-9724
CR American Optometric Association, 2004, OPT CLIN PRACT GUID
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Arimura E, 2011, INVEST OPHTH VIS SCI, V52, P128, DOI 10.1167/iovs.09-3535
   Aulhon E, 1989, PERIMETRY UPDATE 198, P331
   Bedell HE, 2009, OPTOMETRY VISION SCI, V86, P485, DOI 10.1097/OPX.0b013e31819fa6e2
   Black JM, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002730
   Bressler NM, 2000, BRIT MED J, V321, P1425, DOI 10.1136/bmj.321.7274.1425
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Delahunt PB, 2008, J VISION, V8, DOI 10.1167/8.3.5
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Dinc UA, 2008, EUR J OPHTHALMOL, V18, P595, DOI 10.1177/112067210801800416
   Dorr M, 2013, INVEST OPHTH VIS SCI, V54, P7266, DOI 10.1167/iovs.13-11743
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Fang K, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/676049
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Freeman WR, 2004, ARCH OPHTHALMOL-CHIC, V122, P1647, DOI 10.1001/archopht.122.11.1647
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gaffney AJ, 2011, OPTOMETRY VISION SCI, V88, P1080, DOI 10.1097/OPX.0b013e3182223697
   GELLER AM, 1992, J OPT SOC AM A, V9, P472, DOI 10.1364/JOSAA.9.000472
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   GREENSTEIN VC, 1992, INVEST OPHTH VIS SCI, V33, P2781
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Handa S, 2011, EYE, V25, P1170, DOI 10.1038/eye.2011.143
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Hennelly ML, 1998, OPHTHAL PHYSL OPT, V18, P197, DOI 10.1016/S0275-5408(97)00077-X
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   JOHNSON MA, 1987, APPL OPTICS, V26, P1449, DOI 10.1364/AO.26.001449
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kaiser PK, 2013, RETINA-J RET VIT DIS, V33, P1863, DOI 10.1097/IAE.0b013e3182899258
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kollbaum PS, 2014, OPTOMETRY VISION SCI, V91, P291, DOI 10.1097/OPX.0000000000000158
   Liu L, 2010, OPTOMETRY VISION SCI, V87, P532, DOI 10.1097/OPX.0b013e3181e3dc10
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   Luu CD, 2013, INVEST OPHTH VIS SCI, V54, P3560, DOI 10.1167/iovs.12-10465
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   MASSOF RW, 1989, CLIN VISION SCI, V4, P221
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   ONE&REG; Network, 2013, GUID PREF PRACT PATT
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Querques G, 2011, INVEST OPHTH VIS SCI, V52, P7012, DOI 10.1167/iovs.11-7517
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schneck ME, 2004, VISION RES, V44, P2317, DOI 10.1016/j.visres.2004.04.018
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   SEIPLE W, 1995, VISION RES, V35, P2057, DOI 10.1016/0042-6989(94)00289-X
   SLOANE ME, 1988, VISION RES, V28, P1235, DOI 10.1016/0042-6989(88)90039-9
   SMITH VC, 1988, J OPT SOC AM A, V5, P2113, DOI 10.1364/JOSAA.5.002113
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   SZLYK JP, 1995, VISION RES, V35, P1633, DOI 10.1016/0042-6989(94)00275-Q
   Trevino R, 2008, OPHTHAL PHYSL OPT, V28, P183, DOI 10.1111/j.1475-1313.2008.00561.x
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Wang YZ, 2009, OPTOMETRY VISION SCI, V86, P695, DOI 10.1097/OPX.0b013e3181a7b0ff
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   WEALE RA, 1988, J PHYSIOL-LONDON, V395, P577, DOI 10.1113/jphysiol.1988.sp016935
   Winther C, 2010, BRIT J OPHTHALMOL, V94, P324, DOI 10.1136/bjo.2009.164749
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
NR 75
TC 9
Z9 9
U1 0
U2 25
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 956
EP 965
DI 10.1097/OPX.0000000000000324
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500020
PM 24987816
DA 2022-11-30
ER

PT J
AU Shen, JK
   Dong, A
   Hackett, SF
   Bell, WR
   Green, WR
   Campochiaro, PA
AF Shen, J. K.
   Dong, A.
   Hackett, S. F.
   Bell, W. R.
   Green, W. R.
   Campochiaro, P. A.
TI Oxidative damage in age-related macular degeneration
SO HISTOLOGY AND HISTOPATHOLOGY
LA English
DT Article
DE acrolein; choroidal neovascularization; geographic atrophy; reactive
   oxygen species
ID 4-HYDROXYNONENAL PROTEIN; STRESS; PATHOGENESIS; ACTIVATION; DNA
AB Epidemiologic studies have suggested that elderly patients who consumed diets rich in antioxidants throughout their lives are less likely to be afflicted with age-related macular degeneration (AMD). This led to the Age-Related Eye Disease Study, which showed that supplements containing antioxidant vitamins and zinc reduce the risk of progression to severe stages of AMD. Despite these data that indirectly implicate oxidative damage in the pathogenesis of AMD, there has not been any direct demonstration of increased oxidative damage in the retinas of patients with AMD. In this study, we used biomarkers of oxidative damage in postmortem eyes from patients with AMD and comparably aged patients without AMD to directly assess for oxidative damage. Sections from 4 eyes with no pathologic features of AMD showed no immunofluorescent staining for markers of oxidative damage, while sections from 8 of 12 eyes with advanced geographic atrophy showed evidence of widespread oxidative damage in both posterior and anterior retina. Only 2 of 8 eyes with choroidal neovascularization and 2 of 16 eyes with diffuse drusen and no other signs of AMD showed evidence of oxidative damage. These data suggest that widespread oxidative damage occurs in the retina of some patients with AMD and is more likely to be seen in patients with advanced geographic atrophy. This does not rule out oxidative damage as a pathogenic mechanism in patients with CNV, but suggests that a subpopulation of patients with geographic atrophy may have a major deficiency in the oxidative defense system that puts the majority of cells in the retina at risk for oxidative damage.
C1 Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA.
   Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD USA.
   Johns Hopkins Univ, Dept Neurosci, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, 600 N Wolfe St, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
FU NATIONAL EYE INSTITUTE [P30EY001765, R01EY012609] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY12609, EY05951, P30EY1765] Funding Source:
   Medline
CR Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x
   Ando Y, 1998, J NEUROL SCI, V156, P172, DOI 10.1016/S0022-510X(98)00042-2
   Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BENEDETTI A, 1980, BIOCHIM BIOPHYS ACTA, V620, P281, DOI 10.1016/0005-2760(80)90209-X
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   BOWLING AC, 1995, LIFE SCI, V56, P1151, DOI 10.1016/0024-3205(95)00055-B
   Calingasan NY, 1999, J NEUROCHEM, V72, P751, DOI 10.1046/j.1471-4159.1999.0720751.x
   Cauwels A, 2003, NAT IMMUNOL, V4, P387, DOI 10.1038/ni914
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Iadecola C, 1999, NAT NEUROSCI, V2, P157, DOI 10.1038/5715
   Isayama F, 2004, HEPATOLOGY, V39, P721, DOI 10.1002/hep.20137
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kono H, 2003, J PHARMACOL EXP THER, V307, P74, DOI 10.1124/jpet.103.053595
   KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250
   LAI M, 1993, BIOCHEM PHARMACOL, V45, P927, DOI 10.1016/0006-2952(93)90178-Y
   Nyhlin N, 2002, J INTERN MED, V251, P136, DOI 10.1046/j.1365-2796.2002.00940.x
   ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0
   Selley ML, 1998, FREE RADICAL BIO MED, V25, P169, DOI 10.1016/S0891-5849(98)00021-5
   Serviddio G, 2004, HEPATOLOGY, V39, P711, DOI 10.1002/hep.20101
   Shefner JM, 1999, NEUROLOGY, V53, P1239, DOI 10.1212/WNL.53.6.1239
   Toyokuni S, 1999, J HISTOCHEM CYTOCHEM, V47, P833, DOI 10.1177/002215549904700613
   Toyokuni S, 1997, LAB INVEST, V76, P365
   Tuder RM, 2003, AM J RESP CELL MOL, V29, P88, DOI 10.1165/rcmb.2002-0228OC
   Uchida Y, 2004, J BIOL CHEM, V279, P4075, DOI 10.1074/jbc.M304222200
   Usuki F, 2004, ACTA NEUROPATHOL, V108, P1, DOI 10.1007/s00401-004-0844-0
   Van Everbroeck B, 2004, ACTA NEUROPATHOL, V108, P194, DOI 10.1007/s00401-004-0879-2
   Winkler BS, 1999, MOL VIS, V5
   Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696
   Zhang J, 1999, AM J PATHOL, V154, P1423, DOI 10.1016/S0002-9440(10)65396-5
NR 31
TC 126
Z9 139
U1 0
U2 10
PU F HERNANDEZ
PI MURCIA
PA PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN
SN 0213-3911
EI 1699-5848
J9 HISTOL HISTOPATHOL
JI Histol. Histopath.
PD DEC
PY 2007
VL 22
IS 12
BP 1301
EP 1308
PG 8
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA 200FN
UT WOS:000248749400001
PM 17701910
DA 2022-11-30
ER

PT J
AU Mori, Y
   Miyake, M
   Hosoda, Y
   Miki, A
   Takahashi, A
   Muraoka, Y
   Miyata, M
   Sato, T
   Tamura, H
   Ooto, S
   Yamada, R
   Yamashiro, K
   Nakamura, M
   Tajima, A
   Nagasaki, M
   Honda, S
   Tsujikawa, A
AF Mori, Yuki
   Miyake, Masahiro
   Hosoda, Yoshikatsu
   Miki, Akiko
   Takahashi, Ayako
   Muraoka, Yuki
   Miyata, Manabu
   Sato, Takehiro
   Tamura, Hiroshi
   Ooto, Sotaro
   Yamada, Ryo
   Yamashiro, Kenji
   Nakamura, Makoto
   Tajima, Atsushi
   Nagasaki, Masao
   Honda, Shigeru
   Tsujikawa, Akitaka
TI Genome-wide Survival Analysis for Macular Neovascularization Development
   in Central Serous Chorioretinopathy Revealed Shared Genetic
   Susceptibility with Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGY
LA English
DT Article
ID PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; BETA-CELLS; ASSOCIATION;
   VARIANTS; CHANNELS; EYES
AB Purpose: To identify susceptibility genes for macular neovascularization (MNV) development in central serous chorioretinopathy (CSC).
   Design: Genome-wide survival analysis using a longitudinal cohort study.
   Participants: We included 402 and 137 patients with CSC but without MNV at their first visit from the Kyoto CSC Cohort and Kobe CSC dataset, respectively. All patients underwent detailed ophthalmic examinations, including multimodal imaging, such as fundus autofluorescence, spectral-domain OCT, and fluorescein angiography/indocyanine green angiography or OCT angiography.
   Methods: We conducted a genome-wide survival analysis using the Kyoto CSC Cohort. We applied the Cox proportional hazard model to adjust for age, sex, and the first principal component. Single nucleotide polymorphisms (SNPs) with P values < 1.0 x 10(-5) were carried forward to the replication in the Kobe CSC dataset. Moreover, we evaluated the contribution of previously reported age-related macular degeneration (AMD) susceptibility loci. We used FUMA and ToppFun for the functional enrichment analysis.
   Main Outcome Measures: The association between SNPs and MNV development in patients with CSC.
   Results: Rs370974631 near ARMS2 displayed a genome-wide significant association in the meta-analysis of discovery and replication result (hazard ratio [HR](meta), 3.63; P-meta = 5.76 x 10(-9)). Among previously reported AMD susceptibility loci, we additionally identified CFH rs800292 (HR, 0.39, P = 2.55 x 10(-4)), COL4A3 rs4276018 (HR, 0.26, P = 1.56 x 10(-3)), and B3GALTL rs9564692 (HR, 0.56, P = 8.30 x 10(-3)) as susceptibility loci for MNV development in CSC. The functional enrichment analysis revealed significant enrichment of 8 pathways (GO:0051561, GO:0036444, GO:0008282, GO:1990246, GO:0015272, GO:0030955, GO:0031420, and GO:0005242) related to ion transport.
   Conclusions: ARMS2, CFH, COL4A3, and B3GALTL were identified as susceptibility genes for MNV development in CSC. These 4 genes are known as susceptibility genes for AMD, whereas COL4A3 and B3GALTL were previously reported to be polypoidal choroidal vasculopathy (PCV)-specific susceptibility genes. Our findings revealed the shared genetic susceptibility between PCV and MNV secondary to CSC. (c) 2022 by the American Academy of Ophthalmology
C1 [Mori, Yuki; Miyake, Masahiro; Takahashi, Ayako; Muraoka, Yuki; Miyata, Manabu; Tamura, Hiroshi; Ooto, Sotaro; Tsujikawa, Akitaka] Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Kyoto, Japan.
   [Mori, Yuki; Miyake, Masahiro; Yamada, Ryo; Nagasaki, Masao] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Kyoto, Japan.
   [Hosoda, Yoshikatsu] Osaka Red Cross Hosp, Dept Ophthalmol, Osaka, Japan.
   [Miki, Akiko; Nakamura, Makoto] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg, Kobe, Hyogo, Japan.
   [Sato, Takehiro; Tajima, Atsushi] Kanazawa Univ, Grad Sch Adv Prevent Med Sci, Dept Bioinformat & Genom, Kanazawa, Ishikawa, Japan.
   [Yamashiro, Kenji] Kochi Univ, Kochi Med Sch, Dept Ophthalmol & Visual Sci, Nankoku, Kochi, Japan.
   [Honda, Shigeru] Osaka City Univ, Grad Sch Med, Dept Med Stat, Osaka, Japan.
C3 Kyoto University; Kyoto University; Osaka Red Cross Hospital; Kobe
   University; Kanazawa University; Kochi University; Osaka Metropolitan
   University
RP Miyake, M (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Shogoin Kawahara, Kyoto 6068507, Japan.
EM miyakem@kuhp.kyoto-u.ac.jp
RI Tajima, Atsushi/C-1053-2008
OI Tajima, Atsushi/0000-0001-6808-5491
FU JSPS KAKENHI [20H03841]
FX This work was supported by JSPS KAKENHI (grant no: 20H03841)
CR Bernabeu E, 2021, NAT GENET, V53, P1283, DOI 10.1038/s41588-021-00912-0
   Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cordell HJ, 2021, J HEPATOL, V75, P572, DOI 10.1016/j.jhep.2021.04.055
   Dunne MJ, 1999, TRENDS ENDOCRIN MET, V10, P146, DOI 10.1016/S1043-2760(98)00135-0
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gottschalk B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11692-x
   Harper AR, 2021, NAT GENET, V53, P135, DOI 10.1038/s41588-020-00764-0
   Hosoda Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75451-5
   Hosoda Y, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0712-z
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Hutto RA, 2020, CELL DEATH DIFFER, V27, P1067, DOI 10.1038/s41418-019-0398-2
   Kane C, 1997, J CLIN INVEST, V100, P1888, DOI 10.1172/JCI119718
   Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344
   Kido A, 2021, BRIT J OPHTHALMOL, DOI 10.1136/bjophthalmol-2021-319403
   Liu XQ, 2017, NAT GENET, V49, P1152, DOI 10.1038/ng.3870
   Loo RH, 2002, RETINA-J RET VIT DIS, V22, P19, DOI 10.1097/00006982-200202000-00004
   Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402
   Miki A, 2018, INVEST OPHTH VIS SCI, V59, P5542, DOI 10.1167/iovs.18-25497
   Miki A, 2014, OPHTHALMOLOGY, V121, P1067, DOI 10.1016/j.ophtha.2013.11.020
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Miyake M, 2014, INVEST OPHTH VIS SCI, V55, P3223, DOI 10.1167/iovs.14-14059
   Mori Yuki, 2021, Ophthalmol Sci, V1, P100033, DOI 10.1016/j.xops.2021.100033
   Mrejen S, 2019, OPHTHALMOLOGY, V126, P576, DOI 10.1016/j.ophtha.2018.12.048
   Myers TA, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00157
   Nakanishi H, 2010, EYE, V24, P1078, DOI 10.1038/eye.2009.215
   Pan Y, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100456
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Shiragami C, 2018, AM J OPHTHALMOL, V193, P80, DOI 10.1016/j.ajo.2018.06.009
   Small KS, 2018, NAT GENET, V50, P572, DOI 10.1038/s41588-018-0088-x
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Syed H, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1683-z
   Takahashi A, 2021, OPHTHALMOL RETINA, V5, P910, DOI 10.1016/j.oret.2020.12.004
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Watanabe K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01261-5
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Yaddanapudi Lakshmi Narayana, 2016, J Anaesthesiol Clin Pharmacol, V32, P421, DOI 10.4103/0970-9185.194772
   Yamashiro K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072034
   Yeo JH, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/7217906
NR 41
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2022
VL 129
IS 9
BP 1034
EP 1042
DI 10.1016/j.ophtha.2022.04.018
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3V2KG
UT WOS:000841489000038
PM 35490733
DA 2022-11-30
ER

PT J
AU Hanus, J
   Zhao, FK
   Wang, SS
AF Hanus, Jakub
   Zhao, Fangkun
   Wang, Shusheng
TI Current therapeutic developments in atrophic age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; FACTOR-H
   POLYMORPHISM; GEOGRAPHIC ATROPHY; FUNDUS AUTOFLUORESCENCE; OXIDATIVE
   STRESS; COMPLEMENT INHIBITION; STEM-CELLS; DISEASE; GENERATION
AB Age-related macular degeneration (AMD), a degenerative disorder of the central retina, is the leading cause of irreversible blindness in the elderly. The underlying mechanism of the advanced form of dry AMD, also named geographic atrophy (GA) or atrophic AMD, remains unclear. Consequently, no cure is available for dry AMD or GA. The only prevention option currently available is the Age-Related Eye Disease Study (AREDS) formulation, which has been demonstrated to slow down the progression of dry AMD. This review summarises recent advances in therapy for dry AMD and GA. Building on the new understanding of the disease and recent technological breakthroughs, numerous ongoing clinical trials have the goal of meeting the need to cure AMD. Therapeutic agents are being developed to target the key features of the disease, including inhibiting the complement pathway and other inflammatory pathways, reducing oxidative stress and protecting retinal pigment epithelial (RPE) cells, inhibiting lipofuscin and visual cycle, regenerating RPE cells from stem cells and restoring choroidal blood flow. Some of these therapeutic options, especially the stem cell-based therapy, hold great promise, which brings great hope for this devastating blinding disease.
C1 [Hanus, Jakub; Zhao, Fangkun; Wang, Shusheng] Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA.
   [Zhao, Fangkun] China Med Univ, Affiliated Hosp 4, Shenyang 110001, Liaoning, Peoples R China.
   [Wang, Shusheng] Tulane Univ, Dept Ophthalmol, New Orleans, LA 70118 USA.
C3 Tulane University; China Medical University; Tulane University
RP Wang, SS (通讯作者)，Tulane Univ, Dept Ophthalmol, Dept Cell & Mol Biol, 2000 Percival Stern Hall,6400 Freret St, New Orleans, LA 70118 USA.
EM swang1@tulane.edu
FU US Department of Health and Human Services > National Institutes of
   Health > National Eye Institute [EY021862]; Tulane University; Research
   to Prevent Blindness foundation; Bright Focus Foundation Award in
   Age-related Macular Degeneration; NATIONAL EYE INSTITUTE [R01EY021862]
   Funding Source: NIH RePORTER
FX US Department of Health and Human Services > National Institutes of
   Health > National Eye Institute EY021862. Startup fund from Tulane
   University. Career development award from the Research to Prevent
   Blindness foundation and Bright Focus Foundation Award in Age-related
   Macular Degeneration.
CR Aharoni R, 2014, J AUTOIMMUN, V54, P81, DOI 10.1016/j.jaut.2014.05.005
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Becker Silke, 2012, Cells, V1, P851, DOI 10.3390/cells1040851
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Cai X, 2012, FRONT BIOSCI-LANDMRK, V17, P1976, DOI 10.2741/4033
   Camardo J, 2003, TRANSPL P, V35, p18S, DOI 10.1016/S0041-1345(03)00356-7
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJ, 2009, MOL VIS, V15, P283
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiou G, 2012, RETINA TODAY, P69
   Cho MS, 2012, STEM CELL RES, V9, P101, DOI 10.1016/j.scr.2012.05.002
   Cuenca N, 2013, INVEST OPHTH VIS SCI, V54, P6745, DOI 10.1167/iovs.13-12860
   Cunnusamy K, 2012, PHARM PAT ANAL, V1, P193, DOI 10.4155/PPA.12.12
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gordois A, 2010, GLOBAL EC COST VISUA
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hands SL, 2009, AGING-US, V1, P586, DOI 10.18632/aging.100070
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz F.G., 2012, AGE RELATED MACULAR
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468
   Jiang W, 2009, INT J OPHTHALMOL-CHI, V2, P324
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Kubota R, 2014, RETINA-J RET VIT DIS, V34, P603, DOI 10.1097/01.iae.0000434565.80060.f8
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Legendre CM, 2013, NEW ENGL J MED, V368, P2169, DOI 10.1056/NEJMoa1208981
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Mathieu JM, 2009, MICROB CELL FACT, V8, DOI 10.1186/1475-2859-8-21
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   Parsons CG, 2015, NEUROPHARMACOLOGY, V92, P158, DOI 10.1016/j.neuropharm.2014.12.038
   Patel HR, 2015, OSLI RETINA, V46, P8, DOI 10.3928/23258160-20150101-01
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rozanowska M, 2004, INVEST OPHTH VIS SCI, V45, P1052, DOI 10.1167/iovs.03-0277
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Sayegh RG, 2015, INVEST OPHTH VIS SCI, V56, P5246, DOI 10.1167/iovs.14-15114
   Sayegh RG, 2014, BRIT J OPHTHALMOL, V98, P1050, DOI 10.1136/bjophthalmol-2014-305195
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Suzuki M, 2007, MOL VIS, V13, P772
   Tanito M, 2010, EXP EYE RES, V91, P111, DOI 10.1016/j.exer.2010.04.012
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wei Jiang CG, 2009, INT J OPHTHALMOL, V2, P324
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zampros I, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/319728
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhu DH, 2011, INVEST OPHTH VIS SCI, V52, P1573, DOI 10.1167/iovs.10-6413
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 76
TC 52
Z9 54
U1 1
U2 48
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2016
VL 100
IS 1
BP 122
EP 127
DI 10.1136/bjophthalmol-2015-306972
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CZ2OJ
UT WOS:000366944200020
PM 26553922
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Santarelli, M
   Diplotti, L
   Samassa, F
   Veritti, D
   Kuppermann, BD
   Lanzetta, P
AF Santarelli, Martina
   Diplotti, Laura
   Samassa, Francesco
   Veritti, Daniele
   Kuppermann, Baruch D.
   Lanzetta, Paolo
TI Advances in pharmacotherapy for wet age-related macular degeneration
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Review
DE age related macular degeneration; angiogenesis inhibitors; choroidal
   neovascularization; drug therapy
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PHOTODYNAMIC THERAPY; CHOROIDAL
   NEOVASCULARIZATION; FUSION PROTEIN; SIRNA PF-04523655; RANIBIZUMAB;
   ANGIOGENESIS; CONTRIBUTES; MECHANISMS; INHIBITION
AB Introduction: In developed countries, neovascular age-related macular degeneration (AMD) is the leading cause of irreversible central blindness. Although AMD pathogenesis is complex and still not fully understood, many involved mechanisms are already partially known and could be promising targets for future therapies. Currently, anti-VEGF drugs are the standard care of this condition.
   Areas covered: This review summarizes both the current available and the emerging pharmacological therapies for the management of neovascular AMD. At first, we briefly focused on anti-VEGF compounds that are commonly used. Then, we reviewed the mechanisms of action and potential advantages of new candidate drugs that are being evaluated in clinical trials.
   Expert opinion: Although anti-VEGF drugs have shown mild-term good efficacy and safety profile in the treatment of neovascular AMD, they are far away from being a perfect therapy. Pharmacological research should focus on finding new molecular targets in the AMD pathogenetical pathway and on developing longer lasting agents or new drug delivery systems. Besides the development of new drugs, a better characterization of patients is also needed, taking into account variables such as choroidal neovascularization subtypes and genetic factors, in order to identify a tailored treatment for each patient.
C1 [Santarelli, Martina; Diplotti, Laura; Samassa, Francesco; Veritti, Daniele; Lanzetta, Paolo] Univ Udine, Dept Med & Biol Sci Ophthalmol, I-33100 Udine, Italy.
   [Veritti, Daniele; Lanzetta, Paolo] IEMO, Ist Europe Microchirurg Oculare, Udine, Italy.
   [Kuppermann, Baruch D.] Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA USA.
C3 University of Udine; University of California System; University of
   California Irvine
RP Lanzetta, P (通讯作者)，Univ Udine, Dept Med & Biol Sci Ophthalmol, Piazza Santa Maria Misericordia, I-33100 Udine, Italy.
EM paolo.lanzetta@uniud.it
OI VERITTI, Daniele/0000-0003-0148-5348; Diplotti,
   Laura/0000-0002-9039-8352
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], SQUAL
   [Anonymous], PAN 90806 OUR LEAD D
   [Anonymous], 2014, STAG 3 PHAS 2 STUD D
   [Anonymous], PHAS 2 STUD DARPIN A
   [Anonymous], 2013, ARVO 2013 ANN M SCI
   [Anonymous], AB
   Barik S, 2004, ANN MED, V36, P540, DOI 10.1080/07853890410018817
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Binz HK, 2004, NAT BIOTECHNOL, V22, P575, DOI 10.1038/nbt962
   Boersma YL, 2011, CURR OPIN BIOTECH, V22, P849, DOI 10.1016/j.copbio.2011.06.004
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Castellon R, 2002, EXP EYE RES, V74, P523, DOI 10.1006/exer.2001.1161
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chowers I, 2008, MOL VIS, V14, P2263
   Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Dugel P, 2014, P AM SOC RET SPEC AN
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gabai A, 2014, EUR J OPHTHALMOL, V24, P396, DOI 10.5301/ejo.5000385
   Gaengel K, 2009, ARTERIOSCL THROM VAS, V29, P630, DOI 10.1161/ATVBAHA.107.161521
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   Genaidy M, 2002, RETINA-J RET VIT DIS, V22, P772, DOI 10.1097/00006982-200212000-00014
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gutierrez-Hernandez JC, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.4.1
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hanout M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/830837
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Humayun M, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.6.5
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   Kaiser PK, 2007, CURR MED RES OPIN, V23, P477, DOI 10.1185/030079907X167624
   Kaiser PK, 2014, RETINA
   Kaiser PK, 2013, OPHTHALMOLOGY S5, V120, P11
   Kaiser RS, 2013, RETINA TODAY
   Kauper K, 2014, ARVO 2014 ANN M
   Kim Ramasamy, 2007, Indian Journal of Ophthalmology, V55, P413
   Krader CG, 2010, OPHTHALMOLOGY TIMES
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lanzetta P, 2015, P 6 WORLD C CONTR OP
   Lanzetta P, 2013, BRIT J OPHTHALMOL, V97, P1497, DOI 10.1136/bjophthalmol-2013-303394
   Li H, 2012, EXP EYE RES, V97, P154, DOI 10.1016/j.exer.2011.09.002
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Miao H, 2012, MOL VIS, V18, P574
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Moutray T, 2011, THER ADV CHRONIC DIS, V2, P325, DOI 10.1177/2040622311415895
   Nelson R, 2013, OPHTHALMOLOGY TIMES
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Nguyen QD, 2012, INVEST OPHTH VIS SCI, V53, P7666, DOI 10.1167/iovs.12-9961
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043
   Quiroz-Mercado H., 2013, RETINA TODAY
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Regeneron Pharmaceuticals Inc., ANN REP FORM 10 K
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Replenish Inc., PROD DESCR DEV DEV
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Rubio RG, 2014, RETINA TODAY
   Sabbadini RA, 2011, BRIT J PHARMACOL, V162, P1225, DOI 10.1111/j.1476-5381.2010.01118.x
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Selvaraj SK, 2003, BLOOD, V102, P1515, DOI 10.1182/blood-2002-11-3423
   Semenza GL, 2000, GENE DEV, V14, P1983
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Sills AK, 1998, CANCER RES, V58, P2784
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer Michael, 2014, F1000Prime Rep, V6, P29, DOI 10.12703/P6-29
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Sonpavde G, 2008, EXPERT OPIN INV DRUG, V17, P253, DOI 10.1517/13543784.17.2.253
   Stumpp MT, 2008, DRUG DISCOV TODAY, V13, P695, DOI 10.1016/j.drudis.2008.04.013
   Veritti D, 2013, J OCUL PHARMACOL TH, V29, P437, DOI 10.1089/jop.2012.0173
   Veritti D, 2013, RETINA-J RET VIT DIS, V33, P982, DOI 10.1097/IAE.0b013e31826d8ff4
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Wang F, 2013, GRAEF ARCH CLIN EXP, V251, P2131, DOI 10.1007/s00417-013-2392-6
   Xia Y, 2012, EUR J MED CHEM, V49, P24, DOI 10.1016/j.ejmech.2012.01.033
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Zhou AY, 2013, OPHTHALMIC RES, V50, P180, DOI 10.1159/000353437
NR 95
TC 23
Z9 25
U1 1
U2 34
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD AUG
PY 2015
VL 16
IS 12
BP 1769
EP 1781
DI 10.1517/14656566.2015.1067679
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CO8CJ
UT WOS:000359392300005
PM 26165696
DA 2022-11-30
ER

PT J
AU Luaces-Rodriguez, A
   Mondelo-Garcia, C
   Zarra-Ferro, I
   Gonzalez-Barcia, M
   Aguiar, P
   Fernandez-Ferreiro, A
   Otero-Espinar, FJ
AF Luaces-Rodriguez, Andrea
   Mondelo-Garcia, Cristina
   Zarra-Ferro, Irene
   Gonzalez-Barcia, Miguel
   Aguiar, Pablo
   Fernandez-Ferreiro, Anxo
   Otero-Espinar, Francisco J.
TI Intravitreal anti-VEGF drug delivery systems for age-related macular
   degeneration
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Intravitreal; Drug delivery systems; Anti-VEGF; Ranibizumab;
   Aflibercept; Bevacizumab; Age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; MESOPOROUS SILICA NANOPARTICLES; REVERSE
   THERMAL GEL; INTRAOCULAR PHARMACOKINETICS; CONTROLLED-RELEASE;
   SUSTAINED-RELEASE; CHOROIDAL NEOVASCULARIZATION; IN-VIVO; BIODEGRADABLE
   MICROSPHERES; CHITOSAN NANOPARTICLES
AB Age-related macular degeneration is the most common cause of vision loss in elderly people in developed countries. Nowadays, in clinical practice, three anti-VEGF drugs are commonly used (bevacizumab, aflibercept and ranibizumab), requiring repeated intravitreal injections. In order to minimise the number of injections, research on intravitreal drug delivery systems (DDSs) is needed. In this review, the DDSs developed up to date regarding intravitreal anti-VEGF drugs have been summarised, which include systems as hydrogels, liposomes, microparticles, nanoparticles or implants. Most of the studies have focused on the extended in vitro release behaviour of the developed DDSs, but data as antibody bioactivity, biocompatibility or in vivo stability is sometimes scarce. Moreover, as DDS development relies on in vivo pharmacokinetic analyses to evaluate the extended drug release, all the information regarding anti-VEGF intravitreal pharmacokinetics in different animal species have been compiled.
C1 [Luaces-Rodriguez, Andrea; Gonzalez-Barcia, Miguel; Fernandez-Ferreiro, Anxo; Otero-Espinar, Francisco J.] Univ Santiago de Compostela, Fac Pharm, Pharmacol Pharm & Pharmaceut Technol Dept, Santiago De Compostela, Spain.
   [Luaces-Rodriguez, Andrea; Mondelo-Garcia, Cristina; Zarra-Ferro, Irene; Gonzalez-Barcia, Miguel; Fernandez-Ferreiro, Anxo; Otero-Espinar, Francisco J.] Hlth Res Inst Santiago de Compostela FIDIS, Pharmacol Grp, Santiago De Compostela, Spain.
   [Mondelo-Garcia, Cristina; Zarra-Ferro, Irene; Gonzalez-Barcia, Miguel; Fernandez-Ferreiro, Anxo] Univ Clin Hosp Santiago de Compostela SERGAS, Pharm Dept, A Choupana S-N, E-15706 Santiago De Compostela, Spain.
   [Aguiar, Pablo] Univ Clin Hosp Santiago de Compostela SERGAS, Nucl Med Dept, Santiago De Compostela, Spain.
   [Aguiar, Pablo] Hlth Res Inst Santiago de Compostela FIDIS, Mol Imaging Grp, Santiago De Compostela, Spain.
C3 Universidade de Santiago de Compostela; Complexo Hospitalario
   Universitario de Santiago de Compostela; Complexo Hospitalario
   Universitario de Santiago de Compostela
RP Otero-Espinar, FJ (通讯作者)，Univ Santiago de Compostela, Fac Pharm, Pharmacol Pharm & Pharmaceut Technol Dept, Santiago De Compostela, Spain.; Fernandez-Ferreiro, A (通讯作者)，Univ Clin Hosp Santiago de Compostela SERGAS, Pharm Dept, A Choupana S-N, E-15706 Santiago De Compostela, Spain.
EM anxordes@gmail.com; francisco.otero@usc.es
RI Otero-Espinar, F. J./K-1337-2014; Aguiar, Pablo/S-3371-2019; Fernández,
   Pablo Aguiar/ABD-9169-2022
OI Otero-Espinar, F. J./0000-0001-9030-2253; Aguiar,
   Pablo/0000-0002-7322-2195; Mondelo-Garcia, Cristina/0000-0001-8555-1415;
   Zarra Ferro, Irene/0000-0003-0835-034X
FU Instituto de Salud Carlos III (ISCIII) - FEDER [PI17/00940,
   RD16/0008/0003, RD12/0034/0017]; Spanish Ministry of Science, Innovation
   and Universities [RTI2018-099597-B-100]
FX This work was partially supported by Instituto de Salud Carlos III
   (ISCIII) cofunded by FEDER (PI17/00940, RETICS Oftared, RD16/0008/0003
   and RD12/0034/0017) and by the Spanish Ministry of Science, Innovation
   and Universities (RTI2018-099597-B-100).
CR Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Adamson P, 2016, J CONTROL RELEASE, V244, P1, DOI 10.1016/j.jconrel.2016.10.026
   Agrahari V, 2017, EXPERT OPIN DRUG DEL, V14, P1145, DOI 10.1080/17425247.2017.1272569
   Ahmed EM, 2015, J ADV RES, V6, P105, DOI 10.1016/j.jare.2013.07.006
   Ahn J, 2013, J OCUL PHARMACOL TH, V29, P612, DOI 10.1089/jop.2013.0009
   Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P567, DOI 10.1167/iovs.13-13054
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   Anwary M, 2018, ARTIF CELL NANOMED B, V46, P1074, DOI 10.1080/21691401.2018.1478845
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Awwad S, 2018, MACROMOL BIOSCI, V18, DOI 10.1002/mabi.201700255
   Badiee P, 2018, J BIOMED MATER RES A, V106, P2261, DOI 10.1002/jbm.a.36424
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Burgalassi S, 2018, DRUG DELIV TRANSL RE, V8, P461, DOI 10.1007/s13346-018-0520-x
   Christoforidis JB, 2013, CURR EYE RES, V38, P761, DOI 10.3109/02713683.2013.763988
   Christoforidis JB, 2013, RETINA-J RET VIT DIS, V33, P946, DOI 10.1097/IAE.0b013e3182753b12
   Christoforidis JB, 2012, CURR EYE RES, V37, P1171, DOI 10.3109/02713683.2012.727521
   Christoforidis JB, 2011, INVEST OPHTH VIS SCI, V52, P5899, DOI 10.1167/iovs.10-6862
   Christoforidis JB, 2017, INVEST OPHTH VIS SCI, V58, P5636, DOI 10.1167/iovs.17-22431
   Chua HY, 2018, EXPERT OPIN DRUG DEL, V15, P1143, DOI 10.1080/17425247.2018.1538209
   DeFail AJ, 2006, BIOMATERIALS, V27, P1579, DOI 10.1016/j.biomaterials.2005.08.013
   Delplace V, 2019, J CONTROL RELEASE, V293, P10, DOI 10.1016/j.jconrel.2018.11.012
   Ding DW, 2018, MAT SCI ENG C-MATER, V92, P1041, DOI 10.1016/j.msec.2017.12.036
   Do DV, 2020, RETINA-J RET VIT DIS, V40, P643, DOI 10.1097/IAE.0000000000002566
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   Fredenberg S, 2011, INT J PHARMACEUT, V415, P34, DOI 10.1016/j.ijpharm.2011.05.049
   Garcia-Quintanilla L, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080365
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Gasmi H, 2016, INT J PHARMACEUT, V514, P189, DOI 10.1016/j.ijpharm.2016.08.032
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gavini E, 2018, CURR DRUG DELIV, V15, P930, DOI 10.2174/1567201815666180226121020
   Gil-Martinez M, 2020, CURR MED CHEM, V27, P583, DOI 10.2174/0929867326666190726121711
   Gote V, 2019, J PHARMACOL EXP THER, V370, P602, DOI 10.1124/jpet.119.256933
   Herrero-Vanrell R, 2014, PROG RETIN EYE RES, V42, P27, DOI 10.1016/j.preteyeres.2014.04.002
   Hu CC, 2014, BIO-MED MATER ENG, V24, P1941, DOI 10.3233/BME-141003
   Huang XN, 2019, DRUG DISCOV TODAY, V24, P1510, DOI 10.1016/j.drudis.2019.05.005
   Iyer S, 2019, J CONTROL RELEASE, V296, P140, DOI 10.1016/j.jconrel.2019.01.007
   Joseph M, 2017, EXPERT OPIN DRUG DEL, V14, P631, DOI 10.1080/17425247.2016.1227783
   Kakinoki M, 2012, INVEST OPHTH VIS SCI, V53, P5877, DOI 10.1167/iovs.12-10164
   Kang-Mieler JJ, 2018, INVEST OPHTH VIS SCI, V59
   Kelly SJ, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6030092
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Lance KD, 2016, DRUG DELIV TRANSL RE, V6, P771, DOI 10.1007/s13346-016-0298-7
   Lau CML, 2018, ADV DRUG DELIVER REV, V126, P145, DOI 10.1016/j.addr.2018.03.013
   Lee SS, 2010, PHARM RES-DORDR, V27, P2043, DOI 10.1007/s11095-010-0159-x
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Liu JX, 2019, INT J PHARMACEUT, V563, P228, DOI 10.1016/j.ijpharm.2019.04.012
   Liu WQ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.12
   Liu WQ, 2019, CURR EYE RES, V44, P264, DOI 10.1080/02713683.2018.1533983
   Liu XY, 2019, IRAN J RADIOL, V16, DOI 10.5812/iranjradiol.68697
   Lovett ML, 2015, EUR J PHARM BIOPHARM, V95, P271, DOI 10.1016/j.ejpb.2014.12.029
   Lu Y, 2014, INT J OPHTHALMOL-CHI, V7, P1, DOI 10.3980/j.issn.2222-3959.2014.01.01
   Madni A, 2014, J PHARM PHARM SCI, V17, P401, DOI 10.18433/J3CP55
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Minh KN, 2010, MACROMOL BIOSCI, V10, P563, DOI 10.1002/mabi.200900402
   Miyake T, 2010, INVEST OPHTH VIS SCI, V51, P1606, DOI 10.1167/iovs.09-4140
   Mohammed MA, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9040053
   Moisseiev E, 2014, GRAEF ARCH CLIN EXP, V252, P331, DOI 10.1007/s00417-013-2495-0
   Mu HJ, 2018, DRUG DELIV, V25, P1372, DOI 10.1080/10717544.2018.1474967
   Najafabadi HS, 2017, ARCH IRAN MED, V20, P525
   Narayan R, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030118
   Naskar S, 2019, J DRUG TARGET, V27, P379, DOI 10.1080/1061186X.2018.1512112
   Niwa Y, 2015, INVEST OPHTH VIS SCI, V56, P6501, DOI 10.1167/iovs.15-17279
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Osswald CR, 2017, CURR EYE RES, V42, P1293, DOI 10.1080/02713683.2017.1302590
   Osswald CR, 2016, CURR EYE RES, V41, P1216, DOI 10.3109/02713683.2015.1101140
   Osswald CR, 2015, ANN BIOMED ENG, V43, P2609, DOI 10.1007/s10439-015-1314-7
   Pan CK, 2011, J OCUL PHARMACOL TH, V27, P219, DOI 10.1089/jop.2010.0158
   Park D, 2013, MACROMOL BIOSCI, V13, P464, DOI 10.1002/mabi.201200384
   Rauck BM, 2014, INVEST OPHTH VIS SCI, V55, P469, DOI 10.1167/iovs.13-13120
   Sakurai E, 2001, OPHTHALMIC RES, V33, P31, DOI 10.1159/000055638
   Savin CL, 2019, MAT SCI ENG C-MATER, V98, P843, DOI 10.1016/j.msec.2019.01.036
   Sinapis CI, 2011, CLIN OPHTHALMOL, V5, P697, DOI 10.2147/OPTH.S19555
   Slowing II, 2007, ADV FUNCT MATER, V17, P1225, DOI 10.1002/adfm.200601191
   Sousa F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03959-4
   Stein S, 2018, EUR J PHARM BIOPHARM, V127, P270, DOI 10.1016/j.ejpb.2018.02.034
   Subrizi A, 2019, DRUG DISCOV TODAY, V24, P1446, DOI 10.1016/j.drudis.2019.02.001
   Sun JG, 2019, INT J NANOMED, V14, P1489, DOI 10.2147/IJN.S195504
   Tanetsugu Y, 2017, BIOL PHARM BULL, V40, P145, DOI 10.1248/bpb.b16-00437
   Thakur SS, 2014, EXPERT OPIN DRUG DEL, V11, P1575, DOI 10.1517/17425247.2014.927864
   van de Weert M, 2000, PHARM RES-DORDR, V17, P1159, DOI 10.1023/A:1026498209874
   Varshochian R, 2015, J BIOMED MATER RES A, V103, P3148, DOI 10.1002/jbm.a.35446
   Varshochian R, 2013, EUR J PHARM SCI, V50, P341, DOI 10.1016/j.ejps.2013.07.014
   Vollrath M, 2017, EUR J PHARM BIOPHARM, V117, P244, DOI 10.1016/j.ejpb.2017.04.017
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xie BB, 2015, INT J PHARMACEUT, V490, P375, DOI 10.1016/j.ijpharm.2015.05.071
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Xu QG, 2013, J CONTROL RELEASE, V167, P76, DOI 10.1016/j.jconrel.2013.01.018
   Yandrapu SK, 2013, MOL PHARMACEUT, V10, P4676, DOI 10.1021/mp400487f
   Ye Z, 2015, INT J OPHTHALMOL-CHI, V8, P653, DOI 10.3980/j.issn.2222-3959.2015.04.02
   Yu J, 2014, INT J PHARMACEUT, V470, P151, DOI 10.1016/j.ijpharm.2014.04.053
   Yu Y, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.5
   Zhang LL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135608
   Zhang XP, 2018, BIOMED PHARMACOTHER, V107, P1056, DOI 10.1016/j.biopha.2018.08.092
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 104
TC 20
Z9 20
U1 5
U2 28
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29a, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JAN 5
PY 2020
VL 573
AR 118767
DI 10.1016/j.ijpharm.2019.118767
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA JZ3KO
UT WOS:000505001000031
PM 31669558
DA 2022-11-30
ER

PT J
AU Thompson, CL
   Klein, BEK
   Klein, R
   Xu, ZY
   Capriotti, J
   Joshi, T
   Leontiev, D
   Lee, KE
   Elston, RC
   Iyengar, SK
AF Thompson, Cheryl L.
   Klein, Barbara E. K.
   Klein, Ronald
   Xu, Zhiying
   Capriotti, Jennifer
   Joshi, Tripti
   Leontiev, Dmitry
   Lee, Kristine E.
   Elston, Robert C.
   Iyengar, Sudha K.
TI Complement factor H and hemicentin-1 in age-related macular degeneration
   and renal phenotypes
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; GLOMERULAR-FILTRATION-RATE;
   MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; CREATININE CLEARANCE;
   SUSCEPTIBILITY LOCI; STRONG ASSOCIATION; SERUM CREATININE;
   GENOMEWIDE-SCAN; Y402H VARIANT; GENE
AB In this study, we investigated the associations of complement factor H (CFH) and hemicentin-1 (HMCN1) with age-related macular degeneration (AMD) and renal function. Three scales, measuring the course of AMD and drusen development, were examined in two samples: the Family Age-Related Macular degeneration Study (FARMS), consisting of families ascertained through a single individual with severe AMD, and an unascertained population-based family cohort, the Beaver Dam Eye Study (BDES), which was also used to assess longitudinal changes in AMD and associations with renal function. Associations were performed by a regression accounting for known risk factors as well as familial and sibling effects. Strong evidence of the association of rs1061170 (Y402H) variation with AMD was confirmed (P = 9.15 x 10(-5) in BDES, P = 0.016 in FARMS). This association was observed in multiple AMD scales, suggesting that its role is not phenotype-specific. Polymorphisms in both CFH and HMCN1 appeared to influence the longitudinal rate of change of AMD. The rs1061170 polymorphism was also associated with a reduction in estimated glomerular filtration rate (eGFR) (P = 0.046). Another CFH polymorphism, rs800292, was similarly associated with eGFR [beta = - 0.90 (P = 0.022)]. Associations between rs743137 (P = 0.05) and rs680638 (P = 0.022) in HMCN1 with calculated creatinine clearance progression were also observed. Both genes appear to play a role in both AMD and renal path ophysiology. These findings support evidence for common pathways influencing ocular and renal function and suggest that further work is required on their common determinants.
C1 Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA.
   Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
C3 Case Western Reserve University; Case Western Reserve University; Case
   Western Reserve University; University of Wisconsin System; University
   of Wisconsin Madison
RP Iyengar, SK (通讯作者)，Case Western Reserve Univ, Dept Epidemiol & Biostat, Wolstein Res Bldg,Room 1315,2103 Cornell Rd, Cleveland, OH 44106 USA.
EM ski@case.edu
RI /S-1190-2019
OI /0000-0001-7488-250X
FU NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003655] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY015810, U10EY006594, R01EY015286,
   R03EY013438, R01EY010605] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK057292]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCES [R01GM028359] Funding Source: NIH RePORTER; NCI NIH HHS [P30
   CA43703] Funding Source: Medline; NCRR NIH HHS [RR03655] Funding Source:
   Medline; NEI NIH HHS [EY015286, EY015810, EY10605, EY13438, U10 EY06594]
   Funding Source: Medline; NHLBI NIH HHS [HL07567] Funding Source:
   Medline; NIDDK NIH HHS [U01 DK057292] Funding Source: Medline; NIGMS NIH
   HHS [GM28359] Funding Source: Medline
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786
   Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Alexander JJ, 2007, J AM SOC NEPHROL, V18, P1157, DOI 10.1681/ASN.2006101125
   Alexander JJ, 2005, J AM SOC NEPHROL, V16, P52, DOI 10.1681/ASN.2004090778
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bielsky IE, 2005, BEHAV BRAIN RES, V164, P132, DOI 10.1016/j.bbr.2005.06.005
   Bontekoe CJM, 2002, HUM MOL GENET, V11, P487, DOI 10.1093/hmg/11.5.487
   Buddles MRH, 2000, AM J HUM GENET, V66, P1721, DOI 10.1086/302877
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Cohn DH, 2000, AM J HUM GENET, V67, P647, DOI 10.1086/303051
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Constantiner M, 2005, AM J KIDNEY DIS, V45, P833, DOI 10.1053/j.ajkd.2005.02.012
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2007, BRIT J OPHTHALMOL, V91, P966, DOI 10.1136/bjo.2007.114090
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fox CS, 2004, J AM SOC NEPHROL, V15, P2457, DOI 10.1097/01.ASN.0000135972.13396.6F
   Frantz S, 2001, HYPERTENSION, V38, P216, DOI 10.1161/01.HYP.38.2.216
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Fukamauchi F, 1997, EUR J PHARMACOL, V338, P7, DOI 10.1016/S0014-2999(97)01298-3
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Huang SJ, 2003, RETINA-J RET VIT DIS, V23, P429, DOI 10.1097/00006982-200306000-00036
   Hunt SC, 2004, AM J HYPERTENS, V17, P511, DOI 10.1016/j.amjhyper.2004.02.019
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jun G, 2005, INVEST OPHTH VIS SCI, V46, P3081, DOI 10.1167/iovs.04-1360
   Klein BEK, 2003, OPHTHALMIC EPIDEMIOL, V10, P97, DOI 10.1076/opep.10.2.97.13896
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, WINCONSIN AGE RELATE
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Manjunath G, 2001, CURR OPIN NEPHROL HY, V10, P785, DOI 10.1097/00041552-200111000-00009
   Neary JJ, 2002, J AM SOC NEPHROL, V13, P2052, DOI 10.1097/01.ASN.0000022006.49966.F8
   Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Podolin PL, 1997, J IMMUNOL, V159, P1835
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Saleem M, 2006, ANN CLIN BIOCHEM, V43, P309, DOI 10.1258/000456306777695573
   Saunders RE, 2006, HUM MUTAT, V27, P21, DOI 10.1002/humu.20268
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shi WB, 2002, CIRCULATION, V105, P2078, DOI 10.1161/01.CIR.0000015853.59427.32
   Souied EH, 2005, MOL VIS, V11, P1135
   Thompson CL, 2007, INVEST OPHTH VIS SCI, V48, P3005, DOI 10.1167/iovs.06-1325
   Tsukaguchi H, 2000, J AM SOC NEPHROL, V11, P1674, DOI 10.1681/ASN.V1191674
   Van Agtmael T, 2005, HUM MOL GENET, V14, P3161, DOI 10.1093/hmg/ddi348
   Vollmer M, 1998, AM J HUM GENET, V63, P1724, DOI 10.1086/302162
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Ying LH, 1999, AM J HUM GENET, V65, P1538, DOI 10.1086/302673
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
   2005, S A G E 5 0 STAT ANA
NR 73
TC 42
Z9 44
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD SEP 1
PY 2007
VL 16
IS 17
BP 2135
EP 2148
DI 10.1093/hmg/ddm164
PG 14
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 219LJ
UT WOS:000250086400012
PM 17591627
OA hybrid
DA 2022-11-30
ER

PT J
AU Connell, PP
   Keane, PA
   O'Neill, EC
   Altaie, R
   Loane, E
   Neelam, K
   Nolan, JM
   Beatty, S
AF Connell, Paul P.
   Keane, Pearse A.
   O'Neill, Evelyn C.
   Altaie, RashaW.
   Loane, Edward
   Neelam, Kumari
   Nolan, John M.
   Beatty, Stephen
TI Risk Factors for Age-Related Maculopathy
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID COMPLEMENT-FACTOR-H; C-REACTIVE-PROTEIN; APOLIPOPROTEIN-E GENE;
   CHLAMYDIA-PNEUMONIAE INFECTION; CHOROIDAL BLOOD-FLOW; 3RD
   NATIONAL-HEALTH; LONG-TERM INCIDENCE; 15-YEAR CUMULATIVE INCIDENCE;
   HORMONE REPLACEMENT THERAPY; PATHOLOGIES-OCULAIRES-LIEES
AB Age-related maculopathy (ARM) is the leading cause of blindness in the elderly. Although beneficial therapeutic strategies have recently begun to emerge, much remains unclear regarding the etiopathogenesis of this disorder. Epidemiologic studies have enhanced our understanding of ARM, but the data, often conflicting, has led to difficulties with drawing firm conclusions with respect to risk for this condition. As a consequence, we saw a need to assimilate the published findings with respect to risk factors for ARM, through a review of the literature appraising results from published cross-sectional studies, prospective cohort studies, case series, and case control studies investigating risk for this condition. Our review shows that, to date, and across a spectrum of epidemiologic study designs, only age, cigarette smoking, and family history of ARM have been consistently demonstrated to represent risk for this condition. In addition, genetic studies have recently implicated many genes in the pathogenesis of age-related maculopathy, including Complement Factor H, PLEKHA 1, and LOC387715/HTRA1, demonstrating that environmental and genetic factors are important for the development of ARM suggesting that gene-environment interaction plays an important role in the pathogenesis of this condition. Copyright (C) 2009 Paul P. Connell et al.
C1 [Connell, Paul P.; Keane, Pearse A.; O'Neill, Evelyn C.; Altaie, RashaW.; Loane, Edward; Neelam, Kumari; Beatty, Stephen] Waterford Reg Hosp, Waterford, Ireland.
   [Nolan, John M.; Beatty, Stephen] Waterford Inst Technol, Macular Pigment Res Grp, Waterford, Ireland.
C3 South East Technological University (SETU)
RP Connell, PP (通讯作者)，Waterford Reg Hosp, Dunmore Rd, Waterford, Ireland.
EM drpaulconnell@gmail.com
RI Keane, Pearse A/H-1860-2011; Keane, Pearse/AAE-5709-2019; Nolan,
   John/N-4921-2014
OI Keane, Pearse/0000-0002-9239-745X; Nolan, John/0000-0002-5503-7084
CR AKIYAMA H, 1994, TOHOKU J EXP MED, V174, P295, DOI 10.1620/tjem.174.295
   ALVAREZ RA, 1987, AM J CLIN NUTR, V46, P481, DOI 10.1093/ajcn/46.3.481
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Assink JJM, 2005, OPHTHALMOLOGY, V112, P482, DOI 10.1016/j.ophtha.2004.10.035
   Athyros VG, 2008, ATHEROSCLEROSIS, V200, P1, DOI 10.1016/j.atherosclerosis.2008.02.026
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Badimon L, 2001, THROMB HAEMOSTASIS, V86, P356
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bazan N G, 1989, Prog Clin Biol Res, V312, P95
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bernhard D, 2007, CURR MED CHEM, V14, P1703
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BORISH ET, 1987, CARCINOGENESIS, V8, P1517, DOI 10.1093/carcin/8.10.1517
   BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943
   Braunstein RE, 2005, ARCH OPHTHALMOL-CHIC, V123, P547, DOI 10.1001/archopht.123.4.547
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   CEDERBAUM AI, 1989, FREE RADICAL BIO MED, V7, P537, DOI 10.1016/0891-5849(89)90029-4
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chamberlain M, 2006, SURV OPHTHALMOL, V51, P576, DOI 10.1016/j.survophthal.2006.08.003
   Cheung N, 2007, BRIT J OPHTHALMOL, V91, P430, DOI 10.1136/bjo.2006.106054
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   De Lorenzo A, 2007, AM J CLIN NUTR, V85, P40, DOI 10.1093/ajcn/85.1.40
   Defay R, 2004, ANN EPIDEMIOL, V14, P202, DOI 10.1016/S1047-2797(03)00130-3
   Defay R, 2001, INT J OBESITY, V25, P512, DOI 10.1038/sj.ijo.0801570
   del Sol AI, 2001, STROKE, V32, P1532, DOI 10.1161/01.STR.32.7.1532
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 2005, AM J OPHTHALMOL, V140, P924, DOI 10.1016/j.ajo.2005.05.002
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Freeman EE, 2005, OPHTHAL EPIDEMIOL, V12, P37, DOI 10.1080/09286580490907779
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501
   GERHARD M, 1995, CIRCULATION, V92, P5, DOI 10.1161/01.CIR.92.1.5
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   GORDON DL, 1995, J IMMUNOL, V155, P348
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701
   Grosso A, 2007, AM J OPHTHALMOL, V143, P157, DOI 10.1016/j.ajo.2006.07.040
   GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2849, DOI 10.1001/jama.256.20.2849
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Hackam DG, 2003, JAMA-J AM MED ASSOC, V290, P932, DOI 10.1001/jama.290.7.932
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 1996, EXP EYE RES, V62, P293, DOI 10.1006/exer.1996.0035
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   HOLZ FG, 1994, AM J OPHTHALMOL, V117, P19, DOI 10.1016/S0002-9394(14)73010-7
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Kardys I, 2007, AM J CARDIOL, V100, P646, DOI 10.1016/j.amjcard.2007.03.079
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keys SA, 1999, EXP EYE RES, V68, P693, DOI 10.1006/exer.1999.0657
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2004, AM J OPHTHALMOL, V137, P435, DOI 10.1016/j.ajo.2003.10.020
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2005, AM J OPHTHALMOL, V140, P129, DOI 10.1016/j.ajo.2004.12.049
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Leske MC, 2004, OPHTHALMOLOGY, V111, P706, DOI 10.1016/j.ophtha.2003.07.003
   Leveziel N, 2007, MOL VIS, V13, P2153
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Lichtenstein AH, 1998, NUTR REV, V56, pS3
   Liew G, 2006, OPHTHALMOLOGY, V113, P1481, DOI 10.1016/j.ophtha.2006.03.051
   Linet MS, 2008, AM J EPIDEMIOL, V167, P1416, DOI 10.1093/aje/kwn089
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   LOTFI K, 1991, INVEST OPHTH VIS SCI, V32, P3028
   MACHLIN LJ, 1987, FASEB J, V1, P441, DOI 10.1096/fasebj.1.6.3315807
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   Mainster MA, 2005, ARCH OPHTHALMOL-CHIC, V123, P550, DOI 10.1001/archopht.123.4.550
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Marutsuka K, 2005, J ATHEROSCLER THROMB, V12, P1
   MASON CG, 1977, J TOXICOL ENV HEALTH, V2, P977, DOI 10.1080/15287397709529497
   Mattace-Raso FUS, 2007, J HYPERTENS, V25, P1421, DOI 10.1097/HJH.0b013e32811d6a07
   McCarty CA, 2006, BRIT J OPHTHALMOL, V90, P1073, DOI 10.1136/bjo.2006.098897
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   MEYERS SM, 1988, ARCH OPHTHALMOL-CHIC, V106, P651
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Moss SE, 1998, OPHTHALMOLOGY, V105, P789, DOI 10.1016/S0161-6420(98)95016-3
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Nirmalan PK, 2004, INVEST OPHTH VIS SCI, V45, P4273, DOI 10.1167/iovs.04-0285
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Nolan JM, 2007, INVEST OPHTH VIS SCI, V48, P571, DOI 10.1167/iovs.06-0864
   Obisesan TO, 1998, J AM GERIATR SOC, V46, P1
   Odink AE, 2008, J HUM HYPERTENS, V22, P205, DOI 10.1038/sj.jhh.1002315
   PACKER L, 1990, ADV EXP MED BIOL, V264, P93
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Polak K, 2003, EYE, V17, P84, DOI 10.1038/sj.eye.6700246
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ridker PM, 2001, JAMA-J AM MED ASSOC, V285, P2481, DOI 10.1001/jama.285.19.2481
   RITTER LL, 1995, AM J OPHTHALMOL, V120, P190, DOI 10.1016/S0002-9394(14)72607-8
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Robman L, 2004, OPHTHAL EPIDEMIOL, V11, P161, DOI 10.1080/09286580490514469
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Rosano GMC, 2006, ANN NY ACAD SCI, V1092, P341, DOI 10.1196/annals.1365.031
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Rozanowski B, 2008, PHOTOCHEM PHOTOBIOL, V84, P658, DOI 10.1111/j.1751-1097.2007.00291.x
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   RYAN SJ, 1980, A GRAEF ARCH KLIN EX, V215, P1, DOI 10.1007/BF00413392
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Santos Laura Patrícia Ferreira, 2005, Arq. Bras. Oftalmol., V68, P229, DOI 10.1590/S0004-27492005000200014
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   SIES H, 1991, AM J MED, V91, pS31, DOI 10.1016/0002-9343(91)90281-2
   Singh U, 2007, VITAM HORM, V76, P519, DOI 10.1016/S0083-6729(07)76020-X
   Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818
   Smith J K, 2001, Exerc Sport Sci Rev, V29, P49
   Smith JK, 1999, JAMA-J AM MED ASSOC, V281, P1722, DOI 10.1001/jama.281.18.1722
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1996, AM J OPHTHALMOL, V122, P743, DOI 10.1016/S0002-9394(14)70503-3
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   SPERDUTO RD, 1981, ARCH OPHTHALMOL-CHIC, V99, P1004
   STEPHENS RJ, 1988, EXP EYE RES, V47, P237, DOI 10.1016/0014-4835(88)90007-3
   Subbiah MTR, 1998, P SOC EXP BIOL MED, V217, P23
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tamakoshi A, 1997, BRIT J OPHTHALMOL, V81, P901, DOI 10.1136/bjo.81.10.901
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   THURNHAM DI, 1986, ANN CLIN BIOCHEM, V23, P514, DOI 10.1177/000456328602300505
   Tikellis G, 2007, ARCH OPHTHALMOL-CHIC, V125, P68, DOI 10.1001/archopht.125.1.68
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tomany SC, 2003, OPHTHALMOLOGY, V110, P1526, DOI 10.1016/S0161-6420(03)00539-6
   Tomany SC, 2001, AM J OPHTHALMOL, V132, P271, DOI 10.1016/S0002-9394(01)00895-9
   UTERMANN G, 1980, AM J HUM GENET, V32, P339
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   van Leuven SI, 2008, RHEUMATOLOGY, V47, P3, DOI 10.1093/rheumatology/kem202
   van Popele NM, 2006, J HYPERTENS, V24, P2371, DOI 10.1097/01.hjh.0000251896.62873.c4
   VANDENBERG TJTP, 1991, VISION RES, V31, P1361, DOI 10.1016/0042-6989(91)90057-C
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P53
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2006, OBESITY, V14, P206, DOI 10.1038/oby.2006.27
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   Wang JJ, 2004, CLIN EXP OPHTHALMOL, V32, P255, DOI 10.1111/j.1442-9071.2004.00813.x
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   Warburton DER, 2006, CAN MED ASSOC J, V174, P801, DOI 10.1503/cmaj.051351
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wilund KR, 2007, CLIN SCI, V112, P543, DOI 10.1042/CS20060368
   Wong TY, 2006, OPHTHALMOLOGY, V113, P255, DOI 10.1016/j.ophtha.2005.10.048
   Wong TY, 2004, NEW ENGL J MED, V351, P2310, DOI 10.1056/NEJMra032865
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu LA, 2006, AM J OPHTHALMOL, V142, P688, DOI 10.1016/j.ajo.2006.05.028
   Zheng ZJ, 2005, AM J PREV MED, V29, P42, DOI 10.1016/j.amepre.2005.07.019
NR 293
TC 26
Z9 27
U1 0
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2009
VL 2009
AR 360764
DI 10.1155/2009/360764
PG 39
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V24IH
UT WOS:000208403600008
PM 20339564
OA Green Published, Green Accepted, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Wang, PP
   Wang, J
   Ma, J
   Jin, G
   Guan, XQ
AF Wang, Peipei
   Wang, Jie
   Ma, Jun
   Jin, Ge
   Guan, Xueqiang
TI The Association between Age-Related Macular Degeneration and the Risk of
   Mortality
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID VISUAL IMPAIRMENT; EYE DISEASES; METAANALYSIS; SURVIVAL; VISION; WOMEN
AB Studies have investigated the association between age-related macular degeneration (AMD) and subsequent risks of mortality, but results have been equivocal. We conducted a comprehensive analysis of prospective cohort studies to assess the association of AMD and the risk of mortality in the general population. We searched PubMed and EMBASE for trials published from 1980 to 2016. We included 11 cohort studies that reported relative risks with 95% confidence intervals for the association of AMD and mortality, involving 57,069 participants. In a random-effects model, the adjusted RR (95% confidence interval) associated with AMD was 1.09 (1.02-1.17) for all-cause mortality. Findings from this research provide support that persons with AMD had a higher subsequent risk of mortality than persons without AMD.
C1 [Wang, Peipei; Wang, Jie; Ma, Jun; Jin, Ge; Guan, Xueqiang] Wenzhou Med Univ, Affiliated Hosp 2, Dept Cardiol, Xueyuanxi Rd 109, Wenzhou 325000, Zhejiang, Peoples R China.
   [Wang, Peipei; Wang, Jie; Ma, Jun; Jin, Ge; Guan, Xueqiang] Wenzhou Med Univ, Yuying Childrens Hosp, Xueyuanxi Rd 109, Wenzhou 325000, Zhejiang, Peoples R China.
   [Wang, Peipei] Wenzhou City Hosp Tradit Chinese Med & Western Me, Dept Neurol, Wenzhou, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University
RP Guan, XQ (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Cardiol, Xueyuanxi Rd 109, Wenzhou 325000, Zhejiang, Peoples R China.; Guan, XQ (通讯作者)，Wenzhou Med Univ, Yuying Childrens Hosp, Xueyuanxi Rd 109, Wenzhou 325000, Zhejiang, Peoples R China.
EM wzsgxq@163.com
FU Wenzhou City Hospital of Traditional Chinese Medicine and Western
   Medicine
FX The authors would like to acknowledge Wenzhou City Hospital of
   Traditional Chinese Medicine and Western Medicine Combined for
   supporting the work in this study.
CR Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Burkner PC, 2014, STAT MED, V33, P3061, DOI 10.1002/sim.6177
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   DerSimonian R, 2015, CONTEMP CLIN TRIALS, V45, P139, DOI 10.1016/j.cct.2015.09.002
   Fisher DE, 2015, OPHTHALMOLOGY, V122, P382, DOI 10.1016/j.ophtha.2014.08.006
   Gopinath B, 2016, MATURITAS, V84, P63, DOI 10.1016/j.maturitas.2015.11.001
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Khanna RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078002
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Kulmala J, 2008, AGING CLIN EXP RES, V20, P25
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pedula KL, 2015, J AM GERIATR SOC, V63, P910, DOI 10.1111/jgs.13405
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Siantar RG, 2015, SCI REP-UK, V5, DOI 10.1038/srep16304
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   Tolman J, 2005, GERONTOLOGIST, V45, P747, DOI 10.1093/geront/45.6.747
   WANG J, 2016, BIOMED RES INT, V2016, DOI DOI 10.1155/2016/8212063
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu L, 2008, OPHTHALMOLOGICA, V222, P378, DOI 10.1159/000151468
   Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690
NR 26
TC 4
Z9 5
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2017
VL 2017
AR 3489603
DI 10.1155/2017/3489603
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA EW0KC
UT WOS:000402178200001
PM 28607930
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ly, A
   Nivison-Smith, L
   Assaad, N
   Kalloniatis, M
AF Ly, Angelica
   Nivison-Smith, Lisa
   Assaad, Nagi
   Kalloniatis, Michael
TI Fundus Autofluorescence in Age-related Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Review
DE age-related macular degeneration; autofluorescence; chair-side
   reference; drusen; imaging
ID OPTICAL COHERENCE TOMOGRAPHY; SCANNING LASER OPHTHALMOSCOPE; GEOGRAPHIC
   ATROPHY SECONDARY; CHOROIDAL NEOVASCULARIZATION; RETICULAR PSEUDODRUSEN;
   FELLOW EYE; PERIPHERAL AUTOFLUORESCENCE; JAPANESE PATIENTS; PATTERNS;
   DISEASE
AB Fundus autofluorescence (FAF) provides detailed insight into the health of the retinal pigment epithelium (RPE). This is highly valuable in age-related macular degeneration (AMD) as RPE damage is a hallmark of the disease. The purpose of this paper is to critically appraise current clinical descriptions regarding the appearance of AMD using FAF and to integrate these findings into a chair-side reference. Awide variety of FAF patterns have been described in AMD, which is consistent with the clinical heterogeneity of the disease. In particular, FAF imaging in early to intermediate AMD has the capacity to reveal RPE alterations in areas that appear normal on funduscopy, which aids in the stratification of cases and may have visually significant prognostic implications. It can assist in differential diagnoses and also represents a reliable, sensitive method for distinguishing reticular pseudodrusen. FAF is especially valuable in the detection, evaluation, and monitoring of geographic atrophy and has been used as an endpoint in clinical trials. In neovascular AMD, FAF reveals distinct patterns of classic choroidal neovascularization noninvasively and may be especially useful for determining which eyes are likely to benefit from therapeutic intervention. FAF represents a rapid, effective, noninvasive imaging method that has been underutilized, and incorporation into the routine assessment of AMD cases should be considered. However, the practicing clinician should also be aware of the limitations of the odality, such as in the detection of foveal involvement and in the distinction of phenotypes (hypo-autofluorescent drusen from small areas of geographic atrophy).
C1 [Ly, Angelica; Nivison-Smith, Lisa; Assaad, Nagi; Kalloniatis, Michael] Ctr Eye Hlth, Sydney, NSW, Australia.
   [Ly, Angelica; Nivison-Smith, Lisa; Kalloniatis, Michael] Univ New South Wales Australia, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
   [Assaad, Nagi] Prince Wales Hosp, Dept Ophthalmol, Randwick, NSW, Australia.
C3 University of New South Wales Sydney
RP Kalloniatis, M (通讯作者)，Univ New South Wales Australia, Ctr Eye Hlth, Sydney, NSW 2052, Australia.
EM m.kalloniatis@unsw.edu.au
RI Nivison-Smith, Lisa/H-3297-2019; Ly, Angelica/J-2070-2019
OI Ly, Angelica/0000-0001-7881-1522; Kalloniatis,
   Michael/0000-0002-5264-4639; Nivison-Smith, Lisa/0000-0001-6677-1949
FU University of New South Wales [P535430]; Medical Research Council
   (NHMRC) [1033224]; NHMRC grant
FX This work was supported, in part, by grants and awards from the
   University of New South Wales (Early Career Research Grant 2015
   #P535430), an Australian Postgraduate Award, and a National Health and
   Medical Research Council (NHMRC) grant (#1033224). Guide Dogs NSW/ACT is
   a partner in the NHMRC grant and also provided a supplementary PhD
   scholarship for AL and support for LN-S.
CR American Academy of Ophthalmology Retina, 2015, PREF PRACT PATT GUID
   Batioglu F, 2014, OPHTHALMIC RES, V52, P53, DOI 10.1159/000361077
   Batioglu F, 2014, OPTOMETRY VISION SCI, V91, P950, DOI 10.1097/OPX.0000000000000321
   Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   Biarnes M, 2012, GRAEF ARCH CLIN EXP, V250, P485, DOI 10.1007/s00417-011-1846-y
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Boon CJF, 2009, OPHTHALMOLOGY, V116, P771, DOI 10.1016/j.ophtha.2008.12.019
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Canadian Journal of Optometry, 2015, CANADIAN J OPTOMETRY
   Caramoy A, 2012, BRIT J OPHTHALMOL, V96, P1211, DOI 10.1136/bjophthalmol-2012-301750
   Dosunmu EO, 2011, SEMIN OPHTHALMOL, V26, P209, DOI 10.3109/08820538.2011.577134
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Framme C, 2006, OPHTHAL SURG LAS IM, V37, P406, DOI 10.3928/15428877-20060901-08
   Fujimura S, 2013, GRAEF ARCH CLIN EXP, V251, P1, DOI 10.1007/s00417-013-2363-y
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Landa G, 2012, OPHTHALMIC RES, V47, P81, DOI 10.1159/000324988
   Lee MY, 2014, RETINA-J RET VIT DIS, V34, P69, DOI 10.1097/IAE.0b013e318295f701
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   Nivison-Smith L, 2014, OPTOMETRY VISION SCI, V91, P832, DOI 10.1097/OPX.0000000000000281
   Peng Q, 2013, GENET MOL RES, V12, P6140, DOI 10.4238/2013.December.2.11
   Pilotto E, 2013, GRAEF ARCH CLIN EXP, V251, P27, DOI 10.1007/s00417-012-2031-7
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1241, DOI 10.1097/IAE.0b013e31827b639e
   Querques G, 2013, GRAEF ARCH CLIN EXP, V251, P705, DOI 10.1007/s00417-012-2106-5
   Reznicek L, 2012, INVEST OPHTH VIS SCI, V53, P2193, DOI 10.1167/iovs.11-8483
   Royal College of Ophthalmologists (UK), 2013, AG REL MAC DEG GUID
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   Sallo FB, 2015, RETINA-J RET VIT DIS, V35, P742, DOI 10.1097/IAE.0000000000000365
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Tan CS, 2013, OPHTHALMOLOGY, V120, P1271, DOI 10.1016/j.ophtha.2012.12.002
   Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Vujosevic S, 2007, GRAEF ARCH CLIN EXP, V245, P1453, DOI 10.1007/s00417-007-0574-9
   Westeneng-van Haaften SC, 2012, OPHTHALMOLOGY, V119, P1199, DOI 10.1016/j.ophtha.2012.01.005
   Witmer MT, 2012, ACTA OPHTHALMOL, V90, pe428, DOI 10.1111/j.1755-3768.2012.02434.x
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Wolf-Schnurrbusch UEK, 2011, INVEST OPHTH VIS SCI, V52, P9497, DOI 10.1167/iovs.11-8346
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Xuan Yi, 2010, Zhonghua Yan Ke Za Zhi, V46, P708
   Yamamoto Manabu, 2009, Osaka City Med J, V55, P19
NR 65
TC 26
Z9 27
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD FEB
PY 2017
VL 94
IS 2
BP 246
EP 259
DI 10.1097/OPX.0000000000000997
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EJ7QJ
UT WOS:000393417000013
PM 27668639
OA Green Published
DA 2022-11-30
ER

PT J
AU SanGiovanni, JP
   Chew, EY
AF SanGiovanni, John Paul
   Chew, Emily Y.
TI Clinical Applications of Age-Related Macular Degeneration Genetics
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; HIGH-RISK; PSYCHIATRIC-DISORDERS; COMPLEX
   TRAITS; CLASSIFICATION; IDENTIFICATION; HERITABILITY; DISEASE; BIOLOGY;
   VARIANT
AB Understanding genetic causes of age-related macular degeneration (AMD) will eventually yield effective discoveries and improvements in predictive/prognostic methods. These include, but are not limited to, reliable disease prediction (screening for increased discrimination of clinical risk), differential classification of AMD subtypes with biomarkers (development of risk-linked molecular taxonomies), selection of optimal preventive and therapeutic interventions (guided by a biologically meaningful understanding of treatment response), and drug dosing. In this review, we discuss clinical applications informed by key findings in AMD genetics, and provide commentary on leveraging extant and forthcoming evidence to improve AMD risk prediction, AMD classification, and knowledge on the genetic basis of drug activity and toxicity. Advances in translating AMD genetics findings for AMD risk prediction require development of a genetics-based causality for AMD incidence and progression. Molecular subtyping of AMD phenotypes requires a set of dynamic biomarkers presenting prognostic value; although these have yet to be identified, the formation of multidisciplinary teams and their participation in large-scale consortia may yield promising results. Drugs targeting complement and vascular endothelial growth factor (VEGF) systems are under evaluation, and forthcoming work on rare variants and noncoding DNA in AMD pathogenesis will likely reveal biochemical pathways enriched with AMD-associated genetic variants. Pharmacologic targets in these pathways may inform a rational and effective therapeutic approach to preventing and treating this sight-threatening disease.
C1 [SanGiovanni, John Paul; Chew, Emily Y.] NEI, Clin Trials Branch, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Chew, EY (通讯作者)，NEI, Clin Trials Branch, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
EM jpsangio@post.harvard.edu; echew@nei.nih.gov
RI Mitchell, Paul/P-1498-2014; SanGiovanni, John Paul/AAU-3895-2020
FU NATIONAL EYE INSTITUTE [ZIAEY000485] Funding Source: NIH RePORTER
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Cichon S, 2009, AM J PSYCHIAT, V166, P540, DOI 10.1176/appi.ajp.2008.08091354
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman G.S., 2008, WEBVISION ORG RETINA
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536
   Lee PH, 2012, BIOINFORMATICS, V28, P1797, DOI 10.1093/bioinformatics/bts191
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Manolio TA, 2013, NAT REV GENET, V14, P549, DOI 10.1038/nrg3523
   Manolio TA, 2013, GENET MED, V15, P258, DOI 10.1038/gim.2012.157
   Manolio TA, 2011, CELL, V147, P14, DOI 10.1016/j.cell.2011.09.012
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   SanGiovanni JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071239
   SanGiovanni John Paul, 2009, V99, P105, DOI 10.1159/000193002
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   Smoller JW, 2013, LANCET, V381, P1371, DOI 10.1016/S0140-6736(12)62129-1
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Ward LD, 2012, NAT BIOTECHNOL, V30, P1095, DOI 10.1038/nbt.2422
   Yang JA, 2010, NAT GENET, V42, P565, DOI 10.1038/ng.608
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 36
TC 5
Z9 5
U1 0
U2 3
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD OCT
PY 2014
VL 4
IS 10
AR a017228
DI 10.1101/cshperspect.a017228
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AW8OI
UT WOS:000346521400002
PM 25125423
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Yang, J
   Zhang, QQ
   Motulsky, EH
   Thulliez, M
   Shi, YY
   Lyu, CC
   De Sisternes, L
   Durbin, MK
   Feuer, W
   Wang, RK
   Gregori, G
   Rosenfeld, PJ
AF Yang, Jin
   Zhang, Qinqin
   Motulsky, Elie H.
   Thulliez, Marie
   Shi, Yingying
   Lyu, Cancan
   De Sisternes, Luis
   Durbin, Mary K.
   Feuer, William
   Wang, Ruikang K.
   Gregori, Giovanni
   Rosenfeld, Philip J.
TI Two-Year Risk of Exudation in Eyes with Nonexudative Age-Related Macular
   Degeneration and Subclinical Neovascularization Detected with Swept
   Source Optical Coherence Tomography Angiography
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SOURCE OCT ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION; SPECTRAL-DOMAIN;
   FELLOW EYES; DRUSEN; CLASSIFICATION
AB PURPOSE: Swept source optical coherence tomography angiography (SS-OCTA) was used to study the prevalence, incidence, and natural history of subclinical macular neovascularization (MNV) in eyes with unilateral nonexudative age-related macular degeneration.
   DESIGN: Prospective cohort study.
   METHODS: Patients were imaged using 3- x 3-mm and 6- x 6-mm SS-OCTA scan patterns. MNV was detected using the outer retina to choriocapillaris en face slab. Prevalence and incidence of subclinical MNV, Kaplan-Meier cumulative estimates for the overall risk of exudation, and the association between neovascular lesion size and the risk of exudation were assessed through 2 years.
   RESULTS: From August 2014 through March 2018, 227 patients (154 intermediate and 73 late age-related macular degeneration eyes) underwent SS-OCTA imaging. Thirty eyes (13.2%) had subclinical MNV at first imaging and 12 eyes (8.9%) developed subclinical MNV during follow-up. Of the 191 eyes with > 1 visit, 19 developed exudation. Fourteen of these eyes had preexisting subclinical MNV. The incidence of exudation from the time of first detection of any subclinical MNV was 34.5%. The relative risk of exudation after detection of subclinical MNV was 13.6 times greater (95% confidence interval 4.9-37.7) than in the absence of subclinical MNV (P < .001). There was no significant risk of exudation based on lesion size alone (P = .91).
   CONCLUSIONS: By 24 months, the risk of exudation was 13.6 times greater for eyes with subclinical MNV detected by SS-OCTA compared with eyes without sub clinical MNV. For eyes with subclinical MNV in the absence of symptomatic exudation, we recommend close follow-up without treatment. ((C) 2019 Elsevier Inc. All rights reserved.)
C1 [Yang, Jin; Motulsky, Elie H.; Thulliez, Marie; Shi, Yingying; Lyu, Cancan; Feuer, William; Gregori, Giovanni; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [Zhang, Qinqin; Wang, Ruikang K.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   [De Sisternes, Luis; Durbin, Mary K.] Carl Zeiss Meditec Inc, Res & Dev, Dublin, CA USA.
   [Yang, Jin] Tianjin Med Univ, Eye Hosp, Tianjin, Peoples R China.
C3 Bascom Palmer Eye Institute; University of Miami; University of
   Washington; University of Washington Seattle; Carl Zeiss AG; Tianjin
   Medical University
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@miami.edu
RI Lyu, Cancan/ABC-4635-2021; Wang, Ruikang/L-3889-2019
OI Wang, Ruikang/0000-0001-5169-8822; Lyu, Cancan/0000-0003-2078-3471;
   Feuer, William/0000-0002-9442-3076
FU Carl Zeiss Meditec. (Dublin, California, USA); National Eye Institute
   [R01EY024158, R0IEY028753]; Seattle Foundation; National Eye Institute
   Center Core Grant [P30EY014801]; Research to Prevent Blindness; NATIONAL
   EYE INSTITUTE [R01EY028753, P30EY014801, R01EY024158] Funding Source:
   NIH RePORTER
FX Supported by grants from Carl Zeiss Meditec. (Dublin, California, USA),
   National Eye Institute Grants R01EY024158 and R0IEY028753, the Seattle
   Foundation, National Eye Institute Center Core Grant P30EY014801, and an
   unrestricted grant from Research to Prevent Blindness to the Department
   of Ophthalmology, University of Miami Miller School of Medicine.
CR Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Huang YP, 2014, OSLI RETINA, V45, P382, DOI 10.3928/23258160-20140909-08
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Moreira-Neto CA, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8125267
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Ploner SB, 2016, RETINA-J RET VIT DIS, V36, pS118, DOI 10.1097/IAE.0000000000001328
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Schneider U, 1997, INT OPHTHALMOL, V21, P79, DOI 10.1023/A:1005848806641
   Wang RK, 2010, OPT LETT, V35, P1467, DOI 10.1364/OL.35.001467
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yanagi Y, 2018, JAMA OPHTHALMOL, V136, P905, DOI 10.1001/jamaophthalmol.2018.2154
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
   Zhang AQ, 2015, BIOMED OPT EXPRESS, V6, P4130, DOI 10.1364/BOE.6.004130
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
   Zhang QQ, 2015, RETINA-J RET VIT DIS, V35, P2285, DOI 10.1097/IAE.0000000000000840
   Zheng F, 2017, INVEST OPHTH VIS SCI, V58, P5098, DOI 10.1167/iovs.17-22506
   Zheng F, 2016, OSLI RETINA, V47, P517, DOI 10.3928/23258160-20160601-02
NR 32
TC 30
Z9 31
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2019
VL 208
BP 1
EP 11
DI 10.1016/j.ajo.2019.06.017
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JZ0OI
UT WOS:000504803400001
PM 31229464
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Tomany, SC
   Wang, HJ
   van Leeuwen, R
   Klein, R
   Mitchell, P
   Vingerling, JR
   Klein, BEK
   Smith, W
   de Jong, PTVM
AF Tomany, SC
   Wang, HJ
   van Leeuwen, R
   Klein, R
   Mitchell, P
   Vingerling, JR
   Klein, BEK
   Smith, W
   de Jong, PTVM
TI Risk factors for incident age-related macular degeneration - Pooled
   findings from 3 continents
SO OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; RETINAL-PIGMENT EPITHELIUM; BEAVER DAM EYE;
   CHOROIDAL NEOVASCULARIZATION; 5-YEAR INCIDENCE; LASER PHOTOCOAGULATION;
   CIGARETTE-SMOKING; 10-YEAR INCIDENCE; GRADING SYSTEM; VISUAL-ACUITY
AB Objective: To examine risk factors for incident age-related macular degeneration (AMD) after combining data from 3 population-based cohort studies.
   Design: Population-based cohort study.
   Population: A population of 9523 adults (age range, 43-95 years at baseline) living in Australia, The Netherlands, and the United States who participated in a baseline examination and a follow-up examination on average 5 or 6 years later.
   Methods: Similar procedures were used at all study sites. Examinations included a standardized questionnaire, pupillary dilation, and stereoscopic color fundus photography. Fundus photographs were graded for lesions associated with AMD using the Wisconsin and International Age-Related Maculopathy Grading Systems. Senior investigators from each site adjudicated all photos graded as late AMD.
   Main Outcomes Measure: Incidence of late AMD.
   Results: Among studies, distributions for most risk factors differed, and overall incidence rates were similar. In the Beaver Dam Eye Study, total serum cholesterol was inversely associated with incident neovascular AMD. In the Blue Mountains Eye Study, current smoking (defined as smoking at the time of the baseline examination) was associated with an increased risk of incident geographic atrophy and late AMD; increased total serum cholesterol, having diabetes, and older age at menopause were positively associated with incident geographic atrophy; and an increase in high-density lipoprotein serum cholesterol was inversely related to incident geographic atrophy. In the Rotterdam Study, current smoking was associated with an increased risk of incident geographic atrophy, neovascular AMD, and late AMD; past smoking was associated with an increased risk of incident neovascular AMD and late AMD; and an increased number of years between menarche and menopause was directly related to incident geographic atrophy. After pooling data, the only statistically significant relationships found were between smoking and total serum cholesterol and incident AMD. Current smoking was associated with an increased incidence of geographic atrophy and late AMD (odds ratios [ORs] relative to nonsmokers: 2.83 and 2.35, respectively; ORs relative to past smokers: 2.80 and 1.82, respectively), and total serum cholesterol was associated directly with incident geographic atrophy (OR: 1.08 per 10 mg/dl) and inversely with incident neovascular AMD (OR: 0.94 per 10 mg/dl).
   Conclusions: Pooled data support a growing body of evidence indicating that smoking is related to an increased risk of incident AMD. Current smokers were at higher risk of incident AMD than both past smokers and those who never smoked. The relationships found in this study between total serum cholesterol and incident geographic atrophy and neovascular AMD are not readily explained. (C) 2004 by the American Academy of Ophthalmology.
C1 Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   Royal Netherlands Acad Arts & Sci, Netherlands Ophthalm Res Inst, Amsterdam, Netherlands.
   Univ Newcastle, Ctr Biostat & Epidemiol, Newcastle, NSW 2308, Australia.
   Erasmus Univ, Dept Ophthalmol, Rotterdam, Netherlands.
   Erasmus Univ, Med Ctr, Rotterdam, Netherlands.
   Univ Sydney, Westmead Hosp, Westmead, NSW 2145, Australia.
C3 University of Wisconsin System; University of Wisconsin Madison; Royal
   Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); University of Newcastle; Erasmus University
   Rotterdam; Erasmus University Rotterdam; Erasmus MC; University of
   Sydney
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, 610 N Walnut St, Madison, WI 53726 USA.
RI wang, jie/GRS-0942-2022; Mitchell, Paul/P-1498-2014; Wang, Jie
   Jin/P-1499-2014
OI Wang, Jie Jin/0000-0001-9491-4898
FU NEI NIH HHS [EY06594] Funding Source: Medline
CR Agresti A., 1990, CATEGORICAL DATA ANA
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BARONDES MJ, 1992, BRIT J OPHTHALMOL, V76, P5, DOI 10.1136/bjo.76.1.5
   BAUN O, 1993, ACTA OPHTHALMOL, V71, P398
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616
   GREEN WR, 1992, OPHTHALMOLOGY, V100, P1519
   HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1991, BEAVER DAM EYE STUDY
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   ROY M, 1990, Eye (London), V4, P813
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   *SAS I, 1999, SAS ONL STAT STAT US
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   2002, PREVENT BLINDNESS AM, P1
NR 37
TC 446
Z9 465
U1 0
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2004
VL 111
IS 7
BP 1280
EP 1287
DI 10.1016/j.ophtha.2003.11.010
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 834NX
UT WOS:000222418900005
PM 15234127
DA 2022-11-30
ER

PT J
AU Nguyen, DH
   Luo, J
   Zhang, K
   Zhang, M
AF Nguyen, Duy H.
   Luo, Jing
   Zhang, Kang
   Zhang, Ming
TI Current Therapeutic Approaches in Neovascular Age-related Macular
   Degeneration
SO DISCOVERY MEDICINE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; TRAP-EYE; RANIBIZUMAB
AB Age-related macular degeneration (AMD) is the leading eye disease to cause visual impairment in the elderly. Neovascular AMD is a type of advanced AMD that is characterized by pathologic proliferation and leakage of abnormal blood vessels in the eye. While the pathogenesis of neovascular AMD is not completely known, one of the important milestones in neovascular AMD research was the identification of vascular endothelial growth factor (VEGF) as a major stimulus of abnormal angiogenesis that can be targeted for intravitreal treatment. Anti-VEGF therapies that neutralize or block the induction of angiogenesis by VEGF have recently revolutionized the therapeutic approach to neovascular AMD. The scientific literature regarding the efficacy and safety of anti-VEGF treatment has been hugely enriched with results from various recent randomized clinical trials involving the three most commonly utilized anti-VEGF pharmacologic agents - ranibizumab, bevacizumab, and aflibercept. The potential to stop and reverse the progressive loss of vision due to neovascular AMD is evident. Continued investigation into inhibiting VEGF as well as targeting other crucial factors that contribute to neovascular AMD is an active field of research that is expected to accelerate the progress of neovascular AMD therapy.
C1 [Nguyen, Duy H.; Luo, Jing; Zhang, Kang] Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92093 USA.
   [Zhang, Ming] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu 610041, Peoples R China.
C3 University of California System; University of California San Diego;
   Sichuan University
RP Zhang, K (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92093 USA.
EM kanghang@gmail.com; zhangminscu@126.com
RI Zhang, Kang/Y-2740-2019; Nguyen, Duy/HDO-8098-2022
OI Zhang, Kang/0000-0002-4549-1697; Luo, Jing/0000-0002-8905-9388
FU Genentech
FX K.Z. receives research funding from Genentech and is a consultant for
   Thrombogenics and Acucela. D.N., J.L., and M.Z. report no conflicts of
   interest.
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown DM, 2009, OPHTHALMOLOGY, V116, pe55
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
NR 19
TC 20
Z9 20
U1 1
U2 3
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539-6509
EI 1944-7930
J9 DISCOV MED
JI Discov. Med.
PD JUN
PY 2013
VL 15
IS 85
BP 343
EP 348
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 202EO
UT WOS:000323196600002
PM 23819948
DA 2022-11-30
ER

PT J
AU Sahel, JA
   Bandello, F
   Augustin, A
   Maurel, F
   Negrini, C
   Berdeaux, GH
AF Sahel, Jose-Alain
   Bandello, Francesco
   Augustin, Albert
   Maurel, Frederique
   Negrini, Cristina
   Berdeaux, Gilles H.
CA MICMAC Study Grp
TI Health-related quality of life and utility in patients with age-related
   macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL FUNCTION QUESTIONNAIRE; CHOROIDAL NEOVASCULARIZATION SECONDARY;
   COPENHAGEN CITY EYE; BEAVER DAM EYE; IMPAIRMENT PROJECT; 5-YEAR
   INCIDENCE; MACULOPATHY; PREVALENCE; BLINDNESS; IMPACT
AB Objective: To assess the impact of best-eye and worst-eye visual acuity (BEVA and WEVA, respectively) on health-related quality of life and utility in patients with wet age-related macular degeneration.
   Design: This cross-sectional, prospective, observational, multicenter study was performed in France, Germany, and Italy. Patients were stratified into 4 severity groups (BEVA, 20/40; WEVA, 20/200). Patients completed the National Eye Institute 25-Item Visual Function Questionnaire, the Macular Disease Quality of Life Scale, and the Health Utility Index 3. Analysis of variance was used to adjust for age, sex, and country.
   Results: Patients (N = 360) were mainly female (59.6%), with a mean age of 77 years and mean time since age-related macular degeneration diagnosis of 2.3 years. Health Utility Index 3 scores decreased with VA severity from 0.62 to 0.39. The National Eye Institute 25-Item Visual Function Questionnaire global score decreased with VA severity from 67.0 to 40.7 and was related to the BEVA (P < .001) and WEVA (P = .03). Corresponding changes were observed on the general vision, distance vision, driving, and mental health dimensions. The average weighted impact score on the Macular Disease Quality of Life varied from -4.6 to -2.6, decreasing with VA severity. Both eyes contributed to the average weighted impact score.
   Conclusion: The BEVA and WEVAs influenced vision-related quality of life independently, as measured by the National Eye Institute 25-Item Visual Function Questionnaire and Macular Disease Quality of Life Scale.
C1 Alcon France, F-92563 Rueil Malmaison, France.
   Hosp XV XX, Dept 4, Paris, France.
   Conservatoire Natl Arts & Metiers, Paris, France.
   Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
   Augenklin, Karlsruhe, Germany.
   Aremis Consultants, Neuilly Sur Seine, France.
   PBE Consulting, Verona, Italy.
C3 Novartis; Alcon; heSam Universite; Conservatoire National Arts & Metiers
   (CNAM); University of Udine; University of Hamburg; University Medical
   Center Hamburg-Eppendorf
RP Berdeaux, GH (通讯作者)，Alcon France, 4 Rue Henri St Claire Deville, F-92563 Rueil Malmaison, France.
EM gilles.berdeaux@alconlabs.com
RI bandello, francesco/AAH-2405-2019; Sahel, Jose-Alain/F-3172-2017
OI bandello, francesco/0000-0003-3238-9682; Sahel,
   Jose-Alain/0000-0002-4831-1153; Augustin, Prof. Dr. Albert
   J./0000-0003-1591-0536
CR Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Brown Melissa M., 2001, International Ophthalmology, V24, P123, DOI 10.1023/A:1021171000838
   Brown MM, 2003, OPHTHALMOLOGY, V110, P1076, DOI 10.1016/S0161-6420(03)00254-9
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Chassany O, 2002, DRUG INF J, V36, P209, DOI 10.1177/009286150203600127
   Coscas G, 1991, Rev Prat, V41, P2320
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Feeny D, 2002, MED CARE, V40, P113, DOI 10.1097/00005650-200202000-00006
   FEENY D, 1995, PHARMACOECONOMICS, V7, P490, DOI 10.2165/00019053-199507060-00004
   Feeny D, 1998, MED PEDIATR ONCOL, P54
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Furlong WJ, 2001, ANN MED, V33, P375, DOI 10.3109/07853890109002092
   FURLONG WJ, 2002, HTLH UTILITIES INDEX
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Horsman John, 2003, Health Qual Life Outcomes, V1, P54, DOI 10.1186/1477-7525-1-54
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Maddigan Sheri L, 2003, Health Qual Life Outcomes, V1, P78, DOI 10.1186/1477-7525-1-78
   Mangione C., 2000, NATL EYE I 25 ITEM V
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   Mitchell J, 2004, QUAL LIFE RES, V13, P1548, DOI 10.1023/B:QURE.0000031348.51292.4a
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   O'Shea JG, 1998, POSTGRAD MED J, V74, P203, DOI 10.1136/pgmj.74.870.203
   Rohrschneider K, 2004, KLIN MONATSBL AUGENH, V221, P116, DOI 10.1055/s-2004-812724
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Soubrane G, 2002, PRESSE MED, V31, P1282
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 51
TC 26
Z9 27
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUL
PY 2007
VL 125
IS 7
BP 945
EP 951
DI 10.1001/archopht.125.7.945
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 188BE
UT WOS:000247892600012
PM 17620576
OA Bronze
DA 2022-11-30
ER

PT J
AU Cazet-Supervielle, A
   Gozlan, J
   Cabasson, S
   Boissonnot, M
   Manic, H
   Leveziel, N
AF Cazet-Supervielle, Agathe
   Gozlan, Julien
   Cabasson, Severin
   Boissonnot, Michele
   Manic, Helene
   Leveziel, Nicolas
TI Intravitreal Ranibizumab in Daily Clinical Practice for Age-Related
   Macular Degeneration: Treatment of Exudative Age-Related Macular
   Degeneration in Real Life
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Anti-vascular endothelial growth
   factor; Exudative age-related macular degeneration; Lucentis;
   Ranibizumab; Real-life setting; Retinal degeneration
ID OPTICAL COHERENCE TOMOGRAPHY; VISUAL-ACUITY; CHOROIDAL
   NEOVASCULARIZATION; GREEN ANGIOGRAPHY; SUBGROUP ANALYSIS; DOSING
   REGIMEN; FOLLOW-UP; BEVACIZUMAB; OUTCOMES; MACULOPATHY
AB Purpose: To describe the anatomical and functional outcomes in patients with exudative age-related macular degeneration (AMD) undergoing ranibizumab therapy in real-life practice. Methods: This is a retrospective analysis of patients with exudative AMD treated with ranibizumab. Visual acuity (VA) and optic coherence tomography characteristics at baseline and at the end of the follow-up, clinical forms of the disease, delay between diagnosis and treatment as well as the number of follow-up visits and of intravitreal injections were collected. Results: One hundred and seventy-nine patients (220 eyes) were followed up during a mean of 24 months. The mean delay between diagnosis and treatment was 20.3 days (SD +/- 16.8). VA stabilization was observed in 46.4% of eyes, 21.7% of eyes gained >= 15 ETDRS (Early Treatment Diabetic Retinopathy Study) letters and 31.9% lost >= 15 ETDRS letters. The mean central retinal thickness decreased from 380.6 mu m at baseline to 295.6 mu m at the final examination. A lower baseline VA score was associated with a greater gain of letters (OR 1.04, 95% CI 1.02-1.06; p < 0.001). Conclusion: Shortening the delays in diagnosis appears to be a key point in real-life situations. (C) 2015 S. Karger AG, Basel
C1 [Cazet-Supervielle, Agathe; Gozlan, Julien; Boissonnot, Michele; Manic, Helene; Leveziel, Nicolas] Univ Poitiers Hosp, Dept Ophthalmol, Poitiers, France.
   [Cabasson, Severin] Univ Poitiers Hosp, Med Resuscitat Unit, Poitiers, France.
C3 CHU Poitiers; Universite de Poitiers; CHU Poitiers; Universite de
   Poitiers
RP Leveziel, N (通讯作者)，Dept Ophthalmol, 2 Rue Mil, FR-86021 Poitiers, France.
EM nicolas.leveziel@chu-poitiers.fr
OI Nicolas, Leveziel/0000-0001-8533-9457
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Fang K, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/676049
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hariprasad SM, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/690641
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Khoshnood B, 2010, OPHTHAL PHYSL OPT, V30, P816, DOI 10.1111/j.1475-1313.2010.00766.x
   Kniestedt Christoph, 2003, Ophthalmol Clin North Am, V16, P155, DOI 10.1016/S0896-1549(03)00013-0
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Piguet B, 1996, KLIN MONATSBL AUGENH, V208, P327, DOI 10.1055/s-2008-1035228
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wolf S, 1996, GER J OPHTHALMOL, V5, P251
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
   World Health Organization, 2000, WHOPBL9761
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 45
TC 6
Z9 6
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2015
VL 234
IS 1
BP 26
EP 32
DI 10.1159/000430470
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CQ9KP
UT WOS:000360933700003
PM 26111575
DA 2022-11-30
ER

PT J
AU Enders, P
   Muether, PS
   Hermann, M
   Ristau, T
   Fauser, S
AF Enders, Philip
   Muether, Philipp S.
   Hermann, Manuel
   Ristau, Tina
   Fauser, Sascha
TI LONG-TERM ALTERATIONS OF SYSTEMIC VASCULAR ENDOTHELIAL GROWTH FACTOR
   LEVELS IN PATIENTS TREATED WITH RANIBIZUMAB FOR AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE vascular endothelial growth factor; ranibizumab; age-related macular
   degeneration; plasma
ID INTRAVITREAL INJECTION; PLASMA-LEVELS; BEVACIZUMAB; TRIAL
AB Purpose: To analyze long-term changes of systemic vascular endothelial growth factor (VEGF) levels in patients treated with ranibizumab for neovascular age-related macular degeneration.
   Methods: Sixty-one patients with neovascular age-related macular degeneration and 68 age-matched controls were included in the study. Patients were treated with ranibizumab on a pro re nata regimen. Plasma samples were collected before initiation of treatment and after 1 year (30 patients) or 2 years (31 patients) of treatment. Vascular endothelial growth factor was measured by Luminex microbead analysis.
   Results: At baseline, patients with neovascular age-related macular degeneration and controls did not differ significantly in VEGF levels (P = 0.062). There was a significant decline in systemic VEGF levels of 39.5% after 1 year (34.2 +/- 17.2 pg/mL to 20.7 +/- 14.0 pg/mL; P = 7.50 x 10(-5)) and of 46.7% after 2 years (40.4 +/- 24.1 pg/mL to 21.5 +/- 23.3 pg/mL; P = 2.48 x 10(-4)) of treatment. Patients with persistent activity of choroidal neovascularization showed a significantly smaller decrease of plasma VEGF levels than patients with dry intervals despite the higher number of injections (P = 0.048).
   Conclusion: In addition to immediate effects limited to days if not hours, ranibizumab also leads to long-term alterations of systemic VEGF to subnormal levels. Patients with persistent choroidal neovascularization activity showed a less pronounced VEGF decrease. Therefore, VEGF levels might be a useful marker for treatment response.
C1 [Enders, Philip; Muether, Philipp S.; Hermann, Manuel; Ristau, Tina; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, D-50924 Cologne, Germany.
C3 University of Cologne
RP Fauser, S (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM sascha.fauser@uk-koeln.de
OI Enders, Philip/0000-0002-9527-4957
CR Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Grierson R, 2013, J OCUL PHARMACOL TH, V29, P530, DOI 10.1089/jop.2012.0013
   Gu XY, 2014, CURR EYE RES, V39, P518, DOI 10.3109/02713683.2013.848899
   Kim H, 2009, MOL VIS, V15
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Yeung YA, 2010, CANCER RES, V70, P3269, DOI 10.1158/0008-5472.CAN-09-4580
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 11
TC 10
Z9 10
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2015
VL 35
IS 3
BP 454
EP 458
DI 10.1097/IAE.0000000000000320
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC4AO
UT WOS:000350293100023
PM 25170863
DA 2022-11-30
ER

PT J
AU Armento, A
   Ueffing, M
   Clark, SJ
AF Armento, Angela
   Ueffing, Marius
   Clark, Simon J.
TI The complement system in age-related macular degeneration
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Age-related macular degeneration; Ophthalmology; Complement system;
   Genetics; Ageing; Retinal biology
AB Age-related macular degeneration (AMD) is a chronic and progressive degenerative disease of the retina, which culminates in blindness and affects mainly the elderly population. AMD pathogenesis and pathophysiology are incredibly complex due to the structural and cellular complexity of the retina, and the variety of risk factors and molecular mechanisms that contribute to disease onset and progression. AMD is driven by a combination of genetic predisposition, natural ageing changes and lifestyle factors, such as smoking or nutritional intake. The mechanism by which these risk factors interact and converge towards AMD are not fully understood and therefore drug discovery is challenging, where no therapeutic attempt has been fully effective thus far. Genetic and molecular studies have identified the complement system as an important player in AMD. Indeed, many of the genetic risk variants cluster in genes of the alternative pathway of the complement system and complement activation products are elevated in AMD patients. Nevertheless, attempts in treating AMD via complement regulators have not yet been successful, suggesting a level of complexity that could not be predicted only from a genetic point of view. In this review, we will explore the role of complement system in AMD development and in the main molecular and cellular features of AMD, including complement activation itself, inflammation, ECM stability, energy metabolism and oxidative stress.
C1 [Armento, Angela; Ueffing, Marius; Clark, Simon J.] Eberhard Karls Univ Tubingen, Inst Ophthalm Res, Dept Ophthalmol, Tubingen, Germany.
   [Ueffing, Marius; Clark, Simon J.] Eberhard Karls Univ Tubingen, Univ Eye Clin, Dept Ophthalmol, Tubingen, Germany.
   [Clark, Simon J.] Univ Manchester, Fac Biol Med & Hlth, Lydia Becker Inst Immunol & Inflammat, Manchester, Lancs, England.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital; University of Manchester
RP Ueffing, M; Clark, SJ (通讯作者)，Eberhard Karls Univ Tubingen, Inst Ophthalm Res, Dept Ophthalmol, Tubingen, Germany.; Ueffing, M; Clark, SJ (通讯作者)，Eberhard Karls Univ Tubingen, Univ Eye Clin, Dept Ophthalmol, Tubingen, Germany.; Clark, SJ (通讯作者)，Univ Manchester, Fac Biol Med & Hlth, Lydia Becker Inst Immunol & Inflammat, Manchester, Lancs, England.
EM marius.ueffing@uni-tuebingen.de; simon.clark@uni-tuebingen.de
OI Clark, Simon/0000-0001-8394-8355
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL.
CR Acar IE, 2020, OPHTHALMOLOGY
   Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Ajana S, 2020, OPHTHALMOLOGY
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Aredo B, 2015, INVEST OPHTH VIS SCI, V56, P3427, DOI 10.1167/iovs.14-16089
   Armento A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67292-z
   Asgari E, 2013, BLOOD, V122, P3473, DOI 10.1182/blood-2013-05-502229
   Behnke V, 2020, CELL MOL LIFE SCI, V77, P781, DOI 10.1007/s00018-019-03419-4
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   BOK D, 1993, J CELL SCI, P189
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cantsilieris Stuart, 2009, Recent Pat DNA Gene Seq, V3, P102
   Cerniauskas E, 2020, STEM CELL TRANSL MED, V9, P1585, DOI 10.1002/sctm.20-0211
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Chen ER, 2020, CLIN OPHTHALMOL, V14, P1349, DOI 10.2147/OPTH.S194234
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Choudhury R, 2020, BIORXIV
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Clark SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01778
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   Colijn JM, 2020, OPHTHALMOLOGY
   Cserhalmi M, 2019, SEMIN IMMUNOL, V45, DOI 10.1016/j.smim.2019.101341
   Curcio C.A., 2013, RETINA-J RET VIT DIS, V5th, P465
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   de Breuk A, 2020, OPHTHALMOLOGY
   de Cordoba SR, 1999, MOL IMMUNOL, V36, P803, DOI 10.1016/S0161-5890(99)00100-5
   Degn SE, 2011, CURR OPIN ORGAN TRAN, V16, P21, DOI 10.1097/MOT.0b013e32834253df
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Du Hongjun, 2016, Open J Ophthalmol, V6, P43
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fanelli G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15212-z
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fernandez-Godino R, 2018, HUM MOL GENET, V27, P147, DOI 10.1093/hmg/ddx392
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Fields MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177763
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   FONTAINE M, 1989, BIOCHEM J, V258, P927, DOI 10.1042/bj2580927
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Gong J, 2020, STEM CELL TRANSL MED, V9, P364, DOI 10.1002/sctm.19-0321
   Grassmann F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0548-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Hallam TM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.18
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Handa JT, 2020, SURV OPHTHALMOL
   Heesterbeek TJ, 2020, EXP EYE RES, V201, DOI 10.1016/j.exer.2020.108324
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hogasen K, 1996, LIVER, V16, P140, DOI 10.1111/j.1600-0676.1996.tb00719.x
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   JAFFE G, 2020, OPHTHALMOLOGY
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25557-8
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Kernt M, 2010, CLIN OPHTHALMOL, V4, P121
   Kimberley FC, 2007, MOL IMMUNOL, V44, P73, DOI 10.1016/j.molimm.2006.06.019
   King BC, 2019, CELL METAB, V29, P202, DOI 10.1016/j.cmet.2018.09.009
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klos A, 2009, MOL IMMUNOL, V46, P2753, DOI 10.1016/j.molimm.2009.04.027
   Kolb H., 1995, WEBVISION ORG RETINA
   Kortvely E, 2016, HUM MOL GENET, V25, P3143, DOI 10.1093/hmg/ddw162
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Krilis M, 2018, FREE RADICAL BIO MED, V129, P237, DOI 10.1016/j.freeradbiomed.2018.09.034
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Langford-Smith A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147576
   Li K, 2012, IMMUNOBIOLOGY, V217, P65, DOI 10.1016/j.imbio.2011.07.033
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Linetsky M, 2018, CHEM RES TOXICOL, V31, P666, DOI 10.1021/acs.chemrestox.8b00028
   Liszewski MK, 2013, IMMUNITY, V39, P1143, DOI 10.1016/j.immuni.2013.10.018
   Liu WJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07889-z
   Liu ZL, 2016, INVEST OPHTH VIS SCI, V57, pOCT533, DOI 10.1167/iovs.16-19106
   Lohman RJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00414-w
   Lueck K, 2015, OPHTHALMIC RES, V54, P195, DOI 10.1159/000439596
   Lyzogubov VV, 2014, EXP EYE RES, V127, P143, DOI 10.1016/j.exer.2014.07.021
   Madeira MH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20733-2
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Mastellos DC, 2019, NAT REV DRUG DISCOV, V18, P707, DOI 10.1038/s41573-019-0031-6
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   McLeod DS, 2017, INVEST OPHTH VIS SCI, V58, P5879, DOI 10.1167/iovs.17-22989
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nashine S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159828
   Ogura S, 2020, FASEB J, V34, P10117, DOI 10.1096/fj.202000807R
   Pauly D, 2019, CELL REP, V29, P2835, DOI 10.1016/j.celrep.2019.10.084
   Paun CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep26568
   Pietkiewicz J, 2008, POSTEP HIG MED DOSW, V62, P511
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Rasmussen A, 2014, CURR OPIN OPHTHALMOL, V25, P158, DOI 10.1097/ICU.0000000000000050
   Ratnapriya R, 2020, HUM MOL GENET, V29, P2022, DOI 10.1093/hmg/ddaa057
   Ricklin D, 2018, NAT REV NEPHROL, V14, P26, DOI 10.1038/nrneph.2017.156
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Roddy GW, 2020, CURR EYE RES, V45, P726, DOI 10.1080/02713683.2019.1694156
   Roginska D, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5306790
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Sahebjada Srujana, 2011, Recent Pat DNA Gene Seq, V5, P185
   Schmidt CQ, 2016, IMMUNOL REV, V274, P152, DOI 10.1111/imr.12475
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Sivapathasuntharam C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37673-6
   Taylor RL, 2019, OPHTHALMOLOGY, V126, P1410, DOI 10.1016/j.ophtha.2019.03.013
   Trakkides TO, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8110548
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Vorup-Jensen T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02716
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   Wang D, 2019, NAT REV DRUG DISCOV, V18, P358, DOI 10.1038/s41573-019-0012-9
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Winkler TW, 2020, BMC MED GENOMICS, V13, DOI 10.1186/s12920-020-00760-7
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Wyatt MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068088
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zhang Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129945
   Zhang YL, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101222
NR 160
TC 37
Z9 37
U1 5
U2 14
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAY
PY 2021
VL 78
IS 10
BP 4487
EP 4505
DI 10.1007/s00018-021-03796-9
EA MAR 2021
PG 19
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA SQ8EM
UT WOS:000626819400001
PM 33751148
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Stuart, A
   Ford, JA
   Duckworth, S
   Jones, C
   Pereira, A
AF Stuart, Arabella
   Ford, John A.
   Duckworth, Susan
   Jones, Colin
   Pereira, Augustine
TI Anti-VEGF therapies in the treatment of choroidal neovascularisation
   secondary to non-age-related macular degeneration: a systematic review
SO BMJ OPEN
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; PHOTODYNAMIC THERAPY; INTRAVITREAL
   BEVACIZUMAB; PATHOLOGICAL MYOPIA; RANIBIZUMAB; VERTEPORFIN; INJECTIONS;
   OUTCOMES; TRIAL
AB Objectives: The aim of this study is to systematically review the evidence for anti-vascular endothelial growth factor (VEGF) therapy in choroidal neovascularisation secondary to conditions other than age-related macular degeneration.
   Data sources: MEDLINE, MEDLINE in-process, EMBASE and CENTRAL databases and conference abstracts were searched (from inception to Jan 2014).
   Study eligibility criteria, participants and interventions: Randomised and non-randomised comparative studies with follow-up of at least 6 months were included and were used to assess clinical effectiveness.
   Study appraisal and synthesis method: Risk of bias was assessed using the Cochrane risk of bias tool and modified Newcastle-Ottawa Scale. Meta-analysis was not possible due to methodological heterogeneity.
   Results: 16 studies met the inclusion criteria (1091 eyes; 963 pathological myopia, 74 other conditions). There was large variation in risk of bias across studies. An improvement in best-corrected visual acuity in anti-VEGF arms over comparators was reported in all studies. The proportion of patients improving by at least 15 letters in anti-VEGF arms ranged from 27.3% to 70%. There were no significant differences between bevacizumab and ranibizumab.
   Limitations: Owing to the rarity of choroidal neovascularisation secondary to conditions other than age-related macular degeneration or pathological myopia, there are unlikely to ever be sufficiently powered trials in these populations.
   Conclusions: Bevacizumab and ranibizumab appear to be effective in improving visual acuity for patients with choroidal neovascularisation secondary to conditions other than age-related macular degeneration. The evidence base is strongest for choroidal neovascularisation secondary to pathological myopia, however, based on current evidence and likely pharmacological pathways, clinicians should consider treatment with either bevacizumab or ranibizumab for rarer causes.
C1 [Stuart, Arabella; Duckworth, Susan; Pereira, Augustine] Norfolk Cty Council, Publ Hlth Directorate, Norwich, Norfolk, England.
   [Ford, John A.] Univ E Anglia, Norwich NR4 7TJ, Norfolk, England.
   [Jones, Colin] Norfolk & Norwich Univ Hosp NHS Fdn Trust, Norwich, Norfolk, England.
C3 University of East Anglia; Norfolk & Norwich University Hospitals NHS
   Foundation Trust
RP Ford, JA (通讯作者)，Univ E Anglia, Norwich NR4 7TJ, Norfolk, England.
EM John.ford@uea.ac.uk
OI Ford, John/0000-0001-8033-7081
FU National Institute for Health Research [ACF-2012-15-002] Funding Source:
   researchfish
CR Baba T, 2010, BRIT J OPHTHALMOL, V94, P864, DOI 10.1136/bjo.2009.166025
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P81, DOI 10.1159/000317908
   Chang LK, 2008, ARCH OPHTHALMOL-CHIC, V126, P941, DOI 10.1001/archopht.126.7.941
   Cionni DA, 2012, OPHTHALMOLOGY, V119, P327, DOI 10.1016/j.ophtha.2011.08.032
   Cornish KS, 2011, EUR J OPHTHALMOL, V21, P440, DOI 10.5301/EJO.2010.6117
   Curtin B J, 1970, Trans Am Ophthalmol Soc, V68, P312
   Dethorey G, 2012, J FR OPHTALMOL, V35, P106, DOI 10.1016/j.jfo.2011.03.028
   Duan HH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/408268
   El Matri L, 2013, J FR OPHTALMOL, V36, P29, DOI 10.1016/j.jfo.2012.03.015
   El Matri L, 2011, GRAEF ARCH CLIN EXP, V249, P1287, DOI 10.1007/s00417-011-1654-4
   Europea Medicines Agency, 2014, EYL EMEA 000236 PIP0
   Ford JA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004120
   Ford JA, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002269
   Gharbiya M, 2010, AM J OPHTHALMOL, V149, P458, DOI 10.1016/j.ajo.2009.10.010
   Gliem M, 2013, RETINA-J RET VIT DIS, V33, P1300, DOI 10.1097/IAE.0b013e3182914d2b
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009
   Hayashi K, 2010, OPHTHALMOLOGY, V117, pe1, DOI DOI 10.1016/j.ophtha.2009.11.003
   Hayashi K, 2010, OPHTHALMOLOGY, V117, P1595, DOI 10.1016/j.ophtha.2009.11.003
   Hayashi K, 2009, AM J OPHTHALMOL, V148, P396, DOI 10.1016/j.ajo.2009.03.026
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Iacono P, 2012, RETINA-J RET VIT DIS, V32, P1539, DOI 10.1097/IAE.0b013e31826956b7
   Ikuno Y, 2010, AM J OPHTHALMOL, V149, P140, DOI 10.1016/j.ajo.2009.08.008
   Kang HM, 2013, AM J OPHTHALMOL, V155, P713, DOI 10.1016/j.ajo.2012.10.010
   Lai TYY, 2012, EYE, V26, P1004, DOI 10.1038/eye.2012.97
   Liu ZQ, 2013, INT EYE SCI, V13, P953
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   NICE, 2013, TA298 NICE
   Parodi MB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1100, DOI 10.1001/archophthalmol.2010.205
   Poku E., 2012, BEVACIZUMAB EYE COND
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saw SM, 2006, BRIT J OPHTHALMOL, V90, P525, DOI 10.1136/bjo.2005.087999
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P67, DOI 10.1111/j.1442-9071.2011.02719.x
   Tufail A, 2013, EYE, V27, P709, DOI 10.1038/eye.2013.8
   Wang EQ, 2013, RETINA-J RET VIT DIS, V33, P1375, DOI 10.1097/IAE.0b013e31827d260a
   Wolf S, 2014, OPHTHALMOLOGY, V121, P682, DOI 10.1016/j.ophtha.2013.10.023
   Wong TY, 2014, AM J OPHTHALMOL, V157, P9, DOI 10.1016/j.ajo.2013.08.010
   Yoon JU, 2012, RETINA-J RET VIT DIS, V32, P949, DOI [10.1097/IAE.0b013e318227aa09, 10.1097/IAE.0b013e318227a9ef]
   Yoon JU, 2010, RETINA-J RET VIT DIS, V30, P418, DOI 10.1097/IAE.0b013e3181bd2fe4
NR 42
TC 14
Z9 14
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2015
VL 5
IS 4
AR e007746
DI 10.1136/bmjopen-2015-007746
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CI4GB
UT WOS:000354705000115
PM 25941188
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lee, J
   Zeng, J
   Hughes, G
   Chen, Y
   Grob, S
   Zhao, L
   Lee, C
   Krupa, M
   Quach, J
   Luo, J
   Zeng, J
   Wei, X
   Zhang, X
   Zhu, J
   Duan, Y
   Ferreyra, H
   Goldbaum, M
   Haw, W
   Shaw, PX
   Tang, L
   Zhang, K
AF Lee, J.
   Zeng, J.
   Hughes, G.
   Chen, Y.
   Grob, S.
   Zhao, L.
   Lee, C.
   Krupa, M.
   Quach, J.
   Luo, J.
   Zeng, J.
   Wei, X.
   Zhang, X.
   Zhu, J.
   Duan, Y.
   Ferreyra, H.
   Goldbaum, M.
   Haw, W.
   Shaw, P. X.
   Tang, L.
   Zhang, K.
TI Association of LIPC and advanced age-related macular degeneration
SO EYE
LA English
DT Article
DE LIPC; hepatic lipase; advanced age-related macular degeneration;
   genetics
ID HIGH-DENSITY-LIPOPROTEIN; COMPLEMENT FACTOR-H; HEPATIC LIPASE GENE;
   PROMOTER POLYMORPHISM; GEOGRAPHIC ATROPHY; FACTOR-B; RISK; VARIANT;
   HTRA1; SUSCEPTIBILITY
AB Purpose To determine whether there is an association between hepatic lipase (LIPC) and age-related macular degeneration (AMD) in two independent Caucasian cohorts.
   Methods A discovery cohort of 1626 patients with advanced AMD and 859 normal controls and a replication cohort of 2159 cases and 1150 controls were genotyped for two single-nucleotide polymorphisms (SNPs) in the promoter region of LIPC. The associations between the SNPs and AMD were examined by chi(2) tests.
   Results In the discovery cohort, rs493258 and rs10468017 were both associated with advanced AMD (P = 9.63E -3 and P = 0.048, respectively). The association was corroborated in the replication cohort (P = 4.48E -03 for rs493258 and P = 0.015 for rs10468017). Combined analysis resulted in even more significant associations (P = 1.21E -04 for rs493258 and P = 1.67E -03 for rs10468017).
   Conclusion The LIPC promoter variants rs493258 and rs10468017 were associated with advanced AMD in two independent Caucasian populations, confirming that LIPC polymorphisms may be a genetic risk factor for AMD in the Caucasian population. Eye (2013) 27, 265-271; doi:10.1038/eye.2012.276; published online 25 January 2013
C1 [Lee, J.; Zeng, J.; Hughes, G.; Chen, Y.; Grob, S.; Zhao, L.; Lee, C.; Krupa, M.; Quach, J.; Luo, J.; Zeng, J.; Wei, X.; Zhang, X.; Zhu, J.; Duan, Y.; Ferreyra, H.; Goldbaum, M.; Haw, W.; Shaw, P. X.; Zhang, K.] Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92093 USA.
   [Lee, J.; Zeng, J.; Hughes, G.; Chen, Y.; Grob, S.; Zhao, L.; Lee, C.; Krupa, M.; Quach, J.; Luo, J.; Zeng, J.; Wei, X.; Zhang, X.; Zhu, J.; Duan, Y.; Ferreyra, H.; Goldbaum, M.; Haw, W.; Shaw, P. X.; Zhang, K.] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   [Lee, J.; Zeng, J.; Hughes, G.; Chen, Y.; Grob, S.; Zhao, L.; Lee, C.; Krupa, M.; Quach, J.; Luo, J.; Zeng, J.; Wei, X.; Zhang, X.; Zhu, J.; Duan, Y.; Ferreyra, H.; Goldbaum, M.; Haw, W.; Shaw, P. X.; Zhang, K.] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
   [Zeng, J.; Shaw, P. X.] Cent S Univ, Xiangya Hosp 2, Dept Ophthalmol, Changsha 410083, Hunan, Peoples R China.
   [Zeng, J.; Chen, Y.; Shaw, P. X.] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Salt Lake City, UT USA.
   [Chen, Y.; Shaw, P. X.] Fudan Univ, Dept Ophthalmol & Vis Sci, Eye & ENT Hosp, Shanghai Med Sch, Shanghai 200433, Peoples R China.
   [Zhang, K.] Vet Adm Healthcare Syst, San Diego, CA USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   Central South University; Utah System of Higher Education; University of
   Utah; Fudan University
RP Zhang, K (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, 9500 Gilman Dr MC0838, La Jolla, CA 92093 USA.
EM kangzhang@ucsd.edu
RI Zhang, Kang/Y-2740-2019; Goldbaum, Michael/AAG-4258-2020; Zhao,
   Ling/D-9005-2015
OI Zhang, Kang/0000-0002-4549-1697; Goldbaum, Michael/0000-0002-7721-2736;
   Zhao, Ling/0000-0002-6644-2886; Luo, Jing/0000-0002-8905-9388
FU 973 Program [2011CB510200, 2013CB967504]; Genentech; NEI/NIH (Bethesda);
   KACST -UCSD Center of Excellence in Nanomedicine; Research to Prevent
   Blindness (New York); VA Merit Award (San Diego)
FX We thank Chao Zhao, Kevin Wang, Daniel Kasuga, and Jean Guan for their
   assistance with this study. We also thank all the participating AMD
   patients and their families. This study is supported by 973 Program
   (2011CB510200, 2013CB967504); Genentech, NEI/NIH (Bethesda), KACST -UCSD
   Center of Excellence in Nanomedicine, Research to Prevent Blindness (New
   York), and VA Merit Award (San Diego).
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chamberlain AM, 2008, ATHEROSCLEROSIS, V200, P322, DOI 10.1016/j.atherosclerosis.2007.12.045
   Chen SN, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-111
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eifert S, 2009, J CARDIOTHORAC SURG, V4, DOI 10.1186/1749-8090-4-46
   Feitosa MF, 2009, ATHEROSCLEROSIS, V204, P171, DOI 10.1016/j.atherosclerosis.2008.09.007
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hindorff LA, 2008, PHARMACOGENET GENOM, V18, P677, DOI 10.1097/FPC.0b013e3283033528
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Knoblauch H, 2004, HUM MOL GENET, V13, P993, DOI 10.1093/hmg/ddh119
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   McCarthy JJ, 2003, HUM GENET, V114, P87, DOI 10.1007/s00439-003-1026-1
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Santamarina-Fojo S, 2004, ARTERIOSCL THROM VAS, V24, P1750, DOI 10.1161/01.ATV.0000140818.00570.2d
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Stancakova A, 2006, PHYSIOL RES, V55, P483, DOI 10.33549/physiolres.930836
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Valdivielso P, 2008, J DIABETES COMPLICAT, V22, P273, DOI 10.1016/j.jdiacomp.2007.06.011
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yu AL, 2009, EXP EYE RES, V88, P495, DOI 10.1016/j.exer.2008.10.028
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
NR 38
TC 13
Z9 14
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2013
VL 27
IS 2
BP 266
EP 270
DI 10.1038/eye.2012.276
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 115JE
UT WOS:000316807600019
PM 23348725
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Rovner, BW
   Casten, RJ
AF Rovner, BW
   Casten, RJ
TI Activity loss and depression in age-related macular degeneration
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
ID CHRONIC DISEASE SCORE; SYMPTOMS; IMPAIRMENT; DISABILITY; ASSOCIATION;
   THERAPY; IMPACT
AB Age-related macular degeneration (AMD) is the most frequent cause of severe vision loss in older persons and is associated with high rates of disability and depression. The authors evaluated 51 patients with bilateral AMD to investigate the interrelationships of disease severity disability and depression and focused on loss of valued activities as an emblematic disabling consequence of AMD They characterized depression by the Center for Epidemiologic Studies-Depression (CES-D) score, a syndromal state based on the CES-D, and as a level of distress (Index of Affective Suffering; IAS). Thirty subjects (58.8%,) had loss of a valued, discretionary activity. They had worse visual acuity and more depressive symptoms and were represented in higher-IAS levels than other subjects. Visual acuity was significantly correlated with IAS levels, but not with CES-D scores or syndromal depression. A regression model demonstrated that activity loss mediated the relationship between visual acuity and IAS level Affective distress occurs in AMD, largely to the extent that valued activities are relinquished because of vision loss, IAS levels best illuminated this relationship, suggesting the value of this dimension of affective functioning in studies of tbe consequences of chronic disease.
C1 Wills Eye Hosp & Res Inst, Jefferson Med Coll, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA.
   Thomas Jefferson Univ Hosp, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA.
C3 Jefferson University; Jefferson University
RP Rovner, BW (通讯作者)，Wills Eye Hosp & Res Inst, Jefferson Med Coll, Dept Psychiat & Human Behav, 900 Walnut St,8th Floor, Philadelphia, PA 19107 USA.
EM rovner1@aol.com
CR Bagby RM, 1998, AM J PSYCHIAT, V155, P437, DOI 10.1176/ajp.155.3.437
   BANDURA A, 1982, AM PSYCHOL, V37, P122, DOI 10.1037/0003-066X.37.2.122
   Barrett JE, 1999, GEN HOSP PSYCHIAT, V21, P260, DOI 10.1016/S0163-8343(99)00023-7
   Bruce ML, 1999, AM J GERIAT PSYCHIAT, V7, P8
   BRUCE ML, 1994, AM J PUBLIC HEALTH, V84, P1796, DOI 10.2105/AJPH.84.11.1796
   Caine ED, 1996, AM J GERIAT PSYCHIAT, V4, pS45
   Chen PJ, 1999, ARCH GEN PSYCHIAT, V56, P261, DOI 10.1001/archpsyc.56.3.261
   CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004
   Crews J E, 1994, J Am Optom Assoc, V65, P63
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Frank J. D., 1974, PERSUASION HEALING C
   GANGULI M, 1995, AM J GERIAT PSYCHIAT, V3, P144, DOI 10.1097/00019442-199500320-00006
   GURLAND BJ, 1988, INT J GERIATR PSYCH, V3, P163, DOI 10.1002/gps.930030304
   Gurland BJ, 1997, AM J GERIAT PSYCHIAT, V5, P192, DOI 10.1097/00019442-199700530-00003
   HECKHAUSEN J, 1995, PSYCHOL REV, V102, P284, DOI 10.1037/0033-295X.102.2.284
   KAHN RL, 1960, AM J PSYCHIAT, V117, P326, DOI 10.1176/ajp.117.4.326
   Kennedy G J, 1990, J Community Health, V15, P93, DOI 10.1007/BF01321314
   MCCRAE RR, 1990, PERSONALITY ABULTHOO
   Penninx BWJH, 1998, JAMA-J AM MED ASSOC, V279, P1720, DOI 10.1001/jama.279.21.1720
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Reuben DB, 1999, J AM GERIATR SOC, V47, P930, DOI 10.1111/j.1532-5415.1999.tb01286.x
   SALIVE ME, 1994, J AM GERIATR SOC, V42, P287, DOI 10.1111/j.1532-5415.1994.tb01753.x
   Suh T, 1997, PSYCHOL MED, V27, P1051, DOI 10.1017/S0033291797005205
   Vali FM, 1998, MED CARE, V36, P1073, DOI 10.1097/00005650-199807000-00013
   VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G
   Williamson GM, 2000, HEALTH PSYCHOL, V19, P339, DOI 10.1037//0278-6133.19.4.339
NR 26
TC 134
Z9 135
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD MAY-JUN
PY 2002
VL 10
IS 3
BP 305
EP 310
PG 6
WC Geriatrics & Gerontology; Gerontology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology; Psychiatry
GA 552LM
UT WOS:000175621900010
PM 11994218
DA 2022-11-30
ER

PT J
AU Friberg, TR
   Tolentino, M
AF Friberg, Thomas R.
   Tolentino, Michael
CA LEVEL Study Grp
TI Pegaptanib sodium as maintenance therapy in neovascular age-related
   macular degeneration: the LEVEL study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE; RANIBIZUMAB; BEVACIZUMAB;
   SAFETY
AB Aim To assess the efficacy of pegaptanib as maintenance therapy in neovascular age-related macular degeneration (NV-AMD) patients after induction therapy.
   Methods A phase IV, prospective, open-label, uncontrolled exploratory study including subjects with subfoveal NV-AMD who had had one to three induction treatments 30-120 days before entry and showed investigator-determined clinical/anatomical NV-AMD improvement. Lesions in the study eye were: any subtype, 12 or fewer disc areas; postinduction centre point thickness (CPT) 275 mu m or less or thinning of 100 mm or more (optical coherence tomography); visual acuity (VA) 20/20-20/400. Intravitreal pegaptanib 0.3 mg was administered as maintenance every 6 weeks for 48 weeks with follow-up to week 54. Booster treatment additional unscheduled treatment for wet age-related macular degeneration, was allowed in the study eye at the investigators' discretion for clinical deterioration.
   Results Of 568 enrolled subjects, 86% completed 1 year of pegaptanib. Mean VA improvement during induction (49.6 to 65.5 letters) was well preserved (54-week mean 61.8 letters). Mean CPT was relatively stable during maintenance (20 mu m increase during the study). Fifty per cent did not receive unscheduled booster treatment to week 54; 46% did have one such booster (mean 147 days after maintenance initiation).
   Conclusions An induction-maintenance strategy, using non-selective then selective vascular endothelial growth factor (VEGF) inhibitors, could be considered for NV-AMD. This approach may have particular relevance for patients with systemic comorbidities who require long-term anti-VEGF therapy for NV-AMD.
C1 [Friberg, Thomas R.] Univ Pittsburgh, Med Ctr, Ctr Eye, Pittsburgh, PA USA.
   [Tolentino, Michael] Ctr Retina & Macular Dis, Winter Haven, FL USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Friberg, TR (通讯作者)，Inst Eye & Ear, Retina Serv, Room 825,203 Lothrop St, Pittsburgh, PA 15213 USA.
EM friberg@pitt.edu
OI Krzystolik, Magdalena G./0000-0002-4199-3649
FU Eyetech, Inc; OSI Pharmaceuticals
FX This study was sponsored by Eyetech, Inc and OSI Pharmaceuticals.
CR Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Bombeli T, 1997, BLOOD, V89, P2429, DOI 10.1182/blood.V89.7.2429
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Farah SE, 2008, OPHTHAL SURG LAS IM, V39, P294, DOI 10.3928/15428877-20080701-05
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Gordon MS, 2005, ONCOLOGY-BASEL, V69, P25, DOI 10.1159/000088481
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hughes MS, 2006, OPHTHAL SURG LAS IM, V37, P446, DOI 10.3928/15428877-20061101-01
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Marcus DM, 2008, INVEST OPHTHALMOL VI, V49
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Moncada S, 2006, BRIT J PHARMACOL, V147, pS193, DOI 10.1038/sj.bjp.0706458
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Russell DA, 2008, BRIT J SURG, V95, P576, DOI 10.1002/bjs.6100
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Uhlmann S, 2001, MICROVASC RES, V62, P179, DOI 10.1006/mvre.2001.2334
   Verheul HMW, 2007, NAT REV CANCER, V7, P475, DOI 10.1038/nrc2152
NR 25
TC 33
Z9 35
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2010
VL 94
IS 12
BP 1611
EP 1617
DI 10.1136/bjo.2009.174946
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 683IJ
UT WOS:000284469000013
PM 20472746
OA Green Submitted, hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Wu, YL
   Yanase, E
   Feng, XD
   Siegel, MM
   Sparrow, JR
AF Wu, Yalin
   Yanase, Emiko
   Feng, Xidong
   Siegel, Marshall M.
   Sparrow, Janet R.
TI Structural characterization of bisretinoid A2E photocleavage products
   and implications for age-related macular degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE advanced glycation end products; lipofuscin; photofragmentation;
   photooxidation; retinal pigment epithelial cells
ID PIGMENT EPITHELIAL-CELLS; RECESSIVE STARGARDT-DISEASE; TANDEM
   MASS-SPECTROMETRY; FACTOR-H POLYMORPHISM; ELECTROSPRAY-IONIZATION;
   PHOTOOXIDATION PRODUCTS; LIPOFUSCIN FLUOROPHORE; COMPLEMENT ACTIVATION;
   BRUCHS MEMBRANE; RPE LIPOFUSCIN
AB Fluorescent bisretinoids, such as A2E and all-trans-retinal dimer, form as a by-product of vitamin A cycling in retina and accumulate in retinal pigment epithelial (RPE) cells as lipofuscin pigments. These pigments are implicated in pathological mechanisms involved in several vision-threatening diseases including age-related macular degeneration. Efforts to understand damaging events initiated by these bisretinoids have revealed that photoexcitation of A2E by wavelengths in the visible spectrum leads to singlet oxygen production and photooxidation of A2E. Here we have employed liquid chromatography coupled to electrospray ionization mass spectrometry together with tandem mass spectrometry (MS/MS), to demonstrate that A2E also undergoes photooxidation-induced degradation and we have elucidated the structures of some of the aldehyde-bearing cleavage products. Studies in which A2E was incubated with a singlet oxygen generator yielded results consistent with a mechanism involving bisretinoid photocleavage at sites of singlet molecular oxygen addition. We provide evidence that one of the products released by A2E photodegradation is methylglyoxal, a low molecular weight reactive dicarbonyl with the capacity to form advanced glycation end products. Methylglyoxal is already known to be generated by carbohydrate and lipid oxidation; this is the first report of its production via bisretinoid photocleavage. It is significant that AGE-modified proteins are detected in deposits (drusen) that accumulate below RPE cells in vivo; drusen have been linked to age-related macular degeneration pathogenesis. Whereas various processes play a role in drusen formation, these findings are indicative of a contribution from lipofuscin photooxidation in RPE.
C1 [Wu, Yalin; Yanase, Emiko; Sparrow, Janet R.] Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
   [Feng, Xidong; Siegel, Marshall M.] Wyeth Res, Pearl River, NY 10965 USA.
   [Sparrow, Janet R.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA.
C3 Columbia University; Pfizer; Columbia University
RP Sparrow, JR (通讯作者)，Columbia Univ, Dept Ophthalmol, 630 W 168th St, New York, NY 10032 USA.
EM jrs88@columbia.edu
OI Yanase, Emiko/0000-0002-6652-4259
FU National Institutes of Health [EY 12951]; Research to Prevent Blindness;
   NATIONAL EYE INSTITUTE [P30EY019007, R01EY012951] Funding Source: NIH
   RePORTER
FX We thank Dr. Jiangao He for LC-MS assistance. This work was supported by
   National Institutes of Health Grant EY 12951 and a grant to the
   Department of Ophthalmology from Research to Prevent Blindness.
CR Alvarez-Diez TM, 2004, DRUG METAB DISPOS, V32, P1345, DOI 10.1124/dmd.104.000406
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   De Hoffmann E., 2007, MASS SPECTROMETRY PR, V3
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Dillon J, 2004, EXP EYE RES, V79, P537, DOI 10.1016/j.exer.2004.06.024
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hsu FF, 2008, J AM SOC MASS SPECTR, V19, P1673, DOI 10.1016/j.jasms.2008.07.007
   Jang YP, 2005, J BIOL CHEM, V280, P39732, DOI 10.1074/jbc.M504933200
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104
   Kim SR, 2008, EXP EYE RES, V86, P975, DOI 10.1016/j.exer.2008.03.016
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maiti P, 2006, BIOCHEMISTRY-US, V45, P852, DOI 10.1021/bi0518545
   Marmorstein AD, 2009, PROG RETIN EYE RES, V28, P206, DOI 10.1016/j.preteyeres.2009.04.004
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Passarelli M, 2005, DIABETES, V54, P2198, DOI 10.2337/diabetes.54.7.2198
   Price CL, 2009, TRENDS ENDOCRIN MET, V20, P312, DOI 10.1016/j.tem.2009.03.010
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Sell DR, 2008, ANN NY ACAD SCI, V1126, P205, DOI 10.1196/annals.1433.065
   Shroyer NF, 1999, VISION RES, V39, P2537, DOI 10.1016/S0042-6989(99)00037-1
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Thornalley Paul J., 2008, Drug Metabolism and Drug Interactions, V23, P125
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tombran-Tink J, 2007, RETINAL DEGENERATION, P213
   TURRO NJ, 1981, J AM CHEM SOC, V103, P7218, DOI 10.1021/ja00414a029
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Vasireddy V, 2009, EXP EYE RES, V89, P905, DOI 10.1016/j.exer.2009.07.021
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P1251, DOI 10.1562/2006-04-01-RA-864
   Wu Y, 2009, J BIOL CHEM, V284, P20155, DOI 10.1074/jbc.M109.021345
   Yan GQ, 2007, RAPID COMMUN MASS SP, V21, P3613, DOI 10.1002/rcm.3243
   Yan SF, 2009, J MOL MED, V87, P235, DOI 10.1007/s00109-009-0439-2
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou JL, 2006, REJUV RES, V9, P256, DOI 10.1089/rej.2006.9.256
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 52
TC 105
Z9 109
U1 0
U2 14
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 20
PY 2010
VL 107
IS 16
BP 7275
EP 7280
DI 10.1073/pnas.0913112107
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 586FU
UT WOS:000276892300033
PM 20368460
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Dias, JRDO
   de Andrade, GC
   Kniggendorf, VF
   Novais, EA
   Maia, A
   Meyer, C
   Watanabe, SES
   Farah, ME
   Rodrigues, EB
AF de Oliveira Dias, Joao Rafael
   de Andrade, Gabriel Costa
   Kniggendorf, Vinicius Ferreira
   Novais, Eduardo Amorim
   Maia, Andre
   Meyer, Carsten
   Watanabe, Sung Eun Song
   Farah, Michel Eid
   Rodrigues, Eduardo Buschele
TI CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL
   ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE ziv-aflibercept; age-related macular degeneration; full-field
   electroretinography; multifocal electroretinography
ID BEVACIZUMAB AVASTIN; ELECTRORETINOGRAPHY; INJECTION; DISEASE; SAFETY;
   VEGF
AB Purpose: To evaluate the 6-month safety and efficacy of ziv-aflibercept intravitreal injections for treating exudative age-related macular degeneration.
   Methods: Fifteen patients with unilateral exudative age-related macular degeneration were enrolled. The best-corrected visual acuity was measured and spectral domain optical coherence tomography was performed at baseline and monthly. Full-field electroretinography and multifocal electroretinography were obtained at baseline and 4, 13, and 26 weeks after the first injection. All patients received three monthly intravitreal injections of ziv-aflibercept (1.25 mg) followed by as-needed treatment.
   Results: Between baseline and 26 weeks, the mean logMAR best-corrected visual acuity improved (P = 0.00408) from 0.93 +/- 0.4 (20/200) to 0.82 +/- 0.5 (20/160) logarithm of the minimum angle of resolution, respectively; the central retinal thickness decreased significantly (P = 0.0007) from 490.3 +/- 155.1 microns to 327.9 +/- 101.5 microns; the mean total macular volume decreased significantly (P < 0.0001) from 9.51 +/- 1.36 mm(3) to 8.08 +/- 1.34 mm(3), and the a-wave implicit time increased, with no differences in the other full-field electroretinography parameters. The average multifocal electroretinography macular responses within the first central 15 degrees showed significantly (P < 0.05) increased P-1 amplitudes at 26 weeks. No systemic or ocular complications developed.
   Conclusion: Intravitreal ziv-aflibercept significantly improved the best-corrected visual acuity, multifocal electroretinography amplitudes, central retinal thickness, and total macular volume from baseline to 26 weeks. No retinal toxicity on full-field electroretinography or adverse events occurred during the follow-up period.
C1 [de Oliveira Dias, Joao Rafael; de Andrade, Gabriel Costa; Kniggendorf, Vinicius Ferreira; Novais, Eduardo Amorim; Maia, Andre; Meyer, Carsten; Watanabe, Sung Eun Song; Farah, Michel Eid; Rodrigues, Eduardo Buschele] Univ Fed Sao Paulo, Paulista Med Sch, Dept Ophthalmol, Rua Botucatu 821,1st Floor, BR-04023062 Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP)
RP Dias, JRDO (通讯作者)，Univ Fed Sao Paulo, Paulista Med Sch, Dept Ophthalmol, Rua Botucatu 821,1st Floor, BR-04023062 Sao Paulo, Brazil.
EM dias_joaor@yahoo.com.br
RI Farah, Michel Eid E/F-3285-2012; Meyer, Carsten/A-3981-2017; Andrade,
   Gabriel/AAV-3155-2020
OI Farah, Michel Eid E/0000-0001-5951-0193; Meyer,
   Carsten/0000-0002-0530-5298; Andrade, Gabriel/0000-0002-5881-8126;
   Buchele Rodrigues, Eduardo/0000-0002-4224-0921
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Sao Paulo,
   Brazil); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (Brasilia, Brazil); Pan-American Association of
   Ophthalmology/Pan-American Ophthalmological Foundation, Paul Kayser
   Global Award, Arlington, TX
FX Supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Sao
   Paulo, Brazil), Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (Brasilia, Brazil), and the Pan-American Association of
   Ophthalmology/Pan-American Ophthalmological Foundation, Paul Kayser
   Global Award, Arlington, TX.
CR Berezovsky A, 2003, DOC OPHTHALMOL, V107, P243, DOI 10.1023/B:DOOP.0000005333.76622.c2
   Berrow EJ, 2010, DOC OPHTHALMOL, V121, P51, DOI 10.1007/s10633-010-9226-1
   Cheng YD, 2013, DRUG DES DEV THER, V7, P1315, DOI 10.2147/DDDT.S52485
   Chhablani J, 2016, RETINA-J RET VIT DIS, V36, P1126, DOI 10.1097/IAE.0000000000000913
   Chhablani J, 2015, INDIAN J OPHTHALMOL, V63, P469, DOI 10.4103/0301-4738.159909
   Chu QSC, 2009, EXPERT OPIN BIOL TH, V9, P263, DOI [10.1517/14712590802666397, 10.1517/14712590802666397 ]
   de Andrade GC, 2016, RETINA-J RET VIT DIS, V36, P1640, DOI 10.1097/IAE.0000000000001000
   de Oliveira Dias Joao Rafael, 2016, Int J Retina Vitreous, V2, P3, DOI 10.1186/s40942-016-0026-y
   Dias JRD, 2015, OSLI RETINA, V46, P91, DOI 10.3928/23258160-20150101-17
   Dias JRD, 2014, OSLI RETINA, V45, P577, DOI 10.3928/23258160-20141118-15
   Frenkel REP, 2010, CLIN OPHTHALMOL, V4, P1279, DOI 10.2147/OPTH.S12846
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Mansour AM, 2015, BRIT J OPHTHALMOL, V99, P1055, DOI 10.1136/bjophthalmol-2014-306319
   Mansour AM, 2016, BR J OPHTHALMOL
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Moschos MM, 2007, DOC OPHTHALMOL, V114, P37, DOI 10.1007/s10633-006-9036-7
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Salomao SR, 2007, CURR EYE RES, V32, P345, DOI 10.1080/02713680701229638
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sharma T, 2013, MINI-REV MED CHEM, V13, P530, DOI 10.2174/1389557511313040006
   Skaat A, 2011, ACTA OPHTHALMOL, V89, pe269, DOI 10.1111/j.1755-3768.2010.02005.x
   Sutter EE, 2001, VISION RES, V41, P1241, DOI 10.1016/S0042-6989(01)00078-5
   Trichonas G, 2013, OPHTHALMOL THER, V2, P89, DOI 10.1007/s40123-013-0015-2
   Videkar Chetan, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-212988
NR 26
TC 10
Z9 10
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2017
VL 37
IS 8
BP 1499
EP 1507
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FB4JU
UT WOS:000406108700010
PM 27798520
OA Green Published
DA 2022-11-30
ER

PT J
AU McGeer, PL
   Sibley, J
AF McGeer, PL
   Sibley, J
TI Sparing of age-related macular degeneration in rheumatoid arthritis
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE inflammation; Antiinflammatory drugs; NSAIDs; Alzheimer disease
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BLUE MOUNTAINS EYE;
   ALZHEIMERS-DISEASE; RISK-FACTORS; MACULOPATHY; PREVALENCE; DRUSEN;
   EPIDEMIOLOGY; THERAPY; COMMON
AB Age-related macular degeneration (AMD), for which inflammatory changes have been demonstrated, is the commonest cause of blindness in the elderly. We compared the prevalence of AMD in a prospectively followed cohort of rheumatoid arthritic (RA) patients from Saskatchewan with published data from four racially similar general populations. For individuals 65 years or older, only three cases of AMD were identified in the Saskatchewan cohort of 993 RA patients (0.2% prevalence). This compares with 67 out of 1955 subjects in the Beaver Dam survey (prevalence 3.43%); 101 out of 4071 in the Rotterdam survey (prevalence 2.48%); and 63 out of 1950 in the Blue Mountains survey (prevalence 3.23%). For individuals 75 years or older, only two cases out of 497 were identified in the RA cohort (prevalence 0.40%), compared with 516 cases out of 13,900 in the United Kingdom survey (prevalence 3.72%). Patients with RA appear to be relatively spared from AMD. We hypothesize that this results from long term antimflarnmatory treatment. Genetic or environmental factors could also be responsible. (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ British Columbia, Kinsmen Lab Neurol Res, Vancouver, BC V6T 1Z3, Canada.
   Univ Saskatchewan, Dept Med, Saskatoon, SK S7N 0W0, Canada.
C3 University of British Columbia; University of Saskatchewan
RP McGeer, PL (通讯作者)，Univ British Columbia, Kinsmen Lab Neurol Res, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.
EM mcgeerpl@interchange.ubc.ca
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Albano SA, 2001, SEMIN ARTHRITIS RHEU, V31, P146, DOI 10.1053/sarh.2001.27719
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Chen HL, 2003, ARCH NEUROL-CHICAGO, V60, P1059, DOI 10.1001/archneur.60.8.1059
   Cibere J, 1997, ARTHRITIS RHEUM, V40, P1580, DOI 10.1002/art.1780400906
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Gabriel SE, 2001, RHEUM DIS CLIN N AM, V27, P269, DOI 10.1016/S0889-857X(05)70201-5
   GOTTLIEB JL, 2002, JAMA-J AM MED ASSOC, V288, P2223
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019
   in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178
   JENKINSON ML, 1989, BRIT J RHEUMATOL, V28, P86
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   MAZZUCA SA, 1994, J RHEUMATOL, V21, P59
   McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9
   MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415
   McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425
   MCGEER PL, 1990, LANCET, V335, P1037, DOI 10.1016/0140-6736(90)91101-F
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Veld BAI, 1998, NEUROBIOL AGING, V19, P607, DOI 10.1016/S0197-4580(98)00096-7
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
   Zandi PP, 2002, NEUROLOGY, V59, P880, DOI 10.1212/WNL.59.6.880
   2004, PREVENT BLINDNESS AM
NR 32
TC 34
Z9 37
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD AUG-SEP
PY 2005
VL 26
IS 8
BP 1199
EP 1203
DI 10.1016/j.neurobiolaging.2005.02.003
PG 5
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 935XO
UT WOS:000229816900009
PM 15917104
DA 2022-11-30
ER

PT J
AU Rozon, JP
   Hebert, M
   Laverdiere, C
   Lachance, A
   Bourgault, S
   Caissie, M
   Letartre, L
   Tourville, E
   Dirani, A
AF Rozon, Jean-Philippe
   Hebert, Melanie
   Laverdiere, Carolane
   Lachance, Alexandre
   Bourgault, Serge
   Caissie, Mathieu
   Letartre, Laurence
   Tourville, Eric
   Dirani, Ali
TI DELAYED FOLLOW-UP IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION TREATED UNDER UNIVERSAL HEALTH COVERAGE Risk Factors and
   Visual Outcomes
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular age-related macular degeneration; delayed follow-up visit;
   risk factors; adherence
ID RANIBIZUMAB; ADHERENCE
AB Background/Purpose: To report the rate of delayed follow-up visits (DFU), to identify risk factors of DFU, and to assess the impact of DFU on outcomes in neovascular age-related macular degeneration. Methods: This retrospective study included all patients with neovascular age-related macular degeneration (n = 1,291) treated with antivascular endothelial growth factor injections between January 2013 and December 2020 in 2 centers in Quebec, Canada. A DFU was defined as a delay of >= 4 weeks than scheduled. Visual outcomes, especially >= 15 letters loss, were reported. Results: A total of 351 patients (27.2%) experienced >= 1 DFU. Odds were greater among older patients (P = 0.005), patients treated at the hospital rather than the clinic (P < 0.001), and patients with worse initial visual acuity (P = 0.024). A DFU was associated with a mean visual acuity loss of 4.2 +/- 13.4 letters (P < 0.001) and an increased incidence of intraretinal fluid and subretinal fluid (P = 0.001, P = 0.005) at 6 months despite resumption of injections. Central foveal thickness increased after DFU but returned to pre-DFU visit at 6 months. Conclusion: The DFU rate in patients with neovascular age-related macular degeneration treated under a universal health care system was around 27%. Delayed follow-up visits caused significant decreases in visual acuity and increases in intraretinal fluid and subretinal fluid on optical coherence tomography that did not recover after injections resumption despite normalization of central foveal thickness.
C1 [Rozon, Jean-Philippe; Lachance, Alexandre] Univ Laval, Fac Med, Quebec City, PQ, Canada.
   [Rozon, Jean-Philippe; Hebert, Melanie; Lachance, Alexandre; Bourgault, Serge; Caissie, Mathieu; Letartre, Laurence; Tourville, Eric; Dirani, Ali] Univ Laval, Ctr Univ Ophtalmol, Dept Ophthalmol, CHU Quebec, Quebec City, PQ, Canada.
   [Laverdiere, Carolane] Univ Laval, Fac Pharm, Quebec City, PQ, Canada.
C3 Laval University; Laval University; Laval University
RP Dirani, A (通讯作者)，Hop St Sacrement, Dept Ophthalmol, 1050 Ste Foy St, Quebec City, PQ, Canada.
EM drdirani@gmail.com
FU CHU de Quebec-Universite Laval Research Center; Caisse Desjardins,
   Canada
FX Supported by a grant from the CHU de Quebec-Universite Laval Research
   Center and the Caisse Desjardins, Canada (2020). These supporting
   organizations had no role in the design or conduct of the research.
CR Angermann R, 2019, GRAEF ARCH CLIN EXP, V257, P2119, DOI 10.1007/s00417-019-04414-y
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Nguyen CL, 2019, OPHTHALMOLOGY, V126, P735, DOI 10.1016/j.ophtha.2018.11.036
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Ehlken C, 2018, CLIN OPHTHALMOL, V12, P11, DOI 10.2147/OPTH.S151611
   Gamache P., 2019, LINDICE D FAVORISATI
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Institut national de sante publique du Quebec, 2021, IND DEF MAT SOC
   Keisler-Starkey K., 2020, HLTH INSURANCE COVER
   Kim JH, 2017, RETINA-J RET VIT DIS, V37, P2254, DOI 10.1097/IAE.0000000000001494
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mehrotra A., 2020, COMMONWEALTH FUND, DOI DOI 10.26099/2V5T-9Y63
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Patel S, 2020, JAMA OPHTHALMOL, V138, P242, DOI 10.1001/jamaophthalmol.2019.4644
   Ramakrishnan MS, 2020, JAMA OPHTHALMOL, V138, P237, DOI 10.1001/jamaophthalmol.2019.4577
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Salive ME, 2013, EPIDEMIOL REV, V35, P75, DOI 10.1093/epirev/mxs009
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Soares RR, 2020, OPHTHALMOL RETINA, V4, P134, DOI 10.1016/j.oret.2019.07.010
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Westborg I, 2017, RETINA-J RET VIT DIS, V37, P2035, DOI 10.1097/IAE.0000000000001431
NR 29
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2022
VL 42
IS 9
BP 1693
EP 1701
DI 10.1097/IAE.0000000000003512
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3W9IM
UT WOS:000842662100010
PM 35504012
DA 2022-11-30
ER

PT J
AU Fletcher, AE
   Bentham, GC
   Agnew, M
   Young, IS
   Augood, C
   Chakravarthy, U
   de Jong, PTVM
   Rahu, M
   Seland, J
   Soubrane, G
   Tomazzoli, L
   Topouzis, F
   Vingerling, JR
   Vioque, J
AF Fletcher, Astrid E.
   Bentham, Graham C.
   Agnew, Maureen
   Young, Ian S.
   Augood, Cristina
   Chakravarthy, Usha
   de Jong, Paulus T. V. M.
   Rahu, Mati
   Seland, Johan
   Soubrane, Gisele
   Tomazzoli, Laura
   Topouzis, Fotis
   Vingerling, Johannes R.
   Vioque, Jesus
TI Sunlight exposure, antioxidants, and age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID SUN EXPOSURE; RISK-FACTORS; ASCORBIC-ACID; MACULOPATHY; LIGHT;
   PREVALENCE; PROTECTION; TRANSMISSION; ZEAXANTHIN; EYE
AB Objective: To examine the association of sunlight exposure and antioxidant level with age-related macular degeneration (AMD).
   Methods: Four thousand seven hundred fifty-three participants aged 65 years or older in the European Eye Study underwent fundus photography, were interviewed For adult lifetime sunlight exposure, and gave blood for antioxidant analysis, Blue light exposure was estimated by combining meteorologic and questionnaire data.
   Results: Data on sunlight exposure and antioxidants were available in 101 individuals with neovascular AMD, 2182 with early AMD, and 2117 controls. No association was found between blue light exposure and neovascular or early AMD. Significant associations were found between blue light exposure and neovascular AMD in individuals in the quartile of lowest antioxidant level-vitamin C. zeaxanthin, vitamin E, and dietary zinc-with an odds ratio of about 1.4 for 1 standard deviation unit increase in blue light exposure. Higher odds ratios for blue light were observed with combined low antioxidant levels, especially vitamin C, zeaxanthin, and vitamin E (odds ratio, 3.7; 95% confidence interval, 1.6-8.9), which were also associated with early stages of AMD.
   Conclusions: Although it is not possible to establish causality between Sunlight exposure and neovascular AM D, Our results suggest that people in the general population Should Use Ocular protection and follow dietary recommendations for the key antioxidant nutrient.
C1 [Young, Ian S.] Queens Univ Belfast, Ctr Clin & Populat Sci, Belfast, Antrim, North Ireland.
   [Chakravarthy, Usha] Queens Univ Belfast, Dept Ophthalmol, Belfast, Antrim, North Ireland.
   [de Jong, Paulus T. V. M.] Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   [Rahu, Mati] Natl Inst Hlth Dev, Dept Epidemiol & Biostat, Tallinn, Estonia.
   [Seland, Johan] Univ Bergen, Haukeland Sykehus, Bergen, Norway.
   [Soubrane, Gisele] Univ Paris 12, Clin Ophthalmol, Paris, France.
   [Tomazzoli, Laura] Univ Verona, Clin Oculist, Verona, Italy.
   [Topouzis, Fotis] Aristotle Univ Thessaloniki, Sch Med, Dept Ophthalmol, GR-54006 Thessaloniki, Greece.
   [Vingerling, Johannes R.] Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   [Vingerling, Johannes R.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Vioque, Jesus] Univ Miguel Hernandez, Dept Salud Publ, Alicante, Spain.
   [Vioque, Jesus] Ctr Invest Biomed Red Epidemiol & Salud Publ, Barcelona, Spain.
   [Fletcher, Astrid E.; Augood, Cristina] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
   [Bentham, Graham C.; Agnew, Maureen] Univ E Anglia, Ctr Environm Risk, Norwich NR4 7TJ, Norfolk, England.
C3 Queens University Belfast; Queens University Belfast; Royal Netherlands
   Academy of Arts & Sciences; Netherlands Institute for Neuroscience
   (NIN-KNAW); University of Amsterdam; Academic Medical Center Amsterdam;
   Erasmus University Rotterdam; Erasmus MC; National Institute for Health
   Development - Estonia; University of Bergen; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); University of Verona; Aristotle
   University of Thessaloniki; Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; Universidad Miguel Hernandez
   de Elche; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP;
   University of London; London School of Hygiene & Tropical Medicine;
   University of East Anglia
RP Fletcher, AE (通讯作者)，London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
EM astrid.fletcher@lshtm.ac.uk
RI Vioque, Jesus/A-1066-2008; Rahu, Mati/A-9981-2008
OI Vioque, Jesus/0000-0002-2284-148X; Chakravarthy,
   Usha/0000-0002-2606-3734; Topouzis, Fotis/0000-0002-8966-537X; Young,
   Ian/0000-0003-3890-3152
FU European Commission V<SUP>th</SUP> Framework [QLK6-CT-1999-02094];
   Macular Disease Society; Estonian Ministry of Education and Science
   [01921112s02]; Spanish Ministry of Health [FIS 01/1692E, RCESP C03/09];
   Centro de Investigacion Biomedica en Red de Epidemiologia y Salud
   Publica; Generalitat Valenciana [CTGCA/2002/06, G03/1-36]; Economic and
   Social Research Council [ES/G007438/1] Funding Source: researchfish;
   ESRC [ES/G007438/1] Funding Source: UKRI
FX The EUREYE Study was supported by grant QLK6-CT-1999-02094 from the
   European Commission V<SUP>th</SUP> Framework. Additional funding for
   cameras was provided by the Macular Disease Society. Dr Rahu was
   supported by grant 01921112s02 from the Estonian Ministry of Education
   and Science. The Alicante site was supported by grants FIS 01/1692E and
   RCESP C03/09 from the Spanish Ministry of Health; by Centro de
   Investigacion Biomedica en Red de Epidemiologia y Salud Publica; and by
   grants CTGCA/2002/06 and G03/1-36 from the Generalitat Valenciana.
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   BINGHAM M, 2001, VALUE HEALTH, V4, P1
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brubacher D, 2000, INT J VITAM NUTR RES, V70, P226, DOI 10.1024/0300-9831.70.5.226
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Davies NP, 2004, PROG RETIN EYE RES, V23, P533, DOI 10.1016/j.preteyeres.2004.05.004
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DIFFEY BL, 1993, EPIDEMIOLOGICAL ASPE, P81
   Dillon J, 2004, EXP EYE RES, V79, P753, DOI 10.1016/j.exer.2004.06.025
   FEISTER U, 1995, PHOTOCHEM PHOTOBIOL, V62, P736, DOI 10.1111/j.1751-1097.1995.tb08723.x
   FREDERICK JE, 1995, J APPL METEOROL, V34, P2755, DOI 10.1175/1520-0450(1995)034<2755:TTOSTC>2.0.CO;2
   Gies PH, 1998, MUTAT RES-FUND MOL M, V422, P15, DOI 10.1016/S0027-5107(98)00181-X
   Holick MF, 2006, MAYO CLIN PROC, V81, P353, DOI 10.4065/81.3.353
   Holland B., 1991, MCCANCE WIDDOWSONS C, V5
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Kricker A, 2007, CANCER CAUSE CONTROL, V18, P295, DOI 10.1007/s10552-006-0091-x
   Lykkesfeldt J, 1997, AM J CLIN NUTR, V65, P959, DOI 10.1093/ajcn/65.4.959
   MADRONICH S, 1997, NATO ASI SER, V52, P23
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Meyers Sanford M, 2004, Trans Am Ophthalmol Soc, V102, P83
   Otten JJ., 2006, DIETARY REFERENCE IN
   ROSENTHAL FS, 1988, INVEST OPHTH VIS SCI, V29, P649
   ROSENTHAL FS, 1986, AM J PUBLIC HEALTH, V76, P1216, DOI 10.2105/AJPH.76.10.1216
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Vajdic CM, 2002, INT J CANCER, V101, P175, DOI 10.1002/ijc.10579
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   West SK, 1998, JAMA-J AM MED ASSOC, V280, P714, DOI 10.1001/jama.280.8.714
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
   Winkler BS, 1999, MOL VIS, V5
   Wrona M, 2004, FREE RADICAL BIO MED, V36, P1094, DOI 10.1016/j.freeradbiomed.2004.02.005
   Wrona M, 2003, FREE RADICAL BIO MED, V35, P1319, DOI 10.1016/j.freeradbiomed.2003.07.005
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 43
TC 146
Z9 151
U1 2
U2 34
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD OCT
PY 2008
VL 126
IS 10
BP 1396
EP 1403
DI 10.1001/archopht.126.10.1396
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 358EU
UT WOS:000259900700009
PM 18852418
DA 2022-11-30
ER

PT J
AU Chen, GH
   Li, WS
   Tzekov, R
   Jiang, FZ
   Mao, SH
   Tong, YH
AF Chen, Guohai
   Li, Wensheng
   Tzekov, Radouil
   Jiang, Fangzheng
   Mao, Sihong
   Tong, Yuhua
TI BEVACIZUMAB VERSUS RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION A Meta-analysis of Randomized Controlled Trials
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizumab; ranibizumab;
   meta-analysis
ID ENDOTHELIAL GROWTH-FACTOR; ANGIOGENESIS; CANCER; BIAS; VEGF
AB Purpose: To evaluate the relative efficacy and safety of bevacizumab versus ranibizumab for the treatment of the neovascular form of age-related macular degeneration.
   Methods: A comprehensive literature search using the Cochrane Methodology Register to identify randomized controlled trials comparing bevacizumab with ranibizumab in patients with neovascular age-related macular degeneration. Efficacy estimates were determined by comparing weighted mean differences in the change of best-corrected visual acuity and central macular thickness from baseline. Safety estimates were determined by calculating the risk ratio for rates of death, arteriothrombotic events, venous thrombotic events, and at least 1 serious systemic adverse event. Statistical analysis was performed using the RevMan 5.1 software.
   Results: A total of 6 randomized controlled trials were selected for this meta-analysis, including 2,612 patients (1,292 patients in the bevacizumab group and 1,320 patients in the ranibizumab group). There were no significant differences between bevacizumab and ranibizumab in best-corrected visual acuity mean change at 1 year or 2 years (weighted mean difference = -0.40, 95% confidence interval [CI], -1.48 to 0.69, P = 0.47 and weighted mean difference = -1.16, 95% CI, -2.82 to 0.51, P = 0.17, respectively). Ranibizumab was found to be more efficacious in reducing central macular thickness at 1 year (weighted mean difference = 4.35, 95% CI, 0.92-7.78, P = 0.01). The pooled risk ratios comparing the rates of serious systemic adverse events at 1 year and 2 years were slightly in favor of ranibizumab (risk ratio = 1.24, 95% CI, 1.04-1.48, P = 0.02 and risk ratio = 1.20, 95% CI, 1.05-1.37, P = 0.008, respectively), whereas the rates of death, arteriothrombotic events, and venous thrombotic events did not differ statistically.
   Conclusion: Bevacizumab and ranibizumab had equivalent efficacy for best-corrected visual acuity in the treatment of neovascular age-related macular degeneration. Ranibizumab tended to have a better anatomical outcome. There were no differences between drugs in rates of death, arteriothrombotic events or venous thrombotic events, and differences in rates of serious systemic adverse events that require further study.
C1 [Chen, Guohai; Jiang, Fangzheng; Mao, Sihong; Tong, Yuhua] Quzhou Peoples Hosp, Dept Ophthalmol, Quzhou, Peoples R China.
   [Li, Wensheng] Xiamen Univ, Xiamen Eye Ctr, Xiamen 361000, Peoples R China.
   [Tzekov, Radouil] Roskamp Inst, Sarasota, FL USA.
   [Tzekov, Radouil] Univ S Florida, Dept Ophthalmol, Tampa, FL USA.
C3 Xiamen University; State University System of Florida; University of
   South Florida
RP Li, WS (通讯作者)，Xiamen Univ, Xiamen Eye Ctr, Xiamen 361000, Peoples R China.
EM drlws@vip.tom.com
OI Tzekov, Radouil/0000-0002-3662-9818
CR Beaumont P, 2011, CLIN EXPT OPHTHALMOL, V39, P588
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
NR 27
TC 29
Z9 31
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2015
VL 35
IS 2
BP 187
EP 193
DI 10.1097/IAE.0000000000000301
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CA2UU
UT WOS:000348764200005
PM 25105318
DA 2022-11-30
ER

PT J
AU Souied, EH
   Aslam, T
   Garcia-Layana, A
   Holz, FG
   Leys, A
   Silva, R
   Delcourt, C
AF Souied, Eric H.
   Aslam, Tariq
   Garcia-Layana, Alfredo
   Holz, Frank G.
   Leys, Anita
   Silva, Rufino
   Delcourt, Cecile
TI Omega-3 Fatty Acids and Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE Macular degeneration; Epidemiology; Clinical trial; Fatty acids
ID DIETARY FATTY-ACIDS; FISH INTAKE; RISK; PROGRESSION; MACULOPATHY;
   ASSOCIATION; CONSUMPTION; HEALTH
AB Against a background of considerable epidemiological and other evidence implicating omega-3 fatty acids in the prevention of age-related macular degeneration (AMD), the negative results of the Age-Related Disease Study 2 (AREDS2) were unexpected. The possibility that the design, setting, intake or subjects of AREDS2 may not have permitted the prophylactic potential of omega-3 to be adequately demonstrated is considered. Epidemiological studies had indicated potential preventative effects of omega-3, and an earlier randomised prospective study (NAT2) showed that patients who achieved high red blood cell membrane EPA/DHA (eicosapentaenoic acid/docosahexaenoic acid) levels were significantly protected against AMD compared with those with permanently low EPA/DHA levels. Various methodological differences between these studies are considered. NAT2 included a true placebo group, whereas control subjects in AREDS2 received a nutritional formula already found to be effective in AREDS1, but no placebo for DHA/EPA supplementation. Differences in the handling of non-compliant subjects and the formulation of the test formulations are considered. Given these considerations, and other lines of evidence from laboratory and clinical studies, closing the chapter on omega-3 in AMD prevention may be premature. (c) 2015 S. Karger AG, Basel
C1 [Aslam, Tariq] Univ Manchester, Fac Med & Human Sci, Manchester, Lancs, England.
   [Aslam, Tariq] Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
   [Aslam, Tariq] Heriot Watt Univ, Edinburgh, Midlothian, Scotland.
   [Garcia-Layana, Alfredo] Univ Navarra Clin, Pamplona, Spain.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Leys, Anita] Univ Hosp Leuven, Dept Ophthalmol, Leuven, Belgium.
   [Silva, Rufino] CHUC, Dept Ophthalmol, Coimbra, Portugal.
   [Silva, Rufino] Univ Coimbra FMUC, Fac Med, Coimbra, Portugal.
   [Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Souied, Eric H.] Univ Paris Est, Hop Intercommunal Creteil, Creteil, France.
   [Delcourt, Cecile] Univ Bordeaux, ISPED, FR-33076 Bordeaux, France.
   [Delcourt, Cecile] Ctr Inserm U897 Epidemiol Biostat, INSERM, Bordeaux, France.
C3 University of Manchester; University of Manchester; Wythenshawe Hospital
   NHS Foundation Trust; Heriot Watt University; University of Navarra;
   University of Bonn; KU Leuven; University Hospital Leuven; Universidade
   de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; UDICE-French
   Research Universities; Universite de Bordeaux; Institut National de la
   Sante et de la Recherche Medicale (Inserm)
RP Delcourt, C (通讯作者)，Univ Bordeaux, ISPED, INSERM, U897, 146 Rue Leo Saignat, FR-33076 Bordeaux, France.
EM cecile.delcourt@isped.fr
RI Silva, Rufino M/J-2817-2012; Delcourt, Cecile/I-2627-2013; Aslam,
   Tariq/A-8532-2016
OI Silva, Rufino M/0000-0001-8676-0833; Delcourt,
   Cecile/0000-0002-2099-0481; Aslam, Tariq/0000-0002-9739-7280
CR Agaku Israel, 2012, Morbidity and Mortality Weekly Report, V61, P889
   Arab L, 2003, J NUTR, V133, p925S, DOI 10.1093/jn/133.3.925S
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Dyerberg J, 2010, PROSTAG LEUKOTR ESS, V83, P137, DOI 10.1016/j.plefa.2010.06.007
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Querques G, 2009, EUR J OPHTHALMOL, V19, P100, DOI 10.1177/112067210901900115
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Sackett Catherine Stewart, 2002, Insight, V27, P5
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
NR 31
TC 35
Z9 35
U1 0
U2 21
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2016
VL 55
IS 2
BP 62
EP 69
DI 10.1159/000441359
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA8SI
UT WOS:000368076000002
PM 26610051
OA Bronze
DA 2022-11-30
ER

PT J
AU Krebs, I
   Hagen, S
   Smretschnig, E
   Womastek, I
   Brannath, W
   Binder, S
AF Krebs, Ilse
   Hagen, Stefan
   Smretschnig, Eva
   Womastek, Irene
   Brannath, Werner
   Binder, Susanne
TI Reproducibility of segmentation error correction in age-related macular
   degeneration: Stratus versus Cirrus OCT
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL THICKNESS MEASUREMENTS;
   FLUORESCEIN ANGIOGRAPHY; RANIBIZUMAB
AB Introduction The accuracy of retinal thickness measurement in age-related macular degeneration by optical coherence tomography (OCT) is affected by threshold algorithm line errors. The reproducibility of error correction in Stratus and Cirrus OCT should be examined.
   Methods OCT examinations of a consecutive series of 104 patients with neovascular age-related macular degeneration included in another study were reviewed. 72 eyes exhibited failures in Stratus OCT and 32 eyes in Cirrus OCT and were included in this new study. Algorithm line failures of Stratus OCT (retinal thickness program) and Cirrus OCT (Macular Cube 5123128 program) were corrected independently twice by two ophthalmologists and two residents, respectively, using the Stratus and Cirrus OCT built-in software. Reproducibility was assessed by the interclass correlation coefficient (ICC).
   Results The corrected values of central retinal thickness were significantly lower than the automated measured values in Stratus OCT for all examiners (p<0.001), while in Cirrus OCT the differences were not significant (p = 0.06-0.09). For Stratus OCT, the ICC for central retinal thickness was 0.991 and 0.997 for the experienced ophthalmologists and 0.89 and 0.97 for the residents. For Cirrus OCT, the ICC was 1.0 and 1.0 for the experienced ophthalmologists and 0.99 and 0.95 for the residents.
   Conclusion The reproducibility of threshold algorithm line failure correction was good overall in Stratus and Cirrus OCT and can therefore be recommended to improve retinal thickness measurement, particularly when experienced examiners perform the corrections.
C1 [Krebs, Ilse; Hagen, Stefan; Binder, Susanne] Rudolf Fdn Clin, Dept Ophthalmol, A-1030 Vienna, Austria.
   [Krebs, Ilse; Hagen, Stefan; Smretschnig, Eva; Binder, Susanne] Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Vienna, Austria.
   [Womastek, Irene; Brannath, Werner] Med Univ, Core Unit Med Stat & Informat, Vienna, Austria.
C3 Ludwig Boltzmann Institute
RP Krebs, I (通讯作者)，Rudolf Fdn Clin, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM ilse.krebs@wienkav.at
CR Ahlers C, 2008, BRIT J OPHTHALMOL, V92, P197, DOI 10.1136/bjo.2007.120956
   Browning DJ, 2008, OPHTHALMOLOGY, V115, P1366, DOI 10.1016/j.ophtha.2007.12.004
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Friedman M, 1937, J AM STAT ASSOC, V32, P675, DOI 10.2307/2279372
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Krebs I, 2008, BRIT J OPHTHALMOL, V92, P933, DOI 10.1136/bjo.2007.128447
   Krebs I, 2008, GRAEF ARCH CLIN EXP, V246, P811, DOI 10.1007/s00417-007-0755-6
   Krebs I, 2009, INVEST OPHTH VIS SCI, V50, P995, DOI 10.1167/iovs.08-2617
   Malamos P, 2009, INVEST OPHTH VIS SCI, V50, P4926, DOI 10.1167/iovs.09-3610
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Tatlipinar S, 2007, OPHTHALMOLOGICA, V221, P227, DOI 10.1159/000101923
NR 17
TC 8
Z9 8
U1 0
U2 2
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2012
VL 96
IS 2
BP 271
EP 275
DI 10.1136/bjo.2010.194662
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 879GW
UT WOS:000299318700025
PM 21486740
DA 2022-11-30
ER

PT J
AU Sabbadini, RA
AF Sabbadini, Roger A.
TI Sphingosine-1-phosphate antibodies as potential agents in the treatment
   of cancer and age-related macular degeneration
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Review
DE Sphingosine-1-phosphate; S1P; cancer; age-related macular degeneration;
   wet AMD; antibody therapeutics; ocular disease; choroidal
   neovascularization; retinal pigmented epithelial cells
ID SPHINGOSINE KINASE 1; ENDOTHELIAL-CELL MIGRATION; PROTEIN-COUPLED
   RECEPTOR; TISSUE GROWTH-FACTOR; CROSS-TALK; CHOROIDAL
   NEOVASCULARIZATION; THERAPEUTIC TARGETS; CYTOKINE PRODUCTION; POOR
   SURVIVAL; TUMOR-GROWTH
AB Sphingosine-1-phosphate (S1P) is a pleiotropic bioactive lipid thought to be dysregulated in a variety of disease conditions. In this review, we discuss the roles of S1P in cancer and in wet age-related macular degeneration. We also explore potential treatment strategies for these disorders, including the utility of anti-S1P antibodies acting as molecular sponges to neutralize dysregulated S1P in relevant tissues.
C1 [Sabbadini, Roger A.] Lpath Inc, San Diego, CA 92121 USA.
   [Sabbadini, Roger A.] San Diego State Univ, Dept Biol, San Diego, CA 92182 USA.
C3 California State University System; San Diego State University
RP Sabbadini, RA (通讯作者)，Lpath Inc, 6335 Ferris Sq,Suite A, San Diego, CA 92121 USA.
EM rsabbadini@lpath.com
FU National Eye Institute (NEI) [R43EYO18020]; National Cancer Institute
   (NCI) [5R44CA110298]; NATIONAL CANCER INSTITUTE [R44CA110298] Funding
   Source: NIH RePORTER
FX This work was supported by Award Number R43EYO18020 from the National
   Eye Institute (NEI) and 5R44CA110298 from the National Cancer Institute
   (NCI). The content is solely the responsibility of the author and does
   not necessarily represent the official views of the NEI, NCI or the
   National Institutes of Health. The author has a potential conflict of
   interest associated with being a consultant for Lpath, Inc., having
   stock in Lpath and as an inventor on key patents that are held by Lpath.
   Appreciation goes to Sophie Chambers for the illustration in Figure 1.
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Ader I, 2008, CANCER RES, V68, P8635, DOI 10.1158/0008-5472.CAN-08-0917
   Agrawal RN, 2007, NAT PROTOC, V2, P67, DOI 10.1038/nprot.2007.4
   Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200
   Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200
   Alvarez SE, 2010, NATURE, V465, P1084, DOI 10.1038/nature09128
   An SZ, 1998, J CELL BIOCHEM, P147
   Anliker B, 2004, SEMIN CELL DEV BIOL, V15, P457, DOI 10.1016/j.semcdb.2004.05.005
   Argraves KM, 2004, J BIOL CHEM, V279, P50580, DOI 10.1074/jbc.M404432200
   Arikawa K, 2003, J BIOL CHEM, V278, P32841, DOI 10.1074/jbc.M305024200
   Bektas M, 2005, J CELL BIOL, V169, P801, DOI 10.1083/jcb.200407123
   Bektas M, 2005, ONCOGENE, V24, P178, DOI 10.1038/sj.onc.1208019
   Beljanski V, 2010, J PHARMACOL EXP THER, V333, P454, DOI 10.1124/jpet.109.163337
   Birgbauer E, 2006, CELL MOL LIFE SCI, V63, P2695, DOI 10.1007/s00018-006-6155-y
   Bode C, 2010, J CELL BIOCHEM, V109, P1232, DOI 10.1002/jcb.22507
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012
   Camerer E, 2009, J CLIN INVEST, V119, P1871, DOI 10.1172/JCI38575
   Chae SS, 2004, J CLIN INVEST, V114, P1082, DOI 10.1172/JCI200422716
   Clair T, 2003, CANCER RES, V63, P5446
   Colombaioni L, 2004, BRAIN RES REV, V46, P328, DOI 10.1016/j.brainresrev.2004.07.014
   Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0
   Cuvillier Olivier, 2010, Curr Mol Pharmacol, V3, P53
   Cyster JG, 2005, ANNU REV IMMUNOL, V23, P127, DOI 10.1146/annurev.immunol.23.021704.115628
   Facchinetti MM, 2010, CELLS TISSUES ORGANS, V192, P314, DOI 10.1159/000318173
   French KJ, 2006, J PHARMACOL EXP THER, V318, P596, DOI 10.1124/jpet.106.101345
   French KJ, 2003, CANCER RES, V63, P5962
   Fukuoka Y, 2001, CURR EYE RES, V23, P320, DOI 10.1076/ceyr.23.5.320.5437
   Fyrst H, 2010, NAT CHEM BIOL, V6, P489, DOI [10.1038/NCHEMBIO.392, 10.1038/nchembio.392]
   Gardell SE, 2006, TRENDS MOL MED, V12, P65, DOI 10.1016/j.molmed.2005.12.001
   Gellings Lowe N, 2009, CARDIOVASC RES, V82, P303, DOI 10.1093/cvr/cvp056
   Goetzl Edward J, 2002, ScientificWorldJournal, V2, P324
   Goparaju SK, 2005, MOL CELL BIOL, V25, P4237, DOI 10.1128/MCB.25.10.4237-4249.2005
   Gordon MS, 2010, J CLIN ONCOL, V28, p219s
   Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje
   Gude DR, 2008, FASEB J, V22, P2629, DOI 10.1096/fj.08-107169
   Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007
   Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   He XX, 2009, J CHROMATOGR B, V877, P983, DOI 10.1016/j.jchromb.2009.02.048
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hla T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI 10.1016/j.semcdb.2004.05.002
   Ho JWY, 2005, MOL CANCER THER, V4, P1430, DOI 10.1158/1535-7163.MCT-05-0021
   Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559
   Igarashi J, 2003, P NATL ACAD SCI USA, V100, P10664, DOI 10.1073/pnas.1934494100
   Im DS, 2009, PROSTAG OTH LIPID M, V89, P53, DOI 10.1016/j.prostaglandins.2009.01.002
   ISHIBASHI T, 1995, ARCH OPHTHALMOL-CHIC, V113, P227, DOI 10.1001/archopht.1995.01100020111041
   Johnson KR, 2005, J HISTOCHEM CYTOCHEM, V53, P1159, DOI 10.1369/jhc.4A6606.2005
   Kapitonov D, 2009, CANCER RES, V69, P6915, DOI 10.1158/0008-5472.CAN-09-0664
   Katsuma S, 2005, FEBS LETT, V579, P2576, DOI 10.1016/j.febslet.2005.03.073
   Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje
   Keller CD, 2007, AM J PATHOL, V170, P281, DOI 10.2353/ajpath.2007.060485
   LaMontagne K, 2006, CANCER RES, V66, P221, DOI 10.1158/0008-5472.CAN-05-2001
   Langlois S, 2004, BLOOD, V103, P3020, DOI 10.1182/blood-2003-08-2968
   Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X
   Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586
   Lepley D, 2005, CANCER RES, V65, P3788, DOI 10.1158/0008-5472.CAN-04-2311
   Li JY, 2008, J NEURO-ONCOL, V88, P11, DOI 10.1007/s11060-008-9529-1
   Li W, 2009, CLIN CANCER RES, V15, P1393, DOI 10.1158/1078-0432.CCR-08-1158
   Li X, 2008, BLOOD, V111, P3489, DOI 10.1182/blood-2007-05-092148
   Liu Q, 2008, BLOOD, V111, P275, DOI 10.1182/blood-2006-10-053884
   Long JS, 2010, MOL CELL BIOL, V30, P3827, DOI 10.1128/MCB.01133-09
   Lucas da Silva Lea Bueno, 2008, J Exp Ther Oncol, V7, P9
   Lucke S, 2010, CELL PHYSIOL BIOCHEM, V26, P87, DOI 10.1159/000315109
   Maceyka M, 2005, PROSTAG OTH LIPID M, V77, P15, DOI 10.1016/j.prostaglandins.2004.09.010
   Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4
   Maines LW, 2006, INVEST OPHTH VIS SCI, V47, P5022, DOI 10.1167/iovs.05-1236
   Melendez AJ, 2000, GENE, V251, P19, DOI 10.1016/S0378-1119(00)00205-5
   Melendez AJ, 2004, J IMMUNOL, V173, P1596, DOI 10.4049/jimmunol.173.3.1596
   Michaud J, 2010, J IMMUNOL, V184, P1475, DOI 10.4049/jimmunol.0901586
   Milstien S, 2006, CANCER CELL, V9, P148, DOI 10.1016/j.ccr.2006.02.025
   Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702
   Murata N, 2000, ANAL BIOCHEM, V282, P115, DOI 10.1006/abio.2000.4580
   Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809
   Neviani P, 2007, J CLIN INVEST, V117, P2408, DOI 10.1172/JCI31095
   O'Brien N, 2009, J LIPID RES, V50, P2245, DOI 10.1194/jlr.M900048-JLR200
   Olivera A, 2005, J IMMUNOL, V174, P1153, DOI 10.4049/jimmunol.174.3.1153
   Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545
   Paik JH, 2004, GENE DEV, V18, P2392, DOI 10.1101/gad.1227804
   Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200
   Paugh SW, 2008, BLOOD, V112, P1382, DOI 10.1182/blood-2008-02-138958
   Pchejetski D, 2008, MOL CANCER THER, V7, P1836, DOI 10.1158/1535-7163.MCT-07-2322
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Puneet P, 2010, SCIENCE, V328, P1290, DOI 10.1126/science.1188635
   Pushparaj PN, 2008, INT J BIOCHEM CELL B, V40, P1817, DOI 10.1016/j.biocel.2008.01.015
   Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875
   Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094
   Raguz S, 2008, BRIT J CANCER, V99, P387, DOI 10.1038/sj.bjc.6604510
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Ruckhaberle E, 2008, BREAST CANCER RES TR, V112, P41, DOI 10.1007/s10549-007-9836-9
   Sabbadini RA, 2006, BRIT J CANCER, V95, P1131, DOI 10.1038/sj.bjc.6603400
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200
   Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127
   Schmid G, 2005, TRANSPL P, V37, P110, DOI 10.1016/j.transproceed.2004.12.278
   Shida D, 2008, CANCER RES, V68, P6569, DOI 10.1158/0008-5472.CAN-08-0411
   Shida D, 2008, CURR DRUG TARGETS, V9, P662, DOI 10.2174/138945008785132402
   Skoura A, 2007, J CLIN INVEST, V117, P2506, DOI 10.1172/JCI31123
   Skoura A, 2009, CARDIOVASC RES, V82, P221, DOI 10.1093/cvr/cvp088
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   Stamer WD, 2009, EXP EYE RES, V89, P980, DOI 10.1016/j.exer.2009.08.008
   Stoller G, 2010, INVEST OPHTH VIS SCI, V51
   Swaney JS, 2008, EXP EYE RES, V87, P367, DOI 10.1016/j.exer.2008.07.005
   Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113
   Takuwa N, 2010, CARDIOVASC RES, V85, P484, DOI 10.1093/cvr/cvp312
   Takuwa Y, 2002, BBA-MOL CELL BIOL L, V1582, P112, DOI 10.1016/S1388-1981(02)00145-2
   Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200
   Teicher BA, 2011, BIOCHEM PHARMACOL, V81, P6, DOI 10.1016/j.bcp.2010.09.023
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Van Brocklyn JR, 2005, J NEUROPATH EXP NEUR, V64, P695, DOI 10.1097/01.jnen.0000175329.59092.2c
   Vinores SA, 2000, GEN PHARMACOL-VASC S, V35, P233, DOI 10.1016/S0306-3623(01)00117-3
   Visentin B, 2006, CANCER CELL, V9, P225, DOI 10.1016/j.ccr.2006.02.023
   Vlasenko LP, 2005, J IMMUNOL, V174, P6456, DOI 10.4049/jimmunol.174.10.6456
   Weigert A, 2009, IMMUNOBIOLOGY, V214, P748, DOI 10.1016/j.imbio.2009.06.003
   Wojciak JM, 2009, P NATL ACAD SCI USA, V106, P17717, DOI 10.1073/pnas.0906153106
   Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
   Xin CY, 2004, J BIOL CHEM, V279, P35255, DOI 10.1074/jbc.M312091200
   Yamagishi S, 2005, INT J TISSUE REACT, V27, P125
   Yamanaka M, 2004, J BIOL CHEM, V279, P53994, DOI 10.1074/jbc.M410144200
   Yasui KJ, 1996, AM J PHYSIOL-CELL PH, V270, pC645, DOI 10.1152/ajpcell.1996.270.2.C645
   Yatomi Y, 2000, BLOOD, V96, P3431
   Yatomi Y, 2006, CURR PHARM DESIGN, V12, P575, DOI 10.2174/138161206775474404
   Zhu DH, 2010, VISION RES, V50, P643, DOI 10.1016/j.visres.2009.09.002
NR 124
TC 59
Z9 63
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD MAR
PY 2011
VL 162
IS 6
BP 1225
EP 1238
DI 10.1111/j.1476-5381.2010.01118.x
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 724NL
UT WOS:000287583200001
PM 21091645
OA Green Published
DA 2022-11-30
ER

PT J
AU Blasiak, J
AF Blasiak, Janusz
TI Senescence in the pathogenesis of age-related macular degeneration
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Age-related macular degeneration (AMD); Senescence; Stress-induced
   premature senescence; Oxidative stress; Inflammaging; A2E; Amyloid-beta;
   DNA damage
ID RETINAL-PIGMENT EPITHELIUM; RPE CELL SENESCENCE; CYCLIC GMP-AMP;
   OXIDATIVE STRESS; AMYLOID-BETA; DNA-DAMAGE; SECRETORY PHENOTYPE; BRUCHS
   MEMBRANE; ENDOGENOUS 2ND-MESSENGER; POTENTIAL ROLE
AB Age-related macular degeneration (AMD) is a complex eye disease underlined by the death of photoreceptors and degeneration of retinal pigment epithelium (RPE) and choriocapillaris (CC). The mechanism(s) responsible for massive and progressive retinal degeneration is not completely known. Senescence, a state of permanent inhibition of cell growth, may be induced by many factors important for AMD pathogenesis and results in senescence-associated secretory phenotype (SASP) that releases growth factors, cytokines, chemokines, proteases and other molecules inducing inflammation and other AMD-related effects. These effects can be induced in the affected cell and neighboring cells, leading to progression of AMD phenotype. Senescent cells also release reactive oxygen species that increase SASP propagation. Many other pathways of senescence-related AMD pathogenesis, including autophagy, the cGAS-STING signaling, degeneration of CC by membrane attack complex, can be considered. A2E, a fluorophore present in lipofuscin, amyloid-beta peptide and humanin, a mitochondria-derived peptide, may link AMD with senescence. Further studies on senescence in AMD pathogenesis to check the possibility of opening a perspective of the use of drugs killing senescent cells (senolytics) and terminating SASP bystander effects (senostatics) might be beneficial for AMD that at present is an incurable disease.
C1 [Blasiak, Janusz] Univ Lodz, Dept Mol Genet, Fac Biol & Environm Protect, Pomorska 141-143, Lodz, Poland.
C3 University of Lodz
RP Blasiak, J (通讯作者)，Univ Lodz, Dept Mol Genet, Fac Biol & Environm Protect, Pomorska 141-143, Lodz, Poland.
EM janusz.blasiak@biol.uni.lodz.pl
OI Blasiak, Janusz/0000-0001-9539-9584
FU National Science Centre, Poland [2017/27/B/NZ3/00872]
FX The author thanks Ms. Monika Kicinska for help in figures preparation.
   This work was supported by National Science Centre, Poland grant number
   2017/27/B/NZ3/00872.
CR Akiguchi I, 2017, NEUROPATHOLOGY, V37, P293, DOI 10.1111/neup.12373
   Alaimo A, 2019, ARCH TOXICOL, V93, P1401, DOI 10.1007/s00204-019-02409-6
   Arend N, 2015, OPHTHALMOLOGICA, V234, P73, DOI 10.1159/000381726
   Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600
   Barber GN, 2015, NAT REV IMMUNOL, V15, P760, DOI 10.1038/nri3921
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1551, DOI 10.2741/3804
   Bodzioch M, 2009, GENOMICS, V94, P247, DOI 10.1016/j.ygeno.2009.05.006
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   BURKE JM, 1988, INVEST OPHTH VIS SCI, V29, P1784
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Campisi J, 2014, INTERD T GERONT GERI, V39, P45, DOI 10.1159/000358899
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Cao SJ, 2013, MOL VIS, V19, P718
   Chae SY, 2018, MOL MED REP, V18, P5182, DOI 10.3892/mmr.2018.9538
   Chaum E, 2015, MAMM GENOME, V26, P210, DOI 10.1007/s00335-015-9568-9
   Childs BG, 2014, EMBO REP, V15, P1139, DOI 10.15252/embr.201439245
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   Cobb LJ, 2016, AGING-US, V8, P796, DOI 10.18632/aging.100943
   Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002
   Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144
   Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Di Guardo G, 2015, EUR J HISTOCHEM, V59, P72, DOI 10.4081/ejh.2015.2485
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Dvashi Z, 2014, INVEST OPHTH VIS SCI, V55, P5679, DOI 10.1167/iovs.14-14349
   Eymann J, 2019, J COMP NEUROL, V527, P2356, DOI 10.1002/cne.24677
   Feng L, 2019, DISCOV MED, V27, P153
   Feng L, 2016, DISCOV MED, V21, P149
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Garcia-Castineiras S, 2010, EXP EYE RES, V90, P664, DOI 10.1016/j.exer.2010.03.003
   Gluck S, 2017, NAT CELL BIOL, V19, P1061, DOI 10.1038/ncb3586
   Gong ZW, 2018, J CELL BIOL, V217, P635, DOI 10.1083/jcb.201606095
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Haag SM, 2018, NATURE, V559, P269, DOI 10.1038/s41586-018-0287-8
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498
   HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9
   Heinrichs A, 2012, NAT STRUCT MOL BIOL, V19, P663, DOI [10.1038/nsmb.2342, DOI 10.1038/NSMB.2342]
   Herranz N, 2018, J CLIN INVEST, V128, P1238, DOI 10.1172/JCI95148
   Herranz N, 2015, NAT CELL BIOL, V17, P1370, DOI 10.1038/ncb3243
   Hohn A, 2010, FREE RADICAL BIO MED, V48, P1100, DOI 10.1016/j.freeradbiomed.2010.01.030
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hussain AA, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.100775
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Huy H, 2018, AGING CELL, V17, DOI 10.1111/acel.12836
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Jadeja RN, 2018, AGING-US, V10, P1306, DOI 10.18632/aging.101469
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jun JI, 2010, AGING-US, V2, P627, DOI 10.18632/aging.100201
   Jun JI, 2010, NAT CELL BIOL, V12, P676, DOI 10.1038/ncb2070
   Justice JN, 2019, EBIOMEDICINE, V40, P554, DOI 10.1016/j.ebiom.2018.12.052
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kampik Anselm, 2005, Retina, V25, P1445, DOI 10.1097/00006982-200507001-00010
   Kang C, 2016, AUTOPHAGY, V12, P898, DOI 10.1080/15548627.2015.1121361
   Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kato K, 2017, ANNU REV BIOCHEM, V86, P541, DOI 10.1146/annurev-biochem-061516-044813
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P359, DOI 10.1016/S0167-4943(02)00012-2
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Konig J, 2017, REDOX BIOL, V11, P673, DOI 10.1016/j.redox.2017.01.017
   Kozhevnikova OS, 2018, BIOGERONTOLOGY, V19, P223, DOI 10.1007/s10522-018-9751-y
   Kozlowski MR, 2015, J OCUL PHARMACOL TH, V31, P87, DOI 10.1089/jop.2014.0071
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049
   Laberge RM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.199
   Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195
   Lazzarini R, 2018, AGING-US, V10, P3173, DOI 10.18632/aging.101624
   Lee HC, 2002, J BIOMED SCI, V9, P517, DOI 10.1159/000064724
   Lee Y, 2015, INVEST OPHTH VIS SCI, V56, P8403, DOI 10.1167/iovs.15-16936
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Masuda N, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1076-3
   Matsunaga H, 1999, INVEST OPHTH VIS SCI, V40, P197
   Mazzitello KI, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.051908
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Minasyan L, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1675230
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mosieniak G, 2015, NEOPLASIA, V17, P882, DOI 10.1016/j.neo.2015.11.008
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Nelson G, 2012, AGING CELL, V11, P345, DOI 10.1111/j.1474-9726.2012.00795.x
   NEWSOME DA, 1981, ARCH OPHTHALMOL-CHIC, V99, P873, DOI 10.1001/archopht.1981.03930010873017
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Passos JF, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.5
   Pinto M, 2015, FREE RADICAL BIO MED, V85, P250, DOI 10.1016/j.freeradbiomed.2015.05.005
   Prieur A, 2008, CURR OPIN CELL BIOL, V20, P150, DOI 10.1016/j.ceb.2008.01.007
   Rabanal-Ruiz Y, 2017, ESSAYS BIOCHEM, V61, P565, DOI 10.1042/EBC20170027
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Rea IM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00586
   Ritschka B, 2017, GENE DEV, V31, P172, DOI 10.1101/gad.290635.116
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   Rodier F, 2011, J CELL SCI, V124, P68, DOI 10.1242/jcs.071340
   Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909
   Roggia MF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134870
   Rubsam LZ, 1998, CANCER RES, V58, P3873
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Short S, 2019, EBIOMEDICINE, V41, P683, DOI 10.1016/j.ebiom.2019.01.056
   Sikora E, 2016, CURR DRUG TARGETS, V17, P377, DOI 10.2174/1389450116666151019094724
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Stefanova NA, 2014, CELL CYCLE, V13, P898, DOI 10.4161/cc.28255
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458
   Sun Q, 2018, CURR MOL MED, V18, P575, DOI 10.2174/1566524019666190107154250
   Sun S, 2019, AGING-US, V11, P4323, DOI 10.18632/aging.102039
   Sun Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0794-4
   Tsao SW, 2018, OSLI RETINA, V49, pS23, DOI 10.3928/23258160-20180814-04
   Tsunemi T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003799
   Ugarte M, 2013, SURV OPHTHALMOL, V58, P585, DOI 10.1016/j.survophthal.2012.12.002
   van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193
   Vemuganti Geeta K., 2002, Indian Journal of Ophthalmology, V50, P183
   Wang J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0200-7
   Washington I, 2016, ADV EXP MED BIOL, V854, P347, DOI 10.1007/978-3-319-17121-0_46
   Wellinger RJ, 2014, MOL CELL, V53, P855, DOI 10.1016/j.molcel.2014.03.008
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Williams AB, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026070
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963
   Wu Y, 2019, CLIN INTERV AGING, V14, P1277, DOI 10.2147/CIA.S200637
   Yang H, 2017, P NATL ACAD SCI USA, V114, pE4612, DOI 10.1073/pnas.1705499114
   Ye Z, 2018, INT J OPHTHALMOL-CHI, V11, P929, DOI 10.18240/ijo.2018.06.06
   Yin YL, 2017, INT J BIOCHEM CELL B, V84, P22, DOI 10.1016/j.biocel.2017.01.001
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Zhang C, 2013, NUCLEIC ACIDS RES, V41, P7144, DOI 10.1093/nar/gkt443
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
NR 135
TC 63
Z9 63
U1 5
U2 23
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAR
PY 2020
VL 77
IS 5
BP 789
EP 805
DI 10.1007/s00018-019-03420-x
EA JAN 2020
PG 17
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA KS7QS
UT WOS:000505379200001
PM 31897543
DA 2022-11-30
ER

PT J
AU Shelley, EJ
   Madigan, MC
   Natoli, R
   Penfold, PL
   Provis, JM
AF Shelley, Elizabeth J.
   Madigan, Michele C.
   Natoli, Riccardo
   Penfold, Philip L.
   Provis, Jan M.
TI Cone Degeneration in Aging and Age-Related Macular Degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID HUMAN RETINA; MULTIFOCAL ELECTRORETINOGRAM; VISUAL FUNCTION; PRIMATE
   RETINA; CELL-TYPES; MACULOPATHY; PHOTORECEPTORS; SENSITIVITY;
   DYSFUNCTION; PROGRESSION
AB Objective: To examine the morphological features of macular photoreceptors in histologically normal retina from normal donor eyes and eyes with age-related macular degeneration (AMD).
   Methods: The macular region was excised from 18 donor eyes (aged 22-96 years) and cryosectioned. Sections were stained with hematoxylin-eosin or double immunolabeled using opsin antibodies or synaptic markers.
   Results: Three of 8 retinas studied in detail had AMD lesions; the remainder were histologically normal. Immunoreactivity to cone opsin was abnormal in parts of all retinas (3.5%-95.0% of each sample) and was associated with swelling of and altered immunoreactivity in the mainly in nonfoveal macular locations. The nature of the anomalies was identical in non-AMD retinas and in parts of AMD retinas adjacent to overt degeneration.
   Conclusion: Redistribution of opsin and anomalies in the distal cone axon are common in the aging human macula and may indicate susceptibility to AMD.
   Clinical Relevance: The findings are consistent with tests of cone function in aging and early AMD, which suggests that integrated cone functions-including contrast sensitivity, color matching, and short wavelength-sensitive cone sensitivity-are the most reliable prognostic indicators of progression in AMD.
C1 [Shelley, Elizabeth J.; Natoli, Riccardo; Penfold, Philip L.; Provis, Jan M.] Australian Natl Univ, Res Sch Biol Sci, Canberra, ACT 2601, Australia.
   [Provis, Jan M.] Australian Natl Univ, Sch Med, Canberra, ACT 2601, Australia.
   [Madigan, Michele C.] Univ Sydney, Save Sight Inst, Sydney, NSW 2006, Australia.
C3 Australian National University; Australian National University;
   University of Sydney
RP Provis, JM (通讯作者)，Australian Natl Univ, Res Sch Biol Sci, GPO Box 475, Canberra, ACT 2601, Australia.
EM Jan.Provis@anu.edu.au
RI Provis, Jan/C-9529-2009
OI Provis, Jan/0000-0002-6405-2868; Natoli, Riccardo/0000-0002-9350-0439
FU Australian Research Council Centres of Excellence program; National
   Institute of Child Health and Development; Department of Biological
   Sciences at The University of Iowa
FX This study was supported by the Australian Research Council Centres of
   Excellence program. The antibody to SV2 was obtained from the
   Developmental Studies Hybridoma Bank under the auspices of the National
   Institute of Child Health and Development and maintained by the
   Department of Biological Sciences at The University of Iowa.
CR Abadi RV, 1996, OPHTHAL PHYSL OPT, V16, P455, DOI 10.1046/j.1475-1313.1996.96000129.x
   APPLEGATE RA, 1987, APPL OPTICS, V26, P1458, DOI 10.1364/AO.26.001458
   Arden GB, 2004, BRIT J OPHTHALMOL, V88, P1180, DOI 10.1136/bjo.2003.033480
   BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659
   Bonilha Vera L, 2005, Ophthalmic Genet, V26, P69, DOI 10.1080/13816810590968041
   Brown B, 1987, CLIN EXP OPTOM, V70, P145
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Curcio CA, 2000, OPHTHALMOLOGY, V107, P334, DOI 10.1016/S0161-6420(99)00037-8
   DACEY DM, 1994, CIBA F SYMP, V184, P12
   Dacey DM, 1999, PROG RETIN EYE RES, V18, P737, DOI 10.1016/S1350-9462(98)00013-5
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Eliasieh K, 2007, INVEST OPHTH VIS SCI, V48, P2824, DOI 10.1167/iovs.06-1228
   Ethen CM, 2005, INVEST OPHTH VIS SCI, V46, P769, DOI 10.1167/iovs.04-0810
   GARTNER S, 1981, BRIT J OPHTHALMOL, V65, P23, DOI 10.1136/bjo.65.1.23
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gong J, 2006, BRAIN RES, V1082, P73, DOI 10.1016/j.brainres.2006.01.111
   GREGORY CY, 1995, BRIT J OPHTHALMOL, V79, P186, DOI 10.1136/bjo.79.2.186
   Gregory-Evans K, 1998, OPHTHALMOLOGY, V105, P2306, DOI 10.1016/S0161-6420(98)91233-7
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   Jackson GR, 2005, MACULAR DEGENERATION, P45, DOI 10.1007/3-540-26977-0_3
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   John SK, 2000, MOL VIS, V6, P204
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Leveillard T, 2004, NAT GENET, V36, P755, DOI 10.1038/ng1386
   MARTIN PR, 1992, J COMP NEUROL, V323, P269, DOI 10.1002/cne.903230210
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   Mohand-Said S, 1998, P NATL ACAD SCI USA, V95, P8357, DOI 10.1073/pnas.95.14.8357
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Pow DV, 2007, EXP EYE RES, V84, P850, DOI 10.1016/j.exer.2007.01.005
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   Rex TS, 2002, INVEST OPHTH VIS SCI, V43, P1234
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SMITH VC, 1988, J OPT SOC AM A, V5, P2113, DOI 10.1364/JOSAA.5.002113
   Stone J, 1999, PROG RETIN EYE RES, V18, P689, DOI 10.1016/S1350-9462(98)00032-9
   Sullivan RKP, 2007, INVEST OPHTH VIS SCI, V48, P2782, DOI 10.1167/iovs.06-1283
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
NR 45
TC 61
Z9 63
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2009
VL 127
IS 4
BP 483
EP 492
DI 10.1001/archophthalmol.2008.622
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 431ZN
UT WOS:000265103400019
PM 19365029
OA Bronze
DA 2022-11-30
ER

PT J
AU Phipps, JA
   Dang, TM
   Vingrys, AJ
   Guymer, RH
AF Phipps, JA
   Dang, TM
   Vingrys, AJ
   Guymer, RH
TI Flicker perimetry losses in age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID VISUAL-FIELD; CONTRAST SENSITIVITY; FUNDUS APPEARANCE; FULL THRESHOLD;
   ROD CONE; MACULOPATHY; EYES; ADAPTATION; LUMINANCE; SYSTEM
AB PURPOSE. To compare static and flicker perimetry outcomes in patients with early age-related macular degeneration (AMD).
   METHODS. Perimetry was performed in the central visual field of one eye of each of 25 patients with good visual acuity ( > 6/12) and early AMD using static and flickering targets. These results were compared with data obtained from a single eye of 34 age-matched control subjects, 33 of whom were retested at 1 to 3 months after their initial visits.
   RESULTS. In all cases, patients with early AMD had greater mean defects for flickering than static targets, returning a significantly larger group average in response to flicker (4.3 +/- 0.6 dB) than to static ( 1.8 +/- 0.6 dB; P <0.005). Greater pattern defect losses were also present in AMD-affected eyes with flicker compared with static perimetry ( P < 0.02). These give a higher diagnostic sensitivity for flicker (68% vs. 42%, P < 0.05) at 90% specificity. Sensitivity can be increased to 84% +/- 6% ( specificity 92% +/- 4%) if the criterion for failure is a more than 10-dB loss in the foveal region (1 degrees- 3 degrees).
   CONCLUSIONS. Flickering targets expose foveal deficits in early AMD better than do static targets. Flicker perimetry is an easy, short procedure that may be useful for monitoring the progression of AMD.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3052, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Melbourne
RP Guymer, RH (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St E, Melbourne, Vic 3002, Australia.
EM rhg@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356; Vingrys, Algis/0000-0001-5920-4604
CR Anderson AJ, 2000, CLIN EXP OPHTHALMOL, V28, P223, DOI 10.1046/j.1442-9071.2000.00299.x
   Anderson AJ, 2001, PERIMETRY UPDATE 2000/2001, P115
   Anderson AJ, 2001, VISION RES, V41, P2449, DOI 10.1016/S0042-6989(01)00139-0
   Anderson AJ, 2000, VISION RES, V40, P2579, DOI 10.1016/S0042-6989(00)00121-8
   Artes PH, 2002, INVEST OPHTH VIS SCI, V43, P2654
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P788
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   Brown B, 1987, CLIN EXP OPTOM, V70, P112
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   COLETTA NJ, 1986, VISION RES, V26, P917, DOI 10.1016/0042-6989(86)90150-1
   COLETTA NJ, 1984, VISION RES, V24, P1333, DOI 10.1016/0042-6989(84)90188-3
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DEMIREL S, 1995, PERIMETRY UPDATE 1994/1995, P83
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1994, J OPT SOC AM A, V11, P33, DOI 10.1364/JOSAA.11.000033
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   GOLDBERG SH, 1983, SCIENCE, V221, P180, DOI 10.1126/science.6857279
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HAEGERSTROMPORTNOY G, 1989, CLIN VISION SCI, V4, P165
   Harper R, 1999, INVEST OPHTH VIS SCI, V40, P1650
   KIRYU J, 1995, INVEST OPHTH VIS SCI, V36, P1240
   LACHENMAYR BJ, 1992, INVEST OPHTH VIS SCI, V33, P3539
   Landers J, 2003, BRIT J OPHTHALMOL, V87, P690, DOI 10.1136/bjo.87.6.690
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3150
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   McKendrick A.M., 2003, ADLERS PHYSL EYE, P511
   McKendrick AM, 2000, INVEST OPHTH VIS SCI, V41, P1239
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Riva CE, 2001, INVEST OPHTH VIS SCI, V42, P756
   Rohrschneider K, 1995, Ger J Ophthalmol, V4, P197
   SJOSTRAND J, 1979, ACTA OPHTHALMOL, V57, P832
   SMITH VC, 1988, J OPT SOC AM A, V5, P2113, DOI 10.1364/JOSAA.5.002113
   Spry PGD, 2001, OPTOMETRY VISION SCI, V78, P436, DOI 10.1097/00006324-200106000-00017
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   Turpin A, 2002, INVEST OPHTH VIS SCI, V43, P709
   VANTOI V, 1994, J PHYSL, V482, P189
   VINGRYS AJ, 1995, PERIMETRY UPDATE 1994/1995, P159
   Vingrys AJ., 1990, CLIN EXP OPTOM, V73, P3, DOI [10.1111/j.1444-0938.1990.tb03092.x, DOI 10.1111/J.1444-0938.1990.TB03092.X]
   Wild JM, 1999, INVEST OPHTH VIS SCI, V40, P1152
NR 47
TC 58
Z9 59
U1 1
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2004
VL 45
IS 9
BP 3355
EP 3360
DI 10.1167/iovs.04-0253
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 848XH
UT WOS:000223500900066
PM 15326161
DA 2022-11-30
ER

PT J
AU Handa, JT
   Rickman, CB
   Dick, AD
   Gorin, MB
   Miller, JW
   Toth, CA
   Ueffing, M
   Zarbin, M
   Farrer, LA
AF Handa, James T.
   Rickman, Cathy Bowes
   Dick, Andrew D.
   Gorin, Michael B.
   Miller, Joan W.
   Toth, Cynthia A.
   Ueffing, Marius
   Zarbin, Marco
   Farrer, Lindsay A.
TI A systems biology approach towards understanding and treating
   non-neovascular age-related macular degeneration
SO NATURE COMMUNICATIONS
LA English
DT Article
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM; GENOME-WIDE
   ASSOCIATION; APOLIPOPROTEIN-E; HIGH-RISK; PRECISION MEDICINE; BRUCHS
   MEMBRANE; EYE DISEASE; GENE; VARIANT
AB Age-related macular degeneration (AMD) is the most common cause of blindness among the elderly in the developed world. While treatment is effective for the neovascular or "wet" form of AMD, no therapy is successful for the non-neovascular or "dry" form. Here we discuss the current knowledge on dry AMD pathobiology and propose future research directions that would expedite the development of new treatments. In our view, these should emphasize system biology approaches that integrate omic, pharmacological, and clinical data into mathematical models that can predict disease onset and progression, identify biomarkers, establish disease causing mechanisms, and monitor response to therapy.
C1 [Handa, James T.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21287 USA.
   [Rickman, Cathy Bowes; Toth, Cynthia A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27708 USA.
   [Dick, Andrew D.] Univ Bristol, Translat Hlth Sci Ophthalmol, Bristol BS8 1TH, Avon, England.
   [Dick, Andrew D.] UCL, Inst Ophthalmol, London WC1E 6BT, England.
   [Dick, Andrew D.] Moorfields Eye Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London WC1E 6BT, England.
   [Dick, Andrew D.] UCL, Inst Ophthalmol, London WC1E 6BT, England.
   [Gorin, Michael B.] UCLA, David Geffen Sch Med, Jules Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Gorin, Michael B.] UCLA, Brain Res Inst, Los Angeles, CA 90095 USA.
   [Miller, Joan W.] Harvard Med Sch, Retina Serv, Dept Ophthalmol, Massachusetts Eye & Ear,Harvard Ophthalmol AMD Ct, Boston, MA 02114 USA.
   [Ueffing, Marius] Univ Tubingen, Inst Ophthalm Res, Dept Ophthalmol, D-72076 Tubingen, Germany.
   [Zarbin, Marco] Rutgers State Univ, New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Newark, NJ 07103 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Epidemiol, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Biostat, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Med Biomed Genet, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Neurol, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Ophthalmol, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Duke University;
   University of Bristol; University of London; University College London;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital; Rutgers State University
   Newark; Rutgers State University New Brunswick; Rutgers State University
   Medical Center; Boston University; Boston University; Boston University;
   Boston University; Boston University; Boston University; Boston
   University; Boston University; Boston University; Boston University
RP Handa, JT (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21287 USA.; Farrer, LA (通讯作者)，Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA.; Farrer, LA (通讯作者)，Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.; Farrer, LA (通讯作者)，Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.; Farrer, LA (通讯作者)，Boston Univ, Sch Med, Dept Epidemiol, Boston, MA 02118 USA.; Farrer, LA (通讯作者)，Boston Univ, Sch Med, Dept Biostat, Boston, MA 02118 USA.; Farrer, LA (通讯作者)，Boston Univ, Sch Publ Hlth, Dept Med Biomed Genet, Boston, MA 02118 USA.; Farrer, LA (通讯作者)，Boston Univ, Sch Publ Hlth, Dept Neurol, Boston, MA 02118 USA.; Farrer, LA (通讯作者)，Boston Univ, Sch Publ Hlth, Dept Ophthalmol, Boston, MA 02118 USA.; Farrer, LA (通讯作者)，Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA.; Farrer, LA (通讯作者)，Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA.
EM jthanda@jhmi.edu; farrer@bu.edu
RI Farrer, Lindsay/AAS-1035-2020
OI Zarbin, Marco/0000-0002-7811-7132; Gorin, Michael/0000-0001-9498-7982;
   Miller, Joan/0000-0003-2046-3996; Bowes Rickman,
   Catherine/0000-0002-8555-9596; Dick, Andrew/0000-0002-0742-3159
FU NIH [EY027691, R42 EY029625-01, R01 EY026161, P30 EY005722,
   U01-AG032984, UF1-AG046198, R01-AG048927, RF1-AG057519]; Wilmer-Bayer
   Alliance Grant; Research to Prevent Blindness (Wilmer Eye Institute);
   Robert Bond Welch Professorship; Research to Prevent Blindness
   (RPB)/International Retinal Research Foundation (IRRF) Catalyst Award
   for Innovative Research Approaches for AMD; RPB; Fighting Blindness
   Individual Investigator Award; NIH/NEI [R01 EY09859]; NEI Core Facility
   Grant [EY014104]; Yeatts Retina Fund; Retina Research Fund; Champalimaud
   Vision Award; Horizon 2020 program of the European Union; Joseph J. and
   Marguerite DiSepio Retina Research Fund;  [634479]; NATIONAL EYE
   INSTITUTE [R01EY027691, R01EY026161, P30EY014104, P30EY005722,
   R42EY029625] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG048927, RF1AG057519, U01AG032984] Funding Source: NIH RePORTER
FX We thank Paul Sieving, MD, Ph.D., Director of the NEI and the National
   Eye Institute for organizing the AMD Pathobiology group. We also thank
   Anna E. Mazzucco, Ph.D. for her contributions to the group. J.T.H.: NIH
   EY027691; NIH R42 EY029625-01; BrightFocus Foundation; Macular
   Degeneration Foundation; Wilmer-Bayer Alliance Grant, Bayer
   Pharmaceuticals, Inc.; Unrestricted Grant from Research to Prevent
   Blindness (Wilmer Eye Institute), Robert Bond Welch Professorship.
   C.B.R.: NIH R01 EY026161; P30 EY005722 to Duke University, a Research to
   Prevent Blindness (RPB)/International Retinal Research Foundation (IRRF)
   Catalyst Award for Innovative Research Approaches for AMD, an
   unrestricted grant from RPB (to the Duke Eye Center), and a Fighting
   Blindness Individual Investigator Award. A.D. D.: NIHR Biomedical
   Research Centre Moorfields Eye Hospital and UCL-Institute of
   Ophthalmology, National Eye Research Centre UK, Macular Society UK,
   Medical Research Council UK, Rosetrees Trust UK. M.B.G.: Harold and
   Pauline Price Foundation, Research to Prevent Blindness, NY, NY, NIH/NEI
   R01 EY09859 Gorin (PI). J.W.M.: NEI Core Facility Grant EY014104, Yeatts
   Retina Fund, Research to Prevent Blindness, Retina Research Fund,
   Champalimaud Vision Award. C.A.T.: an unrestricted grant from RPB (to
   the Duke Eye Center). M.U.: EYE-RISK is funded by the Horizon 2020
   program of the European Union. Funding is provided to Marius Ueffing in
   the period of 2015-2019 under Grant Agreement number 634479. M.Z.:
   Joseph J. and Marguerite DiSepio Retina Research Fund; Eng Family
   Foundation; New Jersey Lions Eye Research Foundation; Paid Consultant
   for: California Institute of Regenerative Medicine, Cell Cure, Chengdu
   Kanghong Biotechnology Co., Coherus Biosciences, Inc., Daiichi Sankyo,
   Frequency Therapeutics, Foundation Fighting Blindness, Genentech/Roche,
   Healios KK, Inc., Iridex, Isarna Therapeutics, Makindus, Novartis Pharma
   AG, Ophthotech Corp., Percept Corp. L.A.F.: NIH U01-AG032984, NIH
   UF1-AG046198, NIH R01-AG048927, NIH RF1-AG057519.
CR Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   Boretsky A, 2012, LASER SURG MED, V44, P603, DOI 10.1002/lsm.22070
   Budak G, 2018, EXP EYE RES, V168, P57, DOI 10.1016/j.exer.2018.01.009
   Camelo S, 2016, OPHTHALMOLOGICA, V236, P53, DOI 10.1159/000446587
   Cano M, 2011, AM J PATHOL, V179, P850, DOI 10.1016/j.ajpath.2011.04.010
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Corominas J, 2018, OPHTHALMOLOGY, V125, P1433, DOI 10.1016/j.ophtha.2018.03.040
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR246, DOI 10.1093/hmg/ddx343
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dubra A, 2011, BIOMED OPT EXPRESS, V2, P1864, DOI 10.1364/BOE.2.001864
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   el Bouhaddani S, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2371-3
   Elsner AE, 2007, J OPT SOC AM A, V24, P1468, DOI 10.1364/JOSAA.24.001468
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Farrer Lindsay A, 2017, Stem Cell Investig, V4, P92, DOI 10.21037/sci.2017.10.07
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Friedman AA, 2015, NAT REV CANCER, V15, P747, DOI 10.1038/nrc4015
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fujihara M, 2014, INVEST OPHTH VIS SCI, V55, P7285, DOI 10.1167/iovs.14-15195
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grapov D, 2018, OMICS, V22, P630, DOI 10.1089/omi.2018.0097
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hall JB, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0760-4
   He Y, 2010, ADV EXP MED BIOL, V664, P165, DOI 10.1007/978-1-4419-1399-9_20
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hofer H, 2001, OPT EXPRESS, V8, P631, DOI 10.1364/OE.8.000631
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jun GG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025775
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khaliq A, 1996, INVEST OPHTH VIS SCI, V37, P436
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kortvely E, 2012, ADV EXP MED BIOL, V723, P61, DOI 10.1007/978-1-4614-0631-0_9
   Kosmidou C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17634-1
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   Mahmoudi S, 2012, CURR OPIN CELL BIOL, V24, P744, DOI 10.1016/j.ceb.2012.10.004
   Maiese K, 2009, MOLECULES, V14, P3446, DOI 10.3390/molecules14093446
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Merino J, 2018, ANN NY ACAD SCI, V1411, P140, DOI 10.1111/nyas.13588
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Morgan DJ, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017210
   Morrison MA, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00238
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Murakami Y, 2014, CELL DEATH DIFFER, V21, P270, DOI 10.1038/cdd.2013.109
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Persad PJ, 2017, INVEST OPHTH VIS SCI, V58, P4027, DOI 10.1167/iovs.17-21734
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, pBIO121, DOI 10.1167/iovs.17-21764
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rohrer B, 2016, ADV EXP MED BIOL, V854, P793, DOI 10.1007/978-3-319-17121-0_106
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   SanGiovanni JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053155
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Starnes AC, 2016, VISUAL NEUROSCI, V33, DOI 10.1017/S0952523815000310
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Taskintuna I, 2016, MIDDLE EAST AFR J OP, V23, P13, DOI 10.4103/0974-9233.173134
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Theodoropoulou S, 2017, J PATHOL, V241, P45, DOI 10.1002/path.4816
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Trichonas G, 2010, P NATL ACAD SCI USA, V107, P21695, DOI 10.1073/pnas.1009179107
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03856-y
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Williams AM, 2016, JAMA OPHTHALMOL, V134, P351, DOI 10.1001/jamaophthalmol.2015.5492
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 121
TC 118
Z9 126
U1 6
U2 30
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL 26
PY 2019
VL 10
AR 3347
DI 10.1038/s41467-019-11262-1
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IM0UK
UT WOS:000477704900001
PM 31350409
OA Green Published, gold
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Wolffsohn, JS
   Dinardo, C
   Vingrys, AJ
AF Wolffsohn, JS
   Dinardo, C
   Vingrys, AJ
TI Benefit of coloured lenses for age-related macular degeneration
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE age-related macular degeneration; coloured lenses; visually impaired;
   visual function
ID YELLOW FILTER GLASSES; LOW-VISION PATIENTS; CONTRAST SENSITIVITY; TINTED
   LENSES; LIGHT; RELIABILITY; VALIDITY; ORANGE; TESTS
AB Purpose: To evaluate and compare the functional and perceived benefits of wearing coloured lenses by patients with age-related macular degeneration (ARMD).
   Method: Ten subjects with early ARMD and five elderly controls wore a selection of NoIR wraparound coloured lenses (yellow 29.7% light transmission, orange 22.9%, red 16.8% and grey 10.3%), each for a duration of 7 days. Contrast sensitivity, colour vision, visual acuity, the effect of glare and peripheral sensitivity were measured for each lens and compared with a control (no lens) condition. Subjective ratings of visual performance were also scored.
   Results: Compared with the no filter condition, red and grey lenses reduced contrast sensitivity whereas yellow and orange lenses increased contrast sensitivity. These objective changes were supported by subjective ratings in subjects with ARMD. Grey lenses reduced the loss of contrast sensitivity usually suffered in the presence of glare, whereas visual acuity and peripheral sensitivity decreased with red lenses. Colour vision became distorted with red lenses in control subjects, but was relatively unaffected by the use of coloured lenses in subjects with ARMD.
   Conclusions: The subjective benefit of coloured lenses appears to be due to a minor enhancement of contrast sensitivity.
C1 Aston Univ, Sch Life & Hlth Sci, Neurosci Res Inst, Birmingham B4 7ET, W Midlands, England.
   Victorian Coll Optometry, Carlton, Vic, Australia.
   Univ Melbourne, Dept Optometry & Vis Sci, Melbourne, Vic 3053, Australia.
C3 Aston University; University of Melbourne
RP Wolffsohn, JS (通讯作者)，Aston Univ, Sch Life & Hlth Sci, Neurosci Res Inst, Astron Triangle, Birmingham B4 7ET, W Midlands, England.
EM j.s.w.wolffsohn@aston.ac.uk
OI Vingrys, Algis/0000-0001-5920-4604; Wolffsohn, James/0000-0003-4673-8927
CR AARNISALO E, 1987, ACTA OPHTHALMOL, V65, P274
   AARNISALO E, 1990, ACTA OPHTHALMOL, V68, P168
   AARNISALO EA, 1988, AM J OPHTHALMOL, V105, P408, DOI 10.1016/0002-9394(88)90307-8
   Barron C, 1987, J Am Optom Assoc, V58, P50
   Chung STL, 1999, OPTOMETRY VISION SCI, V76, P59, DOI 10.1097/00006324-199901000-00029
   CHYLACK LT, 1988, ARCH OPHTHALMOL-CHIC, V106, P330
   CLARK BAJ, 1969, AMER J OPT ARCH AM A, V46, P825
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   FASCE F, 1992, INVEST OPHTH VIS SCI, V33, P967
   FAYE EE, 1984, CLIN LOW VISION, P257
   FRENNESSON IC, 1993, DOC OPHTHALMOL, V84, P135, DOI 10.1007/BF01206248
   Garway-Heath DF, 2000, INVEST OPHTH VIS SCI, V41, P1774
   GAWANDE A, 1992, J VIS IMP BLINDNESS, V86, P225
   GREEVES AL, 1987, AM J OPTOM PHYS OPT, V64, P832
   HELLINGER G, 1983, J VISUAL IMPAIR BLIN, V77, P449
   HOEFT WW, 1981, AM J OPTOM PHYS OPT, V58, P841
   HOVIS JK, 1989, OPTOMETRY VISION SCI, V66, P682, DOI 10.1097/00006324-198910000-00004
   KELLY SA, 1990, J OPT SOC AM A, V7, P1905, DOI 10.1364/JOSAA.7.001905
   KELLY SA, 1984, AM J OPTOM PHYS OPT, V61, P657
   KINNEY JAS, 1983, AM J OPTOM PHYS OPT, V60, P132
   KUYK TK, 1990, OPTOMETRY VISION SCI, V67, P522, DOI 10.1097/00006324-199007000-00010
   LEAT SJ, 1990, OPHTHAL PHYSL OPT, V10, P219, DOI 10.1111/j.1475-1313.1990.tb00855.x
   LEGUIRE LE, 1993, OPHTHAL PHYSL OPT, V13, P124, DOI 10.1111/j.1475-1313.1993.tb00440.x
   LOVIEKITCHIN JE, 1988, OPHTHAL PHYSL OPT, V8, P363, DOI 10.1111/j.1475-1313.1988.tb01170.x
   LURIA SM, 1972, AMER J OPT ARCH AM A, V49, P818
   Maino J H, 1986, J Am Optom Assoc, V57, P532
   Miller D, 1974, Surv Ophthalmol, V19, P38
   Provines W F, 1997, J Am Optom Assoc, V68, P353
   Rabin J, 1996, OPHTHAL PHYSL OPT, V16, P68, DOI 10.1046/j.1475-1313.1996.94000093.x
   Rosenblum YZ, 2000, OPHTHAL PHYSL OPT, V20, P335, DOI 10.1016/S0275-5408(00)00006-5
   TAYLOR MM, 1967, J ACOUST SOC AM, V41, P782, DOI 10.1121/1.1910407
   VANDENBERG TJTP, 1994, VISION RES, V34, P1453, DOI 10.1016/0042-6989(94)90146-5
   VINGRYS AJ, 1992, OPHTHAL PHYSL OPT, V12, P38, DOI 10.1016/0275-5408(92)90009-L
   VINGRYS AJ, 1988, INVEST OPHTH VIS SCI, V29, P50
   Vingrys Algis J, 1998, Clin Exp Optom, V81, P238
   WALSH JE, 1949, J AM STAT ASSOC, V44, P342, DOI 10.2307/2280233
   WHITAKER D, 1993, OPTOMETRY VISION SCI, V70, P963, DOI 10.1097/00006324-199311000-00014
   Wolffsohn JS, 2000, OPTOMETRY VISION SCI, V77, P73, DOI 10.1097/00006324-200002000-00011
   YAP M, 1984, OPHTHAL PHYSL OPT, V4, P227, DOI 10.1111/j.1475-1313.1984.tb00360.x
   ZIGMAN S, 1990, OPTOMETRY VISION SCI, V67, P100, DOI 10.1097/00006324-199002000-00007
NR 40
TC 21
Z9 21
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD JUL
PY 2002
VL 22
IS 4
BP 300
EP 311
DI 10.1046/j.1475-1313.2002.00036.x
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 574BP
UT WOS:000176868800005
PM 12162481
DA 2022-11-30
ER

PT J
AU Cruickshanks, KJ
   Nondahl, DM
   Johnson, LJ
   Dalton, DS
   Fisher, ME
   Huang, GH
   Klein, BE
   Klein, R
   Schubert, CR
AF Cruickshanks, Karen J.
   Nondahl, David M.
   Johnson, Lauren J.
   Dalton, Dayna S.
   Fisher, Mary E.
   Huang, Guan-Hua
   Klein, Barbara E.
   Klein, Ronald
   Schubert, Carla R.
TI Generational Differences in the 5-Year Incidence of Age-Related Macular
   Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID CORONARY-HEART-DISEASE; UNITED-STATES; BABY BOOMERS; MACULOPATHY;
   PREVALENCE; SMOKING; COHORT; WISCONSIN; MORTALITY; DECLINE
AB IMPORTANCE Whether a reported decline in the risk of developing age-related macular degeneration (AMD) continued for people born during the Baby Boom years (1946-1964) or later is unknown. These data are important to plan for ocular health care needs in the 21st century.
   OBJECTIVES To determine whether the 5-year risk for AMD declined by generation and to identify factors that contributed to improvement in risk.
   DESIGN, SETTING, AND PARTICIPANTS Data came from the longitudinal cohort Beaver Dam Eye Study (March 1, 1988, through September 15, 1990, and March 1, 1993, through June 15, 1995) and the Beaver Dam Offspring Study (June 8, 2005, through August 4, 2008, and July 12, 2010, through March 21, 2013). These population-based studies examined residents of Beaver Dam, Wisconsin, aged 43 to 84 years in 1987 through 1988 and their adult offspring aged 21 to 84 years in 2005 through 2008. A total of 4819 participants were at risk for developing AMD based on fundus images obtained at baseline visits. Data were analyzed from February 18, 2016, through June 22, 2017, with additional analyses ending September 22, 2017.
   MAIN OUTCOMES AND MEASURES Fundus images were graded for AMD using the Wisconsin Age-related Maculopathy Grading System. The incidence of AMD was defined as the presence at the 5-year follow-up examination of pure geographic atrophy or exudative macular degeneration, any type of drusen with pigmentary abnormalities, or soft indistinct drusen without pigmentary abnormalities.
   RESULTS Among the 4819 participants, the mean (SD) baseline age of the cohort was 54 (11) years; 2117 were men (43.9%) and 2702 were women (56.1%). The 5-year age-and sex-adjusted incidence of AMD was 8.8% in the Greatest Generation (born during 1901-1924), 3.0% in the Silent Generation (born during 1925-1945), 1.0% in the Baby Boom Generation (born during 1946-1964), and 0.3% in Generation X (born during 1965-1984). Adjusting for age and sex, each generation was more than 60% less likely to develop AMD than the previous generation (relative risk, 0.34; 95% CI, 0.24-0.46). The generational association (relative risk, 0.40; 95% CI, 0.28 to 0.57) remained significant after adjusting for age, sex, smoking, educational attainment, exercise, levels of non-high-density lipoprotein cholesterol and high-sensitivity C-reactive protein, and use of nonsteroidal anti-inflammatory drugs, statins, and multivitamins.
   CONCLUSIONS AND RELEVANCE The 5-year risk for AMD declined by birth cohorts throughout the 20th century. Factors that explain this decline in risk are not known. However, this pattern is consistent with reported declines in risks for cardiovascular disease and dementia, suggesting that aging Baby Boomers may experience better retinal health at older ages than did previous generations.
C1 [Cruickshanks, Karen J.; Nondahl, David M.; Dalton, Dayna S.; Fisher, Mary E.; Klein, Barbara E.; Klein, Ronald; Schubert, Carla R.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610Walnut St,1038WARF, Madison, WI 53726 USA.
   [Cruickshanks, Karen J.; Johnson, Lauren J.; Huang, Guan-Hua] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA.
   [Huang, Guan-Hua] Natl Chiao Tung Univ, Inst Stat, Hsinchu, Taiwan.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   National Yang Ming Chiao Tung University
RP Cruickshanks, KJ (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610Walnut St,1038WARF, Madison, WI 53726 USA.
EM kjcruick@wisc.edu
FU National Institute on Aging [R01AG021917]; National Eye Institute
   [U10EY06594]; Research to Prevent Blindness; NATIONAL EYE INSTITUTE
   [U10EY006594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG021917] Funding Source: NIH RePORTER
FX This study was supported by grant R01AG021917 from the National
   Institute on Aging and the National Eye Institute (Dr Cruickshanks),
   grant U10EY06594 from the National Eye Institute (Drs B. E. Klein and R.
   Klein), and an unrestricted grant from Research to Prevent Blindness.
CR Arias Elizabeth, 2015, Natl Vital Stat Rep, V64, P1
   ATKINSON W, 1996, EPIDEMIOLOGY PREVENT
   Badley EM, 2015, MILBANK Q, V93, P40, DOI 10.1111/1468-0009.12105
   BARKER DJP, 1988, ARCH DIS CHILD, V63, P867, DOI 10.1136/adc.63.7.867
   CASSEL J, 1976, AM J EPIDEMIOL, V104, P107, DOI 10.1093/oxfordjournals.aje.a112281
   Cohn D., 2010, BABY BOOMERS APPROAC
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   DOLL R, 1991, AM J EPIDEMIOL, V134, P675, DOI 10.1093/oxfordjournals.aje.a116143
   Doll Richard, 1981, CAUSES CANC, P1197
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Ford ES, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001097
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Garte S, 2008, WHERE WE STAND SUPRI
   Gerstorf D, 2011, DEV PSYCHOL, V47, P1026, DOI 10.1037/a0023426
   Goff DC, 2012, ANN EPIDEMIOL, V22, P554, DOI 10.1016/j.annepidem.2012.04.021
   Jones DS, 2013, AM J PUBLIC HEALTH, V103, P1207, DOI 10.2105/AJPH.2013.301226
   King DE, 2013, JAMA INTERN MED, V173, P385, DOI 10.1001/jamainternmed.2013.2006
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Knudtson MD, 2003, CURR EYE RES, V27, P143, DOI 10.1076/ceyr.27.3.143.16049
   Matthews FE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11398
   McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P141, DOI 10.1080/09286586.2016.1259422
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Nash SD, 2013, J AM GERIATR SOC, V61, P1269, DOI 10.1111/jgs.12382
   Nieto FJ, 1998, AM J EPIDEMIOL, V148, P937, DOI 10.1093/oxfordjournals.aje.a009570
   Satizabal C, 2016, NEW ENGL J MED, V375, P93, DOI 10.1056/NEJMc1604823
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Vincent GK, 2010, NEXT 4 DECADES OLDER
   Zhan WH, 2010, AM J EPIDEMIOL, V171, P260, DOI 10.1093/aje/kwp370
   Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090
NR 35
TC 24
Z9 24
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD DEC
PY 2017
VL 135
IS 12
BP 1417
EP 1423
DI 10.1001/jamaophthalmol.2017.5001
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA FQ0OO
UT WOS:000418056800027
PM 29145549
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Ersoy, L
   Ristau, T
   Lechanteur, YT
   Hahn, M
   Hoyng, CB
   Kirchhof, B
   den Hollander, AI
   Fauser, S
AF Ersoy, Lebriz
   Ristau, Tina
   Lechanteur, Yara T.
   Hahn, Moritz
   Hoyng, Carel B.
   Kirchhof, Bernd
   den Hollander, Anneke I.
   Fauser, Sascha
TI Nutritional Risk Factors for Age-Related Macular Degeneration
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID DIETARY-FAT; CONSUMPTION; MEAT; NEOVASCULARIZATION; PREVENTION; LOCI;
   RED
AB Purpose. To evaluate the role of nutritional factors, serum lipids, and lipoproteins in late age-related macular degeneration (late AMD). Methods. Intake of red meat, fruit, fish, vegetables, and alcohol, smoking status, and body mass index (BMI) were ascertained questionnaire-based in 1147 late AMD cases and 1773 controls from the European Genetic Database. Serum levels of lipids and lipoproteins were determined. The relationship between nutritional factors and late AMD was assessed using logistic regression. Based on multivariate analysis, area-under-the-curve (AUC) was calculated by receiver-operating-characteristics (ROC). Results. In a multivariate analysis, besides age and smoking, obesity (odds ratio (OR): 1.44, P = 0.014) and red meat intake (daily: OR: 2.34, P = 8.22 x 10(-6); 2-6x/week: OR: 1.67, P = 7.98 x 10(-5)) were identified as risk factors for developing late AMD. Fruit intake showed a protective effect (daily: OR: 0.52, P = 0.005; 2-6x/week: OR: 0.58, P = 0.035). Serum lipid and lipoprotein levels showed no significant association with late AMD. ROC for nutritional factors, smoking, age, and BMI revealed an AUC of 0.781. Conclusion. Red meat intake and obesity were independently associated with increased risk for late AMD, whereas fruit intake was protective. A better understanding of nutritional risk factors is necessary for the prevention of AMD.
C1 [Ersoy, Lebriz; Ristau, Tina; Kirchhof, Bernd; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, D-50924 Cologne, Germany.
   [Lechanteur, Yara T.; Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 GA Nijmegen, Netherlands.
   [Hahn, Moritz] Univ Cologne, Inst Med Stat Informat & Epidemiol, D-50924 Cologne, Germany.
C3 University of Cologne; Radboud University Nijmegen; University of
   Cologne
RP Fauser, S (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM sascha.fauser@uk-koeln.de
RI Hollander, Anneke den/N-4911-2014; Hoyng, C.B./H-8050-2014; Lechanteur,
   Yara/ABB-6875-2020; Lehtimäki, Terho/AAD-1094-2022
OI Lechanteur, Yara/0000-0003-0951-4625; Lehtimäki,
   Terho/0000-0002-2555-4427
FU Retinovit Foundation, Germany
FX This work was supported by a grant from the Retinovit Foundation,
   Germany.
CR Amirul Islam F. M., 2014, OPHTHALMOLOGY
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1678, DOI 10.1001/archophthalmol.2009.312
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Connor W E, 1990, Adv Intern Med, V35, P139
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Fan Jianglin, 2003, J Atheroscler Thromb, V10, P63
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Goldberg T, 2004, J AM DIET ASSOC, V104, P1287, DOI 10.1016/j.jada.2004.05.214
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Hughes R, 2001, CARCINOGENESIS, V22, P199, DOI 10.1093/carcin/22.1.199
   Humphries JM, 2003, J AGR FOOD CHEM, V51, P1322, DOI 10.1021/jf026073e
   MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Micha R, 2010, CIRCULATION, V121, P2271, DOI 10.1161/CIRCULATIONAHA.109.924977
   Obisesan TO, 1998, J AM GERIATR SOC, V46, P1
   Otto MCD, 2012, J NUTR, V142, P526, DOI 10.3945/jn.111.149781
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
NR 29
TC 34
Z9 35
U1 0
U2 16
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
VL 2014
AR 413150
DI 10.1155/2014/413150
PG 6
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AL1CO
UT WOS:000338863600001
PM 25101280
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Sene, A
   Khan, AA
   Cox, D
   Nakamura, REI
   Santeford, A
   Kim, BM
   Sidhu, R
   Onken, MD
   Harbour, JW
   Hagbi-Levi, S
   Chowers, I
   Edwards, PA
   Baldan, A
   Parks, JS
   Ory, DS
   Apte, RS
AF Sene, Abdoulaye
   Khan, Aslam A.
   Cox, Douglas
   Nakamura, Rei E. I.
   Santeford, Andrea
   Kim, Bryan M.
   Sidhu, Rohini
   Onken, Michael D.
   Harbour, J. William
   Hagbi-Levi, Shira
   Chowers, Itay
   Edwards, Peter A.
   Baldan, Angel
   Parks, John S.
   Ory, Daniel S.
   Apte, Rajendra S.
TI Impaired Cholesterol Efflux in Senescent Macrophages Promotes
   Age-Related Macular Degeneration
SO CELL METABOLISM
LA English
DT Article
ID BINDING CASSETTE TRANSPORTER; HIGH-DENSITY-LIPOPROTEIN;
   APOLIPOPROTEIN-A-I; BRUCHS MEMBRANE; FOAM CELLS; HOMEOSTASIS;
   ACTIVATION; RECEPTOR; DRUSEN; ABCG1
AB Pathologic angiogenesis mediated by abnormally polarized macrophages plays a central role in common age-associated diseases such as atherosclerosis, cancer, and macular degeneration. Here we demonstrate that abnormal polarization in older macrophages is caused by programmatic changes that lead to reduced expression of ATP binding cassette transporter ABCA1. Downregulation of ABCA1 by microRNA-33 impairs the ability of macrophages to effectively efflux intracellular cholesterol, which in turn leads to higher levels of free cholesterol within senescent macrophages. Elevated intracellular lipid polarizes older macrophages to an abnormal, alternatively activated phenotype that promotes pathologic vascular proliferation. Mice deficient for Abca1, but not Abcg1, demonstrate an accelerated aging phenotype, whereas restoration of cholesterol efflux using LXR agonists or miR-33 inhibitors reverses it. Monocytes from older humans with age-related macular degeneration showed similar changes. These findings provide an avenue for therapeutic modulation of macrophage function in common age-related diseases.
C1 [Sene, Abdoulaye; Khan, Aslam A.; Cox, Douglas; Nakamura, Rei E. I.; Santeford, Andrea; Kim, Bryan M.; Onken, Michael D.; Harbour, J. William; Apte, Rajendra S.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Sidhu, Rohini; Ory, Daniel S.] Washington Univ, Sch Med, Diabet Cardiovasc Dis Ctr, St Louis, MO 63110 USA.
   [Apte, Rajendra S.] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA.
   [Hagbi-Levi, Shira; Chowers, Itay] Hadassah Hebrew Univ, Med Ctr, IL-91120 Jerusalem, Israel.
   [Edwards, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.
   [Baldan, Angel] St Louis Univ, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA.
   [Parks, John S.] Wake Forest Sch Med, Sect Lipid Sci, Dept Pathol, Winston Salem, NC 27157 USA.
   [Parks, John S.] Wake Forest Sch Med, Dept Biochem, Winston Salem, NC 27157 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL); Hebrew University of Jerusalem; Hadassah University
   Medical Center; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Saint Louis University;
   Wake Forest University; Wake Forest University
RP Apte, RS (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
EM apte@vision.wustl.edu
RI Sene, Abdoulaye/D-3342-2015; Sidhu, Rohini/G-3547-2012; Onken, Michael
   D/H-5620-2013; Harbour, J. William/B-1448-2015
OI Sene, Abdoulaye/0000-0001-9194-7264; Sidhu, Rohini/0000-0003-1703-2167;
   Onken, Michael D/0000-0003-4082-1105; Harbour, J.
   William/0000-0002-1104-9809; Hagbi-Levi, Shira/0000-0002-2891-0079
FU NIH [K08EY016139, R01EY019287, P30EY02687, P01HL049373, R01 HL094525,
   R01 HL067773, HL-107794, HL-30568]; U.S. Civilian Research and
   Development Foundation; Carl Marshall Reeves and Mildred Almen Reeves
   Foundation Inc.; Research to Prevent Blindness Inc.; International
   Retina Research Foundation; American Health Assistance Foundation; Lacy
   Foundation; Thome Foundation; NATIONAL EYE INSTITUTE [P30EY002687,
   R01EY019287, K08EY016139] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [P01HL049373, R01HL107794, R01HL094525,
   P01HL030568, R01HL067773] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020579,
   P60DK020579] Funding Source: NIH RePORTER
FX This work was supported by NIH grant K08EY016139 (R.S.A.); NIH grant
   R01EY019287 (R.S.A.); NIH Vision Core Grant P30EY02687, U.S. Civilian
   Research and Development Foundation (R.S.A. and I.C.); NIH grants
   P01HL049373 (J.S.P.) and R01 HL094525 (J.S.P.); NIH grant R01 HL067773
   (D.S.O.); NIH grant HL-107794 (A.B.); NIH grant HL-30568 (P.A.E.); the
   Carl Marshall Reeves and Mildred Almen Reeves Foundation Inc. Award
   (R.S.A.); the Research to Prevent Blindness Inc. Career Development
   Award (R.S.A.); the International Retina Research Foundation (R.S.A.);
   the American Health Assistance Foundation (R.S.A.); the Lacy Foundation
   Research Award (A.S.); the Thome Foundation (R.S.A.); and a Research to
   Prevent Blindness Inc. Unrestricted Grant to Washington University. Mass
   spectrometry and mouse serum analysis, respectively, were performed in
   the Metabolomics Facility and the Diabetes Research Center (NIH P60 DK
   20579) at Washington University in Saint Louis. The authors would like
   to acknowledge the insights and constructive input of Drs. Douglas
   Green, Jayakrishna Ambati, Steve Teitelbaum, Shiming Chen, and Thomas
   Ferguson regarding these studies. R.S.A. is named as an inventor in a
   patent application filed by Washington University on the intellectual
   property presented in this article.
CR Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Baldan A, 2006, J BIOL CHEM, V281, P29401, DOI 10.1074/jbc.M606597200
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Chakravarthy MV, 2005, CELL METAB, V1, P309, DOI 10.1016/j.cmet.2005.04.002
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200
   Gelissen IC, 1999, J LIPID RES, V40, P1636
   Gelissen IC, 1996, J BIOL CHEM, V271, P17852, DOI 10.1074/jbc.271.30.17852
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0
   Jiang XT, 2011, J LIPID RES, V52, P1435, DOI 10.1194/jlr.D015735
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Kennedy MA, 2005, CELL METAB, V1, P121, DOI 10.1016/j.cmet.2005.01.002
   Khan AA, 2008, IMMUNOBIOLOGY, V213, P695, DOI 10.1016/j.imbio.2008.07.014
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KRITHARIDES L, 1995, ARTERIOSCL THROM VAS, V15, P276, DOI 10.1161/01.ATV.15.2.276
   Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Marquart TJ, 2010, P NATL ACAD SCI USA, V107, P12228, DOI 10.1073/pnas.1005191107
   Moore KJ, 2011, CELL, V145, P341, DOI 10.1016/j.cell.2011.04.005
   Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325
   Najafi-Shoushtari SH, 2010, SCIENCE, V328, P1566, DOI 10.1126/science.1189123
   Nakamura K, 2004, J BIOL CHEM, V279, P45980, DOI 10.1074/jbc.M408652200
   Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298
   Niederkorn JY, 2006, NAT IMMUNOL, V7, P354, DOI 10.1038/ni1328
   Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862
   Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2
   Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524
   Tall AR, 2008, CELL METAB, V7, P365, DOI 10.1016/j.cmet.2008.03.001
   TARLING EJ, 2011, BIOCHIM BIOPHYS ACTA, V1821, P386
   Tarling EJ, 2011, P NATL ACAD SCI USA, V108, P19719, DOI 10.1073/pnas.1113021108
   Timmins JM, 2005, J CLIN INVEST, V115, P1333, DOI 10.1172/JCI200523915
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Vedhachalam C, 2007, J BIOL CHEM, V282, P25123, DOI 10.1074/jbc.M704590200
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Zhu X, 2008, J BIOL CHEM, V283, P22930, DOI 10.1074/jbc.M801408200
NR 41
TC 162
Z9 171
U1 0
U2 26
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD APR 2
PY 2013
VL 17
IS 4
BP 549
EP 561
DI 10.1016/j.cmet.2013.03.009
PG 13
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 242TR
UT WOS:000326265600010
PM 23562078
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Alex, D
   Giridhar, A
   Gopalakrishnan, M
   Indurkhya, S
   Madan, S
AF Alex, Divya
   Giridhar, Anantharaman
   Gopalakrishnan, Mahesh
   Indurkhya, Swati
   Madan, Shivam
TI Subretinal hyperreflective material morphology in neovascular
   age-related macular degeneration: A case control study
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Anti-VEGF therapy; geographic atrophy; neovascular age-related macular
   degeneration; scar formation; subretinal hyper reflective material;
   visual acuity
ID VISUAL-ACUITY
AB Purpose: The aim of this study was to evaluate the association of morphological features of subretinal hyperreflective material (SHRM) with visual acuity (VA), geographic atrophy (GA) and scar formation in eyes with neovascular age-related macular degeneration (neovascular AMD) and to compare with controls of neovascular AMD without SHRM. Methods: Retrospective analysis of 157 wet AMD eyes with SHRM and 50 eyes without SHRM treated with Anti-VEGF. Baseline spectral domain-OCT characteristics (SHRM location, height, width, area, reflectivity, border definition) were collected and were correlated with VA at baseline, 3, 6, 12 months and looked for development of scar and geographical atrophy (GA) and were compared to the control group. Results: When compared to the control, baseline parameters with a significant predictive value of 12-VA were presence of SHRM, foveal involvement of SHRM, high reflective SHRM, well-defined SHRM borders and thick SHRM. VA was decreased with greater SHRM height, width and area (P < 0.001). Decreasing reflectivity of SHRM lesions and disappearance of SHRM correlated with better VA at 12 months (P < 0.05). At 12 months, scar and GA was present more often in eyes with persistent SHRM than in eyes with SHRM that resolved and those without SHRM in the control group. Conclusion: SHRM can be considered as a surrogate OCT biomarker in predicting final visual outcome in neovascular age-related macular degeneration. Baseline parameters predicting poorer vision at 12-follow-up were presence of SHRM involving the fovea, well-defined SHRM borders, greater SHRM height, width and area and persistence of SHRM with Anti-VEGF therapy.
C1 [Alex, Divya; Giridhar, Anantharaman; Gopalakrishnan, Mahesh; Indurkhya, Swati; Madan, Shivam] Giridhar Eye Inst, Dept Vitreoretinal Serv, Ponneth Temple Rd, Cochin 682020, Kerala, India.
RP Alex, D (通讯作者)，Giridhar Eye Inst, Dept Vitreoretinal Serv, Ponneth Temple Rd, Cochin 682020, Kerala, India.
EM alex.divya@gmail.com
CR Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Casalino G, 2016, INVEST OPHTH VIS SCI, V57, pOCT288, DOI 10.1167/iovs.15-18753
   Charafeddin W, 2015, OSLI RETINA, V46, P523, DOI 10.3928/23258160-20150521-03
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Finger RP, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01554-2
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Kumar JB, 2020, RETINA-J RET VIT DIS, V40, P845, DOI 10.1097/IAE.0000000000002552
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Pokroy R, 2018, RETINA-J RET VIT DIS, V38, P1485, DOI 10.1097/IAE.0000000000001748
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Saxena S, 2014, CLIN OPHTHALMOL, V8, P2507, DOI 10.2147/OPTH.S72132
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 22
TC 1
Z9 1
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUL
PY 2021
VL 69
IS 7
BP 1862
EP 1866
DI 10.4103/ijo.IJO_3156_20
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UK5FM
UT WOS:000691995400048
PM 34146045
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Coscas, GJ
   Lupidi, M
   Coscas, F
   Cagini, C
   Souied, EH
AF Coscas, Gabriel J.
   Lupidi, Marco
   Coscas, Florence
   Cagini, Carlo
   Souied, Eric H.
TI OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY VERSUS TRADITIONAL MULTIMODAL
   IMAGING IN ASSESSING THE ACTIVITY OF EXUDATIVE AGE-RELATED MACULAR
   DEGENERATION A New Diagnostic Challenge
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE amplitude decorrelation angiography; choroidal neovascularization;
   exudative AMD; multi-modal imaging; optical coherence tomography
   angiography
ID EXPERIMENTAL SUBRETINAL NEOVASCULARIZATION; INDOCYANINE GREEN
   ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY;
   THERAPY; HISTORY; AMD
AB Purpose: To compare optical coherence tomography angiography (OCTA) with traditional multimodal imaging in patients with exudative age-related macular degeneration in terms of guiding the treatment decision.
   Methods: Prospective case series of 80 eyes of 73 consecutive patients with exudative age-related macular degeneration (39 women, mean age: 79.4 5.3 years) diagnosed with different types of choroidal neovascularization (CNV) (58 Type I, 2 Type II, 6 mixed Type I and II, 3 retinal angiomatous proliferation, and 11 age-related macular degeneration-related polyps). The data obtained from traditional multimodal imaging, based on fluorescein angiography, indocyanine green angiography, and OCT were used to assess the need for treatment, those obtained from OCTA to identify two different patterns of CNV. Traditional multimodal imaging and OCTA findings were then compared with evaluate possible correspondence between treatment decision and CNV aspect on OCTA.
   Results: A CNV lesion was identified as Group A (requiring treatment) in 58 eyes (72.5%) in traditional multimodal imaging. On OCTA in 59 eyes (73.7%), the lesion was defined as Pattern I and the remaining 21 (26.3%) as Pattern II. There was 94.9% correspondence between the Pattern I CNV on OCTA and the cases Group A on conventional multimodal imaging. It was also computed 90.5% correspondence between Pattern II CNV on OCTA and the Group B (not requiring treatment) cases on conventional multimodal imaging. There was high (P < 0.05) interobserver agreement both for treatment decision in conventional multimodal and for Patterns (I or II) defining on OCTA imaging analysis.
   Conclusion: This study demonstrates a high level of correspondence, in patients with exudative age-related macular degeneration, between different CNV patterns identified on OCTA and treatment decisions established on conventional multimodal imaging. Although fluorescein angiography remains the gold standard for determining the presence of leakage, and OCT shows fluid accumulation and its variations, OCTA may now offer noninvasive monitoring of the CNV, aiding for each treatment decision during the follow-up.
C1 [Coscas, Gabriel J.; Lupidi, Marco; Coscas, Florence] Odeon Ophthalm Ctr, Paris, France.
   [Coscas, Gabriel J.; Coscas, Florence; Souied, Eric H.] Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
   [Lupidi, Marco; Cagini, Carlo] Univ Perugia, Dept Biomed & Surg Sci, Sect Ophthalmol, S Maria della Misericordia Hosp, I-06100 Perugia, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Hospital
   Santa Maria della Misericordia; University of Perugia
RP Coscas, GJ (通讯作者)，Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
EM gabriel.coscas@gmail.com
RI Cagini, Carlo/H-3431-2019; Cagini, Carlo/L-2914-2016
OI Cagini, Carlo/0000-0002-3812-9219; Cagini, Carlo/0000-0002-3812-9219;
   Lupidi, Marco/0000-0002-6817-2488
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Coscas G., 2009, OPTICAL COHERENCE TO, pP159
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gass J.D., 1967, AM J OPHTHALMOL, V63, pS1
   Giovannini A, 1999, BRIT J OPHTHALMOL, V83, P438, DOI 10.1136/bjo.83.4.438
   HYVARINEN L, 1980, ACTA OPHTHALMOL, V58, P528
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Laser Institute of America, 2007, Z136 ANSI, P1
   Lawman GA, 2009, AM J OPHTHALMOL, V148
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   OHKUMA H, 1983, INVEST OPHTH VIS SCI, V24, P481
   OHKUMA H, 1983, ARCH OPHTHALMOL-CHIC, V101, P1102, DOI 10.1001/archopht.1983.01040020104018
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Su ZA, 2012, J OCUL PHARMACOL TH, V28, P410, DOI 10.1089/jop.2011.0221
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
NR 27
TC 201
Z9 210
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2015
VL 35
IS 11
BP 2219
EP 2228
DI 10.1097/IAE.0000000000000766
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CV5LD
UT WOS:000364311100008
PM 26398697
DA 2022-11-30
ER

PT J
AU Kucuk, MF
   Ayan, A
   Toslak, D
   Suren, E
   Yaprak, L
   Cetinkaya, E
   Erol, MK
   Coban, DT
AF Kucuk, Mehmet Fatih
   Ayan, Ayse
   Toslak, Devrim
   Suren, Elcin
   Yaprak, Lutfiye
   Cetinkaya, Ersan
   Erol, Muhammet Kazim
   Coban, Deniz Turgut
TI Is age-related macular degeneration a local manifestation of systemic
   disorder? Changes in nailfold capillaries at age-related macular
   degeneration
SO IRISH JOURNAL OF MEDICAL SCIENCE
LA English
DT Article
DE Age-related macular degeneration; Nailfold capillaroscopy;
   Pathophysiology
ID 15-YEAR CUMULATIVE INCIDENCE; CARDIOVASCULAR-DISEASE; RISK-FACTORS;
   VIDEOCAPILLAROSCOPY; DRUSEN; EYE
AB Aims Determining whether nailfold capillary involvement is present in patients with Age-related macular degeneration (AMD) and whether there are different nailfold capillaroscopy findings between wet and dry types. Methods From January 2016 to December 2017, with an initial diagnosis of AMD, 53 consecutive adult patients (AMD group) and 91 age- and sex-matched healthy individuals were studied prospectively. There was no history of any other ocular disease and other disease affecting nailfold capillaries. All subjects underwent a complete ophthalmic examination. The classified and advanced stages of wet and dry types were not included. All nailfold capillaroscopy examinations were performed by the same rheumatologist. Results It was found that the frequency of major capillaroscopic findings such as capillary ectasia, micro-hemorrhage, tortuosity, neo-formation, bizarre capillary, and bushy capillaries increased in the AMD group according to the normal group, but no significant relationship was found for capillary aneurysm. In dry or wet type of AMD in terms of ectasia, micro-hemorrhage, tortuosity, neo-formation, bizarre structure, bushy structure, or aneurism of nailfold capillaries, no significant correlation was found. Conclusions Nailfold capillaroscopy can detect microvascular changes in the nailfold capillary, in early and late stages of AMD. There were morphological changes in the nailfold capillaries of AMD patients, suggesting that there are systemic superficial microvascular changes that may be due to the systemic nature of the disease.
C1 [Kucuk, Mehmet Fatih] Alanya Alaaddin Keykubat Univ, Fac Med, Dept Ophthalmol, Temel Tip Bilimleri Binasi Kestel Kampusu Alanya, TR-07070 Antalya, Turkey.
   [Ayan, Ayse] Hlth Sci Univ, Antalya Training & Res Hosp, Dept Rheumatol, Antalya, Turkey.
   [Toslak, Devrim; Suren, Elcin; Yaprak, Lutfiye; Cetinkaya, Ersan; Erol, Muhammet Kazim; Coban, Deniz Turgut] Hlth Sci Univ, Antalya Training & Res Hosp, Dept Ophthalmol, Antalya, Turkey.
C3 Alanya Alaaddin Keykubat University; Antalya Training & Research
   Hospital; University of Health Sciences Turkey; Antalya Training &
   Research Hospital; University of Health Sciences Turkey
RP Kucuk, MF (通讯作者)，Alanya Alaaddin Keykubat Univ, Fac Med, Dept Ophthalmol, Temel Tip Bilimleri Binasi Kestel Kampusu Alanya, TR-07070 Antalya, Turkey.
EM mehmet.kucuk@alanya.edu.tr
RI Toslak, Devrim/AAH-1591-2019; Toslak, Devrim/AAK-6970-2021; Küçük,
   Mehmet Fatih/AAA-2469-2022; Küçük, Mehmet Fatih/AAU-2375-2021; Toslak,
   Devrim/ABC-2814-2021
OI Küçük, Mehmet Fatih/0000-0002-2548-7869; Ayan, Ayse/0000-0001-9488-2611;
   EROL, Muhammet Kazim/0000-0002-1720-8065
CR Aird WC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006429
   Algvere PV, 2016, ACTA OPHTHALMOL, V94, P427, DOI 10.1111/aos.13011
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Arifoglu HB, 2016, AGING CLIN EXP RES, V28, P853, DOI 10.1007/s40520-015-0377-5
   Baba T, 2009, INVEST OPHTH VIS SCI, V50, P3503, DOI 10.1167/iovs.08-2614
   Ballermann BJ, 2005, KIDNEY INT, V67, P1668, DOI 10.1111/j.1523-1755.2005.00260.x
   Bentov I, 2015, MICROVASC RES, V100, P25, DOI 10.1016/j.mvr.2015.04.004
   Bergman R, 2003, ARCH DERMATOL, V139, P1027, DOI 10.1001/archderm.139.8.1027
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chirco KR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00539
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cousins CC, 2017, EYE, V31, P698, DOI 10.1038/eye.2016.312
   Cutolo M, 2000, J RHEUMATOL, V27, P155
   Cutolo M, 2013, RHEUMATOLOGY, V52, P1933, DOI 10.1093/rheumatology/ket153
   Cutolo M, 2013, BEST PRACT RES CL RH, V27, P237, DOI 10.1016/j.berh.2013.03.001
   Cutolo M, 2008, BEST PRACT RES CL RH, V22, P1093, DOI 10.1016/j.berh.2008.09.001
   Erol MK, 2016, GRAEF ARCH CLIN EXP, V254, P1889, DOI 10.1007/s00417-016-3322-1
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Friedman E, 2008, AM J OPHTHALMOL, V146, P348, DOI 10.1016/j.ajo.2008.05.017
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Kosior-Jarecka E, 2018, CURR EYE RES, V43, P747, DOI 10.1080/02713683.2018.1438632
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Lopez MLSS, 2003, AM J PHYSIOL-REG I, V284, pR1126, DOI 10.1152/ajpregu.00543.2002
   Molins B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00808
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   PIETTE JC, 1990, J MAL VASCUL, V15, P410
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   Ryan SJ, 2001, RETINA, P1005
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Uretmen O, 2003, OPHTHALMOLOGICA, V217, P137, DOI 10.1159/000068559
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Warwick A, 2014, J CLIN MED, V3, P1234, DOI 10.3390/jcm3041234
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 46
TC 0
Z9 0
U1 0
U2 4
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0021-1265
EI 1863-4362
J9 IRISH J MED SCI
JI Irish J. Med. Sci.
PD MAY
PY 2020
VL 189
IS 2
BP 727
EP 733
DI 10.1007/s11845-019-02109-1
EA OCT 2019
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA LG2JM
UT WOS:000492324700003
PM 31650451
DA 2022-11-30
ER

PT J
AU Al-Khersan, H
   Hussain, RM
   Ciulla, TA
   Dugel, PU
AF Al-Khersan, Hasenin
   Hussain, Rehan M.
   Ciulla, Thomas A.
   Dugel, Pravin U.
TI Innovative therapies for neovascular age-related macular degeneration
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Review
DE Age-related macular degeneration; vascular endothelial growth factor;
   abicipar pegol; brolucizumab; conbercept; X-82; Tie-2 receptor;
   faricimab; nesvacumab; gene therapy; RGX-314; ADVM-022
ID ENDOTHELIAL GROWTH-FACTOR; DAILY CLINICAL-PRACTICE; VISUAL-ACUITY
   OUTCOMES; TREAT-AND-EXTEND; GENE-THERAPY; INTRAVITREAL RANIBIZUMAB;
   OPEN-LABEL; FOLLOW-UP; PDGF-B; PHASE-1
AB Introduction: Investigational anti-VEGF treatments for neovascular age-related macular degeneration (nAMD) aim to improve visual outcomes and reduce treatment burden; these include long-acting agents, combination strategies, topical agents, sustained-release, and genetic therapies. Areas covered: The authors provide a comprehensive review of investigational therapies for nAMD, focusing on therapies currently in clinical trial. Expert opinion: Long-acting anti-VEGF agents have demonstrated promising results in phase 3 studies, and include Brolucizumab, a single-chain antibody fragment, and Abicipar, a designed ankyrin repeat protein (DARPin). Other unique anti-VEGF agents in current trials include Conbercept - a fusion protein of the VEGF receptor domains, KSI-301 - an anti-VEGF antibody biopolymer conjugate, and OPT-302 - an inhibitor of VEGF-C/D. Strategies to activate the Tie-2 receptor, some in combination with VEGF inhibition, are of interest, with recent trials of Faricimab, ARP-1536, and nesvacumab. Topical anti-VEGF +/- anti-PDGF agents, such as pazopanib, squalamine lactate, regorafenib, and LHA510 have shown limited efficacy and/or have not been advanced, although PAN-90806 continues to advance with promising initial results. Sustained-release anti-VEGF treatments, to address treatment burden, include the ranibizumab Port Delivery System, GB-102, NT-503, hydrogel depot, Durasert, and ENV1305. Similarly, genetic therapies, including RGX-314 and ADVM-022, aim to provide sustained anti-VEGF expression from the retina.
C1 [Al-Khersan, Hasenin; Hussain, Rehan M.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [Ciulla, Thomas A.] Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Ciulla, Thomas A.] Midwest Eye Inst, Retina Serv, Indianapolis, IN USA.
   [Ciulla, Thomas A.] Clearside Biomed, Alpharetta, GA USA.
   [Dugel, Pravin U.] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Dugel, Pravin U.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Los Angeles, CA 90033 USA.
C3 Bascom Palmer Eye Institute; University of Miami; Indiana University
   System; Indiana University Bloomington; University of Southern
   California
RP Hussain, RM (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM rhussain27@gmail.com
RI Ciulla, Thomas/AAA-1299-2020
OI Ciulla, Thomas/0000-0001-5557-6777
CR [Anonymous], 2018, LADDER TRIAL PORT DE
   [Anonymous], 2019, GRAYBUG VISION PRESE
   [Anonymous], 2019, ADVERUM BIOTECHNOLOG
   [Anonymous], 2019, ALLERGAN MOL PARTNER
   [Anonymous], 2018, PANOPTICA DOSES 1 PA
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7
   Baek SU, 2016, CUTAN OCUL TOXICOL, V35, P310, DOI 10.3109/15569527.2015.1124886
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bhattacharya D, 2015, EXP MOL PATHOL, V98, P455, DOI 10.1016/j.yexmp.2015.03.026
   Binley K, 2012, HUM GENE THER, V23, P980, DOI 10.1089/hum.2012.008
   Boyer DS, 2016, AFLIBERCEPT COMBINAT
   Bracha P, 2018, SURV OPHTHALMOL, V63, P281, DOI 10.1016/j.survophthal.2017.08.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2016, AM AC OPHTH ANN M CH
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Ciulla TA, 2019, OPHTHALMOL RETINA
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Davis S, 1999, CURR TOP MICROBIOL, V237, P173
   Donald J, 1967, AM J OPHTHALMOL 2, V63, p573/1
   Dugel PU, 2018, PHASE 3 RANDOMIZED D
   Dugel PU, 2017, AM ACAD OPHTHALMOLOG
   Dunn EN, 2017, OSLI RETINA, V48, P100, DOI 10.3928/23258160-20170130-02
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   Fachinger G, 1999, ONCOGENE, V18, P5948, DOI 10.1038/sj.onc.1202992
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hansen TM, 2010, CELL SIGNAL, V22, P527, DOI 10.1016/j.cellsig.2009.11.007
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hellstrom M, 1999, DEVELOPMENT, V126, P3047
   Helzner J, 2018, RETIN PHYS
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holmes DIR, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-2-209
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hussain RM, 2017, OSLI RETINA, V48, P780, DOI 10.3928/23258160-20170928-01
   Igarashi T, 2003, GENE THER, V10, P219, DOI 10.1038/sj.gt.3301878
   Jackson TL, 2017, JAMA OPHTHALMOL, V135, P761, DOI 10.1001/jamaophthalmol.2017.1571
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Joussen A, 2016, COMBINED PHASE 2A B
   Khanani AM, 2018, SIMULTANEOUS INHIBIT
   Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200
   Kirker RM, 2018, CLIN TRIAL CLOSEUP D
   Lai CM, 2012, GENE THER, V19, P999, DOI 10.1038/gt.2011.169
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Lurker N., 2016, OPHTH INN SUMM AM AC
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rayess N, 2016, AM J OPHTHALMOL, V165, P88, DOI 10.1016/j.ajo.2016.02.028
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Rubio RG, 2014, RETINA TODAY
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   van Asten F, 2015, ACTA OPHTHALMOL, V93, P126, DOI 10.1111/aos.12610
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 78
TC 48
Z9 50
U1 3
U2 32
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD OCT 13
PY 2019
VL 20
IS 15
BP 1879
EP 1891
DI 10.1080/14656566.2019.1636031
EA JUL 2019
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA JA6WJ
UT WOS:000476444100001
PM 31298960
DA 2022-11-30
ER

PT J
AU Gehrs, KM
   Jackson, JR
   Brown, EN
   Allikmets, R
   Hageman, GS
AF Gehrs, Karen M.
   Jackson, Jared R.
   Brown, Eric N.
   Allikmets, Rando
   Hageman, Gregory S.
TI Complement, Age-Related Macular Degeneration and a Vision of the Future
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; DENSE DEPOSIT DISEASE; FACTOR-H POLYMORPHISM;
   BLUE-MOUNTAINS-EYE; BEAVER DAM EYE; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; KRYPTON LASER PHOTOCOAGULATION; HIGH-DOSE
   SUPPLEMENTATION; BODY-MASS INDEX; PHOTODYNAMIC THERAPY
AB Age-related macular degeneration (AMD) is one of the most well-characterized late-onset, complex trait diseases. Remarkable advances in our understanding of the genetic and biological foundations of this disease were derived from a recent convergence of scientific and clinical data. Importantly, the more recent identification of AMD-associated variations in a number of complement pathway genes has provided strong support for earlier, paradigm-shifting studies that suggested that aberrant function of the complement system plays a key role in disease etiology. Collectively, this wealth of information has provided an impetus for the development of powerful tools to accurately diagnose disease risk and progression and complement-based therapeutics that will ultimately delay or prevent AMD. Indeed, we are poised to witness a new era of a personalized approach toward the assessment, management, and treatment of this debilitating, chronic disease. Arch Ophthalmol. 2010;128(3):349-358
C1 [Hageman, Gregory S.] Univ Utah, Dept Ophthalmol & Visual Sci, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA.
   [Gehrs, Karen M.; Jackson, Jared R.; Brown, Eric N.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
   [Allikmets, Rando] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   [Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA.
C3 Utah System of Higher Education; University of Utah; University of Iowa;
   Columbia University; Columbia University
RP Hageman, GS (通讯作者)，Univ Utah, Dept Ophthalmol & Visual Sci, John A Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM gregory.hageman@hsc.utah.edu
RI Brown, Eric N/A-1018-2010; Allikmets, Rando/ABD-4533-2021
OI Brown, Eric N/0000-0002-2641-1890; Gehrs, Karen/0000-0003-4510-9678
FU National Institutes of Health [R24 EY017404, R01 EY13435]; Research to
   Prevent Blindness Inc; Macula Vision Research Foundation; Wallach
   Foundation; Elyachar Foundation; Kaplen Foundation; Wigdeon Point
   Charitable Foundation; Ruth and Milton Steinbach Foundation; Alcon
   Research Institute; NATIONAL EYE INSTITUTE [R01EY013435, R24EY017404]
   Funding Source: NIH RePORTER
FX This study was supported by grants R24 EY017404 (Dr Hageman) and R01
   EY13435 (Dr Allikmets) from the National Institutes of Health;
   unrestricted grants to the Department of Ophthalmology and Visual
   Sciences, University of Utah, the Department of Ophthalmology and Visual
   Sciences, University of Iowa, and the Department of Ophthalmology, and
   Columbia University from Research to Prevent Blindness Inc; the Macula
   Vision Research Foundation (Dr Allikmets); the Wallach Foundation (Dr
   Allikmets); the Elyachar Foundation (Dr Allikmets); the Kaplen
   Foundation (Dr Allikmets); the Wigdeon Point Charitable Foundation (Dr
   Allikmets); the Ruth and Milton Steinbach Foundation (Dr Allikmets); and
   the Alcon Research Institute (Drs Allikmets and Hageman).
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Amara U, 2008, ADV EXP MED BIOL, V632, P71, DOI 10.1007/978-0-387-78952-1_6
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 2007, MICROBE
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   ARVILOMMI H, 1974, NATURE, V251, P740, DOI 10.1038/251740a0
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   BARTOK I, 1995, J IMMUNOL, V154, P5367
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   DESPRIET DD, 2008, INVEST OPHTHALMOL VI
   Despriet DDG, 2007, ARCH OPHTHALMOL-CHIC, V125, P1270, DOI 10.1001/archopht.125.9.1270
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2008, ADV EXP MED BIOL, V613, P211, DOI 10.1007/978-0-387-74904-4_24
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fang CJ, 2008, BRIT J HAEMATOL, V143, P336, DOI 10.1111/j.1365-2141.2008.07324.x
   FINN JE, 1993, CLIN EXP IMMUNOL, V91, P410
   FINN JE, 1994, NEPHROL DIAL TRANSPL, V9, P1564
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   FRANCOIS J, 1977, OPHTHALMOLOGICA, V175, P67, DOI 10.1159/000308637
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   GOBEL RJ, 1987, BIOMATERIALS, V8, P285, DOI 10.1016/0142-9612(87)90116-5
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   GUYER MS, 1993, AM J DIS CHILD, V147, P1145, DOI 10.1001/archpedi.1993.02160350019003
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAN DP, 1988, OPHTHALMOLOGY, V95, P1380
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   KEW RR, 1987, CLIN IMMUNOL IMMUNOP, V44, P248, DOI 10.1016/0090-1229(87)90069-9
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   KOCHOUNIAN HH, 1991, J CATARACT REFR SURG, V17, P139, DOI 10.1016/S0886-3350(13)80243-X
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   LOKKI ML, 1991, IMMUNOGENETICS, V34, P242, DOI 10.1007/BF00215259
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   Markiewski MM, 2008, J CELL MOL MED, V12, P2245, DOI 10.1111/j.1582-4934.2008.00504.x
   MONDINO BJ, 1987, ARCH OPHTHALMOL-CHIC, V105, P989
   MONDINO BJ, 1983, ACTA OPHTHALMOL, V61, P76
   MONDINO BJ, 1985, INVEST OPHTH VIS SCI, V26, P905
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Okamoto H, 2006, MOL VIS, V12, P156
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Parmeggiani F, 2009, PHARMACOGENOMICS, V10, P81, DOI 10.2217/14622416.10.1.81
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   RAMBAUSEK M, 1987, Nephrology Dialysis Transplantation, V2, P208
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Shi J, 2009, SCI CHINA SER C, V52, P17, DOI 10.1007/s11427-009-0011-x
   Silvestri G, 1997, MOL MED TODAY, V3, P84, DOI 10.1016/S1357-4310(96)10057-5
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Singh KK, 2009, EXP EYE RES, V88, P479, DOI 10.1016/j.exer.2008.10.019
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   SORENSON JA, 1985, OPHTHALMOLOGY, V92, P1059
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Walker PD, 2007, CURR OPIN NEPHROL HY, V16, P204, DOI 10.1097/MNH.0b013e3280bdc0f4
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   WELCH TR, 1990, J PEDIATR-US, V116, pS92, DOI 10.1016/S0022-3476(05)82709-X
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 110
TC 114
Z9 125
U1 1
U2 14
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAR
PY 2010
VL 128
IS 3
BP 349
EP 358
DI 10.1001/archophthalmol.2010.18
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 565QC
UT WOS:000275308100012
PM 20212207
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Barakat, MR
   Kaiser, PK
AF Barakat, Mark Rami
   Kaiser, P. K.
TI VEGF inhibitors for the treatment of neovascular age-related macular
   degeneration
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Review
DE age-related macular degeneration; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL INJECTION; CHOROIDAL
   NEOVASCULARIZATION; OCULAR NEOVASCULARIZATION; RANIBIZUMAB LUCENTIS;
   BEVACIZUMAB AVASTIN; IMATINIB MESYLATE; PHARMACOKINETICS; SIROLIMUS;
   ANTIBODY
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the Western world for those patients aged 50 years or older. Neovascular AMD, a subtype characterized by the growth of new, pathologic blood vessels, results in most of the cases of severe and rapid vision loss associated with AMD. A critical activator of angiogenesis in neovascular AMD is VEGF. Several therapies have been and are now being developed for neovascular AMD, with the goal of inhibiting VEGF. These VEGF inhibitors include the RNA aptamer pegaptanib, partial and full-length antibodies ranibizumab and bevacizumab, VEGF receptor decoy VEGF Trap, small interfering RNA-based therapies bevasiranib and AGN211745, sirolimus, and tyrosine kinase inhibitors including vatalanib, pazopanib, TG100801, TG101095, AG013958 and AL39324. At present, established therapies have met with great success in reducing the vision loss associated with neovascular AMD, whereas those still investigational in nature offer the potential for further advances.
C1 [Barakat, Mark Rami; Kaiser, P. K.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Kaiser, PK (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM pkkaiser@mac.com
OI Kaiser, Peter/0000-0001-5126-045X
FU Allergan; Pfizer; Novartis; Genentech; QLT; Regeneron
FX PK Kaiser is a consultant for Genentech and has received research grant
   support from Allergan, Pfizer, Novartis, Genentech, QLT and Regeneron.
CR BINGAMAN D, 2007, INVEST OPHTHALMOL VI, V48
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brucker A, 2006, COMB RET SOC GON SOC
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   CHEN ZZ, 2007, INVEST OPHTHALMOL VI, V48
   *CLINICALTRIALS, SAF EFF OR PTK787 PA
   *CLINICALTRIALS, STUD SAF EFF AG 013
   *CLINICALTRIALS, STUD EV PHARM SAF PH
   *CLINICALTRIALS, STUD US INTR INJ SMA
   *CLINICALTRIALS, SAF EFF STUD EV COMB
   *CLINICALTRIALS, DOS ESC TRIAL INTR I
   *CLINICALTRIALS, PHAS 1 2 STUD OC SIR
   *CLINICALTRIALS, OP LAB PIL STUD TG10
   ClinicalTrials.gov, PHAS 2 STUD OC SIR R
   ClinicalTrials.gov, COMP AG REL MAC DEG
   Dejneka NS, 2004, MOL VIS, V10, P964
   Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461
   Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811
   Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336
   Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   *GEN INC, 2008, LUC RAN INJ PRESCR I
   George Suzanne, 2007, Curr Oncol Rep, V9, P323, DOI 10.1007/s11912-007-0040-1
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128
   GUTTMAN C, INTRAVITREAL RANIBIZ
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kiefer FN, 2003, CURR PHARM DESIGN, V9, P1733, DOI 10.2174/1381612033454540
   Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   KLEINMAN D, 2007, INVEST OPHTHALMOL VI, V48
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Konner Jason, 2004, Clin Colorectal Cancer, V4 Suppl 2, pS81
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LALWANI G, ALL PRONTO STUDY YIE
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Maier P, 2005, GRAEF ARCH CLIN EXP, V243, P593, DOI 10.1007/s00417-004-1021-9
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Merkel S, 2006, TRANSPL P, V38, P714, DOI 10.1016/j.transproceed.2006.01.044
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Morath C, 2007, TRANSPLANT P, V39, P99, DOI 10.1016/j.transproceed.2006.10.219
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Nishida T, 2008, INT J CLIN ONCOL, V13, P244, DOI 10.1007/s10147-007-0746-y
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Reich S, 2003, MOL VIS, V9, P210
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Ruiter D J, 1993, Behring Inst Mitt, P258
   Sawada O, 2007, ARCH OPHTHALMOL-CHIC, V125, P1363, DOI 10.1001/archopht.125.10.1363
   Sehgal SN, 2003, TRANSPLANT P, V35, p7S, DOI 10.1016/S0041-1345(03)00211-2
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Toso C, 2007, TRANSPLANTATION, V83, P1162, DOI 10.1097/01.tp.0000262607.95372.e0
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Yano K, 2001, J CLIN INVEST, V107, P409, DOI 10.1172/JCI11317
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
   2008 RET SOC M
NR 73
TC 37
Z9 61
U1 3
U2 19
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3784
EI 1744-7658
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD MAY
PY 2009
VL 18
IS 5
BP 637
EP 646
DI 10.1517/13543780902855316
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 447LF
UT WOS:000266191900008
PM 19388880
DA 2022-11-30
ER

PT J
AU Kwa, FAA
   Thrimawithana, TR
AF Kwa, Faith A. A.
   Thrimawithana, Thilini R.
TI Epigenetic modifications as potential therapeutic targets in age-related
   macular degeneration and diabetic retinopathy
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID PIGMENT EPITHELIAL-CELLS; HISTONE DEACETYLASE INHIBITORS; DNA
   METHYLATION; VALPROIC ACID; GENE-EXPRESSION; RETINITIS-PIGMENTOSA;
   ISCHEMIC-INJURY; ANGIOGENESIS; ACETYLATION; DISEASE
AB Recently, aberrant epigenetic modifications have been identified in the pathogenesis of the posterior eye diseases, age-related macular degeneration (AMD) and diabetic retinopathy (DR). This has led to the development of alternative therapies that can alter aberrant chromatin-remodelling processes involved in AMD and DR. These novel therapeutic agents could help to ameliorate the challenges associated with current treatments that are limited by variable patient response and disease heterogeneity. However, research on the use of epigenetic-based therapies in these diseases is relatively young and, therefore, preclinical studies that evaluate their mechanism of action, specificity and adverse effects are warranted.
C1 [Kwa, Faith A. A.] RMIT Univ, Sch Med Sci, Discipline Lab Med, Bundoora, Vic 3083, Australia.
   [Thrimawithana, Thilini R.] RMIT Univ, Sch Med Sci, Discipline Pharm, Bundoora, Vic 3083, Australia.
C3 Royal Melbourne Institute of Technology (RMIT); Royal Melbourne
   Institute of Technology (RMIT)
RP Kwa, FAA (通讯作者)，RMIT Univ, Sch Med Sci, Discipline Lab Med, Bundoora, Vic 3083, Australia.
EM faith.kwa@rmit.edu.au
OI Kwa, Faith/0000-0002-9702-0563
CR Baird PN, 2013, EPIGENOMICS-UK, V5, P239, DOI [10.2217/EPI.13.19, 10.2217/epi.13.19]
   Balaiya S, 2012, MOL VIS, V18, P114
   Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200
   Bhalla S, 2013, BRIT J OPHTHALMOL, V97, P895, DOI 10.1136/bjophthalmol-2013-303084
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Blanchard F, 2005, DRUG DISCOV TODAY, V10, P197, DOI 10.1016/S1359-6446(04)03309-4
   Bode KA, 2007, IMMUNOLOGY, V122, P596, DOI 10.1111/j.1365-2567.2007.02678.x
   Brewer GJ, 2010, EXP GERONTOL, V45, P173, DOI 10.1016/j.exger.2009.11.007
   Buysschaert I, 2008, J CELL MOL MED, V12, P2533, DOI 10.1111/j.1582-4934.2008.00515.x
   Crosson CE, 2010, INVEST OPHTH VIS SCI, V51, P3639, DOI 10.1167/iovs.09-4538
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cvekl A, 2010, HEREDITY, V105, P135, DOI 10.1038/hdy.2010.16
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Donati G, 2007, OPHTHALMOLOGICA, V221, P366, DOI 10.1159/000107495
   Fan J, 2013, INVEST OPHTH VIS SCI, V54, P4072, DOI 10.1167/iovs.12-11529
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Gibney ER, 2010, HEREDITY, V105, P4, DOI 10.1038/hdy.2010.54
   Gnana-Prakasam JP, 2013, INVEST OPHTH VIS SCI, V54, P63, DOI 10.1167/iovs.12-10312
   Gupta SK, 2011, J OCUL PHARMACOL TH, V27, P123, DOI 10.1089/jop.2010.0123
   Halili MA, 2009, CURR TOP MED CHEM, V9, P309, DOI 10.2174/156802609788085250
   He SK, 2013, MOL VIS, V19, P665
   Hellebrekers DMEI, 2006, MOL CANCER THER, V5, P467, DOI 10.1158/1535-7163.MCT-05-0417
   Heng LZ, 2013, DIABETIC MED, V30, P640, DOI 10.1111/dme.12089
   Hjelmeland L.M, 2010, INVEST OPHTH VIS SCI, V52, P1622
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Kadiyala CSR, 2012, J BIOL CHEM, V287, P25869, DOI 10.1074/jbc.M112.375204
   Katoh M, 2013, INT J MOL MED, V32, P763, DOI 10.3892/ijmm.2013.1444
   Kilmko PG, 2004, Alcon Incorporated Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases, Patent No. [WO2004/043352, 2004043352]
   Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507
   Kohli RM, 2013, NATURE, V502, P472, DOI 10.1038/nature12750
   Kowluru RA, 2006, INVEST OPHTH VIS SCI, V47, P1594, DOI 10.1167/iovs.05-1276
   Kowluru RA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/635284
   Kowluru RA, 2011, DIABETES, V60, P3023, DOI 10.2337/db11-0816
   Kwa FAA, 2011, DRUG DISCOV TODAY, V16, P543, DOI 10.1016/j.drudis.2011.05.012
   Lopez L, 1999, EUR NEUROL, V41, P201, DOI 10.1159/000008051
   Michaelis M, 2004, MOL PHARMACOL, V65, P520, DOI 10.1124/mol.65.3.520
   Nencioni A, 2007, CLIN CANCER RES, V13, P3933, DOI 10.1158/1078-0432.CCR-06-2903
   Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001
   Rosberger DF, 2013, ENDOCRIN METAB CLIN, V42, P721, DOI 10.1016/j.ecl.2013.08.001
   Rossig L, 2002, CIRC RES, V91, P837, DOI 10.1161/01.RES.0000037983.07158.B1
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sedivy JM, 2008, EXP CELL RES, V314, P1909, DOI 10.1016/j.yexcr.2008.02.023
   Sharma RA, 2005, EUR J CANCER, V41, P1955, DOI 10.1016/j.ejca.2005.05.009
   Sisk RA, 2012, BRIT J OPHTHALMOL, V96, P1154, DOI 10.1136/bjophthalmol-2012-301950
   Soufi FG, 2012, PHARMACOL REP, V64, P1505, DOI 10.1016/S1734-1140(12)70948-9
   Suuronen T, 2007, BIOCHEM BIOPH RES CO, V357, P397, DOI 10.1016/j.bbrc.2007.03.135
   Syreeni A, 2011, DIABETES, V60, P3073, DOI 10.2337/db11-0073
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P979, DOI 10.1167/iovs.04-1120
   Tewari S, 2012, INVEST OPHTH VIS SCI, V53, P4881, DOI 10.1167/iovs.12-9732
   Tewari S, 2012, ANTIOXID REDOX SIGN, V17, P492, DOI 10.1089/ars.2011.4333
   Tezel TH, 2006, INVEST OPHTH VIS SCI, V47, P5075, DOI 10.1167/iovs.05-1557
   Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896
   Torres JM, 2013, PEDIATR DIABETES, V14, P90, DOI 10.1111/pedi.12015
   Uchida H, 2005, EXP EYE RES, V80, P23, DOI 10.1016/j.exer.2004.08.004
   Wang LL, 2013, MOL NUTR FOOD RES, V57, P1557, DOI 10.1002/mnfr.201200718
   Wang LL, 2012, GLIA, V60, P1896, DOI 10.1002/glia.22405
   Wang SS, 2008, P NATL ACAD SCI USA, V105, P7738, DOI 10.1073/pnas.0802857105
   Wang XJ, 2012, ACTA PHARM SIN B, V2, P387, DOI 10.1016/j.apsb.2012.06.005
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300
   Zhang ZZ, 2012, EXP EYE RES, V94, P98, DOI 10.1016/j.exer.2011.11.013
   Zhong Q, 2013, DIABETES, V62, P2559, DOI 10.2337/db12-1141
   Zhong Q, 2013, INVEST OPHTH VIS SCI, V54, P244, DOI 10.1167/iovs.12-10854
   Zhong Q, 2011, DIABETES, V60, P1304, DOI 10.2337/db10-0133
   Zhong Q, 2010, J CELL BIOCHEM, V110, P1306, DOI 10.1002/jcb.22644
   Zhou JL, 2006, REJUV RES, V9, P256, DOI 10.1089/rej.2006.9.256
NR 67
TC 22
Z9 25
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD SEP
PY 2014
VL 19
IS 9
BP 1387
EP 1393
DI 10.1016/j.drudis.2014.03.026
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AQ2GP
UT WOS:000342604100013
PM 24717156
DA 2022-11-30
ER

PT J
AU Ferrara, D
   Seddon, JM
AF Ferrara, Daniela
   Seddon, Johanna M.
TI Phenotypic Characterization of Complement Factor H R1210C Rare Genetic
   Variant in Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; HIGH-RISK; CLINICAL PHENOTYPE; MUTATIONS;
   DRUSEN; GLOMERULONEPHRITIS; SYSTEM; CFH; C3; ASSOCIATION
AB IMPORTANCE The complement factor H R1210C rare variant confers the strongest genetic risk for age-related macular degeneration and earlier age at onset; however, its associated phenotype has not been well characterized.
   OBJECTIVE To describe specific fundus features of a white population with the R1210C rare variant.
   DESIGN, SETTING, AND PARTICIPANTS Fundus features specific for diagnosis and disease staging were retrospectively characterized by systematic review of all available fundus images for each patient, including color photography, fluorescein angiography, fundus autofluorescence, and optical coherence tomography, at a tertiary ophthalmologic referral center. For this retrospective observational study conducted from 2012 to 2014, enrolled patients with the variant and their family members without the variant were identified from the Age-Related Macular Degeneration Study for a family-based study arm. For patients with the variant but without a family member enrolled in the study, age-matched comparison individuals without the variant were selected randomly from the database.
   MAIN OUTCOMES AND MEASURES The presence of drusen in the macula (macular drusen score) and estimated number (total macular drusen score) were assessed. The presence of drusen in the extramacular regions (extramacular drusen score), pigmentary abnormalities, and disease staging were also evaluated. Binary logistic regression models were used to evaluate the association between rare variant status and ocular phenotypes.
   RESULTS Images from a total of 143 patients (283 eyes), including 62 patients with the rare variant, were analyzed. Drusen score covariates were associated with the R1210C rare variant. A larger proportion of patients carrying the variant had the highest level of macular and total macular drusen scores compared with those without the variant (57.9% vs 16.7% and 52.9% vs 14.2%, respectively; P for trend < .001 for both scores). Patients carrying the rare variant had a much greater likelihood of having advanced disease (odds ratio, 7.0; 95% CI, 3.1-16.2; P < .001). A higher prevalence of geographic atrophy was observed among patients carrying the variant (odds ratio, 13.7; 95% CI, 5.0-37.7; P < .001).
   CONCLUSIONS AND RELEVANCE The typical phenotype of the complement factor H R1210C rare variant is associated with extensive drusen accumulation in the macula and throughout the fundus, as well as with a high risk for having advanced disease. Better characterization of genetic profiles in age-related macular degeneration may be important for screening and future therapeutic strategies for this vision-threatening condition.
C1 [Ferrara, Daniela; Seddon, Johanna M.] Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
C3 Tufts University; Tufts University
RP Seddon, JM (通讯作者)，Tufts Med Ctr, Dept Ophthalmol, Ophthalm Epidemiol & Genet Serv, 800 Washington St,POB 450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
FU National Institutes of Health [RO1-EY11309, RO1-EY022445]; Massachusetts
   Lions Eye Research Fund Inc, New Bedford; Research to Prevent Blindness
   Inc, New York, New York; Foundation Fighting Blindness, Columbia,
   Maryland; American Macular Degeneration Foundation, Northampton,
   Massachusetts; Age-Related Macular Degeneration Research Fund,
   Ophthalmic Epidemiology and Genetics Service, Tufts Medical Center,
   Tufts University School of Medicine, Boston, Massachusetts; NATIONAL EYE
   INSTITUTE [R01EY011309, R01EY022445] Funding Source: NIH RePORTER
FX This study was supported by grants RO1-EY11309 and RO1-EY022445 from the
   National Institutes of Health; the Massachusetts Lions Eye Research Fund
   Inc, New Bedford; unrestricted grants from Research to Prevent Blindness
   Inc, New York, New York; Foundation Fighting Blindness, Columbia,
   Maryland; the American Macular Degeneration Foundation, Northampton,
   Massachusetts; and the Age-Related Macular Degeneration Research Fund,
   Ophthalmic Epidemiology and Genetics Service, Tufts Medical Center,
   Tufts University School of Medicine, Boston, Massachusetts.
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   Bresin E, 2013, J AM SOC NEPHROL, V24, P475, DOI 10.1681/ASN.2012090884
   Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kavanagh D, 2013, SEMIN NEPHROL, V33, P508, DOI 10.1016/j.semnephrol.2013.08.003
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Le Quintrec M, 2013, AM J TRANSPLANT, V13, P663, DOI 10.1111/ajt.12077
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Martinez-Barricarte R, 2008, J AM SOC NEPHROL, V19, P639, DOI 10.1681/ASN.2007080923
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676
   Noris M, 2010, CLIN J AM SOC NEPHRO, V5, P1844, DOI 10.2215/CJN.02210310
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rosner B, 2006, BIOMETRICS, V62, P1251, DOI 10.1111/j.1541-0420.2006.00582.x
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon J. M., 2015, INVEST OPHTH VIS SCI, DOI [10.1167/iovs.14-15841, DOI 10.1167/I0VS.14-15841]
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Servais A, 2007, J MED GENET, V44, P193, DOI 10.1136/jmg.2006.045328
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 46
TC 34
Z9 34
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2015
VL 133
IS 7
BP 785
EP 791
DI 10.1001/jamaophthalmol.2015.0814
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM6TO
UT WOS:000357823100011
PM 25880396
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Cui, J
   Xia, D
   Hu, Q
   Huang, L
   Zhou, WY
   Liu, MZ
   Wang, KM
   Liu, P
AF Cui, Jing
   Xia, Di
   Hu, Qi
   Huang, Lei
   Zhou, Wenyan
   Liu, Mingzhu
   Wang, Kemeng
   Liu, Ping
TI Correlation of ABCA4 polymorphisms with age-related macular degeneration
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE ATP-binding cassette; sub-family A; member 4 (ABCA4) gene; age-related
   macular degeneration (AMD); polymorphisms
ID STARGARDT DISEASE; RACIAL/ETHNIC GROUPS; VISUAL IMPAIRMENT; TRANSPORTER
   GENE; RISK-FACTORS; MACULOPATHY; PREVALENCE; POPULATION; PROGRESSION;
   MUTATIONS
AB Aims: This research aimed to explore the correlation of ATP-binding cassette, sub-family A, member 4 (ABCA4) gene polymorphisms (rs560426 and 6389T> A) with the occurrence of age-related macular degeneration (AMD). Methods: Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to detect the genotypes of rs560426 and 6389T> A polymorphisms in 110 AMD patients and 125 healthy controls. Cases and controls were matched with each other by age and gender. Genotypic frequencies between cases and controls were compared by chi-square test. Relative risk of AMD was expressed by odds ratios (ORs) and 95% confidence intervals (CIs). Results: Variant homozygote and variant allele of rs560426 were frequently detected in cases. But the difference had no statistical significance (P > 0.05), indicating no significant association existed between rs560426 polymorphism and AMD risk. Similar results were observed in TA and AA genotypes of 6389T> A polymorphism (P > 0.05). However, significant correlation existed between 6389A allele and AMD susceptibility (P = 0.016, OR = 1.677, 95% CI = 1.098-2.564). Conclusion: ABCA4 gene rs560426 polymorphism had no obvious association with the occurrence of AMD, 6389A allele might associate with the onset of AMD.
C1 [Cui, Jing; Hu, Qi; Huang, Lei; Zhou, Wenyan; Liu, Mingzhu; Wang, Kemeng; Liu, Ping] Harbin Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Harbin 150001, Heilongjiang, Peoples R China.
   [Xia, Di] Harbin Med Univ, Affiliated Hosp 5, Dept Ophthalmol, Daqing 163316, Heilongjiang, Peoples R China.
C3 Harbin Medical University; Harbin Medical University
RP Hu, Q; Liu, P (通讯作者)，Harbin Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Harbin 150001, Heilongjiang, Peoples R China.
EM hquirose@163.com
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Audere M, 2015, CASE REP OPHTHALMOL, V2015, DOI 10.1155/2015/452068
   Baum L, 2003, OPHTHALMOLOGICA, V217, P111, DOI 10.1159/000068553
   Biswas EE, 2000, BIOCHEMISTRY-US, V39, P15879, DOI 10.1021/bi0015966
   Biswas-Fiss EE, 2006, BIOCHEMISTRY-US, V45, P3813, DOI 10.1021/bi052059u
   Brion M, 2011, ACTA OPHTHALMOL, V89, pE12, DOI 10.1111/j.1755-3768.2010.02040.x
   Burke TR, 2011, OPHTHALMIC GENET, V32, P165, DOI 10.3109/13816810.2011.565397
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Issa PC, 2015, P NATL ACAD SCI USA, V112, P8415, DOI 10.1073/pnas.1506960112
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein R, 2013, AM J OPHTHALMOL, V156, P1010, DOI 10.1016/j.ajo.2013.06.004
   Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6
   Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins RF, 2012, INVEST OPHTH VIS SCI, V53, P1883, DOI 10.1167/iovs.12-9477
   Nasonkin I, 1998, HUM GENET, V102, P21, DOI 10.1007/s004390050649
   Ritter M, 2013, INVEST OPHTH VIS SCI, V54, P6416, DOI 10.1167/iovs.12-11550
   Sallo FB, 2009, CURR EYE RES, V34, P238, DOI 10.1080/02713680802714058
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 1999, AM J OPHTHALMOL, V128, P173, DOI 10.1016/S0002-9394(99)00145-2
   Testa F, 2012, INVEST OPHTH VIS SCI, V53, P4409, DOI 10.1167/iovs.11-8201
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wu Y, 2015, INT J CLIN EXP PATHO, V8, P7403
   Yi JH, 2012, MOL MED REP, V6, P1045, DOI 10.3892/mmr.2012.1063
NR 36
TC 0
Z9 0
U1 0
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2017
VL 10
IS 1
BP 811
EP 816
PG 6
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA EH8DO
UT WOS:000392002100099
DA 2022-11-30
ER

PT J
AU Steel, DHW
   Sandhu, SS
AF Steel, David Henry William
   Sandhu, Sukhpal Singh
TI Submacular haemorrhages associated with neovascular age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID TISSUE-PLASMINOGEN-ACTIVATOR; PARS-PLANA VITRECTOMY; OCCULT CHOROIDAL
   NEOVASCULARIZATION; EXPERIMENTAL SUBRETINAL HEMORRHAGE; INTRAVITREAL
   BEVACIZUMAB; PNEUMATIC DISPLACEMENT; RETINAL TOXICITY; NATURAL-HISTORY;
   PERFLUOROCARBON LIQUID; INJECTION
AB The exact incidence of submacular haemorrhage (SMH) in patients with neovascular age-related macular degeneration (nAMD) is unknown, and risk factors for its occurrence ill defined. It is known, however, to be a relatively common problem and important because the visual prognosis of these patients is poor. Unfortunately, patients with significant SMH were excluded from all the recent major randomised control trials for nAMD with antivascular endothelial growth factor (VEGF) agents and photodynamic therapy, and as such, the optimum management of patients is uncertain. SMH can present initially or during treatment of nAMD. The location, size, thickness and duration of SMH have an important bearing on treatment and outcomes. Thin or extrafoveal SMH are probably best treated with anti-VEGF agents alone. It has been proposed that patients with moderate-sized SMH, particularly thick haemorrhages, have an improved prognosis with surgical SMH displacement combined with treatment of CNVM if present. SMH drainage, macular translocation and RPE patch grafting are reserved for more severe extensive cases of SMH. Using these techniques, outcomes better than the natural history have been achieved. This review aims to summarise what is known about SMH in nAMD and will discuss a variety of therapeutic interventions.
C1 [Steel, David Henry William] Sunderland Eye Infirm, Sunderland SR2 9HP, England.
   [Sandhu, Sukhpal Singh] Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia
RP Steel, DHW (通讯作者)，Sunderland Eye Infirm, Queen Alexandra Rd, Sunderland SR2 9HP, England.
EM david.steel@chs.northy.nhs.uk
RI Steel, David H W/I-8053-2015
OI Steel, David H W/0000-0001-8734-3089
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Baeteman C, 2009, J FR OPHTALMOL, V32, P309, DOI 10.1016/j.jfo.2009.04.001
   Bakri SJ, 2006, OPHTHAL SURG LAS IM, V37, P278, DOI 10.3928/15428877-20060701-03
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Biester Sabine, 2009, Retin Cases Brief Rep, V3, P62, DOI 10.1097/ICB.0b013e318159e813
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chen SN, 2003, OPHTHALMOLOGY, V110, P704, DOI 10.1016/S0161-6420(02)01979-6
   Chen W L, 1999, Zhonghua Yi Xue Za Zhi (Taipei), V62, P268
   Do DV, 2004, AM J OPHTHALMOL, V137, P558, DOI 10.1016/j.ajo.2003.08.001
   Fang IM, 2009, EYE, V23, P397, DOI 10.1038/sj.eye.6703017
   Gibran S, 2009, GRAEF ARCH CLIN EXP, V247, P187, DOI 10.1007/s00417-008-0958-5
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P210, DOI 10.1136/bjo.2007.127902
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   HERIOT W, 1996, INTRAVITREAL GAS RTP
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   HILLENKAMP J, GRAEFES ARCH CLIN EX
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   HOHN F, 2009, OPHTHALMOLOGE
   Hrach CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659
   Johnson MW, 2000, OPHTHALMOLOGY, V107, P2120, DOI 10.1016/S0161-6420(00)00568-6
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Karagiannis DA, 2009, OPHTHALMOLOGICA, V223, P279, DOI 10.1159/000213644
   Krepler K, 2000, RETINA-J RET VIT DIS, V20, P251, DOI 10.1097/00006982-200003000-00005
   Krishnan R, 2009, CLIN EXP OPHTHALMOL, V37, P384, DOI 10.1111/j.1442-9071.2009.02043.x
   LAUDE A, 2009, PROG RETIN EYE RES
   Levine JP, 2009, RETINA-J RET VIT DIS, V29, P1074, DOI 10.1097/IAE.0b013e3181b09443
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LEWIS H, 1991, AM J OPHTHALMOL, V111, P197, DOI 10.1016/S0002-9394(14)72259-7
   Lincoff H, 2001, RETINA-J RET VIT DIS, V21, P191, DOI 10.1097/00006982-200104000-00021
   Lincoff H, 2008, RETINA-J RET VIT DIS, V28, P56, DOI 10.1097/IAE.0b013e31806e60db
   Luke M, 2007, BRIT J OPHTHALMOL, V91, P1077, DOI 10.1136/bjo.2006.111260
   Ma ZZ, 2009, INVEST OPHTH VIS SCI, V50, P2975, DOI 10.1167/iovs.08-2573
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   McAllister IL, 2006, CLIN EXP OPHTHALMOL, V34, P787, DOI 10.1111/j.1442-9071.2006.01369.x
   McKibbin M, 2010, EYE, V24, P994, DOI 10.1038/eye.2009.271
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Muqit MMK, 2008, EUR J OPHTHALMOL, V18, P591, DOI 10.1177/112067210801800415
   NASRALLAH F, 1989, AM J OPHTHALMOL, V107, P38, DOI 10.1016/0002-9394(89)90812-X
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Oshima Y, 2007, BRIT J OPHTHALMOL, V91, P193, DOI 10.1136/bjo.2006.101444
   Rowley SA, 2004, BRIT J OPHTHALMOL, V88, P573, DOI 10.1136/bjo.2003.027466
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shah SP, 2009, OPHTHAL SURG LAS IM, V40, P308, DOI 10.3928/15428877-20090430-16
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   Solomon SD, 2009, RETINA-J RET VIT DIS, V29, P1080, DOI 10.1097/IAE.0b013e3181b1baeb
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Thompson John T, 2005, Trans Am Ophthalmol Soc, V103, P98
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   TREUMER F, BR J OPHTHALMOL
   Tsai San-Chang, 2003, Kaohsiung Journal of Medical Sciences, V19, P608
   Vote BJ, 2004, RETINA-J RET VIT DIS, V24, P808, DOI 10.1097/00006982-200410000-00024
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
   Wong D, 2004, BRIT J OPHTHALMOL, V88, P186, DOI 10.1136/bjo.2003.019273
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
NR 63
TC 38
Z9 39
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2011
VL 95
IS 8
BP 1051
EP 1057
DI 10.1136/bjo.2010.182253
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 793ST
UT WOS:000292844100004
PM 20813746
DA 2022-11-30
ER

PT J
AU Li, ML
   Huisingh, C
   Messinger, J
   Dolz-Marco, R
   Ferrara, D
   Freund, KB
   Curcio, CA
AF Li, Miaoling
   Huisingh, Carrie
   Messinger, Jeffrey
   Dolz-Marco, Rosa
   Ferrara, Daniela
   Freund, K. Bailey
   Curcio, Christine A.
TI HISTOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR
   DEGENERATION A Multilayer Approach
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; retina; photoreceptors; Muller cells;
   retinal pigment epithelium; choriocapillaris; Bruch membrane; geographic
   atrophy; histology; morphometry
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM;
   BRUCHS-MEMBRANE; FUNDUS AUTOFLUORESCENCE; CHOROIDAL VASCULATURE;
   MORPHOMETRIC-ANALYSIS; DARK-ADAPTATION; MULLER CELLS; EYES;
   CHORIOCAPILLARIS
AB Purpose: To systematically characterize histologic features of multiple chorioretinal layers in eyes with geographic atrophy, or complete retinal pigment epithelium (RPE) and outer retinal atrophy, secondary to age-related macular degeneration, including Henle fiber layer and outer nuclear layer; and to compare these changes to those in the underlying RPE-Bruch membrane-choriocapillaris complex and associated extracellular deposits.
   Methods: Geographic atrophy was delimited by the external limiting membrane (ELM) descent towards Bruch membrane. In 13 eyes, histologic phenotypes and/or thicknesses of Henle fiber layer, outer nuclear layer, underlying supporting tissues, and extracellular deposits at four defined locations on the non-atrophic and atrophic sides of the ELM descent were assessed and compared across other tissue layers, with generalized estimating equations and logit models.
   Results: On the non-atrophic side of the ELM descent, distinct Henle fiber layer and outer nuclear layer became dyslaminated, cone photoreceptor inner segment myoids shortened, photoreceptor nuclei and mitochondria translocated inward, and RPE was dysmorphic. On the atrophic side of the ELM descent, all measures of photoreceptor health declined to zero. Henle fiber layer/outer nuclear layer thickness halved, and only Muller cells remained, in the absence of photoreceptors. Sub-RPE deposits remained, Bruch membrane thinned, and choriocapillaris density decreased.
   Conclusion: The ELM descent sharply delimits an area of marked gliosis and near-total photoreceptor depletion clinically defined as Geographic atrophy (or outer retinal atrophy), indicating severe and potentially irreversible tissue damage. Degeneration of supporting tissues across this boundary is gradual, consistent with steady age-related change and suggesting that RPE and Muller cells subsequently respond to a threshold of stress. Novel clinical trial endpoints should be sought at age-related macular degeneration stages before intense gliosis and thick deposits impede therapeutic intervention.
C1 [Li, Miaoling; Huisingh, Carrie; Messinger, Jeffrey; Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, Birmingham, AL USA.
   [Li, Miaoling] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.
   [Dolz-Marco, Rosa; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Dolz-Marco, Rosa; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Dolz-Marco, Rosa] Oftalvist Clin, Valencia, Spain.
   [Ferrara, Daniela] Genentech Inc, San Francisco, CA USA.
   [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
C3 University of Alabama System; University of Alabama Birmingham; Sun Yat
   Sen University; Vitreous Retina Macula Consultants of New York;
   Manhattan Eye Ear & Throat Hospital; Roche Holding; Genentech; New York
   University
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, EyeSight Fdn, Dept Ophthalmol,Alabama Vis Res Labs, 1670 Univ Blvd Room 360, Birmingham, AL 35294 USA.
EM curcio@uab.edu
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Hoffman LaRoche; Macula Foundation, Inc; EyeSight Foundation of Alabama;
   NIH [EY06109]; International Retinal Research Foundation; Edward N. and
   Della L. Thome Foundation; Arnold and Mabel Beckman Initiative for
   Macular Research; NEI Core grant [P30 EY003039]; Research to Prevent
   Blindness, Inc; NATIONAL EYE INSTITUTE [R01EY006109, R01EY027948]
   Funding Source: NIH RePORTER
FX Supported by Hoffman LaRoche, the Macula Foundation, Inc, and
   unrestricted funds to the Department of Ophthalmology from Research to
   Prevent Blindness, Inc, and EyeSight Foundation of Alabama. Project
   MACULA tissue acquisition and website construction was supported by NIH
   grants EY06109 (C.A.C.), International Retinal Research Foundation,
   Edward N. and Della L. Thome Foundation, Arnold and Mabel Beckman
   Initiative for Macular Research, and NEI Core grant P30 EY003039.
CR Adhi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133080
   ANDERSON DH, 1986, INVEST OPHTH VIS SCI, V27, P168
   [Anonymous], 2011, CTGTAC M 52 CELL GEN, V2016
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Balaratnasingam C, 2016, AM J OPHTHALMOL, V172, P28, DOI 10.1016/j.ajo.2016.09.008
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Boretsky A, 2012, LASER SURG MED, V44, P603, DOI 10.1002/lsm.22070
   Bressler NM, 2006, AGE RELATED MACULAR, VII, P1041
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Bringmann A, 2012, OPHTHALMOLOGICA, V227, P1, DOI 10.1159/000328979
   Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001
   Burris C, 2002, J COMP NEUROL, V453, P100, DOI 10.1002/cne.10397
   Chen W, 2012, EUR J OPHTHALMOL, V22, P590, DOI 10.5301/ejo.5000092
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Corbelli E, 2017, INVEST OPHTH VIS SCI, V58, P5201, DOI 10.1167/iovs.17-22508
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2000, OPHTHALMOLOGY, V107, P334, DOI 10.1016/S0161-6420(99)00037-8
   Curcio CA., 2012, RETINA-J RET VIT DIS, V1, P466
   Curcio C, 2017, INVEST OPHTH VIS SCI, V58
   Curcio CA, 2015, AM J OPHTHALMOL, V160, P1024, DOI 10.1016/j.ajo.2015.08.001
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Drasdo N, 2007, VISION RES, V47, P2901, DOI 10.1016/j.visres.2007.01.007
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Ebneter A, 2016, INVEST OPHTH VIS SCI, V57
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   ERICKSON PA, 1987, EXP EYE RES, V44, P37, DOI 10.1016/S0014-4835(87)80023-4
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Hanout M, 2015, CURR OPIN OPHTHALMOL, V26, P149, DOI 10.1097/ICU.0000000000000153
   Hariri AH, 2016, AM J OPHTHALMOL, V168, P122, DOI 10.1016/j.ajo.2016.05.007
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   Kvanta A, 2017, RETINA-J RET VIT DIS, V37, P936, DOI 10.1097/IAE.0000000000001248
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Lewis GP, 2010, MOL VIS, V16, P1361
   Litts KM, 2017, RETINA-J RET VIT DIS, V37, P978, DOI 10.1097/IAE.0000000000001265
   Litts KM, 2016, INVEST OPHTH VIS SCI, V57, P2647, DOI 10.1167/iovs.16-19262
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Lujan BJ, 2015, RETINA-J RET VIT DIS, V35, P1511, DOI 10.1097/IAE.0000000000000527
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Mones J, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.026
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Newman EA, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0195
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Ouyang YL, 2013, GRAEF ARCH CLIN EXP, V251, P2311, DOI 10.1007/s00417-013-2308-5
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Panorgias A, 2013, INVEST OPHTH VIS SCI, V54, P4372, DOI 10.1167/iovs.12-11525
   Pellegrini M, 2016, OPHTHALMOLOGY, V123, P1879, DOI 10.1016/j.ophtha.2016.05.041
   PERRY VH, 1988, NEUROSCIENCE, V25, P225, DOI 10.1016/0306-4522(88)90021-8
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Pilotto E, 2013, CAN J OPHTHALMOL, V48, P386, DOI 10.1016/j.jcjo.2013.03.022
   Pilotto E, 2011, BRIT J OPHTHALMOL, V95, P1140, DOI 10.1136/bjo.2010.187344
   Polyak S. L., 1941, RETINA-J RET VIT DIS
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P1735, DOI 10.1097/IAE.0000000000000553
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Reeves C, 2016, BRAIN PATHOL, V26, P319, DOI 10.1111/bpa.12298
   Rodriguez IR, 2014, EXP EYE RES, V128, P151, DOI 10.1016/j.exer.2014.09.009
   Rudolf M, 2018, CURR EYE RES, V43, P135, DOI 10.1080/02713683.2017.1370118
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sadiq MA, 2015, OSLI RETINA, V46, P914, DOI 10.3928/23258160-20151008-03
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sayegh RG, 2014, BRIT J OPHTHALMOL, V98, P1050, DOI 10.1136/bjophthalmol-2014-305195
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Stetson PF, 2014, INVEST OPHTH VIS SCI, V55, P792, DOI 10.1167/iovs.13-13199
   Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P2349, DOI 10.1167/iovs.16-21237
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zayit-Soudry S, 2013, INVEST OPHTH VIS SCI, V54, P7498, DOI 10.1167/iovs.13-12433
NR 113
TC 71
Z9 71
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2018
VL 38
IS 10
BP 1937
EP 1953
DI 10.1097/IAE.0000000000002182
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VS
UT WOS:000454005600016
PM 29746415
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Garcia-Quintanilla, L
   Luaces-Rodriguez, A
   Gil-Martinez, M
   Mondelo-Garcia, C
   Maronas, O
   Mangas-Sanjuan, V
   Gonzalez-Barcia, M
   Zarra-Ferro, I
   Aguiar, P
   Otero-Espinar, FJ
   Fernandez-Ferreiro, A
AF Garcia-Quintanilla, Laura
   Luaces-Rodriguez, Andrea
   Gil-Martinez, Maria
   Mondelo-Garcia, Cristina
   Maronas, Olalla
   Mangas-Sanjuan, Victor
   Gonzalez-Barcia, Miguel
   Zarra-Ferro, Irene
   Aguiar, Pablo
   Otero-Espinar, Francisco J.
   Fernandez-Ferreiro, Anxo
TI Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular
   Degeneration
SO PHARMACEUTICS
LA English
DT Review
DE vascular endothelial growth factor/antagonists & inhibitors;
   ranibizumab; aflibercept; bevacizumab; Age-Related Macular Degeneration;
   pharmacokinetics; intravitreal
ID ENDOTHELIAL GROWTH-FACTOR; INTRAOCULAR PHARMACOKINETICS; OCULAR
   PHARMACOKINETICS; RANIBIZUMAB; BEVACIZUMAB; INJECTION; AFLIBERCEPT;
   RABBIT; MODEL; VITRECTOMY
AB Intravitreal administration of anti-vascular endothelial growth factor (VEGF) antibodies has become the standard treatment for Age-Related Macular Degeneration; however, the knowledge of their pharmacokinetics is limited. A comprehensive review of the preclinical and clinical pharmacokinetic data that were obtained in different studies with intravitreal bevacizumab, ranibizumab, and aflibercept has been conducted. Moreover, the factors that can influence the vitreous pharmacokinetics of these drugs, as well as the methods that were used in the studies for analytical determination, have been exposed. These anti-VEGF drugs present different charge and molecular weights, which play an important role in vitreous distribution and elimination. The pharmacokinetic parameters that were collected differ depending on the species that were involved in the studies and on physiological and pathological conditions, such as vitrectomy and lensectomy. Knowledge of the intravitreal pharmacokinetics of the anti-VEGF drugs that were used in clinical practice is of vital importance.
C1 [Garcia-Quintanilla, Laura; Mondelo-Garcia, Cristina; Gonzalez-Barcia, Miguel; Zarra-Ferro, Irene; Fernandez-Ferreiro, Anxo] Univ Clin Hosp Santiago de Compostela SERGAS, Pharm Dept, Santiago De Compostela 15706, Spain.
   [Garcia-Quintanilla, Laura; Luaces-Rodriguez, Andrea; Mondelo-Garcia, Cristina; Gonzalez-Barcia, Miguel; Zarra-Ferro, Irene; Fernandez-Ferreiro, Anxo] Hlth Res Inst Santiago de Compostela FIDIS, Pharmacol Grp, Santiago De Compostela 15706, Spain.
   [Luaces-Rodriguez, Andrea; Otero-Espinar, Francisco J.; Fernandez-Ferreiro, Anxo] USC, Fac Pharm, Dept Pharmacol Pharm & Pharmaceut Technol, Santiago De Compostela 15782, Spain.
   [Gil-Martinez, Maria] Univ Clin Hosp Santiago de Compostela SERGAS, Ophthalmol Dept, Santiago De Compostela 15706, Spain.
   [Maronas, Olalla] Hlth Res Inst Santiago de Compostela FIDIS, Galician Publ Fdn Genom Med, Genom Med Grp, Santiago De Compostela 15706, Spain.
   [Mangas-Sanjuan, Victor] Univ Valencia, Dept Pharm & Pharmaceut Technol & Parasitol, E-46100 Valencia, Spain.
   [Mangas-Sanjuan, Victor] Univ Politecn Valencia, Interuniv Res Inst Mol Recognit & Technol Dev, Valencia 46100, Spain.
   [Aguiar, Pablo] Univ Clin Hosp Santiago de Compostela SERGAS, Nucl Med Dept, Santiago De Compostela 15706, Spain.
   [Aguiar, Pablo] Hlth Res Inst Santiago de Compostela FIDIS, Mol Imaging Grp, Santiago De Compostela 15706, Spain.
C3 Complexo Hospitalario Universitario de Santiago de Compostela;
   Universidade de Santiago de Compostela; Complexo Hospitalario
   Universitario de Santiago de Compostela; University of Valencia;
   Universitat Politecnica de Valencia; Complexo Hospitalario Universitario
   de Santiago de Compostela
RP Fernandez-Ferreiro, A (通讯作者)，Univ Clin Hosp Santiago de Compostela SERGAS, Pharm Dept, Santiago De Compostela 15706, Spain.; Fernandez-Ferreiro, A (通讯作者)，Hlth Res Inst Santiago de Compostela FIDIS, Pharmacol Grp, Santiago De Compostela 15706, Spain.; Otero-Espinar, FJ; Fernandez-Ferreiro, A (通讯作者)，USC, Fac Pharm, Dept Pharmacol Pharm & Pharmaceut Technol, Santiago De Compostela 15782, Spain.
EM francisco.otero@usc.es; anxo.fernandez.ferreiro@sergas.es
RI Fernández, Pablo Aguiar/ABD-9169-2022; Otero-Espinar, F. J./K-1337-2014;
   Sanjuan, Victor Mangas/AAE-5930-2020; Garcia-Quintanilla,
   Laura/AAV-2083-2021; Aguiar, Pablo/S-3371-2019; Mangas-Sanjuan,
   Victor/K-9116-2014
OI Otero-Espinar, F. J./0000-0001-9030-2253; Sanjuan, Victor
   Mangas/0000-0002-3388-5023; Aguiar, Pablo/0000-0002-7322-2195;
   Garcia-Quintanilla, Laura/0000-0002-4411-7097; Mangas-Sanjuan,
   Victor/0000-0002-2503-3373; Maronas Amigo, Olalla/0000-0001-6952-3377;
   Zarra Ferro, Irene/0000-0003-0835-034X; Luaces-Rodriguez,
   Andrea/0000-0002-6794-3551; Mondelo-Garcia, Cristina/0000-0001-8555-1415
FU ISCIII - FEDER [PI17/00940, RD16/0008/0003, RD12/0034/0017]; Spanish
   Ministry of Science, Innovation and Universities [RTI2018-099597-B-100]
FX This work was partially supported by the ISCIII (PI17/00940, RETICS
   Oftared, RD16/0008/0003 and RD12/0034/0017) cofunded by FEDER and by the
   Spanish Ministry of Science, Innovation and Universities
   (RTI2018-099597-B-100).
CR Ahn J, 2013, J OCUL PHARMACOL TH, V29, P612, DOI 10.1089/jop.2013.0009
   Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P567, DOI 10.1167/iovs.13-13054
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   ANGI M, 2012, MEDIAT INFLAMM, V2012, DOI DOI 10.1155/2012/148039
   [Anonymous], 2015, AFL EYL TREATM NEOV
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bhagat R, 2014, J OCUL PHARMACOL TH, V30, P854, DOI 10.1089/jop.2014.0082
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Celik N, 2015, INVEST OPHTH VIS SCI, V56, P5574, DOI 10.1167/iovs.15-16418
   Christoforidis JB, 2013, CURR EYE RES, V38, P761, DOI 10.3109/02713683.2013.763988
   Christoforidis JB, 2013, RETINA-J RET VIT DIS, V33, P946, DOI 10.1097/IAE.0b013e3182753b12
   Christoforidis JB, 2012, CURR EYE RES, V37, P1171, DOI 10.3109/02713683.2012.727521
   Christoforidis JB, 2011, INVEST OPHTH VIS SCI, V52, P5899, DOI 10.1167/iovs.10-6862
   Christoforidis JB, 2017, INVEST OPHTH VIS SCI, V58, P5636, DOI 10.1167/iovs.17-22431
   Cioffi C.L., 2016, 2016 MED CHEM REV, V51, P261
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dedania VS, 2016, CURR OPIN OPHTHALMOL, V27, P224, DOI 10.1097/ICU.0000000000000257
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Dickmann LJ, 2015, INVEST OPHTH VIS SCI, V56, P6991, DOI 10.1167/iovs.15-17457
   Dinc E, 2014, CUTAN OCUL TOXICOL, V33, P275, DOI 10.3109/15569527.2013.855227
   Do DV, 2020, RETINA-J RET VIT DIS, V40, P643, DOI 10.1097/IAE.0000000000002566
   Edington M, 2017, EXPERT OPIN DRUG MET, V13, P1217, DOI 10.1080/17425255.2017.1404987
   Empeslidis T, 2019, ADV THER, V36, P1532, DOI 10.1007/s12325-019-00971-0
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gadkar K, 2015, INVEST OPHTH VIS SCI, V56, P5390, DOI 10.1167/iovs.15-17108
   Gal-Or O, 2016, EXP EYE RES, V145, P412, DOI 10.1016/j.exer.2016.02.006
   Garcia-Layana A, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/412903
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Giannos SA, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2368-7
   Gisladottir S, 2009, GRAEF ARCH CLIN EXP, V247, P1677, DOI 10.1007/s00417-009-1141-3
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kaiser PK, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2018-000185
   Kakinoki M, 2012, INVEST OPHTH VIS SCI, V53, P5877, DOI 10.1167/iovs.12-10164
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2015, RETINA-J RET VIT DIS, V35, P69, DOI 10.1097/IAE.0000000000000265
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Laude A, 2010, PROG RETIN EYE RES, V29, P466, DOI 10.1016/j.preteyeres.2010.04.003
   Li SK, 2011, J PHARMACEUT BIOMED, V55, P603, DOI 10.1016/j.jpba.2010.12.027
   Liu XY, 2019, IRAN J RADIOL, V16, DOI 10.5812/iranjradiol.68697
   Lowe J, 2018, J IMMUNOL METHODS, V461, P44, DOI 10.1016/j.jim.2018.05.007
   Lowe J, 2010, J PHARMACEUT BIOMED, V52, P680, DOI 10.1016/j.jpba.2010.01.048
   Manolis E, 2017, CPT-PHARMACOMET SYST, V6, P416, DOI 10.1002/psp4.12223
   Marshall SF, 2016, CPT-PHARMACOMET SYST, V5, P93, DOI 10.1002/psp4.12049
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Meyer CH, 2012, ACTA OPHTHALMOL, V90, P68, DOI 10.1111/j.1755-3768.2009.01842.x
   Missel PJ, 2012, PHARM RES-DORDR, V29, P3251, DOI 10.1007/s11095-012-0721-9
   Miyake T, 2010, INVEST OPHTH VIS SCI, V51, P1606, DOI 10.1167/iovs.09-4140
   Moisseiev E, 2014, GRAEF ARCH CLIN EXP, V252, P331, DOI 10.1007/s00417-013-2495-0
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Mould DR, 2012, CPT-PHARMACOMET SYST, V1, DOI 10.1038/psp.2012.4
   Muether PS, 2013, AM J OPHTHALMOL, V156, P989, DOI 10.1016/j.ajo.2013.06.020
   Neumann R, 2019, DRUG DISCOV TODAY, V24, P1433, DOI 10.1016/j.drudis.2019.03.018
   Niwa Y, 2015, INVEST OPHTH VIS SCI, V56, P6501, DOI 10.1167/iovs.15-17279
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Park SJ, 2016, INVEST OPHTH VIS SCI, V57, P2612, DOI 10.1167/iovs.16-19204
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pershing S, 2019, AM J OPHTHALMOL, V207, P385, DOI 10.1016/j.ajo.2019.05.011
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Rohrer B, 2019, MOL VIS, V25, P79
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saunders DJ, 2015, BRIT J OPHTHALMOL, V99, P1554, DOI 10.1136/bjophthalmol-2015-306771
   Schmidt-Erfurth U, 2017, OPHTHALMOLOGICA, V237, P185, DOI 10.1159/000458539
   SHEINER LB, 1980, J PHARMACOKINET BIOP, V8, P553, DOI 10.1007/BF01060053
   SHEINER LB, 1972, COMPUT BIOMED RES, V5, P441, DOI 10.1016/0010-4809(72)90051-1
   Sinapis CI, 2011, CLIN OPHTHALMOL, V5, P697, DOI 10.2147/OPTH.S19555
   STANSKI DR, 1990, ANESTHESIOLOGY, V72, P412, DOI 10.1097/00000542-199003000-00003
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Stewart MA, 2011, ADV GLOB CHANGE RES, V45, P1, DOI [10.1007/978-94-007-0934-8_1, 10.4081/eye.2011.e5]
   Stewart MW, 2014, EXPERT REV CLIN PHAR, V7, P167, DOI 10.1586/17512433.2014.884458
   Tew WP, 2010, CLIN CANCER RES, V16, P358, DOI 10.1158/1078-0432.CCR-09-2103
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Ulrich JN, 2008, CLIN EXP OPHTHALMOL, V36, P431, DOI 10.1111/j.1442-9071.2008.01793.x
   Vellonen KS, 2018, ADV DRUG DELIVER REV, V126, P3, DOI 10.1016/j.addr.2017.12.009
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Xu QG, 2013, J CONTROL RELEASE, V167, P76, DOI 10.1016/j.jconrel.2013.01.018
   Xu Y, 2012, INVEST OPHTH VIS SCI, V53, P5221, DOI 10.1167/iovs.12-9702
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
   Zhang Y, 2014, OPHTHALMOLOGY, V121, P2237, DOI 10.1016/j.ophtha.2014.05.012
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 93
TC 48
Z9 49
U1 1
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD AUG
PY 2019
VL 11
IS 8
AR 365
DI 10.3390/pharmaceutics11080365
PG 22
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA IV8KT
UT WOS:000484515100042
PM 31370346
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Dias, JRD
   Xavier, CO
   Maia, A
   de Moraes, NSB
   Meyer, C
   Farah, ME
   Rodrigues, EB
AF de Oliveira Dias, Joao Rafael
   Xavier, Camilla Oliveira
   Maia, Andre
   Bueno de Moraes, Nilva Simeren
   Meyer, Carsten
   Farah, Michel Eid
   Rodrigues, Eduardo Buechele
TI Intravitreal Injection of Ziv-Aflibercept in Patient With Refractory
   Age-Related Macular Degeneration
SO Ophthalmic Surgery Lasers & Imaging Retina
LA English
DT Article
ID TRAP-EYE; CANCER
AB The results of a patient with exudative age-related macular degeneration who received an intravitreal injection of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Paris, France) in the right eye are described. A complete ocular examination as well as color fundus photography, optical coherence tomography, fluorescein angiography, microperimetry, full-field electroretinography, and multifocal electroretinography were performed and repeated 1 month later. The patient experienced subjective and objective improvement of visual acuity with a decrease in intraretinal and subretinal fluid. Microperimetric improvement also occurred. Electroretinographic changes were noted from baseline to the 30-day follow-up. No adverse events were observed at any time point. Ziv-aflibercept demonstrated short-term safety and efficacy after intravitreal administration for neovascular macular degeneration.
C1 [de Oliveira Dias, Joao Rafael; Xavier, Camilla Oliveira; Maia, Andre; Bueno de Moraes, Nilva Simeren; Meyer, Carsten; Farah, Michel Eid; Rodrigues, Eduardo Buechele] Fed Univ Sao Paulo UNIFESP, EPM, Dept Ophthalmol, Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP)
RP Dias, JRD (通讯作者)，Rua Ytaipu 587,Ap 114, BR-01529020 Sao Paulo, SP, Brazil.
EM dias_joaor@yahoo.com.br
RI de Oliveira Dias, João/J-6735-2016; Farah, Michel Eid E/F-3285-2012;
   Rodrigues, Eduardo Büchele/C-6852-2015; Meyer, Carsten/A-3981-2017
OI Farah, Michel Eid E/0000-0001-5951-0193; Meyer,
   Carsten/0000-0002-0530-5298; Buchele Rodrigues,
   Eduardo/0000-0002-4224-0921
CR Bababeygy S, SAFETY PROFILE ANTI
   Cheng YD, 2013, DRUG DES DEV THER, V7, P1315, DOI 10.2147/DDDT.S52485
   del Carpio JC, EFFECTS RANIBIZUMAB
   Dias JR, PRE CLIN SAFETY INTR, P69
   Frenkel REP, 2010, CLIN OPHTHALMOL, V4, P1279, DOI 10.2147/OPTH.S12846
   Gaya A, 2012, CANCER TREAT REV, V38, P484, DOI 10.1016/j.ctrv.2011.12.008
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
NR 8
TC 21
Z9 21
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JAN
PY 2015
VL 46
IS 1
BP 91
EP 94
DI 10.3928/23258160-20150101-17
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA CG5TO
UT WOS:000353358500016
PM 25559518
DA 2022-11-30
ER

PT J
AU Hopley, C
   Salkeld, G
   Mitchell, P
AF Hopley, C
   Salkeld, G
   Mitchell, P
TI Cost utility of photodynamic therapy for predominantly classic
   neovascular age related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL IMPAIRMENT; DIABETIC-RETINOPATHY; OLDER
   AUSTRALIANS; HEALTH; IMPACT; MACULOPATHY; PREVALENCE; BLINDNESS; SMOKING
AB Background/aim: Age related macular degeneration (AMD) is the leading cause of severe vision impairment and blindness in older people throughout the developed world and currently affects around 420 000 UK citizens. Choroidal neovascularisation (CNV) is treatable with photodynamic therapy (PDT) but is expensive at over pound1200 per treatment. The aim of this study was to assess the cost utility of PDT for better eye, predominantly classic, subfoveal choroidal neovascular lesions secondary to AMD.
   Methods: Cost utility analysis (CUA) was conducted to estimate the cost effectiveness of PDT for scenarios involving reasonable (6/12) and poor (6/60) visual acuity. The models incorporated data from the Treatment of Age-related Macular Degeneration with PDT ( TAP) Study and patient based utilities. The incremental CUA was based on decision analytical models, comparing treatment to a placebo comparator. Extensive one way sensitivity analysis of parameters was conducted to determine the robustness of the model. A discount rate of 6% was used for costs and quality adjusted life years (QALY).
   Results: Model 1: in people with reasonable initial visual acuity, the cost utility of treating applicable neovascular AMD lesions was pound31 607 per QALY saved, with a sensitivity analysis range from pound25 285 to pound37 928. Model 2: in people with poor initial visual acuity, the cost utility was pound63 214 per QALY saved, with a sensitivity analysis range from pound54 183 to pound75 856.
   Conclusions: PDT treatment is the only available treatment for some forms of neovascular ("wet'') AMD. Under these assumptions, PDT can be considered moderately cost effective for those with reasonable visual acuity but less cost effective for those with initial poor visual acuity. These findings have implications for ophthalmic practice and healthcare planning.
C1 Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia.
   Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia.
C3 University of Sydney; Westmead Institute for Medical Research;
   University of Sydney; University of Sydney
RP Mitchell, P (通讯作者)，Univ Sydney, Westmead Hosp, Dept Ophthalmol, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paul_mitchell@wmi.usyd.edu.au
RI Mitchell, Paul/P-1498-2014
CR *AUSTR BUR STAT, 1997, DEATHS AUSTR 1996, V3302, P62
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown G C, 2001, Trans Am Ophthalmol Soc, V99, P199
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   CHIANG YP, 1992, MILBANK Q, V70, P319, DOI 10.2307/3350062
   Drummond MF., 2015, METHODS EC EVALUATIO, V4
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Ivers RQ, 2003, J AM GERIATR SOC, V51, P356, DOI 10.1046/j.1532-5415.2003.51109.x
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473
   LORD SR, 1991, J AM GERIATR SOC, V39, P1194, DOI 10.1111/j.1532-5415.1991.tb03574.x
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Mitchell P, 1999, MED J AUSTRALIA, V171, P173, DOI 10.5694/j.1326-5377.1999.tb123591.x
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Sharma S, 2003, BRIT J OPHTHALMOL, V87, P259, DOI 10.1136/bjo.87.3.259
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P3, DOI 10.1076/opep.10.1.3.13773
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   Wang JJ, 2000, INVEST OPHTH VIS SCI, V41, P49
   Wright SE, 2000, CLIN EXP OPHTHALMOL, V28, P140, DOI 10.1046/j.1442-9071.2000.00296.x
NR 33
TC 45
Z9 49
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2004
VL 88
IS 8
BP 982
EP 987
DI 10.1136/bjo.2003.039131
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 838QD
UT WOS:000222727100003
PM 15258009
OA Green Published, Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Fine, HF
   Iranmanesh, R
   Del Priore, LV
   Barile, GR
   Chang, LK
   Chang, S
   Schiff, WM
AF Fine, Howard F.
   Iranmanesh, Reza
   Del Priore, Lucian V.
   Barile, Gaetano R.
   Chang, Louis K.
   Chang, Stanley
   Schiff, William M.
TI SURGICAL OUTCOMES AFTER MASSIVE SUBRETINAL HEMORRHAGE SECONDARY TO
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; subretinal hemorrhage; tissue
   plasminogen activator; vitrectomy
ID TISSUE-PLASMINOGEN ACTIVATOR; THICK SUBMACULAR HEMORRHAGE; PARS-PLANA
   VITRECTOMY; PNEUMATIC DISPLACEMENT; CLINICOPATHOLOGICAL CORRELATION;
   NATURAL-HISTORY; VISUAL-ACUITY; INJECTION; MANAGEMENT; RENEWAL
AB Purpose: Massive subretinal hemorrhage (SRH), defined as a thick submacular bleed that extends past the equator in at least two quadrants, is a rare sequela of age-related macular degeneration. This report describes outcomes after surgical intervention for massive SRH.
   Methods: The study design is a retrospective interventional case series. Records of consecutive patients who underwent surgical intervention for massive SRH were reviewed. Outcomes included change from baseline in postoperative acuity at Months 1, 3, 6, 9, and 12 and postoperative complications.
   Results: Fifteen consecutive eyes of 13 patients who underwent surgery for massive SRH were included. Procedures performed on initial surgery included subretinal instillation of 25 mu g/0.1 mL tissue plasminogen activator (15 of 15), gas tamponade (12 of 15), oil tamponade (3 of 15), 180 degrees or greater retinotomy (4 of 15), and/or cataract extraction (2 of 15). Patients were followed for a median of 20 months (range, 3-66 months). The median visual acuity at baseline and postoperative Month 1 was hand motions but improved to counting fingers at postoperative Months 3 (P = 0.04), 6 (P = 0.04), 9 (P = 0.04), and 12 (P = 0.10). Of the 15 eyes, 9 required at least 1 additional procedure for an indication of hyphema and/or vitreous hemorrhage (n = 6), retinal detachment (n = 2), glaucoma (n = 1), cataract (n = 1), and aphakia (n = 1). At the time of the onset of SRH, 5 of 13 patients were anticoagulated with warfarin (4 patients) or clopidogrel (1 patient), and 1 was diagnosed with a coagulopathy, factor XI deficiency.
   Conclusion: Massive SRH related to age-related macular degeneration has a grave prognosis. Risk factors may include anticoagulation and coagulopathy. Limitations of the study include its retrospective nature, small sample size, imprecision in acuity measurements below 20/400, and lack of a control group. In this series, surgical intervention was associated with a modest improvement in median visual acuity up to 1 year post-operatively. RETINA 30:1588-1594, 2010
C1 [Fine, Howard F.; Iranmanesh, Reza; Del Priore, Lucian V.; Barile, Gaetano R.; Chang, Louis K.; Chang, Stanley; Schiff, William M.] Columbia Univ Coll Phys & Surg, Dept Ophthalmol, Edward S Harkness Eye Inst, New York, NY 10032 USA.
C3 Columbia University
RP Fine, HF (通讯作者)，Columbia Univ Coll Phys & Surg, Dept Ophthalmol, Edward S Harkness Eye Inst, 635 W 165th St, New York, NY 10032 USA.
EM h_f_fine@yahoo.com
RI Chang, Stanley/AAL-2741-2021
FU Eye Surgery Fund; Research to Prevent Blindness; Glaubinger Foundation
FX Supported by the Eye Surgery Fund, Research to Prevent Blindness, and
   Glaubinger Foundation.
CR ANDERSON DH, 1978, INVEST OPHTH VIS SCI, V17, P117
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Boesze-Battaglia K, 2002, INT REV CYTOL, V217, P183
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Castellarin AA, 1997, BRIT J OPHTHALMOL, V81, P994, DOI 10.1136/bjo.81.11.994
   Castellarin AA, 1998, RETINA-J RET VIT DIS, V18, P143, DOI 10.1097/00006982-199818020-00008
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   DELPRIORE LV, 1995, ARCH OPHTHALMOL-CHIC, V113, P939, DOI 10.1001/archopht.1995.01100070113034
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Halliwell T J, 1980, Trans Ophthalmol Soc N Z, V32, P79
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Jabs DA, 2005, AM J OPHTHALMOL, V139, P900, DOI 10.1016/j.ajo.2004.12.009
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Leonard DS, 1997, INVEST OPHTH VIS SCI, V38, P1094
   Nasir MA, 1997, BRIT J OPHTHALMOL, V81, P481, DOI 10.1136/bjo.81.6.481
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Oshima Y, 2007, BRIT J OPHTHALMOL, V91, P193, DOI 10.1136/bjo.2006.101444
   Ron Y, 2007, OPHTHALMOLOGICA, V221, P57, DOI 10.1159/000096524
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   Tezel TH, 1996, OPHTHALMOLOGY, V103, P1829, DOI 10.1016/S0161-6420(96)30419-3
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Tsai San-Chang, 2003, Kaohsiung Journal of Medical Sciences, V19, P608
   Winkler BS, 2008, INVEST OPHTH VIS SCI, V49, P3259, DOI 10.1167/iovs.08-1785
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YOUNG RW, 1974, EXP EYE RES, V18, P215, DOI 10.1016/0014-4835(74)90150-X
NR 34
TC 35
Z9 37
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2010
VL 30
IS 10
BP 1588
EP 1594
DI 10.1097/IAE.0b013e3181e2263c
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 678HL
UT WOS:000284064600005
PM 20856172
DA 2022-11-30
ER

PT J
AU Becerri, EV
   Fernandez, RG
   Torres, LP
   Lacomba, MS
   Galera, JMG
AF Villegas Becerri, Enrique
   Gonzalez Fernandez, Rafael
   Perula Torres, Luis
   Santos Lacomba, Manuel
   Gallardo Galera, Jose Maria
TI HLA B27 as Predisposition Factor to Suffer Age Related Macular
   Degeneration
SO CELLULAR & MOLECULAR IMMUNOLOGY
LA English
DT Article
DE HLA alleles; ARMD; HLA B27; patient with ARMD
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; RHEUMATOID-ARTHRITIS; EXPRESSION;
   ANTIGENS; MHC; POLYMORPHISMS; PATHOGENESIS; FREQUENCIES; MONOCYTES;
   DISEASE
AB To research whether specific alleles HLA class I (HLA-A and HLA-B) and class II (HLA-DR) are risk factors for the development of exudative type of Age Related Macular Degeneration(ARMD), HLA antigens are expressed both in normal and affected eyes with ARMD. We designed a prospective case-controlled study. We recruited 75 patients with choroidal neovascularization predominantly classic or occult, secondary to ARMD, and treated with photodynamic therapy. Two hundred and fifty patients over 55 years old, without ophthalmologic pathology who went to hospital for an analytical routine check were used as control. The analysis of the data shows a significant difference between two groups. Allele HLA-B27 correlated positively with ARMD (p < 0.0113). However, we didn't find alleles negatively associated. Thus HLA-B27 is an allele predisposed to suffer ARMD. Cellular & Molecular Immunology. 2009;6(4):303-307.
C1 [Villegas Becerri, Enrique; Gonzalez Fernandez, Rafael; Perula Torres, Luis; Santos Lacomba, Manuel; Gallardo Galera, Jose Maria] Hosp Univ Reina Sofia, Cordoba, Spain.
   [Santos Lacomba, Manuel] Univ Cordoba, Fac Med, E-14071 Cordoba, Spain.
C3 Hospital Universitario Reina Sofia - Cordoba; Universidad de Cordoba
RP Becerri, EV (通讯作者)，Hosp Univ Reina Sofia, C Conchita Cintron 4 Atico 2 CP 14011, Cordoba, Spain.
EM drvill@terra.es
RI Pérula De Torres, Luis Angel/GZG-8600-2022
OI Perula de Torres, Luis Angel/0000-0002-8784-4905
CR ABIHANNA D, 1988, TRANSPLANTATION, V45, P610, DOI 10.1097/00007890-198803000-00021
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   ArnaizVillena A, 1997, IMMUNOGENETICS, V47, P37, DOI 10.1007/s002510050324
   BAKKER M, 1986, DOC OPHTHALMOL, V61, P271, DOI 10.1007/BF00142353
   Balsa A, 2000, RHEUMATOLOGY, V39, P844, DOI 10.1093/rheumatology/39.8.844
   Balsa A, 2001, ANN RHEUM DIS, V60, P573, DOI 10.1136/ard.60.6.573
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cabello A, 2003, HUM IMMUNOL, V64, P1045, DOI 10.1016/j.humimm.2003.08.353
   Chang JH, 2005, SURV OPHTHALMOL, V50, P364, DOI 10.1016/j.survophthal.2005.04.003
   Charron D, 2005, CURR OPIN IMMUNOL, V17, P493, DOI 10.1016/j.coi.2005.07.007
   Collantes Eduardo, 1997, British Journal of Rheumatology, V36, P125
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   de Vries N, 2002, ARTHRITIS RHEUM-US, V46, P921, DOI 10.1002/art.10210
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Goverdhan SV, 2005, INT J IMMUNOGENET, V32, P333, DOI 10.1111/j.1744-313X.2005.00548.x
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Green PHR, 2006, ANNU REV MED, V57, P207, DOI 10.1146/annurev.med.57.051804.122404
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Louka AS, 2003, TISSUE ANTIGENS, V61, P105, DOI 10.1034/j.1399-0039.2003.00017.x
   Lozano JM, 2002, AIDS, V16, P347, DOI 10.1097/00002030-200202150-00005
   Muro M, 2001, HUM IMMUNOL, V62, P910, DOI 10.1016/S0198-8859(01)00290-7
   Orchard TR, 2000, GASTROENTEROLOGY, V118, P274, DOI 10.1016/S0016-5085(00)70209-5
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   PENFOLD PL, 1993, J NEUROIMMUNOL, V45, P183, DOI 10.1016/0165-5728(93)90179-3
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Perez-Guijo V, 2002, JOINT BONE SPINE, V69, P458, DOI 10.1016/S1297-319X(02)00430-X
   Reveille JD, 2005, AM J MED, V118, P592, DOI 10.1016/j.amjmed.2005.01.001
   Sanchez-Velasco P, 1999, TISSUE ANTIGENS, V53, P65, DOI 10.1034/j.1399-0039.1999.530107.x
   Siebold C, 2004, P NATL ACAD SCI USA, V101, P1999, DOI 10.1073/pnas.0308458100
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Thorsby E, 2005, TRANSPL IMMUNOL, V14, P175, DOI 10.1016/j.trim.2005.03.021
   Trowsdale J, 2005, CURR OPIN IMMUNOL, V17, P498, DOI 10.1016/j.coi.2005.07.015
   VILLANUEVA JL, 1993, ANN RHEUM DIS, V52, P155, DOI 10.1136/ard.52.2.155
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 41
TC 5
Z9 8
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1672-7681
EI 2042-0226
J9 CELL MOL IMMUNOL
JI Cell. Mol. Immunol.
PD AUG
PY 2009
VL 6
IS 4
BP 303
EP 307
DI 10.1038/cmi.2009.40
PG 5
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 552WH
UT WOS:000274324000009
PM 19728932
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Tao, Y
   Jonas, JB
AF Tao, Yong
   Jonas, Jost B.
TI INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
   Effect on Different Subfoveal Membranes
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE exudative age-related macular degeneration; intravitreal bevacizumab;
   Avastin; intraocular neovascularization
ID OCCULT CHOROIDAL NEOVASCULARIZATION; PIGMENT EPITHELIAL DETACHMENT;
   PHOTODYNAMIC THERAPY; AVASTIN TREATMENT; RANIBIZUMAB; VERTEPORFIN;
   SECONDARY
AB Purpose: The purpose of this study was to assess an association between specific types of subfoveal neovascularization and the change in visual acuity after intravitreal injections of bevacizumab (F. Hoffmann-La Roche AG, Basel, Switzerland) as treatment for exudative age-related macular degeneration.
   Methods: This retrospective clinical interventional comparative study included 307 patients (378 eyes) who received 3 consecutive intravitreal injections of bevacizumab at intervals of 2 months each. The study group was divided into eyes with a predominantly or purely classic type of subfoveal neovascular membrane (n = 81), those with an occult type with or without minimally classic subfoveal neovascularization (n = 232), and eyes with a detachment of the retinal pigment epithelium (n = 65).
   Results: The gain in best-corrected visual acuity did not vary significantly among the 3 subgroups at 2 months after baseline (P = 0.35 and P = 0.27), at 4 months after baseline (P = 0.63 and P = 0.56), or at the final follow-up at 7 months after baseline (P = 0.85 and P = 0.76). In multivariate linear regression analysis, the gain in best-corrected visual acuity at the final follow-up was significantly associated with the best-corrected visual acuity at baseline (P < 0.001). It was not significantly associated with age (P = 0.61), sex (P = 0.12), self-reported diabetes (P = 0.79), lens status (P = 0.84), or type of subfoveal neovascularization (P = 0.53).
   Conclusion: After an intravitreal application of bevacizumab given as therapy for exudative age-related macular degeneration at 2-month intervals, the patient's gain in visual acuity did not depend on the type of the subfoveal neovascular membranes. RETINA 30: 1426-1431, 2010
C1 [Tao, Yong; Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
   [Tao, Yong] Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100871, Peoples R China.
C3 Ruprecht Karls University Heidelberg; Peking University
RP Jonas, JB (通讯作者)，Univ Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
OI Tao, Yong/0000-0003-1443-2667
FU German Academic Exchange Service (DAAD)
FX Supported by the K.C. Wong Fellowship from the German Academic Exchange
   Service (DAAD) (to Y.T.).
CR Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Azad RV, 2008, JPN J OPHTHALMOL, V52, P52, DOI 10.1007/s10384-007-0496-4
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Fong KCS, 2008, CLIN EXP OPHTHALMOL, V36, P748, DOI 10.1111/j.1442-9071.2008.01873.x
   Furino C, 2009, ACTA OPHTHALMOL, V87, P404, DOI 10.1111/j.1755-3768.2008.01262.x
   Ghazi NG, 2008, RETINA-J RET VIT DIS, V28, P689, DOI 10.1097/IAE.0b013e318162d982
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P210, DOI 10.1136/bjo.2007.127902
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jonas JB, 2009, OPHTHALMIC RES, V41, P21, DOI 10.1159/000162113
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Khetpal V, 2009, ACTA OPHTHALMOL, V87, P115, DOI 10.1111/j.1755-3768.2008.01176.x
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Mitchell P, 2009, BR J OPHTHALMOL
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 42
TC 5
Z9 6
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2010
VL 30
IS 9
BP 1426
EP 1431
DI 10.1097/IAE.0b013e3181d5e964
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 659JC
UT WOS:000282561800011
PM 20539255
DA 2022-11-30
ER

PT J
AU Wickremasinghe, SS
   Sandhu, SS
   Amirul-Islam, FM
   Abedi, F
   Richardson, AJ
   Baird, PN
   Guymer, RH
AF Wickremasinghe, Sanjeewa S.
   Sandhu, Sukhpal S.
   Amirul-Islam, Fakir M.
   Abedi, Farshad
   Richardson, Andrea J.
   Baird, Paul N.
   Guymer, Robyn H.
TI POLYMORPHISMS IN THE APOE GENE AND THE LOCATION OF RETINAL FLUID IN EYES
   WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; apolipoprotein E gene; choroidal neovascularization;
   intraretinal fluid; optical coherence tomography; subretinal fluid
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; INTRAVITREAL BEVACIZUMAB;
   SUBGROUP ANALYSIS; APOLIPOPROTEIN-E; RANIBIZUMAB; ASSOCIATION; THERAPY;
   REGIMEN; VEGF
AB Background: Previous reports suggest that the outcome of age-related macular degeneration treatment is dependent on variants in the apolipoprotein E (APOE) gene. We wish to establish if variants in this gene are associated with anatomical location of fluid within the macula on optical coherence tomography imaging before and after three anti-vascular endothelial growth factor treatments.
   Methods: Patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration were prospectively enrolled and monitored over a 12-month period. Main outcome measures were logMAR best-corrected visual acuity and correlation of qualitative optical coherence tomography features (intraretinal fluid [IRF] and/or subretinal fluid) at baseline and after three anti-vascular endothelial growth factor injections with genetic variants of the APOE gene.
   Results: One hundred and eighty-six eyes of 186 patients aged 79.4 years (range, 58-103 years). Subjects with an epsilon 2 allele were more likely to have IRF at baseline compared with the eyes without (odds ratio: 2.98, 95% confidence interval: 1.22-7.29, P = 0.02). After 3 injections, 184 eyes remained. Of these, 114 of eyes (62.0%) were classified as "dry" on optical coherence tomography, whereas 48 eyes (26.1%) still had a component of IRF, and 22 (12.0%) had subretinal fluid alone. There was no statistically significant association between APOE variants and presence of persistent IRF, although there were almost double the number of subjects with epsilon 2 (40%) who had persistent fluid compared with those with epsilon 3/epsilon 4 (23%) (P = 0.06).
   Conclusion: In patients with neovascular age-related macular degeneration, the presence of the epsilon 2 allele of the APOE gene was associated with having IRF at baseline. Larger studies are required to determine if a greater proportion of those with the epsilon 2 allele retain this fluid after three initial injections.
C1 [Wickremasinghe, Sanjeewa S.; Sandhu, Sukhpal S.; Amirul-Islam, Fakir M.; Abedi, Farshad; Richardson, Andrea J.; Baird, Paul N.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Wickremasinghe, SS (通讯作者)，Ctr Eye Res Australia, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM Sanj.Wickremsinghe@eyeandear.au
RI ; Islam, Fakir M Amirul/P-6665-2015
OI Guymer, Robyn/0000-0002-9441-4356; Baird, Paul/0000-0002-1305-3502;
   Islam, Fakir M Amirul/0000-0003-3897-3302
FU National Health and Medical Research Council (NHMRC) [590205, 1008979];
   NHMRC-Clinical Research Excellence grant [529923]; NHMRC practitioner
   fellowship [529905]; NHMRC Senior Research Fellowship [1028444]
FX Supported by National Health and Medical Research Council (NHMRC)
   through project grant 590205 and 1008979, an NHMRC-Clinical Research
   Excellence grant 529923-Translational Clinical Research in Major Eye
   Diseases, NHMRC practitioner fellowship 529905 (R.H.G.), and NHMRC
   Senior Research Fellowship 1028444 (P.N.B.). The Centre for Eye Research
   Australia (CERA) receives Operational Infrastructure Support from the
   Victorian Government.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Crane IJ, 2000, IMMUNOLOGY, V101, P426, DOI 10.1046/j.0019-2805.2000.01105.x
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Judson R, 2004, ATHEROSCLEROSIS, V177, P345, DOI 10.1016/j.atherosclerosis.2004.07.012
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lee SJ, 2007, J MICROBIOL BIOTECHN, V17, P1024
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosvall L, 2009, NEUROBIOL AGING, V30, P1545, DOI 10.1016/j.neurobiolaging.2007.12.003
   Schupf N, 2013, NEUROBIOL AGING, V34, P1287, DOI 10.1016/j.neurobiolaging.2012.08.019
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Teper SJ, 2010, MOL VIS, V16, P2598
   Wickremasinghe SS, 2012, OPHTHALMOLOGY, V119, P2413, DOI 10.1016/j.ophtha.2012.06.056
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
NR 27
TC 3
Z9 3
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2014
VL 34
IS 12
BP 2367
EP 2375
DI 10.1097/IAE.0000000000000258
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU9KK
UT WOS:000345911300012
PM 25077528
DA 2022-11-30
ER

PT J
AU Hooper, P
   Jutai, JW
   Strong, G
   Russell-Minda, E
AF Hooper, Phil
   Jutai, Jeffrey W.
   Strong, Graham
   Russell-Minda, Elizabeth
TI Age-related macular degeneration and low-vision rehabilitation: a
   systematic review
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Review
DE retinal degeneration; vision disorders; assistive technology;
   evidence-based medicine; rehabilitation
ID QUALITY-OF-LIFE; VISUAL FUNCTION QUESTIONNAIRE; COMPUTER TASK ACCURACY;
   SELF-MANAGEMENT; PERFORMANCE; DEPRESSION; MAGNIFIERS; IMPAIRMENT;
   DISABILITY; RELOCATION
AB Background: Because of the prevalence and devastating consequences of age-related macular degeneration (AMD), a systematic review devoted to low-vision rehabilitation and AMD seems timely and appropriate.
   Methods: Several electronic databases were searched for studies from 1980 to 2006 involving individuals with low vision or visual impairment and rehabilitation interventions. Studies were assessed for quality and level of evidence.
   Results:The findings indicate that standard low-vision rehabilitation programs, conventional in-clinic assessments, and optical devices are effective ways of managing and living with vision loss. Areas of unmet need include determining which types of orientation and mobility programs and devices are most effective and developing methods of matching assistive technologies with the individual's visual and environmental requirements.
   Interpretation: Additional randomized controlled trials with similar intervention comparisons and outcome measures are needed to form stronger conclusions for the most effective low-vision rehabilitation interventions for individuals with AMD.
C1 [Jutai, Jeffrey W.] Rehabil & Geriat Care Res Ctr, Lawson Hlth Res Inst, London, ON N6C 5J1, Canada.
   [Hooper, Phil] Univ Western Ontario, Ivey Eye Inst, London, ON N6A 3K7, Canada.
   [Strong, Graham] Univ Waterloo, Ctr Sight Enhancement, Waterloo, ON N2L 3G1, Canada.
   [Strong, Graham] Univ Waterloo, Sch Optometry, Waterloo, ON N2L 3G1, Canada.
   [Russell-Minda, Elizabeth] Univ Western Ontario, Dept Phys Med & Rehabil, London, ON, Canada.
C3 Western University (University of Western Ontario); Western University
   (University of Western Ontario); University of Waterloo; University of
   Waterloo; Western University (University of Western Ontario)
RP Jutai, JW (通讯作者)，Rehabil & Geriat Care Res Ctr, Lawson Hlth Res Inst, Parkwood Hosp B-3002 A 801 Commissioners Rd E, London, ON N6C 5J1, Canada.
EM jjutai@uwo.ca
OI Jutai, Jeffrey/0000-0002-7294-1323
CR Adams E., 2003, OPTICAL DEVICES ADUL
   *AG HEALTHC RES Q, 2002, SYST RAT STRENGTH SC
   *AG HEALTHC RES QU, 2004, VIS REH ELD IND LOW
   Al-Karmi R, 2006, CAN J OPHTHALMOL, V41, P313, DOI 10.1139/I06-016
   Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Bowers Alex R, 2001, Clin Exp Optom, V84, P139
   Bowers AR, 2001, OPTOMETRY VISION SCI, V78, P325, DOI 10.1097/00006324-200105000-00016
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Canadian Task Force on the Periodic Health Examination, 1979, CAN MED ASSOC J, V121, P1193
   Cheong AMY, 2005, OPTOMETRY VISION SCI, V82, P114, DOI 10.1097/01.OPX.0000153244.93582.FF
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Culham LE, 2004, OPHTHAL PHYSL OPT, V24, P281, DOI 10.1111/j.1475-1313.2004.00193.x
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DAVIS C, 1995, J VISUAL IMPAIR BLIN, V89, P16
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Eklund K, 2004, DISABIL REHABIL, V26, P401, DOI 10.1080/09638280410001662950
   Eperjesi F, 2004, ACTA OPHTHALMOL SCAN, V82, P695, DOI 10.1111/j.1600-0420.2004.00371.x
   Eperjesi F, 2004, OPHTHAL PHYSL OPT, V24, P17, DOI 10.1046/j.1475-1313.2003.00157.x
   Foley Norine C, 2003, Top Stroke Rehabil, V10, P1
   Fosse P, 2001, OPTOMETRY VISION SCI, V78, P162, DOI 10.1097/00006324-200103000-00009
   Fosse P., 2004, J VISUAL IMPAIR BLIN, V98, P389, DOI DOI 10.1177/0145482X0409800702
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Goodrich G L, 2001, Optometry, V72, P519
   Goodrich G. L., 2003, VISUAL IMPAIRMENT RE, V5, P57, DOI DOI 10.1076/VIMR.5.2.57.26265
   Ivanoff SD, 2002, AM J OCCUP THER, V56, P322, DOI 10.5014/ajot.56.3.322
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   JUTAI J, 2006, VISION REHABILITION, V1
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan SA, 2002, CLIN EXP OPHTHALMOL, V30, P404, DOI 10.1046/j.1442-9071.2002.00569.x
   Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Maberley DAL, 2006, EYE, V20, P341, DOI 10.1038/sj.eye.6701879
   McCabe P, 2000, Ophthalmic Epidemiol, V7, P259, DOI 10.1076/opep.7.4.259.4173
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   *NAT ADV EYE COUNC, 1998, NIH PUBL
   *NAT EY I, CLIN STUD DAT
   NILSSON UL, 1990, CLIN VISION SCI, V6, P3
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Owsley C, 2004, OPHTHALMOLOGY, V111, P2259, DOI 10.1016/j.ophtha.2004.06.026
   Paz SH, 2003, ARCH OPHTHALMOL-CHIC, V121, P1021, DOI 10.1001/archopht.121.7.1021
   *PUBL HLTH VIS TAS, 2002, DET INF NEEDS PREV V
   Reeves BC, 2004, BRIT J OPHTHALMOL, V88, P1443, DOI 10.1136/bjo.2003.037457
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   ROSENBERG R, 1989, OPTOMETRY VISION SCI, V66, P747, DOI 10.1097/00006324-198911000-00004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Scanlan JM, 2004, J VISUAL IMPAIR BLIN, V98, P601, DOI 10.1177/0145482X0409801005
   Scilley K, 2004, OPHTHAL EPIDEMIOL, V11, P131, DOI 10.1076/opep.11.2.131.28159
   Scott IU, 2002, AM J OPHTHALMOL, V134, P857, DOI 10.1016/S0002-9394(02)01795-6
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   Scott IU, 2001, AM J OPHTHALMOL, V131, P584, DOI 10.1016/S0002-9394(01)00832-7
   Smith HJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P1042, DOI 10.1001/archopht.123.8.1042
   Stelmack J, 1991, J Am Optom Assoc, V62, P53
   Stelmack J, 2001, OPTOMETRY VISION SCI, V78, P335, DOI 10.1097/00006324-200105000-00017
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Virgili G, 2006, COCHRANE DB SYST REV, V4
   VIRGILI G, 2006, COCHRANE DB SYST REV, V3
   Virgili G, 2007, ACTA OPHTHALMOL SCAN, V85, P6, DOI 10.1111/j.1600-0420.2006.00711.x
   Wolffsohn JS, 2002, OPHTHAL PHYSL OPT, V22, P300, DOI 10.1046/j.1475-1313.2002.00036.x
NR 62
TC 224
Z9 225
U1 2
U2 29
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD APR
PY 2008
VL 43
IS 2
BP 180
EP 187
DI 10.3129/i08-001
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 290BU
UT WOS:000255098500005
PM 18347620
DA 2022-11-30
ER

PT J
AU Chen, YFN
   Powell, AM
   Mao, A
   Sheidow, TG
AF Chen, Yufeng N.
   Powell, Anne-Marie
   Mao, Alex
   Sheidow, Tom G.
TI RETROSPECTIVE REVIEW OF LUCENTIS "TREAT AND EXTEND" PATTERNS AND
   OUTCOMES IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AMD; anti-VEGF; Lucentis; treat and extend
ID DOSING REGIMEN; RANIBIZUMAB; EFFICACY; SAFETY
AB Purpose:To assess patterns and outcomes of a Treat and Extend dosing regimen of ranibizumab in patients with age-related macular degeneration.Methods:Three hundred and thirty two treatment-naive age-related macular degeneration patients starting therapy with ranibizumab between January 1, 2011, and June 30, 2012, at the Ivey Eye Institute were reviewed, and 79 met inclusion criteria. Patients on Treat and Extend dosing regimen underwent an induction phase with monthly injections and then moved onto an extension phase. Change in visual acuity and central retinal thickness during the induction and extension phases were recorded.Results:During the induction phase, patients had a significant gain in vision and decrease in central retinal thickness (+8.4 letters, P < 0.001 and -81.3 m, P < 0.001). During the extension phase, patients did not have significant change in vision (-0.5 letters, P = 0.81) and did not have significant change in central retinal thickness (-11.5 m, P = 0.17). The average extension interval between treatments was 47.7 days, with patients receiving an average of 8.6 injections per year. Cost analysis showed it cost US $16,659 to treat 1 patient in the first year on Treat and Extend dosing regimen compared with US $20,614 on monthly dosing.Conclusion:Treat and Extend dosing regimen allows similar visual outcomes to monthly dosing, while reducing the total number of injections, visits, and overall cost.
C1 [Chen, Yufeng N.] Univ Western Ontario, Dept Ophthalmol, London, ON, Canada.
   [Powell, Anne-Marie; Mao, Alex; Sheidow, Tom G.] Univ Western Ontario, Ivey Eye Inst, Dept Ophthalmol, London, ON, Canada.
C3 Western University (University of Western Ontario); Western University
   (University of Western Ontario)
RP Sheidow, TG (通讯作者)，Ivey Eye Inst, 268 Grosvenor St, London, ON N6A 4V2, Canada.
EM sheidowt@rogers.com
FU Novartis; Pfizer; QLT
FX T. G. Sheidow received research support from Novartis, Pfizer, QLT, and
   is also on advisory boards for Novartis, Alcon, Bayer, QLT.
CR Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Rahimy E, 2014, AM J OPHTHALMOL, V158, P345, DOI 10.1016/j.ajo.2014.05.013
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
NR 16
TC 9
Z9 9
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2016
VL 36
IS 2
BP 272
EP 278
DI 10.1097/IAE.0000000000000691
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DC9AU
UT WOS:000369513500006
PM 26200511
DA 2022-11-30
ER

PT J
AU Geirsdottir, A
   Stefansson, E
   Jonasson, F
   Helgadottir, G
   Sigurdsson, H
AF Geirsdottir, Asbjorg
   Stefansson, Einar
   Jonasson, Fridbert
   Helgadottir, Gudleif
   Sigurdsson, Haraldur
TI Age-related macular degeneration in very old individuals with family
   history
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULOPATHY; PREVALENCE; EYE
AB PURPOSE: To study age-related macular degeneration (AMD) in old and very old individuals with family history of AMD to find the proportion of those with early and advanced AMD.
   DESIGN: Retrospective cross-sectional cohort study of individuals with family history of AMD.
   METHODS: Database of 897 AMD patients ages 75 to 102 years with family history of AMD was compiled. Color fundus photographs were graded in a masked fashion according to the International Classification of AMD.
   RESULTS: With increasing age, a gradually larger pro. portion of participants had advanced AMD; 54% (469 of 863) of all those 75 years and older had advanced AMD, 64% (258 of 406) of all those 85 years and older, 74% (37 of 50) of all those 95 years and older, and all (eight of eight) 100 years and older had advanced AMD.
   CONCLUSIONS: All the centenarians in the present study had advanced AMD.
C1 Landspitali Univ Hosp, Dept Ophthalmol, IS-101 Reykjavik, Iceland.
C3 Landspitali National University Hospital
RP Sigurdsson, H (通讯作者)，Landspitali Univ Hosp, Dept Ophthalmol, Eiriksgata 37, IS-101 Reykjavik, Iceland.
EM haraldsi@landspitali.is
RI Jonasson, Fridbert/ABA-9889-2021
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   de Jong PTVM, 2001, EYE, V15, P396, DOI 10.1038/eye.2001.143
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
NR 6
TC 10
Z9 10
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2007
VL 143
IS 5
BP 889
EP 890
DI 10.1016/j.ajo.2006.11.057
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 165FF
UT WOS:000246288800033
PM 17452183
DA 2022-11-30
ER

PT J
AU Michels, S
   Rosenfeld, PJ
AF Michels, S
   Rosenfeld, PJ
TI Treatment of neovascular age-related macular degeneration with
   Ranibizumab/Lucentis(TM)
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Review
DE Ranibizumab; vascular endothelial growth factor; age-related macular
   degeneration; choroidal neovascularization; angiogenesis
ID ENDOTHELIAL GROWTH-FACTOR; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   RETINAL-PIGMENT EPITHELIUM; INCREASED EXPRESSION; TRANSGENIC MICE;
   FACTOR VEGF; ANTIBODY; PHARMACOKINETICS; RANIBIZUMAB; RECEPTORS
AB Vascular endothelial growth factor (VEGF) is considered to play an essential role in the pathogenesis of age-related macular degeneration due to its vascular permeability-inducing and angiogenic properties. Ranibizumab, a small antibody fragment designed to competitively bind all VEGF isoforms, passes after intravitreal injection all retinal layers reaching the retinal pigment epithelium-choroid complex. Experimental animal models showed the drug to be safe and effective. Subsequently, Phase I/II clinical trials conducted in patients with neovascular AMD demonstrated a good safety profile, and a significant functional benefit. Ranibizumab therapy repeated every four weeks for the treatment of neovascular AMD is currently in Phase III clinical trials. Combination therapy trials aiming for improved treatment durability and effectiveness are currently ongoing as well as new treatment strategies using intermittent, optical coherence tomography (OCT) guided therapy. Anti-VEGF therapy using Ranibizumab is a promising new treatment option for neovascular AMD.
C1 Med Univ Wien, Klin Augenheilkunde & Optometrie, A-1090 Vienna, Austria.
   Univ Miami, Sch Med, Bascom Palmer Eye Inst, Miami, FL USA.
C3 Medical University of Vienna; Bascom Palmer Eye Institute; University of
   Miami
RP Michels, S (通讯作者)，Med Univ Wien, Klin Augenheilkunde & Optometrie, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM stephan.michels@meduniwien.ac.at
CR ANTOSZYK AN, 2003, RHUFAB V2 WET AMD CH
   Bernatchez PN, 2002, J CELL BIOCHEM, V85, P629, DOI 10.1002/jcb.10155
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   DAMICO LA, 2004, IOVS, V45
   Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3
   Feletou M, 2001, BRIT J PHARMACOL, V132, P1342, DOI 10.1038/sj.bjp.0703941
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   GAUDREAULT J, 2002, IOVS, P43
   GAUDREAULT J, 2003, IOVS, V44
   GAUDREAULT J, 2004, IOVS, P45
   HEIER J, 2004, IOVS, P45
   Heier JS, 2003, VEGF ANTIBODY APPROA
   HEIER JS, 2004, ANTI VEGF GENENTECH
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   MICHELS S, 2005, IN PRESS OPHTHALMOLO
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Okamoto N, 1997, AM J PATHOL, V151, P281
   ONEILL CA, 2001, IOVS, V41
   Plate KH, 1997, J NEURO-ONCOL, V35, P365
   Presta LG, 1997, CANCER RES, V57, P4593
   PULIAFITO CA, 2003, RHUFAB V2 DOSE ESCAL
   Robinson CJ, 2001, J CELL SCI, V114, P853
   ROSENFELD PJ, 2003, IOVS, P44
   ROSENFELD PJ, 2001, SAFETY RHUFABV2 ANTI, P121
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002
   Tilton RG, 1999, INVEST OPHTH VIS SCI, V40, P689
NR 35
TC 32
Z9 47
U1 0
U2 3
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD JUN
PY 2005
VL 222
IS 6
BP 480
EP 484
DI 10.1055/s-2005-858315
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 941UY
UT WOS:000230240900003
PM 15973626
DA 2022-11-30
ER

PT J
AU Maguire, MG
   Ying, GS
   Jaffe, GJ
   Toth, CA
   Daniel, E
   Grunwald, J
   Martin, DF
   Hagstrom, SA
AF Maguire, Maureen G.
   Ying, Gui-shuang
   Jaffe, Glenn J.
   Toth, Cynthia A.
   Daniel, Ebenezer
   Grunwald, Juan
   Martin, Daniel F.
   Hagstrom, Stephanie A.
CA CATT Res Grp
TI Single-Nucleotide Polymorphisms Associated With Age-Related Macular
   Degeneration and Lesion Phenotypes in the Comparison of Age-Related
   Macular Degeneration Treatments Trials
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; RETINAL ANGIOMATOUS PROLIFERATION; POLYPOIDAL
   CHOROIDAL VASCULOPATHY; GENOME-WIDE ASSOCIATION; BEVACIZUMAB; GENOTYPE;
   Y402H; RISK; CFH; RANIBIZUMAB
AB IMPORTANCE Single-nucleotide polymorphisms (SNPs) associated with the CFH, ARMS2, C3, LIPC, CFB, and C2 genes are associated with age-related macular degeneration (AMD); however, the association of these SNPs with angiographic features of neovascular AMD has been inconsistent in previous studies, and to date, no studies have addressed their association with features on optical coherence tomography.
   OBJECTIVE To evaluate the influence of genotype of SNPs previously associated with AMD on the phenotype of neovascular lesions.
   DESIGN, SETTING, AND PARTICIPANTS Participants for this cross-sectional study were recruited from the 1185 patients enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), a randomized clinical trial. Eligibility criteria for CATT specified that eyes have choroidal neovascularization and visual acuity between 20/25 and 20/320. A subgroup of 835 patients provided blood samples from July 2010 through September 2011 and were genotyped for the SNPs rs1061170 (CFH), rs10490924 (ARMS2), rs2230199 (C3), rs10468017 (LIPC), rs4151667 (CFB), rs547154 (C2) using TaqMan SNP genotyping assays. Data analysis was initiated in November 2013 and completed in January 2016.
   MAIN OUTCOMES AND MEASURES Pretreatment ocular characteristics on fluorescein angiography (lesion type, area of neovascularization and total lesion, retinal angiomatous proliferation) and on time-domain optical coherence tomography (presence of intraretinal, subretinal, and subretinal pigment epithelium fluid; thickness at the foveal center of the retina, subretinal fluid, and subretinal tissue complex), visual acuity, and age.
   RESULTS A total of 835 (73%) of 1150 CATT patients were genotyped. Mean age decreased with the number of risk alleles for CFH (P < .001), ARMS2 (P < .001), and C3 (P = .005). The following results were found as the number of risk alleles increased from 0 to 1 to 2. For CFH, mean total thickness decreased from 476 to 476 to 434 mu m (P = .01; adjusted for age, sex, and smoking status). For ARMS2, the mean area of the total lesion increased from 2.0 to 2.8 to 2.4 mm(2) (P = .03), the proportion with retinal angiomatous proliferation lesions increased from 8% to 10% to 12%(P = .05), and the proportion with intraretinal fluid increased from 72% to 71% to 82% (P = .008). For C3, the proportion with intraretinal fluid decreased from 78% to 69% to 64%(P = .001), and the mean retinal thickness decreased from 225 to 207 to 197 mu m (P = .02).
   CONCLUSIONS AND RELEVANCE CFH, ARMS2, and C3 were associated with specific features of neovascularization at the time patients were enrolled in CATT. Previously identified associations of ARMS2 and CFH with type of choroidal neovascularization on fluorescein angiography were not confirmed. New associations with OCT features identified in CATT need confirmation to establish whether a true association exists.
   TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00593450.
C1 [Maguire, Maureen G.; Ying, Gui-shuang; Daniel, Ebenezer; Grunwald, Juan] Univ Penn, Dept Ophthalmol, 3535 Market St,Ste 700, Philadelphia, PA 19104 USA.
   [Jaffe, Glenn J.; Toth, Cynthia A.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Martin, Daniel F.; Hagstrom, Stephanie A.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 University of Pennsylvania; Duke University; Cleveland Clinic Foundation
RP Maguire, MG (通讯作者)，Univ Penn, Dept Ophthalmol, 3535 Market St,Ste 700, Philadelphia, PA 19104 USA.
EM maguirem@mail.med.upenn.edu
RI Toth, Cynthia/L-5534-2019
OI Toth, Cynthia/0000-0002-2324-0854
FU National Eye Institute of the National Institutes of Health, US
   Department of Health and Human Services [U10 EY017823, U10 EY017825, U10
   EY017826, U10 EY017828]; NATIONAL EYE INSTITUTE [U10EY017828,
   U10EY017826, U10EY017825, R21EY023689, U10EY017823] Funding Source: NIH
   RePORTER
FX The Comparison of Age-related Macular Degeneration Treatment Trials is
   supported by grants U10 EY017823, U10 EY017825, U10 EY017826, and U10
   EY017828 from the National Eye Institute of the National Institutes of
   Health, US Department of Health and Human Services.
CR Akagi-Kurashige Y, 2015, OPHTHALMOLOGY, V122, P2295, DOI 10.1016/j.ophtha.2015.07.032
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Caramoy A, 2014, ACTA OPHTHALMOL, V92, P745, DOI 10.1111/aos.12437
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chowers I, 2008, MOL VIS, V14, P1829
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hogg RE, 2012, RETINA-J RET VIT DIS, V32, P1950, DOI 10.1097/IAE.0b013e31824dadf1
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Seitsonen S, 2008, ACTA OPHTHALMOL, V86, P390, DOI 10.1111/j.1600-0420.2007.01050.x
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
NR 30
TC 11
Z9 11
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUN
PY 2016
VL 134
IS 6
BP 674
EP 681
DI 10.1001/jamaophthalmol.2016.0669
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DR0KL
UT WOS:000379596300012
PM 27099955
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Hunt, DWC
   Margaron, P
AF Hunt, DWC
   Margaron, P
TI Status of therapies in development for the treatment of age-related
   macular degeneration
SO IDRUGS
LA English
DT Review
ID EPITHELIUM-DERIVED FACTOR; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   UNIQUE NONSTEROIDAL PRODRUG; INDUCED OCULAR INFLAMMATION; PHOTODYNAMIC
   THERAPY; POTENTIAL UTILITY; ANGIOGENESIS; VERTEPORFIN; SQUALAMINE;
   NEPAFENAC
AB Age-related macular degeneration (AMD) is among the leading causes of visual impairment in the elderly. The FDA has approved only two treatments, laser photocoagulation and Visudyne(R) photodynamic therapy (PDT), approved for the wet form of AMD, a progressive condition characterized by the presence of choroidal neovascularization (CNV). Current pharmaceutical activities aimed at the treatment of wet-type AMD are largely focused on the development of anti-angiogenic drugs that would inhibit further CNV formation or even reduce existing CNV. However, other lines of attack for the treatment of wet AMD include anti-inflammatory agents as well as new PDT agents. This review will summarize ongoing activities for these different approaches.
C1 QLT Inc, Preclin Dev, Vancouver, BC V5T 4T5, Canada.
RP Hunt, DWC (通讯作者)，QLT Inc, Preclin Dev, 887 Great No Way, Vancouver, BC V5T 4T5, Canada.
EM dhunt@qltinc.com
CR *ALC INC, 2002, ALC LAUNCH NEW AN AC
   ARMSTRONG D, 2002, INVEST OPHTHALMOL VI, V43
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Brown S B, 2001, Expert Opin Pharmacother, V2, P351
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P3337
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Flaxel Christina J, 2002, Ophthalmol Clin North Am, V15, P437, DOI 10.1016/S0896-1549(02)00038-X
   Folkman J, 2001, SEMIN ONCOL, V28, P536, DOI 10.1016/S0093-7754(01)90021-1
   Gamache DA, 2000, INFLAMMATION, V24, P357, DOI 10.1023/A:1007049015148
   Genaidy M, 2002, RETINA-J RET VIT DIS, V22, P772, DOI 10.1097/00006982-200212000-00014
   GILLIES MC, 2002, INVEST OPHTHALMOL VI, V43
   Granville DJ, 2001, HISTOL HISTOPATHOL, V16, P309, DOI 10.14670/HH-16.309
   Granville DJ, 1999, AM J PATHOL, V155, P1021, DOI 10.1016/S0002-9440(10)65202-9
   Griggs J, 2001, LANCET ONCOL, V2, P82, DOI 10.1016/S1470-2045(00)00224-2
   Hammond BR, 2002, NUTR REV, V60, P283, DOI 10.1301/002966402320387215
   HEIER JS, 2003, ANN M ASS RES VIS OP
   Higgins RD, 2000, INVEST OPHTH VIS SCI, V41, P1507
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Jonas JB, 2000, BRIT J OPHTHALMOL, V84, P1064, DOI 10.1136/bjo.84.9.1064
   Kaven C, 2001, OPHTHALMOLOGICA, V215, P284, DOI 10.1159/000050875
   Ke TL, 2000, INFLAMMATION, V24, P371, DOI 10.1023/A:1007001131987
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lim Jennifer I, 2002, Ophthalmol Clin North Am, V15, P473, DOI 10.1016/S0896-1549(02)00044-5
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Obana A, 1999, LASER SURG MED, V24, P209, DOI 10.1002/(SICI)1096-9101(1999)24:3<209::AID-LSM6>3.0.CO;2-L
   Obana A, 2001, INVEST OPHTH VIS SCI, V42, P2639
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Renno RZ, 2001, ADV DRUG DELIVER REV, V52, P63, DOI 10.1016/S0169-409X(01)00195-8
   Renno RZ, 2002, INVEST OPHTH VIS SCI, V43, P1574
   ROSENFELD PJ, 2003, ANN M ASS RES VIS OP
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sills AK, 1998, CANCER RES, V58, P2784
   SINGERMAN LJ, 2002, INVEST OPHTHALMOL VI, V43
   SLAKTER JS, 2002, INVEST OPHTHALMOL VI, V43
   Soubrane G, 2001, BRIT J OPHTHALMOL, V85, P483, DOI 10.1136/bjo.85.4.483
   SPAIDE RF, 2003, ANN M ASS REV VIS OP
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stone Thomas W, 2002, Ophthalmol Clin North Am, V15, P479, DOI 10.1016/S0896-1549(02)00052-4
   *STUD GROUP PRINC, 2002, RETINA, V22, P6
   Takahashi K, 2003, INVEST OPHTH VIS SCI, V44, P409, DOI 10.1167/iovs.02-0346
   *THER STUD GROUP, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Thompson J, 1998, Radiol Technol, V70, P85
   Woodburn KW, 2002, RETINA-J RET VIT DIS, V22, P391, DOI 10.1097/00006982-200208000-00001
   YOSHIKAWA K, 1995, JPN J OPHTHALMOL, V39, P71
NR 54
TC 12
Z9 15
U1 1
U2 6
PU THOMSON REUTERS (SCIENTIFIC) LTD
PI LONDON
PA 77 HATTON GARDEN, LONDON, EC1N 8JS, ENGLAND
SN 1369-7056
EI 2040-3410
J9 IDRUGS
JI IDrugs
PD MAY
PY 2003
VL 6
IS 5
BP 464
EP 469
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 695YY
UT WOS:000183859000018
PM 12789601
DA 2022-11-30
ER

PT J
AU Tuo, JS
   Grob, S
   Zhang, K
   Chan, CC
AF Tuo, Jingsheng
   Grob, Seanna
   Zhang, Kang
   Chan, Chi-Chao
TI Genetics of Immunological and Inflammatory Components in Age-related
   Macular Degeneration
SO OCULAR IMMUNOLOGY AND INFLAMMATION
LA English
DT Article
DE age-related macular degeneration (AMD); complement factor;
   cytokine/chemokine; gene; innate immunity
ID COMPLEMENT-FACTOR-H; GENOME-WIDE ASSOCIATION; COPY-NUMBER VARIATION;
   SYSTEMIC-LUPUS-ERYTHEMATOSUS; HTRA1 PROMOTER POLYMORPHISM; TOLL-LIKE
   RECEPTOR-3; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   SUSCEPTIBILITY LOCI; LOC387715 GENOTYPES
AB Age-related macular degeneration (AMD), affecting 30 to 50 million elder individuals worldwide, is a disease affecting the macular retina and choroid that can lead to irreversible central vision loss and blindness. Recent findings support a role for immunologic processes in AMD pathogenesis, including generation of inflammatory related molecules in the Bruch's membrane, recruitment of macrophages, complement activation, microglial activation and accumulation in the macular lesions. Pro-inflammatory effects of chronic inflammation and oxidative stress can result in abnormal retinal pigment epithelium, photoreceptor atrophy and choroidal neovascularization. The associations of immunological and inflammatory genes, in particular the genes related to innate immunity with AMD support the involvement of various immunological pathways in the AMD pathogenesis. We review the literature on the involvements of inflammatory genes in AMD, highlight recent genetic discoveries, and discuss the potential application of such knowledge in the management of patients with AMD.
C1 [Tuo, Jingsheng; Chan, Chi-Chao] NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Grob, Seanna; Zhang, Kang] Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92093 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of California System; University of California San
   Diego
RP Chan, CC (通讯作者)，NEI, Immunopathol Sect, Immunol Lab, NIH, 10 Ctr Dr,10-10N103, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
RI Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697; Tuo, Jingsheng/0000-0002-1372-7810
FU NEI; NATIONAL EYE INSTITUTE [ZICEY000461, ZIAEY000222] Funding Source:
   NIH RePORTER
FX The NEI Intramural Research program provided funding.
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Aitman TJ, 2006, NATURE, V439, P851, DOI 10.1038/nature04489
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Bell CG, 2010, BRIEF FUNCT GENOMICS, V9, P477, DOI 10.1093/bfgp/elq026
   Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Cho Y, 2009, INVEST OPHTHALMOL VI
   Cho YG, 2011, LAB INVEST, V91, P519, DOI 10.1038/labinvest.2010.184
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Coin LJM, 2010, NAT METHODS, V7, P541, DOI [10.1038/NMETH.1466, 10.1038/nmeth.1466]
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Conrad DF, 2010, NATURE, V464, P704, DOI 10.1038/nature08516
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Damiani D, 2008, J NEUROSCI, V28, P4878, DOI 10.1523/JNEUROSCI.0828-08.2008
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   DOSSO AA, 1992, OPHTHALMOLOGICA, V205, P24, DOI 10.1159/000310307
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fernandez-Morera JL, 2010, TISSUE ANTIGENS, V76, P431, DOI 10.1111/j.1399-0039.2010.01587.x
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2010, JPN J OPHTHALMOL, V54, P609, DOI 10.1007/s10384-010-0865-2
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hinds DA, 2006, NAT GENET, V38, P82, DOI 10.1038/ng1695
   Hollox EJ, 2008, NAT GENET, V40, P23, DOI 10.1038/ng.2007.48
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Huffmeier U, 2010, J INVEST DERMATOL, V130, P979, DOI 10.1038/jid.2009.385
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jiang ST, 2009, HUM MOL GENET, V18, P1566, DOI 10.1093/hmg/ddp068
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Kutty RK, 2010, BIOCHEM BIOPH RES CO, V402, P390, DOI 10.1016/j.bbrc.2010.10.042
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lee AY, 2008, PHARMACOGENOMICS, V9, P1547, DOI 10.2217/14622416.9.10.1547
   Leveziel N, 2007, MOL VIS, V13, P2153
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li YW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017106
   Liu MM, 2011, INVEST OPHTHALMOL VI
   Liu SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015778
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   McKibbin M, 2011, BR J OPHTHALMOL
   Meyer KJ, 2011, HUM GENET, V129, P91, DOI 10.1007/s00439-010-0904-6
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Narendran N, 2005, EYE, V19, P11, DOI 10.1038/sj.eye.6701435
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Parmeggiani F, 2009, PHARMACOGENOMICS, V10, P81, DOI 10.2217/14622416.10.1.81
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045
   Ptacek T, 2008, CYTOGENET GENOME RES, V123, P142, DOI 10.1159/000184701
   Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ryu E, 2010, MOL VIS, V16, P2811
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278
   Smith TC, 2007, AUST FAM PHYSICIAN, V36, P359
   Sng CCA, 2011, OPHTHALMIC RES, V45, P191, DOI 10.1159/000321387
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spencer KL, 2011, INVEST OPHTH VIS SCI, V52, P1748, DOI 10.1167/iovs.09-5112
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Willcocks LC, 2008, J EXP MED, V205, P1573, DOI 10.1084/jem.20072413
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Yang Y, 2007, AM J HUM GENET, V80, P1037, DOI 10.1086/518257
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu ZX, 2011, J BIOL CHEM, V286, P18960, DOI 10.1074/jbc.M110.217422
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zerbib J, EXP EYE RES IN PRESS
   Zhang F, 2009, ANNU REV GENOM HUM G, V10, P451, DOI 10.1146/annurev.genom.9.081307.164217
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 119
TC 63
Z9 66
U1 0
U2 15
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0927-3948
EI 1744-5078
J9 OCUL IMMUNOL INFLAMM
JI Ocul. Immunol. Inflamm.
PD FEB
PY 2012
VL 20
IS 1
BP 27
EP 36
DI 10.3109/09273948.2011.628432
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 892AO
UT WOS:000300259000006
PM 22324898
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Moshfeghi, DM
   Kaiser, PK
   Gertner, M
AF Moshfeghi, Darius M.
   Kaiser, Peter K.
   Gertner, Michael
TI Stereotactic low-voltage x-ray irradiation for age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB; SECONDARY; THERAPY; SAFETY
AB The IRay stereotactic low-voltage x-ray irradiation treatment system for age-related macular degeneration consists of a low voltage x-ray tube, an eye tracking system, a robotically controlled delivery system, a coupling device to facilitate tracking and stabilisation, a graphical user interface and gating software. Low-voltage x-rays are delivered in a series of three spots to the macula in a non-invasive manner through the inferior pars plana. These beams are designed to overlap on the centre of the macula. Each beam delivers one-third of the total dose, such that the total macula dose is three times an individual beam's dose. The device is designed to run off standard domestic electrical power, and no special shielding is necessary for the room. This system has been validated in Monte Carlo simulations, human cadaver eye studies, pre-clinical animal studies and in a phase I clinical trial.
C1 [Moshfeghi, Darius M.] Stanford Univ, Sch Med, Dept Ophthalmol, Eye Inst,Stanford Vitreoretinal Ctr, Palo Alto, CA 94303 USA.
   [Kaiser, Peter K.] Cleveland Clin Fdn, Dept Ophthalmol, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Gertner, Michael] Oraya Therapeut Inc, Dept Ophthalmol, Newark, CA USA.
C3 Stanford University; Cleveland Clinic Foundation
RP Moshfeghi, DM (通讯作者)，Stanford Univ, Sch Med, Dept Ophthalmol, Eye Inst,Stanford Vitreoretinal Ctr, 2452 Watson Court, Palo Alto, CA 94303 USA.
EM dariusm@stanford.edu
OI Kaiser, Peter/0000-0001-5126-045X; Moshfeghi, Darius
   Mohammad/0000-0003-2254-292X
CR Archer D B, 1994, Curr Opin Ophthalmol, V5, P59, DOI 10.1097/00055735-199406000-00011
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hanlon J, 2009, MED PHYS, V36, P3671, DOI 10.1118/1.3168554
   Lee C, 2008, MED PHYS, V35, P5151, DOI 10.1118/1.2990780
   PARSONS JT, 1994, INT J RADIAT ONCOL, V30, P765, DOI 10.1016/0360-3016(94)90347-6
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Senan S, 2007, ONCOLOGIST, V12, P465, DOI 10.1634/theoncologist.12-4-465
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, V4
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
NR 14
TC 36
Z9 37
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2011
VL 95
IS 2
BP 185
EP 188
DI 10.1136/bjo.2009.163907
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 709RI
UT WOS:000286458700008
PM 20852318
DA 2022-11-30
ER

PT J
AU Jeganathan, VSE
   Verma, N
AF Jeganathan, V. Swetha E.
   Verma, Nitin
TI Safety and efficacy of intravitreal anti-VEGF injections for age-related
   macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE humans; injections; safety; treatment outcome
ID PHOTODYNAMIC THERAPY; COLORECTAL-CANCER; RANIBIZUMAB; BEVACIZUMAB;
   PEGAPTANIB; TRIAL; TRIAMCINOLONE
AB Purpose of review To report the safety and efficacy of intravitreal injections for age-related macular degeneration (AMD).
   Recent findings Injecting antivascular endothelial growth factor drugs into the vitreal cavity brings new hope to many AMD patients. Currently, several antivascular endothelial growth factor drugs such as pegaptanib, ranibizumab, and bevacizumab are used via the intravitreal route for neovascular AMD. However, these injections are not without ocular or systemic complications.
   Summary Review of current literature suggests that intravitreal antivascular endothelial growth factor agents are generally a safe and effective treatment for neovascular AMD for up to 2-3 years. Presently, there is level I evidence to substantiate this conclusion for pegaptanib and ranibizumab, but not bevacizumab.
C1 [Jeganathan, V. Swetha E.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Jeganathan, V. Swetha E.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Verma, Nitin] Royal Hobart Hosp, Dept Ophthalmol, Hobart, Tas, Australia.
   [Verma, Nitin] Hobart Eye Surg, Hobart, Tas, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; National
   University of Singapore; Singapore National Eye Center; Royal Hobart
   Hospital
RP Jeganathan, VSE (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM vswetha@ausdoctors.net
CR Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Donati G, 2007, OPHTHALMOLOGICA, V221, P366, DOI 10.1159/000107495
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   HEIER JS, 2006, OPHTHALMOLOGY, V113
   Hurwitz H, 2005, ONCOLOGY-BASEL, V69, P17, DOI 10.1159/000088480
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jonas JB, 2006, OPHTHALMIC RES, V38, P218, DOI 10.1159/000093796
   Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Lanzl IM, 2008, AM J OPHTHALMOL, V145, P185, DOI 10.1016/j.ajo.2007.08.037
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   2006, PRESCRIRE INT, V15, P127
NR 21
TC 34
Z9 36
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2009
VL 20
IS 3
BP 223
EP 225
DI 10.1097/ICU.0b013e328329b656
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 446TN
UT WOS:000266144200013
PM 19367163
DA 2022-11-30
ER

PT J
AU Cozzupoli, GM
   Borrelli, E
   Capuano, V
   Sacconi, R
   Astroz, P
   Battista, M
   Bandello, F
   Souied, E
   Querques, G
AF Cozzupoli, Grazia M.
   Borrelli, Enrico
   Capuano, Vittorio
   Sacconi, Riccardo
   Astroz, Polina
   Battista, Marco
   Bandello, Francesco
   Souied, Eric
   Querques, Giuseppe
TI InCASEOf scoring system for distinction between pachychoroid-associated
   macular neovascularization and neovascular age-related macular
   degeneration in patients older than 50 years
SO SCIENTIFIC REPORTS
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   ENDOTHELIAL GROWTH-FACTOR; ANGIOGRAPHY
AB To develop a novel scoring system aiming at guiding the differential diagnosis between macular neovascularization secondary to pachychoroid disease (pMNV) and neovascular age-related macular degeneration (AMD) in patients aged 50 years and older. In this retrospective study performed at University Vita-Salute San Raffaele (Milan, Italy) and Creteil University Eye Clinic (Creteil, France), we enrolled patients 50 years of age and older, visited between January 2017 and January 2019, who were diagnosed with either treatment-naive pMNV or neovascular AMD. At the time of diagnosis, all patients underwent a comprehensive ophthalmologic evaluation, spectral-domain optical coherence tomography, fluorescein angiography, indocyanine green angiography, and optical coherence tomography angiography. Univariate comparison between pMNV and neovascular AMD groups was performed to identify the main clinical predictors for pMNV. The selected predictors were taken into a binomial logistic regression and eventually served as the basis for the development of InCASEOf scoring system. Receiver operating characteristic (ROC) curves were used to study the model performance. Forty-eight right eyes from 48 patients with pMNV and 39 right eyes from 39 patients with neovascular AMD were considered in this study. Age (+ 2 points), sex (+ 2 points), choroidal thickness (+ 2 points), early pachyvessels (+ 2 points), and evidence of MNV at OCTA (+ 3 points) turned out to be predictors for pMNV. Four additional factors significant at univariate analysis were considered: type 2 and type 3 MNVs and presence of intraretinal fluid (- 0.5 points each), and presence of subretinal fluid (+ 0.5 points). InCASEOf scoring system was built with a high score of 11.5 points. The cutoff value of 6.5 showed good accuracy in separating pMNVs from neovascular AMDs. InCASEOf is a straightforward clinical scoring system, accessible to comprehensive ophthalmologists, with the purpose of enabling easy distinction and expert-like diagnosis of pMNV and neovascular AMD in patients aged 50 years or older.
C1 [Cozzupoli, Grazia M.; Capuano, Vittorio; Astroz, Polina; Souied, Eric] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Borrelli, Enrico; Sacconi, Riccardo; Battista, Marco; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.
   [Borrelli, Enrico; Sacconi, Riccardo; Battista, Marco; Bandello, Francesco; Querques, Giuseppe] IRCCS San Raffaele Sci Inst, Div Head & Neck, Ophthalmol Unit, Milan, Italy.
   [Querques, Giuseppe] Univ Vita Salute San Raffaele, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 58, I-20132 Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.; Querques, G (通讯作者)，IRCCS San Raffaele Sci Inst, Div Head & Neck, Ophthalmol Unit, Milan, Italy.; Querques, G (通讯作者)，Univ Vita Salute San Raffaele, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 58, I-20132 Milan, Italy.
EM giuseppe.querques@hotmail.it
OI Sacconi, Riccardo/0000-0003-2891-2012
CR Borooah S, 2021, ACTA OPHTHALMOL, V99, pE806, DOI 10.1111/aos.14683
   Borrelli E, 2019, SCI REP-UK, V10, P1
   Bousquet E, 2018, RETINA-J RET VIT DIS, V38, P629, DOI 10.1097/IAE.0000000000001580
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Hosoda Y, 2020, SCI REP-UK, V10, P1
   Hwang H, 2020, RETINA-J RET VIT DIS, V40, P1724, DOI 10.1097/IAE.0000000000002662
   Jung BJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38504-y
   Kietsiriroje N, 2020, CLIN ENDOCRINOL, V92, P196, DOI 10.1111/cen.14142
   Lee JH, 2016, RETINA-J RET VIT DIS, V36, P889, DOI 10.1097/IAE.0000000000000809
   Lee M, 2018, INVEST OPHTH VIS SCI, V59, P4896, DOI 10.1167/iovs.18-25018
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82093-8
   Matsumoto H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55918-w
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Phasukkijwatana N, 2018, RETINA-J RET VIT DIS, V38, P1652, DOI 10.1097/IAE.0000000000001907
   Sacconi R, 2019, EYE, V33, P1809, DOI 10.1038/s41433-019-0511-2
   Savastano MC, 2021, RETINA-J RET VIT DIS, V41, P302, DOI 10.1097/IAE.0000000000002810
   Sharma A, 2021, EYE, V35, P1545, DOI 10.1038/s41433-021-01423-2
   Shiragami C, 2018, AM J OPHTHALMOL, V193, P80, DOI 10.1016/j.ajo.2018.06.009
   Siedlecki J, 2019, OPHTHALMOL RETINA, V3, P1013, DOI 10.1016/j.oret.2019.08.002
   Spaide RF, 2022, PROG RETIN EYE RES, V86, DOI 10.1016/j.preteyeres.2021.100973
   Spaide RF, 2021, RETINA-J RET VIT DIS, V41, P231, DOI 10.1097/IAE.0000000000003057
   Spaide RF, 2021, RETINA-J RET VIT DIS, V41, P997, DOI 10.1097/IAE.0000000000003004
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Takahashi A, 2018, OPHTHALMOL RETINA, V2, P295, DOI 10.1016/j.oret.2017.08.016
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yamashiro K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072034
   Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5
NR 35
TC 0
Z9 0
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 21
PY 2022
VL 12
IS 1
AR 2938
DI 10.1038/s41598-022-06968-0
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ZE7UK
UT WOS:000759084600065
PM 35190608
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Njiric, S
   Misljenovic, T
   Mikulicic, M
   Pavicevic, L
AF Njiric, Sanja
   Misljenovic, Tamara
   Mikulicic, Maga
   Pavicevic, Luciana
TI Incidence of age related macular degeneration in correlation with age,
   sex and occupation
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Review
DE ARMD; UV radiation; UV exposure
ID BEAVER-DAM EYE; MACULOPATHY; RISK
AB This study assesses the relation between age related macular degeneration (ARMD) and age, sex and occupation. It is designed as a retrospective study conducted on patients presenting to the Eye Polyclinic >> Dr. L. Pavicevic <<, Rijeka, Croatia, during the years 1995, 2000 and 2005. and included total of 6617 patients. The number of patients diagnosed with ARMD, their age and sex distribution, as well as the correlation between occupation type (indoor /outdoor) and the incidence of ARMD were analyzed. The results of our study show that the incidence of ARMD is slightly increased in female vs. male, strongly age related, as expected, and significantly increased in patients with outdoor type of occupation. Besides, an increasing trend of incidence is noted.
C1 Eye Polyclin Dr L Pavicev, Rijeka, Croatia.
RP Njiric, S (通讯作者)，Eye Polyclin Dr L Pavicev, Trg Republike Hrvatske 2, Rijeka, Croatia.
EM snjiric2@net.hr
RI Vuceric, Tamara Misljenovic/AAF-4128-2020
CR Bergmanson Jan P. G., 1997, CLAO Journal, V23, P196
   *CAN OPHT SOC, 2004, POL STAT GUID ULTR R
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Heck DE, 2004, TOXICOL APPL PHARM, V195, P288, DOI 10.1016/j.taap.2003.09.028
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JOHN RH, 1994, BASIC CLIN SCI COURS
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Klein R, 2001, AM J OPHTHALMOL, V132, P128, DOI 10.1016/S0002-9394(00)00931-4
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LEIBOWITZ HM, 2001, SURV OPHTHALMOL, V108, P697
   NAKAISHI H, 2004, IND HLTH, V122, P750
   NARENDRAN V, 2000, INVEST OPHTH VIS SCI, V41, P119
   Roberts JE, 2001, J PHOTOCH PHOTOBIO B, V64, P136, DOI 10.1016/S1011-1344(01)00196-8
   Sliney DH, 2002, INT J TOXICOL, V21, P501, DOI 10.1080/10915810290169927
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
NR 16
TC 12
Z9 12
U1 0
U2 0
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RES, P O BOX 290, ULICA GRADA VUKOVARA 72/IV, 10000
   ZAGREB, CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD JAN
PY 2007
VL 31
SU 1
BP 107
EP 110
PG 4
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 143XD
UT WOS:000244758800025
PM 17469763
DA 2022-11-30
ER

PT J
AU Tosi, GM
   Orlandini, M
   Galvagni, F
AF Tosi, Gian Marco
   Orlandini, Maurizio
   Galvagni, Federico
TI The Controversial Role of TGF-beta in Neovascular Age-Related Macular
   Degeneration Pathogenesis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE neovascular age-related macular degeneration (nAMD); TGF-beta;
   angiogenesis; choroidal neovascularization (CNV)
ID GROWTH-FACTOR-BETA; PIGMENT EPITHELIAL-CELLS; INDUCED CHOROIDAL
   NEOVASCULARIZATION; MESENCHYMAL TRANSITION; AQUEOUS-HUMOR;
   RETINAL-DETACHMENT; ENDOTHELIAL-CELLS; MESSENGER-RNA; III RECEPTOR;
   AMYLOID-BETA
AB The multifunctional transforming growth factors-beta (TGF-beta s) have been extensively studied regarding their role in the pathogenesis of neovascular age-related macular degeneration (nAMD), a major cause of severe visual loss in the elderly in developed countries. Despite this, their effect remains somewhat controversial. Indeed, both pro- and antiangiogenic activities have been suggested for TGF-beta signaling in the development and progression of nAMD, and opposite therapies have been proposed targeting the inhibition or activation of the TGF-beta pathway. The present article summarizes the current literature linking TGF-beta and nAMD, and reviews experimental data supporting both pro- and antiangiogenic hypotheses, taking into account the limitations of the experimental approaches.
C1 [Tosi, Gian Marco] Univ Siena, Dept Med Surg & Neurosci, Ophthalmol Unit, I-53100 Siena, Italy.
   [Orlandini, Maurizio; Galvagni, Federico] Univ Siena, Dept Biotechnol Chem & Pharm, I-53100 Siena, Italy.
C3 University of Siena; University of Siena
RP Orlandini, M; Galvagni, F (通讯作者)，Univ Siena, Dept Biotechnol Chem & Pharm, I-53100 Siena, Italy.
EM gmtosi18@gmail.com; maurizio.orlandini@unisi.it;
   federico.galvagni@unisi.it
RI Orlandini, Maurizio/AAF-8247-2020; Galvagni, Federico/F-9186-2013
OI Orlandini, Maurizio/0000-0002-6112-4889; 
FU MIUR (Ministero dell'Istruzione, dell'Universita e della Ricerca)
FX The study was partially supported by MIUR (Ministero dell'Istruzione,
   dell'Universita e della Ricerca) Grant "Dipartimento di eccellenza
   2018-2022".
CR AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   ANDERSON DH, 1995, J NEUROSCI RES, V42, P63, DOI 10.1002/jnr.490420108
   Awwad K, 2015, CARDIOVASC RES, V106, P284, DOI 10.1093/cvr/cvv098
   Bai YJ, 2014, MOL VIS, V20, P1258
   Beier M, 2006, NEUROSCI RES, V56, P193, DOI 10.1016/j.neures.2006.07.002
   Bian ZM, 2007, EXP EYE RES, V84, P812, DOI 10.1016/j.exer.2006.12.016
   Blanco FJ, 2005, J CELL PHYSIOL, V204, P574, DOI 10.1002/jcp.20311
   Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7
   Braunger BM, 2013, J NEUROSCI, V33, P14246, DOI 10.1523/JNEUROSCI.0991-13.2013
   Budi EH, 2017, TRENDS CELL BIOL, V27, P658, DOI 10.1016/j.tcb.2017.04.005
   Chae DK, 2017, MOL CARCINOGEN, V56, P1992, DOI 10.1002/mc.22655
   CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767
   CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533
   CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027
   Choudhary P, 2016, STEM CELL TRANSL MED, V5, P925, DOI 10.5966/sctm.2015-0247
   CONNOR TB, 1989, J CLIN INVEST, V83, P1661, DOI 10.1172/JCI114065
   Cunha SI, 2010, J EXP MED, V207, P85, DOI 10.1084/jem.20091309
   Dai Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/486386
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   del Re E, 2004, J BIOL CHEM, V279, P22765, DOI 10.1074/jbc.M401350200
   Dvashi Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122229
   Dyer LA, 2014, TRENDS ENDOCRIN MET, V25, P472, DOI 10.1016/j.tem.2014.05.003
   Farjood F, 2017, MOL VIS, V23, P431
   Fisichella V, 2016, EUR J PHARMACOL, V787, P72, DOI 10.1016/j.ejphar.2016.02.002
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gamulescu MA, 2006, EXP EYE RES, V83, P212, DOI 10.1016/j.exer.2005.12.007
   Garrido-Martin EM, 2013, CIRC RES, V112, P113, DOI 10.1161/CIRCRESAHA.112.275586
   GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014
   Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743
   Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200
   Hill CS, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022079
   Hinck AP, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022103
   Hirasawa M, 2011, MOL VIS, V17, P1222
   Hirase K, 2005, OPHTHALMOLOGICA, V219, P222, DOI 10.1159/000085731
   Hirase K, 1998, ARCH OPHTHALMOL-CHIC, V116, P738, DOI 10.1001/archopht.116.6.738
   Hirsch L, 2015, CYTOKINE, V71, P394, DOI 10.1016/j.cyto.2014.11.014
   Honjo Y, 2007, BIOCHEM BIOPH RES CO, V352, P418, DOI 10.1016/j.bbrc.2006.11.033
   Huang T, 2014, BIOCHEMISTRY-US, V53, P5737, DOI 10.1021/bi500647d
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Itoh F, 2012, BLOOD, V119, P5320, DOI 10.1182/blood-2011-12-395772
   Itoh Y, 2007, EXP EYE RES, V84, P464, DOI 10.1016/j.exer.2006.10.017
   Iwanishi H, 2016, LAB INVEST, V96, P641, DOI 10.1038/labinvest.2016.30
   Jia Y, 2017, BIOMED REP, V7, P573, DOI 10.3892/br.2017.1004
   Kaven C, 2000, CURR EYE RES, V20, P480, DOI 10.1076/0271-3683(200006)20:6;1-Y;FT480
   Khuu LA, 2017, ACTA OPHTHALMOL, V95, pE206, DOI 10.1111/aos.13230
   Kim KS, 2016, CELL TRANSPLANT, V25, P1145, DOI 10.3727/096368915X688263
   Kimoto K, 2004, INVEST OPHTH VIS SCI, V45, P2431, DOI 10.1167/iovs.03-1276
   Kita T, 2008, P NATL ACAD SCI USA, V105, P17504, DOI 10.1073/pnas.0804054105
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kobayashi Y, 2018, INVEST OPHTH VIS SCI, V59
   Kon CH, 1999, INVEST OPHTH VIS SCI, V40, P705
   Kusakabe M, 2008, J CELL BIOCHEM, V103, P311, DOI 10.1002/jcb.21407
   KVANTA A, 1994, OPHTHALMIC RES, V26, P361, DOI 10.1159/000267502
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Larrivee B, 2012, DEV CELL, V22, P489, DOI 10.1016/j.devcel.2012.02.005
   Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109
   Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8
   LUTTY GA, 1993, INVEST OPHTH VIS SCI, V34, P477
   Miller DW, 1999, INT J CANCER, V81, P568, DOI 10.1002/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.0.CO;2-X
   Mitsuhiro MRKH, 2003, ACTA OPHTHALMOL SCAN, V81, P630, DOI 10.1111/j.1395-3907.2003.00170.x
   Nagineni CN, 2007, J CELL PHYSIOL, V210, P192, DOI 10.1002/jcp.20839
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Nagineni CN, 2005, J CELL PHYSIOL, V203, P35, DOI 10.1002/jcp.20213
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Noma H, 2010, EUR J OPHTHALMOL, V20, P402, DOI 10.1177/112067211002000222
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ntumba K, 2016, ONCOTARGET, V7, P55957, DOI 10.18632/oncotarget.11182
   Ogata N, 1997, CURR EYE RES, V16, P9, DOI 10.1076/ceyr.16.1.9.5121
   Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626
   Ohlmann A, 2016, HISTOCHEM CELL BIOL, V146, P769, DOI 10.1007/s00418-016-1461-4
   Paglinawan R, 2003, GLIA, V44, P219, DOI 10.1002/glia.10286
   PASQUALE LR, 1993, INVEST OPHTH VIS SCI, V34, P23
   Peng HM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014750
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   PFEFFER BA, 1994, EXP EYE RES, V59, P323, DOI 10.1006/exer.1994.1114
   Platania CBM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102076
   Poniatowski LA, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/137823
   Ray BN, 2010, CARCINOGENESIS, V31, P435, DOI 10.1093/carcin/bgp327
   Recalde S, 2011, INVEST OPHTH VIS SCI, V52, P7090, DOI 10.1167/iovs.11-7300
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Saika S, 2001, DEV BIOL, V240, P419, DOI 10.1006/dbio.2001.0480
   Sanford LP, 1997, DEVELOPMENT, V124, P2659
   SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567
   Schlecht A, 2017, AM J PATHOL, V187, P2570, DOI 10.1016/j.ajpath.2017.06.018
   Seitz R, 2018, INVEST OPHTH VIS SCI, V59, P2240, DOI 10.1167/iovs.17-23403
   Seki T, 2003, CIRC RES, V93, P682, DOI 10.1161/01.RES.0000095246.40391.3B
   Sugino IK, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.1.8
   Sugioka K, 2013, EXP EYE RES, V115, P13, DOI 10.1016/j.exer.2013.06.020
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   TANIHARA H, 1993, INVEST OPHTH VIS SCI, V34, P413
   Torsney E, 2002, INFLAMM RES, V51, P464, DOI 10.1007/PL00012413
   Tosi GM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26442-0
   Tosi GM, 2017, INVEST OPHTH VIS SCI, V58, P162, DOI 10.1167/iovs.16-20922
   Velasco S, 2008, J CELL SCI, V121, P913, DOI 10.1242/jcs.023283
   Walshe TE, 2011, NEUROSCIENCE, V189, P123, DOI 10.1016/j.neuroscience.2011.05.020
   Walshe TE, 2010, MICROVASC RES, V80, P166, DOI 10.1016/j.mvr.2010.03.003
   Walshe TE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005149
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   Wang XM, 2013, NATURE, V499, P306, DOI 10.1038/nature12345
   Xiao B, 2012, ONCOL REP, V27, P559, DOI 10.3892/or.2011.1514
   Xu J, 2012, ANGIOGENESIS, V15, P213, DOI 10.1007/s10456-012-9254-4
   Yafai Y, 2014, GLIA, V62, P1476, DOI 10.1002/glia.22694
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
   Zarranz-Ventura J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065434
   Zhang H, 2012, INT J OPHTHALMOL-CHI, V5, P307, DOI 10.3980/j.issn.2222-3959.2012.03.11
   Zhang RS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146808
NR 115
TC 29
Z9 30
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2018
VL 19
IS 11
AR 3363
DI 10.3390/ijms19113363
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HC0ZM
UT WOS:000451528500079
PM 30373226
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Andreatta, W
   El-Sherbiny, S
AF Andreatta, Walter
   El-Sherbiny, Samer
TI Evidence-Based Nutritional Advice for Patients Affected by Age-Related
   Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Review
DE Age-related macular degeneration; Vision; Nutrition
ID BETA-CAROTENE; COMBINATION; ASSOCIATION; PREVALENCE
AB This paper presents the evidence available in the literature on the role of nutrients in preventing the occurrence of age-related macular degeneration (AMD) and its progression to more advanced stages. In our analysis we considered publications on vitamins B, C, E and D, carotenoids (i.e. lutein, zeaxanthin and beta-carotene), Omega-3 polyunsaturated fatty acids and zinc published between 2003 and 2013. While the evidence supporting supplementation and higher dietary intake of nutrients for AMD prevention is weak to moderate, large and robust randomised controlled trials showed that the AREDS formula leads to a 25% reduction in progression to advanced AMD in individuals belonging to AREDS categories 3 and 4. After reviewing the current literature, which includes the AREDS2 study, we suggest an 'evidence-based formula'. (c) 2014 S. Karger AG, Basel
C1 [Andreatta, Walter; El-Sherbiny, Samer] Sandwell & West Birmingham Hosp NHS Trust, Birmingham & Midland Eye Ctr, Birmingham, W Midlands, England.
RP Andreatta, W (通讯作者)，Birmingham & Midland Eye Ctr, Dudley Rd, Birmingham B18 7QH, W Midlands, England.
EM andreattawalter@hotmail.com
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Bartlett H, 2010, CLIN EXP OPTOM, V93, P300, DOI 10.1111/j.1444-0938.2010.00499.x
   Bernstein PS, 2012, INVEST OPHTH VIS SCI, V53, P6178, DOI 10.1167/iovs.12-10275
   Buring Julie E., 1994, Annals of Epidemiology, V4, P111
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Christen WG, 1996, ANN EPIDEMIOL, V6, P60, DOI 10.1016/1047-2797(95)00094-1
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Evans J., 1996, HEALTH TRENDS, V28, P5
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Evans JR, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000253.PUB3
   HENNEKENS CH, 1985, PREV MED, V14, P165, DOI 10.1016/0091-7435(85)90031-3
   Julien S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029245
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lawrenson JG, 2012, COCHRANE DB SYST REV, V11, DOI DOI 10.1186/1471-2415-7-3
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Taylor HR, 2001, INVEST OPHTH VIS SCI, V42, pS311
NR 26
TC 8
Z9 8
U1 0
U2 19
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2014
VL 231
IS 4
BP 185
EP 190
DI 10.1159/000357528
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AH2GJ
UT WOS:000335939200001
PM 24821294
OA Bronze
DA 2022-11-30
ER

PT J
AU Nebbioso, M
   Franzone, F
   Lambiase, A
   Taurone, S
   Artico, M
   Gharbiya, M
   Greco, A
   Polimeni, A
AF Nebbioso, Marcella
   Franzone, Federica
   Lambiase, Alessandro
   Taurone, Samanta
   Artico, Marco
   Gharbiya, Magda
   Greco, Antonio
   Polimeni, Antonella
TI Complement Mediators in Development to Treat Age-Related Macular
   Degeneration
SO DRUGS & AGING
LA English
DT Article
ID GEOGRAPHIC ATROPHY PROGRESSION; FACTOR-H; R102G POLYMORPHISM;
   ASSOCIATION; DRUSEN; RISK; C3; SUSCEPTIBILITY; RANIBIZUMAB; VARIANT
AB Over recent years, great attention has been paid to the role of the complement system in the pathogenesis of age-related macular degeneration (AMD). In particular, several studies have highlighted a link between AMD development and complement dysregulation, which can probably be explained as a complement cascade hyperactivation resulting from the presence of a series of risk factors such as aging; smoking; obesity; alcohol consumption; exposure to pesticides, industrial chemicals, or pollution; and other causes of oxidative stress. This hypothesis has been mainly supported by the presence of complement mediators as constituents of drusen, representing one of the earliest and most characteristic signs of retinal damage in AMD. Additionally, activated complement mediators and some complement regulators, such as vitronectin, have been found not only in the drusen and adjacent retinal areas but also in the peripheral blood of patients with AMD. Therefore, we aim to provide a review of recently studied complement factors to highlight their role in the pathogenesis of AMD and to evaluate new potential therapeutic strategies.
C1 [Nebbioso, Marcella; Franzone, Federica; Lambiase, Alessandro; Artico, Marco; Gharbiya, Magda; Greco, Antonio] Sapienza Univ Rome, Dept Sense Organs, Piazzle A Moro 5, I-00185 Rome, Italy.
   [Taurone, Samanta] Fdn Bietti, IRCCS, Via Livenza 3, I-00198 Rome, Italy.
   [Polimeni, Antonella] Sapienza Univ Rome 5, Dept Oral & Maxillofacial Sci, I-00185 Rome, Italy.
   [Nebbioso, Marcella; Franzone, Federica] Sapienza Univ Rome, Ocular Electrophysiol Ctr, Dept Sense Organs, Policlin Umberto I, Viale Policlin 155, I-00161 Rome, Italy.
C3 Sapienza University Rome; IRCCS - Fondazione "G.B. Bietti" per lo Studio
   e la Ricerca in Oftalmologia; Sapienza University Rome; University
   Hospital Sapienza Rome
RP Nebbioso, M; Franzone, F (通讯作者)，Sapienza Univ Rome, Dept Sense Organs, Piazzle A Moro 5, I-00185 Rome, Italy.; Nebbioso, M; Franzone, F (通讯作者)，Sapienza Univ Rome, Ocular Electrophysiol Ctr, Dept Sense Organs, Policlin Umberto I, Viale Policlin 155, I-00161 Rome, Italy.
EM marcella.nebbioso@uniroma1.it; federica.franzone91@gmail.com
RI Lambiase, Alessandro/K-3902-2016; Nebbioso, Marcella/K-6878-2018
OI Lambiase, Alessandro/0000-0002-8974-991X; Nebbioso,
   Marcella/0000-0002-5512-0849
CR Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Biasella F, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.2
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cipriani V, 2021, AM J HUM GENET, V108, P1385, DOI 10.1016/j.ajhg.2021.05.015
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   de Boer ECW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.578069
   Dentchev T, 2003, MOL VIS, V9, P184
   Donders FC, 1854, ARCH OPHTHALMOL-CHIC, V1, P106
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Enriquez AB, 2021, JAMA OPHTHALMOL, V139, P441, DOI 10.1001/jamaophthalmol.2020.7085
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Halawa OA, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122580
   Halili MA, 2009, BIOCHEMISTRY-US, V48, P8466, DOI 10.1021/bi900679r
   Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hoy SM, 2021, DRUGS, V81, P1423, DOI 10.1007/s40265-021-01560-8
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jaffe GJ, 2020, INVEST OPHTH VIS SCI, V61
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Kim JB, 2021, DRUG AGING, V38, P17, DOI 10.1007/s40266-020-00822-6
   Klein BEK, 2002, OPHTHALMOLOGY, V109, P2052, DOI 10.1016/S0161-6420(02)01249-6
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lin MK, 2018, AGING CELL, V17, DOI 10.1111/acel.12710
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michelis G, 2021, J NEUROCHEM, V159, P840, DOI 10.1111/jnc.15454
   Moult EM, 2020, AM J OPHTHALMOL, V214, P172, DOI 10.1016/j.ajo.2019.12.006
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nebbioso M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071693
   Nebbioso M, 2017, CRIT REV FOOD SCI, V57, P559, DOI 10.1080/10408398.2014.893504
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Park YG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136851
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   PILLEMER L, 1954, SCIENCE, V120, P279, DOI 10.1126/science.120.3112.279
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sanchez-Corral P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01607
   SCHIFFERLI JA, 1986, NEW ENGL J MED, V315, P488
   Schmidt CQ, 2010, J MOL BIOL, V395, P105, DOI 10.1016/j.jmb.2009.10.010
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Scholl HPN, 2005, OPHTHALMOLOGE, V102, P1029, DOI 10.1007/s00347-005-1270-y
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Steinle NC, 2021, AM J OPHTHALMOL, V227, P116, DOI [10.1016/i.aio.2021.02.031, 10.1016/j.ajo.2021.02.031]
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Thulliez M, 2019, OPHTHALMOL RETINA, V3, P478, DOI 10.1016/j.oret.2019.01.024
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Varma Rohit, 2018, Invest Ophthalmol Vis Sci, V59, pAMD195, DOI 10.1167/iovs.18-24238
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   Williams BL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103617118
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2021, OPHTHALMOLOGY, V128, P1325, DOI 10.1016/j.ophtha.2021.02.025
   Yanagisawa S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028847
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zerbib J, 2010, MOL VIS, V16, P1324
   Zipfel PF, 2009, IMMUNOL LETT, V126, P1, DOI 10.1016/j.imlet.2009.07.005
NR 81
TC 3
Z9 3
U1 1
U2 2
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PD FEB
PY 2022
VL 39
IS 2
BP 107
EP 118
DI 10.1007/s40266-021-00914-x
EA JAN 2022
PG 12
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA ZH9ZH
UT WOS:000744867100001
PM 35050489
DA 2022-11-30
ER

PT J
AU SanGiovanni, JP
   Chen, J
   Gupta, AS
   Smith, LEH
   Sapieha, P
   Lee, PH
AF SanGiovanni, John Paul
   Chen, Jing
   Gupta, Ankur S.
   Smith, Lois E. H.
   Sapieha, Przemyslaw
   Lee, Phil H.
TI Netrin-1-DCC Signaling Systems and Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; ANGIOGENESIS; HYPOXIA; DISEASE; GROWTH
AB We conducted a nested candidate gene study and pathway-based enrichment analysis on data from a multi-national 77,000-person project on the molecular genetics of age-related macular degeneration (AMD) to identify AMD-associated DNA-sequence variants in genes encoding constituents of a netrin-1 (NTN1)-based signaling pathway that converges on DNA-binding transcription complexes through a 3'-5'-cyclic adenosine monophosphate-calcineurin (cAMP-CN)-dependent axis. AMD-associated single nucleotide polymorphisms (SNPs) existed in 9 linkage disequilibrium-independent genomic regions; these included loci overlapping NTN1 (rs9899630, P <= 9.48 x 10(-5)), DCC (Deleted in Colorectal Cancer)-the gene encoding a primary NTN1 receptor (rs8097127, P <= 3.03 x 10(-5)), and 6 other netrin-related genes. Analysis of the NTN1-DCC pathway with exact methods demonstrated robust enrichment with AMD-associated SNPs (corrected P-value = 0.038), supporting the idea that processes driven by NTN1-DCC signaling systems operate in advanced AMD. The NTN1-DCC pathway contains targets of FDA-approved drugs and may offer promise for guiding applied clinical research on preventive and therapeutic interventions for AMD.
C1 [SanGiovanni, John Paul] NIAAA, Sect Nutr Neurosci, NIH, Bethesda, MD 20892 USA.
   [Chen, Jing; Smith, Lois E. H.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston Childrens Hosp, Boston, MA USA.
   [Gupta, Ankur S.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
   [Sapieha, Przemyslaw] Univ Montreal, Dept Ophthalmol, Maisonneuve Rosemont Hosp, Res Ctr, Montreal, PQ, Canada.
   [Lee, Phil H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Analyt & Translat Genet Unit,Ctr Human Genet Res, Boston, MA USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute on
   Alcohol Abuse & Alcoholism (NIAAA); Harvard University; Boston
   Children's Hospital; Harvard Medical School; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; Universite de
   Montreal; Harvard University; Harvard Medical School; Massachusetts
   General Hospital
RP SanGiovanni, JP (通讯作者)，NIAAA, Sect Nutr Neurosci, NIH, Bethesda, MD 20892 USA.
EM jpsangio@post.harvard.edu
RI SanGiovanni, John Paul/AAU-3895-2020
FU Canadian Institutes of Health Research [221478]; Foundation Fighting
   Blindness; U.S. National Institute of Mental Health (NIMH) grant
   [K99MH101367]; U.S. National Eye Institute [NEI EY022274, EY017017, PO1
   HD18655, R01 EY024963]; Lowey Medical Research Institute; European
   Commission FP7 Project [305485]; NIH Intramural Research Program; Bright
   Focus Foundation; NATIONAL EYE INSTITUTE [R01EY024963, R01EY017017]
   Funding Source: NIH RePORTER
FX PS holds a Canada Research Chair in Retinal Cell Biology and is
   supported by operating grants from the Canadian Institutes of Health
   Research (221478) and the Foundation Fighting Blindness. PHL is
   supported by U.S. National Institute of Mental Health (NIMH) grant
   K99MH101367. LEHS was supported by grants from the U.S. National Eye
   Institute (NEI EY022274, EY017017, PO1 HD18655), The Lowey Medical
   Research Institute, European Commission FP7 Project 305485 PREVENT-ROP.
   JPSG was supported by the NIH Intramural Research Program. JC was
   supported by the Bright Focus Foundation and a grant from the U.S.
   National Eye Institute (R01 EY024963). None of these funders had a role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.; Extant GWA study findings were published
   by Fritsche et al.[12] The data used for the original genetic analyses
   were obtained from the NEI Study of Age-Related Macular Degeneration
   (NEI-AMD) Database found at
   http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id =
   phs000182.v2.p1 (dbGaP Study Accession: phs000182.v2.p1). We thank
   NEI-AMD and AGC participants and the NEI-AMD and AGC Research Groups for
   their valuable contributions to this research project. JPSG was
   supported by the NIH Intramural Research Program. PS holds a Canada
   Research Chair in Retinal Cell Biology and is supported by operating
   grants from the Canadian Institutes of Health Research (221478) and the
   Foundation Fighting Blindness.
CR Binet F, 2013, CELL METAB, V17, P353, DOI 10.1016/j.cmet.2013.02.003
   Bretz CA, 2013, INVEST OPHTH VIS SCI, V54, P7020, DOI 10.1167/iovs.13-12183
   Cho YG, 2011, LAB INVEST, V91, P519, DOI 10.1038/labinvest.2010.184
   de Frutos S, 2010, AM J PHYSIOL-HEART C, V299, pH356, DOI 10.1152/ajpheart.00341.2010
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gomez MF, 2003, J BIOL CHEM, V278, P46847, DOI 10.1074/jbc.M304765200
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Lee PH, 2012, BIOINFORMATICS, V28, P1797, DOI 10.1093/bioinformatics/bts191
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Park KW, 2004, P NATL ACAD SCI USA, V101, P16210, DOI 10.1073/pnas.0405984101
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Riveros C, 2015, METHODS MOL BIOL, V1253, P217, DOI 10.1007/978-1-4939-2155-3_12
   Rosenberger P, 2009, NAT IMMUNOL, V10, P195, DOI 10.1038/ni.1683
   SanGiovanni JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071239
   Sapieha P, 2012, BLOOD, V120, P2182, DOI 10.1182/blood-2012-04-396846
   Smoller JW, 2013, LANCET, V381, P1371, DOI 10.1016/S0140-6736(12)62129-1
   Sun KLW, 2011, DEVELOPMENT, V138, P2153, DOI 10.1242/dev.044529
   Urso K, 2011, BLOOD, V118, P795, DOI 10.1182/blood-2010-12-322701
   Ward LD, 2012, NAT BIOTECHNOL, V30, P1095, DOI 10.1038/nbt.2422
   Wilson BD, 2006, SCIENCE, V313, P640, DOI 10.1126/science.1124704
   Yang JA, 2010, NAT GENET, V42, P565, DOI 10.1038/ng.608
NR 24
TC 2
Z9 2
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 7
PY 2015
VL 10
IS 5
AR e0125548
DI 10.1371/journal.pone.0125548
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DA4RU
UT WOS:000367788800006
PM 25950802
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Gao, JY
   Liu, RT
   Cao, SJ
   Cui, JZ
   Wang, AK
   To, E
   Matsubara, JA
AF Gao, Jiangyuan
   Liu, Ruozhou Tom
   Cao, Sijia
   Cui, Jing Z.
   Wang, Aikun
   To, Eleanor
   Matsubara, Joanne A.
TI NLRP3 Inflammasome: Activation and Regulation in Age-Related Macular
   Degeneration
SO MEDIATORS OF INFLAMMATION
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; HUMAN RPE CELLS; NF-KAPPA-B; AMYLOID-BETA;
   ALZHEIMERS-DISEASE; OXIDATIVE STRESS; ALU RNA; COMPLEMENT ACTIVATION;
   GEOGRAPHIC ATROPHY; NALP3 INFLAMMASOME
AB Age-related macular degeneration (AMD) is the leading cause of legal blindness in the elderly in industrialized countries. AMD is a multifactorial disease influenced by both genetic and environmental risk factors. Progression of AMD is characterized by an increase in the number and size of drusen, extracellular deposits, which accumulate between the retinal pigment epithelium (RPE) and Bruch's membrane (BM) in outer retina. The major pathways associated with its pathogenesis include oxidative stress and inflammation in the early stages of AMD. Little is known about the interactions among these mechanisms that drive the transition from early to late stages of AMD, such as geographic atrophy (GA) or choroidal neovascularization (CNV). As part of the innate immune system, inflammasome activation has been identified in RPE cells and proposed to be a causal factor for RPE dysfunction and degeneration. Here, we will first review the classic model of inflammasome activation, then discuss the potentials of AMD-related factors to activate the inflammasome in both nonocular immune cells and RPE cells, and finally introduce several novel mechanisms for regulating the inflammasome activity.
C1 [Gao, Jiangyuan; Liu, Ruozhou Tom; Cao, Sijia; Cui, Jing Z.; Wang, Aikun; To, Eleanor; Matsubara, Joanne A.] Univ British Columbia, Fac Med, Dept Ophthalmol & Visual Sci, Vancouver, BC V5Z 3N9, Canada.
C3 University of British Columbia
RP Matsubara, JA (通讯作者)，Univ British Columbia, Fac Med, Dept Ophthalmol & Visual Sci, Vancouver, BC V5Z 3N9, Canada.
EM jms@mail.ubc.ca
FU Canadian Institutes of Health Research Grant [CIHR MOP-97806]; Vancouver
   General Hospital; UBC Hospital Foundation, Faculty of Medicine (UBC)
FX The authors apologize to those whose publications were not cited due to
   space limitations. This work was supported by the Canadian Institutes of
   Health Research Grant (CIHR MOP-97806) to Joanne A. Matsubara and by
   Vancouver General Hospital and UBC Hospital Foundation, Faculty of
   Medicine (UBC).
CR Access-Economics, GLOB EC COST VIS IMP
   Aliprantis AO, 2000, EMBO J, V19, P3325, DOI 10.1093/emboj/19.13.3325
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Arnoult D, 2011, EMBO REP, V12, P901, DOI 10.1038/embor.2011.157
   Asgari E, 2013, BLOOD, V122, P3473, DOI 10.1182/blood-2013-05-502229
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Belgnaoui SM, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-13
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Bressler SB, 2014, RETINA, V2, P1150
   Bruey JM, 2007, CELL, V129, P45, DOI 10.1016/j.cell.2007.01.045
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405
   de Carvalho JER, 2013, INVEST OPHTH VIS SCI, V54, P6489, DOI 10.1167/iovs.13-12374
   Dentchev T, 2003, MOL VIS, V9, P184
   Di Virgilio F, 2013, PHARMACOL REV, V65, P872, DOI 10.1124/pr.112.006171
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dupraz P, 2000, J BIOL CHEM, V275, P37672, DOI 10.1074/jbc.M005150200
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Glenn JV, 2012, GRAEF ARCH CLIN EXP, V250, P349, DOI 10.1007/s00417-011-1856-9
   Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Iannaccone A, 2012, ADV EXP MED BIOL, V723, P11, DOI 10.1007/978-1-4614-0631-0_2
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237
   Iyer SS, 2009, P NATL ACAD SCI USA, V106, P20388, DOI 10.1073/pnas.0908698106
   Janssens S, 2002, TRENDS BIOCHEM SCI, V27, P474, DOI 10.1016/S0968-0004(02)02145-X
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Juliana C, 2012, J BIOL CHEM, V287, P36617, DOI 10.1074/jbc.M112.407130
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558
   Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469
   Kenney MC, 2014, HUM MOL GENET, V23, P3537, DOI 10.1093/hmg/ddu065
   Kenney MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054339
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007
   Lamkanfi M, 2011, IMMUNOL REV, V243, P163, DOI 10.1111/j.1600-065X.2011.01042.x
   Laudisi F, 2013, J IMMUNOL, V191, P1006, DOI 10.4049/jimmunol.1300489
   Lawlor KE, 2014, BBA-GEN SUBJECTS, V1840, P1433, DOI 10.1016/j.bbagen.2013.08.014
   Lawlor KE, 2013, J LEUKOCYTE BIOL, V93, P585, DOI 10.1189/jlb.0412190
   Lev-Maor G, 2003, SCIENCE, V300, P1288, DOI 10.1126/science.1082588
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Lopez-Castejon G, 2012, EXPERT OPIN INV DRUG, V21, P995, DOI 10.1517/13543784.2012.690032
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Madani R, 2006, J NEUROSCI RES, V84, P1871, DOI 10.1002/jnr.21074
   Malik D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099003
   Mariner PD, 2008, MOL CELL, V29, P499, DOI 10.1016/j.molcel.2007.12.013
   Meissner F, 2008, NAT IMMUNOL, V9, P866, DOI 10.1038/ni.1633
   Meissner F, 2010, BLOOD, V116, P1570, DOI 10.1182/blood-2010-01-264218
   Menu P, 2011, CLIN EXP IMMUNOL, V166, P1, DOI 10.1111/j.1365-2249.2011.04440.x
   Mevorach D, 2010, APOPTOSIS, V15, P1114, DOI 10.1007/s10495-010-0530-8
   Minton K, 2014, NAT REV IMMUNOL, V14, P580, DOI 10.1038/nri3730
   Mirza S, 2010, MOL VIS, V16, P2425
   Misawa T, 2013, NAT IMMUNOL, V14, P454, DOI 10.1038/ni.2550
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016
   Murphy N, 2014, NEUROMOL MED, V16, P205, DOI 10.1007/s12017-013-8274-6
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Py BF, 2013, MOL CELL, V49, P331, DOI 10.1016/j.molcel.2012.11.009
   Rodgers MA, 2014, J EXP MED, V211, P1331, DOI 10.1084/jem.20132486
   Rubartelli A, 2012, J LEUKOCYTE BIOL, V92, P951, DOI 10.1189/jlb.0512265
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmid CW, 1998, NUCLEIC ACIDS RES, V26, P4541, DOI 10.1093/nar/26.20.4541
   Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sutterwala FS, 2014, ANN NY ACAD SCI, V1319, P82, DOI 10.1111/nyas.12458
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   van de Veerdonk FL, 2010, P NATL ACAD SCI USA, V107, P3030, DOI 10.1073/pnas.0914795107
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   World-Health-Organization, 2014, PREV BLINDN VIS IMP
   Yi P, 2003, FEBS LETT, V534, P61, DOI 10.1016/S0014-5793(02)03778-X
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhang XY, 2008, INVEST OPHTH VIS SCI, V49, P3622, DOI 10.1167/iovs.07-1559
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831
NR 113
TC 69
Z9 76
U1 1
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2015
VL 2015
AR 690243
DI 10.1155/2015/690243
PG 11
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA CA8MU
UT WOS:000349175600001
PM 25698849
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Byon, I
   Ji, Y
   Alagorie, AR
   Tiosano, L
   Sadda, SR
AF Byon, Iksoo
   Ji, Yongsok
   Alagorie, Ahmed R.
   Tiosano, Liran
   Sadda, Srinivas R.
TI TOPOGRAPHIC ASSESSMENT OF CHORIOCAPILLARIS FLOW DEFICITS IN THE
   INTERMEDIATE AGE-RELATED MACULAR DEGENERATION EYES WITH HYPOREFLECTIVE
   CORES INSIDE DRUSEN
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choriocapillaris; drusen; flow deficit; hyporeflective core; optical
   coherence tomography angiography
ID FEATURES; ATROPHY
AB Purpose: To evaluate the choriocapillaris (CC) flow deficit (FD) in eyes with hyporeflective cores (HCs) inside drusen in eyes with intermediate age-related macular degeneration. Methods: Intermediate age-related macular degeneration subjects underwent optical coherence tomography and optical coherence tomography angiography using a Cirrus HD-optical coherence tomography (Carl Zeiss Meditec, Dublin, CA). All B-scans were inspected for the presence of drusen with an HC that was defined as dark, condense materials inside drusen. Drusen regions delineated in the manufactures advanced retinal pigment epithelium elevation map were superimposed to the compensated CC optical coherence tomography angiography images. Quantitative analysis of CC FD% was performed under drusen with and without HCs, 150-mu m-wide ring region around drusen with and without HCs, drusen-free region, and whole macula. Results: Fifty eyes were included in this cross-sectional study. Twenty eyes had drusen with HCs. Thirty eyes without HCs were matched for age and sex. The CC FD% of whole macula was significantly greater in eyes with an HC than those without it (46.3% vs. 42.9%; P = 0.001). In eyes with HCs, regional CC FD% was the greater under drusen (59.8%) and in a 150-mu m-wide ring surrounding drusen with HCs (53.0%) than corresponding regions for drusen without HCs (52.5% and 47.3%, respectively) (P < 0.005 in all, Bonferroni correction). The CC FD% in macular regions remote from drusen was 43.2%. Conclusion: Intermediate age-related macular degeneration eyes with HCs demonstrated more impaired CC flow, compared with those without this featured. The CC was also more severely impaired directly below these drusen with HCs. These findings highlight that the appearance of HCs may be an indicator of a more advanced disease phenotype.
C1 [Byon, Iksoo; Ji, Yongsok; Alagorie, Ahmed R.; Tiosano, Liran; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading & Res Lab, 1355 San Pablo St,Suite 211, Los Angeles, CA 90033 USA.
   [Byon, Iksoo; Ji, Yongsok; Alagorie, Ahmed R.; Tiosano, Liran; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Byon, Iksoo] Pusan Natl Univ, Pusan Natl Univ Hosp, Biomed Res Inst, Dept Ophthalmol,Sch Med, Busan, South Korea.
   [Ji, Yongsok] Chonnam Natl Univ Med Sch & Hosp, Dept Ophthalmol, Gwangju, South Korea.
   [Alagorie, Ahmed R.] Tanta Univ, Fac Med, Dept Ophthalmol, Tanta, Egypt.
   [Tiosano, Liran] Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, Jerusalem, Israel.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Pusan National
   University; Pusan National University Hospital; Chonnam National
   University; Chonnam National University Hospital; Egyptian Knowledge
   Bank (EKB); Tanta University; Hebrew University of Jerusalem
RP Sadda, SR (通讯作者)，Doheny Eye Inst, Doheny Image Reading & Res Lab, 1355 San Pablo St,Suite 211, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI Alagorie, Ahmed/AAW-5304-2020
OI Alagorie, Ahmed/0000-0001-5489-0617; Byon, Iksoo/0000-0002-2638-8192
CR Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nassisi M, 2019, GRAEF ARCH CLIN EXP, V257, P2079, DOI 10.1007/s00417-019-04403-1
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
NR 29
TC 8
Z9 8
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2021
VL 41
IS 2
BP 393
EP 401
DI 10.1097/IAE.0000000000002906
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SL0VU
UT WOS:000656635200034
PM 33475272
DA 2022-11-30
ER

PT J
AU Sonmez, K
   Sonmez, PA
   Ozkan, SS
   Atmaca, LS
AF Sonmez, Kenan
   Sonmez, Pelin Atmaca
   Ozkan, Seyhan S.
   Atmaca, Leyla S.
TI ONE-YEAR OUTCOMES OF LESS FREQUENT BEVACIZUMAB IN AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bevacizumab; choroidal neovascularization; age-related macular
   degeneration
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION SECONDARY;
   INTRAVITREAL BEVACIZUMAB; PHOTODYNAMIC THERAPY; VISUAL-ACUITY; SUBGROUP
   ANALYSIS; AVASTIN; RANIBIZUMAB; PHARMACOKINETICS; VERTEPORFIN
AB Purpose: To evaluate whether a less frequent bevacizumab dosing schedule after repeated doses in short intervals would be effective in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
   Methods: Twenty-seven treatment-naive eyes of patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration participated in this prospective, noncomparative, and interventional study at the Ulucanlar Eye Training and Research Hospital retina clinic. All lesion types were included. Intravitreal injections (1.25 mg/0.05 mL) of bevacizumab were given with a 6-week interval (Day 0, 6 weeks, and 12 weeks) for 3 months and then given at every 12-week interval up to 48 weeks. Main outcome measures of treatment were mean change in visual acuity and foveal center point retinal thickness from baseline documented by optical coherence tomography at 6, 12, 24, 36, and 48 weeks. The effects of patient age, baseline visual acuity, lesion composition, and lesion size on final visual acuity and loss of <15 letters of logarithm of the minimum angle of resolution (logMAR) at 48 weeks were also assessed.
   Results: Of the 27 eyes, 24 eyes of 24 patients (14 men and 10 women) completed the 48-week follow-up and study protocol. Compared with baseline (0.95 +/- 0.27 on Early Treatment Diabetic Retinopathy Study charts), mean best-corrected visual acuity improved to 0.77 +/- 0.21 logMAR (P<0.001) at Week 6, to 0.74 +/- 0.2 logMAR (P<0.001) at Week 12, to 0.79 +/- 0.257 logMAR (P=0.03) at Week 24, to 0.85 +/- 0.26 logMAR (P=0.54) at Week 36, and to 0.87 +/- 0.27 logMAR (P=1) at Week 48. The baseline mean center point retinal thickness that was 343 +/- 64 mu m decreased to 236 +/- 40 mm (P<0.001) at Week 6, to 222 +/- 39 mm (P<0.001) at Week 12, to 237 +/- 37 (P<0.001) at Week 24, to 253 +/- 44 mm (P, 0.001) at Week 36, and to 268 +/- 58 mm (P=0.002) at Week 48. The maximal visual benefit obtained during the frequent dosing schedule significantly decreased by doses every 12 weeks at 48 weeks (P<0.001). This decline in the best-corrected visual acuity gain was associated with an increase in the mean center point retinal thickness on optical coherence tomography. Patients aged <70 years and those having a baseline vision of 20/200 or worse were more likely to gain vision at 48 weeks (P=0.001 and P=0.02, respectively). In addition, a lesion <= 4 disk areas at baseline was less likely to lose, 15 letters from baseline at 48 weeks (P=0.03). No serious ocular and nonocular adverse events were noted.
   Conclusion: Although intravitreal bevacizumab administration on a schedule of a 6-week injection interval for 3 months followed by every 12-week interval for neovascular age-related macular degeneration provided an improvement or stabilization in best-corrected visual acuity with anatomical improvement. This dosing strategy is unable to maintain the visual acuity and optical coherence tomography benefits seen with more frequent dosing.
   RETINA 31: 645-653, 2011
C1 [Sonmez, Kenan; Ozkan, Seyhan S.] Ulucanlar Eye Training & Res Hosp, Eye Clin 2, Ankara, Turkey.
   [Sonmez, Pelin Atmaca] Dr Sami Ulus Childrens Hlth & Dis Educ & Res Hosp, Dept Ophthalmol, Ankara, Turkey.
C3 Ankara Ulucanlar Eye Training & Research Hospital; Dr. Sami Ulus
   Education & Research Hospital
RP Sonmez, K (通讯作者)，GMK Bulvari 23-1-2, Kizilay Ankara, Turkey.
EM kensonmez@yahoo.com
CR Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   European Medicines Agency (EMEA), LUC RAN SCI DISC
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kiss C, 2006, RETINA-J RET VIT DIS, V26, P877, DOI 10.1097/01.iae.0000237080.10627.b7
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, p43e1
   Lashkari K, 2000, AM J PATHOL, V156, P1337, DOI 10.1016/S0002-9440(10)65004-3
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Manku KK, 2007, CLIN EXP OPHTHALMOL, V35, P330, DOI 10.1111/j.1442-9071.2007.01482.x
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Modarres M, 2009, RETINA-J RET VIT DIS, V29, P319, DOI 10.1097/IAE.0b013e318198148e
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Pedersen KB, 2009, ACTA OPHTHALMOL, V87, P714, DOI 10.1111/j.1755-3768.2008.01346.x
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Sonmez K, 2008, OPHTHALMOLOGY, V115, P1065, DOI 10.1016/j.ophtha.2007.08.050
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Stewart MW, 2007, RETINA-J RET VIT DIS, V27, P1196, DOI 10.1097/IAE.0b013e318158ea28
   Tripathi RC, 1998, OPHTHALMOLOGY, V105, P232, DOI 10.1016/S0161-6420(98)92782-8
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 47
TC 11
Z9 12
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2011
VL 31
IS 4
BP 645
EP 653
DI 10.1097/IAE.0b013e3182012d18
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 740HR
UT WOS:000288783200003
PM 21358363
DA 2022-11-30
ER

PT J
AU Paques, M
   Meimon, S
   Rossant, F
   Rosenbaum, D
   Mrejen, S
   Sennlaub, F
   Grieve, K
AF Paques, Michel
   Meimon, Serge
   Rossant, Florence
   Rosenbaum, David
   Mrejen, Sarah
   Sennlaub, Florian
   Grieve, Kate
TI Adaptive optics ophthalmoscopy: Application to age -related macular
   degeneration and vascular diseases
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; SUBRETINAL DRUSENOID DEPOSITS; COHERENCE
   TOMOGRAPHY ANGIOGRAPHY; BLOOD-FLOW-VELOCITY; GEOGRAPHIC ATROPHY;
   MICROVASCULAR ABNORMALITIES; DIABETIC-RETINOPATHY; RETICULAR
   PSEUDODRUSEN; MORPHOMETRIC-ANALYSIS; ATHEROSCLEROSIS RISK
AB Adaptive optics (AO)-enhanced en face retinal imaging, termed here AO ophthalmoscopy (AOO) has reached a level of robustness which fuels its increasing use in research and clinical centers. Here we will review the contribution of clinical AOO to the understanding and monitoring of 1) age-related macular degeneration and 2) vascular diseases. The main contributions of AOO to thephenotyping of AMD are a better identification of drusen, a better delineation of the limits of atrophy, and the identification of novel features such as punctate hyperreflectivity and mobile melanin-containing clumps. Characterization of progression of atrophy is facilitated by time-lapse imaging. In vessels, AOO enables the observation and measurement of parietal structures and the observation of microscopic pathological features such as small hemorrhages and inflammatory cell accumulations.
C1 [Paques, Michel; Mrejen, Sarah; Grieve, Kate] Ctr Hosp Natl Ophtalmol Quinze Vingts, INSERM, DHOS Clin Invest Ctr, F-1423 Paris, France.
   [Meimon, Serge] Off Natl Etud & Rech Aerosp, F-92320 Chatillon, France.
   [Rossant, Florence] Inst Super Elect Paris, F-75006 Paris, France.
   [Rosenbaum, David] UPMC Univ Paris 06, Unite Prevent Cardiovasc, Salpetriere Hosp, Paris, France.
   [Sennlaub, Florian] UPMC Univ Paris 06, Sorbonne Univ, Inst Vis, INSERM,CNRS, 17 Rue Moreau, F-75012 Paris, France.
C3 CHNO des Quinze-Vingts; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Sorbonne
   Universite; National Office for Aerospace Studies & Research (ONERA);
   UDICE-French Research Universities; Universite Paris Saclay; Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere
   - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre
   National de la Recherche Scientifique (CNRS); Institut National de la
   Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite
RP Paques, M (通讯作者)，Paris Adapt Opt Retinal Imaging & Surg PARIS Grp, Paris, France.
EM mpaques@15-20.fr
RI Sennlaub, Florian/F-2756-2017
OI Sennlaub, Florian/0000-0003-4412-1341; Rossant,
   Florence/0000-0003-2517-5213; Grieve, Kate/0000-0002-2937-6285; Mrejen,
   Sarah/0000-0003-3531-9030
FU Institut National de la Sante et de la Recherche Medicale (Contrat
   d'Interface 2011); Agence Nationale de la Recherche
   [ANR-12-TECS-0015-03, LabEx LIFESENSES ANR-10-LABX-65,
   ANR-11-IDEX-0004-02]; Foundation Fighting Blindess
   [C-CL-0912-0600-INSERM01, C-GE-0912-0601-INSERM02]; Thome Foundation;
   European Research Council [ERC-SyG 610110]
FX Jonathan Benesty, Celine Chaumette, Marie-Helene Errera, Elena
   Gofas-Salas, Celine Faure, Xavier Girerd, Edouard Koch, Chahira Miloudi,
   Pedro Mece, Hasan Sawan, Jose-Alain Sahel, Valerie Sarda, Andrea Sodi,
   Iyed Trimeche and the patients that participated in our studies. This
   work was supported by the Institut National de la Sante et de la
   Recherche Medicale (Contrat d'Interface 2011), the Agence Nationale de
   la Recherche (ANR-12-TECS-0015-03, LabEx LIFESENSES ANR-10-LABX-65,
   ANR-11-IDEX-0004-02), the Foundation Fighting Blindess
   (C-CL-0912-0600-INSERM01, C-GE-0912-0601-INSERM02), the Thome Foundation
   and the European Research Council (ERC-SyG 610110). The funding
   organization had no role in the design or conduct of this research.
   Original data provided here are from a clinical research study
   (ClinicalTrials.gov NCT0154618).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Arichika S, 2015, SCI REP-UK, V5, DOI 10.1038/srep12283
   Arichika S, 2014, INVEST OPHTH VIS SCI, V55, P8513, DOI 10.1167/iovs.14-15121
   Arichika S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089679
   Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Burgansky-Eliash Z, 2012, RETINA-J RET VIT DIS, V32, P112, DOI 10.1097/IAE.0b013e31821ba2c4
   Burgansky-Eliash Z, 2010, RETINA-J RET VIT DIS, V30, P765, DOI 10.1097/IAE.0b013e3181c596c6
   Burns SA, 2014, BIOMED OPT EXPRESS, V5, P961, DOI 10.1364/BOE.5.000961
   Chapman N, 2002, CLIN SCI, V103, P111
   Cheung CYL, 2014, J ALZHEIMERS DIS, V42, pS339, DOI 10.3233/JAD-141596
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Chui TYP, 2013, INVEST OPHTH VIS SCI, V54, P7115, DOI 10.1167/iovs.13-13027
   Chui TYP, 2012, BIOMED OPT EXPRESS, V3, P2537, DOI 10.1364/BOE.3.002537
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Couturier A, 2015, RETINA-J RET VIT DIS, V35, P2384, DOI 10.1097/IAE.0000000000000859
   Curcio C, 2017, INVEST OPHTH VIS SCI, V58
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Duan A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02344-5
   Dubow M, 2014, INVEST OPHTH VIS SCI, V55, P1299, DOI 10.1167/iovs.13-13122
   Errera MH, 2014, OPHTHALMOLOGY, V121, P1311, DOI 10.1016/j.ophtha.2013.12.036
   Fouquet S, 2017, INVEST OPHTH VIS SCI, V58, P5746, DOI 10.1167/iovs.17-22097
   Gallo A, 2017, Ann Cardiol Angeiol (Paris), V66, P165, DOI 10.1016/j.ancard.2017.04.007
   Genevois O, 2004, INVEST OPHTH VIS SCI, V45, P594, DOI 10.1167/iovs.03-0764
   Gocho K, 2013, INVEST OPHTH VIS SCI, V54, P3673, DOI 10.1167/iovs.12-10672
   Godara P, 2010, OPTOMETRY VISION SCI, V87, P930, DOI 10.1097/OPX.0b013e3181ff9a8b
   Gofas-Salas E, 2018, APPL OPTICS, V57, P5635, DOI 10.1364/AO.57.005635
   Grauslund J, 2009, OPHTHALMOLOGY, V116, P2170, DOI 10.1016/j.ophtha.2009.04.043
   Grieve K., 2016, INVEST OPHTH VIS SCI, V57
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Hanff TC, 2014, STROKE, V45, P1012, DOI 10.1161/STROKEAHA.113.004166
   Harazny JM, 2011, J HYPERTENS, V29, P777, DOI 10.1097/HJH.0b013e328343c27a
   HEAGERTY AM, 1993, HYPERTENSION, V21, P391, DOI 10.1161/01.HYP.21.4.391
   Hillard JG, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.4.16
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2015, GRAEF ARCH CLIN EXP, V253, P7, DOI 10.1007/s00417-014-2858-1
   JEFFERIES P, 1993, AUST NZ J OPHTHALMOL, V21, P213, DOI 10.1111/j.1442-9071.1993.tb00959.x
   Jonnal RS, 2016, INVEST OPHTH VIS SCI, V57, pOCT51, DOI 10.1167/iovs.16-19103
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kawasaki R, 2009, J HYPERTENS, V27, P2386, DOI 10.1097/HJH.0b013e3283310f7e
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kimura Tsuyoshi, 2005, International Ophthalmology, V26, P151, DOI 10.1007/s10792-007-9033-1
   King BJ, 2017, OPTOMETRY VISION SCI, V94, P411, DOI 10.1097/OPX.0000000000001031
   Klein R., 2011, ARCH OPHTHALMOL CHIC, V75-80
   Koch E, 2014, J HYPERTENS, V32, P890, DOI 10.1097/HJH.0000000000000095
   Kurokawa K, 2017, BIOMED OPT EXPRESS, V8, P1803, DOI 10.1364/BOE.8.001803
   Lecleire-Collet A, 2011, INVEST OPHTH VIS SCI, V52, P2861, DOI 10.1167/iovs.10-5960
   Lerme N, 2016, PATTERN RECOGN LETT, V72, P72, DOI 10.1016/j.patrec.2015.10.011
   Liang JZ, 1997, J OPT SOC AM A, V14, P2884, DOI 10.1364/JOSAA.14.002884
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Linsenmeier RA, 2017, PROG RETIN EYE RES, V58, P115, DOI 10.1016/j.preteyeres.2017.01.003
   Litts KM, 2017, RETINA-J RET VIT DIS, V37, P978, DOI 10.1097/IAE.0000000000001265
   Litts KM, 2016, INVEST OPHTH VIS SCI, V57, P2647, DOI 10.1167/iovs.16-19262
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Lombardo M, 2013, RETINA-J RET VIT DIS, V33, P1630, DOI 10.1097/IAE.0b013e3182899326
   Lu Y, 2016, BIOMED OPT EXPRESS, V7, P4958, DOI 10.1364/BOE.7.004958
   Luo T, 2017, INVEST OPHTH VIS SCI, V58, P2685, DOI 10.1167/iovs.17-21653
   Marcos S, 2017, VISION RES, V132, P3, DOI 10.1016/j.visres.2017.01.006
   Martin JA, 2005, OPHTHALMOLOGY, V112, P2219, DOI 10.1016/j.ophtha.2005.06.033
   MAYROVITZ HN, 1983, AM J PHYSIOL, V245, P1031, DOI 10.1152/ajpheart.1983.245.6.H1031
   Meadway A, 2014, BIOMED OPT EXPRESS, V5, P713, DOI 10.1364/BOE.5.000713
   Meixner E, 2015, GRAEF ARCH CLIN EXP, V253, P1985, DOI 10.1007/s00417-015-3115-y
   Miloudi C, 2015, INVEST OPHTH VIS SCI, V56, P7043, DOI 10.1167/iovs.15-17022
   Morgan JIW, 2009, INVEST OPHTH VIS SCI, V50, P1350, DOI 10.1167/iovs.08-2618
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Murray CD, 1926, P NATL ACAD SCI USA, V12, P207, DOI 10.1073/pnas.12.3.207
   Newman EA, 2013, J CEREBR BLOOD F MET, V33, P1685, DOI 10.1038/jcbfm.2013.145
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Panorgias A, 2013, INVEST OPHTH VIS SCI, V54, P4372, DOI 10.1167/iovs.12-11525
   Paques M, 2003, INVEST OPHTH VIS SCI, V44, P4960, DOI 10.1167/iovs.02-0738
   Paques M, 2015, JAMA OPHTHALMOL, V133, P947, DOI 10.1001/jamaophthalmol.2015.1132
   Paques M, 2010, GLIA, V58, P1663, DOI 10.1002/glia.21037
   Pedersen HR, 2018, BRIT J OPHTHALMOL, V102, P146, DOI 10.1136/bjophthalmol-2017-310719
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Pinhas A, 2013, BIOMED OPT EXPRESS, V4, P1305, DOI 10.1364/BOE.4.001305
   Pircher M, 2017, BIOMED OPT EXPRESS, V8, P2536, DOI 10.1364/BOE.8.002536
   Pollreisz A, 2018, EXP EYE RES, V166, P131, DOI 10.1016/j.exer.2017.10.018
   Querques G, 2016, RETINA-J RET VIT DIS, V36, P247, DOI 10.1097/IAE.0000000000000692
   Querques G, 2014, BRIT J OPHTHALMOL, V98, P1522, DOI 10.1136/bjophthalmol-2014-305455
   Raman R, 2016, INDIAN J OPHTHALMOL, V64, P69, DOI 10.4103/0301-4738.178150
   Reichman S, 2017, STEM CELLS, V35, P1176, DOI 10.1002/stem.2586
   Robman LD, 2015, OPHTHAL EPIDEMIOL, V22, P75, DOI 10.3109/09286586.2015.1010688
   Roorda A, 2015, ANNU REV VIS SCI, V1, P19, DOI 10.1146/annurev-vision-082114-035357
   Roorda A, 2010, OPTOMETRY VISION SCI, V87, P260, DOI 10.1097/OPX.0b013e3181d39479
   Rosenbaum D, 2016, HYPERTENS RES, V39, P536, DOI 10.1038/hr.2016.26
   Rosenbaum D, 2016, J HYPERTENS, V34, P1115, DOI 10.1097/HJH.0000000000000894
   Rossi EA, 2017, P NATL ACAD SCI USA, V114, P586, DOI 10.1073/pnas.1613445114
   Rossi EA, 2013, BIOMED OPT EXPRESS, V4, P2527, DOI 10.1364/BOE.4.002527
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sasongko MB, 2010, DIABETES CARE, V33, P1331, DOI 10.2337/dc10-0055
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Scoles D, 2014, INVEST OPHTH VIS SCI, V55, P4244, DOI 10.1167/iovs.14-14542
   Scoles D, 2013, BIOMED OPT EXPRESS, V4, P1710, DOI 10.1364/BOE.4.001710
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Sharma R, 2016, INVEST OPHTH VIS SCI, V57, P632, DOI 10.1167/iovs.15-17961
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1163, DOI 10.1097/IAE.0b013e3181ed8d05
   Sulai YN, 2014, J OPT SOC AM A, V31, P569, DOI 10.1364/JOSAA.31.000569
   Suzuki N, 2016, AM J OPHTHALMOL, V161, P126, DOI 10.1016/j.ajo.2015.09.038
   Tam J, 2016, INVEST OPHTH VIS SCI, V57, P4376, DOI 10.1167/iovs.16-19503
   Tam J, 2011, INVEST OPHTH VIS SCI, V52, P9257, DOI 10.1167/iovs.11-8481
   Tam J, 2010, INVEST OPHTH VIS SCI, V51, P1691, DOI 10.1167/iovs.09-4483
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P2349, DOI 10.1167/iovs.16-21237
   Vlachopoulos C, 2015, ATHEROSCLEROSIS, V241, P507, DOI 10.1016/j.atherosclerosis.2015.05.007
   Witt NW, 2010, ARTERY RES, V4, P75, DOI 10.1016/j.artres.2010.06.003
   Yatsuya H, 2010, STROKE, V41, P1349, DOI 10.1161/STROKEAHA.110.580837
   ZAMIR M, 1979, J GEN PHYSIOL, V74, P537, DOI 10.1085/jgp.74.4.537
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zayit-Soudry S, 2013, INVEST OPHTH VIS SCI, V54, P7498, DOI 10.1167/iovs.13-12433
   Zhang YH, 2018, RETINA-J RET VIT DIS, V38, P29, DOI 10.1097/IAE.0000000000001504
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 126
TC 33
Z9 34
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD SEP
PY 2018
VL 66
BP 1
EP 16
DI 10.1016/j.preteyeres.2018.07.001
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GW6ZN
UT WOS:000447113700001
PM 30010022
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Chappelow, AV
   Kaiser, PK
AF Chappelow, Aimee V.
   Kaiser, Peter K.
TI Neovascular age-related macular degeneration - Potential therapies
SO DRUGS
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL
   NEOVASCULARIZATION; OCULAR NEOVASCULARIZATION; CLINICAL-TRIALS;
   UNITED-STATES; RANIBIZUMAB; SUPPRESSION; VERTEPORFIN; PREVALENCE
AB Age-related macular degeneration (AMD) affects an estimated 14 million people worldwide, and is the leading cause of severe, irreversible vision loss in individuals over the age of 50 years in Western societies. Choroidal neovascularization (CNV), the hallmark of 'wet', 'exudative' or 'neovascular' AMD, is responsible for approximately 90% of cases of severe vision loss due to AMD. Vascular endothelial growth factor (VEGF) has been shown to play a key role in the regulation of CNV and vascular permeability. Ranibizumab, the current gold standard in the US for the treatment of neovascular AMD, exerts its effect through binding and inhibition of all isoforms of VEGF. Randomized controlled clinical trials have established ranibizumab as the first US FDA-approved therapy for neovascular AMD to result in improvement in visual acuity. Despite impressive outcomes, treatment with ranibizumab requires sustained treatment regimens and frequent intravitreal injections. In this review, we discuss promising emerging therapies for neovascular AMD that aim to improve outcomes, safety and treatment burden through novel mechanisms of action. Currently in phase III clinical trials, VEGF Trap is a receptor decoy that targets VEGF with higher affinity than ranibizumab and other currently available anti-VEGF agents. Another promising therapeutic strategy is the blockade of VEGF effects by inhibition of the tyrosine kinase cascade downstream from the VEGF receptor; such therapies currently in development include vatalanib, TG100801, pazopanib, AGO13958 and AL39324. Small interfering RNA technology-based therapies have been designed to downregulate the production of VEGF (bevasiranib) or VEGF receptors (AGN211745) by degradation of specific messenger RNA. Other potential therapies include pigment epithelium-derived factor-based therapies, nicotinic acetylcholine receptor antagonists, integrin antagonists and sirolimus.
C1 [Chappelow, Aimee V.; Kaiser, Peter K.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Kaiser, PK (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, Desk i3,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM pkkaiser@aol.com
OI Kaiser, Peter/0000-0001-5126-045X
CR BENZ MS, 2007, INVEST OPHTHALMOL VI, V48
   BINGAMAN DP, 2007, INVEST OPHTHALMOL VI, V48
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brucker A, 2006, COMB RET SOC GON SOC
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   CHEN ZZ, 2007, INVEST OPHTHALMOL VI, V48
   *CLINICALTRIALS GO, NCT00304954 CLINICAL
   *CLINICALTRIALS GO, NCT00499590 CLINICAL
   *CLINICALTRIALS GO, NCT00395057 CLINICAL
   *CLINICALTRIALS GO, NCT00463320 CLINICAL
   *CLINICALTRIALS GO, NCT00414999 CLINICAL
   *CLINICALTRIALS GO, NCT00527423 CLINICAL
   *CLINICALTRIALS GO, NCT00138632 CLINICAL
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   *CTR PREV OPHTH BI, 2007, CATT LUC AV TRIAL MA
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Dejneka NS, 2004, MOL VIS, V10, P964
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128
   HARIPRASAD SM, 2006, COMB RET SOC GON SOC
   HARIPRASAD SM, 2007, INVEST OPHTHALMOL VI, V48
   Heeschen C, 2002, J CLIN INVEST, V110, P527, DOI 10.1172/JCI200214676
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   KENGATHARAN M, 2007, INVEST OPHTHALMOL VI, V48
   KLEINMAN DM, 2007, INVEST OPLITHALMOL V, V48
   Maier P, 2005, GRAEF ARCH CLIN EXP, V243, P593, DOI 10.1007/s00417-004-1021-9
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   NGUYEN Q, 2006, COMB RET SOC GON SOC
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   NOZAKI M, 2006, INVEST OPHTHALMOL VI, V47
   Reich S, 2003, MOL VIS, V9, P210
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Umeda N, 2006, MOL PHARMACOL, V69, P1820, DOI 10.1124/mol.105.020941
   *WHO, 2004, 282 WHO
   ZAHN G, 2007, INVEST OPHTHALMOL VI, V48
NR 37
TC 119
Z9 172
U1 0
U2 22
PU ADIS INT LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW
   ZEALAND
SN 0012-6667
J9 DRUGS
JI Drugs
PY 2008
VL 68
IS 8
BP 1029
EP 1036
DI 10.2165/00003495-200868080-00002
PG 8
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 323AT
UT WOS:000257417100002
PM 18484796
DA 2022-11-30
ER

PT J
AU Merle, BMJ
   Richard, F
   Benlian, P
   Puche, N
   Delcourt, C
   Souied, EH
AF Merle, Benedicte M. J.
   Richard, Florence
   Benlian, Pascale
   Puche, Nathalie
   Delcourt, Cecile
   Souied, Eric H.
TI CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with
   Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration
   Patients: The NAT2 Study
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; FATTY-ACIDS; DIETARY OMEGA-3-FATTY-ACIDS;
   CIGARETTE-SMOKING; RISK; SUSCEPTIBILITY; ANTIOXIDANTS; GENE; VARIANT;
   ZINC
AB Purpose
   Genetic susceptibility could be modified by environmental factors and may also influence differential responses to treatments for age-related macular degeneration (AMD). We investigated whether genotype could influence response to docosahexaenoic acid (DHA)-supplementation in the occurrence of choroidal new vessels (CNV).
   Methods
   The Nutritional AMD Treatment 2 (NAT2) study was a randomized, placebo-controlled, double-blind, parallel, comparative study, including 250 patients aged 55 to 85 years with early lesions of age-related maculopathy, visual acuity better than 0.4 Logarithm of Minimum Angle of Resolution units in the study eye and neovascular AMD in the fellow eye. Patients were randomized at baseline to receive either 3 daily fish-oil capsules, each containing 280 mg DHA, 90 mg EPA and 2 mg Vitamin E, or placebo.
   Results
   Patients carrying the risk allele (C) for CFH Y402H had no statistically significant increased risk for developing CNV in the study eye (Hazard Ratio (HR)=0.97; 95% Confidence Interval (CI): 0.54-1.76 for heterozygous and HR=1.29; 95% CI: 0.69-2.40 for homozygous). Patients carrying the risk allele (T) for ARMS2 A69S had no statistically significant increased risk for developing CNV in the study eye (HR=1.68; 95% CI: 0.91-3.12) for heterozygous and HR=1.78; 95% CI: 0.90-3.52 for homozygous). A significant interaction was observed between CFH Y402H and DHA-supplementation (p=0.01). We showed a protective effect of DHA-supplementation among homozygous non-risk patients. Among these patients, occurrence of CNV was 38.2% in placebo group versus 16.7% in DHA group (p=0.008).
   Conclusions
   These results suggest that a genetic predisposition to AMD conferred by the CFH Y402H variant limits the benefit provided by DHA supplementation.
C1 [Merle, Benedicte M. J.; Puche, Nathalie; Souied, Eric H.] Univ Paris Est Creteil, Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Richard, Florence] Univ Lille Nord France, INSERM774, Inst Pasteur Lille, Lille, France.
   [Richard, Florence] Univ Lille Nord France, Lille, France.
   [Benlian, Pascale] CHRU, Lille, France.
   [Benlian, Pascale] Hop St Antoine, AP HP, Endocrinol & Metab Dis Dept, F-75012 Paris, France.
   [Benlian, Pascale] Univ Lille 2, Sch Med, Dept Biochem & Mol Biol, F-59045 Lille, France.
   [Delcourt, Cecile] INSERM, Ctr INSERM Epidemiol Biostat U897, F-33000 Bordeaux, France.
   [Delcourt, Cecile] Univ Bordeaux, ISPED, F-33000 Bordeaux, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Le Reseau
   International des Instituts Pasteur (RIIP); Universite de Lille - ISITE;
   Institut Pasteur Lille; Universite de Lille; Universite de Lille -
   ISITE; Universite de Lille; Universite de Lille - ISITE; CHU Lille;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne
   Universite; Universite de Franche-Comte; Universite de Lille - ISITE;
   CHU Lille; Universite de Lille; Institut National de la Sante et de la
   Recherche Medicale (Inserm); UDICE-French Research Universities;
   Universite de Bordeaux
RP Merle, BMJ (通讯作者)，Univ Paris Est Creteil, Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
EM benedicte.merle@isped.fr
RI Merle, Benedicte MJ/F-1247-2015; Delcourt, Cecile/I-2627-2013; Merle,
   Benedicte MJ/AAQ-5021-2021; Benlian, Pascale/I-7964-2016
OI Merle, Benedicte MJ/0000-0003-1332-0954; Delcourt,
   Cecile/0000-0002-2099-0481; Merle, Benedicte MJ/0000-0003-1332-0954;
   Benlian, Pascale/0000-0002-3423-8979
FU Laboratoire Bausch & Lomb, Clinical Research, 416, rue Samuel Morse,
   Montpellier, Cedex 2, France [CS 99535]
FX This study was sponsored by Laboratoire Bausch & Lomb, Clinical
   Research, 416, rue Samuel Morse, CS 99535, 34961 Montpellier, Cedex 2,
   France. Bausch & Lomb participated in design and conduction of the
   study; but not in collection, management, analysis, and interpretation
   of the data; and not in preparation, review, or approval of the
   manuscript; and not in decision to submit the manuscript for
   publication.
CR Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Benlian P, 2000, CLIN CHEM, V46, P493
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lawlor DA, 2004, LANCET, V363, P1724, DOI 10.1016/S0140-6736(04)16260-0
   Leveziel N, 2007, MOL VIS, V13, P2153
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Resnikoff S, 2002, B WORLD HEALTH ORGAN, V82, P844
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
NR 46
TC 20
Z9 20
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 1
PY 2015
VL 10
IS 7
AR e0130816
DI 10.1371/journal.pone.0130816
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CN1CG
UT WOS:000358153000082
PM 26132079
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Armstrong, GW
   Miller, JB
AF Armstrong, Grayson W.
   Miller, John B.
TI Telemedicine for the Diagnosis and Management of Age-Related Macular
   Degeneration: A Review
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE telemedicine; ophthalmology; age-related macular degeneration
ID HOME; PREVALENCE; DISEASE
AB Use of ophthalmic telemedicine for patients with age-related macular degeneration (AMD) has shown remarkable advances over recent years. The recent COVID pandemic accelerated this transition since in-person evaluation of elderly patients at high risk for advanced AMD and severe vision loss were also at higher risk for complications from COVID infection. To date, ophthalmic telemedicine has been successfully used in remote retinal consultation by general ophthalmologists for AMD management, hybrid testing visits with both in-office testing and remote evaluation, as well as early successes in home-based remote monitoring of patients with high-risk AMD. We therefore review the current literature and evidence base related to ophthalmic telemedicine for AMD.
C1 [Armstrong, Grayson W.; Miller, John B.] Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA.
   [Miller, John B.] Harvard Med Sch, Harvard Retinal Imaging Lab, Boston, MA 02114 USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard Medical School
RP Armstrong, GW (通讯作者)，Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA.
EM grayson_armstrong@meei.harvard.edu; john_miller@meei.harvard.edu
RI Miller, John J/GZG-5663-2022
CR AAO, 2020, NEW REC URG NON PAT
   Andonegui J, 2016, RETINA-J RET VIT DIS, V36, P279, DOI 10.1097/IAE.0000000000000729
   Aweidah H, 2020, CLIN OPHTHALMOL, V14, P3421, DOI 10.2147/OPTH.S276276
   Azzolini C, 2013, J TELEMED TELECARE, V19, P437, DOI 10.1177/1357633X13501760
   Borrelli E, 2021, J CLIN MED, V10, DOI 10.3390/jcm10061265
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2621, DOI 10.1007/s00417-020-04955-7
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2655, DOI 10.1007/s00417-020-04858-7
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Chee Y., 2020, RETIN TODAY
   Chew EY, 2016, RETINA-J RET VIT DIS, V36, P1542, DOI 10.1097/IAE.0000000000000940
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   De Bats F, 2014, OPHTHALMOLOGICA, V231, P172, DOI 10.1159/000356695
   Duchin KS, 2015, OPTOMETRY VISION SCI, V92, P714, DOI 10.1097/OPX.0000000000000598
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Horton MB, 2020, TELEMED E-HEALTH, V26, P495, DOI 10.1089/tmj.2020.0006
   Li B, 2015, JAMA OPHTHALMOL, V133, P276, DOI 10.1001/jamaophthalmol.2014.5014
   Lu E, 2020, RETIN TODAY
   Maloca P, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.8
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Rahimy E., 2020, RETIN PHYS
   Scholl HPN, 2004, OPHTHALMOLOGY, V111, P125, DOI 10.1016/j.ophtha.2003.05.003
   Starr MR, 2019, AM J OPHTHALMOL, V208, P206, DOI 10.1016/j.ajo.2019.03.021
   Tamura H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133628
   Thomas A.S., 2012, INVESTIG OPHTHALMOL, V53, P835
   Tsaousis KT, 2016, ACTA OPHTHALMOL, V94, pe353, DOI 10.1111/aos.12832
   Ulrich JN, 2009, BRIT J OPHTHALMOL, V93, P698, DOI 10.1136/bjo.2008.151357
   von der Burchard C, 2021, GRAEF ARCH CLIN EXP, V259, P1503, DOI 10.1007/s00417-020-05035-6
   Wasser Lauren M, 2020, SN Compr Clin Med, V2, P2546, DOI 10.1007/s42399-020-00614-4
   Wittenborn JS, 2017, JAMA OPHTHALMOL, V135, P452, DOI 10.1001/jamaophthalmol.2017.0255
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 31
TC 2
Z9 2
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD FEB
PY 2022
VL 11
IS 3
AR 835
DI 10.3390/jcm11030835
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA YZ7LH
UT WOS:000755653300001
PM 35160286
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Yasuma, TR
   Nakamura, M
   Nishiguchi, KM
   Kikuchi, M
   Kaneko, H
   Niwa, T
   Hamajima, N
   Terasaki, H
AF Yasuma, Tetsuhiro R.
   Nakamura, Makoto
   Nishiguchi, Koji M.
   Kikuchi, Masato
   Kaneko, Hiroki
   Niwa, Toshimitsu
   Hamajima, Nobuyuki
   Terasaki, Hiroko
TI Elevated C-reactive protein levels and ARMS2/HTRA1 gene variants in
   subjects without age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY; RISK-FACTORS;
   HTRA1; POLYMORPHISM; DISEASE; SUSCEPTIBILITY; ASSOCIATION; MACULOPATHY;
   PREVALENCE
AB Purpose: To investigate the association between the serum high sensitivity C-reactive protein (hs-CRP) levels and variants in age-related maculopathy susceptibility 2 (ARMS2)/HtrA serine peptidase 1 (HTRA1) genes in normal subjects with no evidence of age-related macular degeneration (AMD).
   Methods: After clinical evaluation, information related to medical and social history was collected from 476 Japanese individuals (age range 17-89 years) along with blood samples. These subjects were medical checkup participants recruited at Nagoya University Hospital with no macular disease, as confirmed by fundus photographs. Serum hs-CRP levels were measured using a highly sensitive latex aggregation immunoassay. The genotypes of three polymorphisms in the ARMS2/HTRA1 locus, i.e., *372_815del443ins54 (del/ins), rs10490924, and rs11200638 were determined using direct sequencing and/or PCR-based assays. After the haplotype was constructed and analyzed, the associations between hs-CRP levels and representative del/ins genotypes were studied with and without adjustment for potential confounding factors.
   Results: All three polymorphisms in the ARMS2/HTRA1 region were in almost complete linkage disequilibrium. Haplotype analyses showed the existence of only two common haplotypes, together comprising 98.9%. Regression analyses showed that the level of hs-CRP was positively correlated with increasing age. This age-dependent increase of hs-CRP levels was greatest in those with homozygous del/ins alleles and lowest in those with homozygous wild-type alleles, which was significant assuming an additive model for gene-dosage association (univariate analyses: p=0.016, multivariate analyses including smoking status, past medical history, and BMI: p=0.043). Consequently, the level of hs-CRP was greatest in those with homozygous del/ins alleles and lowest in those with homozygous wild-type alleles when subjects older than 60 were analyzed. This was significant assuming an additive model for gene-dosage association (univariate analyses: p=0.032).
   Conclusions: An age-dependent elevation of serum hs-CRP levels may be accelerated in normal subjects with one or two risk alleles in the ARMS2/HTRA1 locus compared to those with homozygous wild-type alleles. The results of the current study show that the as-yet undetermined function of variants in the ARMS2/HTRA1 locus might be linked to inflammation, possibly contributing to the development of neovascular AMD.
C1 [Yasuma, Tetsuhiro R.; Nakamura, Makoto; Nishiguchi, Koji M.; Kikuchi, Masato; Kaneko, Hiroki; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi 4648601, Japan.
   [Niwa, Toshimitsu] Nagoya Univ, Grad Sch Med, Dept Adv Med Uremia, Nagoya, Aichi 4648601, Japan.
   [Hamajima, Nobuyuki] Nagoya Univ, Grad Sch Med, Dept Prevent Med Biostat & Med Decis Making, Nagoya, Aichi 4648601, Japan.
C3 Nagoya University; Nagoya University; Nagoya University
RP Nishiguchi, KM (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi 4648601, Japan.
EM kojinish@med.nagoya-u.ac.jp
RI Kaneko, Hiroki/AHA-2461-2022; Terasaki, Hiroko/M-5054-2014; Hamajima,
   Nobuyuki/I-7237-2014; Kaneko, Hiroki/O-7695-2015
OI Kaneko, Hiroki/0000-0003-0731-6465; Kaneko, Hiroki/0000-0003-0731-6465;
   Nakamura, Makoto/0000-0002-6464-4302
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [C19592013, B21791676, B20390448]; Ministry of Health, Labor, and
   Welfare of Japan, Tokyo, Japan
FX This work is supported in part by Grant-in Aid for Scientific Research
   from the Ministry of Education, Culture, Sports, Science, and Technology
   of Japan (MN, C19592013; KMN, B21791676; and HT, B20390448), and
   Grant-in Aid from the Ministry of Health, Labor, and Welfare of Japan,
   Tokyo, Japan (Dr. Terasaki).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Goumans MJ, 2009, CELL RES, V19, P116, DOI 10.1038/cr.2008.326
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kim IK, 2008, MOL VIS, V14, P1487
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Nishio Kazuko, 2004, Nagoya J Med Sci, V67, P45
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Zacho J, 2008, NEW ENGL J MED, V359, P1897, DOI 10.1056/NEJMoa0707402
   Zee RYL, 2006, ATHEROSCLEROSIS, V187, P332, DOI 10.1016/j.atherosclerosis.2005.09.009
NR 38
TC 21
Z9 21
U1 0
U2 5
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD DEC 31
PY 2010
VL 16
IS 313-19
BP 2923
EP 2930
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 707UR
UT WOS:000286314500002
PM 21203342
DA 2022-11-30
ER

PT J
AU Gianniou, C
   Dirani, A
   Jang, LN
   Mantel, I
AF Gianniou, Christina
   Dirani, Ali
   Jang, Liuna
   Mantel, Irmela
TI REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIZUBIMAB Functional
   and Structural Outcome
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID ANTI-VEGF THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; OPTICAL COHERENCE
   TOMOGRAPHY; 2.0 MG RANIBIZUMAB; PHOTODYNAMIC THERAPY; RETINAL
   SENSITIVITY; DOSING REGIMEN; AFLIBERCEPT; EFFICACY; SAFETY
AB Purpose:
   To investigate the visual acuity results of eyes with neovascular age-related macular degeneration and refractory fluid despite monthly treatment with ranibizumab, and to investigate differences between refractory subretinal fluid and intraretinal cystic changes.
   Methods:
   Retrospective chart review of consecutive treatment-refractory neovascular age-related macular degeneration, defined as persistent intraretinal or subretinal fluid despite monthly ranibizumab injections during 12 months or more. Data were evaluated for baseline characteristics, type and location of the refractory fluid, mean visual acuity change, number of injections, and the time point of first complete disappearance of all fluid on spectral domain optical coherence tomography.
   Results:
   Seventy-six eyes (74 patients, mean age, 76.8 years) were identified. The mean follow-up was 33.6 months (range, 12-73 months). The mean number of injections was 11.4 in the first year and 27.7 over follow-up. The refractory fluid was located subfoveally in 61.8%. In 27 eyes (35.5%), the fluid resolved after a mean of 21.8 months (range, 13-49 months). Mean visual acuity increased by 9.0, 7.9, and 7.9 letters by Month 12, Month 24, and Month 36, respectively. Subgroup analysis revealed a higher risk for fibrosis (odds ratio, 3.30) or atrophy (odds ratio, 3.34) in patients with refractory cysts as compared with refractory subretinal fluid. Furthermore, refractory cysts showed a higher risk for a 10-letter visual acuity loss (P = 0.018).
   Conclusion:
   Fluid refractory to monthly treatment with ranibizumab for neovascular age-related macular degeneration still allowed for well-maintained visual improvement, even in subfoveal location. Late fluid resolution may occur. However, refractory cysts were associated with poorer anatomical and functional outcome than subretinal fluid.
C1 [Gianniou, Christina; Dirani, Ali; Jang, Liuna; Mantel, Irmela] Univ Lausanne, Dept Ophthalmol, Lausanne, Switzerland.
   [Gianniou, Christina; Dirani, Ali; Jang, Liuna; Mantel, Irmela] Jules Gonin Eye Hosp, Fdn Asylum Blind, Lausanne, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Univ Eye Hosp Jules Gonin, 15 Ave,France Case Postale 133, CH-1000 Lausanne 7, Switzerland.
EM irmela.mantel@fa2.ch
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Augustin Albert, 2009, Retina, V29, pS8, DOI 10.1097/IAE.0b013e3181ad253d
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Ersoy L, 2014, GRAEF ARCH CLIN EXP, V252, P889, DOI 10.1007/s00417-013-2519-9
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gerding H, 2010, KLIN MONATSBL AUGENH, V227, P294, DOI 10.1055/s-0029-1245209
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Investigators IS, 2012, OPHTHALMOLOGY, V119, P1399
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466
   Sulzbacher F, 2013, INVEST OPHTH VIS SCI, V54, P1310, DOI 10.1167/iovs.12-11046
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Wykoff CC, 2013, OPHTHAL SURG LAS IM, V44, P121, DOI 10.3928/23258160-20130313-04
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 29
TC 43
Z9 45
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2015
VL 35
IS 6
BP 1195
EP 1201
DI 10.1097/IAE.0000000000000465
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CJ7KJ
UT WOS:000355673600019
PM 25650710
DA 2022-11-30
ER

PT J
AU Blasiak, J
   Szaflik, J
   Szaflik, JP
AF Blasiak, Janusz
   Szaflik, Jerzy
   Szaflik, Jacek Pawel
TI Implications of altered iron homeostasis for age-related macular
   degeneration
SO FRONTIERS IN BIOSCIENCE-LANDMARK
LA English
DT Article
DE Age-Related Macular Degeneration; AMD; Iron; Oxidative Stress; Iron
   Homeostasis; Review
ID FACTOR-H POLYMORPHISM; RETINAL DEGENERATION; MEDICAL PROGRESS; POTENTIAL
   FACTOR; TRANSFERRIN; TOXICITY; HEPCIDIN; BLOOD; CERULOPLASMIN; FERRITIN
AB Reactive oxygen species (ROS) may contribute to the pathogenesis of age-related macular degeneration (AMD) and they can be produced in the Fenton reaction catalyzed by Fe3+ ions. Therefore, altered homeostasis of iron in the retina may be the source of ROS and its damage resulting in clinically detectable AMD symptoms. The results of some post mortem research indicate a higher concentration of iron in AMD retinas in comparison with non-affected retinas, although those results do not determine whether iron overload is the reason or a consequence of AMD. However, the results of some other research suggest that iron may contribute to the pathogenesis of AMD. Those include increasing of macular iron level with age, involvement of iron in the pathogenesis of some degenerative diseases linked with AMD, upregulation of transferrin in AMD, developing of AMD-like syndromes in mice deficient in ceruloplasmin and hephaestin, association between polymorphism of the iron homeostasis genes and AMD and others. Better understanding of the role of altered iron homeostasis may be useful in prevention and curing of AMD.
C1 [Szaflik, Jerzy; Szaflik, Jacek Pawel] Med Univ Warsaw, Dept Ophthalmol, PL-03710 Warsaw, Poland.
   [Szaflik, Jerzy; Szaflik, Jacek Pawel] Samodzielny Publ Szpital Okulistyczny, PL-03710 Warsaw, Poland.
   [Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90237 Lodz, Poland.
C3 Medical University of Warsaw; University of Lodz
RP Szaflik, JP (通讯作者)，Med Univ Warsaw, Dept Ophthalmol, Sierakowskiego 13, PL-03709 Warsaw, Poland.
EM szaflik@ophthalmology.pl
OI Blasiak, Janusz/0000-0001-9539-9584; Szaflik, Jerzy/0000-0002-7601-1326
FU Ministry of Science and Higher Education [N N402 248336]
FX There is no conflict of interest. This work was supported by Ministry of
   Science and Higher Education, grant number N N402 248336. We thank Ms.
   Anna Luczynska for helping us preparing the manuscript.
CR Aisen P, 2004, INT J BIOCHEM CELL B, V36, P2137, DOI 10.1016/j.biocel.2004.02.007
   Amasheh S, 2009, ANN NY ACAD SCI, V1165, P211, DOI 10.1111/j.1749-6632.2009.04439.x
   Anderson GJ, 2006, NAT GENET, V38, P503, DOI 10.1038/ng0506-503
   Anderson GJ, 2009, CELL MOL LIFE SCI, V66, P3241, DOI 10.1007/s00018-009-0051-1
   Andrews NC, 2007, ANNU REV PHYSIOL, V69, P69, DOI 10.1146/annurev.physiol.69.031905.164337
   Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607
   Araujo A, 2009, HEMATOLOGY, V14, P22, DOI 10.1179/102453309X385179
   Baath JS, 2008, RETINA-J RET VIT DIS, V28, P894, DOI 10.1097/IAE.0b013e3181679f67
   Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777
   BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003
   Burdo JR, 2003, NEUROSCIENCE, V121, P883, DOI 10.1016/S0306-4522(03)00590-6
   Cheah JH, 2006, NEURON, V51, P431, DOI 10.1016/j.neuron.2006.07.011
   Chen L, 2003, MOL VIS, V9, P151
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   Chua ACG, 2007, CRIT REV CL LAB SCI, V44, P413, DOI 10.1080/10408360701428257
   Collins JE, 2008, J NUTR, V138, P2284, DOI 10.3945/jn.108.096347
   De Domenico I, 2007, MOL BIOL CELL, V18, P2569, DOI 10.1091/mbc.E07-01-0060
   Dentchev T, 2005, ARCH OPHTHALMOL-CHIC, V123, P1745, DOI 10.1001/archopht.123.12.1745
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   DOLY M, 1986, OPHTHALMIC RES, V18, P21, DOI 10.1159/000265409
   Dragani TA, 2010, J HEPATOL, V52, P252, DOI 10.1016/j.jhep.2009.11.015
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   GANZ T, 2006, HEMATOL-AM SOC HEMAT, V507, P29, DOI DOI 10.1182/ASHEDUCATION-2006.1.29
   Garinis GA, 2008, NAT CELL BIOL, V10, P1241, DOI 10.1038/ncb1108-1241
   Ghosh B, 2010, J MED CHEM, V53, P2114, DOI 10.1021/jm901618d
   Gnana-Prakasam JP, 2010, IUBMB LIFE, V62, P363, DOI 10.1002/iub.326
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   Hahn P, 2009, EXP GERONTOL, V44, P594, DOI 10.1016/j.exger.2009.06.006
   Haimovici R, 2002, OPHTHALMOLOGY, V109, P164, DOI 10.1016/S0161-6420(01)00947-2
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   HUNT RC, 1992, J CELL PHYSIOL, V152, P102, DOI 10.1002/jcp.1041520114
   HUNT RC, 1989, J CELL SCI, V92, P655
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaarniranta K, 2010, ACTA OPHTHALMOL, V88, P387, DOI 10.1111/j.1755-3768.2009.01840.x
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Kiecolt-Glaser JK, 2010, PSYCHOSOM MED, V72, P365, DOI 10.1097/PSY.0b013e3181dbf489
   KLAASSEN CD, 1996, GOODMAN GILMANS PHAR, P148
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klettner A, 2010, CUTAN OCUL TOXICOL, V29, P122, DOI 10.3109/15569521003745685
   Kohgo Y, 2008, INT J HEMATOL, V88, P7, DOI 10.1007/s12185-008-0120-5
   Koorts A. M., 2007, Archives of Physiology and Biochemistry, V113, P30, DOI 10.1080/13813450701318583
   Lee DW, 2006, MOL INTERV, V6, P89, DOI 10.1124/mi.6.2.6
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Liu G, 2010, METHODS MOL BIOL, V610, P123, DOI 10.1007/978-1-60327-029-8_8
   Loh A, 2009, BBA-GEN SUBJECTS, V1790, P637, DOI 10.1016/j.bbagen.2008.11.001
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Lukinova N, 2009, INVEST OPHTH VIS SCI, V50, P1440, DOI 10.1167/iovs.08-2545
   McKie AT, 2002, BIOCHEM SOC T, V30, P722, DOI 10.1042/bst0300722
   Moiseyev G, 2006, J BIOL CHEM, V281, P2835, DOI 10.1074/jbc.M508903200
   Napier I, 2005, BLOOD, V105, P1867, DOI 10.1182/blood-2004-10-3856
   NEWELL FW, 1979, AM J OPHTHALMOL, V88, P467, DOI 10.1016/0002-9394(79)90648-2
   Ohgami RS, 2005, NAT GENET, V37, P1264, DOI 10.1038/ng1658
   PEDERSEN OO, 1979, EXP EYE RES, V29, P61, DOI 10.1016/0014-4835(79)90166-0
   Perry G, 2002, CNS DRUGS, V16, P339, DOI 10.2165/00023210-200216050-00006
   Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200
   Porter JB, 2009, BLOOD REV, V23, pS3, DOI 10.1016/S0268-960X(09)70003-7
   Radak Z, 2010, FREE RADICAL BIO MED, V49, P587, DOI 10.1016/j.freeradbiomed.2010.05.008
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   Shaw GC, 2006, NATURE, V440, P96, DOI 10.1038/nature04512
   Sheftel AD, 2007, BLOOD, V110, P125, DOI 10.1182/blood-2007-01-068148
   SHICHI H, 1969, EXP EYE RES, V8, P60, DOI 10.1016/S0014-4835(69)80081-3
   SLIWINSKI T, 2010, OKULISTYKA, V1, P59
   TAWARA A, 1986, INVEST OPHTH VIS SCI, V27, P226
   VERGARA O, 1989, EXP EYE RES, V49, P1115, DOI 10.1016/S0014-4835(89)80030-2
   VOGT W, 1991, COMPLEMENT INFLAMMAT, V8, P313, DOI 10.1159/000463202
   WATKINS JA, 1992, BIOCHEMISTRY-US, V31, P5820, DOI 10.1021/bi00140a018
   Waugh WH, 2004, J APPL RES, V4, P208
   Whitnall Megan, 2006, Semin Pediatr Neurol, V13, P186, DOI 10.1016/j.spen.2006.08.008
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Yamaguchi K, 1998, OPHTHALMOLOGICA, V212, P11, DOI 10.1159/000027251
   Yefimova MG, 2002, INVEST OPHTH VIS SCI, V43, P537
   Yefimova MG, 2000, INVEST OPHTH VIS SCI, V41, P2343
   Zacharski LR, 2003, VASC MED, V8, P153, DOI 10.1191/1358863x03vm492ed
NR 85
TC 23
Z9 23
U1 1
U2 7
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093-9946
EI 1093-4715
J9 FRONT BIOSCI-LANDMRK
JI Front. Biosci.
PD JAN 1
PY 2011
VL 16
BP 1551
EP 1559
DI 10.2741/3804
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 757NI
UT WOS:000290093700021
PM 21196247
OA Bronze
DA 2022-11-30
ER

PT J
AU van Leeuwen, R
   Klaver, CCW
   Vingerling, JR
   Hofman, A
   van Duijn, CM
   Stricker, BHC
   de Jong, PTVM
AF van Leeuwen, R
   Klaver, CCW
   Vingerling, JR
   Hofman, A
   van Duijn, CM
   Stricker, BHC
   de Jong, PTVM
TI Cholesterol and age-related macular degeneration: Is there a link?
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CARDIOVASCULAR-DISEASE; MACULOPATHY; ATHEROSCLEROSIS; ROTTERDAM; RISK
AB PURPOSE: To examine the relation among serum cholesterol, apolipoprotein E genotype (APOE), and the risk of early and late age-related macular degeneration (AMD).
   DESIGN: The Rotterdam Study, a population based prospective cohort study.
   METHODS: Serum levels of total and high-density lipoprotein (HDC) cholesterol as well as APOE genotype were determined at baseline. Of 3,944 subjects, 400 were diagnosed with incident early and late AMD after a mean follow,up of 5.2 years.
   RESULTS: Serum HDL, but not total, cholesterol was associated with an increased risk of AMD (odds ratio/SD, 1.20; 95% confidence interval; 1.06-1.35). The association remained unchanged after adjustment for APOE genotype. When stratifying for APOE genotype, the association was strongest in persons with the e 4 allele; an inverse association seemed to be present for e 2 carriers.
   CONCLUSION: Elevated HDL but not total cholesterol is associated with an increased risk of AMD. Apolipoprotein E genotype does not explain this association but may be an effect modifier. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Netherlands Ophthalm Res Inst, KNAW, NL-1105 BA Amsterdam, Netherlands.
   Erasmus Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands.
   Erasmus Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
   Acad Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
C3 Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; University of Amsterdam;
   Academic Medical Center Amsterdam
RP de Jong, PTVM (通讯作者)，Netherlands Ophthalm Res Inst, KNAW, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.
EM p.dejong@ioi.knaw.nl
RI Klaver, Caroline C.W./A-2013-2016
OI Van Duijn, Cornelia/0000-0002-2374-9204; Klaver,
   Caroline/0000-0002-2355-5258
CR Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
NR 6
TC 89
Z9 89
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2004
VL 137
IS 4
BP 750
EP 752
DI 10.1016/S0002-9394(03)01089-4
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 811HK
UT WOS:000220762800021
PM 15059717
DA 2022-11-30
ER

PT J
AU Urbanska, K
   Stepien, PW
   Nowakowska, KN
   Stefaniak, M
   Osial, N
   Choragiewicz, T
   Toro, MD
   Nowomiejska, K
   Rejdak, R
AF Urbanska, Karolina
   Stepien, Piotr Witold
   Nowakowska, Katarzyna Natalia
   Stefaniak, Martyna
   Osial, Natalia
   Choragiewicz, Tomasz
   Toro, Mario Damiano
   Nowomiejska, Katarzyna
   Rejdak, Robert
TI The Role of Dysregulated miRNAs in the Pathogenesis, Diagnosis and
   Treatment of Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; miRNA; microRNA; AMD biomarkers; miRNA
   therapeutics; AMD pathogenesis
ID CHOROIDAL NEOVASCULARIZATION; VITREOUS-HUMOR; CIRCULAR RNAS;
   ANGIOGENESIS; BIOMARKERS; MICRORNAS; EXPRESSION
AB Age-related macular degeneration (AMD) is an eye disease causing damage to the macular region of the retina where most of the photoreceptors responsible for central visual acuity are located. MicroRNAs (miRNAs) are small single-stranded non-coding RNA molecules that negatively regulate genes by silent post-transcriptional gene expressions. Previous studies have shown that changes in specific miRNAs are involved in the pathogenesis of eye diseases, including AMD. Altered expressions of miRNAs are related to disturbances of regulating oxidative stress, inflammation, angiogenesis, apoptosis and phagocytosis, which are known factors in the pathogenesis of AMD. Moreover, dysregulation of miRNA is involved in drusen formation. Thus, miRNAs may be used as potential molecular biomarkers for the disease and, furthermore, tailoring therapeutics to particular disturbances in miRNAs may, in the future, offer hope to prevent irreversible vision loss. In this review, we clarify the current state of knowledge about the influence of miRNA on the pathogenesis, diagnosis and treatment of AMD. Our study material consisted of publications, which were found in PubMed, Google Scholar and Embase databases using "Age-related macular degeneration", "miRNA", "AMD biomarkers", "miRNA therapeutics" and "AMD pathogenesis" as keywords. Paper search was limited to articles published from 2011 to date. In the section "Retinal, circulating and vitreous body miRNAs found in human studies", we limited the search to studies with patients published in 2016-2021.
C1 [Urbanska, Karolina; Stepien, Piotr Witold; Nowakowska, Katarzyna Natalia; Stefaniak, Martyna; Osial, Natalia; Choragiewicz, Tomasz; Toro, Mario Damiano; Nowomiejska, Katarzyna; Rejdak, Robert] Med Univ Lublin, Chair & Dept Gen & Pediat Ophthalmol, PL-20079 Lublin, Poland.
   [Toro, Mario Damiano] Univ Naples Federico II, Publ Hlth Dept, Eye Clin, I-80131 Naples, Italy.
C3 Medical University of Lublin; University of Naples Federico II
RP Choragiewicz, T (通讯作者)，Med Univ Lublin, Chair & Dept Gen & Pediat Ophthalmol, PL-20079 Lublin, Poland.
EM k.urbanska.98@gmail.com; piotr.stepien.dysk@gmail.com;
   k.nowakowska98@gmail.com; martynastefaniakk@gmail.com;
   natalia.osial@gmail.com; tomaszchoragiewicz@umlub.pl;
   toro.mario@email.it; katarzyna.nowomiejska@umlub.pl;
   robert.rejdak@umlub.pl
OI Stepien, Piotr Witold/0000-0002-1596-0122; Urbanska,
   Karolina/0000-0002-8432-7232; Nowomiejska,
   Katarzyna/0000-0002-5805-8761; Osial, Natalia/0000-0003-2081-5592
CR Alexandrov PN, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00181
   Arruabarrena C, 2021, J CLIN MED, V10, DOI 10.3390/jcm10153281
   Bajan S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010137
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Bhattacharjee S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150211
   Blasiak J, 2019, J CELL MOL MED, V23, P8464, DOI 10.1111/jcmm.14731
   Cai JJ, 2019, EXP CELL RES, V374, P231, DOI 10.1016/j.yexcr.2018.11.028
   Cao DD, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060842
   Chen QY, 2020, CLIN EXP OPHTHALMOL, V48, P682, DOI 10.1111/ceo.13751
   Chen SJ, 2017, CLIN CHIM ACTA, V466, P167, DOI 10.1016/j.cca.2017.01.025
   Elbay A, 2019, SCAND J CLIN LAB INV, V79, P388, DOI 10.1080/00365513.2019.1637931
   ElShelmani H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222212321
   ElShelmani H, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.2.12
   Elshelmani H, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.28
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fuchs HR, 2020, EXP EYE RES, V201, DOI 10.1016/j.exer.2020.108258
   Garcia TY, 2015, INVEST OPHTH VIS SCI, V56, P7480, DOI 10.1167/iovs.15-17251
   Gnanaguru G, 2021, MOL THER, V29, P2281, DOI 10.1016/j.ymthe.2021.03.014
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Guo N, 2019, INT J MED SCI, V16, P513, DOI 10.7150/ijms.29750
   Hyttinen JMT, 2021, AGEING RES REV, V67, DOI 10.1016/j.arr.2021.101260
   Jiang C, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0481-5
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Kaneko H, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.5
   Lian CP, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107791
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Lin JB, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120157
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Liu J, 2019, CLIN EXP PHARMACOL P, V46, P883, DOI 10.1111/1440-1681.13142
   Menard C, 2020, AGING-US, V12, P24836, DOI 10.18632/aging.202404
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Murad N, 2014, FEBS J, V281, P5251, DOI 10.1111/febs.13066
   Natoli R, 2018, ADV EXP MED BIOL, V1074, P37, DOI 10.1007/978-3-319-75402-4_5
   Oltra M, 2020, J CELL MOL MED, V24, P1428, DOI 10.1111/jcmm.14822
   Pogue AI, 2018, CELL MOL NEUROBIOL, V38, P1021, DOI 10.1007/s10571-017-0572-3
   Ragusa M, 2015, CANCER BIOL THER, V16, P1387, DOI 10.1080/15384047.2015.1046021
   Ragusa M, 2013, MOL VIS, V19, P430
   Ren CD, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6666506
   Ren CD, 2017, CELL PHYSIOL BIOCHEM, V41, P1413, DOI 10.1159/000467941
   Roblain Q, 2021, AGING-US, V13, P12359, DOI 10.18632/aging.203035
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Russo A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174297
   Shewmaker F, 2011, J BIOL CHEM, V286, P16533, DOI 10.1074/jbc.R111.227108
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Strafella C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071578
   Tasharrofi N, 2017, J CELL BIOCHEM, V118, P4854, DOI 10.1002/jcb.26160
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Toro MD, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.6.23
   Ulanczyk Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225750
   Wang K, 2016, EUR HEART J, V37, P2602, DOI 10.1093/eurheartj/ehv713
   Wang L, 2016, J PHYSIOL BIOCHEM, V72, P583, DOI 10.1007/s13105-016-0496-2
   Wang L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060895
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu XZ, 2019, FREE RADICAL BIO MED, V143, P387, DOI 10.1016/j.freeradbiomed.2019.08.024
   Yan JZ, 2018, J PHOTOCH PHOTOBIO B, V186, P9, DOI 10.1016/j.jphotobiol.2018.04.005
   Zhang SJ, 2017, INVEST OPHTH VIS SCI, V58, P6500, DOI 10.1167/iovs.17-22698
   Zhou L, 2016, BBA-MOL CELL BIOL L, V1861, P2062, DOI 10.1016/j.bbalip.2016.02.020
   Zhou QB, 2014, MOL THER, V22, P378, DOI 10.1038/mt.2013.243
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 61
TC 0
Z9 0
U1 5
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2022
VL 23
IS 14
AR 7761
DI 10.3390/ijms23147761
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 3H4QB
UT WOS:000832020800001
PM 35887109
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ryu, CL
   Al-Humaid, S
   Rampakakis, E
   Galic, IJ
   Chen, JC
AF Ryu, Christina L.
   Al-Humaid, Sulaiman
   Rampakakis, Emmanouil
   Galic, Ivan J.
   Chen, John C.
TI CORRELATION OF VISUAL ACUITY WITH FIBROTIC SCAR LOCATION IN TREATED
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION EYES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE anti-VEGF; disciform scar; exudative age-related macular degeneration;
   spectral domain optical coherence tomography
ID OCCULT CHOROIDAL NEOVASCULARIZATION; MORPHOLOGY; THERAPY; VEGF
AB Purpose: To determine whether the optical coherence tomography location of a subfoveal fibrovascular scar is correlated with visual outcome in eyes successfully treated with antivascular endothelial growth factor agents for neovascular age-related macular degeneration.
   Methods: Fifty-six eyes from 56 patients with a subfoveal disciform scar after antivascular endothelial growth factor treatment were included. The initial and final visual acuity, fluorescein angiography, and spectral domain optical coherence tomography scar characteristics were retrospectively reviewed.
   Results: Thirty-five of 56 eyes (62.5%) were classified as having entirely subretinal pigment epithelial (sub-RPE) scars, and 21 eyes (37.5%) had subretinal component scars. Mean initial visual acuity was similar between sub-RPE and subretinal scars (20/100 vs. 20/125, P = 0.517); mean final visual acuity was better in the sub-RPE scar group (20/60 vs. 20/200, P = 0.001). Eyes with sub-RPE scar had better preservation of the external limiting membrane, ellipsoid layer, and retinal thickness (P < 0.001, P = 0.017, P = 0.004, respectively) than subretinal component scar eyes. There was no difference between the groups in scar thickness or scar area (P = 0.707, P = 0.186, respectively).
   Conclusion: Sub-RPE location of subfoveal scarring in eyes treated for neovascular age-related macular degeneration is associated with better preservation of outer retinal structures and better vision, when compared with a subretinal scar.
C1 [Ryu, Christina L.; Al-Humaid, Sulaiman; Galic, Ivan J.; Chen, John C.] McGill Univ, Dept Ophthalmol, Montreal, PQ H3A 2T5, Canada.
   [Rampakakis, Emmanouil] JSS Med Res, Sci Affairs, Montreal, PQ, Canada.
C3 McGill University
RP Chen, JC (通讯作者)，McGill Univ, Dept Ophthalmol, 4120 Rue St Catherine Ouest,Suite 200, Westmount, PQ H3Z 1P4, Canada.
EM john.chen@mcgill.ca
OI Rampakakis, Emmanouil/0000-0002-7427-8246
FU Bayer (Canada)
FX The authors would like to thank Bayer (Canada) for providing partial
   funding support for this project with an educational grant.
   Contributions of authors: Design of the study ( C. L. R., S. A., J. C.
   C.), providing patients for the study ( J. C. C., I. J. G.), obtaining
   funding for the study ( I. J. G., J. C. C.), conduct of the study ( C.
   L. R., S. A., J. C. C.), analysis and interpretation of the data ( C. L.
   R., E. R., J. C. C.), preparation of the manuscript ( C. L. R., E. R.,
   J. C. C.), review and approval of the manuscript ( C. L. R., S. A., E.
   R., I. J. G., J. C. C.). The authors would like to thank Dima Kalachi
   for her assistance with data collection.
CR Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   El-Emam S, 2013, RETINA-J RET VIT DIS, V33, P1249, DOI 10.1097/IAE.0b013e31827b6439
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kiernan DF, 2012, RETINA-J RET VIT DIS, V32, P1077, DOI 10.1097/IAE.0b013e31823c23bc
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Liu TYA, 2013, JAMA OPHTHALMOL, V131, P335, DOI 10.1001/jamaophthalmol.2013.818
   Obana Akira, 2008, Nippon Ganka Gakkai Zasshi, V112, P863
   Riusala A, 2005, GRAEF ARCH CLIN EXP, V243, P947, DOI 10.1007/s00417-005-1161-6
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 25
TC 6
Z9 6
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2016
VL 36
IS 7
BP 1324
EP 1330
DI 10.1097/IAE.0000000000000877
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DP6GK
UT WOS:000378595100031
PM 26583310
DA 2022-11-30
ER

PT J
AU DeAngelis, MM
   Owen, LA
   Morrison, MA
   Morgan, DJ
   Li, MY
   Shakoor, A
   Vitale, A
   Iyengar, S
   Stambolian, D
   Kim, IK
   Farrer, LA
AF DeAngelis, Margaret M.
   Owen, Leah A.
   Morrison, Margaux A.
   Morgan, Denise J.
   Li, Mingyao
   Shakoor, Akbar
   Vitale, Albert
   Iyengar, Sudha
   Stambolian, Dwight
   Kim, Ivana K.
   Farrer, Lindsay A.
TI Genetics of age-related macular degeneration (AMD)
SO HUMAN MOLECULAR GENETICS
LA English
DT Review
ID COMPLEMENT FACTOR-H; CLINICALLY SIGNIFICANT ASSOCIATION; VEGF TREATMENT
   RESPONSE; CARDIOVASCULAR-DISEASE; ALZHEIMERS-DISEASE; CHOROIDAL
   NEOVASCULARIZATION; RANIBIZUMAB TREATMENT; GEOGRAPHIC ATROPHY; ARMS2
   GENOTYPES; MOUSE MODELS
AB Age-related macular degeneration (AMD) is a progressive blinding disease and represents the leading cause of visual impairment in the aging population. AMD affects central vision which impairs one's ability to drive, read and recognize faces. There is no cure for this disease and current treatment modalities for the exudative form of the disease require repeated intravitreal injections which may be painful, are incompletely efficacious, and represent a significant treatment burden for both the patient and physician. As such, AMD represents a significant and important clinical problem.
   It is anticipated that in three years' time, 196 million individuals will be affected with AMD. Over 250 billion dollars per year are spent on care for AMD patients in the US. Over half of the heritability is explained by two major loci, thus AMD is considered the most well genetically defined of the complex disorders. A recent GWAS on 43,566 subjects identified novel loci and pathways associated with AMD risk, which has provided an excellent platform for additional functional studies. Genetic variants have been investigated, particularly with respect to anti-VEGF treatment, however to date, no pharmacogenomic associations have been consistently identified across these studies. It may be that if the goal of personalized medicine is to be realized and biomarkers are to have predictive value for determining the magnitude of risk for AMD at the genetic level, one will need to examine the relationships between these pathways across disease state and relative to modifiable risk factors such as hypertension, smoking, body mass index, and hypercholesterolemia. Further studies investigating protective alleles in populations with low AMD prevalence may lead to this goal.
C1 [DeAngelis, Margaret M.; Owen, Leah A.; Morrison, Margaux A.; Morgan, Denise J.; Shakoor, Akbar; Vitale, Albert] Univ Utah, Sch Med, John Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   [DeAngelis, Margaret M.] Univ Utah, Dept Pharmacotherapy, LS Skaggs Sch Pharm, Salt Lake City, UT 84132 USA.
   [Li, Mingyao] Univ Penn, Perelman Sch Med, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA.
   [Iyengar, Sudha] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA.
   [Stambolian, Dwight] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Kim, Ivana K.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA.
   [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; University of Pennsylvania;
   Pennsylvania Medicine; Case Western Reserve University; University of
   Pennsylvania; Pennsylvania Medicine; Harvard University; Harvard Medical
   School; Massachusetts Eye & Ear Infirmary; Boston University; Boston
   University; Boston University; Boston University; Boston University
RP DeAngelis, MM (通讯作者)，Univ Utah, Dept Ophthalmol & Visual Sci, Sch Med, John A Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM margaret.deangelis@utah.edu
RI Farrer, Lindsay/AAS-1035-2020; /S-1190-2019
OI /0000-0001-7488-250X; Farrer, Lindsay/0000-0001-5533-4225; Kim,
   Ivana/0000-0003-0310-6129; Owen, Leah/0000-0003-3802-3868
FU Macular Degeneration Foundation; CARL MARSHALL REEVES & MILDRED ALMEN
   REEVES FOUNDATION, INC.; National Institutes of Health [EY014800];
   Research to Prevent Blindness, Inc., New York, NY; EUNICE KENNEDY
   SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
   [K12HD085852] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [P30EY014800, R01EY023164] Funding Source: NIH RePORTER
FX This research was supported by the Macular Degeneration Foundation; CARL
   MARSHALL REEVES & MILDRED ALMEN REEVES FOUNDATION, INC.; National
   Institutes of Health (EY014800), and an Unrestricted Grant from Research
   to Prevent Blindness, Inc., New York, NY, to the Department of
   Ophthalmology & Visual Sciences, University of Utah.
CR Aging N. I., 2011, ALZH DIS FACT SHEET
   [Anonymous], 2015, AG REL MAC DEG FACTS
   Awh CC, 2015, OPHTHALMOLOGY, V122, pE46, DOI 10.1016/j.ophtha.2014.12.042
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Butler JM, 2015, HUM GENET, V134, P705, DOI 10.1007/s00439-015-1552-7
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14517
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Chew EY, 2017, OPHTHALMOLOGICA, V238, P1, DOI 10.1159/000473865
   Chew EY, 2015, OPHTHALMOLOGY, V122, P2155, DOI 10.1016/j.ophtha.2015.08.007
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Cruz-Gonzalez F, 2014, GRAEF ARCH CLIN EXP, V252, P469, DOI 10.1007/s00417-014-2585-7
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding JD, 2014, ADV EXP MED BIOL, V801, P213, DOI 10.1007/978-1-4614-3209-8_28
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Feehan M, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-83
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gemenetzi M, 2017, OPHTHALMOL THER, V6, P79, DOI 10.1007/s40123-017-0087-5
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Harper AR, 2015, NAT REV GENET, V16, P689, DOI 10.1038/nrg4017
   Hasegawa E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106507
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Morgan DJ, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017210
   Morrison MA, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00238
   Obert E, 2017, J MOL MED, V95, P535, DOI 10.1007/s00109-017-1506-8
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Pennington KL, 2015, J EXP NEUROSCI, V9, P51, DOI 10.4137/JEN.S25513
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Riaz M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37924
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Stefanova NA, 2014, CELL CYCLE, V13, P898, DOI 10.4161/cc.28255
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Veleri S, 2015, DIS MODEL MECH, V8, P109, DOI 10.1242/dmm.017913
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Williams MA, 2014, J ALZHEIMERS DIS, V42, P909, DOI 10.3233/JAD-140243
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yildiz BK, 2016, OPHTHALMIC RES, V56, P132, DOI 10.1159/000446186
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
NR 77
TC 63
Z9 64
U1 1
U2 21
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 1
PY 2017
VL 26
IS R1
BP R45
EP R50
DI 10.1093/hmg/ddx228
PG 6
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA FC4EW
UT WOS:000406792500007
PM 28854576
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Sheybani, A
   Brantley, MA
   Apte, RS
AF Sheybani, Arsham
   Brantley, Milam A., Jr.
   Apte, Rajendra S.
TI Pattern Electroretinography in Age-Related Macular Degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EPIDEMIOLOGY; RANIBIZUMAB; MACULOPATHY; VEGF
AB Objective: To determine whether prolonged vascular endothelial growth factor inhibition is toxic to the retina by using pattern electroretinographic imaging in participants with neovascular age-related macular degeneration (AMD).
   Methods: We performed a prospective, single-arm clinical trial of 17 eyes in 17 treatment-naive participants with subfoveal choroidal neovascularization from AMD. On-label intravitreous ranibizumab was injected monthly for 6 months. Then pattern electroretinographic imaging was performed before and at 1 month, 3 months, and 6 months after first treatment, and results were interpreted by a trained reader masked to the clinical data. The primary outcome measure was the change in pattern electroretinographic imaging (positive wave peaking at 50 milliseconds [P50] and negative wave peaking at 95 milliseconds [N95] values) from baseline at 6 months. The secondary outcome measure was the change in visual acuity at 6 months.
   Results: The mean participant age was 79.6 years (range, 69.5-90.4 years). At baseline, mean (SD) P50 and N95 amplitudes were 1.3 (0.69) mu V and 1.5 (0.71) mu V, respectively. By 6 months, no decrease in P50 or N95 amplitudes from baseline was observed (1.4 [0.47] mu V, P=.46; and 1.8 [0.96] mu V, P=.14, respectively). Mean visual acuity before treatment was 20/85 with improvement to a mean of 20/55 (P=.004) at 6 months.
   Conclusions: This study found no decrease in P50 and N95 amplitudes in participants treated with ranibizumab for neovascular AMD. These findings indicate that vascular endothelial growth factor inhibition with monthly injections of ranibizumab for 6 months likely does not lead to retinal damage.
C1 [Sheybani, Arsham; Brantley, Milam A., Jr.; Apte, Rajendra S.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Brantley, Milam A., Jr.; Apte, Rajendra S.] Barnes Retina Inst, St Louis, MO USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Apte, RS (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,POB 8096, St Louis, MO 63110 USA.
EM apte@vision.wustl.edu
CR Bach Michael, 2000, Documenta Ophthalmologica, V101, P11
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Feigl B, 2007, CLIN OPHTHALMOL, V1, P167
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Holder GE, 2001, PROG RETIN EYE RES, V20, P531, DOI 10.1016/S1350-9462(00)00030-6
   Holder GE, 2007, DOC OPHTHALMOL, V114, P111, DOI 10.1007/s10633-007-9053-1
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Luke M, 2009, BRIT J OPHTHALMOL, V93, P1396, DOI 10.1136/bjo.2009.157511
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Oner A, 2009, DOC OPHTHALMOL, V119, P37, DOI 10.1007/s10633-009-9167-8
   Ozkiris A, 2010, DOC OPHTHALMOL, V120, P243, DOI 10.1007/s10633-010-9219-0
   Pucci S, 2008, PROG BRAIN RES, V173, P555, DOI 10.1016/S0079-6123(08)01138-2
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Shams Naveed, 2006, Ophthalmol Clin North Am, V19, P335
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
NR 19
TC 1
Z9 1
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2011
VL 129
IS 5
BP 580
EP 584
DI 10.1001/archophthalmol.2011.83
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 761XU
UT WOS:000290437100006
PM 21555610
OA Bronze
DA 2022-11-30
ER

PT J
AU Tzoumas, N
   Kavanagh, D
   Cordell, HJ
   Lotery, AJ
   Patel, PJ
   Steel, DH
AF Tzoumas, Nikolaos
   Kavanagh, David
   Cordell, Heather J.
   Lotery, Andrew J.
   Patel, Praveen J.
   Steel, David H.
CA UK Biobank Eye Vision Consortium
TI Rare complement factor I variants associated with reduced macular
   thickness and age-related macular degeneration in the UK Biobank
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; CFI GENE; HIGH-RISK; AMPLIFICATION;
   TOPOGRAPHY; EXPRESSION; MUTATIONS; DENSITY
AB To evaluate potential diagnostic and therapeutic biomarkers for age-related macular degeneration (AMD), we identified 8433 UK Biobank participants with rare complement Factor I gene (CFI) variants, 579 with optical coherence tomography-derived macular thickness data. We stratified these variants by predicted gene expression and measured their association with retinal pigment epithelium-Bruch's membrane (RPE-BM) complex and retinal thicknesses at nine macular subfields, as well as AMD risk, using multivariable regression models adjusted for the common complement Factor H gene (CFH) p.Y402H and age-related maculopathy susceptibility protein 2 gene (ARMS2) p.A69S risk genotypes. CFI variants associated with low Factor I levels predicted a thinner mean RPE-BM (95% confidence interval [CI] -1.66 to -0.37 mu m, P = 0.002) and retina (95% CI -5.88 to -0.13 mu m, P = 0.04) and a higher AMD risk (odds ratio [OR] = 2.26, 95% CI 1.56 to 3.27, P < 0.001). CFI variants associated with normal Factor I levels did not impact mean RPE-BM/retinal thickness (P = 0.28; P = 0.99) or AMD risk (P = 0.97). CFH p.Y402H was associated with a thinner RPE-BM (95% CI -0.31 to -0.18 mu m, P < 0.001 heterozygous; 95% CI -0.62 to -0.42 mu m, P < 0.001 homozygous) and retina (95% CI -0.73 to -0.12 mu m, P = 0.007 heterozygous; 95% CI -1.08 to -0.21 mu m, P = 0.004 homozygous). ARMS2 p.A69S did not influence RPE-BM (P = 0.80 heterozygous; P = 0.12 homozygous) or retinal thickness (P = 0.75 heterozygous; P = 0.07 homozygous). p.Y402H and p.A69S exhibited a significant allele-dose response with AMD risk. Thus, CFI rare variants associated with low Factor I levels are robust predictors of reduced macular thickness and AMD. The observed association between macular thickness and CFH p.Y402H, but not ARMS2 p.A69S, highlights the importance of complement dysregulation in early pathogenesis.
C1 [Tzoumas, Nikolaos; Steel, David H.] Newcastle Univ, Biosci Inst, Newcastle Upon Tyne, Tyne & Wear, England.
   [Tzoumas, Nikolaos; Kavanagh, David] Newcastle Univ, Translat & Clin Res Inst, Complement Therapeut Res Grp, Newcastle Upon Tyne, Tyne & Wear, England.
   [Kavanagh, David] Royal Victoria Infirm, Natl Renal Complement Therapeut Ctr, Newcastle Upon Tyne, Tyne & Wear, England.
   [Cordell, Heather J.] Newcastle Univ, Populat Hlth Sci Inst, Newcastle Upon Tyne, Tyne & Wear, England.
   [Lotery, Andrew J.] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton, Hants, England.
   [Patel, Praveen J.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Patel, Praveen J.] UCL Inst Ophthalmol, London, England.
   [Steel, David H.] Sunderland Eye Infirm, Sunderland, Durham, England.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle
   University - UK; Newcastle University - UK; University of Southampton;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Tzoumas, N (通讯作者)，Newcastle Univ, Int Ctr Life, Biosci Inst, Cent Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
EM nik.tzoumas@ncl.ac.uk
RI Kavanagh, David/E-8498-2011; Steel, David/I-8053-2015
OI Kavanagh, David/0000-0003-4718-0072; Steel, David/0000-0001-8734-3089;
   Tzoumas, Nikolaos/0000-0003-2081-6042; Cordell,
   Heather/0000-0002-1879-5572
CR Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Bienaime F, 2010, KIDNEY INT, V77, P339, DOI 10.1038/ki.2009.472
   Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z
   Chua SYL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55484-1
   Clark SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01778
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de Jong S, 2020, HUM MOL GENET, V29, P2313, DOI 10.1093/hmg/ddaa114
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Farrah TE, 2020, KIDNEY INT, V98, P323, DOI 10.1016/j.kint.2020.01.039
   Fremeaux-Bacchi V, 2013, CLIN J AM SOC NEPHRO, V8, P554, DOI 10.2215/CJN.04760512
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geerlings MJ, 2018, CLIN GENET, V94, P330, DOI 10.1111/cge.13392
   Hallam TM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.18
   Harboe M, 2004, CLIN EXP IMMUNOL, V138, P439, DOI 10.1111/j.1365-2249.2004.02627.x
   Java A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.37
   JONAS JB, 1992, GRAEF ARCH CLIN EXP, V230, P505, DOI 10.1007/BF00181769
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25557-8
   Kavanagh D, 2008, MOL IMMUNOL, V45, P95, DOI 10.1016/j.molimm.2007.05.004
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Ko F, 2017, OPHTHALMOLOGY, V124, P105, DOI 10.1016/j.ophtha.2016.07.033
   Kosmidis I, 2020, STAT COMPUT, V30, P43, DOI 10.1007/s11222-019-09860-6
   Lachmann PJ, 2009, ADV IMMUNOL, V104, P115, DOI 10.1016/S0065-2776(08)04004-2
   Levine AP, 2020, J AM SOC NEPHROL, V31, P365, DOI 10.1681/ASN.2019040433
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   May A, 2021, EXP EYE RES, V210, DOI 10.1016/j.exer.2021.108605
   Mbatchou J, 2021, NAT GENET, V53, P1097, DOI 10.1038/s41588-021-00870-7
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Mukai R, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00015
   Nilsson SC, 2009, EUR J IMMUNOL, V39, P310, DOI 10.1002/eji.200838702
   Pauly D, 2019, CELL REP, V29, P2835, DOI 10.1016/j.celrep.2019.10.084
   Ramon C, 2019, CLIN EXP OPTOM, V102, P601, DOI 10.1111/cxo.12894
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Tan PL, 2017, INVEST OPHTH VIS SCI, V58, P1570, DOI 10.1167/iovs.16-20867
   Tzoumas N, 2021, SURV OPHTHALMOL, V66, P378, DOI 10.1016/j.survophthal.2020.10.008
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Weedon MN, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n214
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wong EKS, 2018, SEMIN IMMUNOPATHOL, V40, P49, DOI 10.1007/s00281-017-0663-8
   Xu XY, 2017, AM J OPHTHALMOL, V175, P87, DOI 10.1016/j.ajo.2016.11.021
   Zhan XW, 2016, BIOINFORMATICS, V32, P1423, DOI 10.1093/bioinformatics/btw079
   Zouache MA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78059-x
NR 50
TC 1
Z9 1
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 23
PY 2022
VL 31
IS 16
BP 2678
EP 2692
DI 10.1093/hmg/ddac060
EA MAR 2022
PG 15
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 3Z2TL
UT WOS:000784542200001
PM 35285476
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Schleicher, M
   Weikel, K
   Garber, C
   Taylor, A
AF Schleicher, Molly
   Weikel, Karen
   Garber, Caren
   Taylor, Allen
TI Diminishing Risk for Age-Related Macular Degeneration with Nutrition: A
   Current View
SO NUTRIENTS
LA English
DT Review
DE AMD; antioxidants; carotenoids; nutrition; glycemic index; aging
ID RETINAL-PIGMENT EPITHELIUM; 3RD NATIONAL-HEALTH; DIETARY GLYCEMIC INDEX;
   FACTOR-H POLYMORPHISM; FATTY-ACIDS; VITAMIN-E; OPTICAL-DENSITY; EYE
   DISEASE; ANTIOXIDANT PARAMETERS; DOCOSAHEXAENOIC ACID
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly. Clinical hallmarks of AMD are observed in one third of the elderly in industrialized countries. Preventative interventions through dietary modification are attractive strategies, because they are more affordable than clinical therapies, do not require specialists for administration and many studies suggest a benefit of micro- and macro-nutrients with respect to AMD with few, if any, adverse effects. The goal of this review is to provide information from recent literature on the value of various nutrients, particularly omega-3 fatty acids, lower glycemic index diets and, perhaps, some carotenoids, with regard to diminishing risk for onset or progression of AMD. Results from the upcoming Age-Related Eye Disease Study (AREDS) II intervention trial should be particularly informative.
C1 [Schleicher, Molly; Garber, Caren; Taylor, Allen] Tufts Univ, JM USDA Human Nutr Res Ctr Aging, Lab Nutr & Vis Res, Boston, MA 02111 USA.
   [Weikel, Karen] Boston Med Ctr, Boston, MA 02118 USA.
C3 Tufts University; United States Department of Agriculture (USDA); Boston
   Medical Center
RP Taylor, A (通讯作者)，Tufts Univ, JM USDA Human Nutr Res Ctr Aging, Lab Nutr & Vis Res, 711 Washington St, Boston, MA 02111 USA.
EM molly.schleicher@tufts.edu; karen.weikel@bmc.org;
   caren.garber@tufts.edu; allen.taylor@tufts.edu
OI Weikel, Karen/0000-0003-0317-7891
FU NATIONAL EYE INSTITUTE [R01EY021212] Funding Source: NIH RePORTER; NEI
   NIH HHS [R01 EY021212] Funding Source: Medline
CR Al-Hussaini H, 2009, EXP EYE RES, V88, P610, DOI 10.1016/j.exer.2008.09.021
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Belda JI, 1999, MECH AGEING DEV, V107, P159, DOI 10.1016/S0047-6374(98)00144-4
   Biarnes M, 2011, OPTOMETRY VISION SCI, V88, P881, DOI 10.1097/OPX.0b013e31821988c1
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Brand-Miller JC, 2002, AM J CLIN NUTR, V76, p281S, DOI 10.1093/ajcn/76.1.281S
   *BRIGHT FOC FDN FA, 2012, FACTS MAC DEG MAC DE
   Bucheli P, 2011, OPTOMETRY VISION SCI, V88, P257, DOI 10.1097/OPX.0b013e318205a18f
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   Chew EY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1678, DOI 10.1001/archophthalmol.2009.312
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2011, NUTR REV, V69, P231, DOI 10.1111/j.1753-4887.2011.00382.x
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Christen WG, 2012, OPHTHALMOLOGY, V119, P1642, DOI 10.1016/j.ophtha.2012.01.053
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Christen WG, 2010, ARCH OPHTHALMOL-CHIC, V128, P1397, DOI 10.1001/archophthalmol.2010.266
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P3452, DOI 10.1167/iovs.10-6713
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Granado F, 2003, BRIT J NUTR, V90, P487, DOI 10.1079/BJN2003927
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Ishihara Nanae, 1997, Nippon Ganka Gakkai Zasshi, V101, P248
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   King JC, 2011, AM J CLIN NUTR, V94, p679S, DOI 10.3945/ajcn.110.005744
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P1203, DOI 10.1016/j.ophtha.2007.09.011
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kuzniarz M, 2002, OPHTHAL EPIDEMIOL, V9, P283, DOI 10.1076/opep.9.4.283.1511
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Loughman J, 2012, INVEST OPHTH VIS SCI, V53, P7871, DOI 10.1167/iovs.12-10690
   Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Maiani G, 2009, MOL NUTR FOOD RES, V53, pS194, DOI 10.1002/mnfr.200800053
   Mance TC, 2011, COLLEGIUM ANTROPOL, V35, P307
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Meyer BJ, 2003, LIPIDS, V38, P391, DOI 10.1007/s11745-003-1074-0
   Michikawa T, 2009, ASIA PAC J CLIN NUTR, V18, P1
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   Morris MS, 2007, OPHTHAL EPIDEMIOL, V14, P288, DOI 10.1080/09286580601186759
   *NATL EYE I, 2010, N I H FACTS AG REL M
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Pilkington SM, 2011, EXP DERMATOL, V20, P537, DOI 10.1111/j.1600-0625.2011.01294.x
   Richer S, 1996, J Am Optom Assoc, V67, P30
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2012, AM J CLIN NUTR, V96, p1223S, DOI 10.3945/ajcn.112.038240
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   Schweigert FJ, 2011, KLIN MONATSBL AUGENH, V228, P537, DOI 10.1055/s-0029-1245527
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2010, MOL VIS, V16, P2412
   SHAKIB M, 1973, International Ophthalmology Clinics, V13, P189, DOI 10.1097/00004397-197301330-00015
   Shen XL, 2012, J NUTR HEALTH AGING, V16, P201, DOI 10.1007/s12603-011-0350-8
   Simonelli F, 2002, CLIN CHIM ACTA, V320, P111, DOI 10.1016/S0009-8981(02)00056-6
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SOUIED EH, 2013, OPHTHALMOLOGY, V7, P7
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Sung CH, 2010, J CELL BIOL, V190, P953, DOI 10.1083/jcb.201006020
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   TREMPE CL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1517, DOI 10.1001/archopht.1992.01080230015002
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Weikel KA, 2012, INVEST OPHTH VIS SCI, V53, P622, DOI 10.1167/iovs.11-8545
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   YUZBASIYANGURKAN V, 1989, ARCH OPHTHALMOL-CHIC, V107, P1723, DOI 10.1001/archopht.1989.01070020805004
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zeimer M, 2009, OPHTHALMOLOGE, V106, P29, DOI 10.1007/s00347-008-1773-4
NR 137
TC 30
Z9 31
U1 2
U2 25
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JUL
PY 2013
VL 5
IS 7
BP 2405
EP 2456
DI 10.3390/nu5072405
PG 52
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 274TD
UT WOS:000328628200009
PM 23820727
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Chen, XY
   Jhanji, V
   Chen, CP
   Chen, HY
AF Chen, Xueyu
   Jhanji, Vishal
   Chen, Chupeng
   Chen, Haoyu
TI Serological Association of Chlamydia pneumoniae Infection with
   Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID NEOVASCULAR MEMBRANES; INFLAMMATION; EXPOSURE; HETEROGENEITY;
   POLYMORPHISMS; PATHOGENESIS; PROGRESSION; GENE; AMD
AB Background: We investigated the serological association of Chlamydia pneumoniae infection with age-related macular degeneration (AMD).
   Methods: A systematic review and meta-analysis was performed. PubMed, Embase, Web of Science and the Association of Research in Vision and Ophthalmology abstracts were searched to identify studies investigating the serological association of Chlamydia pneumoniae infection with age-related macular degeneration. The quality of original studies was assessed using the Newcastle-Ottawa scale. Heterogeneity was explored with meta-regression. The odds ratios (ORs) and standardized mean differences (SMD) of Chlamydia pneumoniae infection between AMD patients and controls were pooled.
   Results: In total, 9 studies met the inclusion criteria using the Newcastle-Ottawa scale scores ranging from 4 to 9. There was heterogeneity among studies due to a difference in the study designs and measurement of exposure to Chlamydia pneumoniae infection. The overall OR of Chlamydia pneumoniae infection with AMD was 1.11 (95% confidence interval: 0.78-1.57, P = 0.56). The overall SMD of antibody titer between AMD and control was 0.43 (95% confidence interval: -0.12 to 0.99, P = 0.13).
   Conclusions: Evidence from the current published literature suggested no statistically significant association between Chlamydia pneumoniae infection and AMD.
C1 [Chen, Xueyu; Chen, Chupeng] Sun Yat Sen Univ Shantou, Affiliated Shantou Hosp, Shantou Cent Hosp, Dept Emergency Med, Shantou, Peoples R China.
   [Jhanji, Vishal; Chen, Haoyu] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Jhanji, Vishal; Chen, Haoyu] Shantou Univ, Joint Shantou Int Eye Ctr, Shantou, Peoples R China.
   [Jhanji, Vishal; Chen, Haoyu] Chinese Univ Hong Kong, Shantou, Peoples R China.
   [Jhanji, Vishal] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 Sun Yat Sen University; Chinese University of Hong Kong; Shantou
   University; Centre for Eye Research Australia; University of Melbourne
RP Chen, CP (通讯作者)，Sun Yat Sen Univ Shantou, Affiliated Shantou Hosp, Shantou Cent Hosp, Dept Emergency Med, Shantou, Peoples R China.
EM 13923998922@139.com; drchenhaoyu@gmail.com
RI Chu, Kai On/E-2325-2016; Jhanji, Vishal/I-5676-2014; Chen,
   Haoyu/A-7432-2013
OI Chen, Haoyu/0000-0003-0676-4610
FU National Nature Science Foundation of China [30901646, 81170853];
   Guangdong Science and Technology Project [2011B031300013]
FX This study was supported by the National Nature Science Foundation of
   China (30901646 and 81170853) and Guangdong Science and Technology
   Project (2011B031300013). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Blasi F., 1998, Clin Microbiol Infect, V4 Suppl 4, pS1
   Carter JD, 2010, CURR OPIN RHEUMATOL, V22, P424, DOI 10.1097/BOR.0b013e32833a43a2
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Deeks J J, 2003, Health Technol Assess, V7, piii
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fujimoto T, 2010, INVEST OPHTH VIS SCI, V51, P4694, DOI 10.1167/iovs.09-4464
   Guymer R, 2007, CLIN EXP OPHTHALMOL, V35, P89, DOI 10.1111/j.1442-9071.2006.01392.x
   Haas P, 2009, EYE, V23, P2228, DOI 10.1038/eye.2008.422
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Ishida Osamu, 2005, Bulletin of the Osaka Medical College, V51, P17
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kalayoglu MV, 2007, CLIN EXP OPHTHALMOL, V35, P3, DOI 10.1111/j.1442-9071.2007.01432.x
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kessler W, 2006, ACTA OPHTHALMOL SCAN, V84, P333, DOI 10.1111/j.1600-0420.2005.00591.x
   Khandhadia S, 2012, MOL VIS, V18, P29
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Robman L, 2007, INVEST OPHTH VIS SCI, V48, P4007, DOI 10.1167/iovs.06-1434
   Shen D, 2009, BRIT J OPHTHALMOL, V93, P405, DOI 10.1136/bjo.2008.145383
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
   THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351
   Turgut Burak, 2010, J Clin Med Res, V2, P85, DOI 10.4021/jocmr2010.03.282w
   Watson C, 2008, CLIN SCI, V114, P509, DOI 10.1042/CS20070298
   Wells GA., NEWCASTLE OTTAWA SCA
   Wolf-Schnurrbusch Ute E K, 2013, Ocul Immunol Inflamm, V21, P36, DOI 10.3109/09273948.2012.726393
NR 36
TC 3
Z9 3
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 25
PY 2014
VL 9
IS 7
AR e103466
DI 10.1371/journal.pone.0103466
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AM6RP
UT WOS:000339992600072
PM 25062085
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cozzi, M
   Monteduro, D
   Parrulli, S
   Ristoldo, F
   Corvi, F
   Zicarelli, F
   Staurenghi, G
   Invernizzi, A
AF Cozzi, Mariano
   Monteduro, Davide
   Parrulli, Salvatore
   Ristoldo, Federica
   Corvi, Federico
   Zicarelli, Federico
   Staurenghi, Giovanni
   Invernizzi, Alessandro
TI Prechoroidal cleft thickness correlates with disease activity in
   neovascular age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Prechoroidal cleft; Pigment epithelial detachment; Neovascular
   age-related macular degeneration; Macular neovascularization; Optical
   coherence tomography; Exudation
ID PIGMENT EPITHELIAL DETACHMENT; RANIBIZUMAB; THERAPY
AB Purpose The purpose of this study was to investigate the structural variations of the hyporeflective pocket of fluid (prechoroidal cleft) located between Bruch's membrane and the hyperreflective material within the pigment epithelial detachment (PED) in patients with neovascular age-related macular degeneration (nAMD).
   Methods In this retrospective, observational case series study, patients diagnosed with nAMD and prechoroidal cleft associated with other activity signs of the macular neovascularization (MNV) were included. Structural optical coherence tomography (OCT) scans were evaluated to obtain anatomical measurements of prechoroidal cleft and PED at three different visits (T0, inactive MNV; T1, active MNV; T2, treated inactive MNV). The variations in size of the cleft and the PED were correlated with nAMD activity.
   Results Twenty-nine eyes from 27 patients were included. The subfoveal measurements showed a significant increase of prechoroidal cleft height and width from T0 to T1 (P < 0.05) and a subsequent decrease of the cleft height after treatment with anti-VEGF agents (P = 0.004). A similar significant trend was observed for the greatest prechoroidal cleft height and width, obtained assessing the whole OCT raster. In the multivariate analysis, the cleft height was significantly affected by both time (P = 0.001) and PED height (P < 0.0001). By contrast, the effect of fibrovascular tissue size within the PED was not significant. Visual acuity did not correlate with prechoroidal cleft size.
   Conclusion Prechoroidal cleft increased in association with MNV reactivation and decreased after treatment. Our results suggest that prechoroidal cleft could represent an accumulation of fluid actively exudating from the MNV and should be considered a sign of nAMD activity.
C1 [Cozzi, Mariano; Monteduro, Davide; Parrulli, Salvatore; Ristoldo, Federica; Corvi, Federico; Zicarelli, Federico; Staurenghi, Giovanni; Invernizzi, Alessandro] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Via GB Grassi 74, I-20157 Milan, Italy.
   [Invernizzi, Alessandro] Univ Sydney, Save Sight Inst, Fac Hlth & Med, Sydney, NSW, Australia.
C3 University of Milan; Luigi Sacco Hospital; University of Sydney
RP Invernizzi, A (通讯作者)，Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Via GB Grassi 74, I-20157 Milan, Italy.; Invernizzi, A (通讯作者)，Univ Sydney, Save Sight Inst, Fac Hlth & Med, Sydney, NSW, Australia.
EM alessandro.invernizzi@gmail.com
OI Cozzi, Mariano/0000-0001-7777-2461; Corvi, Federico/0000-0002-2661-5500
FU Universita degli Studi di Milano within the CRUI-CARE Agreement
FX Open access funding provided by Universita degli Studi di Milano within
   the CRUI-CARE Agreement.
CR Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2021, EYE, V35, P2983, DOI 10.1038/s41433-020-01354-4
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   He LM, 2016, RETINA-J RET VIT DIS, V36, P492, DOI 10.1097/IAE.0000000000000749
   Invernizzi A, 2018, INVEST OPHTH VIS SCI, V59, P3836, DOI 10.1167/iovs.18-23960
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Khurana RN, 2019, AM J OPHTHALMOL, V200, P161, DOI 10.1016/j.ajo.2019.01.005
   Kim JH, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/2578349
   Kim JM, 2017, RETINA-J RET VIT DIS, V37, P2047, DOI 10.1097/IAE.0000000000001435
   Kumar JB, 2020, RETINA-J RET VIT DIS, V40, P845, DOI 10.1097/IAE.0000000000002552
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Mukai R, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-159
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P1735, DOI 10.1097/IAE.0000000000000553
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sanchez-Monroy J., 2020, RETINA PUBLISH, DOI [10.1097/IAE.0000000000003061, DOI 10.1097/IAE.0000000000003061]
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Singh SR, 2020, SURV OPHTHALMOL, V65, P451, DOI 10.1016/j.survophthal.2020.01.001
   Souied EH, 2020, AM J OPHTHALMOL, V214, P151, DOI 10.1016/j.ajo.2020.02.016
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
NR 30
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2022
VL 260
IS 3
BP 781
EP 789
DI 10.1007/s00417-021-05384-w
EA SEP 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZB5IP
UT WOS:000693509000002
PM 34491426
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Kenmochi, J
   Ito, Y
   Terasaki, H
AF Kenmochi, Junya
   Ito, Yasuki
   Terasaki, Hiroko
TI CHANGES OF OUTER RETINAL THICKNESS WITH INCREASING AGE IN NORMAL EYES
   AND IN NORMAL FELLOW EYES OF PATIENTS WITH UNILATERAL AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; aging; Bruch membrane; cone sheath;
   photoreceptor inner segment; photoreceptor outer segment; retinal
   pigment epithelium; spectral domain optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; SEGMENT TIPS LINE; PIGMENT-EPITHELIUM;
   CONE PHOTORECEPTORS; VISUAL-ACUITY; HIGH-SPEED; HOLE; MEMBRANE; SURGERY;
   REGION
AB Purpose: To test the hypothesis that the thickness of outer retinal layers will change with increasing age in normal eyes and in the normal fellow eyes of patients with unilateral age-related macular degeneration.
   Methods: Spectral domain optical coherence tomography images of 127 normal eyes of 127 subjects and 58 normal fellow eyes of 58 patients with unilateral age-related macular degeneration were studied. The thickness between the retinal pigment epithelium line and the cone outer segment tips line, between the cone outer segment tips line and the photoreceptor inner segment/outer segment line, and between the inner segment/outer segment line and the external limiting membrane line were measured at the fovea in both groups.
   Results: The thickness between retinal pigment epithelium line and the cone outer segment tips line, and between inner segment/outer segment line and the external limiting membrane line were significantly and negatively associated with age in the normal group. Cone outer segment tips line and the photoreceptor inner segment/outer segment thickness was not significantly associated with age. Retinal pigment epithelium line and the cone outer segment tips line was thinner in the fellow eyes of patients with unilateral age-related macular degeneration than in the age-matched normal eyes. Cone outer segment tips line and the photoreceptor inner segment/outer segment and inner segment/outer segment line and the external limiting membrane line thicknesses in the fellow eyes were not significantly different from that of normal eyes.
   Conclusion: The tissue between the retinal pigment epithelium line and the cone outer segment tips line may become atrophic in older eyes and in the normal fellow eyes of patients with unilateral age-related macular degeneration.
C1 [Kenmochi, Junya; Ito, Yasuki; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi, Japan.
C3 Nagoya University
RP Ito, Y (通讯作者)，Nagoya Univ, Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.
EM yasu@med.nagoya-u.ac.jp
RI Ito, Yasuki/M-4876-2014
OI Ito, Yasuki/0000-0001-9219-9261
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [C25462710]
FX Supported by Grant-in Aid for Scientific Research from the Ministry of
   Education, Culture, Sports, Science, and Technology of Japan (Y.I.,
   C25462710).
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   FRIEDMAN E, 1968, ARCH OPHTHALMOL-CHIC, V79, P315, DOI 10.1001/archopht.1968.03850040317017
   Fujita K, 2012, AM J OPHTHALMOL, V154, P579, DOI 10.1016/j.ajo.2012.03.043
   HOLLYFIELD JG, 1989, RETINA-J RET VIT DIS, V9, P59, DOI 10.1097/00006982-198909010-00008
   Itoh Y, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.023
   Itoh Y, 2012, AM J OPHTHALMOL, V153, P111, DOI 10.1016/j.ajo.2011.05.039
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MIYAKE Y, 1989, INVEST OPHTH VIS SCI, V30, P1743
   Morgan JIW, 2009, INVEST OPHTH VIS SCI, V50, P1350, DOI 10.1167/iovs.08-2618
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rii T, 2012, AM J OPHTHALMOL, V153, P524, DOI 10.1016/j.ajo.2011.08.021
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Shimozono M, 2012, AM J OPHTHALMOL, V153, P698, DOI 10.1016/j.ajo.2011.09.011
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P1571, DOI 10.1167/iovs.07-0838
   STEINBERG RH, 1977, PHILOS T ROY SOC B, V277, P459, DOI 10.1098/rstb.1977.0028
   STREETEN BW, 1969, ARCH OPHTHALMOL-CHIC, V81, P383
   Takahashi A, 2011, RETINA-J RET VIT DIS, V31, P127, DOI 10.1097/IAE.0b013e3181e7997b
   Tsunoda K, 2011, ARCH OPHTHALMOL-CHIC, V129, P1099, DOI 10.1001/archophthalmol.2011.217
   Zhang Y, 2006, OPT EXPRESS, V14, P4380, DOI 10.1364/OE.14.004380
NR 21
TC 12
Z9 13
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2017
VL 37
IS 1
BP 47
EP 52
DI 10.1097/IAE.0000000000001131
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EH7JF
UT WOS:000391948300007
PM 27347643
DA 2022-11-30
ER

PT J
AU Tarita-Nistor, L
   Gonzalez, EG
   Markowitz, SN
   Steinbach, MJ
AF Tarita-Nistor, L
   Gonzalez, EG
   Markowitz, SN
   Steinbach, MJ
TI Binocular function in patients with age-related macular degeneration: a
   review
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID VISUAL-ACUITY; CONTRAST SENSITIVITY; PERIPHERAL FIELD; FACE RECOGNITION;
   OLDER PATIENTS; SUMMATION; VISION; INHIBITION; RIVALRY; PERFORMANCE
AB Normally sighted observers typically benefit from binocular viewing when monocular sensitivities are equivalent. Age-related macular degeneration (AMD) not only destroys the foveal vision, however, but it also affects the 2 eyes unequally, providing grounds for impairment of binocular function. The aim of the present article is to provide a review of the current research on the effect of AMD on binocular vision. The main findings to date reveal that a high proportion of patients show characteristics of binocular contrast inhibition at low and medium spatial frequencies. Yet binocular acuity gain is not different from that of age-matched control participants without AMD. Additional findings show that rivalry processes are severely disrupted in patients with AMD. The effects of the disease on other binocular functions have yet to be explored. Knowledge of binocular function in AMD may one day help clinicians decide on the most appropriate management and rehabilitation techniques.
C1 Toronto Western Hosp, Vis Sci Res Program, Toronto, ON M5T 2S8, Canada.
   York Univ, Ctr Vis Res, Toronto, ON M3J 2R7, Canada.
   Univ Toronto, Dept Ophthalmol, Toronto, ON M5S 1A1, Canada.
C3 University of Toronto; University Toronto Affiliates; University Health
   Network Toronto; York University - Canada; University of Toronto
RP Tarita-Nistor, L (通讯作者)，Toronto Western Hosp, Vis Sci Res Program, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.
EM lumi.tarita-nistor@rogers.com
CR Azen SP, 2002, INVEST OPHTH VIS SCI, V43, P1742
   BLAKE R, 1973, PERCEPT PSYCHOPHYS, V14, P161, DOI 10.3758/BF03198631
   BLAKE R, 1992, VISUAL NEUROSCI, V8, P469, DOI 10.1017/S0952523800004971
   Blake R, 2002, NAT REV NEUROSCI, V3, P13, DOI 10.1038/nrn701
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   CAGENELLO R, 1993, J OPT SOC AM A, V10, P1841, DOI 10.1364/JOSAA.10.001841
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DEBELSUNCE S, 1991, INVEST OPHTH VIS SCI, V32, P2645
   EDWARDS MG, 1999, OPHTHALMOLOGY
   ELLIOTT DB, 1995, OPHTHAL PHYSL OPT, V15, P553, DOI 10.1016/0275-5408(95)00025-9
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Faubert J, 2000, J AM GERIATR SOC, V48, P375, DOI 10.1111/j.1532-5415.2000.tb04693.x
   Gagnon RWC, 2003, CURR EYE RES, V27, P315, DOI 10.1076/ceyr.27.5.315.17225
   Gonzalez EG., 2004, U HLTH NETW RES DAY
   HARRIS MJ, 1985, OPHTHALMOLOGY, V92, P1550
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   HERAVIAN JS, 1990, OPHTHAL PHYSL OPT, V10, P257, DOI 10.1111/j.1475-1313.1990.tb00861.x
   HOME R, 1978, VISION RES, V18, P579, DOI 10.1016/0042-6989(78)90206-7
   HOROWITZ MW, 1949, J EXP PSYCHOL, V39, P581, DOI 10.1037/h0056892
   HOWARD JP, 2002, SEEING DEPTH, V1, P319
   LEVELT WJM, 1996, BRIT J PSYCHOL, V57, P225
   Logothetis NK, 1996, NATURE, V380, P621, DOI 10.1038/380621a0
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pardhan S, 2003, CURR EYE RES, V26, P297, DOI 10.1076/ceyr.26.4.297.15430
   PARDHAN S, 1990, OPTOMETRY VISION SCI, V67, P688, DOI 10.1097/00006324-199009000-00006
   Pardhan S, 1997, CURR EYE RES, V16, P252, DOI 10.1076/ceyr.16.3.252.15407
   Pardhan S, 1996, CURR EYE RES, V15, P315, DOI 10.3109/02713689609007626
   Pardhan S, 2000, CURR EYE RES, V20, P35, DOI 10.1076/0271-3683(200001)20:1;1-H;FT035
   Quillen DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1725
   ROSS JE, 1985, BRIT J OPHTHALMOL, V69, P51, DOI 10.1136/bjo.69.1.51
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Tarita-Nistor L, 2006, VISION RES, V46, P2487, DOI 10.1016/j.visres.2006.01.035
   TAYLOR R H, 1991, Eye (London), V5, P704
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Ukai K, 2003, PERCEPT MOTOR SKILL, V97, P393, DOI 10.2466/pms.2003.97.2.393
   Valberg A, 2002, J OPT SOC AM A, V19, P223, DOI 10.1364/JOSAA.19.000223
NR 37
TC 13
Z9 13
U1 0
U2 5
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2006
VL 41
IS 3
BP 327
EP 332
DI 10.1139/I06-029
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 054AX
UT WOS:000238348900006
PM 16767188
DA 2022-11-30
ER

PT J
AU Klein, R
   Myers, CE
   Cruickshanks, KJ
   Gangnon, RE
   Danforth, LG
   Sivakumaran, TA
   Iyengar, SK
   Tsai, MY
   Klein, BEK
AF Klein, Ronald
   Myers, Chelsea E.
   Cruickshanks, Karen J.
   Gangnon, Ronald E.
   Danforth, Lorraine G.
   Sivakumaran, Theru A.
   Iyengar, Sudha K.
   Tsai, Michael Y.
   Klein, Barbara E. K.
TI Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction
   and the 20-Year Cumulative Incidence of Early Age-Related Macular
   Degeneration The Beaver Dam Eye Study
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; RETINAL-PIGMENT EPITHELIUM;
   VISUAL-ACUITY; CHOROIDAL NEOVASCULARIZATION; CARDIOVASCULAR-DISEASE;
   ATHEROSCLEROSIS RISK; LIPID-PEROXIDATION; UNITED-STATES; MACULOPATHY
AB IMPORTANCE Modifying levels of factors associated with age-related macular degeneration (AMD) may decrease the risk for visual impairment in older persons.
   OBJECTIVE To examine the relationships of markers of inflammation, oxidative stress, and endothelial dysfunction to the 20-year cumulative incidence of early AMD.
   DESIGN, SETTING, AND PARTICIPANTS This longitudinal population-based cohort study involved a random sample of 975 persons in the Beaver Dam Eye Study without signs of AMD who participated in the baseline examination in 1988-1990 and up to 4 follow-up examinations in 1993-1995,1998-2000, 2003-2005, and 2008-2010.
   EXPOSURES Serum markers of inflammation (high-sensitivity C-reactive protein, tumor necrosis factor-a receptor 2, interleukin-6, and white blood cell count), oxidative stress (8-isoprostane and total carbonyl content), and endothelial dysfunction (soluble vascular cell adhesion molecule-1 and soluble intercellular adhesion molecule-i) were measured. Interactions with complement factor H (rs1061170), age-related maculopathy susceptibility 2 (rs10490924), complement component 3 (rs2230199), and complement component 2/complement factor B (rs4151667) were examined using multiplicative models. Age-related macular degeneration was assessed from fundus photographs.
   MAIN OUTCOMES AND MEASURES Early AMD defined by the presence of any size drusen and the presence of pigmentary abnormalities or by the presence of large-sized drusen (> 125-pm diameter) in the absence of late AMD.
   RESULTS The 20-year cumulative incidence of early AMD was 23.0%. Adjusting for age, sex, and other risk factors, high-sensitivity C-reactive protein (odds ratio comparing fourth with first quartile, 2.18; P =.005), tumor necrosis factor-a receptor 2 (odds ratio, 1.78; P =.04), and interleukin-6 (odds ratio, 1.78; P =.03) were associated with the incidence of early AMD. Increased incidence of early AMD was associated with soluble vascular cell adhesion molecule-1 (odds ratio per SD on the logarithmic scale, 1.21; P =.04).
   CONCLUSIONS AND RELEVANCE We found modest evidence of relationships of serum high-sensitivity C-reactive protein, tumor necrosis factor-a receptor 2, interleukin-6, and soluble vascular cell adhesion molecule-1 to the 20-year cumulative incidence of early AMD independent of age, smoking status, and other factors. It is not known whether these associations represent a cause and effect relationship or whether other unknown confounders accounted for the findings. Even if inflammatory processes are a cause of early AMD, it is not known whether interventions that reduce systemic inflammatory processes will reduce the incidence of early AMD.
C1 [Klein, Ronald; Myers, Chelsea E.; Cruickshanks, Karen J.; Danforth, Lorraine G.; Klein, Barbara E. K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [Klein, Ronald; Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53726 USA.
   [Cruickshanks, Karen J.; Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA.
   [Sivakumaran, Theru A.; Iyengar, Sudha K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Sivakumaran, Theru A.; Iyengar, Sudha K.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
   [Sivakumaran, Theru A.; Iyengar, Sudha K.] Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA.
   [Sivakumaran, Theru A.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA.
   [Tsai, Michael Y.] Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison; Case
   Western Reserve University; Case Western Reserve University; Case
   Western Reserve University; Cincinnati Children's Hospital Medical
   Center; University of Minnesota System; University of Minnesota Twin
   Cities
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, WARF, 610 N Walnut St,4th Fl, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI /S-1190-2019
OI /0000-0001-7488-250X; Tsai, Michael/0000-0001-7553-3408; Gangnon,
   Ronald/0000-0003-2587-6714
FU National Institutes of Health [EY06594]; National Institute on Aging
   [AG11099]; National Institute of Diabetes and Digestive and Kidney
   Diseases [DK073217]; National Institutes of Health; National Eye
   Institute and National Institute of Diabetes and Digestive and Kidney
   Diseases; Research to Prevent Blindness, New York, New York; NATIONAL
   EYE INSTITUTE [U10EY006594] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073217]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011099,
   R37AG011099] Funding Source: NIH RePORTER
FX This study was supported by National Institutes of Health grant EY06594
   (Drs B. E. K. Klein and R. Klein), National Institute on Aging grant
   AG11099 (Dr Cruickshanks), and National Institute of Diabetes and
   Digestive and Kidney Diseases grant DK073217, National Institutes of
   Health, as well as, in part, by Research to Prevent Blindness, New York,
   New York. The National Eye Institute and National Institute of Diabetes
   and Digestive and Kidney Diseases provided funding for this study
   including collection and analyses of data; Research to Prevent Blindness
   provided additional support for data analyses.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], [No title captured]
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Black RA, 2003, BIOCHEM SOC SYMP, V70, P39, DOI 10.1042/bss0700039
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Boey PY, 2010, INVEST OPHTH VIS SCI, V51, P1880, DOI 10.1167/iovs.09-4063
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P460, DOI 10.1016/j.ajo.2011.08.033
   Burger D, 2012, J AM SOC HYPERTENS, V6, P85, DOI 10.1016/j.jash.2011.11.003
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cai X, 2012, FRONT BIOSCI-LANDMRK, V17, P1976, DOI 10.2741/4033
   Chambless LE, 2003, J CLIN EPIDEMIOL, V56, P880, DOI 10.1016/S0895-4356(03)00055-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Davies MJ, 1999, FREE RADICAL BIO MED, V27, P1151, DOI 10.1016/S0891-5849(99)00206-3
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318
   Ferris FL, 2004, ARCH OPHTHALMOL-CHIC, V122, P451, DOI 10.1001/archopht.122.4.451
   Fessel JP, 2005, ANTIOXID REDOX SIGN, V7, P202, DOI 10.1089/ars.2005.7.202
   Folsom AR, 2006, ARCH INTERN MED, V166, P1368, DOI 10.1001/archinte.166.13.1368
   Fontes JD, 2013, ATHEROSCLEROSIS, V228, P217, DOI 10.1016/j.atherosclerosis.2013.01.019
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handelman GJ, 2000, BLOOD PURIFICAT, V18, P343, DOI 10.1159/000014460
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Hosmer DW, 1989, APPL LOGISTIC REGRES, P238
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein BE, 2010, BEAVER DAM EYE STUDY
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2005, MACULAR DEGENERATION, P79
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, OPHTHALMIC IN PRESS
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nash SD, 2013, J AM GERIATR SOC, V61, P1269, DOI 10.1111/jgs.12382
   Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Perkins SJ, 2012, IMMUNOBIOLOGY, V217, P281, DOI 10.1016/j.imbio.2011.10.003
   Pow DV, 2005, MACULAR DEGENERATION, P123, DOI 10.1007/3-540-26977-0_8
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Scholl HPN, 2007, MOL VIS, V13, P196
   Schwedhelm E, 2003, CLIN CHEM LAB MED, V41, P1552, DOI 10.1515/CCLM.2003.238
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Sies H, 1997, EXP PHYSIOL, V82, P291, DOI 10.1113/expphysiol.1997.sp004024
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Tsao YP, 2006, LIFE SCI, V79, P545, DOI 10.1016/j.lfs.2006.01.041
   Wu TY, 2004, CANCER EPIDEM BIOMAR, V13, P1399
NR 78
TC 99
Z9 101
U1 0
U2 19
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD APR
PY 2014
VL 132
IS 4
BP 446
EP 455
DI 10.1001/jamaophthalmol.2013.7671
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ7QF
UT WOS:000337890500011
PM 24481424
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Swanson, MW
AF Swanson, Mark W.
TI Smoking Deception and Age-Related Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE cotinine; nicotine; macular degeneration; smoking deception; self-report
ID SELF-REPORTED SMOKING; UNITED-STATES; VALIDITY; PREVALENCE; POPULATION;
   NONSMOKERS; NICOTINE; SMOKERS
AB Purpose. Smoking has been identified as a major modifiable risk factor for age-related macular degeneration (AMD). Smoking deception or failing to self-report as a smoker is a recognized concern among studies of smoking-related disease. To date, no studies have evaluated the rates of smoking deception in macular degeneration.
   Methods. Data from the 2005 to 2008 National Health and Nutrition Examination Survey were used to produce estimates of smoking deception among three ethnic groups within the US population. Comparisons of self-reported rates of cigarette use, any nicotine product use, and serum cotinine levels were used to produce estimates of potential smoking deception among adults older than 40 years with any-level macular degeneration and those at risk of late-stage disease.
   Results. Any-level AMD was found to be present in 6.7% (95% confidence interval [CI] = 5.6% to 7.8%) of this cohort. Excluding those with late AMD, 9.7% (95% CI = 8.3% to 11.0%) were at risk of developing late-stage disease. Among individuals with any level of macular degeneration, 5.4% (95% CI = 2.1% to 8.6%) were potential smoking deceivers. A similar rate was seen among those at risk of late-stage disease at 5.0% (95% CI = 2.3% to 7.6%).
   Conclusions. The rate of possible smoking deception seems higher for macular degeneration and those at risk of late-stage AMD than is generally reported in the US population. While the deception rate is low at the individual level, as many as 450,000 adults in the US population at risk of late-stage AMD may misclassify their smoking status.
C1 [Swanson, Mark W.] Univ Alabama Birmingham, Sch Optometry, Dept Optometry, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham
RP Swanson, MW (通讯作者)，Univ Alabama Birmingham, Sch Optometry, 1716 Univ Blvd, Birmingham, AL 35294 USA.
EM mswanson@uab.edu
CR AGUINIS H, 1993, J APPL SOC PSYCHOL, V23, P352, DOI 10.1111/j.1559-1816.1993.tb01092.x
   Benowitz NL, 2009, AM J EPIDEMIOL, V169, P236, DOI 10.1093/aje/kwn301
   BENOWITZ NL, 1993, CLIN PHARMACOL THER, V53, P316, DOI 10.1038/clpt.1993.27
   Centers for Medicare & Medicaid Services, 2014, 2014 PHYS QUAL REP S
   Ford RPK, 1997, J EPIDEMIOL COMMUN H, V51, P246, DOI 10.1136/jech.51.3.246
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Garrett BE, 2013, MMWR-MORBID MORTAL W, V62, P81
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   JARVIS M, 1984, J EPIDEMIOL COMMUN H, V38, P335, DOI 10.1136/jech.38.4.335
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein JD, 2007, MED CARE, V45, P691, DOI 10.1097/MLR.0b013e3180326145
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   National Health and Nutrition Examination Survey, 2007, 2007 2008 DAT DOC CO
   Parna K, 2005, MATERN CHILD HLTH J, V9, P385, DOI 10.1007/s10995-005-0022-6
   Pell JP, 2008, NICOTINE TOB RES, V10, P861, DOI 10.1080/14622200802023858
   The National Health and Nutrition Examination Survey, OPHTH PROC MAN
   Tynan Michael A., 2012, Morbidity and Mortality Weekly Report, V61, P565
   *US DEP HHS, 2005, NAT HLTH NUTR EX SUR
   US Department of Health and Human Services. Agency for Healthcare Research and Quality, CLIN CAR GUID TREAT
   US Surgeon General, 1988, HLTH CONS SMOK NIC A
   Yeager DS, 2010, MED CARE, V48, P1128, DOI 10.1097/MLR.0b013e3181ef9948
NR 22
TC 7
Z9 7
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 865
EP 871
DI 10.1097/OPX.0000000000000315
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500009
PM 24978870
DA 2022-11-30
ER

PT J
AU Nitoda, E
   Koutsilieris, M
   Brouzas, D
   Koutsandrea, C
   Philippou, A
   Ladas, D
   Moschos, MM
AF Nitoda, Eirini
   Koutsilieris, Michael
   Brouzas, Dimitrios
   Koutsandrea, Chryssanthi
   Philippou, Anastasios
   Ladas, Dimitrios
   Moschos, Marilita M.
TI Correlation of platelet activating factor and age-related macular
   degeneration
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Article
DE age-related macular degeneration; angiogenesis; para-inflammation;
   platelet activating factor
ID RECURRENT CHOROIDAL NEOVASCULARIZATION; PIGMENT EPITHELIAL-CELLS; FACTOR
   PAF; PHOTODYNAMIC THERAPY; INTRAVITREAL AFLIBERCEPT; OXIDATIVE STRESS;
   5-YEAR INCIDENCE; GENE DELIVERY; TRAP-EYE; 2.0 MG
AB Objective: To investigate the role of Platelet Activating Factor (PAF) in the pathogenesis and development of Age-Related Macular Degeneration (ARMD).
   Research design and methods: Fifty six patients with ARMD (24 patients with dry ARMD and 32 patients with wet ARMD) and 25 age-matched control participants underwent ophthalmological examination, including visual acuity measurement and evaluation of the retina. The participants were classified into three groups according to their retinal status, based on indirect fundoscopy, Optical Coherence Tomography and fluorescein angiography findings. In order to evaluate the concentrations of PAF in serum, blood samples were collected from all participants and were analyzed with ELISA technique.
   Results: The concentrations of PAF differed significantly according to macular lesions and were found to be lower in patients with ARMD than control participants.
   Conclusions: PAF levels are decreased along with the severity of ARMD. Understanding the role of PAF in pathogenesis of ARMD could be the impetus for the development of new therapies field of treatment of ARMD or even other retinal diseases.
C1 [Nitoda, Eirini; Brouzas, Dimitrios; Koutsandrea, Chryssanthi; Ladas, Dimitrios; Moschos, Marilita M.] Univ Athens, Dept Ophthalmol 1, Sch Med, Athens 11528, Greece.
   [Koutsilieris, Michael; Philippou, Anastasios] Univ Athens, Dept Expt Physiol, Sch Med, Athens 11528, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens;
   Athens Medical School; National & Kapodistrian University of Athens
RP Moschos, MM (通讯作者)，Univ Athens, Dept Ophthalmol 1, Sch Med, Athens 11528, Greece.
EM moschosmarilita@yahoo.fr
RI Philippou, Anastassios/H-2748-2019; Koutsilieris, Michael/AAD-3648-2019
OI Philippou, Anastassios/0000-0003-0047-3003
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Al-Latayfeh M, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006411
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Arai H, 2002, PROSTAG OTH LIPID M, V68-9, P83, DOI 10.1016/S0090-6980(02)00023-0
   Baer CA, 2008, RETINA-J RET VIT DIS, V28, P1221, DOI 10.1097/IAE.0b013e31817d5bce
   Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Barnett BR, 2013, GERONTOLOGY, V59, P297, DOI 10.1159/000346169
   Bazan NG, 2005, MOL NEUROBIOL, V32, P89, DOI 10.1385/MN:32:1:089
   Beauchamp MH, 2002, INVEST OPHTH VIS SCI, V43, P3327
   Bhatia M, 2005, SCAND J SURG, V94, P97, DOI 10.1177/145749690509400203
   Blenkinsop TA, 2012, REGEN MED, V7, P32, DOI [10.2217/RME.12.77, 10.2217/rme.12.77]
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   BUSSOLINO F, 1989, J LIPID MEDIATOR, V1, P283
   Cao SJ, 2013, MOL VIS, V19, P718
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Catchpole I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065518
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617
   Chen HL, 2011, INT J NANOMED, V6, P453, DOI 10.2147/IJN.S17057
   de la Cruz JP, 1998, EUR J PHARMACOL, V360, P37, DOI 10.1016/S0014-2999(98)00664-5
   Derewenda ZS, 1998, CELL MOL LIFE SCI, V54, P446, DOI 10.1007/s000180050172
   DHARMA S, 1991, CURR EYE RES, V10, P1031, DOI 10.3109/02713689109020341
   DOLY M, 1987, INT J TISSUE REACT, V9, P33
   Doly M, 1992, Lens Eye Toxic Res, V9, P529
   DOLY M, 1993, OPHTHALMIC RES, V25, P314, DOI 10.1159/000267331
   Droy-Lefaix M T, 1992, Lens Eye Toxic Res, V9, P521
   Du HJ, 2013, P NATL ACAD SCI USA, V110, P2377, DOI 10.1073/pnas.1221729110
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Ferreira MAND, 2007, LIFE SCI, V81, P210, DOI 10.1016/j.lfs.2007.05.003
   Friberg TR, 2010, BRIT J OPHTHALMOL, V94, P1611, DOI 10.1136/bjo.2009.174946
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Garcia-Layana A, 2013, NUTRIENTS, V5, P543, DOI 10.3390/nu5020543
   Garland RC, 2011, FASEB J, V25, P1284, DOI 10.1096/fj.10-160051
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Guma M, 2009, P NATL ACAD SCI USA, V106, P8760, DOI 10.1073/pnas.0902659106
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hardy P, 2005, PROSTAG LEUKOTR ESS, V72, P301, DOI 10.1016/j.plefa.2005.02.004
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   He YG, 2009, CURR EYE RES, V34, P957, DOI 10.3109/02713680903231135
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   HU WM, 1991, BRIT J PHARMACOL, V104, P773, DOI 10.1111/j.1476-5381.1991.tb12504.x
   Ianopol N, 1998, Oftalmologia, V42, P5
   Inoue Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI 10.1136/bjo.2006.111583
   Jayaraman MS, 2012, MOL VIS, V18, P2300
   Jo DH, 2011, INT J MOL SCI, V12, P8288, DOI 10.3390/ijms12118288
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kalishwaralal K, 2010, J CONTROL RELEASE, V145, P76, DOI 10.1016/j.jconrel.2010.03.022
   Kanski Jack J., 2007, CLIN OPHTHALMOLOGY S
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kume K, 1997, J BIOL CHEM, V272, P22898, DOI 10.1074/jbc.272.36.22898
   Kutty RK, 2013, MOL VIS, V19, P737
   Lim JI, 2008, AGE RELATED MACULAR
   Luo WT, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/925267
   Ma X, 2004, INVEST OPHTH VIS SCI, V45, P2915, DOI 10.1167/iovs.04-0128
   Manjila SB, 2013, INT J PHARM INVESTIG, V3, P1, DOI 10.4103/2230-973X.108958
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McManus LM, 2000, CRIT REV ORAL BIOL M, V11, P240, DOI 10.1177/10454411000110020701
   Menerath JM, 1997, J OCUL PHARMACOL TH, V13, P81, DOI 10.1089/jop.1997.13.81
   MEYNIEL G, 1992, CR ACAD SCI III-VIE, V314, P61
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mirshahi Alireza, 2012, J Ophthalmic Vis Res, V7, P39
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Moutray T, 2011, THER ADV CHRONIC DIS, V2, P325, DOI 10.1177/2040622311415895
   Mueller EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030874
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Okumura N, 2006, J OCUL PHARMACOL TH, V22, P347, DOI 10.1089/jop.2006.22.347
   Orosz K, 2004, MOL VIS, V10, P555
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Nguyen QD, 2012, J OCUL PHARMACOL TH, V28, P581, DOI 10.1089/jop.2011.0261
   REME C, 1992, GRAEF ARCH CLIN EXP, V230, P580, DOI 10.1007/BF00181782
   Rollin S, 2004, BLOOD, V103, P3789, DOI 10.1182/blood-2003-07-2272
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Sharif NA, 2009, MOL VIS, V15, P1153
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   SMITH D, 1994, EXP EYE RES, V59, P425, DOI 10.1006/exer.1994.1127
   Sohn Jeong-Hyeon, 2007, Chem Immunol Allergy, V92, P105, DOI 10.1159/000099261
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sung HJ, 2012, MOL VIS, V18, P234
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   THIERRY A, 1989, EUR J PHARMACOL, V163, P97, DOI 10.1016/0014-2999(89)90400-7
   Thomson H, 2009, NANOMEDICINE-UK, V4, P599, DOI 10.2217/nnm.09.43
   Thumann G, 2012, CURR GENOMICS, V13, P350, DOI 10.2174/138920212801619214
   Vinores SA, 2007, J NEUROIMMUNOL, V182, P73, DOI 10.1016/j.jneuroim.2006.09.015
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Woodburn KW, 2002, RETINA-J RET VIT DIS, V22, P391, DOI 10.1097/00006982-200208000-00001
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068173
   Zinchuk O, 2005, MOL VIS, V11, P114
NR 102
TC 4
Z9 4
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1472-8222
EI 1744-7631
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD SEP
PY 2014
VL 18
IS 9
BP 987
EP 997
DI 10.1517/14728222.2014.930439
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AN2QI
UT WOS:000340430000004
PM 25077601
DA 2022-11-30
ER

PT J
AU Birch, DG
   Liang, FQ
AF Birch, David G.
   Liang, Fong Qi
TI Age-related macular degeneration: a target for nanotechnology derived
   medicines
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Review
DE macular; nanotechnology; AMD; retinal degeneration; gene therapy
ID RETINAL-PIGMENT EPITHELIUM; FACTOR-H POLYMORPHISM; BRUCHS MEMBRANE;
   PHOTODYNAMIC THERAPY; STARGARDT-DISEASE; OXIDATIVE STRESS; DRUSEN
   FORMATION; POTENTIAL ROLE; GENE DELIVERY; VITAMIN-A
AB Despite the fact that the retina is a fairly accessible portion of the central nervous system, there are virtually no treatments for early age-related macular degeneration (AMD). AMD is a degenerative retinal disease that causes progressive loss of central vision and is the leading cause of irreversible vision loss and legal blindness in individuals over the age of 50. Both environmental and genetic components play a role in its development. AMD is a multifactorial disease with characteristics that include drusen, hyperpigmentation and/or hypopignnentation of the retinal pigment epithelium (RPE), geographic atrophy and, in a subset of patients, late-stage choroidal neovascularization (CNV). Drugs that inhibit vascular endothelial growth factor (VEGF) have proven effective in treating late-stage CNV, but optimal means of drug delivery remains to be determined. Microscopic particles, whose size is on the nanometer scale, show considerable promise for drug delivery to the retina, for gene therapy, and for powering prosthetic "artificial retinas." This article summarizes the pathophysiology of AMD stressing potential applications from nanotechnology.
C1 [Birch, David G.] Retina Fdn SW, Dallas, TX 75231 USA.
   [Birch, David G.] Univ Texas SW Med Ctr Dallas, Dept Ophthalmol, Dallas, TX 75390 USA.
   [Liang, Fong Qi] Adv Vis Therapies Inc, Gaithersburg, MD USA.
C3 Retina Foundation of the Southwest; University of Texas System;
   University of Texas Southwestern Medical Center Dallas
RP Birch, DG (通讯作者)，Retina Fdn SW, 9900 N Cent Expressway, Dallas, TX 75231 USA.
EM dbirch@retinafoundation.org
FU NEI NIH HHS [EY05235, EY09076, R01 EY009076, R01 EY005235] Funding
   Source: Medline; NATIONAL EYE INSTITUTE [R01EY009076] Funding Source:
   NIH RePORTER
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   AUKUNURU JV, 2003, INVEST OPHTH VIS SCI, V44, P3562
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bejjani R, 2005, MOL VIS, V11, P124
   Ben-Shabat S, 2001, BIOORG MED CHEM LETT, V11, P1533, DOI 10.1016/S0960-894X(01)00314-6
   BOULTON M, 1984, GRAEF ARCH CLIN EXP, V221, P214, DOI 10.1007/BF02134143
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   BRESSLER SB, 1999, RETINA VITREOUS MACU, P79
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chapman JA, 2006, ANN PHARMACOTHER, V40, P1322, DOI 10.1345/aph.1G604
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DAMICO DJ, 2006, OPHTHALMOLOGY, V113
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Dinauer N, 2005, BIOMATERIALS, V26, P5898, DOI 10.1016/j.biomaterials.2005.02.038
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Evans J. R., 2002, COCHRANE DB SYST REV, V2
   FAURY G, 1995, J VASC RES, V32, P112, DOI 10.1159/000159084
   FEENEYBURNS L, 1990, AM J OPHTHALMOL, V109, P265, DOI 10.1016/S0002-9394(14)74549-0
   Fishbein I, 2000, J CONTROL RELEASE, V65, P221, DOI 10.1016/S0168-3659(99)00244-8
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gullberg E, 2006, J PHARMACOL EXP THER, V319, P632, DOI 10.1124/jpet.106.107847
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HAYES KC, 1974, INVEST OPHTH VISUAL, V13, P499
   HEIER JS, 2006, OPHTHALMOLOGY, V113
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Ideta R, 2005, NANO LETT, V5, P2426, DOI 10.1021/nl051679d
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Ito A, 2005, TISSUE ENG, V11, P489, DOI 10.1089/ten.2005.11.489
   IWASAKI M, 1988, INVEST OPHTH VIS SCI, V29, P671
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATZ ML, 1978, INVEST OPHTH VIS SCI, V17, P1049
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P359, DOI 10.1016/S0167-4943(02)00012-2
   Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023
   KEMP CM, 1989, EXP EYE RES, V49, P49
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kranz H, 2000, J PHARM SCI-US, V89, P1558
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   LIU J, 2006, INVEST OPHTH VIS SCI, VS, P39
   LOEFFLER KU, 1992, ARCH OPHTHALMOL-CHIC, V110, P15
   Loewenstein JI, 2004, ARCH OPHTHALMOL-CHIC, V122, P587, DOI 10.1001/archopht.122.4.587
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Massof RW, 2002, OPTOMETRY VISION SCI, V79, P31, DOI 10.1097/00006324-200201000-00010
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Merodio M, 2002, BIOMATERIALS, V23, P1587, DOI 10.1016/S0142-9612(01)00284-8
   Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04-2747rev
   Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004
   Moshfeghi AA, 2005, ADV DRUG DELIVER REV, V57, P2047, DOI 10.1016/j.addr.2005.09.006
   MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483
   NAASH M, 2006, INVEST OPHTHALMOL, VS, P53
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   PintoMartin JA, 1996, PEDIATR NEUROL, V14, P281, DOI 10.1016/0887-8994(96)00051-3
   Prow T, 2006, MOL VIS, V12, P606
   Renno RZ, 2001, ADV DRUG DELIVER REV, V52, P63, DOI 10.1016/S0169-409X(01)00195-8
   ROBISON WG, 1980, INVEST OPHTH VIS SCI, V19, P1030
   ROSEFELD PJ, 2006, OPHTHALMOLOGY, V113
   SAKAI T, 2006, INVEST OPHTH VIS SCI, VS, P48
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Thomas TP, 2004, BIOMACROMOLECULES, V5, P2269, DOI 10.1021/bm049704h
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Vijayanathan V, 2002, BIOCHEMISTRY-US, V41, P14085, DOI 10.1021/bi0203987
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 102
TC 42
Z9 57
U1 1
U2 7
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2007
VL 2
IS 1
BP 65
EP 77
DI 10.2147/nano.2007.2.1.65
PG 13
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 247AD
UT WOS:000252048600011
PM 17722514
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Saksens, NTM
   Lechanteur, YTE
   Verbakel, SK
   Groenewoud, JMM
   Daha, MR
   Schick, T
   Fauser, S
   Boon, CJF
   Hoyng, CB
   den Hollander, AI
AF Saksens, Nicole T. M.
   Lechanteur, Yara T. E.
   Verbakel, Sanne K.
   Groenewoud, Joannes M. M.
   Daha, Mohamed R.
   Schick, Tina
   Fauser, Sascha
   Boon, Camiel J. F.
   Hoyng, Carel B.
   den Hollander, Anneke I.
TI Analysis of Risk Alleles and Complement Activation Levels in Familial
   and Non-Familial Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; CHOROIDAL NEOVASCULARIZATION; COMPONENT 3;
   FACTOR-B; GENE; ASSOCIATION; VARIANT; CFH; METAANALYSIS; AGGREGATION
AB Aims
   Age-related macular degeneration (AMD) is a multifactorial disease, in which complement-mediated inflammation plays a pivotal role. A positive family history is an important risk factor for developing AMD. Certain lifestyle factors are shown to be significantly associated with AMD in non-familial cases, but not in familial cases. This study aimed to investigate whether the contribution of common genetic variants and complement activation levels differs between familial and sporadic cases with AMD.
   Methods and Results
   1216 AMD patients (281 familial and 935 sporadic) and 1043 controls (143 unaffected members with a family history of AMD and 900 unrelated controls without a family history of AMD) were included in this study. Ophthalmic examinations were performed, and lifestyle and family history were documented with a questionnaire. Nine single nucleotide polymorphisms (SNPs) known to be associated with AMD were genotyped, and serum concentrations of complement components C3 and C3d were measured. Associations were assessed in familial and sporadic individuals. The association with risk alleles of the age-related maculopathy susceptibility 2 (ARMS2) gene was significantly stronger in sporadic AMD patients compared to familial cases (p = 0.017 for all AMD stages and p = 0.003 for advanced AMD, respectively). ARMS2 risk alleles had the largest effect in sporadic cases but were not significantly associated with AMD in densely affected families. The C3d/C3 ratio was a significant risk factor for AMD in sporadic cases and may also be associated with familial cases. In patients with a densely affected family this effect was particularly strong with ORs of 5.37 and 4.99 for all AMD and advanced AMD respectively.
   Conclusion
   This study suggests that in familial AMD patients, the common genetic risk variant in ARMS2 is less important compared to sporadic AMD. In contrast, factors leading to increased complement activation appear to play a larger role in patients with a positive family history compared to sporadic patients. A better understanding of the different contributions of risk factors in familial compared to non-familial AMD will aid the development of reliable prediction models for AMD, and may provide individuals with more accurate information regarding their individual risk for AMD. This information is especially important for individuals who have a positive family history for AMD.
C1 [Saksens, Nicole T. M.; Lechanteur, Yara T. E.; Verbakel, Sanne K.; Boon, Camiel J. F.; Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
   [Groenewoud, Joannes M. M.] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat & Hlth Technol Assessment, NL-6525 ED Nijmegen, Netherlands.
   [Daha, Mohamed R.] Leiden Univ, Nijmegen Med Ctr, Dept Nephrol, Leiden, Netherlands.
   [Schick, Tina; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Boon, Camiel J. F.] Leiden Univ, Med Ctr, Dept Ophthalmol, Albinusdreef 2, Leiden, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Leiden
   University; Leiden University - Excl LUMC; University of Cologne; Leiden
   University; Leiden University Medical Center (LUMC); Leiden University -
   Excl LUMC; Radboud University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.; den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.
EM Anneke.denHollander@radboudumc.nl
RI Lehtimäki, Terho/AAD-1094-2022; Hollander, Anneke den/N-4911-2014;
   Groenewoud, Hans JMM/R-3588-2017; Verbakel, Sanne K/P-8160-2015;
   Lechanteur, Yara/ABB-6875-2020; Boon, CJF/P-7534-2014
OI Lehtimäki, Terho/0000-0002-2555-4427; Groenewoud, Hans
   JMM/0000-0002-4974-150X; Verbakel, Sanne K/0000-0002-0187-379X;
   Lechanteur, Yara/0000-0003-0951-4625; Boon, CJF/0000-0002-6737-7932
FU Foundation Fighting Blindness USA [C-GE-0811-0548-RAD04]; Salentein
   fellowship part of the 'Diana-Hermes foundation'; MD Fonds; Nederlandse
   Oogonderzoek Stichting; Oogfonds; Algemene Nederlandse Vereniging ter
   Voorkoming van Blindheid; Stichting Nederlands Oogheelkundig Onderzoek;
   Gelderse Blindenstichting
FX This work was supported by: Foundation Fighting Blindness USA (grant
   C-GE-0811-0548-RAD04; received by Anneke den Hollander); Salentein
   fellowship part of the 'Diana-Hermes foundation' (received by Carel
   Hoyng); Anneke den Hollander and Carel Hoyng received: MD Fonds,
   Nederlandse Oogonderzoek Stichting, Oogfonds, Algemene Nederlandse
   Vereniging ter Voorkoming van Blindheid, Stichting Nederlands
   Oogheelkundig Onderzoek, and Gelderse Blindenstichting. All funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Aiyar L, 2014, GENET MED, V16, P231, DOI 10.1038/gim.2013.115
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Howard KP, 2014, INVEST OPHTH VIS SCI, V55, P2592, DOI 10.1167/iovs.13-13763
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Saksens NTM, 2014, INVEST OPHTH VIS SCI, V55, P7085, DOI 10.1167/iovs.14-14659
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2014, HUM MOL GEN IN PRESS
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 45
TC 8
Z9 8
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 3
PY 2016
VL 11
IS 6
AR e0144367
DI 10.1371/journal.pone.0144367
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DN8ZV
UT WOS:000377369700001
PM 27258093
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Zhang, YH
   Wang, XL
   Godara, P
   Zhang, TJ
   Clark, ME
   Witherspoon, CD
   Spaide, RF
   Owsley, C
   Curcio, CA
AF Zhang, Yuhua
   Wang, Xiaolin
   Godara, Pooja
   Zhang, Tianjiao
   Clark, Mark E.
   Witherspoon, C. Douglas
   Spaide, Richard F.
   Owsley, Cynthia
   Curcio, Christine A.
TI DYNAMISM OF DOT SUBRETINAL DRUSENOID DEPOSITS IN AGE-RELATED MACULAR
   DEGENERATION DEMONSTRATED WITH ADAPTIVE OPTICS IMAGING
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; subretinal drusenoid deposits; retina;
   adaptive optics scanning laser ophthalmoscopy; multimodal imaging;
   photoreceptors
ID SCANNING LASER OPHTHALMOSCOPY; RETINAL-PIGMENT EPITHELIUM; RETICULAR
   PSEUDODRUSEN; COHERENCE TOMOGRAPHY; GEOGRAPHIC-ATROPHY; LONGITUDINAL
   ANALYSIS; FELLOW-EYES; SOFT DRUSEN; PROGRESSION; FUNDUS
AB Purpose: To investigate the natural history of dot subretinal drusenoid deposits (SDD) in age-related macular degeneration, using high-resolution adaptive optics scanning laser ophthalmoscopy.
   Methods: Six eyes of four patients with intermediate age-related macular degeneration were studied at baseline and 1 year later. Individual dot SDD within the central 30 degrees retina were examined with adaptive optics scanning laser ophthalmoscopy and optical coherence tomography.
   Results: A total of 269 solitary SDD were identified at baseline. Over 12.25 +/- 1.18 months, all 35 Stage 1 SDD progressed to advanced stages. Eighteen (60%) Stage 2 lesions progressed to Stage 3 and 12 (40%) remained at Stage 2. Of 204 Stage 3 SDD, 12 (6.4%) disappeared and the rest remained. Twelve new SDD were identified, including 6 (50%) at Stage 1, 2 (16.7%) at Stage 2, and 4 (33.3%) at Stage 3. The mean percentage of the retina affected by dot SDD, measured by the adaptive optics scanning laser ophthalmoscopy, increased in 5/6 eyes (from 2.31% to 5.08% in the most changed eye) and decreased slightly in 1/6 eye (from 10.67% to 10.54%). Dynamism, the absolute value of the areas affected by new and regressed lesions, ranged from 0.7% to 9.3%.
   Conclusion: Adaptive optics scanning laser ophthalmoscopy reveals that dot SDD, like drusen, are dynamic.
C1 [Zhang, Yuhua; Wang, Xiaolin; Godara, Pooja; Clark, Mark E.; Witherspoon, C. Douglas; Owsley, Cynthia; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Volker Hall 390C,1670 Univ Blvd, Birmingham, AL 35294 USA.
   [Zhang, Tianjiao] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.
   [Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of California System; University of California Berkeley;
   Vitreous Retina Macula Consultants of New York
RP Zhang, YH (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Volker Hall 390C,1670 Univ Blvd, Birmingham, AL 35294 USA.
EM zhanghua@uab.edu
RI zhang, tian/GZK-6001-2022; Spaide, Richard/ABD-7368-2020
OI Witherspoon, Clark/0000-0003-4456-9437
FU Topcon Inc, Tokyo, Japan; Bausch and Lomb, Rochester, NY;  [EY021903]; 
   [EY024378];  [AG04212];  [EY06109]; NATIONAL EYE INSTITUTE [R21EY021903,
   R01EY006109, R01EY024378] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON AGING [R01AG004212] Funding Source: NIH RePORTER
FX Supported in part by EY021903, EY024378, AG04212, and EY06109 and
   institutional support from Research to Prevent Blindness, EyeSight
   Foundation of Alabama, Buck Trust of Alabama, the Dorsett Davis
   Discovery Fund.; R. F. Spaide receives consultant and royalty payment
   from Topcon Inc, Tokyo, Japan; Bausch and Lomb, Rochester, NY. The
   remaining authors have no financial/conflicting interests to disclose.
CR Alten F, 2014, INVEST OPHTH VIS SCI, V55, P6073, DOI 10.1167/iovs.13-13804
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Meadway A, 2014, BIOMED OPT EXPRESS, V5, P713, DOI 10.1364/BOE.5.000713
   Meadway A, 2013, OPT EXPRESS, V21, P29792, DOI 10.1364/OE.21.029792
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Putnam NM, 2010, OPT EXPRESS, V18, P24902, DOI 10.1364/OE.18.024902
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Rolfs M, 2009, VISION RES, V49, P2415, DOI 10.1016/j.visres.2009.08.010
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Smith RT, 2010, BRIT J OPHTHALMOL, V94, P1618, DOI 10.1136/bjo.2009.166843
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1163, DOI 10.1097/IAE.0b013e3181ed8d05
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Steinberg JS, 2016, AM J OPHTHALMOL, V168, P52, DOI 10.1016/j.ajo.2016.04.025
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Steinberg JS, 2015, OPHTHALMOLOGICA, V233, P35, DOI 10.1159/000368168
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Talcott KE, 2011, INVEST OPHTH VIS SCI, V52, P2219, DOI 10.1167/iovs.10-6479
   Vogel CR, 2006, OPT EXPRESS, V14, P487, DOI 10.1364/OPEX.14.000487
   Vongkulsiri S, 2015, RETINA-J RET VIT DIS, V35, P1211, DOI 10.1097/IAE.0000000000000514
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Xu X, 2016, AM J OPHTHALMOL, DOI [10.1016/j.ajo.2016.11.021, DOI 10.1016/J.AJ0.2016.11.021]
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yu YX, 2015, OPT EXPRESS, V23, P23035, DOI 10.1364/OE.23.023035
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 59
TC 14
Z9 14
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2018
VL 38
IS 1
BP 29
EP 38
DI 10.1097/IAE.0000000000001504
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GB0KM
UT WOS:000428734800009
PM 28196054
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Bilgic, A
   Kodjikian, L
   Mathis, T
   Sudhalkar, AA
   Vasavada, SA
   Bhojwani, DM
AF Bilgic, Alper
   Kodjikian, Laurent
   Mathis, Thibaud
   Sudhalkar, Aditya A.
   Vasavada, Shail A.
   Bhojwani, Deepak M.
TI SINGLE INJECTION RESPONSE TO ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR
   AGENTS IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION Incidence
   and Characteristics
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; antivascular endothelial growth factor
   agent; choroidal neovascularisation; recurrence; single injection
ID OPTICAL COHERENCE TOMOGRAPHY; DOSING REGIMEN; RANIBIZUMAB; EFFICACY;
   HORIZON; SAFETY; TREAT
AB Purpose: To determine the incidence of complete resolution of choroidal neovascular membrane-associated exudation with a single antivascular endothelial growth factor injection in treatment-naive wet age-related macular degeneration patients and its associated characteristics. Methods: Retrospective, observational study of naive wet age-related macular degeneration patients who received antivascular endothelial growth factor therapy with ranibizumab/aflibercept and demonstrated complete resolution of retinal exudation with a single injection. Complete resolution was defined as the total disappearance of the intraretinal fluid, cysts, and subretinal fluid and a return of retinal thickness to mu m on spectral-domain optical coherence tomography. All relevant data were collected. Follow-up was scheduled on Days 1, 7, and 30 postoperatively and then monthly, with at least 9 visits mandatory per year if the macula remained fluid free. Appropriate statistical analyses were performed. Results: Sixty-three patients (29 men; mean age 67.25 +/- 4.40 years) were identified. The mean baseline and final-corrected distance visual acuity was 20/160 and 20/45, respectively. Patients completed a mean of 10.9 follow-up visits per year. Smaller choroidal neovascular membranes (mu m), early presentation, better presenting corrected distance visual acuity, subfoveal choroidal neovascular membranes, absence of blood/fibrosis, and use of aflibercept (2 mg) favored resolution with one injection. Conclusion: A subset (13.76%; 63/458, 95% confidence intervals: 10.73-17.25) of patients with treatment-naive wet age-related macular degeneration demonstrates resolution of choroidal neovascular membrane-associated exudation with a single antivascular endothelial growth factor injection, sustained over 2 years or more. This can lower therapy costs, treatments, office visits, and the potential risk of geographic atrophy.
C1 [Bilgic, Alper; Sudhalkar, Aditya A.] Alphavis Augenzentrum, Bremerhaven, Germany.
   [Kodjikian, Laurent; Mathis, Thibaud] Univ Lyon 1, Hosp Civils Lyon, Hop Univ Croix Rousse, Serv Ophtalmol, Lyon, France.
   [Kodjikian, Laurent; Mathis, Thibaud] Univ Lyon 1, Lab UMR CNRS 5510 Mateis, Villeurbanne, France.
   [Sudhalkar, Aditya A.] Sudhalkar Eye Hosp & Retina Ctr, Baroda, Gujarat, India.
   [Sudhalkar, Aditya A.; Vasavada, Shail A.; Bhojwani, Deepak M.] Raghudeep Eye Hosp, Ahmadabad, Gujarat, India.
C3 CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard
   Lyon 1; Institut National des Sciences Appliquees de Lyon - INSA Lyon;
   UDICE-French Research Universities; Universite Claude Bernard Lyon 1
RP Sudhalkar, AA (通讯作者)，Sudhalkar Eye Hosp & Retina Ctr, Shiv Bungalow, 22C Pratapgunj, Baroda 390002, Gujarat, India.; Sudhalkar, AA (通讯作者)，Raghudeep Eye Hosp, Shiv Bungalow, 22C Pratapgunj, Baroda 390002, Gujarat, India.
EM adityasudhalkar@yahoo.com
CR Barbazetto I, 2010, RETINA-J RET VIT DIS, V30, P1376, DOI 10.1097/IAE.0b013e3181dcfb0b
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gale RP, 2019, EYE, V33, DOI 10.1038/s41433-018-0300-3
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim RHF, 2017, INT J OPHTHALMOL-CHI, V10, P423, DOI 10.18240/ijo.2017.03.15
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Park SS, 2010, INVEST OPHTH VIS SCI, V51, P4200, DOI 10.1167/iovs.09-4256
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Scoles D, 2020, JAMA OPHTHALMOL, V138, P276, DOI 10.1001/jamaophthalmol.2019.5831
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Stewart MW, 2015, J CLIN MED, V4, P1079, DOI 10.3390/jcm4051079
   Sudhalkar A, 2015, INDIAN J OPHTHALMOL, V63, P899, DOI 10.4103/0301-4738.176025
   Tano Y, 2011, ACTA OPHTHALMOL, V89, P208, DOI 10.1111/j.1755-3768.2010.02065.x
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 28
TC 2
Z9 2
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2021
VL 41
IS 9
BP 1901
EP 1910
DI 10.1097/IAE.0000000000003106
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5QE
UT WOS:000711821200036
PM 33411472
DA 2022-11-30
ER

PT J
AU Pidaparti, RM
   Lee, JH
   Yang, H
AF Pidaparti, Ramana M.
   Lee, Jae-Hwan
   Yang, Hu
TI Micro-channel diffusion characteristics of an implantable drug delivery
   device for age-related macular degeneration
SO MICROSYSTEM TECHNOLOGIES-MICRO-AND NANOSYSTEMS-INFORMATION STORAGE AND
   PROCESSING SYSTEMS
LA English
DT Article
ID EYE
AB There is an increasing need to develop implantable drug delivery devices for effective therapeutic management of chronic ocular diseases such as age-related macular degeneration (AMD). In this work, we designed four different micro-channel configurations for an implantable device and elucidate drug diffusion characteristics using both simulation and experimental measurements. Our simulation and experimental results show that three micro-channel configurations are capable of sustaining drug release and can be incorporated into an implantable device to exert long-term drug release required for therapeutic management of AMD.
C1 [Pidaparti, Ramana M.] Univ Georgia, Coll Engn, Athens, GA 30602 USA.
   [Pidaparti, Ramana M.; Lee, Jae-Hwan] Virginia Commonwealth Univ, Dept Mech & Nucl Engn, Richmond, VA 23284 USA.
   [Yang, Hu] Virginia Commonwealth Univ, Dept Biomed Engn, Richmond, VA 23284 USA.
C3 University System of Georgia; University of Georgia; Virginia
   Commonwealth University; Virginia Commonwealth University
RP Pidaparti, RM (通讯作者)，Univ Georgia, Coll Engn, Athens, GA 30602 USA.
EM rmparti@uga.edu
RI Yang, Hu/AAB-5474-2019
OI Yang, Hu/0000-0003-3030-004X
FU NSF [NSF-ECCS-1430374]; Div Of Electrical, Commun & Cyber Sys [1430374]
   Funding Source: National Science Foundation
FX The authors thank the NSF for supporting this work through
   NSF-ECCS-1430374.
CR Bhagav P., 2010, PHARM LETT, V2, P106
   Gaudana R, 2009, PHARM RES-DORDR, V26, P1197, DOI 10.1007/s11095-008-9694-0
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   Holden CA, 2012, NANOMED-NANOTECHNOL, V8, P776, DOI 10.1016/j.nano.2011.08.018
   Jaffe GJ, 2000, INVEST OPHTH VIS SCI, V41, P3569
   Keister JC, 1997, J PHARM SCI, V86, P1040, DOI 10.1021/js960510k
   LEE JH, 2012, J DRUG DELIV, V2012
   Li TL, 1997, J CONTROL RELEASE, V48, P57, DOI 10.1016/S0168-3659(97)00033-3
   Lo R, 2009, BIOMED MICRODEVICES, V11, P959, DOI 10.1007/s10544-009-9313-9
   Molokhia SA, 2010, VISION RES, V50, P680, DOI 10.1016/j.visres.2009.10.013
   Ranta VP, 2006, ADV DRUG DELIVER REV, V58, P1164, DOI 10.1016/j.addr.2006.07.025
   Staples M, 2006, PHARM RES-DORDR, V23, P847, DOI 10.1007/s11095-006-9906-4
   Swanson S., 2006, P INT SOC MAGNETIC R, P1848
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
NR 14
TC 2
Z9 2
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0946-7076
EI 1432-1858
J9 MICROSYST TECHNOL
JI Microsyst. Technol.
PD SEP
PY 2015
VL 21
IS 9
SI SI
BP 1967
EP 1974
DI 10.1007/s00542-014-2307-4
PG 8
WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Science & Technology - Other Topics; Materials Science;
   Physics
GA CP5TW
UT WOS:000359948500018
DA 2022-11-30
ER

PT J
AU Cekic, O
   Bardak, Y
   Yesildag, A
AF Cekic, Osman
   Bardak, Yavuz
   Yesildag, Ahmet
TI Color Doppler Imaging of Ocular Blood Flow after Combined Photodynamic
   Therapy with Intravitreal Triamcinolone in Age-Related Macular
   Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascular membrane; Color
   Doppler imaging; Intravitreal triamcinolone; Ocular perfusion; Ocular
   photodynamic therapy
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN; PERFUSION;
   TRANSLOCATION; CIRCULATION; MACULOPATHY; PARAMETERS; ACETONIDE; EDEMA;
   TAP
AB Methods: Intravitreal triamcinolone (4 mg, 0.1 cc) and photodynamic therapy with verteporfin were applied to 48 eyes of 33 subjects (25 male and 8 female; mean age: 68.9 years) with subfoveal choroidal neovascular membrane secondary to age-related macular degeneration. Patients were assessed for ocular hemodynamic parameters with color Doppler imaging 24 hr before and 1 week, 1 month, and 3 months after a single-dose administration of combined intravitreal triamcinolone and photodynamic therapy.
   Results: Throughout the study period, no significant difference in resistance index, peak systolic velocity, or end diastolic velocity existed in the ophthalmic artery (P == 0.58, P == 0.18, and P == 0.19, respectively), the posterior ciliary arteries (P == 0.73, P == 0.19, and P == 0.34, respectively), or the central retinal artery (P == 0.09, P == 0.32, and P == 0.47, respectively).
   Conclusion: Combined intravitreal triamcinolone and photodynamic therapy was not associated with any alteration in ocular blood flow or flow velocity over 3 months in eyes with age-related macular degeneration.
C1 [Cekic, Osman] Vakif Gureba Training & Res Hosp, Dept Ophthalmol, Istanbul, Turkey.
   [Cekic, Osman; Bardak, Yavuz] Suleyman Demirel Univ, Sch Med, Dept Ophthalmol, TR-32200 Isparta, Turkey.
   [Yesildag, Ahmet] Suleyman Demirel Univ, Sch Med, Dept Radiol, TR-32200 Isparta, Turkey.
C3 Bezmialem Vakif University; Suleyman Demirel University; Suleyman
   Demirel University
RP Cekic, O (通讯作者)，Kucukyali Dervisbey Sitesi,B2-40, Istanbul, Turkey.
EM ocekic@hotmail.com
RI Yeşildağ, Ahmet/AAK-5774-2021; Cekic, Osman/H-3027-2019
OI Yeşildağ, Ahmet/0000-0003-2425-6951; Cekic, Osman/0000-0003-0911-8649
CR Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   BARDAK Y, INVEST OPHTHALMOL VI, V47
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cekic O, 2004, RETINA-J RET VIT DIS, V24, P210, DOI 10.1097/00006982-200404000-00003
   Cekic O, 2004, RETINA-J RET VIT DIS, V24, P51
   Cekic Osman, 2007, International Ophthalmology, V27, P313, DOI 10.1007/s10792-007-9080-7
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P3337
   Dimitrova G, 2010, SURV OPHTHALMOL, V55, P193, DOI 10.1016/j.survophthal.2009.06.010
   FINGAR VH, 1992, CANCER RES, V52, P4914
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Frimpong-Boateng A, 2009, ACTA OPHTHALMOL, V87, P183, DOI 10.1111/j.1755-3768.2008.01213.x
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Maar N, 2009, ACTA OPHTHALMOL, V87, P631, DOI 10.1111/j.1755-3768.2008.01311.x
   Mawatari Y, 2005, AM J OPHTHALMOL, V140, P948, DOI 10.1016/j.ajo.2005.06.002
   Mete A, 2010, J CLIN ULTRASOUND, V38, P66, DOI 10.1002/jcu.20650
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Moreau-Gaudry VV, 2010, EYE, V24, P706, DOI 10.1038/eye.2009.130
   Tsai CC, 2006, EYE, V20, P1025, DOI 10.1038/sj.eye.6702070
   Turkcuoglu P, 2008, CLIN EXP OPHTHALMOL, V36, P39, DOI 10.1111/j.1442-9071.2007.01644.x
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
NR 25
TC 3
Z9 3
U1 0
U2 5
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0271-3683
J9 CURR EYE RES
JI Curr. Eye Res.
PD FEB
PY 2011
VL 36
IS 2
BP 149
EP 153
DI 10.3109/02713683.2010.533809
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 717XK
UT WOS:000287080800010
PM 21158585
DA 2022-11-30
ER

PT J
AU Tang, MH
   Li, AY
   Wu, MX
   Chen, X
   Xiong, XJ
   Zhou, ZX
   Liu, DN
AF Tang, Manhan
   Li, Aiyu
   Wu, Mingxing
   Chen, Xu
   Xiong, Xiaojing
   Zhou, Zixi
   Liu, Danning
TI rs10490924 surroundingHTRA1/ARMS2regulates the susceptibility of
   age-related macular degeneration
SO JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION
LA English
DT Article
DE AMD; rs10490924; HTRA1; ARMS2
ID GENE POLYMORPHISMS; HTRA1; ASSOCIATION; LOC387715; ARMS2; CFH; VARIANTS;
   METAANALYSIS; RISK
AB Multiple studies have assessed the contribution of rs10490924 on chromosome 10q26 surroundingHTRA1/ARMS2gene to age-related macular degeneration (AMD) risk. However, the causal allele at this locus is still inconclusive. In this meta-analysis, we systematically characterized the potential association between rs10490924 polymorphism and AMD risk. Data available from 12 case-control studies, including a total of 5244 cases and 2755 controls in three different ethnic populations, were used to evaluate the correlation between rs10490924 G/T polymorphism (Ala69Ser) and AMD risk. In overall populations, the results indicated the Ala69Ser polymorphism was significantly associated with AMD under allelic (OR = 0.35, 95% CI = 0.30-0.40), homozygous (OR = 0.12, 95%CI = 0.09-0.17), dominant (OR = 0.18, 95%CI = 0.14-0.24), recessive (OR = 0.33, 95%CI = 0.28-0.39), and heterozygous genetic models (OR = 0.26, 95% CI = 0.21-0.33). Similar results were observed in subgroup analysis. This meta-analysis suggests that rs10490924 (Ala69Ser) polymorphism was significantly associated with the susceptibility of AMD in all ethnicities, Ala69 carriers are resistant to AMD risk.
C1 [Tang, Manhan; Wu, Mingxing; Chen, Xu; Xiong, Xiaojing; Zhou, Zixi; Liu, Danning] Chongqing Med Univ, Affiliated Hosp 2, Dept Ophthalmol, Chongqing 400010, Peoples R China.
   [Li, Aiyu] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthoped, Chongqing, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University
RP Liu, DN (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Ophthalmol, Chongqing 400010, Peoples R China.
EM ilzvnyz@163.com
FU National High Technology Research and Development Program of China (863
   project) [2014AA021604]; Sichuan Province Science and Technology Support
   Program [2015SZ0140]
FX This study was supported by the National High Technology Research and
   Development Program of China (863 project) via #2014AA021604, and
   Sichuan Province Science and Technology Support Program via #2015SZ0140.
CR Almeida LN, 2013, OPHTHALMIC RES, V50, P117, DOI 10.1159/000350549
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Chowers I, 2008, MOL VIS, V14, P2263
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fourgeux C, 2012, INVEST OPHTH VIS SCI, V53, P7026, DOI 10.1167/iovs.12-9652
   Francis PJ, 2008, MOL VIS, V14, P1395
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hirata FE, 2015, OPHTHALMIC GENET, V36, P224, DOI 10.3109/13816810.2013.867449
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kaur I, 2013, MOL VIS, V19, P822
   Leveziel N, 2007, MOL VIS, V13, P2153
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Magro CM, 2014, AM J DERMATOPATH, V36, P303, DOI 10.1097/DAD.0b013e31829beaa7
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Nazari Khanamiri Hossein, 2014, J Ophthalmic Vis Res, V9, P181
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Solano JM, 2007, OPHTHALMIC GENET, V28, P73, DOI 10.1080/13816810701351347
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Tanaka K, 2011, MOL VIS, V17, P2751
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang GF, 2013, JAMA OPHTHALMOL, V131, P804, DOI 10.1001/jamaophthalmol.2013.589
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Xu L, 2008, OPHTHALMOLOGICA, V222, P378, DOI 10.1159/000151468
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zerbib J, 2014, GRAEF ARCH CLIN EXP, V252, P899, DOI 10.1007/s00417-013-2537-7
   Zhou J, 2013, CLIN BIOCHEM, V46, P1689, DOI 10.1016/j.clinbiochem.2013.07.002
NR 41
TC 1
Z9 1
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1079-9893
EI 1532-4281
J9 J RECEPT SIG TRANSD
JI J. Recept. Signal Transduct.
PD MAR 4
PY 2021
VL 41
IS 2
BP 188
EP 195
DI 10.1080/10799893.2020.1805625
EA AUG 2020
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA QH0TQ
UT WOS:000557997400001
PM 32777973
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Ho, CPS
   Lai, TYY
AF Ho, Christine P. S.
   Lai, Timothy Y. Y.
TI Current management strategy of polypoidal choroidal vasculopathy
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Anti-VEGF therapy; neovascular age-related macular degeneration;
   photodynamic therapy; polypoidal choroidal vasculopathy
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PHOTODYNAMIC THERAPY; INDOCYANINE
   GREEN ANGIOGRAPHY; ANTI-VEGF TREATMENT; MACULAR DEGENERATION;
   INTRAVITREAL BEVACIZUMAB; EXTEND REGIMEN; FUNDUS AUTOFLUORESCENCE;
   RISK-FACTORS; HEMORRHAGIC COMPLICATIONS
AB Polypoidal choroidal vasculopathy (PCV) is a retinal disorder commonly found in Asians presenting as neovascular age-related macular degeneration and is characterized by serous macular detachment, serous or hemorrhagic pigment epithelial detachment, subretinal hemorrhage, and occasionally visible orange-red subretinal nodular lesions. PCV is diagnosed using indocyanine green angiography (ICGA), and the lesions appear as polypoidal aneurysmal vascular lesions with or without abnormal branching vascular network. Although ICGA remains the gold standard for the diagnosis of PCV, various imaging modalities have also facilitated the diagnosis and monitoring of PCV. Recent advances in imaging technology including the use of high resolution spectral domain optical coherence tomography (OCT) and OCT angiography have provided new insights on the pathogenesis of PCV, suggesting a link between PCV and pachychoroid spectrum of macular disorders. With the evolving understanding on the pathogenesis and clinical characteristics of PCV, different therapeutic options have been proposed. These include intravitreal anti-vascular endothelial growth factor (anti-VEGF) monotherapy, combination therapy with anti-VEGF and verteporfin photodynamic therapy, and thermal laser photocoagulation. In recent years, major multi-center randomized clinical trials such as EVEREST, EVEREST II, and PLANET studies have been conducted to compare the efficacy and safety of various treatment options for PCV. This review aims to summarize the results of recent literature, clinical trials and studies to provide an update on the management options of PCV. An overall management strategy for PCV will also be proposed.
C1 [Ho, Christine P. S.] Univ Hong Kong, Fac Med, Hong Kong, Hong Kong, Peoples R China.
   [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
   [Ho, Christine P. S.; Lai, Timothy Y. Y.] 2010 Retina & Macula Ctr, Kowloon, Hong Kong, Peoples R China.
C3 University of Hong Kong; Chinese University of Hong Kong
RP Lai, TYY (通讯作者)，Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM tyylai@cuhk.edu.hk
RI Lai, Timothy Y Y/AAC-2120-2020
OI Lai, Timothy Y Y/0000-0002-7832-6428
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Arakawa A, 2017, CLIN OPHTHALMOL, V11, P797, DOI 10.2147/OPTH.S129164
   Azuma K, 2016, RETINA-J RET VIT DIS, V36, P2158, DOI 10.1097/IAE.0000000000001047
   Chan EW, 2018, ACTA OPHTHALMOL, V96, pe258, DOI 10.1111/aos.13533
   Chan SY, 2018, RETINA-J RET VIT DIS, V38, P1187, DOI 10.1097/IAE.0000000000001702
   Chan WM, 2010, GRAEF ARCH CLIN EXP, V248, P613, DOI 10.1007/s00417-010-1307-z
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chatziralli IP, 2016, RETINA-J RET VIT DIS, V36, P2319, DOI 10.1097/IAE.0000000000001070
   Chen XL, 2018, GRAEF ARCH CLIN EXP, V256, P1449, DOI 10.1007/s00417-018-4020-y
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cheung CMG, 2017, SCI REP-UK, V7, DOI 10.1038/srep41386
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Fan Q, 2017, J HUM GENET, V62, P1049, DOI 10.1038/jhg.2017.83
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fujiwara K, 2018, SEMIN OPHTHALMOL, V7, P1
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hikichi T, 2018, BRIT J OPHTHALMOL, V102, P97, DOI 10.1136/bjophthalmol-2017-310448
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Honda S, 2014, OPHTHALMOLOGICA, V232, P92, DOI 10.1159/000360308
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Huang YM, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/3479695
   Huang Z, 2019, RETINA-J RET VIT DIS, V39, P889, DOI 10.1097/IAE.0000000000002035
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jain P, 2018, INDIAN J OPHTHALMOL, V66, P1119, DOI 10.4103/ijo.IJO_1222_17
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jeong SY, 2017, BRIT J OPHTHALMOL, V101, P758, DOI 10.1136/bjophthalmol-2016-309144
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee H, 2016, RETINA-J RET VIT DIS, V36, P465, DOI 10.1097/IAE.0000000000000645
   Lee JH, 2015, RETINA-J RET VIT DIS, V35, P1561, DOI 10.1097/IAE.0000000000000498
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Liang XY, 2014, EYE, V28, P1502, DOI 10.1038/eye.2014.226
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Maruyama-Inoue M, 2018, RETINA-J RET VIT DIS, V38, P2001, DOI 10.1097/IAE.0000000000001818
   Miyamoto N, 2019, BRIT J OPHTHALMOL, V103, P844, DOI 10.1136/bjophthalmol-2018-312419
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Ng DSC, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20519
   Ng TK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28639
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Ozkaya A, 2016, EYE, V30, P958, DOI 10.1038/eye.2016.71
   Ozkok A, 2016, RETINA-J RET VIT DIS, V36, P2191, DOI 10.1097/IAE.0000000000001034
   Pak KY, 2017, RETINA-J RET VIT DIS, V37, P561, DOI 10.1097/IAE.0000000000001195
   Qu JF, 2016, RETINA-J RET VIT DIS, V36, P926, DOI 10.1097/IAE.0000000000000875
   Rishi P, 2013, EYE, V27, P1038, DOI 10.1038/eye.2013.106
   Rishi P, 2017, INDIAN J OPHTHALMOL, V65, P712, DOI 10.4103/ijo.IJO_174_17
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Semoun O, 2016, BRIT J OPHTHALMOL, V100, P1028, DOI 10.1136/bjophthalmol-2015-307494
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Singh SR, 2017, ASIA-PAC J OPHTHALMO, V6, P561, DOI 10.22608/APO.2017263
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Videkar Chetan, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-212988
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Wong IY, 2018, RETINA-J RET VIT DIS, V38, P725, DOI 10.1097/IAE.0000000000001614
   Yamagishi T, 2012, OPHTHALMOLOGY, V119, P1650, DOI 10.1016/j.ophtha.2012.02.016
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yang LH, 2013, RETINA-J RET VIT DIS, V33, P1584, DOI 10.1097/IAE.0b013e318285cbb3
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Zhao XY, 2018, GRAEF ARCH CLIN EXP, V256, P1101, DOI 10.1007/s00417-018-3980-2
NR 101
TC 12
Z9 12
U1 0
U2 7
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD DEC
PY 2018
VL 66
IS 12
BP 1727
EP 1735
DI 10.4103/ijo.IJO_975_18
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HB0BS
UT WOS:000450676000014
PM 30451173
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sato, E
   Feke, GT
   Menke, MN
   McMeel, JW
AF Sato, E.
   Feke, G. T.
   Menke, M. N.
   Wallace McMeel, J.
TI Retinal haemodynamics in patients with age-related macular degeneration
SO EYE
LA English
DT Article
DE age-related macular degeneration; retinal haemodynamics; laser Doppler;
   pulsatility indices
ID BLOOD-FLOW; RETROBULBAR CIRCULATION; RISK-FACTORS; PATHOGENESIS;
   ATHEROSCLEROSIS; ASSOCIATION; MACULOPATHY; CORRESPOND; STATIN; MODEL
AB Objective To investigate whether there is an association between the magnitude of retinal haemodynamic abnormalities in patients with age-related macular degeneration (AMD) and the degree of severity of the AMD.
   Methods A retinal laser Doppler system (Canon CLBF 100) was used to measure retinal arterial haemodynamic parameters in 25 eyes of 25 patients with AMD and nine eyes of nine age-matched control subjects. Severity of AMD was classified into Mild (n = 11), Moderate (n = 7), or Severe (n = 7). The pulsatility ratio (PR), the pulsatility index (PI), and the resistivity index (RI) were determined.
   Results PR, PI, and RI in the patients with AMD were each significantly higher than in the control group, and increased monotonically with increasing severity of AMD. However, there were no differences in mean blood velocity, arterial diameter, or blood flow rate among the groups. This suggests that the increased blood flow pulsatility in the retinal arteries of the eyes with AMD is not due to increased distal vascular resistance, but instead is likely due to a loss of compliance in the arterial vasculature leading to the eye.
   Conclusion Our results suggest that an increasing vascular rigidity in the systemic arterial circulation is directly associated with an increasing severity of AMD.
C1 Schepens Retina Associates Fdn, Boston, MA 02215 USA.
RP Feke, GT (通讯作者)，Schepens Retina Associates Fdn, 1 Autum St,6th Floor, Boston, MA 02215 USA.
EM feke@schepens.com
OI Menke, Marcel/0000-0002-6561-6178
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bude RO, 1999, RADIOLOGY, V211, P411, DOI 10.1148/radiology.211.2.r99ma48411
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Dimitrova G, 2002, EYE, V16, P580, DOI 10.1038/sj.eye.6700161
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hosal BM, 1998, EUR J OPHTHALMOL, V8, P234, DOI 10.1177/112067219800800406
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Martyn CN, 1997, LANCET, V350, P953, DOI 10.1016/S0140-6736(96)10508-0
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Polska E, 2001, AM J PHYSIOL-HEART C, V280, pH1442, DOI 10.1152/ajpheart.2001.280.4.H1442
   Pourcelot L, 1975, Rev Prat, V25, P4671
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Yoshida A, 2003, AM J OPHTHALMOL, V135, P356, DOI 10.1016/S0002-9394(02)01949-9
NR 26
TC 44
Z9 46
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2006
VL 20
IS 6
BP 697
EP 702
DI 10.1038/sj.eye.6701951
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 060KU
UT WOS:000238801900010
PM 15933745
OA Bronze
DA 2022-11-30
ER

PT J
AU Tomita, Y
   Nagai, N
   Suzuki, M
   Shinoda, H
   Uchida, A
   Mochimaru, H
   Izumi-Nagai, K
   Sasaki, M
   Tsubota, K
   Ozawa, Y
AF Tomita, Yohei
   Nagai, Norihiro
   Suzuki, Misa
   Shinoda, Hajime
   Uchida, Atsuro
   Mochimaru, Hiroshi
   Izumi-Nagai, Kanako
   Sasaki, Mariko
   Tsubota, Kazuo
   Ozawa, Yoko
TI Functional Visual Acuity in Age-Related Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE functional visual acuity; interdigitation zone; optical coherence
   tomography; age-related macular degeneration; retina
ID POPULATION; EYE; PREVALENCE; MEMBRANE
AB Purpose We evaluated whether a functional visual acuity (FVA) system can detect subtle changes in central visual acuity that reflect pathological findings associated with age-related macular degeneration (AMD).
   Methods Twenty-eight patients with unilateral AMD and logMAR monocular best corrected VA better than 0 in both eyes, as measured by conventional chart examination, were analyzed between November 2012 and April 2013. After measuring conventional VA, FVA, and contrast VA with best correction, routine eye examinations including spectral domain-optical coherence tomography were performed. Standard Schirmer test was performed, and corneal and lens densities were measured.
   Results The FVA score (p < 0.001) and visual maintenance ratio (p < 0.001) measured by the FVA system, contrast VA (p < 0. 01), and conventional VA (p < 0.01) were significantly worse in the AMD-affected eyes than in the fellow eyes. No significant differences were observed in the anterior segment conditions. Forward stepwise regression analysis demonstrated that the length of interdigitation zone disruption, as visualized by optical coherence tomography imaging, correlated with the FVA score (p < 0.01) but not with any other parameters investigated.
   Conclusions The FVA system detects subtle changes in best corrected VA in AMD-affected eyes and reflects interdigitation zone disruption, an anatomical change in the retina recorded by optical coherence tomography. Further studies are required to understand the value of the FVA system in detecting subtle changes in AMD.
C1 [Tomita, Yohei; Nagai, Norihiro; Suzuki, Misa; Shinoda, Hajime; Uchida, Atsuro; Mochimaru, Hiroshi; Izumi-Nagai, Kanako; Sasaki, Mariko; Tsubota, Kazuo; Ozawa, Yoko] Keio Univ, Dept Ophthalmol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan.
C3 Keio University
RP Ozawa, Y (通讯作者)，Keio Univ, Dept Ophthalmol, Sch Med, 35 Shinanomachi Shinjuku Ku, Tokyo 1608582, Japan.
EM ozawa@a5.keio.jp
RI Tomita, Yohei/AAC-6968-2021; Uchida, Atsuro/GVT-8593-2022; Ozawa,
   Yoko/AAH-9888-2020
OI Tomita, Yohei/0000-0003-1013-5737; Uchida, Atsuro/0000-0002-1378-7151
CR Canan H, 2014, CLIN INTERV AGING, V9, P141, DOI 10.2147/CIA.S56863
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Goto E, 2002, AM J OPHTHALMOL, V133, P181, DOI 10.1016/S0002-9394(01)01365-4
   Hashemi H, 2012, OPHTHALMOLOGY, V119, P541, DOI 10.1016/j.ophtha.2011.08.030
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Ishida R, 2005, AM J OPHTHALMOL, V139, P253, DOI 10.1016/j.ajo.2004.08.075
   Kaido M, 2011, JPN J OPHTHALMOL, V55, P451, DOI 10.1007/s10384-011-0049-8
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Nishi Y, 2013, ACTA OPHTHALMOL, V91, pE353, DOI 10.1111/aos.12060
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Rii T, 2012, AM J OPHTHALMOL, V153, P524, DOI 10.1016/j.ajo.2011.08.021
   Sasaki M, 2014, OPTOMETRY VISION SCI, V91, P849, DOI 10.1097/OPX.0000000000000317
   Shin HJ, 2013, RETINA-J RET VIT DIS, V33, P964, DOI 10.1097/IAE.0b013e3182835f70
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Wakamatsu TH, 2011, J CATARACT REFR SURG, V37, P258, DOI 10.1016/j.jcrs.2010.08.048
   Yamaguchi T, 2011, CURR OPIN OPHTHALMOL, V22, P31, DOI 10.1097/ICU.0b013e3283414f36
NR 19
TC 15
Z9 15
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD JAN
PY 2016
VL 93
IS 1
BP 70
EP 76
DI 10.1097/OPX.0000000000000755
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA1FF
UT WOS:000367541000011
PM 26583795
OA Green Published
DA 2022-11-30
ER

PT J
AU Moshfeghi, AA
   Puliafito, CA
AF Moshfeghi, AA
   Puliafito, CA
TI Pegaptanib sodium for the treatment of neovascular age-related macular
   degeneration
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; choroidal
   neovascularisation; Macugen (TM); pegaptanib; pegaptanib sodium; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   VASCULAR-PERMEABILITY FACTOR; RANDOMIZED CLINICAL-TRIAL; PIGMENT
   EPITHELIAL-CELLS; PHOTODYNAMIC THERAPY; IRIS NEOVASCULARIZATION; LASER
   PHOTOCOAGULATION; VERTEPORFIN; PRIMATE
AB This article reviews pegaptanib sodium, a compound developed by Eyetech Pharmaceuticals Inc. and Pfizer Inc., for the treatment of neovascular age-related macular degeneration (AMD). Traditional treatment approaches to neovascular AMD have included destructive therapies such as thermal laser photocoagulation and photodynamic therapy; the use of pegaptanib sodium heralds a new treatment approach that is a non-destructive therapy based on the inhibition of vascular endothelial growth factor activity in the eye. This diminishes the neovascular drive in the pathologically hyperpermeable state of the diseased eye. Pegaptanib sodium is one of the first therapeutics belonging to the class of compounds known as aptamers. The chemistry, mechanism of action, pharmacokinetics and rationale for the clinical use of the drug are reviewed. The article highlights and summarises the results of the multi-centre, randomised, sham-controlled clinical trials with pegaptanib sodium to treat subfoveal choroidal neovascularisation in AMD. In addition, the safety profile is reviewed.
C1 Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Puliafito, CA (通讯作者)，Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM cpuliafito@med.miami.edu
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   *AG REL EYE DIS ST, 2000, OPHTHALMOLOGY, V107, P2224
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   *EYET PFIZ, 2004, PEG SOD INJ TREATM N
   *EYET PFIZ, 2004, FDA DERM OPHTH DRUGS
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hofman P, 2000, CURR EYE RES, V21, P637, DOI 10.1076/0271-3683(200008)21:2;1-V;FT637
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915
   Paskowitz DM, 2004, INVEST OPHTH VIS SCI, V45, P4190, DOI 10.1167/iovs.04-0676
   Shima DT, 1996, INVEST OPHTH VIS SCI, V37, P1334
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   The Eye Tech Study Group, 2002, RETINA, V22
   Tolentino MJ, 1998, INT OPHTHALMOL CLIN, V38, P77, DOI 10.1097/00004397-199803810-00007
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 34
TC 48
Z9 51
U1 3
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3784
EI 1744-7658
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD MAY
PY 2005
VL 14
IS 5
BP 671
EP 682
DI 10.1517/13543784.14.5.671
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 932QA
UT WOS:000229567200010
PM 15926872
DA 2022-11-30
ER

PT J
AU Silva, R
   Goncalves, C
   Meireles, A
   Teixeira, C
   Rosa, P
   Monteiro-Grillo, M
   Canelas, J
   Carneiro, A
   Flores, R
AF Silva, Rufino
   Goncalves, Carla
   Meireles, Angelina
   Teixeira, Carla
   Rosa, Paulo
   Monteiro-Grillo, Manuel
   Canelas, Joaquim
   Carneiro, Angela
   Flores, Rita
TI A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in
   Patients with Wet Age-Related Macular Degeneration from Portugal
SO ACTA MEDICA PORTUGUESA
LA English
DT Article
DE Portugal; Ranibizumab; Visual Acuity; Wet Macular Degeneration
ID CLINICAL-PRACTICE; INTRAVITREAL RANIBIZUMAB; THERAPY; AMD
AB Introduction: Anti-vascular endothelial growth factor therapy has revolutionized the treatment of wet age-related macular degeneration; however, it is important to monitor actual use of ranibizumab and related treatment outcomes in routine practice.
   Material and Methods: This was a retrospective, observational study to monitor the 2-year outcomes following ranibizumab treatment for wet age-related macular degeneration in Portugal. Patients treated between January 2009 and December 2009 were retrospectively evaluated. All decisions were made by the treating physician in accordance with their usual routine clinical practice. The primary assessment was mean change in visual acuity score using Early Treatment Diabetic Retinopathy Study or Snellen equivalent.
   Results: A total of 128 patients with wet age-related macular degeneration were analyzed (mean age 79.4 years; mean visual acuity score 54.2 letters). Mean change in visual acuity score from baseline was - 1.6 letters (n = 82) at year one and -5.1 letters (n = 72) at year two. The mean number of ranibizumab injections was 3.8 (year one) and 1.6 (year two). On average, patients attended 8.6 and 5.0 visits and optical coherence tomography was used in 75.0% of patients in year one and in 56.3% of patients in year two, respectively.
   Discussion: Despite a relatively high number of visits, including monitoring visits and use of optical coherence tomography - guided therapy, few injections were administered and visual acuity was not improved.
   Conclusion: These findings indicate that as-needed treatment resulted in under-dosing in a real-life setting in Portugal. Such limitations may also be related to increasing numbers of patients, resulting in clinic saturation.
C1 [Silva, Rufino] Univ Coimbra, Fac Med, Dept Ophthalmol, Coimbra, Portugal.
   [Silva, Rufino] Ctr Hosp & Univ Coimbra, Dept Ophthalmol, Coimbra, Portugal.
   [Silva, Rufino] Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
   [Goncalves, Carla] Bayer Portugal, Carnaxide, Portugal.
   [Meireles, Angelina] Ctr Hosp Porto, Dept Ophthalmol, Oporto, Portugal.
   [Teixeira, Carla] Unidade Local Saude Matosinhos, Dept Ophthalmol, Matosinhos, Portugal.
   [Rosa, Paulo] Inst Oftalmol Gama Pinto, Dept Ophthalmol, Lisbon, Portugal.
   [Monteiro-Grillo, Manuel; Canelas, Joaquim] Ctr Hosp Lisboa Norte, Dept Ophthalmol, Lisbon, Portugal.
   [Carneiro, Angela] Univ Porto, Fac Med, Dept Sense Organs, Oporto, Portugal.
   [Carneiro, Angela] Hosp Sao Joao, Dept Ophthalmol, Oporto, Portugal.
   [Flores, Rita] Ctr Hosp Lisboa Cent, Dept Ophthalmol, Lisbon, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e
   Universitario de Coimbra (CHUC); Universidade de Coimbra; Universidade
   de Lisboa; Universidade do Porto; Sao Joao Hospital; Centro Hospitalar
   de Lisboa Central, EPE; Universidade de Lisboa
RP Silva, R (通讯作者)，Univ Coimbra, Fac Med, Dept Ophthalmol, Coimbra, Portugal.; Silva, R (通讯作者)，Ctr Hosp & Univ Coimbra, Dept Ophthalmol, Coimbra, Portugal.; Silva, R (通讯作者)，Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
EM rufino.silva@oftalmologia.co.pt
RI Flores, Rita/AAU-9934-2020; Silva, Rufino M/J-2817-2012; Carneiro,
   Angela/N-9680-2013
OI Flores, Rita/0000-0002-7523-2418; Silva, Rufino M/0000-0001-8676-0833;
   Carneiro, Angela/0000-0002-3370-7243
FU Bayer HealthCare Pharmaceuticals [NCT01933152]
FX This study was funded by Bayer HealthCare Pharmaceuticals.
   ClinicalTrials.gov Identifier: NCT01933152.
CR Amoaku W., 2013, ROYAL COLL OPHTHALMO
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Gallego-Pinazo R, 2015, CURR OPIN OPHTHALMOL, V26, P200, DOI 10.1097/ICU.0000000000000151
   Hariprasad SM, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/690641
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Marques IR, 2013, OPHTHALMOLOGICA, V229, P158, DOI 10.1159/000343709
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
NR 17
TC 3
Z9 3
U1 0
U2 2
PU ORDEM MEDICOS
PI LISBON
PA AV ALMIRANTE GAGO COUTINHO, 151, LISBON, 1749-084, PORTUGAL
SN 1646-0758
J9 ACTA MEDICA PORT
JI Acta Medica Port.
PD JUN
PY 2017
VL 30
IS 6
BP 449
EP 456
DI 10.20344/amp.8217
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FC0GJ
UT WOS:000406516400005
PM 28898611
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Hikichi, T
   Agarie, M
   Kubo, N
   Yamauchi, M
AF Hikichi, Taiichi
   Agarie, Mitsuko
   Kubo, Natsuki
   Yamauchi, Moe
TI PREDICTORS OF RECURRENT EXUDATION IN CHOROIDAL NEOVASCULARIZATION IN
   AGE-RELATED MACULAR DEGENERATION DURING A TREATMENT-FREE PERIOD
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE anti&#8211; vascular endothelial growth factor therapy; choroidal
   neovascularization; neovascular age-related macular degeneration;
   optical coherence tomography angiography
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; GROWTH-FACTOR THERAPY; 2.0 MG
   RANIBIZUMAB; CHORIOCAPILLARIS; EFFICACY; OUTCOMES; SAFETY
AB Purpose: To investigate predictors of recurrent exudation in choroidal neovascularization (CNV) of age-related macular degeneration on optical coherence tomography angiography (OCTA) images during an anti-vascular endothelium growth factor therapy-free period. Methods: Optical coherence tomography angiography images of 41 eyes of 41 patients with more than a 3-year history of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration at the study baseline were evaluated retrospectively. The patients thereafter had a treatment-free period exceeding 6 months under an as-needed regimen and could be followed for an additional 6 months. Results: The square root of the CNV area in 19 eyes with recurrence during the second 6-month period enlarged significantly (P = 0.036) from 2.31 +/- 0.81 (mean +/- SD) to 2.86 +/- 0.87 mm during the treatment-free period but not in the 22 eyes without a recurrence. The percentages of branching with tiny vessels (42%) and peripheral arcades at the CNV termini (42%) were significantly (P < 0.001, respectively) higher in the recurrence group compared with the group in which the CNV was no longer active (14% and 5%, respectively). Conclusion: Choroidal neovascularization enlargement and features may guide treatment timing in eyes with exudative-free periods.
C1 [Hikichi, Taiichi; Kubo, Natsuki; Yamauchi, Moe] Hikichi Eye Clin, Sapporo, Hokkaido, Japan.
   [Agarie, Mitsuko] Carl Zeiss Meditec Co Ltd, Tokyo, Japan.
C3 Carl Zeiss AG
RP Hikichi, T (通讯作者)，Hikichi Eye Clin, Kita Ku, Kita 7 Nishi 5 7-1 Kita Sky Bldg,14 Floor, Sapporo, Hokkaido 0600807, Japan.
EM thikichi@hikichi-eye.jp
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cole ED, 2016, RETINA-J RET VIT DIS, V36, pS83, DOI 10.1097/IAE.0000000000001338
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hikichi T, 2019, INVEST OPHTH VIS SCI, V60, P1088, DOI 10.1167/iovs.18-24522
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Madhusudhana KC, 2016, BRIT J OPHTHALMOL, V100, P1617, DOI 10.1136/bjophthalmol-2015-308077
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miere A, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/3751702
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Munk MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177059
   Qin VL, 2018, RETINA-J RET VIT DIS, V38, P1500, DOI 10.1097/IAE.0000000000001753
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2016, DEV OPHTHALMOL, V56, P18, DOI 10.1159/000442773
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Teussink MM, 2015, INVEST OPHTH VIS SCI, V56, P5229, DOI 10.1167/iovs.15-17140
   Uji A, 2017, OPHTHALMOLOGY, V124, P944, DOI 10.1016/j.ophtha.2017.02.006
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
NR 33
TC 5
Z9 5
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2020
VL 40
IS 11
BP 2158
EP 2165
DI 10.1097/IAE.0000000000002745
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OP0WT
UT WOS:000587803100017
PM 31922495
DA 2022-11-30
ER

PT J
AU Hautamaki, A
   Kivioja, J
   Vavuli, S
   Kakko, S
   Savolainen, ER
   Savolainen, MJ
   Liinamaa, MJ
   Seitsonen, S
   Onkamo, P
   Jarvela, I
   Immonen, I
AF Hautamaki, Asta
   Kivioja, Jarno
   Vavuli, Satu
   Kakko, Sakari
   Savolainen, Eeva-Riitta
   Savolainen, Markku J.
   Liinamaa, M. Johanna
   Seitsonen, Sanna
   Onkamo, Paivi
   Jarvela, Irma
   Immonen, Ilkka
TI INTERLEUKIN 8 PROMOTER POLYMORPHISM PREDICTS THE INITIAL RESPONSE TO
   BEVACIZUMAB TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bevacizumab; exudative AMD; interleukin 8; optical coherence tomography;
   pharmacogenetics; single-nucleotide polymorphism; treatment response
ID COMPLEMENT-FACTOR-H; RETINAL VEIN OCCLUSION; AORTIC ENDOTHELIAL-CELLS;
   C-REACTIVE PROTEIN; INTRAVITREAL BEVACIZUMAB; GENE-EXPRESSION;
   ERYTHROPOIETIN GENE; AQUEOUS-HUMOR; SIGNIFICANT ASSOCIATION; JAPANESE
   POPULATION
AB Purpose: To study the association of single-nucleotide polymorphisms of interleukin 8, vascular endothelial growth factor, erythropoietin, complement factor H, complement component C3, and LOC387715 genes with the response to bevacizumab treatment in exudative age-related macular degeneration.
   Methods: Clinical records, smoking history, optical coherence tomography, and angiographies of 96 bevacizumab-treated exudative age-related macular degeneration patients were analyzed retrospectively. Blood DNA was collected. Based on the disappearance of intra-or subretinal fluid in optical coherence tomography, patients were graded as responders, partial responders, or nonresponders after 3 initial treatment visits and a median time of 3.5 months.
   Results: Interleukin 8 promoter polymorphism -251A/T was significantly associated with persisting fluid in optical coherence tomography. The A allele was more frequent in nonresponders than in responders (P = 0.033). In multivariate modeling, the AA genotype of -251A/T (P = 0.043) and occult (P = 0.042) or predominantly classic (P = 0.040) lesions predicted poorer outcome. Visual acuity change was better in responders than in nonresponders (P = 0.006). Baseline lesion size (P = 0.006) and retinal cysts after the treatment (P < 0.001) correlated with less visual acuity gain.
   Conclusion: The A allele and the homozygous AA genotype of interleukin 8 -251A/T were associated with anatomical nonresponse to bevacizumab treatment.
C1 [Hautamaki, Asta; Seitsonen, Sanna; Immonen, Ilkka] Univ Helsinki, Cent Hosp, Dept Ophthalmol, Helsinki 00029, Finland.
   [Kivioja, Jarno; Jarvela, Irma] Univ Helsinki, Dept Med Genet, Helsinki 00029, Finland.
   [Vavuli, Satu; Liinamaa, M. Johanna] Univ Oulu, Dept Ophthalmol, Inst Clin Med, SF-90220 Oulu, Finland.
   [Vavuli, Satu; Kakko, Sakari; Savolainen, Markku J.; Liinamaa, M. Johanna] Univ Oulu, Dept Internal Med, Clin Res Ctr, SF-90220 Oulu, Finland.
   [Vavuli, Satu; Kakko, Sakari; Savolainen, Markku J.; Liinamaa, M. Johanna] Univ Oulu, Bioctr Oulu, Oulu, Finland.
   [Savolainen, Eeva-Riitta] Oulu Univ Hosp, Dept Clin Chem, Oulu, Finland.
   [Onkamo, Paivi] Univ Helsinki, Dept Biosci, Helsinki 00029, Finland.
C3 University of Helsinki; Helsinki University Central Hospital; University
   of Helsinki; University of Oulu; University of Oulu; University of Oulu;
   University of Oulu; University of Helsinki
RP Hautamaki, A (通讯作者)，Univ Helsinki, Cent Hosp, Dept Ophthalmol, POB 220, Helsinki 00029, Finland.
EM asta.hautamaki@hus.fi
RI Jarvela, Irma E/L-5836-2013; Hautamaki, Asta/G-3098-2014
OI Jarvela, Irma E/0000-0002-1770-6187; Kivioja, Jarno/0000-0002-4046-0963;
   Liinamaa, Johanna/0000-0003-3424-7207; Hautamaki,
   Asta/0000-0002-9454-8434
FU Eye Foundation, Helsinki, Finland; Eye and Tissue Bank Foundation,
   Helsinki, Finland; Evald and Hilda Nissi Foundation, Helsinki, Finland;
   Mary and Georg C. Ehrnrooth Foundation, Helsinki, Finland
FX Supported by grants from The Eye Foundation, Helsinki, Finland; The Eye
   and Tissue Bank Foundation, Helsinki, Finland; The Evald and Hilda Nissi
   Foundation, Helsinki, Finland; and Mary and Georg C. Ehrnrooth
   Foundation, Helsinki, Finland.
CR Abdel-Malak NA, 2008, BLOOD, V111, P4145, DOI 10.1182/blood-2007-08-110338
   Abhary S, 2010, ARCH OPHTHALMOL-CHIC, V128, P102, DOI 10.1001/archophthalmol.2009.355
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Cao RH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002748
   DEFORGE LE, 1993, J BIOL CHEM, V268, P25568
   Devaraj S, 2004, J MOL CELL CARDIOL, V36, P405, DOI 10.1016/j.yjmcc.2003.12.005
   Fonollosa A, 2010, EYE, V24, P1284, DOI 10.1038/eye.2009.340
   Forooghian F, 2010, INVEST OPHTH VIS SCI, V51, P2388, DOI 10.1167/iovs.09-4065
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Funk M, 2010, RETINA-J RET VIT DIS, V30, P1412, DOI 10.1097/IAE.0b013e3181e095c0
   Funk M, 2009, INVEST OPHTH VIS SCI, V50, P1025, DOI 10.1167/iovs.08-2510
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Hildebrand F, 2007, CYTOKINE, V37, P192, DOI 10.1016/j.cyto.2007.03.008
   Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965
   Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023
   Hull J, 2001, AM J HUM GENET, V69, P413, DOI 10.1086/321291
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Ito H, 2005, J HUM GENET, V50, P567, DOI 10.1007/s10038-005-0296-y
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Kramer M, 2005, OCUL IMMUNOL INFLAMM, V13, P305, DOI 10.1080/09273940590950990
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lee WP, 2005, CLIN CANCER RES, V11, P6431, DOI 10.1158/1078-0432.CCR-05-0942
   Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369
   Ma WL, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-163
   Maier R, 2011, OPHTHALMOLOGY, V118, P1125, DOI 10.1016/j.ophtha.2010.10.014
   Martin D, 2009, J BIOL CHEM, V284, P6038, DOI 10.1074/jbc.C800207200
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Ohyauchi M, 2005, GUT, V54, P330, DOI 10.1136/gut.2003.033050
   Perez-Santonja JJ, 2010, AM J OPHTHALMOL, V150, P519, DOI 10.1016/j.ajo.2010.04.024
   Petreaca ML, 2007, MOL BIOL CELL, V18, P5014, DOI 10.1091/mbc.E07-01-0004
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Roh MI, 2009, OPHTHALMOLOGY, V116, P80, DOI 10.1016/j.ophtha.2008.09.036
   Sadda SR, 2010, GRAEF ARCH CLIN EXP, V248, P175, DOI 10.1007/s00417-009-1193-4
   Schultheis AM, 2008, CLIN CANCER RES, V14, P7554, DOI 10.1158/1078-0432.CCR-08-0351
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Sohn HJ, 2011, AM J OPHTHALMOL, V152, P686, DOI 10.1016/j.ajo.2011.03.033
   Steinbrugger I, 2009, MOL VIS, V15, P609
   Stentz FB, 2006, BIOCHEM BIOPH RES CO, V346, P721, DOI 10.1016/j.bbrc.2006.05.159
   STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570
   Taguchi A, 2005, CANCER EPIDEM BIOMAR, V14, P2487, DOI 10.1158/1055-9965.EPI-05-0326
   Talavera D, 2004, J GEN VIROL, V85, P1801, DOI 10.1099/vir.0.19652-0
   Teper SJ, 2010, MOL VIS, V16, P2598
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Tong ZZ, 2008, P NATL ACAD SCI USA, V105, P6998, DOI 10.1073/pnas.0800454105
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Wang Y, 2010, EXP EYE RES, V91, P135, DOI 10.1016/j.exer.2010.02.008
   Wang ZX, 2010, CYTOKINE, V50, P268, DOI 10.1016/j.cyto.2010.02.007
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
NR 59
TC 26
Z9 29
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2013
VL 33
IS 9
BP 1815
EP 1827
DI 10.1097/IAE.0b013e318285cf92
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297DL
UT WOS:000330235500009
PM 23584701
DA 2022-11-30
ER

PT J
AU Fisher, DE
   Jonasson, F
   Eiriksdottir, G
   Sigurdsson, S
   Klein, R
   Launer, LJ
   Gudnason, V
   Cotch, MF
AF Fisher, Diana E.
   Jonasson, Fridbert
   Eiriksdottir, Gudny
   Sigurdsson, Sigurdur
   Klein, Ronald
   Launer, Lenore J.
   Gudnason, Vilmundur
   Cotch, Mary Frances
TI Age-Related Macular Degeneration and Mortality in Community-Dwelling
   Elders The Age, Gene/Environment Susceptibility Reykjavik Study
SO OPHTHALMOLOGY
LA English
DT Article
ID BEAVER-DAM-EYE; BLUE-MOUNTAINS-EYE; RISK-FACTORS;
   CARDIOVASCULAR-DISEASE; VISUAL IMPAIRMENT; OLDER-PEOPLE; MACULOPATHY;
   ATHEROSCLEROSIS; PROGRESSION; SURVIVAL
AB Objective: To investigate the association between age-related macular degeneration (AMD) and mortality in older persons.
   Design: Population-based prospective cohort study.
   Participants: Participants 67 to 96 years of age (43.1% male) enrolled between 2002 and 2006 in the Age, Gene/Environment Susceptibility-Reykjavik Study.
   Methods: Retinal photographs of the macula were acquired digitally and evaluated for the presence of AMD lesions using the Wisconsin Age-Related Maculopathy grading scheme. Mortality was assessed prospectively through 2013 with cause of death available through 2009. The association between AMD and death, resulting from any cause and specifically cardiovascular disease (CVD), was examined using Cox proportional hazards regression with age as the time scale, adjusted for significant risk factors and comorbid conditions. To address a violation in the proportional hazards assumption, analyses were stratified into 2 groups based on the mean age at death (83 years).
   Main Outcome Measures: Mortality resulting from all causes and CVD.
   Results: Among 4910 participants, after a median follow-up of 8.6 years, 1742 died (35.5%), of whom 614 (35.2%) had signs of AMD at baseline. Cardiovascular disease was the cause of death for 357 people who died before the end of 2009, of whom 144 (40%) had AMD (101 with early disease and 43 with late disease). After considering covariates, including comorbid conditions, having early AMD at any age or having late AMD in individuals younger than 83 years (n = 4179) were not associated with all-cause or CVD mortality. In individuals 83 years of age and older (n = 731), late AMD was associated significantly with increased risk of all-cause mortality (hazard ratio [HR], 1.76; 95% confidence interval [CI], 1.20-2.57) and CVD-related mortality (HR, 2.37; 95% CI, 1.41-3.98). In addition to having AMD, older individuals who died were more likely to be male and to have low body mass index, impaired cognition, and microalbuminuria.
   Conclusions: Competing risk factors and concomitant conditions are important in determining mortality risk resulting from AMD. Individuals with early AMD are not more likely to die than peers of comparable age. Late AMD becomes a predictor of mortality by the mid-octogenarian years. (C) 2015 by the American Academy of Ophthalmology.
C1 [Fisher, Diana E.; Cotch, Mary Frances] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Jonasson, Fridbert] Landspitali Univ Hosp, Dept Ophthalmol, Reykjavik, Iceland.
   [Jonasson, Fridbert; Gudnason, Vilmundur] Univ Iceland, Fac Med, Reykjavik, Iceland.
   [Eiriksdottir, Gudny; Sigurdsson, Sigurdur; Gudnason, Vilmundur] Iceland Heart Assoc, Kopavogur, Iceland.
   [Klein, Ronald] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Launer, Lenore J.] NIA, Lab Epidemiol & Populat Sci, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Landspitali National University Hospital; University of Iceland;
   Icelandic Heart Association; University of Wisconsin System; University
   of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH
   National Institute on Aging (NIA)
RP Fisher, DE (通讯作者)，Bldg 10-CRC,Room 3-2521, Bethesda, MD 20892 USA.
EM diana.fisher@nih.gov
RI Gudnason, Vilmundur/AAE-7126-2019; Gudnason, Vilmundur/K-6885-2015;
   Jonasson, Fridbert/ABA-9889-2021
OI Gudnason, Vilmundur/0000-0001-5696-0084; Gudnason,
   Vilmundur/0000-0001-5696-0084; Cotch, Mary Frances/0000-0002-2046-4350;
   Klein, Ronald/0000-0002-4428-6237
FU Intramural Research Programs of the National Institute of Aging
   [ZIAG007380]; National Eye Institute [ZIAEY000401]; National Institutes
   of Health, Bethesda, Maryland [N01-AG-1-2100, ZIAEY00401]; Icelandic
   Heart Association, Kopavogur, Iceland; Icelandic Parliament, Reykjavik,
   Iceland; University of Iceland Research Fund, Reykjavik, Iceland; Helga
   Jonsdottir and Sigurlidi Kristjansson Research Fund, Reykjavik, Iceland;
   NATIONAL EYE INSTITUTE [ZIAEY000401] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [ZIAAG007380, N01AG012100] Funding Source:
   NIH RePORTER
FX Supported by the Intramural Research Programs of the National Institute
   of Aging (award no.: ZIAG007380) and the National Eye Institute (award
   no.: ZIAEY000401), National Institutes of Health (contract no.:
   N01-AG-1-2100), Bethesda, Maryland (grant no.: ZIAEY00401); the
   Icelandic Heart Association, Kopavogur, Iceland; the Icelandic
   Parliament, Reykjavik, Iceland; the University of Iceland Research Fund,
   Reykjavik, Iceland; and the Helga Jonsdottir and Sigurlidi Kristjansson
   Research Fund, Reykjavik, Iceland. The funders had no role in data
   collection; management, analysis, and interpretation of the data;
   preparation, writing, and approval of the manuscript; or decision to
   submit the manuscript for publication.
CR Adams MKM, 2012, HUM MOL GENET, V21, P5229, DOI 10.1093/hmg/dds364
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   Fisher D, 2014, AGE AGEING, V43, P69, DOI 10.1093/ageing/aft122
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Harris TB, 2007, AM J EPIDEMIOL, V165, P1076, DOI 10.1093/aje/kwk115
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Jylhava J, 2009, EXP GERONTOL, V44, P297, DOI 10.1016/j.exger.2008.10.006
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Saczynski JS, 2008, AM J EPIDEMIOL, V168, P1132, DOI 10.1093/aje/kwn228
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Xu L, 2009, OPHTHALMOLOGY, V116, P732, DOI 10.1016/j.ophtha.2008.11.003
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 30
TC 24
Z9 26
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2015
VL 122
IS 2
BP 382
EP 390
DI 10.1016/j.ophtha.2014.08.006
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AZ5WT
UT WOS:000348290000031
PM 25264026
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Marneros, AG
AF Marneros, Alexander G.
TI NLRP3 Inflammasome Blockade Inhibits VEGF-A-Induced Age-Related Macular
   Degeneration
SO CELL REPORTS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; CHOROIDAL NEOVASCULARIZATION; BASAL
   DEPOSITS; DRUSEN; MACULOPATHY; ACTIVATION; EXPRESSION; CELLS; EYES; MICE
AB The NLRP3 inflammasome is activated in age-related macular degeneration (AMD), but it remains unknown whether its activation contributes to AMD pathologies. VEGF-A is increased in neovascular ("wet") AMD, but it is not known whether it plays a role in inflammasome activation, whether an increase of VEGF-A by itself is sufficient to cause neovascular AMD and whether it can contribute to nonexudative ("dry") AMD that often co-occurs with the neovascular form. Here, it is shown that an increase in VEGF-A results in NLRP3 inflammasome activation and is sufficient to cause both forms of AMD pathologies. Targeting NLRP3 or the inflammasome effector cytokine IL-1 beta inhibits but does not prevent VEGF-A-induced AMD pathologies, whereas targeting IL-18 promotes AMD. Thus, increased VEGF-A provides a unifying pathomechanism for both forms of AMD; combining therapeutic inhibition of both VEGF-A and IL-1 beta or the NLRP3 inflammasome is therefore likely to suppress both forms of AMD.
C1 [Marneros, Alexander G.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
   [Marneros, Alexander G.] Harvard Univ, Sch Med, Dept Dermatol, Charlestown, MA 02129 USA.
C3 Harvard University; Massachusetts General Hospital; Harvard University
RP Marneros, AG (通讯作者)，Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
EM amarneros@partners.org
OI Marneros, Alexander/0000-0003-3866-020X
FU NEI [R01-EY019297]; NATIONAL EYE INSTITUTE [R01EY019297] Funding Source:
   NIH RePORTER
FX I would like to thank Drs. Andras Nagy, Lucile Miquerol, and Annette
   Damert for providing VEGF-A<SUP>hyper</SUP> and VEGF-A<SUP>hypo</SUP>
   mice and Dr. Napoleone Ferrara for providing VEGF-A<SUP>fl/fl</SUP>
   mice. This work was supported by a grant to A. G. M. from the NEI
   R01-EY019297.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brydges SD, 2009, IMMUNITY, V30, P875, DOI 10.1016/j.immuni.2009.05.005
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Cervi D, 2007, BLOOD, V109, P2139, DOI 10.1182/blood-2005-11-026823
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Damert A, 2002, DEVELOPMENT, V129, P1881
   Dorrell MI, 2009, J CLIN INVEST, V119, P611, DOI 10.1172/JCI35977
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Glaccum MB, 1997, J IMMUNOL, V159, P3364
   He LZ, 2013, AM J PATHOL, V182, P2407, DOI 10.1016/j.ajpath.2013.02.032
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jafarifar F, 2011, EMBO J, V30, P1324, DOI 10.1038/emboj.2011.38
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klettner A, 2009, GRAEF ARCH CLIN EXP, V247, P1487, DOI 10.1007/s00417-009-1139-x
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miquerol L, 1999, DEV BIOL, V212, P307, DOI 10.1006/dbio.1999.9355
   Monaghan-Benson E, 2009, J BIOL CHEM, V284, P25602, DOI 10.1074/jbc.M109.009894
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Takeda K, 1998, IMMUNITY, V8, P383, DOI 10.1016/S1074-7613(00)80543-9
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Wen HT, 2012, NAT IMMUNOL, V13, P352, DOI 10.1038/ni.2228
   Wen HT, 2011, NAT IMMUNOL, V12, P408, DOI 10.1038/ni.2022
   Wilkie AL, 2002, DEVELOPMENT, V129, P3349
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 40
TC 81
Z9 87
U1 2
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD SEP
PY 2013
VL 4
IS 5
BP 945
EP 958
DI 10.1016/j.celrep.2013.08.002
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 216LZ
UT WOS:000324286300012
PM 24012762
OA Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Pham, QTM
   Ahn, S
   Song, SJ
   Shin, J
AF Pham, Quang T. M.
   Ahn, Sangil
   Song, Su Jeong
   Shin, Jitae
TI Automatic Drusen Segmentation for Age-Related Macular Degeneration in
   Fundus Images Using Deep Learning
SO ELECTRONICS
LA English
DT Article
DE deep learning; drusen segmentation; high-resolution
ID CLASSIFICATION; SYSTEM; VESSEL; MODEL
AB Drusen are the main aspect of detecting age-related macular degeneration (AMD). Ophthalmologists can evaluate the condition of AMD based on drusen in fundus images. However, in the early stage of AMD, the drusen areas are usually small and vague. This leads to challenges in the drusen segmentation task. Moreover, due to the high-resolution fundus images, it is hard to accurately predict the drusen areas with deep learning models. In this paper, we propose a multi-scale deep learning model for drusen segmentation. By exploiting both local and global information, we can improve the performance, especially in the early stages of AMD cases.
C1 [Pham, Quang T. M.; Ahn, Sangil; Shin, Jitae] Sungkyunkwan Univ, Coll Informat & Commun Engn, Suwon 16419, South Korea.
   [Song, Su Jeong] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Ophthalmol, Seoul 03181, South Korea.
   [Song, Su Jeong] Sungkyunkwan Univ, Biomed Inst Convergence BICS, Suwon 16419, South Korea.
C3 Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU);
   Sungkyunkwan University (SKKU)
RP Shin, J (通讯作者)，Sungkyunkwan Univ, Coll Informat & Commun Engn, Suwon 16419, South Korea.; Song, SJ (通讯作者)，Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Ophthalmol, Seoul 03181, South Korea.; Song, SJ (通讯作者)，Sungkyunkwan Univ, Biomed Inst Convergence BICS, Suwon 16419, South Korea.
EM quangpham@skku.edu; il2s@skku.edu; ssjeye@skku.edu; jtshin@skku.edu
OI Shin, Jitae/0000-0002-2599-3331; Pham Tran Minh,
   Quang/0000-0003-1652-299X
FU National Research Foundation of Korea (NRF) - Korean government (MSIT)
   [2020R1F1A1065626]; MSIT (Ministry of Science and ICT), Korea, under
   ITRC (Information Technology Research Center) support program
   [IITP-2020-2018-0-01798]; Biomedical Institute for Convergence (BICS),
   Sungkyunkwan University
FX This work was partly supported by a National Research Foundation of
   Korea (NRF) grant funded by the Korean government (MSIT) (No.
   2020R1F1A1065626) and was partly supported by the MSIT (Ministry of
   Science and ICT), Korea, under the ITRC (Information Technology Research
   Center) support program (IITP-2020-2018-0-01798) supervised by the IITP
   (Institute for Information & communications Technology Promotion). It
   was also partly supported by the research fund from Biomedical Institute
   for Convergence (BICS), Sungkyunkwan University.
CR Asgari R, 2019, LECT NOTES COMPUT SC, V11764, P192, DOI 10.1007/978-3-030-32239-7_22
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen LCE, 2018, LECT NOTES COMPUT SC, V11211, P833, DOI 10.1007/978-3-030-01234-2_49
   Ciecholewski M, 2018, SYMMETRY-BASEL, V10, DOI 10.3390/sym10110589
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018
   Eelbode T., 2020, OPTIMIZATION MED IMA
   Guo S, 2019, NEUROCOMPUTING, V349, P52, DOI 10.1016/j.neucom.2019.04.019
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Hu J, 2018, PROC CVPR IEEE, P7132, DOI [10.1109/TPAMI.2019.2913372, 10.1109/CVPR.2018.00745]
   Huang LF, 2019, IEEE SIGNAL PROC LET, V26, P1026, DOI 10.1109/LSP.2019.2917779
   Huang YL, 2004, ULTRASOUND MED BIOL, V30, P625, DOI 10.1016/j.ultrasmedbio.2003.12.001
   Jiang Y, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10113777
   Joachim NDL, 2015, JAMA OPHTHALMOL, V133, P698, DOI 10.1001/jamaophthalmol.2015.0498
   Khojasteh P, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0954-4
   Kim YJ, 2018, COMPUT MATH METHOD M, V2018, DOI 10.1155/2018/6084798
   Lee J, 2019, AM J OPHTHALMOL, V208, P103, DOI 10.1016/j.ajo.2019.07.013
   Liu HY, 2014, 2014 IEEE VISUAL COMMUNICATIONS AND IMAGE PROCESSING CONFERENCE, P161, DOI 10.1109/VCIP.2014.7051529
   Masoumi H, 2012, BIOMED SIGNAL PROCES, V7, P429, DOI 10.1016/j.bspc.2012.01.002
   Meyer MI, 2018, LECT NOTES COMPUT SC, V11071, P39, DOI 10.1007/978-3-030-00934-2_5
   Mishra S, 2020, I S BIOMED IMAGING, P1254, DOI 10.1109/ISBI45749.2020.9098403
   Mittal D, 2015, COMPUT ELECTR ENG, V47, P82, DOI 10.1016/j.compeleceng.2015.08.014
   Mohaimin SM, 2018, IET IMAGE PROCESS, V12, P919, DOI 10.1049/iet-ipr.2017.0685
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   Nguyen DCT, 2018, MED IMAGE ANAL, V48, P58, DOI 10.1016/j.media.2018.05.006
   Raza G, 2013, P 2013 IEEE JORD C A, P1
   Ren XX, 2018, IEEE ACCESS, V6, P2952, DOI 10.1109/ACCESS.2017.2786271
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Tan JH, 2017, INFORM SCIENCES, V420, P66, DOI 10.1016/j.ins.2017.08.050
   Tian ZQ, 2016, IEEE T MED IMAGING, V35, P791, DOI 10.1109/TMI.2015.2496296
   Yan F, 2018, LECT NOTES COMPUT SC, V11071, P48, DOI 10.1007/978-3-030-00934-2_6
   Zhao YT, 2015, IEEE T MED IMAGING, V34, P1797, DOI 10.1109/TMI.2015.2409024
   Zheng YJ, 2013, I S BIOMED IMAGING, P1448
   Zheng YJ, 2011, I S BIOMED IMAGING, P689, DOI 10.1109/ISBI.2011.5872500
NR 34
TC 6
Z9 6
U1 1
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2079-9292
J9 ELECTRONICS-SWITZ
JI Electronics
PD OCT
PY 2020
VL 9
IS 10
AR 1617
DI 10.3390/electronics9101617
PG 11
WC Computer Science, Information Systems; Engineering, Electrical &
   Electronic; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Physics
GA OL4NX
UT WOS:000585320000001
OA gold
DA 2022-11-30
ER

PT J
AU Yasuhara, S
   Miyata, M
   Ooto, S
   Tamura, H
   Ueda-Arakawa, N
   Uji, A
   Muraoka, Y
   Miyake, M
   Takahashi, A
   Wakazono, T
   Yamashiro, K
   Tsujikawa, A
AF Yasuhara, Satoshi
   Miyata, Manabu
   Ooto, Sotaro
   Tamura, Hiroshi
   Ueda-Arakawa, Naoko
   Uji, Akihito
   Muraoka, Yuki
   Miyake, Masahiro
   Takahashi, Ayako
   Wakazono, Tomotaka
   Yamashiro, Kenji
   Tsujikawa, Akitaka
TI PREDICTORS OF RETINAL PIGMENT EPITHELIUM TEAR DEVELOPMENT AFTER
   TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION USING SWEPT
   SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; image
   analysis; optical coherence tomography angiography; retinal pigment
   epithelium tear
ID INTRAVITREAL BEVACIZUMAB INJECTION; ANTI-VEGF THERAPY; CHOROIDAL
   NEOVASCULARIZATION; RANIBIZUMAB; DETACHMENT
AB Purpose: The purpose of this study was to investigate the predictors of retinal pigment epithelium (RPE) tear development after treatment for neovascular age-related macular degeneration using swept source optical coherence tomography angiography. Methods: This prospective study included 152 treatment-naive eyes with neovascular age-related macular degeneration without high myopia that were followed up for 1 year after treatment. Eligible eyes were classified into eyes with or without RPE tear development. They were matched in a 1:2 ratio. The areas of choroidal neovascularization (CNV) and RPE detachment (pigment epithelial detachment [PED]) were measured from optical coherence tomography angiography and OCT en face images, respectively. The optical coherence tomography angiography-specific parameters representing CNV status were analyzed. Results: Eight (5.3%) of the 152 eyes developed RPE tears (RPE tear group). After matching, 16 eyes without RPE tears were analyzed (non-RPE tear group). The ratio of the CNV/PED area was lower in the RPE tear group than that in the non-RPE tear group (P = 0.007). The PED area was broader (P = 0.008), and PED height was greater in the RPE tear group (P = 0.04). Optical coherence tomography angiography-specific parameters did not differ between the two groups. Conclusion: Neovascular age-related macular degeneration with pretreatment broad PED, high PED, and small CNV area relative to the PED area has a high risk of RPE tear development after therapy. However, CNV status may not have an association.
C1 [Yasuhara, Satoshi; Miyata, Manabu; Ooto, Sotaro; Tamura, Hiroshi; Ueda-Arakawa, Naoko; Uji, Akihito; Muraoka, Yuki; Miyake, Masahiro; Takahashi, Ayako; Wakazono, Tomotaka; Yamashiro, Kenji; Tsujikawa, Akitaka] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto, Japan.
   [Yamashiro, Kenji] Red Cross Otsu Hosp, Dept Ophthalmol, Otsu, Shiga, Japan.
C3 Kyoto University
RP Miyata, M (通讯作者)，Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, Shogoin Kawahara Cho 54, Kyoto, Kyoto 6068507, Japan.
EM miyatam@kuhp.kyoto-u.ac.jp
RI Miyata, Manabu/U-9008-2018
OI Miyata, Manabu/0000-0002-7574-1749
CR Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Casalino G, 2019, INT J RETINA VITR, V5, DOI 10.1186/s40942-019-0155-1
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan Clement K, 2020, Am J Ophthalmol Case Rep, V20, P100916, DOI 10.1016/j.ajoc.2020.100916
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Cho HJ, 2015, AM J OPHTHALMOL, V160, P1000, DOI 10.1016/j.ajo.2015.07.023
   Chu ZD, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.6.066008
   Clemens CR, 2017, ACTA OPHTHALMOL, V95, P683, DOI 10.1111/aos.13359
   Clemens CR, 2014, ACTA OPHTHALMOL, V92, pE50, DOI 10.1111/aos.12234
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   DECKER WL, 1983, OPHTHALMOLOGY, V90, P507
   Eandi CM, 2017, INVEST OPHTH VIS SCI, V58, P3690, DOI 10.1167/iovs.17-21941
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Hosoda Y, 2018, OPHTHALMOL RETINA, V2, P1118, DOI 10.1016/j.oret.2018.04.011
   Konstantinidis L, 2010, ACTA OPHTHALMOL, V88, P736, DOI 10.1111/j.1755-3768.2009.01547.x
   Mitchell P, 2021, RETINA-J RET VIT DIS, V41, P671, DOI 10.1097/IAE.0000000000003083
   Musashi K, 2007, AM J OPHTHALMOL, V143, P883, DOI 10.1016/j.ajo.2006.12.024
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Sawai Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62607-6
   Watzke RC, 2000, OPHTHALMOLOGY, V107, P1601, DOI 10.1016/S0161-6420(00)00218-9
NR 28
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2022
VL 42
IS 6
BP 1020
EP 1027
DI 10.1097/IAE.0000000000003426
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1K9HA
UT WOS:000798904200006
PM 35125477
DA 2022-11-30
ER

PT J
AU Christoforidis, JB
   Tecce, N
   Dell'Omo, R
   Mastropasqua, R
   Verolino, M
   Costagliola, C
AF Christoforidis, John B.
   Tecce, Nicola
   Dell'Omo, Roberto
   Mastropasqua, Rodolfo
   Verolino, Marco
   Costagliola, Ciro
TI Age Related Macular Degeneration and Visual Disability
SO CURRENT DRUG TARGETS
LA English
DT Review
DE Age related macular degeneration; visual disability; magnifying glasses;
   telescopes and electronic aids; prescription filters; epidemiology; risk
   factors
ID OPTICAL COHERENCE TOMOGRAPHY; RISK-FACTORS; RACIAL-DIFFERENCES;
   CHOROIDAL NEOVASCULARIZATION; PREVALENCE; MACULOPATHY; IMPAIRMENT;
   ANGIOGRAPHY; PROGRESSION; MANAGEMENT
AB Age-related macular degeneration (AMD) is the leading cause of central blindness or low vision among the elderly in industrialized countries. AMD is caused by a combination of genetic and environmental factors. Among modifiable environmental risk factors, cigarette smoking has been associated with both the dry and wet forms of AMD and may increase the likelihood of worsening pre-existing AMD. Despite advances, the treatment of AMD has limitations and affected patients are often referred for low vision rehabilitation to help them cope with their remaining eyesight. The characteristic visual impairment for both forms of AMD is loss of central vision (central scotoma). This loss results in severe difficulties with reading that may be only partly compensated by magnifying glasses or screen-projection devices. The loss of central vision associated with the disease has a profound impact on patient quality of life. With progressive central visual loss, patients lose their ability to perform the more complex activities of daily living.
   Common vision aids include low vision filters, magnifiers, telescopes and electronic aids. Low vision rehabilitation (LVR) is a new subspecialty emerging from the traditional fields of ophthalmology, optometry, occupational therapy, and sociology, with an ever-increasing impact on the usual concepts of research, education, and services for visually impaired patients. Relatively few ophthalmologists practise LVR and fewer still routinely use prismatic image relocation (IR) in AMD patients. IR is a method of stabilizing oculomotor functions with the purpose of promoting better function of preferred retinal loci (PRLs). The aim of vision rehabilitation therapy consists in the achievement of techniques designed to improve PRL usage. The use of PRLs to compensate for diseased foveae has offered hope to these patients in regaining some function. However, in a recently published meta-analysis, prism spectacles were found to be unlikely to be of substantial benefit in people with age-related macular degeneration.
   Prescription filters are one of the most beneficial visual aids for people with macular degeneration. In principle, one aims both at reducing short-wavelength light to reduce glare and at identifying light with specific wavelengths (colours) preferred by the patient for viewing. In both instances, such interventions result in apparent improved contrast sensitivity and better visual acuity. Although specific tests are performed to determine the best colour, tint, lens material, and type of frame for the patient's need, no scientific protocol has been developed so far to assist in prescribing tinted or selective transmission lenses.
   Magnifying optical lenses are available in a wide range of dioptric powers and are made from materials that correct for weight (plastic), thickness (high index), spherical aberrations (aspherical), and variable light intensities (photochromatic). These lenses can be used as loose lenses, mounted on optical frames, or used with a wide variety of attachments. As the dioptric power of plus lenses increases, the viewing distance of the target decreases, hence their usefulness mainly for tasks requiring near resolution acuity, like reading. Magnification can also be achieved with the use of telescopic devices that are built of two or more plus and (or) minus (minifying) optical lenses. Normal resolution acuity levels can be achieved with these devices for all viewing distances. Therefore, all telescopic devices are useful only for stationary patient tasks that do not require mobility and orientation. Electronic magnification has the great advantage over plus lenses of producing an acuity reserve enabling reading skills for almost all levels of visual acuity. The additional benefit provided is preservation of binocularity, even at high levels of visual disparity between the two eyes.
   Vision rehabilitation can help patients to maximize their remaining vision and adapt to activities of daily living. The support of the patient's social network is critical to patient's well-being as patients adjust to being partially sighted.
C1 [Christoforidis, John B.] Ohio State Univ, Dept Ophthalmol, Columbus, OH 43212 USA.
   [Tecce, Nicola; Dell'Omo, Roberto; Mastropasqua, Rodolfo; Costagliola, Ciro] Univ Molise, Cattedra Clin Oculist, Dipartimento Sci Salute, Campobasso, Italy.
   [Verolino, Marco] Presidio Osped Boscotrecase, Unita Operat Oculist, Azienda Sanit Locale Napoli Sud 3, Naples, Italy.
C3 Ohio State University; University of Molise
RP Christoforidis, JB (通讯作者)，Ohio State Univ, Dept Ophthalmol, 915 Olentangy River Rd,Ste 5000, Columbus, OH 43212 USA.
EM John.Christoforidis@osumc.edu
RI dell'Omo, Roberto/K-7328-2016; Costagliola, Ciro/G-5707-2012;
   Mastropasqua, Rodolfo/AAC-6453-2022
OI dell'Omo, Roberto/0000-0002-7663-8874; Costagliola,
   Ciro/0000-0001-8477-6188; 
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Arden GB, 2004, BRIT J OPHTHALMOL, V88, P1180, DOI 10.1136/bjo.2003.033480
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Banerjee A, 2008, INDIAN J OPHTHALMOL, V56, P469
   Birk T, 2004, GERONTOLOGIST, V44, P836, DOI 10.1093/geront/44.6.836
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Comer GM, 2004, DRUG AGING, V21, P967, DOI 10.2165/00002512-200421150-00002
   COSTAGLIOLA C, 1985, METABOLISM, V34, P712, DOI 10.1016/0026-0495(85)90019-8
   COSTAGLIOLA C, 1989, EXP EYE RES, V48, P583, DOI 10.1016/0014-4835(89)90041-9
   Costagliola C, 1990, Metab Pediatr Syst Ophthalmol (1985), V13, P96
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   DERUAZ A, 2006, BMC OPHTHALMOL, V23, P6
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P413, DOI 10.1016/j.exer.2004.10.008
   EVANS J, 1995, CAUSES BLINDNESS PAR
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Gohdes Dorothy M, 2005, Prev Chronic Dis, V2, pA17
   Green W R, 1999, Mol Vis, V5, P27
   Hassenstein A, 2009, CLIN EXP OPHTHALMOL, V37, P130, DOI 10.1111/j.1442-9071.2009.02017.x
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur C, 2008, CLIN OPHTHALMOL, V2, P879, DOI 10.2147/opth.s3361
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEEN SR, 1981, AM J OPTOM PHYS OPT, V58, P200
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Kramer M, 2000, AM J OPHTHALMOL, V129, P495, DOI 10.1016/S0002-9394(99)00388-8
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Lovie-Kitchin JE, 2000, OPTOMETRY VISION SCI, V77, P412, DOI 10.1097/00006324-200008000-00008
   Lowe JB, 2000, OPTOMETRY VISION SCI, V77, P260, DOI 10.1097/00006324-200005000-00013
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Markowitz SN, 2006, CAN J OPHTHALMOL, V41, P289, DOI 10.1139/I06-027
   Massin P, 2006, ACTA OPHTHALMOL SCAN, V84, P466, DOI 10.1111/j.1600-0420.2006.00694.x
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Newland H S, 1996, Ophthalmic Epidemiol, V3, P97, DOI 10.3109/09286589609080114
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Reeves BC, 2004, BRIT J OPHTHALMOL, V88, P1443, DOI 10.1136/bjo.2003.037457
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   TAYLOR HR, 1990, T AM OPHTHAL SOC, V997, P163
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Virgili G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003303.pub2
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
   World Health Organization, 1993, INT STAT CLASS DIS I
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 69
TC 24
Z9 28
U1 0
U2 68
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
EI 1873-5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD FEB
PY 2011
VL 12
IS 2
BP 221
EP 233
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 720RX
UT WOS:000287299000010
PM 20887239
DA 2022-11-30
ER

PT J
AU Jones, A
   Kumar, S
   Zhang, N
   Tong, ZZ
   Yang, JH
   Watt, C
   Anderson, J
   Amrita
   Fillerup, H
   McCloskey, M
   Luo, L
   Yang, ZL
   Ambati, B
   Marc, R
   Oka, C
   Zhang, K
   Fu, YB
AF Jones, Alex
   Kumar, Sandeep
   Zhang, Ning
   Tong, Zongzhong
   Yang, Jia-Hui
   Watt, Carl
   Anderson, James
   Amrita
   Fillerup, Heather
   McCloskey, Manabu
   Luo, Ling
   Yang, Zhenglin
   Ambati, Balamurali
   Marc, Robert
   Oka, Chio
   Zhang, Kang
   Fu, Yingbin
TI Increased expression of multifunctional serine protease, HTRA1, in
   retinal pigment epithelium induces polypoidal choroidal vasculopathy in
   mice
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; INTRAVITREAL
   BEVACIZUMAB; PROMOTER POLYMORPHISM; JAPANESE POPULATION; MESSENGER-RNA;
   ARMS2; VARIANTS; DISEASE; SUSCEPTIBILITY
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly. Wet AMD includes typical choroidal neovascularization (CNV) and polypoidal choroidal vasculopathy (PCV). The etiology and pathogenesis of CNV and PCV are not well understood. Genome-wide association studies have linked a multifunctional serine protease, HTRA1, to AMD. However, the precise role of HTRA1 in AMD remains elusive. By transgenically expressing human HTRA1 in mouse retinal pigment epithelium, we showed that increased HTRA1 induced cardinal features of PCV, including branching networks of choroidal vessels, polypoidal lesions, severe degeneration of the elastic laminae, and tunica media of choroidal vessels. In addition, HTRA1 mice displayed retinal pigment epithelium atrophy and photoreceptor degeneration. Senescent HTRA1 mice developed occult CNV, which likely resulted from the degradation of the elastic lamina of Bruch's membrane and up-regulation of VEGF. Our results indicate that increased HTRA1 is sufficient to cause PCV and is a significant risk factor for CNV.
C1 [Jones, Alex; Kumar, Sandeep; Zhang, Ning; Tong, Zongzhong; Yang, Jia-Hui; Watt, Carl; Anderson, James; Amrita; Fillerup, Heather; McCloskey, Manabu; Luo, Ling; Ambati, Balamurali; Marc, Robert; Fu, Yingbin] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   [Fu, Yingbin] Univ Utah, Sch Med, Dept Neurobiol & Anat, Salt Lake City, UT 84132 USA.
   [Yang, Zhenglin] Sichuan Acad Med Sci, Key Lab Human Dis Gene Study Sichuan Prov, Chengdu 610072, Peoples R China.
   [Yang, Zhenglin] Sichuan Prov Peoples Hosp, Chengdu 610072, Peoples R China.
   [Oka, Chio] Nara Inst Sci & Technol, Div Gene Funct Anim, Nara 6300192, Japan.
   [Zhang, Kang] Sichuan Univ, W China Hosp, Mol Med Res Ctr, Chengdu 610041, Peoples R China.
   [Zhang, Kang] Sichuan Univ, W China Hosp, Dept Ophthalmol, Chengdu 610041, Peoples R China.
   [Zhang, Kang] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92037 USA.
   [Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92037 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Sichuan Provincial People's
   Hospital; Sichuan Provincial People's Hospital; Nara Institute of
   Science & Technology; Sichuan University; Sichuan University; University
   of California System; University of California San Diego; University of
   California System; University of California San Diego
RP Fu, YB (通讯作者)，Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
EM Yingbin.fu@hsc.utah.edu
RI Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697; kumar, sandeep/0000-0002-2918-8276
FU National Eye Institute/National Institutes of Health; National Basic
   Research Program of China (973 Program) [2011CB510200]; Chinese National
   985 Project; West China Hospital; Veterans Administration Merit Award;
   Nara Institute of Science and Technology; Inamori Foundation; Ministry
   of Education, Culture, Sports, Science, and Technology, Japan; Career
   Development Award; Karl Kirchgessner Foundation; NATIONAL EYE INSTITUTE
   [R01EY021374, R01EY002576, P30EY014800, R01EY018660] Funding Source: NIH
   RePORTER; Veterans Affairs [I01BX001898] Funding Source: NIH RePORTER
FX We thank N. Esumi for providing the VMD2 promoter, G. Hageman for
   assistance in H&E staining, W. D. Ferrell for assistance in histology
   imaging, and M. E. Hartnett and P. S. Bernstein for discussions and
   comments on the manuscript. K.Z. was supported by grants from the
   National Eye Institute/National Institutes of Health, National Basic
   Research Program of China (973 Program, 2011CB510200), Chinese National
   985 Project to Sichuan University and West China Hospital, and a
   Veterans Administration Merit Award; C.O. was supported by research
   grants from the Nara Institute of Science and Technology and the Inamori
   Foundation, and by Grants-in-Aid from the Ministry of Education,
   Culture, Sports, Science, and Technology, Japan; Y.F. was supported by
   the Career Development Award (Research to Prevent Blindness), a Research
   to Prevent Blindness departmental unrestricted grant, and the Karl
   Kirchgessner Foundation Award for Vision Research.
CR An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Barnhart KM, 1998, HUM GENE THER, V9, P2545
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Canfield AE, 2007, BIOCHEM SOC T, V35, P669, DOI 10.1042/BST0350669
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Esumi N, 2004, J BIOL CHEM, V279, P19064, DOI 10.1074/jbc.M309881200
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Murwantoko, 2004, BIOCHEM J, V381, P895, DOI 10.1042/BJ20040435
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ng TK, 2011, INVEST OPHTH VIS SCI, V52, P3706, DOI 10.1167/iovs.10-6773
   Nie GY, 2003, BIOCHEM J, V371, P39, DOI 10.1042/BJ20021569
   Ong ST, 2005, HUM GENE THER, V16, P1404, DOI 10.1089/hum.2005.16.1404
   Picanco-Castro V, 2008, GENET MOL RES, V7, P314, DOI 10.4238/vol7-2gmr447
   Runyon ST, 2007, PROTEIN SCI, V16, P2454, DOI 10.1110/ps.073049407
   Sivaprasad S, 2005, INVEST OPHTH VIS SCI, V46
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zurawa-Janicka D, 2010, EXPERT OPIN THER TAR, V14, P665, DOI 10.1517/14728222.2010.487867
NR 51
TC 116
Z9 127
U1 0
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 30
PY 2011
VL 108
IS 35
BP 14578
EP 14583
DI 10.1073/pnas.1102853108
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 814DH
UT WOS:000294425900045
PM 21844367
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ho, EXP
   Cheung, CMG
   Sim, S
   Chu, CW
   Wilm, A
   Lin, CB
   Mathur, R
   Wong, D
   Chan, CM
   Bhagarva, M
   Laude, A
   Lim, TH
   Wong, TY
   Cheng, CY
   Davila, S
   Hibberd, M
AF Ho, Eliza Xin Pei
   Cheung, Chui Ming Gemmy
   Sim, Shuzhen
   Chu, Collins Wenhan
   Wilm, Andreas
   Lin, Clarabelle Bitong
   Mathur, Ranjana
   Wong, Doric
   Chan, Choi Mun
   Bhagarva, Mayuri
   Laude, Augustinus
   Lim, Tock Han
   Wong, Tien Yin
   Cheng, Ching Yu
   Davila, Sonia
   Hibberd, Martin
TI Human pharyngeal microbiota in age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; NEISSERIA-MENINGITIDIS;
   STREPTOCOCCUS-PYOGENES; BINDING-AFFINITY; RISK-FACTORS; GENE; DISEASE;
   POLYMORPHISM; ASSOCIATION
AB Background
   While the aetiology of age-related macular degeneration (AMD)-a major blinding disease -remains unknown, the disease is strongly associated with variants in the complement factor H (CFH) gene. CFH variants also confer susceptibility to invasive infection with several bacterial colonizers of the nasopharyngeal mucosa. This shared susceptibility locus implicates complement deregulation as a common disease mechanism, and suggests the possibility that microbial interactions with host complement may trigger AMD. In this study, we address this possibility by testing the hypothesis that AMD is associated with specific microbial colonization of the human nasopharynx.
   Results
   High-throughput Illumina sequencing of the V3-V6 region of the microbial 16S ribosomal RNA gene was used to comprehensively and accurately describe the human pharyngeal microbiome, at genus level, in 245 AMD patients and 386 controls. Based on mean and differential microbial abundance analyses, we determined an overview of the pharyngeal microbiota, as well as candidate genera (Prevotella and Gemella) suggesting an association towards AMD health and disease conditions.
   Conclusions
   Utilizing an extensive study population from Singapore, our results provided an accurate description of the pharyngeal microbiota profiles in AMD health and disease conditions. Through identification of candidate genera that are different between conditions, we provide preliminary evidence for the existence of microbial triggers for AMD.
   Ethical approval for this study was obtained through the Singapore Health Clinical Institutional Review Board, reference numbers R799/63/2010 and 2010/585/A.
C1 [Ho, Eliza Xin Pei; Sim, Shuzhen; Chu, Collins Wenhan; Wilm, Andreas; Lin, Clarabelle Bitong; Davila, Sonia; Hibberd, Martin] Genome Inst Singapore, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Mathur, Ranjana; Wong, Doric; Chan, Choi Mun; Wong, Tien Yin; Cheng, Ching Yu] Natl Univ Singapore, Duke NUS Med Sch, Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Bhagarva, Mayuri] Natl Univ Singapore, Dept Ophthalmol, Singapore, Singapore.
   [Bhagarva, Mayuri] Natl Univ Hlth Syst, Singapore, Singapore.
   [Laude, Augustinus; Lim, Tock Han] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore, Singapore.
   [Hibberd, Martin] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England.
C3 Agency for Science Technology & Research (A*STAR); A*STAR - Genome
   Institute of Singapore (GIS); National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore; Tan Tock Seng Hospital; University of
   London; London School of Hygiene & Tropical Medicine
RP Ho, EXP (通讯作者)，Genome Inst Singapore, Singapore, Singapore.
EM hoxpe@gis.a-star.edu.sg
RI Cheng, Ching-Yu/Y-2229-2019; Lin, Clarabelle/AAK-4409-2020; Wong, Tien
   Yin/AAC-9724-2020
OI Cheng, Ching-Yu/0000-0003-0655-885X; Wong, Tien Yin/0000-0002-8448-1264;
   Wong, Damon/0000-0003-4601-9121; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Hibberd, Martin/0000-0001-8587-1849
FU Biomedical Research Council, Singapore [10/1/35/19/671]
FX This project is funded by grant number 10/1/35/19/671 from the
   Biomedical Research Council, Singapore. The funders had no role in study
   design, data collection, analysis, and interpretation, manuscript
   preparation, or decision to publish.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Bogaert D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017035
   Boutin S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116029
   Charlson ES, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015216
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Chua MC, 2017, J PEDIAT GASTROENTER
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Davila S, 2010, NAT GENET, V42, P772, DOI 10.1038/ng.640
   DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Freeley S, 2016, IMMUNOL REV, V274, P16, DOI 10.1111/imr.12472
   Gao Zhancheng, 2014, Genomics Proteomics & Bioinformatics, V12, P144, DOI 10.1016/j.gpb.2014.06.001
   Gong HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066476
   Gong HL, 2014, APPL ENVIRON MICROB, V80, P7356, DOI 10.1128/AEM.02329-14
   Haapasalo K, 2012, J IMMUNOL, V188, P426, DOI 10.4049/jimmunol.1102545
   Haapasalo K, 2008, MOL MICROBIOL, V70, P583, DOI 10.1111/j.1365-2958.2008.06347.x
   Hang J, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-31
   Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234
   Igartua C, 2017, MICROBIOME, V5, DOI 10.1186/s40168-016-0227-5
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Khor CC, 2012, TRENDS GENET, V28, P233, DOI 10.1016/j.tig.2012.02.001
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Matsuki T, 2004, APPL ENVIRON MICROB, V70, P7220, DOI 10.1128/AEM.70.12.7220-7228.2004
   Meri T, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003308
   Miller CS, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-5-r44
   Morris A, 2013, AM J RESP CRIT CARE, V187, P1067, DOI 10.1164/rccm.201210-1913OC
   Ong SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060811
   Picard FJ, 2004, J CLIN MICROBIOL, V42, P3686, DOI 10.1128/jcm.42.8.3686-3695.2004
   Potempa M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000316
   Reese SE, 2013, BIOINFORMATICS, V29, P2877, DOI 10.1093/bioinformatics/btt480
   Scher JU, 2013, ELIFE, V2, DOI 10.7554/eLife.01202
   Schneider MC, 2009, NATURE, V458, P890, DOI 10.1038/nature07769
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   The HC, 2017, GUT MICROBES
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yazdankhah SP, 2004, J MED MICROBIOL, V53, P821, DOI 10.1099/jmm.0.45529-0
NR 43
TC 18
Z9 19
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 8
PY 2018
VL 13
IS 8
AR e0201768
DI 10.1371/journal.pone.0201768
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GP7NS
UT WOS:000441090300049
PM 30089174
OA Green Submitted, Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Hoshikawa, A
   Tagami, T
   Morimura, C
   Fukushige, K
   Ozeki, T
AF Hoshikawa, Akihiro
   Tagami, Tatsuaki
   Morimura, Chisa
   Fukushige, Kaori
   Ozeki, Tetsuya
TI Ranibizumab biosimilar/polyethyleneglycol-conjugated gold nanoparticles
   as a novel drug delivery platform for age-related macular degeneration
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Age-related macular degeneration; Biosimilar; Gold nanoparticles;
   PEGylation; Ranibizumab
ID ANGIOGENESIS; PHARMACOKINETICS; BIODISTRIBUTION; VEGF
AB Ranibizumab is a first-line therapy against age -related macular degeneration. For further improvement of ranibizumab-based treatment, we developed ranibizumab biosimilar (Mab)/polyethyleneglycol (PEG) conjugated small gold nanoparticles (core size: approximately 5 nm) as a novel platform of ranibizumab biosimilar (Mab) delivery. Mab/PEG-conjugated gold nanoparticles were successfully prepared, and the particles were characterized by transmission electron microscopy and dynamic light scattering method. The mean diameters of Mab/PEG-conjugated gold nanoparticles and PEG-conjugated gold nanoparticles were varied using different lengths of PEG chain (5 kDa and 10 kDa). The Mab conjugation efficiency was optimized by changing the amount of PEG in preparation, which showed a high conjugation efficiency (>70%). We found that Mab/PEG-conjugated gold nanoparticles effectively inhibited the tube formation of human umbilical vein endothelial cells based on Matrigel in vitro. PEG -conjugated gold nanoparticles without Mab inhibited the tube formation unexpectedly. The Mab/PEG-conjugated gold nanoparticles did not affect cell proliferation in human endothelial cells. These results suggest that Mab/PEGconjugated gold nanoparticles can be used as a good and novel colloidal formulation against angiogenesis-related diseases in local sites such as age-related macular degeneration. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Hoshikawa, Akihiro; Tagami, Tatsuaki; Morimura, Chisa; Fukushige, Kaori; Ozeki, Tetsuya] Nagoya City Univ, Drug Delivery & Nano Pharmaceut, Grad Sch Pharmaceut Sci, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.
C3 Nagoya City University
RP Ozeki, T (通讯作者)，Nagoya City Univ, Drug Delivery & Nano Pharmaceut, Grad Sch Pharmaceut Sci, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.
EM ozekit@phar.nagoya-cu.ac.jp
CR Alten R, 2015, SEMIN ARTHRITIS RHEU, V44, pS2, DOI 10.1016/j.semarthrit.2015.04.002
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   BATTEGAY EJ, 1995, J MOL MED, V73, P333
   BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801
   Cabuzu D, 2015, CURR TOP MED CHEM, V15, P1605
   Chen WW, 2016, ADV MATER, V28, P8567, DOI 10.1002/adma.201602080
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Lee H, 2014, ACS NANO, V8, P4790, DOI 10.1021/nn500685h
   Libutti SK, 2010, CLIN CANCER RES, V16, P6139, DOI 10.1158/1078-0432.CCR-10-0978
   Mielke J, 2016, BRIT J CLIN PHARMACO, V82, P1444, DOI 10.1111/bcp.13076
   Mukherjee P, 2005, CLIN CANCER RES, V11, P3530, DOI 10.1158/1078-0432.CCR-04-2482
   Pan YL, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/418624
   Pandya NM, 2006, VASC PHARMACOL, V44, P265, DOI 10.1016/j.vph.2006.01.005
   Polverini Peter J, 2002, J Dent Educ, V66, P962
   Pozarowska D, 2016, CENT EUR J IMMUNOL, V41, P311, DOI 10.5114/ceji.2016.63132
   Tanetsugu T., 2017, BIOL PHARM BULL, V40, P1
   Turecek PL, 2016, J PHARM SCI-US, V105, P460, DOI 10.1016/j.xphs.2015.11.015
   Xia QY, 2016, CURR DRUG METAB, V17, P849, DOI 10.2174/1389200217666160629114941
   Zhang GD, 2009, BIOMATERIALS, V30, P1928, DOI 10.1016/j.biomaterials.2008.12.038
NR 21
TC 12
Z9 12
U1 0
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1773-2247
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PD APR
PY 2017
VL 38
BP 45
EP 50
DI 10.1016/j.jddst.2017.01.004
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EP9IG
UT WOS:000397686700006
DA 2022-11-30
ER

PT J
AU Csaky, KG
   Patel, PJ
   Sepah, YJ
   Birch, DG
   Do, DV
   Ip, MS
   Guymer, RH
   Luu, CD
   Gune, S
   Lin, H
   Ferrara, D
AF Csaky, Karl G.
   Patel, Praveen J.
   Sepah, Yasir J.
   Birch, David G.
   Do, Diana, V
   Ip, Michael S.
   Guymer, Robyn H.
   Luu, Chi D.
   Gune, Shamika
   Lin, Hugh
   Ferrara, Daniela
TI Microperimetry for geographic atrophy secondary to age-related macular
   degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE microperimetry; geographic atrophy; age-related macular degeneration;
   anatomic-functional correlation; retinal sensitivity; visual function
ID OPTICAL COHERENCE TOMOGRAPHY; LUMINANCE VISUAL-ACUITY; TEST-RETEST
   VARIABILITY; RETINAL SENSITIVITY; FUNDUS AUTOFLUORESCENCE; MULTIFOCAL
   ELECTRORETINOGRAPHY; RETICULAR PSEUDODRUSEN; AUTOMATED PERIMETRY; NIDEK
   MP1; PROGRESSION
AB Geographic atrophy (GA) is a progressive, advanced form of age-related macular degeneration leading to visual function impairment and irreversible vision loss. Standard clinical tests to evaluate visual function in patients with GA provide poor anatomic-functional correlation, whereas fundus imaging does not assess the visual function deficit. Microperimetry is a psychophysical visual function test that spatially maps retinal sensitivity and allows for identification of correlation of anatomic features with visual function. In this review, we present an overview of mesopic microperimetry for GA, including commercially available microperimetry devices, strategies to capture a mesopic microperimetry test, and strategies to assess and interpret microperimetry data in patients with GA. We demonstrate the importance of microperimetry data for assessing GA progression and for evaluating visual function loss through anatomic-functional correlations. Although valuable, current microperimetry tests require an extensive time commitment from the patient and examiner, and the development of faster, more reproducible and accessible methods is important to enable broader use of microperimetry in both clinical and research settings. (C) 2019 The Authors. Published by Elsevier Inc.
C1 [Csaky, Karl G.] Texas Retina Associates, Dallas, TX USA.
   [Csaky, Karl G.; Birch, David G.] Retina Fdn Southwest, 9600 N Cent Expressway,Suite 200, Dallas, TX 75231 USA.
   [Patel, Praveen J.] Moorfields Eye Hosp, NIHR Biomed Res Ctr, London, England.
   [Patel, Praveen J.] UCL Inst Ophthalmol, London, England.
   [Sepah, Yasir J.; Do, Diana, V] Stanford Univ, Sch Med, Byers Eye Inst, Palo Alto, CA 94304 USA.
   [Ip, Michael S.] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Guymer, Robyn H.; Luu, Chi D.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
   [Guymer, Robyn H.; Luu, Chi D.] Univ Melbourne, Dept Surg Ophthalmol, Melbourne, Vic, Australia.
   [Gune, Shamika; Lin, Hugh; Ferrara, Daniela] Genentech Inc, San Francisco, CA 94080 USA.
C3 Retina Foundation of the Southwest; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust; University
   of London; University College London; Stanford University; Doheny Eye
   Institute; Centre for Eye Research Australia; Royal Victorian Eye & Ear
   Hospital; University of Melbourne; University of Melbourne; Roche
   Holding; Genentech
RP Csaky, KG (通讯作者)，Retina Fdn Southwest, 9600 N Cent Expressway,Suite 200, Dallas, TX 75231 USA.
EM kcsaky@retinafoundation.org
FU F. Hoffmann-La Roche Ltd.; NATIONAL EYE INSTITUTE [R01EY009076] Funding
   Source: NIH RePORTER
FX Funding was provided by F. Hoffmann-La Roche Ltd. for third-party
   writing assistance, which was provided by Charlotte A. Osborne, PhD, of
   Envision Pharma Group.
CR Acton JH, 2013, CAN J OPHTHALMOL, V48, P358, DOI 10.1016/j.jcjo.2013.03.021
   Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Batioglu F, 2014, OPHTHALMIC RES, V52, P53, DOI 10.1159/000361077
   Biarnes M, 2011, OPTOMETRY VISION SCI, V88, P881, DOI 10.1097/OPX.0b013e31821988c1
   Cassels NK, 2018, SURV OPHTHALMOL, V63, P40, DOI 10.1016/j.survophthal.2017.05.007
   Chaikitmongkol V, 2016, CURR OPIN OPHTHALMOL, V27, P217, DOI 10.1097/ICU.0000000000000259
   Chen FK, 2011, RETINA-J RET VIT DIS, V31, P371, DOI 10.1097/IAE.0b013e3181e46af3
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Cideciyan AV, 2012, INVEST OPHTH VIS SCI, V53, P841, DOI 10.1167/iovs.11-8415
   Convento E, 2007, PERIMETRY FUNDUS INT, P229
   Crossland MD, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-5
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Forte R, 2013, RETINA-J RET VIT DIS, V33, P482, DOI 10.1097/IAE.0b013e318276e11e
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Goerdt L, 2017, INVEST OPHTH VIS SCI, V58
   Hanout M, 2015, CURR OPIN OPHTHALMOL, V26, P149, DOI 10.1097/ICU.0000000000000153
   Hariri AH, 2016, AM J OPHTHALMOL, V168, P122, DOI 10.1016/j.ajo.2016.05.007
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   HEIJL A, 1975, ACTA OPHTHALMOL, V53, P293
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lindner M, 2017, INVEST OPHTH VIS SCI, V58
   Liu HT, 2015, GRAEF ARCH CLIN EXP, V253, P2137, DOI 10.1007/s00417-015-2974-6
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Markowitz SN, 2013, CAN J OPHTHALMOL, V48, P350, DOI 10.1016/j.jcjo.2012.03.004
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Morales MU, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.6.6
   Ooto S, 2015, RETINA-J RET VIT DIS, V35, P1726, DOI 10.1097/IAE.0000000000000608
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Panorgias A, 2013, INVEST OPHTH VIS SCI, V54, P4372, DOI 10.1167/iovs.12-11525
   PFAU M, 2017, INVEST OPHTH VIS SCI, V58, pBIO12, DOI DOI 10.1167/I0VS.17-21764
   Pfau M, 2018, EYE, V32, P1819, DOI 10.1038/s41433-018-0183-3
   Pfau M, 2018, BRIT J OPHTHALMOL, V102, P1054, DOI 10.1136/bjophthalmol-2017-311012
   Pfau M, 2017, OPHTHALMOLOGICA, V237, P42, DOI 10.1159/000453079
   Pilotto E, 2014, MICROPERIMETRY MULTI, P77
   Pilotto E, 2016, JAMA OPHTHALMOL, V134, P873, DOI 10.1001/jamaophthalmol.2016.1535
   Pilotto E, 2013, CAN J OPHTHALMOL, V48, P386, DOI 10.1016/j.jcjo.2013.03.022
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sayegh RG, 2014, BRIT J OPHTHALMOL, V98, P1050, DOI 10.1136/bjophthalmol-2014-305195
   Sayegh RG, 2017, AM J OPHTHALMOL, V179, P118, DOI 10.1016/j.ajo.2017.03.031
   Schonbach EM, 2017, INVEST OPHTH VIS SCI, V58
   Schtinbach EM, 2017, OPHTHALMOL RETINA, V1, P68
   Seiple W, 2012, OPTOMETRY VISION SCI, V89, P1182, DOI 10.1097/OPX.0b013e3182640c83
   Simunovic MP, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.3.10
   Steinberg JS, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.7
   STEINMAN RM, 1965, J OPT SOC AM, V55, P1158, DOI 10.1364/JOSA.55.001158
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006
   Wong EN, 2017, ASIA-PAC J OPHTHALMO, V6, P70, DOI 10.22608/APO.201643
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.13
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2606, DOI 10.1167/iovs.14-15977
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, INVEST OPHTH VIS SCI, V55, P6431, DOI 10.1167/iovs.14-14407
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 71
TC 14
Z9 14
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2019
VL 64
IS 3
BP 353
EP 364
DI 10.1016/j.survophthal.2019.01.014
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ID5UG
UT WOS:000471740900007
PM 30703401
OA hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Desideri, LF
   Traverso, CE
   Nicolo, M
AF Desideri, L. Ferro
   Traverso, C. E.
   Nicolo, M.
TI An update on conbercept to treat wet age-related macular degeneration
SO DRUGS OF TODAY
LA English
DT Article
DE Conbercept; Wet age-related macular degeneration; Vascular endothelial
   growth factor (VEGF) inhibitors; Ocular diseases
ID ENDOTHELIAL GROWTH-FACTOR; FUSION PROTEIN; INTRAVITREAL INJECTION;
   FACTOR VEGF; RANIBIZUMAB; PHARMACOKINETICS; FP3; CARCINOMA; SAFETY;
   KH902
AB Wet age-related macular degeneration (w-AMD) represents the main cause of vision loss in the elderly in the western countries. The important role displayed by vascular endothelial growth factor (VEGF) in the pathogenesis of this disease has been largely demonstrated. For this reason, anti-VEGF drugs have been developed and currently are considered as the first-line treatment options in the management of w-AMD. Among the novel anti-VEGF agents studied, conbercept is a fusion protein composed of the combination between VEGF receptor domains with the Fc fragment of human immunoglobulin. It was already approved in China in 2014 for treating w-AMD. In this regard, the phase III PHOENIX trial has reported a good clinical efficacy and safety profile of conbercept for w-AMD, also by adopting a quarterly regimen. In this review, we will discuss its pharmacokinetics, pharmacodynamics, clinical efficacy, without neglecting also its safety and tolerability profile.
C1 [Desideri, L. Ferro; Traverso, C. E.; Nicolo, M.] IRCCS Osped Policlin San Martino, Univ Eye Clin Genoa, Genoa, Italy.
   [Traverso, C. E.; Nicolo, M.] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy.
   [Nicolo, M.] Macula Onlus Fdn, Genoa, Italy.
C3 University of Genoa
RP Desideri, LF (通讯作者)，IRCCS Osped Policlin San Martino, Univ Eye Clin Genoa, Genoa, Italy.
EM lorenzoferrodes@gmail.com
RI Desideri, Lorenzo Ferro/AAM-5368-2020
CR Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P567, DOI 10.1167/iovs.13-13054
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Cui J, 2018, EYE, V32, P391, DOI 10.1038/eye.2017.187
   Desideri LF, 2019, EXPERT OPIN BIOL TH, V19, P735, DOI 10.1080/14712598.2019.1627322
   Dong XF, 2012, INT J MOL MED, V30, P126, DOI 10.3892/ijmm.2012.968
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Huang J, 2012, DIABETES OBES METAB, V14, P644, DOI 10.1111/j.1463-1326.2012.01584.x
   Huang Z, 2019, RETINA-J RET VIT DIS, V39, P889, DOI 10.1097/IAE.0000000000002035
   Jin EZ, 2017, RETINA-J RET VIT DIS, V37, P971, DOI 10.1097/IAE.0000000000001274
   Jin KT, 2011, HEPATO-GASTROENTEROL, V58, P1814, DOI 10.5754/hge11136
   Lan HR, 2013, EXP THER MED, V5, P85, DOI 10.3892/etm.2012.773
   Li H, 2012, EXP EYE RES, V97, P154, DOI 10.1016/j.exer.2011.09.002
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Li X, 2019, OPHTHALMIC RES, V62, P93, DOI 10.1159/000500118
   Li X, 2019, RETINA-J RET VIT DIS, V39, P1353, DOI 10.1097/IAE.0000000000002152
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Melincovici CS, 2018, ROM J MORPHOL EMBRYO, V59, P455
   Moisseiev E, 2014, GRAEF ARCH CLIN EXP, V252, P331, DOI 10.1007/s00417-013-2495-0
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rezzola S, 2014, ANGIOGENESIS, V17, P429, DOI 10.1007/s10456-013-9398-x
   Shams Naveed, 2006, Ophthalmol Clin North Am, V19, P335
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu BH, 2019, INT J OPHTHALMOL-CHI, V12, P252, DOI 10.18240/ijo.2019.02.11
   Wu ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057642
   Yu DC, 2012, MOL THER, V20, P938, DOI 10.1038/mt.2011.285
   Zhang JX, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0807-1
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Zhou AY, 2013, OPHTHALMIC RES, V50, P180, DOI 10.1159/000353437
NR 35
TC 13
Z9 13
U1 5
U2 5
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 1699-3993
EI 1699-4019
J9 DRUG TODAY
JI Drugs Today
PD MAY
PY 2020
VL 56
IS 5
BP 311
EP 320
DI 10.1358/dot.2020.56.5.3137164
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA LL9EY
UT WOS:000531857000002
PM 32406878
DA 2022-11-30
ER

PT J
AU Seddon, JM
   George, S
   Rosner, B
AF Seddon, Johanna M.
   George, Sarah
   Rosner, Bernard
TI Cigarette smoking, fish consumption, omega-3 fatty acid intake, and
   associations with Age-Related Macular Degeneration - The US twin study
   age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; DIETARY-FAT; RISK-FACTORS;
   MACULOPATHY; REPRODUCIBILITY; POLYMORPHISM; PROGRESSION; GENE
AB Objective: To evaluate modifiable risk and protective factors for age-related macular degeneration (AMD) among elderly twins.
   Methods: The US Twin Study of Age-Related Macular Degeneration comprises elderly male twins from the National Academy of Sciences-National Research Council World War II Veteran Twin Registry. To determine genetic and environmental risk factors for AMD, twins were surveyed for a prior diagnosis of AMD and underwent an eye examination, fundus photography, and food frequency and risk factor questionnaires. This environmental component of the study includes 681 twins: 222 twins with AMD (intermediate or late stages) and 459 twins with no maculopathy or early signs. Risk for AMD according to cigarette smoking and dietary fat intake was estimated using logistic regression analyses. past smokers had about a 1.7-fold increased risk (95% confidence interval, 1.2-2.6, P=.009). Increased intake of fish reduced risk of AMD, particularly for 2 or more servings per week (P trend =.04). Dietary omega-3 fatty intake was inversely associated with AMD (odds ratio, 0.55; 95% confidence interval, 0.32-0.95) comparing the highest vs lowest quartile. Reduction in risk of AMD with higher intake of omega-3 fatty acids was seen primarily among subjects with low levels (below median) of linoleic acid intake, an omega-6 fatty acid (P trend <.001). The attributable risk percentage was 32% for smoking and the preventive fraction was 22% for higher omega-3 intake. Conclusions: This study of twins provides further evidence that cigarette smoking increases risk while fish consumption and omega-3 fatty acid intake reduce risk of AMD.
   Results: Current smokers had a 1.9-fold increased risk (95% confidence interval, 0.99-3.68, P=.06) of AMD while past smokers had about a 1.7-fold increased risk (95% confidence interval, 1.2-2.6, P=.009). Increased intake of fish reduced risk of AMD, particularly for 2 or more servings per week (P trend =.04). Dietary omega-3 fatty intake was inversely associated with AMD (odds ratio, 0.55; 95% confidence interval, 0.32-0.95) comparing the highest vs lowest quartile. Reduction in risk of AMD with higher intake of omega-3 fatty acids was seen primarily among subjects with low levels (below median) of linoleic acid intake, an omega-6 fatty acid (P trend <.001). The attributable risk percentage was 32% for smoking and the preventive fraction was 22% for higher omega-3 intake.
   Conclusions: This study of twins provides further evidence that cigarette smoking increases risk while fish consumption and omega-3 fatty acid intake reduce risk of AMD.
C1 Harvard Univ, Epidemiol Unit, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard Medical School
RP Seddon, JM (通讯作者)，Harvard Univ, Epidemiol Unit, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02115 USA.
EM johanna_seddon@meei.harvard.edu
FU NEI NIH HHS [EY 10012] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R01EY010012] Funding Source: NIH RePORTER
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   AJANI UA, 1994, INVEST OPHTH VIS SCI, V35, P2725
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   GIST YJ, WE PEOPL AG US CENS
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   He K, 2002, JAMA-J AM MED ASSOC, V288, P3130, DOI 10.1001/jama.288.24.3130
   Hooper L, 2004, J HUM NUTR DIET, V17, P337, DOI 10.1111/j.1365-277X.2004.00533.x
   Horrocks LA, 1999, PHARMACOL RES, V40, P211, DOI 10.1006/phrs.1999.0495
   HRUBEC Z, 1984, NEW ENGL J MED, V310, P435, DOI 10.1056/NEJM198402163100706
   JABLON S, 1967, AM J HUM GENET, V19, P133
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   McCullagh P., 1989, GEN LINEAR MODELS MO
   *NAT ADV EY COUNC, 1999, VIS RES NAT PLAN 199, V1
   *NAT CTR CHRON DIS, 2005, HLTH AG OLD AD
   *NAT CTR CHRON DIS, 2005, AD CIG SMOK US CURR
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SEDDON J, 1994, INVEST OPHTH VIS SCI, V35, P2003
   Seddon J. M., 1997, Investigative Ophthalmology and Visual Science, V38, pS676
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   SEDDON JM, 1990, INVEST OPHTH VIS SCI, V31, P1592
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   SEDDON JM, 2005, RETINA, V2
   Simopoulos AP, 2002, BIOMED PHARMACOTHER, V56, P365, DOI 10.1016/S0753-3322(02)00253-6
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Trebble TM, 2004, AM J CLIN NUTR, V80, P1137, DOI 10.1093/ajcn/80.5.1137
   Willett W., 1990, NUTR EPIDEMIOLOGY
   WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086
   Young G, 2005, REPROD NUTR DEV, V45, P1, DOI 10.1051/rnd:2005001
NR 43
TC 282
Z9 294
U1 0
U2 20
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUL
PY 2006
VL 124
IS 7
BP 995
EP 1001
DI 10.1001/archopht.124.7.995
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 064XE
UT WOS:000239123200008
PM 16832023
OA Bronze
DA 2022-11-30
ER

PT J
AU Imamura, Y
   Noda, S
   Hashizume, K
   Shinoda, K
   Yamaguchi, M
   Uchiyama, S
   Shimizu, T
   Mizushima, Y
   Shirasawa, T
   Tsubota, K
AF Imamura, Yutaka
   Noda, Setsuko
   Hashizume, Kouhei
   Shinoda, Kei
   Yamaguchi, Mineko
   Uchiyama, Satoshi
   Shimizu, Takahiko
   Mizushima, Yutaka
   Shirasawa, Takuji
   Tsubota, Kazuo
TI Drusen, choroidal neovascularization, and retinal pigment epithelium
   dysfunction in SOD1-deficient mice: A model of age-related macular
   degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE animal model; superoxide dismutase
ID CAUSE-SPECIFIC PREVALENCE; FACTOR-H POLYMORPHISM; SUPEROXIDE-DISMUTASE;
   ANTIOXIDANT ENZYMES; OXIDATIVE STRESS; BRUCHS MEMBRANE; PATHOGENESIS;
   RISK; ETIOLOGY; EYES
AB Oxidative stress has long been linked to the pathogenesis of neurodegenerative diseases; however, whether it is a cause or merely a consequence of the degenerative process is still unknown. We show that mice deficient in Cu, Zn-superoxide dismutase (SOD1) have features typical of age-related macular degeneration in humans. Investigations of senescent Sod1(-/-) mice of different ages showed that the older animals had drusen, thickened Bruch's membrane, and choroidal neovascularization. The number of drusen increased with age, and exposure of young Sod1(-/-) mice to excess light induced drusen. The retinal pigment epithelial cells of Sod1(-/-) mice showed oxidative damage, and their beta-catenin-mediated cellular integrity was disrupted, suggesting that oxidative stress may affect the junctional proteins necessary for the barrier integrity of the retinal pigment epithelium. These observations strongly suggest that oxidative stress may play a causative role in age-related retinal degeneration, and our findings provide evidence for the free radical theory of aging. In addition, these results demonstrate that the Sod1(-/-) mouse is a valuable animal model to study human age-related macular degeneration.
C1 Keio Univ, Sch Med, Dept Ophthalmol, Shinjuku Ku, Tokyo 1608582, Japan.
   Tokai Univ, Sch Hlth Sci, Dept Nursing, Isehara, Kanagawa 2591193, Japan.
   Natl Hosp Org, Tokyo Med Ctr, Natl Inst Sensory Organs, Lab Visual Physiol,Meguro Ku, Tokyo 1528902, Japan.
   Tokyo Metropolitan Inst Gerontol, Res Team Mol Biomarkers, Itabashi Ku, Tokyo 1730015, Japan.
   Jikei Univ, DDS Inst, Sch Med, Minato Ku, Tokyo 1058461, Japan.
   Tokyo Dent Coll, Dept Ophthalmol, Chiba 2728513, Japan.
C3 Keio University; Tokai University; Tokyo Metropolitan Institute of
   Gerontology; Jikei University; Tokyo Dental College
RP Imamura, Y (通讯作者)，Keio Univ, Sch Med, Dept Ophthalmol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM imamura@sc.itc.keio.ac.jp; tsubota@sc.itc.keio.ac.jp
RI Shinoda, Kei/ABC-7993-2020
OI Shinoda, Kei/0000-0002-1543-9345
CR Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Behndig A, 1998, INVEST OPHTH VIS SCI, V39, P471
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   GREEN RG, 1999, AGE RELATED MACULAR, P81
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   KASAI H, 1991, Journal of Toxicological Sciences, V16, P95
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Matzuk MM, 1998, ENDOCRINOLOGY, V139, P4008, DOI 10.1210/en.139.9.4008
   OSHIMA Y, 2001, BR J OPHTHALMOL, V39, P367
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Sandbach JM, 2001, INVEST OPHTH VIS SCI, V42, P2173
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Semkova I, 2003, INVEST OPHTH VIS SCI, V44, P5349, DOI 10.1167/iovs.02-0732
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Teesalu T, 2001, AM J PATHOL, V159, P2227, DOI 10.1016/S0002-9440(10)63073-8
   Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
NR 47
TC 294
Z9 324
U1 1
U2 20
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 25
PY 2006
VL 103
IS 30
BP 11282
EP 11287
DI 10.1073/pnas.0602131103
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 068DZ
UT WOS:000239353900033
PM 16844785
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Gensler, G
   Klein, ML
   Milton, RC
AF Seddon, JM
   Gensler, G
   Klein, ML
   Milton, RC
TI Evaluation of plasma homocysteine and risk of age-related macular
   degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ASSOCIATION; DISEASE
AB PURPOSE: To assess the relationship between plasma levels of homocysteine and age,related macular degeneration (AMD).
   DESIGN: Cross-sectional,case-control study.
   METHODS: Fasting plasma homocysteine levels were measured at two centers in 934 individuals who were participating in an ancillary study of the Age,Related Eye Disease Study. There were 547 cases and 387 control subjects, who were determined by fundus photography. Conditional logistic regression analyses were conducted to assess the association of homocysteine with AMD.
   RESULTS: Median values of homocysteine were higher among advanced AMD cases (9.51 mmol/l) compared with persons with no AMD (8.81 mmol/l; P = .01). Values of > 12 mmol/l vs <= 12 mmol/l were also associated with an increased risk of AMD (P = .023), when controlled for other covariates.
   CONCLUSION: Results are consistent with a possible small, independent association between higher homocysteine levels and AMD. Homocysteine may be a modifiable risk factor for AMD.
C1 Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Epidemiol Unit,Dept Ophthalmol, Boston, MA 02114 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02114 USA.
   Devers Eye Inst, Portland, OR USA.
   EMMES Corp, Rockville, MD USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard T.H. Chan School of Public
   Health; Devers Eye Institute; Emmes Corporation
RP Seddon, JM (通讯作者)，Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Epidemiol Unit,Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM Johanna_Seddon@meei.harvard.edu
FU NATIONAL EYE INSTITUTE [R01EY013982, N01EY002126, N01EY002117] Funding
   Source: NIH RePORTER; NEI NIH HHS [N01 EY 02117, N01 EY 02126, R01 EY
   13982] Funding Source: Medline
CR Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   JACOBS DS, 2001, LAB TEST HDB KEY WOR, P193
   Malinow MR, 1996, ATHEROSCLEROSIS, V126, P27, DOI 10.1016/0021-9150(96)05890-X
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
NR 7
TC 57
Z9 58
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2006
VL 141
IS 1
BP 201
EP 203
DI 10.1016/j.ajo.2005.07.059
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 000FQ
UT WOS:000234446700036
PM 16387004
DA 2022-11-30
ER

PT J
AU Mones, JM
   Lopez, MA
   Prieto, JA
   Rodriguez, JP
AF Mones, Jordi M.
   Lopez, Mauricio A.
   Prieto, Jorge A.
   Rodriguez, Juan P.
TI Extrafoveal choroidal neovascularization secondary to wet age-related
   macular degeneration treated with intravitreal bevacizumab
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID PHOTOCOAGULATION
AB Considering the risk of recurrence of extrafoveal or juxtafoveal lesions after thermal laser treatment and the risk of poor response to photodynamic therapy, it seems reasonable to discuss with the patient the risks and benefits of antiangiogenic therapy. A case of age-related macular degeneration with an extrafoveal choroidal neovascularization treated with a single injection of intravitreal bevacizumab is described. The patient showed both anatomic and visual acuity improvement at 1 month following treatment that persisted even at the 8-month follow-up visit. Further studies are needed to validate the real risk-benefit ratio of intravitreal bevacizumab for extrafoveal exudative lesions versus the current treatments available.
C1 Univ Autonoma Barcelona, E-08193 Barcelona, Spain.
   Inst Microcirugia Ocular, Barcelona, Spain.
C3 Autonomous University of Barcelona
RP Lopez, MA (通讯作者)，10 Munner St, Barcelona 08022, Spain.
RI mones, jordi/CAJ-2963-2022
OI mones, jordi/0000-0003-3685-2160
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   2005, RETINA, V25, P119
   2002, RETINA, V22, P6
NR 9
TC 9
Z9 9
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAY-JUN
PY 2007
VL 38
IS 3
BP 226
EP 228
DI 10.3928/15428877-20070501-07
PG 3
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 168RO
UT WOS:000246541900007
PM 17552389
DA 2022-11-30
ER

PT J
AU Elsner, AE
   Burns, SA
   Weiter, JJ
AF Elsner, AE
   Burns, SA
   Weiter, JJ
TI Cone photopigment in older subjects: decreased optical density in early
   age-related macular degeneration
SO JOURNAL OF THE OPTICAL SOCIETY OF AMERICA A-OPTICS IMAGE SCIENCE AND
   VISION
LA English
DT Article
ID HIGH ILLUMINANCES; GOOD ACUITY; EYES; DISEASE; DRUSEN
AB We measured changes to cone photoreceptors in patients with early age-related macular degeneration. The data of 53 patients were compared with normative data for color matching measurements of long- and middle-wavelength-sensitive cones in the central macula. A four-parameter model quantified cone photopigment optical density and kinetics. Cone photopigment optical density was on average less for the patients than for normal subjects and was uncorrelated with visual acuity. More light was needed to reduce the photopigment density by 50% in the steady state for patients. These results imply that cone photopigment optical density is reduced by factors other than slowed kinetics. (C) 2002 Optical Society of America.
C1 Schepens Eye Res Inst, Boston, MA 02114 USA.
   Harvard Univ, Boston, MA 02114 USA.
   Retina Specialists Boston, Boston, MA 02114 USA.
C3 Harvard University; Schepens Eye Research Institute; Harvard University
RP Elsner, AE (通讯作者)，Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
RI Burns, Stephen A/D-9259-2011; Burns, Stephen/AAN-3044-2021
OI Burns, Stephen A/0000-0001-5348-035X; 
FU NATIONAL EYE INSTITUTE [R29EY007624, R01EY007624, R01EY004395] Funding
   Source: NIH RePORTER; NEI NIH HHS [R01 EY004395, EYO4395, EYO7624, R01
   EY007624, R01 EY004395-22] Funding Source: Medline
CR ALPERN M, 1979, J PHYSIOL-LONDON, V288, P85
   APPLEGATE RA, 1987, APPL OPTICS, V26, P1458, DOI 10.1364/AO.26.001458
   Brown B, 1987, CLIN EXP OPTOM, V70, P112
   BURNS SA, 1993, J OPT SOC AM A, V10, P221, DOI 10.1364/JOSAA.10.000221
   BURNS SA, 1988, APPL OPTICS, V27, P1045, DOI 10.1364/AO.27.001045
   BURNS SA, 1987, INVEST OPHTH VIS SCI, V28, P711
   BURNS SA, 1985, J OPT SOC AM A, V2, P698, DOI 10.1364/JOSAA.2.000698
   BURNS SA, 1987, INVEST OPHTHALMOL  S, V28, P128
   BURNS SA, 1991, 1991 OSA TECHNICAL D, V1, P194
   COILE DC, 1992, VISUAL NEUROSCI, V8, P27, DOI 10.1017/S0952523800006465
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1824
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Elsner AE, 1998, INVEST OPHTH VIS SCI, V39, P2394
   ELSNER AE, 1988, J OPT SOC AM A, V5, P2106, DOI 10.1364/JOSAA.5.002106
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   ELSNER AE, 1987, APPL OPTICS, V26, P1378, DOI 10.1364/AO.26.001378
   ELSNER AE, 1987, INVEST OPHTH VIS SCI, V28, P718
   ELSNER AE, 1984, INVEST OPHTHALMOL  S, V25, P311
   ELSNER AE, 1989, 1989 OSA TECHNICAL D, V18, P214
   ELSNER AE, 1998, PRACTICAL ATLAS RETI, P19
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   HAEGERSTROMPORTNOY G, 1989, CLIN VISION SCI, V4, P165
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   KEUNEN JEE, 1987, INVEST OPHTH VIS SCI, V28, P985
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lakowski R., 1958, ADV SCI, V15, P231
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MORAES L, 1998, INVEST OPHTHALMOL  S, V39, pB602
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   REMKY A, IN PRESS BR J OPHTHA
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   SANDBERG MA, 1995, RETINA-J RET VIT DIS, V15, P407, DOI 10.1097/00006982-199515050-00006
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Smith V C, 1978, Mod Probl Ophthalmol, V19, P284
   SMITH VC, 1976, VISION RES, V16, P1087, DOI 10.1016/0042-6989(76)90247-9
   SMITH VC, 1988, J OPT SOC AM A, V5, P2113, DOI 10.1364/JOSAA.5.002113
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Sunness JS, 1999, MOL VIS, V5
   Swanson WH, 1996, VISION RES, V36, P2079, DOI 10.1016/0042-6989(95)00280-4
   SWANSON WH, 1995, J OPT SOC AM A, V12, P2230, DOI 10.1364/JOSAA.12.002230
   Walker J. P., 1997, Investigative Ophthalmology and Visual Science, V38, pS94
NR 46
TC 27
Z9 27
U1 0
U2 6
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1084-7529
EI 1520-8532
J9 J OPT SOC AM A
JI J. Opt. Soc. Am. A-Opt. Image Sci. Vis.
PD JAN
PY 2002
VL 19
IS 1
BP 215
EP 222
DI 10.1364/JOSAA.19.000215
PG 8
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA 505TA
UT WOS:000172930600030
PM 11778727
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Vogl, WD
   Bogunovic, H
   Waldstein, SM
   Riedl, S
   Schmidt-Erfurth, U
AF Vogl, Wolf-Dieter
   Bogunovic, Hrvoje
   Waldstein, Sebastian M.
   Riedl, Sophie
   Schmidt-Erfurth, Ursula
TI Spatio-temporal alterations in retinal and choroidal layers in the
   progression of age-related macular degeneration (AMD) in optical
   coherence tomography
SO SCIENTIFIC REPORTS
LA English
DT Article
ID 2.0 MG RANIBIZUMAB; CLASSIFICATION; PREDICTION; EFFICACY; SAFETY; IMAGES
AB Age-related macular degeneration (AMD) is the predominant cause of vision loss in the elderly with a major impact on ageing societies and healthcare systems. A major challenge in AMD management is the difficulty to determine the disease stage, the highly variable progression speed and the risk of conversion to advanced AMD, where irreversible functional loss occurs. In this study we developed an optical coherence tomography (OCT) imaging based spatio-temporal reference frame to characterize the morphologic progression of intermediate age-related macular degeneration (AMD) and to identify distinctive patterns of conversion to the advanced stages macular neovascularization (MNV) and macular atrophy (MA). We included 10,040 OCT volumes of 518 eyes with intermediate AMD acquired according to a standardized protocol in monthly intervals over two years. Two independent masked retina specialists determined the time of conversion to MNV or MA. All scans were aligned to a common reference frame by intra-patient and inter-patient registration. Automated segmentations of retinal layers and the choroid were computed and en-face maps were transformed into the common reference frame. Population maps were constructed in the subgroups converting to MNV (n=135), MA (n=50) and in non-progressors (n=333). Topographically resolved maps of changes were computed and tested for statistical significant differences. The development over time was analysed by a joint model accounting for longitudinal and right-censoring aspect. Significantly enhanced thinning of the outer nuclear layer (ONL) and retinal pigment epithelium (RPE)-photoreceptorinner segment/outer segment (PR-IS/OS) layers within the central 3 mm and a faster thinning speed preceding conversion was documented for MA progressors. Converters to MNV presented an accelerated thinning of the choroid and appearance changes in the choroid prior to MNV onset. The large-scale automated image analysis allowed us to distinctly assess the progression of morphologic changes in intermediate AMD based on conventional OCT imaging. Distinct topographic and temporal patterns allow to prospectively determine eyes with risk of progression and thereby greatly improving early detection, prevention and development of novel therapeutic strategies.
C1 [Vogl, Wolf-Dieter; Bogunovic, Hrvoje; Waldstein, Sebastian M.; Riedl, Sophie; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
C3 Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
FU Christian Doppler Research Association; Austrian Federal Ministry for
   Digital and Economic Affairs; National Foundation for Research,
   Technology and Development; Austrian Science Fund [FWF I2714-B31];
   Genentech; Bayer
FX The financial support by the Christian Doppler Research Association, the
   Austrian Federal Ministry for Digital and Economic Affairs and the
   National Foundation for Research, Technology and Development and by the
   Austrian Science Fund (FWF I2714-B31) is gratefully acknowledged. This
   study was in part supported by Genentech and Bayer by a research grant
   to S.M.W.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Asgari R, 2019, LECT NOTES COMPUT SC, V11764, P192, DOI 10.1007/978-3-030-32239-7_22
   Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004
   Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   Bolles R. C., 1981, P 7 INT JOINT C ART, P637
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Brandl C, 2019, INVEST OPHTH VIS SCI, V60, P1581, DOI 10.1167/iovs.18-25332
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   ClinicalTrials.gov, STUD RAN ADM MONTH A
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Frangi AF, 1998, LECT NOTES COMPUT SC, V1496, P130, DOI 10.1007/bfb0056195
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Gillies RJ, 2016, RADIOLOGY, V278, P563, DOI 10.1148/radiol.2015151169
   HARALICK RM, 1979, P IEEE, V67, P786, DOI 10.1109/PROC.1979.11328
   Henderson R, 2000, Biostatistics, V1, P465, DOI 10.1093/biostatistics/1.4.465
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Johnson H.J, 2015, TEMPLATETHE ITK SOFT, V1
   Lee S, 2017, MED IMAGE ANAL, V35, P570, DOI 10.1016/j.media.2016.08.012
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Lujan BJ, 2015, RETINA-J RET VIT DIS, V35, P1511, DOI 10.1097/IAE.0000000000000527
   Matsuda H, 2013, AGING DIS, V4, P29
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Montuoro A, 2014, LECT NOTES COMPUT SC, V8674, P130, DOI 10.1007/978-3-319-10470-6_17
   Moreira-Neto CA, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8125267
   Orlando JI, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62329-9
   Rizopoulos D, 2016, J STAT SOFTW, V72, P1, DOI 10.18637/jss.v072.i07
   Rohrschneider K, 2004, INVEST OPHTH VIS SCI, V45, P3257, DOI 10.1167/iovs.03-1157
   Russakoff DB, 2019, INVEST OPHTH VIS SCI, V60, P712, DOI 10.1167/iovs.18-25325
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Vogl WD, 2017, IEEE T MED IMAGING, V36, P1773, DOI 10.1109/TMI.2017.2700213
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Zhang L, 2015, INVEST OPHTH VIS SCI, V56, P3202, DOI 10.1167/iovs.14-15669
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
   Zuiderveld K., 1994, GRAPHICS GEMS, VIV, P474, DOI [10.1016/b978-0-12-336156-1.50061-6, DOI 10.1016/B978-0-12-336156-1.50061-6]
NR 43
TC 9
Z9 9
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 11
PY 2021
VL 11
IS 1
AR 5743
DI 10.1038/s41598-021-85110-y
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA QX8WH
UT WOS:000629623300017
PM 33707539
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Freund, KB
   Mrejen, S
   Gallego-Pinazo, R
AF Freund, K. Bailey
   Mrejen, Sarah
   Gallego-Pinazo, Roberto
TI An update on the pharmacotherapy of neovascular age-related macular
   degeneration
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Review
DE aflibercept; age-related macular degeneration; anti-angiogenic therapy;
   bevacizumab; choroidal neovascularization; intravitreal injection;
   pegaptanib sodium; ranibizumab; VEGF; verteporfin
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; VERTEPORFIN PHOTODYNAMIC THERAPY;
   BEVACIZUMAB AVASTIN THERAPY; GROWTH-FACTOR THERAPY; CHOROIDAL
   NEOVASCULARIZATION; EDEMA SECONDARY; DOSING REGIMEN; VEGF-TRAP;
   INTRAOCULAR PHARMACOKINETICS; PEGAPTANIB SODIUM
AB Introduction: Neovascular age-related macular degeneration (AMD) is currently the most common cause of legal blindness in industrialized countries. The advent of pharmacotherapy with intravitreal VEGF inhibitors has greatly improved outcomes for the treatment of this disease.
   Areas covered: The present review is divided into two major sections: the period prior to the use of anti-VEGF agents (triamcinolone acetonide, verteporfin photodynamic therapy) and the period following their introduction (pegaptanib sodium, bevacizumab, ranibizumab, aflibercept). The main pharmacological and clinical characteristics of each therapy are summarized.
   Expert opinion: Monotherapy with anti-VEGF agents is currently the 'gold standard' for treating neovascular AMD, but, with several drug choices and various different dosing regimens available, there is still wide variability in how individual clinicians manage their patients. Despite improved visual outcomes, there remains a significant unmet need for better treatments as the frequent office visits and injections associated with anti- VEGF therapy are costly and place a significant burden on patients, their family members and physicians.
C1 [Freund, K. Bailey; Mrejen, Sarah; Gallego-Pinazo, Roberto] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Freund, K. Bailey; Mrejen, Sarah; Gallego-Pinazo, Roberto] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, New York, NY 10016 USA.
   [Mrejen, Sarah] Ctr Hosp Natl Ophtalmol Quinze Vingts, Paris, France.
   [Gallego-Pinazo, Roberto] Univ & Polytech Hosp La Fe, Dept Ophthalmol, Valencia, Spain.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; New York University; CHNO des Quinze-Vingts;
   UDICE-French Research Universities; Sorbonne Universite
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Mrejen, Sarah/G-2089-2016; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Macula Foundation, Inc., New York, NY
FX This paper is supported by the Macula Foundation, Inc., New York, NY.
   The authors of this manuscript do not have a proprietary interest. KB
   Freund: Genentech: Advisory Board, Honoraria; Regeneron Pharmaceuticals,
   Inc.: Advisory Board, Consultant, Honoraria; Digisight: Advisory Board;
   Bayer: Consultant, Honoraria. S Mrejen: None. R Gallego-Pinazo:
   Novartis: Advisory Board, Investigator, Grants, Consultant, Speaker;
   Allergan: Investigator, Grants; Bayer: Grants, Consultant; Carl Zeiss
   Meditec: Grants, Consultant, Speaker.
CR Ahmadi MA, 2008, EXPERT OPIN PHARMACO, V9, P3045, DOI [10.1517/14656560802473480, 10.1517/14656560802473480 ]
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   AVELINE B, 1994, PHOTOCHEM PHOTOBIOL, V59, P328, DOI 10.1111/j.1751-1097.1994.tb05042.x
   Baath J, 2007, J OCUL PHARMACOL TH, V23, P304, DOI 10.1089/jop.2006.125
   Bakri SJ, 2004, EXPERT OPIN PHARMACO, V5, P195, DOI 10.1517/14656566.5.1.195
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Biarnes M, 2011, OPTOMETRY VISION SCI, V88, P881, DOI 10.1097/OPX.0b013e31821988c1
   Binz HK, 2003, J MOL BIOL, V332, P489, DOI 10.1016/S0022-2836(03)00896-9
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Campochiaro PA, 2012, AM J OPHTHALMOL
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2012, BRIT J OPHTHALMOL, V96, P1351, DOI 10.1136/bjophthalmol-2011-301444
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Connolly B, 2006, OPHTHALMOL CLIN N AM, V19, pvi
   Connolly Brian, 2006, Ophthalmol Clin North Am, V19, P381
   DAMICO DJ, 1994, NEW ENGL J MED, V331, P95, DOI 10.1056/NEJM199407143310207
   Dhingra N, 2009, EYE, V23, P1868, DOI 10.1038/eye.2009.203
   Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811
   Elman MJ, 2011, OPHTHALMOLOGY, V118, P609, DOI 10.1016/j.ophtha.2010.12.033
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gonzalez S, 2012, AM J OPHTHALMOL, V153, P196, DOI 10.1016/j.ajo.2011.11.023
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Ip MS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1101, DOI 10.1001/archophthalmol.2009.234
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kiernan DF, 2012, EXPERT OPIN PHARMACO, V13, P1679, DOI 10.1517/14656566.2012.690736
   Kiernan DF, 2009, EXPERT OPIN PHARMACO, V10, P2511, DOI 10.1517/14656560903160671
   KOFF R, 1950, JAMA-J AM MED ASSOC, V144, P1259, DOI 10.1001/jama.1950.62920150004009a
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   KWAK HW, 1992, ARCH OPHTHALMOL-CHIC, V110, P259, DOI 10.1001/archopht.1992.01080140115038
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lee J, 2007, RETINA-J RET VIT DIS, V27, P1205, DOI 10.1097/IAE.0b013e31815ec367
   Li YL, 2012, RETINA-J RET VIT DIS, V32, P364, DOI 10.1097/IAE.0b013e31821e1f7c
   Maberley D, 2009, OPHTHALMOLOGY, V116, P2149, DOI 10.1016/j.ophtha.2009.04.032
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meleth AD, 2011, CURR OPIN OPHTHALMOL, V22, P190, DOI 10.1097/ICU.0b013e32834594b0
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Ramezani A, 2012, GRAEF ARCH CLIN EXP, V250, P1149, DOI 10.1007/s00417-012-1941-8
   Reibaldi M, 2010, AM J OPHTHALMOL, V149, P307, DOI 10.1016/j.ajo.2009.08.026
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Scott IU, 2009, ARCH OPHTHALMOL-CHIC, V127, P1115, DOI 10.1001/archophthalmol.2009.233
   Shimura M, 2011, RETINA-J RET VIT DIS, V31, P748, DOI 10.1097/IAE.0b013e3181f04991
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Stewart MA, 2011, ADV GLOB CHANGE RES, V45, P1, DOI [10.1007/978-94-007-0934-8_1, 10.4081/eye.2011.e5]
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Sultan MB, 2011, OPHTHALMOLOGY, V118, P1107, DOI 10.1016/j.ophtha.2011.02.045
   THEODORE F H, 1950, Eye Ear Nose Throat Mon, V29, P314
   Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vinores SA, 2003, CURR OPIN MOL THER, V5, P673
   Wroblewski JJ, 2010, AM J OPHTHALMOL, V149, P147, DOI 10.1016/j.ajo.2009.08.005
   Wroblewski JJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P374, DOI 10.1001/archophthalmol.2009.14
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 92
TC 33
Z9 34
U1 0
U2 23
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD JUN
PY 2013
VL 14
IS 8
BP 1017
EP 1028
DI 10.1517/14656566.2013.787410
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 140GN
UT WOS:000318642500005
PM 23560774
DA 2022-11-30
ER

PT J
AU Di Carlo, E
   Augustin, AJ
AF Di Carlo, Emiliano
   Augustin, Albert J.
TI Prevention of the Onset of Age-Related Macular Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE age-related macular degeneration; prevention; nutrients; lifestyle
ID POLYUNSATURATED FATTY-ACIDS; PHYSICAL-ACTIVITY; MEDITERRANEAN DIET;
   SLEEP DURATION; GENETIC RISK; CIGARETTE-SMOKING; SUPPLEMENTATION;
   PREVALENCE; PROGRESSION; ASSOCIATION
AB Age-related macular degeneration (AMD) represents the leading cause of irreversible blindness in elderly people, mostly after the age of 65. The progressive deterioration of visual function in patients affected by AMD has a significant impact on quality of life and has also high social costs. The current therapeutic options are only partially able to slow down the natural course of the disease, without being capable of stopping its progression. Therefore, better understanding of the possibilities to prevent the onset of the disease is needed. In this regard, a central role is played by the identification of risk factors, which might participate to the development of the disease. Among these, the most researched are dietary risk factors, lifestyle, and light exposure. Many studies showed that a higher dietary intake of nutrients, such as lutein, zeaxanthin, beta carotene, omega-3 fatty acids and zinc, reduced the risk of early AMD. Regarding lifestyle habits, the association between smoking and AMD is currently accepted. Finally, retinal damage caused by ultraviolet rays and blue light is also worthy of attention. The scope of this review is to summarize the present knowledge focusing on the measures to adopt in order to prevent the onset of AMD.
C1 [Di Carlo, Emiliano; Augustin, Albert J.] Stadt Klinikum Karlsruhe, Dept Ophthalmol, D-76133 Karlsruhe, Germany.
C3 Municipal Hospital Karlsruhe
RP Di Carlo, E (通讯作者)，Stadt Klinikum Karlsruhe, Dept Ophthalmol, D-76133 Karlsruhe, Germany.
EM emi.dicarlo@hotmail.it; albertjaugustin@googlemail.com
OI di carlo, emiliano/0000-0002-1968-0195
CR Achiron Asaf, 2021, Ophthalmology, V128, P410, DOI 10.1016/j.ophtha.2020.07.039
   [Anonymous], 2001, DUTCH FOOD COMPOSITI
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Behar-Cohen F, 2014, CLIN OPHTHALMOL, V8, P87, DOI 10.2147/OPTH.S46189
   BILEZIKIAN JP, 1994, JAMA-J AM MED ASSOC, V272, P1942, DOI 10.1001/jama.1994.03520240070044
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Bovier ER, 2013, NUTRIENTS, V5, P750, DOI 10.3390/nu5030750
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Cappuccio FP, 2010, SLEEP, V33, P585, DOI 10.1093/sleep/33.5.585
   Garcia-Domene MC, 2018, OPTOMETRY VISION SCI, V95, P1129, DOI 10.1097/OPX.0000000000001309
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Despres JP, 2012, CIRCULATION, V126, P1301, DOI 10.1161/CIRCULATIONAHA.111.067264
   Downie LE, 2019, JAMA OPHTHALMOL, V137, P694, DOI 10.1001/jamaophthalmol.2019.0019
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   Hammond BR, 2019, CLIN OPHTHALMOL, V13, P2427, DOI 10.2147/OPTH.S213280
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Huang LL, 2008, INVEST OPHTH VIS SCI, V49, P3864, DOI 10.1167/iovs.07-1420
   Ikram MA, 2017, EUR J EPIDEMIOL, V32, P807, DOI 10.1007/s10654-017-0321-4
   Jin GM, 2018, BRIT J OPHTHALMOL, V102, P625, DOI 10.1136/bjophthalmol-2017-310368
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Kakigi CLM, 2015, JAMA OPHTHALMOL, V133, P746, DOI 10.1001/jamaophthalmol.2015.0514
   Kassebaum NJ, 2016, LANCET, V388, P1603, DOI [10.1016/S0140-6736(16)31460-X, 10.1016/S0140-6736(16)31470-2]
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Khurana RN, 2016, RETINA-J RET VIT DIS, V36, P255, DOI 10.1097/IAE.0000000000000706
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 2014, OPHTHALMOLOGY, V121, P1220, DOI 10.1016/j.ophtha.2014.01.003
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Kuo JZ, 2013, EXPERT REV OPHTHALMO, V8, P127, DOI 10.1586/EOP.13.3
   Lawrenson JG, 2017, OPHTHAL PHYSL OPT, V37, P644, DOI 10.1111/opo.12406
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Mahendra CK, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1904178
   Mahendra CK., 2019, PDDBS, V2, P1, DOI DOI 10.36877/PDDBS.A0000021
   Mane A.B., 2014, J GERONTOL GERIATR R, V3, P186
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P141, DOI 10.1080/09286586.2016.1259422
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moshfeghi AA, 2020, OSLI RETINA, V51, pS6, DOI 10.3928/23258160-20200401-01
   Mukhtar S, 2019, INT OPHTHALMOL, V39, P2975, DOI 10.1007/s10792-019-01140-6
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Nagai H, 2015, J CATARACT REFR SURG, V41, P1855, DOI 10.1016/j.jcrs.2015.01.017
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Perez-Canales JL, 2016, OPHTHAL EPIDEMIOL, V23, P20, DOI 10.3109/09286586.2015.1119288
   Pipis A, 2015, EUR J OPHTHALMOL, V25, P128, DOI 10.5301/ejo.5000520
   Querques G, 2014, SURV OPHTHALMOL, V59, P532, DOI 10.1016/j.survophthal.2014.01.001
   Rojas-Fernandez CH, 2017, ANN PHARMACOTHER, V51, P264, DOI 10.1177/1060028016680643
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Schick T, 2016, RETINA-J RET VIT DIS, V36, P787, DOI 10.1097/IAE.0000000000000756
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Sigler EJ, 2014, EYE, V28, P838, DOI 10.1038/eye.2014.100
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   SPERDUTO RD, 1990, ARCH OPHTHALMOL-CHIC, V108, P1403, DOI 10.1001/archopht.1990.01070120051026
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Walchuk Chelsey, 2020, Adv Food Nutr Res, V93, P293, DOI 10.1016/bs.afnr.2020.04.003
   Wang DC, 2019, CURR EYE RES, V44, P657, DOI 10.1080/02713683.2019.1576907
   WERNER JS, 1982, J OPT SOC AM, V72, P247, DOI 10.1364/JOSA.72.000247
   WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S
   Williams PT, 2009, INVEST OPHTH VIS SCI, V50, P101, DOI 10.1167/iovs.08-2165
   Wojda U, 2008, IUBMB LIFE, V60, P575, DOI 10.1002/iub.91
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Yamashiro K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072034
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zimmer Z, 2016, SSM-POPUL HLTH, V2, P373, DOI 10.1016/j.ssmph.2016.04.009
NR 87
TC 7
Z9 7
U1 1
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2021
VL 10
IS 15
AR 3297
DI 10.3390/jcm10153297
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA TV9ZM
UT WOS:000682071900001
PM 34362080
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Downie, LE
   Cheng, AS
   Vingrys, AJ
AF Downie, Laura E.
   Cheng, Ada S.
   Vingrys, Algis J.
TI Color Vision Deficits in Intermediate Age-Related Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE color vision; age-related macular degeneration; AMD; cone-contrast;
   photoreceptor; intermediate AMD; Bruch membrane; cone
ID RETINAL-PIGMENT EPITHELIUM; MEDIATED DARK-ADAPTATION; BRUCHS MEMBRANE;
   MORPHOMETRIC-ANALYSIS; VISUAL FUNCTION; CONE CONTRAST; MACULOPATHY;
   EYES; ROD; IMPAIRMENT
AB Purpose. To assess the effect of intermediate age-related macular degeneration (AMD) on foveal cone-contrast thresholds.
   Methods. We measured L-M and S-cone-contrast thresholds in subjects with intermediate AMD (n = 10) and age-matched control subjects (n = 10). Monocular, foveal 3-degree Gaussian blobs (600-millisecond raised cosine) were presented at 16 cone ratios throughout L-, M-, and S-cone space, and threshold contours were modeled with probability summation between two independent detection mechanisms. The role that preretinal absorption plays in aging was also evaluated by simulation with FG15 and neutral-density filters.
   Results. Aging results in loss of neural sensitivity, not explained by lens changes. On average, intermediate AMD was associated with reduced sensitivity in both color and luminance channels (p < 0.05) that appeared to indicate greater involvement of S-cones. When data were normalized to age-expected values, the changes to cone sensitivity were shown to be consistent (similar to 200% loss) across L-M, M-L, and S-cone mechanisms. In comparison, the luminance (L + M) mechanism showed relative sparing (155% loss, p < 0.05).
   Conclusions. Eyes with the same phenotype of intermediate AMD can have varying degrees of color threshold loss. Functional markers enhance the clinical definition of disease expression in AMD.
C1 [Downie, Laura E.; Cheng, Ada S.; Vingrys, Algis J.] Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3010, Australia.
C3 University of Melbourne
RP Vingrys, AJ (通讯作者)，Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3010, Australia.
EM algis@unimelb.edu.au
OI Vingrys, Algis/0000-0001-5920-4604; Downie, Laura/0000-0002-1596-2259
CR APPLEGATE RA, 1987, APPL OPTICS, V26, P1458, DOI 10.1364/AO.26.001458
   Arden GB, 2004, BRIT J OPHTHALMOL, V88, P1180, DOI 10.1136/bjo.2003.033480
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Binns AM, 2007, INVEST OPHTH VIS SCI, V48, P2806, DOI 10.1167/iovs.06-0392
   BOWMAN KJ, 1980, ACTA OPHTHALMOL, V58, P337
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Collins MJ, 1986, CLIN EXP OPTOM, V69, P223, DOI DOI 10.1111/J.1444-0938.1986.TB04596.X
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman E, 2008, AM J OPHTHALMOL, V146, P348, DOI 10.1016/j.ajo.2008.05.017
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   HAEGERSTROMPORTNOY G, 1989, CLIN VISION SCI, V4, P165
   HART WM, 1987, SURV OPHTHALMOL, V32, P10, DOI 10.1016/0039-6257(87)90070-1
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KNOBLAUCH K, 1987, APPL OPTICS, V26, P1441, DOI 10.1364/AO.26.001441
   Kollner H., 1912, STORUNGEN FARBENSINN
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   METHA AB, 1993, BEHAV RES METH INSTR, V25, P371, DOI 10.3758/BF03204528
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   POKORNY J, 1980, International Ophthalmology Clinics, V20, P53, DOI 10.1097/00004397-198002010-00005
   Rabin J, 2011, INVEST OPHTH VIS SCI, V52, P816, DOI 10.1167/iovs.10-6283
   Schneck ME, 1993, COLOUR VISION DEFICI, P357
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   SMITH VC, 1975, VISION RES, V15, P161, DOI 10.1016/0042-6989(75)90203-5
   SMITH VC, 1988, J OPT SOC AM A, V5, P2113, DOI 10.1364/JOSAA.5.002113
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Vingrys AJ, 1997, DOC OPHTH P, V59, P431
   VINGRYS AJ, 1993, INVEST OPHTH VIS SCI, V34, P750
NR 41
TC 8
Z9 8
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 932
EP 938
DI 10.1097/OPX.0000000000000246
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500017
PM 24748029
DA 2022-11-30
ER

PT J
AU Guymer, RH
   Chong, EWT
AF Guymer, Robyn H.
   Chong, Elaine Wei-Tinn
TI Modifiable risk factors for age-related macular degeneration
SO MEDICAL JOURNAL OF AUSTRALIA
LA English
DT Article
ID DIETARY-FAT; BETA-CAROTENE; CARDIOVASCULAR-DISEASE; VITAMIN-E;
   LUNG-CANCER; FISH INTAKE; MACULOPATHY; SUPPLEMENTATION; ASSOCIATION;
   PROGRESSION
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in Australia and other Western countries.
   As there is no cure for AMD, and treatments to stop its progression have met with limited success, there is an interest in identifying modifiable risk factors to prevent or slow disease progression.
   To date, smoking is the only proven modifiable risk factor for AMD. Other factors under study include (i) cardiovascular risk factors such as hypertension, body mass index, and atherosclerosis; and (ii) dietary risk factors including fat and antioxidant intake, but so far these studies have produced conflicting results.
   Dietary fat in relation to AMD has recently attracted media attention. Despite very limited work supporting an association between vegetable fat and AMD, widespread publicity advocating margarine as a cause of AMD and encouraging use of butter instead has caused confusion and anxiety among sufferers of AMD and the general public, as well as concern among health professionals.
   The antioxidant carotenoids-lutein and zeaxanthin-found in dark green or yellow vegetables exist in high concentrations in the macula and are hypothesised to play a protective role. Of nine controlled trials of supplementation with carotenoids and other antioxidants, three suggested that various combinations of antioxidants and carotenoids were protective.
   While a low-fat diet rich in dark green and yellow vegetables is advocated in general, any specific recommendations regarding certain fats or antioxidant supplementation and AMD are not based on consistent findings at this stage.
C1 Univ Melbourne, Ctr Eye Res Australia, Dept Ophthalmol, Macular Res Unit, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; University of Melbourne
RP Chong, EWT (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Dept Ophthalmol, Macular Res Unit, Melbourne, Vic, Australia.
EM elainechongwt@gmail.com
OI Guymer, Robyn/0000-0002-9441-4356
CR Access Economics, 2004, CLEAR INS EC IMP COS
   Alves-Rodrigues A, 2004, TOXICOL LETT, V150, P57, DOI 10.1016/j.toxlet.2003.10.031
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   CHUA B, 2006, IN PRESS ARCH OPHTHA
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   GUYMER RH, 2005, CAN HMG COA REDUCTAS
   HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mansour M P, 1993, Asia Pac J Clin Nutr, V2, P155
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   VIDAURRI JS, 1984, OPHTHALMOLOGICA, V188, P243, DOI 10.1159/000309370
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
NR 38
TC 54
Z9 57
U1 0
U2 9
PU AUSTRALASIAN MED PUBL CO LTD
PI PYRMONT
PA LEVEL 2, 26-32 PYRMONT BRIDGE RD, PYRMONT, NSW 2009, AUSTRALIA
SN 0025-729X
EI 1326-5377
J9 MED J AUSTRALIA
JI Med. J. Aust.
PD MAY 1
PY 2006
VL 184
IS 9
BP 455
EP 458
DI 10.5694/j.1326-5377.2006.tb00318.x
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 050UE
UT WOS:000238113400009
PM 16646746
DA 2022-11-30
ER

PT J
AU Bavinger, JC
   Ying, GS
   Daniel, E
   Grunwald, JE
   Maguire, MG
   Williams, DF
   Beardsley, S
   Bennett, S
   Cantrill, H
   Chan-Tram, C
   Cheshier, H
   Damato, K
   Davies, J
   Dev, S
   Enloe, J
   Follano, G
   Gilbert, P
   Johnson, J
   Jones, T
   Mayleben, L
   Mittra, R
   Moos, M
   Neist, R
   Oestreich, N
   Quiram, P
   Ramsay, R
   Ryan, E
   Schindeldecker, S
   Snater, J
   Steele, T
   Selders, D
   Tonsfeldt, J
   Valardi, S
   Fish, GE
   Aguado, HA
   Arceneaux, S
   Arnwine, J
   Bell, K
   Bell, T
   Boleman, B
   Bradley, P
   Callanan, D
   Coors, L
   Creighton, J
   Crew, T
   Cummings, K
   Dock, C
   Duignan, K
   Fuller, D
   Gray, K
   Hendrix, B
   Hesse, N
   Jaramillo, D
   Jost, B
   Lash, S
   Lonsdale, L
   Mackens, M
   Mutz, K
   Potts, M
   Sanchez, B
   Snyder, W
   Solley, W
   Tarter, C
   Wang, R
   Williams, P
   Perkins, SL
   Anderson, N
   Arnold, A
   Blais, P
   Googe, J
   Higdon, TT
   Hunt, C
   Johnson, M
   Miller, J
   Moore, M
   Morris, CK
   Morris, C
   Oelrich, S
   Oliver, K
   Seitz, V
   Whetstone, J
   Doft, BH
   Bedel, J
   Bergren, R
   Borthwick, A
   Conrad, P
   Fec, A
   Fulwylie, C
   Ingram, W
   Latham, S
   Lester, G
   Liu, J
   Lobes, L
   Lucko, NM
   Mechling, H
   Merlotti, L
   McBroom, K
   Olsen, K
   Puskas, D
   Rath, P
   Schmucker, M
   Schueckler, L
   Schultz, C
   Shultz, H
   Steinberg, D
   Vyas, A
   Whale, K
   Yeckel, K
   Orth, DH
   Arredondo, LS
   Brown, S
   Ciscato, BJ
   Civantos, JM
   Figliulo, C
   Hasan, S
   Kosinski, B
   Muir, D
   Nelson, K
   Packo, K
   Pollack, JS
   Rezaei, K
   Shelton, G
   Townsend-Patrick, S
   Walsh, M
   McDonald, HR
   Ansari, N
   Bye, A
   Fu, AD
   Grout, S
   Indermill, C
   Johnson, RN
   Jumper, JM
   Linares, S
   Lujan, BJ
   Munden, A
   Persons, M
   Rodriguez, R
   Rose, JM
   Teske, B
   Urias, Y
   Young, S
   Dreyer, RF
   Daniel, H
   Connaughton, M
   Handelman, I
   Hobbs, S
   Hoerner, C
   Hudson, D
   Kopfer, M
   Lee, M
   Lemley, C
   Logan, J
   Ma, C
   Mallet, C
   Milliron, A
   Peters, M
   Wohlsein, H
   Pearlman, JA
   Andrews, M
   Bartlett, M
   Carlson, N
   Cox, E
   Equi, R
   Gonzalez, M
   Griffin, S
   Hogue, F
   Kennedy, L
   Kryuchkov, L
   Lopez, C
   Lopez, D
   Luevano, B
   McKenna, E
   Patel, A
   Reed, B
   Secor, N
   Sison, IR
   Tsai, T
   Varghis, N
   Waller, B
   Wendel, R
   Yebra, R
   Roth, DB
   Deinzer, J
   Fine, H
   Green, F
   Green, S
   Keyser, B
   Leff, S
   Leviton, A
   Martir, A
   Mosenthine, K
   Muscle, S
   Okoren, L
   Parker, S
   Prenner, J
   Price, N
   Rogers, D
   Rosas, L
   Schlosser, A
   Studenko, L
   Tantum, T
   Wheatley, H
   Trese, MT
   Aaberg, T
   Bell, T
   Bezaire, D
   Bridges, C
   Bryant, D
   Capone, A
   Coleman, M
   Consolo, C
   Cook, C
   DuLong, C
   Garretson, B
   Grooten, T
   Hammersley, J
   Hassan, T
   Jessick, H
   Jones, N
   Kinsman, C
   Krumlauf, J
   Lewis, S
   Locke, H
   Margherio, A
   Markus, D
   Marsh, T
   Neal, S
   Noffke, A
   Oh, K
   Pence, C
   Preston, L
   Raphaelian, P
   Regan, VR
   Roberts, P
   Ruby, A
   Sarrafizadeh, R
   Scherf, M
   Scott, S
   Sneed, S
   Staples, L
   Terry, B
   Trese, MT
   Videtich, J
   Williams, G
   Zajechowski, M
   Joseph, DP
   Blinder, K
   Boyd, L
   Buckley, S
   Crow, M
   Dinatale, A
   Engelbrecht, N
   Forke, B
   Gabel, D
   Grand, G
   Grillion-Cerone, J
   Holekamp, N
   Kelly, C
   Nobel, G
   Pepple, K
   Raeber, M
   Rao, PK
   Ressel, T
   Schremp, S
   Sgorlon, M
   Shears, S
   Thomas, M
   Timma, C
   Vaughn, A
   Walters, C
   Weeks, R
   Wehmeier, J
   Wright, T
   Berinstein, DM
   Ayyad, A
   Barazi, MK
   Bickhart, E
   Brady, T
   Byank, L
   Cronise, A
   Denny, V
   Dunn, C
   Flory, M
   Frantz, R
   Garfinkel, RA
   Gilbert, W
   Lai, MM
   Melamud, A
   Newgen, J
   Newton, S
   Oliver, D
   Osman, M
   Sanders, R
   Fricken, M
   Dugel, P
   Arenas, S
   Balea, G
   Bartoli, D
   Bucci, J
   Cornelius, JA
   Dickens, S
   Doherty, D
   Dunlap, H
   Goldenberg, D
   Jamal, K
   Jimenez, N
   Kavanagh, N
   Kunimoto, D
   Martin, J
   Miner, J
   Mobley, S
   Park, D
   Quinlan, E
   Sipperley, J
   Slagle, C
   Smith, D
   Yafchak, M
   Yager, R
   Flaxel, CJ
   Bailey, S
   Francis, P
   Howell, C
   Hwang, T
   Ira, S
   Klein, M
   Lauer, A
   Liesegang, T
   Lundquist, A
   Nolte, S
   Nolte, SK
   Pickell, S
   Pope, S
   Rossi, J
   Schain, M
   Steinkamp, P
   Toomey, MD
   Vahrenwald, D
   West, K
   Hubbard, B
   Andelman, S
   Bergstrom, C
   Brower, J
   Cribbs, B
   Curtis, L
   Dobbs, J
   DuBois, L
   Gaultney, J
   Gibbs, D
   Jordan, D
   Leef, D
   Martin, DF
   Myles, R
   Olsen, T
   Schwent, B
   Srivastava, S
   Waldron, R
   Antoszyk, AN
   Balasubramaniam, U
   Brooks, D
   Brown, J
   Browning, D
   Clark, L
   Ennis, S
   Held, S
   Helms, JV
   Herby, J
   Karow, A
   Leotaud, P
   Massimino, C
   McClain, D
   McOwen, M
   Mindel, J
   Pereira, C
   Pierce, R
   Powers, M
   Price, A
   Rohrer, J
   Sanders, J
   Avery, RL
   Avery, K
   Basefsky, J
   Beckner, L
   Castellarin, A
   Couvillion, S
   Giust, J
   Giust, M
   Nasir, M
   Pieramici, D
   Rabena, M
   Risard, S
   See, R
   Smith, J
   Wan, LS
   Bakri, SJ
   Abu-Yaghi, N
   Barkmeier, A
   Berg, K
   Burrington, J
   Edwards, A
   Goddard, S
   Howard, S
   Iezzi, R
   Lewison, D
   Link, T
   McCannel, CA
   Overend, J
   Pach, J
   Ruszczyk, M
   Shultz, R
   Stephan, C
   Vogen, D
   Bradford, RH
   Bergman, V
   Burris, R
   Butt, A
   Daniels, B
   Dwiggins, C
   Fransen, S
   Guerrero, T
   Haivala, D
   Harris, A
   Icks, S
   Kingsley, R
   Redden, L
   Richmond, R
   Ross, B
   White, K
   Youngberg, M
   Topping, TM
   Bennett, S
   Chong, S
   Ciotti, M
   Cleary, T
   Corey, E
   Donovan, D
   Frederick, A
   Freese, L
   Graham, M
   Gud, N
   Howard, T
   Jones, M
   Morley, M
   Moses, K
   Stone, J
   Ty, R
   Wiegand, T
   Williams, L
   Winder, B
   Retina, T
   Awh, CC
   Amonette, M
   Arrindell, E
   Beck, D
   Busbee, B
   Dilback, A
   Downs, S
   Guidry, A
   Gutow, G
   Hardin, J
   Hines, S
   Hutchins, E
   LaCivita, K
   Lester, A
   Malott, L
   McCain, M
   Miracle, J
   Moffat, K
   Palazzotta, L
   Robinson, K
   Sonkin, P
   Travis, A
   TrentWallace, R
   Winters, KJ
   Wray, J
   Harris, AE
   Bunnell, M
   Crooks, K
   Fitzgerald, R
   Javid, C
   Kew, C
   Kill, E
   Kline, P
   Kreienkamp, J
   Martinez, M
   Moore, RA
   Saavedra, E
   Taylor, L
   Walsh, M
   Wilson, L
   Ciulla, TA
   Coyle, E
   Harrington, T
   Harris, C
   Hood, C
   Kerr, I
   Maturi, R
   Moore, D
   Morrow, S
   Savage, J
   Sink, B
   Steele, T
   Thukral, N
   Wilburn, J
   Walker, JP
   Banks, J
   Ciampaglia, D
   Dyshanowitz, D
   Frederick, J
   Ghuman, AT
   Grodin, R
   Kiesel, C
   Knips, E
   Mccue, J
   Ortiz, M
   Peters, C
   Raskauskas, P
   Schoeman, E
   Sharma, A
   Wing, G
   Youngblood, R
   Chandra, SR
   Altaweel, M
   Blodi, B
   Burke, K
   Dietzman, KA
   Gottlieb, J
   Knutson, G
   Krolnik, D
   Nork, TM
   Olson, S
   Peterson, J
   Reed, S
   Soderling, B
   Somers, G
   Stevens, T
   Wealti, A
   Bearelly, S
   Branchaud, B
   Bryant, JW
   Crowell, S
   Fekrat, S
   Gammage, M
   Harrison, C
   Jones, S
   McClain, N
   McCuen, B
   Mruthyunjaya, P
   Queen, J
   Sarin, N
   Skalak, C
   Skelly, M
   Suner, I
   Tomany, R
   Welch, L
   Park, SS
   Cassidy, A
   Chandra, K
   Good, I
   Imson, K
   Kaur, S
   Metzler, H
   Morse, L
   Redenbo, E
   Salvador, M
   Telander, D
   Thomas, M
   Wallace, C
   Barr, CC
   Battcher, A
   Bottorff, M
   Chasteen, M
   Clark, K
   Denning, D
   Schoen, D
   Schultz, A
   Tempel, E
   Wheeler, L
   Whittington, GK
   Stone, TW
   Blevins, T
   Buck, M
   Cruz, L
   Heath, W
   Holcomb, D
   Isernhagen, R
   Kidd, T
   Kitchens, J
   Sears, C
   Slade, E
   Van Arsdall, J
   VanHoose, B
   Wolfe, J
   Wood, W
   Zilis, J
   Crooks, C
   Disney, L
   Liu, MM
   Petty, S
   Sall, S
   Folk, JC
   Aly, T
   Brotherton, A
   Critser, D
   Hinz, CJ
   Karakas, S
   Kirschner, V
   Lester, C
   Montague, C
   Russell, S
   Stockman, H
   Taylor, B
   Verdick, R
   Walshire, J
   Thompson, JT
   Connell, B
   Constantine, M
   Davis, JL
   Holsapple, G
   Hunter, L
   Lenane, CN
   Mitchell, R
   Russel, L
   Sjaarda, R
   Brown, DM
   Benz, M
   Burns, L
   Carranza, JG
   Fish, R
   Goates, D
   Hay, S
   Jeffers, T
   Kegley, E
   Kubecka, D
   McGilvra, S
   Richter, B
   Sneed, V
   Stoever, C
   Tellez, I
   Wong, T
   Kim, I
   Andreoli, C
   Barresi, L
   Brett, S
   Callahan, C
   Capaccioli, K
   Carli, W
   Coppola, M
   Emmanuel, N
   Evans, C
   Fagan, A
   Grillo, M
   Head, J
   Lee, E
   Lord, U
   Miretsky, E
   Palitsch, K
   Petrin, T
   Reader, L
   Reznichenko, S
   Robertson, M
   Smith, J
   Vavvas, D
   Wells, J
   Cahill, C
   Clark, WL
   Henry, K
   Johnson, D
   Miller, P
   Oliver, L
   Spivey, R
   Swinford, T
   Taylor, M
   Lambert, M
   Chase, K
   Fredrickson, D
   Khawly, J
   Lazarte, V
   Lowd, D
   Miller, P
   Willis, A
   Ferrone, PJ
   Almonte, M
   Arnott, R
   Aviles, I
   Carbon, S
   Chitjian, M
   DAmore, K
   Elliott, C
   Fastenberg, D
   Golub, B
   Graham, K
   Lavorna, A
   Murphy, L
   Palomo, A
   Puglisi, C
   Rhee, D
   Romero, J
   Rosenblatt, B
   Salcedo, G
   Schlameuss, M
   Shakin, E
   Sookhai, V
   Kaiser, R
   Affel, E
   Brown, G
   Centinaro, C
   Fine, D
   Fineman, M
   Formoso, M
   Garg, S
   Grande, L
   Herbert, C
   Ho, A
   Hsu, J
   Jay, M
   Lavetsky, L
   Liebenbaum, E
   Maguire, J
   Monsonego, J
   O'Connor, L
   Pierce, L
   Regillo, C
   Rosario, M
   Spirn, M
   Vander, J
   Walsh, J
   Davidorf, FH
   Barnett, A
   Chang, S
   Christoforidis, J
   Elliott, J
   Justice, H
   Letson, A
   McKinney, K
   Perry, J
   Salerno, JA
   Savage, S
   Shelley, S
   Singerman, LJ
   Coney, J
   DuBois, J
   DuBois, K
   Greanoff, G
   Himmelman, D
   Ilc, M
   Mcnamara, E
   Novak, M
   Pendergast, S
   Rath, S
   Smith-Brewer, S
   Tanner, V
   Weiss, DE
   Zegarra, H
   Halperin, L
   Aramayo, P
   Dhalla, M
   Fernandez, B
   Fernandez, C
   Lopez, J
   Lopez, M
   Mariano, J
   Murphy, K
   Sherley, C
   Veksler, R
   Rahhal, F
   Babikian, R
   Boyer, D
   Hami, S
   Kessinger, J
   Kurokouchi, J
   Mukarram, S
   Pachman, S
   Protacio, E
   Sierra, J
   Tabandeh, H
   Zamboni, A
   Elman, M
   Belz, J
   Butcher, T
   Coffey, T
   Firestone, D
   Gore, N
   Singletary, P
   Sotirakos, P
   Starr, J
   Meredith, TA
   Barnhart, CJ
   Cantrell, D
   Esquejo-Leon, R
   Houghton, O
   Kaur, H
   Ndure, F
   Glatzer, R
   Joffe, L
   Schindler, R
   Martin, DF
   Fine, SL
   Katz, M
   Maguire, MG
   Brightwell-Arnold, M
   Glaser, R
   Hall, J
   Harkins, S
   Huang, JY
   Khvatov, A
   McWilliams, K
   Nolte, SK
   Peskin, E
   Pistilli, M
   Ryan, S
   Schnader, A
   Ying, GS
   Jaffe, G
   Afrani-Sakyi, J
   Balsley, B
   Bennett, LS
   Brooks, A
   Brower-Lingsch, A
   Bruce, L
   Burns, R
   Busian, D
   Choong, J
   Cloaninger, L
   DeCroos, FC
   DuBois, E
   El-Dairi, M
   Gach, S
   Hall, K
   Hawks, T
   Huang, C
   Heydary, C
   Ho, A
   Kini, S
   McCall, M
   Muhammad, D
   Nicholson, J
   Queen, J
   Rieves, P
   Shields, K
   Skalak, C
   Specker, A
   Stinnett, S
   Subramaniam, S
   Tenbrink, P
   Toth, C
   Towe, A
   Welch, K
   Williams, N
   Winter, K
   Young, E
   Grunwald, JE
   Alexander, J
   Daniel, E
   Daniel, E
   Martin, ER
   Parker, C
   Sepielli, K
   Shannon, T
   Whearry, C
   Redford, M
   Martin, DF
   Avery, RL
   Bakri, SJ
   Daniel, E
   Fine, SL
   Grunwald, JE
   Jaffe, G
   Kopfer, MR
   Maguire, MG
   Meredith, TA
   Peskin, E
   Redford, M
   Williams, DF
   Martin, DF
   Bennett, LS
   Daniel, E
   Ferris, FL
   Fine, SL
   Grunwald, JE
   Jaffe, G
   Maguire, MG
   Peskin, E
   Redford, M
   Toth, C
   Peskin, E
   Brightwell-Arnold, M
   DuPont, J
   Maguire, MG
   McWilliams, K
   Nolte, SK
   Friedman, LM
   Bressler, SB
   DeMets, DL
   Friedlander, M
   Johnson, MW
   Lindblad, A
   Losordo, DW
   Miller, FG
AF Bavinger, J. Clay
   Ying, Gui-shuang
   Daniel, Ebenezer
   Grunwald, Juan E.
   Maguire, Maureen G.
   Williams, David F.
   Beardsley, Sara
   Bennett, Steven
   Cantrill, Herbert
   Chan-Tram, Carmen
   Cheshier, Holly
   Damato, Kathyrn
   Davies, John
   Dev, Sundeep
   Enloe, Julianne
   Follano, Gennaro
   Gilbert, Peggy
   Johnson, Jill
   Jones, Tori
   Mayleben, Lisa
   Mittra, Robert
   Moos, Martha
   Neist, Ryan
   Oestreich, Neal
   Quiram, Polly
   Ramsay, Robert
   Ryan, Edwin
   Schindeldecker, Stephanie
   Snater, John
   Steele, Trenise
   Selders, Dwight
   Tonsfeldt, Jessica
   Valardi, Shelly
   Fish, Gary Edd
   Aguado, Hank A.
   Arceneaux, Sally
   Arnwine, Jean
   Bell, Kim
   Bell, Tina
   Boleman, Bob
   Bradley, Patricia
   Callanan, David
   Coors, Lori
   Creighton, Jodi
   Crew, Timothy
   Cummings, Kimberly
   Dock, Christopher
   Duignan, Karen
   Fuller, Dwain
   Gray, Keith
   Hendrix, Betsy
   Hesse, Nicholas
   Jaramillo, Diana
   Jost, Bradley
   Lash, Sandy
   Lonsdale, Laura
   Mackens, Michael
   Mutz, Karin
   Potts, Michael
   Sanchez, Brenda
   Snyder, William
   Solley, Wayne
   Tarter, Carrie
   Wang, Robert
   Williams, Patrick
   Perkins, Stephen L.
   Anderson, Nicholas
   Arnold, Ann
   Blais, Paul
   Googe, Joseph
   Higdon, Tina T.
   Hunt, Cecile
   Johnson, Mary
   Miller, James
   Moore, Misty
   Morris, Charity K.
   Morris, Christopher
   Oelrich, Sarah
   Oliver, Kristina
   Seitz, Vicky
   Whetstone, Jerry
   Doft, Bernard H.
   Bedel, Jay
   Bergren, Robert
   Borthwick, Ann
   Conrad, Paul
   Fec, Amanda
   Fulwylie, Christina
   Ingram, Willia
   Latham, Shawnique
   Lester, Gina
   Liu, Judy
   Lobes, Louis
   Lucko, Nicole M.
   Mechling, Holly
   Merlotti, Lori
   McBroom, Keith
   Olsen, Karl
   Puskas, Danielle
   Rath, Pamela
   Schmucker, Maria
   Schueckler, Lynn
   Schultz, Christina
   Shultz, Heather
   Steinberg, David
   Vyas, Avni
   Whale, Kim
   Yeckel, Kimberly
   Orth, David H.
   Arredondo, Linda S.
   Brown, Susan
   Ciscato, Barbara J.
   Civantos, Joseph M.
   Figliulo, Celeste
   Hasan, Sohail
   Kosinski, Belinda
   Muir, Dan
   Nelson, Kiersten
   Packo, Kirk
   Pollack, John S.
   Rezaei, Kourous
   Shelton, Gina
   Townsend-Patrick, Shannya
   Walsh, Marian
   McDonald, H. Richard
   Ansari, Nina
   Bye, Amanda
   Fu, Arthur D.
   Grout, Sean
   Indermill, Chad
   Johnson, Robert N.
   Jumper, J. Michael
   Linares, Silvia
   Lujan, Brandon J.
   Munden, Ames
   Persons, Meredith
   Rodriguez, Rosa
   Rose, Jennifer M.
   Teske, Brandi
   Urias, Yesmin
   Young, Stephen
   Dreyer, Richard F.
   Daniel, Howard
   Connaughton, Michele
   Handelman, Irvin
   Hobbs, Stephen
   Hoerner, Christine
   Hudson, Dawn
   Kopfer, Marcia
   Lee, Michael
   Lemley, Craig
   Logan, Joe
   Ma, Colin
   Mallet, Christophe
   Milliron, Amanda
   Peters, Mark
   Wohlsein, Harry
   Pearlman, Joel A.
   Andrews, Margo
   Bartlett, Melissa
   Carlson, Nanette
   Cox, Emily
   Equi, Robert
   Gonzalez, Marta
   Griffin, Sophia
   Hogue, Fran
   Kennedy, Lance
   Kryuchkov, Lana
   Lopez, Carmen
   Lopez, Danny
   Luevano, Bertha
   McKenna, Erin
   Patel, Arun
   Reed, Brian
   Secor, Nyla
   Sison, Iris R.
   Tsai, Tony
   Varghis, Nina
   Waller, Brooke
   Wendel, Robert
   Yebra, Reina
   Roth, Daniel B.
   Deinzer, Jane
   Fine, Howard
   Green, Flory
   Green, Stuart
   Keyser, Bruce
   Leff, Steven
   Leviton, Amy
   Martir, Amy
   Mosenthine, Kristin
   Muscle, Starr
   Okoren, Linda
   Parker, Sandy
   Prenner, Jonathan
   Price, Nancy
   Rogers, Deana
   Rosas, Linda
   Schlosser, Alex
   Studenko, Loretta
   Tantum, Thea
   Wheatley, Harold
   Trese, Michael T.
   Aaberg, Thomas
   Bell, Tina
   Bezaire, Denis
   Bridges, Craig
   Bryant, Doug
   Capone, Antonio
   Coleman, Michelle
   Consolo, Christina
   Cook, Cindy
   DuLong, Candice
   Garretson, Bruce
   Grooten, Tracy
   Hammersley, Julie
   Hassan, Tarek
   Jessick, Heather
   Jones, Nanette
   Kinsman, Crystal
   Krumlauf, Jennifer
   Lewis, Sandy
   Locke, Heather
   Margherio, Alan
   Markus, Debra
   Marsh, Tanya
   Neal, Serena
   Noffke, Amy
   Oh, Kean
   Pence, Clarence
   Preston, Lisa
   Raphaelian, Paul
   Regan, Virginia R.
   Roberts, Peter
   Ruby, Alan
   Sarrafizadeh, Ramin
   Scherf, Marissa
   Scott, Sarita
   Sneed, Scott
   Staples, Lisa
   Terry, Brad
   Trese, Matthew T.
   Videtich, Joan
   Williams, George
   Zajechowski, Mary
   Joseph, Daniel P.
   Blinder, Kevin
   Boyd, Lynda
   Buckley, Sarah
   Crow, Meaghan
   Dinatale, Amanda
   Engelbrecht, Nicholas
   Forke, Bridget
   Gabel, Dana
   Grand, Gilbert
   Grillion-Cerone, Jennifer
   Holekamp, Nancy
   Kelly, Charlotte
   Nobel, Ginny
   Pepple, Kelly
   Raeber, Matt
   Rao, P. Kumar
   Ressel, Tammy
   Schremp, Steven
   Sgorlon, Merrilee
   Shears, Shantia
   Thomas, Matthew
   Timma, Cathy
   Vaughn, Annette
   Walters, Carolyn
   Weeks, Rhonda
   Wehmeier, Jarrod
   Wright, Tim
   Berinstein, Daniel M.
   Ayyad, Aida
   Barazi, Mohammed K.
   Bickhart, Erica
   Brady, Tracey
   Byank, Lisa
   Cronise, Alysia
   Denny, Vanessa
   Dunn, Courtney
   Flory, Michael
   Frantz, Robert
   Garfinkel, Richard A.
   Gilbert, William
   Lai, Michael M.
   Melamud, Alexander
   Newgen, Janine
   Newton, Shamekia
   Oliver, Debbie
   Osman, Michael
   Sanders, Reginald
   von Fricken, Manfred
   Dugel, Pravin
   Arenas, Sandra
   Balea, Gabe
   Bartoli, Dayna
   Bucci, John
   Cornelius, Jennifer A.
   Dickens, Scheleen
   Doherty, Don
   Dunlap, Heather
   Goldenberg, David
   Jamal, Karim
   Jimenez, Norma
   Kavanagh, Nicole
   Kunimoto, Derek
   Martin, John
   Miner, Jessica
   Mobley, Sarah
   Park, Donald
   Quinlan, Edward
   Sipperley, Jack
   Slagle, Carol
   Smith, Danielle
   Yafchak, Miguelina
   Yager, Rohana
   Flaxel, Christina J.
   Bailey, Steven
   Francis, Peter
   Howell, Chris
   Hwang, Thomas
   Ira, Shirley
   Klein, Michael
   Lauer, Andreas
   Liesegang, Teresa
   Lundquist, Ann
   Nolte, Sarah
   Nolte, Susan K.
   Pickell, Scott
   Pope, Susan
   Rossi, Joseph
   Schain, Mitchell
   Steinkamp, Peter
   Toomey, Maureen D.
   Vahrenwald, Debora
   West, Kelly
   Hubbard, Baker
   Andelman, Stacey
   Bergstrom, Chris
   Brower, Judy
   Cribbs, Blaine
   Curtis, Linda
   Dobbs, Jannah
   DuBois, Lindreth
   Gaultney, Jessica
   Gibbs, Deborah
   Jordan, Debora
   Leef, Donna
   Martin, Daniel F.
   Myles, Robert
   Olsen, Timothy
   Schwent, Bryan
   Srivastava, Sunil
   Waldron, Rhonda
   Antoszyk, Andrew N.
   Balasubramaniam, Uma
   Brooks, Danielle
   Brown, Justin
   Browning, David
   Clark, Loraine
   Ennis, Sarah
   Held, Susannah
   Helms, Jennifer V.
   Herby, Jenna
   Karow, Angie
   Leotaud, Pearl
   Massimino, Caterina
   McClain, Donna
   McOwen, Michael
   Mindel, Jennifer
   Pereira, Candace
   Pierce, Rachel
   Powers, Michele
   Price, Angela
   Rohrer, Jason
   Sanders, Jason
   Avery, Robert L.
   Avery, Kelly
   Basefsky, Jessica
   Beckner, Liz
   Castellarin, Alessandro
   Couvillion, Stephen
   Giust, Jack
   Giust, Matthew
   Nasir, Maan
   Pieramici, Dante
   Rabena, Melvin
   Risard, Sarah
   See, Robert
   Smith, Jerry
   Wan, Lisha
   Bakri, Sophie J.
   Abu-Yaghi, Nakhleh
   Barkmeier, Andrew
   Berg, Karin
   Burrington, Jean
   Edwards, Albert
   Goddard, Shannon
   Howard, Shannon
   Iezzi, Raymond
   Lewison, Denise
   Link, Thomas
   McCannel, Colin A.
   Overend, Joan
   Pach, John
   Ruszczyk, Margaret
   Shultz, Ryan
   Stephan, Cindy
   Vogen, Diane
   Bradford, Reagan H., Jr.
   Bergman, Vanessa
   Burris, Russ
   Butt, Amanda
   Daniels, Beth
   Dwiggins, Connie
   Fransen, Stephen
   Guerrero, Tiffany
   Haivala, Darin
   Harris, Amy
   Icks, Sonny
   Kingsley, Ronald
   Redden, Lena
   Richmond, Rob
   Ross, Brittany
   White, Kammerin
   Youngberg, Misty
   Topping, Trexler M.
   Bennett, Steve
   Chong, Sandy
   Ciotti, Mary
   Cleary, Tina
   Corey, Emily
   Donovan, Dennis
   Frederick, Albert
   Freese, Lesley
   Graham, Margaret
   Gud, Natalya
   Howard, Taneika
   Jones, Mike
   Morley, Michael
   Moses, Katie
   Stone, Jen
   Ty, Robin
   Wiegand, Torsten
   Williams, Lindsey
   Winder, Beth
   Retina, Tennessee
   Awh, Carl C.
   Amonette, Michelle
   Arrindell, Everton
   Beck, Dena
   Busbee, Brandon
   Dilback, Amy
   Downs, Sara
   Guidry, Allison
   Gutow, Gary
   Hardin, Jackey
   Hines, Sarah
   Hutchins, Emily
   LaCivita, Kim
   Lester, Ashley
   Malott, Larry
   McCain, MaryAnn
   Miracle, Jayme
   Moffat, Kenneth
   Palazzotta, Lacy
   Robinson, Kelly
   Sonkin, Peter
   Travis, Alecia
   TrentWallace, Roy
   Winters, Kelly J.
   Wray, Julia
   Harris, April E.
   Bunnell, Mari
   Crooks, Katrina
   Fitzgerald, Rebecca
   Javid, Cameron
   Kew, Corin
   Kill, Erica
   Kline, Patricia
   Kreienkamp, Janet
   Martinez, Maricruz
   Moore, Roy Ann
   Saavedra, Egbert
   Taylor, LuAnne
   Walsh, Mark
   Wilson, Larry
   Ciulla, Thomas A.
   Coyle, Ellen
   Harrington, Tonya
   Harris, Charlotte
   Hood, Cindi
   Kerr, Ingrid
   Maturi, Raj
   Moore, Dawn
   Morrow, Stephanie
   Savage, Jennifer
   Sink, Bethany
   Steele, Tom
   Thukral, Neelam
   Wilburn, Janet
   Walker, Joseph P.
   Banks, Jennifer
   Ciampaglia, Debbie
   Dyshanowitz, Danielle
   Frederick, Jennifer
   Ghuman, A. Tom
   Grodin, Richard
   Kiesel, Cheryl
   Knips, Eileen
   Mccue, Jonathan
   Ortiz, Maria
   Peters, Crystal
   Raskauskas, Paul
   Schoeman, Etienne
   Sharma, Ashish
   Wing, Glenn
   Youngblood, Rebecca
   Chandra, Suresh R.
   Altaweel, Michael
   Blodi, Barbara
   Burke, Kathryn
   Dietzman, Kristine A.
   Gottlieb, Justin
   Knutson, Gene
   Krolnik, Denise
   Nork, T. Michael
   Olson, Shelly
   Peterson, John
   Reed, Sandra
   Soderling, Barbara
   Somers, Guy
   Stevens, Thomas
   Wealti, Angela
   Bearelly, Srilaxmi
   Branchaud, Brenda
   Bryant, Joyce W.
   Crowell, Sara
   Fekrat, Sharon
   Gammage, Merritt
   Harrison, Cheala
   Jones, Sarah
   McClain, Noreen
   McCuen, Brooks
   Mruthyunjaya, Prithvi
   Queen, Jeanne
   Sarin, Neeru
   Skalak, Cindy
   Skelly, Marriner
   Suner, Ivan
   Tomany, Ronnie
   Welch, Lauren
   Park, Susanna S.
   Cassidy, Allison
   Chandra, Karishma
   Good, Idalew
   Imson, Katrina
   Kaur, Sashi
   Metzler, Helen
   Morse, Lawrence
   Redenbo, Ellen
   Salvador, Marisa
   Telander, David
   Thomas, Mark
   Wallace, Cindy
   Barr, Charles C.
   Battcher, Amanda
   Bottorff, Michelle
   Chasteen, Mary
   Clark, Kelly
   Denning, Diane
   Schoen, Debra
   Schultz, Amy
   Tempel, Evie
   Wheeler, Lisa
   Whittington, Greg K.
   Stone, Thomas W.
   Blevins, Todd
   Buck, Michelle
   Cruz, Lynn
   Heath, Wanda
   Holcomb, Diana
   Isernhagen, Rick
   Kidd, Terri
   Kitchens, John
   Sears, Cathy
   Slade, Ed
   Van Arsdall, Jeanne
   VanHoose, Brenda
   Wolfe, Jenny
   Wood, William
   Zilis, John
   Crooks, Carol
   Disney, Larry
   Liu, Mimi
   Petty, Stephen
   Sall, Sandra
   Folk, James C.
   Aly, Tracy
   Brotherton, Abby
   Critser, Douglas
   Hinz, Connie J.
   Karakas, Stefani
   Kirschner, Valerie
   Lester, Cheyanne
   Montague, Cindy
   Russell, Stephen
   Stockman, Heather
   Taylor, Barbara
   Verdick, Randy
   Walshire, Jean
   Thompson, John T.
   Connell, Barbara
   Constantine, Maryanth
   Davis, John L., Jr.
   Holsapple, Gwen
   Hunter, Lisa
   Lenane, C. Nicki
   Mitchell, Robin
   Russel, Leslie
   Sjaarda, Raymond
   Brown, David M.
   Benz, Matthew
   Burns, Llewellyn
   Carranza, JoLene G.
   Fish, Richard
   Goates, Debra
   Hay, Shayla
   Jeffers, Theresa
   Kegley, Eric
   Kubecka, Dallas
   McGilvra, Stacy
   Richter, Beau
   Sneed, Veronica
   Stoever, Cary
   Tellez, Isabell
   Wong, Tien
   Kim, Ivana
   Andreoli, Christopher
   Barresi, Leslie
   Brett, Sarah
   Callahan, Charlene
   Capaccioli, Karen
   Carli, William
   Coppola, Matthew
   Emmanuel, Nicholas
   Evans, Claudia
   Fagan, Anna
   Grillo, Marcia
   Head, John
   Lee, Elaine
   Lord, Ursula
   Miretsky, Edward
   Palitsch, Kate
   Petrin, Todd
   Reader, Liz
   Reznichenko, Svetlana
   Robertson, Mary
   Smith, Justin
   Vavvas, Demetrios
   Wells, John
   Cahill, Cassie
   Clark, W. Lloyd
   Henry, Kayla
   Johnson, David
   Miller, Peggy
   Oliver, LaDetrick
   Spivey, Robbin
   Swinford, Tiffany
   Taylor, Mallie
   Lambert, Michael
   Chase, Kris
   Fredrickson, Debbie
   Khawly, Joseph
   Lazarte, Valerie
   Lowd, Donald
   Miller, Pam
   Willis, Arthur
   Ferrone, Philip J.
   Almonte, Miguel
   Arnott, Rachel
   Aviles, Ingrid
   Carbon, Sheri
   Chitjian, Michael
   DAmore, Kristen
   Elliott, Christin
   Fastenberg, David
   Golub, Barry
   Graham, Kenneth
   Lavorna, AnnMarie
   Murphy, Laura
   Palomo, Amanda
   Puglisi, Christina
   Rhee, David
   Romero, Juan
   Rosenblatt, Brett
   Salcedo, Glenda
   Schlameuss, Marianne
   Shakin, Eric
   Sookhai, Vasanti
   Kaiser, Richard
   Affel, Elizabeth
   Brown, Gary
   Centinaro, Christina
   Fine, Deborah
   Fineman, Mitchell
   Formoso, Michele
   Garg, Sunir
   Grande, Lisa
   Herbert, Carolyn
   Ho, Allen
   Hsu, Jason
   Jay, Maryann
   Lavetsky, Lisa
   Liebenbaum, Elaine
   Maguire, Joseph
   Monsonego, Julia
   O'Connor, Lucia
   Pierce, Lisa
   Regillo, Carl
   Rosario, Maria
   Spirn, Marc
   Vander, James
   Walsh, Jennifer
   Davidorf, Frederick H.
   Barnett, Amanda
   Chang, Susie
   Christoforidis, John
   Elliott, Joy
   Justice, Heather
   Letson, Alan
   McKinney, Kathryne
   Perry, Jeri
   Salerno, Jill A.
   Savage, Scott
   Shelley, Stephen
   Singerman, Lawrence J.
   Coney, Joseph
   DuBois, John
   DuBois, Kimberly
   Greanoff, Gregg
   Himmelman, Dianne
   Ilc, Mary
   Mcnamara, Elizabeth
   Novak, Michael
   Pendergast, Scott
   Rath, Susan
   Smith-Brewer, Sheila
   Tanner, Vivian
   Weiss, Diane E.
   Zegarra, Hernando
   Halperin, Lawrence
   Aramayo, Patricia
   Dhalla, Mandeep
   Fernandez, Brian
   Fernandez, Cindy
   Lopez, Jaclyn
   Lopez, Monica
   Mariano, Jamie
   Murphy, Kellie
   Sherley, Clifford
   Veksler, Rita
   Rahhal, Firas
   Babikian, Razmig
   Boyer, David
   Hami, Sepideh
   Kessinger, Jeff
   Kurokouchi, Janet
   Mukarram, Saba
   Pachman, Sarah
   Protacio, Eric
   Sierra, Julio
   Tabandeh, Homayoun
   Zamboni, Adam
   Elman, Michael
   Belz, Jennifer
   Butcher, Tammy
   Coffey, Teresa
   Firestone, Dena
   Gore, Nancy
   Singletary, Pamela
   Sotirakos, Peter
   Starr, Joann
   Meredith, Travis A.
   Barnhart, Cassandra J.
   Cantrell, Debra
   Esquejo-Leon, RonaLyn
   Houghton, Odette
   Kaur, Harpreet
   Ndure, Fatoumatta
   Glatzer, Ronald
   Joffe, Leonard
   Schindler, Reid
   Martin, Daniel F.
   Fine, Stuart L.
   Katz, Marilyn
   Maguire, Maureen G.
   Brightwell-Arnold, Mary
   Glaser, Ruchira
   Hall, Judith
   Harkins, Sandra
   Huang, Jiayan
   Khvatov, Alexander
   McWilliams, Kathy
   Nolte, Susan K.
   Peskin, Ellen
   Pistilli, Maxwell
   Ryan, Susan
   Schnader, Allison
   Ying, Gui-Shuang
   Jaffe, Glenn
   Afrani-Sakyi, Jennifer
   Balsley, Brannon
   Bennett, Linda S.
   Brooks, Adam
   Brower-Lingsch, Adrienne
   Bruce, Lori
   Burns, Russell
   Busian, Dee
   Choong, John
   Cloaninger, Lindsey
   DeCroos, Francis Char
   DuBois, Emily
   El-Dairi, Mays
   Gach, Sarah
   Hall, Katelyn
   Hawks, Terry
   Huang, ChengChenh
   Heydary, Cindy
   Ho, Alexander
   Kini, Shashi
   McCall, Michelle
   Muhammad, Daaimah
   Nicholson, Jayne
   Queen, Jeanne
   Rieves, Pamela
   Shields, Kelly
   Skalak, Cindy
   Specker, Adam
   Stinnett, Sandra
   Subramaniam, Sujatha
   Tenbrink, Patrick
   Toth, Cynthia
   Towe, Aaron
   Welch, Kimberly
   Williams, Natasha
   Winter, Katrina
   Young, Ellen
   Grunwald, Juan E.
   Alexander, Judith
   Daniel, Ebenezer
   Daniel, Ebenezer
   Martin, E. Revell
   Parker, Candace
   Sepielli, Krista
   Shannon, Tom
   Whearry, Claressa
   Redford, Maryann
   Martin, Daniel F.
   Avery, Robert L.
   Bakri, Sophie J.
   Daniel, Ebenezer
   Fine, Stuart L.
   Grunwald, Juan E.
   Jaffe, Glenn
   Kopfer, Marcia R.
   Maguire, Maureen G.
   Meredith, Travis A.
   Peskin, Ellen
   Redford, Maryann
   Williams, David F.
   Martin, Daniel F.
   Bennett, Linda S.
   Daniel, Ebenezer
   Ferris, Frederick L., III
   Fine, Stuart L.
   Grunwald, Juan E.
   Jaffe, Glenn
   Maguire, Maureen G.
   Peskin, Ellen
   Redford, Maryann
   Toth, Cynthia
   Peskin, Ellen
   Brightwell-Arnold, Mary
   DuPont, Joan
   Maguire, Maureen G.
   McWilliams, Kathy
   Nolte, Susan K.
   Friedman, Lawrence M.
   Bressler, Susan B.
   DeMets, David L.
   Friedlander, Martin
   Johnson, Mark W.
   Lindblad, Anne
   Losordo, Douglas W.
   Miller, Franklin G.
CA Comparison Age-Related Macular
TI Association Between Cilioretinal Arteries and Advanced Age-Related
   Macular Degeneration Secondary Analysis of the Comparison of Age-Related
   Macular Degeneration Treatment Trials (CATT)
SO JAMA OPHTHALMOLOGY
LA English
DT Article
AB IMPORTANCE Recent reports suggest that cilioretinal arteries (CRAs) confer protection against developing advanced age-related macular degeneration (AMD).
   OBJECTIVE To further characterize the association between the presence of a CRA and incidence of geographic atrophy (GA) or choroidal neovascularization (CNV).
   DESIGN This cohort study constituted an ad hoc secondary analysis of data from the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) and was performed at 44 clinical centers in the United States among participants in CATT with CNV in the study eye and without advanced AMD in the fellow eye at baseline. The presence of a CRA was determined by 2 graders, masked to clinical data, using color fundus photographs, red-free fundus photographs, and fluorescein angiography. The proportion with CRAs at baseline between the study eye with CNV and fellow eye without CNV was first compared. The association of a CRA with incidence of CNV or GA at 5 years among fellow eyes and with incidence of GA among study (treated) eyes was then assessed. In addition, the association of CRAs with the Age-Related Eye Disease Study severity scale among the fellow eyes at baseline was assessed. Data were collected from February 1, 2008, through April 30, 2015, and analyzed from July 1, 2018, through April 30, 2019.
   EXPOSURES Presence of a CRA.
   MAIN OUTCOMES AND MEASURES The association between the presence of a CRA and incidence of CNV or GA at 5 years of follow-up.
   RESULTS A total of 350 patients (700 eyes) (230 [65.7% women; mean [SD] age, 77 [7.2] years) were included in the analysis. Cilioretinal arteries were present in 67 of 345 (19.4%) fellow eyes without baseline CNV and 73 of 349 (20.9%) study eyes with baseline CNV (P=.60). Cilioretinal arteries in fellow eyes were not associated with incidence of CNV at 5 years (125 of 278 [45.0%] among eyes without CRAs and 30 of 67 [44.8%] among eyes with CRAs; P=.99) or with incidence of GA at 5 years (110 of 278 [39.6%] among eyes without CRAs and 25 of 67 [37.3%] among eyes with CRAs; P=.89). Cilioretinal arteries in study eyes were not associated with incidence of GA at 5 years (105 of 276 [38.0%] study eyes without CRAs and 26 of 73 [35.6%] study eyes with CRAs; P=.72).
   CONCLUSIONS AND RELEVANCE The analysis did not find a protective association between CRAs and incidence of CNV or GA among CATT participants who had unilateral exudative AMD. Why these findings were different from those of previous publications is unclear but may be partially explained by the different techniques used to detect CRAs or by the baseline advanced disease in CATT participants.
C1 [Bavinger, J. Clay; Ying, Gui-shuang; Daniel, Ebenezer; Grunwald, Juan E.; Maguire, Maureen G.] Univ Penn, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
   [Williams, David F.; Beardsley, Sara; Bennett, Steven; Cantrill, Herbert; Chan-Tram, Carmen; Cheshier, Holly; Damato, Kathyrn; Davies, John; Dev, Sundeep; Enloe, Julianne; Follano, Gennaro; Gilbert, Peggy; Johnson, Jill; Jones, Tori; Mayleben, Lisa; Mittra, Robert; Moos, Martha; Neist, Ryan; Oestreich, Neal; Quiram, Polly; Ramsay, Robert; Ryan, Edwin; Schindeldecker, Stephanie; Snater, John; Steele, Trenise; Selders, Dwight; Tonsfeldt, Jessica; Valardi, Shelly] VitreoRetinal Surg PA, Edina, MN USA.
   [Fish, Gary Edd; Aguado, Hank A.; Arceneaux, Sally; Arnwine, Jean; Bell, Kim; Bell, Tina; Boleman, Bob; Bradley, Patricia; Callanan, David; Coors, Lori; Creighton, Jodi; Crew, Timothy; Cummings, Kimberly; Dock, Christopher; Duignan, Karen; Fuller, Dwain; Gray, Keith; Hendrix, Betsy; Hesse, Nicholas; Jaramillo, Diana; Jost, Bradley; Lash, Sandy; Lonsdale, Laura; Mackens, Michael; Mutz, Karin; Potts, Michael; Sanchez, Brenda; Snyder, William; Solley, Wayne; Tarter, Carrie; Wang, Robert; Williams, Patrick] Texas Retina Associates, Dallas, TX USA.
   [Perkins, Stephen L.; Anderson, Nicholas; Arnold, Ann; Blais, Paul; Googe, Joseph; Higdon, Tina T.; Hunt, Cecile; Johnson, Mary; Miller, James; Moore, Misty; Morris, Charity K.; Morris, Christopher; Oelrich, Sarah; Oliver, Kristina; Seitz, Vicky; Whetstone, Jerry] Southeastern Retina Associates, Knoxville, TN USA.
   [Doft, Bernard H.; Bedel, Jay; Bergren, Robert; Borthwick, Ann; Conrad, Paul; Fec, Amanda; Fulwylie, Christina; Ingram, Willia; Latham, Shawnique; Lester, Gina; Liu, Judy; Lobes, Louis; Lucko, Nicole M.; Mechling, Holly; Merlotti, Lori; McBroom, Keith; Olsen, Karl; Puskas, Danielle; Rath, Pamela; Schmucker, Maria; Schueckler, Lynn; Schultz, Christina; Shultz, Heather; Steinberg, David; Vyas, Avni; Whale, Kim; Yeckel, Kimberly] Retina Vitreous Consultants, Pittsburgh, PA USA.
   [Orth, David H.; Arredondo, Linda S.; Brown, Susan; Ciscato, Barbara J.; Civantos, Joseph M.; Figliulo, Celeste; Hasan, Sohail; Kosinski, Belinda; Muir, Dan; Nelson, Kiersten; Packo, Kirk; Pollack, John S.; Rezaei, Kourous; Shelton, Gina; Townsend-Patrick, Shannya; Walsh, Marian] Ingalls Mem Hosp Illinois Retina Associates, Harvey, IL USA.
   [McDonald, H. Richard; Ansari, Nina; Bye, Amanda; Fu, Arthur D.; Grout, Sean; Indermill, Chad; Johnson, Robert N.; Jumper, J. Michael; Linares, Silvia; Lujan, Brandon J.; Munden, Ames; Persons, Meredith; Rodriguez, Rosa; Rose, Jennifer M.; Teske, Brandi; Urias, Yesmin; Young, Stephen] West Coast Retina Med Grp Inc, San Francisco, CA USA.
   [Dreyer, Richard F.; Daniel, Howard; Connaughton, Michele; Handelman, Irvin; Hobbs, Stephen; Hoerner, Christine; Hudson, Dawn; Kopfer, Marcia; Lee, Michael; Lemley, Craig; Logan, Joe; Ma, Colin; Mallet, Christophe; Milliron, Amanda; Peters, Mark; Wohlsein, Harry] Retina Northwest PC, Portland, OR USA.
   [Pearlman, Joel A.; Andrews, Margo; Bartlett, Melissa; Carlson, Nanette; Cox, Emily; Equi, Robert; Gonzalez, Marta; Griffin, Sophia; Hogue, Fran; Kennedy, Lance; Kryuchkov, Lana; Lopez, Carmen; Lopez, Danny; Luevano, Bertha; McKenna, Erin; Patel, Arun; Reed, Brian; Secor, Nyla; Sison, Iris R.; Tsai, Tony; Varghis, Nina; Waller, Brooke; Wendel, Robert; Yebra, Reina; Roth, Daniel B.; Deinzer, Jane; Fine, Howard; Green, Flory; Green, Stuart; Keyser, Bruce; Leff, Steven; Leviton, Amy; Martir, Amy; Mosenthine, Kristin; Muscle, Starr; Okoren, Linda; Parker, Sandy; Prenner, Jonathan; Price, Nancy; Rogers, Deana; Rosas, Linda; Schlosser, Alex; Studenko, Loretta; Tantum, Thea; Wheatley, Harold] Retinal Consultants Med Grp Inc, Sacramento, CA USA.
   [Trese, Michael T.; Aaberg, Thomas; Bell, Tina; Bezaire, Denis; Bridges, Craig; Bryant, Doug; Capone, Antonio; Coleman, Michelle; Consolo, Christina; Cook, Cindy; DuLong, Candice; Garretson, Bruce; Grooten, Tracy; Hammersley, Julie; Hassan, Tarek; Jessick, Heather; Jones, Nanette; Kinsman, Crystal; Krumlauf, Jennifer; Lewis, Sandy; Locke, Heather; Margherio, Alan; Markus, Debra; Marsh, Tanya; Neal, Serena; Noffke, Amy; Oh, Kean; Pence, Clarence; Preston, Lisa; Raphaelian, Paul; Regan, Virginia R.; Roberts, Peter; Ruby, Alan; Sarrafizadeh, Ramin; Scherf, Marissa; Scott, Sarita; Sneed, Scott; Staples, Lisa; Terry, Brad; Trese, Matthew T.; Videtich, Joan; Williams, George; Zajechowski, Mary] Vis Res Fdn Associated Retinal Consultants PC, Royal Oak, MI USA.
   [Joseph, Daniel P.; Blinder, Kevin; Boyd, Lynda; Buckley, Sarah; Crow, Meaghan; Dinatale, Amanda; Engelbrecht, Nicholas; Forke, Bridget; Gabel, Dana; Grand, Gilbert; Grillion-Cerone, Jennifer; Holekamp, Nancy; Kelly, Charlotte; Nobel, Ginny; Pepple, Kelly; Raeber, Matt; Rao, P. Kumar; Ressel, Tammy; Schremp, Steven; Sgorlon, Merrilee; Shears, Shantia; Thomas, Matthew; Timma, Cathy; Vaughn, Annette; Walters, Carolyn; Weeks, Rhonda; Wehmeier, Jarrod; Wright, Tim] Barnes Retina Inst, St Louis, MO USA.
   [Berinstein, Daniel M.; Ayyad, Aida; Barazi, Mohammed K.; Bickhart, Erica; Brady, Tracey; Byank, Lisa; Cronise, Alysia; Denny, Vanessa; Dunn, Courtney; Flory, Michael; Frantz, Robert; Garfinkel, Richard A.; Gilbert, William; Lai, Michael M.; Melamud, Alexander; Newgen, Janine; Newton, Shamekia; Oliver, Debbie; Osman, Michael; Sanders, Reginald; von Fricken, Manfred] Retina Grp Washington, Chevy Chase, MD USA.
   [Dugel, Pravin; Arenas, Sandra; Balea, Gabe; Bartoli, Dayna; Bucci, John; Cornelius, Jennifer A.; Dickens, Scheleen; Doherty, Don; Dunlap, Heather; Goldenberg, David; Jamal, Karim; Jimenez, Norma; Kavanagh, Nicole; Kunimoto, Derek; Martin, John; Miner, Jessica; Mobley, Sarah; Park, Donald; Quinlan, Edward; Sipperley, Jack; Slagle, Carol; Smith, Danielle; Yafchak, Miguelina; Yager, Rohana] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Flaxel, Christina J.; Bailey, Steven; Francis, Peter; Howell, Chris; Hwang, Thomas; Ira, Shirley; Klein, Michael; Lauer, Andreas; Liesegang, Teresa; Lundquist, Ann; Nolte, Sarah; Nolte, Susan K.; Pickell, Scott; Pope, Susan; Rossi, Joseph; Schain, Mitchell; Steinkamp, Peter; Toomey, Maureen D.; Vahrenwald, Debora; West, Kelly] Casey Eye Inst, Portland, OR USA.
   [Hubbard, Baker; Andelman, Stacey; Bergstrom, Chris; Brower, Judy; Cribbs, Blaine; Curtis, Linda; Dobbs, Jannah; DuBois, Lindreth; Gaultney, Jessica; Gibbs, Deborah; Jordan, Debora; Leef, Donna; Martin, Daniel F.; Myles, Robert; Olsen, Timothy; Schwent, Bryan; Srivastava, Sunil; Waldron, Rhonda] Emory Eye Ctr, Atlanta, GA USA.
   [Antoszyk, Andrew N.; Balasubramaniam, Uma; Brooks, Danielle; Brown, Justin; Browning, David; Clark, Loraine; Ennis, Sarah; Held, Susannah; Helms, Jennifer V.; Herby, Jenna; Karow, Angie; Leotaud, Pearl; Massimino, Caterina; McClain, Donna; McOwen, Michael; Mindel, Jennifer; Pereira, Candace; Pierce, Rachel; Powers, Michele; Price, Angela; Rohrer, Jason; Sanders, Jason] Charlotte Eye Ear Nose & Throat Associates Southe, Charlotte, NC USA.
   [Avery, Robert L.; Avery, Kelly; Basefsky, Jessica; Beckner, Liz; Castellarin, Alessandro; Couvillion, Stephen; Giust, Jack; Giust, Matthew; Nasir, Maan; Pieramici, Dante; Rabena, Melvin; Risard, Sarah; See, Robert; Smith, Jerry; Wan, Lisha] Calif Retina Consultants, Santa Barbara, CA USA.
   [Bakri, Sophie J.; Abu-Yaghi, Nakhleh; Barkmeier, Andrew; Berg, Karin; Burrington, Jean; Edwards, Albert; Goddard, Shannon; Howard, Shannon; Iezzi, Raymond; Lewison, Denise; Link, Thomas; McCannel, Colin A.; Overend, Joan; Pach, John; Ruszczyk, Margaret; Shultz, Ryan; Stephan, Cindy; Vogen, Diane] Mayo Clin, Rochester, MN USA.
   [Bradford, Reagan H., Jr.; Bergman, Vanessa; Burris, Russ; Butt, Amanda; Daniels, Beth; Dwiggins, Connie; Fransen, Stephen; Guerrero, Tiffany; Haivala, Darin; Harris, Amy; Icks, Sonny; Kingsley, Ronald; Redden, Lena; Richmond, Rob; Ross, Brittany; White, Kammerin; Youngberg, Misty] Dean A McGee Eye Inst, Oklahoma City, OK USA.
   [Topping, Trexler M.; Bennett, Steve; Chong, Sandy; Ciotti, Mary; Cleary, Tina; Corey, Emily; Donovan, Dennis; Frederick, Albert; Freese, Lesley; Graham, Margaret; Gud, Natalya; Howard, Taneika; Jones, Mike; Morley, Michael; Moses, Katie; Stone, Jen; Ty, Robin; Wiegand, Torsten; Williams, Lindsey; Winder, Beth] Ophthalm Consultants Boston, Boston, MA USA.
   [Retina, Tennessee; Awh, Carl C.; Amonette, Michelle; Arrindell, Everton; Beck, Dena; Busbee, Brandon; Dilback, Amy; Downs, Sara; Guidry, Allison; Gutow, Gary; Hardin, Jackey; Hines, Sarah; Hutchins, Emily; LaCivita, Kim; Lester, Ashley; Malott, Larry; McCain, MaryAnn; Miracle, Jayme; Moffat, Kenneth; Palazzotta, Lacy; Robinson, Kelly; Sonkin, Peter; Travis, Alecia; TrentWallace, Roy; Winters, Kelly J.; Wray, Julia] Tennessee Retina PC, Nashville, TN USA.
   [Harris, April E.; Bunnell, Mari; Crooks, Katrina; Fitzgerald, Rebecca; Javid, Cameron; Kew, Corin; Kill, Erica; Kline, Patricia; Kreienkamp, Janet; Martinez, Maricruz; Moore, Roy Ann; Saavedra, Egbert; Taylor, LuAnne; Walsh, Mark; Wilson, Larry] Retina Associates Southwest PC, Tucson, AZ USA.
   [Ciulla, Thomas A.; Coyle, Ellen; Harrington, Tonya; Harris, Charlotte; Hood, Cindi; Kerr, Ingrid; Maturi, Raj; Moore, Dawn; Morrow, Stephanie; Savage, Jennifer; Sink, Bethany; Steele, Tom; Thukral, Neelam; Wilburn, Janet] Midwest Eye Inst, Indianapolis, IN USA.
   [Walker, Joseph P.; Banks, Jennifer; Ciampaglia, Debbie; Dyshanowitz, Danielle; Frederick, Jennifer; Ghuman, A. Tom; Grodin, Richard; Kiesel, Cheryl; Knips, Eileen; Mccue, Jonathan; Ortiz, Maria; Peters, Crystal; Raskauskas, Paul; Schoeman, Etienne; Sharma, Ashish; Wing, Glenn; Youngblood, Rebecca] Natl Ophthalm Res Inst, Ft Myers, FL USA.
   [Chandra, Suresh R.; Altaweel, Michael; Blodi, Barbara; Burke, Kathryn; Dietzman, Kristine A.; Gottlieb, Justin; Knutson, Gene; Krolnik, Denise; Nork, T. Michael; Olson, Shelly; Peterson, John; Reed, Sandra; Soderling, Barbara; Somers, Guy; Stevens, Thomas; Wealti, Angela] Univ Wisconsin, Madison, WI USA.
   [Bearelly, Srilaxmi; Branchaud, Brenda; Bryant, Joyce W.; Crowell, Sara; Fekrat, Sharon; Gammage, Merritt; Harrison, Cheala; Jones, Sarah; McClain, Noreen; McCuen, Brooks; Mruthyunjaya, Prithvi; Queen, Jeanne; Sarin, Neeru; Skalak, Cindy; Skelly, Marriner; Suner, Ivan; Tomany, Ronnie; Welch, Lauren] Duke Univ, Ctr Eye, Durham, NC USA.
   [Park, Susanna S.; Cassidy, Allison; Chandra, Karishma; Good, Idalew; Imson, Katrina; Kaur, Sashi; Metzler, Helen; Morse, Lawrence; Redenbo, Ellen; Salvador, Marisa; Telander, David; Thomas, Mark; Wallace, Cindy] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA.
   [Barr, Charles C.; Battcher, Amanda; Bottorff, Michelle; Chasteen, Mary; Clark, Kelly; Denning, Diane; Schoen, Debra; Schultz, Amy; Tempel, Evie; Wheeler, Lisa; Whittington, Greg K.] Univ Louisville, Sch Med, Louisville, KY 40292 USA.
   [Stone, Thomas W.; Blevins, Todd; Buck, Michelle; Cruz, Lynn; Heath, Wanda; Holcomb, Diana; Isernhagen, Rick; Kidd, Terri; Kitchens, John; Sears, Cathy; Slade, Ed; Van Arsdall, Jeanne; VanHoose, Brenda; Wolfe, Jenny; Wood, William] Retina Associates Kentucky, Lexington, KY USA.
   [Zilis, John; Crooks, Carol; Disney, Larry; Liu, Mimi; Petty, Stephen; Sall, Sandra] Colorado Retina Associates, Denver, CO USA.
   [Folk, James C.; Aly, Tracy; Brotherton, Abby; Critser, Douglas; Hinz, Connie J.; Karakas, Stefani; Kirschner, Valerie; Lester, Cheyanne; Montague, Cindy; Russell, Stephen; Stockman, Heather; Taylor, Barbara; Verdick, Randy; Walshire, Jean] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA.
   [Thompson, John T.; Connell, Barbara; Constantine, Maryanth; Davis, John L., Jr.; Holsapple, Gwen; Hunter, Lisa; Lenane, C. Nicki; Mitchell, Robin; Russel, Leslie; Sjaarda, Raymond] Retina Specialists, Towson, MD USA.
   [Brown, David M.; Benz, Matthew; Burns, Llewellyn; Carranza, JoLene G.; Fish, Richard; Goates, Debra; Hay, Shayla; Jeffers, Theresa; Kegley, Eric; Kubecka, Dallas; McGilvra, Stacy; Richter, Beau; Sneed, Veronica; Stoever, Cary; Tellez, Isabell; Wong, Tien] Retina Consultants Houston, Houston, TX USA.
   [Kim, Ivana; Andreoli, Christopher; Barresi, Leslie; Brett, Sarah; Callahan, Charlene; Capaccioli, Karen; Carli, William; Coppola, Matthew; Emmanuel, Nicholas; Evans, Claudia; Fagan, Anna; Grillo, Marcia; Head, John; Lee, Elaine; Lord, Ursula; Miretsky, Edward; Palitsch, Kate; Petrin, Todd; Reader, Liz; Reznichenko, Svetlana; Robertson, Mary; Smith, Justin; Vavvas, Demetrios] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   [Kim, Ivana; Andreoli, Christopher; Barresi, Leslie; Brett, Sarah; Callahan, Charlene; Capaccioli, Karen; Carli, William; Coppola, Matthew; Emmanuel, Nicholas; Evans, Claudia; Fagan, Anna; Grillo, Marcia; Head, John; Lee, Elaine; Lord, Ursula; Miretsky, Edward; Palitsch, Kate; Petrin, Todd; Reader, Liz; Reznichenko, Svetlana; Robertson, Mary; Smith, Justin; Vavvas, Demetrios] Harvard Vanguard Med Associates, Boston, MA 02114 USA.
   [Wells, John; Cahill, Cassie; Clark, W. Lloyd; Henry, Kayla; Johnson, David; Miller, Peggy; Oliver, LaDetrick; Spivey, Robbin; Swinford, Tiffany; Taylor, Mallie] Palmetto Retina Ctr, W Columbia, SC USA.
   [Lambert, Michael; Chase, Kris; Fredrickson, Debbie; Khawly, Joseph; Lazarte, Valerie; Lowd, Donald; Miller, Pam; Willis, Arthur] Retina & Vitreous Texas, Houston, TX USA.
   [Ferrone, Philip J.; Almonte, Miguel; Arnott, Rachel; Aviles, Ingrid; Carbon, Sheri; Chitjian, Michael; DAmore, Kristen; Elliott, Christin; Fastenberg, David; Golub, Barry; Graham, Kenneth; Lavorna, AnnMarie; Murphy, Laura; Palomo, Amanda; Puglisi, Christina; Rhee, David; Romero, Juan; Rosenblatt, Brett; Salcedo, Glenda; Schlameuss, Marianne; Shakin, Eric; Sookhai, Vasanti] Long Isl Vitreoretinal Consultants, Great Neck, NY USA.
   [Kaiser, Richard; Affel, Elizabeth; Brown, Gary; Centinaro, Christina; Fine, Deborah; Fineman, Mitchell; Formoso, Michele; Garg, Sunir; Grande, Lisa; Herbert, Carolyn; Ho, Allen; Hsu, Jason; Jay, Maryann; Lavetsky, Lisa; Liebenbaum, Elaine; Maguire, Joseph; Monsonego, Julia; O'Connor, Lucia; Pierce, Lisa; Regillo, Carl; Rosario, Maria; Spirn, Marc; Vander, James; Walsh, Jennifer] Wills Eye Inst, Philadelphia, PA USA.
   [Davidorf, Frederick H.; Barnett, Amanda; Chang, Susie; Christoforidis, John; Elliott, Joy; Justice, Heather; Letson, Alan; McKinney, Kathryne; Perry, Jeri; Salerno, Jill A.; Savage, Scott; Shelley, Stephen] Ohio State Univ Eye Phys & Surg, Retina Div, Dublin, OH USA.
   [Singerman, Lawrence J.; Coney, Joseph; DuBois, John; DuBois, Kimberly; Greanoff, Gregg; Himmelman, Dianne; Ilc, Mary; Mcnamara, Elizabeth; Novak, Michael; Pendergast, Scott; Rath, Susan; Smith-Brewer, Sheila; Tanner, Vivian; Weiss, Diane E.; Zegarra, Hernando] Retina Associates Cleveland, Beachwood, OH USA.
   [Halperin, Lawrence; Aramayo, Patricia; Dhalla, Mandeep; Fernandez, Brian; Fernandez, Cindy; Lopez, Jaclyn; Lopez, Monica; Mariano, Jamie; Murphy, Kellie; Sherley, Clifford; Veksler, Rita] Retina Grp Florida, Ft Lauderdale, FL USA.
   [Rahhal, Firas; Babikian, Razmig; Boyer, David; Hami, Sepideh; Kessinger, Jeff; Kurokouchi, Janet; Mukarram, Saba; Pachman, Sarah; Protacio, Eric; Sierra, Julio; Tabandeh, Homayoun; Zamboni, Adam] Retina Vitreous Associates Med Grp, Beverly Hills, CA USA.
   [Elman, Michael; Belz, Jennifer; Butcher, Tammy; Coffey, Teresa; Firestone, Dena; Gore, Nancy; Singletary, Pamela; Sotirakos, Peter; Starr, Joann] Elman Retina Grp PA, Baltimore, MD USA.
   [Meredith, Travis A.; Barnhart, Cassandra J.; Cantrell, Debra; Esquejo-Leon, RonaLyn; Houghton, Odette; Kaur, Harpreet] Univ N Carolina, Chapel Hill, NC 27515 USA.
   [Martin, Daniel F.] Cleveland Clin, Cleveland, OH 44106 USA.
   [Fine, Stuart L.; Katz, Marilyn] Univ Colorado, Denver, CO 80202 USA.
   [Maguire, Maureen G.; Brightwell-Arnold, Mary; Glaser, Ruchira; Hall, Judith; Harkins, Sandra; Huang, Jiayan; Khvatov, Alexander; McWilliams, Kathy; Nolte, Susan K.; Peskin, Ellen; Pistilli, Maxwell; Ryan, Susan; Schnader, Allison; Ying, Gui-Shuang] Univ Penn, Philadelphia, PA 19104 USA.
   [Jaffe, Glenn; Afrani-Sakyi, Jennifer; Balsley, Brannon; Bennett, Linda S.; Brooks, Adam; Brower-Lingsch, Adrienne; Bruce, Lori; Burns, Russell; Busian, Dee; Choong, John; Cloaninger, Lindsey; DeCroos, Francis Char; DuBois, Emily; El-Dairi, Mays; Gach, Sarah; Hall, Katelyn; Hawks, Terry; Huang, ChengChenh; Heydary, Cindy; Ho, Alexander; Kini, Shashi; McCall, Michelle; Muhammad, Daaimah; Nicholson, Jayne; Queen, Jeanne; Rieves, Pamela; Shields, Kelly; Skalak, Cindy; Specker, Adam; Stinnett, Sandra; Subramaniam, Sujatha; Tenbrink, Patrick; Toth, Cynthia; Towe, Aaron; Welch, Kimberly; Williams, Natasha; Winter, Katrina; Young, Ellen] Duke Univ, OCT Reading Ctr, Durham, NC USA.
   [Grunwald, Juan E.; Alexander, Judith; Daniel, Ebenezer; Daniel, Ebenezer; Martin, E. Revell; Parker, Candace; Sepielli, Krista; Shannon, Tom; Whearry, Claressa] Univ Penn, Fundus Photograph Reading Ctr, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Washington University (WUSTL); Mayo Clinic;
   Ophthalmic Consultants of Boston; University of Wisconsin System;
   University of Wisconsin Madison; Duke University; University of
   California System; University of California Davis; University of
   Louisville; University of Iowa; Harvard University; Massachusetts Eye &
   Ear Infirmary; Harvard Vanguard Medical Associates; Jefferson
   University; Retina Associates of Cleveland, Inc.; Retina Vitreous
   Associates Medical Group; University of North Carolina; University of
   North Carolina Chapel Hill; Cleveland Clinic Foundation; University of
   Colorado System; University of Colorado Denver; University of
   Pennsylvania; Duke University; University of Pennsylvania
RP Bavinger, JC (通讯作者)，Univ Penn, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
EM claybavinger@gmail.com
RI Mittra, Robert/AAC-8249-2021; Ramsay, Robert G/C-3291-2015; Ciulla,
   Thomas/AAA-1299-2020
OI Ramsay, Robert G/0000-0001-5003-0433; Ciulla, Thomas/0000-0001-5557-6777
FU National Eye Institute [U10 EY017823, U10 EY017825, U10 EY017826, U10
   EY017828, U10 EY023530, R21 EY028998]
FX The Comparison of Age-Related Macular Degeneration Treatments Trials
   (CATT) was supported by grants U10 EY017823, U10 EY017825, U10 EY017826,
   U10 EY017828, U10 EY023530, and R21 EY028998 from the National Eye
   Institute.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Baneke AJ, 2018, GRAEF ARCH CLIN EXP, V256, P333, DOI 10.1007/s00417-017-3859-7
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Ebraheem A, 2018, OPHTHALMOL RETINA, V2, P469, DOI 10.1016/j.oret.2017.09.003
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hayreh SS, 2011, PROG RETIN EYE RES, V30, P359, DOI 10.1016/j.preteyeres.2011.05.001
   Inan UU, 2007, KLIN MONATSBL AUGENH, V224, P127, DOI 10.1055/s-2006-927316
   Jain I S, 1972, Indian J Ophthalmol, V20, P141
   Liu L, 2011, INT J OPHTHALMOL-CHI, V4, P323, DOI 10.3980/j.issn.2222-3959.2011.03.24
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Snyder K, 2018, JAMA OPHTHALMOL, V136, P1008, DOI 10.1001/jamaophthalmol.2018.2650
NR 15
TC 5
Z9 5
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD NOV
PY 2019
VL 137
IS 11
BP 1306
EP 1311
DI 10.1001/jamaophthalmol.2019.3509
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JW7DV
UT WOS:000503209300016
PM 31513262
OA Green Published
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Baek, JS
   Lee, DW
   Cho, SW
   Kim, CG
   Kim, JW
AF Cho, Han Joo
   Baek, Ji Sun
   Lee, Dong Won
   Cho, Sung Won
   Kim, Chul Gu
   Kim, Jong Woo
TI EFFECTS OF VITREOMACULAR ADHESION ON ANTI-VASCULAR ENDOTHELIAL GROWTH
   FACTOR TREATMENT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; antivascular endothelial growth
   factor; polypoidal choroidal vasculopathy; vitreomacular adhesion
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; PHOTODYNAMIC
   THERAPY; RANIBIZUMAB; RISK; PATHOGENESIS; INFLAMMATION; BEVACIZUMAB
AB Purpose: To evaluate the effect of posterior vitreomacular adhesion (VMA), documented by optical coherence tomography, on the outcome of anti-vascular endothelial growth factor treatment of polypoidal choroidal vasculopathy.
   Methods: Medical records of 102 patients (104 eyes) with polypoidal choroidal vasculopathy were retrospectively reviewed and categorized according to the presence of posterior VMA into 2 subgroups: VMA positive (+) group (23 eyes) and VMA negative (-) group (81 eyes). Best-corrected visual acuity and central macular thickness after anti-vascular endothelial growth factor treatment were compared between the 2 groups at baseline and at 1 month, 3 months, 6 months, and 12 months.
   Results: At the last follow-up, average number of injections was 4.82 +/- 1.27 in the VMA (+) group and 4.92 +/- 1.45 in the VMA (-) group. After injection, the mean logarithm of the minimum angle of resolution of best-corrected visual acuity improved from 0.81 +/- 0.53 (Snellen equivalent, 20/129) to 0.67 +/- 0.52 (Snellen equivalent, 20/93) in the VMA (+) group (P = 0.01) and from 0.79 +/- 0.50 (Snellen equivalent, 20/123) to 0.64 +/- 0.58 (Snellen equivalent, 20/91) in the VMA (-) group (P = 0.02). Average central macular thickness decreased from 354.4 +/- 124.5 mu m to 249.6 +/- 112.5 mm in the VMA (+) group (P = 0.01) and from 361.2 +/- 140.2 mu m to 267.3 +/- 103.5 mu m in the VMA (-) group (P = 0.01). Polyp regression rate was 21.7% (5 eyes of 23 eyes) in the VMA (+) group and 22.2% (18 eyes of 81 eyes) in the VMA (-) group. There was no statistically significant difference in the best-corrected visual acuity improvement, central macular thickness improvement, and polyp regression rate between the groups.
   Conclusion: Unlike typical age-related macular degeneration, posterior VMA was not associated with a visual outcome after intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
C1 [Cho, Han Joo; Baek, Ji Sun; Lee, Dong Won; Cho, Sung Won; Kim, Chul Gu; Kim, Jong Woo] Konyang Univ, Kims Eye Hosp, Coll Med, Dept Ophthalmol, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Cho, HJ (通讯作者)，Kims Eye Hosp, 156,4Ga, Seoul, South Korea.
EM chojoo@kimeye.com
OI Cho, Han Joo/0000-0001-7336-5762
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chang LK, 2008, AM J OPHTHALMOL, V146, P121, DOI 10.1016/j.ajo.2008.03.001
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1415, DOI 10.1136/bjo.2010.192385
   Lai TY, 2010, INVEST OPHTH VIS SCI, V51
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nigam N, 2010, RETINA-J RET VIT DIS, V30, P246, DOI 10.1097/IAE.0b013e3181baf6dc
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 31
TC 10
Z9 10
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2013
VL 33
IS 10
BP 2126
EP 2132
DI 10.1097/IAE.0b013e3182899296
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297EI
UT WOS:000330237900018
PM 23609123
DA 2022-11-30
ER

PT J
AU Hou, XW
   Wang, Y
   Pan, CW
AF Hou, Xiao-Wen
   Wang, Ying
   Pan, Chen-Wei
TI Metabolomics in Age-Related Macular Degeneration: A Systematic Review
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Review
DE age-related macular degeneration; metabolomics; biomarker; metabolic
   pathway
ID OXIDATIVE STRESS; AQUEOUS-HUMOR; CARNITINE; IDENTIFICATION; BIOMARKERS;
   DEFICIENCY; METABOLISM; GENOMICS; PATHWAY; DISEASE
AB PURPOSE. Age-related macular degeneration (AMD) is one of the leading causes of blindness among the elderly, and the exact pathogenesis of the AMD remains unclear. The purpose of this review is to summarize potential metabolic biomarkers and pathways of AMD that might facilitate risk predictions and clinical diagnoses of AMD.
   METHODS. We obtained relevant publications of metabolomics studies of human beings by systematically searching the MEDLINE (PubMed) database before June 2020. Studies were included if they performed mass spectrometry-based or nuclear magnetic resonance-based metabolomics approach for humans. In addition, AMD was assessed from fundus photographs based on standardized protocols. The metabolic pathway analysis was performed using MetaboAnalyst 3.0.
   RESULTS. Thirteen studies were included in this review. Repeatedly identified metabolites including phenylalanine, adenosine, hypoxanthine, tyrosine, creatine, citrate, carnitine, proline, and maltose have the possibility of being biomarkers of AMD. Validation of the biomarker panels was observed in one study. Dysregulation of metabolic pathways involves lipid metabolism, carbohydrate metabolism, nucleotide metabolism, amino acid metabolism, and translation, which might play important roles in the development and progression of AMD.
   CONCLUSIONS. This review summarizes the potential metabolic biomarkers and pathways related to AMD, providing opportunities for the construction of diagnostic or predictive models for AMD and the discovery of new therapeutic targets.
C1 [Hou, Xiao-Wen; Wang, Ying; Pan, Chen-Wei] Soochow Univ, Med Coll, Sch Publ Hlth, 199 Ren Ai Rd, Suzhou 215123, Peoples R China.
C3 Soochow University - China
RP Pan, CW (通讯作者)，Soochow Univ, Med Coll, Sch Publ Hlth, 199 Ren Ai Rd, Suzhou 215123, Peoples R China.
EM pcwonly@gmail.com
FU National Natural Science Foundation of China [81973061]; Priority
   Academic Program Development of Jiangsu Higher Education Institutions
   (PAPD)
FX Supported by the National Natural Science Foundation of China (no.
   81973061) and the Priority Academic Program Development of Jiangsu
   Higher Education Institutions (PAPD).
CR Acar IE, 2020, OPHTHALMOLOGY, V127, P1693, DOI 10.1016/j.ophtha.2020.06.020
   Bartlett H, 2003, OPHTHAL PHYSL OPT, V23, P383, DOI 10.1046/j.1475-1313.2003.00130.x
   Bino RJ, 2004, TRENDS PLANT SCI, V9, P418, DOI 10.1016/j.tplants.2004.07.004
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P460, DOI 10.1016/j.ajo.2011.08.033
   Brown CN, 2019, METABOLITES, V9, DOI 10.3390/metabo9010004
   Country MW, 2017, BRAIN RES, V1672, P50, DOI 10.1016/j.brainres.2017.07.025
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de la Barca JMC, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030631
   Du JH, 2016, J BIOL CHEM, V291, P4698, DOI 10.1074/jbc.M115.698985
   Eandi CM, 2016, EUR J PHARMACOL, V787, P78, DOI 10.1016/j.ejphar.2016.03.002
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gao Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58346-3
   Glantzounis GK, 2005, CURR PHARM DESIGN, V11, P4145, DOI 10.2174/138161205774913255
   Greenwood J, 1996, J NEUROIMMUNOL, V71, P51, DOI 10.1016/S0165-5728(96)00130-0
   Han GG, 2020, J PROTEOME RES, V19, P2358, DOI 10.1021/acs.jproteome.0c00036
   Heazell AEP, 2011, PLACENTA, V32, pS119, DOI 10.1016/j.placenta.2010.12.001
   Ji YH, 2017, EXP EYE RES, V159, P147, DOI 10.1016/j.exer.2017.03.004
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Ke CF, 2019, METABOLOMICS, V15, DOI 10.1007/s11306-019-1615-1
   KENDLER BS, 1986, PREV MED, V15, P373, DOI 10.1016/0091-7435(86)90005-8
   Kersten E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218457
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kori M, 2016, OMICS, V20, P645, DOI 10.1089/omi.2016.0106
   Lains I, 2019, METABOLITES, V9, DOI 10.3390/metabo9070127
   Lains I, 2019, J PROTEOME RES, V18, P1278, DOI 10.1021/acs.jproteome.8b00877
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Li ML, 2016, SCI REP-UK, V6, DOI 10.1038/srep38342
   Lindon JC, 2003, ANAL CHEM, V75, p384A, DOI 10.1021/ac031386+
   Liu K, 2020, J PROTEOME RES, V19, P699, DOI 10.1021/acs.jproteome.9b00574
   Lumbreras B, 2008, CLIN BIOCHEM, V41, P1316, DOI 10.1016/j.clinbiochem.2008.06.018
   Luo D, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0555-7
   Madeira MH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20733-2
   Mayordomo-Febrer A, 2015, EXP EYE RES, V131, P84, DOI 10.1016/j.exer.2014.11.012
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Mitchell SL, 2018, INVEST OPHTH VIS SCI, V59, P4978, DOI 10.1167/iovs.18-25137
   Murdaugh LS, 2010, EXP EYE RES, V90, P564, DOI 10.1016/j.exer.2010.01.014
   Nag TC, 2019, ANN ANAT, V223, P8, DOI 10.1016/j.aanat.2019.01.006
   Long NP, 2018, METABOLOMICS, V14, DOI 10.1007/s11306-018-1404-2
   Ohno Y, 2017, BIOL PHARM BULL, V40, P2110, DOI 10.1248/bpb.b17-00461
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Ouyang XS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3909
   Rajan S Irudaya, 2003, J Aging Soc Policy, V15, P11, DOI 10.1300/J031v15n02_02
   Reichenbach A, 2016, NEUROPHARMACOLOGY, V104, P194, DOI 10.1016/j.neuropharm.2015.05.005
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Sahel JA, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax2324
   Shah SH, 2012, CIRCULATION, V126, P1110, DOI 10.1161/CIRCULATIONAHA.111.060368
   Shen JJ, 2000, J INHERIT METAB DIS, V23, P27, DOI 10.1023/A:1005694712583
   Sissler M, 2017, TRENDS MOL MED, V23, P693, DOI 10.1016/j.molmed.2017.06.002
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   STUMPF DA, 1985, NEUROLOGY, V35, P1041, DOI 10.1212/WNL.35.7.1041
   Sun Y, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz240
   Szabados L, 2010, TRENDS PLANT SCI, V15, P89, DOI 10.1016/j.tplants.2009.11.009
   Thao MT, 2018, NITRIC OXIDE-BIOL CH, V79, P51, DOI 10.1016/j.niox.2018.07.006
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Vessey KA, 2014, J COMP NEUROL, V522, P2928, DOI 10.1002/cne.23558
   Wang JH, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0376
   Wert KJ, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102636
   WINTER SC, 1989, AM J DIS CHILD, V143, P1337, DOI 10.1001/archpedi.1989.02150230095030
   Wishart DS, 2016, NAT REV DRUG DISCOV, V15, P473, DOI 10.1038/nrd.2016.32
   Witkovsky P, 2004, DOC OPHTHALMOL, V108, P17, DOI 10.1023/B:DOOP.0000019487.88486.0a
   Xia Jianguo, 2016, Curr Protoc Bioinformatics, V55, DOI 10.1002/cpbi.11
   Yacout SM, 2019, PHOTOCHEM PHOTOBIOL, V95, P183, DOI 10.1111/php.12934
   Yam M, 2019, J BIOL CHEM, V294, P10278, DOI 10.1074/jbc.RA119.007983
   Yanshole VV, 2019, METABOLOMICS, V15, DOI 10.1007/s11306-019-1495-4
   Zhu W, 2017, INT J NANOMED, V12, P7589, DOI 10.2147/IJN.S140275
NR 67
TC 12
Z9 12
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2020
VL 61
IS 14
AR 13
DI 10.1167/iovs.61.14.13
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PN0YS
UT WOS:000604213900005
PM 33315052
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Baird, PN
   Hageman, GS
   Guymer, RH
AF Baird, Paul N.
   Hageman, Gregory S.
   Guymer, Robyn H.
TI New era for personalized medicine: the diagnosis and management of
   age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; genetic; risk factor
ID COMPLEMENT FACTOR-H; JAPANESE POPULATION; GENE POLYMORPHISMS; PIGMENT
   EPITHELIUM; ASSOCIATION; RISK; VARIANT; CFH; SUSCEPTIBILITY; MACULOPATHY
AB P>It can be argued that age-related macular degeneration is one of the best characterized complex trait diseases. Extensive information related to genetic and environmental risk factors exists, and a number of different biological pathways are strongly implicated in its aetiology. Along with recent improvements in high throughput and relatively inexpensive genetic technologies, we are now in a position to consider developing a presymptomatic, personalized approach towards the assessment, management and treatment of this disease. We explore the applicability and challenges of this approach if it is to become commonplace for guiding treatment decisions for individuals with pre-existing disease or for those at high risk of developing it.
C1 [Baird, Paul N.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Hageman, Gregory S.] Univ Iowa, Dept Ophthalmol & Visual Sci, Coralville, IA USA.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Iowa
RP Baird, PN (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM pnb@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356; Baird, Paul/0000-0002-1305-3502
FU CSO, of Optherion, Inc.; NATIONAL EYE INSTITUTE [R24EY017404] Funding
   Source: NIH RePORTER
FX Conflict of Interest: GSH has a financial interest in, and is the CSO,
   of Optherion, Inc.
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Borry P, 2009, NAT REV GENET, V10, P8, DOI 10.1038/nrg2501
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Centre of Eye Research Australia, 2006, CENTR FOC IMP AG REL
   Chen LJ, 2006, MOL VIS, V12, P1536
   Cheung N, 2007, SURV OPHTHALMOL, V52, P180, DOI 10.1016/j.survophthal.2006.12.003
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Despriet DDG, 2007, ARCH OPHTHALMOL-CHIC, V125, P1270, DOI 10.1001/archopht.125.9.1270
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P571
   Hogarth S, 2008, ANNU REV GENOM HUM G, V9, P161, DOI 10.1146/annurev.genom.9.081307.164319
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kaye J, 2008, HUM MOL GENET, V17, pR180, DOI 10.1093/hmg/ddn253
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuehn BM, 2008, JAMA-J AM MED ASSOC, V300, P2715, DOI 10.1001/jama.2008.823
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lin JM, 2008, AM J OPHTHALMOL, V145, P716, DOI 10.1016/j.ajo.2007.11.006
   Mackey DA, 2003, BRIT J OPHTHALMOL, V87, P637, DOI 10.1136/bjo.87.5.637
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344
   Okamoto H, 2006, MOL VIS, V12, P156
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   TUO J, 2004, FASEB J, V11, P1297
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zeggini E, 2005, NAT GENET, V37, P1320, DOI 10.1038/ng1670
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 66
TC 24
Z9 24
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD NOV
PY 2009
VL 37
IS 8
BP 814
EP 821
DI 10.1111/j.1442-9071.2009.02136.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 513GX
UT WOS:000271311800012
PM 19878229
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kiel, C
   Nebauer, CA
   Strunz, T
   Stelzl, S
   Weber, BHF
AF Kiel, Christina
   Nebauer, Christoph A.
   Strunz, Tobias
   Stelzl, Simon
   Weber, Bernhard H. F.
TI Epistatic interactions of genetic loci associated with age-related
   macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; METABOLISM; EXPRESSION; MECHANISMS; EQTL
AB The currently largest genome-wide association study (GWAS) for age-related macular degeneration (AMD) defines disease association with genome-wide significance for 52 independent common and rare genetic variants across 34 chromosomal loci. Overall, these loci contain over 7200 variants and are enriched for genes with functions indicating several shared cellular processes. Still, the precise mechanisms leading to AMD pathology are largely unknown. Here, we exploit the phenomenon of epistatic interaction to identify seemingly independent AMD-associated variants that reveal joint effects on gene expression. We focus on genetic variants associated with lipid metabolism, organization of extracellular structures, and innate immunity, specifically the complement cascade. Multiple combinations of independent variants were used to generate genetic risk scores allowing gene expression in liver to be compared between low and high-risk AMD. We identified genetic variant combinations correlating significantly with expression of 26 genes, of which 19 have not been associated with AMD before. This study defines novel targets and allows prioritizing further functional work into AMD pathobiology.
C1 [Kiel, Christina; Nebauer, Christoph A.; Strunz, Tobias; Stelzl, Simon; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
   [Weber, Bernhard H. F.] Univ Hosp Regensburg, Inst Clin Human Genet, Regensburg, Germany.
C3 University of Regensburg; University of Regensburg
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.; Weber, BHF (通讯作者)，Univ Hosp Regensburg, Inst Clin Human Genet, Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI Strunz, Tobias/ABD-9798-2021
OI Strunz, Tobias/0000-0002-3744-9595; Kiel, Christina/0000-0003-3154-4847
FU Institute of Human Genetics Regensburg, Germany [TG77]; Helmut Ecker
   Foundation (Ingolstadt, Germany) [05/17]; Common Fund of the Office of
   the Director of the National Institutes of Health; NCI; NHGRI; NHLBI;
   NIDA; NIMH; NINDS
FX We thank Patricia Berber (Institute of Human Genetics, University of
   Regensburg) for critically reading the manuscript. The study was
   supported in part by institutional funds (TG77) of the Institute of
   Human Genetics Regensburg, Germany, and by a grant from the Helmut Ecker
   Foundation (Ingolstadt, Germany) to B.H.F.W. (No. 05/17). The
   Genotype-Tissue Expression (GTEx) Project was supported by the Common
   Fund of the Office of the Director of the National Institutes of Health,
   and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the
   analyses described in this manuscript were obtained from the GTEx Portal
   under dbGaP accession number phs000424.v8.p2.
CR Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776
   Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277
   Albert FW, 2015, NAT REV GENET, V16, P197, DOI 10.1038/nrg3891
   ALPER CA, 1969, SCIENCE, V163, P286, DOI 10.1126/science.163.3864.286
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Battle A, 2014, HUM GENET, V133, P727, DOI 10.1007/s00439-014-1446-0
   Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Betzler BK, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10040645
   Boulton SJ, 2006, BIOCHEM SOC T, V34, P633, DOI 10.1042/BST0340633
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Chu XK, 2014, AGE, V36, P1453, DOI 10.1007/s11357-014-9627-2
   Clark SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01778
   Danecek P, 2011, BIOINFORMATICS, V27, P2156, DOI 10.1093/bioinformatics/btr330
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Huang H, 2017, EMBO J, V36, P2334, DOI 10.15252/embj.201695518
   Innocenti F, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002078
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kiel C, 2017, SCI REP-UK, V7, DOI 10.1038/srep41835
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lewis GF, 2005, CIRC RES, V96, P1221, DOI 10.1161/01.RES.0000170946.56981.5c
   Morgan BP, 1997, CLIN EXP IMMUNOL, V107, P1, DOI 10.1046/j.1365-2249.1997.d01-890.x
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Okamoto H, 2000, NATURE, V406, P203, DOI 10.1038/35018119
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   PATTERSON MK, 1968, J BIOL CHEM, V243, P376
   R Team Core, 2017, LANG ENV STAT COMP
   R-Development-Core-Team, 2011, R LANG ENV STAT COMP, V1
   Rathje M, 2021, MOL PSYCHIATR, V26, P508, DOI 10.1038/s41380-018-0314-z
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Reimand J, 2016, NUCLEIC ACIDS RES, V44, pW83, DOI 10.1093/nar/gkw199
   Rosen Eliot M., 2013, Frontiers in Genetics, V4, P85, DOI 10.3389/fgene.2013.00085
   Schadt EE, 2008, PLOS BIOL, V6, P1020, DOI 10.1371/journal.pbio.0060107
   Schroder A, 2013, PHARMACOGENOMICS J, V13, P12, DOI 10.1038/tpj.2011.44
   Shabalin AA, 2012, BIOINFORMATICS, V28, P1353, DOI 10.1093/bioinformatics/bts163
   Shay JW, 2016, CANCER DISCOV, V6, P584, DOI 10.1158/2159-8290.CD-16-0062
   Strunz T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58510-9
   Strunz T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24219-z
   White RR, 2016, MOL CELL, V63, P729, DOI 10.1016/j.molcel.2016.08.004
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Zheng XW, 2012, BIOINFORMATICS, V28, P3326, DOI 10.1093/bioinformatics/bts606
NR 46
TC 0
Z9 0
U1 1
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 23
PY 2021
VL 11
IS 1
AR 13114
DI 10.1038/s41598-021-92351-4
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA TE4QJ
UT WOS:000669995600001
PM 34162900
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chaudhary, V
   Brent, M
   Lam, WC
   Devenyi, R
   Teichman, J
   Mak, M
   Barbosa, J
   Kaur, H
   Carter, R
   Farrokhyar, F
AF Chaudhary, Varun
   Brent, Michael
   Lam, Wai-Ching
   Devenyi, Robert
   Teichman, Joshua
   Mak, Michael
   Barbosa, Joshua
   Kaur, Harneel
   Carter, Ronald
   Farrokhyar, Forough
TI Genetic Risk Evaluation in Wet Age-Related Macular Degeneration
   Treatment Response
SO OPHTHALMOLOGICA
LA English
DT Article
DE Genetics; Visual acuity; Age-related macular degeneration
ID RANIBIZUMAB TREATMENT; CFH; POLYMORPHISM; DELETION; VARIANT; Y402H;
   PHARMACOGENETICS; SUSCEPTIBILITY; ASSOCIATION; THERAPY
AB Objective: To evaluate the pharmacogenetic relationship between CFH haplotypes and single nucleotide polymorphisms (SNPs) with response to ranibizumab treatment for neovascular age-related macular degeneration (nAMD). Patients and Methods: This was a prospective cohort study involving 70 treatment-naive nAMD patients. Patients were genotyped for CFH haplotypes and SNPs in the C3, ARMS2, and mtDNA genes. Visual acuity and central macular thickness were assessed at baseline and during 6 monthly follow-up visits. Multivariate logistic regression was used to determine the association between genotypes and a gain of >= 15 letters at the 6-month endpoint after adjusting for potential confounders. Results: CFH haplotypes were associated with a gain of letters at the 6-month endpoint (p = 0.046). Patients expressing protective haplotypes were more likely to achieve a gain of >= 15 letters relative to the greatly increased risk haplotypes [OR 6.58 (95% CI: 1.37, 31.59)]. Conclusion: CFH is implicated in nAMD patient treatment response to ranibizumab. (C) 2016 S. Karger AG, Basel
C1 [Chaudhary, Varun; Teichman, Joshua; Barbosa, Joshua; Kaur, Harneel] McMaster Univ, St Josephs Healthcare Hamilton, Hamilton Reg Eye Inst, Div Ophthalmol,Dept Surg, Hamilton, ON, Canada.
   [Brent, Michael; Lam, Wai-Ching; Devenyi, Robert; Mak, Michael] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Farrokhyar, Forough] McMaster Univ, Dept Surg, Hamilton, ON, Canada.
   [Carter, Ronald] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada.
C3 McMaster University; University of Toronto; McMaster University;
   McMaster University
RP Chaudhary, V (通讯作者)，Hamilton Reg Eye Inst, Dept Surg, Div Ophthalmol, 2757 King St East, Hamilton, ON L8G 5E4, Canada.
EM surghrs@mcmaster.ca
RI Chaudhary, Varun/AAQ-2371-2021; Farrokhyar, Forough/AAQ-6005-2021
OI Chaudhary, Varun/0000-0002-9988-4146; Farrokhyar,
   Forough/0000-0001-9928-9016; Lam, Wai-Ching/0000-0003-2057-9374
CR Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gerding H, 2014, KLIN MONATSBL AUGENH, V231, P427, DOI 10.1055/s-0034-1368241
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Holz FG, 2016, BR J OPHTHALMOL
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Teper SJ, 2010, MOL VIS, V16, P2598
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 23
TC 7
Z9 7
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2016
VL 236
IS 2
BP 88
EP 94
DI 10.1159/000446819
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DY1RG
UT WOS:000384871500005
PM 27362858
DA 2022-11-30
ER

PT J
AU Daniel, E
   Maguire, MG
   Grunwald, JE
   Toth, CA
   Jaffe, GJ
   Martin, DF
   Ying, GS
AF Daniel, Ebenezer
   Maguire, Maureen G.
   Grunwald, Juan E.
   Toth, Cynthia A.
   Jaffe, Glenn J.
   Martin, Daniel F.
   Ying, Gui-Shuang
CA Comparison Age-Related Macular Deg
TI Incidence and Progression of Nongeographic Atrophy in the Comparison of
   Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL ATROPHY; GEOGRAPHIC ATROPHY; CHOROIDAL
   NEOVASCULARIZATION; VISUAL-ACUITY; RISK-FACTORS; RANIBIZUMAB; GROWTH;
   MORPHOLOGY
AB This post hoc analysis of a cohort study within the Comparison of Age-Related Treatments Trials (CATT) clinical trial seeks to determine incidence and progression of and risk factors for nongeographic atrophy in eyes treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
   Importance Retinal hypopigmentation and hyperpigmentation are precursors of geographic atrophy (GA). Incidence and progression to GA in eyes treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration (nAMD) have not been investigated. Objective To determine the incidence and progression of non-GA (NGA) and associated risk factors. Design, Setting, and Participants This study is a post hoc analysis of a cohort study within the Comparison of Age-Related Treatments Trials (CATT) clinical trial. Participants were recruited February 20, 2008, through December 9, 2009; released from protocol follow-up and treatment after 2 years; and recalled from March 14, 2014, through March 31, 2015. Data analyses were conducted from January 11, 2019, through November 27, 2019. Interventions Participants were randomized to ranibizumab or bevacizumab for (1) 2 years of monthly or as-needed injections or (2) monthly injections for 1 year and as-needed injections the following year. Participants were treated according to best medical judgement thereafter. Main Outcomes and Measures Incidence of nAMD-associated NGA (hypopigmentation and hyperpigmentation in color images) and progression; adjusted risk ratios (aRR) for baseline characteristics. Results Among 1107 participants, risk of NGA was 35% (391 eyes), 59% (246 eyes), and 81% (122 eyes) at 1, 2, and 5 years, respectively. Risk factors for NGA included worse visual acuity (20/200-20/320: aRR, 1.74 [95% CI, 1.24-2.43], compared with <= 20/40; P = .006), larger neovascularization area (>4 disc areas: aRR, 1.31 [95% CI, 1.01-1.71], compared with <= 1 disc areas; P = .007), switched drug regimen (aRR, 1.28 [95% CI, 1.06-1.54], compared with as-needed injections; P = .02), and single-nucleotide variants Age-Related Maculopathy Susceptibility 2 (ARMS2) (TT variant: relative risk [RR], 1.53 [95% CI, 1.22-1.93]; P = .001) and HtrA Serine Peptidase 1 (HTRA1) (AG variant: RR, 1.23 [95% CI, 1.01-1.48]; AA variant: RR, 1.51 [95% CI, 1.20-1.91]; P = .002). Sub-retinal pigment epithelium thickness was protective (>275 mu m: aRR, 0.59 [95% CI, 0.46-0.75], compared with <= 75 mu m; P < .001). Among 389 eyes with NGA by 2 years and subsequent color images, risk of progression to GA was 29%, 43%, and 50% at 1, 3, and 4 years, respectively. Risk factors for progression to GA included worse visual acuity (20/200-20/320: aRR, 2.75 [95% CI, 1.54-4.93], compared with <= 20/40; P < .001), worse fellow-eye visual acuity (<20/40: aRR, 1.77 [95% CI, 1.12-2.79], compared with >= 20/40; P = .01), fellow-eye GA (aRR, 1.71 [95% CI, 1.06-2.75]; P = .03), and pseudodrusen in either eye (aRR, 1.65 [95% CI, 1.17-2.34]; P = .005). Subretinal fluid was associated with a decreased risk of progression (aRR, 0.42 [95% CI, 0.28-0.63]; P < .001). Conclusions and Relevance In this study, after 2 years of protocol-guided anti-vascular endothelial growth factor treatment for nAMD, more than half of the eyes in the study developed NGA in the location of nAMD. After 3 additional years of regular care, half of them progressed to GA.
   Question What is the incidence of nongeographic atrophy (NGA) in eyes treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration, and how often does it progress to geographic atrophy (GA)? Findings In this longitudinal study, the cumulative risk of NGA was 35%, 59%, and 81% at 1-year, 2-year, and 5-year follow-ups, respectively. The cumulative risk of progression from incident NGA in years 1 and 2 to GA was 29%, 43%, and 50% at 1, 3, and 4 years, respectively. Meaning Nongeographic atrophy, as defined in CATT, is common and progresses to GA in about 50% of participants by 4 years after onset.
C1 [Daniel, Ebenezer; Maguire, Maureen G.; Grunwald, Juan E.; Ying, Gui-Shuang] Univ Penn, Dept Ophthalmol, 3711 Market St,Ste 801, Philadelphia, PA 19104 USA.
   [Toth, Cynthia A.; Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 University of Pennsylvania; Duke University; Cleveland Clinic Foundation
RP Daniel, E (通讯作者)，Univ Penn, Dept Ophthalmol, 3711 Market St,Ste 801, Philadelphia, PA 19104 USA.
EM ebdaniel@pennmedicine.upenn.edu
OI Russell, Stephen/0000-0003-3776-1367; Folk, James/0000-0002-6271-2906
FU National Institutes of Health [U10 EY017823, U10 EY017825, U10 EY017826,
   U10 EY017828, U10 EY023530, R21EY028998]
FX This study was supported by the National Institutes of Health
   (cooperative agreements U10 EY017823, U10 EY017825, U10 EY017826, U10
   EY017828, U10 EY023530 and R21EY028998).
CR American Academy of Ophthalmology Retina/Vitreous Panel, 2015, AG REL MAC DEG PPP 2
   Bailey C, 2019, OPHTHALMOLOGY, V126, P75, DOI 10.1016/j.ophtha.2018.07.013
   Channa R, 2015, AM J OPHTHALMOL, V159, P9, DOI 10.1016/j.ajo.2014.09.012
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Daniel E, 2019, OPHTHALMOLOGY, V126, P743, DOI 10.1016/j.ophtha.2018.11.020
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Kim JH, 2019, GRAEF ARCH CLIN EXP, V257, P1661, DOI 10.1007/s00417-019-04373-4
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sakurada Y, 2019, JPN J OPHTHALMOL, V63, P374, DOI 10.1007/s10384-019-00680-9
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Solomon SD, 2009, RETINA-J RET VIT DIS, V29, P1080, DOI 10.1097/IAE.0b013e3181b1baeb
   Sunness JS, 2006, BRIT J OPHTHALMOL, V90, P398, DOI 10.1136/bjo.2005.084830
   Toth CA, 2019, OPHTHALMOL RETINA, V3, P316, DOI 10.1016/j.oret.2018.11.011
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   2008, OPHTHALMOLOGY, V115, P1474
NR 35
TC 8
Z9 8
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2020
VL 138
IS 5
BP 510
EP 518
DI 10.1001/jamaophthalmol.2020.0437
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LS2QZ
UT WOS:000536235300013
PM 32191267
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Al-Zamil, WM
   Yassin, SA
AF Al-Zamil, Waseem M.
   Yassin, Sanaa A.
TI Recent developments in age-related macular degeneration: a review
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Review
DE age-related macular degeneration; anti-VEGF; risk factors; treatment
ID VERTEPORFIN PHOTODYNAMIC THERAPY; ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT
   FACTOR-H; RETINAL-PIGMENT EPITHELIUM; GENOME-WIDE ASSOCIATION; FUNDUS
   AUTOFLUORESCENCE PATTERNS; COHERENCE TOMOGRAPHY ANGIOGRAPHY; ANKYRIN
   REPEAT PROTEIN; VEGF TRAP-EYE; CHOROIDAL NEOVASCULARIZATION
AB Background: Visual impairment in elderly people is a considerable health problem that significantly affects quality of life of millions worldwide. The magnitude of this issue is becoming more evident with an aging population and an increasing number of older individuals.
   Objective: The objective of this article was to review the clinical and pathological aspects of age-related macular degeneration (AMD), diagnostic tools, and therapeutic modalities presently available or underway for both atrophic and wet forms of the disease.
   Methods: An online review of the PubMed database was performed, searching for the key words. The search was limited to articles published since 1980 to date.
   Results: Several risk factors have been linked to AMD, such as age (> 60 years), lifestyle (smoking and diet), and family history. Although the pathogenesis of AMD remains unclear, genetic factors have been implicated in the condition. Treatment for atrophic AMD is mainly close observation, coupled with nutritional supplements such as zinc and antioxidants, whereas treatment of wet AMD is based on targeting choroidal neovascular membranes.
   Conclusion: Identification of modifiable risk factors would improve the possibilities of preventing the progression of AMD. The role of anti-vascular endothelial growth factor (anti-VEGF) agents has transformed the therapeutic approach of the potentially blinding disease "wet AMD" into a more favorable outcome.
C1 [Al-Zamil, Waseem M.; Yassin, Sanaa A.] Imam Abdulrahman Bin Faisal Univ, Dept Ophthalmol, POB 40097, Al Khobar 31952, Saudi Arabia.
C3 Imam Abdulrahman Bin Faisal University
RP Yassin, SA (通讯作者)，Imam Abdulrahman Bin Faisal Univ, Dept Ophthalmol, POB 40097, Al Khobar 31952, Saudi Arabia.
EM syassin@uod.edu.sa
RI Yassin, Sanaa/A-3311-2015
OI Yassin, Sanaa/0000-0001-5585-145X
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   [Anonymous], 1986, Arch Ophthalmol, V104, P694
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Au A, 2017, BRIT J OPHTHALMOL, V101, P970, DOI 10.1136/bjophthalmol-2016-309434
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Barbosa DTQ, 2014, EYE, V28, P472, DOI 10.1038/eye.2014.8
   BARONDES M, 1990, BRIT J OPHTHALMOL, V74, P180, DOI 10.1136/bjo.74.3.180
   Batioglu F, 2014, OPHTHALMIC RES, V52, P53, DOI 10.1159/000361077
   Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler NM, 2013, RETINA, P1183
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen FK, 2010, BRIT J OPHTHALMOL, V94, P1337, DOI 10.1136/bjo.2009.172593
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Christen WG, 2000, ANN EPIDEMIOL, V10, P125, DOI 10.1016/S1047-2797(99)00042-3
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   ClinicalTrials.gov, PHAS 3 SAF EFF STUD
   ClinicalTrials.gov, EFF SAF RTH258 VERS
   ClinicalTrials.gov, COMPL INH EC TREATM
   ClinicalTrials.gov, SAF EFF STUD AB PEG
   ClinicalTrials.gov, STUD INV EFF SAF LAM
   ClinicalTrials.gov, STUD MTP 131 TOP OPH
   ClinicalTrials.gov, STUD EFF SAF RAN POR
   ClinicalTrials.gov, CLIN STUD EV TREATM
   ClinicalTrials.gov, PHAS 1 SAF TOL PHARM
   ClinicalTrials.gov, SAF EFF STUD E10030
   ClinicalTrials.gov, PROT RAD THER MAC DE
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Crossland M, 2007, BRIT J OPHTHALMOL, V91, P391, DOI 10.1136/bjo.2006.095315
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Di Caprio R, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/329418
   DUGEL PU, 2016, INVEST OPHTH VIS SCI, V57
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Friedman D, 2012, RETINA-J RET VIT DIS, V32, P19, DOI 10.1097/IAE.0b013e318219e5e9
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gabriele ML, 2011, INVEST OPHTH VIS SCI, V52, P2425, DOI 10.1167/iovs.10-6312
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Gaynes Bruce I, 2004, Expert Opin Drug Saf, V3, P345, DOI 10.1517/14740338.3.4.345
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gianniou C, 2015, EYE, V29, P342, DOI 10.1038/eye.2014.258
   Giansanti F, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006931.pub2
   Glazer-Hockstein C, 2006, RETINA-J RET VIT DIS, V26, P1, DOI 10.1097/00006982-200601000-00001
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hajar S, 2015, SAUDI MED J, V36, P449, DOI 10.15537/smj.2015.4.10371
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kaiser PK, 2014, MASSACHUSETTS EYE EA
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kertes PJ, 2004, RETINA-J RET VIT DIS, V24, P219, DOI 10.1097/00006982-200404000-00005
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Kijlstra A, 2015, OPHTHALMIC RES, V54, P64, DOI 10.1159/000432401
   Kim BJ, 2014, AM J OPHTHALMOL, V158, P128, DOI 10.1016/j.ajo.2014.04.004
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kovacs KD, 2011, RETINA-J RET VIT DIS, V31, P446, DOI 10.1097/IAE.0b013e3181f6391f
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Guerrero-Naranjo JL, 2013, INVEST OPHTH VIS SCI, V54
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   MAGUIRE MG, 1995, ARCH OPHTHALMOL-CHIC, V113, P190
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Medina FM, 2015, OPHTHALMIC RES, V54, P169, DOI 10.1159/000439172
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Moriarty-Craige SE, 2005, AM J OPHTHALMOL, V140, P1020, DOI 10.1016/j.ajo.2005.06.043
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Neffendorf JE, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1676-7
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Park DH, INT OPHTHALMOL
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Piermarocchi S, 2008, ARCH OPHTHALMOL-CHIC, V126, P1367, DOI 10.1001/archopht.126.10.1367
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Ranjbar M, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005729
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Replenish, OUR TECHN OPHTH MICR
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   Sawa M, 2006, RETINA-J RET VIT DIS, V26, P119, DOI 10.1097/00006982-200601000-00025
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shaikh AH, 2015, OSLI RETINA, V46, P62, DOI 10.3928/23258160-20150101-10
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Shijo T, 2017, GRAEF ARCH CLIN EXP, V255, P1125, DOI 10.1007/s00417-017-3622-0
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Soderberg AC, 2012, BRIT J OPHTHALMOL, V96, P714, DOI 10.1136/bjophthalmol-2011-300721
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Szeto HH, 2014, CLIN PHARMACOL THER, V96, P672, DOI 10.1038/clpt.2014.174
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   Tsai JC, 2013, CAN J OPHTHALMOL, V48, P141, DOI 10.1016/j.jcjo.2013.02.003
   van Romunde SHM, 2015, OPHTHALMOLOGY, V122, P1366, DOI 10.1016/j.ophtha.2015.03.012
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Vottonen P, 2016, ACTA OPHTHALMOL, V94, P652, DOI 10.1111/aos.13185
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yanai R, 2014, P NATL ACAD SCI USA, V111, P9603, DOI 10.1073/pnas.1401191111
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zhu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058821
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 192
TC 181
Z9 187
U1 5
U2 54
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2017
VL 12
BP 1313
EP 1330
DI 10.2147/CIA.S143508
PG 18
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA FE3EC
UT WOS:000408098200003
PM 28860733
OA Green Published, gold
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Behnke, V
   Wolf, A
   Langmann, T
AF Behnke, Verena
   Wolf, Anne
   Langmann, Thomas
TI The role of lymphocytes and phagocytes in age-related macular
   degeneration (AMD)
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Lymphocytes; Phagocytes; Inflammation; Immune response; AMD
ID CHOROIDAL NEOVASCULARIZATION; T-CELLS; SUBRETINAL INFLAMMATION;
   EXPRESSION; MONOCYTES; ACTIVATION; MEMBRANE; RECEPTOR; ACCUMULATION;
   LEUKOCYTES
AB Age-related macular degeneration (AMD) is a leading cause of visual impairment of the elderly population. Since AMD is a multifactorial age-related disease with various genetic risk factors, the understanding of its complex pathophysiology is still limited. However, animal experiments, genome-wide association data and the molecular profiling of AMD patient samples have highlighted a key role of systemic and local immune processes that contribute to this chronic eye disease. In this overview article, we concentrate on the role of lymphocytes and mononuclear phagocytes and their interplay in triggering a persistent immune response in the AMD retina. We preferentially review findings from human immune cell analyses and complement these with related findings in experimental models. We conclude that both immune cell types as their signaling network may be a rich source to identify novel molecular targets for immunomodulation in AMD.
C1 [Behnke, Verena; Wolf, Anne; Langmann, Thomas] Univ Cologne, Lab Expt Immunol Eye, Dept Ophthalmol, Fac Med, D-50931 Cologne, Germany.
   [Behnke, Verena; Wolf, Anne; Langmann, Thomas] Univ Cologne, Univ Hosp Cologne, D-50931 Cologne, Germany.
   [Langmann, Thomas] CMMC, D-50931 Cologne, Germany.
C3 University of Cologne; University of Cologne; University of Cologne
RP Langmann, T (通讯作者)，Univ Cologne, Lab Expt Immunol Eye, Dept Ophthalmol, Fac Med, D-50931 Cologne, Germany.; Langmann, T (通讯作者)，Univ Cologne, Univ Hosp Cologne, D-50931 Cologne, Germany.; Langmann, T (通讯作者)，CMMC, D-50931 Cologne, Germany.
EM verena.behnke@uk-koeln.de; anne.wolf@uk-koeln.de;
   thomas.langmann@uk-koeln.de
OI Behnke, Verena/0000-0002-7483-3190; Wolf, Anne/0000-0003-2551-9821
FU Deutsche Forschungsgemeinschaft [FOR2240, LA1209/11-2]; Helmut Ecker
   Foundation [03/17]; Pro Retina Foundation [1/2015]; Hans and Marlies
   Stock Foundation [S061-10.013]; Velux Foundation
FX The research in our laboratory is supported by funds from the Deutsche
   Forschungsgemeinschaft (FOR2240, LA1209/11-2), the Helmut Ecker
   Foundation (03/17), the Pro Retina Foundation (1/2015), the Hans and
   Marlies Stock Foundation (S061-10.013), and the Velux Foundation
   (Project 967). We thank Dr. Marion Rozowski for critical reading of the
   manuscript.
CR Akhtar-Schafer I, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708259
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Balser C, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1419-2
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chen JJ, 2017, CELL PHYSIOL BIOCHEM, V44, P357, DOI 10.1159/000484907
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Coughlin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23794
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Cruz-Guilloty F, 2011, NATURE, V478, P42, DOI 10.1038/478042a
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Ezzat MK, 2008, BRIT J OPHTHALMOL, V92, P976, DOI 10.1136/bjo.2007.129742
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Falk MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112473
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Haas P, 2011, AM J OPHTHALMOL, V152, P396, DOI 10.1016/j.ajo.2011.02.017
   Hasegawa E, 2013, J IMMUNOL, V190, P1778, DOI 10.4049/jimmunol.1202495
   Hasegawa E, 2012, J LEUKOCYTE BIOL, V91, P267, DOI 10.1189/jlb.1110603
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lasagni L, 2003, J EXP MED, V197, P1537, DOI 10.1084/jem.20021897
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Lipo E, 2013, INVEST OPHTH VIS SCI, V54, P7107, DOI 10.1167/iovs.13-12923
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Madelung CF, 2015, CLIN OPHTHALMOL, V9, DOI 10.2147/OPTH.S82116
   Martin S, 2004, CIRCULATION, V109, P1653, DOI 10.1161/01.CIR.0000124065.31211.6E
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   Mullins RF, 2017, HUM MOL GENET, V26, pR51, DOI 10.1093/hmg/ddx181
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nielsen MK, 2019, CLIN EXP OPHTHALMOL, V47, P69, DOI 10.1111/ceo.13362
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Raoul W, 2008, J NEUROIMMUNOL, V198, P56, DOI 10.1016/j.jneuroim.2008.04.014
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Romagnani P, 2001, J CLIN INVEST, V107, P53, DOI 10.1172/JCI9775
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Singh A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00741-4
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Subhi Y, 2017, AGING-US, V9, P2436, DOI 10.18632/aging.101329
   Subhi Y, 2017, INVEST OPHTH VIS SCI, V58, P5242, DOI 10.1167/iovs.17-22479
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Szatmari-Toth M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.133
   Tahiri H, 2016, SCI REP-UK, V6, DOI 10.1038/srep37391
   Tan X, 2015, SCI REP-UK, V5, DOI 10.1038/srep15702
   Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816
   Toomey CB, 2018, INVEST OPHTH VIS SCI, V59, P662, DOI 10.1167/iovs.17-23134
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Weng NP, 2009, TRENDS IMMUNOL, V30, P306, DOI 10.1016/j.it.2009.03.013
   Will-Orrego A, 2018, J OCUL PHARMACOL TH, V34, P489, DOI 10.1089/jop.2017.0131
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xi HK, 2016, J EXP MED, V213, P189, DOI 10.1084/jem.20150894
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang DL, 2009, INVEST OPHTH VIS SCI, V50, P4998, DOI 10.1167/iovs.09-3620
   Zhao ZY, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15166
   Zhou R, 2012, J IMMUNOL, V188, P1742, DOI 10.4049/jimmunol.1102415
NR 72
TC 18
Z9 18
U1 4
U2 8
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAR
PY 2020
VL 77
IS 5
BP 781
EP 788
DI 10.1007/s00018-019-03419-4
EA JAN 2020
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA KS7QS
UT WOS:000505379200002
PM 31897541
DA 2022-11-30
ER

PT J
AU Ron, Y
   Ehrlich, R
   Axer-Siegel, R
   Rosenblatt, I
   Weinberger, D
AF Ron, Yonina
   Ehrlich, Rita
   Axer-Siegel, Ruth
   Rosenblatt, Irit
   Weinberger, Dov
TI Pneumatic displacement of submacular hemorrhage due to age-related
   macular degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; pneumatic displacement; submacular
   hemorrhage
ID TISSUE-PLASMINOGEN-ACTIVATOR; SUBRETINAL HEMORRHAGE; RETINAL TOXICITY;
   SURGICAL REMOVAL; NATURAL-HISTORY; INJECTION; GAS; MANAGEMENT; RABBITS;
   EYES
AB Purpose: Subretinal hemorrhage is one of the most serious complications of exudative age-related macular degeneration (AMD). Treatment with vitreous surgery with or without plasminogen activator, fluid-gas exchange, or perfluorocarbon yields only a small improvement in visual acuity. Patients and Methods: The files of 24 patients with submacular hemorrhage secondary to AMD who were treated by injection of perfluoropropane gas (C3F8) (11 patients) or sulfur hexafluoride (SF6) (13 patients) were reviewed for visual acuity before and after the procedure and time of treatment from onset of symptoms. Results: For the whole sample, pneumatic displacement led to a statistically significant improvement in mean visual acuity (p = 0.015). A significant difference between pre- and postoperative visual acuity was found for the patients treated with SF6 (p = 0.034), but not for the patients treated with C3F8 (p = 0.245). Conclusion: The use of gas injection to displace submacular hemorrhage can significantly improve visual acuity. Copyright (c) 2007 S. Karger AG, Basel.
C1 Rabin Med Ctr, Dept Ophthalmol, IL-49100 Petah Tiqwa, Israel.
   Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
C3 Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine
RP Ron, Y (通讯作者)，Rabin Med Ctr, Dept Ophthalmol, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.
EM yoninadi@netvision.net.il
OI Ehrlich, Rita/0000-0002-4167-8809
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Chen SN, 2003, OPHTHALMOLOGY, V110, P704, DOI 10.1016/S0161-6420(02)01979-6
   Chen W L, 1999, Zhonghua Yi Xue Za Zhi (Taipei), V62, P268
   Daneshvar H, 1999, CAN J OPHTHALMOL, V34, P385
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hrach CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659
   IRVINE WD, 1991, ARCH OPHTHALMOL-CHIC, V109, P718, DOI 10.1001/archopht.1991.01080050134044
   Johnson MW, 2000, OPHTHALMOLOGY, V107, P2119, DOI 10.1016/S0161-6420(00)00452-8
   JOHNSON MW, 1990, ARCH OPHTHALMOL-CHIC, V108, P259, DOI 10.1001/archopht.1990.01070040111042
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
NR 25
TC 18
Z9 19
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2007
VL 221
IS 1
BP 57
EP 61
DI 10.1159/000096524
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 120DP
UT WOS:000243064200011
PM 17183203
DA 2022-11-30
ER

PT J
AU Loewenstein, A
AF Loewenstein, Anat
TI Use of Home Device for Early Detection of Neovascular Age-Related
   Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Preferential hyperacuity perimetry; Foresee Home
ID PREFERENTIAL HYPERACUITY PERIMETER; CHOROIDAL NEOVASCULARIZATION;
   SUBGROUP ANALYSIS; RANIBIZUMAB; PHP
AB Early treatment for choroidal neovascularization (CNV) is an important part of preserving visual function for patients with age-related macular degeneration. Preferential hyperacuity perimetry (PHP) provides high accuracy, sensitivity and specificity for detecting changes in lesions in diagnostic and treatment stages. The Foresee Home is a PHP device designed for home use by patients. Regular use alerts retina specialists and patients of detected changes and allows patients to come in for visits when CNV begins or recurs. To maximize the benefit of recent breakthroughs in CNV treatment, patients should be better monitored with the Foresee Home to detect new CNV while their vision is still good, and to promptly manage recurrence after treatment. Copyright (C) 2012 S. Karger AG, Basel
C1 Tel Aviv Univ, Dept Ophthalmol, Tel Aviv Med Ctr, Sidney A Fox Chair Ophthalmol,Sackler Fac Med, IL-64239 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine
RP Loewenstein, A (通讯作者)，Tel Aviv Univ, Dept Ophthalmol, Tel Aviv Med Ctr, Sidney A Fox Chair Ophthalmol,Sackler Fac Med, IL-64239 Tel Aviv, Israel.
EM anatl@dvmc.gov.il
CR Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Das R, 2009, RETINA-J RET VIT DIS, V29, P1013, DOI 10.1097/IAE.0b013e3181a91dbf
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   Heier JS, 2011, ANG EX DEG 2011 MIAM
   Isaac David Leonardo Cruvinel, 2007, Arq. Bras. Oftalmol., V70, P771, DOI 10.1590/S0004-27492007000500009
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kampmeier J, 2006, KLIN MONATSBL AUGENH, V223, P752, DOI 10.1055/s-2006-926880
   Lai YH, 2011, RETINA-J RET VIT DIS, V31, P1620, DOI 10.1097/IAE.0b013e31820d3ed1
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   Loewenstein A, 2010, RETINA-J RET VIT DIS, V30, P1058, DOI 10.1097/IAE.0b013e3181d1a75e
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Querques G, 2011, INVEST OPHTH VIS SCI, V52, P7012, DOI 10.1167/iovs.11-7517
   Querques G, 2011, BRIT J OPHTHALMOL, V95, P986, DOI 10.1136/bjo.2010.190942
   Rauch R, 2011, RETINA
   Schmidt-Erfurth U, 2011, ANG EX DEG 2011 MIAM
   Stur M, 2010, OPHTHAL SURG LAS IM, V41, P598, DOI 10.3928/15428877-20100830-05
   VANDER JF, 1989, OPHTHALMOLOGY, V96, P1422
NR 21
TC 5
Z9 5
U1 0
U2 8
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2012
VL 48
SU 1
BP 11
EP 15
DI 10.1159/000339842
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 994FT
UT WOS:000307917000003
PM 22907144
DA 2022-11-30
ER

PT J
AU Sarangarajan, R
   Apte, S
AF Sarangarajan, R
   Apte, S
TI Melanization and phagocytosis: Implications for age related macular
   degeneration
SO MOLECULAR VISION
LA English
DT Review
ID PIGMENT EPITHELIAL-CELLS; PHOTORECEPTOR OUTER SEGMENTS; ENDOTHELIAL
   GROWTH-FACTOR; ELECTRON-SPIN-RESONANCE; FOCAL ADHESION KINASE;
   RETINITIS-PIGMENTOSA; APOLIPOPROTEIN-E; LIPOFUSCIN ACCUMULATION; OXYGEN
   DISTRIBUTION; MOUSE MODEL
AB Signaling pathways that upregulate melanization in the retinal pigment epithelium (RPE) may also be implicated in the downregulation of rod outer segment (ROS) phagocytosis by the RPE. Melanization activating pathways may also modulate oxygen consumption by the photoreceptors, apolipoprotein E4 levels, and the rate of photoisomerization events such that the net effect may be a reduction in drusen and/or lipofuscin accumulation. An increase in melanin at the apical microvilli of the RPE may shield ROS from light thereby contributing in part to the decrease in the rate of ROS phagocytosis. This decrease in ROS phagocytosis by the RPE may serve to maintain a balance between ingestion and degradation/recycling thereby avoiding an increase to its already substantial metabolic load. Several experimental drugs for age related macular degeneration (ARMD) coincidentally are also capable of decreasing the rate of ROS phagocytosis. This review attempts to identify the signaling pathways that may link the upregulation of melanization to the downregulation of ROS phagocytosis. Phagocytic pathways that are modulated by melanization need to be studied in isolation to determine what role, if any, they possess in ameliorating the onset and progression of ARMD. Many more empirical studies are needed to unravel specific pathways and mechanisms that seem to link melanization with ARMD.
C1 Massachusetts Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Worcester, MA USA.
   Baxter IV Syst, Murray Hill, NJ USA.
RP Apte, S (通讯作者)，2313 Welch Pl, Mansfield, TX 76063 USA.
EM shireeshpapte@msn.com
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Akeo K, 2002, PIGM CELL RES, V15, P341, DOI 10.1034/j.1600-0749.2002.02054.x
   Ancans J, 2001, EXP CELL RES, V268, P26, DOI 10.1006/excr.2001.5251
   ANDERSON DH, 1980, EXP EYE RES, V30, P559, DOI 10.1016/0014-4835(80)90040-8
   Arden GB, 2001, BRIT J OPHTHALMOL, V85, P366, DOI 10.1136/bjo.85.3.366
   Baehr W, 2003, VISION RES, V43, P2957, DOI 10.1016/j.visres.2003.10.001
   BAKER BN, 1986, EXP EYE RES, V42, P547, DOI 10.1016/0014-4835(86)90045-X
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   BECQUET F, 1994, EXP CELL RES, V212, P374, DOI 10.1006/excr.1994.1157
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659
   Bird A, 1996, BRIT J OPHTHALMOL, V80, P2, DOI 10.1136/bjo.80.1.2
   Bird AC, 1997, ARCH OPHTHALMOL-CHIC, V115, P1311, DOI 10.1001/archopht.1997.01100160481017
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   BOYLE D, 1991, INVEST OPHTH VIS SCI, V32, P1464
   BRAUN RD, 1995, INVEST OPHTH VIS SCI, V36, P542
   Busca R, 1998, MOL BIOL CELL, V9, P1367, DOI 10.1091/mbc.9.6.1367
   Busca R, 1996, J BIOL CHEM, V271, P31824, DOI 10.1074/jbc.271.50.31824
   BUSH RA, 1994, INVEST OPHTH VIS SCI, V35, P91
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Casadevall A, 2000, CURR OPIN MICROBIOL, V3, P354, DOI 10.1016/S1369-5274(00)00103-X
   CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P821
   Chowers I, 2004, INVEST OPHTH VIS SCI, V45, P2098, DOI 10.1167/iovs.03-0863
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   Cox D, 2002, NAT CELL BIOL, V4, P469, DOI 10.1038/ncb805
   Crabb JW, 2002, PROTEIN SCI, V11, P831, DOI 10.1110/ps.4400102
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   DEGUCHI J, 1994, INVEST OPHTH VIS SCI, V35, P568
   DIMENT S, 1995, J BIOL CHEM, V270, P4213, DOI 10.1074/jbc.270.9.4213
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   DOOLITTLE DP, 1996, GENETIC VARIANTS STR, P17
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dorey K, 1993, RETINAL DEGENERATION, P3
   DRAGER UC, 1985, P NATL ACAD SCI USA, V82, P6716, DOI 10.1073/pnas.82.19.6716
   Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899
   ECKMILLER MS, 1983, INVEST OPHTH VIS SCI, V24, P1328
   EDWARDS RB, 1980, INVEST OPHTH VIS SCI, V19, P1184
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Finnemann SC, 2003, EMBO J, V22, P4143, DOI 10.1093/emboj/cdg416
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Fuller BB, 2001, EXP CELL RES, V262, P197, DOI 10.1006/excr.2000.5092
   Futter CE, 2004, MOL BIOL CELL, V15, P2264, DOI 10.1091/mbc.E03-10-0772
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   GAZZAH N, 1993, J NEUROCHEM, V61, P1057, DOI 10.1111/j.1471-4159.1993.tb03620.x
   GEREMIA E, 1984, COMP BIOCHEM PHYS B, V79, P67, DOI 10.1016/0305-0491(84)90078-6
   Gollapalli DR, 2004, P NATL ACAD SCI USA, V101, P10030, DOI 10.1073/pnas.0401936101
   Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103
   GREGORY CY, 1994, INVEST OPHTH VIS SCI, V35, P819
   Guo XX, 1997, INVEST OPHTH VIS SCI, V38, P1873
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hall MO, 2002, EXP EYE RES, V75, P391, DOI 10.1006/exer.2002.2030
   Hall MO, 2001, EXP EYE RES, V73, P509, DOI 10.1006/exer.2001.1062
   HALL MO, 1993, INVEST OPHTH VIS SCI, V34, P2392
   HALL MO, 1991, EXP EYE RES, V52, P591, DOI 10.1016/0014-4835(91)90061-I
   HAYAKAWA M, 1993, AM J OPHTHALMOL, V115, P168, DOI 10.1016/S0002-9394(14)73920-0
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hoppe G, 2001, INVEST OPHTH VIS SCI, V42, P2714
   Hu DN, 1997, EXP EYE RES, V64, P397, DOI 10.1006/exer.1996.0223
   Ikemoto A, 2000, J NUTR, V130, P3059, DOI 10.1093/jn/130.12.3059
   Imokawa G, 1996, BIOCHEM J, V314, P305, DOI 10.1042/bj3140305
   Jackson IJ, 1997, HUM MOL GENET, V6, P1613, DOI 10.1093/hmg/6.10.1613
   Karlsson AM, 2000, CELL SIGNAL, V12, P469, DOI 10.1016/S0898-6568(00)00089-9
   KATZ ML, 1986, EXP EYE RES, V43, P561, DOI 10.1016/S0014-4835(86)80023-9
   Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023
   KAYATZ P, 1998, 96 DTSCH OPHTH GES A
   KENNEDY CJ, 1994, EXP CELL RES, V210, P209, DOI 10.1006/excr.1994.1031
   Kim I T, 1998, Korean J Ophthalmol, V12, P85
   KingSmith C, 1996, J CELL SCI, V109, P33
   KLAVER CC, 1998, AM J HUM GENET, V63, P1252
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KORYTOWSKI W, 1986, BIOCHIM BIOPHYS ACTA, V882, P145, DOI 10.1016/0304-4165(86)90149-2
   KORYTOWSKI W, 1995, ARCH BIOCHEM BIOPHYS, V319, P142, DOI 10.1006/abbi.1995.1276
   KURIYAMA S, 1995, INVEST OPHTH VIS SCI, V36, P730
   Lahdenranta J, 2001, P NATL ACAD SCI USA, V98, P10368, DOI 10.1073/pnas.181329198
   Lavallee CR, 2003, J NEUROPHYSIOL, V90, P3654, DOI 10.1152/jn.00736.2003
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   LINSENMEIER RA, 1986, J GEN PHYSIOL, V88, P521, DOI 10.1085/jgp.88.4.521
   LINSENMEIER RA, 1992, J GEN PHYSIOL, V99, P177, DOI 10.1085/jgp.99.2.177
   MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976
   Manga P, 2001, PIGM CELL RES, V14, P362, DOI 10.1034/j.1600-0749.2001.140508.x
   Mannerstrom M, 2001, PHARMACOL TOXICOL, V88, P27, DOI 10.1034/j.1600-0773.2001.088001027.x
   Miceli MV, 1996, CURR EYE RES, V15, P804
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Miceli MV, 1996, CURR EYE RES, V15, P17, DOI 10.3109/02713689609017607
   Mousavi SA, 2001, BBA-BIOMEMBRANES, V1510, P243, DOI 10.1016/S0005-2736(00)00354-0
   MURRAY RL, 1975, J CELL BIOL, V64, P705, DOI 10.1083/jcb.64.3.705
   Naash MI, 1996, J NEUROSCI, V16, P7853
   Nguyen-Legros J, 2000, INT REV CYTOL, V196, P245
   Nilsson HM, 2000, CELL MOTIL CYTOSKEL, V47, P209, DOI 10.1002/1097-0169(200011)47:3<209::AID-CM4>3.0.CO;2-W
   Nir I, 2002, J NEUROSCI, V22, P2063, DOI 10.1523/JNEUROSCI.22-06-02063.2002
   Nosanchuk JD, 1999, ANTIMICROB AGENTS CH, V43, P233, DOI 10.1093/jac/43.2.233
   Nosanchuk JD, 1997, INFECT IMMUN, V65, P1836, DOI 10.1128/IAI.65.5.1836-1841.1997
   Ohkubo N, 2001, J BIOL CHEM, V276, P3046, DOI 10.1074/jbc.M005070200
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Pruett R C, 1983, Trans Am Ophthalmol Soc, V81, P693
   Radu RA, 2004, P NATL ACAD SCI USA, V101, P5928, DOI 10.1073/pnas.0308302101
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Rakoczy P, 1998, AUST NZ J OPHTHALMOL, V26, P67
   Rakoczy PE, 1997, BIOCHEM J, V324, P935, DOI 10.1042/bj3240935
   Reilein AR, 1998, J CELL BIOL, V142, P803, DOI 10.1083/jcb.142.3.803
   ROBINSON SR, 1995, VISUAL NEUROSCI, V12, P767, DOI 10.1017/S0952523800009020
   RomeroGraillet C, 1996, J BIOL CHEM, V271, P28052, DOI 10.1074/jbc.271.45.28052
   Rossi AG, 1998, J IMMUNOL, V160, P3562
   Ryeom SW, 1996, J CELL SCI, V109, P387
   Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536
   SARNA T, 1985, PHOTOCHEM PHOTOBIOL, V42, P529, DOI 10.1111/j.1751-1097.1985.tb01605.x
   SARNA T, 1986, BIOCHIM BIOPHYS ACTA, V883, P162, DOI 10.1016/0304-4165(86)90147-9
   SARNA T, 2001, 9 C EUR SOC PHOT SEP
   Schutt F, 2001, OPHTHALMOLOGE, V98, P721, DOI 10.1007/s003470170078
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   SEALY RC, 1984, PHOTOCHEM PHOTOBIOL, V40, P453, DOI 10.1111/j.1751-1097.1984.tb04617.x
   Sieving PA, 2001, P NATL ACAD SCI USA, V98, P1835, DOI 10.1073/pnas.041606498
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Snodderly DM, 2002, INVEST OPHTH VIS SCI, V43, P2815
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sparrow JR, 2003, P NATL ACAD SCI USA, V100, P4353, DOI 10.1073/pnas.1031478100
   Stepien K, 2000, ACTA BIOCHIM POL, V47, P931
   Sun H, 2001, SCI AM, V285, P69, DOI 10.1038/scientificamerican1001-68
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Sundelin SP, 2001, FREE RADICAL BIO MED, V30, P74, DOI 10.1016/S0891-5849(00)00444-5
   Travis GH, 1998, AM J HUM GENET, V62, P503, DOI 10.1086/301772
   Tsatmali M, 2002, J HISTOCHEM CYTOCHEM, V50, P125, DOI 10.1177/002215540205000201
   ULISS AE, 1986, OPHTHALMOLOGY, V93, P1599
   Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198
   Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481
   WEITER JJ, 1988, AM J OPHTHALMOL, V106, P286, DOI 10.1016/0002-9394(88)90363-7
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Wihlmark U, 1996, APMIS, V104, P272, DOI 10.1111/j.1699-0463.1996.tb00717.x
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Winkler BS, 1999, MOL VIS, V5
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   ZAREBA M, 1995, BBA-MOL BASIS DIS, V1271, P343, DOI 10.1016/0925-4439(95)00058-C
   Zhao MW, 1999, INVEST OPHTH VIS SCI, V40, P2713
   Zhu NW, 2002, J INVEST DERMATOL, V119, P1165, DOI 10.1046/j.1523-1747.2002.19516.x
NR 142
TC 24
Z9 28
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 7
PY 2005
VL 11
IS 54-56
BP 482
EP 490
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 946WF
UT WOS:000230603300003
PM 16030499
DA 2022-11-30
ER

PT J
AU Witmer, MT
   Kozbial, A
   Daniel, S
   Kiss, S
AF Witmer, Matthew T.
   Kozbial, Andrzej
   Daniel, Sara
   Kiss, Szilard
TI Peripheral autofluorescence findings in age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; autofluorescence; peripheral
   abnormalities; ultra-wide-field imaging
ID FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; HIGH-RISK; CLASSIFICATION;
   PATTERNS
AB . Purpose: To describe the peripheral autofluorescent findings in patients with age-related macular degeneration (AMD) using ultrawide-field imaging. Methods: We retrospectively reviewed the ultra-wide-field autofluorescent images of all patients diagnosed with AMD or macular drusen at the Department of Ophthalmology of Weill Cornell Medical College from July 2010 to September 2011. Peripheral autofluorescent phenotypes included normal autofluorescence, focal pinpoint hyperfluorescence, granular fluorescent changes, patchy hypofluorescence, and reticular hypofluorescence. Results: One hundred and ten consecutive patients (220 eyes) with a diagnosis of AMD or macular drusen were imaged using ultra-wide-field autofluorescent technology during the study period. Eighty-three patients (157 eyes) were included in the final analysis. Peripheral autofluorescent abnormalities were present in 63.6% of eyes with AMD versus 35.7% of control eyes (p = 0.049). Granular fluorescent changes (p = 0.0001) and patchy hypofluorescence (p = 0.0015) were more common in eyes with advanced AMD than in eyes with early AMD or control eyes. Granular fluorescent changes were also more common in eyes with choroidal neovascularization (p = 0.026) or geographic atrophy (p = 0.0001). Patchy hypofluorescence (0.0001) was more common in eyes with geographic atrophy. Conclusions: Peripheral autofluorescent abnormalities are common in eyes with AMD. The peripheral findings in eyes with AMD may represent different phenotypes, which may indicate different environmental or genetic factors in the development of AMD. Characterizing the different peripheral phenotypes may have implications for diagnosis and treatment of AMD subtypes.
C1 [Witmer, Matthew T.; Kozbial, Andrzej; Daniel, Sara; Kiss, Szilard] Weill Cornell Med Coll, Dept Ophthalmol, New York, NY 10021 USA.
C3 Cornell University
RP Witmer, MT (通讯作者)，Weill Cornell Med Coll, Dept Ophthalmol, 1305 York Ave,11th Floor, New York, NY 10021 USA.
EM maw2052@med.cornell.edu
OI Kiss, Szilard/0000-0003-3433-8432
FU Research to Prevent Blindness
FX This work was supported in part by an unrestricted educational grant to
   the Weill Cornell Department of Ophthalmology from the Research to
   Prevent Blindness. Dr. Szilard Kiss serves as a consultant to Optos,
   PLC, the manufacturer of the ultra-wide-field autofluorescence device
   utilized for the current analysis. The authors maintained full control
   of the study design, collection of data, data analysis and writing of
   the manuscript. Neither the company nor any of its representatives were
   involved in any aspect of the presented research. This study was carried
   out with prospective approval from the Institutional Review Board (IRB)
   of the Weill Cornell Medical College. The study is in accordance with
   HIPAA regulations. None of the content of this report has been presented
   or published previously.
CR [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Atkinson AMazoC, 2011, IMAGED AREA RETINA
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Glasgow BJ, 1994, DUANES CLIN OPHTHALM, V3, P1
   Haab O, 1885, CENTRALBLAT AUGENHEI, V9, P384
   Heussen FM, 2011, OPHTHAL SURG LAS IM, V42, P272, DOI 10.3928/15428877-20110505-01
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Sadda SR, 2011, RET SOC M ROM IT SAT
   Seidensticker F, 2011, CLIN OPHTHALMOL, V5, P1667, DOI 10.2147/OPTH.S26224
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
NR 20
TC 32
Z9 34
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2012
VL 90
IS 6
BP e428
EP e433
DI 10.1111/j.1755-3768.2012.02434.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 996JB
UT WOS:000308079900002
PM 22578271
OA Bronze
DA 2022-11-30
ER

PT J
AU Perepelkina, T
   Fulton, AB
AF Perepelkina, Tatiana
   Fulton, Anne B.
TI Artificial Intelligence (AI) Applications for Age-Related Macular
   Degeneration (AMD) and Other Retinal Dystrophies
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Artificial intelligence (AI); Machine learning; AI in ophthalmology;
   Retinal dystrophies; Stargardt disease
ID ATROPHY
AB Artificial intelligence (AI), with its subdivisions (machine and deep learning), is a new branch of computer science that has shown impressive results across a variety of domains. The applications of AI to medicine and biology are being widely investigated. Medical specialties that rely heavily on images, including radiology, dermatology, oncology and ophthalmology, were the first to explore AI approaches in analysis and diagnosis. Applications of AI in ophthalmology have concentrated on diseases with high prevalence, such as diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration (AMD), and glaucoma. Here we provide an overview of AI applications for diagnosis, classification, and clinical management of AMD and other macular dystrophies.
C1 [Perepelkina, Tatiana; Fulton, Anne B.] Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School
RP Perepelkina, T (通讯作者)，Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
EM tatiana.perepelkina@childrens.harvard.edu
OI Perepelkina, Tatiana/0000-0002-3131-7110
CR Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   BESSANT D, 2001, CURR OPIN GENET DEV, V11
   BOGUNOVIC H, 2017, INVEST OPHTH VIS SCI, V58
   BOGUNOVIC SH, 2017, INVEST OPHTH VIS SCI, V58
   BURLINA P, 2017, JAMA OPHTHALMOL, V135
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   Charng J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73339-y
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Ching T, 2018, J R SOC INTERFACE, V15, DOI 10.1098/rsif.2017.0387
   CIRESAN D, 2013, LECT NOTES COMPUT SC, V16
   DU X, 2018, INT J OPHTHALMOL-CHI, V11
   Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056
   Feeny AK, 2015, COMPUT BIOL MED, V65, P124, DOI 10.1016/j.compbiomed.2015.06.018
   Fujinami-Yokokawa Y, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/1691064
   Gilbert C, 2008, EARLY HUM DEV, V84, P77, DOI 10.1016/j.earlhumdev.2007.11.009
   Goodman B, 2017, AI MAG, V38, P50, DOI 10.1609/aimag.v38i3.2741
   GULSHAN V, 2016, JAMA-J AM MED ASSOC, V316
   Kapoor R, 2019, SURV OPHTHALMOL, V64, P233, DOI 10.1016/j.survophthal.2018.09.002
   Kooi T, 2017, MED IMAGE ANAL, V35, P303, DOI 10.1016/j.media.2016.07.007
   Kreft D, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6935-6
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Liu YY, 2011, MED IMAGE ANAL, V15, P748, DOI 10.1016/j.media.2011.06.005
   LOIS N, 2001, ARCH OPHTHALMOL-CHIC, V119
   Lu W, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5278196
   McCulloch W.S., 1943, B MATH BIOPHYS, V5, P115, DOI [DOI 10.1007/BF02478259, 10.1007/BF02478259]
   Miere A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103303
   Muller PL, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082428
   PAKDEMIRLI E, 2019, ACTA RADIOL OPEN, V8
   Rusk N, 2016, NAT METHODS, V13, P35, DOI 10.1038/nmeth.3707
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   SCHMIDTERFURTH U, 2018, INVEST OPHTH VIS SCI, V59
   Shah M, 2020, ACTA OPHTHALMOL, V98, pE715, DOI 10.1111/aos.14353
   Shiraishi J, 2011, SEMIN NUCL MED, V41, P449, DOI 10.1053/j.semnuclmed.2011.06.004
   SRINIVASAN P, 2014, BIOMED OPT EXPRESS, V5
   Stevenson CH, 2019, CLIN EXP OPHTHALMOL, V47, P484, DOI 10.1111/ceo.13433
   Strauss RW, 2016, OPHTHALMOLOGY, V123, P817, DOI 10.1016/j.ophtha.2015.12.009
   Sun YK, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.1.016012
   Swaminathan S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188532
   VANGRINSVEN M, 2015, INVEST OPHTH VIS SCI, V56
   VANGRINSVEN M, 2013, INVEST OPHTH VIS SCI, V54
   Venhuizen FG, 2017, INVEST OPHTH VIS SCI, V58, P2318, DOI 10.1167/iovs.16-20541
   WALIA S, 2009, OPHTHALMIC GENET, V30
   Wang D, 2016, J TRAVEL RES, V55, P52, DOI 10.1177/0047287514535847
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yan Q, 2020, NAT MACH INTELL, V2, P141, DOI 10.1038/s42256-020-0154-9
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   Zobor D, 2018, INVEST OPHTH VIS SCI, V59, P3041, DOI 10.1167/iovs.18-24033
NR 47
TC 5
Z9 5
U1 5
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY 19
PY 2021
VL 36
IS 4
SI SI
BP 304
EP 309
DI 10.1080/08820538.2021.1896756
EA MAR 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SB4FX
UT WOS:000632836100001
PM 33764255
DA 2022-11-30
ER

PT J
AU Pandi, SPS
   Ratnayaka, JA
   Lotery, AJ
   Teeling, JL
AF Pandi, Sudha Priya Soundara
   Ratnayaka, J. Arjuna
   Lotery, Andrew J.
   Teeling, Jessica L.
TI Progress in developing rodent models of age-related macular degeneration
   (AMD)
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Animal models; Rodents; Oxidative
   stress; Hypoxia; Inflammation; Retina
AB Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss, typically affecting individuals from mid-life onwards. Its multifactorial aetiology and the lack of any effective treatments has spurred the development of animal models as research and drug discovery tools. Several rodent models have been developed which recapitulate key features of AMD and provide insights into its underlying pathology. These have contributed to making significant progress in understanding the disease and the identification of novel therapeutic targets. However, a major caveat with existing models is that they do not demonstrate the full disease spectrum. In this review, we outline advances in rodent AMD models from the last decade. These models feature various hallmarks associated with AMD, including oxidative stress, hypoxia, immune dysregulation, genetic mutations and environmental risk factors. The review summarises the methods by which each model was created, its pathological characteristics as well as its relation to the disease in humans.
C1 [Pandi, Sudha Priya Soundara; Ratnayaka, J. Arjuna; Lotery, Andrew J.] Univ Southampton, Fac Med, Clin & Expt Sci, MP806,Tremona Rd, Southampton S016 6YD, Hants, England.
   [Lotery, Andrew J.] Univ Hosp Southampton NHS Fdn Trust, Eye Unit, Southampton SO16 6YD, Hants, England.
   [Teeling, Jessica L.] Univ Southampton, Fac Nat & Environm Sci, Biol Sci, MP840,Tremona Rd, Southampton SO16 6YD, Hants, England.
C3 University of Southampton; University of Southampton; University
   Hospital Southampton NHS Foundation Trust; University of Southampton
RP Ratnayaka, JA; Lotery, AJ (通讯作者)，Univ Southampton, Fac Med, Clin & Expt Sci, MP806,Tremona Rd, Southampton S016 6YD, Hants, England.; Teeling, JL (通讯作者)，Univ Southampton, Fac Nat & Environm Sci, Biol Sci, MP840,Tremona Rd, Southampton SO16 6YD, Hants, England.
EM J.Ratnayaka@soton.ac.uk; a.j.lotery@soton.ac.uk; J.Teeling@soton.ac.uk
OI Soundara Pandi, Sudha Priya/0000-0002-0308-0742; Lotery,
   Andrew/0000-0001-5541-4305; Ratnayaka, J. Arjuna/0000-0002-1027-6938
FU National Institute of Health Research senior investigator award
FX This work was supported by the Gift of Sight Appeal and a National
   Institute of Health Research senior investigator award to AL.
CR Abbas RO, 2013, OPHTHALMIC GENET, V34, P209, DOI 10.3109/13816810.2012.762934
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anastasopoulos E, 2012, CURR EYE RES, V37, P1148, DOI 10.3109/02713683.2012.705413
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Ayub H, 2019, ANN HUM GENET, V83, P285, DOI 10.1111/ahg.12311
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Bhutto Imran A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD143, DOI 10.1167/iovs.18-24245
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bishop-Bailey D, 2008, PPAR RES, V2008, DOI 10.1155/2008/825970
   Bishop-Bailey D, 2009, PHARMACOL THERAPEUT, V124, P141, DOI 10.1016/j.pharmthera.2009.06.011
   Biswal MR, 2016, ADV EXP MED BIOL, V854, P30, DOI 10.1007/978-3-319-17121-0_5
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Caprara C, 2012, PROG RETIN EYE RES, V31, P89, DOI 10.1016/j.preteyeres.2011.11.003
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061381
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Criscuolo C, 2018, NEUROBIOL AGING, V67, P181, DOI 10.1016/j.neurobiolaging.2018.03.017
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Dentchev T, 2003, MOL VIS, V9, P184
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Green RW, 1999, MOL VIS, V5
   Gu BJ, 2013, FASEB J, V27, P1479, DOI 10.1096/fj.12-215368
   Guo XX, 2014, AM J PATHOL, V184, P1017, DOI 10.1016/j.ajpath.2013.12.012
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Gurubaran IS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061976
   Hageman G.S., 1995, ORIANIZATION RETINA
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HOLERS VM, 1992, IMMUNOL TODAY, V13, P231
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Ibbett P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43906-z
   Iejima Daisuke, 2015, J Stem Cells, V10, P193
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kim SY, 2014, INVEST OPHTH VIS SCI, V55, P6031, DOI 10.1167/iovs.14-15091
   Kivinen N, 2016, BIOGERONTOLOGY, V17, P749, DOI 10.1007/s10522-016-9647-7
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koivunen P, 2007, J BIOL CHEM, V282, P30544, DOI 10.1074/jbc.M704988200
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Leinonen H, 2016, HUM MOL GENET, V25, P3810, DOI 10.1093/hmg/ddw228
   Li HL, 2017, EXPERT OPIN INV DRUG, V26, P1103, DOI 10.1080/13543784.2017.1369042
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Liszewski MK, 2005, SPRINGER SEMIN IMMUN, V27, P345, DOI 10.1007/s00281-005-0002-3
   Liszewski MK, 2000, J BIOL CHEM, V275, P37692, DOI 10.1074/jbc.M004650200
   Luhmann UFO, 2013, EXP EYE RES, V107, P80, DOI 10.1016/j.exer.2012.11.015
   Lynn SA, 2017, NEURAL REGEN RES, V12, P538, DOI 10.4103/1673-5374.205083
   Lyzogubov V, 2014, AM J PATHOL, V184, P2537, DOI 10.1016/j.ajpath.2014.06.001
   Lyzogubov VV, 2016, AM J PATHOL, V186, P2088, DOI 10.1016/j.ajpath.2016.03.021
   Lyzogubov VV, 2014, EXP EYE RES, V127, P143, DOI 10.1016/j.exer.2014.07.021
   Lyzogubov VV, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.204701
   Ma Q, 2011, EXPERT OPIN DRUG MET, V7, P1267, DOI 10.1517/17425255.2011.614947
   Ma WX, 2012, ADV EXP MED BIOL, V723, P37, DOI 10.1007/978-1-4614-0631-0_6
   Malek G, 2014, ADV EXP MED BIOL, V801, P317, DOI 10.1007/978-1-4614-3209-8_40
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Marneros AG, 2005, FASEB J, V19, P716, DOI 10.1096/fj.04-2134rev
   Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Moghimi SM, 2006, J LIPOSOME RES, V16, P167, DOI 10.1080/08982100600848801
   Mohamad NA, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0197-3
   Monif M, 2010, INT J BIOCHEM CELL B, V42, P1753, DOI 10.1016/j.biocel.2010.06.021
   Moutray T, 2011, THER ADV CHRONIC DIS, V2, P325, DOI 10.1177/2040622311415895
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006
   Oehme F, 2002, BIOCHEM BIOPH RES CO, V296, P343, DOI 10.1016/S0006-291X(02)00862-8
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Osterberg G.A., 1935, TOPOGRAPHY LAYER ROD, V13, P1
   Park SW, 2017, ONCOTARGET, V8, P40006, DOI 10.18632/oncotarget.16967
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Ratnayaka JA, 2020, NEURAL REGEN RES, V15, P863, DOI 10.4103/1673-5374.268972
   Ratnayaka JA, 2016, UPDATE ON DEMENTIA, P85, DOI 10.5772/64790
   Remington L.A., 2011, CLIN ANATOMY PHYSL V, Vthird, P314
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   Rohrer B, 2019, MOL VIS, V25, P79
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Rowan S, 2014, INVEST OPHTH VIS SCI, V55, P492, DOI 10.1167/iovs.13-12413
   Ryan S.J., 2012, MECH OXIDATIVE STRES, Vfifth
   Saint-Geniez M, 2013, AM J PATHOL, V182, P255, DOI 10.1016/j.ajpath.2012.09.003
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Satish S, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9248640
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Sinha D, 2012, TRANSGENIC RES, V21, P1033, DOI 10.1007/s11248-012-9608-0
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Stuck MW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032484
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Valapala M, 2014, AGING CELL, V13, P1091, DOI 10.1111/acel.12274
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237
   Vessey KA, 2017, AM J PATHOL, V187, P1670, DOI 10.1016/j.ajpath.2017.04.016
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Wiley JS, 2012, PURINERG SIGNAL, V8, P579, DOI 10.1007/s11302-012-9308-5
   Winkler BS, 1999, MOL VIS, V5
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang M, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032698
   Zhao ZY, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15166
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zigler JS, 2015, PROG RETIN EYE RES, V44, P62, DOI 10.1016/j.preteyeres.2014.11.002
   Zigler JS, 2011, J CELL SCI, V124, P523, DOI 10.1242/jcs.078790
NR 143
TC 9
Z9 9
U1 2
U2 9
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD FEB
PY 2021
VL 203
AR 108404
DI 10.1016/j.exer.2020.108404
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QG8HN
UT WOS:000617822500002
PM 33340497
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Klevay, LM
AF Klevay, Leslie M.
TI Calcium can delay age-related macular degeneration via enhanced copper
   metabolism
SO MEDICAL HYPOTHESES
LA English
DT Article
ID DEFICIENCY; ZINC
AB Secondary analyses of data from the Age-Related Eye Disease Study (AREDS) revealed that higher calcium intakes were associated with slower progression to age-related macular degeneration (AMD). Earlier, primary analyses had revealed that a supplement containing copper reduced the odds of developing AMD while lengthening life. Because ocular lesions are being reported increasingly in neuropathy from copper deficiency and because higher dietary calcium can have beneficial effects on copper metabolism, it is hypothesized that the association of calcium intakes with better vision was mediated by improved copper utilization of study participants who were eating too little copper. Nutrition surveys reveal that amounts of copper proved insufficient for men and women in controlled studies are readily available to the general population. Observations on eye anatomy of animals deficient in copper and on decreased retinal superoxide dismutase, an enzyme dependent on copper for activity, in people with AMD support this hypothesis. Eradication of AMD will require new approaches based on hypotheses that fail falsification.
C1 [Klevay, Leslie M.] Univ North Dakota, Sch Med & Hlth Sci, 1301 North Columbia Rd, Grand Forks, ND 58202 USA.
C3 University of North Dakota Grand Forks
RP Klevay, LM (通讯作者)，Univ North Dakota, Sch Med & Hlth Sci, 1301 North Columbia Rd, Grand Forks, ND 58202 USA.
EM leslie.klevay@ndus.edu
CR [Anonymous], 2000, DRUG INFORM HLTH CAR, P986
   [Anonymous], 2006, DIETARY DRI REFERENC, P304
   Baker DH, 1999, J NUTR, V129, P2278, DOI 10.1093/jn/129.12.2278
   Bharathselvi M, 2016, INDIAN J MED RES, V143, P756, DOI 10.4103/0971-5916.192026
   Brelen ME, 2019, JAMA OPHTHALMOL
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   DAKE Y, 1991, EXP EYE RES, V52, P277, DOI 10.1016/0014-4835(91)90091-R
   Golden MHN, OXFORD TXB MED, V1
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelkar Praful, 2008, J Clin Neuromuscul Dis, V10, P1, DOI 10.1097/CND.0b013e3181828cf7
   Klevay L. M., 2014, BMJ-BRIT MED J, V348, pg3691
   Klevay LM, 2017, INDIAN J MED RES, V146, P430, DOI 10.4103/ijmr.IJMR_246_17
   Klevay LM, 2016, J TRACE ELEM MED BIO, V34, P38, DOI 10.1016/j.jtemb.2015.10.005
   Klevay LM, 2011, J TRACE ELEM MED BIO, V25, P204, DOI 10.1016/j.jtemb.2011.08.146
   KLEVAY LM, 1982, BIOL TRACE ELEM RES, V4, P95, DOI 10.1007/BF02783250
   KLEVAY LM, 1993, P SOC EXP BIOL MED, V203, P214, DOI 10.3181/00379727-203-43594
   Klevay LM., 2010, ENCY DIETARY SUPPLEM, V2nd, P175
   Klevay LM, 2005, NUTR DRINKING WATER, P92
   Kumar N, 2006, MAYO CLIN PROC, V81, P1371, DOI 10.4065/81.10.1371
   Mishima K, 1996, EXP EYE RES, V63, P85, DOI 10.1006/exer.1996.0094
   OLIN KL, 1995, P SOC EXP BIOL MED, V208, P370, DOI 10.3181/00379727-208-43864
   Owen Jr C.A., 1981, COPPER DEFICIENCY TO, P6
   Owen Jr CA, 1982, BIOCH ASPECTS COPPER, P75
   Pepys MB, 1996, OXFORD TXB MED, P1527
   Prodan Calin I, 2011, J Clin Neuromuscul Dis, V12, P122, DOI 10.1097/CND.0b013e3181dc34c0
   Rapoport Y, 2016, J NEURO-OPHTHALMOL, V36, P178, DOI 10.1097/WNO.0000000000000333
   Romasz R. S., 1977, Trace substances in environmental health. 11., P289
   Ropper AH, 2009, ADAMS VICTORS PRINCI, P1120
   Shah Ankoor R, 2014, Retin Cases Brief Rep, V8, P73, DOI 10.1097/ICB.0000000000000008
   Tisdale AK, 2019, JAMA OPHTHALMOL
NR 30
TC 0
Z9 0
U1 0
U2 3
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD FEB
PY 2020
VL 135
AR 109467
DI 10.1016/j.mehy.2019.109467
PG 2
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA KK1AN
UT WOS:000512482600005
PM 31805481
DA 2022-11-30
ER

PT J
AU Thomas, CN
   Sim, DA
   Lee, WH
   Alfahad, N
   Dick, AD
   Denniston, AK
   Hill, LJ
AF Thomas, Chloe N.
   Sim, Dawn A.
   Lee, Wen Hwa
   Alfahad, Nada
   Dick, Andrew D.
   Denniston, Alastair K.
   Hill, Lisa J.
TI Emerging therapies and their delivery for treating age-related macular
   degeneration
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Review
DE age&#8208; related macular degeneration; anti&#8208; VEGF; complement;
   drug delivery; immunotherapy; ocular disease; retina
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; GEOGRAPHIC
   ATROPHY SECONDARY; VASCULAR-PERMEABILITY FACTOR; MEMBRANE ATTACK
   COMPLEX; ANKYRIN REPEAT PROTEIN; CHOROIDAL NEOVASCULARIZATION;
   AMYLOID-BETA; GENE-THERAPY; INTRAVITREAL INJECTION
AB Age-related macular degeneration (AMD) is the most common cause of blindness in the Western world and is characterised in its latter stages by retinal cell death and neovascularisation and earlier stages with the loss of parainflammatory homeostasis. Patients with neovascular AMD (nAMD) are treated with frequent intraocular injections of anti-vascular endothelial growth factor (VEGF) therapies, which are not only unpopular with patients but carry risks of sight-threatening complications. A minority of patients are unresponsive with no alternative treatment available, and some patients who respond initially eventually develop a tolerance to treatment. New therapeutics with improved delivery methods and sustainability of clinical effects are required, in particular for non-neovascular AMD (90% of cases and no current approved treatments). There are age-related and disease-related changes that occur which can affect ocular drug delivery. Here, we review the latest emerging therapies for AMD, their delivery routes and implications for translating to clinical practice.
C1 [Thomas, Chloe N.; Alfahad, Nada; Hill, Lisa J.] Univ Birmingham, Inst Clin Sci, Sch Biomed Sci, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England.
   [Sim, Dawn A.] Moorfields Eye Hosp NHS Fdn Trust, London, England.
   [Sim, Dawn A.] UCL Inst Ophthalmol, London, England.
   [Sim, Dawn A.; Dick, Andrew D.; Denniston, Alastair K.] Moorfields Eye Hosp, Natl Inst Hlth Res NIHR Biomed Res Ctr, London, England.
   [Sim, Dawn A.; Dick, Andrew D.; Denniston, Alastair K.] UCL, Inst Ophthalmol, London, England.
   [Lee, Wen Hwa] Act AMD, London, England.
   [Lee, Wen Hwa] Univ Oxford, Oxford Martin Sch, Affordable Med Programme, Oxford, England.
   [Dick, Andrew D.] Univ Bristol, Acad Unit Ophthalmol, Bristol Med Sch, Bristol, Avon, England.
   [Dick, Andrew D.] Univ Bristol, Sch Cellular & Mol Med, Bristol, Avon, England.
   [Denniston, Alastair K.] Univ Birmingham, Coll Med & Dent Sci, Inst Inflammat & Ageing, Acad Unit Ophthalmol, Birmingham, W Midlands, England.
   [Denniston, Alastair K.] Univ Hosp Birmingham NHS Fdn Trust, Dept Ophthalmol, Birmingham, W Midlands, England.
   [Denniston, Alastair K.] Univ Birmingham, Inst Appl Hlth Res, Ctr Patient Reported Outcome Res, Birmingham, W Midlands, England.
   [Denniston, Alastair K.] Univ Birmingham, Birmingham Hlth Partners Ctr Regulatory Sci & Inn, Birmingham, W Midlands, England.
   [Denniston, Alastair K.] Hlth Data Res UK, London, England.
C3 University of Birmingham; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust; University of
   London; University College London; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust; University
   of London; University College London; University of Oxford; University
   of Bristol; University of Bristol; University of Birmingham; University
   of Birmingham; University of Birmingham; University of Birmingham
RP Thomas, CN; Hill, LJ (通讯作者)，Univ Birmingham, Inst Clin Sci, Sch Biomed Sci, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England.
EM c.thomas.4@bham.ac.uk; l.j.hill@bham.ac.uk
RI Hill, Lisa J/AAO-1560-2021; Thomas, Chloe N/AAQ-9647-2021; Lee, Wen
   Hwa/GZA-8183-2022
OI Hill, Lisa J/0000-0001-8431-7029; Thomas, Chloe N/0000-0002-6202-1347;
   Lee, Wen Hwa/0000-0002-4098-5225; Dick, Andrew/0000-0002-0742-3159; Sim,
   Dawn/0000-0002-6363-7805; Denniston, Alastair/0000-0001-7849-0087
FU Fight for Sight UK [5093/5094]
FX Fight for Sight UK, Grant/Award Number: 5093/5094
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Akhtar-Schafer I, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708259
   Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS1, DOI 10.1111/bph.14747
   ALVARADO J, 1981, INVEST OPHTH VIS SCI, V21, P714
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Annamalai B, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.2.3
   [Anonymous], 2019, PANOPTICA ANTI VEGF
   Augustine J, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1625-y
   Bascones-Martinez A, 2014, MED ORAL PATOL ORAL, V19, pE24, DOI 10.4317/medoral.19087
   Berger B, 2013, INVEST OPHTH VIS SCI, V54
   Bhatt P, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1474-0
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Canna SW, 2017, INVEST OPHTH VIS SCI, V58, P1764, DOI 10.1167/iovs.17-21697
   Cao LN, 2013, INT J MOL MED, V31, P1105, DOI 10.3892/ijmm.2013.1310
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Ciulla TA, 2003, RETINA-J RET VIT DIS, V23, P808, DOI 10.1097/00006982-200312000-00011
   Clare AJ, 2020, J CELL MOL MED, V24, P13546, DOI 10.1111/jcmm.16000
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Danis R, 2014, BRIT J OPHTHALMOL, V98, P172, DOI 10.1136/bjophthalmol-2013-303117
   de Cogan F, 2017, INVEST OPHTH VIS SCI, V58, P2578, DOI 10.1167/iovs.16-20072
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Di Zazzo A, 2019, INVEST OPHTH VIS SCI, V60, P1769, DOI 10.1167/iovs.18-25822
   DIESTELHORST M, 1992, INT OPHTHALMOL, V16, P305, DOI 10.1007/BF00917981
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Doyle SL, 2015, INVEST OPHTH VIS SCI, V56, P8237, DOI 10.1167/iovs.15-18714
   Doyle SL, 2015, INVEST OPHTH VIS SCI, V56, P5424, DOI 10.1167/iovs.15-17264
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Dugel PU, 2015, RETINA-J RET VIT DIS, V35, P1173, DOI 10.1097/IAE.0000000000000606
   Dunn EN, 2017, OSLI RETINA, V48, P100, DOI 10.3928/23258160-20170130-02
   Ellis S, 2020, INVEST OPHTH VIS SCI, V61
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Garber K, 2015, NAT BIOTECHNOL, V33, P890, DOI 10.1038/nbt0915-890
   Gipson IK, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12840
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gonzalez-Chomon C, 2011, MATERIALS, V4, P1927, DOI 10.3390/ma4111927
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GraybugVision, 2019, GRAYBUG VISION INITI
   GraybugVision, 2019, GRAYBUG VISION PRESE
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Heier JS, 2020, OPHTHALMOL RETINA, V4, P384, DOI 10.1016/j.oret.2019.11.011
   Heier JS, 2020, OPHTHALMOLOGY, V127, P211, DOI 10.1016/j.ophtha.2019.09.021
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Hermann R, 2019, GAL 101 NOVEL PHASE
   Hirano Y, 2014, NAT MED, V20, P1372, DOI 10.1038/nm.3671
   Ho AC, 2017, AM J OPHTHALMOL, V179, P67, DOI 10.1016/j.ajo.2017.04.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Hwang DK, 2019, THERANOSTICS, V9, P232, DOI 10.7150/thno.28447
   Ijima R, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15367
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jaffe GJ, 2020, INVEST OPHTH VIS SCI, V61
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Joussen AM, 2019, BRIT J CLIN PHARMACO, V85, P347, DOI 10.1111/bcp.13794
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kauper K, 2013, INVEST OPHTH VIS SCI, V54
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Khanani AM, 2020, INVEST OPHTH VIS SCI, V61
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   Khurana RN, 2021, OPHTHALMOLOGY, V128, P1027, DOI 10.1016/j.ophtha.2020.11.017
   Kim J, 2015, BIOCHEM BIOPH RES CO, V456, P53, DOI 10.1016/j.bbrc.2014.11.033
   Kiss S., 2016, KEY LEARNINGS PHASE
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Lai CM, 2009, INVEST OPHTH VIS SCI, V50, P4279, DOI 10.1167/iovs.08-3253
   Lakkaraju A, 2014, ADV EXP MED BIOL, V801, P267, DOI 10.1007/978-1-4614-3209-8_34
   Lamkanfi M, 2009, IMMUNITY, V31, P5, DOI 10.1016/j.immuni.2009.06.011
   Lee KS, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02088-0
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   LEWIS ML, 1993, GRAEF ARCH CLIN EXP, V231, P615, DOI 10.1007/BF00921954
   Liew FY, 2016, NAT REV IMMUNOL, V16, P676, DOI 10.1038/nri.2016.95
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Mains J, 2013, J OCUL PHARMACOL TH, V29, P143, DOI 10.1089/jop.2012.0138
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mandai M, 2017, STEM CELL REP, V8, P1112, DOI 10.1016/j.stemcr.2017.03.024
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Matsuda Y, 2019, MOL THER-NUCL ACIDS, V17, P819, DOI 10.1016/j.omtn.2019.07.018
   Matsumura N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039890
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Nia HT, 2019, CLIN CANCER RES, V25, P2024, DOI 10.1158/1078-0432.CCR-18-3724
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nor MNM, 2020, NEUROTHERAPEUTICS, V17, P371, DOI 10.1007/s13311-019-00786-5
   Novartis, 2015, CLIN TRIAL RES MULT
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Pescina S, 2018, J CONTROL RELEASE, V284, P84, DOI 10.1016/j.jconrel.2018.06.023
   Poor SH, 2018, INVEST OPHTH VIS SCI, V59
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Ramo K, 2008, INVEST OPHTH VIS SCI, V49, P4126, DOI 10.1167/iovs.08-2025
   Regeneron, 2017, REG PROV UPD EYLEA A
   Ren XY, 2016, EXP EYE RES, V145, P352, DOI 10.1016/j.exer.2016.02.004
   Robertson MJ, 2008, CLIN CANCER RES, V14, P3462, DOI 10.1158/1078-0432.CCR-07-4740
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1488, DOI 10.1016/j.ophtha.2018.06.002
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ross C, 2002, J INTERF CYTOK RES, V22, P421, DOI 10.1089/10799900252952208
   Sandhu HS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203492
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0422-5
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Shaw LT, 2020, EXPERT OPIN INV DRUG, V29, P547, DOI 10.1080/13543784.2020.1763953
   Shen JK, 2014, J CELL PHYSIOL, V229, P974, DOI 10.1002/jcp.24575
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   Theodoropoulou S, 2017, J PATHOL, V241, P45, DOI 10.1002/path.4816
   Therapeutics LC, 2020, PIPELINE
   Tsujinaka H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14340-x
   Unity Biotechnology I, 2019, UNITY BIOT ANN COMPL
   von der Emde L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47565-y
   Willcox MDP, 1997, INVEST OPHTH VIS SCI, V38, P1
   Wolf A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16400-8
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Xi HK, 2016, J EXP MED, V213, P189, DOI 10.1084/jem.20150894
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Yafai Y, 2011, EUR J PHARMACOL, V666, P12, DOI 10.1016/j.ejphar.2011.05.016
   Yang M, 2016, INVEST OPHTH VIS SCI, V57
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
NR 148
TC 10
Z9 10
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD MAY
PY 2022
VL 179
IS 9
BP 1908
EP 1937
DI 10.1111/bph.15459
EA MAY 2021
PG 30
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 0F8WF
UT WOS:000649439700001
PM 33769566
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Kozlowski, MR
AF Kozlowski, Michael R.
TI RPE cell senescence: A key contributor to age-related macular
   degeneration
SO MEDICAL HYPOTHESES
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; LEUKOCYTE TELOMERE LENGTH; ENDOTHELIAL
   GROWTH-FACTOR; FACTOR-H POLYMORPHISM; CIGARETTE-SMOKING; VITAMIN-D;
   GEOGRAPHIC ATROPHY; RISK; PROLIFERATION; ASSOCIATION
AB Age-related macular degeneration (AMD) is the leading cause of blindness in industrialized countries. Although much progress has been made recently in the management of later stages of the disease, no agents have yet been developed for the early stages or for prophylactic use. Furthermore, even the treatments for the later stages have limited effectiveness. The process of developing improved treatments for AMD is complicated by the existence of several theories concerning the cause of the disorder, each suggesting a different strategy for finding effective therapeutics. One of the potential contributors to AMD pathology is retinal pigment epithelial (RPE) cell senescence. The present paper hypothesizes that RPE senescence plays a central role in the etiology of AMD. This hypothesis is supported by the ability of RPE cell senescence to account for the signs, risk factors, and successful treatment modalities of the disorder. This hypothesis also points to several new prophylactic and treatment strategies for AMD. (C) 2012 Elsevier Ltd. All rights reserved.
C1 Midwestern Univ, Arizona Coll Optometry, Glendale, AZ 85308 USA.
C3 Midwestern University; Midwestern University - Arizona College of
   Optometry
RP Kozlowski, MR (通讯作者)，Midwestern Univ, Arizona Coll Optometry, 19555 N 59th Ave, Glendale, AZ 85308 USA.
EM mkozlo@midwestern.edu
OI Kozlowski, Michael/0000-0003-1213-7015
CR Alexander U, 2002, PRIMARY CARE POSTERI, P94
   [Anonymous], 2007, GLOBAL INITIATIVE EL, P32
   Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268
   Bandyopadhyay D, 2006, PIGMENTARY SYSTEM, P464
   Bayne S, 2008, CELL RES, V18, P1141, DOI 10.1038/cr.2008.291
   Binder S, 2006, AGE RELATED MACULAR, P314
   BURKE JM, 1988, INVEST OPHTH VIS SCI, V29, P1784
   Burton DGA, 2009, AGE, V31, P1, DOI 10.1007/s11357-008-9075-y
   Cassidy A, 2010, AM J CLIN NUTR, V91, P1273, DOI 10.3945/ajcn.2009.28947
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Coppe JP, 2006, J BIOL CHEM, V281, P29568, DOI 10.1074/jbc.M603307200
   Cuervo AM, 2000, EXP GERONTOL, V35, P119, DOI 10.1016/S0531-5565(00)00075-9
   Daniel C, 2009, AM J PHYSIOL-RENAL, V297, pF1299, DOI 10.1152/ajprenal.00254.2009
   Darrat Ilaaf, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P358, DOI 10.1097/MOO.0b013e3282efa641
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Eaton EM, 2010, RETINA TODAY, V10, P57
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farzaneh-Far R, 2010, JAMA-J AM MED ASSOC, V303, P250, DOI 10.1001/jama.2009.2008
   Fauce SR, 2008, J IMMUNOL, V181, P7400, DOI 10.4049/jimmunol.181.10.7400
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Franco Sonia, 2006, Alzheimers Dement, V2, P164, DOI 10.1016/j.jalz.2006.03.001
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Fuster JJ, 2007, J HYPERTENS, V25, P2185, DOI 10.1097/HJH.0b013e3282ef6196
   Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harley CB, 2011, REJUV RES, V14, P45, DOI 10.1089/rej.2010.1085
   HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0
   Hwang ES, 2009, CELL MOL LIFE SCI, V66, P2503, DOI 10.1007/s00018-009-0034-2
   Iyer M, 2006, AGE RELATED MACULAR, P72
   Jaronczyk K, 2005, BIOCHEM J, V387, P561, DOI 10.1042/BJ20041822
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kanski JJ, 2007, CLIN OPHTHALMOLOGY S, P23
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim SM, 2009, CANCER EPIDEM BIOMAR, V18, P816, DOI 10.1158/1055-9965.EPI-08-0935
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P360, DOI 10.1001/archopht.116.3.360
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Ksiazek K, 2007, SENS 3 C
   Kurz DJ, 2000, J CELL SCI, V113, P3613
   Lange-Asschenfeldt B, 2002, BLOOD, V99, P538, DOI 10.1182/blood.V99.2.538
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lukens JN, 2009, ALZHEIMERS DEMENT, V5, P463, DOI 10.1016/j.jalz.2009.05.666
   Lung FW, 2008, J HUM HYPERTENS, V22, P230, DOI 10.1038/sj.jhh.1002314
   Mammone T, 2006, CELL BIOL INT, V30, P903, DOI 10.1016/j.cellbi.2006.06.010
   Marasa BS, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000442
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsunaga H, 1999, INVEST OPHTH VIS SCI, V40, P197
   McGrath M, 2007, CANCER EPIDEM BIOMAR, V16, P815, DOI 10.1158/1055-9965.EPI-06-0961
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Minamino T, 2007, CIRC RES, V100, P15, DOI 10.1161/01.RES.0000256837.40544.4a
   Mirabello L, 2009, AGING CELL, V8, P405, DOI 10.1111/j.1474-9726.2009.00485.x
   Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590
   Morla M, 2006, EUR RESPIR J, V27, P525, DOI 10.1183/09031936.06.00087005
   Mudhasani R, 2008, J CELL BIOL, V181, P1055, DOI 10.1083/jcb.200802105
   Nemoto K, 2000, BIOCHEM PHARMACOL, V59, P401, DOI 10.1016/S0006-2952(99)00334-2
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Niu S, 1992, Cell Transplant, V1, P355
   Nordfjall K, 2005, P NATL ACAD SCI USA, V102, P16374, DOI 10.1073/pnas.0501724102
   Organesian A, 1997, INT OPHTHALMOL, V21, P165
   Panossian LA, 2003, NEUROBIOL AGING, V24, P77, DOI 10.1016/S0197-4580(02)00043-X
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Pavanello S, 2011, INT J CANCER, V129, P983, DOI 10.1002/ijc.25999
   Pinkhasov RM, 2010, INT J CLIN PRACT, V64, P465, DOI 10.1111/j.1742-1241.2009.02289.x
   Rastmanesh R, 2011, MED HYPOTHESES, V76, P79, DOI 10.1016/j.mehy.2010.08.036
   Ren JL, 2009, CELL SIGNAL, V21, P378, DOI 10.1016/j.cellsig.2008.10.011
   Richards JB, 2007, AM J CLIN NUTR, V86, P1420, DOI 10.1093/ajcn/86.5.1420
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   ROIDER J, 1992, ARCH OPHTHALMOL-CHIC, V110, P1786, DOI 10.1001/archopht.1992.01080240126045
   Salpea KD, 2010, ATHEROSCLEROSIS, V209, P35, DOI 10.1016/j.atherosclerosis.2009.12.021
   Samani NJ, 2001, LANCET, V358, P472, DOI 10.1016/S0140-6736(01)05633-1
   Sanin E, 2010, NATURE, V464, P520
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5
   Slakter J, 2010, AM AC OPHTH M CHIC I
   Spaide R, 2006, AGE RELATED MACULAR, P23
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Thompson W, 2006, AGE RELATED MACULAR, P44
   Valdes AM, 2007, OSTEOPOROSIS INT, V18, P1203, DOI 10.1007/s00198-007-0357-5
   Valdes AM, 2005, LANCET, V366, P662, DOI 10.1016/S0140-6736(05)66630-5
   Vergara C, 2004, BRAIN RES REV, V47, P161, DOI 10.1016/j.brainresrev.2004.07.010
   VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471
   Werner C, 2009, CIRCULATION, V120, P2438, DOI 10.1161/CIRCULATIONAHA.109.861005
   Yamagiwa Y, 2006, LIFE SCI, V78, P2494, DOI 10.1016/j.lfs.2005.10.015
   Zarbin MA, 2008, AM J OPHTHALMOL, V146, P151, DOI 10.1016/j.ajo.2008.05.027
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhu HD, 2011, CLIN SCI, V120, P427, DOI 10.1042/CS20100385
   Zhu HD, 2011, J PEDIATR-US, V158, P215, DOI 10.1016/j.jpeds.2010.08.007
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 93
TC 68
Z9 70
U1 0
U2 12
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD APR
PY 2012
VL 78
IS 4
BP 505
EP 510
DI 10.1016/j.mehy.2012.01.018
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 920ZT
UT WOS:000302448500025
PM 22296808
DA 2022-11-30
ER

PT J
AU Atmaca, L
   Idil, A
   Atmaca-Sonmez, P
AF Atmaca, Leyla
   Idil, Aysun
   Atmaca-Sonmez, Pelin
TI Laser treatment in 341 patients with exudative age-related macular
   degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE red krypton laser; green argon laser; dye laser; exudative age-related
   macular degeneration; indocyanine green angiography
ID CHOROIDAL NEOVASCULARIZATION; VIDEOANGIOGRAPHY
AB AIM: To document the prognosis of laser treatment in patients with exudative age-related macular degeneration (AMD).
   METHODS: Efficacy of the intervention was evaluated using a before-after method.
   RESULTS: A total of 392 eyes of 341 patients with exudative AMD were examined. 77.6% had choroideal neovascularisation (CNV). Before the use of indocyanine green (ICG) angiography, occult CNV was detected in only 1.8% of the eyes, but after the use of ICG angiography, this increased to 19.5% (P<0.001). Of the 349 eyes which were followed up, visual acuity had remained stable in 68.2% of the eyes. There was a statistically significant relationship between localisation of lesion and visual acuity changes on pre- and post-laser treatment (P<0.001). Also there was a statistically significant relationship between localisation of lesion and recurrence (P<0.05). The recurrence was less in subfoveal lesions than that in juxtafoveal and extrafoveal lesions.
   CONCLUSION: ICG angiography is highly important in the treatment of occult CNV.
C1 [Atmaca, Leyla] Dept Ophthalmol, Ankara, Turkey.
   [Idil, Aysun] Ankara Univ, Fac Med, Low Vis Rehabil & Res Ctr, Dept Publ Hlth, TR-06100 Ankara, Turkey.
   [Atmaca-Sonmez, Pelin] Nurlu Eye Ctr, Dept Ophthalmol, Ankara, Turkey.
C3 Ankara University
RP Atmaca, L (通讯作者)，Gazi Mustafa Kemal Bulvari 23-1, TR-06440 Ankara, Turkey.
EM leylaatmaca@ttmail.com
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Atmaca LS, 1997, ACTA OPHTHALMOL SCAN, V75, P44
   Atmaca LS, 1996, OPHTHALMOLOGICA, V210, P148, DOI 10.1159/000310695
   ATMACA LS, 1993, OPHTHALMOLOGICA, V207, P46, DOI 10.1159/000310405
   Augustin AJ, 2009, CLIN OPHTHALMOL, V3, P175
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   *MAC PHOT STUD GRO, 1199, ARCH OPHTHALMOL-CHIC, V108, P825
   YANUZZI LA, 1992, RETINA, V12, P191
   YUZAWA M, 1995, OPHTHALMOLOGY, V102, P622, DOI 10.1016/S0161-6420(95)30990-6
NR 13
TC 1
Z9 1
U1 0
U2 1
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD FEB 18
PY 2011
VL 4
IS 1
BP 73
EP 77
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 724IA
UT WOS:000287568100017
PM 22553614
DA 2022-11-30
ER

PT J
AU Tsujikawa, A
   Ojima, Y
   Yamashiro, K
   Ooto, S
   Tamura, H
   Nakata, I
   Yoshimura, N
AF Tsujikawa, A.
   Ojima, Y.
   Yamashiro, K.
   Ooto, S.
   Tamura, H.
   Nakata, I.
   Yoshimura, N.
TI Development of polypoidal lesions in age-related macular degeneration
SO EYE
LA English
DT Article
DE age-related macular degeneration; indocyanine green angiography;
   polypoidal choroidal vasculopathy
ID INDOCYANINE GREEN VIDEOANGIOGRAPHY; CHOROIDAL VASCULOPATHY; INTRAVITREAL
   BEVACIZUMAB; CLINICAL CHARACTERISTICS; PHOTODYNAMIC THERAPY; GENE
   POLYMORPHISMS; JAPANESE PATIENTS; RANIBIZUMAB; ANGIOGRAPHY; FEATURES
AB Purpose To investigate the development of polypoidal lesions using indocyanine green angiography (IA) in eyes with typical age-related macular degeneration (AMD).
   Methods We retrospectively reviewed the medical records of 47 consecutive patients (47 eyes) with typical AMD who had been followed up with IA for at least 2 years.
   Results At the initial visit, although all eyes showed classic and/or occult choroidal neovascularization (CNV) associated with AMD, no eyes showed polypoidal lesions by IA. However, during follow-up, 13 (27.7%) of the 47 eyes did show polypoidal lesions. All polypoidal lesions developed at the edge of persistent CNV or, more often, at the terminus of recently progressed CNV. Of 12 eyes with a final lesion area 48 disc area, 7 (58.3%) showed newly developed polypoidal lesions. In the eyes with these newly developed polypoidal lesions, the mean area of the vascular lesion had extended significantly from 10.50 +/- 7.88 mm(2) to 20.87 +/- 10.21 mm(2) during follow-up (P = 0.0018).
   Conclusion The current observation suggests that IA of active AMD sometimes reveals polypoidal lesions if there is progression of the CNV in the subretinal pigment epithelium space. Eye (2011) 25, 481-488; doi:10.1038/eye.2010.232; published online 21 January 2011
C1 [Tsujikawa, A.] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Yamashiro,
   Kenji/0000-0001-9354-8558; Tsujikawa, Akitaka/0000-0003-0779-7799
FU Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
   [21592256]; Japan National Society for the Prevention of Blindness,
   Tokyo, Japan
FX This study was supported in part by the Japan Society for the Promotion
   of Science (JSPS), Tokyo, Japan (Grant-in-Aid for Scientific Research,
   no. 21592256), and the Japan National Society for the Prevention of
   Blindness, Tokyo, Japan.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gass JDM, 2004, AM SOC RETINA SPECIA, V3, P2004
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   GUYER DR, 1992, OPHTHALMOLOGY, V99, P287
   Imaizumi Hiroko, 1999, Nippon Ganka Gakkai Zasshi, V103, P527
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Okubo A, 2008, GRAEF ARCH CLIN EXP, V246, P491, DOI 10.1007/s00417-007-0680-8
   Okubo A, 2010, ACTA OPHTHALMOL, V88, pe107, DOI 10.1111/j.1755-3768.2009.01850.x
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoneya S, 1998, INVEST OPHTH VIS SCI, V39, P1286
   Yuzawa M, 1992, Eur J Ophthalmol, V2, P115
NR 42
TC 11
Z9 12
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD APR
PY 2011
VL 25
IS 4
BP 481
EP 488
DI 10.1038/eye.2010.232
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 750NI
UT WOS:000289554500013
PM 21252945
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Peng, Q
   Dong, Y
   Zhao, PQ
AF Peng, Q.
   Dong, Y.
   Zhao, P. Q.
TI Fundus autofluorescence in exudative age-related macular degeneration
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article
DE Exudative; Age-related macular degeneration; Autofluorescence
ID RETINAL-PIGMENT EPITHELIUM; OCCULT CHOROIDAL NEOVASCULARIZATION;
   GEOGRAPHIC ATROPHY; NATURAL COURSE; PATTERNS; CLASSIFICATION; IMPACT;
   ZONE
AB The aim of this study was to investigate the characteristics of fundus autofluorescence (FAF) in patients with wet (exudative) age-related macular degeneration (AMD). Color fundus photographs, fundus fluorescein angiograms, indocyanine green angiograms, and FAF images were obtained from 61 patients (72 eyes) with exudative AMD. The FAF results for different patterns of exudative AMD were compared to those revealed by other fundus images. Of the 72 eyes evaluated, which were classified into three patterns based on the results of fundus fluorescein angiography, 68 had abnormal FAF. Forty-six eyes (63.9%) had classic wet AMD with abnormal FAF. Among these, 10 exhibited a slightly decreased FAF with near-normal or background FAF signal at the center of the lesion area; 36 demonstrated not only decreased FAF at the center of the lesion but also an increased FAF signal toward the lesion edge. Sixteen eyes (22.2%) had occult wet AMD, of which 12 exhibited heterogeneous fluorescence at the lesion site; 4 yielded normal FAF images. Ten eyes (13.9%) had a mixed pattern of wet AMD with abnormal FAF. FAF imaging suggested that the areas of blood and exudates decreased; however, fluorescence angiography revealed that lesions with hyperfluorescence had background or slightly increased FAF. These results showed that various patterns of wet AMD exhibit different autofluorescence characteristics. These represent the functional and metabolic features of retinal pigment epithelial cells. Therefore, FAF can be used to monitor disease development and evaluate the severity and prognosis of AMD.
C1 [Peng, Q.; Dong, Y.; Zhao, P. Q.] Shanghai JiaoTong Univ Sch Med, Xinhua Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Zhao, PQ (通讯作者)，Shanghai JiaoTong Univ Sch Med, Xinhua Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
EM zhaopeiquan2@126.com
FU Shanghai Science and Technology Commission of Shanghai Municipality
   [11JC1410602]; Shanghai Municipal Education Commission [S30205]
FX Research supported by the Shanghai Science and Technology Commission of
   Shanghai Municipality (grant #11JC1410602) and the Shanghai Municipal
   Education Commission (grant #S30205).
CR Barry C, 2007, J OPHTHALMIC PHOTOGR, V29, P54
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Bui TV, 2006, J BIOL CHEM, V281, P18112, DOI 10.1074/jbc.M601380200
   Dandekar SS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1507, DOI 10.1001/archopht.123.11.1507
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hughes EH, 2005, AM J OPHTHALMOL, V139, P344, DOI 10.1016/j.ajo.2004.07.058
   Karadimas P, 2005, AM J OPHTHALMOL, V140, P1163, DOI 10.1016/j.ajo.2005.07.037
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Yah Y, 2008, INT J OPHTHALMOL, V8, P985
   Zhao Pei-Quan, 2008, Zhonghua Yan Ke Za Zhi, V44, P772
   马敏旺, 2006, [中华眼底病杂志, Chinese Journal of Ocular Fundus Diseases], V22, P357
NR 23
TC 6
Z9 6
U1 0
U2 3
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000,
   BRAZIL
SN 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2013
VL 12
IS 4
BP 6140
EP 6148
DI 10.4238/2013.December.2.11
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AB2FG
UT WOS:000331608000202
PM 24338407
OA Bronze
DA 2022-11-30
ER

PT J
AU Yanagi, Y
   Ueta, T
   Obata, R
   Iriyama, A
   Fukuda, T
   Hashimoto, H
AF Yanagi, Yasuo
   Ueta, Takashi
   Obata, Ryo
   Iriyama, Aya
   Fukuda, Takashi
   Hashimoto, Hideki
TI Utility values in Japanese patients with exudative age-related macular
   degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; quality of life; utility value
ID PHOTODYNAMIC THERAPY; COST-EFFECTIVENESS; FELLOW EYES
AB To investigate the utility values associated with visual loss due to age-related macular degeneration (AMD) in Japanese patients.
   Utility values in 48 Japanese patients with bilateral exudative AMD were measured using the time trade-off and standard gamble methods.
   The time trade-off method utility values correlated with the best-corrected visual acuity (BCVA) in the better-seeing eye. The estimated utility values according to the BCVA in the better-seeing eye were 0.534 (BCVA, 0.01-0.15), 0.574 (0.2-0.3), 0.613 (0.4-0.6), and 0.653 (0.7-1.0). The utility values obtained by the standard gamble method were not significantly correlated with BCVA in the betterseeing eye.
   The present results concur with those of previous studies showing that AMD causes a substantial decrease in patient utility values. The utility values obtained in the current study provide important information for use in cost-utility analysis of interventions for Japanese AMD patients.
C1 [Yanagi, Yasuo] Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan.
   [Fukuda, Takashi; Hashimoto, Hideki] Univ Tokyo, Sch Publ Hlth, Dept Hlth Econ & Epidemiol Res, Tokyo, Japan.
C3 University of Tokyo; University of Tokyo
RP Yanagi, Y (通讯作者)，Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM yanagi-tky@umin.ac.jp
RI Yanagi, Yasuo/AAF-2670-2020; Yanagi, Yasuo/AAA-5441-2022
OI Obata, Ryo/0000-0002-1762-0797; Yanagi, Yasuo/0000-0002-0362-7285
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
FX This study was supported in part by a Grant-in-Aid from the Ministry of
   Education, Culture, Sports, Science and Technology of Japan.
CR Bansback N, 2007, EYE, V21, P1455, DOI 10.1038/sj.eye.6702636
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown Gary C, 2007, Trans Am Ophthalmol Soc, V105, P160
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Carlton J, 2008, HEALTH TECHNOL ASSES, V12, P1
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Karnon J, 2008, Health Technol Assess, V12, piii
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kymes SM, 2007, OPTOMETRY VISION SCI, V84, P809, DOI 10.1097/OPX.0b013e3181337638
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MEADS C, 2003, HEALTH TECHNOL ASSES, V9, P1
   MEADS C, 2003, HEALTH TECHNOL ASSES, V9, pR5
   Saito K, 2009, JPN J OPHTHALMOL, V53, P512, DOI 10.1007/s10384-009-0703-6
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Suzukamo Yoshimi, 2005, Health Qual Life Outcomes, V3, P65, DOI 10.1186/1477-7525-3-65
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
NR 19
TC 10
Z9 12
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN
PY 2011
VL 55
IS 1
BP 35
EP 38
DI 10.1007/s10384-010-0893-y
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 723WQ
UT WOS:000287538400007
PM 21331690
DA 2022-11-30
ER

PT J
AU Hopley, C
   Carter, R
   Mitchell, P
AF Hopley, C
   Carter, R
   Mitchell, P
TI Measurement of the economic impact of visual impairment from age-related
   macular degeneration in Australia
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; cost-of-illness; economic impact
ID BLUE-MOUNTAINS EYE; COST-OF-ILLNESS; RISK-FACTORS; 5-YEAR INCIDENCE;
   DECISION-MAKING; HEART-FAILURE; MACULOPATHY; PREVALENCE; SMOKING;
   BLINDNESS
AB The purpose of this report was to: (i) outline the potential value of health economic studies into age-related macular degeneration (AMD); (ii) provide an overview of health economic studies pertinent to AMD; and (iii) outline the basic frame work of cost-of-illness studies (a useful first step in applying economic methods). The detection and management of sensory loss in the elderly plays a key role in the Australian Government's Healthy Ageing Strategy. Age-related macular degeneration is currently the leading cause of blindness in elderly Australians. Although a large proportion of AMD cases remain untreatable, the introduction of photo-dynamic therapy provides a relatively expensive and possibly cost-effective innovation for others. Antioxidant therapy has also been proven effective in reducing progression of early to late disease. The discipline of economics can contribute to an understanding of AMD prevention and treatment through: (i) describing the current burden of disease; (ii) predicting the changes in the burden of disease over time, and (iii) evaluating the efficiency of different interventions. Cost-of-illness studies have been performed in many fields of medicine. Little work, however, has been done on describing the economic impact from AMD. A number of different economic evaluation methods can be used in judging the efficiency of possible interventions to reduce the disease burden of AMD. Although complementary in nature, each has specific uses and limitations. Studies of the economic impact of eye diseases are both feasible and necessary for informed health care decision-making.
C1 Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Westmead Hosp, Westmead, NSW 2145, Australia.
   Univ Melbourne, Dept Publ Hlth, Melbourne, Vic, Australia.
C3 University of Sydney; University of Melbourne
RP Mitchell, P (通讯作者)，Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Westmead Hosp, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paul_mitchell@wmi.usyd.edu.au
OI Carter, Rob/0000-0002-1586-5619
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Birnbaum HG, 2002, J ALLERGY CLIN IMMUN, V109, P264, DOI 10.1067/mai.2002.121310
   BISHOP B, 1999, NATL STRATEGY AGEING, P17
   Bloom BS, 2001, PHARMACOECONOMICS, V19, P207, DOI 10.2165/00019053-200119020-00007
   CARTER R, 1994, AUST ECON REV, V106, P105
   *CTR HLTH EC RES E, 1991, 4 CHERE
   Dewey HM, 2001, STROKE, V32, P2409, DOI 10.1161/hs1001.097222
   Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275
   Drummond MF., 2015, METHODS EC EVALUATIO, V4
   Eisenstein EL, 2001, MED CARE, V39, P824, DOI 10.1097/00005650-200108000-00008
   Foran S, 2000, CLIN EXP OPHTHALMOL, V28, P143, DOI 10.1046/j.1442-9071.2000.00292.x
   Gergen PJ, 2001, J ALLERGY CLIN IMMUN, V107, pS445, DOI 10.1067/mai.2001.114992
   HALL J, 1991, 2 CHERE
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Koopmanschap MA, 1998, PHARMACOECONOMICS, V14, P143, DOI 10.2165/00019053-199814020-00001
   LUCE BR, 1996, COST EFFECTIVENESS H, P176
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Mitchell P, 1999, MED J AUSTRALIA, V171, P173, DOI 10.5694/j.1326-5377.1999.tb123591.x
   Mitchell P, 2000, OPHTHALMOLOGY, V107, P1027, DOI 10.1016/S0161-6420(00)00068-3
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Murray C.J, 1994, GLOBAL COMP ASSESSME
   O'Brien J A, 2001, Value Health, V4, P258, DOI 10.1046/j.1524-4733.2001.43017.x
   O'Neill C, 2001, DRUG AGING, V18, P233, DOI 10.2165/00002512-200118040-00001
   Payne KA, 2002, PHARMACOECONOMICS, V20, P813, DOI 10.2165/00019053-200220120-00002
   Rice D P, 2000, Inj Prev, V6, P177, DOI 10.1136/ip.6.3.177
   RICE DP, 1994, LANCET, V344, P1519, DOI 10.1016/S0140-6736(94)90342-5
   Ryden-Bergsten T, 1999, J INTERN MED, V246, P275, DOI 10.1046/j.1365-2796.1999.00520.x
   SHIELL A, 1987, HEALTH POLICY, V8, P317, DOI 10.1016/0168-8510(87)90007-8
   Smith A F, 2001, Ophthalmic Epidemiol, V8, P13, DOI 10.1076/opep.8.1.13.1542
   Smith AF, 2000, BRIT J OPHTHALMOL, V84, P794, DOI 10.1136/bjo.84.7.794
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stewart S, 2002, EUR J HEART FAIL, V4, P361, DOI 10.1016/S1388-9842(01)00198-2
   *TRATM AG REL MAC, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   van-Molken MPMHR, 2001, PHARMACOECONOMICS, V19, P1
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Varmus H., 2000, DIS SPECIFIC ESTIMAT
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Ward MM, 2002, J CLIN EPIDEMIOL, V55, P260, DOI 10.1016/S0895-4356(01)00468-1
   Wright SE, 2000, CLIN EXP OPHTHALMOL, V28, P140, DOI 10.1046/j.1442-9071.2000.00296.x
NR 42
TC 11
Z9 11
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD DEC
PY 2003
VL 31
IS 6
BP 522
EP 529
DI 10.1046/j.1442-9071.2003.00715.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 745FM
UT WOS:000186678700013
PM 14641161
DA 2022-11-30
ER

PT J
AU Kuhli-Hattenbach, C
   Fischer, IB
   Schalnus, R
   Hattenbach, LO
AF Kuhli-Hattenbach, Claudia
   Fischer, Ina Barbara
   Schalnus, Rainer
   Hattenbach, Lars-Olof
TI Subretinal Hemorrhages Associated with Age-Related Macular Degeneration
   in Patients Receiving Anticoagulation or Antiplatelet Therapy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SPONTANEOUS SUPRACHOROIDAL HEMORRHAGE; MASSIVE INTRAOCULAR HEMORRHAGE;
   TISSUE-PLASMINOGEN-ACTIVATOR; SUB-RETINAL HEMORRHAGE; COMPLICATIONS;
   GLAUCOMA; ASPIRIN; RISK
AB PURPOSE: To evaluate the incidence of and risk factors for subretinal hemorrhages in age-related macular degeneration (AMD) patients on anticoagulation or antiplatelet therapy.
   DESIGN: Retrospective, observational case series.
   METHODS: We retrospectively reviewed the medical and photographic records of 71 consecutive patients who sought treatment at our institution with acute subretinal hemorrhages complicating age-related macular degeneration. The size of the subretinal hemorrhage was measured in standardized Macular Photocoagulation Study disc areas. Data on the use of medications and medical indications for anticoagulation and antiplatelet therapy were obtained.
   RESULTS: Overall, patients receiving antithrombotic therapy had a significantly larger subretinal hemorrhage size (mean, 9.71 disc areas) than patients not receiving anticoagulant or antiplatelet therapy (mean, 2.99 disc areas). Subgroup analysis revealed that both antiplatelet (P < .0001) and anticoagulant therapy (P = .003) were associated with a significantly larger bleeding size. Moreover, subgroup analysis among patients with arterial hypertension revealed that individuals receiving anti, thrombotic therapy had a statistically significantly larger hemorrhage size than hypertensive patients who did not receive anticoagulants or antiplatelet agents (P < .0001).
   CONCLUSIONS: Our results indicate that anticoagulants and antiplatelet agents are strongly associated with the development of large subretinal hemorrhages in AMD patients. Moreover, arterial hypertension is a strong risk factor for large subretinal hemorrhages in AMD patients receiving anticoagulants or antiplatelet agents. Physicians should be aware of an increased risk of extensive subretinal hemorrhage in AMD patients when deciding on the initiation and duration of anticoagulant and antiplatelet therapy. (Am J Ophthalmol 2010;149: 316-321. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Kuhli-Hattenbach, Claudia; Fischer, Ina Barbara; Schalnus, Rainer; Hattenbach, Lars-Olof] Klinikum Johann Wolfgang Goethe Univ Frankfurt, Klin Augenheilkunde, Frankfurt, Germany.
   [Hattenbach, Lars-Olof] Augenklin Klinikums Ludwigshafen, Ludwigshafen, Germany.
C3 Goethe University Frankfurt; Goethe University Frankfurt Hospital;
   Ludwigshafen Hospital
RP Kuhli-Hattenbach, C (通讯作者)，Johann Wolfgang Goethe Univ Hosp, Dept Ophthalmol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
EM kuhli@med.uni-frankfurt.de
RI Hattenbach, Lars-Olof/AAC-5621-2020
OI Hattenbach, Lars-Olof/0000-0002-5275-8118
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Barequet IS, 2007, AM J OPHTHALMOL, V144, P719, DOI 10.1016/j.ajo.2007.07.029
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   BLOOME MA, 1978, AM J OPHTHALMOL, V86, P630, DOI 10.1016/0002-9394(78)90181-2
   BROWN GC, 1982, CAN J OPHTHALMOL, V17, P227
   Caronia RM, 1998, AM J OPHTHALMOL, V126, P307, DOI 10.1016/S0002-9394(98)00101-9
   Cavallini A, 2008, NEUROL SCI, V29, pS266, DOI 10.1007/s10072-008-0959-5
   Chang WJ, 1996, AM J OPHTHALMOL, V122, P907, DOI 10.1016/S0002-9394(14)70399-X
   Dayani PN, 2007, AM J OPHTHALMOL, V144, P451, DOI 10.1016/j.ajo.2007.05.006
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Faxon David P, 2005, Rev Cardiovasc Med, V6 Suppl 4, pS3
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Greenfield DS, 1999, AM J OPHTHALMOL, V128, P98, DOI 10.1016/S0002-9394(99)00024-0
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Jneid Hani, 2003, Expert Opin Emerg Drugs, V8, P349, DOI 10.1517/eoed.8.2.349.21131
   JOHNSON MW, 1991, RETINA-J RET VIT DIS, V11, P250, DOI 10.1097/00006982-199111020-00011
   KAGELER WV, 1976, AM J OPHTHALMOL, V82, P631, DOI 10.1016/0002-9394(76)90553-5
   Knox FA, 2002, EYE, V16, P669, DOI 10.1038/sj.eye.6700109
   LANDEFELD CS, 1989, AM J MED, V87, P144
   Law SK, 2008, AM J OPHTHALMOL, V145, P736, DOI 10.1016/j.ajo.2007.12.007
   Levine MN, 2001, CHEST, V119, p108S, DOI 10.1378/chest.119.1_suppl.108S
   LEWIS H, 1988, GRAEF ARCH CLIN EXP, V226, P59, DOI 10.1007/BF02172720
   Schulman S, 2003, NEW ENGL J MED, V349, P675, DOI 10.1056/NEJMcp025373
   Serebruany VL, 2005, AM J CARDIOL, V95, P1218, DOI 10.1016/j.amjcard.2005.01.049
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Weir CR, 2000, ACTA OPHTHALMOL SCAN, V78, P492, DOI 10.1034/j.1600-0420.2000.078004492.x
   Wong JS, 1999, AUST NZ J OPHTHALMOL, V27, P433
   Yang SS, 2003, RETINA-J RET VIT DIS, V23, P139, DOI 10.1097/00006982-200304000-00001
NR 31
TC 32
Z9 33
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2010
VL 149
IS 2
BP 316
EP 321
DI 10.1016/j.ajo.2009.08.033
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 551OU
UT WOS:000274219700021
PM 19939348
DA 2022-11-30
ER

PT J
AU Ishikawa, K
   Terasaki, H
   Kobayashi, C
   Niwa, Y
   Piao, CH
   Ito, Y
   Kondo, M
   Miyake, Y
AF Ishikawa, K
   Terasaki, H
   Kobayashi, C
   Niwa, Y
   Piao, CH
   Ito, Y
   Kondo, M
   Miyake, Y
TI Changes in foveal thickness and macular function after transpupillary
   thermotherapy for age-related macular degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE transpupillary thermotherapy; age-related macular degeneration;
   choroidal neovascularization; optical coherence tomography; focal
   macular electroretinograms
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; EPIRETINAL
   MEMBRANE; ELECTRORETINOGRAMS; REMOVAL; PHOTOCOAGULATION; VERTEPORFIN;
   LESIONS; EYES
AB Purpose: To evaluate the effect of transpupillary thermotherapy (TTT) on foveal thickness and macular function in eyes with choroidal neovascularization (CNV) associated with age-related macular degeneration. Methods: Sixteen eyes with occult CNV and 6 eyes with classic CNV were treated with TTT. Optical coherence tomography and focal macular electroretinograms (FMERGs) elicited by a 15-degree stimulus were performed before, 3 months after TTT in 22 eyes and 6 months after TTT in 18 eyes. Results: Before TTT, the fovea in 20 of the 22 eyes with CNV was significantly thicker than that of normal subjects. The foveal thickness was reduced after TTT in 11 of 14 eyes with occult CNV and remained unchanged in 2 eyes. One eye with occult CNV before TTT developed a classic CNV with significant macular edema and increased foveal thickness 3 months after TTT. The amplitudes of the FMERGs were reduced in all eyes before TTT. In eyes with occult CNV, the mean b-wave amplitude increased significantly after TTT ( p = 0.0260 at 3 months, p = 0.0142 at 6 months). When the change of foveal thickness was less than 20% after TTT, all eyes with occult CNV had a 30% or more increase in the b-wave amplitude. In eyes with classic CNV, the mean amplitude of the a- and b-waves did not change significantly after TTT. Conclusions: TTT improves macular function in eyes with occult CNV associated with age-related macular degeneration more when the change of foveal thickness is slight. Copyright (C) 2005 S. Karger AG, Basel.
C1 Nagoya Univ, Sch Med, Dept Ophthalmol, Showa Ku, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University
RP Terasaki, H (通讯作者)，Nagoya Univ, Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.
EM terasaki@med.nagoya-u.ac.jp
RI Terasaki, Hiroko/M-5054-2014; Ito, Yasuki/M-4876-2014
OI Ito, Yasuki/0000-0001-9219-9261
CR Auer C, 2002, KLIN MONATSBL AUGENH, V219, P250, DOI 10.1055/s-2002-30649
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   Connolly BP, 2003, OPHTHALMOLOGY, V110, P415, DOI 10.1016/S0161-6420(02)01561-0
   Falsini B, 2003, INVEST OPHTH VIS SCI, V44, P2133, DOI 10.1167/iovs.02-0716
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAYASHI H, 1997, J JPN OPHTHALMOL SOC, V101, P417
   JourneedeKorver JG, 1997, BRIT J OPHTHALMOL, V81, P234, DOI 10.1136/bjo.81.3.234
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   MIYAKE Y, 1988, INVEST OPHTH VIS SCI, V29, P1631
   MIYAKE Y, 1988, ACTA SOC OPHTHALMOL, V92, P1418
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Niwa T, 2003, INVEST OPHTH VIS SCI, V44, P1652, DOI 10.1167/iovs.02-0404
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Rogers AH, 2001, CURR OPIN OPHTHALMOL, V12, P212, DOI 10.1097/00055735-200106000-00012
   Suzuki T, 2003, AM J OPHTHALMOL, V136, P62, DOI 10.1016/S0002-9394(03)00149-1
   Terasaki H, 2004, INVEST OPHTH VIS SCI, V45, P567, DOI 10.1167/iovs.03-0187
   Terasaki H, 2003, INVEST OPHTH VIS SCI, V44, P4465, DOI 10.1167/iovs.02-1313
   Terasaki H, 2002, INVEST OPHTH VIS SCI, V43, P1540
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
NR 21
TC 2
Z9 2
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2005
VL 37
IS 1
BP 34
EP 42
DI 10.1159/000083020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 920BX
UT WOS:000228663800007
PM 15637420
DA 2022-11-30
ER

PT J
AU De Rosa, I
   Ohayon, A
   Semoun, O
   Miere, A
   Jung, C
   Capuano, V
   Cirafici, P
   Souied, EH
AF De Rosa, Irene
   Ohayon, Avi
   Semoun, Oudy
   Miere, Alexandra
   Jung, Camille
   Capuano, Vittorio
   Cirafici, Paola
   Souied, Eric H.
TI REAL-COLOR VERSUS PSEUDO-COLOR IMAGING OF FIBROTIC SCARS IN EXUDATIVE
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; color fundus photography; macular
   scar; multicolor; optical coherence tomography; optos; subretinal
   fibrosis; ultra-widefield color fundus photography
AB Purpose: To compare the morphological characteristics of subretinal fibrosis in late age-related macular degeneration using multicolor (MC) imaging, color fundus photography (CFP), and ultra-widefield CFP (UWFCFP).
   Methods: Thirty-two eyes of 31 patients diagnosed with subretinal fibrosis complicating exudative age-related macular degeneration were included. Included eyes were imaged by MC, CFP, and UWFCFP. The overall ability to visualize fibrosis, its margins, and dissimilarity with surrounding atrophy was graded using a score (0: not visible, 1: barely visible, 2: mostly visible, and 3: fully visible) by two readers. Area of fibrosis was calculated. Scaling, lesion colocalization on all three imaging techniques, and area measurements were performed using ImageJ.
   Results: Ninety-six images of 32 eyes were graded. The average area of fibrosis was 14.59 +/- 8.94 mm(2) for MC, 13.84 +/- 8.56 mm(2) for CFP, and 13.76 +/- 8.79 mm(2) for UWFCFP. Fibrosis was fully visible in 87.5% of cases using MC and 50% using CFP and UWFCFP. Fibrosis' margins were sharply defined in 40.6% of eyes with MC, 15.6% and 9.4% with CFP and UWFCFP, respectively. Multicolor imaging provided superior distinction between fibrosis and atrophy (100% for MC vs. 13.4% for CFP and 33.3% for UWFCFP). The inter- and intra-reader agreement was high for all measurements (P < 0.0001).
   Conclusion: Multicolor technology allows for improved visualization and analysis of subretinal fibrosis when compared with CFP and UWFCFP, especially when surrounding atrophy is present.
C1 [De Rosa, Irene; Ohayon, Avi; Semoun, Oudy; Miere, Alexandra; Jung, Camille; Capuano, Vittorio; Cirafici, Paola; Souied, Eric H.] Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Jung, Camille] Ctr Hosp Intercommunal Creteil, Clin Res Ctr, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP De Rosa, I (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM iryderosa@yahoo.it
RI Miere, Alexandra/AIC-4074-2022; Ohayon, Avi/R-2676-2018
OI Miere, Alexandra/0000-0003-4123-8210; Ohayon, Avi/0000-0002-4435-8659
CR [Anonymous], Retinal physician-focus on
   Ben Moussa N, 2015, BRIT J OPHTHALMOL, V99, P842, DOI 10.1136/bjophthalmol-2014-305643
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bruyere E, 2015, AM J OPHTHALMOL, V160, P749, DOI 10.1016/j.ajo.2015.07.004
   Chakravarthy U, AM AC OPTH ANN M 201
   Channa R, 2015, AM J OPHTHALMOL, V159, P9, DOI 10.1016/j.ajo.2014.09.012
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Daniel E, 2019, OPHTHALMOLOGY, V126, P743, DOI 10.1016/j.ophtha.2018.11.020
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Evans JR, 2002, BRIT J OPHTHALMOL, V86, P795, DOI 10.1136/bjo.86.7.795
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Graham KW, 2018, RETINA-J RET VIT DIS, V38, P1751, DOI 10.1097/IAE.0000000000001777
   Kernt M, 2010, CLIN OPHTHALMOL, V4, P829
   Kuiper EJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1457, DOI 10.1001/archopht.124.10.1457
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P352, DOI 10.1097/IAE.0000000000001525
   Ores R, 2014, AM J OPHTHALMOL, V158, P354, DOI 10.1016/j.ajo.2014.04.025
   Pang CE, 2014, AM J OPHTHALMOL, V158, P171, DOI 10.1016/j.ajo.2014.03.003
   Querques G, 2013, OPHTHALMOLOGY, V120, P872, DOI 10.1016/j.ophtha.2012.12.007
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Tan ACS, 2016, OPHTHALMOLOGICA, V236, P8, DOI 10.1159/000446857
   Toth LA, 2015, RETINA-J RET VIT DIS, V35, P1957, DOI 10.1097/IAE.0000000000000583
NR 26
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2020
VL 40
IS 12
BP 2277
EP 2284
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QI4NW
UT WOS:000618957100004
PM 32039941
DA 2022-11-30
ER

PT J
AU Broadhead, GK
   Grigg, JR
   Chang, AA
   McCluskey, P
AF Broadhead, Geoffrey K.
   Grigg, John R.
   Chang, Andrew A.
   McCluskey, Peter
TI Dietary modification and supplementation for the treatment of
   age-related macular degeneration
SO NUTRITION REVIEWS
LA English
DT Review
DE Age-related macular degeneration; antioxidants; diet; dietary
   supplements
ID PIGMENT OPTICAL-DENSITY; COMPLEMENT FACTOR-H; LONG-TERM INCIDENCE; EYE
   DISEASE; GLYCEMIC INDEX; LUTEIN SUPPLEMENTATION; VISUAL PERFORMANCE;
   RISK-FACTORS; VITAMIN-E; GENETIC SUSCEPTIBILITY
AB Age-related macular degeneration (AMD) causes a significant proportion of visual loss in the developed world. Currently, little is known about its pathogenesis, and treatment options are limited. Dietary intake is one of the few modifiable risk factors for this condition. The best-validated therapies remain oral antioxidant supplements based on those investigated in the Age-Related Eye Disease Study (AREDS) and the recently completed Age-Related Eye Disease Study 2 (AREDS2). In this review, current dietary guidelines related to AMD, along with the underlying evidence to support them, are presented in conjunction with current treatment recommendations. Both AREDS and AREDS2 are discussed, as are avenues for further research, including supplementation with vitamin D and saffron. Despite the considerable disease burden of atrophic AMD, few effective therapies are available to treat it, and further research is required.
C1 [Broadhead, Geoffrey K.; Grigg, John R.; Chang, Andrew A.; McCluskey, Peter] Univ Sydney, Dept Ophthalmol, Save Sight Inst, Sydney, NSW 2000, Australia.
   [Broadhead, Geoffrey K.; Chang, Andrew A.] Sydney Inst Vis Sci, Sydney, NSW 2000, Australia.
C3 University of Sydney
RP Broadhead, GK (通讯作者)，Univ Sydney, Dept Ophthalmol, Level 13,Pk House,187 Macquarie St, Sydney, NSW 2000, Australia.
EM gbro8081@uni.sydney.edu.au
RI Grigg, John/A-6851-2013; McCluskey, Peter J/H-7607-2013
OI Grigg, John/0000-0002-6763-8119; McCluskey, Peter J/0000-0002-8177-1637
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Arnold C, 2013, NUTRITION, V29, P1412, DOI 10.1016/j.nut.2013.05.012
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Bernstein PS, 2012, INVEST OPHTH VIS SCI, V53, P6178, DOI 10.1167/iovs.12-10275
   Broadhead GK, 2012, ASIA-PAC J OPHTHALMO, V1, P312, DOI 10.1097/APO.0b013e31826e1d4a
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bucheli P, 2011, OPTOMETRY VISION SCI, V88, P257, DOI 10.1097/OPX.0b013e318205a18f
   Burke JD, 2005, J NUTR, V135, P1208, DOI 10.1093/jn/135.5.1208
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Charkoudian LD, 2008, OPHTHALMOLOGY, V115, P1032, DOI 10.1016/j.ophtha.2007.08.003
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chowdhury R, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6698
   Christen WG, 2014, OPHTHALMOLOGY, V121, P525, DOI 10.1016/j.ophtha.2013.09.038
   Christen WG, 2012, OPHTHALMOLOGY, V119, P1642, DOI 10.1016/j.ophtha.2012.01.053
   Christen WG, 2010, OPHTHALMOLOGY, V117, P1163, DOI 10.1016/j.ophtha.2009.10.043
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Connolly EE, 2011, INVEST OPHTH VIS SCI, V52, P9207, DOI 10.1167/iovs.11-8025
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P3452, DOI 10.1167/iovs.10-6713
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Engles M, 2007, INVEST OPHTH VIS SCI, V48, P2922, DOI 10.1167/iovs.06-0883
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Garcia-Layana A, 2013, NUTRIENTS, V5, P543, DOI 10.3390/nu5020543
   Gerstenblith AT, 2013, JAMA OPHTHALMOL, V131, P365, DOI 10.1001/jamaophthalmol.2013.642
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond BR, 2005, OPHTHAL PHYSL OPT, V25, P315, DOI 10.1111/j.1475-1313.2005.00271.x
   HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hochstetler BS, 2010, RETINA-J RET VIT DIS, V30, P1166, DOI 10.1097/IAE.0b013e3181cea5c6
   JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kanis MJ, 2007, GRAEF ARCH CLIN EXP, V245, P767, DOI 10.1007/s00417-006-0478-0
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Kaya S, 2012, ACTA OPHTHALMOL, V90, pe399, DOI 10.1111/j.1755-3768.2012.02423.x
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kristo AS, 2013, NUTRIENTS, V5, P1071, DOI 10.3390/nu5041071
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Lawrenson JG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub2
   Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338
   Loughman J, 2012, INVEST OPHTH VIS SCI, V53, P7871, DOI 10.1167/iovs.12-10690
   Loughman J, 2010, VISION RES, V50, P1249, DOI 10.1016/j.visres.2010.04.009
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Moeller SM, 2009, J NUTR, V139, P1692, DOI 10.3945/jn.109.107748
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   National Eye Institute, 2013, FACTS AG REL MAC DEG
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   Nolan JM, 2011, VISION RES, V51, P459, DOI 10.1016/j.visres.2010.12.016
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Patryas L, 2014, GRAEF ARCH CLIN EXP, V252, P657, DOI 10.1007/s00417-014-2564-z
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Piccardi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429124
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Puell MC, 2013, ACTA OPHTHALMOL, V91, pE298, DOI 10.1111/aos.12067
   Raman R, 2012, EYE, V26, P1052, DOI 10.1038/eye.2012.86
   Raman R, 2012, EYE, V26, P950, DOI 10.1038/eye.2012.69
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Rodriguez-Carmona M, 2006, OPHTHAL PHYSL OPT, V26, P137, DOI 10.1111/j.1475-1313.2006.00386.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2012, AM J CLIN NUTR, V96, p1223S, DOI 10.3945/ajcn.112.038240
   Sasaki M, 2012, ARCH OPHTHALMOL-CHIC, V130, P254, DOI 10.1001/archopthalmol.2011.1368
   Sasamoto Y, 2011, GRAEF ARCH CLIN EXP, V249, P1847, DOI 10.1007/s00417-011-1780-z
   Schleicher M, 2013, NUTRIENTS, V5, P2405, DOI 10.3390/nu5072405
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Shah SU, 2013, CAN J OPHTHALMOL, V48, P204, DOI 10.1016/j.jcjo.2013.01.013
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Stringham JM, 2007, OPTOMETRY VISION SCI, V84, P859, DOI 10.1097/OPX.0b013e3181559c2b
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Yao Y, 2013, NUTRITION, V29, P958, DOI 10.1016/j.nut.2012.10.017
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
NR 139
TC 39
Z9 39
U1 0
U2 55
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0029-6643
EI 1753-4887
J9 NUTR REV
JI Nutr. Rev.
PD JUL
PY 2015
VL 73
IS 7
BP 448
EP 462
DI 10.1093/nutrit/nuv005
PG 15
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA CP1QU
UT WOS:000359651100004
PM 26081455
DA 2022-11-30
ER

PT J
AU Johnson, EJ
AF Johnson, EJ
TI Obesity, lutein metabolism, and age-related macular degeneration: A web
   of connections
SO NUTRITION REVIEWS
LA English
DT Review
DE lutein; obesity; zeaxanthin; macular degeneration
ID C-REACTIVE PROTEIN; BODY-MASS INDEX; OXIDATIVE STRESS; PIGMENT DENSITY;
   VITAMIN-E; TISSUE CONCENTRATIONS; GENE-EXPRESSION; PROTECTIVE ROLE;
   ADIPOSE-TISSUE; RISK-FACTORS
AB Age-related macular degeneration (AMD) is a major cause of visual impairment in the United States. Currently there is no effective cure for this disease. Risk factors include decreased lutein and zeaxanthin status and obesity. Obesity is also an increasing public health concern. The alarming increase in the prevalence of obesity further exacerbates the public health concern of AMD. The mechanism by which obesity increases the risk of AMD may be related to the physiologic changes that occur with this condition. These include increased oxidative stress, changes in the lipoprotein profile, and increased inflammation. These changes would also result in an increased destruction and a decreased circulatory delivery of lutein and zeaxanthin to the macula of the eye. Therefore, the mechanism by which obesity is related to AMD risk may be through indirect effects on changes in lutein and zeaxanthin status and metabolism.
C1 Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
C3 Tufts University; United States Department of Agriculture (USDA)
RP Johnson, EJ (通讯作者)，Tufts Univ, USDA, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.
EM elizabeth.johnson@tufts.edu
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Barton M, 2000, HYPERTENSION, V35, P329, DOI 10.1161/01.HYP.35.1.329
   Bazan N G, 1989, Prog Clin Biol Res, V312, P95
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   BERKENMEIER G, 1996, NEUROREPORT, V8, P149
   Block G, 2002, AM J EPIDEMIOL, V156, P274, DOI 10.1093/aje/kwf029
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BRADY WE, 1996, J NUTR, V126, P128
   Brasier AR, 2002, ARTERIOSCL THROM VAS, V22, P1257, DOI 10.1161/01.ATV.0000021412.56621.A2
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Davi G, 2002, JAMA-J AM MED ASSOC, V288, P2008, DOI 10.1001/jama.288.16.2008
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   DELMELLE M, 1978, PHOTOCHEM PHOTOBIOL, V28, P357, DOI 10.1111/j.1751-1097.1978.tb07718.x
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Grolier P, 2000, BRIT J NUTR, V84, P711
   HAEGERSTROMPORTNOY G, 1988, J OPT SOC AM A, V5, P2140, DOI 10.1364/JOSAA.5.002140
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   HAMMOND BR, 1998, INVEST OPHTH VIS SCI, V39, P387
   HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621
   JAFFE GJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P445
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   KAPLAN LA, 1990, CLIN PHYSIOL BIOCH, V8, P1
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keaney JF, 2003, ARTERIOSCL THROM VAS, V23, P434, DOI 10.1161/01.ATV.0000058402.34138.11
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Kopp HP, 2003, ARTERIOSCL THROM VAS, V23, P1042, DOI 10.1161/01.ATV.0000073313.16135.21
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   KRINSKY NI, 1989, FREE RADICAL BIO MED, V7, P617, DOI 10.1016/0891-5849(89)90143-3
   Kritchevsky SB, 2000, AM J EPIDEMIOL, V152, P1065, DOI 10.1093/aje/152.11.1065
   Kuno T, 1998, FREE RADICAL RES, V28, P81, DOI 10.3109/10715769809097878
   Kunsch C, 1999, CIRC RES, V85, P753, DOI 10.1161/01.RES.85.8.753
   Lemieux I, 2001, ARTERIOSCL THROM VAS, V21, P961, DOI 10.1161/01.ATV.21.6.961
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Miller NJ, 1996, FEBS LETT, V384, P240, DOI 10.1016/0014-5793(96)00323-7
   *NAT CTR CHRON DIS, 1985, US OB TRENDS
   Parker RS, 1996, FASEB J, V10, P542, DOI 10.1096/fasebj.10.5.8621054
   PARKER RS, 1989, J NUTR, V119, P101, DOI 10.1093/jn/119.1.101
   Rawson ES, 2003, MED SCI SPORT EXER, V35, P1160, DOI 10.1249/01.MSS.0000074565.79230.AB
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   SCHALCH W, 1909, FREE RADICALS AGING, P280
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SHANMUGARATNAM J, 1997, BRAIN RES MOL BRAIN, V59, P113
   SICKEL W, 1972, HDB SENSORY PHYSL, P667
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Suzuki Koji, 2003, Asian Pac J Cancer Prev, V4, P259
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Tchernof A, 2002, CIRCULATION, V105, P564, DOI 10.1161/hc0502.103331
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   Trevisan M, 2001, AM J EPIDEMIOL, V154, P348, DOI 10.1093/aje/154.4.348
   *USDA, 1998, USDANCC CAR DAT US F
   WEITER JJ, 1988, AM J OPHTHALMOL, V106, P286, DOI 10.1016/0002-9394(88)90363-7
   Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI20514
   Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017
   Yeum K J, 1998, J Nutr Health Aging, V2, P79
NR 66
TC 53
Z9 53
U1 1
U2 19
PU INT LIFE SCIENCES INST NORTH AMERICA
PI WASHINGTON
PA ONE THOMAS CIRCLE, N W, 9TH FLOOR, WASHINGTON, DC 20005 USA
SN 0029-6643
J9 NUTR REV
JI Nutr. Rev.
PD JAN
PY 2005
VL 63
IS 1
BP 9
EP 15
DI 10.1301/nr.2004.janr.9-15
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 903OU
UT WOS:000227436200002
PM 15730230
OA Bronze
DA 2022-11-30
ER

PT J
AU Jarrett, SG
   Boulton, ME
AF Jarrett, Stuart G.
   Boulton, Michael E.
TI Consequences of oxidative stress in age-related macular degeneration
SO MOLECULAR ASPECTS OF MEDICINE
LA English
DT Review
DE Retina; Age-related macular degeneration; Oxidative stress;
   Mitochondria; Reactive oxygen species; Antioxidants; Cell regeneration
ID MITOCHONDRIAL-DNA DAMAGE; RETINAL-PIGMENT EPITHELIUM; MANGANESE
   SUPEROXIDE-DISMUTASE; UBIQUITIN-CONJUGATING ENZYMES; BASE
   EXCISION-REPAIR; EMBRYONIC STEM-CELLS; LIGHT-INDUCED DAMAGE; HABER-WEISS
   CYCLE; S-TRANSFERASE M1; LIPID-PEROXIDATION
AB The retina resides in an environment that is primed for the generation of reactive oxygen species (ROS) and resultant oxidative damage. The retina is one of the highest oxygen-consuming tissues in the human body. The highest oxygen levels are found in the choroid, but this falls dramatically across the outermost retina, creating a large gradient of oxygen towards the retina and inner segments of the photoreceptors which contain high levels of polyunsaturated fatty acids. This micro-environment together with abundant photosensitizers, visible light exposure and a high energy demand supports a highly oxidative milieu. However, oxidative damage is normally minimized by the presence of a range of antioxidant and efficient repair systems. Unfortunately, as we age oxidative damage increases, antioxidant capacity decreases and the efficiency of reparative systems become impaired. The result is retinal dysfunction and cell loss leading to visual impairment. It appears that these age-related oxidative changes are a hallmark of early age-related macular degeneration (AMD) which, in combination with hereditary susceptibility and other retinal modifiers, can progress to the pathology and visual morbidity associated with advanced AMD. This review reassesses the consequences of oxidative stress in AMD and strategies for preventing or reversing oxidative damage in retinal tissues. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Boulton, Michael E.] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32611 USA.
   [Jarrett, Stuart G.] Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY USA.
C3 State University System of Florida; University of Florida; University of
   Kentucky
RP Boulton, ME (通讯作者)，Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32611 USA.
EM meboulton@ufl.edu
OI Jarrett, Stuart/0000-0001-8029-1554
FU NIH [EY018358, EY019688, EY021626]; NATIONAL EYE INSTITUTE [R01EY018358,
   R21EY021626, P30EY021721, R01EY019688] Funding Source: NIH RePORTER
FX This work was supported by NIH Grants EY018358, EY019688 and EY021626.
   The authors thank Lynn Shaw for the art work.
CR Al-Shabrawey M, 2005, AM J PATHOL, V167, P599, DOI 10.1016/S0002-9440(10)63001-5
   Al-Shabrawey M, 2008, INVEST OPHTH VIS SCI, V49, P3231, DOI 10.1167/iovs.08-1754
   Altuntas I., 2002, Journal of Basic and Clinical Physiology and Pharmacology, V13, P69
   AMES BN, 1992, ANN NY ACAD SCI, V663, P85, DOI 10.1111/j.1749-6632.1992.tb38652.x
   Ames BN, 2010, MECH AGEING DEV, V131, P473, DOI 10.1016/j.mad.2010.04.005
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Antonenkov VD, 2010, ANTIOXID REDOX SIGN, V13, P525, DOI 10.1089/ars.2009.2996
   Bamonti F, 2006, CLIN CHEM LAB MED, V44, P391, DOI 10.1515/CCLM.2006.084
   Barnstable CJ, 2006, ADV EXP MED BIOL, V572, P291
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Bensasson R.V., 1993, CONTRIBUTIONS FLASH
   Bi YY, 2009, NEUROSCI RES, V65, P215, DOI 10.1016/j.neures.2009.07.008
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Blank LM, 2010, ANTIOXID REDOX SIGN, V13, P349, DOI 10.1089/ars.2009.2931
   Bohr V, 1998, TOXICOL LETT, V103, P47
   Bohr VA, 2007, NEUROSCIENCE, V145, P1183, DOI 10.1016/j.neuroscience.2007.03.015
   Bonekamp NA, 2009, BIOFACTORS, V35, P346, DOI 10.1002/biof.48
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Boulton M. E., 2009, FUNDUS AUTOFLUORESCE, P14
   Bove J, 2011, NAT REV NEUROSCI, V12, P437, DOI 10.1038/nrn3068
   Braca A, 2011, CURR DRUG TARGETS, V12, P302, DOI 10.2174/138945011794815284
   Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034
   BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3
   Bylund J, 2010, FREE RADICAL BIO MED, V49, P1834, DOI 10.1016/j.freeradbiomed.2010.09.016
   Cameron JM, 2011, MITOCHONDRION, V11, P191, DOI 10.1016/j.mito.2010.09.008
   Cantin Andre M, 2010, Proc Am Thorac Soc, V7, P368, DOI 10.1513/pats.201001-014AW
   Cantu D, 2011, J NEUROCHEM, V118, P79, DOI 10.1111/j.1471-4159.2011.07290.x
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   CASTORINA C, 1992, NEUROCHEM RES, V17, P599, DOI 10.1007/BF00968789
   Catala Angel, 2011, Front Biosci (Schol Ed), V3, P52, DOI 10.2741/s131
   Chan-Ling T, 2006, AM J PATHOL, V168, P1031, DOI 10.2353/ajpath.2006.050697
   Chaturvedi RK, 2008, ANN NY ACAD SCI, V1147, P395, DOI 10.1196/annals.1427.027
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P2118, DOI 10.1167/iovs.10-6304
   Comporti MM, 1998, FREE RADICAL RES, V28, P623, DOI 10.3109/10715769809065818
   Cortes-Rojo C, 2011, MINI-REV MED CHEM, V11, P625, DOI 10.2174/138955711795906879
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CRAWFORD DR, 1994, ENVIRON HEALTH PERSP, V102, P25, DOI 10.2307/3432208
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Danesh-Meyer HV, 2011, CURR OPIN OPHTHALMOL, V22, P78, DOI 10.1097/ICU.0b013e32834372ec
   Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Desouki MM, 2005, CANCER BIOL THER, V4, P1367, DOI 10.4161/cbt.4.12.2233
   Dhubhghaill SSN, 2010, ADV EXP MED BIOL, V664, P437, DOI 10.1007/978-1-4419-1399-9_50
   Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285
   Dikalova AE, 2010, CIRC RES, V107, P106, DOI 10.1161/CIRCRESAHA.109.214601
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dizdaroglu M, 2002, FREE RADICAL BIO MED, V32, P1102, DOI 10.1016/S0891-5849(02)00826-2
   Du HJ, 2011, SEMIN OPHTHALMOL, V26, P216, DOI 10.3109/08820538.2011.577498
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Feher J, 2003, OPHTHALMOLOGICA, V217, P351, DOI 10.1159/000071351
   Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRIEDRICHSON T, 1995, CURR EYE RES, V14, P693, DOI 10.3109/02713689508998497
   Gabriel HE, 2006, CANCER EPIDEM BIOMAR, V15, P993, DOI 10.1158/1055-9965.EPI-05-0664
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Galan P, 2005, EUR J CLIN NUTR, V59, P1181, DOI 10.1038/sj.ejcn.1602230
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Godley BF, 2002, EXP EYE RES, V74, P663, DOI 10.1006/exer.2001.1146
   Gomez-Cabrera MC, 2009, PHYSICIAN SPORTSMED, V37, P116, DOI 10.3810/psm.2009.12.1749
   Gorgun E, 2010, INVEST OPHTH VIS SCI, V51, P4732, DOI 10.1167/iovs.09-4842
   Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607
   Graziewicz MA, 2002, NUCLEIC ACIDS RES, V30, P2817, DOI 10.1093/nar/gkf392
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gutteridge JMC, 2000, ANN NY ACAD SCI, V899, P136, DOI 10.1111/j.1749-6632.2000.tb06182.x
   Guven M, 2011, OPHTHALMIC RES, V46, P31, DOI 10.1159/000321940
   HALLIWEL B, 1999, FREE RADICALS BIOL M
   HALLIWELL B, 1992, FREE RADICAL RES COM, V16, P75, DOI 10.3109/10715769209049161
   HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Harrison JF, 2005, NUCLEIC ACIDS RES, V33, P4660, DOI 10.1093/nar/gki759
   Hartnett ME, 2010, DOC OPHTHALMOL, V120, P25, DOI 10.1007/s10633-009-9181-x
   Helmersson J, 2005, ATHEROSCLEROSIS, V181, P201, DOI 10.1016/j.atherosclerosis.2004.11.026
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Ivashchenko O, 2011, MOL BIOL CELL, V22, P1440, DOI 10.1091/mbc.E10-11-0919
   Jackson MJ, 2005, PHILOS T R SOC B, V360, P2285, DOI 10.1098/rstb.2005.1773
   JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218
   Jarrett SG, 2005, FREE RADICAL BIO MED, V38, P1382, DOI 10.1016/j.freeradbiomed.2005.02.003
   Jarrett SG, 2007, OPHTHALMIC RES, V39, P213, DOI 10.1159/000104683
   Jarrett SG, 2006, REDOX REP, V11, P144, DOI 10.1179/135100006X116646
   Jarrett SG, 2006, FREE RADICAL RES, V40, P1155, DOI 10.1080/10715760600876613
   Jarrett SG, 2010, OPHTHALMIC RES, V44, P179, DOI 10.1159/000316480
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jin GF, 2001, CURR EYE RES, V23, P11, DOI 10.1076/ceyr.23.1.11.5423
   Jomova K, 2010, MOL CELL BIOCHEM, V345, P91, DOI 10.1007/s11010-010-0563-x
   Jones DP, 2006, ANTIOXID REDOX SIGN, V8, P1865, DOI 10.1089/ars.2006.8.1865
   Jones M, 2004, AM J OPHTHALMOL, V138, P1051, DOI 10.1016/j.ajo.2004.06.026
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kalariya NM, 2009, CURR EYE RES, V34, P737, DOI 10.1080/02713680903046855
   Kaminskyy V., 2011, BIOCH BIOPHYSICA ACT
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Kanwar M, 2007, INVEST OPHTH VIS SCI, V48, P3805, DOI 10.1167/iovs.06-1280
   Karl MO, 2010, TRENDS MOL MED, V16, P193, DOI 10.1016/j.molmed.2010.02.003
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kim JS, 2008, HEPATOLOGY, V47, P1725, DOI 10.1002/hep.22187
   Kim SH, 2003, NUTRITION, V19, P240, DOI 10.1016/S0899-9007(02)01002-X
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Kong QM, 2010, CELL MOL LIFE SCI, V67, P1817, DOI 10.1007/s00018-010-0277-y
   Kong QM, 2008, FREE RADICAL RES, V42, P773, DOI 10.1080/10715760802311187
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Koppenol WH, 2001, REDOX REP, V6, P229, DOI 10.1179/135100001101536373
   Kowalski M, 2010, MED SCI MONITOR, V16, pCR190
   Kowluru RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-8
   Kruft BI, 2011, PHOTOCHEM PHOTOBIOL, V87, P1204, DOI 10.1111/j.1751-1097.2011.00993.x
   Lamba DA, 2009, PROG BRAIN RES, V175, P23, DOI 10.1016/S0079-6123(09)17502-7
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Leonarduzzi G, 2011, CURR PHARM DESIGN, V17, P3994, DOI 10.2174/138161211798764906
   Li LN, 2006, METABOLISM, V55, P1516, DOI 10.1016/j.metabol.2006.06.022
   Li QH, 2008, MOL THER, V16, P1688, DOI 10.1038/mt.2008.164
   Liang FQ, 2005, EXP EYE RES, V80, P113, DOI 10.1016/j.exer.2004.08.017
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liao JH, 2002, BIOCHEM BIOPH RES CO, V297, P309, DOI 10.1016/S0006-291X(02)02185-X
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Liochev SI, 2002, REDOX REP, V7, P55, DOI 10.1179/135100002125000190
   Liu JK, 2002, ANN NY ACAD SCI, V959, P133, DOI 10.1111/j.1749-6632.2002.tb02090.x
   Lowe GM, 2003, MOL ASPECTS MED, V24, P363, DOI 10.1016/S0098-2997(03)00032-3
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Maeda A, 2005, BIOCHEMISTRY-US, V44, P480, DOI 10.1021/bi048016f
   Markovets AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021682
   Markovets AM, 2011, AGING-US, V3, P44
   MCCORD JM, 1969, J BIOL CHEM, V244, P6056
   MCCORD JM, 1969, J BIOL CHEM, V244, P6049
   Mellerio J., 1994, PRINCIPLES PRACTICE, V1, P1326
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Miyamura N, 2004, INVEST OPHTH VIS SCI, V45, P1562, DOI 10.1167/iovs.02-0761
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Murphy RT, 2004, FREE RADICAL BIO MED, V36, P959, DOI 10.1016/j.freeradbiomed.2004.01.018
   Negre-Salvayre A, 2008, BRIT J PHARMACOL, V153, P6, DOI 10.1038/sj.bjp.0707395
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   NOELL WK, 1971, SCIENCE, V172, P76, DOI 10.1126/science.172.3978.76
   Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561
   Ooto S, 2004, P NATL ACAD SCI USA, V101, P13654, DOI 10.1073/pnas.0402129101
   Organisciak D, 2006, PHOTOCHEM PHOTOBIOL, V82, P1088, DOI 10.1562/2005-06-30-RA-599
   ORGANISCIAK DT, 1977, INVEST OPHTH VIS SCI, V16, P188
   Osakada F, 2007, J NEUROSCI, V27, P4210, DOI 10.1523/JNEUROSCI.4193-06.2007
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Oz O, 2006, EUR J OPHTHALMOL, V16, P105
   Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006
   Paravicini TM, 2008, DIABETES CARE, V31, pS170, DOI 10.2337/dc08-s247
   Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5
   Pawlak A, 2003, PHOTOCHEM PHOTOBIOL, V77, P253, DOI 10.1562/0031-8655(2003)077<0253:COTAPO>2.0.CO;2
   Polidori MC, 2003, BRIT J NUTR, V90, P147, DOI 10.1079/BJN2003890
   PRYOR WA, 1992, FREE RADICAL BIO MED, V13, P659
   Reddy VN, 2004, EXP EYE RES, V79, P859, DOI 10.1016/j.exer.2004.04.005
   Reinke LA, 2002, FREE RADICAL BIO MED, V32, P953, DOI 10.1016/S0891-5849(02)00795-5
   Romano Antonino D, 2010, J Nephrol, V23 Suppl 15, pS29
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   Rozanowska M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305, DOI 10.1562/2004-11-13-IR-371
   Rozanowska M, 2004, INVEST OPHTH VIS SCI, V45, P1052, DOI 10.1167/iovs.03-0277
   Rozanowska M, 2002, INVEST OPHTH VIS SCI, V43, P2088
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Rozanowski B, 2008, PHOTOCHEM PHOTOBIOL, V84, P650, DOI 10.1111/j.1751-1097.2007.00259.x
   Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030
   Sanz Alberto, 2008, Curr Aging Sci, V1, P10
   Sarkar S, 2008, MOL BIOSYST, V4, P895, DOI 10.1039/b804606a
   Sarkar S, 2007, J BIOL CHEM, V282, P5641, DOI 10.1074/jbc.M609532200
   Sarkar S, 2006, AUTOPHAGY, V2, P132, DOI 10.4161/auto.2387
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   Sastre J, 2000, IUBMB LIFE, V49, P427
   Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4
   Schon EA, 2010, TRENDS MOL MED, V16, P268, DOI 10.1016/j.molmed.2010.04.007
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N
   Sengupta N, 2009, MOL THER, V17, P1594, DOI 10.1038/mt.2009.145
   Shacka JJ, 2008, FRONT BIOSCI-LANDMRK, V13, P718, DOI 10.2741/2714
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Sohal R.S., 2011, FREE RADICAL BIOL ME
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spencer WA, 2012, CHEM RES TOXICOL, V25, P305, DOI 10.1021/tx200356v
   Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142
   Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191
   Stahl W, 2005, BBA-MOL BASIS DIS, V1740, P101, DOI 10.1016/j.bbadis.2004.12.006
   Sugiura H, 2011, NITRIC OXIDE-BIOL CH, V25, P138, DOI 10.1016/j.niox.2011.03.079
   Sun GY, 2007, J NEUROCHEM, V103, P1, DOI 10.1111/j.1471-4159.2007.04670.x
   Sun GY, 2010, NEUROMOL MED, V12, P133, DOI 10.1007/s12017-009-8092-z
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Synowiec E., 2012, EXPT EYE RES
   Szaflik JP, 2009, MUTAT RES-FUND MOL M, V669, P169, DOI 10.1016/j.mrfmmm.2009.06.008
   Szweda PA, 2003, AGEING RES REV, V2, P383, DOI 10.1016/S1568-1637(03)00028-X
   Tanito M, 2010, EXP EYE RES, V91, P111, DOI 10.1016/j.exer.2010.04.012
   Tawfik A, 2009, INVEST OPHTH VIS SCI, V50, P878, DOI 10.1167/iovs.08-2005
   TAYLOR A, 1995, MECH AGEING DEV, V79, P33, DOI 10.1016/0047-6374(94)01541-S
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Traber MG, 2001, FREE RADICAL BIO MED, V31, P1368, DOI 10.1016/S0891-5849(01)00723-7
   Tsimikas S, 2008, AM J CARDIOL, V101, p34D, DOI 10.1016/j.amjcard.2008.02.006
   Tsukamoto H, 2001, FASEB J, V15, P1335, DOI 10.1096/fj.00-0650rev
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   Ushio-Fukai M, 2004, MOL CELL BIOCHEM, V264, P85, DOI 10.1023/B:MCBI.0000044378.09409.b5
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Voloboueva LA, 2007, FASEB J, V21, P4077, DOI 10.1096/fj.07-8396com
   Voulgaridou GP, 2011, MUTAT RES-FUND MOL M, V711, P13, DOI 10.1016/j.mrfmmm.2011.03.006
   Vugler A, 2007, MECH DEVELOP, V124, P807, DOI 10.1016/j.mod.2007.08.002
   Waldeck AR, 1996, CHEM RES TOXICOL, V9, P954, DOI 10.1021/tx960057s
   Wallace DC, 2009, COLD SH Q B, V74, P383, DOI 10.1101/sqb.2009.74.031
   Wallace DC, 2010, ENVIRON MOL MUTAGEN, V51, P440, DOI 10.1002/em.20586
   Wang AL, 2008, MOL VIS, V14, P644
   Wardman P, 1996, RADIAT RES, V145, P523, DOI 10.2307/3579270
   Weissig V, 2007, NANOMEDICINE-UK, V2, P275, DOI 10.2217/17435889.2.3.275
   Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006
   Winkler B S, 1999, Mol Vis, V5, P32
   Winslow A.R., 2008, BIOCH BIOPHYSICA ACT
   Wong W.T., 2010, INVEST OPHTHALMOL, V51, P613
   Xu SC, 2011, J PINEAL RES, V51, P426, DOI 10.1111/j.1600-079X.2011.00906.x
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   Yang JL, 2008, DNA REPAIR, V7, P1110, DOI 10.1016/j.dnarep.2008.03.012
   Yatsuga S, 2012, HUM MOL GENET, V21, P526, DOI 10.1093/hmg/ddr482
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhao Z., 2011, PLOS ONE, V6
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 238
TC 332
Z9 337
U1 12
U2 124
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0098-2997
EI 1872-9452
J9 MOL ASPECTS MED
JI Mol. Asp. Med.
PD AUG
PY 2012
VL 33
IS 4
SI SI
BP 399
EP 417
DI 10.1016/j.mam.2012.03.009
PG 19
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 983WR
UT WOS:000307149900005
PM 22510306
OA Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Schramm, EC
   Clark, SJ
   Triebwasser, MP
   Raychaudhuri, S
   Seddon, JM
   Atkinson, JP
AF Schramm, Elizabeth C.
   Clark, Simon J.
   Triebwasser, Michael P.
   Raychaudhuri, Soumya
   Seddon, Johanna M.
   Atkinson, John P.
TI Genetic variants in the complement system predisposing to age-related
   macular degeneration: A review
SO MOLECULAR IMMUNOLOGY
LA English
DT Review
DE Age-related macular degeneration; Complement system; Alternative
   pathway; Genetic variants
ID HEMOLYTIC-UREMIC SYNDROME; DISEASE-ASSOCIATED FORM; DENSE DEPOSIT
   DISEASE; FACTOR-H POLYMORPHISM; FACTOR-B; HIGH-RISK; FACTOR-I; BRUCHS
   MEMBRANE; MUTATIONS; COMMON
AB Age-related macular degeneration (AMD) is a major cause of visual impairment in the western world. It is characterized by the presence of lipoproteinaceous deposits (drusen) in the inner layers of the retina. Immunohistochemistry studies identified deposition of complement proteins in the drusen as well as in the choroid. In the last decade, genetic studies have linked both common and rare variants in genes of the complement system to increased risk of development of AMD. Here, we review the variants described to date and discuss the functional implications of dysregulation of the alternative pathway of complement in AMD. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Schramm, Elizabeth C.; Triebwasser, Michael P.; Atkinson, John P.] Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA.
   [Clark, Simon J.] Univ Manchester, Inst Human Dev, Ctr Hearing & Vis Res, Manchester M13 9PT, Lancs, England.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Dept Med, Div Rheumatol, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya] Partners Ctr Personalized Genet Med, Boston, MA USA.
   [Raychaudhuri, Soumya] MIT, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02139 USA.
   [Raychaudhuri, Soumya] Harvard Univ, Cambridge, MA 02138 USA.
   [Raychaudhuri, Soumya] Univ Manchester, Fac Med & Human Sci, Manchester, Lancs, England.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
C3 Washington University (WUSTL); University of Manchester; Harvard
   University; Brigham & Women's Hospital; Harvard University; Brigham &
   Women's Hospital; Harvard University; Massachusetts Institute of
   Technology (MIT); Broad Institute; Harvard University; University of
   Manchester; Tufts University; Tufts Medical Center
RP Atkinson, JP (通讯作者)，Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA.
EM jatkinso@DOM.wustl.edu
OI Clark, Simon/0000-0001-8394-8355; Raychaudhuri,
   Soumya/0000-0002-1901-8265
FU Medical Research Council [MR/K004441/1, MR/K024418/1] Funding Source:
   Medline; NEI NIH HHS [R01-EY11309, R01 EY011309] Funding Source:
   Medline; NHLBI NIH HHS [U54 HL112303] Funding Source: Medline; NIAID NIH
   HHS [R01 AI041592] Funding Source: Medline; NIAMS NIH HHS [P30AR48335,
   P30 AR048335] Funding Source: Medline; NIGMS NIH HHS [R01 GM099111]
   Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011309] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [U54HL112303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASES [R01AI041592] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN
   DISEASES [P30AR048335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   OF GENERAL MEDICAL SCIENCES [R01GM099111] Funding Source: NIH RePORTER;
   MRC [MR/K004441/1, MR/K024418/1] Funding Source: UKRI
CR Abrera-Abeleda MA, 2011, J AM SOC NEPHROL, V22, P1551, DOI 10.1681/ASN.2010080795
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Avery RL, 2010, OPHTHALMOLOGY, V117, P2442, DOI 10.1016/j.ophtha.2010.08.052
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   de Jorge EG, 2007, P NATL ACAD SCI USA, V104, P240, DOI 10.1073/pnas.0603420103
   de Jorge EG, 2013, P NATL ACAD SCI USA, V110, P4685, DOI 10.1073/pnas.1219260110
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fremeaux-Bacchi V, 2008, BLOOD, V112, P4948, DOI 10.1182/blood-2008-01-133702
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haapasalo K, 2008, MOL MICROBIOL, V70, P583, DOI 10.1111/j.1365-2958.2008.06347.x
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hebecker M, 2012, J BIOL CHEM, V287, P19528, DOI 10.1074/jbc.M112.364471
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Kavanagh D, 2005, J AM SOC NEPHROL, V16, P2150, DOI 10.1681/ASN.2005010103
   Kavanagh D, 2008, ANNU REV MED, V59, P293, DOI 10.1146/annurev.med.59.060106.185110
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Lachmann PJ, 2009, ADV IMMUNOL, V104, P115, DOI 10.1016/S0065-2776(08)04004-2
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liszewski MK, 2011, HEMATOL-AM SOC HEMAT, P9, DOI 10.1182/asheducation-2011.1.9
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Noris M, 2003, LANCET, V362, P1542, DOI 10.1016/S0140-6736(03)14742-3
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Richards A, 2003, P NATL ACAD SCI USA, V100, P12966, DOI 10.1073/pnas.2135497100
   Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Seddon JM, 2013, FARADAY DISCUSS, V161, P9, DOI 10.1039/c2fd90045a
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Tortajada A, 2013, J CLIN INVEST, V123, P2434, DOI 10.1172/JCI68280
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   YU Y, 2014, HUM MOL GENET
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 67
TC 81
Z9 82
U1 0
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD OCT
PY 2014
VL 61
IS 2
SI SI
BP 118
EP 125
DI 10.1016/j.molimm.2014.06.032
PG 8
WC Biochemistry & Molecular Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Immunology
GA AP7NZ
UT WOS:000342265300009
PM 25034031
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Carvounis, PE
   Kopel, AC
   Benz, MS
AF Carvounis, Petros E.
   Kopel, Andrew C.
   Benz, Matthew S.
TI Retinal pigment epithelium tears following ranibizumab for exudative
   age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To report two cases of retinal pigment epithelium (RPE) tears following intravitreous ranibizumab injection for age-related macular degeneration (AMD)-associated serous pigment epithelium detachment (PED).
   DESIGN: Noncomparative case series.
   METHODS: The charts of two patients who received intravitreous ranibizumab for AMD-associated PED and developed RPE tears were reviewed. Fundus photography, fluorescein angiography and optical coherence tomography performed prior to injection and upon follow,up confirmed the diagnosis.
   RESULTS: Two patients with serous PED and occult choroidal neovascularization associated with AMD developed RPE tears within four weeks of injection with ranibizumab.
   CONCLUSIONS: RPE tears may complicate ranibizumab intravitreous injection for the treatment of AMD-associated PEDs. Further studies need be undertaken to deter, mine whether this complication may also occur when treating choroidal neovascular membranes not associated with PED and whether certain angiographic subtypes are more susceptible to this complication.
C1 Vitreoretinal Consultants, Dis & Surg Retina & Vitreous, Houston, TX 77030 USA.
   Baylor Coll Med, Cullen Eye Inst, Houston, TX 77030 USA.
C3 Baylor College of Medicine
RP Benz, MS (通讯作者)，Vitreoretinal Consultants, Dis & Surg Retina & Vitreous, 6560 Fannin,Scurlock Tower,Suite 750, Houston, TX 77030 USA.
EM msbmd@houstonretina.com
OI Carvounis, Petros/0000-0002-3879-3486
CR COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
NR 7
TC 51
Z9 53
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2007
VL 143
IS 3
BP 504
EP 505
DI 10.1016/j.ajo.2006.11.028
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 141CZ
UT WOS:000244555700018
PM 17317395
DA 2022-11-30
ER

PT J
AU Bressler, NM
   Chang, TS
   Varma, R
   Suner, I
   Lee, P
   Dolan, CM
   Ward, J
   Ianchulev, T
   Fine, J
AF Bressler, Neil M.
   Chang, Tom S.
   Varma, Rohit
   Suner, Ivan
   Lee, Paul
   Dolan, Chantal M.
   Ward, James
   Ianchulev, Tsontcho
   Fine, Jennifer
TI Driving Ability Reported by Neovascular Age-related Macular Degeneration
   Patients after Treatment with Ranibizumab
SO OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL FUNCTION QUESTIONNAIRE; CHOROIDAL
   NEOVASCULARIZATION; PSYCHOMETRIC PROPERTIES; RESOURCE UTILIZATION;
   SUBMACULAR SURGERY; OLDER-ADULTS; NEI-VFQ; VERTEPORFIN; IMPAIRMENT
AB Objectives: To determine the impact of ranibizumab on driving status, driving ability perception, and having 20/40 vision or better in patients with choroidal neovascularization resulting from age-related macular degeneration (AMD).
   Design: Phase III, multicenter, randomized clinical trials (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration [MARINA] and Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration [ANCHOR]).
   Participants: One thousand one hundred twenty-six patients with choroidal neovascularization resulting from AMD.
   Methods: Participants were assigned randomly to sham (n = 238), 0.3-mg ranibizumab monthly injections (n = 238), or 0.5-mg ranibizumab monthly injections (n = 240) for 24 months (MARINA), or were randomized to verteporfin photodynamic therapy (PDT; n = 143), 0.3-mg ranibizumab monthly injections (n = 140), or 0.5-mg ranibizumab monthly injections (n = 140) for 24 months (ANCHOR).
   Main Outcome Measures: Self-reported driving status and driving ability perception were assessed as exploratory outcomes at baseline through 24 months after baseline using the 25-item National Eye Institute Visual Function Questionnaire. Best-corrected visual acuity in each eye was assessed monthly through 24 months.
   Results: At baseline, 68.6% of patients in the MARINA trial and 62.7% of patients in the ANCHOR trial reported driving. Among patients driving at baseline in the MARINA trial 2 years after randomization, 67.2% (95% confidence interval [CI], 59.2-75.2) of sham patients and 78.4% (95% CI, 71.8-85.0) of 0.5-mg patients reported that they were still driving. Among patients driving at baseline in the ANCHOR trial at 2 years after randomization, 71.6% (95% CI, 60.8-82.4) of PDT patients and 91.4% (95% CI, 85.3-97.5) of 0.5-mg patients were still driving. Also in the ANCHOR trial, ranibizumab-treated patients who were not driving at baseline seemed more likely to drive by months 12 and 24 than PDT patients. Perception of driving ability was correlated with improvement in visual acuity (VA) in the better-seeing eye at 12 and 24 months (R-2 = 0.17 and R-2 = 0.20 at 12 and 24 months, respectively [P<0.001], in the MARINA trial; R-2 = 0.13 and R-2 = 0.14, respectively [P<0.001], in the ANCHOR trial). Visual acuity in one or both eyes 2 years after randomization was more likely to be 20/40 or better in the ranibizumab-treated groups.
   Conclusions: These results suggest that patients with neovascular AMD treated with ranibizumab are more likely to report driving ability and have vision of at least 20/40 than patients given sham treatment or PDT.
C1 [Bressler, Neil M.] Johns Hopkins Univ, Wilmer Eye Inst, Retina Div, Sch Med, Baltimore, MD 21287 USA.
   [Chang, Tom S.] Retina Inst Calif, Pasadena, CA USA.
   [Varma, Rohit] Univ So Calif, Doheny Eye Inst, Los Angeles, CA USA.
   [Suner, Ivan] Retina Associates Florida, Tampa, FL USA.
   [Lee, Paul] Duke Univ Sch Med, Duke Eye Ctr, Durham, NC USA.
   [Dolan, Chantal M.; Ward, James; Fine, Jennifer] Genentech Inc, San Francisco, CA 94080 USA.
   [Ianchulev, Tsontcho] Transcend Med, Menlo Pk, CA USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Doheny Eye Institute;
   University of Southern California; Duke University; Roche Holding;
   Genentech
RP Bressler, NM (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, Sch Med & Hosp, 600 N Wolfe St,Maumenee 752, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
OI Lee, Paul/0000-0002-3338-136X
FU Allergan; Bausch Lomb; Carl Zeiss Meditec; Genentech; Notal Vision Inc;
   Novartis; Othera; QLT; Regeneron; Steba Pharmaceuticals; Department of
   Ophthalmology; Optovue; Pfizer; advisory board-Optos; Alcon
FX Neil M. Bressler: Neil M. Bressler's employer, the Johns Hopkins
   University (JHU), but not Dr. Bressler, receives funding from Allergan,
   Bausch & Lomb, Carl Zeiss Meditec, Genentech, Notal Vision Inc,
   Novartis, Othera, QLT, Regeneron, and Steba Pharmaceuticals for
   sponsored projects by the Department of Ophthalmology for the efforts of
   Dr. Bressler. Dr. Bressler receives salary support for these sponsored
   projects; the terms of these projects are negotiated and administered by
   JHU's Office of Research Administration. Under JHU's policy, support for
   the costs of research, administered by the institution, does not
   constitute a conflict of interest.; Rohit Varma: Consultant-Alcon,
   Allergan, Aquesys, Bausch & Lomb, Genentech, Merck, Replenish, and
   Pfizer; financial support-Allergan, Genentech, Optovue, and Pfizer.;
   Ivan Suner: Consultant-Bausch & Lomb, Eyetech, Genentech, Optos, and
   Pfizer; financial support-Genentech; advisory board-Optos.; Paul Lee:
   Consultant-Pfizer and Genentech; financial support-Alcon and Pfizer;
   equity owner-Pfizer and Merck.
CR American Medical Association, 2010, PHYS GUID ASS COUNS
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Broman AT, 2001, INVEST OPHTH VIS SCI, V42, P606
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Casson EJ, 2000, CAN J OPHTHALMOL, V35, P192, DOI 10.1016/S0008-4182(00)80030-7
   Edwards JD, 2009, J GERONTOL A-BIOL, V64, P300, DOI 10.1093/gerona/gln019
   Fonda SJ, 2001, J GERONTOL B-PSYCHOL, V56, pS343, DOI 10.1093/geronb/56.6.S343
   Hawkins BS, 2005, ARCH OPHTHALMOL-CHIC, V123, P78, DOI 10.1001/archopht.123.1.78
   KINGTON R, 1994, AM J PUBLIC HEALTH, V84, P1327, DOI 10.2105/AJPH.84.8.1327
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Mangione CM, VERSION 2000 NATL EY
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Owsley C, 1999, SURV OPHTHALMOL, V43, P535, DOI 10.1016/S0039-6257(99)00035-1
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Talic I, 2022, LEARN INSTR, V81, DOI [10.1016/j.learninstruc.2022.101594, 10.1016/j.ajo.2004.02.011]
NR 23
TC 17
Z9 18
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2013
VL 120
IS 1
BP 160
EP 168
DI 10.1016/j.ophtha.2012.07.027
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 063PI
UT WOS:000313011700023
PM 23009891
DA 2022-11-30
ER

PT J
AU Karagiannis, DA
   Soublis, V
   Kandarakis, A
AF Karagiannis, Dimitrios A.
   Soublis, Vasilios
   Kandarakis, Artemios
TI A case of polypoidal choroidal vasculopathy. Periphery is equally
   important for such patients
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Article
DE argon laser; peripheral vision; polypoidal choroidal vasculopathy
AB Background: To report a case of peripheral polypoidal choroidal vasculopathy (PCV) which was treated successfully.
   Methods: Interventional case report. Best-corrected visual acuity measurements (BCVA), slit-lamp examination, fundus biomicroscopy, fluorescein angiography (FFA), and indocyanine green angiography (ICGA) were performed at baseline examination and during the follow-up period. The patient underwent ICGA-guided argon laser to treat the active polyps.
   Results: An 82-year-old Caucasian man presented complaining of sudden deterioration of peripheral vision in his left eye (LE). His previous ocular history was associated with advanced age-related macular degeneration (AMD) involving both eyes (BE). Fundus examination revealed macular scars in BE and a large hemorrhagic pigment epithelial detachment (PED) temporal to the macula in the LE. ICGA revealed active polyps at the margins of the PED. The patient underwent ICGA-guided argon laser to treat the active polyps. Six months post-laser, the patient regained his peripheral vision with resolution of the hemorrhagic PED and remains stable until now, one year after treatment.
   Conclusions: Appropriate treatment and regular follow-up is important in patients with PCV and peripheral lesions even if central vision is lost.
C1 [Karagiannis, Dimitrios A.; Soublis, Vasilios; Kandarakis, Artemios] Ophthalmiatrio Eye Hosp Athens, Dept Ophthalmol 1, Athens, Greece.
RP Karagiannis, DA (通讯作者)，5 Dimokratias Ave, Athens 14572, Greece.
EM dimitrioskaragiannis@doctors.org.uk
CR Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 8
TC 5
Z9 6
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1176-9092
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2009
VL 4
BP 315
EP 317
PG 3
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA V21WZ
UT WOS:000208239000033
PM 19750233
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Chen, YY
   Chen, YY
   Sheu, SJ
AF Chen, Yu-Yen
   Chen, Ying-Ying
   Sheu, Shwu-Jiuan
TI Spontaneous Suprachoroidal Hemorrhage Associated with Age-related
   Macular Degeneration and Anticoagulation Therapy
SO JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
LA English
DT Article
DE age-related macular degeneration; anticoagulation therapy; choroidal
   drainage; spontaneous suprachoroidal hemorrhage
ID CHOROIDAL HEMORRHAGE
AB Suprachoroidal hemorrhage is a rare but dreadful event. We report the case of an 86-year-old man with age-related macular degeneration (ARMD) in both eyes. He had been receiving anticoagulation therapy for several years for systemic disease. He presented with severe headache and intractable pain in his right eye. Vision was no light perception, and the intraocular pressure was 50 mmHg in the right eye despite maximal antiglaucoma medications. Slit-lamp and B-scan examination disclosed suprachoroidal hemorrhage in the right eye. Nine days later, he underwent choroidal drainage, which only relieved the symptoms for 1 day. Suprachoroidal hemorrhage recurred and evisceration was performed. This case illustrates how ARMD with anticoagulation therapy could cause spontaneous suprachoroidal hemorrhage. Therefore, anticoagulants should be meticulously prescribed with prothrombin time monitored regularly in ARMD patients. [J Chin Med Assoc 2009;72(7):385-387]
C1 [Chen, Yu-Yen; Chen, Ying-Ying; Sheu, Shwu-Jiuan] Kaohsiung Vet Gen Hosp, Dept Ophthalmol, Kaohsiung 813, Taiwan.
   [Chen, Ying-Ying; Sheu, Shwu-Jiuan] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
C3 Kaohsiung Veterans General Hospital; National Yang Ming Chiao Tung
   University
RP Chen, YY (通讯作者)，Kaohsiung Vet Gen Hosp, Dept Ophthalmol, 386 Ta Chung 1st Rd, Kaohsiung 813, Taiwan.
EM yychen971209@yahoo.com.tw
CR Alexandrakis G, 1998, RETINA-J RET VIT DIS, V18, P485, DOI 10.1097/00006982-199805000-00023
   Chorich LJ, 1998, OPHTHALMOLOGY, V105, P428, DOI 10.1016/S0161-6420(98)93023-8
   Chu TG, 1999, SURV OPHTHALMOL, V43, P471, DOI 10.1016/S0039-6257(99)00037-5
   Khawly JA, 1996, AM J OPHTHALMOL, V121, P577, DOI 10.1016/S0002-9394(14)75438-8
   Knox FA, 2002, EYE, V16, P669, DOI 10.1038/sj.eye.6700109
   Scott IU, 1997, OPHTHALMOLOGY, V104, P2039, DOI 10.1016/S0161-6420(97)30042-6
   WONG JS, 1997, AUST NZ J OPHTHALMOL, V27, P433
   Yang SS, 2003, RETINA-J RET VIT DIS, V23, P139, DOI 10.1097/00006982-200304000-00001
NR 8
TC 5
Z9 6
U1 0
U2 1
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 1726-4901
J9 J CHIN MED ASSOC
JI J. Chin. Med. Assoc.
PD JUL
PY 2009
VL 72
IS 7
BP 385
EP 387
DI 10.1016/S1726-4901(09)70393-4
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 475GC
UT WOS:000268345600010
PM 19581147
OA Bronze
DA 2022-11-30
ER

PT J
AU Cimaglia, G
   Votruba, M
   Morgan, JE
   Andre, H
   Williams, PA
AF Cimaglia, Gloria
   Votruba, Marcela
   Morgan, James E.
   Andre, Helder
   Williams, Pete A.
TI Potential Therapeutic Benefit of NAD(+)Supplementation for Glaucoma and
   Age-Related Macular Degeneration
SO NUTRIENTS
LA English
DT Review
DE nicotinamide adenine dinucleotide; glaucoma; age-related macular
   degeneration; mitochondria; retina; optic nerve; retinal pigment
   epithelium
ID VERTEPORFIN PHOTODYNAMIC THERAPY; LIGHT-INDUCED PHOTORECEPTOR; LEBER
   CONGENITAL AMAUROSIS; RETINAL GANGLION-CELLS; OXIDATIVE STRESS;
   MITOCHONDRIAL DYSFUNCTION; LIFE-SPAN; DIPHOSPHOPYRIDINE NUCLEOTIDE;
   WALLERIAN DEGENERATION; NICOTINAMIDE RIBOSIDE
AB Glaucoma and age-related macular degeneration are leading causes of irreversible blindness worldwide with significant health and societal burdens. To date, no clinical cures are available and treatments target only the manageable symptoms and risk factors (but do not remediate the underlying pathology of the disease). Both diseases are neurodegenerative in their pathology of the retina and as such many of the events that trigger cell dysfunction, degeneration, and eventual loss are due to mitochondrial dysfunction, inflammation, and oxidative stress. Here, we critically review how a decreased bioavailability of nicotinamide adenine dinucleotide (NAD; a crucial metabolite in healthy and disease states) may underpin many of these aberrant mechanisms. We propose how exogenous sources of NAD may become a therapeutic standard for the treatment of these conditions.
C1 [Cimaglia, Gloria; Andre, Helder; Williams, Pete A.] Karolinska Inst, Dept Clin Neurosci, Div Eye & Vis, St Erik Eye Hosp, S-11282 Stockholm, Sweden.
   [Cimaglia, Gloria; Votruba, Marcela; Morgan, James E.] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF24 4HQ, Wales.
   [Votruba, Marcela] Univ Hosp Wales, Cardiff Eye Unit, Cardiff CF14 4XW, Wales.
   [Morgan, James E.] Cardiff Univ, Sch Med, Cardiff CF14 4YS, Wales.
C3 Karolinska Institutet; Cardiff University; Cardiff University; Cardiff
   University
RP Andre, H; Williams, PA (通讯作者)，Karolinska Inst, Dept Clin Neurosci, Div Eye & Vis, St Erik Eye Hosp, S-11282 Stockholm, Sweden.
EM CimagliaG@cardiff.ac.uk; VotrubaM@cardiff.ac.uk;
   morganje3@cardiff.ac.uk; Helder.Andre@ki.se; Pete.Williams@ki.se
RI Morgan, James/GRO-2905-2022
OI Morgan, James/0000-0002-8920-1065; Andre, Helder/0000-0002-2926-2376;
   Williams, Pete/0000-0001-6194-8397
FU Fight for Sight Studentship [515905]; Vetenskapsradet (the Swedish
   Research Council) [2018-02124]; Karolinska Institutet
FX Fight for Sight Studentship (515905; James Morgan) and Vetenskapsradet
   (the Swedish Research Council; 2018-02124; Pete Williams) provided
   funding. Pete Williams is supported by the Karolinska Institutet in the
   form of a Board of Research Faculty Funded Career Position. PeteWilliams
   and Helder Andre are supported by St. Erik Eye Hospital philanthropic
   donations.
CR Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Algvere PV, 2016, ACTA OPHTHALMOL, V94, P427, DOI 10.1111/aos.13011
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   Alqawlaq Samih, 2019, Exp Eye Res, V183, P88, DOI 10.1016/j.exer.2018.11.005
   Aman Y, 2020, MECH AGEING DEV, V185, DOI 10.1016/j.mad.2019.111194
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Andre H, 2015, INVEST OPHTH VIS SCI, V56, P6591, DOI 10.1167/iovs.15-16476
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Attar Mayssa, 2005, Expert Opin Drug Deliv, V2, P891, DOI 10.1517/17425247.2.5.891
   Audrito V, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01720
   Bai S, 2013, EXP EYE RES, V108, P76, DOI 10.1016/j.exer.2012.12.007
   Bergen Arthur A, 2017, Stem Cell Investig, V4, P81, DOI 10.21037/sci.2017.09.05
   Berger F, 2005, J BIOL CHEM, V280, P36334, DOI 10.1074/jbc.M508660200
   Berrino E, 2019, EXPERT OPIN THER PAT, V29, P817, DOI 10.1080/13543776.2019.1670812
   Bieganowski P, 2004, CELL, V117, P495, DOI 10.1016/S0092-8674(04)00416-7
   Binley KE, 2016, EUR J NEUROSCI, V44, P2028, DOI 10.1111/ejn.13295
   Boatright J, 2019, ACTA OPHTHALMOL, V97, DOI 10.1111/j.1755-3768.2019.8302
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Canto C, 2015, CELL METAB, V22, P31, DOI 10.1016/j.cmet.2015.05.023
   Carelli V, 2009, BBA-BIOENERGETICS, V1787, P518, DOI 10.1016/j.bbabio.2009.02.024
   Casson RJ, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100881
   Castro-Portuguez R, 2020, EXP GERONTOL, V132, DOI 10.1016/j.exger.2020.110841
   Chaban Y, 2014, BBA-BIOENERGETICS, V1837, P418, DOI 10.1016/j.bbabio.2013.10.004
   Cheng SY, 2020, P NATL ACAD SCI USA, V117, P13094, DOI 10.1073/pnas.2000339117
   Chew E.Y., 2018, RETIN PHYS, V15, P31
   Chong RS, 2014, EXPERT REV OPHTHALMO, V9, P149, DOI 10.1586/17469899.2014.917048
   Conforti L, 2007, TRENDS NEUROSCI, V30, P159, DOI 10.1016/j.tins.2007.02.004
   Conlon R, 2017, CAN J OPHTHALMOL, V52, P114, DOI 10.1016/j.jcjo.2016.07.013
   Conze D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46120-z
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Demmig-Adams B, 2020, MOLECULES, V25, DOI 10.3390/molecules25163607
   Di Caprio R, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/329418
   Di Marco S, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8070224
   Di Polo A, 1998, P NATL ACAD SCI USA, V95, P3978, DOI 10.1073/pnas.95.7.3978
   Di Stefano M, 2017, CURR BIOL, V27, P784, DOI 10.1016/j.cub.2017.01.070
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Eastlake K, 2020, CURR EYE RES, V45, P339, DOI 10.1080/02713683.2019.1648831
   Ebeling MC, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101552
   Ermak G, 2002, MOL IMMUNOL, V38, P713, DOI 10.1016/S0161-5890(01)00108-0
   Falk MJ, 2012, NAT GENET, V44, P1040, DOI 10.1038/ng.2361
   Fang EF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13172-8
   Fang EF, 2017, TRENDS MOL MED, V23, P899, DOI 10.1016/j.molmed.2017.08.001
   Fang EF, 2017, AUTOPHAGY, V13, P442, DOI 10.1080/15548627.2016.1257467
   Fang EF, 2016, CELL METAB, V24, P566, DOI 10.1016/j.cmet.2016.09.004
   Feher J, 2012, ACAD PR SER BIOM ENG, P419
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fricker RA, 2018, INT J TRYPTOPHAN RES, V11, DOI 10.1177/1178646918776658
   Gasperi V, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040974
   Giansanti F, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006931.pub2
   Gilley J, 2019, HUM MOL GENET, V28, P448, DOI 10.1093/hmg/ddy356
   Gilley J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000300
   Green DR, 2014, SCIENCE, V345, P1466, DOI 10.1126/science.1250256
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Gurubaran IS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061976
   Haiden A, 1906, P R SOC LOND B-CONTA, V78, P369
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Harden A, 1906, P R SOC LOND B-CONTA, V77, P405, DOI 10.1098/rspb.1906.0029
   Hegyi J, 2004, INT J DERMATOL, V43, P1, DOI 10.1111/j.1365-4632.2004.01959.x
   Heitmar R, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030649
   Hicks AN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047869
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Howell GR, 2007, J CELL BIOL, V179, P1523, DOI 10.1083/jcb.200706181
   Hoyng PFJ, 2002, SURV OPHTHALMOL, V47, pS116, DOI 10.1016/S0039-6257(02)00322-3
   Hui FR, 2020, CLIN EXP OPHTHALMOL, V48, P903, DOI 10.1111/ceo.13818
   Hyttinen JMT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225800
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622
   Imai S, 2014, TRENDS CELL BIOL, V24, P464, DOI 10.1016/j.tcb.2014.04.002
   Ito YA, 2017, MITOCHONDRION, V36, P186, DOI 10.1016/j.mito.2017.08.014
   Jadeja RN, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2692794
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Ji D, 2008, NEUROCHEM INT, V52, P786, DOI 10.1016/j.neuint.2007.09.012
   Ji JZ, 2004, EUR J NEUROSCI, V19, P265, DOI 10.1111/j.0953-816X.2003.03107.x
   Johnson EC, 2009, J GLAUCOMA, V18, P341, DOI 10.1097/IJG.0b013e31818c6ef6
   Johnson EC, 2009, EXP EYE RES, V88, P808, DOI 10.1016/j.exer.2009.02.004
   Jonas JB, 2017, LANCET, V390, P2183, DOI 10.1016/S0140-6736(17)31469-1
   Jones M, 2004, AM J OPHTHALMOL, V138, P1051, DOI 10.1016/j.ajo.2004.06.026
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaiser PK, 2007, CURR MED RES OPIN, V23, P477, DOI 10.1185/030079907X167624
   Kamel K, 2017, MITOCHONDRION, V35, P44, DOI 10.1016/j.mito.2017.05.004
   Katsyuba E, 2020, NAT METAB, V2, P9, DOI 10.1038/s42255-019-0161-5
   Kertes PJ, 2004, RETINA-J RET VIT DIS, V24, P219, DOI 10.1097/00006982-200404000-00005
   Khan NA, 2014, EMBO MOL MED, V6, P721, DOI 10.1002/emmm.201403943
   Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805
   Kitaoka Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.391
   Knip M, 2000, DIABETOLOGIA, V43, P1337, DOI 10.1007/s001250051536
   Koenekoop RK, 2012, NAT GENET, V44, P1035, DOI 10.1038/ng.2356
   Kong GYX, 2009, J GLAUCOMA, V18, P93, DOI 10.1097/IJG.0b013e318181284f
   Kuribayashi H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0907-0
   Lambiase A, 2009, P NATL ACAD SCI USA, V106, P13469, DOI 10.1073/pnas.0906678106
   Lamin A, 2019, EYE, V33, P910, DOI 10.1038/s41433-019-0338-x
   Lautrup S, 2019, CELL METAB, V30, P630, DOI 10.1016/j.cmet.2019.09.001
   Lee CF, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39419-4
   Lee DA, 2005, AM J HEALTH-SYST PH, V62, P691, DOI 10.1093/ajhp/62.7.691
   Leveillard T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030762
   Levin LA, 2017, EXP EYE RES, V157, P34, DOI 10.1016/j.exer.2016.12.005
   Li L, 2015, EXP EYE RES, V136, P116, DOI 10.1016/j.exer.2015.04.020
   Libby RT, 2005, VISUAL NEUROSCI, V22, P637, DOI 10.1017/S0952523805225130
   Libby RT, 2005, PLOS GENET, V1, P17, DOI 10.1371/journal.pgen.0010004
   Lightowlers RN, 2014, EMBO MOL MED, V6, P705, DOI 10.15252/emmm.201404179
   Lin JB, 2018, PROG RETIN EYE RES, V67, P118, DOI 10.1016/j.preteyeres.2018.06.002
   Lin JB, 2016, CELL REP, V17, P69, DOI 10.1016/j.celrep.2016.08.073
   Lin MK, 2012, INVEST OPHTH VIS SCI, V53, P6197, DOI 10.1167/iovs.11-8936
   Lindqvist N, 2004, EXP NEUROL, V187, P487, DOI 10.1016/j.expneurol.2004.02.002
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Loreto A, 2020, NEUROBIOL DIS, V134, DOI 10.1016/j.nbd.2019.104678
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Luo HD, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00366
   Maes ME, 2017, PROG RETIN EYE RES, V57, P1, DOI 10.1016/j.preteyeres.2017.01.002
   Mammadzada P, 2020, CELL MOL LIFE SCI, V77, P819, DOI 10.1007/s00018-019-03422-9
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Marshak D.W., 2009, RETINAL GANGLION CEL, P211
   Martens CR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03421-7
   Mattson MP, 2018, CELL METAB, V27, P1176, DOI 10.1016/j.cmet.2018.05.011
   McElnea E.M., 2011, INVESTIG OPHTHALMOL, V52, P2677, DOI [10.1186/1471-2415-14-15325444463, DOI 10.1186/1471-2415-14-15325444463]
   Mi WQ, 2005, BRAIN, V128, P405, DOI 10.1093/brain/awh368
   Mimura T, 2013, EXP EYE RES, V116, P17, DOI 10.1016/j.exer.2013.07.017
   Morabia A, 2008, J ROY SOC MED, V101, P566, DOI 10.1258/jrsm.2008.08k010
   Morgan JE, 2017, EYE, V31, P199, DOI 10.1038/eye.2016.290
   Morgan JE, 2012, CLIN EXP OPHTHALMOL, V40, P364, DOI 10.1111/j.1442-9071.2012.02789.x
   Morgan JE, 2000, EYE, V14, P437, DOI 10.1038/eye.2000.128
   Murillo AG, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090390
   Naik S, 2020, EUR J PHARMACOL, V881, DOI 10.1016/j.ejphar.2020.173208
   Nocentini A, 2019, EXPERT OPIN THER PAT, V29, P805, DOI 10.1080/13543776.2019.1665023
   Nzoughet JK, 2019, INVEST OPHTH VIS SCI, V60, P2509, DOI 10.1167/iovs.19-27099
   Opitz CA, 2015, BIOCHEM SOC T, V43, P1127, DOI 10.1042/BST20150133
   Orrenius S, 2015, BIOCHEM BIOPH RES CO, V460, P72, DOI 10.1016/j.bbrc.2015.01.137
   Osborne NN, 2010, EXP EYE RES, V90, P750, DOI 10.1016/j.exer.2010.03.008
   Papa L, 2014, MOL CELL BIOL, V34, P699, DOI 10.1128/MCB.01337-13
   Pellegrino MW, 2013, BBA-MOL CELL RES, V1833, P410, DOI 10.1016/j.bbamcr.2012.02.019
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pfeiffer RL, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.07.004
   Poddar SK, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9010034
   Poljsak B, 2018, TRENDS FOOD SCI TECH, V79, P198, DOI 10.1016/j.tifs.2018.07.020
   PREISS J, 1958, J BIOL CHEM, V233, P488
   PREISS J, 1958, J BIOL CHEM, V233, P493
   Qu J, 2010, EXP EYE RES, V91, P48, DOI 10.1016/j.exer.2010.04.002
   Quarona V, 2013, CYTOM PART B-CLIN CY, V84B, P207, DOI 10.1002/cyto.b.21092
   Rasti G, 2020, PRINCIPLES OF NUTRIGENETICS AND NUTRIGENOMICS: FUNDAMENTALS OF INDIVIDUALIZED NUTRITION, P287, DOI 10.1016/B978-0-12-804572-5.00038-0
   Reinecke F, 2009, BBA-MOL BASIS DIS, V1792, P1113, DOI 10.1016/j.bbadis.2009.04.003
   Rogina B, 2002, SCIENCE, V298, P1745, DOI 10.1126/science.1078986
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Sasaki Y, 2006, J NEUROSCI, V26, P8484, DOI 10.1523/JNEUROSCI.2320-06.2006
   Sasaki Y, 2015, J BIOL CHEM, V290, P17228, DOI 10.1074/jbc.M115.637850
   Sasaki Y, 2009, J NEUROSCI, V29, P6526, DOI 10.1523/JNEUROSCI.1429-09.2009
   Sasaki Y, 2009, J NEUROSCI, V29, P5525, DOI 10.1523/JNEUROSCI.5469-08.2009
   Sauve AA, 2008, J PHARMACOL EXP THER, V324, P883, DOI 10.1124/jpet.107.120758
   Schultz MB, 2016, CELL METAB, V23, P965, DOI 10.1016/j.cmet.2016.05.022
   Schwartz Kenneth, 2004, Curr Opin Ophthalmol, V15, P119, DOI 10.1097/00055735-200404000-00011
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Sedlackova L., 2020, AUTOPHAGY PROMOTES C, DOI 10.1101/2020.01.31.928424
   Seitz R, 2013, CELL TISSUE RES, V353, P339, DOI 10.1007/s00441-013-1666-y
   Sheline CT, 2010, MOL VIS, V16, P2639
   Shpilka T, 2018, NAT REV MOL CELL BIO, V19, P109, DOI 10.1038/nrm.2017.110
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Smith RO, 2020, ELIFE, V9, DOI 10.7554/eLife.54056
   Solleiro-Villavicencio H, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00114
   Song SB, 2019, METABOLOMICS, V15, DOI 10.1007/s11306-019-1604-4
   Srivastava S, 2017, GENES-BASEL, V8, DOI 10.3390/genes8120398
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Syc-Mazurek SB, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.07.002
   Tamm ER, 2017, EXP EYE RES, V157, P5, DOI 10.1016/j.exer.2017.02.006
   TANG BL, 2019, CELLS-BASEL, V8, DOI DOI 10.3390/CELLS8030267
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tezel G, 2008, PROG BRAIN RES, V173, P409, DOI 10.1016/S0079-6123(08)01128-X
   Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638
   van der Veer E, 2007, J BIOL CHEM, V282, P10841, DOI 10.1074/jbc.C700018200
   Vazquez BN, 2017, NUCLEUS-PHILA, V8, P107, DOI 10.1080/19491034.2016.1264552
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   Verdin E, 2015, SCIENCE, V350, P1208, DOI 10.1126/science.aac4854
   Verdin E, 2014, NAT MED, V20, P25, DOI 10.1038/nm.3447
   Vrabec JP, 2007, EYE, V21, pS11, DOI 10.1038/sj.eye.6702880
   Wang H, 2011, INVEST OPHTH VIS SCI, V52, P570, DOI 10.1167/iovs.10-5595
   Wang XD, 2001, GENE DEV, V15, P2922
   Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Wen YH, 2011, MOL CELL NEUROSCI, V48, P1, DOI 10.1016/j.mcn.2011.05.002
   Westenskow Peter D, 2017, Stem Cell Investig, V4, P86, DOI 10.21037/sci.2017.10.01
   Whitmore AV, 2005, PROG RETIN EYE RES, V24, P639, DOI 10.1016/j.preteyeres.2005.04.004
   Williams O, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0068800, 10.1371/journal.pone.0080616, 10.1371/journal.pone.0079344, 10.1371/journal.pone.0081098]
   Williams P.A., 2020, BIORXIV, DOI [10.1101/2020.05.02.072215, DOI 10.1101/2020.05.02.072215]
   Williams Pete A, 2018, Commun Integr Biol, V11, pe1356956, DOI 10.1080/19420889.2017.1356956
   Williams PA, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00232
   Williams PA, 2017, SCIENCE, V355, P756, DOI 10.1126/science.aal0092
   Williams PA, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0091-6
   Williams PA, 2012, BRAIN, V135, P493, DOI 10.1093/brain/awr330
   Williams PA, 2010, BRAIN, V133, P2942, DOI 10.1093/brain/awq218
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yanez M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46678-8
   Yang ZY, 2007, INVEST OPHTH VIS SCI, V48, P5539, DOI 10.1167/iovs.07-0542
   Yates PA, 2015, INVEST OPHTH VIS SCI, V56
   Zabka TS, 2015, TOXICOL SCI, V144, P163, DOI 10.1093/toxsci/kfu268
   Zhang DX, 2016, METABOLISM, V65, P454, DOI 10.1016/j.metabol.2015.11.010
   Zhao GS, 2017, MOL CANCER THER, V16, P2677, DOI 10.1158/1535-7163.MCT-16-0674
   Zhao W, 2008, GRAEF ARCH CLIN EXP, V246, P1413, DOI 10.1007/s00417-008-0858-8
   Zhou L, 2019, EXP EYE RES, V180, P77, DOI 10.1016/j.exer.2018.12.006
   Zhou M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00501
   Zhu YL, 2013, INVEST OPHTH VIS SCI, V54, P25, DOI 10.1167/iovs.12-10861
   Zhu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep26322
NR 215
TC 5
Z9 5
U1 1
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD SEP
PY 2020
VL 12
IS 9
AR 2871
DI 10.3390/nu12092871
PG 21
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA OE2IA
UT WOS:000580359600001
PM 32961812
OA Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Momozawa, Y
   Akiyama, M
   Kamatani, Y
   Arakawa, S
   Yasuda, M
   Yoshida, S
   Oshima, Y
   Mori, R
   Tanaka, K
   Mori, K
   Inoue, S
   Terasaki, H
   Yasuma, T
   Honda, S
   Miki, A
   Inoue, M
   Fujisawa, K
   Takahashi, K
   Yasukawa, T
   Yanagi, Y
   Kadonosono, K
   Sonoda, KH
   Ishibashi, T
   Takahashi, A
   Kubo, M
AF Momozawa, Yukihide
   Akiyama, Masato
   Kamatani, Yoichiro
   Arakawa, Satoshi
   Yasuda, Miho
   Yoshida, Shigeo
   Oshima, Yuji
   Mori, Ryusaburo
   Tanaka, Koji
   Mori, Keisuke
   Inoue, Satoshi
   Terasaki, Hiroko
   Yasuma, Tetsuhiro
   Honda, Shigeru
   Miki, Akiko
   Inoue, Maiko
   Fujisawa, Kimihiko
   Takahashi, Kanji
   Yasukawa, Tsutomu
   Yanagi, Yasuo
   Kadonosono, Kazuaki
   Sonoda, Koh-Hei
   Ishibashi, Tatsuro
   Takahashi, Atsushi
   Kubo, Michiaki
TI Low-frequency coding variants in CETP and CFB are associated with
   susceptibility of exudative age-related macular degeneration in the
   Japanese population
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; HIGH-RISK; CHOLESTEROL EFFLUX;
   GENETIC-VARIANTS; RARE; LOCI; MACROPHAGES; PREVALENCE; CONFERS
AB Age-related macular degeneration (AMD) is a major cause of blindness in the elderly. Previous sequencing studies of AMD susceptibility genes have revealed the association of rare coding variants in CFH, CFI, C3 and C9 in European population; however, the impact of rare or low-frequency coding variants on AMD susceptibility in other populations is largely unknown. To identify the role of low-frequency coding variants on exudative AMD susceptibility in a Japanese population, we analysed the association of coding variants of 34 AMD candidate genes in the two-stage design by a multiplex PCR-based target sequencing method. We used a total of 2,886 (1st: 827, 2nd: 2,059) exudative AMD cases including typical AMD, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation and 9,337 (1st: 3,247 2nd: 6,090) controls. Gene-based analysis found a significant association of low-frequency variants (minor allele frequency (MAF)<0.05) in CETP, C2 and CFB. The association of CETP remained after conditioned with all known genome-wide association study (GWAS) associated variants. In addition, when we included only disruptive variants, enrichment of rare variants (MAF<0.01) was also observed after conditioned with all GWAS associated variants (P = 1.03 x 10(-6), odds ratio (OR) = 2.48). Haplotype and conditional analysis of the C2-CFB-SKIV2L locus showed a low-frequency variant (R74H) in CFB would be individually associated with AMD susceptibility independent of the GWAS associated SNP. These findings highlight the importance of target sequencing to reveal the impact of rare or low-frequency coding variants on disease susceptibility in different ethnic populations.
C1 [Momozawa, Yukihide; Akiyama, Masato; Kubo, Michiaki] RIKEN Ctr Integrat Med Sci, Lab Genotyping Dev, Yokohama, Kanagawa, Japan.
   [Akiyama, Masato; Kamatani, Yoichiro; Takahashi, Atsushi] RIKEN Ctr Integrat Med Sci, Lab Stat Anal, Yokohama, Kanagawa, Japan.
   [Akiyama, Masato; Arakawa, Satoshi; Yasuda, Miho; Yoshida, Shigeo; Oshima, Yuji; Sonoda, Koh-Hei; Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka, Japan.
   [Arakawa, Satoshi; Fujisawa, Kimihiko] Kyushu Hosp, Japan Community Hlth Care Org, Fukuoka, Japan.
   [Mori, Ryusaburo; Tanaka, Koji] Nihon Univ, Sch Med, Nihon Univ Hosp, Div Ophthalmol,Dept Visual Sci, Tokyo, Japan.
   [Mori, Keisuke] Saitama Med Univ, Dept Ophthalmol, Saitama, Japan.
   [Mori, Keisuke] Int Univ Hlth & Welf Hosp, Dept Ophthalmol, Shimoutske, Tochigi, Japan.
   [Inoue, Satoshi] Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Saitama, Japan.
   [Terasaki, Hiroko; Yasuma, Tetsuhiro] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi, Japan.
   [Honda, Shigeru; Miki, Akiko] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol, Kobe, Hyogo, Japan.
   [Inoue, Maiko] Yokohama City Univ, Med Ctr, Dept Ophthalmol, Yokohama, Kanagawa, Japan.
   [Takahashi, Kanji] Kansai Med Univ, Dept Ophthalmol, Osaka, Japan.
   [Yasukawa, Tsutomu] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi, Japan.
   [Yanagi, Yasuo] Univ Tokyo, Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Yanagi, Yasuo] Singapore Eye Res Inst, Singapore, Singapore.
   [Yanagi, Yasuo] Singapore Natl Eye Ctr, Med Retina Dept, Singapore, Singapore.
   [Kadonosono, Kazuaki] Yokohama City Univ, Grad Sch Med, Dept Ophthalmol & Microtechnol, Yokohama, Kanagawa, Japan.
C3 RIKEN; RIKEN; Kyushu University; Nihon University; Saitama Medical
   University; International University of Health & Welfare; Saitama
   Medical University; Nagoya University; Kobe University; Yokohama City
   University; Kansai Medical University; Nagoya City University;
   University of Tokyo; National University of Singapore; Singapore
   National Eye Center; Singapore National Eye Center; Yokohama City
   University
RP Kubo, M (通讯作者)，RIKEN, Ctr Integrat Med Sci, Lab Genotyping Dev, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.
EM michiaki.kubo@riken.jp
RI Honda, Shigeru/W-4761-2019; Yanagi, Yasuo/AAA-5441-2022; Yanagi,
   Yasuo/AAF-2670-2020; Tanaka, Koji/H-3119-2019; Akiyama,
   Masato/AHC-2589-2022
OI Tanaka, Koji/0000-0003-3323-4148; Yoshida, Shigeo/0000-0003-1049-8909;
   Yanagi, Yasuo/0000-0002-0362-7285
FU Japan Agency for Medical Research and Development; Ministry of
   Education, Culture, Sports, Sciences and Technology of the Japanese
   government; JSPS KAKENHI [24249083]
FX This work was conducted as part of the BioBank Japan Project supported
   by the Japan Agency for Medical Research and Development and by the
   Ministry of Education, Culture, Sports, Sciences and Technology of the
   Japanese government. This work was also partially supported by JSPS
   KAKENHI [grant number 24249083].
CR Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Auton A., 2015, NATURE, V7571, P68, DOI 10.1038/nature15393
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806
   Farrell CM, 2014, NUCLEIC ACIDS RES, V42, pD865, DOI 10.1093/nar/gkt1059
   Feng S, 2014, BIOINFORMATICS, V30, P2828, DOI 10.1093/bioinformatics/btu367
   Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Harismendy O, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-r124
   Hughes AE, 2011, MOL VIS, V17, P983
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp324, 10.1093/bioinformatics/btp100]
   Matsuura F, 2006, J CLIN INVEST, V116, P1435, DOI 10.1172/JCI27602
   Morgenthaler S, 2007, MUTAT RES-FUND MOL M, V615, P28, DOI 10.1016/j.mrfmmm.2006.09.003
   Nagano Makoto, 2004, J Atheroscler Thromb, V11, P110
   Nakamura Yusuke, 2007, Clin Adv Hematol Oncol, V5, P696
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Stephens M, 2005, AM J HUM GENET, V76, P449, DOI 10.1086/428594
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wu MC, 2011, AM J HUM GENET, V89, P82, DOI 10.1016/j.ajhg.2011.05.029
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zuk O, 2014, P NATL ACAD SCI USA, V111, pE455, DOI 10.1073/pnas.1322563111
NR 36
TC 42
Z9 43
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD NOV 15
PY 2016
VL 25
IS 22
BP 5027
EP 5034
DI 10.1093/hmg/ddw335
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA EP0FO
UT WOS:000397062700015
PM 28173125
DA 2022-11-30
ER

PT J
AU Schmier, JK
   Jones, ML
   Halpern, MT
AF Schmier, JK
   Jones, ML
   Halpern, MT
TI The burden of age-related macular degeneration
SO PHARMACOECONOMICS
LA English
DT Article
ID PHOTODYNAMIC THERAPY; COST-EFFECTIVENESS; VISUAL IMPAIRMENT; LASER
   PHOTOCOAGULATION; RISK-FACTORS; LOW-VISION; EYE CARE; UTILITY;
   PREVALENCE; SERVICES
AB As age-related macular degeneration (AMD) becomes more prevalent as a result of longer life expectancy and the number of elderly people worldwide, it will become increasingly important to understand its potential health and economic impact for appropriate healthcare planning. This review identified published literature on costs and resource use associated with AMD.
   Despite the increasing prevalence of AMD, the worldwide burden of illness is unknown. Several studies of direct medical costs, both those associated with ophthalmic care and those associated with other care, have been conducted and have identified increased medical care associated with AMD. Direct non-medical costs include the cost for vision aids; while these costs may be substantial, they are difficult to quantify as no comprehensive sources track the distribution or use of vision aids. Because AMD is uncommon among people of working age, there is less concern regarding the impact of indirect (workplace) costs among AMD patients. However, indirect costs are incurred by caregivers who leave the workforce early or change their work patterns in order to provide assistance to AMD patients; the magnitude of caregiver-related costs is unknown.
   The cost effectiveness of some interventions for AMID has been explored. Supplementation with zinc and antioxidants for non-exudative (dry) AMD has been shown to result in an acceptable cost per QALY and is considered cost effective. Studies suggest that laser photocoagulation is cost effective but that photodynamic therapy with verteporfin appears to be cost effective only among patients with good visual acuity at baseline or when models extend longer than 5 years.
   Further research is needed to integrate the information on various components of AMD-related costs into a comprehensive burden of illness estimate and to evaluate basic utility assumptions in existing models.
RP Halpern, MT (通讯作者)，Exponent, Alexandria, VA 22314 USA.
EM mhalpern@exponent.com
RI Schmier, Jordana/I-2994-2019
OI Schmier, Jordana/0000-0002-4662-8800; Halpern,
   Michael/0000-0001-8514-6313
CR Aditya BS, 2003, CLIN REHABIL, V17, P108, DOI 10.1191/0269215503cr567oa
   *AM AC OPHTH RET P, AG REL MAC DEG ONL
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2000, OPHTHALMOLOGY, V107, P1374, DOI 10.1016/S0161-6420(00)00169-X
   Busbee BG, 2003, RETINA-J RET VIT DIS, V23, P279, DOI 10.1097/00006982-200306000-00001
   Churchill AJ, 1998, BRIT J OPHTHALMOL, V82, P373, DOI 10.1136/bjo.82.4.373
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   DILTS DM, 1994, OPTOMETRY VISION SCI, V71, P422, DOI 10.1097/00006324-199407000-00002
   Dorfman LT, 1997, SOC WORK HEALTH CARE, V26, P33, DOI 10.1300/J010v26n02_03
   Ellwein LB, 1996, OPHTHALMOLOGY, V103, P1732, DOI 10.1016/S0161-6420(96)30433-8
   Ellwein LB, 2002, ARCH OPHTHALMOL-CHIC, V120, P804
   Foran S, 2002, ARCH OPHTHALMOL-CHIC, V120, P613, DOI 10.1001/archopht.120.5.613
   FRENKEL M, 1986, ARCH OPHTHALMOL-CHIC, V104, P1609
   Garattini Livio, 2004, Eur J Health Econ, V5, P22
   Goodrich G L, 2001, Optometry, V72, P519
   Greiner R A, 2001, Semin Ophthalmol, V16, P218, DOI 10.1076/soph.16.4.218.10302
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Hopley C, 2003, CLIN EXP OPHTHALMOL, V31, P522, DOI 10.1046/j.1442-9071.2003.00715.x
   Javitt JC, 1996, OPHTHALMIC SURG LAS, V27, P575
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEINMAN L, 2002, CONSULTANT PHARM, V17, P497
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Legood R, 2002, INJ PREV, V8, P155, DOI 10.1136/ip.8.2.155
   MARX MS, 1992, J AM GERIATR SOC, V40, P1018, DOI 10.1111/j.1532-5415.1992.tb04479.x
   McIlwaine G G, 1991, Eye (Lond), V5 ( Pt 5), P607
   MEADS C, 2001, 24 U BIRM DEP PUBL H
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Moore MJ, 2001, J GERONTOL B-PSYCHOL, V56, pS219, DOI 10.1093/geronb/56.4.S219
   Morse AR, 1999, ARCH OPHTHALMOL-CHIC, V117, P943
   O'Neill C, 2001, DRUG AGING, V18, P233, DOI 10.2165/00002512-200118040-00001
   Park W, 1999, INT OPHTHALMOL CLIN, V39, P143, DOI 10.1097/00004397-199903940-00010
   Rechtman Ehud, 2002, Expert Opin Pharmacother, V3, P931, DOI 10.1517/14656566.3.7.931
   SCHMIER JK, 2004, JOINT M AM AC OPHTH
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Trevithick JR, 2004, OPHTHAL EPIDEMIOL, V11, P337, DOI 10.1080/09286580490888780
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
NR 50
TC 27
Z9 30
U1 0
U2 12
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-7690
EI 1179-2027
J9 PHARMACOECONOMICS
JI Pharmacoeconomics
PY 2006
VL 24
IS 4
BP 319
EP 334
DI 10.2165/00019053-200624040-00003
PG 16
WC Economics; Health Care Sciences & Services; Health Policy & Services;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Business & Economics; Health Care Sciences & Services; Pharmacology &
   Pharmacy
GA 038OU
UT WOS:000237233000003
PM 16605279
DA 2022-11-30
ER

PT J
AU Erie, JC
   Good, JA
   Butz, JA
   Hodge, DO
   Pulido, JS
AF Erie, Jay C.
   Good, Jonathan A.
   Butz, John A.
   Hodge, David O.
   Pulido, Jose S.
TI Urinary cadmium and age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID 3RD NATIONAL-HEALTH; 10-YEAR INCIDENCE; OXIDATIVE-STRESS; US POPULATION;
   EXPOSURE; MACULOPATHY; METAL; CIGARETTES; SMOKING; BLOOD
AB PURPOSE: To evaluate the association between urinary and blood cadmium (Cd) levels with age-related macular degeneration (AMD).
   DESIGN: Prospective case,control study.
   METHODS: In 53 participants older than 60 years with AMD in both eyes and in 53 age-matched (+/- 3 years) controls without AMD, Cd levels were measured in blood and urine specimens (with and without creatinine adjustment) by using inductively coupled plasma-mass spectrometry. Data on age, gender, smoking status, and family history were obtained. By using color stereoscopic fundus photographs, the degree of AMD was graded using the Age-Related Eye Disease Study's 4-stage AMD severity scale. The inclusion criterion for AMD cases was a photographic severity level of two to four in both eyes. Median blood and urine Cd and median urine Cd/creatinine concentrations in cases and controls were compared by using the rank-sum test, stratifying for smoking status.
   RESULTS: Current and former smokers with AMD had median urine Cd/creatinine levels (1.18 mu g/g; range, 0.84 to 1.44 mu g/g) that were 97% higher than smokers without AMD (0.60 mu g/g; range, 0.49 to 0.90 mu g/g; P=.02), 111% higher than never smokers with AMD (0.56 mu g/g; range, 0.40 to 0.80 mu g/g; P <.001) and 107% higher than never smokers without AMD (0.57 mu g/g; 0.40 to 0.65 mu g/g; P <.001). Blood Cd levels, indicative of short-term exposure levels, were not associated with AMD (P <.06).
   CONCLUSIONS: A higher urinary Cd level, which reflects the total body burden of Cd, was associated with AMD in smokers. Accumulated Cd exposure may be important in the development of smoking-related AMD.
C1 Mayo Clin, Coll Med, Dept Ophthalmol, Rochester, MN 55905 USA.
   Mayo Clin, Coll Med, Met Lab, Rochester, MN USA.
   Mayo Clin, Coll Med, Dept Hlth Sci, Rochester, MN USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Erie, JC (通讯作者)，Mayo Clin, Coll Med, Dept Ophthalmol, Rochester, MN 55905 USA.
EM erie.jay@mayo.edu
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   *ATSDR, 1999, TOX PROF CAD, P199
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BHATTACHARYYA MH, 2000, MOL BIOL TOXICOLOGY, P276
   Bjorkman L, 2000, ENVIRON HEALTH PERSP, V108, P719, DOI 10.2307/3434724
   CONNALLY G, 2000, 1999 MASSACHUSETTS B
   ELINDER CG, 1983, ENVIRON RES, V32, P220, DOI 10.1016/0013-9351(83)90209-8
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   FLEISCHER M, 1974, Environmental Health Perspectives, V7, P253, DOI 10.2307/3428019
   HIRST RN, 1973, AM REV RESPIR DIS, V108, P30
   Ikeda M, 2003, TOXICOL LETT, V145, P197, DOI 10.1016/S0378-4274(03)00320-5
   Jarup L, 2000, OCCUP ENVIRON MED, V57, P668, DOI 10.1136/oem.57.10.668
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Lee DH, 2006, ENVIRON HEALTH PERSP, V114, P350, DOI 10.1289/ehp.8518
   Mannino DM, 2004, THORAX, V59, P194, DOI 10.1136/thorax.2003.012054
   Mason HJ, 1998, OCCUP ENVIRON MED, V55, P132, DOI 10.1136/oem.55.2.132
   MUSSALORAUHAMAA H, 1986, ARCH ENVIRON HEALTH, V41, P49, DOI 10.1080/00039896.1986.9935765
   Navas-Acien A, 2005, ENVIRON HEALTH PERSP, V113, P164, DOI 10.1289/ehp.7329
   Paschal DC, 2000, ARCH ENVIRON CON TOX, V38, P377, DOI 10.1007/s002449910050
   ROELS HA, 1981, ENVIRON RES, V26, P217, DOI 10.1016/0013-9351(81)90199-7
   STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H
   Trzcinka-Ochocka M, 2004, ENVIRON RES, V95, P143, DOI 10.1016/j.envres.2003.10.003
   ULSHAFER RJ, 1990, ARCH OPHTHALMOL-CHIC, V108, P113, DOI 10.1001/archopht.1990.01070030119041
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Yiin SJ, 1999, J TOXICOL ENV HEAL A, V57, P403, DOI 10.1080/009841099157601
NR 29
TC 30
Z9 31
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2007
VL 144
IS 3
BP 414
EP 418
DI 10.1016/j.ajo.2007.05.020
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 209TW
UT WOS:000249411900012
PM 17631267
DA 2022-11-30
ER

PT J
AU Stringham, JM
   Hammond, BR
   Nolan, JM
   Wooten, BR
   Mammen, A
   Smollon, W
   Snodderly, DM
AF Stringham, J. M.
   Hammond, B. R.
   Nolan, J. M.
   Wooten, B. R.
   Mammen, A.
   Smollon, W.
   Snodderly, D. M.
TI The utility of using customized heterochromatic flicker photometry
   (cHFP) to measure macular pigment in patients with age-related macular
   degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE macular pigment; heterochromatic flicker photometry; lutein; zeaxanthin;
   psychophysics; retina; age-related; macular degeneration
ID OPTICAL-DENSITY; LUTEIN SUPPLEMENTATION; SPATIAL-DISTRIBUTION;
   SENSITIVITY; CAROTENOIDS; LIPOPROTEINS; ZEAXANTHIN
AB The purpose of this study was to assess the utility and validity of using customized heterochromatic flicker photometry (cHFP) to measure macular pigment optical density (MPOD) in patients with intermediate stages of age-related macular degeneration (AMD). The measurement procedure was optimized to accommodate individual differences in temporal vision related to age, disease, or other factors. The validity criteria were based on the similarity of the spectral absorption curves to ex vivo curves of lutein and zeaxanthin and the similarity of spatial density profiles to those measured in subjects without retinal disease. Macular pigment optical density (MPOD) spatial profiles were measured with an LED-based macular densitometer; spectral absorption curves were measured with a 3-channel Maxwellian view system including a monochromator. All patients were characterized via clinical exams and all but 2 subjects from whom data were obtained had masked grading of color fundus photographs using the Wisconsin Age-Related Maculopathy Grading System. Most of the patients were in AREDS category 2 (27%) or 3 (57%). Patients with visual acuity as poor as 20/80 were included, and could perform the task as long as they could see the stimulus. Eighty-one percent of the patients screened were able to perform the cHFP task, and data were obtained from 30 AMD patients. Spatial profiles of MPOD were measured in 19 subjects who could see the stimulus at all tested loci. These profiles were highly similar to those that have been measured with HFP in subjects without retinal disease. The average shape of the spectral absorption curves for the AMD subjects corresponded well to an ex vivo template. These data support both the utility and validity of the cHFP method for measuring MPOD in subjects with intermediate stages of AMD. The ability to measure the retinal response to nutritional intervention is of practical importance for monitoring patients being supplemented with lutein and zeaxanthin in hopes of retarding visual loss and/or disease progression. (c) 2008 Elsevier Ltd. All rights reserved.
C1 [Snodderly, D. M.] Univ Texas Austin, Inst Neurosci, Dept Nutr Sci, Austin, TX 78712 USA.
   [Snodderly, D. M.] Univ Texas Austin, Ctr Perceptual Syst, Austin, TX 78712 USA.
   [Stringham, J. M.; Hammond, B. R.] Univ Georgia, Vis Sci Lab, Athens, GA 30602 USA.
   [Nolan, J. M.] Waterford Inst Technol, Dept Chem & Life Sci, Waterford, Ireland.
   [Wooten, B. R.; Smollon, W.] Brown Univ, Walter S Hunter Lab, Providence, RI 02912 USA.
   [Nolan, J. M.; Mammen, A.; Snodderly, D. M.] Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA.
C3 University of Texas System; University of Texas Austin; University of
   Texas System; University of Texas Austin; University System of Georgia;
   University of Georgia; South East Technological University (SETU); Brown
   University; University System of Georgia; Augusta University
RP Snodderly, DM (通讯作者)，Univ Texas Austin, Inst Neurosci, Dept Nutr Sci, 1 Univ Stn A2700, Austin, TX 78712 USA.
EM max.snodderly@mail.utexas.edu
RI Nolan, John/N-4921-2014
OI Nolan, John/0000-0002-5503-7084; Snodderly, Donald/0000-0002-3428-609X;
   Hammond, Billy/0000-0002-5762-0206
FU Lousie Pfeiffer Research Foundation; Research to Prevent Blindness
   [PD04042]
FX Supported by grants from Gustavus and Lousie Pfeiffer Research
   Foundation and Fight for Sight, Research to Prevent Blindness (PD04042).
   We thank julian J. Nussbaum for access to patients with AMD, and the
   Fundus Photography Reading Center of the University of Wisconsin,
   Madison for grading fundus photographs of the patients.
CR *AG REL EY DIS STU, 1994, WISC AG REL MAC GRAD
   Aleman TS, 2007, INVEST OPHTH VIS SCI, V48, P1319, DOI 10.1167/iovs.06-0764
   ALEXANDER KR, 1987, VISION RES, V27, P1077, DOI 10.1016/0042-6989(87)90022-8
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhosale P, 2007, INVEST OPHTH VIS SCI, V48, P543, DOI 10.1167/iovs.06-0558
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P1338
   Delori FC, 2006, J OPT SOC AM A, V23, P521, DOI 10.1364/JOSAA.23.000521
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Gallaher KT, 2007, VISION RES, V47, P1253, DOI 10.1016/j.visres.2007.01.013
   Hammond BR, 2005, OPTOMETRY VISION SCI, V82, P387, DOI 10.1097/01.OPX.0000162652.85875.D2
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Iannaccone A, 2007, INVEST OPHTH VIS SCI, V48, P1458, DOI 10.1167/iovs.06-0438
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Richer S, 1999, J Am Optom Assoc, V70, P24
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Roodenburg AJC, 2000, AM J CLIN NUTR, V71, P1187
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   SMOLLON WE, 2005, INVEST OPHTH VIS SCI, V46, P4569
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   SNODDERLY DM, 1999, CRC MOD NUT, P251
   SNODDERLY DM, 2004, MACULAR PIGMENT DENS
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   TYLER CW, 1989, J OPT SOC AM A, V6, P481, DOI 10.1364/JOSAA.6.000481
   Unlu NZ, 2005, J NUTR, V135, P431, DOI 10.1093/jn/135.3.431
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   WERNER JS, 1987, VISION RES, V27, P257, DOI 10.1016/0042-6989(87)90188-X
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Wooten BR, 2005, OPTOMETRY VISION SCI, V82, P378, DOI 10.1097/01.OPX.0000162654.32112.A1
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
NR 39
TC 79
Z9 83
U1 0
U2 9
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD NOV
PY 2008
VL 87
IS 5
BP 445
EP 453
DI 10.1016/j.exer.2008.08.005
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 374CT
UT WOS:000261020700007
PM 18778703
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Takayama, K
   Ito, Y
   Kaneko, H
   Nagasaka, Y
   Tsunekawa, T
   Sugita, T
   Terasaki, H
AF Takayama, Kei
   Ito, Yasuki
   Kaneko, Hiroki
   Nagasaka, Yosuke
   Tsunekawa, Taichi
   Sugita, Tadasu
   Terasaki, Hiroko
TI Cross-sectional pupillographic evaluation of relative afferent pupillary
   defect in age-related macular degeneration
SO MEDICINE
LA English
DT Article
DE age-related macular degeneration; pupillometry; relative afferent
   pupillary defect
ID SWINGING FLASHLIGHT TEST; INTRAVITREAL INJECTIONS; VISUAL FUNCTION;
   ELECTRORETINOGRAMS
AB To evaluate, using pupillography, the difference between eyes affected by age-related macular degeneration and their contralateral normal eyes with regard to the mean relative afferent pupillary defect (RAPD) score. Also, to ascertain any correlations between this difference in RAPD score and differences in visual acuity or age-related macular degeneration (AMD) dimensions. Measurements were made using the RAPDx pupillographer (Konan Medical, Nishinomiya, Japan), which analyzes pupil response to light stimulation. Both best corrected visual acuity (converted to logMAR) and greatest linear dimension (GLD; calculated on the basis of fluorescence angiography images) were measured. The correlations between RAPD difference and logMAR difference, and GLD difference were then analyzed. The study included 32 patients (18 men, 14 women; mean age = 74.8 +/- 9.7 years) who had AMD in 1 eye and a normal fundus in the contralateral eye. Mean resting pupil diameter, mean latency onset of constriction, mean velocity of constriction, and recovery were not significantly different in AMD eyes compared with normal eyes. The mean amplitude of constriction was smaller (P = 0.028), and the mean latency of maximum constriction was shorter (P=0.0013) in AMD eyes than in normal eyes. Regarding RAPD scores, there was a significant correlation between visual acuity difference and RAPD score differences of both amplitude (P<0.001, r = 0.53) and latency (P = 0.034, r = 0.33). GLD difference was also significantly correlated with differences in both amplitude (P = 0.021, r = 0.36) and latency (P = 0.033, r = 0.33) scores. RAPD outcomes were correlated with visual acuity and AMD dimension. Automated pupillography may be a useful tool in monitoring the progression of AMD and assessing changes in retinal function that result from novel interventions.
C1 [Takayama, Kei; Ito, Yasuki; Kaneko, Hiroki; Nagasaka, Yosuke; Tsunekawa, Taichi; Sugita, Tadasu; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University
RP Takayama, K (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM keitaka1234@med.nagoya-u.ac.jp
RI Ito, Yasuki/M-4876-2014; Kaneko, Hiroki/AHA-2461-2022
OI Ito, Yasuki/0000-0001-9219-9261; Kaneko, Hiroki/0000-0003-0731-6465;
   Takayama, Kei/0000-0002-1477-9014
FU Japan Society for the Promotion of Science [20647458]; Japan Intractable
   Diseases Research Foundation; Takeda Science Foundation; Takeda Medical
   Research Foundation; Yokoyama Foundation for Clinical Pharmacology
   [YRY1411]; Uehara Memorial Foundation
FX This work was supported by a Grant-in-Aid for Young Scientists (A) Grant
   Number 20647458 from the Japan Society for the Promotion of Science
   (H.K.). The study was also supported by the Japan Intractable Diseases
   Research Foundation (H.K.), the Takeda Science Foundation (H.K.), the
   Takeda Medical Research Foundation (H.K.), the Yokoyama Foundation for
   Clinical Pharmacology (YRY1411, H.K.), and the Uehara Memorial
   Foundation (H.K.).
CR BELL RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P938, DOI 10.1001/archopht.1993.01090070056019
   Burton JM, 2014, MULT SCLER RELAT DIS, V3, P22, DOI 10.1016/j.msard.2013.06.013
   Charalel RA, 2014, J GLAUCOMA, V23, P169, DOI 10.1097/IJG.0b013e31826a9742
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   Hennessy AL, 2011, BRIT J OPHTHALMOL, V95, P1203, DOI 10.1136/bjo.2010.194217
   Ishikawa K, 2011, GRAEF ARCH CLIN EXP, V249, P273, DOI 10.1007/s00417-010-1548-x
   Ishikawa K, 2009, RETINA-J RET VIT DIS, V29, P803, DOI 10.1097/IAE.0b013e31819c631a
   Iwata E, 2012, INVEST OPHTH VIS SCI, V53, P4185, DOI 10.1167/iovs.11-9335
   KAWASAKI A, 1995, AM J OPHTHALMOL, V120, P622, DOI 10.1016/S0002-9394(14)72209-3
   Lankaranian D, 2005, T AM OPHTHAL SOC, V103, P207
   Lankaranian Dara, 2005, Trans Am Ophthalmol Soc, V103, P200
   Levatin P, 1969, Trans Pac Coast Otoophthalmol Soc Annu Meet, V50, P161
   LEVATIN P, 1973, CAN J OPHTHALMOL, V8, P356
   Link B, 2006, INVEST OPHTH VIS SCI, V47, P4947, DOI 10.1167/iovs.06-0021
   Miki A, 2006, CAN J OPHTHALMOL, V41, P469, DOI 10.1016/S0008-4182(06)80009-8
   Modica P A, 1996, Optom Clin, V5, P1
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Nishihara H, 2008, INVEST OPHTH VIS SCI, V49, P3121, DOI 10.1167/iovs.08-1835
   Nishimura T, 2012, CLIN OPHTHALMOL, V6, P1073, DOI 10.2147/OPTH.S31674
   Ozeki N, 2013, BRIT J OPHTHALMOL, V97, P1538, DOI 10.1136/bjophthalmol-2013-303825
   Sanderson J, 2014, EXP EYE RES, V127, P270, DOI 10.1016/j.exer.2014.08.009
   Sarezky D, 2016, J GLAUCOMA, V25, P312, DOI 10.1097/IJG.0000000000000213
   Schiefer U, 2012, BRIT J OPHTHALMOL, V96, P629, DOI 10.1136/bjophthalmol-2011-300776
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Swienton DJ, 2014, SEMIN ULTRASOUND CT, V35, P487, DOI 10.1053/j.sult.2014.06.007
   Tatham AJ, 2014, OPHTHALMOLOGY, V121, P1185, DOI 10.1016/j.ophtha.2013.12.015
   Terasaki H, 1997, AM J OPHTHALMOL, V123, P207, DOI 10.1016/S0002-9394(14)71037-2
   Terasaki H, 2002, INVEST OPHTH VIS SCI, V43, P1540
   THOMPSON HS, 1981, SURV OPHTHALMOL, V26, P39, DOI 10.1016/0039-6257(81)90124-7
   Volpe NJ, 2009, CURR EYE RES, V34, P606, DOI 10.1080/02713680902993891
   Volpe NJ, 2000, OPHTHALMOLOGY, V107, P1913, DOI 10.1016/S0161-6420(00)00354-7
   Wilhelm H, 2007, J NEURO-OPHTHALMOL, V27, P263, DOI 10.1097/WNO.0b013e31815bf865
   YAYLALI S, 2012, INT OPHTHALMOL, V32, P25, DOI DOI 10.1007/S10792-012-9519-3
   Zaidi FH, 2007, CURR BIOL, V17, P2122, DOI 10.1016/j.cub.2007.11.034
NR 36
TC 8
Z9 8
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD SEP
PY 2016
VL 95
IS 39
AR e4978
DI 10.1097/MD.0000000000004978
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DZ0PE
UT WOS:000385541400058
PM 27684848
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Huber, AL
   Angermann, R
   Nowosielski, Y
   Seifarth, C
   Kralinger, MT
   Zehetner, C
AF Huber, Anna Lena
   Angermann, Reinhard
   Nowosielski, Yvonne
   Seifarth, Christof
   Kralinger, Martina T.
   Zehetner, Claus
TI Effects of Intravitreal Aflibercept on the Systemic Insulin-like Growth
   Factor-I and Vascular Endothelial Growth Factor-A in Patients with
   Diabetic Retinopathy and Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EYE DISEASE
AB Purpose. To analyze the effect of intravitreal aflibercept injections on systemic levels of insulin-like growth factor-1 and vascular endothelial growth factor-A in patients with diabetic retinopathy and age-related macular degeneration. Methods. Vascular endothelial growth factor-A and insulin-like growth factor-1 levels were determined before and one week and four weeks after intravitreal injection of aflibercept (2.0 mg/50 mu l) for 19 patients with age-related macular degeneration (mean age, 76 +/- 11 years) and 18 patients with diabetic retinopathy (mean age, 64 +/- 14 years). Twenty-two healthy individuals were enrolled as controls. Results. A significant decline in systemic vascular endothelial growth factor-A level, from 43 (30-57) pg/ml at baseline to 8 (8-8) pg/ml (p<0.001) at week one and 17 (8-25) pg/ml (p=0.0054) at week four, was observed in the age-related macular degeneration group. In the diabetic retinopathy group, vascular endothelial growth factor-A levels declined from 53 (35-117) pg/ml to 2 (1-5) pg/ml (p<0.0001) one week after injection and 16 (13-22) pg/ml four weeks after injection (p=0.0327). At baseline, systemic insulin-like growth factor-1 concentration was higher in the diabetic retinopathy group (57 [37-99] pg/ml) than in the age-related macular degeneration group (35 [24-51] pg/ml) (p=0.0056). A subgroup analysis showed that patients in the proliferative diabetic retinopathy subgroup had significantly higher systemic insulin-like growth factor-1 concentrations (71 [44.7-243] pg/ml) than those in the nonproliferative diabetic retinopathy subgroup (43 [29-66] pg/ml) (p=0.0048). Conclusions. The difference between the baseline systemic insulin-like growth factor-1 levels of the age-related macular degeneration and diabetic retinopathy groups and the higher insulin-like growth factor-1 levels in the proliferative diabetic retinopathy subgroup one week after aflibercept therapy suggest that insulin-like growth factor-1 may play a role in the pathomechanism of diabetic retinopathy.
C1 [Huber, Anna Lena; Angermann, Reinhard; Nowosielski, Yvonne; Seifarth, Christof; Kralinger, Martina T.; Zehetner, Claus] Med Univ Innsbruck, Dept Ophthalmol, Innsbruck, Austria.
   [Angermann, Reinhard] Paracelsus Med Univ Salzburg, Dept Ophthalmol, Salzburg, Austria.
C3 Medical University of Innsbruck; Paracelsus Private Medical University
RP Zehetner, C (通讯作者)，Med Univ Innsbruck, Dept Ophthalmol, Innsbruck, Austria.
EM claus.zehetner@i-med.ac.at
OI Zehetner, Claus/0000-0003-1405-7457
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Castellino N, 2018, AGING-US, V10, P4241, DOI 10.18632/aging.101727
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Danis RP, 1997, OPHTHALMOLOGY, V104, P1661, DOI 10.1016/S0161-6420(97)30081-5
   Kaiser PK, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2018-000185
   Kawasaki R, 2019, DIABETOL INT, V10, P3, DOI 10.1007/s13340-018-0357-z
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859
   Liu Y, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016280
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   Merimee T, 1997, J CLIN ENDOCR METAB, V82, P2806, DOI 10.1210/jc.82.9.2806
   MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877
   Osher E, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080895
   Payne JF, 2011, MOL VIS, V17, P2318
   Powner MB, 2014, INVEST OPHTH VIS SCI, V55, P1607, DOI 10.1167/iovs.13-12574
   Ruberte J, 2004, J CLIN INVEST, V113, P1149, DOI 10.1172/JCI200419478
   Semeraro F, 2019, DIABETES METAB, V45, P517, DOI 10.1016/j.diabet.2019.04.002
   Shao MH, 2012, MOL CANCER THER, V11, P1576, DOI 10.1158/1535-7163.MCT-11-0961
   Smith LEH, 1999, NAT MED, V5, P1390, DOI 10.1038/70963
   van Beijnum JR, 2017, BIOL REV, V92, P1755, DOI 10.1111/brv.12306
   Waltl I, 2018, CURR EYE RES, V43, P368, DOI 10.1080/02713683.2017.1403632
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Xi G, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/6456032
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   Zhang J, 2017, INT J CLIN EXP MED, V10, P1325
NR 29
TC 0
Z9 0
U1 1
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD DEC 15
PY 2021
VL 2021
AR 7058505
DI 10.1155/2021/7058505
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1Y8EZ
UT WOS:000808372600002
PM 34956670
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU VanNasdale, DA
   Elsner, AE
   Malinovsky, VE
   Peabody, TD
   Kohne, KD
   Haggerty, BP
   Clark, CA
AF VanNasdale, Dean A.
   Elsner, Ann E.
   Malinovsky, Victor E.
   Peabody, Todd D.
   Kohne, Kimberly D.
   Haggerty, Bryan P.
   Clark, Christopher A.
TI Polarization Variability in Age-related Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SCANNING LASER POLARIMETRY; CENTRAL SEROUS
   CHORIORETINOPATHY; BLOOD-VESSEL QUANTIFICATION; NERVE-FIBER LAYER;
   IMAGING POLARIMETRY; SUBRETINAL STRUCTURES; GEOGRAPHIC ATROPHY; IMPROVED
   CONTRAST; SD-OCT
AB SIGNIFICANCE: Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss. Complementary imaging techniques can be used to better characterize and quantify pathological changes associated with AMD. By assessing specific light-tissue interactions, polarization-sensitive imaging can be used to detect tissue disruption early in the disease process.
   PURPOSE: The aim of this study was to compare variability in central macular polarization properties in patients with nonexudative AMD and age-matched control subjects.
   METHODS: A scanning laser polarimeter (GDx, LDT/CZM) was used to acquire 15 x 15-degreemacular images in 10 subjects diagnosed with nonexudative AMD and 10 age-matched control subjects. The coefficient of variation (COV, SD/mean) was used to quantify variability in pixel intensity in the central 3.3 degrees of the macula for custom images emphasizing multiply scattered light (the depolarized light image) and polarization-retaining light (the maximum of the parallel detector image). The intensity COV was compared across subject categories using paired t tests for each image type.
   RESULTS: The COV in the central macula was significantly higher in the AMD subject group (average, 0.221; 95% confidence interval [CI], 0.157 to 0.265) when compared with matched control subjects (average 0.120; 95% CI, 0.107 to 0.133) in the depolarized light image (P = .01). The COV in the maximum of the parallel detector image was not statistically different between the two subject groups (AMD average, 0.162 [95% CI, 0.138 to 0.185]; control average, 0.137 [95% CI, 0.115 to 0.158]; P = .21).
   CONCLUSIONS: Variability in multiply scattered light is higher than that of light that is more polarization preserving in patients with nonexudative AMD. Multiple scattering may act as an early indicator representing disruption to the macula in early AMD. Copyright (C) 2018 American Academy of Optometry.
C1 [VanNasdale, Dean A.] Ohio State Univ, Coll Optometry, 338 W 10th Ave, Columbus, OH 43210 USA.
   [Elsner, Ann E.; Malinovsky, Victor E.; Peabody, Todd D.; Kohne, Kimberly D.; Haggerty, Bryan P.; Clark, Christopher A.] Indiana Univ, Sch Optometry, Bloomington, IN USA.
C3 University System of Ohio; Ohio State University; Indiana University
   System; Indiana University Bloomington
RP VanNasdale, DA (通讯作者)，Ohio State Univ, Coll Optometry, 338 W 10th Ave, Columbus, OH 43210 USA.
EM vannasdale.1@osu.edu
FU National Eye Institute [K23-EY017886, RO1-EY007624, RO1-EB002346,
   P30-EY019008]; NATIONAL EYE INSTITUTE [R01EY007624] Funding Source: NIH
   RePORTER
FX This project was supported by grants K23-EY017886 (to DAV), RO1-EY007624
   (to AEE), RO1-EB002346 (to AEE), and P30-EY019008 (principal
   investigator Stephen A. Burns) from the National Eye Institute. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Eye Institute
   or the National Institutes of Health.
CR Acton JH, 2011, ACTA OPHTHALMOL, V89, pE404, DOI 10.1111/j.1755-3768.2011.02123.x
   Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Barteselli G, 2013, AM J OPHTHALMOL, V156, P588, DOI 10.1016/j.ajo.2013.04.030
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Burns SA, 2003, INVEST OPHTH VIS SCI, V44, P4061, DOI 10.1167/iovs.03-0124
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Elsner AE, 2000, OPT EXPRESS, V7, P95, DOI 10.1364/OE.7.000095
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Elsner AE, 1999, 1999 OSA TECHNICAL D, P276
   Elsner AE, 2007, J OPT SOC AM A, V24, P1468, DOI 10.1364/JOSAA.24.001468
   Elsner AE, 2008, VISION RES, V48, P2578, DOI 10.1016/j.visres.2008.04.031
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Greenfield DS, 2000, AM J OPHTHALMOL, V129, P715, DOI 10.1016/S0002-9394(00)00353-6
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Kunze C, 1999, OPHTHALMOLOGY, V106, P1830, DOI 10.1016/S0161-6420(99)90364-0
   Makita S, 2014, OPT LETT, V39, P6783, DOI 10.1364/OL.39.006783
   Mellem-Kairala MB, 2005, INVEST OPHTH VIS SCI, V46, P1099, DOI 10.1167/iovs.04-0574
   Miura M, 2005, AM J OPHTHALMOL, V140, P1014, DOI 10.1016/j.ajo.2005.06.033
   Miura M, 2002, RETINA-J RET VIT DIS, V22, P300, DOI 10.1097/00006982-200206000-00008
   Miura M, 2008, INVEST OPHTH VIS SCI, V49, P2661, DOI 10.1167/iovs.07-0501
   Miura M, 2007, J OPT SOC AM A, V24, P1431, DOI 10.1364/JOSAA.24.001431
   Oh J, 2012, INVEST OPHTH VIS SCI, V53, P179, DOI 10.1167/iovs.11-8704
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1163, DOI 10.1097/IAE.0b013e3181ed8d05
   Theelen T, 2009, GRAEF ARCH CLIN EXP, V247, P1625, DOI 10.1007/s00417-009-1148-9
   VanNasdale DA, 2009, J VIS, V9, P1
   VanNasdale DA, 2012, OPTOMETRY VISION SCI, V89, P667, DOI 10.1097/OPX.0b013e31824eeb25
   VanNasdale DA, 2011, VISION RES, V51, P2263, DOI 10.1016/j.visres.2011.08.017
   Weber A, 2007, EYE, V21, P353, DOI 10.1038/sj.eye.6702203
   Weber A, 2004, OPT EXPRESS, V12, P5178, DOI 10.1364/OPEX.12.005178
   WEINREB RN, 1995, AM J OPHTHALMOL, V119, P627, DOI 10.1016/S0002-9394(14)70221-1
   Wolf-Schnurrbusch UEK, 2011, INVEST OPHTH VIS SCI, V52, P9497, DOI 10.1167/iovs.11-8346
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 47
TC 4
Z9 4
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD APR
PY 2018
VL 95
IS 4
BP 277
EP 291
DI 10.1097/OPX.0000000000001197
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GE4JK
UT WOS:000431181500002
PM 29561503
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zarbin, M
   Szirth, B
AF Zarbin, Marco
   Szirth, Bernard
TI Current treatment of age-related macular degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   geographic atrophy; pharmacology; ocular imaging; clinical trials
ID ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL BEVACIZUMAB AVASTIN; OPTICAL COHERENCE TOMOGRAPHY; PHASE-I
   TRIAL; PHOTODYNAMIC THERAPY; TRIAMCINOLONE ACETONIDE; OCULAR
   NEOVASCULARIZATION; VASCULAR-PERMEABILITY; ANGIOSTATIC STEROIDS
AB Purpose. To review proved and experimental treatments for exudative and nonexudative complications of age-related macular degeneration (AMD), to consider the impact of current therapy on the structure of future clinical trials, and to consider the role of improved diagnostic imaging techniques on the effectiveness of current therapy as well as the structure of future clinical trials in AMD patients.
   Results. Defining the cell biology of choroidal new vessel (CNV) formation and geographic atrophy will lead to identification of different biochemical pathways that are the target of AMD treatment. Many treatments and treatment combinations are under study for AMD, but all work through a finite number of pathways. Currently, the most effective proved therapy for AMD-associated CNVs is administered by repeated intravitreal injection of agents that inhibit vascular endothelial growth factor, e.g., ranibizumab. Improved drug delivery will enhance patient satisfaction and possibly will enhance the effectiveness and reduce the risk of current pharmacotherapy for AMD-associated CNVs. Combination therapy (e.g., verteporfin-photodynamic therapy + ranibizumab) appears to reduce the risk and enhance the effectiveness of CNV treatment compared with monotherapy with currently available agents. Improved noninvasive diagnostic imaging may lead to better visual outcomes with existing therapeutic modalities. Improved imaging also may alter favorably the design of future clinical trials for AMD-associated CNVs and thus reduce cost and increase the diversity of sight-saving treatments.
   Conclusions. Delineation of the biochemical basis for CNV formation has led to development of pathway-based pharmacotherapy for AMD patients. Areas of investigation that will advance the field further include combination therapy, improved drug delivery, and improved noninvasive, high-resolution diagnostic imaging. The logistics of future clinical trials will be complicated by the need for an active treatment control group, more stringent definition of successful treatment, and the increased numbers of patients required for combination therapy studies.
C1 Univ Med & Dent New Jersey, Inst Ophthalmol & Visual sci, Newark, NJ 07103 USA.
C3 Rutgers State University New Brunswick; Rutgers State University Medical
   Center
RP Zarbin, M (通讯作者)，Univ Med & Dent New Jersey, Inst Ophthalmol & Visual sci, 90 Bergen St Room 6156, Newark, NJ 07103 USA.
EM zarbin@umdnj.edu
CR Alam S, 2006, OPHTHALMOLOGY, V113, P1425, DOI 10.1016/j.ophtha.2006.03.020
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arias L, 2006, OPHTHALMOLOGY, V113, P2243, DOI 10.1016/j.ophtha.2006.04.039
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fingar V H, 1996, J Clin Laser Med Surg, V14, P323
   FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hellstrom M, 1999, DEVELOPMENT, V126, P3047
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Jaffe GJ, 2006, OPHTHALMOLOGY, V113, P1020, DOI 10.1016/j.ophtha.2006.02.021
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829
   Lee CG, 2000, CANCER RES, V60, P5565
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   Liggett PE, 2006, AM J OPHTHALMOL, V142, P1072, DOI 10.1016/j.ajo.2006.07.029
   Luttun A, 2002, ANN NY ACAD SCI, V979, P80, DOI 10.1111/j.1749-6632.2002.tb04870.x
   Matsuda S, 2005, INVEST OPHTH VIS SCI, V46, P1062, DOI 10.1167/iovs.04-0761
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   Nauck M, 1998, EUR J PHARMACOL, V341, P309, DOI 10.1016/S0014-2999(97)01464-7
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Paskowitz DM, 2007, INVEST OPHTH VIS SCI, V48, P430, DOI 10.1167/iovs.06-0690
   Paskowitz DM, 2004, INVEST OPHTH VIS SCI, V45, P4190, DOI 10.1167/iovs.04-0676
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Podoleanu A G, 2006, Bull Soc Belge Ophtalmol, P133
   PROIA AD, 1993, EXP EYE RES, V57, P693, DOI 10.1006/exer.1993.1177
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Reich S, 2003, MOL VIS, V9, P210
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2005, EUR J OPHTHALMOL, V15, P482, DOI 10.1177/112067210501500411
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Treatment Age Related Macular Dege, 2005, ARCH OPHTHALMOL-CHIC, V123, P1283
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   WILSON CA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1155, DOI 10.1001/archopht.1992.01080200135041
   Wolfing JI, 2006, OPHTHALMOLOGY, V113, P1014, DOI 10.1016/j.ophtha.2006.01.056
   Zarbin M, 2006, ARCH OPHTHALMOL-CHIC, V124, P563, DOI 10.1001/archopht.124.4.563
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 81
TC 19
Z9 20
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD JUL
PY 2007
VL 84
IS 7
BP E559
EP E572
DI 10.1097/OPX.0b013e3180de4dd7
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 190VH
UT WOS:000248088200003
DA 2022-11-30
ER

PT J
AU Neto, JM
   Viturino, MGM
   Ananina, G
   Bajano, FF
   Costa, SMD
   Roque, AB
   Borges, GFS
   Franchi, R
   Rim, PHH
   Medina, FM
   Costa, FF
   de Melo, MB
   de Vasconcellos, JPC
AF Neto, Jamil M.
   Viturino, Marina G. M.
   Ananina, Galina
   Bajano, Flavia F.
   Costa, Sueli M. da S.
   Roque, Alicia B.
   Borges, Gessica F. S.
   Franchi, Raissa
   Rim, Priscila H. H.
   Medina, Flavio M.
   Costa, Fernando F.
   de Melo, Monica B.
   de Vasconcellos, Jose P. C.
TI Association of genetic variants rs641153 (CFB), rs2230199 (C3), and
   rs1410996 (CFH) with age-related macular degeneration in a Brazilian
   population
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Complement pathway; age-related macular degeneration; rs641153;
   rs1410996; rs2230199; genetic risk
ID COMPLEMENT FACTOR-H; COMPONENT 2 C2; FACTOR-B BF; NONCODING VARIANT;
   RISK; POLYMORPHISM; SUSCEPTIBILITY; PERSPECTIVE; IMPAIRMENT; PREVALENCE
AB This study aimed to investigate the association among genetic variants of the complement pathway CFB R32Q (rs641153), C3 R102G (rs2230199), and CFH (rs1410996) with age-related macular degeneration (AMD) in a sample of the Brazilian population. In a case-control study, 484 AMD patients were classified according to the clinical age-related maculopathy grading system (CARMS) and compared to 479 unrelated controls. The genetic variants rs1410996 of complement H (CFH), rs641153 of complement factor B (CFB), and rs2230199 of complement 3 (C3) were evaluated through polymerase chain reaction (PCR) and direct sequencing. The associations between single nucleotide polymorphisms (SNPs) and AMD, adjusted by age, were assessed by using logistic regression models. A statistically significant association was observed between AMD risk and rs2230199 variant with an OR of 2.01 (P = 0.0002) for CG individuals compared to CC individuals. Regarding the comparison of advanced AMD versus the control group, the OR was 2.12 (P = 0.0036) for GG versus AA genotypes for rs1410996 variant. Similarly, the OR for rs2230199 polymorphism was 2.3034 (P = 5.47(e-05)) when comparing CG individuals to CC carriers. In contrast, the rs641153 variant showed a significant protective effect against advanced AMD for GA versus GG genotype (OR = 0.4406; P = 0.0019). When comparing wet AMD versus controls, a significant association was detected for rs1410996 variant (OR = 2.16; P = 0.0039) comparing carriers of the homozygous GG versus AA genotype, as well as in the comparisons of GG (OR = 3.0713; P = 0.0046) and CG genotypes (OR = 2.2249; P = 0.0002) versus CC genotype for rs2230199 variant, respectively. The rs641153 variant granted a significant protective effect against wet AMD for GA versus GG genotypes (OR = 0.4601; P = 0.0044). Our study confirmed the risk association between rs2230199 and rs1410996 variants and AMD, and the protective role against AMD for rs641153 variant.
C1 [Neto, Jamil M.; Viturino, Marina G. M.; Roque, Alicia B.; Borges, Gessica F. S.; Rim, Priscila H. H.; de Vasconcellos, Jose P. C.] Univ Estadual Campinas, Dept Ophthalmol, Fac Med Sci, BR-13083887 Campinas, SP, Brazil.
   [Ananina, Galina; Bajano, Flavia F.; Costa, Sueli M. da S.; Franchi, Raissa; de Melo, Monica B.] Univ Estadual Campinas, Ctr Mol Biol & Genet Engn CBMEG, Lab Human Genet, BR-13083875 Campinas, SP, Brazil.
   [Medina, Flavio M.] Univ Estado Rio De Janeiro, Fac Med Sci, Dept Ophthalmol, BR-20551030 Rio De Janeiro, RJ, Brazil.
   [Costa, Fernando F.] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, BR-13083878 Campinas, SP, Brazil.
C3 Universidade Estadual de Campinas; Universidade Estadual de Campinas;
   Universidade do Estado do Rio de Janeiro; Universidade Estadual de
   Campinas
RP de Vasconcellos, JPC (通讯作者)，Univ Estadual Campinas, Dept Ophthalmol, Fac Med Sci, BR-13083887 Campinas, SP, Brazil.
EM cabraljp@uol.com.br
RI Miguel-Neto, Jamil/GLT-9254-2022; Medina, Flavio/AFM-1303-2022; Costa,
   Fernando F/D-1566-2012
OI Miguel-Neto, Jamil/0000-0002-7024-1294; Costa, Fernando
   F/0000-0002-4632-572X
FU Fund for Support to Teaching, Research and Outreach Activities (FAEPEX)
   [1525/15, 251/18]; Sao Paulo Research Foundation (FAPESP) [2010/18353-9]
FX This study was supported by the Fund for Support to Teaching, Research
   and Outreach Activities (FAEPEX) grants 1525/15 and 251/18 and by Sao
   Paulo Research Foundation (FAPESP) grant 2010/18353-9.
CR ALSENZ J, 1985, BIOCHEM J, V232, P841, DOI 10.1042/bj2320841
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Cui L, 2010, INVEST OPHTH VIS SCI, V51, P1116, DOI 10.1167/iovs.09-4265
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hedrick PW, 1999, EVOLUTION, V53, P313, DOI [10.1111/j.1558-5646.1999.tb03767.x, 10.2307/2640768]
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lu FT, 2018, GENET TEST MOL BIOMA, V22, P526, DOI 10.1089/gtmb.2018.0110
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Schellini SA, 2009, BMC OPHTHALMOL, V9, DOI 10.1186/1471-2415-9-8
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Su Y, 2020, EUR J OPHTHALMOL, V30, P743, DOI 10.1177/1120672119840245
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Waples RS, 1998, J HERED, V89, P438, DOI 10.1093/jhered/89.5.438
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Wu L, 2013, INVEST OPHTH VIS SCI, V54, P170, DOI 10.1167/iovs.12-10453
   Wu MX, 2016, OPHTHALMIC RES, V55, P135, DOI 10.1159/000442257
   Yanagisawa S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028847
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang J, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0945-5
   Zhang MX, 2015, GENET MOL RES, V14, P12567, DOI 10.4238/2015.October.16.24
NR 44
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD NOV
PY 2021
VL 246
IS 21
BP 2290
EP 2296
AR 15353702211024543
DI 10.1177/15353702211024543
EA JUL 2021
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA WU4FJ
UT WOS:000682604300001
PM 34233521
OA Green Published
DA 2022-11-30
ER

PT J
AU Schmidt-Erfurth, UM
   Pruente, C
AF Schmidt-Erfurth, Ursula M.
   Pruente, Christian
TI Management of neovascular age-related macular degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL TRIAMCINOLONE
   ACETONIDE; PHOTODYNAMIC THERAPY; VERTEPORFIN THERAPY; BEVACIZUMAB
   AVASTIN; OPHTHALMIC FINDINGS; SUBMACULAR SURGERY; MEDIATED DELIVERY;
   PEGAPTANIB SODIUM; INDUCED BREAKDOWN
AB Neovascular age-related macular degeneration (AMD) is becoming an increasing socio-medical problem as the proportion of the aged population is continuously increasing. However, new insights in the pathogenesis of the disease offer the opportunity to develop targeted therapies that attack the disease process more successfully than ever.
   This review article will focus on summarizing the actual options in the management of neovascular AMD and provide a short overview about recent therapeutic options in clinical and preclinical evaluation.
   The recent development of anti-VEGF substances for use in clinical routine has markedly improved the prognosis of patients with neovascular AMD. Intravitreal treatment with substances targeting all isotypes of vascular endothelial growth factor (VEGF), for the first time in the history of AMD treatments, results in a significant increase in visual acuity in patients with neovascular AMD. Overall, anti-angiogenic approaches provide vision maintenance in over 90% and substantial improvement in 25-40% of patients. The combination with occlusive therapies like photodynamic therapy (PDT) potentially offers a reduction of re-treatment frequency and long-term maintenance of the treatment benefit. Further developments interacting with various steps in the angiogenic cascade are under clinical or preclinical evaluation and may soon become available.
   Nevertheless, the growing number of novel therapeutic options will have to provide proof of concept in randomized controlled clinical trials, a major challenge in view of the rapidly evolving field. For those therapies, which are already in clinical use, reasonable diagnostic tools for follow-up need to be developed, as the burden of continuous clinical monitoring of all patients and all indications is significant for patients and doctors. Ultimately, economic issues will be the limiting factor for the clinical availability of different treatment options. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
C3 Medical University of Vienna
RP Schmidt-Erfurth, UM (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
CR *AAO, 2005, PREF PRACT PATT AGE
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   BANKER AS, 2006, ASRS EVRS CANNES RET
   BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P1954
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brunel JM, 2005, CURR CANCER DRUG TAR, V5, P267, DOI 10.2174/1568009054064642
   Cashman SM, 2006, INVEST OPHTH VIS SCI, V47, P3496, DOI 10.1167/iovs.05-1610
   CHANG TS, 2006, SELFREPORTED VISION
   Chen WH, 2006, BIOCONJUGATE CHEM, V17, P1582, DOI 10.1021/bc060220n
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Clark A F, 1997, Expert Opin Investig Drugs, V6, P1867, DOI 10.1517/13543784.6.12.1867
   Clark AF, 1999, INVEST OPHTH VIS SCI, V40, P2158
   CUILLA TA, 2003, RETINA, V23, P808
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Falkner CI, 2007, GRAEF ARCH CLIN EXP, V245, P490, DOI 10.1007/s00417-005-0184-3
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRAGOUDAS ES, 2005, AC OPHTH SUBSP M OCT
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   HEIER JS, 2005, AAO SUBSP DAY RET CH
   Higgins RD, 2004, PEDIATR RES, V56, P144, DOI 10.1203/01.PDR.0000128977.55799.34
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Kinose F, 2005, MOL VIS, V11, P366
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Marano RJ, 2004, EXP EYE RES, V79, P525, DOI 10.1016/j.exer.2004.06.023
   Marano RJ, 2005, GENE THER, V12, P1544, DOI 10.1038/sj.gt.3302579
   McNatt LG, 1999, J OCUL PHARMACOL TH, V15, P413, DOI 10.1089/jop.1999.15.413
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Moshfeghi AA, 2005, EXPERT OPIN INV DRUG, V14, P671, DOI 10.1517/13543784.14.5.671
   Mulcahy MF, 2005, EXPERT OPIN BIOL TH, V5, P997, DOI 10.1517/14712598.5.7.997
   Nambu H, 2003, INVEST OPHTH VIS SCI, V44, P3650, DOI 10.1167/iovs.02-0985
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Pieramici DJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P660
   Reich S, 2003, MOL VIS, V9, P210
   Renno RZ, 2004, ARCH OPHTHALMOL-CHIC, V122, P1002, DOI 10.1001/archopht.122.7.1002
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Saishin Y, 2003, J CELL PHYSIOL, V195, P210, DOI 10.1002/jcp.10238
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   SCHMIDTERFURTH U, 2006, AS PAC ASS OPHTH ANN
   SCHMIDTERFURTH UM, 2006, PRELIMINARY RESULTS
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Sheu SJ, 2005, EXP EYE RES, V81, P673, DOI 10.1016/j.exer.2005.04.005
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   Takeda A, 2003, GRAEF ARCH CLIN EXP, V241, P765, DOI 10.1007/s00417-003-0688-7
   THOMAS EL, 2006, ASRS EVRS CANN RET F
   Thylefors B, 1998, AM J OPHTHALMOL, V125, P90, DOI 10.1016/S0002-9394(99)80239-6
   Treatment Age Related Macular Dege, 2005, ARCH OPHTHALMOL-CHIC, V123, P1283
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
   WILLIAMS DF, 2006, ASRS EVRS CANN RET F
NR 79
TC 62
Z9 81
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JUL
PY 2007
VL 26
IS 4
BP 437
EP 451
DI 10.1016/j.preteyeres.2007.03.002
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 181RH
UT WOS:000247453300005
PM 17512238
DA 2022-11-30
ER

PT J
AU Cho, YK
   Park, DH
   Jeon, IC
AF Cho, Yeon-Kyoung
   Park, Dae-Hun
   Jeon, In-Chul
TI Medication Trends for Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration (AMD); medication; device-based
   therapy; anti-inflammatory drugs; anti-VEGFs; natural products
ID PIGMENT EPITHELIAL-CELLS; ANTI-VEGF ANTIBODY; OXIDATIVE STRESS;
   CHOROIDAL NEOVASCULARIZATION; PROPHYLACTIC LASER; ARPE-19 CELLS;
   BILE-ACIDS; INFLAMMATION; ANGIOGENESIS; BEVACIZUMAB
AB Age-related macular degeneration (AMD) is central vision loss with aging, was the fourth main cause of blindness in 2015, and has many risk factors, such as cataract surgery, cigarette smoking, family history, hypertension, obesity, long-term smart device usage, etc. AMD is classified into three categories: normal AMD, early AMD, and late AMD, based on angiogenesis in the retina, and can be determined by bis-retinoid N-retinyl-N-retinylidene ethanolamine (A2E)-epoxides from the reaction of A2E and blue light. During the reaction of A2E and blue light, reactive oxygen species (ROS) are synthesized, which gather inflammatory factors, induce carbonyl stress, and finally stimulate the death of retinal pigment epitheliums (RPEs). There are several medications for AMD, such as device-based therapy, anti-inflammatory drugs, anti-VEGFs, and natural products. For device-based therapy, two methods are used: prophylactic laser therapy (photocoagulation laser therapy) and photodynamic therapy. Anti-inflammatory drugs consist of corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs). Anti-VEGFs are classified antibodies for VEGF, aptamer, soluble receptor, VEGF receptor-1 and -2 antibody, and VEGF receptor tyrosine kinase inhibitor. Finally, additional AMD drug candidates are derived from natural products. For each medication, there are several and severe adverse effects, but natural products have a potency as AMD drugs, as they have been used as culinary materials and/or traditional medicines for a long time. Their major application route is oral administration, and they can be combined with device-based therapy, anti-inflammatory drugs, and anti-VEGFs. In general, AMD drug candidates from natural products are more effective at treating early and intermediate AMD. However, further study is needed to evaluate their efficacy and to investigate their therapeutic mechanisms.
C1 [Cho, Yeon-Kyoung; Jeon, In-Chul] Dongshin Univ, Coll Hlth & Welf, Naju 58245, Jeonnam, South Korea.
   [Park, Dae-Hun] Dongshin Univ, Coll Korean Med, Naju 58245, Jeonnam, South Korea.
C3 Dongshin University; Dongshin University
RP Jeon, IC (通讯作者)，Dongshin Univ, Coll Hlth & Welf, Naju 58245, Jeonnam, South Korea.; Park, DH (通讯作者)，Dongshin Univ, Coll Korean Med, Naju 58245, Jeonnam, South Korea.
EM dhj1221@hanmail.net
OI Park, Dae-Hun/0000-0002-3972-3690; Cho, Yeon-Kyoung/0000-0002-7221-2462
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Ambade A, 2012, INT J HEPATOL, V2012, DOI 10.1155/2012/853175
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Apte RS, 2010, ADV EXP MED BIOL, V664, P15, DOI 10.1007/978-1-4419-1399-9_2
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Aung KH, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.566699
   Baranano DE, 2009, BRIT J OPHTHALMOL, V93, P1387, DOI 10.1136/bjo.2009.157297
   Bazan NG, 2006, ADV EXP MED BIOL, V572, P531
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biswas SK, 2006, AM J NEPHROL, V26, P415, DOI 10.1159/000095707
   Biswas SK, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5698931
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   BRESNICK GH, 1983, OPHTHALMOLOGY, V90, P1301
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brinkmann R, 2006, Bull Soc Belge Ophtalmol, P51
   Butler MC, 2010, INVEST OPHTH VIS SCI, V51, P2705, DOI 10.1167/iovs.08-2862
   Cachofeiro V, 2008, KIDNEY INT, V74, pS4, DOI 10.1038/ki.2008.516
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chatterjee S, 2016, OXIDATIVE STRESS AND BIOMATERIALS, P35, DOI 10.1016/B978-0-12-803269-5.00002-4
   Chen C, 2017, MOL MED REP, V15, P2289, DOI 10.3892/mmr.2017.6252
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Chiang JYL, 2009, J LIPID RES, V50, P1955, DOI 10.1194/jlr.R900010-JLR200
   Chichili GR, 2006, BRIT J NUTR, V96, P643, DOI 10.1079/BJN20061843
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Cotran R.S, 1999, ROBBINS PATHOLOGIC B, P50
   Crouch RK, 2015, PROG MOL BIOL TRANSL, V134, P449, DOI 10.1016/bs.pmbts.2015.06.005
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   FIGGE FHJ, 1948, P SOC EXP BIOL MED, V68, P640
   Findlay Q, 2018, EYE, V32, P972, DOI 10.1038/s41433-018-0035-1
   Francis BA, 1996, OPHTHALMOLOGY, V103, P1884, DOI 10.1016/S0161-6420(96)30411-9
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gamache DA, 2000, INFLAMMATION, V24, P357, DOI 10.1023/A:1007049015148
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Giese AC, 1964, PHOTOPHYSIOLOGY, P1
   Halliwell B, 2006, PLANT PHYSIOL, V141, P312, DOI 10.1104/pp.106.077073
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hitner H., 2019, PHARM INTRO, V7th, P385
   Hofmann AF, 1999, ARCH INTERN MED, V159, P2647, DOI 10.1001/archinte.159.22.2647
   Hong EJ, 2016, ACTA PHARM SIN B, V6, P297, DOI 10.1016/j.apsb.2016.01.007
   Hu-Lowe DD, 2008, CLIN CANCER RES, V14, P7272, DOI 10.1158/1078-0432.CCR-08-0652
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jang Ye Jin, 2020, [Journal of Korean Ophthalmic Optics Society, 한국안광학회지], V25, P421, DOI 10.14479/jkoos.2020.25.4.421
   Jemni-Damer N, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.549089
   Jin XL, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/5604610
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, P630, DOI 10.1111/j.1755-3768.2008.01502.x
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaczara P, 2010, FREE RADICAL BIO MED, V48, P1064, DOI 10.1016/j.freeradbiomed.2010.01.022
   Kang S, 2013, CURR EYE RES, V38, P119, DOI 10.3109/02713683.2012.727520
   Kapugi M, 2019, ORTHOP NURS, V38, P336, DOI 10.1097/NOR.0000000000000595
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kernt M, 2011, OPHTHALMOLOGE, V108, P445, DOI 10.1007/s00347-010-2304-7
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kim DH, 2020, MOLECULES, V25, DOI 10.3390/molecules25071737
   Kim J, 2020, FREE RADICAL BIO MED, V152, P622, DOI 10.1016/j.freeradbiomed.2019.12.003
   Kim Ramasamy, 2007, Indian Journal of Ophthalmology, V55, P413
   Kim SJ, 2010, SURV OPHTHALMOL, V55, P108, DOI 10.1016/j.survophthal.2009.07.005
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Kong JM, 2003, PHYTOCHEMISTRY, V64, P923, DOI 10.1016/S0031-9422(03)00438-2
   Koushan K, 2013, NUTRIENTS, V5, P1823, DOI 10.3390/nu5051823
   Lederman M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087751
   Liu HJ, 2017, MOL MED REP, V16, P2069, DOI 10.3892/mmr.2017.6838
   Lu Ming, 2006, Ophthalmol Clin North Am, V19, P323
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Marie M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223839
   Marti R, 2016, CANCERS, V8, DOI 10.3390/cancers8060058
   Mashayekhi V, 2019, J PORPHYR PHTHALOCYA, V23, P1229, DOI [10.1142/s1088424619300180, 10.1142/S1088424619300180]
   Mayes P.A., 2003, HARPERS ILLUSTRATED, P86
   McGeer PL, 2005, NEUROBIOL AGING, V26, P1199, DOI 10.1016/j.neurobiolaging.2005.02.003
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149
   Moine E, 2021, FREE RADICAL BIO MED, V162, P367, DOI 10.1016/j.freeradbiomed.2020.10.316
   Moon J, 2017, INTEGR BIOL-UK, V9, P436, DOI 10.1039/c7ib00032d
   Nakajima E, 2014, EYE, V28, P85, DOI 10.1038/eye.2013.239
   Ni TM, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190689
   Noel A, 2007, TRENDS MOL MED, V13, P345, DOI 10.1016/j.molmed.2007.06.005
   Nowak-Sliwinska P, 2012, J CELL MOL MED, V16, P1553, DOI 10.1111/j.1582-4934.2011.01440.x
   Oeverhaus M, 2019, OPHTHALMOLOGE, V116, P164, DOI 10.1007/s00347-017-0643-3
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Ponnusamy C, 2019, IET NANOBIOTECHNOL, V13, P868, DOI 10.1049/iet-nbt.2019.0130
   Ramasubramanian A, 2012, BRIT J OPHTHALMOL, V96, P356, DOI 10.1136/bjophthalmol-2011-300141
   REGAN JD, 1982, SCI PHOTOMEDICINE
   Seland JH, 2011, ACTA OPHTHALMOL, V89, P608, DOI 10.1111/j.1755-3768.2009.01794.x
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Subczynski WK, 2010, ARCH BIOCHEM BIOPHYS, V504, P61, DOI 10.1016/j.abb.2010.05.015
   Sun HJ, 2020, PHARMACOLOGY, V105, P28, DOI 10.1159/000502614
   Swanson MW, 2008, OPTOMETRY VISION SCI, V85, P947, DOI 10.1097/OPX.0b013e31818883e0
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   Thiele S, 2013, KLIN MONATSBL AUGENH, V230, P247, DOI 10.1055/s-0032-1328161
   Trichonas G, 2013, OPHTHALMOL THER, V2, P89, DOI 10.1007/s40123-013-0015-2
   Tsuchida T, 1997, PHOTOCHEM PHOTOBIOL, V66, P224, DOI 10.1111/j.1751-1097.1997.tb08647.x
   van den Bergh H, 2001, Semin Ophthalmol, V16, P181, DOI 10.1076/soph.16.4.181.10299
   Vinores SA, 2006, INT J NANOMED, V1, P263
   Von Tappeiner H., 1903, MUNCH MED WOCHENSCHR, V1, P2042
   Vrouenraets MB, 1999, CANCER RES, V59, P1505
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wang YJ, 2012, APOPTOSIS, V17, P1144, DOI 10.1007/s10495-012-0750-1
   Warden C, 2020, EXP EYE RES, V193, DOI 10.1016/j.exer.2020.107974
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood JPM, 2011, LASER SURG MED, V43, P499, DOI 10.1002/lsm.21087
   Ye J, 2014, INVEST OPHTH VIS SCI, V55, P2687, DOI 10.1167/iovs.13-13206
   Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X
   Yoon SM, 2016, ARCH PHARM RES, V39, P21, DOI 10.1007/s12272-015-0683-7
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zhang XL, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/5905269
   Zhao HL, 2019, INT J MOL MED, V43, P936, DOI 10.3892/ijmm.2018.4027
   Zhao M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08125-6
   Zoccali C, 2000, NEPHROL DIAL TRANSPL, V15, P7, DOI 10.1093/ndt/15.suppl_1.7
   Zou MJ, 2021, ACTA OPHTHALMOL, V99, pE330, DOI 10.1111/aos.14589
NR 123
TC 3
Z9 3
U1 2
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2021
VL 22
IS 21
AR 11837
DI 10.3390/ijms222111837
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA XJ6ZS
UT WOS:000726933900001
PM 34769270
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mao, FF
   Yang, XH
   Yang, K
   Cao, XS
   Cao, K
   Hao, J
   Zhang, Y
   Wang, NL
AF Mao, Feifei
   Yang, Xiaohui
   Yang, Ke
   Cao, Xusheng
   Cao, Kai
   Hao, Jie
   Zhang, Ye
   Wang, Ningli
TI Six-Year Incidence and Risk Factors for Age-Related Macular Degeneration
   in a Rural Chinese Population: The Handan Eye Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; incidence; risk; axial length
ID 5-YEAR INCIDENCE; AXIAL LENGTH; MACULOPATHY; PROGRESSION; PREVALENCE;
   ASSOCIATIONS; RIGIDITY
AB PURPOSE. To describe the 6-year incidence of early and late age-related macular degeneration (AMD) and its associated factors in a representative large rural Chinese population.
   METHODS. A population-based longitudinal study was conducted in rural China from 2006 to 2007. In total, 6830 persons aged 30 years or older participated in the study. The 6-year follow-up study was performed between 2012 and 2013. The modified Wisconsin Age-Related Maculopathy Grading System (WARMGS) protocol in the Blue Mountains Eye Study was used as the AMD grading standard.
   RESULTS. Excluding 509 deceased subjects, 5394 (follow-up rate 85.3%) completed the follow-up. Among them, 5048 participants had gradable photographs of at least one eye at both examinations. The incidence of early and late AMD over 6 years was 4.2% (95% CI, 3.8%-4.7%) and 0.2% (95% CI, 0.2%-0.3%), respectively. In the multivariable analysis, per-year increase in age (P < 0.001; OR = 1.06; 95% CI, 1.04-1.07), male sex (P = 0.006; OR = 0.64; 95% CI, 0.47-0.88), and per-millimeter increase in axial length (P = 0.010; OR = 0.78; 95% CI, 0.63-0.94) at baseline were significantly associated with incident early AMD. Early AMD was not associated with systolic blood pressure, diastolic blood pressure, hypertension, diabetes, history of stroke, history of heart disease, body mass index, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, smoking status, refractive error, or corneal curvature radius. There were too few cases of late AMD for a valid statistical analysis of the risk factors.
   CONCLUSIONS. The incidence of early and late AMD over 6 years in a rural Chinese population was 4.2% (95% CI, 3.8%-4.7%) and 0.2% (95% CI, 0.2%-0.3%), respectively. Age, sex, and axial length are relevant risk factors for early AMD in rural China.
C1 [Mao, Feifei; Yang, Ke; Cao, Xusheng; Zhang, Ye; Wang, Ningli] Capital Med Univ, Beijing Ophthalmol & Visual Sci Key Lab, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing, Peoples R China.
   [Mao, Feifei] Capital Med Univ, Beijing DiTan Hosp, Beijing, Peoples R China.
   [Yang, Xiaohui; Cao, Kai; Wang, Ningli] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, 17 Hougou Alley, Beijing 100005, Peoples R China.
   [Hao, Jie] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Clin Res Ctr,Beijing Inst Ophthalmol, Beijing, Peoples R China.
C3 Capital Medical University; Capital Medical University; Capital Medical
   University; Capital Medical University
RP Wang, NL (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, 17 Hougou Alley, Beijing 100005, Peoples R China.
EM wningli@vip.163.com
RI Zhang, Ye/AAF-2989-2020
FU National Basic Research Program of China (973 Program); Ministry of
   Science and Technology of the People's Republic of China [2007CB512201];
   Program of Health Policy for Blindness Prevention from Ministry of
   Health of the People's Republic of China - Key Technologies R&D Program
   from Bureau of Science and Technology of Handan City, Hebei Province,
   China [2006-10903]; Beijing Tongren Hospital; Bureau of Health, Handan
   City, Hebei Province, China
FX Supported by National Basic Research Program of China (973 Program),
   Grant 2007CB512201 from the Ministry of Science and Technology of the
   People's Republic of China, the Program of Health Policy for Blindness
   Prevention from Ministry of Health of the People's Republic of China,
   partially funded by the Key Technologies R&D Program No. 2006-10903 from
   Bureau of Science and Technology of Handan City, Hebei Province, China,
   with additional support from Beijing Tongren Hospital and key discipline
   fund from Bureau of Health, Handan City, Hebei Province, China.
CR Bastawrous A, 2017, JAMA OPHTHALMOL, V135, P631, DOI 10.1001/jamaophthalmol.2017.1109
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1305, DOI 10.1016/j.ophtha.2017.03.056
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe185, DOI 10.1111/j.1755-3768.2011.02316.x
   Jonas JB, 2010, OPHTHALMOLOGY, V117, P2234, DOI 10.1016/j.ophtha.2009.12.006
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lavanya R, 2010, INVEST OPHTH VIS SCI, V51, P6247, DOI 10.1167/iovs.10-5229
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Liang YB, 2009, OPHTHAL EPIDEMIOL, V16, P115, DOI 10.1080/09286580902738159
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   Pan CW, 2013, OPHTHALMOLOGY, V120, P284, DOI 10.1016/j.ophtha.2012.07.065
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Quigley MG, 2018, INVEST OPHTH VIS SCI, V59, P3852, DOI 10.1167/iovs.17-23696
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Vurgese S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029692
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
NR 27
TC 6
Z9 7
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2019
VL 60
IS 15
BP 4966
EP 4971
DI 10.1167/iovs.19-27325
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KD1NV
UT WOS:000507640100003
PM 31790559
OA gold
DA 2022-11-30
ER

PT J
AU de Freitas, LGA
   Isaac, DLC
   Tannure, WT
   Gabriel, LAR
   dos Reis, RG
   Rassi, AR
   de Freitas, CA
   de Avila, MP
AF Azevedo de Freitas, Luiz Guilherme
   Cruvinel Isaac, David Leonardo
   Tannure, William Thomas
   Rassi Gabriel, Luis Alexandre
   dos Reis, Ricardo Gomes
   Rassi, Alan Ricardo
   de Freitas, Clovis Arcoverde
   de Avila, Marcos Pereira
TI Intravitreal bevacizumab combined with infliximab in the treatment of
   choroidal neovascularization secondary to age-related macular
   degeneration: case report series
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Retina; Macular degeneration/complications; Choroidal
   neovascularization/etiology; Intravitreal injections; Optical coherence
   tomography; Angiogenesis inhibitors/therapeutic use
ID RANIBIZUMAB
AB Purpose: To evaluate the feasibility of the combined use of bevacizumab (Avastin (R)) and combined with infliximab (Remicade (R)) in the treatment of naive choroidal neovascularization due to age-related macular degeneration eyes.
   Methods: Intravitreal injections of bevacizumab combined with infliximab in 6 neovascular age-related macular degeneration eyes. All patients underwent complete ophthalmologic examination on the initial visit and at days 1, 30, 60, 90, 120, 150 and 180 following the first injection. Optical coherence tomography and fluorescein angiography were performed during at initial visit and monthly during the 6 months follow-up period. Electroretinography was performed before and 30 days after initial injection, in order to evaluate retinal toxicity induced by such treatment.
   Results: Thirty days after the first injection, 5 eyes (83%) shown decrease in macular thickness. No change was seen in electroretinogram in any eyes compared to initially performed electroretinogram. All phakic eyes developed cataract. One patient developed vitritis and was submitted to medical treatment successfully. At the end of the 6 months follow-up period, 4 patients showed significant improvement in the exudative process of choroidal neovascularization. One eye had mild persistent submacular fluid without active choroidal neovascularization, and another eye had persistent amount of intraretinal fluid due to active choroidal neovascularization.
   Conclusion: The combined use of bevacizumab with infliximab in eyes with neovascular age-related macular degeneration was effective in reducing leakage and improving the macular thickness. However, it is not possible to assert that the results were related to synergic effects of the combination therapy. A controlled study with more cases is necessary to precisely define the complication rates; however the dosage and/or association of drugs studied in this research should not be recommended in clinical practice due to cataract as well as inflammatory reaction.
RP de Freitas, LGA (通讯作者)，Hosp Olhos Santa Luzia, Estr Encanamento 909, BR-52070000 Recife, PE, Brazil.
EM luizgfreitas@gmail.com
RI Isaac, David Leonardo Cruvinel/ABI-5513-2020; Freitas-Neto,
   Clovis/J-5804-2015
OI Isaac, David Leonardo Cruvinel/0000-0002-0821-2660; Freitas-Neto,
   Clovis/0000-0002-5266-5675
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Arias L, 2010, RETINA-J RET VIT DIS, V30, P1601, DOI 10.1097/IAE.0b013e3181e9f942
   Brown G, 2008, CURR OPIN OPHTHALMOL, V19, P175, DOI 10.1097/ICU.0b013e3282fb7c56
   CHANDRA SR, 1974, AM J OPHTHALMOL, V78, P579, DOI 10.1016/S0002-9394(14)76293-2
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Derevjanik NL, 2002, INVEST OPHTH VIS SCI, V43, P2462
   DEVOS AF, 1994, INVEST OPHTH VIS SCI, V35, P3873
   Giganti M, 2010, RETINA-J RET VIT DIS, V30, P71, DOI 10.1097/IAE.0b013e3181bcef3b
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lima Filho AA, 2008, CULTURA MED RIO DE J, V1, P429
   Limb GA, 2001, INVEST OPHTH VIS SCI, V42, P1586
   Magalhaes FP, 2011, ARQ BRAS OFTALMOL, V74, P110, DOI 10.1590/S0004-27492011000200008
   Marcelo LG, 2007, REUMATOOFTALMOLOGIA, P94
   Markomichelakis NN, 2005, AM J OPHTHALMOL
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Rassi AR, 2011, ARQ BRAS OFTALMOL, V74, P352, DOI 10.1590/S0004-27492011000500009
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rodrigues EB, 2009, PROG RETIN EYE RES, V28, P117, DOI 10.1016/j.preteyeres.2008.11.005
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Theodossiadis PG, 2007, RETINA-J RET VIT DIS, V27, P399, DOI 10.1097/MAJ.0b013e3180318fbc
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Theodossiadis P, 2009, GRAEF ARCH CLIN EXP, V247, P273, DOI 10.1007/s00417-008-0967-4
   Wu L, 2011, RETINA-J RET VIT DIS, V31, P298, DOI 10.1097/IAE.0b013e3181eac7a6
NR 24
TC 7
Z9 7
U1 0
U2 2
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAR-JUN
PY 2013
VL 76
IS 3
BP 180
EP 184
DI 10.1590/S0004-27492013000300010
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 199QU
UT WOS:000323010700010
PM 23929080
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Song, DL
   Hua, PY
   VanderBeek, BL
   Dunaief, JL
   Grunwald, JE
   Daniel, E
   Maguire, MG
   Martin, DF
   Ying, GS
AF Song, Delu
   Hua, Peiying
   VanderBeek, Brian L.
   Dunaief, Joshua L.
   Grunwald, Juan E.
   Daniel, Ebenezer
   Maguire, Maureen G.
   Martin, Daniel F.
   Ying, Gui-Shuang
CA CATT Res Grp
TI SYSTEMIC MEDICATION USE AND THE INCIDENCE AND GROWTH OF GEOGRAPHIC
   ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS
   TRIALS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE geographic atrophy; age-related macular degeneration; systemic
   medications; calcium channel blockers
ID CARDIOVASCULAR-DISEASE; RISK-FACTORS; STATINS; ASSOCIATION; PROGRESSION
AB Purpose: To determine associations of systemic medications with the incidence and growth of geographic atrophy (GA) in participants of the comparison of age-related macular degeneration treatments trials. Methods: Participants of comparison of age-related macular degeneration treatments trials with new untreated choroidal neovascularization in the study eye (one study eye per participant) were randomized to receive treatment with bevacizumab or ranibizumab. Participants were released from clinical trial treatment at 2 years and examined at approximately 5 years. Color fundus photographs and fluorescein angiograms taken at baseline, Years 1, 2, and 5 were assessed for the presence and size of GA by two masked graders. Participants were interviewed about systemic medication use at baseline. Systemic medications previously reported to be associated with age-related macular degeneration were evaluated for associations with GA incidence in study eye using univariable and multivariable Cox models and for association with the GA growth using linear mixed effects models. Results: In multivariable analysis of 1,011 study eyes without baseline GA, systemic medications, including cholinesterase inhibitors, angiotensin-converting enzyme inhibitors, calcium channel blockers, beta-blockers, diuretics, aspirin, steroids, statins, hormone replacement therapy, antacids, and drugs targeting G protein-coupled receptors, were not associated with GA incidence in the study eye (all adjusted hazard ratios <= 1.86, P >= 0.18). In multivariable analysis of 214 study eyes with longitudinal GA size measurements, calcium channel blockers were associated with a higher GA growth rate (0.40 vs. 0.30 mm/year, P = 0.02). Conclusion: None of the systemic medications analyzed were associated with GA incidence. However, calcium channel blockers were associated with a higher growth rate of GA in the study eye.
C1 [Song, Delu; VanderBeek, Brian L.; Dunaief, Joshua L.; Grunwald, Juan E.; Daniel, Ebenezer; Maguire, Maureen G.; Ying, Gui-Shuang] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Hua, Peiying; Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Cleveland Clinic
   Foundation
RP Ying, GS (通讯作者)，Univ Penn, Perelman Sch Med, Ctr Prevent Ophthalmol & Biostat, Dept Ophthalmol, 3711 Market St,Suite 801, Philadelphia, PA 19104 USA.
EM gsying@pennmedicine.upenn.edu
OI Russell, Stephen/0000-0003-3776-1367; Folk, James/0000-0002-6271-2906
FU [U10 EY017823];  [U10 EY017825];  [U10 EY017826];  [U10 EY017828];  [U10
   EY023530];  [R21EY028998]
FX Supported by cooperative agreements U10 EY017823, U10 EY017825, U10
   EY017826, U10 EY017828, U10 EY023530, and R21EY028998.
CR Al-Holou SN, 2015, OPHTHALMOLOGY, V122, P2490, DOI 10.1016/j.ophtha.2015.08.028
   Almasieh M, 2013, INVEST OPHTH VIS SCI, V54, P3171, DOI 10.1167/iovs.12-11481
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Chen Y, 2016, ANNU REV PHARMACOL, V56, P273, DOI 10.1146/annurev-pharmtox-010715-103033
   Christen WG, 2014, EXPERT OPIN DRUG SAF, V13, P421, DOI 10.1517/14740338.2014.889680
   Cleland SC, 2021, OPHTHALMOL RETINA, V5, P41, DOI 10.1016/j.oret.2020.07.006
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Edwards DRV, 2010, INVEST OPHTH VIS SCI, V51, P1873, DOI 10.1167/iovs.09-4000
   Erke MG, 2013, BRIT J OPHTHALMOL, V97, P1036, DOI 10.1136/bjophthalmol-2012-302461
   Etminan M, 2008, CURR DRUG SAF, V3, P24, DOI 10.2174/157488608783333952
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Keenan TD, 2019, OPHTHALMOLOGY, V126, P1647, DOI 10.1016/j.ophtha.2019.06.023
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein R, 2014, OPHTHALMOLOGY, V121, P1604, DOI 10.1016/j.ophtha.2014.03.005
   Kolomeyer AM, 2019, RETINA-J RET VIT DIS, V39, P918, DOI 10.1097/IAE.0000000000002059
   Martin GC, 2019, BRIT J OPHTHALMOL, V103, P906, DOI 10.1136/bjophthalmol-2018-312305
   Miller YI, 2011, CIRC RES, V108, P235, DOI 10.1161/CIRCRESAHA.110.223875
   Palczewska G, 2010, NAT MED, V16, P1444, DOI 10.1038/nm.2260
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Song DL, 2019, RETINA-J RET VIT DIS, V39, P1965, DOI 10.1097/IAE.0000000000002295
   Swanson MW, 2008, OPTOMETRY VISION SCI, V85, P947, DOI 10.1097/OPX.0b013e31818883e0
   Tsao SW, 2013, DRUG AGING, V30, P205, DOI 10.1007/s40266-013-0061-4
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Wang SV, 2021, OPHTHALMOLOGY, V128, P248, DOI 10.1016/j.ophtha.2020.08.004
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yeung L, 2017, OPHTHALMOLOGY, V124, P409, DOI 10.1016/j.ophtha.2016.10.023
NR 30
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2021
VL 41
IS 7
BP 1455
EP 1462
DI 10.1097/IAE.0000000000003075
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5LP
UT WOS:000711809200014
PM 33332813
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Shah, AR
   Del Priore, LV
AF Shah, Ankoor R.
   Del Priore, Lucian V.
TI Natural History of Predominantly Classic, Minimally Classic, and Occult
   Subgroups in Exudative Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIAL;
   PHOTODYNAMIC THERAPY; CLINICOPATHOLOGICAL CORRELATION; VERTEPORFIN
   THERAPY; VISUAL-ACUITY; LESIONS; RANIBIZUMAB; RELEVANT; OUTCOMES
AB Objectives: We previously showed that the pattern of vision loss in eyes with subfoveal neovascularization in age-related macular degeneration (AMD) is uniform across a wide range of clinical trials, with apparent differences arising from differences in the time of entry of patients into clinical trials. In the current study, we used a similar analysis to compare the visual loss of untreated control eyes classified as predominantly classic (PC), minimally classic (MC), and occult with no classic (occult) based on fluorescein angiography.
   Design: Meta-analysis of prior clinical trials.
   Participants: Data from patients enrolled in the Macular Photocoagulation Study (MPS), Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study, Verteporfin in Photodynamic Therapy (VIP) Study, Anecortave Acetate (AA) Trial, VEGF Inhibition Study in Ocular Neovascularization (VISION), and Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration (MARINA) Trials.
   Methods: Visual acuity (VA) data of untreated control eyes for each study from appropriate subgroups were plotted on a double reciprocal (Lineweaver-Burke) plot of 1/[Ietters lost] versus 1/[months]. To correct for differences in time of entry into clinical trials, we introduced a horizontal translation factor to shift each data subset.
   Main Outcome Measures: We determined the coefficient of determination before and after adjustments for visual acuity at the time of enrollment.
   Results: On a Lineweaver-Burke plot, the cumulative subgroups had an overall coefficient of determination of only r(2)<0.01 for the raw data but improved to a remarkably high r(2) = 0.90 when data were corrected for time of entry into clinical trials. For each subgroup there was excellent correlation between 1/[Ietters lost] versus 1/[months of exudative disease] for PC (r(2) = 0.91), MC (r(2) = 0.95), and occult (r(2) 0.98) choroidal neovascularization.
   Conclusions: We were able to demonstrate a strong correlation for visual acuity as a function of time that is independent of the fluorescein angiography classification of a lesion, suggesting that initial protocol visual acuity, rather than angiographic classification, is the major determinant of the behavior of visual acuity as a function of time in exudative AMD.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2009; 116:1901-1907 (C) 2009 by the American Academy of Ophthalmology.
C1 [Shah, Ankoor R.; Del Priore, Lucian V.] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
C3 Columbia University
RP Del Priore, LV (通讯作者)，635 W 165th St, New York, NY 10032 USA.
EM ldelpriore@yahoo.com
FU Eye Surgery Fund; Robert L. Burch III Fund; Foundation Fighting
   Blindness, Hickey Foundation; Doris Duke Foundation
FX Supported by the Eye Surgery Fund, Robert L. Burch III Fund, Foundation
   Fighting Blindness, Hickey Foundation, Doris Duke Foundation, and
   unrestricted funds from Research to Prevent Blindness.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   Bressler SB, 2004, ARCH OPHTHALMOL-CHIC, V122, P325, DOI 10.1001/archopht.122.3.325
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   DiLoreto DA, 2003, ARCH OPHTHALMOL-CHIC, V121, P1586, DOI 10.1001/archopht.121.11.1586
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2002, RETINA-J RET VIT DIS, V22, P818, DOI 10.1097/00006982-200212000-00027
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Pieramici DJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P660
   Polito A, 2006, ANN ACAD MED SINGAP, V35, P145
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schneider U, 2005, ACTA OPHTHALMOL SCAN, V83, P141, DOI 10.1111/j.1600-0420.2005.00443.x
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   THOMPSON D, 2005, OPTOMETRY TODAY OPTI, P22
   West SK, 2000, EPIDEMIOL REV, V22, P64, DOI 10.1093/oxfordjournals.epirev.a018025
NR 24
TC 34
Z9 36
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2009
VL 116
IS 10
BP 1901
EP 1907
DI 10.1016/j.ophtha.2009.03.055
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 506RX
UT WOS:000270794600011
PM 19592101
DA 2022-11-30
ER

PT J
AU Paterno, JJ
   Koskela, A
   Hyttinen, JMT
   Vattulainen, E
   Synowiec, E
   Tuuminen, R
   Watala, C
   Blasiak, J
   Kaarniranta, K
AF Paterno, Jussi J.
   Koskela, Ali
   Hyttinen, Juha M. T.
   Vattulainen, Elina
   Synowiec, Ewelina
   Tuuminen, Raimo
   Watala, Cezary
   Blasiak, Janusz
   Kaarniranta, Kai
TI Autophagy Genes for Wet Age-Related Macular Degeneration in a Finnish
   Case-Control Study
SO GENES
LA English
DT Article
DE aging; autophagy; degeneration; macula; neovascularization
ID RETINAL-PIGMENT EPITHELIUM; RANIBIZUMAB TREATMENT; ASSOCIATION; ARMS2;
   DELETION; RPE; CFH
AB Age-related macular degeneration is an eye disease that is the main cause of legal blindness in the elderly in developed countries. Despite this, its pathogenesis is not completely known, and many genetic, epigenetic, environmental and lifestyle factors may be involved. Vision loss in age-related macular degeneration (AMD) is usually consequence of the occurrence of its wet (neovascular) form that is targeted in the clinic by anti-VEGF (vascular endothelial growth factor) treatment. The wet form of AMD is associated with the accumulation of cellular waste in the retinal pigment epithelium, which is removed by autophagy and the proteosomal degradation system. In the present work, we searched for the association between genotypes and alleles of single nucleotide polymorphisms (SNPs) of autophagy-related genes and wet AMD occurrence in a cohort of Finnish patients undergoing anti-VEGF therapy and controls. Additionally, the correlation between treatment efficacy and genotypes was investigated. Overall, 225 wet AMD patients and 161 controls were enrolled in this study. Ten SNPs (rs2295080, rs11121704, rs1057079, rs1064261, rs573775, rs11246867, rs3088051, rs10902469, rs73105013, rs10277) in the mTOR (Mechanistic Target of Rapamycin), ATG5 (Autophagy Related 5), ULK1 (Unc-51-Like Autophagy Activating Kinase 1), MAP1LC3A (Microtubule Associated Protein 1 Light Chain 3 alpha), SQSTM1 (Sequestosome 1) were analyzed with RT-PCR-based genotyping. The genotype/alleles rs2295080-G, rs11121704-C, rs1057079-C and rs73105013-T associated with an increased, whereas rs2295080-TT, rs2295080-T, rs11121704-TT, rs1057079-TT, rs1057079-T, rs573775-AA and rs73105013-C with a decreased occurrence of wet AMD. In addition, the rs2295080-GG, rs2295080-GT, rs1057079-TT, rs11246867-AG, rs3088051-CC and rs10277-CC genotypes were a positively correlated cumulative number of anti-VEGF injections in 2 years. Therefore, variability in autophagy genes may have an impact on the risk of wet AMD occurrence and the efficacy of anti-VEGF treatment.
C1 [Paterno, Jussi J.; Koskela, Ali; Hyttinen, Juha M. T.; Vattulainen, Elina; Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.
   [Paterno, Jussi J.; Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70029, Finland.
   [Synowiec, Ewelina; Blasiak, Janusz] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, PL-90136 Lodz, Poland.
   [Tuuminen, Raimo] Univ Helsinki, Helsinki Retina Res Grp, Helsinki 00014, Finland.
   [Tuuminen, Raimo] Kymenlaakso Cent Hosp, Dept Ophthalmol, Kotka 48100, Finland.
   [Watala, Cezary] Med Univ, Chair Biomed Sci, Dept Haemostat Disorders, PL-92215 Lodz, Poland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; University of Lodz; University of Helsinki
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.; Kaarniranta, K (通讯作者)，Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70029, Finland.
EM jussi.paterno@uef.fi; ali.koskela@uef.fi; juha.hyttinen@uef.fi;
   elivat@student.uef.fi; ewelina.synowiec@biol.uni.lodz.pl;
   raimo.tuuminen@helsinki.fi; cezary.watala@umed.lodz.pl;
   janusz.blasiak@biol.uni.lodz.pl; kai.kaarniranta@uef.fi
OI Blasiak, Janusz/0000-0001-9539-9584; Watala, Cezary/0000-0002-5627-7872;
   Hyttinen, Juha/0000-0002-3414-4032; Tuuminen, Raimo/0000-0003-1550-8125;
   Synowiec, Ewelina/0000-0002-0730-4491
FU Kuopio University Hospital [5503743]; Finnish Eye Foundation; Sigrid
   Juselius Foundation; Finnish Funding Agency for Technology and
   Innovation; Academy of Finland [296840, 333302]; Paivikki and Sakari
   Sohlberg Foundation; National Science Centre, Poland
   [2017/27/B/NZ3/00872]
FX This work was supported by the Kuopio University Hospital (KK) (Grant
   Number 5503743), the Finnish Eye Foundation (JJP, KK), The Sigrid
   Juselius Foundation (KK), the Finnish Funding Agency for Technology and
   Innovation (KK), the Academy of Finland (KK) (Grant Numbers 296840 and
   333302), the Paivikki and Sakari Sohlberg Foundation (KK), National
   Science Centre, Poland (JB) (Grant number 2017/27/B/NZ3/00872).
CR Al-Holou SN, 2015, OPHTHALMOLOGY, V122, P2490, DOI 10.1016/j.ophtha.2015.08.028
   Baek A, 2017, AUTOPHAGY, V13, P248, DOI 10.1080/15548627.2016.1256932
   Barbero-Camps E, 2018, AUTOPHAGY, V14, P1129, DOI 10.1080/15548627.2018.1438807
   Blasiak J, 2019, J CELL MOL MED, V23, P8464, DOI 10.1111/jcmm.14731
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Blasiak Janusz, 2013, Front Biosci (Schol Ed), V5, P412
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cobos E, 2018, ACTA OPHTHALMOL, V96, pe201, DOI 10.1111/aos.13519
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gurubaran IS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061976
   Han SX, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101537
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Jin GM, 2019, CLIN EXP OPHTHALMOL, V47, P1019, DOI 10.1111/ceo.13580
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2012, NEUROSCI LETT, V513, P233, DOI 10.1016/j.neulet.2012.02.050
   Karesvuo P, 2020, ACTA OPHTHALMOL, V98, P472, DOI 10.1111/aos.14376
   Kataja M, 2018, BRIT J OPHTHALMOL, V102, P959, DOI 10.1136/bjophthalmol-2017-311055
   Lahiri V, 2019, CELL METAB, V29, P803, DOI 10.1016/j.cmet.2019.03.003
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Lores-Motta L, 2018, JAMA OPHTHALMOL, V136, P875, DOI 10.1001/jamaophthalmol.2018.2019
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Modjtahedi BS, 2018, AM J OPHTHALMOL, V188, P111, DOI 10.1016/j.ajo.2018.01.012
   Ouimet M, 2013, BBA-MOL CELL BIOL L, V1831, P1124, DOI 10.1016/j.bbalip.2013.03.007
   Rim TH, 2019, OPHTHALMOLOGY, V126, P274, DOI 10.1016/j.ophtha.2018.09.014
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Schroeder M, 2020, ACTA OPHTHALMOL, V98, P274, DOI 10.1111/aos.14239
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Small KW, 2017, RETINA-J RET VIT DIS, V37, P1630, DOI 10.1097/IAE.0000000000001475
   Song CJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171940
   Taipale C, 2020, ADV THER, V37, P2256, DOI 10.1007/s12325-020-01312-2
   Tuuminen R, 2019, ACTA OPHTHALMOL, V97, pE808, DOI 10.1111/aos.14031
   Tuuminen R, 2017, ACTA OPHTHALMOL, V95, DOI 10.1111/aos.13501
   Valverde-Megias A, 2017, GRAEF ARCH CLIN EXP, V255, P2091, DOI 10.1007/s00417-017-3748-0
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Ying GS, 2016, OPHTHALMOLOGY, V123, P352, DOI 10.1016/j.ophtha.2015.09.046
   Zhang Y, 2017, MOL VIS, V23, P228
NR 41
TC 3
Z9 4
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4425
J9 GENES-BASEL
JI Genes
PD NOV
PY 2020
VL 11
IS 11
AR 1318
DI 10.3390/genes11111318
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA OY1OH
UT WOS:000594021800001
PM 33172148
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bojanowski, CM
   Shen, DF
   Chew, EY
   Ning, BT
   Csaky, KG
   Green, WR
   Chan, CC
   Tuo, JS
AF Bojanowski, Christine M.
   Shen, Defen
   Chew, Emily Y.
   Ning, Baitang
   Csaky, Karl G.
   Green, W. Richard
   Chan, Chi-Chao
   Tuo, Jingsheng
TI An Apolipoprotein E variant may protect against age-related macular
   degeneration through cytokine regulation
SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
LA English
DT Article
DE age-related macular degeneration; apolipoprotein E; single nucleotide
   polymorphism; genetic susceptibility; cytokines
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; ENDOTHELIAL GROWTH-FACTOR; E
   GENE; ALZHEIMERS-DISEASE; APOE GENOTYPE; AMYLOID-BETA; ANIMAL-MODEL;
   ASSOCIATION; DRUSEN
AB Age-related macular degeneration (AMD) is the leading cause of visual impairment and blindness among the elderly in Western countries. Genetic factors, age, cigarette smoking, nutrition, and exposure to light have been identified as AMD risk factors. In this study, we investigated the association between ApoE C112R/R158C single nucleotide polymorphisms (which determine the E2, E3, and E4 isoforms) and age-related macular degeneration (AMD), and the mechanism underlying the association. Genomic DNA was extracted from 133 clinically screened controls, 94 volunteers with a younger mean age, 120 patients with advanced AMD, and 40 archived ocular AMD slides for single nucleotide polymorphism typing. The effects of recombinant ApoE isoforms on CCL2 (a chemokine), CX3CR1 (a chemokine receptor), and VEGF (a cytokine) expression in cultured human retinal pigment epithelium (RIPE) cells were tested and serum cholesterol profiles of the clinically screened subjects were analyzed. ApoE112R (EA) distribution differed significantly between AMD patients and controls. ApoE112R allele frequency was 10.9% in the AMD group when compared with 16.5% in the younger controls and 18.8% in the clinically screened controls. The pathologically diagnosed archived AMD cases had the lowest allele frequency of 5%. No significant differences in ApoE158C (E2) distribution were observed among the groups. A meta-analysis of 8 cohorts including 4,289 subjects showed a strong association between AMD and 112R, but not 158C. In vitro studies found that recombinant ApoE suppresses CCL2 and VEGF expression in RIPE cells. However, the E4 isoform showed more suppression than E3 in both cases. These results further confirm the association between ApoE112R and a decreased risk of AMD development. The underlying mechanisms may involve differential regulation of both CCL2 and VEGF by the ApoE isoforms.
C1 NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.
   Natl Ctr Toxicol Res, Div Pharmacogen & Mol Epidemiol, Jefferson, AR 72079 USA.
   NEI, Sect Retinal Dis & Therapeut, NIH, Bethesda, MD 20892 USA.
   Johns Hopkins Med Sch, Wilmer Eye Inst, Baltimore, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); US Food & Drug Administration (FDA); National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   Johns Hopkins University; Johns Hopkins Medicine
RP Tuo, JS (通讯作者)，NEI, Immunol Lab, NIH, 10 Ctr Dr,Bldg 10,Rm 10N103, Bethesda, MD 20892 USA.
EM tuoj@nei.nih.gov
OI Tuo, Jingsheng/0000-0002-1372-7810; Ning, Baitang/0000-0003-0798-0331
FU Intramural NIH HHS [Z01 EY000418-04, Z99 EY999999] Funding Source:
   Medline
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Austin MA, 2004, ANN HUM GENET, V68, P179, DOI 10.1046/j.1529-8817.2004.00078.x
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bland JM, 2000, BRIT MED J, V320, P1468, DOI 10.1136/bmj.320.7247.1468
   Chapman J, 2001, NEUROLOGY, V57, P1482, DOI 10.1212/WNL.57.8.1482
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crane IJ, 2000, IMMUNOLOGY, V101, P426, DOI 10.1046/j.0019-2805.2000.01105.x
   de Jong PTVM, 2001, EYE, V15, P396, DOI 10.1038/eye.2001.143
   Dentchev T, 2003, MOL VIS, V9, P184
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holtkamp GM, 1999, CLIN EXP IMMUNOL, V118, P35
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Jarvik GP, 1997, ANN EPIDEMIOL, V7, P357, DOI 10.1016/S1047-2797(97)00028-8
   Ji ZS, 2002, J BIOL CHEM, V277, P21821, DOI 10.1074/jbc.M112109200
   Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452
   Judson R, 2004, ATHEROSCLEROSIS, V177, P345, DOI 10.1016/j.atherosclerosis.2004.07.012
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Laws SM, 2003, J NEUROCHEM, V84, P1215, DOI 10.1046/j.1471-4159.2003.01615.x
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003
   Marz W, 2004, EUR HEART J, V25, P2109, DOI 10.1016/j.ehj.2004.08.024
   McIntyre LM, 2000, GENET EPIDEMIOL, V19, P18, DOI 10.1002/1098-2272(200007)19:1<18::AID-GEPI2>3.0.CO;2-Y
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342
   Ribalta J, 2003, CURR OPIN CLIN NUTR, V6, P177, DOI 10.1097/00075197-200303000-00006
   Schmidt S, 2000, MOL VIS, V6, P287
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Smith JD, 2000, ANN MED, V32, P118, DOI 10.3109/07853890009011761
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Uetama T, 2003, J CELL PHYSIOL, V197, P77, DOI 10.1002/jcp.10342
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   ZANNIS VI, 1986, METHOD ENZYMOL, V128, P823
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 59
TC 44
Z9 52
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0893-6692
EI 1098-2280
J9 ENVIRON MOL MUTAGEN
JI Environ. Mol. Mutagen.
PD OCT
PY 2006
VL 47
IS 8
BP 594
EP 602
DI 10.1002/em.20233
PG 9
WC Environmental Sciences; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology
GA 099TJ
UT WOS:000241618600004
PM 16823865
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Mones, J
   Biarnes, M
AF Mones, Jordi
   Biarnes, Marc
CA Macbeth Study Grp
TI Intravitreal aflibercept efficacy in neovascular age-related macular
   degeneration with suboptimal response to anti-vascular endothelial
   growth factor-A therapy
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; intravitreal injections; neovascular age-related macular
   degeneration; optical coherence tomography; visual acuity
ID FACTOR TRAP-EYE; CHOROIDAL NEOVASCULARIZATION; FACTOR DRUGS;
   RANIBIZUMAB; BEVACIZUMAB; PREVALENCE
AB Importance: To provide new insights into aflibercept effect in non-naive-treated patients with neovascular age-related macular degeneration. Purpose: To assess the efficacy of intravitreal aflibercept in patients with neovascular age-related macular degeneration without optimal response to previous anti-vascular endothelial growth factor A therapy. Design: Single-arm, multi-centre, prospective study. Participants: Patients > 50 years with active neovascular age-related macular degeneration, best-corrected visual acuity between 20/32 and 20/320 with suboptimal response to ranibizumab or bevacizumab. Methods: Aflibercept was administered monthly (3-first months), and bimonthly thereafter until month 8. Anatomical and functional outcomes were assessed. Main outcome measure: Percentage of eyes without intra or subretinal fluid on optical coherence tomography after 3-monthly loading doses of aflibercept. Results: A total of 46 patients were included. At week 12, 45.7% (95% confidence interval: 31.5%-60.1%) of eyes showed no fluid on optical coherence tomography. The mean (standard deviation) best-corrected visual acuity increased from 65.1 (8.3) to 69.6 (8.1) letters (+4.5 (5.8) p < 0.0001) and was stabilized at week 40 as compared to baseline. Mean central macular thickness decreased from 430 (119) mu m to 323 (100) mu m at week 12 (-107 (90) mu m, p < 0.0001) and was reduced at week 40 (-46 (111) mu m, p = 0.0056). At week 40, 21.7% (95% confidence interval: 9.8%-33.7%) had no fluid. There was a case of presumed noninfectious endophthalmitis that was successfully managed. Conclusion: Almost half of patients presented no fluid on optical coherence tomography at week 12, and there was a clinically significant improvement in best-corrected visual acuity. At week 40, one in five patients did not show intra or subretinal fluid, central macular thickness decreased and best-corrected visual acuity was stabilized compared to baseline.
C1 [Mones, Jordi; Biarnes, Marc] Inst Macula, Barcelona, Spain.
   [Mones, Jordi; Biarnes, Marc] Barcelona Macula Fdn, Barcelona, Spain.
RP Mones, J (通讯作者)，Hosp Quiron Teknon, Inst Macula, C Vilana 12,Off 90, Barcelona 08022, Spain.
EM jmones@institutmacula.com
RI mones, jordi/CAJ-2963-2022
OI mones, jordi/0000-0003-3685-2160; Biarnes, Marc/0000-0003-2584-4894
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bressler NM, 2018, AM J OPHTHALMOL, V195, P93, DOI 10.1016/j.ajo.2018.07.030
   Bressler NM, 2018, JAMA OPHTHALMOL, V136, P257, DOI 10.1001/jamaophthalmol.2017.6565
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Chan Clement K, 2014, Trans Am Ophthalmol Soc, V112, P160
   Chang AA, 2016, OPHTHALMIC RES, V55, P84, DOI 10.1159/000440886
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2014, EUR J OPHTHALMOL, V24, P576, DOI 10.5301/ejo.5000421
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Dugel PU, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S100764
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Ferris FL, 2017, JAMA OPHTHALMOL, V135, P145, DOI 10.1001/jamaophthalmol.2016.4820
   Framme C, 2018, OPHTHALMOL RETINA, V2, P539, DOI 10.1016/j.oret.2017.09.017
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Lazzeri S, 2015, ANGIOGENESIS, V18, P397, DOI 10.1007/s10456-015-9483-4
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sarao V, 2016, RETINA-J RET VIT DIS, V36, P770, DOI 10.1097/IAE.0000000000000751
   Sarao V, 2016, GRAEF ARCH CLIN EXP, V254, P445, DOI 10.1007/s00417-015-3076-1
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P1, DOI 10.1136/bjophthalmol-2014-305502
   Smith TC, 2007, AUST FAM PHYSICIAN, V36, P359
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Stoller GL, 2016, JAMA OPHTHALMOL, V134, P545, DOI 10.1001/jamaophthalmol.2016.0379
   Verma Lalit, 2000, Indian Journal of Ophthalmology, V48, P263
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 40
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP
PY 2020
VL 30
IS 5
BP 1082
EP 1090
DI 10.1177/1120672119848961
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OB6JS
UT WOS:000578575700057
PM 31088111
DA 2022-11-30
ER

PT J
AU Padnick-Silver, L
   Weinberg, AB
   Lafranco, FP
   Macsai, MS
AF Padnick-Silver, Lissa
   Weinberg, Aaron B.
   Lafranco, Frank P.
   Macsai, Marian S.
TI PILOT STUDY FOR THE DETECTION OF EARLY EXUDATIVE AGE-RELATED MACULAR
   DEGENERATION WITH OPTICAL COHERENCE TOMOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; optical
   coherence tomography; retinal imaging
ID CHOROIDAL NEOVASCULARIZATION; VITREOMACULAR TRACTION; RANIBIZUMAB;
   DISEASE
AB Background: Optical coherence tomography (OCT) provides microscopic retinal images. Optical coherence tomography is noninvasive, using light waves to produce detailed retinal images. Here, we investigate the ability of OCT to detect early choroidal neovascularization in age-related macular degeneration.
   Methods: Seventy-nine patients, diagnosed with nonexudative macular degeneration in one eye and exudative macular degeneration in the other were enrolled in this prospective, observational, nonrandomized study. Participants underwent examination (visual acuity, intraocular pressure, biomicroscopy, and ophthalmoscopy) followed by OCT in the study eye (nonexudative macular degeneration eye) every 3 months for 2 years. If examination did not show choroidal neovascularization, but OCT images raised suspicion, patients were reexamined in 4 weeks to 6 weeks and/or fluorescein angiography was performed. Visual acuity, OCT anomaly detected, and time between OCT and fluorescein angiography detection were examined.
   Results: Fifteen (19%) patients developed exudative macular degeneration, as confirmed by fluorescein angiography, in the study eye. Four additional patients showed potential exudative macular degeneration on OCT only. Of the 15 patients who developed exudative macular degeneration, 13 had disease progression identified on OCT before examination and/or fluorescein angiography showed changes. Subretinal pigment epithelium fluid was the most common OCT anomaly, with development of sub-/intraretinal fluid also visible.
   Conclusion: Optical coherence tomography could be a powerful screening tool for patients with age-related macular degeneration at high risk for developing choroidal neovascularization. RETINA 32: 1045-1056, 2012
C1 [Padnick-Silver, Lissa; Macsai, Marian S.] Northshore Univ HealthSyst, Div Ophthalmol, Evanston, IL USA.
   [Padnick-Silver, Lissa; Macsai, Marian S.] Univ Chicago, Pritzker Sch Med, Dept Ophthalmol, Chicago, IL 60637 USA.
   [Weinberg, Aaron B.] Retina Associates Inc, Oak Brook, IL USA.
   [Lafranco, Frank P.] Retina Serv Inc, Skokie, IL USA.
C3 NorthShore University Health System; University of Chicago
RP Padnick-Silver, L (通讯作者)，2050 Pfingsten Rd,Suite 220, Glenview, IL 60026 USA.
EM lissa.silver@sbcglobal.net
FU NorthShore University HealthSystem
FX Supported by a grant from the NorthShore University HealthSystem
   (formerly Evanston Northwestern Healthcare) Women's Auxiliary and
   private patient donations to NorthShore Ophthalmology Research.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Davis MD, 2008, INVEST OPHTH VIS SCI, V49, P1745, DOI 10.1167/iovs.07-1257
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   Lowry R., VASSARSTATS WEBSITE
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Meyer CH, 2001, GRAEF ARCH CLIN EXP, V239, P325, DOI 10.1007/s004170100259
   PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt JC, 2006, BRIT J OPHTHALMOL, V90, P1361, DOI 10.1136/bjo.2006.094201
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Taylor HR, 2001, BRIT J OPHTHALMOL, V85, P261, DOI 10.1136/bjo.85.3.261
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
NR 16
TC 19
Z9 19
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2012
VL 32
IS 6
BP 1045
EP 1056
DI 10.1097/IAE.0b03e31823fb82b
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 948VY
UT WOS:000304532100002
PM 22186740
DA 2022-11-30
ER

PT J
AU Kuroda, Y
   Yamashiro, K
   Miyake, M
   Yoshikawa, M
   Nakanishi, H
   Oishi, A
   Tamura, H
   Ooto, S
   Tsujikawa, A
   Yoshimura, N
AF Kuroda, Yoshimasa
   Yamashiro, Kenji
   Miyake, Masahiro
   Yoshikawa, Munemitsu
   Nakanishi, Hideo
   Oishi, Akio
   Tamura, Hiroshi
   Ooto, Sotaro
   Tsujikawa, Akitaka
   Yoshimura, Nagahisa
TI Factors Associated with Recurrence of Age-Related Macular Degeneration
   after Anti-Vascular Endothelial Growth Factor Treatment
SO OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; INTRAVITREAL RANIBIZUMAB; NEOVASCULAR
   MEMBRANES; PHOTODYNAMIC THERAPY; CLINICAL CHARACTERISTICS; JAPANESE
   PATIENTS; DOSING REGIMEN; VERTEPORFIN; POPULATION; EFFICACY
AB Purpose: To investigate the predictive factors associated with recurrence after anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD).
   Design: Retrospective cohort study.
   Participants: A total of 343 eyes of 326 patients with subfoveal neovascular AMD who were treated with an as-needed regimen after 3 monthly loading doses of intravitreal ranibizumab.
   Methods: Patients were followed up by an as-needed regimen for more than 1 year after the first injection. Baseline data and CFH I62V and ARMS2 A69S polymorphisms were analyzed for their association with recurrence after anti-VEGF treatment. Regression analysis was used to identify independent predictors of visual acuity (VA) prognosis.
   Main Outcome Measures: The primary end point was the presence or absence of recurrence. The secondary end point was VA improvement.
   Results: In total, 236 eyes (68.8%) showed complete resolution of retinal exudative change after the 3 loading injections, and 81 eyes (34.3%) experienced no recurrence during the first year. Of the 236 eyes, 139 (58.9%) were followed for more than 2 years and 35 (25.2%) showed no recurrent retinal exudation during 24 months. Visual acuity improvement was significantly better in eyes without recurrence than in eyes with recurrence during the 2-year period. Baseline characteristics and genotypes had no influence on response to ranibizumab loading treatment. Stepwise analysis revealed that age (P < 0.001), subtype of AMD (P = 0.041), and VA at baseline (P < 0.001) were associated with VA at 24 months. Older patients (P = 0.006) and male patients (P = 0.018) tended to require re-treatment for recurrence during the first year, yet the statistical significance disappeared when evaluated in 2 years. The subtypes of neovascular AMD were solely associated with the interval to the recurrence, which was shorter in eyes with polypoidal choroidal vasculopathy (PCV) than in eyes with typical AMD (P = 0.015).
   Conclusions: Older age and male sex may predict recurrence after 3 monthly ranibizumab injections, and PCV may be associated with shorter interval to recurrence. Predicting the risk of recurrence would help us to choose the most appropriate follow-up treatment strategy for patients with AMD. (C) 2015 by the American Academy of Ophthalmology.
C1 [Kuroda, Yoshimasa; Yamashiro, Kenji; Miyake, Masahiro; Yoshikawa, Munemitsu; Nakanishi, Hideo; Oishi, Akio; Tamura, Hiroshi; Ooto, Sotaro; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan.
   [Tsujikawa, Akitaka] Kagawa Univ, Fac Med, Dept Ophthalmol, Kagawa, Japan.
C3 Kyoto University; Kagawa University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011; Oishi, Akio/AAE-9996-2020; Miyake,
   Masahiro/V-1261-2019
OI TAMURA, Hiroshi/0000-0002-7740-2732; Oishi, Akio/0000-0002-0977-9458;
   Miyake, Masahiro/0000-0001-7410-3764; Yamashiro,
   Kenji/0000-0001-9354-8558; Tsujikawa, Akitaka/0000-0003-0779-7799
FU Japan Society for the Promotion of Science, Tokyo, Japan [24592624];
   Japan National Society for the Prevention of Blindness, Tokyo, Japan
FX Supported in part by grants-in-aid for scientific research (No.
   24592624) from the Japan Society for the Promotion of Science, Tokyo,
   Japan, and the Japan National Society for the Prevention of Blindness,
   Tokyo, Japan. The funding organizations had no role in the design or
   conduct of this research.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P221, DOI 10.1007/s00417-014-2688-1
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kang Haeng Ku, 2012, Korean J Ophthalmol, V26, P414, DOI 10.3341/kjo.2012.26.6.414
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yamashiro K, 2008, JPN J OPHTHALMOL, V52, P457, DOI 10.1007/s10384-008-0582-2
NR 40
TC 67
Z9 71
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2015
VL 122
IS 11
BP 2303
EP 2310
DI 10.1016/j.ophtha.2015.06.053
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CU4IQ
UT WOS:000363491800033
PM 26271842
DA 2022-11-30
ER

PT J
AU Horani, M
   Mahmood, S
   Aslam, TM
AF Horani, Mania
   Mahmood, Sajjad
   Aslam, Tariq M.
TI Macular Atrophy of the Retinal Pigment Epithelium in Patients with
   Neovascular Age-Related Macular Degeneration: What is the Link? Part I:
   A Review of Disease Characterization and Morphological Associations
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Review
DE Anti-VEGF; Fundus autofluorescence; Macular atrophy; Neovascular
   age-related macular degeneration; Optical coherence tomography
ID ENDOTHELIAL GROWTH-FACTOR; 2.0 MG RANIBIZUMAB; TREAT-AND-EXTEND;
   TERM-FOLLOW-UP; GEOGRAPHIC ATROPHY; 7-YEAR OUTCOMES; PROGRESSION;
   FUNDUS; ANCHOR; MARINA
AB IntroductionThe purpose of this review was to explore the potential link between macular atrophy (MA) of the retinal pigment epithelium in patients with neovascular age-related macular degeneration (nAMD) with the disease characteristics and morphological features.MethodsTo this end, we performed a search of peer-reviewed articles published on the PubMed database and included all relevant papers. We then examined these papers for possible risk factors for MA development in the context of nAMD treated with anti-vascular endothelial growth factor drugs, as well as possible protective factors.ResultsOur review of the relevant publications revealed that areas of MA can be directly visualized through multiple imaging modalities. Associations have been identified between MA of the retinal pigment epithelium and choroidal neovascular membrane characteristics, intra- and subretinal fluid, pigment epithelial detachment, choroidal thickness, subretinal hyperreflective material, outer retinal tubulations, hemorrhage, subretinal drusenoid deposits, refractile drusen, hyperreflective foci, retinal angiomatous proliferation, polypoidal choroidal vasculopathy, geographic atrophy in the fellow eye, genetic factors, and age.ConclusionThe findings of this review indicate that a multimodal approach is recommended for the assessment of MA. The conclusions drawn to date on the correlation between MA development or progression of MA and specific risk factors and possible protective factors are mixed. More clinical research is needed to reach a better understanding of this association.
C1 [Horani, Mania] Manchester Univ Fdn NHS Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.
   [Mahmood, Sajjad; Aslam, Tariq M.] Manchester Univ Fdn NHS Trust, Manchester Acad Hlth Sci Ctr, Manchester Royal Eye Hosp, Manchester, Lancs, England.
   [Aslam, Tariq M.] Univ Manchester, Div Pharm & Optometry, Sch Hlth Sci, Fac Biol Med & Hlth, Manchester, Lancs, England.
C3 Manchester Royal Eye Hospital; Manchester Royal Eye Hospital; University
   of Manchester; University of Manchester
RP Horani, M (通讯作者)，Manchester Univ Fdn NHS Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.
EM mania.horani@mft.nhs.uk
RI Mahmood, Sajjad/AAK-7645-2021; Aslam, Tariq/A-8532-2016
OI Aslam, Tariq/0000-0002-9739-7280; Horani, Mania/0000-0003-4774-7614
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   American Academy of Ophthalmology Retina/Vitreous Panel, 2015, PREF PRACT PATT GUID
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   CHAKRAVARTHY U, 2012, OPHTHALMOLOGY, V119
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Dolz-Marco R, 2016, INVEST OPHTH VIS SCI, V57, P6440, DOI 10.1167/iovs.16-20265
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Fan WY, 2018, GRAEF ARCH CLIN EXP, V256, P511, DOI 10.1007/s00417-017-3888-2
   Fleckenstein M, 2010, OPHTHALMOLOGE, V107, P1007, DOI 10.1007/s00347-010-2159-y
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Hata M, 2017, RETINA-J RET VIT DIS, V37, P2069, DOI 10.1097/IAE.0000000000001457
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   HOLZ FG, 2015, INVEST OPHTH VIS SCI, V56
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Holz FG, 2015, GRAEF ARCH CLIN EXP, V253, P7, DOI 10.1007/s00417-014-2858-1
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Kvanta A, 2017, RETINA-J RET VIT DIS, V37, P936, DOI 10.1097/IAE.0000000000001248
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Nguyen DH, 2013, DISCOV MED, V15, P343
   Pedrosa AC, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/4263017
   Pellegrini M, 2016, OPHTHALMOLOGY, V123, P1879, DOI 10.1016/j.ophtha.2016.05.041
   Picton F, 2014, INVEST OPHTH VIS SCI, V55
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Tah V, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/627674
   Tanaka E, 2015, OPHTHALMOLOGY, V122, P153, DOI 10.1016/j.ophtha.2014.07.046
   Thavikulwat AT, 2017, OPHTHALMOL RETINA, V1, P34, DOI 10.1016/j.oret.2016.09.005
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wons J, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7432739
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Zarubina AV, 2017, INVEST OPHTH VIS SCI, V58, P6038, DOI 10.1167/iovs.17-22378
NR 61
TC 10
Z9 12
U1 0
U2 2
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD JUN
PY 2019
VL 8
IS 2
BP 235
EP 249
DI 10.1007/s40123-019-0177-7
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HY4EK
UT WOS:000468080500006
PM 30911999
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Markomichelakis, NN
   Theodossiadis, PG
   Sfikakis, PP
AF Markomichelakis, NN
   Theodossiadis, PG
   Sfikakis, PP
TI Regression of neovascular age-related macular degeneration following
   infliximab therapy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To describe the effects of the antitumor necrosis factor (TNF) monoclonal antibody Infliximab systemic therapy on choroidal neovacularisation (CNV) secondary to age-related macular degeneration (AMD).
   DESIGN: Prospective, noncomparative series of three patients.
   METHODS: A subretinal membrane secondary to AMD was documented by fluoroangiography at baseline in three elderly patients scheduled to receive Infliximab therapy for inflammatory arthritis (infusions of 5 mg/kg at weeks 0, 2, 6, and every 8 weeks thereafter). Follow-up was performed at three months post-baseline, as well as during 18 months of continuing treatment in the first patient.
   RESULTS: CNV regressed partially at three months and resolved at six months in the first patient. Best-corrected visual acuity (BCVA) increased from 0.05 to 0.2; this effect was sustained at 18 months. Regression of subretinal membrane and increase of BCVA was also documented in the other patients. No ocular or extra-ocular side effects were noted.
   CONCLUSIONS: These findings suggest a plausible pathogenetic role of TNF in CNV secondary to AMD. Additional patients should he studied to confirm the promising clinical results. (c) 2005 by Elsevier Inc. All rights reserved.
C1 Univ Athens, Sch Med, Ocular Inflammat & Immunol Serv, Athens, Greece.
   Univ Athens, Sch Med, Dept Ophthalmol, Athens, Greece.
   Univ Athens, Sch Med, Gennimatas Hosp, Athens, Greece.
   Univ Athens, Laikon Hosp, Dept Propedeut Med 1, Sch Med, Athens, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens;
   Athens Medical School; National & Kapodistrian University of Athens;
   Athens Medical School; National & Kapodistrian University of Athens;
   Athens Medical School; Laiko General Hospital; National & Kapodistrian
   University of Athens
RP Sfikakis, PP (通讯作者)，3 Amaryllidos Str, Athens 15452, Greece.
EM psfikakis@med.uoa.gr
RI Sfikakis, Petros/AAD-7289-2019
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   MARKOMICHELAKIS N, 2004, IN PRESS AM J OPHTHA
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Sfikakis PP, 2004, ANN INTERN MED, V140, P404, DOI 10.7326/0003-4819-140-5-200403020-00025
   Sfikakis PP, 2003, CURR OPIN RHEUMATOL, V15, P380, DOI 10.1097/00002281-200307000-00003
NR 5
TC 83
Z9 89
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2005
VL 139
IS 3
BP 537
EP 540
DI 10.1016/j.ajo.2004.09.058
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 907GO
UT WOS:000227704200021
PM 15767068
DA 2022-11-30
ER

PT J
AU Aisenbrey, S
   Ziemssen, F
   Volker, M
   Gelisken, F
   Szurman, P
   Jaissle, G
   Grisanti, S
   Bartz-Schmidt, KU
AF Aisenbrey, S.
   Ziemssen, F.
   Voelker, M.
   Gelisken, F.
   Szurman, P.
   Jaissle, G.
   Grisanti, S.
   Bartz-Schmidt, K. U.
TI Intravitreal bevacizumab (Avastin) for occult choroidal
   neovascularization in age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE avastin; bevacizumab; intravitreal injection; age-related macular
   degeneration; occult choroidal neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; ANGIOGENESIS; INJECTION
AB Background The purpose of the study is to report data on short-term safety of intravitreal bevacizumab treatment and its effect on visual function, central retinal thickness, and angiographical changes of occult choroidal neovascularization due to age-related macular degeneration.
   Methods A consecutive interventional case series of 30 patients with active subfoveal occult choroidal neovascularization secondary to age-related macular degeneration was followed after one intravitreal injection of 1.25 mg bevacizumab at baseline and subsequent injections following standardized criteria. At baseline and follow-up visits patients had visual acuity assessment, intraocular pressure measurement, fluorescein angiography, and optical coherence tomography imaging.
   Results No serious ocular or systemic adverse events were identified. A significant increase of intraocular pressure or signs of retinal toxicity or endophthalmitis were not detected in any patient. Optical coherence tomography revealed significant decrease (p < 0.001) in central retinal thickness after 1 week, 4 weeks, and 12 weeks, respectively. Fluorescein leakage decreased within 1 week and improvement was maintained at week 12 in the majority of patients. Visual acuity improved or remained stable in 29 of 30 patients; improvement of 3 or more lines was seen in 14 of 30 patients; one patients showed improvement of 6 lines. No patient had severe vision loss of 6 lines or more; moderate vision loss of 3 lines was seen in one patient. Re-injections of bevacizumab according to standard criteria were performed one to two times during the follow-up period of 12 weeks with a re-injection interval of 4 to 18 weeks (median 8 weeks).
   Conclusion Short-term results suggest that intravitreal injection of bevacizumab is well tolerated and for the majority of patients with occult choroidal neovascularization in AMD results in improvement of visual acuity, decrease in central retina thickness, and reduction of angiographic leakage of the lesion. Bevacizumab as intravitreal treatment may provide a novel therapeutic option for selected patients with exudative AMD. Randomized prospective multicenter trials seem justified to further evaluate long term effects and impact of intravitreal bevacizumab on different subtypes of AMD compared to established therapies.
C1 Univ Tubingen, Ctr Ophthalmol, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital
RP Aisenbrey, S (通讯作者)，Univ Tubingen, Ctr Ophthalmol, Schleichstr 12, D-72076 Tubingen, Germany.
EM sabine.aisenbrey@med.uni-tuebingen.de
RI Ziemssen, Focke/AAY-1686-2021; , Ziemssen/B-9564-2009
OI , Ziemssen/0000-0002-3873-0581
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   AXELSIEGER R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Jaissle GB, 2005, KLIN MONATSBL AUGENH, V222, P390, DOI 10.1055/s-2005-858231
   Konerding MA, 2004, EXPERT OPIN THER TAR, V8, P255, DOI 10.1517/14728222.8.3.255
   KRYSTOLIK MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Reichel E, 2005, OPHTHAL SURG LAS IM, V36, P270, DOI 10.3928/1542-8877-20050701-03
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 32
TC 73
Z9 80
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2007
VL 245
IS 7
BP 941
EP 948
DI 10.1007/s00417-006-0471-7
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 182KP
UT WOS:000247503800005
PM 17186262
DA 2022-11-30
ER

PT J
AU Russell, SR
   Hudson, HL
   Jerdan, JA
AF Russell, Stephen R.
   Hudson, Henry L.
   Jerdan, Janice A.
CA Anecortave Acetate Clinica
TI Anecortave acetate for the treatment of exudative age-related macular
   degeneration - A review of clinical outcomes
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE anecortave acetate; choroidal neovascularization; exudative age-related
   macular degeneration; photodynamic therapy; posterior juxtascleral depot
   administration
ID CHOROIDAL NEOVASCULAR MEMBRANES; PHOTODYNAMIC THERAPY; ANGIOGRAPHY;
   SAFETY
AB Purpose: The angiostatic cortisene anecortave acetate was evaluated in three safety and efficacy studies of patients with subfoveal choroidal neovascularization secondary to exudative age-related macular degeneration.
   Methods: The Anecortave Acetate Monotherapy Trial enrolled 128 patients randomized to anecortave acetate (3 mg, 15 mg, or 30 mg) or vehicle administered as a sub-Tenon's posterior juxtascleral depot (PJD) at 6-month intervals. The Anecortave Acetate and photodynamic therapy (PDT) with verteporfin Combination Trial enrolled 136 patients randomized to PDT with verteporfin followed by a single depot administration of anecortave acetate (15 mg or 30 mg) or vehicle. The Anecortave Acetate 15 mg versus PDT Comparison Trial enrolled 530 patients to receive either anecortave acetate 15 mg every 6 months + sham PDT every 3 months or PDT with verteporfin every 3 months + sham PJD administration every 6 months.
   Results: Anecortave acetate 15 mg was statistically superior to vehicle in the monotherapy trial at both 12 and 24 months for maintenance of vision and inhibition of CNV lesion growth. In the combination trial, a trend favored adding either anecortave acetate 15 mg or 30 mg to PDT for these two measures of clinical efficacy, but this short-duration study did not achieve statistical significance. Anecortave acetate 15 mg is comparable to PDT for maintaining vision over the 24-month period in the comparison trial.
   Conclusions: Anecortave acetate is safe and effective treatment for exudative age-related macular degeneration.
C1 Univ Iowa Hosp & Clin, Ctr Macular Degenerat, Iowa City, IA 52242 USA.
   Univ Iowa Hosp & Clin, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   Retina Ctr PC, Tucson, AZ USA.
   Univ Arizona, Sch Med, Tucson, AZ USA.
   Alcon Res Ltd, Ft Worth, TX USA.
C3 University of Iowa; University of Iowa; University of Arizona; Novartis;
   Alcon
RP Russell, SR (通讯作者)，200 Hawkins Dr,11196 I PFP, Iowa City, IA 52242 USA.
OI Russell, Stephen/0000-0003-3776-1367
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2005, GRAEF ARCH CLIN EXP, V243, P9, DOI 10.1007/s00417-004-0961-4
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bocci G, 2003, P NATL ACAD SCI USA, V100, P12917, DOI 10.1073/pnas.2135406100
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Clark A F, 1997, Expert Opin Investig Drugs, V6, P1867, DOI 10.1517/13543784.6.12.1867
   Clark AF, 2007, SURV OPHTHALMOL, V52, pS41, DOI 10.1016/j.survophthal.2006.11.004
   DAMICO DJ, 2003, OPHTHALMOLOGY, V110, P2384
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grisanti S, 2004, AM J OPHTHALMOL, V137, P914, DOI 10.1016/j.ajo.2003.12.049
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   Kaiser PK, 2007, SURV OPHTHALMOL, V52, pS62, DOI 10.1016/j.survophthal.2006.10.015
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Regillo CD, 2007, SURV OPHTHALMOL, V52, pS70, DOI 10.1016/j.survophthal.2006.11.001
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Slakter JS, 2007, SURV OPHTHALMOL, V52, pS91, DOI 10.1016/j.survophthal.2006.10.016
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Slaton JW, 2001, CLIN CANCER RES, V7, P2840
   Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393
NR 24
TC 30
Z9 31
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JAN
PY 2007
VL 52
SU 1
BP S79
EP S90
DI 10.1016/j.survophthal.2006.11.005
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 135KZ
UT WOS:000244153800010
PM 17240260
DA 2022-11-30
ER

PT J
AU Blaha, M
   Rencova, E
   Langrova, H
   Lanska, M
   Blaha, V
   Studnicka, J
   Rozsival, P
   Maly, R
   Fatorova, I
   Filip, S
   Drsata, J
   Hejsek, L
   Maly, J
AF Blaha, Milan
   Rencova, Eva
   Langrova, Hana
   Lanska, Miriam
   Blaha, Vladimir
   Studnicka, Jan
   Rozsival, Pavel
   Maly, Radovan
   Fatorova, Ilona
   Filip, Stanislav
   Drsata, Jakub
   Hejsek, Libor
   Maly, Jaroslav
TI The importance of rheological parameters in the therapy of the dry form
   of age-related macular degeneration with rheohaemapheresis
SO CLINICAL HEMORHEOLOGY AND MICROCIRCULATION
LA English
DT Article
DE Rheopheresis; rheology; microcirculation; age related macular
   degeneration
ID MEMBRANE DIFFERENTIAL FILTRATION; PLASMA VISCOSITY; VISUAL FUNCTION;
   MICROCIRCULATION; RHEOPHERESIS; RETINOPATHY; APHERESIS; MEDICINE;
   EFFICACY; DISEASES
AB To date, rheological treatment is the only chance to control the advanced dry form of age-related macular degeneration and arrest its progression to legal blindness. Rheohaemapheresis can change the main rheological parameters, blood and plasma viscosity, as well as change erythrocyte aggregability, improve erythrocyte flexibility and lead to substantial improvement when other methods of therapy fail. In this study, we describe changes in the levels of rheological efficacy indicators after c and their clinical significance in the dry form of age-related macular degeneration (AMD). Seventy-two patients with AMD were randomised; 34 controls, and 38 patients were treated with rheohaemapheresis (separator Cobe Spectra + Evaflux filter). After the procedures, alpha(2)-macroglobulin levels decreased by approximately 58%, fibrinogen by approximately 65%, IgM by approximately 67%, LDL cholesterol by approximately 71%, apolipoprotein B by approximately 65%, and lipoprotein (a) by approximately 42%. These decreases correspond with a decrease in blood and plasma viscosity (14/12%), clinical improvement (arrest of disease progression, even visual improvement in some cases), and heretofore-unreported improvement (even reattachment) of drusen retinal pigment epithelium detachment. Our modification of rheohaemapheresis is safe (5.4% of patients experienced clinically insignificant side effects).
C1 [Blaha, Milan; Lanska, Miriam; Fatorova, Ilona; Maly, Jaroslav] Charles Univ Prague, Dept Internal Med 2, Fac Med, Hradec Kralove 50005, Czech Republic.
   [Blaha, Milan; Rencova, Eva; Langrova, Hana; Lanska, Miriam; Blaha, Vladimir; Studnicka, Jan; Rozsival, Pavel; Maly, Radovan; Fatorova, Ilona; Hejsek, Libor; Maly, Jaroslav] Charles Univ Prague, Fac Hosp, Hradec Kralove 50005, Czech Republic.
   [Rencova, Eva; Langrova, Hana; Studnicka, Jan; Rozsival, Pavel; Hejsek, Libor] Charles Univ Prague, Fac Med, Dept Ophthalmol, Hradec Kralove 50005, Czech Republic.
   [Blaha, Vladimir] Charles Univ Prague, Fac Med, Dept Geriatry & Metab, Hradec Kralove 50005, Czech Republic.
   [Maly, Radovan] Charles Univ Prague, Fac Med, Dept Internal Med 1, Hradec Kralove 50005, Czech Republic.
   [Filip, Stanislav] Charles Univ Prague, Fac Med, Dept Oncol & Radiotherapy, Hradec Kralove 50005, Czech Republic.
   [Drsata, Jakub] Charles Univ Prague, Fac Med, Dept Othorhinolaryngol, Hradec Kralove 50005, Czech Republic.
C3 Charles University Prague; Charles University Prague; Charles University
   Prague; Charles University Prague; Charles University Prague; Charles
   University Prague; Charles University Prague
RP Blaha, M (通讯作者)，Charles Univ Prague, Dept Internal Med 2, Fac Med, Sokolskast 480, Hradec Kralove 50005, Czech Republic.
EM blaham@email.cz
RI Maly, Radovan/AAH-7032-2021; Filip, Stanislav/AAU-9160-2020; Hejsek,
   Libor/O-6022-2019; Blaha, Vladimir/C-1151-2016; Maly,
   Jaroslav/P-6660-2017; Blaha, Milan/H-8955-2016; Studnicka,
   Jan/K-2875-2017; Hejsek, Libor/H-1671-2017; Studnička,
   Jan/AAC-4127-2022; Filip, Stanislav/D-4908-2017
OI Hejsek, Libor/0000-0001-9973-8969; Blaha, Vladimir/0000-0001-8088-9919;
   Maly, Jaroslav/0000-0003-4889-5504; Blaha, Milan/0000-0003-2330-5838;
   Studnicka, Jan/0000-0002-9911-4379; Hejsek, Libor/0000-0001-9973-8969;
   Langrova, Hana/0000-0001-8488-7208; Filip, Stanislav/0000-0002-8567-0745
FU Ministry of Health, CZ [NR/9738-4, NT/12287-5]
FX Supported by a grant from the Ministry of Health, CZ, No. NR/9738-4,
   NT/12287-5.
CR [Anonymous], 2010, CLIN HEMORHEOL MICRO, V44, P1, DOI 10.3233/CH-2010-1256A
   Baskurt OK, 2009, CLIN HEMORHEOL MICRO, V42, P75, DOI 10.3233/CH-2009-1202
   Blaha M, 2009, ATHEROSCLEROSIS SUPP, V10, P17, DOI 10.1016/S1567-5688(09)71804-5
   Blaha M, 2009, CLIN HEMORHEOL MICRO, V42, P37, DOI 10.3233/CH-2009-1184
   Blaha M., 2006, VNITR LEK, P1102
   Blaha M, 2009, THER APHER DIAL, V13, P453, DOI 10.1111/j.1744-9987.2009.00752.x
   Borberg H, 2006, TRANSFUS APHER SCI, V34, P41, DOI 10.1016/j.transci.2005.09.001
   Brunner R, 1996, TRANSFUS SCI, V17, P493, DOI 10.1016/S0955-3886(96)90083-1
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Donaldson MJ, 2006, CURR OPIN OPHTHALMOL, V17, P267, DOI 10.1097/01.icu.0000193101.13551.e5
   Fell AJ, 2002, OPHTHALMOLOGE, V99, P780, DOI 10.1007/s00347-002-0614-0
   Ferrannini M, 2007, INT J ARTIF ORGANS, V30, P923, DOI 10.1177/039139880703001010
   Fiala JC, 2005, J MICROSC-OXFORD, V218, P52, DOI 10.1111/j.1365-2818.2005.01466.x
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   JUNG F, 1992, CLIN HEMORHEOL, V12, P557
   Jung F, 2010, CLIN HEMORHEOL MICRO, V45, P79, DOI 10.3233/CH-2010-1312
   Kishan A.U., 2011, SURV OPHTHALMOL, V24
   Klein R., 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klingel R, 2005, THER APHER DIAL, V9, P473, DOI 10.1111/j.1744-9987.2005.00276.x
   Klingel R, 2003, TRANSFUS APHER SCI, V29, P71, DOI 10.1016/S1473-0502(03)00101-0
   Klingel R, 2000, Ther Apher, V4, P348, DOI 10.1046/j.1526-0968.2000.004005348.x
   Klingel T, 2003, THER APHER DIAL, V7, P444, DOI 10.1046/j.1526-0968.2003.00082.x
   Koss MJ, 2009, GRAEF ARCH CLIN EXP, V247, P1297, DOI 10.1007/s00417-009-1113-7
   Luke C, 2001, J CLIN APHERESIS, V16, P23, DOI 10.1002/jca.1004
   Matschke K, 2008, CLIN HEMORHEOL MICRO, V39, P265, DOI 10.3233/CH-2008-1093
   Matschke K, 2004, CLIN HEMORHEOL MICRO, V30, P263
   Michalska-Malecka K, 2008, CLIN HEMORHEOL MICRO, V38, P209
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Park JW, 2000, ACP-APPL CARDIOPUL P, V9, P19
   Pulido J.S., 2006, T AM OPHTHAL SOC, V104, P1
   Pulido Jose S, 2006, Trans Am Ophthalmol Soc, V104, P221
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Pulido JS, 2005, CAN J OPHTHALMOL, V40, P332, DOI 10.1016/S0008-4182(05)80076-6
   Ramping MW, 2008, CLIN HEMORHEOL MICRO, V39, P9, DOI 10.3233/CH-2008-1063
   Rencova E., 2010, ACTA OPHTHALMOL, V22, P1
   Rozsival P., 2010, TRENDS CURRENT OPHTH
   Santos AOMT, 2011, CLIN HEMORHEOL MICRO, V47, P1, DOI 10.3233/CH-2010-1358
   Siegenthaler N, 2010, CLIN HEMORHEOL MICRO, V46, P299, DOI 10.3233/CH-2010-1354
   To WJ, 2011, CLIN HEMORHEOL MICRO, V47, P131, DOI 10.3233/CH-2010-1374
   WOLF S, 1992, CLIN HEMORHEOL, V12, P725
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yeh JH, 2008, THER APHER DIAL, V12, P500, DOI 10.1111/j.1744-9987.2008.00641.x
NR 43
TC 6
Z9 6
U1 0
U2 26
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1386-0291
EI 1875-8622
J9 CLIN HEMORHEOL MICRO
JI Clin. Hemorheol. Microcirc.
PY 2012
VL 50
IS 4
BP 245
EP 255
DI 10.3233/CH-2011-1431
PG 11
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA 934KP
UT WOS:000303443300002
PM 22240359
DA 2022-11-30
ER

PT J
AU Zhu, ZT
   Liao, H
   Liu, S
   Zhang, J
   Chen, YF
   Wang, W
AF Zhu, Zhuoting
   Liao, Huan
   Liu, Sen
   Zhang, Jian
   Chen, Yifan
   Wang, Wei
TI Cross-sectional study of the association between age-related macular
   degeneration and arthritis in the National Health and Nutrition
   Examination Survey 2005-2008
SO BMJ OPEN
LA English
DT Article
DE epidemiology; rheumatology; ophthalmology
ID ATTRIBUTABLE ACTIVITY LIMITATION; DOCTOR-DIAGNOSED ARTHRITIS; MATRIX
   METALLOPROTEINASES; UNITED-STATES; ASPIRIN USE; FACTOR-H; PREVALENCE;
   INFLAMMATION; GENETICS; ADULTS
AB Objective To explore the association between age-related macular degeneration (AMD) and arthritis in a representative sample of the US population. Design Population-based, cross-sectional study. Setting The National Health and Nutrition Examination Survey (NHANES) 2005-2008. Participants A total of 4813 participants aged 40 years and older with available information on AMD and arthritis in the 2005-2008 NHANES. Methods The status and types of arthritis were obtained from questionnaires. Non-mydriatic fundus photographs were collected. The types of AMD were assessed using the modified Wisconsin Age-Related Maculopathy Grading Classification Scheme. The association between arthritis and AMD was evaluated using logistic regression models. Results After adjusting for covariates, participants with any or early AMD had significantly lower odds of having any type of arthritis (any AMD: OR=0.56, 95% CI: 0.36-0.86; early AMD: OR=0.55, 95% CI: 0.34-0.88) or osteoarthritis (OA) (any AMD: OR=0.43, 95% CI: 0.26-0.71; early AMD: OR=0.44, 95% CI: 0.25-0.76) compared with those without AMD. When considering AMD as the outcome, significant negative associations were also found between any arthritis or OA and any (any arthritis: OR=0.64, 95% CI: 0.43-0.94; OA: OR=0.52, 95% CI: 0.33-0.82) or early AMD (any arthritis: OR=0.61, 95% CI: 0.40-0.93; OA: OR=0.51, 95% CI: 0.31-0.86) in the multivariable logistic models. There was no significant association between different types of arthritis and late AMD. Conclusions People with arthritis, especially those with OA, were less likely to have AMD compared with those without arthritis and vice versa. Further studies are needed to confirm this potential protective effect of arthritis and/or arthritis treatment on AMD and to explore the underlying mechanisms.
C1 [Zhu, Zhuoting] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Ophthalmol, Guangdong Eye Inst, Guangzhou, Peoples R China.
   [Zhu, Zhuoting; Zhang, Jian; Wang, Wei] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China.
   [Liao, Huan] Univ Bonn, Inst Reconstruct Neurobiol, Neural Regenerat Grp, Bonn, Germany.
   [Liu, Sen] Sun Yat Sen Univ, Sch Med, Guangzhou, Peoples R China.
   [Chen, Yifan] Univ Oxford, Med Sci Div, Oxford, England.
C3 Guangdong Academy of Medical Sciences & Guangdong General Hospital; Sun
   Yat Sen University; University of Bonn; Sun Yat Sen University;
   University of Oxford
RP Wang, W (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China.
EM zoc_wangwei@yahoo.com
FU Fundamental Research Funds of the State Key Laboratory of Ophthalmology
FX This study was supported by Fundamental Research Funds of the State Key
   Laboratory of Ophthalmology.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Barbour KE, 2017, MMWR-MORBID MORTAL W, V66, P246, DOI 10.15585/mmwr.mm6609e1
   Burrage PS, 2006, FRONT BIOSCI-LANDMRK, V11, P529, DOI 10.2741/1817
   Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P421
   Centers for Disease Control and Prevention [CDC] National Center for Health Statistics, 2005, NATL NUTR HLTH SURVE
   Chong EW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137322
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   El Miedany Y, 2010, CLIN EXP RHEUMATOL, V28, P734
   Fiedorczyk M, 2006, J RHEUMATOL, V33, P1523
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gill TK, 2013, INT J RHEUM DIS, V16, P766, DOI 10.1111/1756-185X.12175
   Goldring MB, 2011, CURR OPIN RHEUMATOL, V23, P471, DOI 10.1097/BOR.0b013e328349c2b1
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hootman JM, 2016, ARTHRITIS RHEUMATOL, V68, P1582, DOI 10.1002/art.39692
   Keenan TDL, 2015, RETINA-J RET VIT DIS, V35, P2613, DOI 10.1097/IAE.0000000000000651
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Li L, 2015, J CLIN PHARM THER, V40, P144, DOI 10.1111/jcpt.12241
   McGeer PL, 2005, NEUROBIOL AGING, V26, P1199, DOI 10.1016/j.neurobiolaging.2005.02.003
   Milovanovic A, 2004, CLIN CHIM ACTA, V343, P237, DOI 10.1016/j.cccn.2003.12.030
   Modjtahedi BS, 2018, AM J OPHTHALMOL, V188, P111, DOI 10.1016/j.ajo.2018.01.012
   Murphy LB, 2018, ARTHRIT CARE RES, V70, P869, DOI 10.1002/acr.23425
   Reynard LN, 2013, EXPERT REV MOL MED, V15, DOI 10.1017/erm.2013.4
   Sen H., 2007, INVEST OPHTHALMOL VI, V48, P2166
   Silman AJ, 2002, ARTHRITIS RES THER, V4, pS265, DOI 10.1186/ar578
   Sokolove J, 2013, THER ADV MUSCULOSKEL, V5, P77, DOI 10.1177/1759720X12467868
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Trouw LA, 2011, CLIN EXP IMMUNOL, V166, P333, DOI 10.1111/j.1365-2249.2011.04482.x
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu R, 2002, CIRCULATION, V105, P387, DOI 10.1161/hc0302.102609
   Ye J, 2014, INVEST OPHTH VIS SCI, V55, P2687, DOI 10.1167/iovs.13-13206
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang YQ, 2010, CLIN GERIATR MED, V26, P355, DOI [10.1016/j.cger.2010.03.001, 10.1016/j.rdc.2012.10.004]
   Zhu Z, 2018, JAMA OPHTHALMOL
   Zhu ZT, 2020, CURR EYE RES, V45, P1543, DOI 10.1080/02713683.2020.1760306
   Zlateva GP, 2007, RETINA-J RET VIT DIS, V27, P1292, DOI 10.1097/01.iae.0000300915.81866.b8
NR 42
TC 1
Z9 1
U1 2
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 12
AR e035805
DI 10.1136/bmjopen-2019-035805
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA PH1TC
UT WOS:000600203000021
PM 33293303
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Black, JRM
   Clark, SJ
AF Black, James R. M.
   Clark, Simon J.
TI Age-related macular degeneration: genome-wide association studies to
   translation
SO GENETICS IN MEDICINE
LA English
DT Review
DE age-related macular degeneration; complement cascade; genome-wide
   association studies; novel therapeutics
ID COMPLEMENT FACTOR-H; SUSCEPTIBILITY LOCI; GEOGRAPHIC ATROPHY;
   GENETIC-VARIANTS; BRUCHS MEMBRANE; DISEASE RISK; POLYMORPHISM; COMMON;
   BINDING; GLOMERULONEPHRITIS
AB In recent years, genome-wide association studies (GWAS),which are able to analyze the contribution to disease of genetic variations that are common within a population, have attracted considerable investment. Despite identifying genetic variants for many conditions, they have been criticized for yielding data with minimal clinical utility. However, in this regard, age-related macular degeneration (AMD), the most common form of blindness in the Western world, is a striking exception. Through GWAS, common genetic variants at a number of loci have been discovered. Two loci in particular, including genes of the complement cascade on chromosome 1 and the ARMS2/HTRA1 genes on chromosome 10, have been shown to convey significantly increased susceptibility to developing AMD Today, although it is possible to screen individuals for a genetic predisposition to the disease, effective interventional strategies for those at risk of developing AMD are scarce. Ongoing research in this area is nonetheless promising. After providing brief overviews of AMD and common disease genetics, we outline the main recent advances in the understanding of AMD, particularly those made through GWAS. Finally, the true merit of these findings and their current and potential translational value is examined.
C1 [Black, James R. M.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Sir Alexander Fleming Bldg, London, England.
   [Clark, Simon J.] Univ Manchester, Inst Human Dev, Ctr Ophthalmol & Vis Sci, Manchester, Lancs, England.
C3 Imperial College London; University of Manchester
RP Clark, SJ (通讯作者)，Univ Manchester, Inst Human Dev, Ctr Ophthalmol & Vis Sci, Manchester, Lancs, England.
EM simon.clark-3@manchester.ac.uk
RI Black, James/I-2283-2017; Mitchell, Paul/P-1498-2014; Black, James
   Robert Mackinlay/K-1062-2019
OI Black, James/0000-0001-5598-7752; Black, James Robert
   Mackinlay/0000-0001-5598-7752; Clark, Simon/0000-0001-8394-8355
FU Medical Research Council (MRC) Career Development Fellowship
   [MR/K024418/1]; Medical Research Council [MR/K024418/1] Funding Source:
   researchfish; MRC [MR/K024418/1] Funding Source: UKRI
FX The authors thank D.F. Newbury, Wellcome Trust Centre for Human
   Genetics, University of Oxford, Oxford, UK, and S.M. Downes, Oxford Eye
   Hospital, Oxford, UK, for their help with the design of this review.
   S.J.C. is a recipient of a Medical Research Council (MRC) Career
   Development Fellowship (MR/K024418/1).
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Annas GJ, 2014, NEW ENGL J MED, V370, P985, DOI 10.1056/NEJMp1316367
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P900, DOI 10.1136/bjo.73.11.900
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hirschhorn JN, 2011, ANNU REV MED, V62, P11, DOI 10.1146/annurev.med.091708.162036
   Hollands GJ, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4708
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maier LM, 2008, NAT GENET, V40, P131, DOI 10.1038/ng0208-131
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Moutray T, 2011, THER ADV CHRONIC DIS, V2, P325, DOI 10.1177/2040622311415895
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Porter LF, 2014, CLIN GENET, V86, P1, DOI 10.1111/cge.12389
   Pritchard JK, 2001, AM J HUM GENET, V69, P124, DOI 10.1086/321272
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schork NJ, 2009, CURR OPIN GENET DEV, V19, P212, DOI 10.1016/j.gde.2009.04.010
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616
   Smith GD, 2010, PERSPECT PSYCHOL SCI, V5, P527, DOI 10.1177/1745691610383505
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Visscher PM, 2012, AM J HUM GENET, V90, P7, DOI 10.1016/j.ajhg.2011.11.029
   Wood AR, 2014, NAT GENET, V46, P1173, DOI 10.1038/ng.3097
   Wray NR, 2007, GENOME RES, V17, P1520, DOI 10.1101/gr.6665407
   Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 65
TC 81
Z9 83
U1 0
U2 22
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
EI 1530-0366
J9 GENET MED
JI Genet. Med.
PD APR
PY 2016
VL 18
IS 4
BP 283
EP 289
DI 10.1038/gim.2015.70
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DI2XK
UT WOS:000373362300001
PM 26020418
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Weikel, KA
   Chiu, CJ
   Taylor, A
AF Weikel, Karen A.
   Chiu, Chung-Jung
   Taylor, Allen
TI Nutritional modulation of age-related macular degeneration
SO MOLECULAR ASPECTS OF MEDICINE
LA English
DT Review
DE AMD; Antioxidants; Carotenoids; Nutrition; Glycemic index; Aging
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; 3RD
   NATIONAL-HEALTH; LOW-GLYCEMIC INDEX; FACTOR-H POLYMORPHISM; DIETARY
   FATTY-ACIDS; OPTICAL-DENSITY; RISK-FACTORS; VITAMIN-E; BETA-CAROTENE
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly worldwide. It affects 30-50 million individuals and clinical hallmarks of AMD are observed in at least one third of persons over the age of 75 in industrialized countries (Gehrs et al., 2006). Costs associated with AMD are in excess of $340 billion US (American-Health-Assistance-Foundation, 2012). The majority of AMD patients in the United States are not eligible for clinical treatments (Biarnes et al., 2011; Klein et al., 2011). Preventive interventions through dietary modulation are attractive strategies because many studies suggest a benefit of micro- and macronutrients with respect to AMD, as well as other age-related debilities, and with few, if any, adverse effects (Chiu, 2011). Preservation of vision would enhance quality of life for millions of elderly people, and alleviate the personal and public health financial burden of AMD (Frick et al., 2007; Wood et al., 2011). Observational studies indicate that maintaining adequate levels of omega-3 fatty acids (i.e. with 2 servings/week of fish) or a low glycemic index diet may be particularly beneficial for early AMD and that higher levels of carotenoids may be protective, most probably, against neovascular AMD. Intervention trials are needed to better understand the full effect of these nutrients and/or combinations of nutrients on retinal health. Analyses that describe effects of a nutrient on onset and/or progress of AMD are valuable because they indicate the value of a nutrient to arrest AMD at the early stages. This comprehensive summary provides essential information about the value of nutrients with regard to diminishing risk for onset or progress of AMD and can serve as a guide until data from ongoing intervention trials are available. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Weikel, Karen A.; Chiu, Chung-Jung; Taylor, Allen] Tufts Univ, JM USDA Human Nutr Res Ctr Aging, Lab Nutr & Vis Res, Boston, MA 02111 USA.
C3 Tufts University; United States Department of Agriculture (USDA)
RP Taylor, A (通讯作者)，Tufts Univ, JM USDA Human Nutr Res Ctr Aging, Lab Nutr & Vis Res, 711 Washington St, Boston, MA 02111 USA.
EM allen.taylor@tufts.edu
OI Weikel, Karen/0000-0003-0317-7891
FU USDA [1950-510000-060-01A]; Johnson and Johnson Focused Giving; NIH [RO1
   13250, RO1 21212]; NATIONAL EYE INSTITUTE [R01EY021212, R01EY013250]
   Funding Source: NIH RePORTER
FX This research was funded by USDA 1950-510000-060-01A, Johnson and
   Johnson Focused Giving, NIH Grant RO1 13250, NIH Grant RO1 21212. These
   sponsors were not involved in data collection or interpretation or in
   writing this manuscript.
CR Al-Hussaini H, 2009, EXP EYE RES, V88, P610, DOI 10.1016/j.exer.2008.09.021
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   American-Health-Assistance-Foundation, 2012, FACTS MAC DEG MAC DE
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Bacova B, 2010, J PHYSIOL PHARMACOL, V61, P717
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Belda JI, 1999, MECH AGEING DEV, V107, P159, DOI 10.1016/S0047-6374(98)00144-4
   Biarnes M, 2011, OPTOMETRY VISION SCI, V88, P881, DOI 10.1097/OPX.0b013e31821988c1
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bucheli P, 2011, OPTOMETRY VISION SCI, V88, P257, DOI 10.1097/OPX.0b013e318205a18f
   Burri BJ, 2011, BRIT J NUTR, V105, P212, DOI 10.1017/S0007114510003260
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   Chew EY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1678, DOI 10.1001/archophthalmol.2009.312
   Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5
   Chiasson JL, 2003, JAMA-J AM MED ASSOC, V290, P486, DOI 10.1001/jama.290.4.486
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2011, NUTR REV, V69, P231, DOI 10.1111/j.1753-4887.2011.00382.x
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Christen WG, 2010, OPHTHALMOLOGY, V117, P1163, DOI 10.1016/j.ophtha.2009.10.043
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   Crescenzo R., 2011, BR J NUTR, P1
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P3452, DOI 10.1167/iovs.10-6713
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferland A, 2009, DIABETIC MED, V26, P589, DOI 10.1111/j.1464-5491.2009.02734.x
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Frick KD, 2007, ARCH OPHTHALMOL-CHIC, V125, P544, DOI 10.1001/archopht.125.4.544
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   GINSBERG HN, 1994, ARTERIOSCLER THROMB, V14, P576, DOI 10.1161/01.ATV.14.4.576
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Granado F, 2003, BRIT J NUTR, V90, P487, DOI 10.1079/BJN2003927
   Grant CM, 1997, FEBS LETT, V410, P219, DOI 10.1016/S0014-5793(97)00592-9
   Hadley D, 2010, INVEST OPHTH VIS SCI, V51, P2191, DOI 10.1167/iovs.09-3798
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hartig MB, 2011, AM J HUM GENET, V89, P543, DOI 10.1016/j.ajhg.2011.09.007
   Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Hooper L, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002137.pub2, 10.1002/14651858.CD011834]
   Ishihara Nanae, 1997, Nippon Ganka Gakkai Zasshi, V101, P248
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jenkins DJA, 2008, JAMA-J AM MED ASSOC, V300, P2742, DOI 10.1001/jama.2008.808
   JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Juan-Babot JO, 2003, REV ESP CARDIOL, V56, P978, DOI 10.1157/13052386
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   King JC, 2011, AM J CLIN NUTR, V94, p679S, DOI 10.3945/ajcn.110.005744
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P1203, DOI 10.1016/j.ophtha.2007.09.011
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kuzniarz M, 2002, OPHTHAL EPIDEMIOL, V9, P283, DOI 10.1076/opep.9.4.283.1511
   Lakatos A, 2010, NEUROBIOL AGING, V31, P1355, DOI 10.1016/j.neurobiolaging.2010.04.031
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Leveziel N, 2007, MOL VIS, V13, P2153
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P309, DOI 10.1097/IAE.0b013e31814cef3a
   Liu SM, 1999, AM J CLIN NUTR, V70, P412
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Maiani G, 2009, MOL NUTR FOOD RES, V53, pS194, DOI 10.1002/mnfr.200800053
   Marc RE, 2008, MOL VIS, V14, P782
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Markus RA, 1997, AM J CLIN NUTR, V65, P1000, DOI 10.1093/ajcn/65.4.1000
   McKeown NM, 2009, J AM COLL NUTR, V28, P150, DOI 10.1080/07315724.2009.10719766
   Meyer BJ, 2003, LIPIDS, V38, P391, DOI 10.1007/s11745-003-1074-0
   Michikawa T, 2009, ASIA PAC J CLIN NUTR, V18, P1
   Morris MS, 2007, OPHTHAL EPIDEMIOL, V14, P288, DOI 10.1080/09286580601186759
   Nationa Eye Institute N.I.o.H., 2010, FACTS AG REL MAC DEG
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Pilkington SM, 2011, EXP DERMATOL, V20, P537, DOI 10.1111/j.1600-0625.2011.01294.x
   Quintan Ila R.A., 2012, NEUROBIOL AGING, V33, P625
   Quintanilla RA, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.02.007
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Richer S, 1996, J Am Optom Assoc, V67, P30
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Riegersperger M, 2007, J RENAL CARE, V33, P105, DOI 10.1111/j.1755-6686.2007.tb00053.x
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   SACKS FM, 1984, LANCET, V1, P647
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Sapieha P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001571
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   Schild L, 1997, BIOCHEM J, V328, P205, DOI 10.1042/bj3280205
   Schweigert FJ, 2011, KLIN MONATSBL AUGENH, V228, P537, DOI 10.1055/s-0029-1245527
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2010, MOL VIS, V16, P2412
   SHAKIB M, 1973, International Ophthalmology Clinics, V13, P189, DOI 10.1097/00004397-197301330-00015
   Simonelli F, 2002, CLIN CHIM ACTA, V320, P111, DOI 10.1016/S0009-8981(02)00056-6
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Sullivan RKP, 2007, INVEST OPHTH VIS SCI, V48, P2782, DOI 10.1167/iovs.06-1283
   Sung CH, 2010, J CELL BIOL, V190, P953, DOI 10.1083/jcb.201006020
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   TAKEYAMA N, 1993, BIOCHEM J, V294, P719, DOI 10.1042/bj2940719
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   Terasaka N, 2008, J CLIN INVEST, V118, P3701, DOI 10.1172/JCI35470
   Tong Y, 2010, MOL VIS, V16, P1958
   TREMPE CL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1517, DOI 10.1001/archopht.1992.01080230015002
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Weikel KA, 2012, INVEST OPHTH VIS SCI, V53, P622, DOI 10.1167/iovs.11-8545
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wenzel AJ, 2007, OPHTHAL PHYSL OPT, V27, P329, DOI 10.1111/j.1475-1313.2007.00495.x
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Yang RH, 1996, J CARDIOVASC PHARM, V27, P838, DOI 10.1097/00005344-199606000-00011
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YUZBASIYANGURKAN V, 1989, ARCH OPHTHALMOL-CHIC, V107, P1723, DOI 10.1001/archopht.1989.01070020805004
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zeimer M, 2009, OPHTHALMOLOGE, V106, P29, DOI 10.1007/s00347-008-1773-4
NR 183
TC 56
Z9 57
U1 0
U2 35
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0098-2997
EI 1872-9452
J9 MOL ASPECTS MED
JI Mol. Asp. Med.
PD AUG
PY 2012
VL 33
IS 4
SI SI
BP 318
EP 375
DI 10.1016/j.mam.2012.03.005
PG 58
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 983WR
UT WOS:000307149900003
PM 22503690
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Al-Sheikh, M
   Iafe, NA
   Phasukkijwatana, N
   Sadda, SR
   Sarraf, D
AF Al-Sheikh, Mayss
   Iafe, Nicholas A.
   Phasukkijwatana, Nopasak
   Sadda, Srinivas R.
   Sarraf, David
TI BIOMARKERS OF NEOVASCULAR ACTIVITY IN AGE-RELATED MACULAR DEGENERATION
   USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE OCT angiography; quantitative analysis; fractal dimension; Type 1
   neovascularization; active neovascularization; quiescent
   neovascularization; anti-VEGF
ID CHOROIDAL NEOVASCULARIZATION; TYPE-1 NEOVASCULARIZATION; OCT
   ANGIOGRAPHY; FLUORESCEIN ANGIOGRAPHY; QUANTITATIVE-ANALYSIS; MOTION
   CORRECTION; THERAPY; ANGIOGENESIS; RANIBIZUMAB
AB Purpose: To study the qualitative and quantitative features of choroidal neovascular (NV) membranes in age-related macular degeneration using optical coherence tomography angiography in patients with active and quiescent NV lesions before and after treatment with anti-vascular endothelial growth factor.
   Methods: Macular optical coherence tomography angiography images were obtained using RTVue XR Avanti with AngioVue. Morphologic features and quantitative measurements of the NV lesion were analyzed using en face projection images. The NV lesion was subdivided into inner segment and outer fringe for further fractal dimension analysis.
   Results: In a series of 31 eyes, 11 eyes with active NV lesions at baseline and after consecutive follow-up after treatment with anti-vascular endothelial growth factor therapy and 20 eyes with quiescent NV lesions were included in this study. Morphologically, all the quiescent NV lesions versus 63.6% of the active NV lesions demonstrated a prominent central vessel and active leasions demonstrated a greater rate of small vessels branching (82%) and peripheral arcades (82%) than quiescent lesions (30% and 40% respectively) and this was statistically significant. The lesion area and vessel density was not statistically significantly different after treatment or versus quiescent lesions although the latter lesions were reduced in area. Lesion pattern complexity measured by the fractal dimension was statistically significantly lower in the inner part of the lesion after treatment and statistically significantly lower in the total lesion of the quiescent NV compared with the active NV.
   Conclusion: Optical coherence tomography angiography is a new, noninvasive imaging modality that can be used to perform qualitative and quantitative analyses of NV lesions. In the future, OCT angiography may provide biomarkers of activity and guide the evaluation and treatment and monitoring of neovascularization in age-related macular degeneration.
C1 [Al-Sheikh, Mayss; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Al-Sheikh, Mayss; Iafe, Nicholas A.; Phasukkijwatana, Nopasak] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Phasukkijwatana, Nopasak; Sarraf, David] Mahidol Univ, Siriraj Hosp, Dept Ophthalmol, Fac Med, Bangkok, Thailand.
   [Sarraf, David] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Mahidol University; US
   Department of Veterans Affairs; Veterans Health Administration (VHA); VA
   Greater Los Angeles Healthcare System
RP Sarraf, D (通讯作者)，Univ Calif Los Angeles, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Pl, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
RI Phasukkijwatana, Nopasak/T-8630-2019
FU Allergan; Heidelberg; Regeneron; Genentech; Optovue; Optos; Carl Zeiss
   Meditec
FX D. Sarraf is a consultant and speaker for Optovue and consultant for
   Bayer and Genentech and receives research support from Allergan,
   Heidelberg, Regeneron, Genentech, and Optovue. S. R. Sadda is a
   consultant for Optos, Carl Zeiss Meditec, Allergan, Genentech,
   Regeneron, Bayer, Novartis, Iconic and receives research support from
   Optos, Carl Zeiss Meditec, Allergan, and Genentech. The remaining
   authors have no financial/conflicting interests to disclose.
CR Bellou S, 2013, CANCER LETT, V338, P219, DOI 10.1016/j.canlet.2013.05.015
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Dansingani KK, 2015, EYE, V29, P703, DOI 10.1038/eye.2015.27
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Iafe NA, 2016, DEV OPHTHALMOL, V56, P45, DOI 10.1159/000442776
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   LANDINI G, 1995, INVEST OPHTH VIS SCI, V36, P2749
   Liang MC, 2016, RETINA-J RET VIT DIS, V36, P2265, DOI 10.1097/IAE.0000000000001102
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Masters BR, 2004, ANNU REV BIOMED ENG, V6, P427, DOI 10.1146/annurev.bioeng.6.040803.140100
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Nagiel A, 2015, JAMA OPHTHALMOL, V133, P629, DOI 10.1001/jamaophthalmol.2015.0668
   Parsons-Wingerter P, 1998, MICROVASC RES, V55, P201, DOI 10.1006/mvre.1998.2073
   Reif R, 2012, INT J BIOMED IMAGING, V2012, DOI 10.1155/2012/509783
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
NR 32
TC 78
Z9 82
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2018
VL 38
IS 2
BP 220
EP 230
DI 10.1097/IAE.0000000000001628
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GB0KQ
UT WOS:000428735400007
PM 28582276
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Arendt, P
   Yu, SQ
   Munk, MR
   Ebneter, A
   Wolf, S
   Zinkernagel, MS
AF Arendt, Petra
   Yu, Siqing
   Munk, Marion R.
   Ebneter, Andreas
   Wolf, Sebastian
   Zinkernagel, Martin S.
TI EXIT STRATEGY IN A TREAT-AND-EXTEND REGIMEN FOR EXUDATIVE AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal neovascularization; exit strategy; neovascular age-related
   macular degeneration; treat-and-extend regimen
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB TREATMENT; INTRAVITREAL
   RANIBIZUMAB; PROSPECTIVE TRIAL; VISUAL-ACUITY; OUTCOMES; AFLIBERCEPT;
   SUPPRESSION; THERAPY
AB Purpose: To evaluate the outcome of an exit strategy in a treat-and-extend regimen for neovascular age-related macular degeneration.
   Methods: Five hundred and ninety-eight eyes of 488 patients with neovascular age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor injections according to a treat-and-extend regimen were included in this retrospective study. A treat-and-extend regimen with either interval extension by 2 weeks or shortening by 1 week was used. "Exit criteria" were defined as 3 consecutive injections 16 weeks apart with stable findings after which the patient was exited from treatment and followed up at 3 to 4 monthly intervals without therapy. Best-corrected visual acuity, central retinal thickness at treatment initiation and termination, incidence of recurrence after treatment termination, presence of characteristics in the optical coherence tomography, duration of therapy, number and intervals of injections were analyzed.
   Results: Seventeen percent of all included eyes met the exit criteria. The mean number of anti-vascular endothelial growth factor injections was 23.7 +/- 14.7 with a mean treatment duration of 4.5 +/- 2.5 years. Twelve percent reached exit with the minimal number of injections. Thirteen percent had recurrent disease after a mean of 37 +/- 16 weeks. In the subgroup with recurrent disease, rate of pigment epithelial detachment at treatment termination was significantly higher than without recurrence (77% vs. 30%, P = 0.0018) with a significant higher proportion of serous pigment epithelial detachment (31% vs. 7%, P = 0.0247).
   Conclusion: The high percentage of patients meeting the exit criteria and the relatively low incidence of recurrences underline the usefulness of a predefined exit strategy. However, in a subgroup of patients, continuation of therapy may be advisable.
C1 Univ Bern, Bern Univ Hosp, Inselspital, Dept Ophthalmol, Bern, Switzerland.
   Univ Bern, Bern Univ Hosp, Inselspital, Dept Clin Res, Bern, Switzerland.
C3 University of Bern; University Hospital of Bern; University of Bern;
   University Hospital of Bern
RP Zinkernagel, MS (通讯作者)，Univ Bern, Bern Univ Hosp, CH-3010 Bern, Switzerland.
EM martin.zinkernagel@insel.ch
RI Ebneter, Andreas/C-5226-2017
OI Ebneter, Andreas/0000-0001-6666-2558; Yu, Siqing/0000-0002-8360-5552
CR Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Ebneter A, 2016, GRAEFES ARCH CLIN EX, P1
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Farinha CL, 2015, INVEST OPHTH VIS SCI, V56
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giannakaki-Zimmermann H, 2016, OPHTHALMOLOGICA, V236, P201, DOI 10.1159/000452929
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ho L, 2011, ALTERSABHANGIGE MAKU, P3
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Menke MN, 2014, BRIT J OPHTHALMOL, V98, P1197, DOI 10.1136/bjophthalmol-2013-304775
   Muether PS, 2013, AM J OPHTHALMOL, V156, P989, DOI 10.1016/j.ajo.2013.06.020
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 27
TC 24
Z9 24
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2019
VL 39
IS 1
BP 27
EP 33
DI 10.1097/IAE.0000000000001923
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4QS
UT WOS:000480736000013
PM 29135888
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Figurska, M
   Rekas, M
AF Figurska, Malgorzata
   Rekas, Marek
TI Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in
   Polish Therapeutic Programs
SO MEDICINA-LITHUANIA
LA English
DT Article
DE wet age-related macular degeneration; intravitreal injections;
   aflibercept; ranibizumab; electronic registry
ID ROUTINE CLINICAL-PRACTICE; VISUAL-ACUITY OUTCOMES; INTRAVITREAL
   AFLIBERCEPT; RANIBIZUMAB; SAFETY; VIEW
AB Background and Objectives: Wet age-related macular degeneration (wAMD) is a chronic, progressive disease of the central part of the retina. Standard treatment for wAMD consists of multiple intravitreal injections of anti-vascular endothelial growth factor drugs. The study goal was to evaluate the three-year effectiveness of wAMD treatment with aflibercept and ranibizumab as part of the therapeutic program in routine clinical practice. Materials and Methods: 1430 patients (possessing 1430 wAMD eyes) with median age of 78.0 years (71.0, 83.0) were enrolled in a non-randomized, retrospective, observational, multicenter study; 804 (56.2%) eyes were treatment-naive. Therapy was carried out in accordance with the guidelines of the treatment program (the fixed or pro re nata regimen). Results: After the first year of treatment, there was a gain of 2.03 (12.15) letters; after the second, 0.94 (13.72) (p < 0.001); and after the third, 0.17 (14.05) (p < 0.001). There was a significant reduction in the central retinal thickness. In the first year, the patients received 7.00 (5.00, 8.00) injections. In the following years, a significantly lower number of injections (4.00 (2.00, 5.00)) was administered. After the first year, there was a significant difference in the distribution of the best corrected visual acuity according to the Early Treatment Diabetic Retinopathy Study protocol, with more frequent values in the ranges > 35 <= 70 for this parameter and > 70 letters in the treatment naive eye subgroup. After the first year, central retinal thickness in treatment-naive eyes was significantly reduced. Conclusions: Regular treatment of wet age-related macular degeneration as part of the treatment program achieves functional stabilization and significant morphological improvement over a long-term, three-year follow-up, with significantly fewer injections needed after the first year of treatment.
C1 [Figurska, Malgorzata; Rekas, Marek] Cent Clin Hosp, Minist Natl Def, Dept Ophthalmol, Mil Inst Med, PL-04141 Warsaw, Poland.
C3 Military Institute of Aviation Medicine
RP Figurska, M (通讯作者)，Cent Clin Hosp, Minist Natl Def, Dept Ophthalmol, Mil Inst Med, PL-04141 Warsaw, Poland.
EM malgorzata-figurska@wp.pl; mrekas@wim.mil.pl
CR Almuhtaseb H, 2017, EYE, V31, P878, DOI 10.1038/eye.2017.6
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Brynskov T, 2020, ACTA OPHTHALMOL, V98, P132, DOI 10.1111/aos.14183
   Chandra S, 2021, EYE, V35, P409, DOI 10.1038/s41433-020-0851-y
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   Eter N, 2021, GRAEF ARCH CLIN EXP, V259, P2213, DOI 10.1007/s00417-021-05073-8
   Figurska M, 2019, KLIN OCZNA, V121, P194
   Figurska M, 2016, OKULISTYKA, V19, P65
   Figurska M, 2020, EUR J OPHTHALMOL, V30, P586, DOI 10.1177/1120672119874598
   Framme C, 2018, OPHTHALMOL RETINA, V2, P539, DOI 10.1016/j.oret.2017.09.017
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Kaiser PK, 2017, OPHTHALMOL RETINA, V1, P304, DOI 10.1016/j.oret.2017.01.004
   Richard G, 2015, OPHTHALMOLOGY, V122, P2497, DOI 10.1016/j.ophtha.2015.08.014
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Wachtlin J, 2021, GRAEF ARCH CLIN EXP, V259, P601, DOI 10.1007/s00417-020-04803-8
   Weber M, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01468-z
NR 26
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PD JAN
PY 2022
VL 58
IS 1
AR 42
DI 10.3390/medicina58010042
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA YO7XO
UT WOS:000748149500001
PM 35056350
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Li, X
   Luo, HM
   Zuo, C
   Zhang, ZR
   Zhang, JJ
   Zhang, MX
AF Li, Xun
   Luo, Hongmei
   Zuo, Cheng
   Zhang, Zirong
   Zhang, Junjun
   Zhang, Meixia
TI CONBERCEPT IN PATIENTS WITH TREATMENT-NAIVE NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION IN REAL-LIFE SETTING IN CHINA
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF therapy; central retina
   morphology; conbercept; real-life setting
ID OPTICAL COHERENCE TOMOGRAPHY; VISUAL-ACUITY; FUSION PROTEIN; VEGF;
   AFLIBERCEPT; VIEW; MORPHOLOGY; INJECTION; OUTCOMES; THERAPY
AB Purpose: In this study, we aimed to evaluate the efficacy and safety of intravitreal conbercept in patients with treatment-naive neovascular age-related macular degeneration in real-life setting.
   Methods: Three consecutive intravitreal injections of conbercept following a pro re nata protocol. The main outcomes were the changes of Early Treatment Diabetic Retinopathy Study best-corrected visual acuity and central retinal thickness between the baseline and the 12th month.
   Results: Mean best-corrected visual acuity was improved from 39.39 +/- 24.91 letters at the baseline to 44.26 +/- 22.89 letters at the final follow-up (P < 0.001). At the 12th month, the proportion of optimal response was 43.48% compared with 36.96% of poor response and 19.56% of nonresponse. A mean central retinal thickness of 480.94 +/- 178.47 mu m at the baseline was significantly reduced to 366.33 +/- 173.52 mu m at the 12th month. Patients received a median of 5.32 intravitreal injections. At the 12th month, the mean change in best-corrected visual acuity of eyes with intraretinal cystoid fluid from the baseline was markedly lower than that of eyes without intraretinal cystoid fluid. No adverse events were attributed to conbercept.
   Conclusion: With 12-month follow-up, conbercept was proved to be an effective and safety treatment for patients with treatment-naive neovascular age-related macular degeneration in real-life setting.
C1 [Li, Xun; Luo, Hongmei; Zuo, Cheng; Zhang, Zirong; Zhang, Junjun; Zhang, Meixia] Sichuan Univ, Dept Ophthalmol, West China Hosp, Chengdu 610041, Sichuan, Peoples R China.
   [Zuo, Cheng] Third Peoples Hosp Chengdu, Dept Ophthalmol, Chengdu, Sichuan, Peoples R China.
C3 Sichuan University
RP Zhang, MX (通讯作者)，Sichuan Univ, Dept Ophthalmol, West China Hosp, Chengdu 610041, Sichuan, Peoples R China.
EM zhangmeixia@medmail.com.cn
RI Zhang, meixia/AAH-6247-2019
FU National Nature Science Foundation of China [81271019]; Sichuan
   Provincial Science and Technology Support Project [2015SZ0087]
FX Supported in part by the National Nature Science Foundation of China
   (81271019) and the Sichuan Provincial Science and Technology Support
   Project (2015SZ0087).
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Chen X, 2013, DIABETES OBES METAB, V15, P224, DOI 10.1111/dom.12008
   Du LP, 2015, MOL VIS, V21, P185
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Lai K, 2015, EXPERT REV CLIN PHAR, V8, P135, DOI 10.1586/17512433.2015.990379
   Li H, 2012, EXP EYE RES, V97, P154, DOI 10.1016/j.exer.2011.09.002
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Nguyen TT, 2015, EXPERT REV CLIN PHAR, V8, P541, DOI 10.1586/17512433.2015.1075879
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Penha FM, 2013, RETINA-J RET VIT DIS, V33, P459, DOI 10.1097/IAE.0b013e31827d2657
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 31
TC 4
Z9 4
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2019
VL 39
IS 7
BP 1353
EP 1360
DI 10.1097/IAE.0000000000002152
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ5AA
UT WOS:000480761900014
PM 29547454
DA 2022-11-30
ER

PT J
AU Pedersen, KB
   Moller, F
   Sjolie, AK
   Andreasson, S
AF Pedersen, Karen Bjerg
   Moller, Flemming
   Sjolie, Anne Katrin
   Andreasson, Sten
TI ELECTROPHYSIOLOGICAL ASSESSMENT OF RETINAL FUNCTION DURING 6 MONTHS OF
   BEVACIZUMAB TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AMD; Avastin; bevacizumab; CNV; electrophysiology; full-field ERG;
   multifocal ERG
ID INTRAVITREAL INJECTION; PIGMENT EPITHELIUM; AVASTIN TREATMENT; VISUAL
   FUNCTION; MULTIFOCAL-ERG; EYES; PENETRATION; ANTIBODY; CANCER; MONKEY
AB Purpose: The purpose of this study was to assess the alteration of retinal function by multifocal electroretinography and full-field electroretinography in patients with age-related macular degeneration treated with bevacizumab.
   Methods: We performed a prospective pilot study of 26 eyes of 26 previously treatment-naive patients with neovascular age-related macular degeneration receiving intravitreal injections with 1.25 mg bevacizumab. Patients were examined with multifocal electroretinography, full-field electroretinography, optical coherence tomography, and visual acuity. Follow-up was performed at 1 week, 6 weeks, 3 months, and 6 months.
   Results: Mean multifocal electroretinography P1 amplitudes were significantly improved at 1 week in the central zone and after 3 and 6 months, improvement was seen in all 6 concentric rings corresponding to +/-25 degrees of the central visual field. Full-field electroretinography results indicated a decrease in cone photoreceptor function at 3 months, which was normalized at 6 months compared with baseline. Furthermore, 2 of 3 of the combined rod-cone responses showed signs of decreased retinal function at 6 months.
   Conclusion: Our results indicate passing signs of an altered retinal cone photoreceptor function assessed by full-field electroretinography. The results do not show any conclusive signs of global retinal toxicity after 6 months. Multifocal electroretinography results show improved photoreceptor function with no sign of focal toxicity in the central retina. RETINA 30:1025-1033, 2010
C1 [Pedersen, Karen Bjerg; Moller, Flemming; Sjolie, Anne Katrin] Odense Univ Hosp, Dept Ophthalmol, DK-5000 Odense C, Denmark.
   [Andreasson, Sten] Lund Univ, Dept Ophthalmol, Lund, Sweden.
C3 University of Southern Denmark; Odense University Hospital; Lund
   University
RP Pedersen, KB (通讯作者)，Odense Univ Hosp, Dept Ophthalmol, Sdr Blvd 29, DK-5000 Odense C, Denmark.
EM karenbjerg@yahoo.dk
FU Danish Eye Health Society; Danish Eye Research Foundation; Velux
   Foundation; Synoptik Foundation; A.P. Moller Foundation for the
   Advancement of Medical Science
FX Supported by The Danish Eye Health Society, The Danish Eye Research
   Foundation, The Velux Foundation, The Synoptik Foundation, and The A.P.
   Moller Foundation for the Advancement of Medical Science.
CR Chu PHW, 2006, GRAEF ARCH CLIN EXP, V244, P1273, DOI 10.1007/s00417-006-0304-8
   Cohen MH, 2007, ONCOLOGIST, V12, P713, DOI 10.1634/theoncologist.12-6-713
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Grover S, 2003, OPHTHALMOLOGY, V110, P1159, DOI 10.1016/S0161-6420(03)00253-7
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Holopigian K, 1997, OPTOMETRY VISION SCI, V74, P152, DOI 10.1097/00006324-199703000-00026
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Hood DC, 2008, DOC OPHTHALMOL, V116, P1, DOI 10.1007/s10633-007-9089-2
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Karanjia R, 2008, BRIT J OPHTHALMOL, V92, P1248, DOI 10.1136/bjo.2008.138800
   Luke M, 2006, BRIT J OPHTHALMOL, V90, P1178, DOI 10.1136/bjo.2006.094995
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Marmor MF, 2004, DOC OPHTHALMOL, V108, P107, DOI 10.1023/B:DOOP.0000036793.44912.45
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Moschos MM, 2007, DOC OPHTHALMOL, V114, P37, DOI 10.1007/s10633-006-9036-7
   PEDERSEN KB, 2008, ACTA OPHTHALMOL 1216
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Sakurai K, 2009, INVEST OPHTH VIS SCI, V50, P4905, DOI 10.1167/iovs.07-1542
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Shetty R, 2008, DOC OPHTHALMOL, V116, P129, DOI 10.1007/s10633-007-9090-9
   Stahl A, 2009, DOC OPHTHALMOL, V118, P81, DOI 10.1007/s10633-008-9136-7
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Zhao SL, 2001, MOL VIS, V7, P277
   Ziemssen Focke, 2008, International Ophthalmology, V28, P101, DOI 10.1007/s10792-007-9122-1
   Zuo CG, 2009, DOC OPHTHALMOL, V119, P29, DOI 10.1007/s10633-009-9166-9
NR 32
TC 24
Z9 24
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2010
VL 30
IS 7
BP 1025
EP 1033
DI 10.1097/IAE.0b013e3181cafc8f
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 622CE
UT WOS:000279635600005
PM 20616681
DA 2022-11-30
ER

PT J
AU Lee, SC
   Seong, YS
   Kim, SS
   Koh, HJ
   Kwon, OW
AF Lee, SC
   Seong, YS
   Kim, SS
   Koh, HJ
   Kwon, OW
TI Photodynamic therapy with verteporfin for polypoidal choroidal
   vasculopathy of the macula
SO OPHTHALMOLOGICA
LA English
DT Article
DE choroidal neovascularization; photodynamic therapy; polypoidal choroidal
   vasculopathy; subretinal hemorrhage
ID OPTICAL COHERENCE TOMOGRAPHY; NEOVASCULARIZATION; DEGENERATION
AB Purpose: Indications for photodynamic therapy (PDT) have increased from age-related macular degeneration with choroidal neovascularization (CNV), containing more than 50% of the classic component, to occult CNV, myopic CNV and CNV due to ocular histoplasmosis syndrome. In the present study, the effect of PDT with verteporfin was examined in polypoidal choroidal vasculopathy (PCV) of the macula. Methods: PDT was performed in 9 eyes with PCV of the macula. Fundus examination, fluorescein angiography, and indocyanine green angiography were performed before PDT and 3 months after PDT in all eyes. Optical coherence tomography was performed in 6 eyes. Results: After the initial PDT, visual acuity was stabilized or improved in 8 eyes (89%), polypoid elements were obliterated in 7 eyes (78%), and vascular nets were reduced in 8 eyes ( 89%). Of 6 eyes that received optical coherence tomography, pigment epithelium detachment was reduced or disappeared in all eyes except 1, which developed a disciform scar. An additional PDT was performed in 4 eyes to decrease vascular leakage. During the follow-up period of 3 - 18 months, no reactivation of PCV was observed. Conclusion: PDT offers an effective way of treating PCV of the macula, by obliterating polypoid elements of the PCV. However, long-term follow-up is needed. Copyright (C) 2004 S. Karger AG, Basel.
C1 Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Lee, SC (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Sinchondong 134, Seoul 120752, South Korea.
EM sunglee@yumc.yonsei.ac.kr
OI Kim, Sung Soo/0000-0002-0574-7993; Koh, Hyoung Jun/0000-0002-5932-8516;
   , Sung Chul/0000-0001-9438-2385
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Saperstein DA, 2002, OPHTHALMOLOGY, V109, P1499, DOI 10.1016/S0161-6420(02)01103-X
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Schneider U, 1998, BRIT J OPHTHALMOL, V82, P98, DOI 10.1136/bjo.82.1.98
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 20
TC 70
Z9 76
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2004
VL 218
IS 3
BP 193
EP 201
DI 10.1159/000076844
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 814KT
UT WOS:000220974300006
PM 15103216
DA 2022-11-30
ER

PT J
AU Ashraf, M
   Souka, A
   Adelman, RA
AF Ashraf, Mohammed
   Souka, Ahmed
   Adelman, Ron A.
TI Age-related macular degeneration: using morphological predictors to
   modify current treatment protocols
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; anti-VEGF drugs; macula; optical
   coherence tomography; retina
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL AFLIBERCEPT INJECTION; 2.0 MG
   RANIBIZUMAB; VITREOMACULAR INTERFACE; TREATMENT OUTCOMES; VISUAL
   OUTCOMES; CHOROIDAL NEOVASCULARIZATION; SUBGROUP ANALYSIS; PROSPECTIVE
   TRIAL; VISION OUTCOMES
AB To assess predictors of treatment response in neovascular age-related macular degeneration (AMD) in an attempt to develop a patient-centric treatment algorithm. We conducted a systematic search using PubMed, EMBASE and Web of Science for prognostic indicators/predictive factors with the key words: age related macular degeneration', neovascular AMD', choroidal neovascular membrane (CNV)', anti-vascular endothelial growth factor (anti-VEGF)', aflibercept', ranibizumab', bevacizumab', randomized clinical trials', post-hoc', prognostic', predictive', response' injection frequency, treat and extend (TAE), pro re nata (PRN)', bi-monthly' and quarterly'. We only included studies that had an adequate period of follow-up (>1year), a single predefined treatment regimen with a predetermined re-injection criteria, an adequate number of patients, specific morphological [optical coherence tomography (OCT)] criteria that predicted final visual outcomes and injection frequency and did not include switching from one drug to the other. We were able to identify seven prospective studies and 16 retrospective studies meeting our inclusion criteria. There are several morphological and demographic prognostic indicators that can predict response to therapy in wet AMD. Smaller CNV size, subretinal fluid (SRF), retinal angiomatous proliferation (RAP) and response to therapy at 12weeks (visual, angiographic or OCT) can all predict good visual outcomes in patients receiving anti-VEGF therapy. Patients with larger CNV, older age, pigment epithelial detachment (PED), intraretinal cysts (IRC) and vitreomacular adhesion (VMA) achieved less visual gains. Patients having VMA/VMT required more intensive treatment with increased treatment frequency. Patients with both posterior vitreous detachment (PVD) and SRF require infrequent injections. Patients with PED are prone to recurrences of fluid activity with a reduction in visual acuity (VA). A regimen that involves less intensive therapy and extended follow-up intervals (4weekly) can be suggested for patients who show adequate visual response and have both SRF and PVD at baseline. In addition, patients with poor prognostic indicators such as IRC, VMA, large CNV size, older age and poor response at 12weeks should be extended very cautiously with the possibility of fixed monthly/bimonthly (every 2months) treatments if they fail to achieve dryness. Patients with PED at baseline should receive monthly/bimonthly injections of anti-VEGF therapy or can be extended very cautiously (two weekly intervals) using a TAE protocol.
C1 [Ashraf, Mohammed; Souka, Ahmed] Alexandria Univ, Fac Med, Dept Ophthalmol, Infront 27 Maarouf Rasafi St, Alexandria, Egypt.
   [Adelman, Ron A.] Yale Med Sch, Dept Ophthalmol & Visual Studies, EVRS, New Haven, CT USA.
C3 Egyptian Knowledge Bank (EKB); Alexandria University; Yale University
RP Ashraf, M (通讯作者)，Alexandria Univ, Fac Med, Dept Ophthalmol, Infront 27 Maarouf Rasafi St, Alexandria, Egypt.
EM Moah384@gmail.com
RI Souka, Ahmed/AAD-8225-2022; Elmasry, Mohamed Ashraf/Q-8843-2019
OI Souka, Ahmed/0000-0002-1664-704X; Elmasry, Mohamed
   Ashraf/0000-0003-4231-2566
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brijesh T, 2016, AM J OPHTHALMOL, V162, P200, DOI 10.1016/j.ajo.2015.11.002
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Byun YJ, 2010, JPN J OPHTHALMOL, V54, P571, DOI 10.1007/s10384-010-0866-1
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Chen YFN, 2016, RETINA-J RET VIT DIS, V36, P272, DOI 10.1097/IAE.0000000000000691
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   ELDEM MB, 2009, INVEST OPHTH VIS SCI, V50, P2374
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Gianniou C, 2015, EYE, V29, P450, DOI 10.1038/eye.2014.321
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P589, DOI 10.1016/j.ophtha.2014.10.001
   Granstam E, 2016, ACTA OPHTHALMOL, V94, P646, DOI 10.1111/aos.13187
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Houston SK, 2015, RETINA-J RET VIT DIS, V35, P1757, DOI 10.1097/IAE.0000000000000663
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Karaca EE, 2015, RETINA-J RET VIT DIS, V35, P1540, DOI 10.1097/IAE.0000000000000531
   Kikushima W, 2016, J OCUL PHARMACOL TH, V32, P376, DOI 10.1089/jop.2015.0125
   Kolb S, 2012, KLIN MONATSBL AUGENH, V229, P343, DOI 10.1055/s-0031-1299250
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Kvannli L, 2017, ACTA OPHTHALMOL
   Kwon Yoon Hyung, 2014, Korean J Ophthalmol, V28, P386, DOI 10.3341/kjo.2014.28.5.386
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Matsumiya W, 2015, OPHTHALMOLOGICA, V234, P33, DOI 10.1159/000431000
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Moshfeghi DM, 2016, OSLI RETINA, V47, P238, DOI 10.3928/23258160-20160229-06
   Nghiem-Buffet S, 2016, RETINA, V37, P53
   Nomura Y, 2014, JPN J OPHTHALMOL, V58, P443, DOI 10.1007/s10384-014-0333-5
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Rahimy E, 2016, RETINA-J RET VIT DIS, V36, P875, DOI 10.1097/IAE.0000000000000814
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Richard G, 2015, OPHTHALMOLOGY, V122, P2497, DOI 10.1016/j.ophtha.2015.08.014
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Roberts PK, 2016, RETINA, V37, P1492
   Rush RB, 2014, RETINA-J RET VIT DIS, V34, P846, DOI 10.1097/IAE.0000000000000033
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Shona O, 2011, CLIN EXP OPHTHALMOL, V39, P5, DOI 10.1111/j.1442-9071.2010.02424.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Thi HCT, 2011, OPHTHAL SURG LAS IM, V42, P498, DOI 10.3928/15428877-20110804-04
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Torrón Fernández-Blanco C, 2003, Arch Soc Esp Oftalmol, V78, P471
   Tsilimbaris MK, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4367631
   Uney GO, 2014, RETINA-J RET VIT DIS, V34, P32, DOI 10.1097/IAE.0b013e318295f72e
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wang HY, 2013, INT J OPHTHALMOL-CHI, V6, P600, DOI 10.3980/j.issn.2222-3959.2013.05.09
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
NR 73
TC 33
Z9 35
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2018
VL 96
IS 2
BP 120
EP 133
DI 10.1111/aos.13565
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FW5PL
UT WOS:000425369200037
PM 29130626
OA Bronze
DA 2022-11-30
ER

PT J
AU Annweiler, C
   Drouet, M
   Duval, GT
   Pare, PY
   Leruez, S
   Dinomais, M
   Milea, D
AF Annweiler, Cedric
   Drouet, Morgane
   Duval, Guillaume T.
   Pare, Pierre-Yves
   Leruez, Stephanie
   Dinomais, Mickael
   Milea, Dan
TI Circulating vitamin D concentration and age-related macular
   degeneration: Systematic review and meta-analysis
SO MATURITAS
LA English
DT Review
DE Eye; Age-related macular degeneration; Meta-analysis;
   Neuroendocrinology; Vitamin D; Older adults
ID D DEFICIENCY; ASSOCIATION; CALCITRIOL
AB Vitamin D may be involved in ocular function in older adults, but there is no current consensus on a possible association between circulating concentrations of 25-hydroxyvitamin D (25OHD) and the occurrence of age-related macular degeneration (AMD). Our objective was to systematically review and quantitatively assess the association of circulating 25OHD concentration with AMD. A Medline search was conducted in November 2015, with no date limit, using the MeSH terms "Vitamin D" OR "Vitamin D deficiency" OR "Ergocalciferols" OR 'Cholecalcifera combined with "Age-related macular degeneration" OR "Macular degeneration" OR "Retinal degeneration" OR "Macula lutea" OR "Retina". Fixed and random effects meta-analyses were performed to compute (i) standard mean difference in 25OHD concentration between AMD and non-AMD patients; (ii) AMD risk according to circulating 25OHD concentration. Of the 243 retrieved studies, 11 observational studies-10 cross-sectional studies and 1 cohort study-met the selection criteria. The number of participants ranged from 65 to 17,045 (52-100% women), and the number with AMD ranged from 31 to 1440. Circulating 25OHD concentration was 15% lower in AMD compared with non-AMD on average. AMD was inversely associated with the highest 25OHD quintile compared with the lowest (summary odds ratio (OR) = 0.83 [95%CI:0.71-0.97]), notably late AMD (summary OR=0.47 [95%CI:0.28-0.79]). Circulating 250HD <50 nmol/L. was also associated with late-stage AMD (summary OR=2.18 [95%CI:1.34-3.56]), an association that did not persist when all categories of AMD were considered (summary OR=1.26 [95%CI:0.90-1.76]). In conclusion, this meta-analysis provides evidence that high 25OHD concentrations may be protective against AMD, and that 25OHD concentrations below 50 nmol/L, are associated with late AMD. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Annweiler, Cedric; Duval, Guillaume T.; Pare, Pierre-Yves] Univ Angers, LUNAM, Div Geriatr Med, Dept Neurosci, F-49000 Angers, France.
   [Annweiler, Cedric; Duval, Guillaume T.; Pare, Pierre-Yves] Univ Angers, LUNAM, Angers Univ Hosp, Memory Clin,UPRES,EA 4638, F-49000 Angers, France.
   [Annweiler, Cedric] Univ Western Ontario, Dept Med Biophys, Robarts Res Inst, Schulich Sch Med & Dent, London, ON, Canada.
   [Drouet, Morgane; Leruez, Stephanie; Milea, Dan] Angers Univ Hosp, Div Ophthalmol, Dept Neurosci, F-49933 Angers 9, France.
   [Dinomais, Mickael] Univ Angers, LARIS, LUNAM, EA7315, F-49000 Angers, France.
   [Dinomais, Mickael] CHU Angers, Dept Med Phys & Readaptat, F-49933 Angers, France.
   [Milea, Dan] Singapore Eye Res Inst, Singapore, Singapore.
   [Milea, Dan] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Milea, Dan] Duke NUS, Neurosci & Behav Disorders, Singapore, Singapore.
C3 Universite d'Angers; Universite d'Angers; Centre Hospitalier
   Universitaire d'Angers; Western University (University of Western
   Ontario); Universite d'Angers; Centre Hospitalier Universitaire
   d'Angers; Universite d'Angers; Universite d'Angers; Centre Hospitalier
   Universitaire d'Angers; National University of Singapore; Singapore
   National Eye Center; Singapore National Eye Center; National University
   of Singapore
RP Annweiler, C (通讯作者)，Angers Univ Hosp, Dept Neurosci, Div Geriatr Med, F-49933 Angers 9, France.
EM CeAnnweiler@chu-angers.fr
RI Milea, Dan/AAT-8661-2021
OI Annweiler, Cedric/0000-0002-7199-8109
CR Albert DM, 2007, INVEST OPHTH VIS SCI, V48, P2327, DOI 10.1167/iovs.06-1210
   Annweiler C, 2011, GERIATR PSYCHOL NEUR, V9, P259, DOI 10.1684/pnv.2011.0288
   Annweiler C, 2010, NEUROPSYCHOBIOLOGY, V62, P139, DOI 10.1159/000318570
   Artaza JN, 2009, J ENDOCRINOL, V200, P207, DOI 10.1677/JOE-08-0241
   Beauchet O, 2011, J AM GERIATR SOC, V59, P568, DOI 10.1111/j.1532-5415.2010.03299.x
   Bouillon R, 2013, J CLIN ENDOCR METAB, V98, pE1283, DOI 10.1210/jc.2013-1195
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Chung I, 2007, J STEROID BIOCHEM, V103, P768, DOI 10.1016/j.jsbmb.2006.12.042
   Coscas G, 1991, Rev Prat, V41, P2320
   Cougnard-Greoire A, 2015, J NUTR, V145, P1865, DOI 10.3945/jn.115.214387
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Goncalves A, 2015, MATURITAS, V81, P470, DOI 10.1016/j.maturitas.2015.05.008
   Graffe A, 2014, INVEST OPHTH VIS SCI, V55, P5298, DOI 10.1167/iovs.14-13918
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Itty S, 2014, RETINA-J RET VIT DIS, V34, P1779, DOI 10.1097/IAE.0000000000000178
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002
   Mackinnon A, 2000, COMPUT BIOL MED, V30, P127, DOI 10.1016/S0010-4825(00)00006-8
   Millen AE, 2015, JAMA OPHTHALMOL, V133, P1171, DOI 10.1001/jamaophthalmol.2015.2715
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   Pahl L, 2013, EXP EYE RES, V116, P234, DOI 10.1016/j.exer.2013.09.012
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   Reins RY, 2015, EXP EYE RES, V134, P101, DOI 10.1016/j.exer.2015.02.019
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Singh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070948
   Tang J, 2009, J IMMUNOL, V182, P4624, DOI 10.4049/jimmunol.0801543
   Uro M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130879
   von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.1016/j.jclinepi.2007.11.008
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
NR 39
TC 21
Z9 23
U1 0
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-5122
EI 1873-4111
J9 MATURITAS
JI Maturitas
PD JUN
PY 2016
VL 88
BP 101
EP 112
DI 10.1016/j.maturitas.2016.04.002
PG 12
WC Geriatrics & Gerontology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Obstetrics & Gynecology
GA DL6GG
UT WOS:000375737100020
PM 27105707
DA 2022-11-30
ER

PT J
AU Cohen, SY
   Oubraham, H
   Uzzan, J
   Dubois, L
   Tadayoni, R
AF Cohen, Salomon Y.
   Oubraham, Hassiba
   Uzzan, Joel
   Dubois, Lise
   Tadayoni, Ramin
TI CAUSES OF UNSUCCESSFUL RANIBIZUMAB TREATMENT IN EXUDATIVE AGE-RELATED
   MACULAR DEGENERATION IN CLINICAL SETTINGS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; antivascular endothelial growth
   factor; ranibizumab
ID PIGMENT EPITHELIAL TEAR; INTRAVITREAL BEVACIZUMAB INJECTION; OPTICAL
   COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; SUBRETINAL
   HEMORRHAGE; NATURAL-HISTORY; THERAPY; COMPLICATIONS; VERTEPORFIN;
   AVASTIN
AB Purpose: To identify the causes of loss of vision after ranibizumab therapy in patients with exudative age-related macular degeneration treated in three clinical settings.
   Methods: A retrospective multicentric analysis of 290 consecutive eyes comprising cohorts from 3 clinical settings showed that 21 eyes lost >= 15 letters on the Early Treatment Diabetic Retinopathy Study chart 1 year after the start of ranibizumab treatment. Fundus images of these eyes were analyzed by two independent readers to investigate the causes of visual loss. The three cohorts were compared. A search was made for factors predisposing to visual loss. A second analysis was performed to compare the baseline characteristics of patients who gained (visual acuity gainers) or lost (visual acuity losers) >= 15 letters.
   Results: Among the 290 eyes included, the proportions from each center experiencing visual loss were not significantly different (mean, 7.24%, P = 0.2631). Mean visual loss of affected eyes was 27 letters. There was no significant difference between these eyes and others as regards age and gender of patients, laterality, type of choroidal neovascularization, number of visits, or initial visual acuity. Visual loss was secondary to the progression of atrophy in eight eyes, fibrosis in five eyes, a combination of fibrosis and atrophy in three eyes, severe subretinal hemorrhage in three eyes, and retinal pigment epithelial tear in two eyes. A significant difference between visual acuity gainers and losers was observed for 2 parameters: age of patients, 80.9 +/- 5.3 years in visual acuity losers versus 77.5 +/- 7.3 years in visual acuity gainers (P = 0.0473) and visual acuity at diagnosis, respectively, 56.2 +/- 11.2 versus 49.0 +/- 12.0 (P = 0.0288).
   Conclusion: Although uncommon, visual loss may occur during ranibizumab treatment and is because of the natural course of age-related macular degeneration in most cases. RETINA 32:1480-1485, 2012
C1 [Cohen, Salomon Y.; Dubois, Lise] Ctr Ophtalmol Imagerie & Laser, F-75015 Paris, France.
   [Cohen, Salomon Y.; Tadayoni, Ramin] Lariboisiere Hosp, Dept Ophthalmol, Paris, France.
   [Cohen, Salomon Y.; Tadayoni, Ramin] Univ Paris 07, Paris, France.
   [Oubraham, Hassiba] Hosp Orleans, Dept Ophthalmol, Orleans, France.
   [Uzzan, Joel] Ophthalmol Ctr, Rouen, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; UDICE-French Research Universities; Universite
   Paris Cite; Centre Hospitalier Regional d'Orleans
RP Cohen, SY (通讯作者)，Ctr Ophtalmol Imagerie & Laser, 11 Rue Antoine Bourdelle, F-75015 Paris, France.
EM sycsyc75@gmail.com
FU CIL-ASSOC, association for research and education, Paris, France
FX Supported by CIL-ASSOC, association for research and education, Paris,
   France.
CR Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Bakri SJ, 2007, EYE, V21, P424, DOI 10.1038/sj.eye.6702700
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan CK, 2007, EUR J OPHTHALMOL, V17, P674, DOI 10.1177/112067210701700432
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Do DV, 2004, AM J OPHTHALMOL, V137, P558, DOI 10.1016/j.ajo.2003.08.001
   Forooghian F, 2008, CAN J OPHTHALMOL, V43, P246, DOI 10.3129/i08-017
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   Gelisken F, 2006, ACTA OPHTHALMOL SCAN, V84, P833, DOI 10.1111/j.1600-0420.2006.00765.x
   GRABOWSKI WM, 1984, OPHTHALMOLOGY, V91, P1587
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Karagiannis DA, 2009, OPHTHALMOLOGICA, V223, P279, DOI 10.1159/000213644
   Kiss C, 2007, ACTA OPHTHALMOL SCAN, V85, P902, DOI 10.1111/j.1600-0420.2007.00928.x
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee GKY, 2007, GRAEF ARCH CLIN EXP, V245, P1225, DOI 10.1007/s00417-007-0536-2
   Mathews JP, 2007, EYE, V21, P1004, DOI 10.1038/sj.eye.6702805
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Oh IK, 2009, OPHTHALMOLOGICA, V223, P78, DOI 10.1159/000173715
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Shimomura Y, 2009, GRAEF ARCH CLIN EXP, V247, P1089, DOI 10.1007/s00417-009-1054-1
   Wong LJ, 2008, RETINA-J RET VIT DIS, V28, P1151, DOI 10.1097/IAE.0b013e31817e100f
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 35
TC 38
Z9 42
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2012
VL 32
IS 8
BP 1480
EP 1485
DI 10.1097/IAE.0b013e318240a516
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 004HN
UT WOS:000308672300007
PM 22258164
DA 2022-11-30
ER

PT J
AU Mukesh, BN
   Dimitrov, PN
   Leikin, S
   Wang, JJ
   Mitchell, P
   McCarty, CA
   Taylor, HR
AF Mukesh, BN
   Dimitrov, PN
   Leikin, S
   Wang, JJ
   Mitchell, P
   McCarty, CA
   Taylor, HR
TI Five-year incidence of age-related maculopathy - The visual impairment
   project
SO OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; CAUSE-SPECIFIC PREVALENCE; BEAVER DAM EYE; MACULAR
   DEGENERATION; AUSTRALIA; ACUITY
AB Purpose: To describe the 5-year incidence of age-related maculopathy (ARM) and the progression of the early stages of ARM lesions in Melbourne, Australia.
   Design: Population-based cohort study.
   Participants: A total of 3271 participants aged 40 years and older from Melbourne, Victoria, Australia.
   Main Outcome Measures: The 5-year incidence and progression of ARM lesions.
   Methods: Participants were recruited through a cluster random sampling from 9 urban clusters. Baseline examinations were conducted from 1992 through 1994, and the follow-up data were collected from 1997 through 1999. Presence of ARM lesions was graded from color stereo fundus photographs according to the International Classification and Grading System.
   Results: The overall cumulative 5-year incidence of age-related macular degeneration (AMD) was 0.49% (95% confidence interval [CI], 0.2-0.8) and that of early ARM was 17.3% (95% CI, 8.7-26.0). The incidence of all ARM lesions increased with age (all P<0.001). The 5-year incidence of AMD was 0%, 0.69%,1.7%, and 6.3% and that of early ARM was 13%, 22.7%, 29.8%, and 20% for participants aged 60 years and younger, aged 60 to 69 years, aged 70 to 79 years, and aged 80 years and older at baseline, respectively. People with soft indistinct drusen with pigmentary abnormalities had a 9.5 times (95% CI, 1.9-45.6) higher risk of developing AMD compared with people with soft drusen or pigmentary abnormalities. After adjusting for age, people with unilateral early ARM at baseline were 3 times (95% CI, 0.98-8.0) as likely to have early ARM in their second eye when compared with people with no ARM in both eyes.
   Conclusions: These data suggest that 1 in 3 persons aged 70 years or older will have ARM lesions over a 5-year period and that the disease will progress to a more severe form after the age of 80 years. The presence of soft indistinct drusen with pigmentary abnormalities significantly increased the risk for development of AMD. (C) 2004 by the American Academy of Ophthalmology.
C1 Marshfield Med Res Fdn, Marshfield, WI 54449 USA.
   Peter MacCallum Canc Ctr, Melbourne, Australia.
   Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   Univ Sydney, Westmead Hosp, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW, Australia.
C3 Peter Maccallum Cancer Center; Centre for Eye Research Australia;
   University of Melbourne; University of Sydney
RP Mukesh, BN (通讯作者)，Marshfield Med Res Fdn, Marshfield, WI 54449 USA.
EM mukesh.bickol@mcrf.mfldclin.edu
RI Mitchell, Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014; wang,
   jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; Taylor, Hugh/0000-0002-9437-784X;
   McCarty, Catherine/0000-0003-1089-0142
CR *AG REL EYE DIS ST, 2001, 8 AREDS, V119, P1417
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Breslow NE, 1987, STAT METHODS CANC RE, VII
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Cochran WG., 1977, SAMPLING TECHNIQUES, P249
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   KLAVER CC, 2000, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Livingston P M, 1997, Ophthalmic Epidemiol, V4, P73
   Livingston P M, 1994, Ophthalmic Epidemiol, V1, P139, DOI 10.3109/09286589409047222
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 23
TC 71
Z9 77
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2004
VL 111
IS 6
BP 1176
EP 1182
DI 10.1016/j.ophtha.2003.08.042
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 824SY
UT WOS:000221708100015
PM 15177968
DA 2022-11-30
ER

PT J
AU Pokharel, S
   Malla, OK
   Pradhananga, CL
   Joshi, SN
AF Pokharel, S.
   Malla, O. K.
   Pradhananga, C. L.
   Joshi, S. N.
TI A Pattern of Age-related Macular Degeneration
SO JOURNAL OF NEPAL MEDICAL ASSOCIATION
LA English
DT Article
DE Age-related macular degeneration; blindness; Nepalese; prevalence
ID BLUE-MOUNTAINS EYE; RISK-FACTORS; PREVALENCE; MACULOPATHY; ESTROGEN
AB Introduction: Age related macular degeneration is a disorder of the macula most often clinically apparent affecting central vision and is one of the leading causes of blindness in the population above 50 years. The aim of this study is to determine clinical profile of AMD in Nepalese presenting to a Teaching Hospital in Kathmandu.
   Methods: It was a hospital-based cross-sectional study. The subjects included in the study were those presenting to the Ophthalmology department of Kathmandu Medical College Teaching Hospital from July 2007-Dec 2007. The total number of individuals included in the study were 402 and total number of eyes were 804.
   Results: AMD was observed in 5.2% out of 402 subjects of 40 years and above age group with prevalence increasing with age. The prevalence of AMD was 0.7% within 40-50 years of age-group individuals increasing to 2.6% in 51-60 years, 6.5% in 61-70 years and to 19.3% among subjects above 71 years. This study revealed that the prevalence of AMD in females was higher with female preponderance in ratio of 2.5:1. 52.5 % AMD subjects in our study had visual impairment with 6/24-6/60 vision and 15% had vision <3/60-PL. Our study revealed statistically significant increased risk for AMD with aging (p=0.00). Increased risk was observed in female gender and diabetics though the Odds ratio (OR) was statistically insignificant (p=>0.01).
   Conclusions: Prevalence of AMD in Nepalese presenting to Kathmandu Medical College Teaching Hospital was 5% with female preponderance in ratio of 2.5:1. Aging showed statistically significant increased risk for AMD development in this study.
C1 [Pokharel, S.] Teaching Hosp, Kathmandu Med Coll, Dept Ophthalmol, Kathmandu, Nepal.
   [Joshi, S. N.] Inst Med, Dept Ophthalmol, Kathmandu, Nepal.
RP Pokharel, S (通讯作者)，Teaching Hosp, Kathmandu Med Coll, Dept Ophthalmol, Kathmandu, Nepal.
EM supranp@yahoo.com
CR Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GREGOR Z, 1978, BRIT J OPHTHALMOL, V62, P547, DOI 10.1136/bjo.62.8.547
   Jain I S, 1984, Indian J Ophthalmol, V32, P343
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   MICHAEL BG, 2007, ARCH OPHTHALMOL-CHIC, V125, P21
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   NARENDRAN V, 2000, INVEST OPHTH VIS SCI, V41, P119
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SHIHJEN C, 2008, INVEST OPHTH VIS SCI, V49, P3126
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   WU ZQ, 1992, CHINESE J OPHTHALMOL, V28, P246
NR 17
TC 9
Z9 9
U1 0
U2 0
PU NEPAL MEDICAL ASSOC
PI KATHMANDU
PA NMA BUILDING, SIDDIHI SADAN, PO BOX 189, EXHIBITION RD, KATHMANDU,
   00000, NEPAL
SN 0028-2715
EI 1815-672X
J9 J NEPAL MED ASSOC
JI J. Nepal Med. Assoc.
PD JUL-SEP
PY 2009
VL 48
IS 3
BP 217
EP 220
PG 4
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 623TC
UT WOS:000279766200005
PM 20795460
DA 2022-11-30
ER

PT J
AU Hengerer, FH
   Artal, P
   Kohnen, T
   Conrad-Hengerer, I
AF Hengerer, Fritz H.
   Artal, Pablo
   Kohnen, Thomas
   Conrad-Hengerer, Ina
TI Initial Clinical Results of a New Telescopic IOL Implanted in Patients
   With Dry Age-Related Macular Degeneration
SO JOURNAL OF REFRACTIVE SURGERY
LA English
DT Article
ID INTRAOCULAR-LENS; SYSTEM; DISEASE
AB PURPOSE: To evaluate the safety and efficacy of the iol-AMD technology (London Eye Hospital Pharma, London, UK), which includes two injectable, hydrophobic acrylic intraocular lenses (IOLs) in a pilot study of patients diagnosed as having cataract and dry age-related macular degeneration.
   METHODS: The cataract surgery and IOL implantation were performed after a preoperative evaluation using the iolAMD simulator in eyes with bilateral intermediate dry age-related macular degeneration. Outcomes were intraoperative and postoperative complications, subjective and objective visual acuity improvement, visual field changes, and postoperative diplopia.
   RESULTS: Three eyes of 2 patients were evaluated. The surgeries were uneventful. All eyes gained monocular reading vision at the 1-week postoperative visit. One patient with monocular implantation recognized diplopia for distance vision. Preoperative corrected distance visual acuity ranged from 20/800 to 20/125 and corrected near visual acuity was 20/800 or less. Two months after surgery, corrected distance and near visual acuities increased to levels between 20/40 and 20/25 (uncorrected distance visual acuity was 20/60 to 20/32; uncorrected near visual acuity was 20/200 to 20/25).
   CONCLUSIONS: These early results showed that the iolAMD simulator is a promising technology improving near and distance visual acuity in eyes with intermediate dry macular degeneration. The prismatic IOL effect did not lead to diplopia when implanted bilaterally. The surgery was safely performed.
C1 [Hengerer, Fritz H.; Kohnen, Thomas] Goethe Univ Frankfurt, Dept Ophthalmol, D-60054 Frankfurt, Germany.
   [Artal, Pablo] Univ Murcia, Lab Opt, Murcia, Spain.
   [Conrad-Hengerer, Ina] Ruhr Univ Bochum, Dept Ophthalmol, Bochum, Germany.
C3 Goethe University Frankfurt; University of Murcia; Ruhr University
   Bochum
RP Hengerer, FH (通讯作者)，Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
EM fritz.hengerer@kgu.de
RI Artal, Pablo/AGV-7547-2022; Kohnen, Thomas/AAA-2172-2020; Artal,
   Pablo/AAG-4485-2020
OI Artal, Pablo/0000-0003-1284-6591; Kohnen, Thomas/0000-0002-6933-9585;
   Artal, Pablo/0000-0003-1284-6591
CR Amselem L, 2008, J CATARACT REFR SURG, V34, P1571, DOI 10.1016/j.jcrs.2008.05.032
   Artal P, 2014, INVEST OPHTH VIS SCI, P55
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Khoramnia R, 2010, OPHTHALMOLOGE, V107, P274, DOI 10.1007/s00347-009-2094-y
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Orzalesi N, 2007, OPHTHALMOLOGY, V114, P860, DOI 10.1016/j.ophtha.2007.01.005
   Potgieter FJ, 2014, J CATARACT REFR SURG, V40, P1085, DOI 10.1016/j.jcrs.2013.10.049
   Singer MA, 2012, CLIN OPHTHALMOL, V6, P33, DOI 10.2147/OPTH.S15028
   WESTHEIMER G, 1979, ARCH OPHTHALMOL-CHIC, V97, P327
NR 10
TC 15
Z9 19
U1 0
U2 12
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1081-597X
EI 1938-2391
J9 J REFRACT SURG
JI J. Refractive Surg.
PD MAR
PY 2015
VL 31
IS 3
BP 158
EP U83
DI 10.3928/1081597X-20150220-03
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA CF4AM
UT WOS:000352490700003
PM 25751831
DA 2022-11-30
ER

PT J
AU Byeon, SH
   Lee, SC
   Oh, HS
   Kim, SS
   Koh, HJ
   Kwon, OW
AF Byeon, Suk Ho
   Lee, Sung Chul
   Oh, Hyun-Sub
   Kim, Sung Soo
   Koh, Hyoung Jun
   Kwon, Oh Woong
TI Incidence and clinical patterns of polypoidal choroidal vasculopathy in
   Korean patients
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovasculopathy; indocyanine
   green angiography; polypoidal choroidal vasculopathy
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; PHOTODYNAMIC THERAPY;
   JAPANESE PATIENTS; CHINESE PATIENTS; LESIONS; PREVALENCE; HEMORRHAGE
AB Purpose: To determine the incidence, demographic features, and clinical characteristics of polypoidal choroidal vasculopathy (PCV) in Korean patients.
   Methods: A retrospective review was undertaken of 392 eyes of 321 symptomatic patients suspected of having exudative age-related macular degeneration (AMD) after their first visit to a tertiary hospital between February 2002 and May 2006. All patients underwent a complete ophthalmic examination, including fluorescein and indocyanine green angiography (ICGA).
   Results: Of the 321 patients ( 392 eyes), 79 ( 98 eyes, 24.6%) were diagnosed with PCV. The mean PCV patient age was 64.6 +/- 7.6 years. PCV was more common in men (78.5%), and was usually unilateral (75.9%). In terms of PCV clinical manifestation, 52% of patients showed an exudative pattern, 34.7%, a hemorrhagic pattern, and 13.3%, an extensive hemorrhagic pattern. The mean visual acuity at presentation was 0.231 +/- 0.256. Classification was based on ICGA findings; 52% of patients showed relatively large aneurismal dilations, 25.5% showed atypical vessel deformations, and 22.5% showed dense clusters of numerous small hyperfluorescent dots.
   Conclusions: The incidence of PCV in Korean exudative AMD patients was relatively high compared with that in other ethnic groups. As in other Asian patient populations, PCV occurred more commonly in men and was predominantly unilateral.
C1 [Byeon, Suk Ho; Lee, Sung Chul; Oh, Hyun-Sub; Koh, Hyoung Jun; Kwon, Oh Woong] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul 120752, South Korea.
   [Kim, Sung Soo] Yonsei Univ, Coll Med, Youngdong Severance Hosp, Dept Ophthalmol, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System
RP Kwon, OW (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, 134 Shinchon Dong, Seoul 120752, South Korea.
EM owkwon0301@yumc.yonsei.ac.kr
OI Koh, Hyoung Jun/0000-0002-5932-8516; , Sung Chul/0000-0001-9438-2385;
   Byeon, suk ho/0000-0001-8101-0830; Kim, Sung Soo/0000-0002-0574-7993
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   BYEON SH, 2006, J KOREAN OPHTHALMOL, V47, P1410
   Chan WM, 2006, JPN J OPHTHALMOL, V50, P161, DOI 10.1007/s10384-005-0259-z
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Escano MFT, 2000, JPN J OPHTHALMOL, V44, P313, DOI 10.1016/S0021-5155(99)00224-5
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Okubo A, 2004, GRAEF ARCH CLIN EXP, V242, P962, DOI 10.1007/s00417-004-0920-0
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Tan CSH, 2007, EYE, V21, P132, DOI 10.1038/sj.eye.6702455
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 35
TC 102
Z9 112
U1 0
U2 6
PU SPRINGER TOKYO
PI TOKYO
PA 3-3-13, HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD FEB
PY 2008
VL 52
IS 1
BP 57
EP 62
DI 10.1007/s10384-007-0498-2
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 280PM
UT WOS:000254438700010
PM 18369702
DA 2022-11-30
ER

PT J
AU Geringswald, F
   Herbik, A
   Hoffmann, MB
   Pollmann, S
AF Geringswald, Franziska
   Herbik, Anne
   Hoffmann, Michael B.
   Pollmann, Stefan
TI Contextual cueing impairment in patients with age-related macular
   degeneration
SO JOURNAL OF VISION
LA English
DT Article
DE contextual cueing; visual search; visual attention; visuospatial working
   memory; age-related macular degeneration; macular scotoma
ID WORKING-MEMORY LOAD; VISUAL-SEARCH; SPATIAL CONTEXT; PSYCHOPHYSICS
   TOOLBOX; REPEATED DISPLAYS; EYE-MOVEMENTS; ATTENTION; DISEASE; FIXATION;
   SACCADE
AB Visual attention can be guided by past experience of regularities in our visual environment. In the contextual cueing paradigm, incidental learning of repeated distractor configurations speeds up search times compared to random search arrays. Concomitantly, fewer fixations and more direct scan paths indicate more efficient visual exploration in repeated search arrays. In previous work, we found that simulating a central scotoma in healthy observers eliminated this search facilitation. Here, we investigated contextual cueing in patients with age-related macular degeneration (AMD) who suffer from impaired foveal vision. AMD patients performed visual search using only their more severely impaired eye (n = 13) as well as under binocular viewing (n = 16). Normal-sighted controls developed a significant contextual cueing effect. In comparison, patients showed only a small nonsignificant advantage for repeated displays when searching with their worse eye. When searching binocularly, they profited from contextual cues, but still less than controls. Number of fixations and scan pattern ratios showed a comparable pattern as search times. Moreover, contextual cueing was significantly correlated with acuity in monocular search. Thus, foveal vision loss may lead to impaired guidance of attention by contextual memory cues.
C1 [Geringswald, Franziska; Pollmann, Stefan] Otto Von Guericke Univ, Dept Expt Psychol, Magdeburg, Germany.
   [Herbik, Anne; Hoffmann, Michael B.] Otto Von Guericke Univ, Ophthalm Dept, Visual Proc Lab, Magdeburg, Germany.
   [Hoffmann, Michael B.; Pollmann, Stefan] Ctr Behav Brain Sci, Magdeburg, Germany.
C3 Otto von Guericke University; Otto von Guericke University
RP Pollmann, S (通讯作者)，Otto Von Guericke Univ, Inst Physiol 2, Magdeburg, Germany.
EM stefan.pollmann@ovgu.de
RI Pollmann, Stefan/AAH-5584-2020; Pollmann, Stefan/D-1999-2013; Hoffmann,
   Michael/E-9115-2010
OI Pollmann, Stefan/0000-0001-5840-5658; Pollmann,
   Stefan/0000-0001-5840-5658; Hoffmann, Michael/0000-0002-6452-9638
FU Deutsche Forschungsgemeinschaft [PO548/8-1, 14/1, HO2002/9-1]
FX This work was supported by the Deutsche Forschungsgemeinschaft
   (PO548/8-1 and 14/1 and HO2002/9-1). We thank Ina Maria Pohl and Katja
   Wilhelm for assistance in data acquisition. We thank Gisela Muller-Plath
   for providing us with the facilities and Carolin Wienrich for helpful
   assistance during testing one patient at Martin-Luther-University, Halle
   (Saale), Germany.
CR [Anonymous], 2012, R LANG ENV STAT COMP
   Arroyo JG, 2006, JAMA-J AM MED ASSOC, V295, P2394, DOI 10.1001/jama.295.20.2394
   Brady TF, 2007, J EXP PSYCHOL HUMAN, V33, P798, DOI 10.1037/0096-1523.33.4.798
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   Brockmole JR, 2006, Q J EXP PSYCHOL, V59, P1177, DOI 10.1080/17470210600665996
   Chun MM, 1999, NAT NEUROSCI, V2, P844, DOI 10.1038/12222
   Chun MM, 1998, COGNITIVE PSYCHOL, V36, P28, DOI 10.1006/cogp.1998.0681
   Cornelissen FW, 2005, OPTOMETRY VISION SCI, V82, P27
   Cornelissen FW, 2002, BEHAV RES METH INS C, V34, P613, DOI 10.3758/BF03195489
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Deubel H, 1996, VISION RES, V36, P1827, DOI 10.1016/0042-6989(95)00294-4
   Faubert J, 2000, J AM GERIATR SOC, V48, P375, DOI 10.1111/j.1532-5415.2000.tb04693.x
   Geringswald F, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00134
   Geyer T, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00272
   Geyer T, 2010, J EXP PSYCHOL HUMAN, V36, P515, DOI 10.1037/a0017448
   HOFFMAN JE, 1995, PERCEPT PSYCHOPHYS, V57, P787, DOI 10.3758/BF03206794
   Hollingworth A, 2006, VIS COGN, V14, P781, DOI 10.1080/13506280500193818
   HOLM S, 1979, SCAND J STAT, V6, P65
   Howard JH, 2004, NEUROPSYCHOLOGY, V18, P124, DOI 10.1037/0894-4105.18.1.124
   Jiang YH, 2005, PSYCHON B REV, V12, P100, DOI 10.3758/BF03196353
   Jiang YH, 2001, Q J EXP PSYCHOL-A, V54, P1105, DOI 10.1080/02724980042000516
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lleras A, 2004, SPATIAL VISION, V17, P465, DOI 10.1163/1568568041920113
   Manginelli AA, 2013, ATTEN PERCEPT PSYCHO, V75, P1103, DOI 10.3758/s13414-013-0466-5
   Manginelli AA, 2013, NEUROIMAGE, V67, P363, DOI 10.1016/j.neuroimage.2012.11.025
   Manginelli AA, 2012, EXP PSYCHOL, V59, P47, DOI 10.1027/1618-3169/a000125
   Manginelli AA, 2009, PSYCHOL RES-PSYCH FO, V73, P212, DOI 10.1007/s00426-008-0211-1
   Nazemi PP, 2005, RETINA-J RET VIT DIS, V25, P446, DOI 10.1097/00006982-200506000-00009
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Nystrom M, 2010, BEHAV RES METHODS, V42, P188, DOI 10.3758/BRM.42.1.188
   Olson IR, 2002, VIS COGN, V9, P273, DOI 10.1080/13506280042000162
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   Peterson RS, 2001, PERCEPT PSYCHOPHYS, V63, P1239, DOI 10.3758/BF03194537
   POSNER MI, 1980, J EXP PSYCHOL GEN, V109, P160, DOI 10.1037/0096-3445.109.2.160
   Quillen DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1725
   SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047
   Schlagbauer B, 2012, J VISION, V12, DOI 10.1167/12.11.25
   Smyth AC, 2008, MEM COGNITION, V36, P403, DOI 10.3758/MC.36.2.403
   Song JH, 2005, J VISION, V5, P322, DOI 10.1167/5.4.4
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Travis SL, 2013, J EXP PSYCHOL LEARN, V39, P208, DOI 10.1037/a0028644
   Tseng YC, 2004, PERCEPT PSYCHOPHYS, V66, P1363, DOI 10.3758/BF03195004
   Valberg A, 2002, J OPT SOC AM A, V19, P223, DOI 10.1364/JOSAA.19.000223
   van Asselen M, 2009, ATTEN PERCEPT PSYCHO, V71, P76, DOI 10.3758/APP.71.1.76
   VANSELST M, 1994, Q J EXP PSYCHOL-A, V47, P631, DOI 10.1080/14640749408401131
   Vickery TJ, 2010, J EXP PSYCHOL HUMAN, V36, P1358, DOI 10.1037/a0020558
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1991, VISION RES, V31, P2209, DOI 10.1016/0042-6989(91)90173-3
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
NR 50
TC 23
Z9 24
U1 1
U2 15
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 1534-7362
J9 J VISION
JI J. Vision
PY 2013
VL 13
IS 3
SI SI
AR 28
DI 10.1167/13.3.28
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA AA2BH
UT WOS:000330899600016
PM 24029899
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Ciulla, TA
   Harris, A
   Kagemann, L
   Danis, RP
   Pratt, LM
   Chung, HS
   Weinberger, D
   Garzozi, HJ
AF Ciulla, TA
   Harris, A
   Kagemann, L
   Danis, RP
   Pratt, LM
   Chung, HS
   Weinberger, D
   Garzozi, HJ
TI Choroidal perfusion perturbations in non-neovascular age related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL CIRCULATION; ANGIOGRAPHY; EYES
AB Aim: Choroidal perfusion, affected in age related macular degeneration (AMD), is difficult to objectively assess given the overlying retinal circulation. This study more objectively compared choroidal perfusion parameters in a group with non-neovascular AMD to an unaffected age matched control group.
   Methods: 21 non-neovascular AMD subjects and 21 age matched control subjects without evidence of AMD underwent assessment of their choroidal blood flow in a case-control study. Scanning laser ophthalmoscope indocyanine green (ICG) angiograms were analysed by a new area dilution analysis technique. Four areas in the perifoveal region and two areas in the temporal peripapillary retina were evaluated by producing a graph of intensity of fluorescence of each area over time. The mean of the filling times and the heterogeneity of the filling times were assessed.
   Results: The means of the filling times within the perifoveal regions and the hetereogeneity of the filling times between regions within the some eyes were significantly greater in the AMD patients compared with the control subjects.
   Conclusions: Delayed and heterogeneous filling of the choroid was objectively demonstrated in eyes with non-neovascular AMD compared with age matched controls without evidence of area dilution analysis technique applied to ICG angiography.
C1 Indiana Univ, Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University-Purdue University
   Indianapolis
RP Harris, A (通讯作者)，IUMC, 702 Rotary Circle, Indianapolis, IN 46202 USA.
RI Kagemann, Larry/B-6255-2013; Ciulla, Thomas/AAA-1299-2020
OI Kagemann, Larry/0000-0001-8961-0187; Ciulla, Thomas/0000-0001-5557-6777
FU NEI NIH HHS [EY10801] Funding Source: Medline
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BISCHOFF PM, 1985, DOC OPHTHALMOL, V60, P235, DOI 10.1007/BF00157827
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   GRUNWALD J, 1998, INVEST OPHTH VIS SCI, P385
   GRUNWALD JE, 1988, BRIT J OPHTHALMOL, V72, P754, DOI 10.1136/bjo.72.10.754
   GRUNWALD JE, 1990, INVEST OPHTH VIS SCI, V31, P521
   HARRIS A, 1998, OPHTHALMOLOGY CLIN N, P331
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   PIGUET B, 1992, AM J OPHTHALMOL, V113, P657, DOI 10.1016/S0002-9394(14)74790-7
   PRUNTE C, 1988, GRAEF ARCH CLIN EXP, V226, P55, DOI 10.1007/BF02172719
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   RIVA CE, 1981, INVEST OPHTH VIS SCI, V21, P34
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   ZHAO J, 1995, INT OPHTHALMOL, V19, P1, DOI 10.1007/BF00156412
NR 18
TC 62
Z9 66
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2002
VL 86
IS 2
BP 209
EP 213
DI 10.1136/bjo.86.2.209
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 519QN
UT WOS:000173737100020
PM 11815349
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Musial-Kopiejka, M
   Polanowska, K
   Dobrowolski, D
   Krysik, K
   Wylegala, E
   Grabarek, BO
   Lyssek-Boron, A
AF Musial-Kopiejka, Magdalena
   Polanowska, Katarzyna
   Dobrowolski, Dariusz
   Krysik, Katarzyna
   Wylegala, Edward
   Grabarek, Beniamin Oskar
   Lyssek-Boron, Anita
TI The Effectiveness of Brolucizumab and Aflibercept in Patients with
   Neovascular Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium;
   neovascular age-related macular degeneration; choroidal
   neovascularization; brolucizumab; aflibercept; VEGF; flow area; select
   area; FOVEA; visus
ID ENDOTHELIAL GROWTH-FACTOR; ANGIOGENESIS; SUPPRESSION; MANAGEMENT;
   OUTCOMES; TARGETS; THERAPY
AB Age-related macular degeneration (AMD) is a progressive, chronic disease of the central area of the retina, which, if untreated, leads to blindness. This study aimed to compare the effectiveness of therapy using anti-VEGF drugs, namely brolucizumab and aflibercept, in patients with neovascular AMD (nAMD) during a monitoring period lasting around 20 weeks. The analysis consisted of 40 patients diagnosed with neovascular age-related macular degeneration, with 20 patients receiving aflibercept (Eylea, Bayer) at a dose of 2 mg/50 mu L into the vitreous chamber at the following intervals-3 doses, 4 weeks apart, followed by a fourth dose after 8 weeks. The remaining 20 patients received brolucizumab (Beovu, Novartis) at a dose of 6 mg/50 mu L, administered in the following schedule-3 initial doses, 4 weeks apart, with the administration of a fourth dose decided for each patient individually by the doctor, depending on disease activity, assessed through imaging tests. To evaluate treatment effectiveness, the following measurements were used: 'read distance and near visual acuity' for each eye separately using the Snellen chart; and non-invasive retinal imaging techniques-optical coherence tomography (OCT) and OCT angiography (OCTA). In patients treated using brolucizumab, during the observation period, statistically significant differences were found in the following parameters: flow area (p = 0.0277); select area (p = 0.0277); FOVEA (p = 0.0073); visus (p = 0.0064). In brolucizumab-treated patients, changes in OCT and OCTA, indicating an improvement, were already visible after the first injection of the drug, whereas in the aflibercept-treated group, changes were only visible after the fourth injection. We found a higher effectiveness of brolucizumab therapy compared to aflibercept in patients with nAMD during an observations period lasting 20 weeks. Our observations are significant, although they require further research.
C1 [Musial-Kopiejka, Magdalena; Polanowska, Katarzyna; Dobrowolski, Dariusz; Krysik, Katarzyna; Lyssek-Boron, Anita] St Barbara Hosp, Dept Ophthalmol, Trauma Ctr, PL-41200 Sosnowiec, Poland.
   [Dobrowolski, Dariusz; Wylegala, Edward] Med Univ Silesia, Div Med Sci Zabrze, Chair & Clin Dept Ophthalmol, PL-40760 Katowice, Poland.
   [Dobrowolski, Dariusz; Wylegala, Edward] Dist Railway Hosp, Dept Ophthalmol, PL-40760 Katowice, Poland.
   [Krysik, Katarzyna; Lyssek-Boron, Anita] Univ Technol, Acad Silesia Katowice, Fac Med Zabrze, Dept Ophthalmol, PL-41800 Zabrze, Poland.
   [Grabarek, Beniamin Oskar] Univ Technol, Acad Silesia Katowice, Fac Med, Dept Histol Cytophysiol & Embryol, PL-41800 Zabrze, Poland.
C3 Medical University Silesia
RP Lyssek-Boron, A (通讯作者)，St Barbara Hosp, Dept Ophthalmol, Trauma Ctr, PL-41200 Sosnowiec, Poland.; Lyssek-Boron, A (通讯作者)，Univ Technol, Acad Silesia Katowice, Fac Med Zabrze, Dept Ophthalmol, PL-41800 Zabrze, Poland.
EM magdamusial73@gmail.com; polanowskakatarzyna@gmail.com; dardobmd@wp.pl;
   kkrysik@gmail.com; ewylegala@sum.edu.pl; bgrabarek7@gmail.com;
   anitaboron3@gmail.com
RI Lyssek-Boroń, Anita/ACV-5312-2022; Wylęgała, Edward
   Aleksander/AGL-6056-2022; Krysik, Katarzyna/ABF-2217-2021; grabarek,
   beniamin/V-3630-2019
OI Lyssek-Boroń, Anita/0000-0003-4405-8020; Wylęgała, Edward
   Aleksander/0000-0002-6707-5790; Krysik, Katarzyna/0000-0001-9737-5391;
   grabarek, beniamin/0000-0003-1633-7145; Polanowska,
   Katarzyna/0000-0002-8388-0474; Dobrowolski, Dariusz/0000-0002-8768-1691
CR Al-Kharashi AS, 2018, SAUDI J OPHTHALMOL, V32, P318, DOI 10.1016/j.sjopt.2018.05.002
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Apte RS, 2021, NEW ENGL J MED, V385, P539, DOI 10.1056/NEJMcp2102061
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Barmas-Alamdari D, 2019, SEMIN OPHTHALMOL, V34, P420, DOI 10.1080/08820538.2019.1641526
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bian S, 2017, AAPS J, V19, P468, DOI 10.1208/s12248-016-0018-8
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Bulirsch LM, 2022, BRIT J OPHTHALMOL, V106, P1288, DOI 10.1136/bjophthalmol-2020-318672
   Costagliola C, 2019, EXPERT OPIN DRUG SAF, V18, P803, DOI 10.1080/14740338.2019.1643838
   Dammak A, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13091376
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   de Guimaraes TAC, 2021, BRIT J OPHTHALMOL, V105, P151, DOI 10.1136/bjophthalmol-2020-316195
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2018, INVEST OPHTH VIS SCI, V59
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Eissing T, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.4.9
   Farnoodian M, 2017, CLIN SCI, V131, P1763, DOI 10.1042/CS20170066
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Fernandes CFC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00653
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Garweg JG, 2020, KLIN MONATSBL AUGENH, V237, P450, DOI 10.1055/a-1101-9126
   Gopal AD, 2021, OPHTHALMOLOGY, V128, P332, DOI 10.1016/j.ophtha.2020.07.028
   Granstam E, 2021, GRAEF ARCH CLIN EXP, V259, P2085, DOI 10.1007/s00417-020-05059-y
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Jung BJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38504-y
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kaplon H, 2021, MABS-AUSTIN, V13, DOI 10.1080/19420862.2020.1860476
   Kaplon H, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2019.1703531
   Khanna S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000398
   Li R, 2019, INT J OPHTHALMOL-CHI, V12, P557, DOI 10.18240/ijo.2019.04.05
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Maloney MH, 2021, OPHTHALMOLOGY, V128, P417, DOI 10.1016/j.ophtha.2020.07.062
   Marchesi N, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092394
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Rasti R, 2020, BIOMED OPT EXPRESS, V11, P1139, DOI 10.1364/BOE.379150
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sharma A, 2020, EYE, V34, P1726, DOI 10.1038/s41433-020-0853-9
   Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
   Singh RP, 2019, INVEST OPHTH VIS SCI, V60
   Takeda A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01431
   Thoongsuwan S, 2022, OPHTHALMOL THER, V11, P739, DOI 10.1007/s40123-022-00471-5
   Ward RA, 2021, CHEM REV, V121, P3297, DOI 10.1021/acs.chemrev.0c00383
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
NR 50
TC 4
Z9 4
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD FEB
PY 2022
VL 19
IS 4
AR 2303
DI 10.3390/ijerph19042303
PG 13
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA ZT2ID
UT WOS:000768976300001
PM 35206485
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Meredith, TA
   McCannel, CA
   Barr, C
   Doft, BH
   Peskin, E
   Maguire, MG
   Martin, DF
   Prenner, JL
AF Meredith, Travis A.
   McCannel, Colin A.
   Barr, Charles
   Doft, Bernard H.
   Peskin, Ellen
   Maguire, Maureen G.
   Martin, Daniel F.
   Prenner, Jonathan L.
CA Comparison Age Related Macular Deg
TI Postinjection Endophthalmitis in the Comparison of Age-Related Macular
   Degeneration Treatments Trials (CATT)
SO OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL INJECTION; ANTIBIOTIC-RESISTANCE; CAUSATIVE ORGANISMS;
   OCULAR SURFACE; BEVACIZUMAB; FLORA; CONTAMINATION; METAANALYSIS;
   RANIBIZUMAB; SURGERY
AB Objective: To describe the incidence and outcomes of endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor agents in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) and to assess the effect of prophylactic topical antimicrobials on incidence.
   Design: Cohort study within a randomized clinical trial.
   Participants: Patients enrolled in CATT.
   Methods: Patients with neovascular age-related macular degeneration received intravitreal injections of ranibizumab or bevacizumab under 1 of 3 dosing regimens. The study protocol specified preinjection preparation to include use of a sterile lid speculum and povidone iodine (5%). Use of preinjection and postinjection antibiotics was at the discretion of the treating ophthalmologist. Patients were followed up monthly for 2 years.
   Main Outcome Measures: Development of endophthalmitis and visual acuity.
   Results: Endophthalmitis developed after 11 of 18 509 injections (1 per 1700 [0.06%]; 95% confidence interval, 0.03%-0.11%), and in 11 of 1185 patients (0.93%; 95% confidence interval, 0.52-1.66). Incidence of endophthalmitis was 0.15% among injections with no antibiotic use, 0.08% among injections with preinjection antibiotics only, 0.06% among injections with postinjection antibiotics only, and 0.04% among injections with preinjection and postinjection antibiotics (P = 0.20). All eyes were treated with intravitreal antibiotics and 4 underwent vitrectomy. Among the 11 affected eyes, the final study visual acuity was 20/40 or better in 4 eyes (36%), 20/50 to 20/80 in 2 eyes (18%), 20/100 to 20/160 in 3 eyes (27%), and worse than 20/800 in 2 eyes (18%). The final visual acuity was within 2 lines of the visual acuity before endophthalmitis in 5 eyes (45%).
   Conclusions: Rates of endophthalmitis were low and similar to those in other large-scale studies. Use of topical antibiotics either before or after injection does not seem to reduce the risk for endophthalmitis. (C) 2015 by the American Academy of Ophthalmology.
C1 [Meredith, Travis A.] Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC USA.
   [McCannel, Colin A.] Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA USA.
   [Barr, Charles] Univ Louisville, Dept Ophthalmol, Louisville, KY 40292 USA.
   [Doft, Bernard H.] Retina Vitreous Consultants, Pittsburgh, PA USA.
   [Peskin, Ellen; Maguire, Maureen G.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Prenner, Jonathan L.] Retina Vitreous Ctr, New Brunswick, NJ USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of California System; University of California Los Angeles;
   University of Louisville; University of Pennsylvania; Cleveland Clinic
   Foundation
RP Maguire, MG (通讯作者)，Univ Penn, Dept Ophthalmol, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM maguirem@mail.med.upenne.edu
OI Maguire, Maureen/0000-0002-4249-2467
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828];
   NATIONAL EYE INSTITUTE [U10EY017828, U10EY017825, U10EY017823,
   U10EY017826] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute, National Institutes of Health,
   Bethesda, Maryland (grant nos.: U10 EY017823, U10 EY017825, U10
   EY017826, and U10 EY017828).
CR Aggio FB, 2007, EYE, V21, P408, DOI 10.1038/sj.eye.6702683
   [Anonymous], 2014, REV OPHTHALMOL
   Artunay O, 2009, EYE, V23, P2187, DOI 10.1038/eye.2009.7
   Bhatt SS, 2011, RETINA-J RET VIT DIS, V31, P2032, DOI 10.1097/IAE.0b013e31820f4b4f
   Bhavsar AR, 2012, ARCH OPHTHALMOL-CHIC, V130, P809, DOI 10.1001/archophthalmol.2012.227
   Bhavsar AR, 2009, ARCH OPHTHALMOL-CHIC, V127, P1581, DOI 10.1001/archophthalmol.2009.304
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2004, OPHTHALMOLOGY, V111, P1495, DOI 10.1016/j.ophtha.2004.01.028
   Cheung CSY, 2012, OPHTHALMOLOGY, V119, P1609, DOI 10.1016/j.ophtha.2012.02.014
   Dave SB, 2013, OPHTHALMOLOGY, V120, P937, DOI 10.1016/j.ophtha.2012.11.005
   De Caro JJ, 2008, RETINA-J RET VIT DIS, V28, P877, DOI 10.1097/IAE.0b013e31816b3180
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Doshi RR, 2012, RETINA-J RET VIT DIS, V32, P473, DOI 10.1097/IAE.0B013E31822C2958
   Eifrig CWG, 2002, OPHTHALMIC SURG LAS, V33, P373
   Fileta JB, 2014, OSLI RETINA, V45, P143, DOI 10.3928/23258160-20140306-08
   Georgopoulos M, 2009, BRIT J OPHTHALMOL, V93, P457, DOI 10.1136/bjo.2008.138479
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   ISENBERG SJ, 1985, ARCH OPHTHALMOL-CHIC, V103, P1340, DOI 10.1001/archopht.1985.01050090092039
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kim SJ, 2011, ARCH OPHTHALMOL-CHIC, V129, P1180, DOI 10.1001/archophthalmol.2011.213
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mason JO, 2008, RETINA-J RET VIT DIS, V28, P564, DOI 10.1097/IAE.0b013e3181633fee
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Milder E, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.016
   Mittra RA, 2008, ASRS 2008 PREFERENCE
   Moss JM, 2009, OPHTHALMOLOGY, V116, P1498, DOI 10.1016/j.ophtha.2009.02.024
   Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   Shane TS, 2003, AM J OPHTHALMOL, V136, P649, DOI 10.1016/S0002-9394(03)00333-7
   Simunovic MP, 2012, BRIT J OPHTHALMOL, V96, P862, DOI 10.1136/bjophthalmol-2011-301439
   Stone TW, 2013, ASRS 2013 PREFERENCE
   VINE AK, 1995, ARCH OPHTHALMOL-CHIC, V113, P1479
   Wen JC, 2011, ARCH OPHTHALMOL-CHIC, V129, P1551, DOI 10.1001/archophthalmol.2011.227
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yin VT, 2013, JAMA OPHTHALMOL, V131, P456, DOI 10.1001/jamaophthalmol.2013.2379
NR 36
TC 57
Z9 57
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2015
VL 122
IS 4
BP 817
EP 821
DI 10.1016/j.ophtha.2014.10.027
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE3EX
UT WOS:000351710100030
PM 25600198
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Erke, MG
   Bertelsen, G
   Peto, T
   Sjolie, AK
   Lindekleiv, H
   Njolstad, I
AF Erke, Maja G.
   Bertelsen, Geir
   Peto, Tunde
   Sjolie, Anne K.
   Lindekleiv, Haakon
   Njolstad, Inger
TI Prevalence of Age-related Macular Degeneration in Elderly Caucasians:
   The Tromso Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; BEAVER DAM EYE; 10-YEAR INCIDENCE; VISUAL
   IMPAIRMENT; MACULOPATHY; PROGRESSION; POPULATION; SUNLIGHT; ROTTERDAM;
   GREENLAND
AB Purpose: To describe the sex- and age-specific prevalence of drusen, geographic atrophy, and neovascular age-related macular degeneration (AMD).
   Design: Population-based, cross-sectional study.
   Participants: Caucasian adults aged 65 to 87 years from the 6th Tromso Study, a population-based study conducted in 2007-2008 in the municipality of Tromso, Norway.
   Methods: Digital color fundus photographs were graded for predominant phenotype based on drusen size, geographic atrophy, and neovascular AMD.
   Main Outcome Measures: Age-related macular degeneration.
   Results: A total of 3025 subjects participated; 89% of those were invited to the eye examinations. Gradable photographs were available for 2631 persons (mean age 72.3 years). Drusen 63-125 mu m as the predominant phenotype were found in 34.9% of participants (95% confidence interval [CI], 33.1-36.8), drusen > 125 mu m were found in 24.1% (95% CI, 22.5-25.8), geographic atrophy was found in 1.0% of participants (95% CI, 0.6 - 1.4), and neovascular AMD was found in 2.5% of participants (95% CI, 1.9 -3.1). Bilateral involvement of late AMD was present in 1.1% of the sample. Eyes with late AMD had a significantly lower refractive error (spherical equivalent 0.078 vs. 0.99 diopters, P<0.0001), and 42.5% of eyes had Snellen visual acuity <= 0.32.
   Conclusions: The prevalence of AMD among the elderly persons in this study was similar to rates in other Caucasian populations. Late AMD was present in 10.9% of subjects aged 80 years or more. No sex differences in prevalence rates of large drusen or late AMD were observed. Lower refractive error was observed in eyes with late AMD than in eyes without late AMD.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012;119:1737-1743 (c) 2012 by the American Academy of Ophthalmology.
C1 [Erke, Maja G.; Bertelsen, Geir] Univ Hosp N Norway, Dept Ophthalmol & Neurosurg, N-9038 Tromso, Norway.
   [Erke, Maja G.; Bertelsen, Geir; Lindekleiv, Haakon; Njolstad, Inger] Univ Tromso, Dept Community Med, Tromso, Norway.
   [Peto, Tunde] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London, England.
   [Peto, Tunde] UCL Inst Ophthalmol, London, England.
   [Sjolie, Anne K.] Odense Univ Hosp, Dept Ophthalmol, DK-5000 Odense, Denmark.
C3 UiT The Arctic University of Tromso; University Hospital of North
   Norway; UiT The Arctic University of Tromso; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; University of Southern
   Denmark; Odense University Hospital
RP Erke, MG (通讯作者)，Univ Hosp N Norway, Dept Ophthalmol & Neurosurg, Box 100, N-9038 Tromso, Norway.
EM maja.g.erke@uit.no
RI Njolstad, Inger/X-3784-2019; Peto, Tunde/G-8812-2018; Bertelsen,
   Geir/ABB-9865-2021
OI Peto, Tunde/0000-0001-6265-0381; 
FU Northern Norway Regional Health Authority [SFP897-09]
FX Supported by Grant SFP897-09 from The Northern Norway Regional Health
   Authority. The funding organization had no role in the design or conduct
   of this research.
CR Andersen MVN, 2008, OPHTHALMOLOGY, V115, P700, DOI 10.1016/j.ophtha.2007.12.013
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bjerregaard P, 2010, INT J CIRCUMPOL HEAL, V69, P13, DOI 10.3402/ijch.v69i1.17387
   Bjornsson OM, 2006, ACTA OPHTHALMOL SCAN, V84, P636, DOI 10.1111/j.1600-0420.2006.00696.x
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Connell PP, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/360764
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Gunnlaugsdottir E, 2008, ACTA OPHTHALMOL, V86, P778, DOI 10.1111/j.1755-3768.2008.01191.x
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jacobsen BK, 2011, INT J EPIDEMIOL
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Mann SS, 2011, GRAEF ARCH CLIN EXP, V249, P209, DOI 10.1007/s00417-010-1483-x
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 31
TC 40
Z9 42
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2012
VL 119
IS 9
BP 1737
EP 1743
DI 10.1016/j.ophtha.2012.03.016
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030OY
UT WOS:000310581200004
PM 22608479
DA 2022-11-30
ER

PT J
AU Li, ML
   Dolz-Marco, R
   Messinger, JD
   Ferrara, D
   Freund, KB
   Curcio, CA
AF Li, Miaoling
   Dolz-Marco, Rosa
   Messinger, Jeffrey D.
   Ferrara, Daniela
   Freund, K. Bailey
   Curcio, Christine A.
TI Neurodegeneration, gliosis, and resolution of haemorrhage in neovascular
   age-related macular degeneration, a clinicopathologic correlation
SO EYE
LA English
DT Article
ID EXTERNAL LIMITING MEMBRANE; COHERENCE TOMOGRAPHIC FINDINGS;
   RETINAL-PIGMENT EPITHELIUM; SUBMACULAR SURGERY TRIALS; PHOTODYNAMIC
   THERAPY; CHOROIDAL NEOVASCULARIZATION; VISUAL PROGNOSIS; EYES; ATROPHY;
   ASSOCIATION
AB Background To analyse cellular and spatiotemporal factors of neurodegeneration and gliosis in a patient with submacular haemorrhage (SMH) secondary to type 1 macular neovascularization in neovascular age-related macular degeneration (nAMD). Methods This is a case study and clinicopathologic correlation of an 84-year-old white man with nAMD treated with antiangiogenic drugs and photodynamic therapy during a 6-year follow-up. Eyes were recovered for histology 8.23 h after death. In vivo multimodal imaging including optical coherence tomography (OCT) and en face modalities was compared with ex vivo OCT and high-resolution histologic images, using a custom image registration procedure. SMH components were defined (intraretinal, subretinal, sub-retinal pigment epithelium (RPE), and dehemoglobinized blood). Neurodegenerative changes in each of these areas were described. One anonymous donor eye with haemorrhagic nAMD was also reviewed as a comparator. Results By in vivo OCT, progressive resolution of the haemorrhage and gradual transformation of sub-RPE fluid to fibrous hyperreflective tissue, progressive macular atrophy, and variation in external limiting membrane (ELM) visibility were observed. Histology showed intense photoreceptor loss with preservation and self-adhesion of macular Muller glia resulting in ELM condensation. The comparator eye exhibited shed cone inner segments among subretinal erythrocytes. Conclusion This is the most detailed clinicopathologic correlation of nAMD with SMH resolution to date, and the first in the OCT era. Our results reveal profound macular neurodegeneration and gliosis, signified by condensed ELM, soon after haemorrhage begins. Intensified OCT reflectivity of the ELM, an important retinal barrier, has potential as a biomarker for severe photoreceptor loss and gliosis.
C1 [Li, Miaoling] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou, Peoples R China.
   [Li, Miaoling; Messinger, Jeffrey D.; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL 35294 USA.
   [Dolz-Marco, Rosa; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Dolz-Marco, Rosa; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Dolz-Marco, Rosa] Oftalvist Clin, Unit Macula, Valencia, Spain.
   [Ferrara, Daniela] Genentech Inc, San Francisco, CA USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
C3 Sun Yat Sen University; University of Alabama System; University of
   Alabama Birmingham; Vitreous Retina Macula Consultants of New York;
   Manhattan Eye Ear & Throat Hospital; Roche Holding; Genentech; New York
   University
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL 35294 USA.
EM christinecurcio@uabmc.edu
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773; Curcio,
   Christine/0000-0001-9769-1538
FU Genentech/Hoffman-LaRoche
FX This work was supported by Genentech/Hoffman-LaRoche. The funding
   organisation had no role in the design and conduct of this study.
   Purchase of the slide scanner was made possible by the Carl G. and
   Pauline Buck Trust.
CR Asai T, 2014, INVEST OPHTH VIS SCI, V55, P226, DOI 10.1167/iovs.13-12658
   Au A, 2018, JAMA OPHTHALMOL, V136, P1182, DOI 10.1001/jamaophthalmol.2018.2979
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bringmann A, 2018, PROG RETIN EYE RES, V66, P49, DOI 10.1016/j.preteyeres.2018.03.006
   Burke TR, 2013, OPHTHALMIC GENET, V34, P75, DOI 10.3109/13816810.2012.707271
   Chen JT, 2020, JPN J OPHTHALMOL, V64, P235, DOI 10.1007/s10384-020-00741-4
   Chen L, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.8
   Chhablani J, 2013, INT J OPHTHALMOL-CHI, V6, P62, DOI 10.3980/j.issn.2222-3959.2013.01.13
   Coxeter H., 1969, INTRO GEOMETRY
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V193, P166, DOI 10.1016/j.ajo.2018.06.020
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2006, AM J OPHTHALMOL, V141, P93, DOI 10.1016/j.ajo.2005.07.076
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Ito S, 2013, BRIT J OPHTHALMOL, V97, P228, DOI 10.1136/bjophthalmol-2011-301418
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Kim JH, 2016, JPN J OPHTHALMOL, V60, P466, DOI 10.1007/s10384-016-0466-9
   Klein ML, 2011, AM J OPHTHALMOL, V151, P161, DOI 10.1016/j.ajo.2010.07.020
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lee K, 2020, RETINA
   LEWIS H, 1991, AM J OPHTHALMOL, V111, P197, DOI 10.1016/S0002-9394(14)72259-7
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Li ML, 2019, RETINA-J RET VIT DIS, V39, P802, DOI 10.1097/IAE.0000000000002461
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Moriyama M, 2011, RETINA-J RET VIT DIS, V31, P74, DOI 10.1097/IAE.0b013e3181e91148
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Omri S, 2010, CLIN OPHTHALMOL, V4, P183
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   PERRY VH, 1988, NEUROSCIENCE, V25, P225, DOI 10.1016/0306-4522(88)90021-8
   Preti RC, 2018, RETINA-J RET VIT DIS, V38, P1518, DOI 10.1097/IAE.0000000000001810
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Roberts P, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14293
   Sarks J, 2006, BRIT J OPHTHALMOL, V90, P442, DOI 10.1136/bjo.2005.083022
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sato T, 2015, RETINA-J RET VIT DIS, V35, P1292, DOI 10.1097/IAE.0000000000000505
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Ueda-Arakawa N, 2012, JPN J OPHTHALMOL, V56, P589, DOI 10.1007/s10384-012-0191-y
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P1
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
NR 58
TC 4
Z9 4
U1 0
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2021
VL 35
IS 2
BP 548
EP 558
DI 10.1038/s41433-020-0896-y
EA MAY 2020
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PX7VQ
UT WOS:000530278200008
PM 32366998
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Fletcher, EL
   Kumar, H
   Greferath, U
   Guymer, RH
AF Wu, Zhichao
   Fletcher, Erica L.
   Kumar, Himeesh
   Greferath, Ursula
   Guymer, Robyn H.
TI Reticular pseudodrusen: A critical phenotype in age-related macular
   degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Age-related macular degeneration; reticular pseudodrusen; Subretinal
   drusenoid deposits; Drusen
ID SUBRETINAL DRUSENOID DEPOSITS; OPTICAL COHERENCE TOMOGRAPHY;
   RETINAL-PIGMENT EPITHELIUM; COMPLEMENT FACTOR-H; POLYPOIDAL CHOROIDAL
   VASCULOPATHY; GEOGRAPHIC ATROPHY SECONDARY; SWEPT-SOURCE OCT;
   DARK-ADAPTATION; ADAPTIVE OPTICS; FELLOW-EYES
AB Reticular pseudodrusen (RPD), or subretinal drusenoid deposits (SDD), refer to distinct lesions that occur in the subretinal space. Over the past three decades, their presence in association with age-related macular degeneration (AMD) has become increasingly recognized, especially as RPD have become more easily distinguished with newer clinical imaging modalities. There is also an increasing appreciation that RPD appear to be a critical AMD phenotype, where understanding their pathogenesis will provide further insights into the processes driving vision loss in AMD. However, key barriers to understanding the current evidence related to the independent impact of RPD include the heterogeneity in defining their presence, and failure to account for the confounding impact of the concurrent presence and severity of AMD pathology. This review thus critically discusses the current evidence on the prevalence and clinical significance of RPD and proposes a clinical imaging definition of RPD that will help move the field forward in gathering further key knowledge about this critical phenotype. It also proposes a putative mechanism for RPD formation and how they may drive progression to vision loss in AMD, through examining current evidence and presenting novel findings from preclinical and clinical studies.
C1 [Wu, Zhichao; Kumar, Himeesh; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia.
   [Wu, Zhichao; Kumar, Himeesh; Guymer, Robyn H.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Australia.
   [Fletcher, Erica L.; Greferath, Ursula] Univ Melbourne, Dept Anat & Physiol, Melbourne, Vic, Australia.
   [Guymer, Robyn H.] Ctr Eye Res Australia Level 7, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne
RP Guymer, RH (通讯作者)，Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia.; Guymer, RH (通讯作者)，Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Australia.; Guymer, RH (通讯作者)，Ctr Eye Res Australia Level 7, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM rhg@unimelb.edu.au
OI Greferath, Ursula/0000-0003-1028-648X; Kumar,
   Himeesh/0000-0001-9169-5335; Guymer, Robyn/0000-0002-9441-4356
FU National Health & Medical Research Council of Australia [APP1181010,
   APP1138253, GNT1103013 [RHG]]; Macular Disease Foundation Australia;
   Victorian Government
FX This work was supported by National Health & Medical Research Council of
   Australia grants APP1181010 [RHG, ELF, ZW] , APP1138253 [ELF, RHG] and
   fellowship GNT1103013 [RHG] ) and a Macular Disease Foundation Australia
   grant [ZW, RHG] . The Centre for Eye Research Australia (CERA) receives
   operational infrastructure support from the Victorian Government. The
   funders had no role in the manuscript writing and the decision to submit
   the manuscript for publication.
CR Agrawal R, 2020, PROG RETIN EYE RES, V77, DOI 10.1016/j.preteyeres.2020.100829
   Aleman TS, 2013, DOC OPHTHALMOL, V127, P239, DOI 10.1007/s10633-013-9403-0
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Alten F, 2014, INVEST OPHTH VIS SCI, V55, P6073, DOI 10.1167/iovs.13-13804
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Alten F, 2012, INVEST OPHTH VIS SCI, V53, P6263, DOI 10.1167/iovs.12-10094
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Augustin M, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.15
   Ban N, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120824
   Beguier F, 2020, IMMUNITY, V53, P429, DOI 10.1016/j.immuni.2020.07.021
   Berkenstock MK, 2020, INT J RETINA VITR, V6, DOI 10.1186/s40942-020-00224-1
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buitendijk GHS, 2016, INVEST OPHTH VIS SCI, V57, P5593, DOI 10.1167/iovs.15-18816
   Burns SA, 2019, PROG RETIN EYE RES, V68, P1, DOI 10.1016/j.preteyeres.2018.08.002
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Capuano V, 2016, BRIT J OPHTHALMOL, V100, P677, DOI 10.1136/bjophthalmol-2015-307169
   Casalino G, 2018, OPHTHALMOL RETINA, V2, P451, DOI 10.1016/j.oret.2017.08.019
   Chae B, 2019, BRIT J OPHTHALMOL, V103, P43, DOI 10.1136/bjophthalmol-2018-311850
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chan H, 2016, INVEST OPHTH VIS SCI, V57, P3058, DOI 10.1167/iovs.16-19487
   Chang YS, 2016, ACTA OPHTHALMOL, V94, pE49, DOI 10.1111/aos.12748
   Chen L, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.1.33
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P618, DOI 10.1097/IAE.0000000000002657
   Cheng H, 2016, CURR EYE RES, V41, P1492, DOI 10.3109/02713683.2015.1127391
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cheung CMG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31109-x
   Chiang TTK, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.59
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Cho HJ, 2021, ACTA OPHTHALMOL, V99, pE540, DOI 10.1111/aos.14631
   Cho HJ, 2020, BRIT J OPHTHALMOL, V104, P1443, DOI 10.1136/bjophthalmol-2019-315496
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Cleland SC, 2021, OPHTHALMOL RETINA, V5, P721, DOI 10.1016/j.oret.2020.12.019
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Corradetti G, 2021, CAN J OPHTHALMOL, V56, P325, DOI 10.1016/j.jcjo.2021.01.005
   Corvi F, 2021, RETINA-J RET VIT DIS, V41, P686, DOI 10.1097/IAE.0000000000002990
   Corvi F, 2019, RETINA-J RET VIT DIS, V39, P2378, DOI 10.1097/IAE.0000000000002335
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P770, DOI 10.1136/bjophthalmol-2016-309115
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P348, DOI 10.1136/bjophthalmol-2016-308548
   Cozzi M, 2020, OPHTHALMOL RETINA, V4, P987, DOI 10.1016/j.oret.2020.04.013
   Crossland M.D., 2012, INVEST OPHTH VIS SCI, V53, P4822
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   De Bats F, 2016, RETINA-J RET VIT DIS, V36, P46, DOI 10.1097/IAE.0000000000000648
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Dutheil C, 2020, JAMA OPHTHALMOL, V138, P467, DOI 10.1001/jamaophthalmol.2020.0266
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elfandi S, 2016, OPHTHALMOLOGY, V123, P2205, DOI 10.1016/j.ophtha.2016.06.052
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fletcher EL, 2019, DRUG DISCOV TODAY, V24, P1598, DOI 10.1016/j.drudis.2019.03.029
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Fletcher EL, 2011, PROG MOL BIOL TRANSL, V100, P211, DOI 10.1016/B978-0-12-384878-9.00006-6
   Flynn OJ, 2018, INVEST OPHTH VIS SCI, V59, P2411, DOI 10.1167/iovs.17-22874
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Forte R, 2014, OPHTHALMIC RES, V51, P32, DOI 10.1159/000354117
   Fraser RG, 2016, INVEST OPHTH VIS SCI, V57, P5436, DOI 10.1167/iovs.16-19295
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gabrielle PH, 2019, INVEST OPHTH VIS SCI, V60, P4838, DOI 10.1167/iovs.19-27283
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Gattoussi S, 2019, RETINA-J RET VIT DIS, V39, P34, DOI 10.1097/IAE.0000000000002237
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Genead MA, 2010, OPHTHALMIC GENET, V31, P66, DOI 10.3109/13816810903584971
   Gerth C, 2009, DOC OPHTHALMOL, V118, P63, DOI 10.1007/s10633-008-9133-x
   Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207
   Gin TJ, 2017, INVEST OPHTH VIS SCI, V58, P2079, DOI 10.1167/iovs.16-20105
   Gliem M, 2015, OPHTHALMOLOGY, V122, P1555, DOI 10.1016/j.ophtha.2015.04.035
   Gliem M, 2015, JAMA OPHTHALMOL, V133, P581, DOI 10.1001/jamaophthalmol.2015.117
   Gouras P, 2008, GRAEF ARCH CLIN EXP, V246, P1395, DOI 10.1007/s00417-008-0910-8
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Grewal DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092841
   Grewal MK, 2022, EYE, V36, P398, DOI 10.1038/s41433-021-01488-z
   Gu BJ, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.634177
   Gu BJ, 2018, BRIT J PHARMACOL, V175, P4195, DOI 10.1111/bph.14470
   Gu BJ, 2013, FASEB J, V27, P1479, DOI 10.1096/fj.12-215368
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Han RC, 2019, BRIT J OPHTHALMOL, V103, P1092, DOI 10.1136/bjophthalmol-2018-312253
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   Ho CYD, 2018, CLIN EXP OPHTHALMOL, V46, P485, DOI 10.1111/ceo.13131
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Holder GE, 2010, CLIN NEUROPHYSIOL, V121, P1393, DOI 10.1016/j.clinph.2010.04.010
   Holekamp N, 2020, OPHTHALMOLOGY, V127, P769, DOI 10.1016/j.ophtha.2019.12.009
   Holmen IC, 2019, OPHTHALMOL RETINA, V3, P724, DOI 10.1016/j.oret.2019.04.011
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Kang SW, 2017, GRAEF ARCH CLIN EXP, V255, P281, DOI 10.1007/s00417-016-3452-5
   Kaszubski PA, 2018, INT OPHTHALMOL, V38, P503, DOI 10.1007/s10792-017-0485-7
   Keenan TD, 2020, RETINA-J RET VIT DIS, V40, P632, DOI 10.1097/IAE.0000000000002434
   Kellner U, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042089
   Kikushima W, 2016, J OCUL PHARMACOL TH, V32, P376, DOI 10.1089/jop.2015.0125
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Kong M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203146
   Kong M, 2019, RETINA-J RET VIT DIS, V39, P1945, DOI 10.1097/IAE.0000000000002263
   Lains I, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100951
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lains I, 2017, AM J OPHTHALMOL, V180, P55, DOI 10.1016/j.ajo.2017.05.021
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Lee MY, 2014, RETINA-J RET VIT DIS, V34, P69, DOI 10.1097/IAE.0b013e318295f701
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Leisy HB, 2017, OPHTHALMOL RETINA, V1, P42, DOI 10.1016/j.oret.2016.08.011
   Lek JJ, 2017, OPHTHALMOL RETINA, V1, P227, DOI 10.1016/j.oret.2016.12.001
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Lin LY, 2018, JAMA OPHTHALMOL, V136, P682, DOI 10.1001/jamaophthalmol.2018.1231
   Litts KM, 2018, RETINA-J RET VIT DIS, V38, P445, DOI 10.1097/IAE.0000000000001946
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Luu CD, 2018, OPHTHALMOL RETINA, V2, P1206, DOI 10.1016/j.oret.2018.06.016
   Lynch AM, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.10.12
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mantel I, 2019, RETINA-J RET VIT DIS, V39, P906, DOI 10.1097/IAE.0000000000002054
   Mantel I, 2019, BRIT J OPHTHALMOL, V103, P900, DOI 10.1136/bjophthalmol-2018-312430
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruyama-Inoue M, 2019, CLIN OPHTHALMOL, V13, P1981, DOI 10.2147/OPTH.S224319
   Mathis T, 2017, AGING CELL, V16, P173, DOI 10.1111/acel.12540
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   May A, 2021, EXP EYE RES, V210, DOI 10.1016/j.exer.2021.108605
   McGuinness MB, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.5.3
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Montorio D., 2021, PHOTODIAGN PHOTODYN, V33, P102094
   Moschos MM, 2018, SEMIN OPHTHALMOL, V33, P461, DOI 10.1080/08820538.2017.1301496
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Nam KT, 2020, RETINA-J RET VIT DIS, V40, P2270, DOI 10.1097/IAE.0000000000002758
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Neely D, 2017, RETINA-J RET VIT DIS, V37, P1329, DOI 10.1097/IAE.0000000000001454
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Nghiem-Buffet S, 2017, RETINA-J RET VIT DIS, V37, P53, DOI 10.1097/IAE.0000000000001134
   Nishida T, 2013, CAN J OPHTHALMOL, V48, pE148, DOI 10.1016/j.jcjo.2013.06.006
   Nishiguchi KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164899
   Nittala MG, 2019, OPHTHALMOL RETINA, V3, P112, DOI 10.1016/j.oret.2018.09.017
   Ooto S, 2015, RETINA-J RET VIT DIS, V35, P1726, DOI 10.1097/IAE.0000000000000608
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Ou WC, 2021, AM J OPHTHALMOL, V226, P148, DOI 10.1016/j.ajo.2021.01.017
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Ozaki S, 1999, BIOCHEM BIOPH RES CO, V258, P524, DOI 10.1006/bbrc.1999.0672
   Pfau M, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100907
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, pBIO121, DOI 10.1167/iovs.17-21764
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Pietraszkiewicz A, 2018, OPHTHALMOLOGY, V125, P398, DOI 10.1016/j.ophtha.2017.10.027
   Pondorfer SG, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.1.5
   Pondorfer SG, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.55
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2014, BRIT J OPHTHALMOL, V98, P1522, DOI 10.1136/bjophthalmol-2014-305455
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Ramon C, 2019, CLIN EXP OPTOM, V102, P601, DOI 10.1111/cxo.12894
   Reiter GS, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.11
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P1360, DOI 10.1016/j.ophtha.2020.03.031
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sakurada Y, 2019, JPN J OPHTHALMOL, V63, P374, DOI 10.1007/s10384-019-00680-9
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sasaki M, 2021, OPHTHALMOL RETINA, V5, P528, DOI 10.1016/j.oret.2020.09.001
   Sassmannshausen M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.19
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Schaal KB, 2017, OPHTHALMOLOGY, V124, P205, DOI 10.1016/j.ophtha.2016.10.009
   Schick T, 2015, INVEST OPHTH VIS SCI, V56, P7269, DOI 10.1167/iovs.15-16989
   Schmitz-Valckenberg S, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100893
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Sergouniotis PI, 2011, OPHTHALMOLOGY, V118, P1661, DOI 10.1016/j.ophtha.2010.12.031
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Simunovic MP, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.3.10
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spooner KL, 2020, OPHTHALMOLOGY, V127, P1663, DOI 10.1016/j.ophtha.2020.06.019
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Steinle NC, 2021, AM J OPHTHALMOL, V227, P116, DOI [10.1016/i.aio.2021.02.031, 10.1016/j.ajo.2021.02.031]
   Storti F, 2019, ELIFE, V8, DOI 10.7554/eLife.45100
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Tan R, 2018, INVEST OPHTH VIS SCI, V59, P4154, DOI 10.1167/iovs.18-23970
   Tan RS, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.3
   Thiele S, 2021, BRIT J OPHTHALMOL, V105, P239, DOI 10.1136/bjophthalmol-2020-316004
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Velaga SB, 2020, RETINA-J RET VIT DIS, V40, P612, DOI 10.1097/IAE.0000000000002667
   Vemala R, 2017, INVEST OPHTH VIS SCI, V58, P247, DOI 10.1167/iovs.17-21771
   Vessey KA, 2017, AM J PATHOL, V187, P1670, DOI 10.1016/j.ajpath.2017.04.016
   Viggiano P, 2022, EUR J OPHTHALMOL, V32, P460, DOI 10.1177/1120672121992009
   Vongkulsiri S, 2014, AM J OPHTHALMOL, V158, P710, DOI 10.1016/j.ajo.2014.07.009
   Wang NK, 2012, DOC OPHTHALMOL, V125, P51, DOI 10.1007/s10633-012-9336-z
   Wilde C, 2018, EYE, V32, P1130, DOI 10.1038/s41433-018-0049-8
   Wood JPM, 2011, LASER SURG MED, V43, P499, DOI 10.1002/lsm.21087
   Wu ZC, 2019, OPHTHALMOL RETINA, V3, P1026, DOI 10.1016/j.oret.2019.07.008
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P2800, DOI 10.1167/iovs.13-11613
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Xu XY, 2020, GRAEF ARCH CLIN EXP, V258, P1931, DOI 10.1007/s00417-020-04774-w
   Xu XY, 2017, AM J OPHTHALMOL, V175, P87, DOI 10.1016/j.ajo.2016.11.021
   Yang X, 2020, ELIFE, V9, DOI 10.7554/eLife.55564
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yazdanie M, 2017, OPHTHALMOLOGY, V124, P1332, DOI 10.1016/j.ophtha.2017.05.005
   Yin GN, 2009, J NEUROSCI RES, V87, P2578, DOI 10.1002/jnr.22081
   Yiu G, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.32
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Yun C, 2016, INVEST OPHTH VIS SCI, V57, P6604, DOI 10.1167/iovs.16-19989
   Zarubina AV, 2017, INVEST OPHTH VIS SCI, V58, P6038, DOI 10.1167/iovs.17-22378
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zatreanu L., 2021, AM J OPHTHALMOL CASE, V21
   Zhang QQ, 2018, QUANT IMAG MED SURG, V8, P658, DOI 10.21037/qims.2018.08.10
   Zhang YH, 2020, OPHTHALMOL RETINA, V4, P274, DOI 10.1016/j.oret.2019.10.012
   Zhang YH, 2018, RETINA-J RET VIT DIS, V38, P29, DOI 10.1097/IAE.0000000000001504
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zheng F, 2016, INVEST OPHTH VIS SCI, V57, P6256, DOI 10.1167/iovs.16-20161
   Zhou Q, 2017, ACTA OPHTHALMOL, V95, pE518, DOI 10.1111/aos.13398
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 265
TC 8
Z9 8
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAY
PY 2022
VL 88
AR 101017
DI 10.1016/j.preteyeres.2021.101017
PG 31
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1W4LD
UT WOS:000806745600003
PM 34752916
DA 2022-11-30
ER

PT J
AU Vinores, SA
AF Vinores, Stanley A.
TI Pegaptanib in the treatment of wet, age-related macular degeneration
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Review
DE age-related macular degeneration; pegaptanib; vascular endothelial
   growth factor; choroidal neovascularization; macular edema
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; APTAMER NX1838;
   VEGF; PHARMACOKINETICS; EXPRESSION; BINDING
AB Age-related macular degeneration (AMD) is a major cause of severe visual loss worldwide. Neovascular (wet) AMD accounts for 90% of the visual loss associated with the disorder and vascular endothelial growth factor (VEGF) has been shown to play a major role in neovascularization and vascular permeability, the major causes of visual loss in AMD, making it an ideal target for therapeutic intervention. To utilize this strategy, pegaptanib, an aptamer that specifically binds to and blocks VEGF(165), the VEGF isoform primarily responsible for abnormal vascular growth and permeability in AMD, was developed. Following encouraging preclinical trials, clinical trials showed that pegaptanib stabilized vision and reduced the risk of severe visual loss in the majority of patients with AMD, with some patients showing visual improvement. Pegaptanib has maintained a good safety profile with only occasional adverse effects. Even greater success was achieved when pegaptanib was used in combination with another therapeutic strategy, such as photodynamic therapy or bevacizumab, a pan isoform VEGF inhibitor. Further investigation of pegaptanib for the therapy of wet AMD, particularly in combination with other modes of therapy, should be encouraged.
C1 Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Vinores, SA (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 825 Maumenee Bldg,600 N Wolfe St, Baltimore, MD 21287 USA.
EM svinores@jhmi.edu
CR Bell C, 1999, IN VITRO CELL DEV-AN, V35, P533
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   COOK GP, 2006, 5123 ASS RES VIS OPH
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Doggrell SA, 2005, EXPERT OPIN PHARMACO, V6, P1421, DOI 10.1517/14656566.6.8.1421
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   EMERSON GG, 2006, 5242 ASS RES VIS OPH
   *EYET PHARM INC, 2005, MEDC
   Eyetech Study Group, 2002, RETINA, V22, P43
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green W R, 1999, Mol Vis, V5, P27
   Hariprasad SM, 2006, AM J OPHTHALMOL, V141, P200, DOI 10.1016/j.ajo.2005.07.053
   HUGHES MS, 2006, 5233 ASS RES VIS OPH
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   IYENGAR S, 2006, 5703 ASS RES VIS OPH
   JU M, 2006, 4175 ASS RES VIS OPH
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   LIGGETT PE, 2006, 5216 ASS RES VIS OPH
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MARTIN SD, 2006, 1437 ASS RES VIS OPH
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   PATEL M, 2006, 2623 ASS RES VIS OPH
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   SHAH AR, 2006, 2190 ASS RES VIS OPH
   Siddiqui MAA, 2005, DRUGS, V65, P1571, DOI 10.2165/00003495-200565110-00010
   STEFFENSMEIER AC, 2006, 4247 ASS RES VIS OPH
   *THOMS CENT, 2005, DRUGS APPR FDA DRUG
   TOLENTINO MJ, 2006, 5912 ASS RES VIS OPH
   Tucker CE, 1999, J CHROMATOGR B, V732, P203, DOI 10.1016/S0378-4347(99)00285-6
   UFRET RL, 2006, 5220 ASS RES VIS OPH
   VANN VR, 2006, 5241 ASS RES VIS OPH
   Vinores SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525
   Vinores SA, 2003, CURR OPIN MOL THER, V5, P673
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
NR 45
TC 65
Z9 68
U1 0
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2006
VL 1
IS 3
BP 263
EP 268
PG 6
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 246ZX
UT WOS:000252048000005
PM 17717967
DA 2022-11-30
ER

PT J
AU Brennan, M
   Horowitz, A
   Reinhardt, JP
   Stuen, C
   Rubio, R
   Oestreicher, N
AF Brennan, Mark
   Horowitz, Amy
   Reinhardt, Joann P.
   Stuen, Cynthia
   Rubio, Roman
   Oestreicher, Nina
TI The Societal Impact of Age-related Macular Degeneration: Use of Social
   Support Resources Differs by the Severity of the Impairment
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
ID DEPRESSION; REHABILITATION; QUESTIONNAIRE; DISABILITY; HEALTH; TIME
AB Objective and subjective severity of visual impairment were examined in relation to the receipt of social support over time among 384 adults with age-related macular degeneration. Both types of impairment were related to greater family support, with those with discrepant subjective and objective impairment (high and low, respectively) reporting the most instrumental support.
C1 [Brennan, Mark; Stuen, Cynthia] Lighthouse Int, New York, NY 10022 USA.
   [Horowitz, Amy] Fordham Univ, Grad Sch Social Serv, Bronx, NY 10458 USA.
   [Reinhardt, Joann P.] Jewish Home Lifecare, Res Inst Aging, New York, NY 10023 USA.
   [Reinhardt, Joann P.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, New York, NY 10025 USA.
   [Oestreicher, Nina] Genentech Inc, Global PRO Strategy, San Francisco, CA 94080 USA.
C3 Fordham University; Icahn School of Medicine at Mount Sinai; Roche
   Holding; Genentech
RP Brennan, M (通讯作者)，Lighthouse Int, 111 E 59th St, New York, NY 10022 USA.
EM mbrennan@acria.org; ahorowitz2@fordham.edu; jreinhardt@jhha.org;
   cstuen@lighthouse.org; rgrubio@gene.com; hill.nina@gene.com
CR Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Cantor M., 2000, SOCIAL CARE ELDERLY
   Cimarolli VR, 2006, J GERONTOL B-PSYCHOL, V61, pS18, DOI 10.1093/geronb/61.1.S18
   Crews JE, 2001, J VISUAL IMPAIR BLIN, V95, P453, DOI 10.1177/0145482X0109500802
   *EARL TREATM DIAB, 1980, MAN OP
   FAYE EE, 1984, CLIN LOW VISION
   Flaig KNL, 2008, EUR J AGEING, V5, P215, DOI 10.1007/s10433-008-0085-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   Horowitz A, 2003, AGING MENT HEALTH, V7, P342, DOI 10.1080/1360786031000150739
   HOROWITZ A, 1991, J GERONTOL SOC WORK, V17, P37, DOI 10.1300/J083v17n03_04
   Horowitz A., 1994, AGE RELATED VI UNPUB
   HOROWITZ A, 1996, 5 ANN INT C LOW VIS
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   *NAT EYE I, 2010, FACTS AG REL MAC DEG
   Owsley C, 2006, REHABIL PSYCHOL, V51, P23, DOI 10.1037/0090-5550.51.1.23
   PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Reinhardt JP, 1996, J GERONTOL B-PSYCHOL, V51, pP268, DOI 10.1093/geronb/51B.5.P268
   Reinhardt JP, 2003, PSYCHOL AGING, V18, P770, DOI 10.1037/0882-7974.18.4.770
   REINHARDT JP, 2001, APPL DEV SCI, V15, P76, DOI DOI 10.1207/S1532480XADS0502_3
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROSENTHAL B, 2003, OPTOMETRY, V7, P16
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Schachat AP, 2005, OPHTHALMOLOGY, V112, P531, DOI 10.1016/j.ophtha.2005.01.018
   SEDDON JF, 2000, PRINCIPLES PRACTICE, V3, P1038
   STUEN C, 1999, FAMILY INVOLVEMENT M
   Wahl HW, 2007, J GERONTOL B-PSYCHOL, V62, pP90, DOI 10.1093/geronb/62.2.P90
NR 33
TC 1
Z9 1
U1 0
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-482X
EI 1559-1476
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD JAN
PY 2011
VL 105
IS 1
BP 5
EP 19
DI 10.1177/0145482X1110500102
PG 15
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA 708HM
UT WOS:000286352900002
DA 2022-11-30
ER

PT J
AU Augustin, A
AF Augustin, Albert
TI Anecortave acetate in the treatment of age-related macular degeneration
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Review
DE age-related macular degeneration (AMD); anecortave acetate; RETAANE
   suspension; exudative AMD; progression of dry AMD
AB RETAANE (R) 15mg (anecortave acetate suspension) is under investigation to treat exudative age-related macular degeneration (AMD), the single largest cause of blindness in the Western world, affecting over 15 million people in the USA. RETAANE suspension is a unique synthetic cortisene and has antiangiogenic properties that were established in multiple experimental models of angiogenesis. The molecule acts at multiple sites of the angiogenic cascade. Clinical trials in patients with exudative AMD have demonstrated the excellent safety record of both the drug anecortave acetate and the posterior juxtascleral depot (PJD) administration procedure. A pivotal study comparing RETAANE suspension with placebo showed a significantly higher chance of maintaining vision in the treatment (73%) as compared with placebo (47%). Another study compared RETAANE suspension with Visudyne (R) photodynamic therapy, revealing no statistically significant differences between the two treatments over 24 months. AMD is a multi-faceted disease and therefore a molecule such as RETAANE suspension with a unique mechanism of action, demonstrated clinical efficacy, and retreatment every six months is an important potential treatment option which should be further investigated both as a monotherapy or in combination with other treatment strategies.
C1 Dept Ophthalmol, D-76133 Karlsruhe, Germany.
RP Augustin, A (通讯作者)，Dept Ophthalmol, Moltkestr 90, D-76133 Karlsruhe, Germany.
EM 106020.560@compuserve.com
OI Augustin, Prof. Dr. Albert J./0000-0003-1591-0536
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Augustin AJ, 2005, GRAEF ARCH CLIN EXP, V243, P9, DOI 10.1007/s00417-004-0961-4
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P1954
   BLEI F, 1993, J CELL PHYSIOL, V155, P568, DOI 10.1002/jcp.1041550315
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Clark A F, 1997, Expert Opin Investig Drugs, V6, P1867, DOI 10.1517/13543784.6.12.1867
   Clark AF, 2000, EXPERT OPIN THER PAT, V10, P427, DOI 10.1517/13543776.10.4.427
   Clark AF, 2003, NAT REV DRUG DISCOV, V2, P448, DOI 10.1038/nrd1106
   Clark AF, 1999, INVEST OPHTH VIS SCI, V40, P2158
   Clark AF, 2003, E COMMUNICATION
   CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056
   DEFALLER JM, 2000, PTERYGIUM, P159
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Liu C, 2005, INVEST OPHTHALMOL VI
   McNatt LG, 1999, J OCUL PHARMACOL TH, V15, P413, DOI 10.1089/jop.1999.15.413
   Newsome DA, 1998, ARCH OPHTHALMOL-CHIC, V106, P192
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Regillo CD, 2005, INVEST OPHTHALMOL VI
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Slakter JS, 2005, INVEST OPHTHALMOL VI
   SWANN PG, 1990, OPHTHAL PHYSL OPT, V10, P149, DOI 10.1111/j.1475-1313.1990.tb00969.x
   Taylor HR, 1990, T AM OPHTHAL SOC, V88, P173
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Yang R, 2005, INVEST OPHTHALMOL VI
NR 33
TC 6
Z9 6
U1 0
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2006
VL 1
IS 3
BP 237
EP 246
DI 10.2147/ciia.2006.1.3.237
PG 10
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA V21WQ
UT WOS:000208238100006
PM 18046876
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Keane, PA
   Patel, PJ
   Liakopoulos, S
   Heussen, FM
   Sadda, SR
   Tufail, A
AF Keane, Pearse A.
   Patel, Praveen J.
   Liakopoulos, Sandra
   Heussen, Florian M.
   Sadda, Srinivas R.
   Tufail, Adnan
TI Evaluation of Age-related Macular Degeneration With Optical Coherence
   Tomography
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization; cystoid
   macular edema; drusen; geographic atrophy; optical coherence tomography;
   pigment epithelium detachment; polypoidal choroidal vasculopathy;
   retinal angiomatous proliferation; subretinal fluid
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL-PIGMENT EPITHELIUM;
   SUBRETINAL DRUSENOID DEPOSITS; INDOCYANINE GREEN ANGIOGRAPHY;
   GROWTH-FACTOR THERAPY; POSTERIOR VITREOMACULAR ADHESION; CENTRAL SEROUS
   CHORIORETINOPATHY; BASAL LAMINAR DRUSEN; GEOGRAPHIC ATROPHY;
   HIGH-RESOLUTION
AB Age-related macular degeneration (AMD) is the leading cause of severe visual loss in people aged 50 years or older in the developed world. In recent years, major advances have been made in the treatment of AMD, with the introduction of anti-angiogenic agents, offering the first hope of significant visual recovery for patients with neovascular AMD. In line with these advances, a new imaging modality-optical coherence tomography (OCT)-has emerged as an essential adjunct for the diagnosis and monitoring of patients with AMD. The ability to accurately interpret OCT images is thus a prerequisite for both retina specialists and comprehensive ophthalmologists. Despite this, the relatively recent introduction of OCT and the absence of formal training, coupled with rapid evolution of the technology, may make such interpretation difficult. These problems are compounded by the phenotypically heterogeneous nature of AMD and its complex morphology as visualized using OCT. We address these issues by summarizing the current understanding of OCT image interpretation in patients with AMD and describe how OCT can best be applied in clinical practice. (Surv Ophthalmol 57:389-414, 2012. (C) 2012 Elsevier Inc. All rights reserved.)
C1 [Keane, Pearse A.; Patel, Praveen J.; Tufail, Adnan] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London EC1V 2PD, England.
   [Keane, Pearse A.; Patel, Praveen J.; Tufail, Adnan] UCL Inst Ophthalmol, London EC1V 2PD, England.
   [Keane, Pearse A.; Heussen, Florian M.; Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Liakopoulos, Sandra] Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, Cologne, Germany.
   [Liakopoulos, Sandra] Univ Cologne, Cologne Image Reading Ctr & Lab, Cologne, Germany.
   [Heussen, Florian M.] Charite, Dept Ophthalmol, D-13353 Berlin, Germany.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Doheny Eye Institute; University of Southern California; University of
   Cologne; University of Cologne; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin
RP Keane, PA (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London EC1V 2PD, England.
EM pearsek@gmail.com
RI Keane, Pearse/AAE-5709-2019
OI Keane, Pearse/0000-0002-9239-745X; Tufail, Adnan/0000-0001-6131-7640;
   Heussen, Florian Moritz/0000-0003-0536-9870
FU Academy of Medical Sciences (AMS) [AMS-SGCL6-Keane] Funding Source:
   researchfish; National Institute for Health Research [CL-2010-18-004]
   Funding Source: researchfish; Department of Health [1286] Funding
   Source: Medline
CR Abe Sachi, 2010, Ophthalmic Surg Lasers Imaging, P1, DOI 10.3928/15428877-20100215-76
   Ahlers C, 2008, BRIT J OPHTHALMOL, V92, P197, DOI 10.1136/bjo.2007.120956
   Ahlers C, 2005, EUR J OPHTHALMOL, V15, P774, DOI 10.1177/112067210501500619
   Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Ahlers C, 2009, INVEST OPHTH VIS SCI, V50, P3417, DOI 10.1167/iovs.08-2759
   Aisenbrey S, 2007, BRIT J OPHTHALMOL, V91, P1027, DOI 10.1136/bjo.2006.108118
   Alders C, 2008, OPHTHALMOLOGY, V115, pc39
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Amoaku W, 2009, EYE, V23, P2140, DOI 10.1038/eye.2008.241
   Amoaku WMK, 2008, EYE, V22, P864, DOI 10.1038/eye.2008.1
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Binder S, 2007, BRIT J OPHTHALMOL, V91, P990, DOI 10.1136/bjo.2007.114009
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bloom SM, 2011, RETINA-J RET VIT DIS, V31, P316, DOI 10.1097/IAE.0b013e3181ed8c9a
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Brar M, 2009, BRIT J OPHTHALMOL, V93, P597, DOI 10.1136/bjo.2008.146233
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRESSLER NM, 1991, ARCH OPHTHALMOL-CHIC, V109, P211, DOI 10.1001/archopht.1991.01080020057043
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2008, AM J OPHTHALMOL, V146, P121, DOI 10.1016/j.ajo.2008.03.001
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Choma MA, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1961474
   Choma MA, 2003, OPT EXPRESS, V11, P2183, DOI 10.1364/OE.11.002183
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Costa RA, 2005, AM J OPHTHALMOL, V140, P107, DOI 10.1016/j.ajo.2005.02.042
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Eriksson U, 2011, ACTA OPHTHALMOL
   Esmaeelpour M, 2010, INVEST OPHTH VIS SCI, V51, P5260, DOI 10.1167/iovs.10-5196
   Ferguson RD, 2004, OPT LETT, V29, P2139, DOI 10.1364/OL.29.002139
   Fernandez EJ, 2008, OPT EXPRESS, V16, P11083, DOI 10.1364/OE.16.011083
   Figueroa MS, 2008, BRIT J OPHTHALMOL, V92, P1244, DOI 10.1136/bjo.2008.144196
   Finger RP, 2010, RETINA-J RET VIT DIS, V30, P1455, DOI 10.1097/IAE.0b013e3181e09829
   Fleckenstein M, 2010, OPHTHALMOLOGE, V107, P1007, DOI 10.1007/s00347-010-2159-y
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Framme C, 2012, ACTA OPHTHALMOL, V90, P49, DOI 10.1111/j.1755-3768.2010.01940.x
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Freund KB, 2011, RETINA, V30, P1333
   Fujimoto JG., 2004, OPTICAL COHERENCE TO, V2nd
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gass J D, 1974, Trans Am Ophthalmol Soc, V72, P139
   Gass JD., 1997, STEREOSCOPIC ATLAS M, V1
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   Ghazi NG, 2009, AM J OPHTHALMOL, V148, P90, DOI 10.1016/j.ajo.2009.02.017
   Giani A, 2011, RETINA-J RET VIT DIS, V31, P942, DOI 10.1097/IAE.0b013e31820a68cc
   Giani A, 2010, RETINA-J RET VIT DIS, V30, P607, DOI 10.1097/IAE.0b013e3181c2e09d
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Gloesmann M, 2003, INVEST OPHTH VIS SCI, V44, P1696, DOI 10.1167/iovs.02-0654
   Gorczynska I, 2009, BRIT J OPHTHALMOL, V93, P603, DOI 10.1136/bjo.2007.136101
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1971, ARCH OPHTHALMOL-CHIC, V86, P487, DOI 10.1001/archopht.1971.01000010489001
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   GREENLEE WF, 1991, RISK ANAL, V11, P565, DOI 10.1111/j.1539-6924.1991.tb00642.x
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hamel CP, 2009, AM J OPHTHALMOL, V147, P609, DOI 10.1016/j.ajo.2008.10.022
   Han IC, 2010, OPHTHALMOLOGY, V117, P1177, DOI 10.1016/j.ophtha.2009.10.029
   Harding SP, 2010, EYE, V24, P497, DOI 10.1038/eye.2009.316
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Hee MR, 1998, OPHTHALMOLOGY, V105, P360, DOI 10.1016/S0161-6420(98)93601-6
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Iida T, 2003, RETINA-J RET VIT DIS, V23, P1, DOI 10.1097/00006982-200302000-00001
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Imamura Y, 2011, AM J OPHTHALMOL, V151, P297, DOI 10.1016/j.ajo.2010.08.014
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Ip LPS, 2004, P ANN INT IEEE EMBS, V26, P1505
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Jun JJ, 2010, RETINA-J RET VIT DIS, V30, P917, DOI 10.1097/IAE.0b013e3181cbd9e5
   Jutley G, 2011, EYE, V25, P675, DOI 10.1038/eye.2011.24
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Karam EZ, 2007, BRIT J OPHTHALMOL, V91, P1139, DOI 10.1136/bjo.2007.114074
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Keane P, 2008, SAUDI J OPHTHALMOL, V22, P231
   Keane PA, 2008, BRIT J OPHTHALMOL, V92, P1081, DOI 10.1136/bjo.2008.138891
   Keane PA, 2010, EYE, V24, P422, DOI 10.1038/eye.2009.309
   Keane PA, 2009, BRIT J OPHTHALMOL, V93, P1461, DOI 10.1136/bjo.2008.155846
   Keane PA, 2009, BRIT J OPHTHALMOL, V93, P274, DOI 10.1136/bjo.2008.148163
   Keane Pearse A, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS85, DOI 10.3928/15428877-20101031-10
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Keane Pearse A, 2009, Int Ophthalmol Clin, V49, P61, DOI 10.1097/IIO.0b013e31819fd54f
   Keane PA, 2009, AM J OPHTHALMOL, V148, P242, DOI 10.1016/j.ajo.2009.03.004
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Keane PA, 2009, RETINA-J RET VIT DIS, V29, P592, DOI 10.1097/IAE.0b013e31819b17a5
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kerbs I, 2009, OPHTHAL SURG LAS IM, V40, P285, DOI [10.9999/15428877-20090430-10, 10.3928/15428877-20090430-10]
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Kiernan DF, 2010, AM J OPHTHALMOL, V149, P18, DOI 10.1016/j.ajo.2009.08.037
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Koizumi H, 2008, AM J OPHTHALMOL, V145, P509, DOI 10.1016/j.ajo.2007.10.014
   Kramer M, 2000, AM J OPHTHALMOL, V129, P495, DOI 10.1016/S0002-9394(99)00388-8
   Krebs I, 2008, BRIT J OPHTHALMOL, V92, P933, DOI 10.1136/bjo.2007.128447
   Krebs I, 2008, GRAEF ARCH CLIN EXP, V246, P811, DOI 10.1007/s00417-007-0755-6
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1552, DOI 10.1136/bjo.2010.194670
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1415, DOI 10.1136/bjo.2010.192385
   Krebs I, 2009, INVEST OPHTH VIS SCI, V50, P995, DOI 10.1167/iovs.08-2617
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Landa G, RETINA, V31, P364
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Legarreta JE, 2008, AM J OPHTHALMOL, V145, P1023, DOI 10.1016/j.ajo.2008.01.014
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Leng T, 2009, RETINA-J RET VIT DIS, V29, P988, DOI 10.1097/IAE.0b013e3181ae7113
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V115, P347
   Lima LH, 2010, RETINA-J RET VIT DIS, V30, P542, DOI 10.1097/IAE.0b013e3181c713e4
   LOPEZ PF, 1992, RETINA-J RET VIT DIS, V12, P147, DOI 10.1097/00006982-199212020-00012
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Lumbroso B, 2011, RETINA-J RET VIT DIS, V31, P553, DOI 10.1097/IAE.0b013e3181eef3eb
   Malamos P, 2011, RETINA-J RET VIT DIS, V31, P453, DOI 10.1097/IAE.0b013e3181eef031
   Malamos P, 2009, INVEST OPHTH VIS SCI, V50, P4926, DOI 10.1167/iovs.09-3610
   Mantel I, 2009, AM J OPHTHALMOL, V148, P932, DOI 10.1016/j.ajo.2009.06.032
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P510, DOI 10.1097/IAE.0b013e3181eef053
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   MENARD C, 1992, J FR OPHTALMOL, V15, P497
   Michels S, 2008, BRIT J OPHTHALMOL, V92, P204, DOI 10.1136/bjo.2007.130047
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mirza RG, 2007, SURV OPHTHALMOL, V52, P397, DOI 10.1016/j.survophthal.2007.04.007
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Miura M, 2008, INVEST OPHTH VIS SCI, V49, P2661, DOI 10.1167/iovs.07-0501
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Monson DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1664, DOI 10.1001/archopht.126.12.1664
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Mujat M, 2010, OPT EXPRESS, V18, P11607, DOI 10.1364/OE.18.011607
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   NOVOTNY HR, 1961, CIRCULATION, V24, P82, DOI 10.1161/01.CIR.24.1.82
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Otani T, 2011, RETINA-J RET VIT DIS, V31, P497, DOI 10.1097/IAE.0b013e3181ed8dae
   Otsuji T, 2000, OPHTHALMIC SURG LAS, V31, P210
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Park SS, 2010, INVEST OPHTH VIS SCI, V51, P4200, DOI 10.1167/iovs.09-4256
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P5405, DOI 10.1167/iovs.09-3505
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P399, DOI 10.1167/iovs.08-1697
   Pece A, 2010, OPHTHALMOLOGICA, V224, P159, DOI 10.1159/000236910
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Povazay B., 2008, INVEST OPHTH VIS SCI, V50, P1856
   Querques G, 2011, OPHTHALMIC RES, V46, P152, DOI 10.1159/000325027
   Querques G, 2010, RETINA-J RET VIT DIS, V30, P222, DOI 10.1097/IAE.0b013e3181bceef0
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Reichel E, 1995, OPHTHALMOLOGY, V102, P1871, DOI 10.1016/S0161-6420(95)30781-6
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rotsos T, 2010, BRIT J OPHTHALMOL, V94, P1205, DOI 10.1136/bjo.2009.173765
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   Sadda SR, 2010, GRAEF ARCH CLIN EXP, V248, P175, DOI 10.1007/s00417-009-1193-4
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sakamoto A, 2008, OPHTHALMOLOGY, V115, P1071, DOI 10.1016/j.ophtha.2007.09.001
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Schlanitz FG, 2010, INVEST OPHTH VIS SCI, V51, P6715, DOI 10.1167/iovs.10-5288
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Schutze C, 2011, ACTA OPHTHALMOL, V89, P235, DOI 10.1111/j.1755-3768.2010.01955.x
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Shah AR, 2009, OPHTHALMOLOGY, V116, P1901, DOI 10.1016/j.ophtha.2009.03.055
   Shields CL, 2009, OPHTHALMOLOGY, V116, P529, DOI 10.1016/j.ophtha.2008.10.015
   Sikorski BL, 2011, OPHTHALMOLOGY, V118, P82, DOI 10.1016/j.ophtha.2010.04.017
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P1571, DOI 10.1167/iovs.07-0838
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sunness JS, 1999, MOL VIS, V5
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Truong SN, 2007, RETINA-J RET VIT DIS, V27, P915, DOI 10.1097/IAE.0b013e31805468fd
   Tsui I, 2009, SEMIN OPHTHALMOL, V24, P25, DOI 10.1080/08820530802520178
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang Y, 2009, BRIT J OPHTHALMOL, V93, P634, DOI 10.1136/bjo.2008.150276
   Wang YM, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2772871
   Wang YM, 2011, INVEST OPHTH VIS SCI, V52, P840, DOI 10.1167/iovs.10-5985
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yamaguchi Y, 2007, AM J OPHTHALMOL, V144, P260, DOI 10.1016/j.ajo.2007.04.007
   Yannuzzi LA, 2004, AM J OPHTHALMOL, V137, P511, DOI 10.1016/j.ajo.2003.12.035
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yasuno Y, 2009, INVEST OPHTH VIS SCI, V50, P405, DOI 10.1167/iovs.08-2272
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Yehoshua Zohar, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS6, DOI 10.3928/15428877-20101031-19
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zarbin MA, 2011, RETINA, V30, P1350
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P229, DOI 10.1097/IAE.0b013e3181f049bd
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 261
TC 169
Z9 173
U1 3
U2 43
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD SEP-OCT
PY 2012
VL 57
IS 5
BP 389
EP 414
DI 10.1016/j.survophthal.2012.01.006
PG 26
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 994DF
UT WOS:000307910400001
PM 22898648
DA 2022-11-30
ER

PT J
AU Demirci, S
   Gunes, A
   Demirci, K
   Demirci, S
   Tok, L
   Tok, O
AF Demirci, Seden
   Gunes, Alime
   Demirci, Kadir
   Demirci, Serpil
   Tok, Levent
   Tok, Ozlem
TI Is Alzheimer disease related to age-related macular degeneration?
SO TURKISH JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Alzheimer disease; dementia; age-related macular degeneration; cognitive
   impairment
ID COGNITIVE IMPAIRMENT; VISUAL IMPAIRMENT; DEMENTIA; PREVALENCE;
   MACULOPATHY; DYSFUNCTION; POPULATION; ROTTERDAM; SCALE; RISK
AB Background/aim: To compare the cognitive functions and define the frequency of Alzheimer disease (AD) between participants with and without age-related macular degeneration (AMD).
   Materials and methods: Fifty-nine patients with late-stage AMD (74.3 +/- 7.3 years) and 49 age-, sex-, and education-matched control subjects were compared for the presence of AD according to the guidelines of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA). Detailed neuropsychological tests were performed for all subjects.
   Results: Neuropsychiatric tests scores were lower in the AMD group than the control group. The frequency of AD was higher in patients with AMD (40.7% in AMD and 20.4% in control group, P = 0.03), and particularly higher in late dry (nonvascular) AMD (d-AMD) patients (71.4% in d-AMD and 31.1% in late wet (vascular) AMD, P = 0.007). d-AMD patients performed worse than controls on all tests. There was also an association between age, sex, and low education and neuropsychiatric tests scores (P < 0.01). However, there was no association between visual acuity and neuropsychiatric tests scores.
   Conclusion: The increased frequency of AD in patients with AMD is significant. This study demonstrated the importance of cognitive assessment in patients with AMD, particularly in the d-AMD type.
C1 [Demirci, Seden; Demirci, Serpil] Suleyman Demirel Univ, Fac Med, Dept Neurol, TR-32200 Isparta, Turkey.
   [Gunes, Alime; Tok, Levent; Tok, Ozlem] Suleyman Demirel Univ, Fac Med, Dept Ophthalmol, TR-32200 Isparta, Turkey.
   [Demirci, Kadir] Suleyman Demirel Univ, Fac Med, Dept Psychiat, TR-32200 Isparta, Turkey.
C3 Suleyman Demirel University; Suleyman Demirel University; Suleyman
   Demirel University
RP Demirci, S (通讯作者)，Suleyman Demirel Univ, Fac Med, Dept Neurol, TR-32200 Isparta, Turkey.
EM sdndemirci@yahoo.com.tr
RI Demirci, Serpil/A-8223-2012; Demirci, Serpil/N-4638-2019
OI Demirci, Serpil/0000-0003-1561-1296; Demirci, Serpil/0000-0003-1561-1296
CR Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3
   Huang YD, 2012, CELL, V148, P1204, DOI 10.1016/j.cell.2012.02.040
   Jackson GR, 2003, NEUROL CLIN, V21, P709, DOI 10.1016/S0733-8619(02)00107-X
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   Morris JC, 1996, NEUROLOGY, V46, P707, DOI 10.1212/WNL.46.3.707
   MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457
   Ott A, 1998, LANCET, V351, P1840, DOI 10.1016/S0140-6736(97)07541-7
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007
   Reyes-Ortiz CA, 2005, J AM GERIATR SOC, V53, P681, DOI 10.1111/j.1532-5415.2005.53219.x
   Roca-Santiago H.M., 2006, Arch Soc Esp Oftalmol, V81, P73
   Rozzini L, 2014, AM J ALZHEIMERS DIS, V29, P256, DOI 10.1177/1533317513517032
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223
   Whitson HE, 2007, J AM GERIATR SOC, V55, P885, DOI 10.1111/j.1532-5415.2007.01093.x
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4
NR 28
TC 10
Z9 10
U1 0
U2 2
PU TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, ANKARA, 00000, TURKEY
SN 1300-0144
EI 1303-6165
J9 TURK J MED SCI
JI Turk. J. Med. Sci.
PY 2015
VL 45
IS 5
SI SI
BP 1115
EP 1121
DI 10.3906/sag-1406-135
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CT0ZI
UT WOS:000362526300021
PM 26738356
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Michalewska, Z
   Nawrocki, J
AF Michalewska, Zofia
   Nawrocki, Jerzy
TI Vitrectomy with the inverted internal limiting membrane flap technique
   in eyes with full-thickness macular hole and dry age-related macular
   degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Inverted internal limiting membrane flap; macular hole; age-related
   macular degeneration; drusen
ID CHOROIDAL NEOVASCULARIZATION; RETINAL-DETACHMENT; SURGICAL REPAIR; SOFT
   DRUSEN; SURGERY; DISAPPEARANCE; OUTCOMES
AB Purpose
   To present effects of the inverted internal limiting membrane flap technique in full-thickness macular holes coexisting with dry age-related macular degeneration.
   Methods
   Our database was retrospectively reviewed in order to spot patients with the simultaneous diagnosis of dry age-related macular degeneration and full-thickness macular hole. Vitrectomy with the inverted internal limiting membrane flap technique was performed. Inclusion criteria were full-thickness macular hole, drusen, vitrectomy performed, and spectral domain optical coherence tomography (Copernicus HR, Optopol, Poland) or swept source optical coherence tomography (Triton, Topcon, Japan) before surgery, then 1 week (+/- 3 days), 1 month (+/- 1 week), 3 months (+/- 1 month), 6 months (+/- 1 month), 12 months (+/- 2 months), and 18 months to 12 years after surgery.
   Main outcome measures
   Closure of macular hole and visual acuity at the final control.
   Results
   A total of 18 eyes of 12 patients (mean age: 68 years) were included. Mean minimum macular hole diameter was 493 mu m. Mean maximum macular hole diameter was 1072 mu m. Macular hole was closed in 16 eyes after first surgery and in all eyes after second surgery. Improvement of visual acuity was statistically significant (P = 0.05), but there was no statistical significant correlation observed between initial macular hole diameters and final visual acuity (P > 0.1).
   Conclusion
   The inverted internal limiting membrane flap technique improves anatomical and functional results in eyes with coexisting dry age-related macular degeneration and full-thickness macular holes. Final development of choroidal neovascularization or geographic atrophy is possible in rare cases.
C1 [Michalewska, Zofia; Nawrocki, Jerzy] Ophthalm Clin Jasne Blonia, Rojna 90, PL-91162 Lodz, Poland.
RP Michalewska, Z (通讯作者)，Ophthalm Clin Jasne Blonia, Rojna 90, PL-91162 Lodz, Poland.
EM zosia_n@yahoo.com
OI Nawrocka, Zofia Anna/0000-0001-8376-9218
CR Baba R, 2017, RETINA-J RET VIT DIS, V37, P466, DOI 10.1097/IAE.0000000000001211
   Banker AS, 1997, OPHTHALMOLOGY, V104, P1442, DOI 10.1016/S0161-6420(97)30118-3
   Berinstein DM, 2000, OPHTHALMOLOGY, V107, P2233, DOI 10.1016/S0161-6420(00)00417-6
   Chaudhry NA, 2000, ARCH OPHTHALMOL-CHIC, V118, P131
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Ho TC, 2018, ACTA OPHTHALMOL, V96, pE46, DOI 10.1111/aos.13514
   Holz FG, 2001, RETINA-J RET VIT DIS, V21, P184, DOI 10.1097/00006982-200104000-00018
   Ismail OM, 2019, J VITREORETIN DIS, V3, P94
   Kinoshita T, 2017, GRAEF ARCH CLIN EXP, V255, P1101, DOI 10.1007/s00417-017-3614-0
   Lee JH, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0029-8
   Lehmann F, 2015, OPHTHALMOLOGE, V112, P424, DOI 10.1007/s00347-013-3007-7
   Li GY, 2017, APPL NURS RES, V38, P95, DOI 10.1016/j.apnr.2017.09.016
   Mete M, 2017, RETINA-J RET VIT DIS, V37, P1923, DOI 10.1097/IAE.0000000000001446
   Meuer SM, 2015, OPHTHALMOLOGY, V122, P787, DOI 10.1016/j.ophtha.2014.10.014
   Michalewska Z, 2015, RETINA-J RET VIT DIS, V35, P1844, DOI 10.1097/IAE.0000000000000555
   Michalewska Z, 2014, RETINA-J RET VIT DIS, V34, P664, DOI 10.1097/IAE.0000000000000042
   Michalewska Z, 2010, OPHTHALMOLOGY, V117, P2018, DOI 10.1016/j.ophtha.2010.02.011
   Michalewska Z, 2010, GRAEF ARCH CLIN EXP, V248, P1249, DOI 10.1007/s00417-010-1370-5
   Oh HN, 2012, CLIN OPHTHALMOL, V6, P1287, DOI 10.2147/OPTH.S33650
   Sasaki H, 2017, EYE, V31, P545, DOI 10.1038/eye.2016.263
   Tabandeh H, 2004, RETINA-J RET VIT DIS, V24, P714, DOI 10.1097/00006982-200410000-00005
   WENDEL RT, 1993, OPHTHALMOLOGY, V100, P1671
NR 22
TC 3
Z9 3
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY
PY 2021
VL 31
IS 3
BP 1320
EP 1325
AR 1120672120921376
DI 10.1177/1120672120921376
EA APR 2020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TZ2CF
UT WOS:000533923200001
PM 32345051
DA 2022-11-30
ER

PT J
AU Kamata, K
   Otsuka, Y
   Imamura, K
   Oishi, A
   Kondo, T
   Suga, M
   Shibukawa, R
   Okanishi, Y
   Sagara, Y
   Tsukita, K
   Yasukawa, T
   Usui, H
   Muguruma, K
   Tsujikawa, A
   Inoue, H
AF Kamata, Kazuma
   Otsuka, Yuki
   Imamura, Keiko
   Oishi, Akio
   Kondo, Takayuki
   Suga, Mika
   Shibukawa, Ran
   Okanishi, Yasue
   Sagara, Yukako
   Tsukita, Kayko
   Yasukawa, Tsutomu
   Usui, Hideaki
   Muguruma, Keiko
   Tsujikawa, Akitaka
   Inoue, Haruhisa
TI Generation of a human induced pluripotent stem cell line, BRCi004-A,
   derived from a patient with age -related macular degeneration
SO STEM CELL RESEARCH
LA English
DT Article
AB Age - related macular degeneration (AMD) is a late -onset progressive blinding disease. We established human induced pluripotent stem cells (iPSCs) from an AMD patient. The generated iPSC line showed pluripotency markers and three -germ layer di fferentiation ability in vitro . This iPSC line will be useful for elucidating the pathomechanisms of and drug discovery for AMD.
C1 [Kamata, Kazuma; Otsuka, Yuki; Imamura, Keiko; Kondo, Takayuki; Suga, Mika; Shibukawa, Ran; Okanishi, Yasue; Sagara, Yukako; Tsukita, Kayko; Inoue, Haruhisa] RIKEN BioResource Res Ctr, IPSC Based Drug Discovery & Dev Team, Kyoto, Japan.
   [Otsuka, Yuki; Oishi, Akio; Tsujikawa, Akitaka; Inoue, Haruhisa] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto, Japan.
   [Otsuka, Yuki; Imamura, Keiko; Kondo, Takayuki; Suga, Mika; Shibukawa, Ran; Tsukita, Kayko; Inoue, Haruhisa] Kyoto Univ, Ctr iPS Cell Res & Applicat CiRA, Kyoto, Japan.
   [Imamura, Keiko; Kondo, Takayuki] RIKEN Ctr Adv Intelligence Project AIP, Med Risk Avoidance Based iPS Cells Team, Kyoto 6068507, Japan.
   [Yasukawa, Tsutomu; Usui, Hideaki] Nagoya City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med Sci, Nagoya, Aichi, Japan.
   [Muguruma, Keiko] RIKEN Ctr Dev Biol, Lab Cell Asymmetry, Kobe, Hyogo 6500047, Japan.
   [Muguruma, Keiko] Kansai Med Univ, Grad Sch Med, Dept iPS Cell Appl Med, Hirakata, Osaka 5731010, Japan.
C3 RIKEN; Kyoto University; Kyoto University; RIKEN; Nagoya City
   University; RIKEN; Kansai Medical University
RP Inoue, H (通讯作者)，RIKEN BioResource Res Ctr, IPSC Based Drug Discovery & Dev Team, Kyoto, Japan.; Inoue, H (通讯作者)，Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto, Japan.; Inoue, H (通讯作者)，Kyoto Univ, Ctr iPS Cell Res & Applicat CiRA, Kyoto, Japan.
EM haruhisa.inoue@riken.jp
RI Oishi, Akio/AAE-9996-2020
OI Oishi, Akio/0000-0002-0977-9458; Tsujikawa, Akitaka/0000-0003-0779-7799;
   Inoue, Haruhisa/0000-0003-4736-9537
FU Core Center for iPS Cell Research of Research Center Network for
   Realization of Regenerative Medicine of the Japan Agency for Medical
   Research and Development (AMED)
FX This research was supported in part by grants from the Core Center for
   iPS Cell Research of Research Center Network for Realization of
   Regenerative Medicine of the Japan Agency for Medical Research and
   Development (AMED) to H.I. There is no financial relationship to the
   work presented in this manuscript. We would like to express our sincere
   gratitude to all of our coworkers and collaborators and to Makiko Yasui
   and Mikie Iijima for their administrative support.
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   DeAngelis M.M., 2017, HUM MOL GENET, V8, P45
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1873-5061
EI 1876-7753
J9 STEM CELL RES
JI Stem Cell Res.
PD MAY
PY 2020
VL 45
AR 101787
DI 10.1016/j.scr.2020.101787
PG 4
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology
GA MG3AR
UT WOS:000545907500019
PM 32416577
OA gold
DA 2022-11-30
ER

PT J
AU Thi, HCT
   Guyader, N
   Guerin, A
   Despretz, P
   Boucart, M
AF Thi Ha Chau Tran
   Guyader, Nathalie
   Guerin, Anne
   Despretz, Pascal
   Boucart, Muriel
TI Figure Ground Discrimination in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OBJECT RECOGNITION; FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; READING
   SPEED; VISION; CONSISTENCY; CONTOURS; CONTEXT
AB PURPOSE. To investigate impairment in discriminating a figure from its background and to study its relation to visual acuity and lesion size in patients with neovascular age-related macular degeneration (AMD).
   METHODS. Seventeen patients with neovascular AMD and visual acuity < 20/50 were included. Seventeen age-matched healthy subjects participated as controls. Complete ophthalmologic examination was performed on all participants. The stimuli were photographs of scenes containing animals (targets) or other objects (distractors), displayed on a computer monitor screen. Performance was compared in four background conditions: the target in the natural scene; the target isolated on a white background; the target separated by a white space from a structured scene; the target separated by a white space front a nonstructured, shapeless background. Target discriminability (d') was recorded.
   RESULTS. Performance was lower for patients than for controls. For the patients, it was easier to detect the target when it was separated from its background (under isolated, structured, and nonstructured conditions) than it was when located in a scene. Performance was improved in patients with increasing exposure time but remained lower in controls. Correlations were found between visual acuity, lesion size, and sensitivity for patients.
   CONCLUSIONS. Figure/ground segregation is impaired in patients with AMD. A white space surrounding an object is sufficient to improve the object's detection and to facilitate figure/ground segregation. These results may have practical applications to the rehabilitation of the environment in patients with AMD. (Invest Ophthalmol Vis Set 201152:1655-1660) DOI: 10.1167/iovs.10-6003
C1 [Thi Ha Chau Tran; Despretz, Pascal; Boucart, Muriel] Univ Lille Nord France, CNRS, Lab Neurosci Fonct & Pathol, Lille, France.
   [Thi Ha Chau Tran] Univ Nord France, Hop St Vincent de Paul, Serv Ophtalmol, Lille, France.
   [Guyader, Nathalie; Guerin, Anne] Inst Natl Polytech Grenoble, CNRS, GIPSA Lab, F-38031 Grenoble, France.
C3 Centre National de la Recherche Scientifique (CNRS); Universite de Lille
   - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de
   Lille; UDICE-French Research Universities; Communaute Universite
   Grenoble Alpes; Institut National Polytechnique de Grenoble; Universite
   Grenoble Alpes (UGA); Centre National de la Recherche Scientifique
   (CNRS)
RP Boucart, M (通讯作者)，Hop Roger Salengro, CHRU Lille, Lab Neurosci & Pathol Fonct, F-59037 Lille, France.
EM m-boucart@chru-lille.fr
RI TRAN, Thi Ha Chau/AAF-2162-2020
OI TRAN, Thi Ha Chau/0000-0001-9066-7092
FU Centre National de la Recherche Scientifique
FX Supported by "Programe Interdisciplinaire longevite-vieillissement" from
   the Centre National de la Recherche Scientifique (NG, AG, MB).
CR BIEDERMA.I, 1972, SCIENCE, V177, P77, DOI 10.1126/science.177.4043.77
   Boucart M, 2008, VISUAL NEUROSCI, V25, P685, DOI 10.1017/S0952523808080826
   BOUMA H, 1970, NATURE, V226, P177, DOI 10.1038/226177a0
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Calabrese A, 2010, INVEST OPHTH VIS SCI, V51, P1247, DOI 10.1167/iovs.09-3682
   Chung STL, 2008, OPTOMETRY VISION SCI, V85, P827, DOI 10.1097/OPX.0b013e31818527ea
   Davenport JL, 2004, PSYCHOL SCI, V15, P559, DOI 10.1111/j.0956-7976.2004.00719.x
   Davenport JL, 2007, MEM COGNITION, V35, P393, DOI 10.3758/BF03193280
   DEGRAEF P, 1990, PSYCHOL RES-PSYCH FO, V52, P317, DOI 10.1007/BF00868064
   EBERT EM, 1986, ARCH OPHTHALMOL-CHIC, V104, P1009
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Joubert OR, 2008, J VISION, V8, DOI 10.1167/8.13.11
   Joubert OR, 2009, J VISION, V9, DOI 10.1167/9.1.2
   Leat SJ, 1999, INVEST OPHTH VIS SCI, V40, P504
   Levi DM, 2008, VISION RES, V48, P635, DOI 10.1016/j.visres.2007.12.009
   Levi DM, 2007, VISION RES, V47, P1833, DOI 10.1016/j.visres.2007.03.005
   Livne T, 2007, J VISION, V7, DOI 10.1167/7.2.4
   MacMillan N. A., 1991, DETECTION THEORY USE
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mendola JD, 1999, J NEUROSCI, V19, P8560
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   Pelli DG, 2004, J VISION, V4, P1136, DOI 10.1167/4.12.12
   Portilla J, 2000, INT J COMPUT VISION, V40, P49, DOI 10.1023/A:1026553619983
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Stanley DA, 2003, NEURON, V37, P323, DOI 10.1016/S0896-6273(02)01148-0
   TANNER WP, 1954, PSYCHOL REV, V61, P401, DOI 10.1037/h0058700
   WURM LH, 1993, J EXP PSYCHOL HUMAN, V19, P899, DOI 10.1037/0096-1523.19.4.899
NR 27
TC 12
Z9 13
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2011
VL 52
IS 3
BP 1655
EP 1660
DI 10.1167/iovs.10-6003
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 742SR
UT WOS:000288965300055
PM 21087956
DA 2022-11-30
ER

PT J
AU Chatard, H
   Tepenier, L
   Jankowski, O
   Aussems, A
   Allieta, A
   Beydoun, T
   Salah, S
   Bucci, MP
AF Chatard, Hortense
   Tepenier, Laure
   Jankowski, Olivier
   Aussems, Antoine
   Allieta, Alain
   Beydoun, Talal
   Salah, Sawsen
   Bucci, Maria P.
TI Effects of Age-Related Macular Degeneration on Postural Sway
SO FRONTIERS IN HUMAN NEUROSCIENCE
LA English
DT Article
DE age-related macular degeneration; postural sway; elderly; visual
   condition; balance
ID PERIPHERAL-VISION; VISUAL IMPAIRMENT; OLDER-ADULTS; PREVALENCE;
   ASSOCIATION; MACULOPATHY; INFORMATION; DISABILITY; PARAMETERS; STABILITY
AB Purpose: To compare the impact of unilateral vs. bilateral age-related macular degeneration (AMD) on postural sway, and the influence of different visual conditions. The hypothesis of our study was that the impact of AMD will be different between unilateral and bilateral AMD subjects compared to age-matched healthy elderly.
   Methods: Postural stability was measured with a platform (TechnoConcept (R)) in 10 elderly unilateral AMD subjects (mean age: 71.1 +/- 4.6 years), 10 elderly bilateral AMD subjects (mean age: 70.8 +/- 6.1 years), and 10 healthy age-matched control subjects (mean age: 69.8 +/- 6.3 years). Four visual conditions were tested: both eyes viewing condition (BEV), dominant eye viewing (DEV), non-dominant eye viewing (NDEV), and eyes closed (EC). We analyzed the surface area, the length, the mean speed, the anteroposterior (AP), and mediolateral (ML) displacement of the center of pressure (CoP).
   Results: Bilateral AMD subjects had a surface area (p < 0.05) and AP displacement of the CoP (p < 0.01) higher than healthy elderly. Unilateral AMD subjects had more AP displacement of the CoP (p < 0.05) than healthy elderly.
   Conclusions: We suggest that ADM subjects could have poor postural adaptive mechanisms leading to increase their postural instability. Further studies will aim to improve knowledge on such issue and to develop reeducation techniques in these patients.
C1 [Chatard, Hortense; Bucci, Maria P.] Univ Paris 07, Robert Debre Univ Hosp, Inst Natl Sante & Rech Med, UMR 1141, Paris, France.
   [Chatard, Hortense; Bucci, Maria P.] Robert Debre Univ Hosp, ENT Dept, Vestibular & Oculomotor Evaluat Unit, Paris, France.
   [Chatard, Hortense; Jankowski, Olivier; Aussems, Antoine; Allieta, Alain] Ctr Ophtalmol Val dOise OPH95, Osny, France.
   [Tepenier, Laure; Beydoun, Talal; Salah, Sawsen] Paris Descartes Univ, Grp Hosp Cochin Hotel Dieu, AP HP, Dept Ophthalmol, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Robert-Debre - APHP; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Universite Paris
   Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Robert-Debre - APHP; UDICE-French Research Universities; Universite
   Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Cochin - APHP; Hopital Universitaire Hotel-Dieu - APHP;
   UDICE-French Research Universities; Universite Paris Cite
RP Chatard, H (通讯作者)，Univ Paris 07, Robert Debre Univ Hosp, Inst Natl Sante & Rech Med, UMR 1141, Paris, France.; Chatard, H (通讯作者)，Robert Debre Univ Hosp, ENT Dept, Vestibular & Oculomotor Evaluat Unit, Paris, France.; Chatard, H (通讯作者)，Ctr Ophtalmol Val dOise OPH95, Osny, France.
EM chatardhortense@gmail.com
OI SALAH, Sawsen/0000-0003-2078-0430
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Agostini V, 2016, GAIT POSTURE, V43, P233, DOI 10.1016/j.gaitpost.2015.10.003
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Bandello F, 2008, DRUG AGING, V25, P255, DOI 10.2165/00002512-200825030-00007
   Berencsi A, 2005, HUM MOVEMENT SCI, V24, P689, DOI 10.1016/j.humov.2005.10.014
   Brandt T., 2003, VERTIGO ITS MULTISEN
   Bucci MP, 2016, FRONT SYST NEUROSCI, V10, DOI [10.3339/fnsys.2016.00067, 10.3389/fnsys.2016.00067]
   CAMPBELL AJ, 1989, J GERONTOL, V44, pM112, DOI 10.1093/geronj/44.4.m112
   Carroll Norman V, 2005, J Manag Care Pharm, V11, P307
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chiari L, 2002, CLIN BIOMECH, V17, P666, DOI 10.1016/S0268-0033(02)00107-9
   Chomistek AK, 2013, J AM COLL CARDIOL, V61, P2346, DOI 10.1016/j.jacc.2013.03.031
   Christoforidis JB, 2011, CURR DRUG TARGETS, V12, P221
   Daubney ME, 1999, PHYS THER, V79, P1177, DOI 10.1093/ptj/79.12.1177
   ELLIOTT DB, 1995, OPHTHAL PHYSL OPT, V15, P553, DOI 10.1016/0275-5408(95)00025-9
   Faraldo-Garcia A, 2016, AURIS NASUS LARYNX, V43, P149, DOI 10.1016/j.anl.2015.07.001
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Fetter M, 1996, BRAIN, V119, P755, DOI 10.1093/brain/119.3.755
   FITZPATRICK R, 1994, J PHYSIOL-LONDON, V478, P173, DOI 10.1113/jphysiol.1994.sp020240
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gagey P., 1993, 8 LESSONS POSTUROLOG
   Gagey P.M., 1999, POSTUROLOGIE REGULAT
   Gagey PM, 2004, POSTUROLOGIE REGULAT
   GEURTS ACH, 1993, ARCH PHYS MED REHAB, V74, P1144
   Gurfinkel V. S., 1973, MOTOR CONTROL
   Hochberg C, 2012, INVEST OPHTH VIS SCI, V53, P3201, DOI 10.1167/iovs.12-9469
   Horak F. B., 1994, VESTIB REHABIL, V13, P69
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   Kotecha A, 2013, INVEST OPHTH VIS SCI, V54, P5408, DOI 10.1167/iovs.12-12026
   Leveziel N, 2009, J FR OPHTALMOL, V32, P440, DOI 10.1016/j.jfo.2009.04.009
   Lions C, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00156
   Loprinzi PD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125394
   Marigold DS, 2008, EXP BRAIN RES, V188, P23, DOI 10.1007/s00221-008-1335-7
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   Moraes R, 2009, NEUROSCI LETT, V460, P209, DOI 10.1016/j.neulet.2009.05.078
   Nashner L M, 1979, Prog Brain Res, V50, P177
   PAILLARD J, 1971, CAH PSYCHOL COGN, V0014, P00261
   Qiu F, 2012, GAIT POSTURE, V35, P630, DOI 10.1016/j.gaitpost.2011.12.013
   Rovner BW, 2009, ALZHEIMERS DEMENT, V5, P12, DOI 10.1016/j.jalz.2008.06.001
   Sengupta S, 2014, OPHTHALMOLOGY, V121, P727, DOI 10.1016/j.ophtha.2013.09.042
   Timmis MA, 2016, GAIT POSTURE, V44, P55, DOI 10.1016/j.gaitpost.2015.11.008
   TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604
   Vuillerme N, 2008, NEUROSCIENCE, V155, P291, DOI 10.1016/j.neuroscience.2008.05.018
   WALRAVEN J, 1975, AM J OPHTHALMOL, V80, P893, DOI 10.1016/0002-9394(75)90286-X
   Wang JL, 2009, AM J EPIDEMIOL, V170, P132, DOI 10.1093/aje/kwp149
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
NR 50
TC 6
Z9 6
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1662-5161
J9 FRONT HUM NEUROSCI
JI Front. Hum. Neurosci.
PD MAR 31
PY 2017
VL 11
AR 158
DI 10.3389/fnhum.2017.00158
PG 9
WC Neurosciences; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychology
GA EQ3PA
UT WOS:000397983800001
PM 28408876
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Dong, LM
   Stark, WJ
   Jefferys, JL
   Al-Hazzaa, S
   Bressler, SB
   Solomon, SD
   Bressler, NM
AF Dong, Li Ming
   Stark, Walter J.
   Jefferys, Joan L.
   Al-Hazzaa, Selwa
   Bressler, Susan B.
   Solomon, Sharon D.
   Bressler, Neil M.
TI Progression of Age-Related Macular Degeneration After Cataract Surgery
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; INTRAOCULAR-LENS; BEAVER DAM; MACULOPATHY;
   EXTRACTION; IMPLANTATION; ASSOCIATION; PREVALENCE
AB Objective: To document age-related macular degeneration (AMD) progression after cataract surgery.
   Methods: Surgeons prospectively enrolled patients with nonneovascular AMD who were awaiting cataract surgery. Fluorescein angiography was performed preoperatively and at the postoperative week 1, month 3, and month 12 visits. Incidence of neovascular AMD development within 12 months after operation was the primary outcome measure.
   Results: A total of 108 subjects were enrolled. Of 86 eyes with preoperatively photographically confirmed nonneovascular AMD, 71 had gradable images by month 12. Neovascular AMD was observed in 9 of 71 eyes (12.7%; 95% confidence interval, 6.0%-22.7%). The progression rate be tween week 1 and month 12 decreased to 3 of 65 eyes (4.6%; 95% confidence interval, 1.0%-12.9%) after excluding 5 neovascular events identified on the postoperative week 1 visit and 1 case with missing photographs at this visit.
   Conclusion: The low incidence rate of neovascular AMD development between 1 week and 1 year after cataract surgery did not support the hypothesis that cataract surgery increases the risk of AMD progression. Several eyes appeared to have disease progression on postsurgery week 1 fluorescein angiograms, suggesting that many cases of presumed progression to neovascular AMD following cataract surgery may have been present prior to cataract surgery, but not recognized owing to lens opacity.
C1 [Stark, Walter J.; Jefferys, Joan L.; Al-Hazzaa, Selwa; Bressler, Susan B.; Solomon, Sharon D.; Bressler, Neil M.] Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Baltimore, MD 21287 USA.
   [Dong, Li Ming] SUNY Stony Brook, Dept Prevent Med, Sch Med, Stony Brook, NY USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; State University of
   New York (SUNY) System; SUNY Community College; State University of New
   York (SUNY) Stony Brook
RP Bressler, NM (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, 600 N Wolfe St,Maumenee 7th Floor, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
RI Solomon, Scott/I-5789-2013
FU Jack Valenti Macular Degeneration Fund; Lincy Foundation; Wilmer Retina
   Research Fund; T. Boone Pickens Professorship of Ophthalmology; Robert
   L. Burch Research Fund
FX This study was supported by the Jack Valenti Macular Degeneration Fund,
   the Lincy Foundation, the Wilmer Retina Research Fund, the T. Boone
   Pickens Professorship of Ophthalmology (Dr Stark); the Julia G. Levy,
   PhD, Professorship of Ophthalmology (Dr S. B. Bressler); the Katharine
   Graham Professorship of Ophthalmology (Dr Solomon); the James P. Gills
   Professorship of Ophthalmology (Dr N. M. Bressler); and the Robert L.
   Burch Research Fund.
CR Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GUTTMAN C, 2003, OPHTHALMOL TIMES, V28, P14
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   *NAT EYE I, HLTH VIS 2010 EYE DI
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   Smith Bradley T, 2005, Curr Opin Ophthalmol, V16, P166, DOI 10.1097/01.icu.0000163030.33401.3d
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   *WHO, 2004, 282 WHO
NR 23
TC 38
Z9 40
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2009
VL 127
IS 11
BP 1412
EP 1419
DI 10.1001/archophthalmol.2009.152
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 516ZY
UT WOS:000271583700001
PM 19901205
OA Bronze
DA 2022-11-30
ER

PT J
AU Chaudhry, NA
   Flynn, HW
   Murray, TG
   Belfort, A
AF Chaudhry, NA
   Flynn, HW
   Murray, TG
   Belfort, A
TI Combined cataract surgery and vitrectomy for breakthrough vitreous
   hemorrhage from age-related macular degeneration
SO OPHTHALMIC SURGERY AND LASERS
LA English
DT Article
ID INTRAOCULAR-LENS INSERTION; PARS-PLANA VITRECTOMY
AB PURPOSE: To report combined cataract extraction (CE), posterior chamber intraocular lens (PCIOL) implantation, and pars plana vitrectomy (PPV) for concurrent cataract and breakthrough vitreous hemorrhage from age-related macular degeneration (AMD).
   METHODS: Retrospective case series.
   RESULTS: Six eyes were included in the study. The postoperative follow-up interval ranged from 3 to 22 months (mean 8 months). Preoperative visual acuity (VA) ranged from 20/400 to hand motion. Postoperatively, 5/6 eyes had 2 or more lines of visual improvement. Three eyes were better than 20/200.
   CONCLUSIONS: Combined CE, PCIOL insertion, and PPV in selected patients with cataract and breakthrough vitreous hemorrhage from AMD was successful in improving VA in the majority of patients.
C1 Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Chaudhry, NA (通讯作者)，New England Retina Associates, Shaws Cove 4,Suite 105, New London, CT 06320 USA.
CR Alexandrakis G, 1999, OPHTHALMIC SURG LAS, V30, P327
   Chaudhry NA, 2000, RETINA-J RET VIT DIS, V20, P257, DOI 10.1097/00006982-200003000-00006
   FOSTER RE, 1993, OPHTHALMIC SURG LAS, V24, P446
   GOOGE JM, 1987, SURV OPHTHALMOL, V32, P123, DOI 10.1016/0039-6257(87)90104-4
   KOENIG SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P1101, DOI 10.1001/archopht.1992.01080200081029
   KRIEGER AE, 1983, RETINA, V3, P318
   ORTH DH, 1982, RETINA-J RET VIT DIS, V2, P89, DOI 10.1097/00006982-198200220-00006
   Scott IU, 1997, OPHTHALMOLOGY, V104, P1041, DOI 10.1016/S0161-6420(97)30189-4
   TANI PM, 1980, AM J OPHTHALMOL, V90, P525, DOI 10.1016/S0002-9394(14)75023-8
NR 9
TC 4
Z9 6
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0022-023X
J9 OPHTHALMIC SURG LAS
JI Ophthalmic Surg. Lasers
PD JAN-FEB
PY 2002
VL 33
IS 1
BP 16
EP 18
PG 3
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 512HF
UT WOS:000173318400003
PM 11820658
DA 2022-11-30
ER

PT J
AU Forte, R
   Querques, G
   Querques, L
   Massamba, N
   Le Tien, V
   Souied, EH
AF Forte, Raimondo
   Querques, Giuseppe
   Querques, Lea
   Massamba, Nathalie
   Le Tien, Valerie
   Souied, Eric H.
TI Multimodal imaging of dry age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; fundus autofluorescence; near-infrared
   autofluorescence; spectral domain optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIAL-CELLS; FUNDUS
   AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; IN-VIVO; HIGH-RESOLUTION; OCULAR
   FUNDUS; DISEASE; FLUORESCENCE; LIPOFUSCIN
AB Purpose: The purpose of this study was to understand clinical significance of near-infrared reflectance (NIR), blue fundus autofluorescence (FAF) and near-infrared autofluorescence (NIA) in dry age-related macular degeneration (AMD), by correlation with fluorescein angiography (FA) and cross-sectional spectral domain optical coherence tomography (SD OCT).
   Methods: We evaluated 110 eyes (62 patients, mean age: 64 +/- 8 years) diagnosed with dry AMD between January 2010 and December 2010, which underwent NIR (lambda = 830 nm), FAF and FA (excitation lambda = 488 nm; emission lambda > 500 nm), NIA (excitation lambda = 787 nm; emission lambda > 800 nm), and simultaneous SD OCT scanning using a combined confocal scanning laser ophthalmoscope/SD OCT device (Spectralis HRA + OCT; Heidelberg Engineering, Heidelberg, Germany).
   Results: Drusen showed variable increased/decreased NIR, FAF, NIA and FA, which corresponded to variable increased/decreased thickness of the retinal pigment epithelium (RPE) and possible presence of subretinal deposits on SD OCT. Geographic atrophy (GA) was present in 43/110 eyes (39.0%) and showed increased NIR and fluorescence (FA), absent FAF and NIA, and loss of RPE on SD OCT. The hyperautofluorescence of the GA margin was never larger in FAF than that in NIA, while in 16.2% of cases, it was larger in NIA than that in FAF and corresponded to mild choroidal hyperreflectivity on SD OCT.
   Conclusions: Simultaneous recording of SD OCT scans provided ultrastructural data for the evaluation of NIR, FAF, NIA and FA in dry AMD. Near-infrared autofluorescence might detect earlier than FAF areas of RPE cell loss at the GA margin.
C1 [Forte, Raimondo; Querques, Giuseppe; Querques, Lea; Massamba, Nathalie; Le Tien, Valerie; Souied, Eric H.] Univ Paris 12, Intercommunal Hosp Creteil, Dept Ophthalmol, F-94000 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Univ Paris 12, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581
CR Acton JH, 2011, ACTA OPHTHALMOL, V89, pE404, DOI 10.1111/j.1755-3768.2011.02123.x
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Gibbs D, 2009, INVEST OPHTH VIS SCI, V50, P4386, DOI 10.1167/iovs.09-3471
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kellner U, 2008, DOC OPHTHALMOL, V116, P119, DOI 10.1007/s10633-007-9105-6
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   Menke MN, 2011, ACTA OPHTHALMOL, V89, P346, DOI 10.1111/j.1755-3768.2009.01692.x
   Peters S, 2000, OPHTHALMIC RES, V32, P52, DOI 10.1159/000055589
   Piccolino FC, 1996, OPHTHALMOLOGY, V103, P1837
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Schmitz-Valckenberg S, 2011, BRIT J OPHTHALMOL, V95, P1134, DOI 10.1136/bjo.2010.189498
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   SmithThomas L, 1996, CURR EYE RES, V15, P1079, DOI 10.3109/02713689608995139
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   Weinberger AWA, 2006, INVEST OPHTH VIS SCI, V47, P3098, DOI 10.1167/iovs.05-1104
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 34
TC 45
Z9 45
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2012
VL 90
IS 4
BP E281
EP E287
DI 10.1111/j.1755-3768.2011.02331.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 980OQ
UT WOS:000306903100005
PM 22269083
OA Bronze
DA 2022-11-30
ER

PT J
AU Ranchod, TM
   Ray, SK
   Daniels, SA
   Leong, CJ
   Ting, TD
   Verne, AZ
AF Ranchod, Tushar M.
   Ray, Subhransu K.
   Daniels, Stewart A.
   Leong, Craig J.
   Ting, T. Daniel
   Verne, Allen Z.
TI A Prospective Study Comparing Ranibizumab plus Dexamethasone Combination
   Therapy Versus Ranibizumab Monotherapy for Neovascular Age-Related
   Macular Degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE dexamethasone; ranibizumab; neovascular age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL
   TRIAMCINOLONE; PHOTODYNAMIC THERAPY; VASCULAR LEAKAGE; COMPLICATIONS;
   VERTEPORFIN; INJECTION; EDEMA
AB Background: The LuceDex prospective randomized pilot trial compared the combination of intravitreal ranibizumab and dexamethasone with ranibizumab monotherapy for treatment of neovascular age-related macular degeneration.
   Methods: Thirty-seven eyes of 37 patients were randomized 1: 1 between combination therapy with intravitreal ranibizumab and dexamethasone (Group 1) and intravitreal ranibizumab monotherapy (Group 2). All study eyes received 4 monthly treatments followed by monthly treatment on indication.
   Results: In the LuceDex study, eyes gained an average of 11.1 and 5.9 Early Treatment of Diabetic Retinopathy Study letters in Groups 1 and 2, respectively, at Month 12. No more than zero Early Treatment of Diabetic Retinopathy Study letters were lost in 88% of Group 1 eyes and 70% of Group 2 eyes. The average number of treatments per study eye by Month 12 was 7.1 in Group 1 and 6.6 in Group 2. Choroidal neovascular membrane size decreased in Group 1 significantly compared with Group 2 (P < 0.05).
   Conclusion: The LuceDex pilot study suggested a possible benefit of adding intravitreal dexamethasone to treatment of neovascular age-related macular degeneration with intravitreal ranibizumab. A larger study is needed to further identify and define possible benefits of this combination therapy.
C1 [Ranchod, Tushar M.; Ray, Subhransu K.; Daniels, Stewart A.; Leong, Craig J.; Ting, T. Daniel; Verne, Allen Z.] Bay Area Retina Associates, Walnut Creek, CA 94598 USA.
RP Ray, SK (通讯作者)，Bay Area Retina Associates, 122 La Casa Via,Suite 223, Walnut Creek, CA 94598 USA.
EM sray@bayarearetina.com
FU Genentech
FX Supported by an unrestricted grant from Genentech.
CR BLANKENSHIP GW, 1991, GRAEF ARCH CLIN EXP, V229, P62, DOI 10.1007/BF00172263
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haller JA, 2011, OPHTHALMOLOGY, V118, P2453, DOI 10.1016/j.ophtha.2011.05.014
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1134, DOI 10.1016/j.ophtha.2010.03.032
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   MEIKLE AW, 1977, AM J MED, V63, P200, DOI 10.1016/0002-9343(77)90233-9
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shah GK, 2000, OPHTHALMOLOGY, V107, P486, DOI 10.1016/S0161-6420(99)00139-6
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Tamura H, 2005, INVEST OPHTH VIS SCI, V46, P1440, DOI 10.1167/iovs.04-0905
   Thompson JT, 2006, AM J OPHTHALMOL, V141, P629, DOI 10.1016/j.ajo.2005.11.050
   Wenzel A, 2001, INVEST OPHTH VIS SCI, V42, P1653
   2001, AM J OPHTHALMOL, V131, P541
NR 17
TC 21
Z9 21
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2013
VL 33
IS 8
BP 1600
EP 1604
DI 10.1097/IAE.0b013e318285cb71
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297CP
UT WOS:000330233200015
PM 23549100
DA 2022-11-30
ER

PT J
AU Liang, MC
   De Carlo, TE
   Baumal, CR
   Reichel, E
   Waheed, NK
   Duker, JS
   Witkin, AJ
AF Liang, Michelle C.
   De Carlo, Talisa E.
   Baumal, Caroline R.
   Reichel, Elias
   Waheed, Nadia K.
   Duker, Jay S.
   Witkin, Andre J.
TI CORRELATION OF SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY
   AND CLINICAL ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal neovascularization; OCT angiography; age-related macular
   degeneration
ID CHOROIDAL NEOVASCULARIZATION; QUANTITATIVE-ANALYSIS; OCT ANGIOGRAPHY;
   RANIBIZUMAB
AB Purpose: To characterize the features of choroidal neovascularization (CNV) in neovascular age-related macular degeneration with spectral domain optical coherence tomography angiography (OCTA) and to determine whether OCTA can be used to determine clinical activity of CNV.
   Methods: Observational, retrospective, consecutive case series.
   Results: Optical coherence tomography angiography revealed CNV in 28 eyes (62.2%) while 17 eyes (37.8%) did not demonstrate CNV vessels. Choroidal neovascularization was classified as well circumscribed in 12 eyes (42.8%) and poorly circumscribed in 16 eyes (57.2%). Twenty-two eyes with a CNV on OCTA were clinically active, whereas six eyes with visible CNV on OCTA were clinically inactive. Of the 17 eyes that did not have evidence of CNV on OCTA imaging, 14 were clinically inactive and 3 were clinically active. Presence of CNV on OCTA correlated with clinical activity and absence of CNV correlated with inactivity (P < 0.0001).
   Conclusion: Optical coherence tomography angiography is a noninvasive imaging technique that can be used to visualize blood flow comprising CNV. Optical coherence tomography angiography detects CNV vessels in some albeit not all eyes with neovascular age-related macular degeneration. Although the presence or absence of CNV vessels on OCTA highly correlated with clinical activity of CNV, the morphologic appearance of CNV on OCTA did not have significant correlation with clinical activity.
C1 [Liang, Michelle C.; Baumal, Caroline R.; Reichel, Elias; Waheed, Nadia K.; Duker, Jay S.; Witkin, Andre J.] Tufts Med Ctr, New England Eye Ctr, Boston, MA USA.
   [De Carlo, Talisa E.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
C3 Tufts Medical Center; Tufts University
RP Witkin, AJ (通讯作者)，New England Eye Ctr, 800 Washington St,Box 450, Boston, MA 02111 USA.
EM ajwitkin@gmail.com
FU Massachusetts Lions Club; Carl Zeiss Meditech Inc; Optovue, Inc.;
   Optovue [01/2015]
FX Supported in part by the Massachusetts Lions Club.; J. S. Duker is a
   consultant for and receives research support from Carl Zeiss Meditech
   Inc and Optovue, Inc. N. K. Waheed has served as a consultant for Carl
   Zeiss Meditech Inc. C. R. Baumal received a travel grant from Optovue
   (01/2015) and served on an Allergan advisory board (4/15). The prototype
   AngioVue OCTA system used in this study was provided on loan by Optovue,
   Inc. The remaining authors have no any financial/conflicting interests
   to disclose.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Baumal CR, 2015, JAMA OPHTHALMOL, V133, P1087, DOI 10.1001/jamaophthalmol.2015.1946
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Dansingani KK, 2015, EYE, V29, P703, DOI 10.1038/eye.2015.27
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   KWITEROVICH KA, 1991, OPHTHALMOLOGY, V98, P1139
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Lopez-Saez MP, 1998, ANN ALLERG ASTHMA IM, V81, P428, DOI 10.1016/S1081-1206(10)63140-7
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Ryan SJ, 2013, RETINA, P1150
   Sadda SR, 2010, GRAEF ARCH CLIN EXP, V248, P175, DOI 10.1007/s00417-009-1193-4
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Shah SM, 2006, INVEST OPHTH VIS SCI, V47, P5460, DOI 10.1167/iovs.06-0012
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 25
TC 33
Z9 33
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2016
VL 36
IS 12
BP 2265
EP 2273
DI 10.1097/IAE.0000000000001102
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ED6DB
UT WOS:000388944100003
PM 27285456
DA 2022-11-30
ER

PT J
AU Morris, B
   Imrie, F
   Armbrecht, AM
   Dhillon, B
AF Morris, Brid
   Imrie, Fraser
   Armbrecht, Ana-Maria
   Dhillon, Baljean
TI Age-related macular degeneration and recent developments: new hope for
   old eyes?
SO POSTGRADUATE MEDICAL JOURNAL
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; BEAVER DAM EYE;
   EPITHELIUM-DERIVED FACTOR; TRANSPUPILLARY THERMOTHERAPY; PHOTODYNAMIC
   THERAPY; RISK-FACTORS; PERIPHERAL RETINECTOMY; ANECORTAVE ACETATE;
   CIGARETTE-SMOKING; CATARACT-SURGERY
AB Age-related macular degeneration (AMD) is the commonest cause of blindness in the population over 60 years of age and accounts for over 50% of those registered blind in the UK. The incidence is increasing and as older generations live longer a growing number of patients will be affected in the future. Affected patients lose central vision, important in all aspects of everyday life. This review outlines risk factors for AMD, clinical features, treatment and management strategies for patients, families and physicians caring for those with AMD. Recent trials are included along with practical clinical advice. While there is no curative treatment at present, intervention can reduce the risk of developing AMD and limit disease progression if it occurs. These modalities are discussed here. As new discoveries in the field of genetics and novel therapies emerge, a brighter future seems certain for the ageing population.
RP Morris, B (通讯作者)，Princess Alexandra Eye Pavil,Chalmers St, Edinburgh EH3 9HA, Midlothian, Scotland.
EM bridcmorris@yahoo.com
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Armbrecht AM, 2004, BRIT J OPHTHALMOL, V88, P1270, DOI 10.1136/bjo.2003.038604
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Flower RW, 2002, AM J OPHTHALMOL, V134, P228, DOI 10.1016/S0002-9394(02)01579-9
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   Maberley DAL, 2005, CAN J OPHTHALMOL, V40, P378, DOI 10.1016/S0008-4182(05)80080-8
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Myint K, 2006, ACTA OPHTHALMOL SCAN, V84, P328, DOI 10.1111/j.1600-0420.2005.00623.x
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rovner BW, 1996, J AM GERIATR SOC, V44, P181, DOI 10.1111/j.1532-5415.1996.tb02436.x
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Stolba U, 2006, BRIT J OPHTHALMOL, V90, P158, DOI 10.1136/bjo.2005.076422
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
NR 49
TC 27
Z9 28
U1 0
U2 2
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0032-5473
J9 POSTGRAD MED J
JI Postgrad. Med. J.
PD MAY
PY 2007
VL 83
IS 979
BP 301
EP 306
DI 10.1136/pgmj.2006.052944
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 165JR
UT WOS:000246302300004
PM 17488857
OA Green Published
DA 2022-11-30
ER

PT J
AU Kishikova, L
   Saad, AAA
   Vaideanu-Collins, D
   Isac, M
   Hamada, D
   El-Haig, WM
AF Kishikova, Lyudmila
   Saad, Ahmed Abdelwahab A.
   Vaideanu-Collins, Daniela
   Isac, Marco
   Hamada, Dina
   El-Haig, Wael M.
TI Comparison between different techniques for treatment of submacular
   haemorrhage due to Age-Related Macular Degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Macular degeneration; submacular haemorrhage; tissue plasminogen
   activator; vitrectomy; subretinal injection
ID TISSUE-PLASMINOGEN ACTIVATOR; DISPLACEMENT; INJECTION; VITRECTOMY; GAS
AB Purpose: To compare the outcome of vitrectomy, subretinal tissue plasminogen activator (TPA), and gas with and without subretinal air versus Intravitreal TPA and gas in the treatment of submacular haemorrhage (SMH) due to Neovascular age related macular degeneration. Methods: We analysed the notes of 29 cases presented with SMH in the period between 01/2016 and 09/2018 at James Cook University Hospital. Presenting visual acuity (BCVA), size and location of SMH, Procedure done, final BCVA at 6 months and any surgical complications were recorded. 11 Cases (Group 1) received intravitreal TPA (50 mu g in 0.1 ML), 0.3 ml of pure sulfur hexafluoride (SF6). 18 cases (Group 2) received 23 G Pars Plana vitrectomy, Subretinal TPA injection (25 mu g in 0.1 ml), and 20% SF6 gas filling. Group 2 was further divided into 2A (10 patients) who received only subretinal TPA and group 2B (8 patients) who received additional 0.1 ml subretinal air. Results: The mean BCVA at presentation was 0.0068 in group 1 and 0.0067 in group 2 (p = 0.8734). The mean postoperative BCVA at 6 months was 0.31 in group 1 and 0.58 in group 2 (p = 0.0015). Subgroup analysis of group 2 didn't show statistically significant difference in outcome when adding subretinal air to the vitrectomy procedure (p = 0.7009). Conclusion: Vitrectomy, gas and subretinal TPA has more successful displacement rate and better visual outcome than Intravitreal TPA & Gas alone in treating SMH involving the fovea in age-related macular degeneration. Additional subretinal air doesn't seem to improve the outcome in cases having vitrectomy.
C1 [Kishikova, Lyudmila; Saad, Ahmed Abdelwahab A.; Vaideanu-Collins, Daniela; Isac, Marco; Hamada, Dina] James Cook Univ Hosp, Marton Rd, Middlesbrough TS4 3BW, N Yorkshire, England.
   [Saad, Ahmed Abdelwahab A.; Hamada, Dina; El-Haig, Wael M.] Zagazig Univ, Zagazig, Egypt.
C3 James Cook University Hospital; Egyptian Knowledge Bank (EKB); Zagazig
   University
RP Kishikova, L (通讯作者)，James Cook Univ Hosp, Marton Rd, Middlesbrough TS4 3BW, N Yorkshire, England.
EM Lyudmila.kishikova@nhs.net
RI El-Haig, Wael/M-8646-2018
OI El-Haig, Wael/0000-0003-1544-3130
CR Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Kadonosono K, 2015, OPHTHALMOLOGY, V122, P123, DOI 10.1016/j.ophtha.2014.07.027
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   Martel JN, 2013, JAMA OPHTHALMOL, V131, P1632, DOI 10.1001/jamaophthalmol.2013.5464
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   Waizel M, 2017, KLIN MONATSBL AUGENH, V234, P487, DOI 10.1055/s-0042-121575
NR 13
TC 4
Z9 4
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP
PY 2021
VL 31
IS 5
BP 2621
EP 2624
AR 1120672120959551
DI 10.1177/1120672120959551
EA SEP 2020
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XG9FP
UT WOS:000577349100001
PM 32993349
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Kerur, N
   Fukuda, S
   Banerjee, D
   Kim, Y
   Fu, DX
   Apicella, I
   Varshney, A
   Yasuma, R
   Fowler, BJ
   Baghdasaryan, E
   Marion, KM
   Huang, XW
   Yasuma, T
   Hirano, Y
   Serbulea, V
   Ambati, M
   Ambati, VL
   Kajiwara, Y
   Ambati, K
   Hirahara, S
   Bastos-Carvalho, A
   Ogura, Y
   Terasaki, H
   Oshika, T
   Kim, KB
   Hinton, DR
   Leitinger, N
   Cambier, JC
   Buxbaum, JD
   Kenney, MC
   Jazwinski, SM
   Nagai, H
   Hara, I
   West, AP
   Fitzgerald, KA
   Sadda, SR
   Gelfand, BD
   Ambati, J
AF Kerur, Nagaraj
   Fukuda, Shinichi
   Banerjee, Daipayan
   Kim, Younghee
   Fu, Dongxu
   Apicella, Ivana
   Varshney, Akhil
   Yasuma, Reo
   Fowler, Benjamin J.
   Baghdasaryan, Elmira
   Marion, Kenneth M.
   Huang, Xiwen
   Yasuma, Tetsuhiro
   Hirano, Yoshio
   Serbulea, Vlad
   Ambati, Meenakshi
   Ambati, Vidya L.
   Kajiwara, Yuji
   Ambati, Kameshwari
   Hirahara, Shuichiro
   Bastos-Carvalho, Ana
   Ogura, Yuichiro
   Terasaki, Hiroko
   Oshika, Tetsuro
   Kim, Kyung Bo
   Hinton, David R.
   Leitinger, Norbert
   Cambier, John C.
   Buxbaum, Joseph D.
   Kenney, M. Cristina
   Jazwinski, S. Michal
   Nagai, Hiroshi
   Hara, Isao
   West, A. Phillip
   Fitzgerald, Katherine A.
   Sadda, SriniVas R.
   Gelfand, Bradley D.
   Ambati, Jayakrishna
TI cGAS drives noncanonical-inflammasome activation in age-related macular
   degeneration
SO NATURE MEDICINE
LA English
DT Article
ID MITOCHONDRIAL PERMEABILITY TRANSITION; RETINAL-PIGMENT EPITHELIUM;
   INNATE IMMUNE-RESPONSES; NLRP3 INFLAMMASOME; CELL-DEATH; ALU RNA;
   OXIDIZED PHOSPHOLIPIDS; CORNEAL ENDOTHELIUM; GENE-EXPRESSION; ARPE-19
   CELLS
AB Geographic atrophy is a blinding form of age-related macular degeneration characterized by retinal pigmented epithelium (RPE) death; the RPE also exhibits DICER1 deficiency, resultant accumulation of endogenous Alu-retroelement RNA, and NLRP3-inflammasome activation. How the inflammasome is activated in this untreatable disease is largely unknown. Here we demonstrate that RPE degeneration in human-cell-culture and mouse models is driven by a noncanonical-inflammasome pathway that activates caspase-4 (caspase-11 in mice) and caspase-1, and requires cyclic GMP-AMP synthase (cGAS)dependent interferon-b production and gasdermin D-dependent interleukin-18 secretion. Decreased DICER1 levels or AluRNA accumulation triggers cytosolic escape of mitochondrial DNA, which engages cGAS. Moreover, caspase-4, gasdermin D, interferon-b, and cGAS levels were elevated in the RPE in human eyes with geographic atrophy. Collectively, these data highlight an unexpected role of cGAS in responding to mobile-element transcripts, reveal cGAS-driven interferon signaling as a conduit for mitochondrial-damage-induced inflammasome activation, expand the immune-sensing repertoire of cGAS and caspase-4 to noninfectious human disease, and identify new potential targets for treatment of a major cause of blindness.
C1 [Kerur, Nagaraj; Fukuda, Shinichi; Banerjee, Daipayan; Kim, Younghee; Fu, Dongxu; Apicella, Ivana; Varshney, Akhil; Yasuma, Reo; Ambati, Kameshwari; Hirahara, Shuichiro; Gelfand, Bradley D.; Ambati, Jayakrishna] Univ Virginia, Sch Med, Ctr Adv Vis Sci, Charlottesville, VA 22908 USA.
   [Kerur, Nagaraj; Fukuda, Shinichi; Banerjee, Daipayan; Kim, Younghee; Fu, Dongxu; Apicella, Ivana; Varshney, Akhil; Yasuma, Reo; Ambati, Kameshwari; Hirahara, Shuichiro; Gelfand, Bradley D.; Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Ophthalmol, Charlottesville, VA 22908 USA.
   [Kerur, Nagaraj; Banerjee, Daipayan; Kim, Younghee; Yasuma, Reo; Fowler, Benjamin J.; Ambati, Kameshwari; Bastos-Carvalho, Ana; Gelfand, Bradley D.; Ambati, Jayakrishna] Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA.
   [Fukuda, Shinichi; Yasuma, Tetsuhiro; Hirano, Yoshio; Oshika, Tetsuro] Univ Tsukuba, Dept Ophthalmol, Ibaraki, Japan.
   [Baghdasaryan, Elmira; Marion, Kenneth M.; Huang, Xiwen; Sadda, SriniVas R.] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Baghdasaryan, Elmira; Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Yasuma, Tetsuhiro; Terasaki, Hiroko] Nagoya Univ, Dept Ophthalmol, Grad Sch Med, Nagoya, Aichi, Japan.
   [Hirano, Yoshio; Ogura, Yuichiro] Nagoya City Univ, Dept Ophthalmol, Grad Sch Med Sci, Nagoya, Aichi, Japan.
   [Serbulea, Vlad; Leitinger, Norbert] Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA.
   [Ambati, Meenakshi; Ambati, Vidya L.] Ctr Digital Image Evaluat, Charlottesville, VA USA.
   [Kajiwara, Yuji; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
   [Kim, Kyung Bo] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY USA.
   [Hinton, David R.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Dept Pathol, Los Angeles, CA USA.
   [Hinton, David R.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Dept Ophthalmol, Los Angeles, CA USA.
   [Cambier, John C.] Univ Colorado, Sch Med, Dept Immunol & Microbiol, Aurora, CO USA.
   [Kenney, M. Cristina] Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA USA.
   [Jazwinski, S. Michal] Tulane Univ, Tulane Ctr Aging, Hlth Sci Ctr, New Orleans, LA 70118 USA.
   [Jazwinski, S. Michal] Tulane Univ, Dept Med, Hlth Sci Ctr, New Orleans, LA 70118 USA.
   [Nagai, Hiroshi] Kobe Univ, Grad Sch Med, Dept Internal Related, Div Dermatol, Kobe, Hyogo, Japan.
   [Hara, Isao] Wakayama Med Univ, Dept Urol, Wakayama, Japan.
   [West, A. Phillip] Texas A&M Univ, Dept Microbial Pathogenesis & Immunol, College Stn, TX USA.
   [Fitzgerald, Katherine A.] Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis & Immunol, Worcester, MA USA.
   [Gelfand, Bradley D.] Univ Virginia, Sch Med, Dept Biomed Engn, Charlottesville, VA 22908 USA.
   [Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA.
   [Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA.
C3 University of Virginia; University of Virginia; University of Kentucky;
   University of Tsukuba; Doheny Eye Institute; University of California
   System; University of California Los Angeles; University of California
   Los Angeles Medical Center; David Geffen School of Medicine at UCLA;
   Nagoya University; Nagoya City University; University of Virginia; Icahn
   School of Medicine at Mount Sinai; University of Kentucky; University of
   Southern California; University of Southern California; University of
   Colorado System; University of Colorado Anschutz Medical Campus;
   University of California System; University of California Irvine; Tulane
   University; Tulane University; Kobe University; Wakayama Medical
   University; Texas A&M University System; Texas A&M University College
   Station; University of Massachusetts System; University of Massachusetts
   Worcester; University of Virginia; University of Virginia; University of
   Virginia
RP Kerur, N (通讯作者)，Univ Virginia, Sch Med, Ctr Adv Vis Sci, Charlottesville, VA 22908 USA.; Kerur, N (通讯作者)，Univ Virginia, Sch Med, Dept Ophthalmol, Charlottesville, VA 22908 USA.; Kerur, N (通讯作者)，Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA.; Ambati, J (通讯作者)，Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA.; Ambati, J (通讯作者)，Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA.
EM nk8m@virginia.edu; ja9qr@virginia.edu
RI Buxbaum, Joseph D/G-6001-2010; Fitzgerald, Katherine/ABE-6317-2020;
   Gelfand, Brad/L-3926-2019; West, A. Phillip/W-8171-2019
OI West, A. Phillip/0000-0003-2884-6895; Varshney,
   Akhil/0000-0003-0759-0982; Fitzgerald, Kate/0000-0003-3175-609X;
   Buxbaum, Joseph/0000-0001-8898-8313; Fukuda,
   Shinichi/0000-0002-4160-8229; Serbulea, Vlad/0000-0002-9988-4410;
   Hirano, Yoshio/0000-0002-9173-0839
FU NIH [DP1GM114862, R01EY018350, R01EY018836, R01EY020672, R01EY022238,
   R01EY024068, K99EY024336, R00EY024336, T32HL091812, UL1RR033173,
   R01EY001545, R21AI099346, R37AG006168, T32GM007055, F31DK108553,
   R01DK096076, P01 HL120840]; Doris Duke Distinguished Clinical Scientist
   Award; Burroughs Wellcome Fund Clinical Scientist Award in Translational
   Research; Ellison Medical Foundation Senior Scholar in Aging Award; John
   Templeton Foundation; Dr. E. Vernon Smith and Eloise C. Smith Macular
   Degeneration Endowed Chair; Beckman Initiative for Macular Research
   (BIMR); Japan Eye Bank Association and Society for the Promotion of
   Science (JSPS); Association for Research in Vision and Ophthalmology
   (ARVO)/Alcon Early Career Clinician-Scientist Research Award; Fight for
   Sight postdoctoral award; Programme for Advanced Medical Education;
   Fundacao Calouste Gulbenkian; Fundacao Champalimaud; Ministerio da Saude
   and Fundacao para a Ciencia e Tecnologia, Portugal; Research to Prevent
   Blindness; Japan Eye Bank Association; American Heart Association;
   National Center for Research Resources; National Center for Advancing
   Translational Sciences, National Institutes of Health [UL1TR000117];
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000117]
   Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES
   [UL1RR033173] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY024068, R01EY022238, R00EY024336, R01EY018350, R01EY020672,
   K99EY024336, R01EY001545, R01EY018836] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL091812, P01HL120840]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASES [R37AI067497, R01AI124487, R21AI099346] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
   KIDNEY DISEASES [R01DK096076, F31DK108553] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [DP1GM114862,
   T32GM007055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R37AG006168] Funding Source: NIH RePORTER
FX We thank Z. Chen, V. Tarallo, and P. Pinton for valuable discussions. We
   thank H. Virgin (Washington University in St. Louis), G. Shadel (Yale
   University), W.T. Wong (NIH), L. Zhao (NIH), and V. Dixit (Genentech)
   for reagents. We thank G. Pattison, E. Ghias, K. Langberg, D. Robertson,
   E. Doswell, X. Zhou, K. Atwood, R. Makin, O. Kirillina, A. Bobrov, E.
   Dinning, L. Pandya, C. Payne, G. Botzet, N. Bell, R. King, L. Xu, L.
   Toll, and A. Uittenbogaard for technical assistance, and the University
   of Kentucky Viral Core (COBRE) for providing lentiviral vectors. J.A.
   was supported by NIH grants (DP1GM114862, R01EY018350, R01EY018836,
   R01EY020672, R01EY022238, and R01EY024068), a Doris Duke Distinguished
   Clinical Scientist Award, a Burroughs Wellcome Fund Clinical Scientist
   Award in Translational Research, an Ellison Medical Foundation Senior
   Scholar in Aging Award, and the John Templeton Foundation; as the Dr. E.
   Vernon Smith and Eloise C. Smith Macular Degeneration Endowed Chair; and
   through a DuPont Guerry, III Professorship. N.K. was supported by NIH
   grants K99EY024336 and R00EY024336, and the Beckman Initiative for
   Macular Research (BIMR). S.F. was supported by a Research Grant from the
   Japan Eye Bank Association and Society for the Promotion of Science
   (JSPS) Overseas Research Fellowship. B.J.F. was supported by NIH grants
   T32HL091812 and UL1RR033173. R.Y. was supported by an Association for
   Research in Vision and Ophthalmology (ARVO)/Alcon Early Career
   Clinician-Scientist Research Award. T.Y. was supported by a Fight for
   Sight postdoctoral award. A.B.-C. was supported by the Programme for
   Advanced Medical Education (sponsored by Fundacao Calouste Gulbenkian,
   Fundacao Champalimaud, Ministerio da Saude and Fundacao para a Ciencia e
   Tecnologia, Portugal). D.R.H. was supported by NIH R01EY001545 and an
   unrestricted departmental grant from Research to Prevent Blindness.
   J.C.C. was supported by NIH R21AI099346. S.F. was supported by a
   Research Grant from the Japan Eye Bank Association. S.M.J. was supported
   by NIH R37AG006168. B.D.G. was supported by the American Heart
   Association and by the National Center for Research Resources and the
   National Center for Advancing Translational Sciences, National
   Institutes of Health, through grant UL1TR000117. V.S. was supported by
   NIH grants T32GM007055 and F31DK108553. N.L. was supported by NIH grants
   R01DK096076 and P01 HL120840. The content is solely the responsibility
   of the authors and does not necessarily represent the official views of
   the NIH.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Aglietti RA, 2016, P NATL ACAD SCI USA, V113, P7858, DOI 10.1073/pnas.1607769113
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434
   Bannwarth S, 2006, NAT PROTOC, V1, P2037, DOI 10.1038/nprot.2006.318
   Bennett EA, 2008, GENOME RES, V18, P1875, DOI 10.1101/gr.081737.108
   Bonora M, 2016, NAT PROTOC, V11, P1067, DOI 10.1038/nprot.2016.064
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Doughty MJ, 2000, CORNEA, V19, P148, DOI 10.1097/00003226-200003000-00006
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Fang CJ, 2016, PROTEIN CELL, V7, P11, DOI 10.1007/s13238-015-0222-9
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fink SL, 2008, P NATL ACAD SCI USA, V105, P4312, DOI 10.1073/pnas.0707370105
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Galluzzi L, 2009, NAT REV NEUROSCI, V10, P481, DOI 10.1038/nrn2665
   Gelfand BD, 2015, CELL REP, V11, P1686, DOI 10.1016/j.celrep.2015.05.023
   Grossniklaus HE, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12711
   Hirano Y, 2014, NAT MED, V20, P1372, DOI 10.1038/nm.3671
   Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015
   Huang J., 2017, EYE CONTACT LENS
   Hung T, 2015, SCIENCE, V350, P455, DOI 10.1126/science.aac7442
   INABA M, 1985, ACTA OPHTHALMOL, V63, P232
   Jin L, 2011, J IMMUNOL, V187, P2595, DOI 10.4049/jimmunol.1100088
   Kagan VE, 2017, NAT CHEM BIOL, V13, P81, DOI [10.1038/nchembio.2238, 10.1038/NCHEMBIO.2238]
   Kajiwara Y, 2014, J IMMUNOL, V193, P335, DOI 10.4049/jimmunol.1303424
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517
   Karijolich J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005260
   Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541
   Kayagaki N, 2013, SCIENCE, V341, P1246, DOI 10.1126/science.1240248
   Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   LAING RA, 1976, EXP EYE RES, V22, P587, DOI 10.1016/0014-4835(76)90003-8
   LAING RA, 1975, ARCH OPHTHALMOL-CHIC, V93, P143
   Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629
   Man SM, 2016, NAT REV IMMUNOL, V16, P7, DOI 10.1038/nri.2015.7
   Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Miceli MV, 2005, INVEST OPHTH VIS SCI, V46, P1765, DOI 10.1167/iovs.04-1327
   MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221
   Nagai H, 2002, J INVEST DERMATOL, V119, P541, DOI 10.1046/j.1523-1747.2002.01866.x
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nunnari J, 2012, CELL, V148, P1145, DOI 10.1016/j.cell.2012.02.035
   Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160
   Rathinam VAK, 2012, CELL, V150, P606, DOI 10.1016/j.cell.2012.07.007
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4
   Schoggins JW, 2014, NATURE, V505, P691, DOI 10.1038/nature12862
   Shaikh TH, 1997, J MOL BIOL, V271, P222, DOI 10.1006/jmbi.1997.1161
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458
   Suschak JJ, 2016, J IMMUNOL, V196, P310, DOI 10.4049/jimmunol.1501836
   Suzuki M, 2007, MOL VIS, V13, P772
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   van Genderen H, 2006, NAT PROTOC, V1, P363, DOI 10.1038/nprot.2006.55
   Wallach D, 2016, SCIENCE, V352, DOI 10.1126/science.aaf2154
   Wang XM, 2012, AM J PHYSIOL-REG I, V302, pR805, DOI 10.1152/ajpregu.00350.2011
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   West AP, 2015, NATURE, V520, P553, DOI 10.1038/nature14156
   West AP, 2011, NAT REV IMMUNOL, V11, P389, DOI 10.1038/nri2975
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yan YQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080029
   Yang DH, 2015, IMMUNITY, V43, P923, DOI 10.1016/j.immuni.2015.10.009
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Zanoni I, 2016, SCIENCE, V352, P1232, DOI 10.1126/science.aaf3036
   Zhang Q, 2010, SHOCK, V34, P55, DOI 10.1097/SHK.0b013e3181cd8c08
NR 81
TC 148
Z9 156
U1 1
U2 48
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD JAN
PY 2018
VL 24
IS 1
BP 50
EP +
DI 10.1038/nm.4450
PG 16
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA FT2JB
UT WOS:000422965900010
PM 29176737
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ren, CD
   Liu, QY
   Wei, QQ
   Cai, WT
   He, MM
   Du, YR
   Xu, D
   Wu, Y
   Yu, J
AF Ren, Chengda
   Liu, Qingyu
   Wei, Qingquan
   Cai, Wenting
   He, Mengmei
   Du, Yaru
   Xu, Ding
   Wu, Yan
   Yu, Jing
TI Circulating miRNAs as Potential Biomarkers of Age-Related Macular
   Degeneration
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Age-related macular degeneration; microRNA; Microarray; Diagnosis;
   Case-control
ID PIGMENT EPITHELIAL-CELLS; COLORECTAL-CANCER; AMD; PLASMA; COMPLEMENT;
   MICRORNAS
AB Backgroud: Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness of the elder people. This research was intended to demonstrate the different expression of microRNAs (miRNA) in AMD patients and whether they can be used as biomarkers for AMD. Methods: MiRNAs expression was measured by microarray of 6 AMD cases and 6 gender matched controls. In a larger-sample case-control study with 126 AMD cases and 140 controls, whole blood samples were detected for the differences of miRNA expression. Results: A total of 216 differentially expressed miRNAs (111 increased and 105 decreased miRNAs) were detected from circulating miRNA microarray. Expanded case-control study results showed that the expression of miR-27a-3p, miR-29b-3p and miR-195-5p was increased significantly. Moreover, the level of miR-27a is higher in patients with wet AMD compared to patients with dry AMD. All 3 miRNAs showed a potential diagnostic value for AMD. Conclusion: Circulating miRNA levels were significantly varied in AMD patients. Three miRNAs, miR-27a-3p, miR-29b-3p and the miR-195-5p, might be potential diagnostic biomarkers for AMD. (C) 2017 The Author(s) Published by S. Karger AG, Basel
C1 [Ren, Chengda; Liu, Qingyu; Cai, Wenting; He, Mengmei; Xu, Ding; Yu, Jing] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Ophthalmol, Shanghai, Peoples R China.
   [Wei, Qingquan] Nanchang Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, Nanchang, Jiangxi, Peoples R China.
   [Du, Yaru] Nanjing Med Univ, Dept Clin Med Coll 1, Shanghai Peoples Hosp 10, Dept Ophthalmol, Nanjing, Jiangsu, Peoples R China.
   [Wu, Yan] Soochow Univ, Affiliated Hosp 1, Dept Ophthalmol, Suzhou, Peoples R China.
C3 Tongji University; Nanchang University; Nanjing Medical University;
   Soochow University - China
RP Xu, D; Wu, Y; Yu, J (通讯作者)，Shanghai Tenth Peoples Hosp, Bldg 6,Yanchang Rd 301, Shanghai, Peoples R China.
EM dryujing@aliyun.com; tmuyan@163.com; daisyxu70@hotmail.com
OI Cai, Wenting/0000-0002-2880-302X
FU National Natural Science Foundation of China [81470648]; Scientific
   Research Project of Shanghai Sanitary Bureau [20124100]
FX This work was supported by the National Natural Science Foundation of
   China (No 81470648) and Scientific Research Project of Shanghai Sanitary
   Bureau (No 20124100).
CR Armstrong DA, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0466-2
   Bhattacharjee S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150211
   Campagne MV, 2016, IMMUNOBIOLOGY, V221, P733, DOI 10.1016/j.imbio.2015.11.007
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Chang PY, 2016, ONCOTARGET, V7, P10663, DOI 10.18632/oncotarget.7119
   Chen HY, 2014, MOL THER, V22, P842, DOI 10.1038/mt.2013.235
   Chen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.92
   Chen XJ, 2015, ONCOTARGET, V6, P37553, DOI 10.18632/oncotarget.6065
   Eandi CM, 2016, EUR J PHARMACOL, V787, P78, DOI 10.1016/j.ejphar.2016.03.002
   Ertekin S, 2014, MOL VIS, V20, P1057
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Karali M, 2016, NUCLEIC ACIDS RES, V44, P1525, DOI 10.1093/nar/gkw039
   Lancon A, 2016, MOLECULES, V21, DOI 10.3390/molecules21030304
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Luttrull JK, 2016, INVEST OPHTH VIS SCI, V57, P265, DOI 10.1167/iovs.15-18163
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Qiu FF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120969
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Smyth, 2004, STAT APPL GENET MOL, V3, P1, DOI DOI 10.2202/1544-6115.1027
   Sun Y, 2016, ONCOTARGET, V7, P11434, DOI 10.18632/oncotarget.7196
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Wang LX, 2014, ONCOTARGET, V5, P2000, DOI 10.18632/oncotarget.1859
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Wu JC, 2015, BIOCHEM BIOPH RES CO, V466, P155, DOI 10.1016/j.bbrc.2015.08.121
   Zhang YJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep17942
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
   Zuo KQ, 2015, CELL PHYSIOL BIOCHEM, V35, P477, DOI 10.1159/000369713
NR 28
TC 36
Z9 37
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2017
VL 41
IS 4
BP 1413
EP 1423
DI 10.1159/000467941
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA EU6SC
UT WOS:000401163100013
PM 28315863
OA gold
DA 2022-11-30
ER

PT J
AU Dikmetas, O
   Kocabeyoglu, S
   Irkec, M
AF Dikmetas, Ozlem
   Kocabeyoglu, Sibel
   Irkec, Murat
TI CHARLES BONNET SYNDROME IN FUNGAL KERATITIS AND AGE-RELATED MACULAR
   DEGENERATION: A CASE REPORT
SO TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI
LA English
DT Article
DE Charles Bonnet Syndrome; Visual hallucinations; Keratitis; Age-related
   macular degeneration; Vision disorders
AB The primary symptom of Charles Bonnet Syndrome is the occurrence of chronic visual hallucinations, which are observed in patients belonging to the geriatric population who had recently experienced a significant loss of vision. Charles Bonnet Syndrome is under-recognised owing to its low awareness among clinicians. We report a case of a 78-year-old man with blindness due to keratitis and age-related macular degeneration brought for a psychiatric consultation after the onset of visual hallucinations. Black insects playing on the patient's body along with visuals of the meals others could not see characterised the patient's hallucinations. Physicians are expected to have substantial knowledge of Charles Bonnet Syndrome for its correct diagnosis and management.
RP Dikmetas, O (通讯作者)，Hacettepe Univ, Sch Med, Dept Ophthalmol, Ankara, Turkey.
EM ozlemdikmetas@gmail.com
RI dikmetas, ozlem/W-1603-2017
OI Dikmetas, Ozlem/0000-0001-5670-2384
CR Anand S, 2019, AUST NZ J PSYCHIAT, V53, P585, DOI 10.1177/0004867419844309
   Hamedani AG, 2019, CURR TREAT OPTION NE, V21, DOI 10.1007/s11940-019-0582-1
   Khan JC, 2008, OPHTHAL EPIDEMIOL, V15, P202, DOI 10.1080/09286580801939320
   Leandro JE, 2017, INVEST OPHTH VIS SCI, V58, P4138, DOI 10.1167/iovs.16-21270
   Nieman Eric, 2018, Pract Neurol, V18, P518, DOI 10.1136/practneurol-2018-002023
   Stojanov O, 2016, VOJNOSANIT PREGL, V73, P881, DOI 10.2298/VSP150321140S
   Vale TC, 2014, ARQ NEURO-PSIQUIAT, V72, P333, DOI 10.1590/0004-282X20140015
NR 7
TC 0
Z9 0
U1 0
U2 1
PU GUNES KITABEVI LTD STI
PI ANKARA
PA M RAUF INAN SOK NO 3, ANKARA, SIHHIYE 06410, TURKEY
SN 1304-2947
EI 1307-9948
J9 TURK J GERIATR
JI Turk. J. Geriatr.
PY 2019
VL 22
IS 4
BP 509
EP 512
DI 10.31086/tjgeri.2020.130
PG 4
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA KA4QW
UT WOS:000505782900015
DA 2022-11-30
ER

PT J
AU Fabre, M
   Mateo, L
   Lamaa, D
   Baillif, S
   Pages, G
   Demange, L
   Ronco, C
   Benhida, R
AF Fabre, Marie
   Mateo, Lou
   Lamaa, Diana
   Baillif, Stephanie
   Pages, Gilles
   Demange, Luc
   Ronco, Cyril
   Benhida, Rachid
TI Recent Advances in Age-Related Macular Degeneration Therapies
SO MOLECULES
LA English
DT Review
DE age-related maculopathy; dry age-related macular degeneration; wet
   age-related macular degeneration; eye's disease; elderly; clinical
   trials
ID RETINAL-PIGMENT EPITHELIUM; GEOGRAPHIC ATROPHY SECONDARY; TYROSINE
   KINASE INHIBITOR; GROWTH-FACTOR SECRETION; PAZOPANIB EYE DROPS;
   OPEN-ANGLE GLAUCOMA; OCULAR BLOOD-FLOW; CHOROIDAL NEOVASCULARIZATION;
   BINDING-PROTEIN; POTENTIAL TREATMENT
AB Age-related macular degeneration (AMD) was described for the first time in the 1840s and is currently the leading cause of blindness for patients over 65 years in Western Countries. This disease impacts the eye's posterior segment and damages the macula, a retina section with high levels of photoreceptor cells and responsible for the central vision. Advanced AMD stages are divided into the atrophic (dry) form and the exudative (wet) form. Atrophic AMD consists in the progressive atrophy of the retinal pigment epithelium (RPE) and the outer retinal layers, while the exudative form results in the anarchic invasion by choroidal neo-vessels of RPE and the retina. This invasion is responsible for fluid accumulation in the intra/sub-retinal spaces and for a progressive dysfunction of the photoreceptor cells. To date, the few existing anti-AMD therapies may only delay or suspend its progression, without providing cure to patients. However, in the last decade, an outstanding number of research programs targeting its different aspects have been initiated by academics and industrials. This review aims to bring together the most recent advances and insights into the mechanisms underlying AMD pathogenicity and disease evolution, and to highlight the current hypotheses towards the development of new treatments, i.e., symptomatic vs. curative. The therapeutic options and drugs proposed to tackle these mechanisms are analyzed and critically compared. A particular emphasis has been given to the therapeutic agents currently tested in clinical trials, whose results have been carefully collected and discussed whenever possible.
C1 [Fabre, Marie; Mateo, Lou; Demange, Luc; Ronco, Cyril; Benhida, Rachid] Univ Cote dAzur, CNRS, Inst Chim Nice UMR 7272, F-06108 Nice, France.
   [Lamaa, Diana; Demange, Luc] Univ Paris Cite 4, Fac Pharm, CNRS, CiTCoM,UMR 8038, Ave Observ, F-75006 Paris, France.
   [Baillif, Stephanie] Univ Hosp Nice, Ophthalmol Dept, 30 Ave Voie Romaine, F-06000 Nice, France.
   [Pages, Gilles] Univ Cote dAzur, CNRS, Inst Res Canc & Aging IRCAN, UMR 7284, 28 Ave Valombrose, F-06107 Nice, France.
   [Pages, Gilles] Univ Cote dAzur, CNRS, INSERM, U1081, 28 Ave Valombrose, F-06107 Nice, France.
   [Benhida, Rachid] Mohamed VI Polytech Univ UM6P, Dept Chem & Biochem Sci Green Proc Engn CBS GPE, Benguerir 43150, Morocco.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of
   Chemistry (INC); UDICE-French Research Universities; Universite Cote
   d'Azur; Centre National de la Recherche Scientifique (CNRS);
   UDICE-French Research Universities; Universite Paris Cite; Universite de
   Franche-Comte; CHU Nice; Centre National de la Recherche Scientifique
   (CNRS); CNRS - National Institute for Biology (INSB); CHU Nice;
   UDICE-French Research Universities; Universite Cote d'Azur; Centre
   National de la Recherche Scientifique (CNRS); Institut National de la
   Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Universite Cote d'Azur
RP Demange, L; Ronco, C; Benhida, R (通讯作者)，Univ Cote dAzur, CNRS, Inst Chim Nice UMR 7272, F-06108 Nice, France.; Demange, L (通讯作者)，Univ Paris Cite 4, Fac Pharm, CNRS, CiTCoM,UMR 8038, Ave Observ, F-75006 Paris, France.; Benhida, R (通讯作者)，Mohamed VI Polytech Univ UM6P, Dept Chem & Biochem Sci Green Proc Engn CBS GPE, Benguerir 43150, Morocco.
EM luc.demange@parisdescartes.fr; cyril.ronco@univ-cotedazur.fr;
   rachid.benhida@univ-cotedazur.fr
OI Lamaa, Diana/0000-0002-2341-4666; baillif,
   stephanie/0000-0003-1700-8570; Ronco, Cyril/0000-0002-9023-5940
FU French ANR (aapg-TARMAC); University Cote d'Azur; CNRS; Region Sud
FX This research was funded by the French ANR (aapg-TARMAC). University
   Cote d'Azur, CNRS and Region Sud are also acknowledged for additional
   funding.
CR Adams CM, 2018, J MED CHEM, V61, P1622, DOI 10.1021/acs.jmedchem.7b01731
   Agostini H, 2020, CURR EYE RES, V45, P1298, DOI 10.1080/02713683.2020.1731832
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Allen E, 2011, CLIN CANCER RES, V17, P5299, DOI 10.1158/1078-0432.CCR-10-2847
   Allergen A, SAFETY EFFICACY STUD
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   amdbook, AGN 745 SIRN 027 WET
   Andreasen N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0098153
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   apellis, AP ANN TOP LIN RES P
   Armstrong M., 2021, ADVERUM HALT RAISES
   Arnon R., 1999, CHEM ISR, V1, P12
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Ashraf M, 2017, EYE, V31, P1523, DOI 10.1038/eye.2017.81
   Assessment of Safety clinicaltrials, TOL PHARM INTR APL 2
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   AVELINE B, 1994, PHOTOCHEM PHOTOBIOL, V59, P328, DOI 10.1111/j.1751-1097.1994.tb05042.x
   Bavik C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124940
   BERNI R, 1992, FEBS LETT, V308, P43, DOI 10.1016/0014-5793(92)81046-O
   Bhide RS, 2010, MOL CANCER THER, V9, P369, DOI 10.1158/1535-7163.MCT-09-0472
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Bracha P, 2017, EXPERT OPIN BIOL TH, V17, P1113, DOI 10.1080/14712598.2017.1346079
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Brycki B, 2015, MOLECULES, V20, P20887, DOI 10.3390/molecules201119735
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Cantor L B, 2000, Expert Opin Pharmacother, V1, P815, DOI 10.1517/14656566.1.4.815
   Carr BI, 2013, J CELL PHYSIOL, V228, P1344, DOI 10.1002/jcp.24291
   Chakradhar S, 2016, NAT MED, V22, P116, DOI 10.1038/nm0216-116
   Chen ER, 2020, CLIN OPHTHALMOL, V14, P1349, DOI 10.2147/OPTH.S194234
   Chen JY, 2018, MOL IMMUNOL, V102, P58, DOI 10.1016/j.molimm.2018.05.018
   Cheng KJ, 2020, J MED CHEM, V63, P10533, DOI 10.1021/acs.jmedchem.9b01033
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chiou B.G., 2012, RETIN TODAY, V1101, P69
   Cholkar K, 2012, WOODH PUB SER BIOMED, P1, DOI 10.1533/9781908818317.1
   Choudhary M, 2016, AGING-US, V8, P1952, DOI 10.18632/aging.101031
   Cioffi CL, 2020, J MED CHEM, V63, P11054, DOI 10.1021/acs.jmedchem.0c00996
   Cioffi CL, 2015, J MED CHEM, V58, P5863, DOI 10.1021/acs.jmedchem.5b00423
   Cioffi CL, 2014, J MED CHEM, V57, P7731, DOI 10.1021/jm5010013
   Clinical Pharmacology and Biopharmaceutics Review Neulasta&REG; (pegfilgrastim) Reference ID 3628157 [Internet], 2014, US FOOD DRUG ADM
   clinicaltrials, ZIMURA SUBJECTS GEOG
   clinicaltrials, RANDOMIZED DOUBLE MA
   clinicaltrials, STUDY IMPLANTATION R
   clinicaltrials, STUDY RO6867461 ADMI
   clinicaltrials, SAFETY EFFICACY BRIM
   clinicaltrials, SAFETY PHARMACOKINET
   clinicaltrials, INTRAVITREAL INJECTI
   clinicaltrials, CLIN TRIAL DESIGNED
   clinicaltrials, PHASE 1 STUDY TOPICA
   clinicaltrials, GEOGRAPHIC ATROPHY T
   clinicaltrials, MSI 1256F SQUALAMINE
   clinicaltrials, TREATMENT ADV DRY AG
   clinicaltrials, EFFICACY SAFETY TOLE
   clinicaltrials, STUDY INTRAVITREAL R
   clinicaltrials, RETINAL PIGMENT EPIT
   clinicaltrials, STUDY ENCAPSULATED C
   clinicaltrials, PHASE 3 STUDY ALK 00
   clinicaltrials, STUDY EVALUATE PAZOP
   clinicaltrials, STUDY COLLECT SAFETY
   clinicaltrials, PILOT STUDY X 82 PAT
   clinicaltrials, PIVOTAL 1 STUDY RGX
   clinicaltrials, STUDY INTRAVITREAL I
   clinicaltrials, X82 TREAT AGE RELATE
   clinicaltrials, PHARMACOKINETIC PHAR
   clinicaltrials, COPAXONE AGE RELATED
   clinicaltrials, SAFETY EFFICACY STUD
   clinicaltrials, EXTENSION STUDY MD71
   clinicaltrials, APL 2 NEOVASCULAR AM
   clinicaltrials, PHARMACOKINETICS CLG
   clinicaltrials, SAFETY INTRAVITREAL
   clinicaltrials, OMEGA STUDY USE EYE
   clinicaltrials, EFFECTS SILDENAFIL C
   clinicaltrials, STUDY ASSESSING SAFE
   clinicaltrials, CLG561 PROOF OF CONC
   clinicaltrials, EVALUATE EFFECTS SAF
   clinicaltrials, PHASE 1 DOSE ESCALAT
   clinicaltrials, STUDY DANICOPAN PART
   clinicaltrials, PILOT STUDY SAFETY M
   clinicaltrials, AAVCAGSCD59 TREATMEN
   clinicaltrials, SAFETY EFFICACY INTR
   clinicaltrials, ADVM 022 INTRAVITREA
   clinicaltrials, CLIN STUDY INVESTIGA
   clinicaltrials, STUDY INVESTIGATING
   clinicaltrials, PROOF OF CONCEPT STU
   clinicaltrials, COMPLEMENT INHIBITIO
   clinicaltrials, ANECORTAVE ACETATE P
   clinicaltrials, RGX 314 GENE THERAPY
   clinicaltrials, SAFETY STUDY HLTH VO
   clinicaltrials, EFFICACY SAFETY STUD
   clinicaltrials, LONG TERM FOLLOW UP
   clinicaltrials, STUDY COMBINATION AN
   clinicaltrials, STUDY EVALUATE EFFIC
   clinicaltrials, PHASE 3 SAFETY EFFIC
   clinicaltrials, SAFETY EFFICACY IONI
   clinicaltrials, STUDY MSI 1256F SQUA
   clinicaltrials, MULTIPLE DOSE STUDY
   clinicaltrials, FLUOCINOLONE ACETONI
   clinicaltrials, ANTIANGIOPOEITIN 2 P
   clinicaltrials, SAFETY TOLERABILITY
   clinicaltrials, WEEKLY VACCINATION C
   clinicaltrials, LONG TERM SAFETY LAM
   clinicaltrials, WEEK PATIENT STUDY N
   clinicaltrials, STUDY EVALUATING TRE
   clinicaltrials, EXPLORE PHASE 2 STUD
   clinicaltrials, LHA510 PROOF OF CONC
   clinicaltrials, PHASE 1 2 STUDY OCUL
   clinicaltrials, STUDY SAFETY BROLUCI
   clinicaltrials, SIROLIMUS ADV AGE RE
   clinicaltrials, SAFETY EFFICACY ABIC
   clinicaltrials, STUDY LAMPALIZUMAB I
   clinicaltrials, EVALUATION AGN 15099
   clinicaltrials, STUDY EVALUATE SAFET
   clinicaltrials, TRIPLE COMBINATION T
   clinicaltrials, ARC1905 ANTIC5 APTAM
   clinicaltrials, VASCULAR ENDOTHELIAL
   clinicaltrials, PHASE 1 SAFETY TOLER
   clinicaltrials, STUDY COMPARE RHUFAB
   clinicaltrials, STUDY ABICIPAR PEGOL
   clinicaltrials, HEAD HEAD STUDY ANTI
   clinicaltrials, STUDY REPEAT DOSING
   clinicaltrials, INTRAVITREAL LFG316
   clinicaltrials, STUDY HUCNS SC SUBRE
   clinicaltrials, SIROLIMUS VERSUS ANT
   clinicaltrials, STUDY FENRETINIDE TR
   clinicaltrials, STUDY APL 2 THERAPY
   clinicaltrials, EXTENSION STUDY EVAL
   clinicaltrials, EFFICACY SAFETY SQUA
   clinicaltrials, ZIMURA COMBINATION L
   clinicaltrials, EFFECTIVENESS ORAL A
   clinicaltrials, STUDY EVALUATING SAF
   clinicaltrials, DEPOT FORMULATION SU
   clinicaltrials, MACULAR PHOTOCOAGULA
   clinicaltrials, SAFETY EFFICACY ATG0
   clinicaltrials, MULTICENTER PROOF OF
   clinicaltrials, DOSE ESCALATION TRIA
   clinicaltrials, 1 HUMAN STUDY EVALUA
   clinicaltrials, EVALUATE THERAPEUTIC
   clinicaltrials, DOSE RANGING STUDY O
   clinicaltrials, ANECORTAVE ACETATE V
   clinicaltrials, STUDY EVALUATE RHUFA
   clinicaltrials, GENERATION INDUCED P
   clinicaltrials, REGORAFENIB EYE DROP
   clinicaltrials, STUDY SUBRETINAL IMP
   clinicaltrials, GOLDEN STUDY STUDY A
   clinicaltrials, STUDY SAFETY EFFICAC
   clinicaltrials, PHASE 1 SAFETY STUDY
   clinicaltrials, EFFICACY SAFETY TRIA
   clinicaltrials, EFFICACY SAFETY RTH2
   clinicaltrials, EVALUATING ABICIPAR
   clinicaltrials, STUDY PAN 90806 EYE
   clinicaltrials, STUDY HUMAN CENTRAL
   clinicaltrials, STUDY USING INTRAVIT
   clinicaltrials, EVALUATE PHARMACODYN
   clinicaltrials, OT 551 ANTIOXIDANT E
   clinicaltrials, PHASE 1 ASCENDING PA
   clinicaltrials, SAFETY STUDY TOPICAL
   clinicaltrials, STUDY SAFETY TOLERAB
   clinicaltrials, LONG TERM FOLLOW SUB
   clinicaltrials, SIROLIMUS CONJUNCTIO
   clinicaltrials, 1 IN HUMAN STUDY LHA
   clinicaltrials, STUDY EVALUATE LONG
   clinicaltrials, SAFETY STUDY EVALUAT
   clinicaltrials, EVALUATION AL 78898A
   clinicaltrials, DOSE RANGING STUDY P
   clinicaltrials, OPEN STUDY COMPARING
   clinicaltrials, PRODUCTION IPSC DERI
   clinicaltrials, SAFETY EFFICACY ASSE
   clinicaltrials, STUDY ARC1905 ANTI C
   clinicaltrials, STUDY COMPARE EFFICA
   clinicaltrials Safety and Efficacy Study of RAAV, SFLT 1 PAT EX AG REL
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P834, DOI 10.1097/IAE.0b013e31822058a3
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Constable I, 2005, EXPERT OPIN BIOL TH, V5, P1373, DOI 10.1517/14712598.5.10.1373
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Costa R, 2016, DRUG DES DEV THER, V10, P873, DOI 10.2147/DDDT.S93459
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Cunningham E.T., JR IMPACT OHR 102 IM
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Davey MP, 2000, AM J OPHTHALMOL, V129, P235, DOI 10.1016/S0002-9394(99)00433-X
   De Jong PTVM, 2018, EYE, V32, P904, DOI 10.1038/eye.2017.298
   de Moraes AV, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165706
   de sante Haute Autorite, 2017, PLAC STRAT THER LUCE
   Diago T, 2008, MAYO CLIN PROC, V83, P231
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dobri N, 2013, INVEST OPHTH VIS SCI, V54, P85, DOI 10.1167/iovs.12-10050
   Dugel PU, 2020, OPHTHALMOL RETINA, V4, P250, DOI 10.1016/j.oret.2019.10.008
   Dugel PU, 2015, RETINA-J RET VIT DIS, V35, P1173, DOI 10.1097/IAE.0000000000000606
   Edgar M., 2018, Compositions and Methods for Treating Ophthalmic Conditions Patent, Patent No. 2012078525
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eng VA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232353
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   European Medicines Agency, 2019, ASS REP BEOV
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   EyePoint Pharmaceuticals Inc, 2020, SECURITIES EXCHANGE, V1933
   Farazdaghi MK, 2019, J OPHTHAL VIS RES, V14, P78, DOI 10.4103/jovr.jovr_125_18
   fda, 2020, US
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FocuS, 1 HUM STUD EV SAF EF
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   Food and Drug Administration, 2012, GLUC
   Forrester J.V., 2016, EYE
   Foye W. O., 2008, FOYES PRINCIPLES MED
   Freeman W.R., BRIMONIDINE DRUG DEL
   French Evaluation Group, FRENCH EVALUATION GR
   Garba AO, 2010, OPHTHALMOL EYE DIS, V2, P75, DOI 10.4137/OED.S4878
   Giddabasappa A, 2016, EXP EYE RES, V145, P373, DOI 10.1016/j.exer.2016.02.010
   Glazer LC, 2016, INVEST OPHTH VIS SCI, V57
   globenewswire, REP TOP LIN RES ITS
   Gohdes Dorothy M, 2005, Prev Chronic Dis, V2, pA17
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grishanin R, 2019, MOL THER, V27, P118, DOI 10.1016/j.ymthe.2018.11.003
   Gross-Goupil M, 2013, CLIN MED INSIGHTS-ON, V7, P269, DOI 10.4137/CMO.S10594
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Haute Autorite de Sante, 2008, NEX
   Haute Autorite de Sante, 2018, RAN
   Haute Autorite de Sante, 2006, VISUDYNE
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Heier J.S., ASK DOCTOR MACULAR D
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   HORIZON, PHAS 2 STUD EV SAF E
   Houle JM, 2002, J CLIN PHARMACOL, V42, P547, DOI 10.1177/00912700222011607
   Hussain RM, 2018, EXPERT OPIN BIOL TH, V18, P1049, DOI 10.1080/14712598.2018.1513486
   Hussain RM, 2018, EXPERT OPIN PHARMACO, V19, P471, DOI 10.1080/14656566.2018.1448060
   Hyman Jaime B, 2020, Crit Care Explor, V2, pe0254, DOI 10.1097/CCE.0000000000000254
   Infliximab, SIR DACL TREAT AG RE
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   Jackson TL, 2017, JAMA OPHTHALMOL, V135, P761, DOI 10.1001/jamaophthalmol.2017.1571
   Jaffe GJ, 2020, INVEST OPHTH VIS SCI, V61
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Jones A.A., 2007, CLINICS PRACT, V36, P1026
   Joussen AM, 2019, BRIT J CLIN PHARMACO, V85, P347, DOI 10.1111/bcp.13794
   Kanemura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085336
   Kang S, 2013, CURR EYE RES, V38, P119, DOI 10.3109/02713683.2012.727520
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaszuba-Bartkowiak K, 2007, ARCH MED SCI, V3, pS65
   Kauper K, 2012, INVEST OPHTH VIS SCI, V53, P7484, DOI 10.1167/iovs.12-9970
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kernt M, 2010, BRIT J OPHTHALMOL, V94, P1533, DOI 10.1136/bjo.2010.182162
   Kernt M, 2008, ACTA OPHTHALMOL, V86, P456, DOI 10.1111/j.1600-0420.2007.01014.x
   Khanani AM, 2021, CLIN OPHTHALMOL, V15, P3747, DOI 10.2147/OPTH.S231801
   Khatol P, 2018, CRIT REV THER DRUG, V35, P65, DOI 10.1615/CritRevTherDrugCarrierSyst.2017020231
   Kim K, 2017, GENOME RES, V27, P419, DOI 10.1101/gr.219089.116
   Kim S, 2014, GENOME RES, V24, P1012, DOI 10.1101/gr.171322.113
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Kubota R, 2014, RETINA-J RET VIT DIS, V34, P603, DOI 10.1097/01.iae.0000434565.80060.f8
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Kunimoto D, 2019, OSLI RETINA, V50, pE10, DOI 10.3928/23258160-20190129-13
   Kuno N, 2010, DRUG AGING, V27, P117, DOI 10.2165/11530970-000000000-00000
   Kuppermann BD, 2021, RETINA-J RET VIT DIS, V41, P144, DOI 10.1097/IAE.0000000000002789
   Kurup SK, 2010, ACTA OPHTHALMOL, V88, pe145, DOI 10.1111/j.1755-3768.2009.01560.x
   Lancon A, 2016, MOLECULES, V21, DOI 10.3390/molecules21030304
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   Lashkari K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195751
   Lem DW, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10081255
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   LESPERANCE FA, 1985, OPHTHALMOLOGY, V92, P1592
   Leung E, 2013, EXPERT REV CLIN PHAR, V6, P565, DOI 10.1586/17512433.2013.829645
   Lewis P.A., 2016, Patent No. 2013188217
   Li JQ, 2020, EUR J EPIDEMIOL, V35, P11, DOI 10.1007/s10654-019-00560-z
   Li L, 2020, J CELL PHYSIOL, V235, P1259, DOI 10.1002/jcp.29041
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Li YW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009495
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lim J.I., 2012, NEOVASCULAR AGE RELA, V3rd ed.
   Lim Jennifer I, 2002, Ophthalmol Clin North Am, V15, P473, DOI 10.1016/S0896-1549(02)00044-5
   Lipecz A, 2019, GEROSCIENCE, V41, P813, DOI 10.1007/s11357-019-00138-3
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Ly A, 2016, OPHTHAL PHYSL OPT, V36, P303, DOI 10.1111/opo.12283
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Malpeli G, 1996, BBA-PROTEIN STRUCT M, V1294, P48, DOI 10.1016/0167-4838(95)00264-2
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Masse H, 2016, J FR OPHTALMOL, V39, P40, DOI 10.1016/j.jfo.2015.10.001
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   McGill TJ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.43
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   McLaughlin MM, 2013, JAMA OPHTHALMOL, V131, P1595, DOI 10.1001/jamaophthalmol.2013.5002
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Metelitsina TI, 2006, EXP EYE RES, V83, P128, DOI 10.1016/j.exer.2005.11.012
   Mettu PS, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100906
   Moschos MM, 2014, J CHEM-NY, V2014, DOI 10.1155/2014/317536
   Napoli KL, 2001, THER DRUG MONIT, V23, P559, DOI 10.1097/00007691-200110000-00012
   Narayanan R, 2017, HANDB EXP PHARMACOL, V242, P309, DOI 10.1007/164_2016_22
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Nguyen TT, 2015, EXPERT REV CLIN PHAR, V8, P541, DOI 10.1586/17512433.2015.1075879
   novartis, NOVARTIS NOVARTIS RE
   Nowak MS, 2007, ARCH MED SCI, V3, P152
   Office of the Commissioner, 2018, COP
   ophthalmologytimes, GRAYBUG VISION RELEA
   Oral Acetazolamide, BRIM TART ANT CHAMB
   Parikh SM, 2017, J AM SOC NEPHROL, V28, P1973, DOI 10.1681/ASN.2017010069
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Park EJ, 2019, EXPERT OPIN EMERG DR, V24, P107, DOI 10.1080/14728214.2019.1604684
   Park YG, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/637316
   Pemp B, 2012, ACTA OPHTHALMOL, V90, P139, DOI 10.1111/j.1755-3768.2010.01878.x
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Pharmacokinetic (PK), PHARM PK STUDY GSK93
   Pichi F, 2018, ACTA OPHTHALMOL, V96, pE549, DOI 10.1111/aos.13602
   Pietras RJ, 2005, EVID-BASED COMPL ALT, V2, P49, DOI 10.1093/ecam/neh066
   Poor SH, 2018, INVEST OPHTH VIS SCI, V59
   Prati F., 2013, CATHETER CARDIO INTE, V254, P363, DOI [10.1007/978-3-642-27676-7_21, DOI 10.1007/978-3-642-27676-7_21]
   Pravin U., DUGEL CLIN TRIAL DOW
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Resch H, 2009, ACTA OPHTHALMOL, V87, P731, DOI 10.1111/j.1755-3768.2008.01338.x
   Rhee KD, 2013, P NATL ACAD SCI USA, V110, pE4520, DOI 10.1073/pnas.1303604110
   Ribatti D, 2008, ENDOTHELIUM-J ENDOTH, V15, P1, DOI 10.1080/10623320802092377
   Richter A M, 1996, J Clin Laser Med Surg, V14, P335
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Risitano AM, 2021, HAEMATOLOGICA, V106, P3188, DOI 10.3324/haematol.2020.261826
   roche, ROCH PROV UPD 1 LAMP
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Rudolf M., 2019, US Patent, Patent No. 20180207233
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Saad L, 2016, ADV EXP MED BIOL, V854, P355, DOI 10.1007/978-3-319-17121-0_47
   Saari JC, 2012, ANNU REV NUTR, V32, P125, DOI 10.1146/annurev-nutr-071811-150748
   Sadiq MA, 2015, SAUDI J OPHTHALMOL, V29, P287, DOI 10.1016/j.sjopt.2015.05.005
   Saini R, 2016, CANCERS, V8, DOI 10.3390/cancers8090083
   Salvi SM, 2006, POSTGRAD MED J, V82, P581, DOI 10.1136/pgmj.2005.040857
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schnabolk G, 2018, MOL THER-METH CLIN D, V9, P1, DOI 10.1016/j.omtm.2017.11.003
   Scholz A, 2015, ANN NY ACAD SCI, V1347, P45, DOI 10.1111/nyas.12726
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shaw LT, 2020, EXPERT OPIN INV DRUG, V29, P547, DOI 10.1080/13543784.2020.1763953
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Shin Y, 2018, BBA-MOL BASIS DIS, V1864, P2420, DOI 10.1016/j.bbadis.2018.04.014
   Singh R, 2014, RETINA-J RET VIT DIS, V34, P1787, DOI 10.1097/IAE.0000000000000179
   Soheilian M, 2011, EUR J OPHTHALMOL, V21, P77, DOI 10.5301/EJO.2010.5696
   Stein MN, 2007, CLIN CANCER RES, V13, P3765, DOI 10.1158/1078-0432.CCR-06-2844
   Sternberg P, 2010, INVEST OPHTH VIS SCI, V51
   Stetson PF, 2014, INVEST OPHTH VIS SCI, V55, P792, DOI 10.1167/iovs.13-13199
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Strauss O, 1998, ACTA ANAT, V162, P101
   Sulaiman RS, 2018, ACS CHEM BIOL, V13, P45, DOI 10.1021/acschembio.7b00854
   Sulaiman RS, 2016, SCI REP-UK, V6, DOI 10.1038/srep25509
   Surendran H, 2019, METHODS MOL BIOL, V2045, P283, DOI 10.1007/7651_2018_140
   Suri R, 2021, INT J BIOL MACROMOL, V191, P548, DOI 10.1016/j.ijbiomac.2021.09.069
   TAC-PF, AV COMB PHOT THER TR
   Terasaki H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069994
   Tolentino MJ, 2015, EXPERT OPIN INV DRUG, V24, P183, DOI 10.1517/13543784.2015.961601
   Tsioumpekou M, 2020, THERANOSTICS, V10, P1122, DOI 10.7150/thno.37851
   Tura A., 2018, NEW FRONT OPHTHALMOL, V4, P1, DOI [10.15761/NFO.1000219, DOI 10.15761/NFO.1000219]
   U.S. Food and Drug Administration, 2018, LENVIMA
   U.S. Food and Drug Administration, 2011, NEXAVAR SOR
   U.S. Food and Drug Administration, 2016, ALPH
   U.S. Food and Drug Administration, 2017, RAP
   U.S. Food and Drug Administration, 2016, IL
   U.S. Food and Drug Administration, 2017, STIV
   U.S. Food and Drug Administration, 2007, SOL
   U.S. Food and Drug Administration, 2018, EYLEA AFL
   US FDA, 2021, FDA AUTH SOFTW CAN H
   Vallee A, 2017, LIFE SCI, V188, P123, DOI 10.1016/j.lfs.2017.09.008
   Vascular Endothelial Growth Factor (VEGF), TRAP EYE INV EFF SAF
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   VILLA RF, 1981, BIOCHEM PHARMACOL, V30, P2399, DOI 10.1016/0006-2952(81)90333-6
   Vuong VS, 2017, INVEST OPHTH VIS SCI, V58
   WAKEFIELD D, 1992, CYTOKINE, V4, P1, DOI 10.1016/1043-4666(92)90028-P
   Walters TR, 1996, SURV OPHTHALMOL, V41, pS19, DOI 10.1016/S0039-6257(96)82028-5
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang YY, 2021, GERONTOLOGY, DOI 10.1159/000518822
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   Wei X, 2018, EXP EYE RES, V168, P2, DOI 10.1016/j.exer.2017.12.009
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   who, EYE CARE VISION IMPA
   Wiegering A, 2014, NEOPLASIA, V16, P972, DOI 10.1016/j.neo.2014.09.008
   Wolf A, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910362
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Xie P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053329
   Xu QY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-017-0647-7
   Yan J, 2018, J PHOTOCH PHOTOBIO B, V183, P133, DOI 10.1016/j.jphotobiol.2018.04.033
   Yannuzzi NA, 2019, CLIN OPHTHALMOL, V13, P1323, DOI 10.2147/OPTH.S184706
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yiu G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41509-2
   Yong VW, 2002, NEUROLOGY, V59, P802, DOI 10.1212/WNL.59.6.802
   Yorston David, 2014, Community Eye Health, V27, P47
   Yuan X, 2017, HAEMATOLOGICA, V102, P466, DOI 10.3324/haematol.2016.153312
   Zarling JA, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00325
   Zhang JY, 2015, J CLIN INVEST, V125, P2781, DOI 10.1172/JCI80950
   Zhang JX, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0807-1
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zhao HL, 2014, THORAC CANCER, V5, P487, DOI 10.1111/1759-7714.12136
   Zhao YH, 2015, MOL NEUROBIOL, V52, P533, DOI 10.1007/s12035-014-8886-3
   Zhu W, 2015, DRUG DES DEV THER, V9, P5337, DOI 10.2147/DDDT.S84979
   Zuo W, 2020, EXPERT REV CLIN PHAR, V13, P191, DOI 10.1080/17512433.2020.1713749
   Zuris JA, 2015, NAT BIOTECHNOL, V33, P73, DOI 10.1038/nbt.3081
NR 423
TC 0
Z9 0
U1 11
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD AUG
PY 2022
VL 27
IS 16
AR 5089
DI 10.3390/molecules27165089
PG 64
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 4A9HV
UT WOS:000845403600001
PM 36014339
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chen, L
   Li, ML
   Messinger, JD
   Ferrara, D
   Curcio, CA
   Freund, KB
AF Chen, Ling
   Li, Miaoling
   Messinger, Jeffrey D.
   Ferrara, Daniela
   Curcio, Christine A.
   Freund, K. Bailey
TI Recognizing Atrophy and Mixed-Type Neovascularization in Age-Related
   Macular Degeneration Via Clinicopathologic Correlation
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; neovascularization; photoreceptors;
   retinal pigment epithelium; Muller glia; choriocapillaris; gliosis;
   atrophy; transdifferentiation; optical coherence tomography; fluorescein
   angiography
ID RETINAL-PIGMENT EPITHELIUM; CHOROIDAL NEOVASCULARIZATION; GEOGRAPHIC
   ATROPHY; CHOLESTEROL; PROGRESSION; EVOLUTION; EYES
AB Purpose: We explored via multimodal imaging and histology an eye with mixed-types 1 and 2 macular neovascularization (MNV) and complete retinal pigment epithelium (RPE) and outer retinal atrophy (cRORA) in age-related macular degeneration.
   Methods: An 82-year-old white man was followed 7 years by optical coherence tomography and treated with intravitreal anti-vascular endothelial growth factor for 3 years. At the last clinic visit, visual acuity was stable at 20/50. Two months later the patient died, and eyes were preserved at 8.33 hours after death. Submicrometer epoxy resin sections of osmicated tissue were stained with toluidine blue and evaluated by oil immersion microscopy.
   Results: A shallow irregular RPE elevation on optical coherence tomography correlated with type 1 MNV with fibrocellular scar and neocapillaries (close to RPE), at a density similar to underlying native choriocapillaris (0.37 vs. 0.42). Type 2 MNV covered the native RPE and was enveloped at the margins by RPE, without neocapillaries. Native RPE cells trans differentiated from age-normal to melanotic and entered type 1 MNV and choroid. Some photoreceptors persisted over MNV. The cRORA initiated at a collapsed druse, expanded during follow-up, and exhibited low choriocapillaris density (0.05).
   Conclusions: An eye with maintained vision on 3 years of anti-vascular endothelial growth factor therapy had type 1 MNV sustaining RPE. Type 2 MNV enveloped by RPE was visible in optical coherence tomography and histology. Persistence of photoreceptors and RPE over MNV contrasted with drusen-associated cRORA.
   Translational Relevance: Vision during long-term anti-vascular endothelial growth factor treatment persists by MNV partially preserving outer retinal cells and by RPE enveloping type 2 MNV.
C1 [Chen, Ling; Messinger, Jeffrey D.; Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, Sch Med, Birmingham, AL 35294 USA.
   [Chen, Ling; Li, Miaoling] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China.
   [Ferrara, Daniela] Genentech Inc, San Francisco, CA USA.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
   [Freund, K. Bailey] Columbia Univ Coll Phys & Surg, Harkness Eye Inst, 630 W 168th St, New York, NY 10032 USA.
C3 University of Alabama System; University of Alabama Birmingham; Sun Yat
   Sen University; Roche Holding; Genentech; Vitreous Retina Macula
   Consultants of New York; Manhattan Eye Ear & Throat Hospital; New York
   University; Columbia University
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, EyeSight Fdn Alabama Vis Res Labs, 1670 Univ Blvd Room 360, Birmingham, AL 35294 USA.
EM christinecurcio@uabmc.edu
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Genentech/Hoffman LaRoche; Heidelberg Engineering; Macula Foundation,
   Inc., New York, NY; Research to Prevent Blindness, Inc.; EyeSight
   Foundation of Alabama
FX Supported by Genentech/Hoffman LaRoche, Heidelberg Engineering, The
   Macula Foundation, Inc., New York, NY; unrestricted funds to the
   Department of Ophthalmology and Visual Sciences (UAB) from Research to
   Prevent Blindness, Inc., and EyeSight Foundation of Alabama.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   ANDERSON DH, 1986, INVEST OPHTH VIS SCI, V27, P168
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Chen L, 2019, RETINA, V40, P618
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Christenbury JG, 2018, RETINA-J RET VIT DIS, V38, P1276, DOI 10.1097/IAE.0000000000001766
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Curcio CA, 2015, AM J OPHTHALMOL, V160, P1024, DOI 10.1016/j.ajo.2015.08.001
   Dhrami-Gavazi Elona, 2015, Int J Retina Vitreous, V1, P15
   Dolz-Marco R, 2016, RETINA, V37, P222
   Dolz-Marco R, 2018, OPHTHALMOLOGY, V125, P1287, DOI 10.1016/j.ophtha.2018.02.036
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fuhrmann S, 2014, EXP EYE RES, V123, P141, DOI 10.1016/j.exer.2013.09.003
   Gambril JA, 2019, INVEST OPHTH VIS SCI, V60, P2481, DOI 10.1167/iovs.19-26949
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Li ML, 2019, RETINA-J RET VIT DIS, V39, P802, DOI 10.1097/IAE.0000000000002461
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mones J, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.026
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Naysan J, 2016, RETINA-J RET VIT DIS, V36, P449, DOI 10.1097/IAE.0000000000000758
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Pang CE, 2014, RETINA-J RET VIT DIS, V34, P1513, DOI 10.1097/IAE.0000000000000163
   Parodi MB, 2016, RETINA-J RET VIT DIS, V36, P104, DOI 10.1097/IAE.0000000000000684
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sarks J, 2006, BRIT J OPHTHALMOL, V90, P442, DOI 10.1136/bjo.2005.083022
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Shen LB, 2018, OPHTHALMOL RETINA, V2, P914, DOI 10.1016/j.oret.2018.01.019
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P2349, DOI 10.1167/iovs.16-21237
   Vance SK, 2011, RETINA-J RET VIT DIS, V31, P717, DOI 10.1097/IAE.0b013e318203c1ef
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Xu XY, 2017, AM J OPHTHALMOL, V175, P87, DOI 10.1016/j.ajo.2016.11.021
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zhang XZ, 2013, OPHTHALMOLOGY, V120, P2678, DOI 10.1016/j.ophtha.2013.05.012
NR 49
TC 17
Z9 17
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JUL
PY 2020
VL 9
IS 8
AR 8
DI 10.1167/tvst.9.8.8
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MY9JT
UT WOS:000558736500009
PM 32855855
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Silva, RM
   Figueira, J
   Cachulo, ML
   Duarte, L
   de Abreu, JRF
   Cunha-Vaz, JG
AF Silva, RM
   Figueira, J
   Cachulo, ML
   Duarte, L
   de Abreu, JRF
   Cunha-Vaz, JG
TI Polypoidal choroidal vasculopathy and photodynamic therapy with
   verteporfin
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE polypoidal choroidal vasculopathy; PDT; photodynamic therapy; laser
   treatment; AMD
ID INDOCYANINE-GREEN VIDEOANGIOGRAPHY
AB Background: We evaluated, in a nonrandomised, institutional, prospective study, the efficacy of photodynamic therapy (PDT) with verteporfin in age-related macular degeneration (AMD) eyes with polypoidal choroidal vasculopathy (PCV) and subfoveal exudation. Methods: A prospective clinical and angiographic study was done in 40 consecutive eyes with PCV treated with PDT using masked best-corrected visual acuity (VA) and fluorescein and indocyanine green angiographic features at baseline and over 2 years. Results: Twenty-one eyes completed 1-year follow-up and showed, after a mean 2.9 PDT sessions, VA improvement in 12 eyes, no change in five eyes, and VA decrease in four eyes. Leakage was absent at the retinal and choroidal level in 14 eyes at 1 year. Recurrence occurred in one eye during the first year. Six eyes completed 2 years of follow-up and showed, after a mean 4 PDT sessions, VA improvement in five eyes and VA decrease in one eye. Leakage was absent at the retinal and choroidal level in five eyes. Recurrence occurred in four of these six eyes during the second year of follow-up. No serious adverse events were observed during the 2 years of follow-up. Conclusions: PDT with verteporfin was shown to be safe and effective for treating AMD eyes with PCV with subfoveal involvement. VA improvement and absence of leakage were achieved, respectively, in 57.1% and 66.6% of the eyes at 1 year. Recurrences were more frequent during the second year of follow-up.
C1 Univ Hosp Coimbra, Dept Ophthalmol, P-3000 Coimbra, Portugal.
   AIBILI Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
   Univ Coimbra, Fac Med, Inst Biomed Res Light & Image, Ctr Ophthalmol, Coimbra, Portugal.
C3 Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Universidade de Coimbra
RP Silva, RM (通讯作者)，Univ Hosp Coimbra, Dept Ophthalmol, P-3000 Coimbra, Portugal.
EM rufino.silva@oftalmologia.co.pt
RI Duarte, Lilianne/AAA-5318-2021; Silva, Rufino M/J-2817-2012
OI Duarte, Lilianne/0000-0003-3953-0730; Silva, Rufino
   M/0000-0001-8676-0833; Cachulo, Maria Luz/0000-0002-0900-4548; Figueira,
   Joao P/0000-0002-3511-1515; Cunha-Vaz, Jose/0000-0002-0947-9850
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 13
TC 119
Z9 129
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2005
VL 243
IS 10
BP 973
EP 979
DI 10.1007/s00417-005-1139-4
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 976GR
UT WOS:000232721500003
PM 15864616
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Devi, SM
   Mahalaxmi, I
   Kaavya, J
   Chinnkulandhai, V
   Balachandar, V
AF Devi, S. Mohana
   Mahalaxmi, I
   Kaavya, J.
   Chinnkulandhai, V
   Balachandar, V
TI Does epigenetics have a role in age related macular degeneration and
   diabetic retinopathy?
SO GENES & DISEASES
LA English
DT Review
DE Age-related macular degeneration (AMD); Diabetic Retinopathy (DR);
   Epigenetics; Gene expression
ID MITOCHONDRIAL TRANSCRIPTION FACTOR; METABOLIC MEMORY; DNA METHYLATION;
   CONTINUED PROGRESSION; OXIDATIVE STRESS; IL17RC PROMOTER; POTENTIAL
   ROLE; COMPLICATIONS; MECHANISMS; HYPOMETHYLATION
AB Epigenetic mechanisms play an important part in the regulation of gene expression and these alterations may induce long-term changes in gene function and metabolism. They have received extensive attention in bridging the gap between environmental exposures and disease development via their influence on gene expression. DNA methylation is the earliest discovered epigenetic alteration. In this review, we try to examine the role of DNA methylation and histone modification in Age related macular degeneration (AMD) and Diabetic Retinopathy (DR), its vascular complications and recent progress. Given the complex nature of AMD and DR, it is crucial to improve therapeutics which will greatly enhance the quality of life and reduce the burden for millions of patients living with these potentially blinding conditions. Copyright (C) 2020, Chongqing Medical University. Production and hosting by Elsevier B.V.
C1 [Devi, S. Mohana] Sankara Nethralaya, SN ONGC Dept Genet & Mol Biol, Vis Res Fdn, 41-18 Coll Rd, Chennai 600006, Tamil Nadu, India.
   [Mahalaxmi, I; Kaavya, J.] Avinashilingam Univ Women, Avinashilingam Inst Home Sci & Higher Educ Women, Dept Zool, Coimbatore 641046, Tamil Nadu, India.
   [Chinnkulandhai, V] DrNGP Arts & Sci Coll, Dept Biochem, Coimbatore 641046, Tamil Nadu, India.
   [Balachandar, V] Bharathiar Univ, Dept Human Genet & Mol Biol, Human Mol Genet & Stem Cells Lab, Coimbatore 641046, Tamil Nadu, India.
C3 Avinashilingam University for Women; Bharathiar University
RP Balachandar, V (通讯作者)，Bharathiar Univ, Dept Human Genet & Mol Biol, Human Mol Genet & Stem Cells Lab, Coimbatore 641046, Tamil Nadu, India.
EM geneticbala@yahoo.co.in
CR Agardh E, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0421-5
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481
   Bianchi C, 2013, CURR DIABETES REP, V13, P403, DOI 10.1007/s11892-013-0371-2
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Chilelli NC, 2013, NUTR METAB CARDIOVAS, V23, P913, DOI 10.1016/j.numecd.2013.04.004
   Elmasry Khaled, 2018, Oncotarget, V9, P12562, DOI 10.18632/oncotarget.24333
   Fedorova E, 2008, BBA-MOL CELL RES, V1783, P2174, DOI 10.1016/j.bbamcr.2008.07.018
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Gauthier AC, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5712341
   Gemenetzi M, 2014, EYE, V28, P1407, DOI 10.1038/eye.2014.225
   Gnana-Prakasam JP, 2013, INVEST OPHTH VIS SCI, V54, P63, DOI 10.1167/iovs.12-10312
   He SK, 2013, MOL VIS, V19, P665
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kowluru RA, 2003, INVEST OPHTH VIS SCI, V44, P5327, DOI 10.1167/iovs.03-0353
   Kowluru RA, 2017, VISION RES, V139, P30, DOI 10.1016/j.visres.2017.02.011
   Kowluru RA, 2016, LAB INVEST, V96, P1040, DOI 10.1038/labinvest.2016.78
   Kowluru RA, 2015, PROG RETIN EYE RES, V48, P40, DOI 10.1016/j.preteyeres.2015.05.001
   Kowluru RA, 2010, EXP EYE RES, V90, P617, DOI 10.1016/j.exer.2010.02.006
   Kwa FAA, 2014, DRUG DISCOV TODAY, V19, P1387, DOI 10.1016/j.drudis.2014.03.026
   Madsen-Bouterse SA, 2010, ANTIOXID REDOX SIGN, V13, P797, DOI 10.1089/ars.2009.2932
   Maghbooli Z, 2014, J DIABETES METAB DIS, V13, DOI 10.1186/2251-6581-13-69
   Mishra M, 2018, DIABETES, V67, P745, DOI 10.2337/db17-0996
   Mishra M, 2015, INVEST OPHTH VIS SCI, V56, P5133, DOI 10.1167/iovs.15-16937
   Mishra M, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15020
   Muthiah MN, 2014, OPHTHALMOLOGY, V121, P430, DOI 10.1016/j.ophtha.2013.10.008
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Pennington KL, 2015, J EXP NEUROSCI, V9, P51, DOI 10.4137/JEN.S25513
   Pons D, 2009, EUR HEART J, V30, P266, DOI 10.1093/eurheartj/ehn603
   Reddy MA, 2015, DIABETOLOGIA, V58, P443, DOI 10.1007/s00125-014-3462-y
   Reik W, 2001, ELECTROPHORESIS, V22, P2838, DOI 10.1002/1522-2683(200108)22:14&lt;2838::AID-ELPS2838&gt;3.0.CO;2-M
   Santos JM, 2014, EXP EYE RES, V121, P168, DOI 10.1016/j.exer.2014.02.010
   Santos JM, 2013, DIABETES-METAB RES, V29, P204, DOI 10.1002/dmrr.2384
   Santos JM, 2012, FREE RADICAL BIO MED, V53, P1729, DOI 10.1016/j.freeradbiomed.2012.08.588
   Santos JM, 2011, INVEST OPHTH VIS SCI, V52, P8791, DOI 10.1167/iovs.11-8203
   Sedivy JM, 2008, EXP CELL RES, V314, P1909, DOI 10.1016/j.yexcr.2008.02.023
   Sharma A, 2018, CLIN GENET, V93, P952, DOI 10.1111/cge.13136
   Sharma K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00151
   Skinner MK, 2010, TRENDS ENDOCRIN MET, V21, P214, DOI 10.1016/j.tem.2009.12.007
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Suuronen T, 2007, BIOCHEM BIOPH RES CO, V357, P397, DOI 10.1016/j.bbrc.2007.03.135
   Syreeni A, 2011, DIABETES, V60, P3073, DOI 10.2337/db11-0073
   Tewari S, 2012, INVEST OPHTH VIS SCI, V53, P4881, DOI 10.1167/iovs.12-9732
   Tewari S, 2012, ANTIOXID REDOX SIGN, V17, P492, DOI 10.1089/ars.2011.4333
   Tonna S, 2010, NAT REV NEPHROL, V6, P332, DOI 10.1038/nrneph.2010.55
   Vavilala DT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113717
   Wang SS, 2008, P NATL ACAD SCI USA, V105, P7738, DOI 10.1073/pnas.0802857105
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   White NH, 2010, DIABETES, V59, P1244, DOI 10.2337/db09-1216
   Willyard C, 2010, NAT MED, V16, P18, DOI 10.1038/nm0110-18
   World Health Organization, AGE RELATED MACULAR
   Xu WY, 2016, GENET EPIGENETICS, V8, P43, DOI 10.4137/GEG.S32160
   Zawia NH, 2009, FREE RADICAL BIO MED, V46, P1241, DOI 10.1016/j.freeradbiomed.2009.02.006
   Zhang XY, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0167-1
   Zhong Q, 2013, INVEST OPHTH VIS SCI, V54, P244, DOI 10.1167/iovs.12-10854
   Zhong Q, 2011, DIABETES, V60, P1304, DOI 10.2337/db10-0133
   Zou L, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/721493
NR 63
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-4820
EI 2352-3042
J9 GENES DIS
JI Genes Dis.
PD MAY
PY 2021
VL 8
IS 3
BP 279
EP 286
DI 10.1016/j.gendis.2020.01.003
EA APR 2021
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA RT5FN
UT WOS:000644485600005
PM 33997175
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Brozou, CG
   Fotiou, D
   Androudi, S
   Theodoridou, E
   Giantselidis, C
   Alexandridis, A
   Brazitikos, P
AF Brozou, Catherine G.
   Fotiou, Dimitrios
   Androudi, Sofia
   Theodoridou, Evelyn
   Giantselidis, Charalambos
   Alexandridis, Alexandros
   Brazitikos, Periklis
TI Pupillometric characteristics in patients with choroidal
   neovascularization due to age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Pupillometry; Age-related macular degeneration
ID PUPILLARY LIGHT REFLEX; ALZHEIMERS-DISEASE; CYCLE TIME; TROPICAMIDE;
   SIZE; PUPILLOGRAPHY; DESIPRAMINE; NEUROPATHY; INDICATOR; LATENCY
AB PURPOSE. To study the pupillary light reflex in patients with choroidal neovascularization due to age-related macular degeneration (AMD).
   METHODS. The study included 15 patients with AMD and 15 control subjects. A full recording of the pupil's reaction to light was registered and the following eight parameters were measured and reported: baseline pupil radius (R1), latency (T1), minimum pupil radius (R2), amplitude (AMP), maximum constriction velocity (VCmax), maximum constriction acceleration (ACmax), time for maximum velocity (T2), and time for maximum constriction (T3).
   RESULTS. All variables measured presented alterations in the AMD group and a number of them were significantly reduced in the AMD group.
   CONCLUSIONS. The presence of neovascular AMD significantly affects the pupil's response to light stimulus when compared to normal subjects. (Eur J Ophthalmol 2009; 19: 254-62)
C1 [Brozou, Catherine G.; Fotiou, Dimitrios; Theodoridou, Evelyn; Giantselidis, Charalambos] Aristotle Univ Thessaloniki, Clin Neurophysiol Lab, Thessaloniki 54636, Greece.
   [Androudi, Sofia; Alexandridis, Alexandros; Brazitikos, Periklis] Aristotle Univ Thessaloniki, Dept Ophthalmol 1, Thessaloniki 54636, Greece.
C3 Aristotle University of Thessaloniki; Aristotle University of
   Thessaloniki
RP Brozou, CG (通讯作者)，Aristotle Univ Thessaloniki, Clin Neurophysiol Lab, 1 Kyriakidi St, Thessaloniki 54636, Greece.
EM brozou@yahoo.com
RI Androudi, Sofia/AAB-7618-2021
OI Androudi, Sofia/0000-0002-5303-7793; Fotiou,
   Dimitrios/0000-0003-2385-2751
CR BAKES A, 1990, BRIT J CLIN PHARMACO, V30, P377, DOI 10.1111/j.1365-2125.1990.tb03787.x
   Bar KJ, 2005, CLIN NEUROPHYSIOL, V116, P790, DOI 10.1016/j.clinph.2004.11.007
   BARBUR JL, 1994, OPHTHAL PHYSL OPT, P139
   Bergamin O, 2003, INVEST OPHTH VIS SCI, V44, P1546, DOI 10.1167/iovs.02-0468
   BRESSLER SB, 2005, RETINA S, V25, pS827
   Eustace P, 1981, NEUROGENETICS NEUROO, P247
   Fotiou D F, 2007, Electromyogr Clin Neurophysiol, V47, P11
   Fotiou DF, 2007, AGING CLIN EXP RES, V19, P364
   Fotiou F, 2000, CLIN PHYSIOL, V20, P336, DOI 10.1046/j.1365-2281.2000.00259.x
   Fotiou F, 2000, INT J PSYCHOPHYSIOL, V37, P111, DOI 10.1016/S0167-8760(00)00099-4
   Gorin MB, 2005, EUR J HUM GENET, V13, P793, DOI 10.1038/sj.ejhg.5201431
   Granholm E, 2004, INT J PSYCHOPHYSIOL, V52, P1, DOI 10.1016/j.ijpsycho.2003.12.001
   Granholm E, 2003, INT J PSYCHOPHYSIOL, V47, P95, DOI 10.1016/S0167-8760(02)00122-8
   GREEN WR, 1992, RETINA, V25, P1519
   GRENBERGER J, 1990, EUR ARCH PSY CLIN N, V240, P109
   IDIAQUEZ J, 1994, J NEUROL NEUROSUR PS, V57, P1544, DOI 10.1136/jnnp.57.12.1544-a
   JACOBSEN J, 1990, ACTA NEUROL SCAND, V82, P392
   KASE M, 1984, INVEST OPHTH VIS SCI, V25, P467
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Kurz A, 1997, PHARMACOPSYCHIATRY, V30, P12, DOI 10.1055/s-2007-979476
   LANTING P, 1988, J NEUROL, V235, P245, DOI 10.1007/BF00314357
   Loupe DN, 1996, OPHTHALMOLOGY, V103, P495
   LOWENFELD IE, 1999, PUPIL ANATOMY PHYSL, P76
   LOWENSTEIN O, 1964, AM J OPHTHALMOL, V57, P569, DOI 10.1016/0002-9394(64)92504-8
   Ludtke H, 1999, GRAEF ARCH CLIN EXP, V237, P207, DOI 10.1007/s004170050220
   MACLEAN H, 1993, EYE, V7, P785, DOI 10.1038/eye.1993.184
   MILLER SD, 1978, AM J OPHTHALMOL, V85, P635, DOI 10.1016/S0002-9394(14)77096-5
   Morad Y, 2000, CURR EYE RES, V21, P535, DOI 10.1076/0271-3683(200007)21:1;1-Z;FT535
   Pong M, 2000, J NEUROPHYSIOL, V84, P964, DOI 10.1152/jn.2000.84.2.964
   Prettyman R, 1997, J NEUROL NEUROSUR PS, V62, P665, DOI 10.1136/jnnp.62.6.665
   ROSSE RB, 1995, ADDICTION, V90, P981, DOI 10.1111/j.1360-0443.1995.tb03508.x
   SACKS B, 1989, J NEUROL NEUROSUR PS, V52, P1294, DOI 10.1136/jnnp.52.11.1294
   SCHACHAT AP, 2001, RETINA, P1039
   SCINTO LFM, 1994, SCIENCE, V266, P1051, DOI 10.1126/science.7973660
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   SHUR E, 1982, BRIT J PSYCHIAT, V140, P181, DOI 10.1192/bjp.140.2.181
   Sokolski KN, 1996, PROG NEURO-PSYCHOPH, V20, P253, DOI 10.1016/0278-5846(95)00308-8
   SZABADI E, 1980, BRIT J PSYCHIAT, V137, P433, DOI 10.1192/bjp.137.5.433
   TAN ETH, 1984, J NEUROL NEUROSUR PS, V47, P61, DOI 10.1136/jnnp.47.1.61
   Thompson HS, 1992, ADLERS PHYSL EYE, P412
   VANDIEMEN HAM, 1992, ELECTROEN CLIN NEURO, V82, P213, DOI 10.1016/0013-4694(92)90170-M
   Wilhelm BJ, 2002, BRAIN, V125, P2296, DOI 10.1093/brain/awf232
   Wilhelm H, 2003, J NEURO-OPHTHALMOL, V23, P42, DOI 10.1097/00041327-200303000-00010
NR 43
TC 4
Z9 5
U1 0
U2 1
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR-APR
PY 2009
VL 19
IS 2
BP 254
EP 262
DI 10.1177/112067210901900213
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 439AO
UT WOS:000265598800013
PM 19253243
DA 2022-11-30
ER

PT J
AU Cao, GQ
   Chen, YL
   Zhang, JL
   Liu, YL
   Zhang, M
   Zhang, K
   Su, ZG
AF Cao, Guiqun
   Chen, Yulong
   Zhang, Jinlong
   Liu, Yulan
   Zhang, Ming
   Zhang, Kang
   Su, Zhiguang
TI Effects of adiponectin polymorphisms on the risk of advanced age-related
   macular degeneration
SO BIOMARKERS
LA English
DT Article
DE Adiponectin; age-related macular degeneration; haplotype; SNPs
ID INDUCED CHOROIDAL NEOVASCULARIZATION; FACTOR-H POLYMORPHISM; GENE;
   VARIANT; ASSOCIATION; INHIBITION; EXPRESSION; INCREASES; PROTEIN; GROWTH
AB Objective: To determine the relationships between variants in adiponectin gene (ADIPOQ) with advanced forms of age-related macular degeneration (AMD) susceptibility.
   Methods: A total of 189 advanced AMD patients and 168 controls were recruited. Seven tagging single-nucleotide polymorphisms in ADIPOQ were genotyped by the SNaPshot method.
   Results: Alleles or genotypes of rs822396 distributed significantly differently in advanced AMD patients and controls. The minor allele G at rs822396 was associated with an increased risk of advanced AMD in a dominant model. Furthermore, haplotype analysis revealed that haplotypes AGGACCT and TGACCCC were significantly increased the advanced AMD susceptibility, whereas haplotypes AGAACGC, TGAACGT and TGACAGC had protective effects.
   Conclusion: ADIPOQ genetic variant rs822396 might affect an individual's susceptibility to AMD, making it efficient genetic biomarkers for early detection of AMD.
C1 [Cao, Guiqun; Chen, Yulong; Zhang, Jinlong; Liu, Yulan; Zhang, Kang; Su, Zhiguang] Sichuan Univ, Mol Med Res Ctr, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.
   [Zhang, Ming; Zhang, Kang] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu 610041, Peoples R China.
C3 Sichuan University; Sichuan University
RP Cao, GQ (通讯作者)，Sichuan Univ, Mol Med Res Ctr, West China Hosp, 1 Ke Yuan 4th Rd,Gao Peng St, Chengdu 610041, Peoples R China.
EM caoguiqun@126.com; zhiguang.su@scu.edu.cn
RI zhang, jin/GXV-9154-2022; Zhang, Kang/Y-2740-2019; Su,
   Zhiguang/AFS-0022-2022
OI Zhang, Kang/0000-0002-4549-1697; 
FU National High Technology Research and Development Program of China (863
   project) [2014AA021604]; Sichuan Province Science and Technology Support
   Program [2015SZ0140]; Program for New Century Excellent Talents in
   University [NCET-100600]
FX The authors report no declarations of interest. This study was supported
   by the National High Technology Research and Development Program of
   China (863 project) (No. 2014AA021604), Sichuan Province Science and
   Technology Support Program (No. 2015SZ0140) and the Program for New
   Century Excellent Talents in University (No. NCET-100600).
CR Bora PS, 2007, FEBS LETT, V581, P1977, DOI 10.1016/j.febslet.2007.04.024
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Guo XQ, 2006, DIABETES, V55, P1723, DOI 10.2337/db05-0428
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hao G, 2013, ATHEROSCLEROSIS, V228, P29, DOI 10.1016/j.atherosclerosis.2013.02.018
   Heid IM, 2006, DIABETES, V55, P375, DOI 10.2337/diabetes.55.02.06.db05-0747
   Heid IM, 2010, ATHEROSCLEROSIS, V208, P412, DOI 10.1016/j.atherosclerosis.2009.11.035
   Higuchi A, 2010, ARTERIOSCL THROM VAS, V30, P46, DOI 10.1161/ATVBAHA.109.198465
   Kaarniranta K, 2012, NEUROSCI LETT, V513, P233, DOI 10.1016/j.neulet.2012.02.050
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   KORB M, 1993, NUCLEIC ACIDS RES, V21, P5901, DOI 10.1093/nar/21.25.5901
   Lumeng CN, 2007, DIABETES, V56, P16, DOI 10.2337/db06-1076
   Lyzogubov VV, 2012, BBA-MOL CELL RES, V1823, P1264, DOI 10.1016/j.bbamcr.2012.05.017
   Lyzogubov VV, 2009, CELL BIOL INT, V33, P765, DOI 10.1016/j.cellbi.2009.04.013
   Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724
   Maralani HG, 2015, RETINA-J RET VIT DIS, V35, P459, DOI 10.1097/IAE.0000000000000338
   Mori T, 2014, SCI REP-UK, V4, DOI 10.1038/srep04895
   Nelson MR, 2012, SCIENCE, V337, P100, DOI 10.1126/science.1217876
   Ohashi K, 2012, BIOCHIMIE, V94, P2137, DOI 10.1016/j.biochi.2012.06.008
   Ohashi K, 2010, J BIOL CHEM, V285, P6153, DOI 10.1074/jbc.M109.088708
   Schaibley VM, 2013, GENOME RES, V23, P1974, DOI 10.1101/gr.154971.113
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-13234
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Wang D, 2015, OPHTHALMIC GENET, V36, P303, DOI 10.3109/13816810.2014.881506
   Xu SC, 2012, ACTA PHARMACOL SIN, V33, P998, DOI 10.1038/aps.2012.69
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Yu ZB, 2012, OBESITY, V20, P396, DOI 10.1038/oby.2011.148
   Yuan YM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050848
   Zhou J, 2013, CLIN BIOCHEM, V46, P1689, DOI 10.1016/j.clinbiochem.2013.07.002
NR 34
TC 3
Z9 3
U1 1
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-750X
EI 1366-5804
J9 BIOMARKERS
JI Biomarkers
PY 2015
VL 20
IS 4
BP 266
EP 270
DI 10.3109/1354750X.2015.1068857
PG 5
WC Biotechnology & Applied Microbiology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Toxicology
GA CR4LP
UT WOS:000361304200007
PM 26301885
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Neuner, B
   Wellmann, J
   Dasch, B
   Behrens, T
   Claes, B
   Dietzel, M
   Pauleikhoff, D
   Hense, HW
AF Neuner, Bruno
   Wellmann, Juergen
   Dasch, Burkhard
   Behrens, Thomas
   Claes, Birte
   Dietzel, Martha
   Pauleikhoff, Daniel
   Hense, Hans-Werner
TI Modeling smoking history: A comparison of different approaches in the
   MARS study on age-related maculopathy
SO ANNALS OF EPIDEMIOLOGY
LA English
DT Article
DE age-related maculopathy; age-related macular degeneration; smoking; time
   since smoking cessation; smoking history
ID MACULAR DEGENERATION; RISK-FACTORS; CIGARETTE-SMOKING; 5-YEAR INCIDENCE;
   FACTOR-H; ASSOCIATION; PROGRESSION; LOC387715; KNOWLEDGE; GLAUCOMA
AB PURPOSE: Smoking is an established risk factor for the development of age-related maculopathy (ARM), and its end stage, age-related macular degeneration (AMD). We evaluated the benefit of various smoking-related variables in modeling the association of smoking with ARM and AMD in a mixed sample of current, former, and never smokers.
   METHODS: This was a cross-sectional study in participants of the Muensteraner Altern- und Retina-Studie (MARS). Participants were classified according to the Rotterdam classification system as healthy, or having ARM or AMD. Using multinomial logistic regression techniques, the association with number of cigarettes, years of smoking, pack-years and time since cessation in former smokers were evaluated.
   RESULTS: Mean age of the 982 participants (58.6% females) was 70.9 +/- 5.5 years. ARM was present in 483 (49.2%) and AMD in 285 (29.0%) individuals. The adjusted prevalence odds ratio (OR) in current smokers versus never smokers was 2.61 (95% confidence interval [CI] 1.34-5.09) for ARM and 3.94 (95% CI 1.91-8.14) for AMD. This effect decreased in former smokers with an OR = 0.55 (95% CI 0.33-0.99) per log-transformed time since smoking cessation for ARM and an OR = 0.52 (95% CI 0.30-0.90) for AMD.
   CONCLUSIONS: By including a variable for time since smoking cessation, we were able to handle current, former, and never smokers in one model that estimates the association of smoking with ARM or AMD. Logarithmical transformation of the time since smoking cessation seemed to increase the model fit and to reflect a non-linear protective effect of smoking cessation on the onset of ARM and AMD in former smokers.
C1 Univ Munster, Inst Epidemiol & Social Med, D-48149 Munster, Germany.
   St Franziskus Hosp, Ophthalmol Hosp, Munster, Germany.
C3 University of Munster; St. Franziskus-Hospital
RP Neuner, B (通讯作者)，Univ Munster, Inst Epidemiol & Social Med, Domagkstr 3, D-48149 Munster, Germany.
EM neuner@uni-muenster.de
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   ALLISON P, 2002, MULTINOMIAL LOGIT AN
   [Anonymous], 1999, GESUNDHEITSWESEN, V61, P121
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Dasch B, 2005, OPHTHALMOLOGE, V102, P1057, DOI 10.1007/s00347-005-1225-3
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Konstas AGP, 2000, EYE, V14, P752, DOI 10.1038/eye.2000.197
   Lau JTF, 2002, BRIT J OPHTHALMOL, V86, P1080, DOI 10.1136/bjo.86.10.1080
   Leffondre K, 2002, AM J EPIDEMIOL, V156, P813, DOI 10.1093/aje/kwf122
   Livingston PM, 1998, BRIT J OPHTHALMOL, V82, P780, DOI 10.1136/bjo.82.7.780
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SAS Institute Inc, 2000, SAS 9 1 3
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Smith Bradley T, 2005, Curr Opin Ophthalmol, V16, P166, DOI 10.1097/01.icu.0000163030.33401.3d
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
NR 30
TC 15
Z9 16
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1047-2797
EI 1873-2585
J9 ANN EPIDEMIOL
JI Ann. Epidemiol.
PD AUG
PY 2007
VL 17
IS 8
BP 615
EP 621
DI 10.1016/j.annepidem.2007.03.005
PG 7
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 199CD
UT WOS:000248672900007
PM 17531503
DA 2022-11-30
ER

PT J
AU Rosenfeld, PJ
AF Rosenfeld, Philip J.
TI Optical Coherence Tomography and the Development of Antiangiogenic
   Therapies in Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE optical coherence tomography; neovascularization; anti-vascular
   endothelial growth factor; antiangiogenesis; exudation
ID ENDOTHELIAL GROWTH-FACTOR; SUBRETINAL HYPERREFLECTIVE MATERIAL; PIGMENT
   EPITHELIAL DETACHMENT; BEVACIZUMAB AVASTIN THERAPY; 2.0 MG RANIBIZUMAB;
   GEOGRAPHIC ATROPHY; INTRAVITREAL INJECTION; TYPE-3 NEOVASCULARIZATION;
   VEGF-TRAP; ANGIOGRAPHY
AB PURPOSE. To explain the pivotal role optical coherence tomography (OCT) imaging had in the development of antiangiogenic therapies for the treatment of neovascular age-related macular degeneration (nvAMD).
   METHODS. A historical literature review was combined with personal perspectives from the introduction of OCT imaging and the early clinical use of vascular endothelial growth factor (VEGF) inhibitors.
   RESULTS. At the time that OCT emerged, the gold standard for imaging of nvAMD was fluorescein angiography (FA), a time-consuming, dye-based, invasive technique that provided en face images of the retina and was used to characterize leakage, perfusion status, and the types of macular neovascularization (MNV). In comparison, OCT imaging was a fast, safe, noninvasive technique that complemented FA imaging by providing cross-sectional images of the macula. OCT was able to visualize and quantify the macular fluid that was associated with the presence of excess VEGF, which was identified by intraretinal fluid, subretinal fluid, and fluid under the retinal pigment epithelium (RPE). Clinicians quickly appreciated the benefits of OCT imaging for following macular fluid after anti-VEGF therapy. By observing the qualitative and quantitative changes in macular fluid depicted by OCT imaging, clinicians were empowered to compare anti-VEGF drugs and move from fixed-dosing regimens to patient-specific dosing strategies requiring fewer injections.
   CONCLUSIONS. Optical coherence tomography imaging was adopted as a VEGF-meter, a method to detect excess VEGF, and evolved to become the gold standard imaging strategy for diagnosing nvAMD, assessing treatment responses to anti-VEGF drugs, deciding when to retreat, and evaluating disease progression.
C1 [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Rosenfeld, PJ (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@miami.edu
FU Carl Zeiss Meditec, Inc. (Dublin, CA, USA); Macula Vision Research
   Foundation; National Eye Institute Center Core Grant [P30EY014801];
   Research to Prevent Blindness; Emma Clyde Hodge Memorial Foundation;
   NATIONAL EYE INSTITUTE [P30EY014801] Funding Source: NIH RePORTER
FX Supported by a grant from Carl Zeiss Meditec, Inc. (Dublin, CA, USA),
   the Macula Vision Research Foundation, a National Eye Institute Center
   Core Grant (P30EY014801), an unrestricted grant from Research to Prevent
   Blindness, and the Emma Clyde Hodge Memorial Foundation.
CR Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Channa R, 2015, AM J OPHTHALMOL, V159, P9, DOI 10.1016/j.ajo.2014.09.012
   Charafeddin W, 2015, OSLI RETINA, V46, P523, DOI 10.3928/23258160-20150521-03
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Chin-Yee D, 2015, BR J OPHTHALMOL
   Emerson GG, 2007, RETINA-J RET VIT DIS, V27, P724, DOI 10.1097/IAE.0b013e318042b3c8
   Erie JC, 2016, OPHTHALMOLOGY, V123, P1257, DOI 10.1016/j.ophtha.2016.02.015
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gabriele ML, 2011, INVEST OPHTH VIS SCI, V52, P2425, DOI 10.1167/iovs.10-6312
   Gass JDM, 1997, STEREOSCOPIC ATLAS M, P130
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hassenstein A, 2001, KLIN MONATSBL AUGENH, V218, P503, DOI 10.1055/s-2001-16293
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Iafe NA, 2016, DEV OPHTHALMOL, V56, P45, DOI 10.1159/000442776
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nguyen TT, 2015, EXPERT REV CLIN PHAR, V8, P541, DOI 10.1586/17512433.2015.1075879
   Pfau M, 2016, KLIN MONATSBL AUGENH, V233, P945, DOI 10.1055/s-0042-101348
   Pron G, 2014, Ont Health Technol Assess Ser, V14, P1
   Puliafito C. A., 2004, OPTICAL COHERENCE TO
   Querques G, 2016, DEV OPHTHALMOL, V56, P57, DOI 10.1159/000442779
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmucker CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137866
   Schneider EW, 2014, INVEST OPHTH VIS SCI, V55, P542, DOI 10.1167/iovs.13-13034
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Souied EH, 2016, DEV OPHTHALMOL, V56, P52, DOI 10.1159/000442777
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Tanaka E, 2015, OPHTHALMOLOGY, V122, P153, DOI 10.1016/j.ophtha.2014.07.046
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wykoff CC, 2016, OPHTHALMOLOGY, V100, P914
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Yehoshua Z, 2013, OSLI RETINA, V44, P127, DOI 10.3928/23258160-20130313-05
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
NR 75
TC 46
Z9 47
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2016
VL 57
IS 9
BP OCT14
EP OCT26
DI 10.1167/iovs.16-19969
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW9MY
UT WOS:000383985400006
PM 27409464
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Maier, M
   Groneberg, T
   Specht, H
   Lohmann, CP
AF Maier, Mathias
   Groneberg, Thomas
   Specht, Holger
   Lohmann, Chris Patrick
TI Critical flicker-fusion frequency in age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Critical flicker-fusion frequency; Age-related macular degeneration;
   Subjective vision test
ID SENSITIVITY; PERIMETRY; EYE
AB To assess the influence of age-related macular degeneration (AMD) on critical flicker-fusion frequency (CFF).
   CFF was measured centrally for a red, green and blue target, and in 10A degrees excentricity with a red target. Twenty-eight patients with non-exsudative AMD, 12 patients with exsudative AMD and 45 age-matched healthy eyes were included.
   CFF decreased in eyes with non-exsudative AMD (red 1.3 Hz, p = 0.025; green 1.4 Hz, p = 0.053; blue 2.1 Hz, p = 0.006) and exsudative AMD (red 2.2 Hz, p = 0.02; green 3.3 Hz, p = 0.001; blue 2.9 Hz, p = 0.02). The difference between central and peripheral CFF increased in non-exsudative AMD (red-red 10A degrees, 0.7 Hz, p = 0.024), but was not significantly increased in exsudative AMD (1.3 Hz, p = 0.059). There was no difference between eyes with non-exsudative AMD with good visual acuity (VA > 20/32, n = 18) and healthy eyes, nor between eyes with non-exsudative (n = 10) and exsudative AMD (n = 9) with VA from 20/100 to 20/40.
   CFF decreased in non-exsudative and exsudative AMD. CFF is not able to distinguish between AMD eyes and healthy eyes of equal visual acuity, and therefore is not applicable as a possible diagnostic test.
C1 [Maier, Mathias; Groneberg, Thomas; Lohmann, Chris Patrick] Tech Univ Munich, Augenklin Rechts Isar, D-81675 Munich, Germany.
   [Specht, Holger] FH Stralsund, Stralsund, Germany.
C3 Technical University of Munich
RP Maier, M (通讯作者)，Tech Univ Munich, Augenklin Rechts Isar, Ismaningerstr 22, D-81675 Munich, Germany.
EM M.Maier@lrz.tum.de; Holger.Specht@fh-stralsund.de
CR Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   CURCIO CA, 1997, J COMP NEUROL, V388, P507
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Grant R, 1930, AM J PHYSIOL, V95, P211, DOI 10.1152/ajplegacy.1930.95.1.211
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   LACHENMAYR BJ, 1992, INVEST OPHTH VIS SCI, V33, P3539
   LACHENMAYR BJ, 1994, INVEST OPHTH VIS SCI, V35, P2741
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   MICHELSON G, 2002, RETINA, V3, P336
   NEETENS A, 1992, GRAEF ARCH CLIN EXP, V230, P358, DOI 10.1007/BF00165945
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Ronan Shawn, 2006, Trans Am Ophthalmol Soc, V104, P232
   Roorda A, 1999, NATURE, V397, P520, DOI 10.1038/17383
NR 16
TC 6
Z9 6
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2010
VL 248
IS 3
BP 409
EP 413
DI 10.1007/s00417-009-1270-8
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 555GP
UT WOS:000274497200017
PM 20076964
DA 2022-11-30
ER

PT J
AU Yavas, GF
   Kusbeci, T
   Inan, UU
AF Yavas, Guliz Fatma
   Kusbeci, Tuncay
   Inan, Umit Ubeyt
TI Multifocal electroretinography in subjects with age-related macular
   degeneration
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Multifocal ERG; Photoreceptors; Retina
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; LECTURE;
   DRUSEN; EYES
AB To evaluate retinal function objectively in subjects with different stages of age-related macular degeneration (AMD) using multifocal electroretinography (mfERG) and compare it with age-matched control group.
   A total of 42 subjects with AMD and 37 age-matched healthy control group aged over 55 years were included in this prospective study. mfERG test was performed to all subjects. Average values in concentric ring analysis in four rings (ring 1, from 0A degrees to 5A degrees of eccentricity relative to fixation; ring 2, from 5A degrees to 10A degrees; ring 3, from 10A degrees to 15A degrees; ring 4, over 15A degrees) and in quadrant analysis (superior nasal quadrant, superior temporal quadrant, inferior nasal quadrant and inferior temporal quadrant) were recorded. Test results were evaluated by one-way ANOVA test and independent samples t test.
   In mfERG concentric ring analysis, N1 amplitude, P1 amplitude and N2 amplitude were found to be lower and N1 implicit time, P1 implicit time and N2 implicit time were found to be delayed in subjects with AMD compared to control group. In quadrant analysis, N1, P1 and N2 amplitude was lower in all quadrants, whereas N1 implicit time was normal and P1 and N2 implicit times were prolonged in subjects with AMD.
   mfERG is a useful test in evaluating retinal function in subjects with AMD. AMD affects both photoreceptors and inner retinal function at late stages.
C1 [Yavas, Guliz Fatma; Kusbeci, Tuncay; Inan, Umit Ubeyt] Afyon Kocatepe Univ, Sch Med, Dept Ophthalmol, Afyon, Turkey.
C3 Afyon Kocatepe University
RP Yavas, GF (通讯作者)，Afyon Kocatepe Univ, Sch Med, Dept Ophthalmol, Afyon, Turkey.
EM gkumbar@gmail.com
RI Kusbeci, Tuncay/AAO-1012-2020
OI Kusbeci, Tuncay/0000-0002-5169-4140
FU Scientific Research Projects Coordination Unit of Afyon Kocatepe
   University
FX This study was supported by Scientific Research Projects Coordination
   Unit of Afyon Kocatepe University.
CR Aoyagi R, 2013, DOC OPHTHALMOL, V126, P253, DOI 10.1007/s10633-013-9378-x
   BIRCH DG, 1992, ARCH OPHTHALMOL-CHIC, V110, P1571, DOI 10.1001/archopht.1992.01080230071024
   BOK D, 1985, INVEST OPHTH VIS SCI, V26, P1659
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Creel Donnell J, 2011, J Vis Exp, DOI 10.3791/3176
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Garcia-Garcia JG, 2013, CLIN OPHTHALMOL, V7, P1303, DOI 10.2147/OPTH.S39258
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   Hwang JU, 2012, INVEST OPHTH VIS SCI, V53, P3562, DOI 10.1167/iovs.12-9762
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Langrova H, 2008, INVEST OPHTH VIS SCI, V49, P5024, DOI 10.1167/iovs.07-1309
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Park S, 2013, DOC OPHTHALMOL, V126, P199, DOI 10.1007/s10633-013-9375-0
   Takiura K, 2001, INVEST OPHTH VIS SCI, V42, pS73
   The Foundation of the American Academy of Ophthalmology, 2002, BASIC CLIN SCI COURS, V4, P141
   WRIGHT CE, 1985, DOC OPHTHALMOL, V59, P365, DOI 10.1007/BF00159171
   Zarbin MA, 2012, ESASO COURSE SER, V1, P125
   Zol'nikova I V, 2009, Vestn Oftalmol, V125, P27
NR 26
TC 8
Z9 11
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD DEC
PY 2014
VL 129
IS 3
BP 167
EP 175
DI 10.1007/s10633-014-9460-z
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AT0BQ
UT WOS:000344602500003
PM 25253559
DA 2022-11-30
ER

PT J
AU Terao, R
   Ahmed, T
   Suzumura, A
   Terasaki, H
AF Terao, Ryo
   Ahmed, Tazbir
   Suzumura, Ayana
   Terasaki, Hiroko
TI Oxidative Stress-Induced Cellular Senescence in Aging Retina and
   Age-Related Macular Degeneration
SO ANTIOXIDANTS
LA English
DT Review
DE aging; age-related macular degeneration; cellular senescence;
   inflammation; oxidative stress
ID PIGMENT EPITHELIAL-CELLS; NF-KAPPA-B; MITOCHONDRIAL-DNA DAMAGE;
   SECRETORY PHENOTYPE; PREMATURE SENESCENCE; TUMOR-SUPPRESSOR;
   BETA-GALACTOSIDASE; ENDOTHELIAL-CELLS; EXPRESSION; ACTIVATION
AB Aging leads to a gradual decline of function in multiple organs. Cataract, glaucoma, diabetic retinopathy, and age-related macular degeneration (AMD) are age-related ocular diseases. Because their pathogenesis is unclear, it is challenging to combat age-related diseases. Cellular senescence is a cellular response characterized by cell cycle arrest. Cellular senescence is an important contributor to aging and age-related diseases through the alteration of cellular function and the secretion of senescence-associated secretory phenotypes. As a driver of stress-induced premature senescence, oxidative stress triggers cellular senescence and age-related diseases by inducing senescence markers via reactive oxygen species and mitochondrial dysfunction. In this review, we focused on the mechanism of oxidative stress-induced senescence in retinal cells and its role in the pathogenesis of AMD.
C1 [Terao, Ryo; Ahmed, Tazbir] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo 1138654, Japan.
   [Terao, Ryo] Washington Univ, Dept Ophthalmol & Visual Sci, Sch Med St Louis, St Louis, MO 63110 USA.
   [Suzumura, Ayana] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi 4668550, Japan.
   [Terasaki, Hiroko] Nagoya Univ, Inst Innovat Future Soc, Nagoya, Aichi 4648601, Japan.
C3 University of Tokyo; Saint Louis University; Washington University
   (WUSTL); Nagoya University; Nagoya University
RP Terao, R (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo 1138654, Japan.; Terao, R (通讯作者)，Washington Univ, Dept Ophthalmol & Visual Sci, Sch Med St Louis, St Louis, MO 63110 USA.
EM rterao-tky@umin.ac.jp
OI Ahmed, Tazbir/0000-0001-5839-9876; Terao, Ryo/0000-0001-6182-4343
FU Bayer Japan Retina Award Foundation
FX This work was partially supported by the Bayer Japan Retina Award
   Foundation.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Aiken CT, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.006924
   Al Bitar S, 2019, CANCERS, V11, DOI 10.3390/cancers11101475
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   de Mera-Rodriguez JA, 2019, DEV DYNAM, V248, P850, DOI 10.1002/dvdy.74
   Apte RS, 2021, NEW ENGL J MED, V385, P539, DOI 10.1056/NEJMcp2102061
   Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932
   Balistreri CR, 2013, IMMUN AGEING, V10, DOI 10.1186/1742-4933-10-24
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Beck J, 2020, VET PATHOL, V57, P747, DOI 10.1177/0300985820943841
   Bellezza I, 2018, BBA-MOL CELL RES, V1865, P721, DOI 10.1016/j.bbamcr.2018.02.010
   Binet F, 2020, SCIENCE, V369, P934, DOI 10.1126/science.aay5356
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Blevins HM, 2022, FRONT AGING NEUROSCI, V14, DOI 10.3389/fnagi.2022.879021
   Blitzer AL, 2021, JAMA OPHTHALMOL, V139, P302, DOI 10.1001/jamaophthalmol.2020.6331
   Brand MD, 2013, BRIT J DERMATOL, V169, P1, DOI 10.1111/bjd.12208
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Caceres-Velez PR, 2022, AGEING RES REV, V75, DOI 10.1016/j.arr.2022.101572
   Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5
   Chae SY, 2018, MOL MED REP, V18, P5182, DOI 10.3892/mmr.2018.9538
   Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010
   Chen J, 2006, AM J PHYSIOL-HEART C, V290, pH1729, DOI 10.1152/ajpheart.01103.2005
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337
   Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029
   Chen Y, 2010, INVEST OPHTH VIS SCI, V51, P5314, DOI 10.1167/iovs.10-5280
   Cheng SC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122957
   Cheong C, 2006, MECH AGEING DEV, V127, P633, DOI 10.1016/j.mad.2006.02.010
   Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711
   Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000
   clinicaltrials, SAFETY TOLERABILITY
   Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003
   Crespo-Garcia S, 2021, CELL METAB, V33, P818, DOI 10.1016/j.cmet.2021.01.011
   Dentchev T, 2003, MOL VIS, V9, P184
   Di Micco R, 2021, NAT REV MOL CELL BIO, V22, P75, DOI 10.1038/s41580-020-00314-w
   Do KV, 2019, P NATL ACAD SCI USA, V116, P24317, DOI 10.1073/pnas.1912959116
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Ehninger D, 2014, CELL MOL LIFE SCI, V71, P4325, DOI 10.1007/s00018-014-1677-1
   Elfawy HA, 2019, LIFE SCI, V218, P165, DOI 10.1016/j.lfs.2018.12.029
   Faget DV, 2019, NAT REV CANCER, V19, P439, DOI 10.1038/s41568-019-0156-2
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Flatt Thomas, 2012, Frontiers in Genetics, V3, P148, DOI 10.3389/fgene.2012.00148
   Fulop GA, 2018, GEROSCIENCE, V40, P513, DOI 10.1007/s11357-018-0047-6
   Georgakopoulou EA, 2013, AGING-US, V5, P37
   Gorbunova V, 2016, CELL, V165, P1312, DOI 10.1016/j.cell.2016.05.061
   Goulielmaki E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13894-9
   Guglielmotto M, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/neuro.24.003.2010
   Han XJ, 2020, MECH AGEING DEV, V191, DOI 10.1016/j.mad.2020.111347
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hellyer JA, 2021, J THORAC ONCOL, V16, P395, DOI 10.1016/j.jtho.2020.11.015
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kapeta S, 2010, J BIOL CHEM, V285, P8171, DOI 10.1074/jbc.M109.031575
   Karimian A, 2016, DNA REPAIR, V42, P63, DOI 10.1016/j.dnarep.2016.04.008
   Katsuumi G, 2018, FRONT CARDIOVASC MED, V5, DOI 10.3389/fcvm.2018.00018
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Kim YW, 2014, BLOOD, V123, P625, DOI 10.1182/blood-2013-09-512749
   Konig J, 2017, REDOX BIOL, V11, P673, DOI 10.1016/j.redox.2017.01.017
   Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475
   Ksiazek K, 2006, J APPL PHYSIOL, V100, P988, DOI 10.1152/japplphysiol.01086.2005
   Kumari R, 2021, FRONT CELL DEV BIOL, V09, DOI 10.3389/fcell.2021.645593
   Kushwaha SS, 2018, ANN NEUROSCI, V25, P223, DOI 10.1159/000490908
   Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195
   Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x
   Lee KS, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02088-0
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin MM, 2022, ACTA PHARMACOL SIN, V43, P2439, DOI 10.1038/s41401-022-00879-6
   Lingappan Krithika, 2018, Current Opinion in Toxicology, V7, P81, DOI 10.1016/j.cotox.2017.11.002
   Liton PB, 2005, EXP GERONTOL, V40, P745, DOI 10.1016/j.exger.2005.06.005
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Liu Y, 2009, CURR OPIN IMMUNOL, V21, P431, DOI 10.1016/j.coi.2009.05.011
   Liu YR, 2021, AGING CELL, V20, DOI 10.1111/acel.13490
   Lopez-Luppo M, 2017, INVEST OPHTH VIS SCI, V58, P2832, DOI 10.1167/iovs.16-20312
   Luo J, 2020, AGEING RES REV, V57, DOI 10.1016/j.arr.2019.100982
   Ma WX, 2013, NEUROBIOL AGING, V34, P2310, DOI 10.1016/j.neurobiolaging.2013.03.022
   Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180
   Mannick JB, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009892
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Matsumaru D, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10121929
   McConnell BB, 1999, MOL CELL BIOL, V19, P1981
   McKeller RN, 2002, P NATL ACAD SCI USA, V99, P3848, DOI 10.1073/pnas.052484199
   Miller TJ, 2006, NEUROTOXICOLOGY, V27, P44, DOI 10.1016/j.neuro.2005.06.001
   Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Moldogazieva NT, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3085756
   Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878
   Moreno-Garcia A, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00464
   Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823
   Munoz-Espin D, 2013, CELL, V155, P1104, DOI 10.1016/j.cell.2013.10.019
   Nakano-Kobayashi A, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc1428
   Neofytou E, 2012, INT J MOL SCI, V13, P16853, DOI 10.3390/ijms131216853
   Ni YQ, 2021, AGING DIS, V12, P1948, DOI 10.14336/AD.2021.0603
   Ok CY, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10020271
   Osman W, 2012, HUM MOL GENET, V21, P2836, DOI 10.1093/hmg/dds103
   Oubaha M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9440
   Patila P, 2019, MECH AGEING DEV, V180, P97, DOI 10.1016/j.mad.2019.04.006
   Piippo N, 2018, CELL PHYSIOL BIOCHEM, V49, P359, DOI 10.1159/000492886
   Pomatto LCD, 2020, FREE RADICAL BIO MED, V152, P650, DOI 10.1016/j.freeradbiomed.2020.01.005
   Powell JD, 2012, ANNU REV IMMUNOL, V30, P39, DOI 10.1146/annurev-immunol-020711-075024
   Qu SC, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1740943
   Quesnel B, 1998, Bull Cancer, V85, P747
   Rizou SV, 2019, METHODS MOL BIOL, V1896, P119, DOI 10.1007/978-1-4939-8931-7_12
   Rocha LR, 2020, AGING CELL, V19, DOI 10.1111/acel.13089
   Romagosa C, 2011, ONCOGENE, V30, P2087, DOI 10.1038/onc.2010.614
   Rovillain E, 2011, ONCOGENE, V30, P2356, DOI 10.1038/onc.2010.611
   Ruan Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031296
   Sadhu S, 2021, J IMMUNOL, V207, P1812, DOI 10.4049/jimmunol.2100284
   Sagiv A, 2013, BIOGERONTOLOGY, V14, P617, DOI 10.1007/s10522-013-9473-0
   Sajadimajd S, 2018, CURR CANCER DRUG TAR, V18, P538, DOI 10.2174/1568009617666171002144228
   Salminen A, 2012, CELL SIGNAL, V24, P835, DOI 10.1016/j.cellsig.2011.12.006
   Salmonowicz H, 2017, AGING CELL, V16, P432, DOI 10.1111/acel.12580
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Seo S, 2017, MOL VIS, V23, P823
   Shao Z, 2021, OSTEOARTHR CARTILAGE, V29, P413, DOI 10.1016/j.joca.2020.11.006
   Shimizu H, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.11.21
   Shu WT, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101469
   Silva RLA, 2005, EMBO J, V24, P2803, DOI 10.1038/sj.emboj.7600751
   Skowronska-Krawczyk D, 2015, MOL CELL, V59, P931, DOI 10.1016/j.molcel.2015.07.027
   Song P, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030671
   Song YS, 2005, MECH AGEING DEV, V126, P580, DOI 10.1016/j.mad.2004.11.008
   Sreekumar PG, 2022, EXP EYE RES, V215, DOI 10.1016/j.exer.2021.108918
   Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101
   Sun Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0794-4
   Suzumura A, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9100920
   Takeda S, 2015, J CLIN INVEST, V125, P1203, DOI 10.1172/JCI77075
   Terman A, 2010, ANTIOXID REDOX SIGN, V12, P503, DOI 10.1089/ars.2009.2598
   Ueda S, 2021, GRAEF ARCH CLIN EXP, V259, P1103, DOI 10.1007/s00417-020-05037-4
   Vida C, 2017, REDOX BIOL, V12, P423, DOI 10.1016/j.redox.2017.03.005
   von Kobbe C, 2018, CELL MOL LIFE SCI, V75, P3553, DOI 10.1007/s00018-018-2879-8
   Vuong L, 2012, INVEST OPHTH VIS SCI, V53, P1362, DOI 10.1167/iovs.11-8909
   Wagner KD, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11121966
   Wang K, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21887
   Wang P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08680-6
   Wang R, 2017, AGING CELL, V16, P564, DOI 10.1111/acel.12587
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Wati SM, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101603
   Weichhart T, 2018, GERONTOLOGY, V64, P127, DOI 10.1159/000484629
   Weng SS, 2017, MOL MED REP, V16, P3461, DOI 10.3892/mmr.2017.6964
   Westlund B, 2009, APOPTOSIS, V14, P31, DOI 10.1007/s10495-008-0285-7
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591-018-0092-9
   Xue QL, 2016, AGING-US, V8, P769, DOI 10.18632/aging.100929
   Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529
   Ye D, 2022, INVEST OPHTH VIS SCI, V63, DOI 10.1167/iovs.63.1.34
   Yosef R, 2017, EMBO J, V36, P2280, DOI 10.15252/embj.201695553
   Yosef R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11190
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
   Yu C, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6635460
   Zhang HQ, 2015, FREE RADICAL BIO MED, V88, P314, DOI 10.1016/j.freeradbiomed.2015.05.036
   Zhang ZY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2896036
   Zhao X, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2524174
   Zhao Z, 2020, GENOMICS, V112, P1309, DOI 10.1016/j.ygeno.2019.07.020
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
   Zhu Q, 2019, ARTIF CELL NANOMED B, V47, P2010, DOI 10.1080/21691401.2019.1608217
   Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178
NR 161
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD NOV
PY 2022
VL 11
IS 11
AR 2189
DI 10.3390/antiox11112189
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA 6A5GI
UT WOS:000880683600001
PM 36358561
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gallego-Pinazo, R
   Figueroa, MS
   Garcia-Layana, A
AF Gallego-Pinazo, Roberto
   Figueroa, Marta S.
   Garcia-Layana, Alfredo
TI Current state of therapeutic strategies with ranibizumab in neovascular
   age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE dosing strategies; neovascular age-related macular degeneration;
   ranibizumab; real-life results
ID ENDOTHELIAL GROWTH-FACTOR; TERM-FOLLOW-UP; INTRAOCULAR-PRESSURE CHANGES;
   ANTI-VEGF TREATMENT; INTRAVITREAL RANIBIZUMAB; CHOROIDAL
   NEOVASCULARIZATION; VISUAL IMPAIRMENT; DOSING REGIMEN; GEOGRAPHIC
   ATROPHY; CLINICAL-PRACTICE
AB Purpose of review
   To summarize the current dosing strategies in the management of neovascular age-related macular degeneration with intravitreal injections of ranibizumab.
   Recent findings
   A variety of therapeutic strategies has been recently described as an alternative to the monthly fixed treatment. The efficacy and local and systemic safety results of each approach is relevant in order to make a clinical decision and to provide patients an accurate information.
   Summary
   The proposed therapeutic strategies achieve positive visual outcomes when compared with monthly fixed regimen in the clinical trials. However, the real-life practice does not reflect these results. The main cause of this difference is the incapability to adopt any of the different strategies as the clinics are completely booked and this turns into a delay in the diagnostic and treatment visits.
C1 [Gallego-Pinazo, Roberto] Univ & Polytech Hosp La Fe, Dept Ophthalmol, Unit Macula, Valencia 46026, Spain.
   [Gallego-Pinazo, Roberto; Figueroa, Marta S.; Garcia-Layana, Alfredo] Inst Hlth Carlos III, Ret Oftared Prevent Early Detect & Treatment Prev, Madrid, Spain.
   [Figueroa, Marta S.] Univ Hosp Ramon & Cajal, Dept Ophthalmol, Madrid, Spain.
   [Garcia-Layana, Alfredo] Univ Navarra Clin, Dept Ophthalmol, Pamplona, Spain.
C3 Hospital Universitario Ramon y Cajal; University of Navarra
RP Gallego-Pinazo, R (通讯作者)，Univ & Polytech Hosp La Fe, Av Fernando Abril Martorell 106, Valencia 46026, Spain.
EM robertogallego@comv.es
FU Retics Oftared, 'Prevention, early detection and treatment of the
   prevalent degenerative and chronic ocular pathology', Institute of
   Health Carlos III, Madrid, Spain [RD12/0034]
FX The authors acknowledge the support provided by the Retics Oftared
   (RD12/0034), 'Prevention, early detection and treatment of the prevalent
   degenerative and chronic ocular pathology', Institute of Health Carlos
   III, Madrid, Spain.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Abedi G, 2013, SEMIN OPHTHALMOL, V28, P126, DOI 10.3109/08820538.2013.771195
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Arias L, 2011, RETINA-J RET VIT DIS, V31, P1261, DOI 10.1097/IAE.0b013e318207d152
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2014, OPHTHALMOLOGY, V121, P1102, DOI 10.1016/j.ophtha.2013.11.029
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Calvo P, J CLIN EXP OPHTHALMO, V5, P324
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Eldem BM, 2015, ACTA OPHTHALMOL, V93, pE458, DOI 10.1111/aos.12540
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Furtado JM, 2012, SURV OPHTHALMOL, V57, P149, DOI 10.1016/j.survophthal.2011.07.002
   Gianniou C, 2015, EYE, V29, P342, DOI 10.1038/eye.2014.258
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hoang QV, 2013, RETINA-J RET VIT DIS, V33, P179, DOI 10.1097/IAE.0b013e318261a6f7
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Matthe E, 2011, OPHTHALMOLOGE, V108, P237, DOI 10.1007/s00347-010-2282-9
   Menke MN, 2014, BRIT J OPHTHALMOL, V98, P1197, DOI 10.1136/bjophthalmol-2013-304775
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Mojica G, 2008, BRIT J OPHTHALMOL, V92, P584, DOI 10.1136/bjo.2007.126193
   Mones J, 2012, GRAEF ARCH CLIN EXP, V250, P1737, DOI 10.1007/s00417-012-2009-5
   Mousa SA, 2010, BIODRUGS, V24, P183, DOI 10.2165/11318550-000000000-00000
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda S, 2014, RETINA SUBSPECIALITY
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Singh RSJ, 2012, DRUG AGING, V29, P949, DOI 10.1007/s40266-012-0031-2
   Solomon SD, 2009, RETINA-J RET VIT DIS, V29, P1080, DOI 10.1097/IAE.0b013e3181b1baeb
   SooHoo JR, 2014, CURR OPIN OPHTHALMOL, V25, P127, DOI 10.1097/ICU.0000000000000036
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
   Tadayoni R, 2012, ACTA OPHTHALMOL, V90, ps249, DOI [10.1111/j.1755-3768.2012.3666.x, DOI 10.1111/J.1755-3768.2012.3666.X]
   Tanaka E, 2015, OPHTHALMOLOGY, V122, P153, DOI 10.1016/j.ophtha.2014.07.046
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 62
TC 1
Z9 1
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2015
VL 26
IS 3
BP 200
EP 205
DI 10.1097/ICU.0000000000000151
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CF1RV
UT WOS:000352326200010
PM 25774961
DA 2022-11-30
ER

PT J
AU Rakoczy, EP
   Lai, CM
   Magno, AL
   Wikstrom, ME
   French, MA
   Pierce, CM
   Schwartz, SD
   Blumenkranz, MS
   Chalberg, TW
   Degli-Esposti, MA
   Constable, IJ
AF Rakoczy, Elizabeth P.
   Lai, Chooi-May
   Magno, Aaron L.
   Wikstrom, Matthew E.
   French, Martyn A.
   Pierce, Cora M.
   Schwartz, Steven D.
   Blumenkranz, Mark S.
   Chalberg, Thomas W.
   Degli-Esposti, Mariapia A.
   Constable, Ian J.
TI Gene therapy with recombinant adeno-associated vectors for neovascular
   age-related macular degeneration: 1 year follow-up of a phase 1
   randomised clinical trial
SO LANCET
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; GEOGRAPHIC
   ATROPHY; OCULAR NEOVASCULARIZATION; INTRAVITREAL RANIBIZUMAB;
   INTRAOCULAR-PRESSURE; DOSING REGIMEN; INHIBITION; INJECTION; VEGF
AB Background Neovascular, or wet, age-related macular degeneration causes central vision loss and represents a major health problem in elderly people, and is currently treated with frequent intraocular injections of anti-VEGF protein. Gene therapy might enable long-term anti-VEGF therapy from a single treatment. We tested the safety of rAAV. sFLT-1 in treatment of wet age-related macular degeneration with a single subretinal injection.
   Methods In this single-centre, phase 1, randomised controlled trial, we enrolled patients with wet age-related macular degeneration at the Lions Eye Institute and the Sir Charles Gairdner Hospital (Nedlands, WA, Australia). Eligible patients had to be aged 65 years or older, have age-related macular degeneration secondary to active subfoveal choroidal neovascularisation, with best corrected visual acuity (BCVA) of 3/60-6/24 and 6/60 or better in the other eye. Patients were randomly assigned (3: 1) to receive either 1 x 10(10) vector genomes (vg; low-dose rAAV. sFLT-1 group) or 1 x 10(11) vg (high-dose rAAV. sFLT-1 group), or no gene-therapy treatment (control group). Randomisation was done by sequential group assignment. All patients and investigators were unmasked. Staff doing the assessments were masked to the study group at study visits. All patients received ranibizumab at baseline and week 4, and rescue treatment during follow-up based on prespecified criteria including BCVA measured on the Early Treatment Diabetic Retinopathy Study (EDTRS) scale, optical coherence tomography, and fluorescein angiography. The primary endpoint was ocular and systemic safety. This trial is registered with ClinicalTrials.gov, number NCT01494805.
   Findings From Dec 16, 2011, to April 5, 2012, we enrolled nine patients of whom eight were randomly assigned to receive either intervention (three patients in the low-dose rAAV. sFLT-1 group and three patients in the high-dose rAAV. sFLT-1 group) or no treatment (two patients in the control group). Subretinal injection of rAAV. sFLT-1 was highly reproducible. No drug-related adverse events were noted; procedure-related adverse events (subconjunctival or subretinal haemorrhage and mild cell debris in the anterior vitreous) were generally mild and self-resolving. There was no evidence of chorioretinal atrophy. Clinical laboratory assessments generally remained unchanged from baseline. Four (67%) of six patients in the treatment group required zero rescue injections, and the other two (33%) required only one rescue injection each.
   Interpretation rAAV. sFLT-1 was safe and well tolerated. These results support ocular gene therapy as a potential long-term treatment option for wet age-related macular degeneration.
C1 [Rakoczy, Elizabeth P.; Lai, Chooi-May; Wikstrom, Matthew E.; Degli-Esposti, Mariapia A.; Constable, Ian J.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Crawley, WA, Australia.
   [French, Martyn A.] Univ Western Australia, Sch Pathol & Lab Med, Crawley, WA, Australia.
   [Rakoczy, Elizabeth P.; Lai, Chooi-May; Magno, Aaron L.; Wikstrom, Matthew E.; Pierce, Cora M.; Degli-Esposti, Mariapia A.; Constable, Ian J.] Lions Eye Inst, Nedlands, WA 6009, Australia.
   [Schwartz, Steven D.] Univ Calif Los Angeles, Los Angeles, CA USA.
   [Blumenkranz, Mark S.] Stanford Univ, Palo Alto, CA 94304 USA.
   [Chalberg, Thomas W.] Avalanche Biotechnol Inc, Menlo Pk, CA USA.
   [Constable, Ian J.] Sir Charles Gairdner Hosp, Nedlands, WA 6009, Australia.
C3 University of Western Australia; University of Western Australia; Lions
   Eye Institute; University of Western Australia; University of California
   System; University of California Los Angeles; Stanford University;
   University of Western Australia
RP Rakoczy, EP (通讯作者)，Lions Eye Inst, 2 Verdun St, Nedlands, WA 6009, Australia.
EM elizabeth.rakoczy@uwa.edu.au
RI Lai, Chooi-May/H-5224-2014
OI French, Martyn/0000-0002-4644-1982; Degli-Esposti,
   Mariapia/0000-0002-7808-5935; Magno, Aaron/0000-0001-6099-819X;
   constable, ian/0000-0002-2140-6478
FU National Health and Medical Research Council of Australia; Richard
   Pearce Bequest; Lions Save Sight Foundation; Brian King Fellowship;
   Avalanche Biotechnologies, Inc.
FX National Health and Medical Research Council of Australia, Richard
   Pearce Bequest, Lions Save Sight Foundation, Brian King Fellowship, and
   Avalanche Biotechnologies, Inc.
CR Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bakri SJ, 2014, OPHTHALMOLOGY, V121, P1102, DOI 10.1016/j.ophtha.2013.11.029
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Channa R, 2015, AM J OPHTHALMOL, V159, P9, DOI 10.1016/j.ajo.2014.09.012
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CZERKINSKY CC, 1983, J IMMUNOL METHODS, V65, P109, DOI 10.1016/0022-1759(83)90308-3
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Lai CM, 2012, GENE THER, V19, P999, DOI 10.1038/gt.2011.169
   Lai CM, 2009, INVEST OPHTH VIS SCI, V50, P4279, DOI 10.1167/iovs.08-3253
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Lebherz C, 2005, DIABETES, V54, P1141, DOI 10.2337/diabetes.54.4.1141
   Lebherz C, 2008, J GENE MED, V10, P375, DOI 10.1002/jgm.1126
   Levison D., 2012, OEI031000360 US DEP
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   Luo L, 2013, ELIFE, V2, DOI 10.7554/eLife.00324
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   MacLaren RE, 2014, LANCET, V383, P1129, DOI 10.1016/S0140-6736(13)62117-0
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Nuzzi R, 2015, SEMIN OPHTHALMOL, V30, P129, DOI 10.3109/08820538.2013.835833
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Pershing S, 2013, OPHTHAL SURG LAS IM, V44, P460, DOI 10.3928/23258160-20130909-07
   Provost N, 2005, MOL THER, V11, P275, DOI 10.1016/j.ymthe.2004.09.022
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda S, 2014, AM AC OPHTH ANN M
   Sahel JA, 2013, ANNU REV NEUROSCI, V36, P467, DOI 10.1146/annurev-neuro-062012-170304
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Sophie R, 2014, OPHTHALMOLOGY, V121, P150
   Sophie R, 2014, OPHTHALMOLOGY, V121, pE34, DOI 10.1016/j.ophtha.2013.12.043
   VEGF Inhibition Study (V.I.S.I.O.N.) Clinical Trial Group, 2005, OPHTHALMOLOGY, V113
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 54
TC 119
Z9 131
U1 2
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD DEC 12
PY 2015
VL 386
IS 10011
BP 2395
EP 2403
DI 10.1016/S0140-6736(15)00345-1
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CY3EE
UT WOS:000366290400033
PM 26431823
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Vitillo, L
   Tovell, VE
   Coffey, P
AF Vitillo, Loriana
   Tovell, Victoria E.
   Coffey, Pete
TI Treatment of Age-Related Macular Degeneration with Pluripotent Stem
   Cell-Derived Retinal Pigment Epithelium
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; retinal pigment epithelium;
   pluripotent stem cells; regenerative medicine; cell therapy; stem cells;
   retina
ID HUMAN BRUCHS MEMBRANE; REGENERATIVE MEDICINE; GENE-EXPRESSION; VISUAL
   FUNCTION; TRANSPLANTATION; RPE; PREVALENCE; DIFFERENTIATION; GENERATION;
   RESISTANCE
AB Retinal pigment epithelium (RPE) degradation is central to the onset and progression of age-related macular degeneration (AMD), a growing and currently incurable form of blindness. Due to its key role in maintaining the retinal structure and homeostasis, cell replacement of the RPE monolayer has emerged as a promising therapy to rescue visual acuity in AMD patients. Thanks to the tremendous progress of pluripotent stem cell technologies over the last decade, a potentially unlimited new source for RPE transplantation has reached clinical trials. This review summarizes the methods by which pluripotent stem cell-based RPE cells are produced for transplantation, the delivery methods currently being adopted and the latest clinical outcomes with regard to the treatment of AMD.
C1 [Vitillo, Loriana; Tovell, Victoria E.; Coffey, Pete] UCL, Inst Ophthalmol, London Project Cure Blindness, London, England.
   [Coffey, Pete] Univ Calif Santa Barbara, Ctr Stem Cell Biol & Engn, Santa Barbara, CA 93106 USA.
   [Coffey, Pete] UCL Inst Ophthalmol, Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
C3 University of London; University College London; University of
   California System; University of California Santa Barbara; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust
RP Tovell, VE (通讯作者)，UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM v.tovell@ucl.ac.uk
OI Tovell, Victoria/0000-0001-8431-7942; Vitillo,
   Loriana/0000-0002-7184-1793; Coffey, Peter/0000-0002-5427-2939
FU Lincy Foundation, USA [P12761]; Macular Disease Society Studentship;
   CIRM (California Institute of Regenerative Medicine) [LA1_C2-02086]; MRC
   [G1000730]; Pfizer; Establishment of The London Project to Cure
   Blindness
FX This work was supported by the Lincy Foundation, USA, The London Project
   To Cure Blindness: Funding Towards The Production Of A Cell Based
   Therapy For Late Stage Age-Related Macular Degeneration [P12761];
   Anonymous Donor, USA, Establishment of The London Project to Cure
   Blindness - Donation; Macular Disease Society Studentship - Donation;
   CIRM (California Institute of Regenerative Medicine) [LA1_C2-02086];
   MRC, Stem Cell Based Treatment Strategy For Age-Related Macular
   Degeneration (AMD) [G1000730]; Pfizer.
CR ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Amer MH, 2015, J PHARM PHARMACOL, V67, P640, DOI 10.1111/jphp.12362
   Arnhold S, 2006, INVEST OPHTH VIS SCI, V47, P4121, DOI 10.1167/iovs.04-1501
   Attwood SW, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030288
   Baker D, 2016, STEM CELL REP, V7, P998, DOI 10.1016/j.stemcr.2016.10.003
   Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   Bharti K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002757
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Blind R, 2004, COST SIGHT LOSS UK
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Carr AJ, 2009, MOL VIS, V15, P283
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Coffey P J, 2000, Prog Brain Res, V127, P489
   Croze RH, 2014, STEM CELL TRANSL MED, V3, P1066, DOI 10.5966/sctm.2014-0079
   Curcio C. A., 2012, RETINA, V1, P465
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   de Rham C, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/518135
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Fairchild PJ, 2016, REGEN MED, V11, P817, DOI 10.2217/rme-2016-0134
   GOURAS P, 1984, AN ACAD BRAS CIENC, V56, P431
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hsiung J, 2015, STEM CELL TRANSL MED, V4, P10, DOI 10.5966/sctm.2014-0205
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kamath A, 2017, FUTUR SCI OA, V3, DOI 10.4155/fsoa-2017-0028
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Kuroda T, 2019, STEM CELL RES, V39, DOI 10.1016/j.scr.2019.101514
   Leach LL, 2015, INVEST OPHTH VIS SCI, V56, P1002, DOI 10.1167/iovs.14-15835
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   Mandai Michiko, 2017, N Engl J Med, V377, P792, DOI 10.1056/NEJMc1706274
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Merkle FT, 2017, NATURE, V545, P229, DOI 10.1038/nature22312
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Noguchi H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040930
   Nommiste B, 2017, PROG BRAIN RES, V231, P225, DOI 10.1016/bs.pbr.2017.03.003
   Oswald J, 2018, THER ADV OPHTHALMOL, V10, DOI 10.1177/2515841418774433
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pauleikhoff D., 1994, Ophthalmologe, V91, P730
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Perrera V, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00076
   Pezzullo L, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2836-0
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Reh TA, 2010, METHODS MOL BIOL, V636, P139, DOI 10.1007/978-1-60761-691-7_9
   Rezai KA, 1997, INVEST OPHTH VIS SCI, V38, P2255
   Rezai KA, 1997, EXP EYE RES, V65, P23, DOI 10.1006/exer.1997.0307
   Rezai KA, 1997, GRAEF ARCH CLIN EXP, V235, P558, DOI 10.1007/BF00947084
   Rizzolo LJ, 2011, PROG RETIN EYE RES, V30, P296, DOI 10.1016/j.preteyeres.2011.06.002
   Robertson NJ, 2007, P NATL ACAD SCI USA, V104, P20920, DOI 10.1073/pnas.0710265105
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Song MJ, 2016, BRAIN RES, V1638, P2, DOI 10.1016/j.brainres.2015.12.011
   Stacey G, 2018, REGEN MED, V13, P935, DOI 10.2217/rme-2018-0120
   Stein JD, 2009, ARCH OPHTHALMOL-CHIC, V127, P1656, DOI 10.1001/archophthalmol.2009.300
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takagi S, 2019, OPHTHALMOL RETINA, V3, P850, DOI 10.1016/j.oret.2019.04.021
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Taylor CJ, 2005, LANCET, V366, P2019, DOI 10.1016/S0140-6736(05)67813-0
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Westenskow PD, 2015, JOVE-J VIS EXP, DOI 10.3791/52247
   Williams DJ, 2016, REGEN MED, V11, P483, DOI 10.2217/rme-2016-0053
   Wilmut I, 2015, REGEN MED, V10, P235, DOI [10.2217/rme.15.1, 10.2217/RME.15.1]
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu HG, 2019, CELL STEM CELL, V24, P566, DOI 10.1016/j.stem.2019.02.005
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 93
TC 9
Z9 9
U1 2
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD MAR 3
PY 2020
VL 45
IS 3
SI SI
BP 361
EP 371
DI 10.1080/02713683.2019.1691237
EA NOV 2019
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KH3IR
UT WOS:000499091600001
PM 31777296
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Maralani, HG
   Tai, BC
   Wong, TY
   Tai, ES
   Li, JL
   Wang, JJ
   Mitchell, P
AF Maralani, Haleh Ghaem
   Tai, Bee Choo
   Wong, Tien Y.
   Tai, E. Shyong
   Li, Jialiang
   Wang, Jie Jin
   Mitchell, Paul
TI METABOLIC SYNDROME AND RISK OF AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; Blue Mountains Eye Study; metabolic
   syndrome
ID LONG-TERM INCIDENCE; CARDIOVASCULAR-DISEASE; MACULOPATHY; ASSOCIATION;
   HEALTH; PROGRESSION; PREVALENCE; EYE
AB Purpose: To investigate the relationship between metabolic syndrome (MetS) and its components with the risk of early-and late-stage age-related macular degeneration (AMD).
   Methods: A prospective cohort of individuals aged older than or equal to 49 years were followed up over a period of 10 years in the Blue Mountains Eye Study, Australia. MetS components were measured at baseline (1992-1994), 5-year (1997-1999), and 10-year (2002-2004) follow-ups. Incident cases of early and late AMD were diagnosed using standard photographic grading of retinal images of 2,218 participants at risk. Mixed-effect logistic regression was conducted to explore the relationship between MetS (and its components) with subsequent development of early/ late AMD.
   Results: Over the 10-year follow-up, early AMD developed in 12% and late AMD in 3% of participants at risk. Amongst subjects aged younger than or equal to 70 years, MetS was associated with the incidence of late AMD. Of the five MetS components, obesity, high glucose, and high triglyceride were associated with the increased incidence of late AMD during the 10-year follow-up. There was no evidence of effect of MetS and its components on the risk of early AMD.
   Conclusion: Metabolic syndrome, obesity, high glucose, and high triglycerides were predictors of progression to late AMD. These data provide additional insights into the pathogenesis of AMD.
C1 [Maralani, Haleh Ghaem; Tai, Bee Choo] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117597, Singapore.
   [Maralani, Haleh Ghaem; Tai, Bee Choo; Wong, Tien Y.; Tai, E. Shyong] Natl Univ Hlth Syst, Singapore, Singapore.
   [Maralani, Haleh Ghaem] Shiraz Univ Med Sci, Sch Hlth, Dept Epidemiol, Shiraz, Iran.
   [Tai, Bee Choo] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117597, Singapore.
   [Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117597, Singapore.
   [Wong, Tien Y.] Duke NUS Grad Med Sch, Singapore, Singapore.
   [Tai, E. Shyong] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117597, Singapore.
   [Li, Jialiang] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore 117597, Singapore.
   [Wang, Jie Jin; Mitchell, Paul] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
C3 National University of Singapore; National University of Singapore;
   Shiraz University of Medical Science; National University of Singapore;
   National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore;
   National University of Singapore; National University of Singapore;
   University of Sydney
RP Tai, BC (通讯作者)，Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, 16 Med Dr MD3, Singapore 117597, Singapore.
EM ephtbc@nus.edu.sg
RI Ghaem, Haleh/L-9985-2016; Li, Jialiang/B-9132-2014; Wong, Tien
   Yin/AAC-9724-2020; wang, jie/GRS-0942-2022; Li, Jialiang/N-8529-2019;
   Mitchell, Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014
OI Ghaem, Haleh/0000-0001-9564-392X; Li, Jialiang/0000-0002-9704-4135;
   Wong, Tien Yin/0000-0002-8448-1264; Li, Jialiang/0000-0002-9704-4135;
   Wang, Jie Jin/0000-0001-9491-4898; Tai, E Shyong/0000-0003-2929-8966
FU Australian National Health and Medical Research Council [974159, 991407,
   211069]
FX The Blue Mountains Eye Study was supported by the Australian National
   Health and Medical Research Council (grant nos. 974159, 991407, 211069).
CR Afridi I, 2003, J HYPERTENS, V21, P1983, DOI 10.1097/01.hjh.0000084751-37215.d2
   Agresti A, 2012, CATEGORICAL DATA ANA, P429
   Alberti KGMM, 2006, DIABETIC MED, V23, P469, DOI 10.1111/j.1464-5491.2006.01858.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown H, 2006, APPL MIXED MODELS ME, p[22, 215]
   Capoulade R, 2012, J AM COLL CARDIOL, V60, P216, DOI 10.1016/j.jacc.2012.03.052
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chiang PPC, 2013, DIABETIC MED, V30, pE32, DOI 10.1111/dme.12053
   Cugati S, 2007, MED J AUSTRALIA, V186, P131, DOI 10.5694/j.1326-5377.2007.tb00836.x
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   FRYCZKOWSKI AW, 1988, ANN OPHTHALMOL, V20, P299
   HIDAYAT AA, 1985, OPHTHALMOLOGY, V92, P512
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 2005, MACULAR DEGENERATION, P79
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Li BY, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-77
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin HF, 2010, ATHEROSCLEROSIS, V210, P155, DOI 10.1016/j.atherosclerosis.2009.11.027
   McCarty CA, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-25
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Mitchell P, 1998, DIABETES RES CLIN PR, V41, P177, DOI 10.1016/S0168-8227(98)00079-5
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   World Health Organization, 1999, DEF DIAGN CLASS DI 1
   Zimmet P, 2005, J ATHEROSCLER THROMB, V12, P295, DOI 10.5551/jat.12.295
NR 40
TC 36
Z9 37
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2015
VL 35
IS 3
BP 459
EP 466
DI 10.1097/IAE.0000000000000338
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC4AO
UT WOS:000350293100024
PM 25207946
DA 2022-11-30
ER

PT J
AU Grassmann, F
   Heid, IM
   Weber, BHF
AF Grassmann, Felix
   Heid, Iris M.
   Weber, Bernhard H. F.
CA Int AMD Genomics Consortium IAMDGC
TI Recombinant Haplotypes Narrow the ARMS2/HTRA1 Association Signal for
   Age-Related Macular Degeneration
SO GENETICS
LA English
DT Article
DE age-related macular degeneration; genetic association studies; linkage
   disequilibrium; haplotypes; ARMS2/HTRA1 gene locus
ID HTRA1; ARMS2; SUSCEPTIBILITY; VARIANTS; COMPLEMENT; LOC387715; IMPAIR;
   10Q26; GENE
AB Age-related macular degeneration (AMD) is the leading cause of blindness in ageing societies, triggered by both environmental and genetic factors. The strongest genetic signal for AMD with odds ratios of up to 2.8 per adverse allele was found previously over a chromosomal region in 10q26 harboring two genes, ARMS2 and HTRA1, although with little knowledge as to which gene or genetic variation is functionally relevant to AMD pathology. In this study, we analyzed rare recombinant haplotypes in 16,144 AMD cases and 17,832 controls from the International AMD Genomics Consortium and identified variants in ARMS2 but not HTRA1 to exclusively carry the AMD risk with P-values between 1.0 x 10(-773) and 6.7 x 10(-5). This now allows prioritization of the gene of interest for subsequent functional studies.
C1 [Grassmann, Felix; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
   [Heid, Iris M.] Univ Regensburg, Dept Genet Epidemiol, D-93053 Regensburg, Germany.
C3 University of Regensburg; University of Regensburg
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI Souzeau, Emmanuelle/AAB-5608-2022; Zhang, Kang/Y-2740-2019; Peachey,
   Neal/G-5533-2010
OI Souzeau, Emmanuelle/0000-0002-2015-6577; Zhang,
   Kang/0000-0002-4549-1697; Peachey, Neal/0000-0002-4419-7226; lake,
   stewart/0000-0003-0078-3319; Weeks, Daniel/0000-0001-9410-7228;
   Michaelides, Michel/0000-0002-1552-7046; Weber, Bernhard
   H.F./0000-0002-8808-7723; Scott, William/0000-0001-9336-6404; constable,
   ian/0000-0002-2140-6478; Craig, Jamie/0000-0001-9955-9696; Branham,
   Kari/0000-0002-2492-254X; Baird, Paul/0000-0002-1305-3502; Blangero,
   John/0000-0001-6250-5723; Ahn, Jeeyun/0000-0001-9017-1652; Guymer,
   Robyn/0000-0002-9441-4356; Hagbi-Levi, Shira/0000-0002-2891-0079;
   Grassmann, Felix/0000-0003-1390-7528
FU German Federal Ministry of Education and Research [BMBF 01ER1206,
   01ER1507]; Freestate of Bavaria; German Research Foundation [WE
   1259/19-2]
FX The authors thank Paul N. Baird (Ocular Genetics Unit, Centre for Eye
   Research, Australia) for critically reading the manuscript. The work was
   funded in part by grants from the German Federal Ministry of Education
   and Research (BMBF 01ER1206 and 01ER1507) to I.M.H., by the
   institutional budget for Research and Teaching from the Freestate of
   Bavaria and the German Research Foundation (WE 1259/19-2) to BHFW.
CR Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Cheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053665
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Imai K, 2010, PSYCHOL METHODS, V15, P309, DOI 10.1037/a0020761
   Jacobo SMP, 2013, MOL CELL BIOL, V33, P1976, DOI 10.1128/MCB.01283-12
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Kichaev G, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004722
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Lake SL, 2003, HUM HERED, V55, P56, DOI 10.1159/000071811
   Maller JB, 2012, NAT GENET, V44, P1294, DOI 10.1038/ng.2435
   O'Connell J, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004234
   Rahpeymai Y, 2006, EMBO J, V25, P1364, DOI 10.1038/sj.emboj.7601004
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Tingley D, 2014, J STAT SOFTW, V59
   van de Bunt M, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005535
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wray NR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000864
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 25
TC 39
Z9 40
U1 2
U2 3
PU GENETICS SOCIETY AMERICA
PI BETHESDA
PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA
SN 0016-6731
EI 1943-2631
J9 GENETICS
JI Genetics
PD FEB
PY 2017
VL 205
IS 2
BP 919
EP 924
DI 10.1534/genetics.116.195966
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EK7ZY
UT WOS:000394144900031
PM 27879347
OA Green Published
DA 2022-11-30
ER

PT J
AU Nguyen, TT
   Guymer, R
AF Nguyen, Thanh T.
   Guymer, Robyn
TI Conbercept (KH-902) for the treatment of neovascular age-related macular
   degeneration
SO EXPERT REVIEW OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE aflibercept; age-related macular degeneration; bevacizumab; conbercept;
   pegaptanib; ranibizumab
ID ENDOTHELIAL GROWTH-FACTOR; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   PIGMENT EPITHELIAL-CELLS; ANTI-VEGF ANTIBODY; INCREASED EXPRESSION;
   MEDIATED EXPRESSION; TUMOR ANGIOGENESIS; TYROSINE KINASE; TRANSGENIC
   MICE; FUSION PROTEIN
AB Age-related macular degeneration (AMD) is a progressive, degenerative disease of the retina that occurs with increasing incidence with age and ranks third among the global causes of visual impairment. VEGF has been implicated in the development and progression of neovascular AMD. Drugs that block VEGF, leading to regression of the abnormal blood vessels, are the mainstay of treatment of neovascular AMD, particularly for subfoveal neovascular lesions. Anti-VEGF agents currently in use in neovascular AMD are pegaptanib (Macugen((R))), ranibizumab (Lucentis((R))), bevacizumab (Avastin((R))) and a soluble VEGF receptor decoy aflibercept (Eylea((R))). Recently, China Food and Drug Administration have approved conbercept for the treatment of neovascular AMD in China. Conbercept appears to offer yet another anti-VEGF drug for use in neovascular AMD. However, there is still a need for large, well-designed, randomized clinical trials to ensure its safety and efficacy.
C1 [Nguyen, Thanh T.; Guymer, Robyn] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; University of Melbourne
RP Guymer, R (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
EM rh.guymer@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chen X, 2013, DIABETES OBES METAB, V15, P224, DOI 10.1111/dom.12008
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, piii
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Du LP, 2015, MOL VIS, V21, P185
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   FERRARA N, 1987, AM J PHYSIOL, V252, pE304, DOI 10.1152/ajpendo.1987.252.3.E304
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Ferrara N, 2010, MOL BIOL CELL, V21, P687, DOI 10.1091/mbc.E09-07-0590
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Kim KJ, 2012, EXP MOL MED, V44, P10, DOI 10.3858/emm.2012.44.1.023
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krader CG, 2015, OPHTHALMOL TIMES
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Li H, 2012, EXP EYE RES, V97, P154, DOI 10.1016/j.exer.2011.09.002
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lim JI, 2005, AM J OPHTHALMOL, V140, P1044, DOI 10.1016/j.ajo.2005.07.021
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Malik AK, 2006, BLOOD, V107, P550, DOI 10.1182/blood-2005-05-2047
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Michaelson IC., 1948, T OPHTHALMOL SOC, V68, P137
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Nork TM, 2011, ARCH OPHTHALMOL-CHIC, V129, P1042, DOI 10.1001/archophthalmol.2011.210
   Okamoto N, 1997, AM J PATHOL, V151, P281
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   Presta LG, 1997, CANCER RES, V57, P4593
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roy H, 2005, HUM GENE THER, V16, P1422, DOI 10.1089/hum.2005.16.1422
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stewart MA, 2011, ADV GLOB CHANGE RES, V45, P1, DOI [10.1007/978-94-007-0934-8_1, 10.4081/eye.2011.e5]
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   WHO, PRIOR EYE DIS MAIN C
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 81
TC 27
Z9 33
U1 2
U2 28
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1751-2433
EI 1751-2441
J9 EXPERT REV CLIN PHAR
JI Expert Rev. Clin. Pharmacol.
PD SEP
PY 2015
VL 8
IS 5
BP 541
EP 548
DI 10.1586/17512433.2015.1075879
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CP7VX
UT WOS:000360098300005
PM 26289225
DA 2022-11-30
ER

PT J
AU Zandi, S
   Nakao, S
   Chun, KH
   Fiorina, P
   Sun, DW
   Arita, R
   Zhao, M
   Kim, E
   Schueller, O
   Campbell, S
   Taher, M
   Melhorn, MI
   Schering, A
   Gatti, F
   Tezza, S
   Xie, F
   Vergani, A
   Yoshida, S
   Ishikawa, K
   Yamaguchi, M
   Sasaki, F
   Schmidt-Ullrich, R
   Hata, Y
   Enaida, H
   Yuzawa, M
   Yokomizo, T
   Kim, YB
   Sweetnam, P
   Ishibashi, T
   Hafezi-Moghadam, A
AF Zandi, Souska
   Nakao, Shintaro
   Chun, Kwang-Hoon
   Fiorina, Paolo
   Sun, Dawei
   Arita, Ryoichi
   Zhao, Ming
   Kim, Enoch
   Schueller, Olivier
   Campbell, Stewart
   Taher, Mahdi
   Melhorn, Mark Ivan
   Schering, Alexander
   Gatti, Francesca
   Tezza, Sara
   Xie, Fang
   Vergani, Andrea
   Yoshida, Shigeo
   Ishikawa, Keijiro
   Yamaguchi, Muneo
   Sasaki, Fumiyuki
   Schmidt-Ullrich, Ruth
   Hata, Yasuaki
   Enaida, Hiroshi
   Yuzawa, Mitsuko
   Yokomizo, Takehiko
   Kim, Young-Bum
   Sweetnam, Paul
   Ishibashi, Tatsuro
   Hafezi-Moghadam, Ali
TI ROCK-Isoform-Specific Polarization of Macrophages Associated with
   Age-Related Macular Degeneration
SO CELL REPORTS
LA English
DT Article
ID NF-KAPPA-B; CARDIAC-HYPERTROPHY; IN-VIVO; MICE; NEOVASCULARIZATION;
   ACTIVATION; DAMAGE; REQUIREMENT; THERAPY; CELLS
AB Age is a major risk factor in age-related macular degeneration (AMD), but the underlying cause is unknown. We find increased Rho-associated kinase (ROCK) signaling and M2 characteristics in eyes of aged mice, revealing immune changes in aging. ROCK isoforms determine macrophage polarization into M1 and M2 subtypes. M2-like macrophages accumulated in AMD, but not in normal eyes, suggesting that these macrophages may be linked to macular degeneration. M2 macrophages injected into the mouse eye exacerbated choroidal neovascular lesions, while M1 macrophages ameliorated them, supporting a causal role for macrophage subtypes in AMD. Selective ROCK2 inhibition with a small molecule decreased M2-like macrophages and choroidal neovascularization. ROCK2 inhibition upregulated M1 markers without affecting macrophage recruitment, underlining the plasticity of these macrophages. These results reveal age-induced innate immune imbalance as underlying AMD pathogenesis. Targeting macrophage plasticity opens up new possibilities for more effective AMD treatment.
C1 [Zandi, Souska; Nakao, Shintaro; Sun, Dawei; Zhao, Ming; Taher, Mahdi; Melhorn, Mark Ivan; Schering, Alexander; Xie, Fang; Hafezi-Moghadam, Ali] Brigham & Womens Hosp, Ctr Excellence Funct & Mol Imaging, Boston, MA 02115 USA.
   [Zandi, Souska; Nakao, Shintaro; Sun, Dawei; Zhao, Ming; Taher, Mahdi; Melhorn, Mark Ivan; Schering, Alexander; Xie, Fang; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
   [Zandi, Souska; Nakao, Shintaro; Sun, Dawei; Taher, Mahdi; Melhorn, Mark Ivan; Schering, Alexander; Xie, Fang; Hafezi-Moghadam, Ali] Massachusetts Eye & Ear Infirm, Angiogenesis Lab, Boston, MA 02114 USA.
   [Zandi, Souska; Nakao, Shintaro; Sun, Dawei; Taher, Mahdi; Melhorn, Mark Ivan; Schering, Alexander; Xie, Fang; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA.
   [Zandi, Souska] Rotkreuz & Berner Augenklin Lindenhofspital, Swiss Eye Inst, Dept Ophthalmol, CH-3012 Bern, Switzerland.
   [Nakao, Shintaro; Arita, Ryoichi; Yoshida, Shigeo; Ishikawa, Keijiro; Yamaguchi, Muneo; Hata, Yasuaki; Enaida, Hiroshi; Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka 8128582, Japan.
   [Chun, Kwang-Hoon] Gachon Univ, Coll Pharm, Gachon Inst Pharmaceut Sci, Inchon 406799, South Korea.
   [Fiorina, Paolo; Gatti, Francesca; Tezza, Sara; Vergani, Andrea] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Nephrol, Boston, MA 02115 USA.
   [Fiorina, Paolo; Gatti, Francesca; Tezza, Sara; Vergani, Andrea] Hosp San Raffaele, Div Transplant Med, I-20132 Milan, Italy.
   [Sun, Dawei; Xie, Fang] Harbin Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Harbin 150086, Peoples R China.
   [Sun, Dawei; Xie, Fang] Harbin Med Univ, Affiliated Hosp 2, Dept Ophthalmol, Harbin 150086, Peoples R China.
   [Zhao, Ming] Sun Yat Sen Univ, Med Imaging Ctr, Minimally Invas Intervent Div, State Key Lab Oncol, Guangzhou 510060, Peoples R China.
   [Kim, Enoch; Schueller, Olivier; Campbell, Stewart; Sweetnam, Paul] Surface Logix Inc, Brighton, MA 02135 USA.
   [Sasaki, Fumiyuki; Yokomizo, Takehiko] Juntendo Univ, Sch Med, Dept Biochem, Tokyo 1138421, Japan.
   [Schmidt-Ullrich, Ruth] Max Delbruck Ctr Mol Med, Dept Signal Transduct Tumor Cells, D-13092 Berlin, Germany.
   [Yuzawa, Mitsuko] Nihon Univ, Sch Med Sci, Dept Ophthalmol, Tokyo 1738610, Japan.
   [Kim, Young-Bum] Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02115 USA.
   [Kim, Young-Bum] Harvard Univ, Sch Med, Boston, MA 02115 USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Harvard Medical School; Harvard University; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard Medical School; Kyushu
   University; Gachon University; Harvard University; Boston Children's
   Hospital; Harvard Medical School; Vita-Salute San Raffaele University;
   IRCCS Ospedale San Raffaele; Harbin Medical University; Harbin Medical
   University; State Key Lab Oncology South China; Sun Yat Sen University;
   Juntendo University; Helmholtz Association; Max Delbruck Center for
   Molecular Medicine; Nihon University; Harvard University; Beth Israel
   Deaconess Medical Center; Harvard University; Harvard Medical School
RP Hafezi-Moghadam, A (通讯作者)，Brigham & Womens Hosp, Ctr Excellence Funct & Mol Imaging, 75 Francis St, Boston, MA 02115 USA.
EM ahm@bwh.harvard.edu
RI Yokomizo, Takehiko/P-5673-2016; Fiorina, Paolo/B-4532-2019
OI Yokomizo, Takehiko/0000-0002-5219-1553; Hafezi-Moghadam,
   Ali/0000-0002-5336-0697; Yoshida, Shigeo/0000-0003-1049-8909; Zandi,
   Souska/0000-0001-9351-4278; Fiorina, Paolo/0000-0002-1093-7724; Taher,
   Mahdi/0000-0001-8454-9751; Campbell, Anthony/0000-0001-5094-9714
FU NIH/National Institute of Diabetes and Digestive and Kidney Diseases
   through Diabetes Complications Consortium [25732-30]; BrightFocus
   Foundation; Malaysian Palm Oil Board; JSPS KAKENHI [25713057]; 
   [R01DK083567]; Grants-in-Aid for Scientific Research [15H05897] Funding
   Source: KAKEN; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [R01DK083567, DP3DK108238] Funding Source: NIH RePORTER
FX We thank Sonja Frimmel, Sepideh Faez, Lola Chabtini, and Roberto Bassi
   for technical assistance and Rebecca Garland for critical review of the
   manuscript. Randy Huang and David M. Dombkowski (Center for Regenerative
   Medicine and Technology, Massachusetts General Hospital) assisted with
   flow cytometry. We thank Professor K.C. Hayes for his commitment to
   mentorship. This work was supported by NIH/National Institute of
   Diabetes and Digestive and Kidney Diseases through Diabetes
   Complications Consortium award 25732-30 (A.H.-M.), the BrightFocus
   Foundation, the Malaysian Palm Oil Board (A.H.-M.), and R01DK083567
   (Y.-B.K.). Grants are from JSPS KAKENHI, Grant-in-Aid for Young
   Scientists (A) (#25713057 to S.N.). E.K., O.S., S.C., and P.S. were
   employed by SurfaceLogix, a company that developed the selective small
   molecule inhibitor against ROCK2, which was used in this work.
CR Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Arita R, 2009, DIABETES, V58, P215, DOI 10.2337/db08-0762
   Aurora AB, 2010, BLOOD, V116, P475, DOI 10.1182/blood-2009-07-232132
   Bastos KRB, 2002, J LEUKOCYTE BIOL, V71, P271
   Cammarano MS, 2001, J BIOL CHEM, V276, P25876, DOI 10.1074/jbc.M011345200
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chun KH, 2012, ENDOCRINOLOGY, V153, P1649, DOI 10.1210/en.2011-1036
   Freund C, 2005, CIRCULATION, V111, P2319, DOI 10.1161/01.CIR.0000164237.58200.5A
   Gustafsson E, 2001, J CELL SCI, V114, P671
   Henke N, 2007, CIRC RES, V101, P268, DOI 10.1161/CIRCRESAHA.107.150474
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Huang H, 2012, NAT NEUROSCI, V15, P1391, DOI 10.1038/nn.3207
   ISHIBASHI T, 1987, INVEST OPHTH VIS SCI, V28, P1116
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Lara-Castillo N, 2009, AM J PATHOL, V175, P2343, DOI 10.2353/ajpath.2009.090439
   London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Ohashi K, 2010, J BIOL CHEM, V285, P6153, DOI 10.1074/jbc.M109.088708
   Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128
   Rikitake Y, 2005, CIRCULATION, V112, P2959, DOI 10.1161/CIRCULATIONAHA.105.584623
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmidt-Ullrich R, 2001, DEVELOPMENT, V128, P3843
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Sun D., 2014, FASEB J
   Tabruyn SP, 2008, ANGIOGENESIS, V11, P101, DOI 10.1007/s10456-008-9094-4
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Zhao H, 2013, INVEST OPHTH VIS SCI, V54, P5321, DOI 10.1167/iovs.13-12122
NR 30
TC 117
Z9 117
U1 1
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD FEB 24
PY 2015
VL 10
IS 7
BP 1173
EP 1186
DI 10.1016/j.celrep.2015.01.050
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CB8YP
UT WOS:000349918700013
PM 25704819
OA Green Accepted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Griffin, SM
   Jia, YL
   Johnson, AJ
   Antony, BJ
   McDonald, HR
   Johnson, RN
   Lujan, BJ
AF Griffin, Shane M.
   Jia, Yali
   Johnson, Alicia J.
   Antony, Bhavna J.
   McDonald, H. Richard
   Johnson, Robert N.
   Lujan, Brandon J.
TI Directional Reflectivity of the Ellipsoid Zone in Dry Age-Related
   Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
AB BACKGROUND AND OBJECTIVE: Ellipsoid zone (EZ) reflectivity on optical coherence tomography (OCT) is affected by the orientation of the scanning beam. The authors sought to determine how directional reflectivity changes in dry age-related macular degeneration (AMD).
   PATIENTS AND METHODS: Retrospective image analysis included 17 control and 20 dry AMD subjects. Directional OCT (D-OCT) was performed using multiple displaced pupil entrance positions. EZ pixel values and apparent incidence angles were measured.
   RESULTS: EZ reflectivity decreased in off-axis scans in controls (P < .001), AMD areas between drusen (P < .001), and AMD areas overlying drusen (P < .001). The magnitude of decrement in EZ reflectivity was significantly higher when incidence angles exceeded 10 degrees in controls than in AMD areas between drusen (P = .024).
   CONCLUSION: EZ reflectivity in dry AMD may vary by incident angle of light less than in controls, possibly indicating alteration of photoreceptor orientation or integrity.
C1 [Griffin, Shane M.; Jia, Yali; Lujan, Brandon J.] Oregon Hlth & Sci Univ, Casey Eye Inst, 3303 S Bond Ave,Bldg 1,11th Floor, Portland, OR 97239 USA.
   [Johnson, Alicia J.] Oregon Hlth & Sci Univ, Biostat & Design Program, Portland State Univ, Sch Publ Hlth, Portland, OR 97239 USA.
   [Antony, Bhavna J.] IBM Res, Melbourne, Vic, Australia.
   [McDonald, H. Richard; Johnson, Robert N.] West Coast Retina Med Grp, San Francisco, CA USA.
C3 Oregon Health & Science University; Oregon Health & Science University;
   Portland State University
RP Lujan, BJ (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, 3303 S Bond Ave,Bldg 1,11th Floor, Portland, OR 97239 USA.
EM lujanb@ohsu.edu
RI Antony, Bhavna Josephine/ABD-1023-2021
OI Antony, Bhavna Josephine/0000-0002-6882-2444; Griffin,
   Shane/0000-0001-6245-9886
CR Abramoff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Carrasco-Zevallos O, 2015, BIOMED OPT EXPRESS, V6, P3405, DOI 10.1364/BOE.6.003405
   Cuenca N, 2020, PROG RETIN EYE RES, V77, DOI 10.1016/j.preteyeres.2019.100828
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fujita A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48825-7
   Gao WH, 2008, OPT EXPRESS, V16, P6486, DOI 10.1364/OE.16.006486
   Gin TJ, 2017, INVEST OPHTH VIS SCI, V58, P2079, DOI 10.1167/iovs.16-20105
   Godara Pooja, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS104, DOI 10.3928/15428877-20101031-07
   Hood DC, 2011, INVEST OPHTH VIS SCI, V52, P9703, DOI 10.1167/iovs.11-8650
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Lujan BJ, 2015, RETINA-J RET VIT DIS, V35, P1511, DOI 10.1097/IAE.0000000000000527
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Makhijani VS, 2013, PROC SPIE, V8571, DOI 10.1117/12.2007141
   Meadway A, 2019, BIOMED OPT EXPRESS, V10, P6531, DOI 10.1364/BOE.10.006531
   Park DW, 2017, OPHTHALMOL RETINA, V1, P394, DOI 10.1016/j.oret.2017.05.005
   Tong KK, 2016, OPTOMETRY VISION SCI, V93, P714, DOI 10.1097/OPX.0000000000000861
   Westheimer G, 2008, P ROY SOC B-BIOL SCI, V275, P2777, DOI 10.1098/rspb.2008.0712
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2013, OPHTHALMOLOGY, V120, P1307, DOI 10.1016/j.ophtha.2012.12.047
   Zayit-Soudry S, 2013, INVEST OPHTH VIS SCI, V54, P7498, DOI 10.1167/iovs.13-12433
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
NR 25
TC 4
Z9 4
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAR
PY 2021
VL 52
IS 3
BP 145
EP 152
DI 10.3928/23258160-20210302-05
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA RF6FC
UT WOS:000634936500005
PM 34038689
DA 2022-11-30
ER

PT J
AU Rovner, BW
   Casten, RJ
   Hegel, MT
   Tasman, WS
AF Rovner, Barry W.
   Casten, Robin J.
   Hegel, Mark T.
   Tasman, William S.
TI Minimal depression and vision function. in age-related macular
   degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL FUNCTION QUESTIONNAIRE; CHRONIC DISEASE SCORE; OLDER-ADULTS;
   RATING-SCALE; HAMILTON DEPRESSION; LATE-LIFE; DISABILITY; COMMUNITY;
   IMPAIRMENT; REMISSION
AB Objective: To evaluate the impact of minimal depression on subjective and objective vision function measures in age-related macular degeneration (AMD).
   Design: Prospective cross-sectional study.
   Participants: Two hundred six outpatients with newly diagnosed neovascular AMD in one eye and preexisting AMD in the fellow eye.
   Methods: Structured clinical evaluations of visual acuity (VA), contrast sensitivity, vision function, and depression.
   Main Outcome Measures: The 17-item National Eye Institute Visual Function Questionnaire (NEI VFQ 17), Melbourne Low-Vision Index (MLVI), Chronic Disease Score, and Hamilton Depression Rating Scale.
   Results: Minimally depressed subjects had significantly worse vision function on both the NEI VFQ 17 and performance-based tasks of the MLVI than nondepressed subjects, independent of severity of VA, contrast sensitivity, and medical status.
   Conclusions: Minimally depressed patients with AMD, who would not be considered depressed according to current diagnostic standards, suffer decrements in vision function that cannot be accounted for by the severity of their eye disease or general medical problems. These data emphasize the need to assess depressive symptoms in research studies that use vision function outcome measures and in clinical practice to identify excess vision-related disability in patients with AMD.
C1 Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat, Philadelphia, PA 19107 USA.
   Thomas Jefferson Univ, Jefferson Med Coll, Dept Neurol, Philadelphia, PA 19107 USA.
   Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA.
   Dartmouth Med Sch, Dept Psychiat, Hanover, NH USA.
   Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH USA.
   Thomas Jefferson Univ, Jefferson Med Coll, Dept Ophthalmol, Wills Eye Hosp, Philadelphia, PA 19107 USA.
C3 Jefferson University; Jefferson University; Jefferson University;
   Dartmouth College; Dartmouth College; Jefferson University
RP Rovner, BW (通讯作者)，Jefferson Hosp Neurosci, 900 Walnut St,4th Floor, Philadelphia, PA 19107 USA.
EM barry.rovner@jefferson.edu
FU NEI NIH HHS [U01 EY015839, U01 EY 015839] Funding Source: Medline; NIMH
   NIH HHS [R01 MH061331, R01 MH61331] Funding Source: Medline; NATIONAL
   EYE INSTITUTE [U01EY015839] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTH [R01MH061331] Funding Source: NIH RePORTER
CR *AM AC OPHTH, 2005, SMART SIGHT
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Bruce ML, 2001, AM J GERIAT PSYCHIAT, V9, P102, DOI 10.1176/appi.ajgp.9.2.102
   CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Devanand DP, 1996, ARCH GEN PSYCHIAT, V53, P175
   DZurilla T. J, 1990, PSYCHOL ASSESSMENT J, V2, P156, DOI 10.1037/1040-3590.2.2.156
   DZURILLA TJ, 2000, PROBLEM SOLVING THER, P95
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FRANK E, 1991, ARCH GEN PSYCHIAT, V48, P851, DOI 10.1001/archpsyc.1991.01810330075011
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   Han B, 2002, J AM GERIATR SOC, V50, P1549, DOI 10.1046/j.1532-5415.2002.50411.x
   Haymes SA, 2001, INVEST OPHTH VIS SCI, V42, P1215
   HOLLADAY JT, 1991, AM J OPHTHALMOL, V111, P372, DOI 10.1016/S0002-9394(14)72328-1
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   HOROWITZ AR, 1997, AGING VISION LOSS EX
   Katon WJ, 2003, ARCH GEN PSYCHIAT, V60, P897, DOI 10.1001/archpsyc.60.9.897
   Lebowitz BD, 1997, JAMA-J AM MED ASSOC, V278, P1186, DOI 10.1001/jama.278.14.1186
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Massof RW, 2001, VISION RES, V41, P397, DOI 10.1016/S0042-6989(00)00249-2
   Owsley C, 2004, OPHTHALMOLOGY, V111, P2259, DOI 10.1016/j.ophtha.2004.06.026
   PARMELEE PA, 1991, J GERONTOL, V46, pP15, DOI 10.1093/geronj/46.1.P15
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Penninx BWJH, 1999, ARCH GEN PSYCHIAT, V56, P889, DOI 10.1001/archpsyc.56.10.889
   Reid MC, 2003, J AM GERIATR SOC, V51, P1710, DOI 10.1046/j.1532-5415.2003.51554.x
   Rovner BW, 1996, J AM GERIATR SOC, V44, P181, DOI 10.1111/j.1532-5415.1996.tb02436.x
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Tasman W, 2004, ARCH OPHTHALMOL-CHIC, V122, P648, DOI 10.1001/archopht.122.4.648
   VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G
   West CG, 2002, J AM GERIATR SOC, V50, P136, DOI 10.1046/j.1532-5415.2002.50019.x
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
   WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742
   Zimmerman M, 2004, J NERV MENT DIS, V192, P595, DOI 10.1097/01.nmd.0000138226.22761.39
NR 37
TC 37
Z9 37
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2006
VL 113
IS 10
BP 1743
EP 1747
DI 10.1016/j.ophtha.2006.05.033
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 092HO
UT WOS:000241087800009
PM 16893569
DA 2022-11-30
ER

PT J
AU Nguyen-Khoa, BA
   Goehring, EL
   Werther, W
   Gower, EW
   Do, DV
   Jones, JK
AF Nguyen-Khoa, Bao-Anh
   Goehring, Earl L., Jr.
   Werther, Winifred
   Gower, Emily W.
   Do, Diana V.
   Jones, Judith K.
TI Hospitalized cardiovascular diseases in neovascular age-related macular
   degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID HEART-DISEASE; MYOCARDIAL-INFARCTION; ATHEROSCLEROSIS RISK;
   CO-MORBIDITY; MACULOPATHY; VALIDITY; INFORMATION; PREVALENCE; DATABASES;
   ACCURACY
AB Objective: To compare the incidence rate of hospitalized myocardial infarctions (MIs) and cerebrovascular accidents (CVAs) in subjects with and without neovascular age-related macular degeneration (AMD).
   Methods: A retrospective database cohort study was performed in subjects with neovascular AMD and controls matched for age, sex, geography, and enrollment duration. Healthcare claims for the study period from January 1, 2002, to June 30, 2005, were used to identify subjects and outcomes. Incidence of hospitalized MI and CVA events and rate ratios adjusted for 11 risk factors were calculated.
   Results: In 7203 subjects with neovascular AMD and 20 208 controls, the rate of MI was 16.2 events per 1000 subjects with neovascular AMD and 23.1 events per 1000 controls. The adjusted rate ratio for MI was 0.58 ( 95% confidence interval, 0.48-0.72; P < .001) for subjects with neovascular AMD vs controls. The rate of CVA was 14.3 events per 1000 subjects with neovascular AMD and 22.1 events per 1000 controls. The adjusted rate ratio for CVA was 0.56 (95% confidence interval, 0.45-0.70; P < . 001).
   Conclusions: Rates of MI or CVA were significantly lower in subjects with neovascular AMD than in controls. These findings could not be explained by systematic differences in case selection, health care use, or comorbidities, although other possible biases cannot be ruled out.
C1 [Nguyen-Khoa, Bao-Anh; Goehring, Earl L., Jr.; Jones, Judith K.] Degge Grp Ltd, Arlington, VA USA.
   [Werther, Winifred] Genentech Inc, San Francisco, CA 94080 USA.
   [Gower, Emily W.; Do, Diana V.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
C3 Roche Holding; Genentech; Johns Hopkins University; Johns Hopkins
   Medicine
RP Nguyen-Khoa, BA (通讯作者)，1616 N Ft Myer Dr,Ste 1430, Arlington, VA USA.
EM bnguyen@deggegroup.com
RI Gower, Emily/A-9688-2009
FU Genentech, Inc
FX The Degge Group received funding for the conduct of this study from
   Genentech, Inc. Dr Werther, senior epidemiologist at Genentech Inc,
   represents the study sponsor.
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Arnold AM, 2005, J AM GERIATR SOC, V53, P211, DOI 10.1111/j.1532-5415.2005.53105.x
   CDC (Cent. Dis. Control Prev.), 2004, MMWR-MORBID MORTAL W, V53, P1069
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Humphries KH, 2000, J CLIN EPIDEMIOL, V53, P343, DOI 10.1016/S0895-4356(99)00188-2
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lethbridge-Cejku M, 2004, VITAL HLTH STAT, V10, P1
   Levy AR, 1999, CAN J CARDIOL, V15, P1277
   Piriyawat P, 2002, AM J EPIDEMIOL, V156, P1062, DOI 10.1093/aje/kwf152
   Pladevall M, 1996, INT J EPIDEMIOL, V25, P948, DOI 10.1093/ije/25.5.948
   Quan HD, 2002, MED CARE, V40, P675, DOI 10.1097/00005650-200208000-00007
   Rawson NSB, 1995, STAT MED, V14, P2627, DOI 10.1002/sim.4780142404
   Reker DM, 2002, MED CARE, V40, P96, DOI 10.1097/00005650-200202000-00004
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shatin D, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P271
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600
   Tirschwell DL, 2002, STROKE, V33, P2465, DOI 10.1161/01.STR.0000032240.28636.BD
   U.S. Census Bureau, 2005, 2005 AM COMM SURV
   Velentgas P, 2006, PHARMACOEPIDEM DR S, V15, P641, DOI 10.1002/pds.1192
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 37
TC 33
Z9 34
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD SEP
PY 2008
VL 126
IS 9
BP 1280
EP 1286
DI 10.1001/archopht.126.9.1280
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 345XQ
UT WOS:000259031500016
PM 18779491
OA Bronze
DA 2022-11-30
ER

PT J
AU Dunaief, JL
   Dentchev, T
   Ying, GS
   Milam, AH
AF Dunaief, JL
   Dentchev, T
   Ying, GS
   Milam, AH
TI The role of apoptosis in age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID CELL-DEATH; GEOGRAPHIC ATROPHY; TRIGGERS APOPTOSIS; UP-REGULATION; FAS;
   GLAUCOMA; INJURY
AB Objective: To investigate apoptosis in human age-related macular degeneration (AMD).
   Methods: Postmortem retinas with AMD and normal retinas were studied by terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) to identify dying cells, and by immunocytochemistry with cell-specific antibodies to identify rods and cones. Sections were also labeled for Fas, a cell surface receptor that triggers apoptosis in other cell types. The maculas with AMD had geographic atrophy (GA) or exudative AMD.
   Results: Maculas with AMD had statistically significant increases in TUNEL-positive cells in the inner choroid, retinal pigment epithelium (RPE), photoreceptors, and inner nuclear layers compared with normal retinas. In eyes with GA, TUNEL-positive rod and RPE cell nuclei were present near edges of RPE atrophy. Photoreceptors; in the maculas of eyes with AMD were strongly Fas-positive, while normal photoreceptors were only weakly labeled.
   Conclusions: Evidence in this study suggests that in human AMD, RPE, photoreceptors, and inner nuclear layer cells die by apoptosis. Most TUNEL-positive RPE and photoreceptor cells were at edges of atrophy, correlating with clinically observed expansion of atrophic areas with vision loss in patients with GA. Increased Fas labeling in AMD photoreceptors indicates that the Fas/Fas ligand system may be involved in photoreceptor apoptosis. This information is essential for developing rational therapy for AMD.
C1 Univ Penn, Stellar Chance Labs 305, FM Kirby Ctr Mol Opthalmol, Scheie Eye Inst, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine
RP Dunaief, JL (通讯作者)，Univ Penn, Stellar Chance Labs 305, FM Kirby Ctr Mol Opthalmol, Scheie Eye Inst, Philadelphia, PA 19104 USA.
EM jdunaief@mail.med.upenn.edu
FU NEI NIH HHS [EY00417] Funding Source: Medline
CR Abler AS, 1996, RES COMMUN MOL PATH, V92, P177
   Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7
   Green DR, 2001, NATURE, V412, P133, DOI 10.1038/35084313
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002
   JIANG S, 2002, ASS RES VIS OPHTH M
   Jiang SN, 2000, INVEST OPHTH VIS SCI, V41, P645
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kerrigan LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1031, DOI 10.1001/archopht.1997.01100160201010
   Kingsbury AE, 1998, MOVEMENT DISORD, V13, P877, DOI 10.1002/mds.870130604
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Li ZY, 1995, DEGENERATIVE DISEASES OF THE RETINA, P1
   Lutty G, 1999, MOL VIS, V5
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   MILAM AH, 2001, METHODS MOL MED
   Natori S, 2001, J HEPATOL, V34, P248, DOI 10.1016/S0168-8278(00)00089-1
   PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974
   Qiu JH, 2002, J NEUROSCI, V22, P3504
   QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774
   RICHARDSON BC, 1994, EUR J IMMUNOL, V24, P2640, DOI 10.1002/eji.1830241111
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Suhara T, 1998, J IMMUNOL, V160, P4042
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464
   Vander Heiden MG, 1999, MOL CELL, V3, P159
   Xu G Z, 1996, Trans Am Ophthalmol Soc, V94, P411
NR 33
TC 399
Z9 427
U1 0
U2 18
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2002
VL 120
IS 11
BP 1435
EP 1442
DI 10.1001/archopht.120.11.1435
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 614RE
UT WOS:000179203400001
PM 12427055
DA 2022-11-30
ER

PT J
AU Williams, MA
   Mckay, GJ
   Carson, R
   Craig, D
   Silvestri, G
   Passmore, P
AF Williams, Michael A.
   Mckay, Gareth J.
   Carson, Robyn
   Craig, David
   Silvestri, Giuliana
   Passmore, Peter
TI Age-Related Macular Degeneration-Associated Genes in Alzheimer Disease
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Alzheimer; genetics; complement
ID FACTOR-H POLYMORPHISM; COMPLEMENT; RISK; HAPLOTYPE; NEURODEGENERATION;
   SUSCEPTIBILITY; INDIVIDUALS; PATHWAY; APOE; C1Q
AB Objectives: Given the clinical and pathological similarities between age-related macular degeneration (AMD) and Alzheimer disease (AD), to assess whether AMD-associated single nucleotide polymorphisms (SNPs), including those from complementrelated genes, are associated with AD. Design: A case-control association study-type design. Setting: A UK tertiary care dementia clinic. Participants: 322 cognitively normal participants and 258 cases with a clinical diagnosis of AD. Measurements: Polymorphisms in the following genes were studied: CFH, ARMS2, C2/CFB, C3, CFI/PLA2G12a, SERPING1, TLR3, TLR4, CRP, APOE, and TOMM40. Haplotypes were analysed for CFH, TOMM40, and APOE. Univariate analysis was performed for each genetic change and case-comparator status, and then correction for multiple testing performed. Results: The presence of an epsilon 4 APOE allele was significantly associated with AD. No association was evident between CFH SNPs or haplotypes, or other AMD-associated SNPs tested, and AD. The exceptions were TOMM40 SNPs, which were associated with AD even after correction for multiple comparisons. The associations disappeared, however, when entered into a regression model including APOE genotypes. Conclusions: The results for most SNPs tested, as well as CFH haplotypes, are novel. The functional effects of abnormal complement activity in AD's pathogenesis may be contradictory, but methodological reasons may underlie the lack of association-for example, genetic changes other than SNPs being involved.
C1 [Williams, Michael A.] Queens Univ Belfast, Ctr Med Educ, Belfast BT12 6BJ, Antrim, North Ireland.
   [Mckay, Gareth J.; Carson, Robyn; Craig, David; Passmore, Peter] Queens Univ Belfast, Ctr Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland.
   [Silvestri, Giuliana] Queens Univ Belfast, Ctr Med Expt, Belfast BT12 6BJ, Antrim, North Ireland.
C3 Queens University Belfast; Queens University Belfast; Queens University
   Belfast
RP Williams, MA (通讯作者)，Queens Univ Belfast, Ctr Med Educ, Royal Victoria Hosp, Mulhouse Bldg,1st Floor, Belfast BT12 6BJ, Antrim, North Ireland.
EM m.williams@qub.ac.uk
RI McKay, Gareth/AAZ-2601-2020
OI McKay, Gareth/0000-0001-8197-6280; Williams,
   Michael/0000-0002-5051-5921; Silvestri, Giuliana/0000-0001-5662-5374
FU Royal College of Physicians/Dunhill Medical Trust Clinical Research
   Fellowship; Alzheimer's Research Trust grant
FX M.A. Williams was supported in this work by a Royal College of
   Physicians/Dunhill Medical Trust Clinical Research Fellowship, and an
   Alzheimer's Research Trust grant.
CR AlzheimerA, 1907, ALLG Z PSYCHIATR PSY, V64, P146, DOI DOI 10.1002/CA.980080612
   Balistreri CR, 2008, CURR PHARM DESIGN, V14, P2672, DOI 10.2174/138161208786264089
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dhiman N, 2008, VACCINE, V26, P1731, DOI 10.1016/j.vaccine.2008.01.017
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gatta LB, 2008, DEMENT GERIATR COGN, V26, P169, DOI 10.1159/000151050
   Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102
   Grupe A, 2007, HUM MOL GENET, V16, P865, DOI 10.1093/hmg/ddm031
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamilton G, 2007, NEUROMOL MED, V9, P331, DOI 10.1007/s12017-007-8013-y
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kim IK, 2008, MOL VIS, V14, P1487
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Le Fur I, 2010, NEUROBIOL AGING, V31, P165, DOI 10.1016/j.neurobiolaging.2008.03.003
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Maier M, 2008, J NEUROSCI, V28, P6333, DOI 10.1523/JNEUROSCI.0829-08.2008
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Minoretti P, 2006, NEUROSCI LETT, V391, P147, DOI 10.1016/j.neulet.2005.08.047
   Moore E, INVEST OPHTHALMOL VI, V48
   Myers AJ, 2012, AM J GERIAT PSYCHIAT, V20, P545, DOI 10.1097/JGP.0b013e318259b9a5
   NERL C, 1984, NEUROLOGY, V34, P310, DOI 10.1212/WNL.34.3.310
   O'Hara R, 2014, AM J GERIAT PSYCHIAT, V22, P953, DOI 10.1016/j.jagp.2014.07.004
   Pasinetti GM, 1996, NEUROBIOL AGING, V17, P707, DOI 10.1016/0197-4580(96)00113-3
   Proitsi P, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.12.036
   Strohmeyer R, 2002, J NEUROIMMUNOL, V131, P135, DOI 10.1016/S0165-5728(02)00272-2
   Terai K, 1997, BRAIN RES, V769, P385, DOI 10.1016/S0006-8993(97)00849-4
   Tikellis G, 2007, ARCH OPHTHALMOL-CHIC, V125, P68, DOI 10.1001/archopht.125.1.68
   Tooyama I, 2001, DEMENT GERIATR COGN, V12, P237, DOI 10.1159/000051265
   Turunen M, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2009.08.010
   van Oijen M, 2007, NEUROBIOL AGING, V28, P1361, DOI 10.1016/j.neurobiolaging.2006.06.015
   Webster S, 1997, AM J PATHOL, V150, P1531
   Williams MA, 2014, J ALZHEIMERS DIS, V42, P909, DOI 10.3233/JAD-140243
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
NR 38
TC 13
Z9 13
U1 3
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD DEC
PY 2015
VL 23
IS 12
BP 1290
EP 1296
DI 10.1016/j.jagp.2015.06.005
PG 7
WC Geriatrics & Gerontology; Gerontology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology; Psychiatry
GA CZ4PZ
UT WOS:000367086500010
PM 26419733
DA 2022-11-30
ER

PT J
AU Schwartz, SG
   Scott, IU
   Flynn, HW
   Stewart, MW
AF Schwartz, Stephen G.
   Scott, Ingrid U.
   Flynn, Harry W., Jr.
   Stewart, Michael W.
TI Drug delivery techniques for treating age-related macular degeneration
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularization;
   intravitreal injection; vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; DEXAMETHASONE INTRAVITREAL IMPLANT;
   BEVACIZUMAB AVASTIN; INTRAOCULAR PHARMACOKINETICS; CHOROIDAL
   NEOVASCULARIZATION; OCULAR NEOVASCULARIZATION; POSTERIOR SEGMENT;
   DEVELOPMENT FOCUS; LONG-TERM; RANIBIZUMAB
AB Introduction: Currently, the standard therapy for neovascular age-related macular degeneration involves the use of anti-vascular endothelial growth factor (VEGF) drugs, which are delivered by repeated office-based intravitreal injections. This treatment is generally very effective in stabilizing or improving vision, although repeated injections create a burden for patients, family members and physicians. In addition, the cumulative risks of endophthalmitis and other complications increase with the number of injections.
   Areas covered: In the clinic, much attention is focused on the relative efficacies of the three major anti-VEGF medications (bevacizumab, ranibizumab and aflibercept) as well as the most popular re-injection regimens (monthly, as-needed and treat-and-extend). In theory, intravitreal anti-VEGF drug delivery with sustained-release devices would offer similar visual results with fewer required re-injections. Various approaches have been studied, including noninvasive techniques, intraocular implants and colloidal carriers, such as liposomes, microparticles and nanoparticles.
   Expert opinion: Despite its theoretical appeal, sustained-release drug delivery will not replace current techniques unless it offers one or more advantages in efficacy, safety, convenience or cost. Currently, many patients maintain stable vision with intravitreal injections at intervals of 2 months or longer, so sustained-release techniques will have to lengthen these intervals substantially to become widely accepted. As we continue to collect data from clinical trials, the role of sustained-release techniques will become better defined.
C1 [Schwartz, Stephen G.; Flynn, Harry W., Jr.] Miami Univ, Miller Sch Med, Naples, FL 34102 USA.
   [Scott, Ingrid U.] Penn State Coll Med, Penn State Hershey Eye Ctr, Ophthalmol & Publ Hlth Sci, Hershey, PA 17033 USA.
   Mayo Clin, Sch Med, Rochester, MN USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Mayo Clinic
RP Scott, IU (通讯作者)，Penn State Coll Med, Penn State Hershey Eye Ctr, Ophthalmol & Publ Hlth Sci, 500 Univ Dr,HU19, Hershey, PA 17033 USA.
EM iscott@hmc.psu.edu
OI Scott, Ingrid/0000-0002-3908-7153; Flynn, Harry/0000-0002-9990-7467
FU Regeneron and ThromboGenics; Genentech; Vindico
FX SG Schwartz has been a consultant for Alimera, Bausch + Lomb and Santen,
   and has received speakers fees from Regeneron and ThromboGenics. IU
   Scott has been a consultant for Alcon, FOVEA, Santen and ThromboGenics
   and has received speakers fees from Genentech. HW Flynn has been a
   consultant for Santen and has received speakers fees from Vindico. MW
   Stewart has served on the advisory boards for Allergan and Regeneron and
   has been a consultant for Boehringer-Ingelheim.
CR Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Araujo J, 2012, NANOMED-NANOTECHNOL, V8, P1034, DOI 10.1016/j.nano.2011.10.015
   Bakri SJ, 2006, RETINA-J RET VIT DIS, V26, P519, DOI 10.1097/01.iae.0000225354.92444.7a
   Callanan DG, 2008, ARCH OPHTHALMOL-CHIC, V126, P1191, DOI 10.1001/archopht.126.9.1191
   Campochiaro PA, 2012, GENE THER, V19, P121, DOI 10.1038/gt.2011.164
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Christoforidis JB, 2012, CURR EYE RES, V37, P1171, DOI 10.3109/02713683.2012.727521
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   del Pozo-Rodriguez A, 2013, J OCUL PHARMACOL TH, V29, P173, DOI 10.1089/jop.2012.0128
   El Sanharawi M, 2013, GENE THER
   Eljarrat-Binstock E, 2007, CURR EYE RES, V32, P639, DOI 10.1080/02713680701528674
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Farjo KM, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-21
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Ghate Deepta, 2006, Expert Opin Drug Deliv, V3, P275, DOI 10.1517/17425247.3.2.275
   Gooch N, 2013, J FUNCT BIOMATER, V4, P14, DOI 10.3390/jfb4010014
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Haller JA, 2011, OPHTHALMOLOGY, V118, P2453, DOI 10.1016/j.ophtha.2011.05.014
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Honda M, 2013, INT J NANOMED, V8, P495, DOI 10.2147/IJN.S30725
   Honda M, 2011, ARCH OPHTHALMOL-CHIC, V129, P317, DOI 10.1001/archophthalmol.2011.12
   Huang J, 2013, OPHTHALMOLOGY
   Hurwitz HI, 2013, ONCOLOGIST, V18, P1004, DOI 10.1634/theoncologist.2013-0107
   Iezzi R, 2012, BIOMATERIALS, V33, P979, DOI 10.1016/j.biomaterials.2011.10.010
   Kang Derwent Jennifer J, 2008, Trans Am Ophthalmol Soc, V106, P206
   Kazokoglu H, 2010, OPHTHAL SURG LAS IM, DOI [10.3928/1542887-20100215-35, DOI 10.3928/1542887-20100215-35]
   Kim JH, 2011, BIOMATERIALS, V32, P1865, DOI 10.1016/j.biomaterials.2010.11.030
   Kompella UB, 2013, PROG RETIN EYE RES, V36, P172, DOI 10.1016/j.preteyeres.2013.04.001
   Kompella UB, 2010, THER DELIV, V1, P435, DOI 10.4155/TDE.10.40
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Kumar A, 2012, GRAEF ARCH CLIN EXP, V250, P685, DOI 10.1007/s00417-011-1890-7
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Loewenstein A., 2013, ANGIOGENESIS EXUDATI
   Lowder C, 2011, ARCH OPHTHALMOL-CHIC, V129, P545, DOI 10.1001/archophthalmol.2010.339
   Mansour AM, 2012, CLIN OPHTHALMOL, V6, P343, DOI 10.2147/OPTH.S29075
   Marano RJ, 2005, GENE THER, V12, P1544, DOI 10.1038/sj.gt.3302579
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maurice D, 2001, J OCUL PHARMACOL TH, V17, P393, DOI 10.1089/108076801753162807
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mukherjee P, 2005, CLIN CANCER RES, V11, P3530, DOI 10.1158/1078-0432.CCR-04-2482
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Pan CK, 2011, J OCUL PHARMACOL TH, V27, P219, DOI 10.1089/jop.2010.0158
   Patane MA, 2013, J OCUL PHARMACOL TH, V29, P760, DOI 10.1089/jop.2012.0175
   Patel SR, 2012, INVEST OPHTH VIS SCI, V53, P4433, DOI 10.1167/iovs.12-9872
   Pershing S, 2013, OPHTHAL SURG LAS IM, V44, P460, DOI 10.3928/23258160-20130909-07
   Pescina S, 2010, J PHARM PHARMACOL, V62, P1189, DOI 10.1111/j.2042-7158.2010.01153.x
   Ramos-Cabrer P, 2013, INT J NANOMED, V8, P951, DOI 10.2147/IJN.S30721
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Saati S, 2010, CURR EYE RES, V35, P192, DOI 10.3109/02713680903521936
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Schultz C, 2011, CLIN EXP OPTOM, V94, P212, DOI 10.1111/j.1444-0938.2010.00553.x
   Schwartz SG, 2011, CURR PHARM BIOTECHNO, V12, P347
   Schwartz SG, 2009, EXPERT OPIN PHARMACO, V10, P2119, DOI 10.1517/14656560903081752
   Sharma S, 2012, CAN J OPHTHALMOL, V47, P275, DOI 10.1016/j.jcjo.2012.03.026
   Shelke NB, 2011, DRUG DELIV TRANSL RE, V1, P76, DOI 10.1007/s13346-010-0009-8
   Sherman S, 2012, INVEST OPHTH VIS SCI, V53, P7894
   Shmueli RB, 2013, BIOMATERIALS, V34, P7544, DOI 10.1016/j.biomaterials.2013.06.044
   Singh RP, 2010, BRIT J OPHTHALMOL, V94, P170, DOI 10.1136/bjo.2009.159541
   Stevenson CL, 2012, ADV DRUG DELIVER REV, V64, P1590, DOI 10.1016/j.addr.2012.02.005
   Stewart MA, 2011, ADV GLOB CHANGE RES, V45, P1, DOI [10.1007/978-94-007-0934-8_1, 10.4081/eye.2011.e5]
   Tetz M, 2012, OPHTHALMOLOGICA, V227, P183, DOI 10.1159/000336045
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Zaman RT, 2012, LASER SURG MED, V44, P30, DOI 10.1002/lsm.21149
NR 76
TC 33
Z9 33
U1 0
U2 35
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1742-5247
EI 1744-7593
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD JAN
PY 2014
VL 11
IS 1
BP 61
EP 68
DI 10.1517/17425247.2013.859135
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 274XI
UT WOS:000328639100006
PM 24219407
DA 2022-11-30
ER

PT J
AU Li, F
   Hu, J
   He, TC
AF Li, Fei
   Hu, Jim
   He, Tong-Chuan
TI iPSC-based treatment of age-related macular degeneration (AMD): The path
   to success requires more than blind faith
SO GENES & DISEASES
LA English
DT Article
DE Autologous iPSC; Human; Macular degeneration; Retinal pigment
   epithelium; Transplantation
ID STEM-CELLS
AB Induced pluripotent stem cells (iPSCs) hold great promise for the treatment of human diseases. Two recent first-of-its-kind clinical case reports on the iPSC-based treatment of age-related macular degeneration (AMD) highlight the hopes and challenges associated with the clinical application of iPSCs. Copyright (C) 2017, Chongqing Medical University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
C1 [Li, Fei] Chongqing Med Univ, Editorial Off Genes & Dis, Chongqing 400046, Peoples R China.
   [Hu, Jim] Univ Toronto, Hosp Sick Children, Dept Pathol & Lab Med, Toronto, ON M5G 0A4, Canada.
   [He, Tong-Chuan] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA.
C3 Chongqing Medical University; University of Toronto; University Toronto
   Affiliates; Hospital for Sick Children (SickKids); University of
   Chicago; University of Chicago Medical Center
RP Li, F (通讯作者)，Chongqing Med Univ, Editorial Off Genes & Dis, Chongqing 400046, Peoples R China.
EM fei@genesndiseases.org
OI Li, Fei/0000-0002-6354-4879
FU National Institutes of Health [AT004418]; Canadian Institutes of Health
   Research [MOP 125882]; Cystic Fibrosis Foundation Therapeutics, Inc.
   [HU15XX0]; Cystic Fibrosis Canada [3032]; NATIONAL CENTER FOR
   COMPLEMENTARY & ALTERNATIVE MEDICINE [P01AT004418] Funding Source: NIH
   RePORTER
FX Work in the authors' laboratories was supported in part by research
   grants from the National Institutes of Health (AT004418 to TCH), from
   the Canadian Institutes of Health Research (MOP 125882 to JH), a Cystic
   Fibrosis Foundation Therapeutics, Inc. grant (HU15XX0 to JH) and a
   Cystic Fibrosis Canada grant (#3032 to JH).
CR Alonso-Alonso ML, 2015, WORLD J STEM CELLS, V7, P641, DOI 10.4252/wjsc.v7.i3.641
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Rebuzzini P, 2016, CELL MOL LIFE SCI, V73, P2453, DOI 10.1007/s00018-016-2171-8
NR 4
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-4820
EI 2352-3042
J9 GENES DIS
JI Genes Dis.
PD JUN
PY 2017
VL 4
IS 2
BP 41
EP 42
DI 10.1016/j.gendis.2017.03.001
PG 2
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA FQ0AJ
UT WOS:000418011000001
PM 30258908
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sergejeva, O
   Botov, R
   Liutkeviciene, R
   Kriauciuniene, L
AF Sergejeva, Olga
   Botov, Roman
   Liutkeviciene, Rasa
   Kriauciuniene, Loresa
TI Genetic factors associated with the development of age-related macular
   degeneration
SO MEDICINA-LITHUANIA
LA English
DT Review
DE Early and late age-related macular degeneration; Risk factors; Genes
ID COMPLEMENT FACTOR-H; CASSETTE TRANSPORTER GENE; GEOGRAPHIC ATROPHY;
   CIGARETTE-SMOKING; HIGH-RISK; STARGARDT-DISEASE; VISUAL IMPAIRMENT;
   VARIANT; PREVALENCE; ABCR
AB Age-related macular degeneration (AMD) affects the macula and is the leading cause of significant and irreversible central visual loss. It is the most common cause of visual loss in people aged more than 60 years. This disease affects 2.5 million individuals in Europe. AMD is caused by both environmental and genetic factors. Numerous risk factors have been reported, but the pathogenesis of AMD is complex and fairly understood. Age, female gender, obesity, race, education status, family history, hyperopia, iris color, cigarette smoking, previous cataract surgery, history of cardiovascular and cerebrovascular disease, diabetes, sunlight exposure and many other factors have been shown to be associated with AMD development. Scientific evidence shows that genes may play a role in the development of nearly 3 out of 4 cases of this devastating eye disease. The genes that have been shown to be associated with AMD are genes encoding complement system components such as CFH, C2, C3, CFB, and other. (C) 2016 The Lithuanian University of Health Sciences. Production and hosting by Elsevier B.V.
C1 [Sergejeva, Olga; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, LT-50161 Kaunas, Lithuania.
   [Botov, Roman] Lithuanian Univ Hlth Sci, Med Acad, Fac Med, LT-50161 Kaunas, Lithuania.
   [Liutkeviciene, Rasa; Kriauciuniene, Loresa] Lithuanian Univ Hlth Sci, Med Acad, Inst Neurosci, Lab Ophthalmol, LT-50161 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences
RP Sergejeva, O (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, LT-50161 Kaunas, Lithuania.
EM Ol4ik.se@gmail.com
FU Research Council of Lithuania [SEN-11/2015]
FX This work was funded by a grant (No. SEN-11/2015) from the Research
   Council of Lithuania.
CR Akagi-Kurashige Y, 2015, OPHTHALMOLOGY, V122, P2295, DOI 10.1016/j.ophtha.2015.07.032
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Allikmets R, 2009, NEW ENGL J MED, V360, P2252
   [Anonymous], 2010, RETINA INTERNATIONAL
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2009, NEW ENGL J MED, V360, P2254
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fakhouri F, 2010, J AM SOC NEPHROL, V21, P859, DOI 10.1681/ASN.2009070706
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fisher SA, 2007, HUM MUTAT, V28, P406, DOI 10.1002/humu.20464
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grixti A, 2014, ISRN OPHTHALMOL, V2014, DOI DOI 10.1155/2014/417603.
   Grizzard WS, 2003, OPHTHAL EPIDEMIOL, V10, P315, DOI 10.1076/opep.10.5.315.17317
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hao XF, 2015, INT J CLIN EXP PATHO, V8, P3186
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Huang C, 2013, MOL VIS, V19, P1211
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Joseph C., 2011, RETINA ITS DISORDERS, P830
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lee J, 2013, EYE, V27, P266, DOI 10.1038/eye.2012.276
   Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251
   Liutkeviciene R, 2015, OPHTHALMIC GENET, V36, P149, DOI 10.3109/13816810.2013.838274
   Liutkeviciene R, 2012, CURR EYE RES, V37, P94, DOI 10.3109/02713683.2011.629069
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   Maga TK, 2010, HUM MUTAT, V31, pE1445, DOI 10.1002/humu.21256
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Nangia V, 2011, RETINA-J RET VIT DIS, V31, P1179, DOI 10.1097/IAE.0b013e3181f57ff2
   Natl. Eye Inst, 2014, AG REL MAC DEG AMD
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Sawitzke J, 2011, OPHTHALMOLOGY, V118, P2442, DOI 10.1016/j.ophtha.2011.05.027
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shroyer NF, 1999, VISION RES, V39, P2537, DOI 10.1016/S0042-6989(99)00037-1
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wang QL, 2004, HUM MOL GENET, V13, P1025, DOI 10.1093/hmg/ddh117
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yam JCS, 2014, INT OPHTHALMOL, V34, P383, DOI 10.1007/s10792-013-9791-x
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2008, J CLIN INVEST, V118, P2908, DOI 10.1172/JCI35891
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
NR 99
TC 20
Z9 20
U1 0
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PY 2016
VL 52
IS 2
BP 79
EP 88
DI 10.1016/j.medici.2016.02.004
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DL7WO
UT WOS:000375851300002
PM 27170480
OA gold
DA 2022-11-30
ER

PT J
AU Rosli, Y
   Bedford, SM
   James, AC
   Maddess, T
AF Rosli, Y.
   Bedford, S. M.
   James, A. C.
   Maddess, T.
TI Photopic and scotopic multifocal pupillographic responses in age-related
   macular degeneration
SO VISION RESEARCH
LA English
DT Article
DE Multifocal pupillography; Age-related macular degeneration; Photopic;
   Scotopic; Pedestal flicker
ID DARK-ADAPTATION; VISUAL FUNCTION; CONE; ROD; MACULOPATHY; VULNERABILITY;
   DYSFUNCTION; PREVALENCE; PERIMETRY; RETINA
AB We compared photopic and scotopic multifocal pupillographic stimuli in age-related macular degeneration (AMD). Both eyes of 18 normal and 14 AMD subjects were tested with four stimulus variants presented at photopic and 126 times lower luminances. The multifocal stimuli presented 24 test regions/eye to the central 60 degrees. The stimulus variants had two different check sizes, and when presented either flickered (15 Hz) for 266 ms, or were steady for 133 ms. Mean differences from normal of 5 to 7 dB were observed in the central visual field for both photopic and scotopic stimuli (all p < 0.00002). The best areas under receiver operating characteristic plots for exudative AMD in the photopic and scotopic conditions were 92.9 +/- 8.0 and 90.3 +/- 5.7% respectively, and in less severely affected eyes 83.8 +/- 9.7% and 76.9 +/- 8.2%. Damage recorded at photopic levels was possibly more diffusely distributed across the visual field. Sensitivity and specificity was similar at photopic and scotopic levels. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Rosli, Y.; Bedford, S. M.; James, A. C.; Maddess, T.] Australian Natl Univ, ARC Ctr Excellence Vis Sci, John Curtin Sch Med Res, Canberra, ACT 0200, Australia.
   [Rosli, Y.] Univ Kebangsaan Malaysia, Program Biomed Sci, Sch Diagnost & Appl Hlth Sci, Fac Hlth Sci, Kuala Lumpur, Malaysia.
C3 Australian National University; John Curtin School of Medical Research;
   Universiti Kebangsaan Malaysia
RP Maddess, T (通讯作者)，Australian Natl Univ, ARC Ctr Excellence Vis Sci, John Curtin Sch Med Res, GPO Box 4, Canberra, ACT 0200, Australia.
EM ted.maddess@anu.edu.au
RI Maddess, Teddy L/A-3200-2008; Rosli, Yanti/ABE-6770-2020; James, Andrew
   C/C-9307-2009; Bedford, Suzanne/N-1931-2015
OI Maddess, Teddy L/0000-0003-4591-3658; James, Andrew
   C/0000-0002-2447-8549; Bedford, Suzanne/0000-0001-7763-1634
FU Australian Research Council (ARC) through the ARC Centre of Excellence
   in Vision Science [CE0561903]; AusIndustry [COM03991]; Seeing Machines
   Ltd., Canberra
FX Financial Support: Australian Research Council (ARC) through the ARC
   Centre of Excellence in Vision Science (CE0561903), AusIndustry
   (COM03991), and Seeing Machines Ltd., Canberra.
CR Bell A, 2010, INVEST OPHTH VIS SCI, V51, P602, DOI 10.1167/iovs.09-3659
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P645
   Carle CF, 2011, INVEST OPHTH VIS SCI, V52, P604, DOI 10.1167/iovs.10-5737
   Carle CF, 2011, INVEST OPHTH VIS SCI, V52, P2365, DOI 10.1167/iovs.10-6335
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   Chrysostomou V, 2009, INVEST OPHTH VIS SCI, V50, P3017, DOI 10.1167/iovs.08-3004
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Dimitrov P. N., 2012, INVESTIGATIVE OPHTHA, P11, DOI 8910.1167/iovs.8911-8958
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Eckmiller MS, 2004, PROG RETIN EYE RES, V23, P495, DOI 10.1016/j.preteyeres.2004.04.005
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P1145, DOI 10.1167/iovs.10-5967
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Gerth C, 2009, DOC OPHTHALMOL, V118, P63, DOI 10.1007/s10633-008-9133-x
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   James A. C., 2011, J GLAUCOMA, V21
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kanis MJ, 2008, INVEST OPHTH VIS SCI, V49, P2077, DOI 10.1167/iovs.07-1181
   Kolic M, 2010, ARVO IOVS, V51
   Leveillard T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000866
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   Maddess T, 2011, J GLAUCOMA, V20, P336, DOI 10.1097/IJG.0b013e3181efb097
   Maddess T, 2009, CLIN EXP OPHTHALMOL, V37, P678, DOI 10.1111/j.1442-9071.2009.02107.x
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Rosli Y., 2009, AKAD SAINS MALAYSIA, V3, P31
   Sabeti F., 2010, ARVO INVESTIGATIVE O, V51, P2794
   Sabeti F, 2012, INVEST OPHTH VIS SCI, V53, P253, DOI 10.1167/iovs.11-8004
   Sabeti F, 2011, OPTOMETRY VISION SCI, V88, P1477, DOI 10.1097/OPX.0b013e318235af61
   Sabeti F, 2011, VISION RES, V51, P303, DOI 10.1016/j.visres.2010.10.015
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   SMITH VC, 1988, J OPT SOC AM A, V5, P2113, DOI 10.1364/JOSAA.5.002113
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
NR 43
TC 14
Z9 14
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
EI 1878-5646
J9 VISION RES
JI Vision Res.
PD SEP 15
PY 2012
VL 69
BP 42
EP 48
DI 10.1016/j.visres.2012.07.019
PG 7
WC Neurosciences; Ophthalmology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA 035FK
UT WOS:000310928500005
PM 22898702
OA Bronze
DA 2022-11-30
ER

PT J
AU Boiko, EV
   Maltsev, DS
AF Boiko, Ernest V.
   Maltsev, Dmitrii S.
TI QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANALYSIS OF RETINAL
   DEGENERATIVE CHANGES IN DIABETIC MACULAR EDEMA AND NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE anti-VEGF therapy; central subfield; diabetic macular edema; inraretinal
   fluid; optical coherence tomography; optical density; outer nuclear
   layer; retinal thickness; visual acuity; visual outcome
ID VISUAL-ACUITY; RANIBIZUMAB; ASSOCIATION; BEVACIZUMAB; PREDICTORS;
   INJECTION; OUTCOMES; VISION
AB Purpose: To investigate the relationship of the pre-anti-vascular endothelial growth factor (VEGF) retinal tissue area (RTA) and optical density (ODRT) of the retinal optical slice portion located in the central subfield, and their ratio (RTA/ODRT), in the presence of diabetic macular edema or of inraretinal cystic fluid in neovascular age-related macular degeneration, to central retinal thickness and best-corrected visual acuity after anti-VEGF treatment with ME resolution.
   Methods: The optical coherence tomography images and medical records of 33 patients (41 eyes) with neovascular age-related macular degeneration, 15 (21 eyes) with diabetic macular edema and 9 healthy individuals (15 eyes) were retrospectively analyzed. RTA, ODRT, and RTA/ODRT were calculated on pre-anti-VEGF B-scan images. Spearman rank correlation was used to assess the relationship of central retinal thickness and best-corrected visual acuity after anti-VEGF treatment with the variables under study.
   Results: Pre-anti-VEGF RTA was positively correlated with post-anti-VEGF central retinal thickness (rho = 0.76; P < 0.001) and best-corrected visual acuity (rho = 0.67; P < 0.001), whereas pre-anti-VEGF ODRT was moderately negatively correlated (rho = -0.26; P = 0.049 and rho = -0.48; P = 0.001, respectively) and pre-anti-VEGF RTA/ODRT ratio was strongly positively correlated (rho = 0.75; P < 0.001 and rho = 0.85; P < 0.001, respectively). The area under curve for RTA/ODRT ratio was 0.93 (P < 0.001), and the cut-off value for post-anti-VEGF LogMAR best-corrected visual acuity of 0.4 (20/50 Snellen equivalent) or worse was 1,406.7 mu m(2)/U (sensitivity: 0.94; specificity: 0.78).
   Conclusion: Both RTA and ODRT, or, preferably, RTA/ODRT ratio alone can be used as predictors of functional and anatomic outcomes in patients with diabetic macular edema or neovascular age-related macular degeneration treated with anti-VEGF therapy.
C1 [Boiko, Ernest V.] S Fyodorov Eye Microsurg Fed State Inst, St Petersburg Branch, St Petersburg, Russia.
   [Boiko, Ernest V.; Maltsev, Dmitrii S.] Mil Med Acad, Dept Ophthalmol, 5 Klin Skaya St, St Petersburg 194044, Russia.
   [Boiko, Ernest V.] Mechnikov North West State Med Univ, Dept Ophthalmol, St Petersburg, Russia.
C3 North-Western State Medical University named after I.I. Mechnikov
RP Maltsev, DS (通讯作者)，Mil Med Acad, Dept Ophthalmol, 5 Klin Skaya St, St Petersburg 194044, Russia.
EM glaz.med@yandex.ru
RI Maltsev, Dmitrii/AAA-9100-2022
OI Maltsev, Dmitrii/0000-0001-6598-3982
CR Al Faran A, 2014, RETINA-J RET VIT DIS, V34, P1208, DOI 10.1097/IAE.0000000000000059
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P1, DOI 10.1111/aos.12272
   Brasil OFM, 2007, BRIT J OPHTHALMOL, V91, P761, DOI 10.1136/bjo.2006.105783
   Browning David J, 2010, Trans Am Ophthalmol Soc, V108, P62
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Jansson RW, 2015, GRAEF ARCH CLIN EXP, V253, P989, DOI 10.1007/s00417-015-3034-y
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Nishijima K, 2014, RETINA-J RET VIT DIS, V34, P732, DOI 10.1097/IAE.0000000000000005
   Pelosini L, 2011, INVEST OPHTH VIS SCI, V52, P2741, DOI 10.1167/iovs.09-4493
   Shin HJ, 2012, GRAEF ARCH CLIN EXP, V250, P61, DOI 10.1007/s00417-011-1774-x
   Wong RLM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/981471
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 14
TC 4
Z9 5
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2018
VL 38
IS 7
BP 1324
EP 1330
DI 10.1097/IAE.0000000000001696
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP2CX
UT WOS:000440630000014
PM 28492427
DA 2022-11-30
ER

PT J
AU Rezar-Dreindl, S
   Eibenberger, K
   Buehl, W
   Georgopoulos, M
   Weigert, G
   Krall, C
   Dunavoelgyi, R
   Schmidt-Erfurth, U
   Sacu, S
AF Rezar-Dreindl, Sandra
   Eibenberger, Katharina
   Buehl, Wolf
   Georgopoulos, Michael
   Weigert, Guenther
   Krall, Christoph
   Dunavoelgyi, Roman
   Schmidt-Erfurth, Ursula
   Sacu, Stefan
TI ROLE OF ADDITIONAL DEXAMETHASONE FOR THE MANAGEMENT OF PERSISTENT OR
   RECURRENT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDER RANIBIZUMAB
   TREATMENT
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; dexamethasone intravitreal implant;
   ranibizumab; choroidal neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL IMPLANT; CHOROIDAL
   NEOVASCULARIZATION; TRIAMCINOLONE ACETONIDE; COMBINATION THERAPY;
   BEVACIZUMAB; EDEMA; OUTCOMES; HORIZON; REGIMEN
AB Purpose: To assess the efficacy of a combination therapy of intravitreal ranibizumab together with a dexamethasone implant in comparison with ranibizumab monotherapy in neovascular age-related macular degeneration.
   Methods: Forty eyes of recurrent or persistent neovascular age-related macular degeneration were included in this prospective study. Patients were randomly assigned to two groups. Based on a pro re nata treatment regimen, the first group received intravitreal ranibizumab monotherapy (IVM). The second group received a combination of intravitreal dexamethasone implant and ranibizumab (intravitreal combination [IVC]) at baseline and was retreated with ranibizumab as needed. A second dexamethasone implant was allowed for retreatment after at least 6 months. Retreatment criteria included evidence of subretinal fluid, cystoid macular edema or new hemorrhage, and/or a visual acuity decrease of 5 Early Treatment Diabetic Retinopathy Study letters.
   Results: During 12 months, a mean of 7.95/5.5 (IVM/IVC; P = 0.042) retreatments were given. The median time until first retreatment differed significantly between the groups (P = 0.004). Functional variables could be maintained in both groups with no differences between them. Visual acuity changed from 62 letters at baseline to 67 at Month 12 in the IVM and remained stable at 68 letters in the IVC group (P = 0.68); macular sensitivity changed from 6.95 dB to 7.01 dB in IVM and from 7.24 dB to 7.12 dB in IVC (P = 0.4). Central retinal thickness decreased, however, with no difference between the groups (P = 0.38). In the IVM/IVC group, 11/12 (55/60%) patients were phakic at the time of study entry. One (9%) patient from the IVM and 4 (33%) from the IVC group were referred to cataract surgery after study completion (P = 0.4).
   Conclusion: This pilot study indicates combined therapy to delay retreatment in patients with persistent/recurrent neovascular age-related macular degeneration and an overall reduction in required ranibizumab retreatments compared with ranibizumab monotherapy with consistent functional outcomes.
C1 [Rezar-Dreindl, Sandra; Eibenberger, Katharina; Buehl, Wolf; Georgopoulos, Michael; Weigert, Guenther; Dunavoelgyi, Roman; Schmidt-Erfurth, Ursula; Sacu, Stefan] Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
   [Krall, Christoph] Med Univ Vienna, Dept Med Stat, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Rezar-Dreindl, S (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM stefan.sacu@meduniwien.ac.at
OI Dunavoelgyi, Roman/0000-0002-1842-240X; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311
CR Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Broadhead GK, 2014, ACTA OPHTHALMOL, V92, P713, DOI 10.1111/aos.12463
   Cao JH, 2014, OPHTHALMOLOGY, V121, P1871, DOI 10.1016/j.ophtha.2014.04.012
   Chang-Lin JE, 2011, INVEST OPHTH VIS SCI, V52, P80, DOI 10.1167/iovs.10-5285
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Haller JA, 2011, OPHTHALMOLOGY, V118, P2453, DOI 10.1016/j.ophtha.2011.05.014
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, P630, DOI 10.1111/j.1755-3768.2008.01502.x
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Kuppermann BD, 2015, OPHTHALMOLOGICA, V234, P40, DOI 10.1159/000381865
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim JI, 2015, BRIT J OPHTHALMOL, V99, P618, DOI 10.1136/bjophthalmol-2014-306002
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michels Stephan, 2006, Expert Opin Investig Drugs, V15, P779, DOI 10.1517/13543784.15.7.779
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Scaramuzzi M, 2015, RETINA-J RET VIT DIS, V35, P1216, DOI 10.1097/IAE.0000000000000443
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V23, P1509
   Veritti D, 2013, J OCUL PHARMACOL TH, V29, P437, DOI 10.1089/jop.2012.0173
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
NR 26
TC 15
Z9 15
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2017
VL 37
IS 5
BP 962
EP 970
DI 10.1097/IAE.0000000000001264
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW0IO
UT WOS:000402173400038
PM 27575409
DA 2022-11-30
ER

PT J
AU Cimarolli, VR
   Laban-Baker, A
   Hamilton, WS
   Stuen, C
AF Cimarolli, Verena R.
   Laban-Baker, Allie
   Hamilton, Wanda S.
   Stuen, Cynthia
TI Awareness, Knowledge, and Concern About Age-Related Macular Degeneration
SO EDUCATIONAL GERONTOLOGY
LA English
DT Article
ID EYE DISEASES; OLDER-ADULTS; DEPRESSION; POPULATION; COMMUNITY
AB Age-related macular degeneration (AMD)-a common eye disease causing vision loss-can be detected early through regular eye-health examinations, and measures can be taken to prevent visual decline. Getting eye examinations requires certain levels of awareness, knowledge, and concern related to AMD. However, little is known about AMD-related awareness, knowledge, and concern levels of population groups who may be affected by or at risk for AMD. The purpose of this descriptive study was to assess these factors among-and health information seeking patterns of-four groups of individuals: [a] the general population, [b] a group at-risk for AMD due to race and advanced age, [c] a group at high-risk for AMD due to race, advanced age, and smoking behavior, and [d] a group diagnosed with AMD. Data were collected through telephone interviews with 894 adults using a computer assisted telephone interview method. Results demonstrate that while AMD awareness is high, knowledge about AMD risk factors and concern about the disease is lacking. The most prominent source of AMD awareness was knowing someone who had been diagnosed, and physicians were the main source for health-related information. AMD-related awareness campaigns should focus on educating older adults about AMD risk factors and involving healthcare professionals and older adults with AMD as peer educators.
C1 [Cimarolli, Verena R.] Jewish Home Lifecare, Res Inst Aging, Guild Ctr Res Vis & Aging, New York, NY 10025 USA.
   [Laban-Baker, Allie] Goucher Coll, Off Commun, Baltimore, MD USA.
   [Hamilton, Wanda S.] Royal Natl Inst Blind People, London, England.
   [Stuen, Cynthia] Lighthouse Int, Off Commun, New York, NY USA.
RP Cimarolli, VR (通讯作者)，Jewish Home Lifecare, Res Inst Aging, Guild Ctr Res Vis & Aging, 120 W 106th St, New York, NY 10025 USA.
EM vcimarolli@jewishhome.org
CR AMD Alliance International, 2009, TYP AMD
   AMD Alliance International, 2003, EARL DET LOW VIS REH
   Attebo K, 1997, AUST NZ J OPHTHALMOL, V25, P283, DOI 10.1111/j.1442-9071.1997.tb01516.x
   BAZARGAN M, 1995, J GERONTOL B-PSYCHOL, V50, pS119, DOI 10.1093/geronb/50B.2.S119
   CARABELLESE C, 1993, J AM GERIATR SOC, V41, P401, DOI 10.1111/j.1532-5415.1993.tb06948.x
   Casten RJ, 2002, J VISUAL IMPAIR BLIN, V96, P399, DOI 10.1177/0145482X0209600603
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   Horowitz A., 1996, ANN M AM AC OPT ORL
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   *NAT EYE I, 2010, FACTS AG REL MAC DEG
   Noertjojo K, 2006, CAN J OPHTHALMOL, V41, P617, DOI 10.1016/S0008-4182(06)80035-9
   Rosenthal Bruce, 2003, Optometry, V74, P16
   The Royal College of Ophthalmologists, 2017, NAT EL AG REL MAC DA
   WAHL HW, 2000, LIGHTHOUSE HDB VISIO, P1069
NR 15
TC 3
Z9 3
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0360-1277
J9 EDUC GERONTOL
JI Educ. Gerontol.
PY 2012
VL 38
IS 8
BP 530
EP 538
DI 10.1080/03601277.2011.595286
PG 9
WC Education & Educational Research; Gerontology
WE Social Science Citation Index (SSCI)
SC Education & Educational Research; Geriatrics & Gerontology
GA 949RO
UT WOS:000304593800004
DA 2022-11-30
ER

PT J
AU ElShelmani, H
   Brennan, I
   Kelly, DJ
   Keegan, D
AF ElShelmani, Hanan
   Brennan, Ian
   Kelly, David J.
   Keegan, David
TI Differential Circulating MicroRNA Expression in Age-Related Macular
   Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE microRNA; age-related macular degeneration; biomarkers; serum; dry AMD;
   wet AMD
ID POTENTIAL BIOMARKERS; MIRNAS; DISEASE; ANGIOGENESIS; MEMBERS; INJURY;
   EYE
AB This study explored the expression of several miRNAs reported to be deregulated in age-related macular degeneration (AMD). Total RNA was isolated from sera from patients with dry AMD (n = 12), wet AMD (n = 14), and controls (n = 10). Forty-two previously investigated miRNAs were selected based on published data and their role in AMD pathogenesis, such as angiogenic and inflammatory effects, and were co-analysed using a miRCURY LNA miRNA SYBR(R) Green PCR kit via quantitative real-time polymerase chain reaction (qRT-PCR) to validate their presence. Unsupervised hierarchical clustering indicated that AMD serum specimens have a different miRNA profile to healthy controls. We successfully validated the differentially regulated miRNAs in serum from AMD patients versus controls. Eight miRNAs (hsa-let-7a-5p, hsa-let-7d-5p, hsa-miR-23a-3p, hsa-miR-301a-3p, hsa-miR-361-5p, hsa-miR-27b-3p, hsa-miR-874-3p, hsa-miR-19b-1-5p) showed higher expression in the serum of dry AMD patients than wet AMD patients and compared with healthy controls. Increased quantities of certain miRNAs in the serum of AMD patients indicate that these miRNAs could potentially serve as diagnostic AMD biomarkers and might be used as future AMD treatment targets. The discovery of significant serum miRNA biomarkers in AMD patients would provide an easy screening tool for at-risk populations.
C1 [ElShelmani, Hanan; Brennan, Ian; Keegan, David] Mater Misericordiae Univ Hosp, Eccles St, Dublin 7, Ireland.
   [Brennan, Ian] Univ Coll Cork, Coll Rd, Cork, Ireland.
   [Kelly, David J.] Univ Dublin, Trinity Coll Dublin, Sch Nat Sci, Zool Dept, Dublin 2, Ireland.
C3 Mater Misericordiae University Hospital; University College Dublin;
   University College Cork; Trinity College Dublin
RP Keegan, D (通讯作者)，Mater Misericordiae Univ Hosp, Eccles St, Dublin 7, Ireland.
EM elshelh@tcd.ie; ibrennan@rcsi.ie; djkelly@tcd.ie; dkeegan@mater.ie
FU Mater Vision Institute; Retina Research Group; HSE Academic Internship
   Training Program
FX This research was funded by the Mater Vision Institute, Retina Research
   Group and the HSE Academic Internship Training Program.
CR Askou AL, 2018, ACTA OPHTHALMOL, V96, P9, DOI 10.1111/aos.13407
   Bai S, 2016, EYE, V30, P1630, DOI 10.1038/eye.2016.189
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Bian HJ, 2019, J CELL MOL MED, V23, P3063, DOI 10.1111/jcmm.14219
   Blasiak J, 2019, J CELL MOL MED, V23, P8464, DOI 10.1111/jcmm.14731
   Chen Z, 2013, J CLIN INVEST, V123, P1057, DOI 10.1172/JCI65344
   Cirillo PDR, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255804
   Donati S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184353
   Elbay A, 2019, SCAND J CLIN LAB INV, V79, P388, DOI 10.1080/00365513.2019.1637931
   ElShelmani H, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.2.12
   Elshelmani H, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.28
   Ertekin S, 2014, MOL VIS, V20, P1057
   Gantier MP, 2012, NUCLEIC ACIDS RES, V40, P8048, DOI 10.1093/nar/gks521
   Glinge C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0167969
   Goodall EF, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20123097
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Hou Q, 2013, INVEST OPHTH VIS SCI, V54, P6481, DOI 10.1167/iovs.13-11873
   Jiang DX, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.108941
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Kozomara A, 2019, NUCLEIC ACIDS RES, V47, pD155, DOI 10.1093/nar/gky1141
   Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181
   Kumar P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069807
   Li J, 2020, INT J MED SCI, V17, P953, DOI 10.7150/ijms.44377
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Liu CH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020649
   McArthur K, 2011, DIABETES, V60, P1314, DOI 10.2337/db10-1557
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Moreno-Garcia L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249582
   Murad N, 2014, FEBS J, V281, P5251, DOI 10.1111/febs.13066
   Murray AR, 2013, INVEST OPHTH VIS SCI, V54, P1689, DOI 10.1167/iovs.12-10921
   Natoli R, 2018, ADV EXP MED BIOL, V1074, P37, DOI 10.1007/978-3-319-75402-4_5
   Nunes DN, 2015, P NATL ACAD SCI USA, V112, P3770, DOI 10.1073/pnas.1500008112
   Oltra M, 2020, J CELL MOL MED, V24, P1428, DOI 10.1111/jcmm.14822
   Pogue AI, 2018, CELL MOL NEUROBIOL, V38, P1021, DOI 10.1007/s10571-017-0572-3
   Ren CD, 2017, CELL PHYSIOL BIOCHEM, V41, P1413, DOI 10.1159/000467941
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Shahriari F, 2020, EXP EYE RES, V190, DOI 10.1016/j.exer.2019.107883
   Smit-McBride Z, 2014, MOL VIS, V20, P1569
   Strafella C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071578
   Su Y, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108427
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Tsai KW, 2016, SCI REP-UK, V6, DOI 10.1038/srep28176
   Ulanczyk Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225750
   Wang L, 2016, J PHYSIOL BIOCHEM, V72, P583, DOI 10.1007/s13105-016-0496-2
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Yao Q, 2019, CURR OPIN CHEM BIOL, V51, P11, DOI 10.1016/j.cbpa.2019.01.024
   Zhang J, 2017, CURR MOL MED, V17, P359, DOI 10.2174/1566524018666171205122540
   Zhang Y, 2013, NAT CELL BIOL, V15, P284, DOI 10.1038/ncb2690
   Zhang ZY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12292-5
   Zhao JY, 2020, EXCLI J, V19, P1141, DOI 10.17179/excli2020-2286
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 53
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2021
VL 22
IS 22
AR 12321
DI 10.3390/ijms222212321
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA XI0VR
UT WOS:000725841200001
PM 34830203
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Jackson, TL
   Danis, RP
   Goldbaum, M
   Slakter, JS
   Shusterman, EM
   O'Shaughnessy, DJ
   Moshfeghi, DM
AF Jackson, Timothy L.
   Danis, Ronald P.
   Goldbaum, Mauro
   Slakter, Jason S.
   Shusterman, E. Mark
   O'Shaughnessy, Denis J.
   Moshfeghi, Darius M.
TI RETINAL VASCULAR ABNORMALITIES IN NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE fluorescein angiography; microvascular; neovascular age-related macular
   degeneration; radiation; retinopathy; wet age-related macular
   degeneration
ID OCULAR BLOOD-FLOW; X-RAY-IRRADIATION; CHOROIDAL NEOVASCULARIZATION;
   MICROVASCULAR ABNORMALITIES; RISK-FACTORS; CARDIOVASCULAR HEALTH;
   ATHEROSCLEROSIS RISK; BRUCHS MEMBRANE; OLDER PERSONS; EYE DISEASE
AB Purpose: To determine the prevalence of retinal vascular abnormalities (RVA) in neovascular age-related macular degeneration (AMD).
   Methods: A post hoc subanalysis of images acquired during a Phase III randomized controlled trial was undertaken, selecting images from participants with untreated, neovascular AMD in at least one eye. Protocol mandated fundus photographs and fluorescein angiograms were acquired at baseline and Year 2, from 107 sham-treated study eyes with neovascular AMD and 107 untreated fellow eyes. Images were reanalyzed by an independent reading center for the presence of RVA, defined as at least one of the following: microaneurysms, vessel staining or leakage, dilated or tortuous vessels, intraretinal hemorrhage, vessel sheathing or narrowing, capillary nonperfusion, or capillary infarcts.
   Results: The baseline prevalence of RVA in the sham-treated study eyes was 14.4% (15 of 104 gradable images) versus 8.3% (5 of 60) in the fellow eyes with dry AMD. The baseline prevalence of individual RVAs in study eyes was: microaneurysms (6.7%), vessel staining or leakage (6.7%), dilated or tortuous vessels (4.8%), intraretinal hemorrhage (4.8%), vessel sheathing or narrowing (2.9%), capillary nonperfusion (0%), and capillary infarcts (0%). Results were similar at 24 months.
   Conclusion: Compared with several studies that relied solely on fundus photographs, this study included fluorescein angiography and found a higher prevalence of RVAs occurring in eyes with neovascular AMD.
C1 [Jackson, Timothy L.] Kings Coll London, Sch Med, Dept Ophthalmol, London WC2R 2LS, England.
   [Danis, Ronald P.] Univ Wisconsin, Fundus Photograph Reading Ctr, Madison, WI USA.
   [Goldbaum, Mauro] Univ Sao Paulo, Hosp Clin, Dept Ophthalmol, Sao Paulo, Brazil.
   [Slakter, Jason S.] Digital Angiog Reading Ctr, New York, NY USA.
   [Shusterman, E. Mark; O'Shaughnessy, Denis J.] Oraya Therapeut Inc, Newark, CA USA.
   [Moshfeghi, Darius M.] Stanford Univ, Sch Med, Horngren Family Vitreoretinal Ctr, Dept Ophthalmol,Byers Eye Inst, Palo Alto, CA 94304 USA.
C3 University of London; King's College London; University of Wisconsin
   System; University of Wisconsin Madison; Universidade de Sao Paulo;
   Stanford University
RP Jackson, TL (通讯作者)，Kings Coll Hosp London, Kings Hlth Partners, Dept Ophthalmol, Denmark Hill, London SE5 9RS, England.
EM t.jackson1@nhs.net
OI Jackson, Timothy/0000-0001-7618-1555; Moshfeghi, Darius
   Mohammad/0000-0003-2254-292X
FU Oraya; NeoVista; Novartis
FX T. L. Jackson's employer received research funding from Oraya, NeoVista,
   and Novartis for other trials, but not in relation to the work reported
   herein. E. M. Shusterman and D. J. O'Shaughnessy are employees of Oraya.
   The reading centers that employ R. P. Danis and J. S. Slakter received
   research funding from Oraya and NeoVista. R. P. Danis, J. S. Slakter,
   and D. M. Moshfeghi are consultants to Oraya. T. L. Jackson served on an
   Oraya Advisory Board and has received conference support from Oraya. D.
   M. Moshfeghi is a shareholder in Oraya. M. Goldbaum is a consultant to
   Valeant Pharmaceuticals.
CR [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   Avila MP, 2012, RETINA-J RET VIT DIS, V32, P10, DOI 10.1097/IAE.0b013e31822528fc
   Barak A, 2012, EUR J OPHTHALMOL, V22, P423, DOI 10.5301/ejo.5000074
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Burganski-Eliash Z, 2012, RETINAL BLOOD FLOW V
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2000, BRIT J RADIOL, V73, P305, DOI 10.1259/bjr.73.867.10817048
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   Chakravarthy U, 2000, AGE RELATED MACULAR, P79
   Chao JR, 2007, INVEST OPHTH VIS SCI, V48, P4019, DOI 10.1167/iovs.07-0206
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Evans JR, 2010, COCHRANE DB SYST REV, V5
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Golan S, 2012, RETINAL PHYS, V9, P4
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gunduz K, 1999, ARCH OPHTHALMOL-CHIC, V117, P609
   Gunnlaugsdottir E, 2012, DIABETOLOGIA, V55, P671, DOI 10.1007/s00125-011-2395-y
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Hillenkamp J, 2004, INVEST OPHTH VIS SCI, V45, P1493, DOI 10.1167/iovs.03-0765
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Horgan N, 2010, CURR OPIN OPHTHALMOL, V21, P233, DOI 10.1097/ICU.0b013e3283386687
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Jackson TL, 2013, OPHTHALMOLOGY, DOI [10.1016/j.ophtha.2013.02.016, DOI 10.1016/J.0PHTHA.2013.02.016]
   Kirwan JF, 2003, EYE, V17, P207, DOI 10.1038/sj.eye.6700306
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P92, DOI 10.1001/archopht.1994.01090130102026
   Klein R, 1997, Trans Am Ophthalmol Soc, V95, P329
   Klein R, 2004, AM J OPHTHALMOL, V137, P435, DOI 10.1016/j.ajo.2003.10.020
   Klein R, 1997, T AM OPHTHAL SOC, V95, P48
   Kuroki AM, 2002, OPHTHALMIC RES, V34, P200, DOI 10.1159/000063886
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Leung H, 2005, EYE, V19, P861, DOI 10.1038/sj.eye.6701668
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Moshfeghi AA, 2011, OPHTHAL SURG LAS IM, V42, P460, DOI 10.3928/15428877-20110804-03
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Navarro Rafael, 2011, Retin Cases Brief Rep, V5, P352, DOI 10.1097/ICB.0b013e3181fff2a6
   Ojaimi E, 2011, OPHTHALMOLOGY, V118, P656, DOI 10.1016/j.ophtha.2010.08.007
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   PRUNTE C, 1988, GRAEF ARCH CLIN EXP, V226, P55, DOI 10.1007/BF02172719
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   STOLK RP, 1995, DIABETES, V44, P11, DOI 10.2337/diabetes.44.1.11
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leiden HA, 2003, ARCH OPHTHALMOL-CHIC, V121, P245, DOI 10.1001/archopht.121.2.245
   van Leiden HA, 2002, DIABETES CARE, V25, P1320, DOI 10.2337/diacare.25.8.1320
   Venkatramani J, 2004, BRIT MED J, V328, P625, DOI 10.1136/bmj.328.7440.625
   Wang S, 2012, OPHTHALMOLOGY, V119, P2592, DOI 10.1016/j.ophtha.2012.06.031
   Warburg O, 1927, BIOCHEM Z, V184, P484
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong TY, 2004, INVEST OPHTH VIS SCI, V45, P2949, DOI 10.1167/iovs.04-0069
   Wong TY, 2003, OPHTHALMOLOGY, V110, P658, DOI 10.1016/S0161-6420(02)01931-0
   Wong TY, 2002, BRIT J OPHTHALMOL, V86, P1007, DOI 10.1136/bjo.86.9.1007
   Wong TY, 2001, LANCET, V358, P1134, DOI 10.1016/S0140-6736(01)06253-5
   Yu T, 1998, ARCH OPHTHALMOL-CHIC, V116, P83, DOI 10.1001/archopht.116.1.83
NR 66
TC 14
Z9 14
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2014
VL 34
IS 3
BP 568
EP 575
DI 10.1097/IAE.0b013e3182a487be
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI6DL
UT WOS:000336960100024
PM 24045343
DA 2022-11-30
ER

PT J
AU Prosser, BE
   Johnson, S
   Roversi, P
   Herbert, AP
   Blaum, BS
   Tyrrell, J
   Jowitt, TA
   Clark, SJ
   Tarelli, E
   Uhrin, D
   Barlow, PN
   Sim, RB
   Day, AJ
   Lea, SM
AF Prosser, Beverly E.
   Johnson, Steven
   Roversi, Pietro
   Herbert, Andrew P.
   Blaum, Barbel S.
   Tyrrell, Jess
   Jowitt, Thomas A.
   Clark, Simon J.
   Tarelli, Edward
   Uhrin, Dusan
   Barlow, Paul N.
   Sim, Robert B.
   Day, Anthony J.
   Lea, Susan M.
TI Structural basis for complement factor H-linked age-related macular
   degeneration
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID DISEASE-ASSOCIATED FORM; HEPARIN-BINDING DOMAIN; C-REACTIVE PROTEIN;
   COMPONENT C3; SIALIC-ACID; POLYMORPHISM; SITE; SEQUENCE; BETA-1H;
   PATHWAY
AB Nearly 50 million people worldwide suffer from age- related macular degeneration ( AMD), which causes severe loss of central vision. A single- nucleotide polymorphism in the gene for the complement regulator factor H ( FH), which causes a Tyr- to- His substitution at position 402, is linked to similar to 50% of attributable risks for AMD. We present the crystal structure of the region of FH containing the polymorphic amino acid His402 in complex with an analogue of the glycosaminoglycans ( GAGs) that localize the complement regulator on the cell surface. The structure demonstrates direct coordination of ligand by the disease- associated polymorphic residue, providing a molecular explanation of the genetic observation. This glycan- binding site occupies the center of an extended interaction groove on the regulator ' s surface, implying multivalent binding of sulfated GAGs. This finding is confirmed by structure- based site- directed mutagenesis, nuclear magnetic resonance - monitored binding experiments performed for both H402 and Y402 variants with this and another model GAG, and analysis of an extended GAG - FH complex.
C1 Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.
   Univ Oxford, Med Res Council Immunochem Unit, Dept Biochem, Oxford OX1 3RE, England.
   Univ Edinburgh, Edinburgh EH9 3JJ, Midlothian, Scotland.
   Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England.
   St Georges Univ, Med Biom Ctr, London SW17 0RE, England.
C3 University of Oxford; University of Oxford; University of Edinburgh;
   University of Manchester; St Georges University London
RP Day, AJ (通讯作者)，Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.
EM anthony.day@manchester.ac.uk; susan.lea@path.ox.ac.uk
RI Roversi, Pietro/F-8925-2011; Barlow, Paul N/G-2853-2011; Herbert, Andy
   P/F-6693-2010; Sim, Bob/A-1354-2008; Roversi, Pietro/AAK-4241-2021;
   Johnson, Steven J/F-9182-2016; Clark, Stewart J/A-3462-2012; Lea, Susan
   M/B-7678-2009; Day, Anthony/O-1658-2015; Herbert, Andrew P/C-4755-2008
OI Roversi, Pietro/0000-0001-9280-9437; Herbert, Andy
   P/0000-0002-4549-6965; Sim, Bob/0000-0002-2855-7455; Roversi,
   Pietro/0000-0001-9280-9437; Johnson, Steven J/0000-0002-7877-3543;
   Clark, Stewart J/0000-0003-4792-7738; Lea, Susan M/0000-0001-9287-8053;
   Day, Anthony/0000-0002-1415-3134; Herbert, Andrew P/0000-0002-4549-6965;
   Jowitt, Thomas/0000-0002-4045-0933; Clark, Simon/0000-0001-8394-8355;
   Blaum, Baerbel/0000-0003-4312-8912
FU MRC [MC_U138274352, G0001089, G0400775] Funding Source: UKRI; Medical
   Research Council [MC_U138274352, G0400775, G0001089] Funding Source:
   Medline; Wellcome Trust [075415/z/04/z, 078780, 078780/z/05/z] Funding
   Source: Medline
CR BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011
   BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   DeLano WL., 2002, CCP4 NEWSL PROTEIN C
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   Janssen BJC, 2007, MOL IMMUNOL, V44, P3, DOI 10.1016/j.molimm.2006.06.017
   Janssen BJC, 2006, ADV EXP MED BIOL, V586, P291
   Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052
   KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krissinel E, 2005, LECT NOTES COMPUT SC, V3695, P163
   MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849
   Ormsby RJ, 2006, MOL IMMUNOL, V43, P1624, DOI 10.1016/j.molimm.2005.09.012
   PANGBURN MK, 1991, J BIOL CHEM, V266, P16847
   Prosser BE, 2007, ACTA CRYSTALLOGR F, V63, P480, DOI 10.1107/S1744309107020052
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Verdugo ME, 1997, EXP EYE RES, V65, P231, DOI 10.1006/exer.1997.0325
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147
NR 31
TC 152
Z9 160
U1 0
U2 15
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
J9 J EXP MED
JI J. Exp. Med.
PD OCT 1
PY 2007
VL 204
IS 10
BP 2277
EP 2283
DI 10.1084/jem.20071069
PG 7
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Research & Experimental Medicine
GA 216HW
UT WOS:000249870100006
PM 17893204
OA Bronze, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Yeoh, J
   Sims, J
   Guymer, RH
AF Yeoh, Jonathan
   Sims, Joanne
   Guymer, Robyn H.
TI A review of drug options in age-related macular degeneration therapy and
   potential new agents
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Review
DE age-related macular degeneration; anti-VEGF agents
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; RETINAL-PIGMENT EPITHELIUM;
   EXPERIMENTAL SUBRETINAL NEOVASCULARIZATION; CHOROIDAL
   NEOVASCULARIZATION; BEVACIZUMAB AVASTIN; PHOTODYNAMIC THERAPY; VISUAL
   IMPAIRMENT; VERTEPORFIN THERAPY; TISSUE INHIBITOR; RISK-FACTORS
AB Age-related macular degeneration (AMD) is the leading cause of legal blindness in people > 50 years of age in the developed world. AMD is both a debilitating and costly disease for the individual and the community. Greater understanding of the mechanisms and pathways involved in causing the visual loss in AMD has resulted in the advent of several newer and more effective treatment options, making it an exciting time in the management of AMD. This paper will examine the principles behind the existing drug therapies available, as well as those being developed in the management or prophylaxis of AMD and its vision-threatening complications.
C1 Univ Melbourne, Ctr Eye Res, Melbourne, Vic 8002, Australia.
   Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3002, Australia.
C3 University of Melbourne; Royal Victorian Eye & Ear Hospital
RP Guymer, RH (通讯作者)，Univ Melbourne, Ctr Eye Res, Locked Bag 8, Melbourne, Vic 8002, Australia.
EM rhg@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356
CR *AG REL EYE DIS ST, 2005, ARCH OPHTHALMOL-CHIC, V12, P1570
   Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473
   Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   *AN AC CLIN STUD G, 2003, OPHTHALMOLOGY, V110, P2371
   AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817
   Ando A, 2002, MOL PHARMACOL, V62, P539, DOI 10.1124/mol.62.3.539
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Arroyo JG, 2003, ARCH OPHTHALMOL-CHIC, V121, P898, DOI 10.1001/archopht.121.6.898
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   BAIRD PN, 2002, CLIN EXP OPHTHALMO S, V30, P275
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BYLSMA G, 2005, CLIN EXP OPTOM, V88, P1
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016
   FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GRAGOUDAS E, 2001, NEW ENGL J MED, V351, P2805
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Grisanti S, 2004, AM J OPHTHALMOL, V137, P914, DOI 10.1016/j.ajo.2003.12.049
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   JOST J, 2005, ACTA OPHTHALMOL SCAN, V83, P645
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaven C, 2001, OPHTHALMOLOGICA, V215, P284, DOI 10.1159/000050875
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   Lim L, 2004, CLIN EXP OPHTHALMOL, V32, P341, DOI 10.1111/j.1442-9071.2004.00832.x
   MASSIMO N, 2006, RETINA, V26, P58
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Presta LG, 1997, CANCER RES, V57, P4593
   Reich S, 2003, MOL VIS, V9, P210
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   ROBERTA P, 2006, RETINA, V26, P257
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Schachat AP, 2005, OPHTHALMOLOGY, V112, P531, DOI 10.1016/j.ophtha.2005.01.018
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V292, P43, DOI 10.1001/jama.292.1.43-b
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Ufret-Vincenty Rafael L., 2004, International Ophthalmology Clinics, V44, P63, DOI 10.1097/00004397-200404430-00009
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   *VIS CLIN TRIAL GR, 2006, OPHTHALMOLOGY, V113, P1508
   Vu HTV, 2006, BRIT J OPHTHALMOL, V90, P389, DOI 10.1136/bjo.2005.078055
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Yourey PA, 2000, J NEUROSCI, V20, P6781, DOI 10.1523/JNEUROSCI.20-18-06781.2000
   Zarbin M, 2006, ARCH OPHTHALMOL-CHIC, V124, P563, DOI 10.1001/archopht.124.4.563
NR 105
TC 9
Z9 12
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD DEC
PY 2006
VL 7
IS 17
BP 2355
EP 2368
DI 10.1517/14656566.7.17.2355
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 109JH
UT WOS:000242303500003
PM 17109611
DA 2022-11-30
ER

PT J
AU Caban-Martinez, AJ
   Davila, EP
   Lam, BL
   Dubovy, SR
   McCollister, KE
   Fleming, LE
   Zheng, DD
   Lee, DJ
AF Caban-Martinez, Alberto J.
   Davila, Evelyn P.
   Lam, Byron L.
   Dubovy, Sander R.
   McCollister, Kathryn E.
   Fleming, Lora E.
   Zheng, Diane D.
   Lee, David J.
TI Age-Related Macular Degeneration and Smoking Cessation Advice by Eye
   Care Providers: A Pilot Study
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID ASSOCIATION
AB Smoking is a modifiable risk factor for age-related macular degeneration (AMD), the leading cause of irreversible vision loss in the United States. We conducted a pilot study among eye care providers and AMD patients to assess smoking cessation preferences and cessation services offered at a large academic medical center. Most patients who smoke reported never being advised to quit smoking, although most eye care providers reported that they had advised smokers to quit. Two-thirds of providers expressed a desire for additional training and resources to support patient quit attempts, indicating the need for the integration of smoking cessation opportunities in the clinic setting.
C1 [Caban-Martinez, Alberto J.; Davila, Evelyn P.; McCollister, Kathryn E.; Fleming, Lora E.; Zheng, Diane D.; Lee, David J.] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA.
   [Lam, Byron L.; Dubovy, Sander R.; Lee, David J.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Miami, FL 33136 USA.
C3 University of Miami; University of Miami
RP Caban-Martinez, AJ (通讯作者)，Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Clin Res Bldg,Room 1075,1120 NW 14th St,10th Fl R, Miami, FL 33136 USA.
EM acaban@med.miami.edu
RI Caban-Martinez, Alberto/AAG-1499-2019; Fleming, Lora E/ABH-1310-2021
OI Caban-Martinez, Alberto/0000-0002-5960-1308; Fleming, Lora
   E/0000-0003-1076-9967
FU National Eye Institute [R21-EY019096]; NATIONAL EYE INSTITUTE
   [R21EY019096] Funding Source: NIH RePORTER
FX Support for this study was provided in part by a National Eye Institute
   grant (no. R21-EY019096). None of the study authors have a commercial
   conflict of interest to declare. We acknowledge the editorial skills of
   Mrs Laura McClure and thank the clinic patients, staff members, and eye
   care providers that participated and supported this pilot study.
CR American Association of Medical Colleges, 2007, PHYS BEH PRACT PATT
   [Anonymous], 2011, TOB US SUPPL CURR PO
   Centers for Disease Control and Prevention, BEH RISK FACT SURV S
   Cheng A. C. K., 2000, Hong Kong Medical Journal, V6, P195
   Curry SJ, 2008, ANNU REV PUBL HEALTH, V29, P411, DOI 10.1146/annurev.publhealth.29.020907.090934
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Tran N, 2010, PREV CHRONIC DIS, V7
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
NR 11
TC 9
Z9 9
U1 0
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD NOV
PY 2011
VL 8
IS 6
AR A147
PG 4
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA 896JZ
UT WOS:000300563000030
PM 22005640
DA 2022-11-30
ER

PT J
AU Ricci, F
   Bandello, F
   Navarra, P
   Staurenghi, G
   Stumpp, M
   Zarbin, M
AF Ricci, Federico
   Bandello, Francesco
   Navarra, Pierluigi
   Staurenghi, Giovanni
   Stumpp, Michael
   Zarbin, Marco
TI Neovascular Age-Related Macular Degeneration: Therapeutic Management and
   New-Upcoming Approaches
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; neovascular AMD; neovascularization;
   vascular endothelial growth factor; anti-VEGF; Ang-2; DARPins
ID ENDOTHELIAL GROWTH-FACTOR; TREAT-AND-EXTEND; ANKYRIN REPEAT PROTEINS;
   EARLY CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB AVASTIN;
   PIGMENTED EPITHELIAL-CELLS; FACTOR-H POLYMORPHISM; 2.0 MG RANIBIZUMAB;
   BRUCHS MEMBRANE; ABICIPAR-PEGOL
AB Age-related macular degeneration (AMD) constitutes a prevalent, chronic, and progressive retinal degenerative disease of the macula that affects elderly people and cause central vision impairment. Despite therapeutic advances in the management of neovascular AMD, none of the currently used treatments cures the disease or reverses its course. Medical treatment of neovascular AMD experienced a significant advance due to the introduction of vascular endothelial growth factor inhibitors (anti-VEGF), which dramatically changed the prognosis of the disease. However, although anti-VEGF therapy has become the standard treatment for neovascular AMD, many patients do not respond adequately to this therapy or experience a slow loss of efficacy of anti-VEGF agents after repeated administration. Additionally, current treatment with intravitreal anti-VEGF agents is associated with a significant treatment burden for patients, caregivers, and physicians. New approaches have been proposed for treating neovascular AMD. Among them, designed ankyrin repeat proteins (DARPins) seem to be as effective as monthly ranibizumab, but with greater durability, which may enhance patient compliance with needed injections.
C1 [Ricci, Federico] Univ Tor Vergata, Dept Expt Med, Viale Oxford, I-00133 Rome, Italy.
   [Bandello, Francesco] Univ Vita Salute, Sci Inst San Raffaele, I-20132 Milan, Italy.
   [Navarra, Pierluigi] Fdn Policlin Univ A Gemelli IRCCS, I-00168 Rome, Italy.
   [Navarra, Pierluigi] Catholic Univ, Med Sch, Dept Pharmacol, I-00198 Rome, Italy.
   [Staurenghi, Giovanni] Luigi Sacco Hosp, Univ Eye Clin, I-20157 Milan, Italy.
   [Stumpp, Michael] Mol Partners AG, Wagistr 14, CH-8952 Zurich, Switzerland.
   [Zarbin, Marco] Rutgers New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Newark, NJ 07103 USA.
C3 University of Rome Tor Vergata; Vita-Salute San Raffaele University;
   IRCCS Ospedale San Raffaele; Catholic University of the Sacred Heart;
   IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart;
   IRCCS Policlinico Gemelli; University of Milan; Luigi Sacco Hospital;
   Rutgers State University New Brunswick; Rutgers State University Medical
   Center
RP Ricci, F (通讯作者)，Univ Tor Vergata, Dept Expt Med, Viale Oxford, I-00133 Rome, Italy.
EM federico.ricci@uniroma2.it; bandello.francesco@hsr.it;
   Pierluigi.Navarra@unicatt.it; giovanni.staurenghi@unimi.it;
   michael.stumpp@molecularpartners.com; zarbin@earthlink.net
OI bandello, francesco/0000-0003-3238-9682; ricci,
   federico/0000-0002-4224-9280; Zarbin, Marco/0000-0002-7811-7132
FU Ciencia y Deporte S.L.; Allergan - Allergan, an AbbVie company
FX Medical writing and Editorial assistant services have been provided by
   Ciencia y Deporte S.L. and covered by a Grant from Allergan. Support for
   this assistance was funded by Allergan, an AbbVie company.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Barchitta M, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/8486406
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Binz HK, 2017, MABS-AUSTIN, V9, P1262, DOI 10.1080/19420862.2017.1305529
   Binz HK, 2003, J MOL BIOL, V332, P489, DOI 10.1016/S0022-2836(03)00896-9
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431
   Broadhead GK, 2014, ACTA OPHTHALMOL, V92, P713, DOI 10.1111/aos.12463
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Caputi AP, 2020, CURR OPIN PHARMACOL, V51, P93, DOI 10.1016/j.coph.2020.05.004
   Carrasco J, 2020, ADV THER, V37, P300, DOI 10.1007/s12325-019-01147-6
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Dugel PU, 2020, OPHTHALMOL RETINA, V4, P250, DOI 10.1016/j.oret.2019.10.008
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Enseleit F, 2017, OPHTHALMOLOGICA, V238, P205, DOI 10.1159/000478665
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferris FL, 2017, JAMA OPHTHALMOL, V135, P145, DOI 10.1001/jamaophthalmol.2016.4820
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Forrer P, 2003, FEBS LETT, V539, P2, DOI 10.1016/S0014-5793(03)00177-7
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Gianniou C, 2015, EYE, V29, P342, DOI 10.1038/eye.2014.258
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammill JA, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0099-4
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Iqbal S, 2004, CANCER CHEMOTH PHARM, V54, pS32, DOI 10.1007/s00280-004-0884-0
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B
   Kertes PJ, 2020, JAMA OPHTHALMOL, V138, P244, DOI 10.1001/jamaophthalmol.2019.5540
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Khanani A.M., 2018, P AM AC OPHTH RET SU
   Khurana R.N., 2019, P AM AC OPHTH ANN M
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Kijlstra A, 2015, OPHTHALMIC RES, V54, P64, DOI 10.1159/000432401
   KILLINGSWORTH MC, 1995, GRAEF ARCH CLIN EXP, V233, P313, DOI 10.1007/BF00200479
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2020, OPHTHALMOLOGY, V127, pS122, DOI 10.1016/j.ophtha.2020.01.033
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Kunimoto D, 2019, OSLI RETINA, V50, pE10, DOI 10.3928/23258160-20190129-13
   Lazzeri S, 2012, SCI WORLD J, DOI 10.1100/2012/420190
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Li JN, 2006, BIOCHEMISTRY-US, V45, P15168, DOI 10.1021/bi062188q
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mammadzada P, 2020, CELL MOL LIFE SCI, V77, P819, DOI 10.1007/s00018-019-03422-9
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martin-Killias P, 2011, CLIN CANCER RES, V17, P100, DOI 10.1158/1078-0432.CCR-10-1303
   Mattapallil MJ, 2017, IMMUNITY, V46, P167, DOI 10.1016/j.immuni.2017.02.008
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Metzger CS, 2015, CYTOKINE, V76, P519, DOI 10.1016/j.cyto.2015.07.015
   Michels Stephan, 2006, Expert Opin Investig Drugs, V15, P779, DOI 10.1517/13543784.15.7.779
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Mulcahy MF, 2005, EXPERT OPIN BIOL TH, V5, P997, DOI 10.1517/14712598.5.7.997
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Otsuji T, 2013, CLIN OPHTHALMOL, V7, P1487, DOI 10.2147/OPTH.S46317
   Ozkaya Abdullah, 2017, Korean J Ophthalmol, V31, P424, DOI 10.3341/kjo.2016.0125
   Papadopoulos KP, 2016, CLIN CANCER RES, V22, P1348, DOI 10.1158/1078-0432.CCR-15-1221
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel PJ, 2011, INVEST OPHTH VIS SCI, V52, P3089, DOI 10.1167/iovs.10-6208
   Patel S.S., 2018, AMD P RET SOC 43 ANN
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pham B, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-022031
   Pluckthun A, 2015, ANNU REV PHARMACOL, V55, P489, DOI 10.1146/annurev-pharmtox-010611-134654
   Prager F, 2008, INVESTIGATIVE OPHTHA, V49
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Sahni J, 2019, OPHTHALMOLOGY, V126, P1155, DOI 10.1016/j.ophtha.2019.03.023
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sanson-Fisher RW, 2007, AM J PREV MED, V33, P155, DOI 10.1016/j.amepre.2007.04.007
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Scholler A, 2014, WIEN KLIN WOCHENSCHR, V126, P355, DOI 10.1007/s00508-014-0539-z
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Simon M, 2014, MOL CANCER THER, V13, P375, DOI 10.1158/1535-7163.MCT-13-0523
   Singh N, 2017, ASIA-PAC J OPHTHALMO, V6, P520, DOI 10.22608/APO.2017416
   Skerka C, 2013, MOL IMMUNOL, V56, P170, DOI 10.1016/j.molimm.2013.06.001
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P3492
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Stahl A, 2013, ANGIOGENESIS, V16, P101, DOI 10.1007/s10456-012-9302-0
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Stumpp MT, 2008, DRUG DISCOV TODAY, V13, P695, DOI 10.1016/j.drudis.2008.04.013
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Syed BA, 2012, NAT REV DRUG DISCOV, V11, P827, DOI 10.1038/nrd3790
   Tamaskovic R, 2012, METHOD ENZYMOL, V503, P101, DOI 10.1016/B978-0-12-396962-0.00005-7
   Theurillat JP, 2010, MODERN PATHOL, V23, P1289, DOI 10.1038/modpathol.2010.103
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Winkler BS, 1999, MOL VIS, V5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Zapata MA, 2017, TELEMED E-HEALTH, V23, P31, DOI 10.1089/tmj.2016.0020
   Zarbin M, 2019, OPHTHALMOLOGY, V126, P849, DOI 10.1016/j.ophtha.2019.01.003
   Zuber-Laskawiec K, 2019, J PHYSIOL PHARMACOL, V70, P779, DOI 10.26402/jpp.2019.5.13
NR 190
TC 32
Z9 32
U1 3
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2020
VL 21
IS 21
AR 8242
DI 10.3390/ijms21218242
PG 40
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA OQ7AW
UT WOS:000588932400001
PM 33153227
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JW
   Kim, CG
AF Kim, Jae Hui
   Kim, Jong Woo
   Kim, Chul Gu
TI Eyes that Do Not Meet the Eligibility Criteria of Clinical Trials on
   Age-Related Macular Degeneration: Proportion of the Real-World Patient
   Population and Reasons for Exclusion
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; OUTCOMES; AFLIBERCEPT; SUBTYPES
AB Background. To evaluate the proportion of eyes that do not meet the eligibility criteria of clinical trials on neovascular age-related macular degeneration (AMD) and the reasons for exclusion. Methods. This retrospective, observational study included 512 eyes of 463 patients diagnosed with treatment-naive neovascular AMD. The proportion of eyes that did not meet the eligibility criteria of the Vascular Endothelial Growth Factor Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW) studies were evaluated. The two most common reasons for exclusion were also evaluated in each subtype of neovascular AMD (typical neovascular AMD, polypoidal choroidal vasculopathy (PCV), and type 3 neovascularization). Results. Among the 512 eyes, 229 (44.7%) did not meet the eligibility criteria. In all the included eyes, the most common reasons for exclusion were good or poor visual acuity (169 eyes, 33.0%), followed by the presence of subretinal hemorrhage (47 eyes, 9.5%). Moreover, good or poor visual acuity was the most common reason for exclusion in all three subtypes of neovascular AMD. The second most common reason was a fovea-involving scar or fibrosis in typical neovascular AMD, subretinal hemorrhage in PCV, and other vascular diseases affecting the retina in type 3 neovascularization. Conclusions. Among the included cases, 44.7% did not meet the eligibility criteria for VIEW study, suggesting that the conclusion derived from clinical trials may not directly reflect the real-world outcomes. Additionally, the reasons for ineligibility differed among the different subtypes of neovascular AMD.
C1 [Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu] Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, Seoul, South Korea.
EM kimoph@gmail.com
OI Kim, Jae Hui/0000-0001-8121-6353
FU Kim's Eye Hospital Research Center
FX This study was supported by Kim's Eye Hospital Research Center.
CR Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Calaprice-Whitty D, 2020, THER INNOV REGUL SCI, V54, P69, DOI 10.1007/s43441-019-00030-4
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Eaton ML, 2015, CURR TOP BEHAV NEURO, V19, P297, DOI 10.1007/7854_2014_337
   Eter N, 2021, GRAEF ARCH CLIN EXP, V259, P2213, DOI 10.1007/s00417-021-05073-8
   George S, 2010, EYE, V24, P1247, DOI 10.1038/eye.2009.301
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jung JJ, 2016, ACTA OPHTHALMOL, V94, pE249, DOI 10.1111/aos.12840
   Kim JH, 2020, GRAEF ARCH CLIN EXP, V258, P107, DOI 10.1007/s00417-019-04474-0
   Kim JH, 2019, GRAEF ARCH CLIN EXP, V257, P891, DOI 10.1007/s00417-018-04228-4
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moore TJ, 2018, JAMA INTERN MED, V178, P1451, DOI 10.1001/jamainternmed.2018.3931
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sertkaya A, 2016, CLIN TRIALS, V13, P117, DOI 10.1177/1740774515625964
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Woo Se Joon, 2019, Korean J Ophthalmol, V33, P150, DOI 10.3341/kjo.2018.0081
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 24
TC 1
Z9 1
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD APR 17
PY 2021
VL 2021
DI 10.1155/2021/6635467
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SV1HW
UT WOS:000663577300002
PM 33953966
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Stahl, A
AF Stahl, Andreas
TI The Diagnosis and Treatment of Age-Related Macular Degeneration
SO DEUTSCHES ARZTEBLATT INTERNATIONAL
LA English
DT Article
ID COMPLEMENT FACTOR-H; BETA-CAROTENE; VISION LOSS; PREVALENCE;
   RANIBIZUMAB; DISEASE; GENE; BEVACIZUMAB; PROGRESSION; BLINDNESS
AB Background: Age-related macular degeneration (AMD) is thought to cause approximately 9% of all cases of blindness worldwide. In Germany, half of all cases of blindness and high-grade visual impairment are due to AMD. In this review, the main risk factors, clinical manifestations, and treatments of this disease are presented.
   Methods: This review is based on pertinent publications retrieved by a selective search in PubMed for original articles and reviews, as well as on current position statements by the relevant specialty societies.
   Results: AMD is subdivided into early, intermediate, and late stages. The early stage is often asymptomatic; patients in the other two stages often have distorted vision or central visual field defects. The main risk factors are age, genetic predisposition, and nicotine consumption. The number of persons with early AMD in Germany rose from 5.7 million in 2002 to ca. 7 million in 2017. Late AMD is subdivided into the dry late form of the disease, for which there is no treatment at present, and the exudative late form, which can be treated with the intravitreal injection of VEGF inhibitors.
   Conclusion: More research is needed on the dry late form of AMD in particular, which is currently untreatable. The treatment of the exudative late form with VEGF inhibitors is labor-intensive and requires a close collaboration of the patient, the ophthalmologist, and the primary care physician.
C1 [Stahl, Andreas] Univ Med Greifswald, Dept Ophthalmol, Greifswald, Germany.
C3 Greifswald Medical School
RP Stahl, A (通讯作者)，Univ Med Greifswald, Klin & Poliklin Augenheilkunde, Ferdinand Sauerbruch Str, D-17475 Greifswald, Germany.
EM andreas.stahl@med.uni-greifswald.de
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, NEW ENGL J MED, V330, P1029, DOI DOI 10.1056/NEJM199404143301501
   [Anonymous], 2006, SCIENCE, V314, P1850
   [Anonymous], 2015, OPHTHALMOLOGE, V112, P237
   Berufsverband Augenarzte Deutschla, 2017, OPHTHALMOLOGE, V114, P617, DOI 10.1007/s00347-017-0508-9
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brandl C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26629-5
   Brandl C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167181
   Brown CN, 2019, METABOLITES, V9, DOI 10.3390/metabo9010004
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chandra S, 2020, EYE LOND
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Curcio CA, 2018, INVEST OPHTH VIS SCI, V59
   Deutsche Ophthalmologische Gesellschaft, 2015, OPHTHALMOLOGE, V112, P35
   Evans JR, 2014, OPHTHAL PHYSL OPT, V34, P390, DOI 10.1111/opo.12142
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2012, DTSCH ARZTEBL INT, V109, P484, DOI 10.3238/arztebl.2012.0484
   Gibson J, 2010, BRIT J OPHTHALMOL, V94, P1382, DOI 10.1136/bjo.2010.182568
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Joachim N, 2017, BRIT J OPHTHALMOL, V101, P1185, DOI 10.1136/bjophthalmol-2016-309729
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Lee S, 2013, J KOREAN MED SCI, V28, P769, DOI 10.3346/jkms.2013.28.5.769
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mauschitz MM, 2019, OPHTHALMOLOGE, V116, P201, DOI 10.1007/s00347-019-0853-y
   Merani Rohan, 2015, Int J Retina Vitreous, V1, P9
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Meyer CH, 2011, ACTA OPHTHALMOL, V89, P70, DOI 10.1111/j.1755-3768.2010.02064.x
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Relhan N, 2018, AM J OPHTHALMOL, V187, pXX, DOI 10.1016/j.ajo.2017.11.021
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schuster AK, 2019, OPHTHALMOLOGE, V116, P829, DOI 10.1007/s00347-019-0894-2
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Wecker T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38934-8
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Wilde C, 2017, EYE, V31, P1042, DOI 10.1038/eye.2017.30
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yoo YJ, 2018, INVEST OPHTH VIS SCI, V59
   Ziemssen F, 2020, OPHTHALMOLOGE, V117, P218, DOI 10.1007/s00347-019-01015-2
NR 54
TC 43
Z9 46
U1 0
U2 5
PU DEUTSCHER AERZTE-VERLAG GMBH
PI COLOGNE
PA DIESELSTRABE 2, POSTFACH 400265, D-50859 COLOGNE, GERMANY
SN 1866-0452
J9 DTSCH ARZTEBL INT
JI Dtsch. Arztebl. Int.
PD JUL 20
PY 2020
VL 117
IS 29-30
BP 513
EP +
DI 10.3238/arztebl.2020.0513
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA OO9DX
UT WOS:000587674800053
PM 33087239
OA Green Published
DA 2022-11-30
ER

PT J
AU Marquioni-Ramella, MD
   Suburo, AM
AF Marquioni-Ramella, Melisa D.
   Suburo, Angela M.
TI Photo-damage, photo-protection and age-related macular degeneration
SO PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES
LA English
DT Article
ID RETINAL LIGHT DAMAGE; PIGMENT EPITHELIAL-CELLS; INDUCED PHOTORECEPTOR
   APOPTOSIS; POLYUNSATURATED FATTY-ACIDS; OUTER NUCLEAR LAYER; SUNLIGHT
   EXPOSURE; OXIDATIVE STRESS; ZEAXANTHIN SUPPLEMENTATION; PHOTOOXIDATIVE
   DAMAGE; PHOTOCHEMICAL DAMAGE
AB Age-related macular degeneration (AMD) is a degenerative retinal disease that causes blindness in people 60-65 years and older, with the highest prevalence appearing in people 90 years-old or more. Epidemiological estimates indicate that the number of cases is increasing, and will almost double in the next 20 years. Preventive measures require precise etiological knowledge. This is quite difficult, since AMD is a multifactorial condition with intricate relationships between causes and risk factors. In this review, we describe the impact of light on the structure and physiology of the retina and the pigment epithelium, taking into account the continuous exposure to natural and artificial light sources along the life of an individual. A large body of experimental evidence demonstrates the toxic effects of some lighting conditions on the retina and the pigment epithelium, and consensus exists about the importance of photo-oxidation phenomena in the causality chain between light and retinal damage. Here, we analyzed the transmission of light to the retina, and compared the aging human macula in healthy and diseased retinas, as shown by histology and non-invasive imaging systems. Finally, we have compared the putative retinal photosensitive molecular structures that might be involved in the genesis of AMD. The relationship between these compounds and retinal damage supports the hypothesis of light as an important initiating cause of AMD.
C1 [Marquioni-Ramella, Melisa D.; Suburo, Angela M.] Univ Austral, Fac Ciencias Biomed, Med Celular & Mol, Buenos Aires, DF, Argentina.
C3 Austral University
RP Suburo, AM (通讯作者)，Univ Austral, Fac Ciencias Biomed, Med Celular & Mol, Pilar B1629AHJ, Buenos Aires, DF, Argentina.
EM amsuburo@austral.edu.ar
OI Suburo, Angela/0000-0002-5713-3301; Marquioni Ramella, Melisa
   Daniela/0000-0003-3377-9789
FU Universidad Austral; Consejo Nacional de Investigaciones Cientificas y
   Tecnicas (CONICET); ANPCyT (Argentina) [PICT 2010-2632, PICT 2013-3200]
FX MMR is a Research Fellow funded by Universidad Austral and Consejo
   Nacional de Investigaciones Cientificas y Tecnicas (CONICET). AMS is
   Principal Researcher at CONICET. Our work was supported by grants from
   the ANPCyT (Argentina), PICT 2010-2632 and PICT 2013-3200. We are very
   grateful to Dr Mariela Marazita for the careful reading of this
   manuscript.
CR Ablonczy Z, 2013, ARCH BIOCHEM BIOPHYS, V539, P196, DOI 10.1016/j.abb.2013.08.005
   Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Age-related Eye Disease Study (AREDS) Research Group, 2001, ARCH OPHTHALMOL-CHIC, P119
   Ait-Ali N, 2015, CELL, V161, P817, DOI 10.1016/j.cell.2015.03.023
   Akuffo KO, 2014, OPHTHAL EPIDEMIOL, V21, P111, DOI 10.3109/09286586.2014.888085
   Alexander I, 2014, INVEST OPHTH VIS SCI, V55, P4999, DOI 10.1167/iovs.14-14054
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992
   ANDERSON DH, 1978, INVEST OPHTH VIS SCI, V17, P117
   [Anonymous], 1997, HEALTH PHYS, V73, P539
   Arnault E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071398
   Aspinall PA, 2014, BRIT J OPHTHALMOL, V98, P1393, DOI 10.1136/bjophthalmol-2014-305032
   Avila F, 2015, PHOTOCHEM PHOTOBIOL, V91, P767, DOI 10.1111/php.12443
   BAILEY JNC, 2014, COLD SPRING HARBOR P, V4
   Balasubramanian D, 2000, J OCUL PHARMACOL TH, V16, P285, DOI 10.1089/jop.2000.16.285
   Barkana Y, 2000, SURV OPHTHALMOL, V44, P459, DOI 10.1016/S0039-6257(00)00112-0
   Bavik C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124940
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Behar-Cohen F, 2011, PROG RETIN EYE RES, V30, P239, DOI 10.1016/j.preteyeres.2011.04.002
   Berchuck JE, 2013, INVEST OPHTH VIS SCI, V54, P2669, DOI 10.1167/iovs.12-11020
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Bianchini P, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2982528
   BIRKLE DL, 1989, NEUROCHEM RES, V14, P185, DOI 10.1007/BF00969637
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Boulton ME, 2014, EXP EYE RES, V126, P61, DOI 10.1016/j.exer.2014.01.016
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Brockmann C, 2013, EYE, V27, P1169, DOI 10.1038/eye.2013.159
   Brockmann C, 2008, J CATARACT REFR SURG, V34, P1161, DOI 10.1016/j.jcrs.2008.03.039
   Brondsted AE, 2013, ACTA OPHTHALMOL, V91, P52, DOI 10.1111/j.1755-3768.2011.02291.x
   Building Technologies Office, 2013, PNNLSA96340 US DEP E
   BUSH RA, 1991, EXP EYE RES, V53, P741, DOI 10.1016/0014-4835(91)90109-R
   Calzia D, 2014, BIOCHIMIE, V102, P78, DOI 10.1016/j.biochi.2014.02.007
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   CELLINI M, 1987, INT OPHTHALMOL, V10, P157, DOI 10.1007/BF00139342
   Charvet C, 2011, J BIOL CHEM, V286, P20413, DOI 10.1074/jbc.M111.232546
   Charvet CD, 2013, J BIOL CHEM, V288, P29267, DOI 10.1074/jbc.M113.498832
   Chen CT, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4859
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chui TYP, 2012, INVEST OPHTH VIS SCI, V53, P3545, DOI 10.1167/iovs.11-8694
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Daneault V, 2012, J BIOL RHYTHM, V27, P257, DOI 10.1177/0748730412441172
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   Dennison JL, 2013, EXP EYE RES, V116, P190, DOI 10.1016/j.exer.2013.08.014
   Dillon J, 2004, EXP EYE RES, V79, P753, DOI 10.1016/j.exer.2004.06.025
   DILORETO DA, 1995, BRAIN RES, V698, P1, DOI 10.1016/0006-8993(95)00647-9
   Donovan M, 2001, J BIOL CHEM, V276, P23000, DOI 10.1074/jbc.M005359200
   Edge R, 1997, J PHOTOCH PHOTOBIO B, V41, P189, DOI 10.1016/S1011-1344(97)00092-4
   Elachouri G, 2015, FREE RADICAL BIO MED, V81, P22, DOI 10.1016/j.freeradbiomed.2015.01.003
   FEENEYBURNS L, 1990, AM J OPHTHALMOL, V109, P265, DOI 10.1016/S0002-9394(14)74549-0
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Ferguson TA, 2014, AUTOPHAGY, V10, P165, DOI 10.4161/auto.26735
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Fletcher LM, 2014, OPTOMETRY VISION SCI, V91, P1089, DOI 10.1097/OPX.0000000000000355
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Gaillard ER, 2011, PHOTOCHEM PHOTOBIOL, V87, P18, DOI 10.1111/j.1751-1097.2010.00837.x
   GARTNER S, 1981, BRIT J OPHTHALMOL, V65, P23, DOI 10.1136/bjo.65.1.23
   Glickman RD, 2011, EYE CONTACT LENS, V37, P196, DOI 10.1097/ICL.0b013e31821e45a9
   Glickman RD, 2002, INT J TOXICOL, V21, P473, DOI 10.1080/10915810290169909
   GORGELS TGMF, 1995, INVEST OPHTH VIS SCI, V36, P851
   Grey AC, 2011, INVEST OPHTH VIS SCI, V52, P3926, DOI 10.1167/iovs.10-7020
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   Hammond BR, 2014, EXP EYE RES, V129, P135, DOI 10.1016/j.exer.2014.09.005
   Hirakawa M, 2008, BRIT J OPHTHALMOL, V92, P630, DOI 10.1136/bjo.2007.130575
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Ito S, 2013, PIGM CELL MELANOMA R, V26, P357, DOI 10.1111/pcmr.12078
   IWASAKI M, 1988, INVEST OPHTH VIS SCI, V29, P671
   Jaadane I, 2015, FREE RADICAL BIO MED, V84, P373, DOI 10.1016/j.freeradbiomed.2015.03.034
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jonnal RS, 2010, OPT EXPRESS, V18, P5257, DOI 10.1364/OE.18.005257
   Kardon RH, 2013, INVEST OPHTH VIS SCI, V54, P5559, DOI 10.1167/iovs.13-12319
   Kaylor JJ, 2014, P NATL ACAD SCI USA, V111, P7302, DOI 10.1073/pnas.1319142111
   Kaylor JJ, 2013, NAT CHEM BIOL, V9, P30, DOI [10.1038/NCHEMBIO.1114, 10.1038/nchembio.1114]
   Keller C, 2001, INVEST OPHTH VIS SCI, V42, P476
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Khatib Nur, 2014, J Optom, V7, P225, DOI 10.1016/j.optom.2013.12.006
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Klein BEK, 2014, INVEST OPHTH VIS SCI, V55, P5855, DOI 10.1167/iovs.14-14602
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Kuse Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05223
   Leasher JL, 2014, BRIT J OPHTHALMOL, V98, P619, DOI 10.1136/bjophthalmol-2013-304013
   Li BX, 2014, P NATL ACAD SCI USA, V111, P10173, DOI 10.1073/pnas.1402526111
   Li BX, 2010, PHOTOCH PHOTOBIO SCI, V9, P1418, DOI 10.1039/c0pp00126k
   Li W, 2009, FREE RADICAL BIO MED, V47, P1539, DOI 10.1016/j.freeradbiomed.2009.09.003
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   Loginova MY, 2008, BIOCHEMISTRY-MOSCOW+, V73, P130, DOI 10.1134/S000629790802003X
   Lucas RJ, 2014, TRENDS NEUROSCI, V37, P1, DOI 10.1016/j.tins.2013.10.004
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   Maeda A, 2014, P NATL ACAD SCI USA, V111, pE1428, DOI 10.1073/pnas.1317986111
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda T, 2012, PHOTOCHEM PHOTOBIOL, V88, P1309, DOI 10.1111/j.1751-1097.2012.01143.x
   Mainster MA, 2011, OPHTHALMOLOGY, V118, P1, DOI 10.1016/j.ophtha.2010.11.016
   Meredith P, 2006, PIGM CELL RES, V19, P572, DOI 10.1111/j.1600-0749.2006.00345.x
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13158, DOI 10.1073/pnas.0705963104
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Nayernia Z, 2014, ANTIOXID REDOX SIGN, V20, P2815, DOI 10.1089/ars.2013.5703
   NEI, 2015, AG REL MAC DEG AMD
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nickell S, 2007, J CELL BIOL, V177, P917, DOI 10.1083/jcb.200612010
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   NOELL WK, 1980, VISION RES, V20, P1163, DOI 10.1016/0042-6989(80)90055-3
   Nolan JM, 2013, EYE, V27, P899, DOI 10.1038/eye.2013.98
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Nolan JM, 2009, INVEST OPHTH VIS SCI, V50, P4777, DOI 10.1167/iovs.08-3277
   Obata R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091873
   Ooto S, 2011, INVEST OPHTH VIS SCI, V52, P8769, DOI 10.1167/iovs.11-8388
   Organisciak DT, 2013, MOL VIS, V19, P1433
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   ORGANISCIAK DT, 1992, INVEST OPHTH VIS SCI, V33, P1599
   Organisciak DT, 1996, INVEST OPHTH VIS SCI, V37, P2243
   Organisciak DT, 1998, INVEST OPHTH VIS SCI, V39, P1107
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743
   Panfoli I, 2013, CELL BIOCHEM FUNCT, V31, P532, DOI 10.1002/cbf.2943
   Park SP, 2013, EXP EYE RES, V108, P1, DOI 10.1016/j.exer.2012.12.011
   Pipis A, 2015, EUR J OPHTHALMOL, V25, P128, DOI 10.5301/ejo.5000520
   Poliakov E, 2003, FASEB J, V17, P2209, DOI 10.1096/fj.03-0086com
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   Quazi F, 2014, P NATL ACAD SCI USA, V111, P5024, DOI 10.1073/pnas.1400780111
   Quazi F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1927
   Radu RA, 2014, J BIOL CHEM, V289, P9113, DOI 10.1074/jbc.M114.548669
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Ramkumar HL, 2013, J NUTR, V143, P1129, DOI 10.3945/jn.112.169649
   Roehlecke C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071570
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Rozanowska M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305, DOI 10.1562/2004-11-13-IR-371
   Rozanowska M, 1999, FREE RADICAL BIO MED, V26, P518, DOI 10.1016/S0891-5849(98)00234-2
   Rozanowska M, 2012, PHOTOCHEM PHOTOBIOL, V88, P1362, DOI 10.1111/j.1751-1097.2012.01161.x
   Rozanowska MB, 2012, PHOTOCHEM PHOTOBIOL, V88, P1303, DOI 10.1111/j.1751-1097.2012.01240.x
   Saari JC, 2012, ANNU REV NUTR, V32, P125, DOI 10.1146/annurev-nutr-071811-150748
   Sabour-Pickett S, 2012, MOL NUTR FOOD RES, V56, P270, DOI 10.1002/mnfr.201100219
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Salomon RG, 2005, CHEM PHYS LIPIDS, V134, P1, DOI 10.1016/j.chemphyslip.2004.12.003
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Shang YM, 2014, ENVIRON HEALTH PERSP, V122, P269, DOI 10.1289/ehp.1307294
   Shiose S, 2011, J BIOL CHEM, V286, P15543, DOI 10.1074/jbc.M111.228551
   SLINEY DH, 1983, OPHTHALMOLOGY, V90, P937
   Smith Bright M., 2014, THESIS AM PUBLIC U S
   Smith RT, 2013, INVEST OPHTH VIS SCI, V54, P5543, DOI 10.1167/iovs.13-12798
   Smolarek-Kasprzak P., 2014, BR J OPHTHALMOL, V2014
   Song HX, 2011, INVEST OPHTH VIS SCI, V52, P7376, DOI 10.1167/iovs.11-7199
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Stringham JM, 2003, J OPT SOC AM A, V20, P1852, DOI 10.1364/JOSAA.20.001852
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Sun H, 2001, J BIOL CHEM, V276, P11766, DOI 10.1074/jbc.M010152200
   Sundelin SP, 2001, FREE RADICAL BIO MED, V30, P74, DOI 10.1016/S0891-5849(00)00444-5
   Suzuki M, 2007, MOL VIS, V13, P772
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tanito M, 2010, J CATARACT REFR SURG, V36, P299, DOI 10.1016/j.jcrs.2009.08.036
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Taylor HR, 1990, T AM OPHTHAL SOC, V88, P173
   Teussink MM, 2015, AM J OPHTHALMOL, V159, P964, DOI 10.1016/j.ajo.2015.02.004
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Torbidoni V, 2005, EXP EYE RES, V81, P265, DOI 10.1016/j.exer.2004.12.024
   TUCKER GS, 1986, INVEST OPHTH VIS SCI, V27, P708
   van Norren D, 2011, PHOTOCHEM PHOTOBIOL, V87, P747, DOI 10.1111/j.1751-1097.2011.00921.x
   VanNasdale DA, 2015, INVEST OPHTH VIS SCI, V56, P284, DOI 10.1167/iovs.14-14459
   Vazquez S, 2004, INVEST OPHTH VIS SCI, V45, P879, DOI 10.1167/iovs.03-0558
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P43
   Vukicevic M, 2008, CLIN EXP OPHTHALMOL, V36, P695, DOI 10.1111/j.1442-9071.2008.01864.x
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   Wang XW, 2008, FREE RADICAL BIO MED, V45, P336, DOI 10.1016/j.freeradbiomed.2008.04.028
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P474, DOI 10.1562/2005-10-21-RA-725
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
   Wielgus AR, 2012, PHOTOCHEM PHOTOBIOL, V88, P1320, DOI 10.1111/j.1751-1097.2012.01174.x
   Wielgus AR, 2010, PHOTOCHEM PHOTOBIOL, V86, P781, DOI 10.1111/j.1751-1097.2010.00750.x
   Winkler B S, 1999, Mol Vis, V5, P32
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Wu L, 2014, INVEST OPHTH VIS SCI, V55, P1910, DOI 10.1167/iovs.14-13867
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Xue YL, 2015, J CLIN INVEST, V125, P727, DOI 10.1172/JCI79651
   Yang XR, 2012, CAN J OPHTHALMOL, V47, P45, DOI 10.1016/j.jcjo.2011.12.001
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
   YOUNG RW, 1971, J CELL BIOL, V49, P303, DOI 10.1083/jcb.49.2.303
   Zayit-Soudry S, 2013, INVEST OPHTH VIS SCI, V54, P7498, DOI 10.1167/iovs.13-12433
   Zhang CW, 2014, OPHTHALMOLOGY, V121, P2371, DOI 10.1016/j.ophtha.2014.06.047
   Zhang JY, 2015, J CLIN INVEST, V125, P2781, DOI 10.1172/JCI80950
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zou X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.190
NR 213
TC 29
Z9 30
U1 2
U2 43
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1474-905X
EI 1474-9092
J9 PHOTOCH PHOTOBIO SCI
JI Photochem. Photobiol. Sci.
PY 2015
VL 14
IS 9
BP 1560
EP 1577
DI 10.1039/c5pp00188a
PG 18
WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Chemistry
GA CQ2UT
UT WOS:000360458100002
PM 26198091
OA Green Published
DA 2022-11-30
ER

PT J
AU Flores, R
   Carneiro, A
   Neri, G
   Fradinho, AC
   Quenderra, B
   Barata, MJ
   Tenreiro, S
   Seabra, MC
AF Flores, Rita
   Carneiro, Angela
   Neri, Guilherme
   Fradinho, Ana C.
   Quenderra, Bruno
   Barata, Maria Joao
   Tenreiro, Sandra
   Seabra, Miguel C.
TI Choroidal Vascular Impairment in Intermediate Age-Related Macular
   Degeneration
SO DIAGNOSTICS
LA English
DT Article
DE intermediate AMD; chorioretinal vasculature; optical coherence
   tomography; OCT-angiography
ID SUBRETINAL DRUSENOID DEPOSITS; RETICULAR PSEUDODRUSEN; PREVALENCE;
   PATHOGENESIS; DISEASE; MODEL
AB Age-related macular degeneration (AMD) is a multifactorial disease, whose complete pathogenesis is still unclear. Local hemodynamics may play a crucial role in its manifestation and progression. To evaluate choroidal and retinal vascular parameters, a total of 134 eyes were analyzed, 100 with intermediate AMD and 34 age matched healthy controls. 131 eyes of 104 patients were eligible for complete image assessment and 3 eyes were excluded for insufficient image quality: Group 1: intermediate AMD (n = 97) and Group 2: healthy controls (n = 34). Spectral domain optic coherence tomography (SD-OCT) with enhanced depth imaging (EDI) and optic coherence tomography angiography (OCT-A) were acquired using Spectralis (Heidelberg Engineering). Choroid and retinal capillary plexus were evaluated and image binarization was used to obtain quantitative data. Mean age was 77.67 years old (YO) and 67.2% were women. Total subfoveal choroidal area and luminal area were significantly reduced in Group 1 compared with Group 2 (0.88 mm(2) and 0.40 mm(2) vs. 1.24 mm(2) and 0.55 mm(2), respectively) (p < 0.05). Regarding choriocapillary flow density, AMD eyes recorded reduced values (34.83%) compared with controls (36.25%) (p < 0.05). Chorioretinal vasculature is impaired in intermediate AMD patients and vascular parameters could be attractive new prognostic biomarkers. Future therapeutic approaches may target this vascular dysfunction and delay disease progression.
C1 [Flores, Rita; Neri, Guilherme; Quenderra, Bruno; Barata, Maria Joao] Ctr Hosp Lisboa Cent EPE, Dept Ophthalmol, P-1169050 Lisbon, Portugal.
   [Flores, Rita; Fradinho, Ana C.; Tenreiro, Sandra; Seabra, Miguel C.] Univ Nova Lisboa, NOVA Med Sch, P-1169056 Lisbon, Portugal.
   [Carneiro, Angela] Ctr Hosp Univ Sao Joao, Dept Ophthalmol, P-4099002 Porto, Portugal.
   [Carneiro, Angela] Univ Porto, Fac Med, P-4099002 Porto, Portugal.
   [Seabra, Miguel C.] UCL Inst Ophthalmol, London EC1V 9EL, England.
C3 Centro Hospitalar de Lisboa Ocidental, EPE; Universidade Nova de Lisboa;
   Universidade do Porto; University of London; University College London
RP Flores, R (通讯作者)，Ctr Hosp Lisboa Cent EPE, Dept Ophthalmol, P-1169050 Lisbon, Portugal.; Flores, R (通讯作者)，Univ Nova Lisboa, NOVA Med Sch, P-1169056 Lisbon, Portugal.
EM rita.flores@fcm.unl.pt; acarneir@med.up.pt;
   jose.pires@chlc.min-saude.pt; ana.fradinho@nms.unl.pt;
   bruno.quendera@chlc.min-saude.pt; maria.barata2@chlc.min-saude.pt;
   stenreiro@nms.unl.pt; miguel.seabra@nms.unl.pt
RI ; Tenreiro, Sandra/A-9289-2013
OI Rio Pedro Flores, Rita Maria/0000-0002-7523-2418; Quendera,
   Bruno/0000-0002-1387-9953; Tenreiro, Sandra/0000-0001-7272-5842; Barata,
   Maria Joao/0000-0002-0889-4809
FU (Universidade Nova de Lisboa, Portugal)
FX Statistical support and assistance was provided by Jorge Mendes, (NOVA
   Information Management School, Universidade Nova de Lisboa, Portugal).
CR A Martillo Miguel, 2012, Med Hypothesis Discov Innov Ophthalmol, V1, P37
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   Bressler NM, 2006, AGE RELATED MACULAR, VII, P1041
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Du HL, 2012, INT J ONCOL, V40, P2049, DOI 10.3892/ijo.2012.1415
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Friedman E, 2008, AM J OPHTHALMOL, V146, P348, DOI 10.1016/j.ajo.2008.05.017
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   Giannaccare G, 2020, RETINA-J RET VIT DIS, V40, P960, DOI 10.1097/IAE.0000000000002459
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Mansouri K, 2013, OPHTHALMOLOGY, V120, P2508, DOI 10.1016/j.ophtha.2013.07.040
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Possek E., 1905, Z AUGENHEILKD, V13, P771, DOI [10.1159/000290375, DOI 10.1159/000290375]
   Remsch H, 2000, GRAEF ARCH CLIN EXP, V238, P960, DOI 10.1007/s004170000202
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Thee EF, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.26
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Trinh M, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.4.20
   Velaga SB, 2020, RETINA-J RET VIT DIS, V40, P612, DOI 10.1097/IAE.0000000000002667
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 34
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD MAY
PY 2022
VL 12
IS 5
AR 1290
DI 10.3390/diagnostics12051290
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 1R6ZH
UT WOS:000803515600001
PM 35626445
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Cho, H
   Weber, ML
   Shah, CP
   Heier, JS
AF Cho, Hyung
   Weber, Marissa L.
   Shah, Chirag P.
   Heier, Jeffrey S.
TI Initial utilization of aflibercept in exudative age-related macular
   degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Age-related macular degeneration; Bevacizumab; Choroidal
   neovascularization; Ranibizumab
ID VEGF-TRAP; RANIBIZUMAB; VERTEPORFIN; EYE
AB Purpose: Intravitreal aflibercept, a fusion protein with high affinity for vascular endothelial growth factor, offers an alternative treatment for exudative age-related macular degeneration. Preclinical studies and early and late phase clinical trials suggest that aflibercept's high binding affinity may impart greater durability of activity and increased efficacy compared to ranibizumab or bevacizumab.
   Methods: A total of 266 eyes of 249 patients with exudative age-related macular degeneration who received aflibercept after treatment with bevacizumab and/or ranibizumab were included in a retrospective review. Mean central subfoveal thickness on spectral-domain optical coherence tomography and mean logarithm of the minimal angle of resolution (logMAR) visual acuity were calculated at 1, 3, 6, and 12 months after the first aflibercept injection. Subgroup analyses were performed in eyes receiving at least 5 bevacizumab and/or ranibizumab injections in the 6 months prior to aflibercept and in eyes receiving at least 10 injections in the 12 months prior to aflibercept.
   Results: Eyes received an average of 14.7 (range 1-43) ranibizumab and/or bevacizumab treatments prior to initiation of aflibercept therapy. The mean central subfoveal thickness decreased from 300 to 275 mu m at 1 month (p<0.001) and was maintained at 6 months. Mean logMAR visual acuity improved from 0.60 (Snellen equivalent 20/80) to 0.54 (20/70, p = 0.01) at 1 month and was stable at 0.55 at 6 months (Snellen equivalent 20/70, p = 0.11, n = 251). In 82 eyes receiving at least 5 injections in the 6 months prior to aflibercept treatment (average of 18.1 injections total), the central subfoveal thickness improved from 296 to 279 mu m at 1 month (p< 0.0001) and was maintained at 6 months (p< 0.0001). Visual acuity did not change (0.48 [20/61] at 1 month compared to baseline, 0.49 [20/62], p = 0.634, and at 6 months 0.51 [20/65], p = 0.601). In 50 eyes receiving at least 10 injections in the 12 months prior to aflibercept treatment (average of 21.8 injections total), the mean central subfoveal thickness decreased by 17 mu m at 1 month (p = 0.0007) and was maintained at 6 months (p = 0.013). Again, visual acuity did not change (0.46 [20/56] at 1 month, baseline 0.44 [20/56], p = 0.547, and 0.50 [20/63] at 6 months, p = 0.2445).
   Conclusions: Aflibercept is a valuable treatment alternative in patients previously treated with bevacizumab and/or ranibizumab injections. Stability of visual acuity and anatomic improvement on spectral-domain optical coherence tomography were observed after initiation of aflibercept treatment in those previously treated with ranibizumab and/or bevacizumab injections every 4-6 weeks.
C1 [Cho, Hyung; Weber, Marissa L.; Shah, Chirag P.; Heier, Jeffrey S.] Ophthalm Consultants Boston, Boston, MA 02114 USA.
C3 Ophthalmic Consultants of Boston
RP Heier, JS (通讯作者)，Ophthalm Consultants Boston, Vitreoretinal Serv, 50 Staniford St,Suite 600, Boston, MA 02114 USA.
EM jsheier@eyeboston.com
OI Shah, Chirag/0000-0001-6369-4917
FU Bayer
FX Supported by a grant from Bayer.
CR Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
NR 16
TC 3
Z9 3
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL-AUG
PY 2014
VL 24
IS 4
BP 576
EP 581
DI 10.5301/ejo.5000421
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AY3FT
UT WOS:000347470700017
PM 24706352
DA 2022-11-30
ER

PT J
AU Daniute, G
   Vilkeviciute, A
   Gedvilaite, G
   Kriauciuniene, L
   Liutkeviciene, R
AF Daniute, Ginte
   Vilkeviciute, Alvita
   Gedvilaite, Greta
   Kriauciuniene, Loresa
   Liutkeviciene, Rasa
TI RP1L1 rs3924612 gene polymorphism and RP1L1 protein associations among
   patients with early age-related macular degeneration
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; gene; polymorphism; protein
ID DYSTROPHY; MUTATION
AB Background: Age-related macular degeneration (AMD) is one of the most common causes of blindness in developed world countries. It mainly affects the elderly. The incidence of the disease is only slightly below that of cancer and cardiovascular diseases. This study aimed to determine the association of RP1L1 single nucleotide polymorphism and serum RP1L1 levels with the onset of the early AMD.Aim: The aim of this study was to determine the association of RP1L1 single nucleotide polymorphism with the onset of the early age-related macular degeneration (AMD).Methods: The study examined 615 subjects: 309 with a diagnosis of the early AMD and 306 healthy controls. Samples of DNA from peripheral blood leukocytes were extracted by the DNA salting-out method. Genotyping was carried out by the real-time polymerase chain reaction. Serum levels of RP1L1 protein were evaluated using an ELISA kit. The results were assessed using the statistical analysis method of "IBM SPSS Statistics 23.0".Results: We have found that the RP1L1 rs3924612 C/G genotype increases the odds of the early AMD development in females (p <.05/2). Also, we found that RP1L1 rs3924612 C/G and G/G genotypes increase the odds of the early AMD in the age group of 56-68 years (p < .05/2). Serum RP1L1 levels were evaluated in study groups but no statistically significant associations were found.Conclusion: Based on these results we concluded that RP1L1 rs3924612 polymorphism was associated with the early AMD development, but not with the RP1L1 level changes
C1 [Daniute, Ginte] Lithuanian Univ Hlth Sci, Med Acad, Kaunas, Lithuania.
   [Vilkeviciute, Alvita; Gedvilaite, Greta; Kriauciuniene, Loresa; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences
RP Gedvilaite, G (通讯作者)，Lithuanian Univ Hlth Sci, LT-50161 Kaunas, Lithuania.
EM greta.gedvilaite@lsmuni.lt
CR Akahori M, 2010, AM J HUM GENET, V87, P424, DOI 10.1016/j.ajhg.2010.08.009
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Browne S, 2003, MOL VIS, V9, P129
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6
   Gedvilaite G, 2019, OPHTHALMIC GENET, V40, P219, DOI 10.1080/13816810.2019.1622022
   Haer-Wigman L, 2017, EUR J HUM GENET, V25, P591, DOI 10.1038/ejhg.2017.9
   Hayashi T, 2012, OPTOMETRY VISION SCI, V89, P684, DOI 10.1097/OPX.0b013e31824eea32
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Hu YS, 2019, INT J OPHTHALMOL-CHI, V12, P915, DOI 10.18240/ijo.2019.06.06
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kabuto T, 2012, MOL VIS, V18, P1031
   Kato Y, 2017, INVEST OPHTH VIS SCI, V58, P6020, DOI 10.1167/iovs.17-21969
   Kikuchi S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/545243
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu SC, 2019, BMC MED GENET, V20, DOI 10.1186/s12881-019-0756-4
   Liutkeviciene R, 2018, GENE, V676, P139, DOI 10.1016/j.gene.2018.07.031
   Okuno T, 2013, DOC OPHTHALMOL, V127, P141, DOI 10.1007/s10633-013-9384-z
   Patel Nisha, 2016, Genet Med, V18, P554, DOI 10.1038/gim.2015.127
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Sidaraite A, 2020, BIOMED PAP, V164, P189, DOI 10.5507/bp.2019.016
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Tong XJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4153
   Tsunoda K, 2012, RETINA-J RET VIT DIS, V32, P1135, DOI 10.1097/IAE.0b013e318232c32e
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Yamashita T, 2009, J NEUROSCI, V29, P9748, DOI 10.1523/JNEUROSCI.5854-08.2009
   Zobor D, 2018, INVEST OPHTH VIS SCI, V59, P3041, DOI 10.1167/iovs.18-24033
NR 33
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD MAR 4
PY 2022
VL 43
IS 2
BP 164
EP 171
DI 10.1080/13816810.2021.2010770
EA DEC 2021
PG 8
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 1A2RR
UT WOS:000727089200001
PM 34865606
DA 2022-11-30
ER

PT J
AU Zampros, I
   Praidou, A
   Brazitikos, P
   Ekonomidis, P
   Androudi, S
AF Zampros, Ilias
   Praidou, Anna
   Brazitikos, Periklis
   Ekonomidis, Panagiotis
   Androudi, Sofia
TI Antivascular Endothelial Growth Factor Agents for Neovascular
   Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID VASCULAR-PERMEABILITY FACTOR; DOUBLE-STRANDED-RNA; CHOROIDAL
   NEOVASCULARIZATION; INTRAVITREAL INJECTION; PHOTODYNAMIC THERAPY;
   DIABETIC-RETINOPATHY; PEGAPTANIB SODIUM; EDEMA SECONDARY; DOSING
   REGIMEN; SERUM-LEVELS
AB Age-related macular degeneration (AMD) is the leading cause of severe visual loss and blindness over the age of 50 in developed countries. Vascular endothelial growth factor (VEGF) is considered as a critical molecule in the pathogenesis of choroidal neovascularization (CNV), which characterizes the neovascular AMD. Anti-VEGF agents are considered the most promising way of effectively inhibition of the neovascular AMD process. VEGF is a heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Two anti-VEGF agents have been approved by the US Food and Drug Administration (FDA) for the treatment of neovascular AMD. Pegaptanib sodium, which is an aptamer and ranibizumab, which is a monoclonal antibody fragment. Another humanized monoclonal antibody is currently off-label used, bevacizumab. This paper aims to discuss in details the effectiveness, the efficacy and safety of these three anti-VEGF agents. New anti-VEGF compounds which are recently investigated for their clinical usage (VEGF-trap, small interfering RNA) are also discussed for their promising outcomes.
C1 [Zampros, Ilias; Praidou, Anna; Brazitikos, Periklis; Ekonomidis, Panagiotis; Androudi, Sofia] Aristotle Univ Thessaloniki, Dept Ophthalmol, Thessaloniki 54124, Greece.
C3 Aristotle University of Thessaloniki
RP Androudi, S (通讯作者)，Aristotle Univ Thessaloniki, Dept Ophthalmol, Thessaloniki 54124, Greece.
EM androudi@otenet.gr
RI Androudi, Sofia/AAB-7618-2021
OI Androudi, Sofia/0000-0002-5303-7793
CR Abouammoh M, 2011, CURR OPIN OPHTHALMOL, V22, P152, DOI 10.1097/ICU.0b013e32834595d0
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
   Barik S, 2004, ANN MED, V36, P540, DOI 10.1080/07853890410018817
   Bauer SM, 2005, J VASC SURG, V41, P699, DOI 10.1016/j.jvs.2005.01.015
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Boyd SR, 2002, ARCH OPHTHALMOL-CHIC, V120, P1644
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Do DV, 2009, BRIT J OPHTHALMOL, V93, P144, DOI 10.1136/bjo.2008.138271
   Do DV, 2011, OPHTHALMOLOGY, V118, P1819, DOI 10.1016/j.ophtha.2011.02.018
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Feucht N, 2008, CLIN OPHTHALMOL, V2, P253
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Garba AO, 2010, OPHTHALMOL EYE DIS, V2, P75, DOI 10.4137/OED.S4878
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin KL, 2000, J MOL NEUROSCI, V14, P197, DOI 10.1385/JMN:14:3:197
   Karkkainen MJ, 2002, NAT CELL BIOL, V4, pE2, DOI 10.1038/ncb0102-e2
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Kriechbaum K, 2008, BRIT J OPHTHALMOL, V92, P518, DOI 10.1136/bjo.2007.127282
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McColm J, 2004, MOL VIS, V10, P512
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Noma H, 2006, GRAEF ARCH CLIN EXP, V244, P309, DOI 10.1007/s00417-004-1087-4
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868
   Perkel JM, 2009, SCIENCE, V326, P454, DOI 10.1126/science.opms.p0900039
   Praidou A, 2011, ACTA OPHTHALMOL, V89, P248, DOI 10.1111/j.1755-3768.2009.01661.x
   Praidou A, 2010, CURR DIABETES REV, V6, P304, DOI 10.2174/157339910793360815
   Praidou A, 2009, CURR EYE RES, V34, P152, DOI 10.1080/02713680802585920
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal KB, 2007, OPHTHALMOLOGE, V104, P285, DOI 10.1007/s00347-007-1509-x
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999
   Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Storkebaum E, 2004, J CLIN INVEST, V113, P14, DOI 10.1172/JCI200420682
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P660, DOI 10.1097/00006982-200408000-00039
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Yonekura H, 1999, J BIOL CHEM, V274, P35172, DOI 10.1074/jbc.274.49.35172
NR 71
TC 33
Z9 33
U1 0
U2 11
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2012
VL 2012
AR 319728
DI 10.1155/2012/319728
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 979CM
UT WOS:000306792500001
PM 22174998
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU El-Hifnawy, MA
   Ibrahim, HA
   Gomaa, AR
   Elmasry, MA
AF El-Hifnawy, Mohamed Abd ElMonaem
   Ibrahim, Hisham Ali
   Gomaa, Amir Ramadan
   Elmasry, Mohamed A.
TI The vitreomacular interface in different types of age-related macular
   degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; vitreomacular interface; optical
   coherence tomography; macula
ID CHOROIDAL NEOVASCULARIZATION; PHARMACOLOGICAL VITREOLYSIS; ADHESION;
   THERAPY; PATHOGENESIS; CLASSIFICATION; INFLAMMATION; OUTCOMES; SMOKING;
   RISK
AB AIM: To evaluate the vitreomacular interface in cases with wet age-related macular degeneration (AMD) and to compare them to eyes with dry AMD and normal eyes.
   METHODS: This was a cross-sectional comparative study that included 87 eyes with wet AMD, 42 eyes with dry AMD and 40 eyes without AMD as a control group. Optical coherence tomography (OCT) examination was performed for all patients to assess the vitreomacular interface.
   RESULTS: In the wet AMD group, 34.5% of cases had vitreomacular adhesion (VMA). Only 14.3% of dry AMD cases and 10% of control cases had VMA. There was a significant difference between the control group and the wet AMD group (P=0.004) as well as the dry and wet AMD group (P=0.017). There was also a significant difference between the incidence of VMA in patients with subretinal choroidal neovascularization (CNV, type 1) and intraretinal CNV (type 2 or type 3) (P=0.020).
   CONCLUSION: There is an association between posterior vitreous attachment and AMD. There is also an increased incidence of VMA with intra-retinal CNV.
C1 [El-Hifnawy, Mohamed Abd ElMonaem; Ibrahim, Hisham Ali; Gomaa, Amir Ramadan; Elmasry, Mohamed A.] Univ Alexandria, Fac Med, Dept Ophthalmol, Khartoum Sq, Alexandria 21526, Egypt.
C3 Egyptian Knowledge Bank (EKB); Alexandria University
RP Elmasry, MA (通讯作者)，Infront 27 Maarouf Rasafl St, Alexandria 21500, Egypt.
EM Moah384@gmail.com
RI Elmasry, Mohamed Ashraf/Q-8843-2019; Gomaa, Amir/H-9702-2017
OI Elmasry, Mohamed Ashraf/0000-0003-4231-2566; El-Hifnawy,
   Mohammad/0000-0002-6925-213X; Gomaa, Amir/0000-0002-3263-6957
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   FOOS R Y, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P480
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Houston SK, 2015, RETINA-J RET VIT DIS, V35, P1757, DOI 10.1097/IAE.0000000000000663
   Jackson TL, 2013, RETINA-J RET VIT DIS, V33, P1099, DOI 10.1097/IAE.0b013e31828991d6
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   McKibbin MA, 2015, RETINA-J RET VIT DIS, V35, P1951, DOI 10.1097/IAE.0000000000000587
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Sebag J, 2005, Trans Am Ophthalmol Soc, V103, P473
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   Sebag J, 2002, RETINA-J RET VIT DIS, V22, P1, DOI 10.1097/00006982-200202000-00001
   SEBAG J, 1991, ARCH OPHTHALMOL-CHIC, V109, P966, DOI 10.1001/archopht.1991.01080070078039
   Sebag J, 1998, RETINA-J RET VIT DIS, V18, P1
   SEBAG J, 1987, GRAEF ARCH CLIN EXP, V225, P89, DOI 10.1007/BF02160337
   Sebag J, 2000, EUR J OPHTHALMOL, V10, P1
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Waldstein SM, 2012, RETINA-J RET VIT DIS, V32, P424, DOI 10.1097/IAE.0b013e3182278b80
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 35
TC 2
Z9 3
U1 0
U2 1
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD FEB 18
PY 2017
VL 10
IS 2
BP 246
EP 253
DI 10.18240/ijo.2017.02.11
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EL2VM
UT WOS:000394478600011
PM 28251084
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Kaneko, H
   Dridi, S
   Tarallo, V
   Gelfand, BD
   Fowler, BJ
   Cho, WG
   Kleinman, ME
   Ponicsan, SL
   Hauswirth, WW
   Chiodo, VA
   Kariko, K
   Yoo, JW
   Lee, DK
   Hadziahmetovic, M
   Song, Y
   Misra, S
   Chaudhuri, G
   Buaas, FW
   Braun, RE
   Hinton, DR
   Zhang, Q
   Grossniklaus, HE
   Provis, JM
   Madigan, MC
   Milam, AH
   Justice, NL
   Albuquerque, RJC
   Blandford, AD
   Bogdanovich, S
   Hirano, Y
   Witta, J
   Fuchs, E
   Littman, DR
   Ambati, BK
   Rudin, CM
   Chong, MMW
   Provost, P
   Kugel, JF
   Goodrich, JA
   Dunaief, JL
   Baffi, JZ
   Ambati, J
AF Kaneko, Hiroki
   Dridi, Sami
   Tarallo, Valeria
   Gelfand, Bradley D.
   Fowler, Benjamin J.
   Cho, Won Gil
   Kleinman, Mark E.
   Ponicsan, Steven L.
   Hauswirth, William W.
   Chiodo, Vince A.
   Kariko, Katalin
   Yoo, Jae Wook
   Lee, Dong-ki
   Hadziahmetovic, Majda
   Song, Ying
   Misra, Smita
   Chaudhuri, Gautam
   Buaas, Frank W.
   Braun, Robert E.
   Hinton, David R.
   Zhang, Qing
   Grossniklaus, Hans E.
   Provis, Jan M.
   Madigan, Michele C.
   Milam, Ann H.
   Justice, Nikki L.
   Albuquerque, Romulo J. C.
   Blandford, Alexander D.
   Bogdanovich, Sasha
   Hirano, Yoshio
   Witta, Jassir
   Fuchs, Elaine
   Littman, Dan R.
   Ambati, Balamurali K.
   Rudin, Charles M.
   Chong, Mark M. W.
   Provost, Patrick
   Kugel, Jennifer F.
   Goodrich, James A.
   Dunaief, Joshua L.
   Baffi, Judit Z.
   Ambati, Jayakrishna
TI DICER1 deficit induces Alu RNA toxicity in age-related macular
   degeneration
SO NATURE
LA English
DT Article
ID EMBRYONIC STEM-CELLS; MICRORNA BIOGENESIS; MOUSE OOCYTES; LDL RECEPTOR;
   RECOMBINATION; ARGONAUTE2; EXPRESSION; CANCER; SIRNAS; DIFFERENTIATION
AB Geographic atrophy (GA), an untreatable advanced form of age-related macular degeneration, results from retinal pigmented epithelium (RPE) cell degeneration. Here we show that the microRNA (miRNA)-processing enzyme DICER1 is reduced in the RPE of humans with GA, and that conditional ablation of Dicer1, but not seven other miRNA-processing enzymes, induces RPE degeneration in mice. DICER1 knockdown induces accumulation of Alu RNA in human RPE cells and Alu-like B1 and B2 RNAs in mouse RPE. Alu RNA is increased in the RPE of humans with GA, and this pathogenic RNA induces human RPE cytotoxicity and RPE degeneration in mice. Antisense oligonucleotides targeting Alu/B1/B2 RNAs prevent DICER1 depletion-induced RPE degeneration despite global miRNA downregulation. DICER1 degrades Alu RNA, and this digested Alu RNA cannot induce RPE degeneration in mice. These findings reveal a miRNA-independent cell survival function for DICER1 involving retrotransposon transcript degradation, show that Alu RNA can directly cause human pathology, and identify new targets for a major cause of blindness.
C1 [Kaneko, Hiroki; Dridi, Sami; Tarallo, Valeria; Gelfand, Bradley D.; Fowler, Benjamin J.; Cho, Won Gil; Kleinman, Mark E.; Justice, Nikki L.; Albuquerque, Romulo J. C.; Blandford, Alexander D.; Bogdanovich, Sasha; Hirano, Yoshio; Baffi, Judit Z.; Ambati, Jayakrishna] Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA.
   [Cho, Won Gil] Yonsei Univ, Wonju Coll Med, Dept Anat, Wonju 220701, South Korea.
   [Ponicsan, Steven L.; Kugel, Jennifer F.; Goodrich, James A.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA.
   [Hauswirth, William W.; Chiodo, Vince A.] Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA.
   [Kariko, Katalin] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA.
   [Yoo, Jae Wook; Lee, Dong-ki] Sungkyunkwan Univ, Sch Chem Mat Sci BK21, Suwon 440746, South Korea.
   [Yoo, Jae Wook; Lee, Dong-ki] Sungkyunkwan Univ, Dept Chem, Suwon 440746, South Korea.
   [Hadziahmetovic, Majda; Song, Ying; Milam, Ann H.; Dunaief, Joshua L.] Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   [Misra, Smita; Chaudhuri, Gautam] Meharry Med Coll, Dept Microbiol & Immunol, Nashville, TN 37208 USA.
   [Buaas, Frank W.; Braun, Robert E.] Jackson Lab, Bar Harbor, ME 04609 USA.
   [Hinton, David R.] Univ So Calif, Doheny Eye Inst, Arnold & Mabel Beckman Macular Res Ctr, Los Angeles, CA 90033 USA.
   [Zhang, Qing; Grossniklaus, Hans E.] Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA.
   [Zhang, Qing; Grossniklaus, Hans E.] Emory Univ, Atlanta, GA 30322 USA.
   [Provis, Jan M.] Australian Natl Univ, ANU Med Sch, ARC Ctr Excellence Vis Sci, Canberra, ACT 0200, Australia.
   [Provis, Jan M.] Australian Natl Univ, Res Sch Biol, Canberra, ACT 0200, Australia.
   [Madigan, Michele C.] Univ New S Wales, Sch Optometry & Vis Sci, Kensington, NSW 2033, Australia.
   [Madigan, Michele C.] Univ Sydney, Save Sight Inst, Sydney, NSW 2001, Australia.
   [Witta, Jassir] Univ Kentucky, Dept Internal Med, Lexington, KY 40506 USA.
   [Fuchs, Elaine] Rockefeller Univ, Howard Hughes Med Inst, Lab Mammalian Cell Biol & Dev, New York, NY 10065 USA.
   [Littman, Dan R.; Chong, Mark M. W.] NYU, Sch Med, Howard Hughes Med Inst, Kimmel Ctr Biol & Med,Skirball Inst, New York, NY 10016 USA.
   [Ambati, Balamurali K.] Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   [Ambati, Balamurali K.] Vet Affairs Salt Lake City Healthcare Syst, Dept Ophthalmol, Salt Lake City, UT 84148 USA.
   [Rudin, Charles M.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Oncol, Baltimore, MD 21231 USA.
   [Chong, Mark M. W.] Walter & Eliza Hall Inst Med Res, Autoimmun & Transplantat Div, Parkville, Vic 3052, Australia.
   [Provost, Patrick] Univ Laval, CHUL Res Ctr CHUQ, Quebec City, PQ G1K 7P4, Canada.
   [Provost, Patrick] Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada.
   [Ambati, Jayakrishna] Univ Kentucky, Dept Physiol, Lexington, KY 40506 USA.
   [Yoo, Jae Wook; Lee, Dong-ki] Sungkyunkwan Univ, Global Res Lab RNAi Med, Suwon 440746, South Korea.
C3 University of Kentucky; Yonsei University; University of Colorado
   System; University of Colorado Boulder; State University System of
   Florida; University of Florida; University of Pennsylvania; Sungkyunkwan
   University (SKKU); Sungkyunkwan University (SKKU); University of
   Pennsylvania; Pennsylvania Medicine; Meharry Medical College; Jackson
   Laboratory; Doheny Eye Institute; University of Southern California;
   Emory University; Emory University; Australian National University;
   Australian National University; University of New South Wales Sydney;
   University of Sydney; University of Kentucky; Howard Hughes Medical
   Institute; Rockefeller University; Howard Hughes Medical Institute; New
   York University; Utah System of Higher Education; University of Utah; US
   Department of Veterans Affairs; Johns Hopkins University; Johns Hopkins
   Medicine; Walter & Eliza Hall Institute; Laval University; Laval
   University; University of Kentucky; Sungkyunkwan University (SKKU)
RP Ambati, J (通讯作者)，Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA.
EM jamba2@email.uky.edu
RI Gelfand, Brad/L-3926-2019; Fowler, Benjamin/F-4987-2012; Kaneko,
   Hiroki/AHA-2461-2022; Rudin, Charles/R-2530-2019; Provis,
   Jan/C-9529-2009; Provost, Patrick/G-2786-2010; Kaneko,
   Hiroki/O-7695-2015; Fuchs, Elaine/G-1565-2016; Dridi, Sami/Q-8207-2019;
   Chong, Mark/H-6684-2016
OI Kaneko, Hiroki/0000-0003-0731-6465; Rudin, Charles/0000-0001-5204-3465;
   Provis, Jan/0000-0002-6405-2868; Provost, Patrick/0000-0002-6099-6562;
   Kaneko, Hiroki/0000-0003-0731-6465; Chong, Mark/0000-0002-3701-7397;
   Hirano, Yoshio/0000-0002-9173-0839; Kleinman, Mark/0000-0001-8557-7949;
   Tarallo, Valeria/0000-0002-6920-4402; hauswirth,
   william/0000-0002-3244-4947
FU National Eye Institute (NEI)/National Institutes of Health (NIH)
   [R01EY015422, R01EY018350, R01EY018836, R01EY020672, R21EY019778,
   RC1EY020442, R01EY017182, R01EY017950, R01HD027215, R21AI076757,
   P30EY06360, U10EY013729, R01EY011123, P30EY008571, R01GM068414,
   R01EY015240, P30EY003040, R01EY001545, T32HL091812]; Doris Duke
   Distinguished Clinical Scientist Award; Burroughs Wellcome Fund Clinical
   Scientist Award in Translational Research; Dr E. Vernon Smith and Eloise
   C. Smith Macular Degeneration Endowed Chair; Research to Prevent
   Blindness Senior Scientist Investigator Awards; University of Kentucky
   Physician Scientist Award; International Retinal Research Foundation;
   American Health Assistance Foundation; VA Merit Award; Department of
   Defense; MEST, Korea; Arnold and Mabel Beckman Foundation; Macular
   Vision Research Foundation and Foundation Fighting Blindness; ARC
   Centres of Excellence [CE0561903]; Sydney Foundation for Medical
   Research; National Health and Medical Research Council, Australia
   [637228]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH
   &HUMAN DEVELOPMENT [R01HD027215] Funding Source: NIH RePORTER; NATIONAL
   EYE INSTITUTE [R01EY018350, R01EY018836, R01EY001545, R01EY015240,
   P30EY014800, P30EY006360, P30EY003040, U10EY013729, R01EY017182,
   R01EY020672, R01EY017950, R21EY019778, P30EY021721, RC1EY020442,
   R01EY011123, R01EY015422, P30EY008571] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL091812] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
   [R21AI076757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCES [R01GM068414] Funding Source: NIH RePORTER
FX We thank M. Chrenek, J. Garcia-Perez, T. Heidmann, C. Kanellopoulou, D.
   M. Livingston, J. V. Moran, R. F. Mullins, J. M. Nickerson, E. A.
   Pearce, A. Tarakhovsky, B. Vogelstein, V. E. Velculescu and D. J. Zack
   for providing mice, reagents or tissues; R. King, L. Xu, M. McConnell,
   C. Payne, G. R. Pattison, G. J. Jaffe, S. Medearis and C. Spee for
   technical assistance; and A. Sinai, R. Mohan, T. S. Khurana, R. A.
   Brekken, P. L. Deininger, S. Bondada, P. A. Pearson, A. M. Rao, G. S.
   Rao and K. Ambati for discussions. J. A. was supported by National Eye
   Institute (NEI)/National Institutes of Health (NIH) grants R01EY015422,
   R01EY018350, R01EY018836, R01EY020672, R21EY019778, RC1EY020442, the
   Doris Duke Distinguished Clinical Scientist Award, the Burroughs
   Wellcome Fund Clinical Scientist Award in Translational Research, and
   the Dr E. Vernon Smith and Eloise C. Smith Macular Degeneration Endowed
   Chair. Research to Prevent Blindness Senior Scientist Investigator
   Awards or departmental unrestricted grants supported J. A., H. E. G. and
   W. W. H.; J. Z. B. was supported by University of Kentucky Physician
   Scientist Award, International Retinal Research Foundation, and American
   Health Assistance Foundation; B. K. A. by VA Merit Award and Department
   of Defense; D.-k. L. by Global Research Laboratory program by MEST,
   Korea; D. R. H. by Arnold and Mabel Beckman Foundation; W. W. H. by
   Macular Vision Research Foundation and Foundation Fighting Blindness; J.
   M. P. by ARC Centres of Excellence Grant CE0561903; M. C. M. by Sydney
   Foundation for Medical Research. B. K. A was supported by NIH
   R01EY017182 and R01EY017950; R. E. B. by NIH R01HD027215; G. C. by NIH
   R21AI076757; H. E. G. by NIH P30EY06360; W. W. H. by NIH U10EY013729,
   R01EY011123, and P30EY008571; J. F. K. and J. A. G. by NIH R01GM068414;
   J. L. D. by NIH R01EY015240; D. R. H. by NIH P30EY003040 and
   R01EY001545; M. E. K. and S. B. by NIH T32HL091812. P. P. is a Senior
   Scholar from the Fonds de la Recherche en Sante du Quebec (FRSQ). M. M.
   W. C. is a QEII Fellow of the Australian Research Council and is
   supported by National Health and Medical Research Council, Australia
   Project Grant 637228. E. F. and D. R. L. are investigators of the Howard
   Hughes Medical Institute.
CR Alexander JJ, 2008, ADV EXP MED BIOL, V613, P121, DOI 10.1007/978-0-387-74904-4_13
   Allen TA, 2004, NAT STRUCT MOL BIOL, V11, P816, DOI 10.1038/nsmb813
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Babiarz JE, 2008, GENE DEV, V22, P2773, DOI 10.1101/gad.1705308
   Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   Chen JF, 2008, P NATL ACAD SCI USA, V105, P2111, DOI 10.1073/pnas.0710228105
   Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868
   Chong MMW, 2008, J EXP MED, V205, P2449, DOI [10.1084/jem.20071219090508c, 10.1084/jem.20081219]
   Chong MMW, 2010, GENE DEV, V24, P1951, DOI 10.1101/gad.1953310
   Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103
   Damiani D, 2008, J NEUROSCI, V28, P4878, DOI 10.1523/JNEUROSCI.0828-08.2008
   Davis TH, 2008, J NEUROSCI, V28, P4322, DOI 10.1523/JNEUROSCI.4815-07.2008
   Diederichs S, 2007, CELL, V131, P1097, DOI 10.1016/j.cell.2007.10.032
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120
   Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466
   Harfe BD, 2005, P NATL ACAD SCI USA, V102, P10898, DOI 10.1073/pnas.0504834102
   Hill DA, 2009, SCIENCE, V325, P965, DOI 10.1126/science.1174334
   Iacovelli J, 2011, INVEST OPHTH VIS SCI, V52, P1378, DOI 10.1167/iovs.10-6347
   Kaneda M, 2009, EPIGENET CHROMATIN, V2, DOI 10.1186/1756-8935-2-9
   Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505
   Kato H, 2008, J EXP MED, V205, P1601, DOI 10.1084/jem.20080091
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kohany O, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-474
   Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209
   LEHRMAN MA, 1985, SCIENCE, V227, P140, DOI 10.1126/science.3155573
   LEHRMAN MA, 1987, CELL, V48, P827, DOI 10.1016/0092-8674(87)90079-1
   Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513
   Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007
   Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785
   Murchison EP, 2005, P NATL ACAD SCI USA, V102, P12135, DOI 10.1073/pnas.0505479102
   Nakagawa A, 2010, SCIENCE, V328, P327, DOI 10.1126/science.1182374
   NICHOLLS RD, 1987, CELL, V49, P369, DOI 10.1016/0092-8674(87)90289-3
   NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203
   O'Carroll D, 2007, GENE DEV, V21, P1999, DOI 10.1101/gad.1565607
   Prades C, 1996, J MOL EVOL, V42, P37, DOI 10.1007/BF00163209
   Saito Y, 2009, ONCOGENE, V28, P2738, DOI 10.1038/onc.2009.140
   Saleh MC, 2006, NAT CELL BIOL, V8, P793, DOI 10.1038/ncb1439
   Schaefer A, 2010, J EXP MED, V207, P1843, DOI 10.1084/jem.20100451
   SCHONBORN J, 1991, NUCLEIC ACIDS RES, V19, P2993, DOI 10.1093/nar/19.11.2993
   Shaikh TH, 1997, J MOL BIOL, V271, P222, DOI 10.1006/jmbi.1997.1161
   Su H, 2009, GENE DEV, V23, P304, DOI 10.1101/gad.1749809
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tam OH, 2008, NATURE, V453, P534, DOI 10.1038/nature06904
   Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973
   WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0
   Watanabe T, 2008, NATURE, V453, P539, DOI 10.1038/nature06908
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yi R, 2009, P NATL ACAD SCI USA, V106, P498, DOI 10.1073/pnas.0810766105
NR 52
TC 438
Z9 467
U1 4
U2 76
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD MAR 17
PY 2011
VL 471
IS 7338
BP 325
EP +
DI 10.1038/nature09830
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 735UE
UT WOS:000288444000034
PM 21297615
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kymionis, GD
   Panagiotoglou, TD
   Yoo, SH
   Tsiklis, NS
   Christodoulakis, E
   Hajithanasis, GC
   Tsilimbaris, MK
   Pallikaris, IG
AF Kymionis, George D.
   Panagiotoglou, Theoni D.
   Yoo, Sonia H.
   Tsiklis, Nikolaos S.
   Christodoulakis, Emmanouel
   Hajithanasis, George C.
   Tsilimbaris, Miltiadis K.
   Pallikaris, Ioannis G.
TI Central corneal thickness in patients with neovascular age-related
   macular degeneration
SO CORNEA
LA English
DT Article
DE corneal thickness; neovascular; age-related macular degeneration
ID RISK-FACTORS; MACULOPATHY; PREVALENCE; RIGIDITY
AB Purpose: To compare the central corneal thickness (CCT) measurements of patients with neovascular age-related macular degeneration (AMD) and control subjects.
   Methods: The CCT value (measured with ultrasound corneal pachymetry) of 130 eyes (130 patients, 1 eye from each patient) with neovascular AMD (AMD group) and 98 eyes (98 patients, 1 eye from each patient) of similar age, sex, and eye's axial length healthy control subjects (normal group) was compared.
   Results: The mean age (AMD group: 69.1 years vs. control group: 69.5 years, P = 0.81), sex (AMD group: 77 women, 59% vs. control group: 59 women, 60%, P = 0.77), and eye's axial length (AMD group: 25.05-mm vs. control group: 24.61-mm, P = 0.38) of patients with neovascular AMD and healthy control subjects were comparable. There were no statistically significant differences in the mean CCT measurements in the neovascular AMD group in comparison with the control group (549.44 vs. 544.35 mu m, P = 0.11).
   Conclusions: CCT measurements do not differ in patients with neovascular AMD compared with healthy control subjects.
C1 Univ Crete, Sch Med, Dept Ophthalmol, Inst Vis & Opt, Iraklion 71110, Crete, Greece.
   Univ Miami, Bascom Palmer Eye Inst, Miami, FL 33152 USA.
C3 University of Crete; Bascom Palmer Eye Institute; University of Miami
RP Kymionis, GD (通讯作者)，Univ Crete, Sch Med, Dept Ophthalmol, Inst Vis & Opt, Iraklion 71110, Crete, Greece.
EM kymionis@med.uoc.gr
OI Tsilimbaris, Miltiadis/0000-0002-0130-1150
CR BUSTED N, 1981, BRIT J OPHTHALMOL, V65, P687, DOI 10.1136/bjo.65.10.687
   Ehlers N, 2004, EXP EYE RES, V78, P543, DOI 10.1016/j.exer.2003.09.017
   Evereklioglu C, 2002, J PEDIAT OPHTH STRAB, V39, P274, DOI 10.3928/0191-3913-20020901-07
   Evereklioglu C, 2002, EUR J OPHTHALMOL, V12, P24, DOI 10.1177/112067210201200105
   Friedenwald J.S., 1937, AM J OPHTHALMOL, V20, P985, DOI [10.1016/s0002-9394(37)90425-2, DOI 10.1016/S0002-9394(37)90425-2, 10.1016/S0002-9394(37)90425-2]
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   HANSEN FK, 1971, ACTA OPHTHALMOL, V49, P467
   Harper CL, 1996, BRIT J OPHTHALMOL, V80, P1068, DOI 10.1136/bjo.80.12.1068
   Herndon LW, 1997, ARCH OPHTHALMOL-CHIC, V115, P1137, DOI 10.1001/archopht.1997.01100160307007
   Jonas JB, 2005, INVEST OPHTH VIS SCI, V46, P1269, DOI 10.1167/iovs.04-0265
   Klein BEK, 1997, AM J OPHTHALMOL, V123, P338, DOI 10.1016/S0002-9394(14)70129-1
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   Pallikaris IG, 2005, INVEST OPHTH VIS SCI, V46, P409, DOI 10.1167/iovs.04-0162
   PEDERSEN U, 1984, ORL J OTO-RHINO-LARY, V46, P38, DOI 10.1159/000275682
   Sanchis-Gimeno JA, 2005, CORNEA, V24, P39, DOI 10.1097/01.ico.0000138836.45070.0f
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Thomas R, 2000, Indian J Ophthalmol, V48, P107
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   WANH JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   WEINREB RN, 1988, AM J OPHTHALMOL, V105, P258, DOI 10.1016/0002-9394(88)90006-2
   Wolfs RC, 1997, AM J OPHTHALMOL, V123, P767, DOI 10.1016/S0002-9394(14)71125-0
NR 24
TC 5
Z9 5
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277-3740
EI 1536-4798
J9 CORNEA
JI Cornea
PD FEB
PY 2007
VL 26
IS 2
BP 182
EP 184
DI 10.1097/ICO.0b013e31802c9def
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131VT
UT WOS:000243899800014
PM 17251809
DA 2022-11-30
ER

PT J
AU Campos, MM
   Abu-Asab, MS
AF Campos, Maria Mercedes
   Abu-Asab, Mones S.
TI Loss of endothelial planar cell polarity and cellular clearance
   mechanisms in age-related macular degeneration
SO ULTRASTRUCTURAL PATHOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); apoptosis; autophagy; Bruch's
   membrane; choriocapillaris; endothelial cells; lysosomes; necrosis;
   planar cell polarity (PCP); retinal pigment epithelium (RPE)
ID RETINAL-PIGMENT EPITHELIUM; VISUAL IMPAIRMENT; BRUCHS MEMBRANE;
   GROWTH-FACTOR; RPE; AUTOPHAGY; DRUSEN; CHORIOCAPILLARIS; FENESTRATIONS;
   INFLAMMATION
AB Apoptosis, autophagosomes, and lysosomes are lacking in the retinal pigment epithelium (RPE) of age-related macular degeneration (AMD) eyes. Necrosis, not apoptosis, appeared to be the prominent type of cell death in RPE, which led to the accumulation of cell debris within and on both sides of Bruch's membrane. The endothelium of the choriocapillaris had an altered planar cell polarity which encompassed the disappearance of fenestrations, the thickening of cytoplasm, and anterior nuclear dislocation. There were no significant differences in RPE and choroidal aberrations between macular and temporal regions. Loss of endothelial polarity could be at the crux of AMD initiation and progression.
C1 [Campos, Maria Mercedes; Abu-Asab, Mones S.] NEI, Sect Histopathol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Abu-Asab, MS (通讯作者)，NEI, Sect Histopathol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM mones@mail.nih.gov
FU National Eye Institute, NIH, Bethesda, Maryland, USA; NATIONAL EYE
   INSTITUTE [ZICEY000461] Funding Source: NIH RePORTER
FX The research was funded by the intramural program of the National Eye
   Institute, NIH, Bethesda, Maryland, USA.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Arutjunyan AV, 2016, CURR AGING SCI, V10, P18
   Ballermann BJ, 2005, KIDNEY INT, V67, P1668, DOI 10.1111/j.1523-1755.2005.00260.x
   BERNSTEIN M. H., 1965, INVEST OPHTHAL MOL, V4, P1016
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   BURNS MS, 1992, CURR EYE RES, V11, P863, DOI 10.3109/02713689209033484
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Devenport D, 2014, J CELL BIOL, V207, P171, DOI 10.1083/jcb.201408039
   Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947
   Fine Y.M, 1979, OCULAR HISTOLOGY TEX, V2nd
   Ford K, 2011, IMMUNOLOGY INFLAMMAT, P325
   Guha S, 2014, EXP EYE RES, V126, P68, DOI 10.1016/j.exer.2014.05.013
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kochounian H, 2009, EXP EYE RES, V88, P1129, DOI 10.1016/j.exer.2009.01.019
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kuwabara T., 1970, FINE STRUCTURE EYE
   Lee CY, 2011, PHYSIOLOGY, V26, P326, DOI 10.1152/physiol.00018.2011
   Li XD, 2013, SCIENCE, V341, P1390, DOI 10.1126/science.1244040
   Lu XW, 2004, NATURE, V430, P93, DOI 10.1038/nature02677
   Lutty G, 1999, MOL VIS, V5
   Lutty GA, 2010, EYE, V24, P408, DOI 10.1038/eye.2009.318
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Murakami Y, 2014, CELL DEATH DIFFER, V21, P270, DOI 10.1038/cdd.2013.109
   Ogilvy AJ, 2014, ULTRASTRUCT PATHOL, V38, P335, DOI 10.3109/01913123.2014.927406
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Satchell SC, 2009, AM J PHYSIOL-RENAL, V296, pF947, DOI 10.1152/ajprenal.90601.2008
   Seifert JRK, 2007, NAT REV GENET, V8, P126, DOI 10.1038/nrg2042
   SELLHEYER K, 1988, GRAEF ARCH CLIN EXP, V226, P65, DOI 10.1007/BF02172721
   Simons M, 2008, ANNU REV GENET, V42, P517, DOI 10.1146/annurev.genet.42.110807.091432
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Spencer WH, 1996, OPHTHALMIC PATHOLOGY, V2
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Stefater JA, 2011, NATURE, V474, P511, DOI 10.1038/nature10085
   Torban E, 2004, TRENDS GENET, V20, P570, DOI 10.1016/j.tig.2004.09.003
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   Zamaraeva MV, 2005, CELL DEATH DIFFER, V12, P1390, DOI 10.1038/sj.cdd.4401661
   Zerlin M, 2008, ANGIOGENESIS, V11, P63, DOI 10.1007/s10456-008-9095-3
NR 43
TC 6
Z9 6
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0191-3123
EI 1521-0758
J9 ULTRASTRUCT PATHOL
JI Ultrastruct. Pathol.
PY 2017
VL 41
IS 5
BP 312
EP 319
DI 10.1080/01913123.2017.1348418
PG 8
WC Microscopy; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Microscopy; Pathology
GA FM8KF
UT WOS:000415335400002
PM 28796562
OA Green Accepted
DA 2022-11-30
ER

EF